azacitidine has been researched along with decitabine in 3173 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 103 (3.25) | 18.7374 |
| 1990's | 160 (5.04) | 18.2507 |
| 2000's | 1118 (35.23) | 29.6817 |
| 2010's | 1674 (52.76) | 24.3611 |
| 2020's | 118 (3.72) | 2.80 |
| Authors | Studies |
|---|---|
| Cook, PD; McNamara, DJ | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Arimondo, PB; Erdmann, A; Fahy, J; Halby, L | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bonnac, L; Clouser, CL; Daly, MB; Kim, B; Landman, SR; Mansky, LM; Patterson, SE; Rawson, JM; Reilly, CS; Roth, ME; Xie, J | 1 |
| Agirre, X; de Miguel, I; Fernandez Perez, R; Fraga, M; Garate, L; García-Barchino, MJ; Liu, Y; Martínez-Climent, JA; Miranda, E; Ordoñez, R; Oyarzabal, J; Prosper, F; Rabal, O; Roa, S; Sáez, E; San José-Enériz, E; Sánchez-Arias, JA; Santamarina, P; Ugarte, A; Vilas-Zornoza, A; Wu, W; Xu, M | 1 |
| Hayashibara, KC; Verdine, GL | 1 |
| Boukamp, P; Chen, J; Fusenig, NE; Gonzales, F; Jones, PA | 1 |
| Keyomarsi, K; Lee, SW; Sager, R; Swisshelm, K; Tomasetto, C | 1 |
| Samid, D; Shack, S; Sherman, LT | 1 |
| Abbruzzese, JL; Anzai, H; Frost, P | 1 |
| Commane, M; McIntyre, P; Perry, ME; Rolfe, M; Stark, GR | 1 |
| Abbruzzese, JL; Frost, P | 1 |
| Laliberté, J; Marquez, VE; Momparler, RL | 1 |
| Crowther, P; Davidson, S; Radley, J; Woodcock, D | 1 |
| Thomas, GA; Williams, ED | 1 |
| Clavel, M; Fosså, S; Kaye, SB; Monfardini, S; Renard, J; Smyth, J | 1 |
| Gartler, SM; Hansen, RS; Sasaki, T | 1 |
| Prasanna, P; Samid, D; Yeh, A | 1 |
| Doré, BT; Momparler, RL | 1 |
| Biard, DS; Maratrat, M; Melcion, C; Sarasin, A; Thybaud, V | 1 |
| Cavalli, F; Renard, J; Sessa, C; Stoter, G; ten Bokkel Huinink, W | 1 |
| Beaulieu, R; Bouchard, J; Lapointe, N; Leclerc, JM; Thibodeau, L; Walker, MC | 1 |
| Haaf, T; Schmid, M | 3 |
| Lutze, LH; Morgan, WF; Phillips, JW; Winegar, RA | 1 |
| Adolph, S; Djalali, M; Hameister, H; Steinbach, P; Winking, H | 1 |
| Abbruzzese, JL; Ellis, M; Frost, P; Hunt, B; Lee, D | 1 |
| Kraakman, ME; Lambert, M; Schuurman, RK; van den Elsen, PJ; van Eggermond, MC | 1 |
| Doré, BT; Momparler, LF; Momparler, RL | 1 |
| Laliberté, J; Momparler, RL | 1 |
| Momparler, LF; Momparler, RL; Onetto-Pothier, N | 1 |
| Bassin, RH; Rimoldi, D; Samid, D; Srikantan, V; Wilson, VL | 1 |
| Chen, J; Jones, PA | 1 |
| Guastalla, JP; Renard, J; Roozendaal, KJ; Splinter, TA; Tumolo, S; Vermorken, JB | 1 |
| Behnam, YT; Maclean, N | 1 |
| Colly, LP; Kluin-Nelemans, JC; Richel, DJ; Willemze, R | 1 |
| Covey, JM; D'Incalci, M; Kohn, KW; Zaharko, DS | 1 |
| Cihák, A; Hovi, T; Raivio, KO | 1 |
| Zaharko, DS | 1 |
| Bourgeois, S; Harmon, JM; Smith, JR; Thompson, EB | 1 |
| Alvarez, E; Frost, P; Kerbel, RS; Liteplo, RG | 1 |
| Cooper, IA; Crowther, PJ; Simmons, DL; Woodcock, DM | 1 |
| Bouchard, J; Momparler, RL; Samson, J | 1 |
| Covey, JM; Zaharko, DS | 4 |
| Jones, PA; Kautiainen, TL | 1 |
| Lin, KT; Momparler, RL; Rivard, GE | 2 |
| Pískala, A; Veselý, J | 2 |
| Moriconi, WJ; Slavik, M; Taylor, S | 1 |
| Chabot, GG; Momparler, RL | 2 |
| Cihák, A; Skoda, J; Vesely, J | 1 |
| Kaysen, J; Kufe, D; Spriggs, D | 1 |
| Gall, HE; Leyva, A; O'Brien, AM; Pinedo, HM; van Groeningen, CJ | 1 |
| Cooper, IA; Crowther, PJ; Morley, AA; Simmons, DL; Trainor, KJ; Woodcock, DM | 1 |
| Holliday, R | 1 |
| Covey, JM; D'Incalci, M; Kohn, KW; Tilchen, EJ; Zaharko, DS | 1 |
| Hildebrandt, A | 1 |
| Bhalla, K; Gleyzer, M; Grant, S | 1 |
| Bartolucci, S; Bouchard, J; Momparler, LF; Momparler, RL; Nucci, R; Raia, CA; Rossi, M; Sepe, S; Vaccaro, C | 1 |
| Nettesheim, P; Walker, C | 1 |
| Colombo, T; D'Incalci, M; Rossi, C | 1 |
| Boeije, LC; de Waal, F; Levva, A; Pinedo, HM; Schwartsmann, G | 1 |
| Jones, PA; Michalowsky, LA | 4 |
| Gyger, M; Momparler, RL; Rivard, GE | 1 |
| Momparler, RL | 3 |
| Haaf, T; Ott, G; Schmid, M | 2 |
| Arundel, CM; Leith, JT | 1 |
| Frost, P; Hunt, B; Kerbel, RS; Man, S; Pathak, S | 1 |
| Gunter, KC; Sneller, MC | 1 |
| Gyger, M; Momparler, LF; Momparler, RL; Onetto, N | 1 |
| Antonsson, BE; Avramis, VI; Holcenberg, JS; Nyce, J | 1 |
| Arnold, M; Bosman, P; Carlow, DA; Elliott, BE; Hampton, N; Ivimey, L | 1 |
| Cihák, A; Madar, J; Nouza, K; Sůla, K | 1 |
| Leyva, A; Pinedo, HM; Schwartsmann, G | 1 |
| Bernheim, J; Buyssens, N; Cortvrindt, R; Roobol, K | 1 |
| Arlin, Z; Baker, M; Bhalla, K; Cole, J; Graham, G; Grant, S; MacLaughlin, W | 1 |
| Banks, GR; Gounari, F; Holliday, R; Jeggo, PA; Khazaie, K | 1 |
| Veselý, J | 2 |
| Abele, R; Bruntsch, U; Clavel, M; Dodion, P; Gundersen, S; Pinedo, HM; Renard, J; Smyth, J; van Glabbeke, M | 1 |
| Ananthaswamy, HN | 1 |
| Alvarez, E; Elliott, BE; Houghton, AN; Kerbel, RS | 1 |
| Bare, RM; McDowell, AE; Miller, MS; Waalkes, MP; Wilson, MJ | 1 |
| Pfeifer, GP; Steigerwald, SD | 1 |
| Axelman, J; Beggs, AH; Migeon, BR | 1 |
| Feinberg, AP; Rainier, S | 1 |
| Colly, LP; Lurvink, E; Richel, DJ; Willemze, R | 1 |
| Braakhuis, BJ; Leyva, A; Snow, GB; van Dongen, GA; van Walsum, M | 1 |
| Frost, P; LeGrue, SJ; Simcik, W | 1 |
| Lachmann, PJ; Snyder, RD | 1 |
| Gonzales, FA; Ma, A; Momparler, LF; Momparler, RL | 1 |
| Augusti-Tocco, G; Bartolucci, S; Estenoz, M; Longo, A; Momparler, RL; Rossi, M; Santoro, B | 1 |
| Constantinides, PG; Davis, CM; Gevers, W; Parker, MI; van der Riet, F; van Schalkwyk, L | 1 |
| Feichtinger, W; Schmid, M | 1 |
| Bittoun, P; Canivet, M; Dianoux, L; Lasneret, J; Lesser, J; Peries, J | 1 |
| Diver, WP; Woodcock, DM | 1 |
| Farooq, M; Holliday, R; Hunter, JL; Matsumura, T | 1 |
| Bouchard, J | 1 |
| Momparler, LF; Momparler, RL | 1 |
| Attadia, V; Bullian, PL; Carbone, A; Colombatti, A; Gattei, V; Monfardini, S; Pinto, A; Zagonel, V | 1 |
| Colly, LP; Richel, DJ; Willemze, R | 1 |
| DeSimone, J; Hall, L; Heller, P; Molokie, RE; Zwiers, D | 1 |
| Adams, RL; Burdon, RH; Davis, T; Kirk, D; Rinaldi, A | 1 |
| Hoang, T; McCulloch, EA; Motoji, T; Tritchler, D | 1 |
| Adams, RL; Burdon, RH; Qureshi, M | 1 |
| Covey, JM; Muneses, CC; Zaharko, DS | 1 |
| Momparler, LF; Momparler, RL; Samson, J | 2 |
| Jones, PA; Taylor, SM | 1 |
| Cihák, A; Veselý, J | 2 |
| Cihak, A; Hynie, S; Vesely, J | 1 |
| Cadman, E; Grant, S; Margolin, J; Rauscher, F | 1 |
| Acs, G; Christman, JK; Creusot, F | 1 |
| Benoit, P; Demers, J; Lin, K; Momparler, LF; Momparler, RL; Raymond, R; Rivard, GE | 1 |
| Jones, PA; Mohandas, T; Shapiro, LJ; Taylor, SM | 1 |
| Frith, CH; Momparler, RL | 1 |
| Adams, RL; Fulton, J; Kirk, D | 1 |
| Chudomel, V; Cihák, A; Cinátl, J; Hrubá, A; Madar, J; Nezvalová, J; Paluska, E | 1 |
| Chabot, GG; Momparler, RL; Rivard, GE | 1 |
| Ellims, PH | 1 |
| Bouchard, J; Chabot, GG; Momparler, RL | 1 |
| Jones, PA; Momparler, RL; Wilson, VL | 1 |
| Christman, JK | 2 |
| Bouchard, J; Momparler, RL; Onetto, N; Rivard, GE | 1 |
| Attadia, V; Di Fiore, PP; Ferrara, F; Fusco, A; Pinto, A; Spada, OA | 1 |
| Momparler, LF; Momparler, RL; Rivard, GE; Samson, J | 1 |
| Flatau, E; Gonzales, FA; Jones, PA; Michalowsky, LA | 1 |
| Kurihara, K; Matsuoka, I; Mizuno, N; Okuse, K | 1 |
| Augusti-Tocco, G; Bartolucci, S; Carpinelli, P; Granata, F; Rossi, M | 1 |
| Schulz, WA; Teubner, B | 1 |
| Herlyn, M; Johnson, B; Lassam, N; Rosenberg, SA; Salgaller, M; Samid, D; Treisman, J; Weber, J | 1 |
| Dolnick, BJ; Hsueh, CT | 1 |
| Bianco, AR; Caraglia, M; Correale, P; Genua, G; Leardi, A; Pepe, S; Pinto, A; Tagliaferri, P; Zagonel, V | 1 |
| De Cabo, SF; Fernández-Piqueras, J; Hazen, MJ; Molero, ML | 1 |
| Bouffard, DY; Momparler, LF; Momparler, RL | 1 |
| Jaenisch, R; Jüttermann, R; Li, E | 1 |
| Honders, WH; Landegent, JE; Ruiz van Haperen, VW; Stegmann, AP; Willemze, R | 1 |
| Adams, EG; Bhuyan, BK; Folz, BA; Smith, KS | 1 |
| Ambinder, RF; Barletta, J; Robertson, KD; Samid, D | 1 |
| Georgiev, G; Grigorian, M; Lukanidin, E; Tkatch, T; Tulchinsky, E | 1 |
| Haaf, T | 1 |
| Alles, AJ; Chernoff, N; Elstein, KH; Francis, BM; Massaro, EJ; Rogers, JM; Rosen, MB; Sulik, KK; Zucker, RM | 1 |
| Dickinson, SL; Fazeli, A; Jackson-Grusby, L; Jaenisch, R; Jung, WE; Laird, PW; Li, E; Weinberg, RA | 1 |
| Baylin, SB; Davidson, NE; Ferguson, AT; Lapidus, RG | 1 |
| Honders, MW; Landegent, JE; Stegmann, AP; Willemze, R | 1 |
| Hagemeijer, A; Hoebee, B; Honders, MW; Landegent, JE; Stegmann, AP; Willemze, R | 1 |
| Bittoun, P; Emanoil-Ravier, R; Lesser, J; Peries, J | 1 |
| Chen, W; Coxon, AB; Kaye, FJ; Khleif, SN; Otterson, GA | 1 |
| Baylin, SB; Burger, PC; Gabrielson, E; Herman, JG; Lee, DJ; Mao, L; Merlo, A; Sidransky, D | 1 |
| Abbruzzese, JL; Chernajovsky, Y; Ellerhorst, JA; Frost, P; Newman, RA | 1 |
| Barrett, JC; West, RW | 1 |
| Doré, BT; Labiberté, J; Momparler, LF; Momparler, RL | 1 |
| Taylor, SM | 1 |
| Babare, R; De Angelis, V; Gattei, V; Lo Re, G; Marotta, G; Monfardini, S; Pinto, A; Sardeo, G; Zagonel, V | 1 |
| De Gregoris, C; Fazi, P; Gattei, V; Latagliata, R; Mandelli, F; Merola, MC; Monfardini, S; Petti, MC; Pinto, A; Zagonel, V | 1 |
| Aldinucci, D; Da Ponte, A; Gattei, V; Petti, MC; Pinto, A; Zagonel, V | 1 |
| Archimbaud, E; Muus, P; Willemze, R | 1 |
| Pinto, A; Zagonel, V | 1 |
| Attadia, V | 1 |
| Honders, MW; Kester, MG; Landegent, JE; Stegmann, AP; Willemze, R | 1 |
| Bishop, PL; Cooper, GE; Turker, MS | 1 |
| Chernoff, N; Elstein, KH; Lau, C; Rogers, JM; Shuey, DL; Zucker, RM | 1 |
| Côté, S; Momparler, RL | 2 |
| He, ZX; Rao, H | 1 |
| Catapano, CV; Colombo, T; Conter, V; Damia, G; Gervasoni, M; Giudici, G; Limonta, M; Liso, V; Masera, G; Specchia, G | 1 |
| Narayan, G; Raman, R | 1 |
| Goyanes, V; Malheiro, I; Mello-Sampayo, T; Porto, B | 1 |
| Berger, MS; Cavenee, WK; Costello, JF; Huang, HS | 1 |
| Hoffman, AR; Hu, JF; Vu, TH | 1 |
| Boon, T; Brasseur, F; De Backer, O; De Smet, C; Faraoni, I; Lurquin, C | 1 |
| Itoh, K; Iwamoto, O; Nagai, K; Sagawa, K; Sakata, M; Shichijo, S; Yamada, A | 1 |
| Carrel, S; Cerottini, JC; Rimoldi, D; Schreyer, M; Spagnoli, G | 1 |
| Akiyoshi, T; Baba, K; Barnard, GF; Haraguchi, M; Inoue, H; Mimori, K; Mori, M; Nakashima, H; Shibuta, K; Tsuji, K; Ueo, H | 1 |
| Branch, S; Brownie, CF; Chernoff, N; Francis, BM | 1 |
| Chung, WY; Feng, L; Hensle, T; Tycko, B; Yuan, L | 1 |
| Chiang, Y; Davis, RG; Vishwanatha, JK | 1 |
| Abril, E; García, A; Garrido, F; Ruiz-Cabello, F; Serrano, A | 1 |
| Bird, AP | 1 |
| Barletta, JM; Feinberg, AP; Rainier, S | 1 |
| Huijgens, PC; Krulder, JW; Neve, P; Wijermans, PW | 2 |
| Côté, S; Eliopoulos, N; Momparler, RL | 2 |
| Baylin, SB; Belinsky, SA; Herman, JG; Middleton, SK; Nikula, KJ; Palmisano, WA; Swafford, DS; Tesfaigzi, J | 1 |
| Bach, C; Cramer, A; Scholtissek, C | 1 |
| Nyce, JW | 1 |
| Jackson-Grusby, L; Jaenisch, R; Laird, PW; Magge, SN; Moeller, BJ | 1 |
| Boon, T; De Plaen, E; De Smet, C; Naerhuyzen, B; Szikora, JP | 1 |
| Archimbaud, E; Berneman, Z; Dardenne, M; Dohner, H; Jaksic, B; Jehn, U; Labar, B; Louwagie, EA; Muus, P; Stryckmans, P; Suciu, S; Tjean, M; Wijermans, P; Willemze, R; Zittoun, R | 1 |
| Di Leone, L; Fernandes, MS; Gerhardt, LM; Kalakun, L; Loitzembauer, B; Moschen, M; Schaan, MD; Schwartsmann, G | 1 |
| Champlin, R; Davis, M; de Vos, D; Giralt, S; Kantarjian, H; O'Brien, S; van Besien, K | 1 |
| Beran, M; de Vos, D; Estey, E; Giralt, S; Kantarjian, HM; Keating, M; O'Brien, SM; Rios, MB; Talpaz, M | 1 |
| Gartler, SM; Hansen, RS; Hornstra, IK; Litt, MD; Yang, TP | 1 |
| Baylin, SB; Bova, GS; Cairns, P; Ewing, CM; Herman, JG; Isaacs, WB; Jarrard, DF; Nguyen, SH; Pin, SS; Sidransky, D | 1 |
| Ayoub, J; Belanger, K; Bouffard, DY; Dionne, J; Momparler, LF; Momparler, RL | 1 |
| Ehrlich, M; Frady, A; Hernandez, R; Varela, M; Zhang, XY | 1 |
| Akiyoshi, T; Fujie, T; Mori, M; Sugimachi, K; Ueo, H | 1 |
| Fearon, ER; Ji, X; Rimm, DL; Woodard, AS | 1 |
| Chen, PW; Ksander, BR; Murray, TG; Reddy, R; Salgaller, ML; Uno, T | 1 |
| Chen, ZJ; Pikaard, CS | 1 |
| Beran, M; de Vos, D; Estey, E; Giralt, S; Kantarjian, HM; Keating, M; Kornblau, S; O'Brien, SM; Rios, MB; Talpaz, M | 1 |
| Ehrlich, M; Frady, A; Hernandez, R; Ji, W; Qu, GZ; Varela, M; Zhang, XY | 1 |
| Culp, LA; Kogerman, P; Sy, MS | 1 |
| Baylin, SB; Davidson, NE; Ferguson, AT; Muller, MT; Spitzner, JR; Vertino, PM | 1 |
| Bender, CM; Jones, PA; Pao, MM | 1 |
| Boon, T; Brasseur, F; Brasseur, R; De Plaen, E; De Smet, C; Lurquin, C; Martelange, V; Monaco, AP; Muscatelli, F | 1 |
| Christiansen-Weber, T; Haas, M; Haggblom, C; Vogt, M; Yeargin, J | 1 |
| Chomienne, C; Doré, BT; Momparler, RL | 1 |
| Branch, S; Brownie, CF; Chernoff, N; Francis, BM; Held, GA; Rosen, MB | 1 |
| Jhaveri, MS; Morrow, CS | 1 |
| Jin, L; Kulig, E; Lloyd, RV; Qian, X | 2 |
| Green, ED; Harada, T; Kohno, K; Kusaba, H; Kuwano, M; Nakayama, M; Scherer, SW; Torigoe, K; Wada, M | 1 |
| Elder, PA; Habuchi, T; Knowles, MA; Luscombe, M | 1 |
| Issa, JP; Lengauer, C | 1 |
| Brachet, P; Canova, C; Chevalier, G; Remy, S; Wion, D | 1 |
| Duley, JA; Fabianowska-Majewska, K; Ruckemann, K; Simmonds, HA | 1 |
| Fabianowska-Majewska, K; Wyczechowska, D | 1 |
| Brown, CJ; Tinker, AV | 1 |
| Ammanamanchi, S; Brattain, MG; Kim, SJ; Sun, LZ | 1 |
| Harada, H; Hatooka, S; Imamura, M; Ishizaki, K; Shimada, Y; Shinoda, M; Tanaka, H | 1 |
| Davidson, NE; Ferguson, AT; Lapidus, RG | 1 |
| Cournoyer, D; Eliopoulos, N; Momparler, RL | 1 |
| Chi, SG; deVere White, RW; Gumerlock, PH; Muenzer, JT | 1 |
| deSilva, M; El-Osta, A; Hu, XF; Kantharidis, P; Nadalin, G; Parkin, JD; Slater, A; Wall, DM; Zalcberg, JR | 1 |
| Prasanna, P; Samid, D; Shack, S; Wilson, VL | 1 |
| Akiyoshi, T; Baba, K; Fujie, T; Li, J; Mori, M; Ueo, H; Yang, Y | 1 |
| Hibino, Y; Hirose, N; Morita, Y; Ohzeki, H; Sugano, N | 1 |
| Côté, S; Momparler, RL; Sinnett, D | 1 |
| Adachi, J; Hanada, R; Hayashi, Y; Nakajima, T; Ogawa, Y; Takita, J; Tanaka, T; Yamaguchi, N; Yamamoto, K; Yokota, J | 1 |
| Bachman, KE; Baylin, SB; Cameron, EE; Herman, JG; Myöhänen, S | 1 |
| Altomonte, M; Cattarossi, I; Cattelan, A; Coral, S; Gasparollo, A; Maio, M; Sigalotti, L; Visintin, A | 1 |
| Nishita, Y; Sado, T; Takagi, N; Yoshida, I | 1 |
| Concha, A; Garrido, F; Hortas, ML; Morell, M; Redondo, M; Ruiz-Cabello, F; Serrano, A | 1 |
| Akimenko, MA; Ekker, M; Laforest, L; Martin, CC | 1 |
| Bachman, KE; Baylin, SB; Cavenee, WK; Corn, PG; Costello, JF; Graff, JR; Herman, JG; Merlo, A | 1 |
| Hinds, PW; Münger, K; Timmermann, S | 1 |
| Crist, KA; Kelloff, GJ; Lantry, LE; Lubet, RA; Wang, Y; You, M; Zhang, Z | 1 |
| Nakamura, N; Takenaga, K | 1 |
| Fu, Y; Guan, RJ; Holt, PR; Pardee, AB | 1 |
| Chae, HS; Chen, A; Deng, G; Hong, J; Kim, YS | 1 |
| Coffee, B; Reines, D; Warren, ST; Zhang, F | 1 |
| Armenante, F; Furia, A; Merola, M; Palmieri, M | 1 |
| Baylin, SB; Herman, JG; Katzenellenbogen, RA | 1 |
| Beauséjour, C; Eliopoulos, N; Momparler, RL | 1 |
| Arden, KC; Boon, T; Boretti, M; Brasseur, F; Chomez, P; Czekay, S; De Backer, O; De Plaen, E; De Smet, C; Van den Eynde, B; van der Bruggen, P; Vantomme, V; Viars, CS | 1 |
| Harada, T; Kohno, K; Kusaba, H; Kuwano, M; Nakayama, M; Nomoto, M; Wada, M | 1 |
| Bovenzi, V; Côte, S; Lê, NL; Momparler, LF; Momparler, RL; Sinnett, D | 1 |
| Bender, CM; Gonzales, FA; Gonzalgo, ML; Jones, PA; Nguyen, CT; Robertson, KD | 1 |
| Branch, S; Brownie, C; Chernoff, N; Francis, BM | 1 |
| Boon, T; De Smet, C; Lethé, B; Lurquin, C; Martelange, V | 1 |
| Bakker, CE; Chiurazzi, P; Neri, G; Oostra, BA; Pietrobono, R; Pomponi, MG | 1 |
| Albertsen, H; Dalley, BK; Jones, DA; Karpf, AR; Peterson, PW; Rawlins, JT; Yang, Q | 1 |
| Beran, M; Cortes, J; Giles, FJ; Kantarjian, HM; Keating, MJ; Koller, CA; O'Brien, S; Rios, MB; Sacchi, S; Talpaz, M | 1 |
| Fenaux, P; Quesnel, B | 1 |
| Bertram, JS; Donlon, TA; Fukushima, LH; Hieber, AD; King, TJ; Shimabukuro, KA | 1 |
| Kim, HS; Lee, JY; Park, J; Park, JB; Shin, JY | 1 |
| Andre, M; Bosly, A; Ferrant, A; Lübbert, M; Ravoet, C; Verhoef, G; Wijermans, P | 1 |
| Jones, PA; Laird, PW; Liang, G; Pao, MM; Tsai, YC; Xiong, Z | 1 |
| Cho, M; Grabmaier, K; Hiasa, Y; Hirao, Y; Kitahori, Y; Nakagawa, Y; Ohnishi, T; Ooesterwijk, E; Uemura, H; Yoshikawa, K | 1 |
| Lu, Y; Steiner, MS; Wang, Y; Zhang, X; Zhang, Y | 1 |
| Ferguson, AT; Orlandi, R; Sacchi, N; Sirchia, SM; Sironi, E; Subramanyan, S; Sukumar, S | 1 |
| Bovenzi, V; Momparler, RL | 3 |
| Adema, GJ; de Bruijn, DR; de Vries, TJ; dos Santos, NR; Kater-Baats, E; Ruiter, DJ; Schreurs, MW; Torensma, R; van Kessel, AG; van Muijen, GN | 1 |
| Boss, JM; Morris, AC; Spangler, WE | 1 |
| Lübbert, M | 1 |
| Ayoub, J; Eliopoulos, N; Momparler, RL | 1 |
| Chan, TA; Evron, E; Ferguson, AT; Futreal, PA; Hermeking, H; Lambers, AR; Marks, JR; Pandita, TK; Stampfer, MR; Sukumar, S; Umbricht, CB | 1 |
| Janeczko, M; Lee, WH; Nanus, DM; Nelson, JB; Nelson, WG; Papandreou, CN; Shen, R; Usmani, BA | 1 |
| Byun, DS; Chi, SG; Kang, MJ; Kim, HJ; Park, BJ; Park, JH; Park, JI | 1 |
| DiLeone, L; Filho, AF; Garbino, C; Gorini, CN; Mans, DR; Muse, I; Sabini, G; Schunemann, H; Schwartsmann, G | 1 |
| Bender, CM; Gonzales, FA; Jones, PA; Liang, G; Markl, ID; Salem, CE | 1 |
| Bang, YJ; Choi, HH; Jong, HS; Kang, SH; Kim, NK; Kim, WH; Ryu, MH; Song, SH | 1 |
| Bearzatto, A; Jiricny, J; Karran, P; Macpherson, P; Szadkowski, M | 1 |
| Chen, B; He, L; Jenkins, JJ; Parham, DM; Savell, VH | 1 |
| Chang, SG; Chi, SG; Kim, JI; Lee, CH; Lee, SJ; Park, BJ; Park, JH | 1 |
| Au, WC; Hageman, N; Lu, R; Pitha, PM; Yeow, WS | 1 |
| Benchaïb, M; Billard, LM; Dante, R; Frappart, L; Guérin, JF; Lenoir, GM; Magdinier, F; Wittmann, G | 1 |
| Anna, CH; Barrett, JC; Devereux, TR; Foley, JF; Patel, AC; Stockton, PS; Tyson, FL | 1 |
| Imai, K; Itoh, F; Kakiuchi, H; Kikuchi, T; Suzuki, H; Toyota, M | 1 |
| Bulut, HE; Colak, A; Korkmaz, M; Onarlioglu, B; Ozdemir, O | 1 |
| Emi, M; Kirita, T; Konishi, N; Nagai, H; Nishimine, M; Sugimura, M; Yamamoto, K | 1 |
| Bressler, L; DeSimone, J; Dorn, L; Hoffman, R; Koshy, M; Lavelle, D; Molokie, R; Talischy, N; van Overveld, W | 1 |
| Baltimore, D; Biniszkiewicz, D; Cherry, SR; Jaenisch, R; van Parijs, L | 1 |
| Chen, C; Yang, MC; Yang, TP | 1 |
| Odum, N; Raghunath, PN; Vonderheid, E; Wasik, MA; Zhang, Q | 1 |
| Brodeur, GM; Eggert, A; Grotzer, MA; Ikegaki, N; Janss, AJ; Marwaha, S; Phillips, PC; Wiewrodt, BR; Zuzak, TJ | 1 |
| Ando, T; Nishimura, M; Oka, Y | 1 |
| Dahiya, R; Dharia, A; Fujimoto, S; Oh, BR; Sasaki, M | 1 |
| Brown, R; Kaye, SB; Plumb, JA; Sludden, J; Strathdee, G | 1 |
| Sasaki, MS; Yang, L | 1 |
| Baek, WK; Carson, DA; Cho, JW; Kwon, T; Park, JB; Park, JW; Pyun, HY; Suh, MH; Suh, SI | 1 |
| Hirokawa, Y; Ito, H; Mizokami, A; Nakayama, T; Sekita, N; Shiraishi, T; Suzuki, H; Toyota, M; Watanabe, M; Yatani, R | 1 |
| Kakudo, K; Mori, I; Nakamura, M; Nakamura, Y; Sakurai, T; Shan, L; Suzuma, T; Tamaki, T; Umemura, T; Utsunomiya, H; Yang, Q; Yoshimura, G | 1 |
| Calzascia, T; Chalmers, D; Dietrich, PY; Saas, P; Schnuriger, V; Walker, PR | 1 |
| Hayashi, Y; Honma, Y; Niitsu, N; Sugita, K | 1 |
| Chen, GA; Fischette, MR; Guo, ZS; Hong, JA; Nguyen, DM; Ohnmacht, GA; Schrump, DS; Weiser, TS | 1 |
| Fukunishi, Y; Hayashizaki, Y; Held, WA; Itoh, M; Kawai, J; Komatsu, S; Muramatsu, M; Okazaki, Y; Shibata, K; Tateno, M | 1 |
| Atweh, GF; Schechter, AN | 1 |
| Francke, U; Fulmer-Smentek, SB | 1 |
| Brodeur, GM; Eggert, A; Grotzer, MA; Ho, R; Ikegaki, N; Wiewrodt, BR; Zuzak, TJ | 1 |
| Beal, MD; Lakshmanan, RR; Otterson, GA; Zhu, WG | 1 |
| Altomonte, M; Cattarossi, I; Ciullo, M; Coral, S; Gasparollo, A; Guardiola, J; Maio, M; Prisco, A; Sigalotti, L | 1 |
| Noma, H; Shibahara, T; Tanzawa, H; Uzawa, K; Yakushiji, T; Yamamoto, N | 1 |
| Jones, DA; Karpf, AR; Moore, BC; Ririe, TO | 1 |
| Ding, BC; Heng, H; Hukku, B; Matherly, LH; Witt, TL; Zhang, L | 1 |
| Kajiwara, T; Kawabe, K; Kitamura, T; Moriyama, N; Narita, Y; Nishimatsu, H; Takeuchi, T; Ueki, K; Ueki, T | 1 |
| Clare, SE; Clark, G; Elkahloun, AG; Hartsough, MT; Mair, M; Osborne, CK; Sgroi, D; Steeg, PS | 1 |
| Ashfaq, R; Fong, KM; Gazdar, AF; Geradts, J; Lam, S; Maitra, A; Milchgrub, S; Minna, JD; Virmani, AK; Zöchbauer-Müller, S | 1 |
| Avula, R; Bible, KC; Hartmann, LC; Huang, H; Kalli, K; Kaufmann, SH; Lee, YK; Shridhar, V; Smith, DI; Staub, J | 1 |
| Bumke-Vogt, C; Foss, HD; Gratchev, A; Hanski, C; Hanski, ML; Hummel, M; Kobalz, U; Lammert, H; Mann, B; Mansmann, U; Riecken, EO; Siedow, A; Stein, H | 1 |
| Bang, YJ; Choi, HH; Inoue, H; Jong, HS; Kim, NK; Song, SH; Tanabe, T | 1 |
| Bashambu, M; Singal, R; van Wert, J | 1 |
| Bergman, W; Frants, RR; Gruis, NA; Hurks, H; Jager, MJ; Metzelaar-Blok, JA; Monique, H; van der Velden, PA | 1 |
| Cho, JH; Hattori, N; Kimura, H; Minami, T; Ohgane, J; Shiota, K; Tanaka, S | 1 |
| Fukamachi, H; Higo, T; Kai, M; Kaito, C; Sekimizu, K; Shiokawa, K; Takayama, E | 1 |
| Dahiya, R; Huang, MC; Lee, C; Yeh, CC | 1 |
| Ammanamanchi, S; Brattain, MG; Freeman, JW; Mimari, D; Venkatasubbarao, K | 1 |
| Dzhandzhugazyan, KN; Guldberg, P; Kirkin, AF; Worm, J | 1 |
| Ito, R; Kuniyasu, H; Kuraoka, K; Oue, N; Shigeishi, H; Yasui, W; Yokozaki, H | 1 |
| Ahlborn, TE; Gupta, A; Li, C; Liu, J; Lu, A; Ma, Y; Shi, EY | 1 |
| Andre, M; Bosly, A; Ferrant, A; Kunzmann, R; Lübbert, M; Ravoet, C; Verhoef, G; Wijermans, P | 1 |
| Johnson, K; Kaplan, M; Mo, RR; Ray, D; Richardson, B; Schneider, K; Yung, R | 1 |
| Anderlini, P; Andersson, B; Champlin, R; Claxton, D; Cohen, A; Davis, M; deVos, D; Donato, M; Gajewski, J; Giralt, S; Kantarjian, H; Khouri, I; Korbling, M; O'Brien, S; Ravandi, F; Ueno, N | 1 |
| Broome, JD; Goodwin, LO; Issa, JP; Koduru, P; Peng, H; Qian, L; Shen, N; Sun, XL | 1 |
| Dahiya, R; Patra, A; Patra, SK | 1 |
| Dahiya, R; Franks, J; Ishii, N; Li, LC; Nakajima, K; Nojima, D; Ribeiro-Filho, L | 1 |
| Fischer, J; Florl, AR; Maas, S; Müller, W; Pulte, T; Santourlidis, S; Schulz, WA; Warskulat, U | 1 |
| Akakura, K; Ichikawa, T; Igarashi, T; Ito, H; Kito, H; Nakayama, T; Sekita, N; Shiraishi, T; Suzuki, H; Toyota, M; Watanabe, M; Yoshie, O | 1 |
| Liao, J; Nie, Y; So, C; Song, Y; Wang, LD; Yang, CS; Yang, G; Zhao, X | 1 |
| Cheung, AL; Lam, KY; Liu, Y; Shen, ZY; Si, HX; Srivastava, G; Tsao, SW; Wong, YC | 1 |
| Davidson, NE; Ferguson, AT; Herman, JG; Nelson, WG; Phillips, DL; Yang, X | 1 |
| Miki, K; Shimizu, E; Sone, S; Tani, K; Yano, S | 1 |
| Beauséjour, CM; Eliopoulos, N; Le, NL; Momparler, L; Momparler, RL | 1 |
| Debatin, KM; Dockhorn-Dworniczak, B; Fulda, S; Küfer, MU; Meyer, E; van Valen, F | 1 |
| Dahiya, R; Dharia, A; Li, LC; Nojima, D; Perinchery, G; Ribeiro-Filho, L; Yen, TS | 1 |
| Garrido, F; Lionello, I; Mendez, R; Ruiz-Cabello, F; Serrano, A; Tanzarella, S; Traversari, C | 1 |
| Ganser, A; Verbeek, W | 1 |
| Ashida, T; Fujiki, T; Fujiya, M; Honda, M; Kohgo, Y; Saitoh, Y; Tanabe, H; Watari, J | 1 |
| Fujita, N; Nakao, M; Okumura, K; Sado, T; Taguchi, H; Takebayashi, S; Tanaka, M | 1 |
| Feng, G; Lotan, R; Xu, X; Youssef, EM | 1 |
| Band, V; Dhar, S; Dimri, G; Evron, E; Goyal, J; Li, B; Sukumar, S; Wazer, DE | 1 |
| Silverman, LR | 2 |
| Chen, A; Deng, G; Kim, YS; Pong, E | 1 |
| Filmus, J; Ladeda, V; Xiang, YY | 1 |
| Entian, KD; Klan, N; Rose, M; Steinhilber, D; Uhl, J; Werz, O | 1 |
| Carling, T; Du, Y; Fang, W; Huang, S; Piao, Z; Sheu, JC | 1 |
| Stimson, KM; Vertino, PM | 1 |
| Ayoub, J; Momparler, RL | 1 |
| Davies, B; Jardine, K; Lau, S; McBurney, MW; Yang, X | 1 |
| Crichton, DN; Hupp, TR; Kernohan, N; McDowell, HE; Nicoll, G; Thompson, AM | 1 |
| Dai, Z; Ding, H; Duan, W; Hall, J; Otterson, GA; Plass, C; Srinivasan, K; Villalona-Calero, MA; Zhu, WG | 1 |
| Chan, MF; Gonzales, FA; Jones, PA; Laird, PW; Li, E; Liang, G; Tomigahara, Y; Tsai, YC | 1 |
| Matsuo, T; Tomonaga, M | 1 |
| den Hollander, AI; Ruiter, DJ; van Kraats, AA; van Muijen, GN; Weidle, UH; Zendman, AJ | 1 |
| Fujita, M; Hosokawa, M; Imai, K; Itoh, F; Kikuchi, T; Suzuki, H; Toyota, M; Yamamoto, H | 1 |
| Czyz, M; Fabianowska-Majewska, K; Wyczechowska, D | 2 |
| Araki, D; Miyakawa, A; Shiiba, M; Tanzawa, H; Uzawa, K; Watanabe, T; Yokoe, H | 1 |
| Giles, FJ | 2 |
| Fujikawa, T; Hanafusa, T; Higashi, T; Nakamura, S; Nakatsukasa, H; Nouso, K; Onishi, T; Takuma, Y; Taniyama, M; Tsuji, T; Uemura, M; Yumoto, E; Yumoto, Y | 1 |
| Cunha, KS; de Andrade, HH; Graf, U; Reguly, ML | 1 |
| Liu, LH; Liu, WW; Xiao, WH | 1 |
| Davis, CD; Uthus, EO | 1 |
| Corsaro, M; Di Croce, L; Fanelli, M; Faretta, M; Fazi, F; Fuks, F; Kouzarides, T; Lo Coco, F; Minucci, S; Nervi, C; Pelicci, PG; Raker, VA | 1 |
| Gonzales, FA; Jones, PA; Liang, G; Orntoft, TF; Thykjaer, T | 1 |
| Hyman, R | 1 |
| Bianco, T; Dobrovic, A; Tan, LW | 1 |
| Ono, K; Suzuki, H; Tanaka, C; Tanzawa, H; Uzawa, K; Yakushiji, T; Yamamoto, N; Yokoe, H | 1 |
| Carbone, A; Mittnacht, S; Platt, G | 1 |
| Hofmann, WK; Koeffler, HP | 1 |
| Johnson, PJ; Liu, C; Lo, YM; Tang, MW; Yeo, W; Zhong, S | 1 |
| Chernoff, N; Rosen, MB | 1 |
| Gonzales, FA; Jones, PA; Nguyen, CT; Tsai, YC; Velicescu, M; Weisenberger, DJ | 1 |
| Issa, JP; Kemp, BL; Khuri, FR; Kurie, JM; Lee, HY; Lee, JI; Liu, DD; Mao, L; Soria, JC; Wang, L | 1 |
| Bressler, L; DeSimone, J; Dorn, L; Koshy, M; Lavelle, D; Molokie, R; Talischy, N | 1 |
| Lee, SW; Park, JH | 1 |
| Danbara, M; Higashihara, M; Kameyama, K; Takagaki, Y | 1 |
| Beauséjour, CM; Gagnon, J; Momparler, RL; Primeau, M | 1 |
| Bharadwaj, S; Prasad, GL | 1 |
| Manev, H; Uz, T | 1 |
| Comai, L; Davison, J; Madlung, A; Masuelli, RW; Reynolds, SH; Watson, B | 1 |
| Bernardino-Sgherri, J; Dutrillaux, B; Flagiello, D | 1 |
| Dallol, A; Forgacs, E; Kishida, T; Latif, F; Maher, ER; Martinez, A; Minna, JD; Rabbitts, P; Sekido, Y; Walker, R | 1 |
| Bocchetta, M; Carbone, M; Gazdar, AF; Minna, JD; Shivapurkar, N; Toyooka, KO; Toyooka, S | 1 |
| Bae, SI; Kim, SH; Kim, WH; Lee, HS | 1 |
| Aird, RE; Chen, H; Cummings, J; Jodrell, DI; Morris, RE; Muir, M; Ritchie, AA; Sadler, PJ | 1 |
| Aparicio, A; Weber, JS | 1 |
| Fukuyama, Y; Gazdar, AF; Minna, JD; Tockman, MS; Toyooka, S; Wistuba, II | 1 |
| Kaminishi, M; Kaneda, A; Nakanishi, Y; Sugimura, T; Ushijima, T | 1 |
| Avner, P; Danoy, P; Matsuda, F; Moore, GE; Rogner, UC; Stanier, P | 1 |
| Bert, T; Gangsauge, S; Lubomierski, N; Münch, K; Prasnikar, N; Printz, H; Robbel, C; Simon, B | 1 |
| Ha, CS; Rankin, EB; Suh, ER; Toyota, M; Traber, PG | 1 |
| Fang, D; Setaluri, V; Tsuji, Y | 1 |
| Chiurazzi, P; Neri, G; Oostra, B; Pietrobono, R; Pomponi, MG; Tabolacci, E | 1 |
| Bayatti, N; Behl, C; Goodenough, S; Manthey, D; van der Burg, B; Zschocke, J | 1 |
| Difilippantonio, MJ; Guo, L; Hu-Li, J; Pannetier, C; Paul, WE; Watson, CJ; Zhu, J | 1 |
| Jones, DA; Karpf, AR | 1 |
| Altomonte, M; Cattarossi, I; Colizzi, F; Coral, S; Engelsberg, A; Jager, E; Maio, M; Maraskovsky, E; Seliger, B; Sigalotti, L | 1 |
| Hashimoto, H; Hishikawa, T; Kaneko, H; Kaneko, Y; Maruyama, N; Ogasawara, H; Okada, M; Sekigawa, I; Yamamoto, N | 1 |
| Bartram, CR; Imamura, M; Imoto, I; Inazawa, J; Inoue, J; Janssen, JW; Shimada, Y; Ueda, M | 1 |
| Ceman, S; Coffee, B; Reines, D; Warren, ST; Zhang, F | 1 |
| Carpenter, MK; Police, S; Rao, N; Xu, C | 1 |
| Daskalakis, M; Guldberg, P; Jones, PA; Köhler, G; Lübbert, M; Nguyen, C; Nguyen, TT; Wijermans, P | 1 |
| Brank, AS; Christman, JK; Eritja, R; Garcia, RG; Marquez, VE | 1 |
| Eisermann, B; Meyer, KL; Santourlidis, S; Trompeter, HI; Uhrberg, M; Weinhold, S; Wernet, P | 1 |
| Chaudhary, PM; Gazdar, AF; Harada, K; Hay, RJ; Maitra, A; Mastrangelo, D; Matta, H; Miyajima, K; Reddy, JL; Shivapurkar, N; Timmons, CF; Tomlinson, GE; Toyooka, S | 1 |
| Caldas, AP; Campos, O; Cancella, AI; Dal Lago, L; DiLeone, LP; Monego, E; Pohlmann, P; Rivoire, W; Schwartsmann, G | 1 |
| Boivin, AJ; Hurtubise, A; Momparler, LF; Momparler, RL | 1 |
| Chen, H; Du, HL; Qi, Y; Ren, LM; Zhu, Y | 1 |
| Collins, N; Dellaire, G; García-Jiménez, C; Kukimoto, I; Poot, RA; Varga-Weisz, PD | 1 |
| Gonzales, FA; Jones, PA; Liang, G; Lin, JC; Nguyen, CT; Velicescu, M; Weisenberger, DJ | 1 |
| Chen, Z; Cheng, X; Wu, Y; Zhu, B | 1 |
| Gagnon, J; Momparler, RL; Primeau, M | 1 |
| Issa, JP; Kondo, Y; Shen, L | 1 |
| Chen, H; Du, H; Ren, L; Shi, Y; Wu, S; Zhu, Q | 1 |
| Bosl, GJ; Chaganti, RS; Donadio, A; Houldsworth, J; Koul, S; Mansukhani, MM; McKiernan, JM; Murty, VV; Reuter, VE | 1 |
| Hoque, MO; Meltzer, SJ; Mori, M; Osada, M; Sato, F; Sidransky, D; Upadhyay, S; Xiao, Y; Yamashita, K | 1 |
| Baylin, SB; Eguchi, S; Fahrner, JA; Herman, JG | 1 |
| Chang, JG; Lin, PM; Lin, SF; Liu, TC; Yang, MY | 1 |
| Benhattar, J; Braunschweig, R; Coindre, JM; Guilleret, I; Guillou, L; Yan, P | 1 |
| Beck, MN; Bourloud, KB; Gross, N; Mühlethaler, A; Yan, P | 1 |
| Bu, DF; Du, HL; Qi, Y; Shi, YJ; Wu, SL | 1 |
| Chen, H; Shi, YJ; Wang, JZ; Wu, SL; Xu, GB; Zhu, Q | 1 |
| Deng, G; Han, SW; Ho, JJ; Kim, YS; Kuan, SF; Pan, PL | 1 |
| Bertoni, F; Cotter, FE; Fu, WN; Jia, L; Kelsey, SM; McElwaine, SM; Newland, AC | 1 |
| Carosella, ED; Dausset, J; Marcou, C; Moreau, P; Mouillot, G; Rousseau, P | 1 |
| El-Osta, A | 1 |
| Godwin, AK; Gupta, A; Liu, J; Lu, A; Vanderveer, L | 1 |
| Cao, Y; Fuxe, J; Hultdin, M; Pettersson, RF; Roos, G; Veitonmäki, N | 1 |
| Goggins, M; Maehara, N; Sato, N; Su, GH | 1 |
| Andersson, B; Champlin, R; Couriel, D; de Lima, M; Donato, M; Gajewski, J; Giralt, S; Kantarjian, H; Khouri, I; Ravandi, F; Shahjahan, M; van Besien, K | 1 |
| Avila, S; Esteller, M; Fraga, MF; Guo, M; Herman, JG; Paz, MF; Pollan, M | 1 |
| Bernstein, M; Momparler, LF; Momparler, RL; Shaker, S | 1 |
| Barge, RM; Honders, MW; Spoelder, HE; Veuger, MJ; Willemze, R | 1 |
| Chan, A; Chang, HW; Kwong, DL; Sham, JS; Wei, WI; Yuen, AP | 1 |
| Gagnon, J; Hurtubise, A; Momparler, RL; Primeau, M; Shaker, S | 1 |
| Chang, JW; Chen, CY; Chen, JT; Lin, RK; Lu, YP; Shih, CM; Tseng, RC; Wang, YC | 1 |
| Durkin, ME; Popescu, NC; Yuan, BZ | 1 |
| Flaswinkel, H; Hoeflich, A; Shi, W; Stojkovic, M; Wolf, E; Zakhartchenko, V | 1 |
| Aparicio, A; Baker, SD; Eads, CA; Laird, PW; Leong, LA; Newman, EM; Synold, TW; Weber, JS; Zhao, M | 1 |
| Demers, M; Magnaldo, T; Mercier, J; Moisan, S; Potworowski, EF; St-Pierre, Y | 1 |
| Brune, K; Fukushima, N; Goggins, M; Hruban, RH; Matsubayashi, H; Sahin, F; Sato, N; Walter, KM; Yeo, CJ | 1 |
| Anderson, LM; Branch, S; Cisneros, FJ; Travlos, G; Wilson, R | 1 |
| Berczi, L; Brent, TP; Danam, RP; Houghton, JA; Howell, SR; Kopper, L; Petak, I; Tillman, DM; Vernes, R | 1 |
| Kim, K; Murnane, MJ; Sengupta, PK; Smith, BD; Smith, EM | 1 |
| Boon, T; De Smet, C; Loriot, A | 1 |
| Altomonte, M; Colizzi, F; Coral, S; Fonsatti, E; Maio, M; Sigalotti, L | 1 |
| Aozasa, K; Hoshida, Y; Nakatsuka, S; Nishii, K; Nishiu, M; Takakuwa, T; Tomita, Y; Yamaguchi, M; Yang, WI | 1 |
| Kumar, PP; Kush, A; Lakshmanan, P; Prakash, AP | 1 |
| Acuña, C; Chavez, A; Dueñas-Gonzalez, A; Lizano, M; Mariscal, I; Perez-Cardenas, E; Salazar, AM; Segura-Pacheco, B; Taja-Chayeb, L; Trejo-Becerril, C | 1 |
| Enright, BP; Kubota, C; Tian, XC; Yang, X | 1 |
| Chen, CL; Ip, SM; Liu, SS; Ng, TY; Ngan, HY; Wong, LC | 1 |
| Altomonte, M; Colizzi, F; Degan, M; Gattei, V; Maio, M; Pinto, A; Rupolo, M; Sigalotti, L; Zagonel, V | 1 |
| Dahiya, R; Deguchi, M; Igawa, M; Kaneuchi, M; Nakajima, K; Shiina, H | 1 |
| Chen, HK; Feng, QS; Li, A; Liu, XQ; Long, QX; Pan, ZG; Wang, XZ; Zeng, YX; Zhang, XS | 1 |
| Arnold, CN; Boland, CR; Goel, A | 1 |
| Burman, R; Ponomoreva, ON; Simpson, J; Thayer, MJ; Turker, MS; Yates, PA | 1 |
| Bang, YJ; Dimtchev, A; Jeong, SJ; Jong, HS; Jung, M; Kim, NK; Kim, TY; Lee, JW; Song, SH | 1 |
| Borczuk, AC; Brody, JS; Busch, S; Capurro, M; D'Armiento, JM; Filmus, J; Kim, H; Lange, J; Powell, CA; Rothman, PB; Xu, GL | 1 |
| Draghici, S; Kraniak, JM; Kulaeva, OI; Land, SJ; Tainsky, MA; Tang, L | 1 |
| Hirokawa, Y; Matsuzaki, T; Shiraishi, T; Sugimura, Y; Suzuki, H; Takagi, A; Watanabe, M; Yamada, Y; Yamanaka, M; Yatani, R | 1 |
| Aurelian, L; Gober, MD; Smith, CC; Toretsky, JA; Ueda, K | 1 |
| Frants, RR; Gruis, NA; Hurks, MHMH; Jager, MJ; Krijgsman, E; Ksander, BR; Pavey, S; Tensen, CP; van der Velden, PA; Willemze, R; Zuidervaart, W | 1 |
| Bang, YJ; Cho, B; Hwang, KS; Jeong, S; Jeoung, DI; Kang, GH; Kim, HY; Lee, H; Lee, HJ; Lee, YS | 1 |
| Bukawa, H; Miyakawa, A; Mochida, Y; Nakatsuru, M; Ono, K; Shiiba, M; Tada, A; Tanzawa, H; Uzawa, K; Yokoe, H | 1 |
| Brambilla, E; Gazdar, AF; Minna, JD; Padar, A; Sathyanarayana, UG; Takahashi, T; Toyooka, S | 1 |
| Chen, K; Shih, JC; Wong, WK | 1 |
| Chen, YH; DeSimone, J; Hankewych, M; Kousnetzova, T; Lavelle, D | 1 |
| Andreeff, M; Bast, RC; Fujii, S; Hu, W; Issa, JP; Kadota, M; Luo, RZ; Oshimura, M; Pan, Y; Sahin, AA; Wang, L; Yu, Y; Yuan, J | 1 |
| Andreeff, M; Cortes, J; Faderl, S; Garcia-Manero, G; Giles, FJ; Issa, JP; Kantarjian, HM; Keating, M; O'Brien, S; Rios, MB; Shan, J; Talpaz, M | 1 |
| Loh, HH; Wang, G; Wei, LN | 1 |
| Steinberg, MH | 1 |
| Bressler, L; Chen, YH; DeSimone, J; Dorn, L; Gavazova, S; Hillery, CA; Hoffman, R; Lavelle, D; Molokie, R; Saunthararajah, Y | 1 |
| Baylin, SB; Belinsky, SA; Crume, KP; Esteller, M; Grimes, MJ; Joste, N; Palmisano, WA; Toyota, M; Winters, SA | 1 |
| Austin, S; Cho, E; Fan, T; Ferris, D; Huang, J; Muegge, K; Yan, Q | 1 |
| Gazdar, AF; Lam, S; Miyajima, K; Padar, A; Reddy, JL; Sathyanarayana, UG; Shivapurkar, N; Tockman, MS; Toyooka, KO; Toyooka, S; Toyota, M | 1 |
| Gołab, J; Jakóbisiak, M; Kamiński, R; Kozar, K; Lasek, W; Machaj, E; Mackiewicz, A; Ołdak, T; Switaj, T; Wysocki, PJ | 1 |
| Corbin, AS; Deininger, MW; Druker, BJ; Johnson, K; La Rosée, P; Mauro, MM; Melo, JV; Moseson, EM; Stoffregen, EP; Willis, S | 1 |
| Fearon, ER; Hinoi, T; Loda, M | 1 |
| Benos, DJ; Bubien, JK; Fuller, CM; Gillespie, GY; Mapstone, TB; Markert, JM; Xia, J; Zhou, ZH | 1 |
| Biallek, M; Jonat, W; Klöppel, G; Lüttges, J; Maass, N; Morohoshi, T; Mundhenke, C; Nagasaki, K; Ohike, N; Zhang, M | 1 |
| Hoffman, AR; Hu, JF; Li, T; Ulaner, GA; Vu, TH; Yang, Y | 1 |
| Benhattar, J; Guilleret, I | 1 |
| Benoit, NE; Dong, SM; Kuzmin, I; Lerman, MI; Sidransky, D; Sun, DI | 1 |
| Heng, HH; Iwata, J; Liang, SB; Ohtsuki, Y; Sonobe, H; Takeuchi, T; Ye, CJ | 1 |
| Bell, SM; Carder, PJ; Hanby, AM; Horgan, K; Lane, S; Lansdown, MR; Markham, AF; Munot, K; Parkes, AT; Skliris, GP; Speirs, V | 1 |
| Imai, S; Kiss, C; Klein, G; Nishikawa, J; Okita, K; Szekely, L; Takada, K | 1 |
| Chan, AS; Chan, TL; Chen, X; Chu, KM; Leung, SY; Li, R; So, S; Tsui, WY; Yuen, ST | 1 |
| Chlenski, A; Cohn, SL; Liu, S; Salwen, HR; Tian, Y; Weinstein, J; Yang, QW | 1 |
| Berx, G; Cirnes, L; Correia da Rocha, AS; Debruyne, PR; Li, X; Mareel, MM; Pocard, M; Poupon, MF; van Roy, FM; Vermeulen, SJ | 1 |
| Leone, G; Lübbert, M; Teofili, L; Voso, MT | 1 |
| Ashhab, Y; Ben-Yehuda, D; Peretz, T; Shteper, PJ; Vlodavsky, I; Zcharia, E | 1 |
| Horiguchi, K; Ishiuchi, S; Kurihara, H; Mori, M; Saito, N; Tomizawa, Y; Tosaka, M | 1 |
| Bayar, E; Cortes, J; Faderl, S; Garcia-Manero, G; Giles, FJ; Issa, JP; Kantarjian, HM; Lyons, J; Mannari, R; Rosenfeld, CS; Thomas, D | 1 |
| Baylin, SB; Belinsky, SA; Herman, JG; Issa, JP; Klinge, DM; March, TH; Stidley, CA | 1 |
| Chayama, K; Ito, R; Kitadai, Y; Nakayama, H; Oshimo, Y; Yasui, W; Yoshida, K | 1 |
| Estecio, MR; Garcia-Manero, G; Issa, JP; Kantarjian, HM; Yang, AS | 1 |
| Davidson, NE; Keen, JC; Mack, KM; Pettit, C; Sharma, D; Smith, D; Yan, L | 1 |
| Blazková, J; Elleder, D; Hájková, P; Hejnar, J; Svoboda, J; Walter, J | 1 |
| Issa, JP | 6 |
| Fukuda, T; Ono, K; Sakai, M; Takano, H; Takio, S | 1 |
| Ching, YP; Jin, DY; Lee, JM; Ng, IO; Wong, CM | 1 |
| Dahiya, R; Igawa, M; Matsubara, A; Mita, K; Mutaguchi, K; Shiina, H; Usui, T; Yasumoto, H | 1 |
| Adams, RJ; Atweh, GF; DeSimone, J; Fabry, ME; Fathallah, H; Nagel, RL; Saunthararajah, Y; Weinberg, RS | 1 |
| Chan, AS; Chan, SY; Chow, LS; Huang, DP; Hui, AB; Kwong, J; Lam, EC; Lo, KW; Teo, PM | 1 |
| Garcia-Manero, G; Giles, FJ; Hennessy, BT; Kantarjian, HM | 1 |
| Baumann, H; Blanchard, F; Chattopadhyay, S; Held, WA; Smith, J; Tracy, E; Wang, Y | 1 |
| Bone, JR; Briggs, KL; Clayman, GL; Coombes, MM; Dent, SY; El-Naggar, AK | 1 |
| Albrecht, S; Berthold, F; Goodyer, CG; Koch, A; Meyer-Puttlitz, B; Pietsch, T; Sörensen, N; Tonn, JC; Waha, A; Weggen, S; Wiestler, OD | 1 |
| Kim, DH; Kwon, HJ; Shim, JS | 1 |
| Astner, H; Cecconi, D; Donadelli, M; Hamdan, M; Missiaglia, E; Palmieri, M; Righetti, PG; Scarpa, A | 1 |
| Bies, J; Garin, MT; Koller, R; Liao, W; Malumbres, M; Perella, C; Powell, D; Tessarollo, L; Wolff, L | 1 |
| Anderton, JA; Bailey, S; Clifford, SC; Ellison, DW; Gilbertson, RJ; Lindsey, JC; Lusher, ME; Pearson, AD | 1 |
| Honoki, K; Mii, Y; Mori, T; Takakura, Y; Tsujiuchi, T; Tsutsumi, M; Yoshitani, K | 1 |
| Erson, AE; Petty, EM | 1 |
| Akino, K; Imai, K; Issa, JP; Itoh, F; Kikuchi, T; Mita, H; Murai, M; Obata, T; Ogi, K; Sasaki, Y; Satoh, A; Suzuki, H; Tokino, T; Toyota, M | 1 |
| Chiba, T; Fukai, K; Hirasawa, Y; Imazeki, F; Kataoka, H; Saisho, H; Tada, M; Yokosuka, O | 1 |
| Dong, Q; Fang, XM; Peng, JP; Sun, LF; Zheng, S | 1 |
| Miyamoto, K; Ushijima, T | 1 |
| Dai, Z; Duan, W; Hileman, T; Ke, Y; Lu, S; Otterson, GA; Plass, C; Tong, T; Villalona-Calero, MA; Wang, P; Zhu, WG | 1 |
| Grossman, D; Hanks, AN; Jones, DA; Karpf, AR; Lasek, AW; Ririe, TO | 1 |
| Cvetkovic, I; Harhaji, Lj; Miljkovic, Dj; Popadic, D; Trajkovic, V; Vuckovic, O | 1 |
| Cheng, JC; Gonzales, FA; Hu, YG; Jones, PA; Liang, G; Marquez, VE; Weisenberger, DJ; Xu, GL | 1 |
| Hoshikawa, Y; Jonat, W; Jünemann, KP; Maass, N; Minei, S; Nagasaki, K; Sato, K; Sugimoto, S; Takimoto, Y; Zhang, M | 1 |
| Chen, YX; Cheng, ZH; Fang, JY; Lu, J; Lu, R; Xiao, SD; Yang, L; Zhu, HY | 1 |
| Esteller, M; Fraga, MF; González de Buitrago, G; Nieto, M; Samper, E; Serrano, M | 1 |
| Akiyama, Y; Endo, S; Fujisawa, K; Higuchi, T; Maesawa, C; Masuda, T; Ogasawara, S; Saito, K; Sato, N; Tomisawa, Y; Wada, K; Yamamoto, M | 1 |
| Cvetkovic, I; Harhaji, L; Markovic, M; Miljkovic, D; Sajic, M; Trajkovic, V; Vuckovic, O | 1 |
| Cheng, JC; Gonzales, FA; Jones, PA; Liang, G; Velicescu, M; Weisenberger, DJ | 1 |
| Hattori, N; Ko, YG; Nishino, K; Ohgane, J; Shiota, K; Tanaka, S | 1 |
| Bayar, E; Fine, G; Lyons, J; McCullar, M; Rolens, R; Rosenfeld, C; Rubinfeld, J | 1 |
| Blaschke, B; Knobbe, CB; Reifenberger, G; Reifenberger, J; Ruzicka, T; Schulte, KW; Sterzinger, AA | 1 |
| Doshi, K; Estécio, MR; Issa, JP; Kondo, Y; Tajara, EH; Yang, AS | 1 |
| Araki, H; DeSimone, J; Hoffman, R; Lavelle, D; Mahmud, N; Milhem, M; Saunthararajah, Y | 1 |
| Li, HH; Li, M; Lou, FD; Lu, XC; Xu, ZM; Yu, L; Zhao, Y | 1 |
| Dowell, JE; Minna, JD | 1 |
| Chen, CQ; Manev, H; Zhang, Z | 1 |
| Akiyama, Y; Fujisawa, K; Honda, T; Ishida, K; Itabashi, T; Maesawa, C; Masuda, T; Noda, Y; Saito, K; Sato, N; Takagane, A; Wada, K | 1 |
| Schrump, DS | 1 |
| Aapola, U; Kaipia, A; Mäenpää, K; Peterson, P | 1 |
| Branch, S; Cisneros, FJ | 1 |
| Buffler, PA; Gunn, L; Leung, K; Ma, X; Smith, MT; Wiemels, JL; Wiencke, JK; Zhang, L; Zheng, S | 1 |
| Blaschke, B; Knobbe, CB; Reifenberger, G; Reifenberger, J | 1 |
| David, GL; De Marzo, AM; Kumar, A; Lin, X; Marchi, VL; Nelson, WG; Yegnasubramanian, S | 1 |
| Chen, XQ; Garcia-Manero, G; Higuchi, E; Issa, JP; Kondo, Y; Lotan, R; Youssef, EM | 1 |
| Bernstein, M; Farinha, NJ; Lemaire, M; Momparler, LF; Momparler, RL | 1 |
| Asaumi, J; Inoue, T; Kawasaki, S; Kishi, K; Kuroda, M; Maki, Y; Matsubara, N; Murakami, J; Nagai, N; Tanaka, N; Tsujigiwa, H; Yanagi, Y | 1 |
| Hirohashi, S; Ino, Y; Kanai, Y; Nam, JS; Sakamoto, M | 1 |
| Becker, M; Ebert, MP; Göhring, UJ; Hoffmann, J; Moser, N; Pur, S; Schöndorf, T; Weisshaar, MP | 1 |
| Endoh, M; Honda, T; Motoyama, T; Nishizuka, S; Tamura, G; Yanagawa, N | 1 |
| Alder, H; Aqeilan, RI; Cesari, R; Croce, CM; Kanematsu, T; Kuroki, T; Matsuyama, A; Mori, M; Nolli, ML; Rattan, S; Trapasso, F; Williams, NN; Yendamuri, S | 1 |
| Jaszewski, R; Kucuk, O; Majumdar, AP; Nagothu, KK; Rishi, AK | 1 |
| Hurtubise, A; Momparler, RL | 2 |
| Akasaka, T; Maesawa, C; Masuda, T; Wada, K | 1 |
| Deng, G; Kim, YS; Pong, E; Sleisenger, M; Song, GA | 1 |
| Aventín, A; Brunet, S; Carnicer, MJ; Estivill, C; Lasa, A; Nomdedéu, JF; Sierra, J | 1 |
| Aoyama, T; Ishibe, T; Nagayama, S; Nakamura, T; Nakayama, T; Nishijo, K; Okamoto, T; Toguchida, J; Yasura, K | 1 |
| Lim, CY; Loh, KS; Qiu, GH; Srivastava, G; Tan, LK; Tao, Q; Tsai, ST; Tsao, SW | 1 |
| Drach, J; Feng, Z; Gazdar, AF; Kroft, SH; McKenna, RW; Miyajima, K; Parikh, G; Reddy, J; Shigematsu, H; Shivapurkar, N; Suzuki, M; Takahashi, T; Timmons, C; Toyooka, S; Zheng, Y; Zöchbauer-Müller, S | 1 |
| Heasley, LE; Winn, RA | 1 |
| Bernstein, M; Momparler, RL; Shaker, S | 1 |
| Fujimoto, H; Imamura, M; Kato, N; Kondo, T; Matsumura, N; Minami, Y; Oishi, I; Tanaka, Y; Tsukada, J; Yoda, A | 1 |
| Fu, HY; Hori, M; Kawano, S; Murata, H; Sakaguchi, Y; Tsuji, S; Tsujii, M | 1 |
| Amagasa, T; Chin, K; Gray, JW; Hirohashi, S; Imamura, M; Imoto, I; Inazawa, J; Inoue, J; Shibata, T; Shimada, Y; Sonoda, I | 1 |
| Airoldi, I; Amadori, A; Banelli, B; Cocco, C; Di Carlo, E; Moserle, L; Pezzolo, A; Pistoia, V; Romani, M; Rossi, E; Sorrentino, C | 1 |
| Liu, ZJ; Yang, X; Zhang, XB; Zhang, Y | 1 |
| Leung, T; Lim, L; Ng, Y; Tan, I | 1 |
| Gottesman, MM; Liang, XJ; Pai-Panandiker, A; Shen, DW; Su, A | 1 |
| Doihara, H; Dote, H; Shimizu, N; Teramoto, A; Toyooka, S; Tsukuda, K; Yano, M | 1 |
| Steensma, DP | 4 |
| Lübbert, M; van den Bosch, J; Verhoef, G; Wijermans, PW | 1 |
| Cutts, SM; Nudelman, A; Parker, BS; Phillips, DR; Rephaeli, A | 1 |
| Chen, YX; Fang, JY; Gu, WQ; Lu, J; Lu, LG; Lu, R; Yang, L; Zhu, HY | 1 |
| Chlenski, A; Cohn, SL; Hasan, C; Kersey, D; Liu, S; Perlman, EJ; Salwen, HR; Tian, Y; Yang, Q | 1 |
| Jin, B; Kim, G; Park, DW; Ryu, DY | 1 |
| Sharma, D; Vertino, PM | 1 |
| Black, KL; Liu, G; Wheeler, CJ; Ying, H; Yu, JS; Zeng, G | 1 |
| Brown, R; Plumb, JA | 1 |
| Branch, C; Gomyo, Y; Mukhopadhyay, T; Roth, JA; Sasaki, J | 1 |
| Kramer, PM; Pereira, MA; Tao, L; Wang, W | 1 |
| Hummel, M; Leithäuser, F; Möller, P; Ritz, O; Stein, H; Ushmorov, A; Wirth, T | 1 |
| Kubo, T; Matsubara, K; Niwa, Y; Shikauchi, Y; Yamamoto, J; Yoshikawa, H | 1 |
| Logsdon, CD; Okami, J; Simeone, DM | 1 |
| Golab, J; Grzela, T; Jakobisiak, M; Kaminski, R; Koronkiewicz, M; Kozar, K; Niderla, J; Skierski, JS; Wilczynski, G | 1 |
| Ekman, P; Fang, X; Liu, Z; Xu, D; Zheng, C | 1 |
| Harada, M; Ishimaru, F; Ito, S; Ogama, Y; Ouchida, M; Shimizu, K; Shiote, Y; Takimoto, H; Tanimoto, M; Yoshino, T | 1 |
| Ayyoub, M; Hesdorffer, CS; Hesdorffer, M; Hibshoosh, H; Keohan, ML; Mansukhani, M; Memeo, L; Metthez, G; Taub, RN; Valmori, D | 1 |
| Kohno, T; Nishioka, M; Ochiai, K; Okamoto, A; Otsuka, A; Tanaka, T; Yanaihara, N; Yokota, J | 1 |
| DeSimone, J; Lavelle, D; Saunthararajah, Y | 1 |
| Anast, JW; Bassett, WW; Carroll, PR; Dahiya, R; Enokida, H; Igawa, M; Kane, CJ; Kawahara, M; Kawakami, T; Li, LC; Nakagawa, M; Ogishima, T; Shiina, H; Terashima, M; Urakami, S; Verma, M | 1 |
| Carpentieri, D; Flake, AW; Hayashi, S; Ikegaki, N; Kim, DY; Kung, B; Riceberg, JS; Robinson, ME; Tang, XX; Titus, TB | 1 |
| Lin, MF; Tong, HY | 1 |
| Gu, J; Li, J; Lin, S; Lu, W; Wang, Y; Yu, J; Zhang, H; Zhu, J | 1 |
| Chen, Y; Deutschmann, N; Hühn, D; Knösel, T; Pacyna-Gengelbach, M; Petersen, I | 1 |
| Altomonte, M; Calabrò, L; Colizzi, F; Fonsatti, E; Gattei, V; Maio, M; Nanni, P; Pezzani, L; Sigalotti, L | 1 |
| Ihn, H; Kato, M; Suzuki, H; Tamaki, K; Yamane, K; Yoshikawa, H | 1 |
| Dai, JL; Liu, H; Sahin, A; Yuan, Y | 1 |
| Chan, FL; Chow, LS; Huang, DP; Kwong, J; Lo, KW; To, KF | 1 |
| Gorbunova, V; Mittelman, D; Seluanov, A; Wilson, JH | 1 |
| Imura, M; Maekita, T; Miyamoto, K; Nakagawa, S; Takada, T; Taketani, Y; Tsao, SW; Ushijima, T; Yagi, Y; Yasugi, T; Yoshino, O | 1 |
| Brambilla, E; Czerniak, B; Fujisawa, T; Gazdar, AF; Mastrangelo, D; Miyajima, K; Pass, HI; Sathyanarayana, UG; Shigematsu, H; Shimizu, N; Shivapurkar, N; Suzuki, M; Takahashi, T; Tomlinson, GE; Toyooka, S | 1 |
| Daskalakis, M; Engelhardt, M; Guo, Y; Kunzmann, R; Lübbert, M; Wijermans, P | 1 |
| Grimm, MO; Jackson, P; Loberg, R; Marreiros, A; Nixdorf, S; Pienta, KJ; Russell, PJ | 1 |
| Bisht, KS; Bradbury, CM; Brandenburg, SA; Chuang, EY; Cook, J; Cui, H; Feinberg, AP; Gius, D; Ho, AS; Hu, Y; Mattson, D; Mitchell, JB; Munson, PJ; Smart, DK; Sun, L; Young, L; Zhao, S | 1 |
| Alikhani-Koopaei, R; Fouladkou, F; Frey, BM; Frey, FJ | 1 |
| Ito, R; Nakayama, H; Oda, N; Yasui, W; Yoshida, K | 1 |
| Li, HM; Liew, CT; Suen, KW; Yau, LM; Yu, F; Zhang, CJ; Zhou, GY | 1 |
| Enkemann, S; Huang, T; Li, CG; McCarthy, S; Sung, J; Turner, J; Yan, P; Yeatman, TJ | 1 |
| Alleman, WG; Aprelikova, ON; Chandramouli, GV; Linehan, WM; Mendoza, A; Rodgers, C; Rogers, C; Sopko, NA; Tabios, RL; Torres-Cabala, C; Vasselli, JR | 1 |
| Chu, PG; Chung, C; Liu, X; Lopez, R; Qiu, W; Shih, J; Yen, Y; Zhou, B; Zou, H | 1 |
| Dörken, B; Lübbert, M; Sattler, N; Schmelz, K; Tamm, I; Wagner, M | 1 |
| Chen, JX; Cui, XY; Fu, PF; Wang, T | 1 |
| Lal, A; Vichinsky, E | 1 |
| DeBaun, MR | 1 |
| Carroll, PR; Dahiya, R; Deguchi, M; Enokida, H; Igawa, M; Ishii, N; Kane, CJ; Kawakami, T; Miura, K; Nakajima, K; Ogishima, T; Shiina, H; Tokizane, T; Urakami, S | 1 |
| Ichimura, S; Kaneda, A; Okochi-Takada, E; Sugimura, T; Ushijima, T | 1 |
| Aldred, MA; Broelsch, CE; Eng, C; Frilling, A; Morrison, CD; Plass, C; Waite, KA; Weber, F | 1 |
| Tuma, RS | 2 |
| Guo, XN; Qiao, SK; Xu, SR | 1 |
| Li, XD; Liu, J; Vaheri, A; Voutilainen, R | 1 |
| Eshleman, JR; Fukushima, N; Goggins, M; Iacobuzio-Donahue, CA; Miyagi, Y; Parker, AR; Sato, N | 1 |
| Arthur, C | 1 |
| Chang, CC; Enright, BP; Sung, LY; Tian, XC; Yang, X | 1 |
| Altomonte, M; Colizzi, F; Coral, S; Danielli, R; Fonsatti, E; Fratta, E; Maio, M; Sigalotti, L; Tanzarella, S; Traversari, C | 1 |
| Dörken, B; Schmelz, K; Tamm, I; Wagner, M | 1 |
| Jang, T; Lee, C; Liu, VC; Park, I; Rubenstein, JN; Zhang, Q | 1 |
| Hong, WK; Mao, L; Sun, SY; Tang, X; Wistuba, II; Wu, W | 1 |
| Crnogorac-Jurcevic, T; Donadelli, M; Lemoine, NR; Missiaglia, E; Palmieri, M; Scarpa, A | 1 |
| Ashida, Y; Azuma, M; Motegi, K; Sato, M; Tamatani, T | 1 |
| Dahle, D; Klibanski, A; Zhang, X; Zhao, J; Zhou, Y | 1 |
| Dürr, M; Harder, F; Jauch, A; Kirchhof, N; Müller, AM; Schmittwolf, C; Zenke, M | 1 |
| Davidson, NE; Garrett-Mayer, E; Herman, JG; Keen, JC; Mack, KM; Manning, J; Pettit, C | 1 |
| Chen, J; Ebert, MP; Götze, T; Klein-Hitpass, L; Leodolter, A; Malfertheiner, P; Röcken, C | 1 |
| Chan, KY; Cheung, AN; Chiu, PM; Ip, P; Khoo, US; Ngan, HY; Shen, DH; Xue, WC | 1 |
| Arnold, W; Deutschmann, N; Klebig, C; Pacyna-Gengelbach, M; Petersen, I; Scherneck, S; Seitz, S | 1 |
| Breault, JE; Carroll, PR; Dahiya, R; Deguchi, M; Enokida, H; Igawa, M; Kane, CJ; Nakagawa, M; Ribeiro-Filho, LA; Shiina, H; Terashima, M; Urakami, S | 1 |
| Fukushima, Y; Okumura, K; Saito, T; Sato, C; Sugimura, K; Taguchi, H; Takebayashi, S | 1 |
| Akino, K; Endo, T; Hinoda, Y; Imai, K; Kusano, M; Mita, H; Murai, M; Sasaki, Y; Satoh, A; Suzuki, H; Takahashi, F; Tokino, T; Toyota, M; Ueno, M; Yanagihara, K | 1 |
| Bassett, WW; Breault, JE; Dahiya, R; Enokida, H; Fujime, M; Igawa, M; Kawakami, T; Li, LC; Ogishima, T; Ribeiro-Filho, LA; Shiina, H; Tabatabai, L; Terashima, M; Urakami, S | 1 |
| Bernstein, ML; Lemaire, M; Marquez, VE; Momparler, LF; Momparler, RL | 1 |
| Fujisawa, T; Gazdar, AF; Iizasa, T; Sathyanarayana, UG; Shigematsu, H; Shivapurkar, N; Suzuki, M; Takahashi, T | 1 |
| Furuta, J; Kaneda, A; Otsuka, F; Sugimura, T; Umebayashi, Y; Ushijima, T | 1 |
| Chan, FL; Chow, LS; Choy, KW; Huang, DP; Kwong, J; Lo, KW; Mok, SC; To, KF | 1 |
| Gan, Y; Shen, YH; Utama, B; Wang, J; Wang, X; Wang, XL | 1 |
| Chang, LJ; Hamazaki, T; Meacham, AM; Oka, M; Rodić, N; Terada, N | 1 |
| Beer, DG; Chen, GA; Fischette, MR; Guo, ZS; Hong, JA; Kassis, ES; Lee, S; Nguyen, DM; Schrump, DS; Steiner, FA; Trepel, JB; Weiser, TS | 1 |
| Chiurazzi, P; Moscato, U; Neri, G; Oostra, BA; Pietrobono, R; Tabolacci, E | 1 |
| Hirohashi, S; Hosoda, H; Imoto, I; Inazawa, J; Inoue, J; Izumi, H; Shibata, T; Sunamori, M; Yokoi, S | 1 |
| Beaulieu, N; Blum, J; Davidson, NE; Macleod, AR; Sharma, D; Yang, X | 1 |
| Kohno, T; Nakano, T; Nishioka, M; Ohwada, S; Otsuka, A; Tani, M; Yokota, J | 1 |
| Ahn, HS; Choi, HS; Kang, HJ; Koh, SH; Park, ES; Shin, HY | 1 |
| Hoon, DS; Huang, S; Kim, J; Koyanagi, K; Mori, T; Takeuchi, H; Umetani, N; Yamano, T | 1 |
| Boucher, K; Busby, L; Cassidy, P; Fitzpatrick, F; Jones, DA; Karpf, AR; Leachman, SA; Porter-Gill, P; Samlowski, WE; Wade, M; Wheeler, R | 1 |
| Pulukuri, SM; Rao, JS | 1 |
| Ishii, M; Kamihira, S; Kusunoki, M; Nakatani, K; Nakazawa, K; Nishioka, J; Nobori, T; Wada, H; Yamada, Y | 1 |
| Biesová, Z; Jakubicková, L; Kettmann, R; Pastorek, J; Pastoreková, S | 1 |
| Gudas, LJ; Mongan, NP | 1 |
| Dote, H; Gazdar, AF; Murakami, M; Naito, M; Ota, T; Shimizu, N; Toyooka, S; Toyota, M; Tsukuda, K; Yano, M | 1 |
| Aoyagi, K; Danjoh, I; Fukaya, M; Nishigaki, M; Sakamoto, H; Sasaki, H; Yanagihara, K; Yoshida, T | 1 |
| Adachi, M; Asano, T; Fujii, H; Fukunaga, Y; Hasegawa, K; Horichi, N; Isoe, T; Nakamura, K; Ohmori, T; Otake, N | 1 |
| Arslan, B; Güntner, S; Huang, TH; Pietsch, T; Waha, A; Wiestler, OD; Yan, PS | 1 |
| Attewell, JR; Dowdy, SC; Eberhardt, NL; Jiang, SW; Jin, F; Podratz, KC; Xiong, Y | 1 |
| Barrett, JC; Kumakura, S; Tsutsui, T; Tsutsui, TW; Yagisawa, J | 1 |
| Higashimoto, K; Joh, K; Kudo, S; Matsukura, S; Matsuo, S; Mukai, T; Nakagawachi, T; Soejima, H; Urano, T; Zhao, W | 1 |
| Bennett, KL; Byrd, JC; Grever, MR; Kipps, TJ; Liyanarachchi, S; Lucas, DM; Matkovic, JJ; Plass, C; Rassenti, L; Raval, A; Young, DC | 1 |
| Bae, SI; Jee, CD; Kim, WH; Lee, HS; Lee, YM; Rho, MS; Yang, HK | 1 |
| Der, CJ; Frantz, K; Muniz-Medina, VM; Pruitt, K; Rangnekar, VM; Rojas, RJ; Shields, JM; Ulkü, AS | 1 |
| Andollo, N; Andrade, R; Aréchaga, J; Arlucea, J; Asumendi, A; Boyano, MD; Eguizabal, C; Zalduendo, MM | 1 |
| Chen, Y; Cui, J; Dou, LP; Lou, FD; Lü, M; Lu, XC; Xu, ZM; Yang, L; Yu, L | 1 |
| Basma, H; Cheng, PW; Choi, KH; Singh, J | 1 |
| Kim, JS; Kim, YH; Whang, YM; Yoo, YD | 1 |
| Hwang, EH; Kim, JH; Paik, YK; Park, HJ; Shim, YH | 1 |
| Jakobsson, J; Lundberg, C; Rosenqvist, N | 1 |
| Cortes, J; Garcia-Manero, G; Gharibyan, V; Issa, JP; Jelinek, J; Kantarjian, HM; Morris, G; Talpaz, M; Verstovsek, S | 1 |
| Dong, S; Liu, Y; Mao, B; Ng, HK; Pang, JC; Poon, WS | 1 |
| Carroll, P; Dahiya, R; Greene, KL; Igawa, M; Kane, CJ; Kishi, H; Li, LC; Shiina, H; Tanaka, Y; Zhao, H | 1 |
| Bakin, AV; Li, X; Quan, L; Safina, AF; Sossey-Alaoui, K; Stourman, NV; Varga, AE; Zheng, Q | 1 |
| Bai, S; Datta, J; Ghoshal, K; Jacob, ST; Kutay, H; Majumder, S; Motiwala, T | 1 |
| Emi, N; Iwai, M; Kinoshita, T; Kiyoi, H; Naoe, T; Ohno, R; Ozeki, K | 1 |
| Jang, TL; Javonovic, B; Kim, SJ; Lee, C; Park, I; Pins, M; Rubenstein, JN; Yang, X; Zhang, Q | 1 |
| Gruss, C; Hu, HG; Illges, H; Knippers, R | 1 |
| Choi, HY; Jeon, YK; Kim, CW; Kim, H; Kim, JE; Kim, YA; Kim, YN; Park, SO; Park, SS | 1 |
| Garcia-Manero, G; Hoshino, K; Kantarjian, H; Sanchez-Gonzalez, B; Yang, H | 1 |
| Cherry, JC; Farrar, WL; Fox, SD; Hodge, DR; Hurt, EM; Kelley, JA; Munroe, DJ; Peng, B | 1 |
| Chen, S; Hao, CL; Tang, KJ; Wang, JX; Wang, M; Xing, HY | 1 |
| Ehrlich, M | 1 |
| Bergin, OE; Brown, R; Byrne, A; Culhane, AC; Currid, CA; Dervan, PA; Easty, DJ; Esteller, M; Fox, EJ; Fraga, MF; Gallagher, WM; Hughes, L; Kelly, ZD; McArdle, L; McDonnell, S; Moss, C; Murphy, AA; Nolan, IM; O'Mahony, F; Plumb, JA; Rafferty, M; Stallings, RL | 1 |
| Choi, EJ; Kim, JS; Kim, YH; Seo, JH; Whang, YM; Yoo, YD | 1 |
| Abe, T; Chang, R; Dhara, S; Goggins, M; Hustinx, SR; Maitra, A; Martin, ST; Sato, N | 1 |
| Furukawa, Y; Ishii, H; Nishimura, M; Saito, Y; Sutheesophon, K; Wada, T | 1 |
| Haller, G; Horak, P; Horvat, R; Krainer, M; Pils, D; Pribill, I; Roessler, M; Tomek, S; Zeillinger, R; Zielinski, C | 1 |
| Hidaka, E; Kamijo, T; Koike, K; Kubota, T; Sakashita, K; Sugane, K; Zhao, XY | 1 |
| Abe, T; Fukushima, N; Goggins, M; Matsubayashi, H; Sato, N | 1 |
| Brambilla, E; Drabkin, HA; Franklin, W; Kusy, S; Minna, J; Potiron, V; Roche, J; Zeng, C | 1 |
| Caporossi, A; Ciccodicola, A; Cinti, C; Giordano, A; La Sala, D; Lazzi, S; Macaluso, M; Massaro-Giordano, M; Tosi, GM; Trimarchi, C | 1 |
| Issa, JP; Kantarjian, HM | 3 |
| Saba, HI; Wijermans, PW | 1 |
| Lübbert, M; Minden, M | 1 |
| Byrd, JC; Issa, JP | 1 |
| Dowdy, SC; Eberhardt, NL; Gonzalez Bosquet, J; Jiang, SW; Podratz, KC; Xiong, Y; Zhao, Y | 1 |
| Decoteau, JF; Dong, WF; Geyer, CR; Hirsch, C; Ichinohasama, R; Sanche, SE; Scott, SA; Sheridan, D | 1 |
| Chang, CC; Ferrone, S; Lin, AF; Yan, WH | 1 |
| Bayatti, N; Behl, C; Clement, AM; Engele, J; Figiel, M; Witan, H; Zschocke, J | 1 |
| Hackanson, B; Lübbert, M; Lyko, F; Mund, C; Stresemann, C | 1 |
| Albergaria, A; Jerónimo, C; Milanezi, F; Oliveira, JT; Paredes, J; Schmitt, FC | 1 |
| Dong, C; Goldschmidt-Clermont, PJ; Zhu, S | 1 |
| Abdullaev, Z; Barrett, JC; Custer, M; Flanagan, PT; Hong, JA; Lobanenkov, VV; Loukinov, DI; Morse, H; Pack, SD; Pugacheva, E; Risinger, JI; Schrump, DS; Vatolin, S | 1 |
| Ikeda, H; Imai, K; Itoh, F; Kobayashi, T; Mita, H; Sasaki, Y; Shinomura, Y; Suzuki, H; Tokino, T; Toyota, M | 1 |
| Imazeki, F; Kanda, T; Nagao, K; Saisho, H; Tada, M; Yokosuka, O | 1 |
| Kuykendall, JR | 1 |
| Awwad, RT; Bisht, KS; Bradbury, CM; Gius, D; Ho, AS; Huang, L; Nguyen, P; Smart, DD; Sun, L | 1 |
| Cho, YG; Kim, CJ; Kim, SY; Lee, JY; Lee, SH; Lee, YS; Nam, SW; Park, WS; Song, JH; Yoo, NJ | 1 |
| Haas, PS; Lübbert, M; Verhoef, G; Wijermans, P | 1 |
| DeSimone, J | 1 |
| Brooks, JD; Kaygusuz, G; Kim, H; Lapointe, J; Li, C; Ong, DE; Pollack, JR; van de Rijn, M | 1 |
| Libermann, TA; Zerbini, LF | 1 |
| Ambinder, R; Gao, Z; Hsieh, WS; Liao, SK; Murray, P; Srivastava, G; Tao, Q; Ying, J | 1 |
| Flores-Morales, A; Johansson, B; Larsson, C; Nilsson, P; Norstedt, G; Pang, ST; Pourian, MR; Pousette, A; Weng, WH | 1 |
| Cardoso, MC; Easwaran, HP; Leonhardt, H; Margot, JB; Schermelleh, L; Spada, F; Zolghadr, K | 1 |
| El-Salem, M; Gimotty, P; Marzec, M; Nagasawa, T; Odum, N; Raghunath, PN; Rook, AH; Szallasi, A; Vonderheid, EC; Wasik, MA; Wong, HY; Zhang, Q | 1 |
| Frühwald, MC; Grotzer, M; Hagemann, C; Jürgens, H; Mühlisch, J; Osada, N; Rickert, CH; Roggendorf, W; Schwering, A; Sörensen, N; Vince, GH | 1 |
| Schmelz, K; Tamm, I; Wagner, M | 1 |
| Broekhuizen, AJ; Creutzig, U; Gibson, BE; Hubeek, I; Kaspers, GJ; Peters, GJ; Sargent, J | 1 |
| Odenike, O; Tefferi, A | 1 |
| Chen, D; Christman, JK; Fang, MZ; Jin, Z; Sun, Y; Yang, CS | 1 |
| Raut, CG; Somasundaram, K; Wajapeyee, N | 1 |
| Chan, TK; Chan, V; Cheng, CK; Chow, LW; Loo, WT | 1 |
| End-Pfützenreuter, A; Fong, KM; Gazdar, AF; Girard, L; Heller, G; Lang, G; Minna, JD; Seidl, S; Zielinski, CC; Zöchbauer-Müller, S | 1 |
| de Vos, D | 1 |
| Rosenfeld, CS | 1 |
| Almstedt, M; Claus, R; Lübbert, M | 1 |
| Bosly, A; Klimek, V; Lübbert, M; Verhoef, G; Wijermans, PW | 1 |
| Han, YC; Kong, WJ; Wang, YJ; Zhang, D; Zhang, S | 1 |
| de Vos, D; van Overveld, W | 1 |
| Balch, C; Craft, T; Huang, TH; Nephew, KP; Skalnik, DG; Yan, P; Young, S | 1 |
| Chuang, JC; Jones, PA; Kwan, JM; Li, TW; Liang, G; Yang, AS; Yoo, CB | 1 |
| Gozzini, A; Santini, V | 1 |
| Mitchell, MD; Sato, TA | 1 |
| Brown, R; Chan, MW; Huang, TH; Liu, JC; Liyanarachchi, S; Matei, DE; Nephew, KP; Wang, Z; Wei, SH; Wen, P; Yan, PS | 1 |
| Chan, AT; Langford, C; Li, H; Murray, P; Putti, T; Seng, TJ; Srivastava, G; Tao, Q; Tsao, SW; Ying, J | 1 |
| Altomonte, M; Colizzi, F; Coral, S; Cortini, E; Di Giacomo, AM; Fonsatti, E; Fratta, E; Maio, M; Nardi, G; Natali, PG; Nicotra, MR; Pezzani, L; Sigalotti, L; Spessotto, A | 1 |
| Andreasen, PA; Gao, S; Krogdahl, A; Skeldal, S; Sørensen, JA | 1 |
| Giles, FJ; Jabbour, E; Kantarjian, HM; Yee, KW | 1 |
| Hsi, LC; Lippman, SM; Wu, Y; Xi, X | 1 |
| Hackanson, B; Lübbert, M; Robbel, C; Wijermans, P | 1 |
| Germing, U; Haas, PS; Kündgen, A; Lübbert, M; Müller-Berndorff, H; Pitako, JA; Van den Bosch, J; Wijermans, PW | 1 |
| Ding, F; Guo, M; Li, J; Li, W; Liu, Z; Wang, Y; Wu, M; Yu, Z; Zhan, Q; Zhang, L | 1 |
| Leithäuser, F; Möller, P; Popov, SW; Sakk, O; Ushmorov, A; Weinhaüsel, A; Wirth, T | 1 |
| Abdelkarim, M; Engelhardt, M; Guo, Y; Lübbert, M; Wider, D | 1 |
| Lübbert, M; Schaefer, HE | 1 |
| Ahsan, MK; Kim, YC; Maeda, M; Masutani, H; Matsuoka, M; Nishinaka, Y; Nosaka, K; Yamaguchi, Y; Yodoi, J | 1 |
| Das, S; Dignam, J; Fackenthal, J; Grushko, TA; Hagos, F; Nanda, R; Olopade, OI; Sveen, L; Tretiakova, M; Wei, M; Xu, J | 1 |
| Daniel, PT; Dörken, B; Gillissen, B; Janz, M; Jung, K; Loening, S; Radetzki, S; Siebert, R; Stephan, C; Sturm, I | 1 |
| Chang, CW; Chen, RA; Chen, SC; Chen, YH; Cheng, CY; Chou, MC; Fang, HY; Hsu, LS; Lee, CH; Lin, CY; Lin, TS; Tai, HL | 1 |
| Hara, E; Hozumi, N; Kihara-Negishi, F; Oikawa, T; Sakurai, T; Suzuki, M; Tenen, DG; Yamada, T | 1 |
| Mufti, GJ; Silverman, LR | 1 |
| Fenaux, P | 1 |
| Baylin, SB | 1 |
| Bartucci, M; Crinò, L; De Maria, R; Eramo, A; Larocca, LM; Lotti, F; Pallini, R; Patti, M; Peschle, C; Ricci-Vitiani, L; Sette, G; Signore, M; Stassi, G | 1 |
| Moriguchi, K; Tatematsu, M; Tsujino, Y; Ushijima, T; Yamashita, S | 1 |
| Cheng, X; Liu, J; Mei, FC; Young, TW | 1 |
| Ajima, R; Fujiwara, T; Kohno, T; Minna, JD; Sasaki, H; Takahashi, K; Tanaka, N; Yokota, J | 1 |
| Bai, T; Tanaka, T; Umesaki, N; Yukawa, K | 1 |
| Daignault, S; Day, ML; Imperiale, MJ; Low, JA; McCabe, MT; Wojno, KJ | 1 |
| Benhattar, J; Bosman, FT; Braunschweig, R; Clément, G; Pasquier, N | 1 |
| Ferrone, S; Kageshita, T; Karpf, AR; Luo, W; Wakasugi, S; Wang, X | 1 |
| Ballestar, E; Carvajal-Gonzalez, JM; Esteller, M; Fernandez-Salguero, PM; Fraga, MF; Herranz, M; Mulero-Navarro, S; Ropero, S | 1 |
| Argani, P; D'Costa, A; Fackler, MJ; Garrett-Mayer, E; Lo, PK; Mehrotra, J; Sukumar, S | 1 |
| Jiang, J; Peng, ZH; Tang, B | 1 |
| Brena, RM; Lang, JC; Lin, M; Morrison, CD; Otterson, GA; Plass, C; Schuller, DE; Smiraglia, DJ; Smith, LT | 1 |
| Li, M; Lu, S; Wang, H; Wang, Z; Zhang, Y | 1 |
| Byrd, JC; Chen, SS; Liu, TH; Matkovic, JJ; Plass, C; Raval, A | 1 |
| Chen, GA; Guo, ZS; Hong, JA; Irvine, KR; Liu, Y; Nguyen, DM; Restifo, NP; Schrump, DS; Spiess, PJ; Wunderlich, JR; Zeng, G | 1 |
| Bernal, ML; Gomez, A; Ingelman-Sundberg, M; Johansson, I; Karlgren, M; Oliw, E; Ramón y Cajal, S; Rodriguez-Antona, C; Stark, K; Svärd, J | 1 |
| Almeida, R; David, L; LePendu, J; Mendes, N; Mesquita, P; Oliveira, C; Reis, CA; Santos-Silva, F; Serpa, J | 1 |
| Chen, JK; Chou, J; He, B; Jablons, DM; Kim, J; Kuchenbecker, K; Lin, YC; Mikami, I; Raz, D; Thung, E; Xu, Z; Yang, CT; You, L | 1 |
| Adachi, H; Dahiya, R; Enokida, H; Igawa, M; Kawakami, T; Kikuno, N; Kishi, H; Konety, BR; Li, LC; Ogishima, T; Ribeiro-Filho, LA; Shigeno, K; Shiina, H; Tanaka, Y; Terashima, M; Tokizane, T; Urakami, S; Yoneda, T | 1 |
| Aliyu, ZY; Kato, GJ; Tumblin, AR | 1 |
| Feng, Q; Geiss, G; Kiviat, N; Lieber, A; Rudolf, V; Sova, P; Strauss, R; Wood, T | 1 |
| Araki, H; Beam, CA; Hoffman, R; Mahmud, N; Milhem, M; Nunez, R; Xu, M | 1 |
| Kuulasmaa, T; Liu, J; Utriainen, P; Voutilainen, R | 1 |
| Bouabdallah, K; Daskalakis, M; Johansson, B; Kunzmann, R; Lübbert, M; Mauritzson, N; Müller-Berndorff, H; Onida, F; Schmitt-Gräff, A | 1 |
| Auer, H; Brena, RM; Byrd, JC; Hackanson, B; Kornacker, K; Plass, C; Raval, A | 1 |
| Ahlquist, DA; Burgart, LJ; Harrington, JJ; Klatt, KK; Lesche, R; Lewin, J; Lofton-Day, C; Molina, JR; Osborn, NK; Zou, H | 1 |
| Barrera-Saldaña, HA; Bernard, HU; Calleja-Macias, IE; Cubie, HA; Cuschieri, K; Kalantari, M; Skomedal, H; Turan, T; Villa, LL | 1 |
| Ballman, KV; Cheville, JC; Lieber, MM; Morlan, BW; Neumann, RM; Tindall, DJ; Vanaja, DK; Young, CY | 1 |
| Chen, BB; Chen, Q; Chen, YM; Song, YF; Xie, Y; Xu, R; Zhang, XH | 1 |
| Aguilera, O; Ballestar, E; Espada, J; Esteller, M; Fraga, MF; García, JM; González-Sancho, JM; Herranz, M; Muñoz, A; Paz, MF | 1 |
| List, AF | 1 |
| Billstrand, C; Kuldanek, S; Ober, C; Tan, Z | 1 |
| Brueckner, B; Lyko, F; Musch, T; Stopper, H; Stresemann, C | 1 |
| Ma, LW; Tong, TJ; Zhang, ZY; Zheng, QH; Zhu, WG | 1 |
| Chen, X; Guo, CK; Kong, W; Kong, WJ; Liu, Z; Wang, YJ; Zhang, D; Zhang, S; Zhang, SL | 1 |
| Byrd, JC; Chan, KK; Grever, M; Liu, Z; Marcucci, G; Xiao, J | 1 |
| Albitar, M; Bennett, JM; de Castro, C; DiPersio, J; Helmer, R; Issa, JP; Kantarjian, H; Klimek, V; Leavitt, R; Nimer, SD; Ravandi, F; Raza, A; Rosenfeld, CS; Saba, H; Shen, L; Slack, J | 1 |
| Letendre, L; Tefferi, A | 1 |
| Lübbert, M; Rüter, B; Wijermans, PW | 1 |
| Guan, M; Popescu, NC; Soulitzis, N; Spandidos, DA; Zhou, X | 1 |
| DeSimone, J; Hankewych, M; Lavelle, D; Singh, M; Vaitkus, K | 1 |
| Catto, JW; Cross, SS; Hamdy, FC; Leiblich, A; Leung, HY; Phillips, JT; Rehman, I | 1 |
| Bernard, O; Gagnon, JF; Guillemette, C; Têtu, B; Villeneuve, L | 1 |
| Lübert, M; Wijermans, P | 1 |
| Bhattacharya, M; Chakraborty, AK; Chakraborty, D; Chatterjee, A; Funasaka, Y; Pawelek, J; Sousa, Jde F | 1 |
| Chen, X; Herzel, HP; Jammas, D; Krapfenbauer, U; Kuban, RJ; Lund, P; Mikeska, T; Schäfer, R; Sers, C; Ungethüm, U; Walter, J; Weisshaupt, K | 1 |
| Chun, K; Costa, R; Haghighi, F; McMinn, J; Minden, M; Tycko, B; White, S; Yuan, E | 1 |
| Baylin, SB; Fahrner, JA; Greene, E; Jenuwein, T; Martens, J; McGarvey, KM | 1 |
| Inoue, H; Kim, MS; Mori, M; Osada, M; Park, HL; Sidransky, D; Tokumaru, Y; Yamashita, K | 1 |
| Belinsky, SA; Hutt, JA; Vuillemenot, BR | 1 |
| Debatin, KM; Fulda, S | 1 |
| Banwell, CM; Campbell, MJ; Colston, KW; Guy, M; MacCartney, DP; Mansi, J; Miles, AE; O'Neill, LP; Stewart, PM; Turner, BM; Uskokovic, MR | 1 |
| Amberger, A; Eichmann, C; Fiegl, H; Fong, D; Gastl, G; Grünewald, K; Haun, M; Margreiter, R; Millinger, S; Obrist, P; Parson, W; Spizzo, G | 1 |
| Eliyahu, E; McGovern, MM; Park, JH; Schuchman, EH; Shtraizent, N; Simonaro, CM | 1 |
| Chang, MS; Jung, EJ; Kim, WH; Lee, BL; Lee, YM | 1 |
| Chen, H; Costa, M; Ke, Q; Kluz, T; Yan, Y | 1 |
| Arai, M; Chiba, T; Fukai, K; Hirasawa, Y; Imazeki, F; Kanda, T; Ochiai, T; Saisho, H; Seki, N; Takiguchi, Y; Yatomi, M; Yokosuka, O | 1 |
| Berenguer, J; Borczuk, AC; Hei, TK; Powell, CA; Shao, G; Zhao, Y | 1 |
| Arai, M; Fukai, K; Imazeki, F; Kanda, T; Kurihara, T; Mikata, R; Saisho, H; Tada, M; Yokosuka, O; Zhang, K | 1 |
| Pantel, K; Schwarzenbach, H; Wischnewski, F | 1 |
| Kinoshita, T; Li, Y; Murohara, T; Nagai, H; Ohashi, H; Ohno, T; Saito, H | 1 |
| Al-Saleem, T; Cairns, P; Dulaimi, E; Hoffman, AM; Ibanez de Caceres, I; Uzzo, RG | 1 |
| Choi, SW; Doshi, KD; Estecio, MR; Garcia-Manero, G; Gharybian, V; Issa, JP; Kantarjian, HM; Luna, R; Mannari, RK; Mason, JB; Rashid, A; Shen, L; Yang, AS | 1 |
| Peng, ZH; Tang, B; Yu, PW; Zeng, DZ; Zhang, C | 1 |
| Lee, KD; Lin, CT; Lin, WH; Tzeng, PY | 1 |
| Chen, HJ; Dannenberg, LO; Edenberg, HJ; Tian, H | 1 |
| Croom, KF; McKeage, K | 1 |
| Garcia-Manero, G; Saba, HI | 1 |
| Cashen, AF; Devine, H; DiPersio, J | 1 |
| Cortes, J; Kantarjian, HM | 1 |
| Akiboye, F; Elsharkawy, A; Mann, DA; Mann, J; Oakley, F; Thorne, AW | 1 |
| Chuang, JC; Coetzee, GA; Egger, G; Friedman, JM; Jones, PA; Liang, G; Saito, Y | 1 |
| Davidson, NE; Saxena, NK; Sharma, D; Vertino, PM | 1 |
| Bayley, JP; Gringhuis, SI; Jones, PA; Kooter, JM; van der Pouw Kraan, TC; van Rietschoten, JG; Verweij, CL; Verzijlbergen, KF; Wierenga, EA | 1 |
| Feinstein, Y; Futscher, BW; Klimecki, WT; Lau, SS; Wozniak, RJ | 1 |
| Pampalakis, G; Sotiropoulou, G | 1 |
| Diamandis, EP; Pampalakis, G; Sotiropoulou, G | 1 |
| Bae, SI; Beaulieu, N; Borden, EC; Cherkassky, L; Leaman, DW; Lindner, D; MacLeod, AR; Reu, FJ | 1 |
| Hirakawa, K; Ohira, M; Ren, J; Yashiro, M; Zhang, X | 1 |
| Bhalla, KN; Huang, C; Inoue, M; Ito, K; Ito, Y; Ko, TK; Lau, QC; Liu, Q; Loh, M; Putti, TC; Raja, E; Salto-Tellez, M; Sukumar, S; Zhu, T | 1 |
| Fahey, J; Field, L; Foltz, G; Frakes, A; Hood, L; Lee, H; Madan, A; Nelson, T; Ryken, TC; Ryu, GY; Sibenaller, Z; Vibhakar, R; Yoon, JG; Zander, K | 1 |
| Hoon, DS; Kitago, M; Martinez, SR; Mori, T; Morton, DL; Nguyen, SL; O'Day, SJ; Tanemura, A; Tran, AN; Umetani, N; Wang, HJ | 1 |
| Igarashi, M; Nakae, D; Takahashi, M; Uematsu, F; Yoshida, M | 1 |
| Dong, WH; He, XH; Huang, ZJ; Li, M; Li, XY; Wang, H; Wang, XY; Wang, ZH | 1 |
| Andreeff, M; Contractor, R; Issa, JP; Jin, L; Kondo, Y; Konopleva, M; Miyake, K; Miyake, N; Nagaoka, I; Ohsaka, A; Ruvolo, V; Tabe, Y; Tsutsumi-Ishii, Y | 1 |
| Das, PM; Ferdinand, L; Gopisetty, G; Ramachandran, K; Reis, IM; Singal, R; Vanwert, J | 1 |
| Lu, Y; Ma, D; Meng, L; Wang, H; Wang, S; Wu, S; Wu, Y; Xi, L; Xu, G; Xu, Q; Zhao, Y; Zhou, J | 1 |
| Blaschke, B; Knobbe, CB; Reifenberger, G; van den Boom, J; Wolter, M | 1 |
| Lahn, BT; Vallender, TW | 1 |
| Amin, HM; Franko, B; Frantz, C; Han, Y; Lai, R; Lee, J; Lin, Q | 1 |
| Benbrahim-Tallaa, L; Boos, J; Liu, J; Qian, X; Qu, W; Waalkes, MP; Xie, Y; Yu, L | 1 |
| Bueso-Ramos, C; Cortes, J; Davis, J; Estrov, Z; Faderl, S; Ferrajoli, A; Garcia-Manero, G; Giles, F; Huang, X; Issa, JP; Kantarjian, H; O'Brien, S; Oki, Y; Ravandi, F; Saba, HI; Shan, J; Wierda, W | 1 |
| Bueso-Ramos, C; Cortes, J; Estey, E; Estrov, Z; Faderl, S; Fiorentino, J; Garcia-Manero, G; Issa, JP; Jabbour, E; Kantarjian, HM; Koller, C; O'brien, S; Ravandi, F; Rosner, G; Rytting, M; Sanchez-Gonzalez, B; Verstovsek, S; Wierda, WG; Xiao, L; Yang, H | 1 |
| Dahiya, R; Igawa, M; Li, LC; Okino, ST; Pookot, D; Shiina, H; Urakami, S; Zhao, H | 1 |
| Fields, CR; Kim, JH; Kim, TY; Robertson, KD; Zhong, S | 1 |
| Gluckman, PD; Lobie, PE; Mitchell, MD; Rahnama, F; Shafiei, F | 1 |
| Dressman, HK; Gollob, JA; Issa, JP; Jelinek, J; Moran, K; Peterson, BL; Richmond, T; Sciambi, CJ; Thoreson, M | 1 |
| Ehrich, M; Louis, DN; Mueller, W; Nutt, CL; Riemenschneider, MJ; van den Boom, D; von Deimling, A | 1 |
| Arens, N; Goerdt, S; Gratchev, A; Grobholz, R; Kannookadan, S; Kzhyshkowska, J; Muller-Molinet, I; Oerther, S; Utikal, J | 1 |
| Thomas, ML | 1 |
| Dover, GJ; Keefer, JR; Mays, A; Purvis, SH; Schneidereith, TA; Smith, KD | 1 |
| Abrams, J; Fridman, AL; Kulaeva, OI; Land, SJ; Li, Q; Nahhas, F; Roberts, PC; Tainsky, MA; Tang, L; Ye, B | 1 |
| Cortez, CC; Egger, G; Escobar, SG; Jeong, S; Jones, PA; Li, TW; Liang, G; Saito, Y; Yoo, CB | 1 |
| Hatzimichael, EC; Makis, AC; Stebbing, J | 1 |
| Chen, X; Chen, Z; Liu, T; Myers, R; Patterson, AP; So, CK; Wang, P; Wang, S; Yan, L; Yang, CS; Zhang, X | 1 |
| Claus, R; Duque, JA; Fliegauf, M; Kolanczyk, M; Lübbert, M; Stock, M | 1 |
| Choi, JS; Kim, IJ; Kim, KH; Ku, JL; Park, JG | 1 |
| Kitazawa, R; Kitazawa, S | 1 |
| Carvalho, AL; Cerveira, N; Costa, VL; Henrique, R; Hoque, MO; Jerónimo, C; Oliveira, J; Ribeiro, FR; Sidransky, D; Teixeira, MR | 1 |
| Albert, SH; Liao, D; Liu, J; Niu, Y; Robertson, KD; Santiago, A; Zhao, LY | 1 |
| Cantor, JP; Collins, JE; Druck, T; Friedberg, JS; Han, SY; Huebner, K; Iliopoulos, D; Lakshman, TV; McCorkell, KA; Rao, AS; Semba, S; Wachsberger, P | 1 |
| Chen, GA; Figg, WD; Fischette, MR; Hancox, A; Hong, JA; Kunst, TF; Li, X; Murgo, AJ; Nguyen, DM; Pishchik, V; Schrump, DS; Steinberg, SM; Zhao, M | 1 |
| Aoki, E; Issa, JP; Oki, Y | 1 |
| Aburatani, H; Hayashi, H; Kaneda, A; Kaneshiro, K; Kozaki, T; Nagae, G; Sugisaki, H; Tsutsumi, S | 1 |
| Brockington, M; Jungbluth, H; Monk, D; Moore, GE; Muntoni, F; Sewry, CA; Stanier, P; Zhou, H | 1 |
| Coleman, WB; Jones, WD; Rivenbark, AG | 1 |
| Mack, GS | 1 |
| Abdelkarim, M; Berg, T; Fliegauf, M; Guo, Y; Lübbert, M | 1 |
| Dai, Z; Liu, S; Marcucci, G; Sadee, W | 1 |
| Fabianowska-Majewska, K; Krawczyk, B | 1 |
| Chen, Y; Costa, E; Grayson, DR; Kundakovic, M | 1 |
| Bartova, E; Fojtova, M; Kovarik, A; Otmar, M; Piskala, A; Votruba, I | 1 |
| Calin, GA; Croce, CM; Di Leva, G; Godwin, AK; Iliopoulos, D; Negrini, M; Nicoloso, MS; Petrocca, F; Qin, HR; Shimizu, M; Trapasso, F; Vecchione, A; Wojcik, SE; Yendamuri, S | 1 |
| Henson, R; Meng, F; Mize-Berge, J; Patel, T; Wehbe, H | 1 |
| Choi, JY; Kim, DS; Kim, MJ; Kim, SY; Lee, JY; Lee, SP; Lee, YM; Park, EK; Yang, JS | 1 |
| Chim, CS; He, H; Jiang, SH; Kung, HF; Leung, SY; Lin, MC; Sun, YW; Tu, SP; Wang, J; Wong, BC; Yang, Y; Yu, LF; Yuen, ST; Zeng, H; Zou, B | 1 |
| Connolly, DC; Dinulescu, DM; Donahoe, PK; Halpern, EF; MacLaughlin, DT; Pearsall, LA; Pieretti-Vanmarcke, R; Seiden, MV | 1 |
| Gore, SD; Jones, C; Kirkpatrick, P | 1 |
| Abraham, JM; Cheng, Y; Greenwald, BD; Hamilton, JP; Ito, T; Jin, Z; Kan, T; Meltzer, SJ; Mori, Y; Paun, BC; Sato, F; Wang, S; Yang, J | 1 |
| Atweh, GF; Fathallah, H | 1 |
| Aribi, A; Cortes, J; Davisson, J; Garcia-Manero, G; Issa, JP; Jabbour, E; Kantarjian, HM; O'Brien, S; Ravandi, F; Shan, J | 1 |
| Aoki, D; Banno, K; Hirao, N; Hirasawa, A; Kawaguchi, M; Susumu, N; Tsukazaki, K; Yanokura, M | 1 |
| Chen, GY; Ding, YB; Xia, JG | 1 |
| Bosenberg, M; Bradbury, CM; Curley, DP; Duraisamy, S; Hobbs, C; Muthusamy, V; Nelson, B | 1 |
| Agirre, X; Calasanz, MJ; Cordeu, L; Garate, L; Heiniger, A; Jiménez-Velasco, A; Prosper, F; Román-Gómez, J; San José-Eneriz, E; Torres, A | 1 |
| Galili, N; Raza, A; Raza, FZ | 1 |
| Cai, X; Long, JE | 1 |
| Atallah, E; Garcia-Manero, G; Kantarjian, H | 1 |
| Huang, W; Li, B; Tian, XL; Wu, LY; Yu, LF; Zhang, YF; Zhong, J | 1 |
| Araki, H; Boccuni, P; Hoffman, R; Mahmud, N; Yoshinaga, K; Zhao, Y | 1 |
| Bandle, R; Clair, T; Koh, E; Roberts, DD; Stracke, ML | 1 |
| Euhus, DM; Fong, KM; Gao, B; Gazdar, AF; Gerald, W; Girard, L; Jiang, A; Kim, YH; Lam, CL; Lewis, CM; Minna, JD; Nanda, R; Olopade, OI; Perou, CM; Pollack, JR; Sato, M; Shames, DS; Shay, JW; Shivapurkar, N; Shyr, Y; Wong, M | 1 |
| Enomoto, M; Iida, S; Ishiguro, M; Kato, K; Makino, H; Morita, S; Sugihara, K; Takagi, Y; Uetake, H | 1 |
| Chen, G; Wen, Q; Zhang, FQ; Zhang, TP; Zhao, YP | 1 |
| Druck, T; Fabbri, M; Han, SY; Huebner, K; Iliopoulos, D; Qin, HR | 1 |
| Agrawal, S; Berdel, WE; Huettner, CS; Koschmieder, S; Müller-Tidow, C; Ottmann, OG; Radomska, HS; Serve, HL; Tenen, DG | 1 |
| Bártová, E; Kozubek, S; Kozubík, A; Pacherník, J | 1 |
| Aparicio, AM; Egger, G; Escobar, SG; Jones, PA | 1 |
| Aribi, A; Borthakur, G; Cortes, J; Davisson, J; Kantarjian, H; Ravandi, F; Shan, J | 1 |
| Dietz, A; Tannapfel, A; Tischoff, I; Weber, A | 1 |
| Agrawal, S; Berdel, WE; Ehrich, M; Hofmann, WK; Koschmieder, S; Müller-Tidow, C; Serve, H; Tidow, N; van den Boom, D | 1 |
| Chen, Y; Deutschmann, N; Knösel, T; Kotb, WF; Lund, P; Pacyna-Gengelbach, M; Petersen, I; Schlüns, K; Sers, C; Usui, T; Yasumoto, H; Ye, F | 1 |
| Cortes, J; Garcia-Manero, G; Gharibyan, V; Issa, JP; Jones, D; Kantarjian, HM; Morris, GM; O'brien, S; Oki, Y; Verstovsek, S | 1 |
| Santini, V | 2 |
| Nguyen, DM; Schrump, DS | 1 |
| Chung, I; Conroy, JM; Johnson, CS; Karpf, AR; Muindi, JR; Nowak, NJ; Trump, DL | 1 |
| Benigno, BB; Bowen, NJ; Dickerson, EB; Matyunina, LV; McDonald, JF; Menendez, L; Polavarapu, N; Walker, D | 1 |
| Berger, W; Depisch, D; Filipits, M; Geradts, J; Heller, G; Kandioler, D; Markis-Ritzinger, EM; Newsham, I; Pirker, R; Stiglbauer, W; Ziegler, B; Zielinski, CC; Zöchbauer-Müller, S | 1 |
| Blum, W; Byrd, J; Chan, KK; Klisovic, R; Liu, S; Liu, Z; Marcucci, G; Paschka, P; Perrotti, D; Xie, Z | 1 |
| Bachmann, A; Rösl, F; Zawatzky, R | 1 |
| Abdullaev, Z; Benhattar, J; Bosman, FT; Guilleret, I; Lobanenkov, V; Loukinov, D; Renaud, S | 1 |
| Akahira, J; Ito, K; Moriya, T; Niikura, H; Okamura, K; Sakuma, M; Sasano, H; Yaegashi, N | 1 |
| Tainsky, MA; Wu, GS; Xu, J; Zhou, JY | 1 |
| Engelbrecher, A; Häuser, R; Titz, B; Uetz, P | 1 |
| Bergeron, A; Fradet, Y; Larue, H; Picard, V | 1 |
| Cui, X; Liu, T; Meng, WT; Xi, YM; Ye, XS | 1 |
| Angeloni, D; Braga, E; Danilkovitch-Miagkova, A; Ivanova, T; Lerman, MI; Zabarovsky, E | 1 |
| Wang, H; Xia, B; Yi, ZC; Zhang, GY | 1 |
| Aletti, G; Chien, J; Molina, J; Narita, K; Pan, Y; Qian, X; Roberts, LR; Scheerer, M; Shridhar, V; Staub, J | 1 |
| Steensma, DP; Tefferi, A | 1 |
| Bueso-Ramos, CE; Cortes, J; Davisson, J; Garcia-Manero, G; Huang, X; Issa, JP; Kantarjian, HM; O'Brien, S; Ravandi, F; Shan, J | 1 |
| Chen, CY; Cheng, YW; Lee, H; Tsai Chang, JH; Wu, TC; Wu, YH | 1 |
| Desmond, JC; Haferlach, T; Hofmann, WK; Koeffler, HP; Raynaud, S; Tung, E | 1 |
| Felsberg, J; Goodyer, CG; Hartmann, W; Hübner, A; Koch, A; Lindberg, I; Mikeska, T; Milde, U; Pietsch, T; Sörensen, N; Waha, A; Wiestler, OD | 1 |
| Cui, J; Huang, Q; Lai, M; Lin, J; Ma, Y; Ruan, W | 2 |
| Schiffer, CA | 1 |
| Arai, M; Fukai, K; Hirasawa, Y; Imazeki, F; Mikata, R; Miyazaki, M; Ochiai, T; Saisho, H; Tada, M; Yokosuka, O | 1 |
| Fang, JC; Feng, ZY; He, D; He, XL; Li, L; Qiu, G; Su, ZL; Zhu, MF | 1 |
| Kantarjian, HM | 1 |
| Garcia-Manero, G; Hoshino, K; Quintás-Cardama, A; Sanchez-Gonzalez, B; Yang, H | 1 |
| Hattori, N; Imao, Y; Nishino, K; Ohgane, J; Shiota, K; Tanaka, S; Yagi, S | 1 |
| Miller, CA; Sweatt, JD | 1 |
| Coral, S; Covre, A; Maio, M; Natali, PG; Nicolay, HJ; Sigalotti, L | 1 |
| Díaz-Montero, CM; Estecio, M; Issa, JP; Mao, L; Montero, AJ; Shen, L; Youssef, EM | 1 |
| Furuta, J; Kikuchi, K; Miyagi, Y; Nakagawa, H; Nakanishi, Y; Nobeyama, Y; Okochi-Takada, E; Ushijima, T; Yamamoto, A | 1 |
| Abecassis, M; Hummel, M; Li, Z; Varghese, TK; Yan, S | 1 |
| Brinkley, DM; Louie, RJ; Michelotti, GA; Morris, DP; Schwinn, DA; Smith, MP | 1 |
| Chan, AT; Chan, SL; Cui, Y; Jin, H; Lee, KY; Li, H; Ng, KM; Rha, SY; Robertson, KD; Srivastava, G; Tao, Q; Tsao, GS; van Hasselt, A; Wang, Y; Zhong, S | 1 |
| Deocaris, CC; Hasan, K; Ishii, T; Kaul, SC; Kaur, K; Sugihara, T; Wadhwa, R; Widodo, N; Yaguchi, T; Yamasaki, K | 1 |
| Kalberer, CP; Langenkamp, U; Rohner, A; Siegler, U; Wodnar-Filipowicz, A | 1 |
| Asuncion, L; Csiszar, K; Dietzsch, E; Fong, KS; Fong, SF; He, Q; Hollosi, P; Parker, MI | 1 |
| Kang, HJ; Kim, H; Kim, NK; Koh, KH; Rhee, H; Yang, E | 1 |
| Day, ML; Gschwend, JE; Kuefer, R; McCabe, MT; Wojno, KJ; Zorn, CS | 1 |
| Armeanu, S; Bitzer, M; Gregor, M; Hsieh, CJ; Lauer, UM; Pathil, A; Venturelli, S; Vonthein, R; Wehrmann, M; Weiss, TS | 1 |
| Bruserud, Ø; Ryningen, A; Stapnes, C | 1 |
| Chumakov, A; Gery, S; Imai, Y; Kawamata, N; Koeffler, HP; Komatsu, N; Kumagai, T; Takai, N; Wakimoto, N; Yin, D | 1 |
| Beri, S; Bonaglia, MC; Giorda, R; Menozzi, G; Sala, C; Tonna, N | 1 |
| Baba, H; Ichimura, T; Kawasuji, M; Koseki, H; Nakao, M; Sakamoto, Y; Watanabe, S | 1 |
| Hwang, KA; Kang, I; Kim, HR; Kim, KC | 1 |
| Dou, KF; Zhao, QZ | 1 |
| Fridman, AL; Li, Q; Rosati, R; Tainsky, MA | 1 |
| Cohn, SL; Cornell, J; McArdle, L; Nair, PN; Stallings, RL | 1 |
| Chang, X; Ethier, SP; Guo, Z; Kim, MS; Kivirikko, KI; Liu, J; Maki, JM; Nagpal, JK; Sidransky, D; Trink, B; Wu, G | 1 |
| Chan, CY; Cheung, OF; Ching, YP; Lee, JM; Ng, IO; Ng, YL; Tung, EK; Wong, CC; Wong, CM | 1 |
| Aubert, JP; Desseyn, JL; Perrais, M; Pigny, P; Van Seuningen, I; Vincent, A | 1 |
| Hou, J; Li, H; Li, J; Liew, CT; Yin, D; Zhang, C; Zhang, J; Zhang, Q; Zhang, T; Zhou, G | 1 |
| Li, H; Peng, D; Ren, CP; Wang, L; Yao, KT; Yi, HM; Zhang, HJ; Zhao, M | 1 |
| Allen, Y; Aniagu, SO; Chipman, JK; Katsiadaki, I; Williams, TD | 1 |
| Fuks, F; Griffioen, AW; Hellebrekers, DM; Herman, JG; Langenkamp, E; Melotte, V; Molema, G; Van Criekinge, W; van Engeland, M; Viré, E | 1 |
| Callet-Bauchu, E; Emura, M; Groenen, P; Kamphues, K; Lehmann, U; Ripperger, T; Rudolph, C; Schlegelberger, B; Schraders, M; Skawran, B; Steinemann, D; Tauscher, M; van Krieken, JH; von Neuhoff, N | 1 |
| Jagodzinski, PP; Piotrowska, H | 2 |
| Iliopoulos, D; Malizos, KN; Tsezou, A | 1 |
| Bennett, KL; Eng, C; Hackanson, B; Lang, JC; Morrison, CD; Plass, C; Schuller, DE; Smith, LT; Weber, F | 1 |
| Bulun, SE; Cheng, YH; Confino, E; Lin, Z; Milad, MP; Reierstad, S; Xue, Q; Yin, P | 1 |
| Huang, TH; Liu, JC; Plass, C; Potter, D; Smith, LT; Wang, SH; Wu, J; Wu, YZ | 1 |
| Erickson, LA; Erlichman, C; Hobday, TJ; Jin, L; Lloyd, RV; Nakamura, N; Ruebel, KH; Rumilla, KM; Stilling, GA; Zhang, HY | 1 |
| Kim, JW; Rossi, JJ; Wu, J; Zern, MA; Zhang, YH | 1 |
| Di, GH; Fan, J; Hou, YF; Lei, W; Li, DQ; Lu, JS; Shao, ZM; Shen, ZZ; Wu, FY; Wu, J; Yin, WJ | 1 |
| Fan, QX; Li, LW; Lu, SH; Wang, LX; Wang, R; Wang, RL; Zhao, PR | 1 |
| Altomonte, M; Calabrò, L; Colizzi, F; Fonsatti, E; Guidoboni, M; Maio, M; Marincola, FM; Nicolay, HJ; Pezzani, L; Sigalotti, L | 1 |
| Hata, H; Mitsuya, H; Okuno, Y; Takeya, M; Tatetsu, H; Tenen, DG; Ueno, S; Yamada, Y | 1 |
| Chen, D; Cheng, L; Gao, L; Lu, ZH; Pan, SY; Shu, YQ; Xie, EF; Yang, D; Zhang, JN; Zhang, LX | 1 |
| Cashen, AF; DiPersio, J; Fisher, N; Shah, AK; Todt, L | 1 |
| Bang, YJ; Im, SA; Jong, HS; Jung, Y; Kim, TY; Park, J; Park, JH; Robertson, KD | 1 |
| Anderton, JA; Clifford, SC; Ellison, DW; Gilbertson, RJ; Lindsey, JC; Lusher, ME | 1 |
| Kelly, TL; Oakes, CC; Robaire, B; Trasler, JM | 1 |
| Fernández-Nestosa, MJ; Hernández, P; Krimer, DB; Schvartzman, JB | 1 |
| Daigle, D; Gradoville, L; Miller, G; Ye, J | 1 |
| Amagasa, T; Imoto, I; Inazawa, J; Kamata, N; Kozaki, KI; Nakagawa, T; Pimkhaokham, A; Suzuki, E | 1 |
| Davie, JR; Diasio, RB; Guarcello, V; Li, L; Soong, R; Wang, K; Zhang, X | 1 |
| Bai, S; Ghoshal, K | 1 |
| Egger, G; Jeong, S; Jones, PA; Liang, G; Phiasivongsa, P; Redkar, S; Tang, C; Yoo, CB | 1 |
| Bruno, E; Hoffman, R; Hu, W; Ishii, T; Lindgren, V; Shi, J; Sozer, S; Xu, M; Zhang, W; Zhao, Y | 1 |
| Henson, R; Meng, F; Patel, T; Smith, H; Wehbe-Janek, H | 1 |
| Bulun, SE; Cheng, YH; Confino, E; Huang, CC; Innes, J; Lin, Z; Marsh, E; Milad, MP; Reierstad, S; Xue, Q; Yin, P | 1 |
| Hu, GF; Ibaragi, S; Katsurano, M; Sasaki, A; Shima, K; Tsuji, T | 1 |
| Chen, R; Garcia-Manero, G; Issa, JP; Jelinek, J; Qin, T; Yang, AS; Youssef, EM | 1 |
| Ekström, L; Gustafsson, O; Morfin, R; Olsson, M; Rane, A; Rietz, BD; Skogastierna, C; Tolf, A | 1 |
| Chen, Y; Tang, Q; Xu, L; Zou, S; Zuo, S | 1 |
| Claus, R; Kunzmann, R; Lübbert, M; Rüter, B; Wijermans, P | 1 |
| Giagounidis, AA | 1 |
| Bae, SI; Borden, EC; Cheriyath, V; Jacobs, BS; Reu, FJ | 1 |
| Harada, T; Izawa, M; Ohama, Y; Takenaka, Y; Taniguchi, F; Terakawa, N | 1 |
| Jeong, YS; Kang, YK; Lee, KK; Park, JS; Shin, ST | 1 |
| Blum, W; Byrd, JC; Chan, KK; Devine, H; Devine, SM; Grever, MR; Hackanson, B; Heerema, NA; Huynh, L; Kefauver, C; Klisovic, RB; Liu, S; Liu, Z; Lozanski, G; Marcucci, G; Murgo, A; Plass, C; Vukosavljevic, T | 1 |
| Atallah, E; Garcia-Manero, G | 1 |
| Byun, HM; Choi, SH; Issa, JP; Kwan, JM; Yang, AS | 1 |
| Iida, S; Kato, K; Morita, S; Sugihara, K; Takagi, Y; Uetake, H | 1 |
| Imreh, S; Klein, G; Popescu, NC; Zhou, X | 1 |
| Chin, J; Desimone, J; Hankewych, M; Lavelle, D; Phiasivongsa, P; Redkar, S; Roxas, B; Saunthararajah, Y; Singh, M; Tang, C; Vaitkus, K; Will, R | 1 |
| Bronner, C; Giordano, A; Gregorio, V; Macaluso, M; Montanari, M; Noto, PB | 1 |
| Issa, JP; Kantarjian, HM; Plimack, ER | 1 |
| Friday, BB; Steensma, DP | 1 |
| Higashi, M; Kinoshita, Y; Maehara, Y; Souzaki, R; Suita, S; Taguchi, T; Tajiri, T; Tatsuta, K | 1 |
| Gollob, JA; Sciambi, CJ | 1 |
| Godley, LA; Kihslinger, JE | 1 |
| Sasaki, A; Satoh, N | 1 |
| Jagodziński, PP; Miller-Kasprzak, E | 1 |
| Baer, MR; Lübbert, M; Rüter, B; Saba, HI; Slack, JL; Wijermans, PW | 1 |
| Campbell, SL; Miller, CA; Sweatt, JD | 1 |
| Chim, CS; Choi, CL; Fung, TK; Liang, R; Pang, R | 1 |
| Keen, JC; Obajimi, O; Pryzbylkowski, P | 1 |
| Akao, Y; Kinoshita, T; Kitade, Y; Nakagawa, Y; Naoe, T | 1 |
| Cheng, YC; Fan, H; Lu, ZH; Shan, YF; Xie, W; Zhang, JQ; Zhao, ZJ | 1 |
| Jasti, BR; Li, X; Mahalingam, R; Ravivarapu, H; Redkar, S | 1 |
| Baek, JH; Chang, X; Dasgupta, S; Kim, MS; Moon, C; Nagpal, JK; Osada, M; Ratovitski, EA; Sidransky, D; Trink, B; Westra, WH; Woo, JH; Wu, G; Yamashita, K | 1 |
| Luo, J; Qi, J; Tao, WH; Zhu, YQ | 1 |
| Issa, JP; Plimack, ER; Stewart, DJ | 1 |
| Appleton, K; Barrett, S; Bellenger, K; Brown, R; Jadayel, D; Judson, I; Kaye, SB; Lee, C; Mackay, HJ; Mackay, L; McCormick, C; Plumb, JA; Reade, S; Schätzlein, A; Setanoians, A; Strathdee, G; Tang, A; Twelves, C | 1 |
| Engers, R; Hader, C; Hoffmann, MJ; Jung, V; Müller, M; Schulz, WA; Wlazlinski, A | 1 |
| Dubovsky, JA; McNeel, DG | 1 |
| Bauters, M; Cassiman, JJ; De Wever, I; Pourebrahim, R; Sciot, R; Tejpar, S; Van Dam, K | 1 |
| Chang, WK; Jeong, YS; Kang, YK; Koo, DB; Lee, KK; Park, JS; Yeo, S | 1 |
| Carén, H; Ejeskär, K; Fransson, S; Kogner, P; Martinsson, T | 1 |
| Christgen, M; Hasemeier, B; Kreipe, H; Länger, F; Lehmann, U; Müller, M; Römermann, D | 1 |
| Bandzuchova, E; Kuba, D; Polakova, K; Russ, G; Tirpakova, J | 1 |
| Akintola, AD; Burghardt, RC; Catania, JM; Chen, G; Crislip, ZL; Parrish, AR; Zimmer, WE | 1 |
| Dai, DQ; Wang, JF | 2 |
| Li, K; Li, Z; Teng, L; Wei, L; Wu, K; Yu, P; Zhang, C; Zhu, J | 1 |
| Domann, FE; Fitzgerald, MP; Krager, K; Provenzano, MJ | 1 |
| Chai, G; Feng, J; Li, L; Lu, S; McNutt, MA; Wang, H; Wu, L; Yang, Y; Yu, Y; Zhao, Y; Zhou, W; Zhu, WG | 1 |
| Chung, DC; Kawasaki, T; Kirley, SD; Kwon, E; Lauwers, GY; Mino-Kenudson, M; Ogino, S; Park, DY; Rueda, BR; Sakamoto, H; Zukerberg, LR | 1 |
| D'Souza, T; Honda, H; Ji, H; Morin, PJ; Pazin, MJ | 1 |
| Brown, KD; Palii, SS; Robertson, KD; Sankpal, UT; Van Emburgh, BO | 1 |
| Lea, R; Patel, R; Shervington, A; Shervington, L | 1 |
| Delmas, AL; Fields, CR; Jin, B; Liu, X; Peng, J; Qiu, J; Robertson, KD; Soo, HM; Tao, Q; Wu, W; Ying, J | 1 |
| Baker, JA; Brown, KW; Chilukamarri, L; Dallosso, AR; Greenhough, A; Hancock, AL; Huang, TH; Malik, K; Malik, S; Royer-Pokora, B; Zabkiewicz, J | 1 |
| Da, L; Li, D; Li, T; Tang, H; Zhao, M | 1 |
| Hájek, M; Holý, A; Krecmerová, M; Tloust'ová, E; Votruba, I | 1 |
| Issa, JP; Jelinek, J; Kantarjian, HM; Oki, Y; Shen, L | 1 |
| Fabianowska-Majewska, K; Krawczyk, B; Rudnicka, K | 1 |
| Chen, J; Huang, T; Liu, K; Wang, G; Zhang, B | 1 |
| Gurdon, JB; Ng, RK | 1 |
| Dion, V; Fyffe, SL; Gorbunova, V; Lin, Y; Price, BA; Seluanov, A; Wilson, JH | 1 |
| Bishop, MC; Li, G; McArdle, SE; Rees, RC; Seth, R; Walton, TJ | 1 |
| Capanni, C; Columbaro, M; D'Apice, MR; Foisner, R; Lattanzi, G; Maraldi, NM; Mattioli, E; Novelli, G; Riccio, M; Santi, S; Squarzoni, S | 1 |
| Bilban, M; Drach, J; Heller, G; Holzer, S; Müllauer, L; Schmidt, WM; Ziegler, B; Zielinski, CC; Zöchbauer-Müller, S | 1 |
| Sloand, EM | 1 |
| Gore, SD; Griffiths, EA | 2 |
| Hattori, N; Maeda, C; Sato, S; Shiota, K; Tanaka, S; Yagi, S | 1 |
| Garcia-Manero, G; Jagasia, M; Yang, AS | 1 |
| Dai, DQ; Liu, HB; Shen, WJ; Teng, Y | 2 |
| Aventín, A; Brunet, S; Carnicer, MJ; Lasa, A; Nomdedéu, JF; Orantes, V; Pena, J; Serrano, E; Sierra, J | 1 |
| Arrouss, I; Billot, K; Cario-Andre, M; Duhamel, M; Navarro, P; Rebollo, A | 1 |
| Guichard, SM; Jodrell, DI; Patel, K | 1 |
| Ito, M; Kawatsura, H; Kondo, Y; Kuzushima, K; Narita, Y; Natsume, A; Sekido, Y; Shimato, S; Tsujimura, K; Wakabayashi, T; Yoshida, J | 1 |
| Bernard, HU; Calleja-Macias, IE; Kalantari, M; Lambert, PF; Lee, D | 1 |
| Ariga, T; Asamoto, M; Hagiwara, H; Hokaiwado, N; Nagashima, Y; Ohde, Y; Sato, H; Seki, T; Shirai, T; Takano, Y; Yano, T | 1 |
| Di, GH; Fan, J; Lu, JS; Shao, ZM; Shen, ZZ; Wang, L; Wu, FY; Wu, J; Yin, WJ | 1 |
| Grosveld, FG; Patrinos, GP | 1 |
| Cirillo, LA; Horswill, MA; Narayan, M; Twining, SS; Warejcka, DJ | 1 |
| Ateeq, B; Rabbani, SA; Szyf, M; Unterberger, A | 1 |
| DeSimone, J; Gowhari, M; Lavelle, D; Molokie, R; Saraf, S; Saunthararajah, Y; Sidhwani, S; Vara, S | 1 |
| Mitani, K | 1 |
| Czymmek, KJ; Kamboj, S; Kudo, S; Kumar, A; LaSalle, JM; Malone, BM; Schanen, NC; Twiss, JL | 1 |
| Jagodziński, PP; Kozłowska, A | 1 |
| Countryman, JK; Gradoville, L; Miller, G | 1 |
| Biacsi, R; Kumari, D; Usdin, K | 1 |
| Hsu, HS; Hsu, WH; Lin, RK; Tseng, C; Tseng, RC; Wang, YC; Wen, CK | 1 |
| Basma, H; Cheng, PW; Christman, J; Klinkebiel, D; Radhakrishnan, P | 1 |
| Chen, J; Gao, WR; Lu, J; Mei, Q; Xu, ZM | 1 |
| Hosoya, K; McDonell, N; Niwa, T; Shirai, T; Takahashi, S; Tsujino, Y; Ushijima, T; Watanabe, N; Yamashita, S | 1 |
| Kuendgen, A; Lübbert, M | 2 |
| Ip, CK; Lai, KP; Law, AY; Wagner, GF; Wong, AS; Wong, CK | 1 |
| He, CX; Huang, AL; Ren, H; Shi, YS; Song, GB; Steinle, A; Tang, KF; Wu, J; Zeng, GL; Zhang, WG | 1 |
| Luo, J; Qi, J; Tao, WH; Zhang, JM; Zhu, YQ | 1 |
| Bernstein, ML; Lemaire, M; Momparler, LF; Momparler, RL; Raynal, NJ | 1 |
| Ahdab, SE; Borthakur, G; Faderl, S; Ferrajoli, A; Issa, JP; Kantarjian, H; Newman, B; Ravandi, F | 1 |
| Garcia-Manero, G; Issa, JP; Jabbour, E; Kantarjian, H | 1 |
| Dahiya, R; Hirata, H; Kawamoto, K; Kikuno, N; Nakagawa, M; Tanaka, Y | 1 |
| Fitzgerald, RC; Gjerset, RA; Huang, Y; Peters, CJ | 1 |
| Chen, XP; Gutmann, DH; Huang, ZY; Xiao, ZY; Xiong, M; Yan, Q; Zhang, ZF | 1 |
| Lyko, F; Stresemann, C | 1 |
| Dahiya, R; Hirata, H; Igawa, M; Kawamoto, K; Kikuno, N; Majid, S; Shiina, H; Tanaka, Y; Urakami, S | 1 |
| Chan, KY; Cheung, AN; Li, AS; Ngan, HY; Siu, MK; Wong, ES; Wong, KY; Zhang, HJ | 1 |
| Bera, TK; Ha, D; Hahn, Y; Kaufman, DS; Lee, B; Lee, Y; Pastan, I; Pera, M; Saint Fleur, A; Yamada, M | 1 |
| Eblin, KE; Futscher, BW; Gandolfi, AJ; Jensen, TJ; Novak, P | 1 |
| Bernstein, ML; Chabot, GG; Hurtubise, A; Lemaire, M; Momparler, LF; Momparler, RL; Raynal, NJ | 1 |
| Cheetham, S; Kennecke, H; Mesak, F; Owen, D; Tai, IT; Tang, MJ | 1 |
| Chen, ZC; Liang, T; Tan, T; Xiao, YH; Xiao, ZQ; Yi, H | 1 |
| Al-Romaih, K; Sadikovic, B; Squire, JA; Wang, Y; Yoshimoto, M; Zielenska, M | 1 |
| Issa, JP; Oki, Y | 1 |
| Ai, GW; Liu, W; Ma, XX; Meng, XQ; Meng, YS; Wei, R; Zhang, YX | 1 |
| Beltran, AS; Blancafort, P; Lizardi, PM; Sun, X | 1 |
| Baron, U; Floess, S; Freyer, J; Garbe, A; Hamann, A; Huehn, J; Kretschmer, K; Olek, S; Polansky, JK; von Boehmer, H | 1 |
| Chen, T; Feng, XZ; He, XS; Jiang, JH; Liu, JL; Luo, Q; Tang, XF; Yang, S; Zhuang, YZ | 1 |
| Hinckley, MR; Molnár, I; Sangueza, OP; Sheehan, DJ; Walsh, SN; Yosipovitch, G | 1 |
| Byun, HM; Choi, SH; Laird, PW; Marquez, VE; Siddiqui, MA; Trinh, B; Yang, AS | 1 |
| Blackburn, ML; Chansky, HA; Hennings, LJ; Ma, X; Pan, J; Roberson, RS; Wu, DY; Yang, L; Yared, M; Zou, J | 1 |
| Allgayer, H; Mudduluru, G | 1 |
| Ito, N; Kamoto, T; Liu, Y; Matsui, Y; Nishiyama, H; Ogawa, O; Shang, D | 1 |
| Chan, MT; Cheyette, BN; Jiang, X; Kivimäe, S; Lee, PL; Li, J; Liu, ET; Stanton, LW; Tan, J; Yang, X; Yu, Q; Zhuang, L | 1 |
| Asa, SL; Ezzat, S; Hurren, R; Mao, X; Schimmer, AD; Zhu, X | 1 |
| Chiba, H; Nakayama, F; Sawada, N; Semba, S; Usami, Y; Yokozaki, H | 1 |
| Chan, DW; Chan, PC; Lee, JM; Ng, IO | 1 |
| An, J; Ji, F; Jiao, H; Sun, H; Wang, R; Zhou, D | 1 |
| Ding, X; Guo, Z; Wang, Y; Zhang, D; Zhang, Y | 1 |
| Califano, JA; Henrique, R; Jeronimo, C; Kim, MS; Lee, J; Liu, JW; Moon, CS; Nagpal, JK; Ostrow, KL; Sidransky, D; Sun, W; Trink, B; Van Criekinge, W; Zhou, S | 1 |
| Asaoka, Y; Fukai, K; Imazeki, F; Kanai, F; Kawabe, T; Muroyama, R; Ohta, M; Omata, M; Seto, M; Tada, M; Tanaka, Y; Tateishi, K; Yokosuka, O | 1 |
| Chai, G; Chen, Y; Hu, YG; Li, L; Lu, S; McNutt, MA; Otterson, GA; Wang, D; Wang, H; Wu, L; Wu, X; Yang, Y; Yu, Y; Zhao, Y; Zhou, W; Zhu, WG | 1 |
| Amariglio, N; Berkun, Y; Cohen, Y; Dominissini, D; Goldstein, I; Nagar, M; Rechavi, G; Vernitsky, H | 1 |
| Holmberg, AR; Liu, Z; Marquez, M; Nilsson, S | 1 |
| Brodeur, GM; Fujita, T; Gotoh, T; Igarashi, J; Kim, J; Kolla, V; London, WB; Manne, J; Maris, JM; Okawa, ER; Pawel, BR; White, PS; Zhao, H | 1 |
| Eu, KW; Hong, Y; Ismail, TM; Liu, Y; Wong, Y; Zhao, Y | 1 |
| Asano, Y; Nakajima, W; Oda-Sato, E; Takeshita, T; Tanaka, N; Uehara, I; Yagi, S | 1 |
| Chen, Y; Fang, J; Lu, R; Sun, D; Toan, X; Wang, X; Zhang, Y | 1 |
| Bologna, M; D'Alessandro, AM; Di Rocco, C; Dolo, V; Festuccia, C; Gravina, GL; Millimaggi, D; Ricevuto, E; Vicentini, C | 1 |
| Arai, M; Imazeki, F; Mikata, R; Ochiai, T; Sakai, Y; Seki, N; Shimada, H; Tada, M; Yokosuka, O | 1 |
| Ammerpohl, O; Fölsch, UR; Kalthoff, H; Koch, D; Müerköster, SS; Schäfer, H; Sipos, B; Tsao, MS; Werbing, V | 1 |
| Atadja, P; Bhalla, K; Chen, J; Eaton, K; Fernandez, P; Fiskus, W; Herger, B; Joshi, R; Kolhe, R; Lee, P; Mandawat, A; Peiper, S; Rao, R; Wang, Y; Yang, Y | 1 |
| Chen, H; El-Rifai, W; Peng, DF; Razvi, M; Roessner, A; Schneider-Stock, R; Washington, K | 1 |
| Chan, AT; Cheng, YY; Cheung, KF; Ebert, MP; Jin, H; Li, H; Poon, FF; Röcken, C; Sung, JJ; Tao, Q; Wang, X; Yu, J | 1 |
| Choi, CH; Kim, KJ; Lee, TB; Min, YD; Park, JH | 1 |
| Daibata, M; Imai, S; Kotani, N; Nemoto, Y; Shuin, T; Taniguchi, A; Yokoyama, A | 1 |
| Kotoula, V; Papaioannou, M; Sapalidis, K | 1 |
| Estey, E | 1 |
| Büsche, G; Dobbelstein, C; Fenner, M; Ganser, A; Hasemeier, B; Krauter, J; Kreipe, H; Lehmann, U; Metzig, K; Römermann, D; Steinemann, D | 1 |
| Iacobazzi, V; Infantino, V; Palmieri, F | 1 |
| Ding, XS; Hang, HM; Jiang, SH; Liu, H; Song, GQ; Wang, XF; Xu, RR; Yang, L | 1 |
| Cho, JS; Hahn, Y; Jang, HR; Jeong, HY; Kim, HM; Kim, JH; Kim, M; Kim, YS; Lee, CW; Noh, SM; Song, KS; Yeom, YI; Yoo, HS | 1 |
| DeRemer, DL; Farrow, S; Jillella, A; Kalla, A; Ustun, C | 1 |
| Bokelmann, I; Lyko, F; Mahlknecht, U; Stresemann, C | 1 |
| Adair, SJ; Hogan, KT | 1 |
| Eling, TE; Kamitani, H; Watanabe, T; Yoshioka, H | 1 |
| Bonazzi, VF; Hayward, NK; Irwin, D | 1 |
| Fu, WL; Huang, Q; Yao, J; Zhang, XB | 1 |
| Kim, DH; Kim, SJ; Lee, BB; Lee, EJ; Park, J; Park, YD | 1 |
| Fang, J; Sun, D; Tian, XQ; Xiong, H; Zhang, Y; Zhao, S | 1 |
| Assaraf, YG; Bram, EE; Gonen, N | 1 |
| Combaret, V; De Paepe, A; Hoebeeck, J; Hoyoux, C; Laureys, G; Michels, E; Pattyn, F; Speleman, F; Vandesompele, J; Vermeulen, J; Yigit, N | 1 |
| Bandzuchová, E; Kuba, D; Poláková, K; Russ, G | 1 |
| Ahuja, N; Baylin, SB; Costello, JF; Easwaran, H; Eberhart, CG; Glöckner, SC; Herman, JG; James, CD; Laterra, J; Lin, S; Ohm, JE; Riggins, G; Schuebel, KE; Tsai, HC; Vescovi, AL; Yi, JM | 1 |
| Miyazawa, K | 1 |
| Brown, KD; Demircan, B; Dyer, LM; Gerace, M; Lobenhofer, EK; Robertson, KD | 1 |
| Garcia-Manero, G | 3 |
| Deng, T; Zhang, Y | 2 |
| Kim, J; Kim, WH; Lee, SH; Lee, YM | 1 |
| Agate, L; Capodanno, A; Ciampi, R; Collecchi, P; Elisei, R; Miasaki, FY; Pinchera, A; Vivaldi, A | 2 |
| Aparicio, SA; Carlton, M; Colledge, B; de Algara, TR; Dixon, J; Heuser, M; Humphries, RK; Leung, M; McKinney, S; Tafech, A; Thresher, R; Yap, DB | 1 |
| Jernberg-Wiklund, H; Nilsson, K; Oberg, F; Tshuikina, M | 1 |
| Issa, JP; Jelinek, J; Qin, T; Shu, J; Si, J | 1 |
| Garcia-Manero, G; Jain, N; Rossi, A | 1 |
| Aoe, K; Date, H; Fujimoto, N; Kimura, K; Kishimoto, T; Kubo, T; Otani, H; Pass, HI; Sano, Y; Soh, J; Suehisa, H; Toyooka, S; Tsukuda, K; Yamamoto, H | 1 |
| Eisenhofer, G; Hagelgans, A; Kostka, H; Menschikowski, M; Siegert, G | 1 |
| Charbonneau, M; Momparler, LF; Momparler, RL; Raynal, NJ | 1 |
| Huang, Y; Li, Y; Sun, B; Tian, K; Wang, Y; Xu, H | 1 |
| Chen, Z; Gao, L; Gu, B; Pan, S; Shu, Y; Wang, F; Xu, J; Yang, D; Zhang, L | 1 |
| Nomdedeu, B | 1 |
| Baer, MR; James, SR; Jones, DA; Karpf, AR; Link, PA | 1 |
| Hostetter, CL; Keen, JC; Licata, LA | 1 |
| Cha, SI; Chae, MH; Choi, JE; Jheon, S; Jung, TH; Kim, CH; Kim, DS; Kim, EJ; Park, JY | 1 |
| Ito, M; Kondo, Y; Maeda, Y; Natsume, A; Oi, S; Saito, K; Shimato, S; Wakabayashi, T | 1 |
| Maekita, T; Nakajima, T; Nakazawa, K; Niwa, T; Ushijima, T; Yamashita, S | 1 |
| Roberts, I; Trompeter, S | 1 |
| Bian, X; Chen, K; Dunlop, NM; Gao, Y; Gong, W; Howard, OM; Huang, J; Wang, JM | 1 |
| Hirakawa, K; Matsuzaki, T; Qiu, H; Shinto, O; Yashiro, M | 1 |
| Stone, RM | 2 |
| Shaffer, JM; Smithgall, TE | 1 |
| Dai, DQ; Guo, KJ; Meng, CF | 1 |
| Estey, E; Scott, BL | 1 |
| Li, Z; Yang, N | 1 |
| Huang, Q; Lai, MD; Lin, J; Shao, LN; Zhu, YM | 1 |
| Aghai, Z; Blokland, E; Bruijn, JA; Goulmy, E; Halfwerk, H; Hambach, L; Ling, KW; Pool, J; Tanke, HJ; van Boven, H; Wieles, B | 1 |
| Baldus, CD; Bohne, A; Heesch, S; Hofmann, WK; Mossner, M; Schlee, C; Thibaut, J; Thiel, E | 1 |
| Bottinger, EP; Bromberg, JS; Ding, Y; Ju, W; Lal, G; Levy, DE; Reid, SP; van der Touw, W; Zhang, N | 1 |
| Chihara, Y; Chuang, JC; Egger, G; Friedman, JM; Liang, G; Saito, Y | 1 |
| Baldwin, AS; Figueroa, ME; Laurenzana, A; Melnick, A; Miller, WH; Paoletti, F; Petruccelli, LA; Pettersson, F | 1 |
| Goto, M; Higashi, M; Nishida, Y; Nomoto, M; Tsutsumida, H; Yamada, N; Yonezawa, S | 1 |
| Danilov, AV; Feeney, DM; Miller, KB; Relias, V | 1 |
| Cornelius, LA; Feng, Y; Gao, L; Yuan, L; Zhao, H; Zheng, H | 1 |
| Champlin, R; Davisson, J; de Lima, M; De Padua Silva, L; Faderl, S; Garcia-Manero, G; Giralt, S; Issa, JP; Kantarjian, H; Kebriaei, P; Ravandi, F | 1 |
| Dullin, C; Ecke, I; Hahn, H; Hess, I; Johnsen, SA; Kimmina, S; Mönkemeyer, S; Nitzki, F; Petry, F; Pirngruber, J; Rosenberger, A; Schulz-Schaeffer, W; Tauber, S; Uhmann, A; Witt, O; Wojnowski, L | 1 |
| Chan, CH; Chen, CC; Gau, JP; Lee, KD; Lin, JT; Lu, CH; You, JY | 1 |
| Arora, S; Hogan, WJ; Litzow, MR; Porcher, JC; Steensma, DP; Van Laar, ES | 1 |
| Brower, JV; Hamazaki, T; Han, C; Hankowski, KE; Lim, CH; Terada, N | 1 |
| Feng, L; Liu, Q; Liu, Y; Lv, W; Shang, D; Tian, Y; Zhang, F | 1 |
| Dai, X; Liu, X; Wu, B | 1 |
| Kato, Y; Tsuji, Y; Tsunoda, Y | 1 |
| Dai, Y; Desai, N; Kwong, J; Mok, SC; Motamed, K; Ramalingam, P; Said, N; Socha, MJ; Trieu, V | 1 |
| Forshell, LP; Höglund, A; Maclean, KH; Nilsson, JA; Nilsson, LM | 1 |
| Fathallah, H | 1 |
| Batz, C; Claus, R; Flotho, C; Ihde, S; Lübbert, M; Niemeyer, CM; Plass, C; Sandrock, I; Schneider, M | 1 |
| Cortés, F; Mateos, S; Orta, ML | 1 |
| Gore, SD | 1 |
| Karp, J | 1 |
| Alonso, MA; Horne, HN; Lee, PS; Marks, JR; Murphy, SK; Olson, JA | 1 |
| Capper, D; Gaiser, T; Habel, A; Hartmann, C; Herold-Mende, C; Mueller, W; Siegelin, MD; von Deimling, A | 1 |
| De Schutter, H; Isebaert, S; Kimpe, M; Nuyts, S | 1 |
| Ahmad, AE; Dahiya, AV; Dahiya, R; Dar, AA; Hirata, H; Kawakami, K; Khatri, G; Majid, S; Saini, S; Shahryari, V; Tanaka, Y | 1 |
| Lin, F; Liu, CY; Liu, HL; Lu, FZ; Wang, XG; Xue, CY; Yu, JN | 1 |
| Choi, E; Deng, G; Kakar, S; Kim, YS; Okudiara, K; Sleisenger, MH | 1 |
| Amatori, S; Bagaloni, I; Catalano, A; Donati, B; Fanelli, M; Lazzarini, R; Papalini, F; Pelicci, PG; Procopio, A; Rippo, MR | 1 |
| Ariyan, S; Bacchiocchi, A; Cheng, E; Deng, M; Enghild, JJ; Halaban, R; Kluger, Y; Kovacs, D; Krauthammer, M; Molinaro, A; Narayan, D; Pelizzola, M; Picardo, M; Sznol, M; Tran, N; Zhang, W | 1 |
| Cai, Y; Gao, X; Gu, SZ; Liu, L; Liu, ZJ; Wang, G; Zhang, XB | 1 |
| Wang, H; Wang, Y | 1 |
| Brown, R; Finn, P; Plumb, JA; Steele, N | 1 |
| Hashizume, K; Kizaki, K; Nakaya, Y; Patel, OV; Takahashi, T | 1 |
| Jin, LH; Lei, L; Li, QM; Shan, ZY; Su, DJ; Wang, N; Zhang, XM | 1 |
| Liao, W; McNutt, MA; Zhu, WG | 1 |
| Bronson, R; Charest, A; Coven, S; Housman, D; Jun, HJ; Lane, K; Woolfenden, S | 1 |
| Boyd, AW; Doecke, J; Herath, NI; Leggett, BA; Spanevello, MD | 1 |
| Atadja, P; Balusu, R; Bhalla, KN; Buckley, K; Chen, J; Fiskus, W; Joshi, A; Joshi, R; Koul, S; Mandawat, A; Rao, R; Upadhyay, S; Wang, Y; Yang, Y | 1 |
| Bapat, B; Briollais, L; Fleshner, N; Kron, K; Ozcelik, H; Pethe, V; Pinthus, J; Sadikovic, B; Sunderji, A; van der Kwast, T; Venkateswaran, V | 1 |
| Jo, I; Kim, YO; Seo, J | 1 |
| Blum, S; Gattermann, N; Germing, U; Haas, R; Habersang, K; Kuendgen, A; Möller, I | 1 |
| Cecconi, D; Dalla Pozza, E; Donadelli, M; Palmieri, M; Righetti, PG; Rinalducci, S; Scarpa, A; Scupoli, MT; Zolla, L | 1 |
| Chen, J; Cui, M; Wen, Z; Yang, Z; Zhang, H | 1 |
| Bermúdez, A; Bureo, E; Iriondo, A; Richard, C; Yánez, L | 1 |
| Bosch, LJ; Carvalho, B; de Bruïne, AP; Derks, S; Herman, JG; Meijer, GA; Moerkerk, PT; Mongera, S; Niessen, HE; van den Bosch, SM; van Engeland, M; Voncken, JW | 1 |
| Csiszar, K; Fong, KS; Fong, SF; Hollosi, P; Yakushiji, JK | 1 |
| Bhat, G; Liu, L; Tollefsbol, TO; Yap, OW | 1 |
| Broaddus, RR; Loose, DS; Nabilsi, NH | 1 |
| Bertz, H; Claus, R; Finke, J; Lübbert, M; Marks, R; Rüter, B; Wäsch, R | 1 |
| Epstein, RJ; Xiong, J | 1 |
| Basile, FG | 1 |
| Dong, ZR; Li, Y; Liu, XJ; Luo, JM; Wang, FX; Wen, SP; Yang, L; Zhang, JY; Zhang, XJ | 1 |
| Banerjee, D; Bertino, JR; Humeniuk, R; Mishra, PJ | 1 |
| Garcia-Manero, G; Lyons, RM; Sekeres, M; Stone, R | 1 |
| Barragán, E; Bolufer, P; Cervera, J; Moscardó, F; Román-Gómez, J; Sanz, GF; Sanz, MA; Such, E; Valencia, A | 1 |
| Drew, PA; Jones, ME; Smith, E | 1 |
| Hou, K; Hu, X; Jing, W; Liu, Y; Qu, X; Teng, Y; Yang, X; Zhang, J; Zhang, Y | 1 |
| Dubovsky, JA; Gordon, J; McNeel, DG; Pinilla-Ibarz, JA; Powers, JJ; Sotomayor, EM | 1 |
| Agirre, X; Arqueros, V; Cervantes, F; Cordeu, L; Fresquet, V; Gárate, L; Heiniger, A; Jiménez-Velasco, A; Martín, V; Martínez-Climent, JA; Prósper, F; Roman-Gomez, J; San José-Eneriz, E; Torres, A | 1 |
| Farzaneh, F; Gaymes, TJ; Lea, NC; MacPherson, LJ; Mufti, GJ; Shall, S; Twine, NA | 1 |
| Ao, L; Cao, J; Cui, ZH; Liu, JY; Liu, WB; Yang, H; Zhou, YH; Zhou, ZY | 1 |
| Araúzo-Bravo, MJ; Do, JT; Han, DW; Jaenisch, R; Lee, HT; Lee, SH; Meissner, A; Schöler, HR | 1 |
| Cai, JP; Feng, J; He, Q; Li, L; Liu, X; McNutt, MA; Sekiguchi, M; Tu, B; Wang, H; Wu, L; Yang, Y; Yu, Y; Zhao, Y; Zhu, WG | 1 |
| Aparicio, A; Barske, L; Bollati, V; Groshen, S; Horne, E; Issa, JP; Jones, P; North, B; Tannir, N; Wang, X; Weisenberger, D; Yang, A; Yoo, C | 1 |
| Ikezoe, T; Koeffler, HP; Komatsu, N; Nishioka, C; Yang, J; Yokoyama, A | 1 |
| Chiyomaru, T; Enokida, H; Kagara, I; Kawahara, K; Kawakami, K; Mori, K; Nakagawa, M; Nishiyama, K; Seki, N; Tatarano, S | 1 |
| Glasow, A; Hildebrandt, G; Jahns, J; Kortmann, RD; Patties, I | 1 |
| Chan, KK; Fan-Havard, P; Huang, TH; Liu, S; Liu, Z; Marcucci, G; Plass, C; Wu, J; Xie, Z | 1 |
| Chang, WS; Chen, PY; Lai, YK; Wu, CW | 1 |
| Foster, BA; Karpf, AR; Mavis, CK; Morey Kinney, SR | 1 |
| Beder, LB; Fujihara, K; Fukushima, K; Grenman, R; Gunduz, E; Gunduz, M; Hotomi, M; Shimada, J; Shimizu, K; Tamura, S; Yamanaka, N; Yaykasli, K | 1 |
| Forni, G; Malentacchi, F; Orlando, C; Vinci, S | 1 |
| Chen, Y; Domann, FE; Hitchler, MJ; Weigel, RJ; Woodfield, GW | 1 |
| Billam, M; Davidson, NE; Sobolewski, MD | 1 |
| An, CH; Cho, HJ; Kang, WK; Kim, JI; Kim, JS; Kim, KH; Kim, SY; Oh, ST | 1 |
| Chen, Y; Collins, C; Huo, D; Nwachukwu, C; Olopade, OI; Rowell, J; Slamon, DJ; Xu, J | 1 |
| Fenaux, P; Itzykson, R | 3 |
| Guo, Z; Gupta, S; Hong, D; Issa, JP; Jelinek, J; Kurzrock, R; Nunez, MI; Oki, Y; Stewart, DJ; Wistuba, II | 1 |
| Burdzy, A; Herring, JL; Neidigh, JW; Perry, CC; Rogstad, DK; Sowers, LC; Theruvathu, JA | 1 |
| Hoory, T; Hung, CF; Lu, D; Monie, A; Wang, MC; Wu, A | 1 |
| Ding, L; Guo, B; Qiu, L; Zhang, J | 1 |
| Hemavathy, K; Wang, JC | 1 |
| Araki, H; Baluchamy, S; DeSimone, J; Lavelle, D; Mahmud, N; Milhem, M; Parajuli, R; Petiwala, S; Petro, B; Yoshinaga, K | 1 |
| Gorantla, B; Knost, JA; Pulukuri, SM; Rao, JS | 1 |
| Hibi, T; Kanai, Y; Matsuzaki, J; Nakagawa, I; Saito, Y; Suzuki, H; Tsugawa, H | 1 |
| Katoh, R; Kawasaki, T; Kobayashi, M; Kondo, T; Ma, D; Mochizuki, K; Nakamura, N; Nakazawa, T; Niu, D; Yamane, T | 1 |
| Abe, M; Cortez, CC; Jones, PA; Kelly, TK; Liang, G; Marquez, VE; Miranda, TB; Yoo, CB | 1 |
| Albitar, M; Arora, S; Baer, MR; Buckstein, R; Cullen, MT; Garcia-Manero, G; Godley, LA; Kantarjian, H; Larsen, JS; Slack, JL; Steensma, DP | 1 |
| Arany, I; Baliga, R; Clark, JS; Ember, I; Nadasi, E; Szanyi, I; Varjas, T | 1 |
| Gangisetty, O; James, SR; Karpf, AR; Link, PA; Shinkai, Y; Tachibana, M; Woloszynska-Read, A | 1 |
| Choi, BK; Choi, GS; Joh, JW; Kim, SH; Kim, SJ; Kwan, JH; Lee, HS; Moon, C; Park, JB; Park, KS | 1 |
| Asaoku, H; Hayashi, T; Imai, K; Ishida, T; Maruyama, R; Maruyama, Y; Mori, M; Nojima, M; Sakai, H; Sasaki, Y; Shinomura, Y; Suzuki, H; Tarasawa, I; Tokino, T; Toyota, M; Yasui, H | 1 |
| Cheng, AS; Deatherage, DE; Hsu, PY; Huang, TH; Liu, J; Liyanarachchi, S; Rodriguez, BA; Weng, YI; Zuo, T | 1 |
| Li, BH; Li, F; Li, PD; Liu, XH; Xu, SB; Yang, XZ; Yuan, J; Yuan, Q; Zhang, WJ; Zhang, Y | 1 |
| Bosque, A; Kauder, SE; Lindqvist, A; Planelles, V; Verdin, E | 1 |
| Hu, YC; Huo, YY; Niu, LJ; Pan, XJ; Sun, XJ; Wu, DC; Yang, ZH; Zhong, KJ; Zhou, PK; Zhu, MX | 1 |
| Banzon, V; Chin, J; DeSimone, J; Ibanez, V; Kouznetsova, T; Lavelle, D; Mahmud, N; Singh, M; Vaitkus, K | 1 |
| Fujita, Y; Kunisada, T; Morimoto, Y; Nishida, K; Numoto, K; Ouchida, M; Ozaki, T; Sugihara, S; Yoneda, Y; Yoshida, A | 1 |
| Ganesan, A; Haglund, C; Hemmes, A; Junnila, S; Kokkola, A; Monni, O; Mrena, J; Nykänen, A; Petrova, TV; Ristimäki, A; Tai, HH; Thiel, A | 1 |
| Kasuga, M; Nagare, T; Okada, Y; Sakaue, H | 1 |
| Gong, F; Ji, SP; Li, AM; Tai, JL; Zhang, YP; Zheng, CQ | 1 |
| Akashi, H; Igarashi, S; Imai, K; Issa, JP; Itoh, F; Kai, M; Maruyama, R; Nojima, M; Sasaki, Y; Shen, L; Shinomura, Y; Sugai, T; Suzuki, H; Tokino, T; Toyota, M; Watanabe, Y; Yamamoto, E; Yamamoto, H | 1 |
| Chen, WN; Feng, H; Niu, D; Sui, J; Zhang, J | 1 |
| Ibrahim, SM; Kunz, M; Schultz, J; Vera, J | 1 |
| Wei, L; Yu, H; Zhang, A; Zhang, L; Zhang, S | 1 |
| Bettuzzi, S; Patra, SK | 1 |
| Chowdhury, S; Marks, PW; Seropian, S | 1 |
| Chen, Y; Jiang, R; Qiu, H; Xiong, H; Zhuang, L | 1 |
| Carambula, SF; Hansen, PJ; Oliveira, LJ | 1 |
| Croteau, DL; Ide, H; Iijima, K; Katafuchi, A; Makino, K; Masuda, T; Matsubara, M; Nakano, T; Pack, SP; Tatsumoto, T; Tauchi, H; Terato, H; Tsuboi, T; Van Houten, B | 1 |
| Bartlett, DL; Gorry, MC; Guo, ZS; Li, Q; O'Malley, ME | 1 |
| Arts, J; Fang, Z; Garcia-Manero, G; Kuang, SQ; Stevenson, W; Tong, WG; Wei, Y; Zhang, M | 1 |
| Galili, N; Raza, A | 2 |
| Enomoto, S; Fujishiro, H; Himeno, S; Okugaki, S; Yasumitsu, S | 1 |
| Chen, XY; Kong, QY; Li, H; Li, Y; Liu, J; Liu, ZL; Sun, Y; Wu, ML; Zhang, KL | 1 |
| Elias, A; Korn, B; Lass, U; Mueller, W; Siegelin, MD; Steinmüller, A; von Deimling, A | 1 |
| Cavallazzi, R; Hirani, A; Marik, PE; Vasu, TS | 1 |
| Bacanamwo, M; Banerjee, S | 1 |
| Gagnon-Kugler, T; Langlois, F; Lessard, F; Moss, T; Stefanovsky, V | 1 |
| Abramowtiz, M; Alencar, C; Braunshweig, I; Jacobson, M; Parekh, S; Silverman, L; Verma, A | 1 |
| Bandzuchova, E; Demitrovicova, L; Mistrik, M; Polakova, K; Russ, G; Sabty, FA | 1 |
| Li, HL; Li, WT; Yin, CG; Zhang, WD | 1 |
| Lyons, RM | 2 |
| Andersson, BS; Champlin, RE; Corn, P; Li, Y; Murray, D; Valdez, BC | 1 |
| Chen, L; Fu, DY; Huang, W; Shao, ZM; Shen, ZZ; Wang, BL; Wang, ZM; Yang, WT | 1 |
| Chin, K; Chua, CL; Eu, KW; Gray, JW; Ho, YM; Hong, GS; Kuo, WL; Lee, AS; Lie, DK; Ong, DC; Rudduck, C; Seow-Choen, F; Tan, PH; Wong, CY | 1 |
| Dey, BR; Hasserjian, RP; Spitzer, TR | 1 |
| Dai, DQ; Meng, CF; Peng, G; Zhu, XJ | 3 |
| Hirabayashi, M; Hochi, S; Kato, M; Yoshizawa, Y | 1 |
| Costanzo, C; Dandrea, M; Donadelli, M; Palmieri, M; Scarpa, A | 1 |
| Jagodzinski, PP; Lianeri, M; Lutkowska, A; Pietkiewicz, PP | 1 |
| Hoffman, R; Ishii, T; Sozer, S; Wang, J; Wang, X; Xu, M; Zhang, W | 1 |
| Dahiya, R; Hinoda, Y; Hirata, H; Ishii, N; Kawakami, K; Kawamoto, K; Kikuno, N; Majid, S; Nakajima, K; Saini, S; Ueno, K; Yamamura, S | 1 |
| Kelleher, NL; Siuti, N | 1 |
| Gyobu, K; Hosoya, K; Takeshima, H; Ushijima, T; Yamashita, S | 1 |
| Chen, J; Diplas, AI; Hu, J; Lambertini, L; Lee, MJ; Lee, YL; Ma, YY; Wetmur, JG | 1 |
| Huang, X; Wang, X; Yin, J; Zhong, J | 1 |
| Belnik, Y; Gafter-Gvili, A; Gurion, R; Raanani, P; Shpilberg, O; Vidal, L; Yeshurun, M | 1 |
| Gotlib, J; Greenberg, PL | 1 |
| Li, HL; Liu, CX; Xu, K; Xu, NR; Xu, YW; Zheng, SB | 1 |
| Luft, FC | 1 |
| Hu, WY; Li, X; Li, XP; Ren, H; Shen, W; Tang, KF; Tian, L; Wang, F; Wu, JF; Yang, M; Zeng, GL | 1 |
| Li, T; Song, M; Song, Y; Wang, H; Wang, X; Wang, Z | 1 |
| Ishikawa, C; Mori, N; Qu, Z; Xiao, G; Yan, P | 1 |
| Borthakur, G; Cortes, J; Faderl, S; Garcia-Manero, G; Issa, JP; Kantarjian, H; O'Brien, S; Pierce, S; Ravandi, F; Shan, J; Verstovsek, S | 1 |
| Chi, SG; Kang, MJ; Kim, YH; Park, HC; Son, MS | 1 |
| Chen, XM; Huang, S; Li, X; Liu, J; Zhou, R | 1 |
| Hagemann, S; Hanna, K; Lyko, F; Schaefer, M | 1 |
| Bui, C; Coughtrie, MW; Fournel-Gigleux, S; Ouzzine, M; Prydz, K; Sharp, S; Talhaoui, I | 1 |
| Claesson, MH; Krishnadath, KK; Milano, F; Pedersen, AW; Weinert, BT; Zocca, MB | 1 |
| Al-Sarraf, N; Baird, AM; Cathcart, MC; Gray, SG; McGovern, E; O'Byrne, KJ | 1 |
| Brown, I; Kastl, L; Schofield, AC | 2 |
| Guo, F; Li, X; Liu, Y; Xu, Y; Zhang, B; Zhao, Y; Zheng, Q | 1 |
| De Grazia, G; Loddo, S; Teti, D; Tripodo, B; Venza, I; Venza, M; Visalli, M | 1 |
| Djulbegovic, B; Hozo, I; Komrokji, R; Kumar, A; List, AF | 1 |
| Ashida, M; Fujikane, T; Hirata, K; Kai, M; Maruyama, R; Nishidate, T; Nishikawa, N; Nojima, M; Ohe-Toyota, M; Ohmura, T; Sasaki, Y; Suzuki, H; Tokino, T; Toyota, M | 1 |
| Harigae, H; Yokoyama, H | 1 |
| Gibson, MB; Goldring, MB; Hashimoto, K; Oreffo, RO; Roach, HI | 1 |
| Aki, N; Emoto, N; Kage, H; Kusakabe, M; Nagase, T; Nakajima, J; Ohishi, N; Takai, D; Watanabe, K; Yatomi, Y | 1 |
| DeCoteau, JF; Geyer, CR; Lakshmikuttyamma, A; Scott, SA | 1 |
| Daurkin, I; Eruslanov, E; Kusmartsev, S; Vieweg, J | 1 |
| Cao, Y; Kotton, D; Mason, RJ; Millien, G; Ramirez, MI; Tagne, JB; Vo, T; Williams, MC | 1 |
| Huang, G; Kleinerman, ES; Koshkina, NV | 1 |
| Belaich, S; Gmyr, V; Kerr-Conte, J; Lefebvre, B; Longue, J; Oberholzer, J; Pattou, F; Vandewalle, B | 1 |
| Ishikawa, T | 2 |
| Alonso-Vega, C; Berthe, A; Braud, VM; Carlier, Y; Hermann, E; Parrado, R; Torrico, F; Truyens, C | 1 |
| Li, BH; Li, F; Li, PD; Liu, XH; Xu, SB; Yuan, J; Yuan, Q; Zhang, WJ; Zhang, Y | 1 |
| Jagodzinski, PP; Kozłowska, A; Lianeri, M; Lutkowska, A; Pietkiewicz, PP; Przybylski, M | 1 |
| Chan, E; Marquez, VE; Sun, F; Wu, Z; Yang, X; Yu, Q | 1 |
| Wu, Y; Xiao, WH | 1 |
| Fujiwara, S; Kataoka, Y; Mishina, R | 1 |
| Beyrouthy, MJ; Dmitrovsky, E; Eastman, A; Freemantle, SJ; Garner, KM; Hever, MP; Spinella, MJ | 1 |
| Albert, M; Gudas, LJ; Scognamiglio, T; Tang, XH | 1 |
| Abraham, JM; Agarwal, R; Cheng, Y; David, S; Hamilton, JP; Jin, Z; Meltzer, SJ; Montgomery, E; Mori, Y; Morin, PJ; Olaru, AV; Selaru, FM; Yang, J | 1 |
| Janssen, CR; Lemière, F; Vandegehuchte, MB; Vanden Berghe, W; Vanhaecke, L | 1 |
| Hattori, N; Iwatani, M; Lim, HW; Shiota, K; Tanaka, S; Yagi, S | 1 |
| Sekeres, MA | 3 |
| Garcia-Manero, G; Issa, JP; Kantarjian, H; Ravandi, F; Santos, FP | 1 |
| Bischof, J; Bonaldo, MF; Costa, FF; Hamm, CA; Hendrix, MJ; Seftor, EA; Soares, MB; Sredni, ST; Vanin, EF; Wang, D; Xie, H | 1 |
| Brentani, H; Calmon, MF; Camargo, AA; Carraro, DM; Cury, PM; da Silva, AM; de Carvalho, AF; Kaneto, CM; Kowalski, LP; Mota, LD; Moura, RP; Nishimoto, IN; Nunes, FD; Pinheiro, DG; Rahal, P; Rodrigues, RV; Silva, SD; Silva, WA; Soares, FA; Tajara, EH; Torres, C; Valentini, SR; Zanelli, CF | 1 |
| Assaraf, YG; Bram, EE; Raz, S; Stark, M | 1 |
| Aw, DC; Chng, WJ; Koh, LP; Liu, TC; Ng, ES; Poon, ML; Tan, KB; Tan, LK; Yap, ES | 1 |
| Cashen, AF; DiPersio, JF; O'Donnell, MR; Schiller, GJ | 1 |
| Jiang, J; Liu, XS; Peng, CY; Zheng, HT | 1 |
| Huo, JR; Ren, JZ | 3 |
| Büchner, T; Krug, U; Lübbert, M | 1 |
| Chan, MW; Chao, TK; Chen, LY; Chou, JL; Davuluri, RV; Deatherage, DE; Hartman-Frey, C; Hsiao, SH; Huang, TH; Huang, YW; Kuo, CT; Lai, HC; Lai, YH; Liao, YP; Lin, HJ; Nephew, KP; Su, HY; Tai, CK; Yan, PS; Yang, HW | 1 |
| Chen, BH; Hsu, HS; Lee, SH; Tsai, WC; Tseng, RC; Tzao, C; Wang, YC | 1 |
| Blagitko-Dorfs, N; Daskalakis, M; Hackanson, B | 1 |
| Akiyama, Y; Hashimoto, Y; Otsubo, T; Shimada, S; Yuasa, Y | 1 |
| Hori, T; Hosokawa, M | 1 |
| Scott, BL | 1 |
| Frame, D | 1 |
| Dunn, JD; Kogan, AJ | 1 |
| Dong, Z; Du, J; Feng, Y; Huang, B; Lu, J; Matloob, AF; Pan, H; Pan, L; Zhao, J; Zhong, Y | 1 |
| Li, HL; Ma, AN | 1 |
| Denner, J; Fiebig, U; Kurth, R; Stengel, S | 1 |
| Chang, YS; Chen, LC; Leu, YW; Li, HP; Lin, KH; Liu, HP; Lu, CY; Lu, YJ; Wang, CS; Wu, CS | 1 |
| Ding, J; Liang, Q; Xu, R; Xu, Z; Zheng, S | 1 |
| Beedanagari, SR; Hankinson, O; Taylor, RT | 1 |
| Gao, A; Guo, W; Niu, P; Song, S; Tian, L; Zuo, X | 1 |
| Aukerman, SL; Brady, H; Heise, C; Hollenbach, PW; Krushel, L; MacBeth, KJ; Nguyen, AN; Ning, Y; Richard, N; Williams, M | 1 |
| Altomonte, M; Calabrò, L; Colizzi, F; Coral, S; Covre, A; Danielli, R; Fonsatti, E; Fratta, E; Maio, M; Nicolay, HJ; Sigalotti, L | 1 |
| Jiao, H; Kere, J; Nistér, M; Qu, M; Ren, ZP; Smits, A; Zhao, J | 1 |
| Hazama, S; Higaki, S; Hinoda, Y; Hirata, H; Kaneko, S; Mitomori, S; Nishioka, M; Oka, M; Okada, T; Okayama, N; Sakai, K; Sakaida, I; Suehiro, Y; Ueno, K | 1 |
| Fleischer, D; Rink, L; Uciechowski, P; Wessels, I | 1 |
| Halaban, R; Krauthammer, M; Ma, S; Rubinstein, JC; Tran, N | 1 |
| Fu, J; Grusby, MJ; Jiang, J; Qu, Z; Smithgall, TE; Xiao, G; Yan, P | 1 |
| Hueng, DY; Jan, HJ; Lai, JH; Lee, CC; Lee, HM; Ma, HI; Shih, YL; Wei, HW | 1 |
| Angst, E; Dawson, DW; Eibl, G; Go, VL; Hines, OJ; Nguyen, A; Park, J; Reber, HA | 1 |
| Cheng, SY; Fu, J; Hu, J; Qu, Z; Xiao, G; Yan, P | 1 |
| Chiba, Y; Fukuchi, M; Hirai, A; Ishimaru, N; Shiraishi, M; Tabuchi, A; Takahashi, N; Tamura, T; Tsuda, M | 1 |
| Allegra, A; Alonci, A; Granata, A; Musolino, C; Penna, G; Russo, S; Sant'antonio, E | 1 |
| Chen, GQ; Chen, HM; Chen, ZF; Du, W; Fang, JY; Han, ZG; Liang, QC; Su, WY; Xiong, H | 1 |
| Bartling, B; Hofmann, HS; Rehbein, G; Silber, RE; Simm, A | 1 |
| Chen, XW; Cheng, HY; Cheng, L; Liu, YD; Lou, G | 1 |
| Eckschlager, T; Hrabeta, J; Hrebackova, J | 1 |
| Califano, JA; Chang, SS; Chang, X; Demokan, S; Kim, MS; Monitto, CL; Sidransky, D; Zhong, X | 1 |
| Brown, P; Figueroa, ME; Irizarry, R; McIntyre, E; Melnick, A; Negi, S; Schafer, E; Small, D | 1 |
| Cheng, W; Du, X; Huang, Q; Huang, W; Jiang, L; Lai, D; Liu, T; Liu, Z; Xu, F; Zhao, Y | 1 |
| Guan, M; Li, J; Li, M; Lin, Y; Liu, C; Liu, W; Lu, Y; Ma, W; Su, B | 1 |
| Gao, A; Guo, W; Liu, Q; Lu, X; Tian, L; Zuo, X | 1 |
| Clark, OH; Duh, QY; Fernandez-Ranvier, G; Kebebew, E; Shen, WT; Suh, I; Weng, J | 1 |
| Manna, S; Mukherjee, P; Mukherjee, S; Pal, D; Panda, CK | 1 |
| Goggins, M; Hong, SM; Li, A; Omura, N | 1 |
| Bazarov, AV; Hines, WC; Mukhopadhyay, R; Yaswen, P | 1 |
| Bentov, I; Plymate, SR; Schayek, H; Sun, S; Werner, H | 1 |
| Dickson, J; Din, S; Jodrell, D; Macleod, K; Patel, K; Ramsahoye, B | 1 |
| Brown, R; Cogle, CR; Hsu, J; Imanirad, I; Scornik, JC; Wiggins, LE; Wingard, JR | 1 |
| Egan, LJ; Foran, E; Garrity-Park, MM; Limburg, PJ; Mureau, C; Newell, J; Smyrk, TC | 1 |
| Dar, AA; de Semir, D; Federman, S; Kashani-Sabet, M; Majid, S; Nosrati, M | 1 |
| Steensma, DP; Stone, RM | 1 |
| Matsuoka, Y; Nakatsuka, R; Nozaki, T; Ohura, K; Sasaki, Y; Shinohara, M; Sonoda, Y; Uemura, Y | 1 |
| Guan, M; Li, J; Li, M; Lin, Y; Liu, C; Liu, W; Lu, Y; Su, B; Ye, C; Zhang, X | 1 |
| Becker, H; Bloomfield, CD; Blum, W; Byrd, JC; Chan, KK; Croce, CM; Devine, H; Devine, SM; Garzon, R; Geyer, S; Grever, MR; Havelange, V; Heerema, NA; Kefauver, C; Klisovic, RB; Liu, S; Marcucci, G; Mickle, J; Schaaf, L; Schwind, S; Villalona-Calero, M; Walker, A | 1 |
| Ahn, JS; He, L; Jang, KL; Jeong, SJ; Jung, M; Kim, BY; Kim, SO; Kwon, O; Lee, HG; Osada, H | 1 |
| Almstedt, M; Blagitko-Dorfs, N; Duque-Afonso, J; Jäger, E; Karbach, J; Lübbert, M; Pfeifer, D | 1 |
| Akbulak, R; Atanackovic, D; Bartels, BM; Bartels, K; Bokemeyer, C; Brümmendorf, TH; Cao, Y; Gontarewicz, A; Gordic, M; Hildebrandt, Y; Kobold, S; Kröger, N; Lajmi, N; Luetkens, T; Meyer, S; Schafhausen, P; Stasche, T; Uhlich, F | 1 |
| Guo, Q; Li, G; Liu, M; Peng, Y; Shen, S; Wang, X | 1 |
| Choi, J; Deych, E; DiPersio, JF; Holt, M; Piwnica-Worms, DR; Prior, JL; Ritchey, J; Shannon, WD | 1 |
| Gergis, U; Wissa, U | 1 |
| Lachs, MS; Ritchie, EK | 1 |
| Koppel, A; Schiller, G | 1 |
| Blagitko-Dorfs, N; Daskalakis, M; Hackanson, B; Lübbert, M | 1 |
| Rogers, BB | 1 |
| Fernandez, SV; Giulianelli, S; Goin, M; Lanari, C; Russo, J; Wargon, V | 1 |
| Bearss, DJ; Chuang, JC; Jones, PA; Qiu, X; Redkar, S; Vankayalapati, H; Vollmer, D; Warner, SL; Yoo, CB | 1 |
| Mirza, S; Pandya, P; Ralhan, R; Sharma, G | 1 |
| Andritsos, L; Baiocchi, R; Benson, DM; Blum, KA; Byrd, JC; Chan, KK; Chen, P; Devine, SM; Flynn, J; Grever, MR; Jones, J; Liu, Z; Lucas, DM; Marcucci, G; Plass, C; Xie, Z | 1 |
| Huang, AL; Li, XP; Yang, M | 1 |
| Gutkin, DW; Shurin, GV; Shurin, MR; Song, EY; Tourkova, IL | 1 |
| Arvia, R; Deledda, C; Gelmini, S; Luciani, P; Malentacchi, F; Mannelli, M; Orlando, C; Peri, A; Simi, L | 1 |
| Kang, HR; Li, QW; Sanren, GW; Song, LP; Wang, RL; Xiao, WH; Ye, M; Zhu, JH | 1 |
| Ishii, J; Kashiwagi, K; Kitamura, H; Masuda, M; Mitsui, H; Ogura, T; Ohmori, T; Okudela, K; Oshiro, H; Sakaeda, M; Sato, H; Shimoyamada, H; Suzuki, T; Tajiri, M; Woo, T; Yazawa, T | 1 |
| Cen, JN; Chen, W; Gao, N; Shen, Y | 1 |
| Kimmins, S; Lambrot, R | 1 |
| Copelan, E; Ebrahem, Q; Gu, X; Hu, Z; Maciejewski, JP; Mahfouz, R; Negrotto, S; Ng, KP; Saunthararajah, Y; Singh, H | 1 |
| Breiling, A; Lyko, F; Musch, T; Oz, Y | 1 |
| Akashi, H; Imai, K; Itoh, F; Kai, M; Kamimae, S; Maruyama, R; Nojima, M; Sasaki, Y; Shinomura, Y; Sugai, T; Suzuki, H; Tokino, T; Toyota, M; Watanabe, Y; Yamamoto, E; Yamano, H; Yamashita, M | 1 |
| Iwata, H; Miyazawa, M; Sato, H; Takano, Y; Ueno, K; Virgona, N; Yano, T; Yano, Y | 1 |
| Momparler, LF; Momparler, RL; Raynal, NJ; Rivard, GE | 1 |
| Higashi, M; Houjou, I; Kitamoto, S; Yamada, N; Yokoyama, S; Yonezawa, S | 1 |
| Batty, GN; Cortés, JE; Garcia-Manero, G; Issa, JP; Jabbour, E; Kantarjian, H; McCue, D; O'Brien, S; Pierce, S; Ravandi, F; Santos, FP | 1 |
| Chan, AW; Chan, MW; Chau, SL; Lee, TL; Leung, PP; Lo, KW; Lung, RW; Ng, DC; So, KK; To, KF; Tong, JH | 1 |
| Huang, TH; Lin, JJ; Liu, TM; Tycko, B; Zuo, T | 1 |
| Chen, M; Patterson, AJ; Xiao, D; Xue, Q; Zhang, L | 1 |
| Chen, F; Fang, J; Liu, J; Rao, Y; Song, T; Wang, Y; Wu, J; Yang, Z; Zeng, F | 1 |
| Chlenski, A; Cohn, SL; Godley, LA; Guerrero, LJ; Ostler, KR; Salwen, HR; Tian, Y; Yang, Q | 1 |
| Chen, Y; Dahiya, R; Deng, G; Hinoda, Y; Hirata, H; Ishii, N; Kawamoto, K; Khatri, G; Kikuno, N; Majid, S; Nakajima, K; Saini, S; Ueno, K; Yamamura, S; Zaman, MS | 1 |
| Han, J; Li, Y; Sui, N; Wang, D; Wei, C; Yang, X | 1 |
| Garcia-Manero, G; Quintás-Cardama, A; Santos, FP | 1 |
| Broquist, AH; Gayden, AE; Nanney, LB; Opalenik, SR; Raju, L; Russell, JD; Russell, SB; Trupin, KM; Williams, SM | 1 |
| Eden, A; Howard, G; Kimhi, S; Lyko, F; Weber, B | 1 |
| Cho, S; Kang, YK; Lee, D; Park, JS; Shin, ST | 1 |
| Balch, C; Breen, T; Fang, F; Kulesavage, C; Li, L; Matei, DE; Nephew, KP; Schilder, J; Shen, C; Snyder, AJ; Zhang, S | 1 |
| Batty, N; Cortes, J; Garcia-Manero, G; Issa, JP; Jabbour, E; Kantarjian, H; O'Brien, S; Ravandi, F; Shan, J | 1 |
| Deeb, KK; Johnson, CS; Karpf, AR; Luo, W; Morrison, CD; Muindi, JR; Trump, DL | 1 |
| Kagey, JD; Kapoor-Vazirani, P; McCabe, MT; Powell, DR; Vertino, PM | 1 |
| Chen, Y; Dahiya, R; Deng, G; Khatri, G; Liu, J; Majid, S; Saini, S; Shahryari, V; Suh, SO; Tanaka, Y; Zaman, MS | 1 |
| Adamson, PC; Blaney, SM; Diller, L; Finkelstein, D; George, RE; Ingle, AM; Krailo, M; Lahti, JM; Neuberg, D; Reid, JM; Zhu, K | 1 |
| Clouser, CL; Mansky, LM; Patterson, SE | 1 |
| Kim, KT; Mossman, D; Scott, RJ | 1 |
| James, SR; Jin, B; Karpf, AR; Odunsi, K; Song, C; Woloszynska-Read, A | 1 |
| Chang, HL; Huang, YW; Lin, YC; Liu, S; Shu, ST; Sugimoto, Y; Wang, LS; Yan, P; Ye, W | 1 |
| Fang, WL; Hu, LY; Kao, HW; Lai, CH; Li, SC; Lin, WC; Tsai, KW; Wu, CW | 1 |
| Fujimoto, J; Hong, WK; Kong, M; Lee, JJ; Lotan, R | 1 |
| Choi, MY; Choi, Y; Joo, YD; Kim, DY; Kim, SD; Kim, SH; Lee, JH; Lee, KH; Lee, SM; Lee, WS; Lim, SN | 1 |
| Han, B; Li, H; Liu, W; Wang, Y; Zhang, C; Zhang, Q; Zhang, T; Zhang, X; Zhou, G | 1 |
| Brennan, DJ; Fitzpatrick, P; Furlong, F; Kay, E; Lawler, M; McCann, A; McGoldrick, A; McGrogan, B; O'Grady, A; Perry, AS; Phelan, S; Prencipe, M; Watson, JA | 1 |
| Jang, JJ; Kang, GH; Kim, BH; Shin, SH; Suh, KS | 1 |
| Gao, J; Ming, S; Sun, T | 1 |
| Ghosh, RP; Horowitz-Scherer, RA; Nikitina, T; Shlyakhtenko, LS; Woodcock, CL | 1 |
| Borden, EC; Cheriyath, V; Luszczek, W; Mekhail, TM | 1 |
| Li, C; Li, M; Peng, F; Ruan, L; Tan, T; Tang, C; Xiao, Y; Xiao, Z; Yi, H; Zhang, P | 1 |
| Guo, SW | 1 |
| Berenson, RJ; Castaneda, SA; Chui, DH; Faller, DV; Fucharoen, S; Perrine, SP; Siritanaratku, N | 1 |
| Akpan, I; Banzon, V; DeSimone, J; Ibanez, V; Lavelle, D; Vaitkus, K | 1 |
| Ahmed, S; Boumber, YA; He, R; Issa, JP; Jelinek, J; Qin, T; Shu, J; Si, J | 1 |
| Lee, HW; Liu, W; Liu, Y; Rodgers, GP; Wang, R | 1 |
| He, Y; Li, P; Wang, J; Wang, Y; Zhang, S; Zhu, S | 1 |
| Amin, R; Blake, T; Choufani, S; Evans, SR; Finegold, M; Jogunoori, W; Kreishman, P; Kumar, R; Mishra, B; Mishra, L; Rashid, A; Reddy, EP; Sidawy, AA; Weksberg, R; Yao, W; Yao, ZX | 1 |
| Arimondo, PB; Champion, C; Guianvarc'h, D; Guieysse-Peugeot, AL; Jeltsch, A; Jurkowska, RZ; Ponger, L; Sénamaud-Beaufort, C | 1 |
| Bazhin, AV; De Smet, C; Golovastova, MO; Philippov, PP; Schmidt, J | 1 |
| Lobie, PE; Logan, PC; Mitchell, MD; Ponnampalam, AP; Rahnama, F | 1 |
| Kondoh, T; Mori, N; Motoji, T; Ohwashi, M; Okada, M; Shimura, H; Shiseki, M; Tomita, K; Wang, YH; Yoshinaga, K | 1 |
| Hoffman, R; Li, Y; Lu, M; Najfeld, V; Tripodi, J; Wang, X; Xu, M; Zhang, W | 1 |
| Berchmans, E; Dubovsky, JA; Pinilla-Ibarz, JA; Powers, JJ; Smith, MA; Sotomayor, EM; Wang, D; Wright, KL | 1 |
| D'Alò, F; Di Ruscio, A; Fabiani, E; Giachelia, M; Guidi, F; Hohaus, S; Leone, G; Saulnier, N; Voso, MT | 1 |
| Costa, VL; Duarte-Pereira, S; Henrique, R; Jerónimo, C; Lobo, F; Oliveira, J; Paiva, F; Patrício, P; Ramalho-Carvalho, J; Ribeiro, FR | 1 |
| Chen, A; Elliott, E; Ezra-Nevo, G; Neufeld-Cohen, A; Regev, L | 1 |
| Esteller, M; Kulis, M | 1 |
| Arias-Bofill, D; Candelaria, M; Cervera, E; de la Cruz-Hernández, E; Dueñas-Gonzalez, A; González-Fierro, A; Herrera, A; Labardini, J; Pérez-Cárdenas, E; Taja-Chayeb, L; Trejo-Becerril, C; Vidal, S | 1 |
| Greco, NJ; Laughlin, MJ; Lesniewski, ML; Weitzel, RP | 1 |
| Grønbæk, K; Hother, C; Jones, PA; Liang, G; Lu, Q; Qiu, X; Ralfkiær, UM; Søgaard, A; Workman, CT | 1 |
| El-Rifai, W; Hu, T; Jackson, K; Marshal, D; Peng, D; Soutto, M | 1 |
| Basquiera, A; Bernard, HI; Iastrebner, M; Jang, JH; Jung, CW; Kim, DH; Kim, K; Klein, G; Korin, J; Nucifora, E; Orlando, S; Sackmann, F; Santini, F; Taborda, G | 1 |
| Fuso, A; Gama, MJ; Milagre, I; Moutinho, M; Nunes, MJ; Rivera, I; Rodrigues, E; Scarpa, S | 1 |
| Moss, T | 1 |
| Karaman, R | 1 |
| Fernandez, G; Zeichner, SL | 1 |
| Buckley, B; Fortin, MC; Richardson, JR; Yang, I | 1 |
| Imakawa, K; Miyazawa, T; Nakaya, Y; Shojima, T; Yasuda, J | 1 |
| Arélin, V; Gruenebach, F; Krusch, M; Salih, HR; Schmidt, SM; Schmiedel, BJ | 1 |
| El-Serafi, AT; Oreffo, RO; Roach, HI | 1 |
| Breinig, M; Breuhahn, K; Dutruel, C; Gdynia, G; Goeppert, B; Kern, MA; Longerich, T; Mehrabi, A; Mittelbronn, M; Oakes, C; Penzel, R; Plass, C; Popanda, O; Renner, M; Schirmacher, P; Schmezer, P; Vogel, MN; Warth, A | 1 |
| Godsey, S; Oyer, JA; Turker, MS; Yates, PA | 1 |
| Asa, SL; Ezzat, S; Zheng, L; Zhu, X | 1 |
| Chai, CY; Chen, WT; Huang, YC; Hung, WC; Jiang, WH; Yu, HS | 1 |
| Dicato, M; Diederich, M; Foliguet, B; Ghelfi, J; Grandjenette, C; Karius, T; Schnekenburger, M | 1 |
| Balgobind, BV; Baruchel, A; Cloos, J; Coenen, EA; Danen-van Oorschot, AA; de Bont, ES; de Haas, V; den Boer, ML; Kaspers, GJ; Kuipers, JE; Marschalek, R; Meyer, C; Pieters, R; Reinhardt, D; Stary, J; van den Heuvel-Eibrink, MM; Zwaan, CM | 1 |
| Chen, JY; Hong, CQ; Ran, YG; Wu, X; You, YJ | 1 |
| Ran, Y; Wu, S; You, Y | 1 |
| Du, C; Huang, G; Huang, T; Lin, L; Ma, N; Mo, Y; Murata, M; Wang, S; Xiao, X; Yu, N; Zhang, J; Zhang, Z; Zhou, X | 1 |
| Galili, N; Gross, CP; Halene, S; Ma, X; Maggiore, RJ; Raza, A; Soulos, PR; Wang, R | 1 |
| Atweh, G; Fathallah, H | 1 |
| Criscuolo, M; D'alo', F; Fabiani, E; Giachelia, M; Greco, M; Guidi, F; Hohaus, S; Leone, G; Rutella, S; Voso, MT | 1 |
| Anti, M; Beggs, A; Bevilacqua, G; de Palo, M; Francesconi, S; Gomes, V; Lessi, F; Macarone Palmieri, R; Segditsas, S; Tomlinson, I | 1 |
| Buim, ME; Carvalho, AL; Coutinho-Camillo, CM; de Carvalho, AC; Fregnani, JH; Kowalski, LP; Lessa, RC; Lourenço, SV; Pereira, CM; Soares, FA; Vettore, AL | 1 |
| Amatori, S; Bagaloni, I; Fanelli, M; Viti, D | 1 |
| Han, W; Jiricny, J; Menigatti, M; Rehrauer, H; Veljkovic, E | 1 |
| Belden, SE; Borger, DR; Curley, MD; Foster, R; Friel, AM; Mohapatra, G; Rueda, BR; Sergent, PA; Therrien, VA; Zhang, L; Zukerberg, LR | 1 |
| Bauer, F; Bilgrami, S; Boruchov, A; Mulay, S | 1 |
| An, ZX; Hua, S; Liu, J; Quan, FS; Wang, LJ; Wang, YS; Xiong, XR; Zhang, Y | 1 |
| Brodská, B; Holoubek, A; Otevřelová, P | 2 |
| Guo, X; Jing, C; Li, C; Li, L; Liu, J; Shi, Y; Wang, J; Zhang, L | 1 |
| Li, YC; Yi, HM; Zhong, RH | 1 |
| Ao, L; Cao, J; Cui, ZH; Liu, JY; Liu, WB; Xiang, YL; Yuan, XY; Zhou, YH; Zhou, ZY | 1 |
| Li, P; Meng, XY; Wang, YJ; Zhang, ST; Zhu, ST; Zong, Y | 1 |
| Chachadi, VB; Cheng, H; Cheng, PW; Christman, JK; Klinkebiel, D | 1 |
| Ahn, SG; Kang, KW; Kim, HS; Kim, SK; Kim, TH; Lee, KY; Lim, SC; Phuong, NT; Yoon, JH | 1 |
| Couillard, J; Estève, PO; Pradhan, S; St-Pierre, Y | 1 |
| Czemerska, M; Grzybowska-Izydorczyk, O; Pluta, A; Robak, T; Szmigielska-Kapłon, A; Wierzbowska, A; Wolska, A | 1 |
| Gazdar, A; Kawaguchi, Y; Nonaka, K; Okumura, N; Osada, S; Takahashi, T; Tokuyama, Y; Yamaguchi, K; Yoshida, K | 1 |
| Katiyar, SK; Nandakumar, V; Vaid, M | 1 |
| Liao, X; Liu, W; Lu, N; Wong, CW; Xu, J | 1 |
| Berz, D; Cassidy, HM; Connell, NT; Winer, ES | 1 |
| Fenaux, P; Garcia-Manero, G | 1 |
| Bast, RC; Feng, Y; Huan, J; Jia, L; Jin, H; Lu, Z; Yao, M; Yu, Y; Zhao, N; Zou, CF | 1 |
| Hsu, CP; Ko, JL; Lai, CH; Liu, YF; Tang, LC; Tang, SC; Wong, RH; Wu, MF | 1 |
| Bi, F; Deng, Q; Huang, CM; Li, AJ; Li, ZP; Liu, Z; Tang, QL; Zhong, RM | 1 |
| Cai, HH; Gao, WT; Miao, Y; Peng, Q; Sun, YM; Yao, J; Zhao, HL | 1 |
| Gong, Y; Guo, MZ; Yang, YS; Ye, ZJ; Zhang, XL; Zhao, YL | 1 |
| Chen, EX; Egorin, MJ; Espinoza-Delgado, I; Hirte, HW; Holleran, JL; Hotte, SJ; Laughlin, A; McGill, S; Moretto, P; Oza, AM; Siu, LL; Stathis, A; Stayner, LA; Wang, L; Webster, S; Zhang, WJ | 1 |
| Baba, T; Fujii, N; Hamanishi, J; Kang, HS; Kharma, B; Kondoh, E; Konishi, I; Mandai, M; Matsumura, N; Murphy, SK; Oishi, S; Yoshioka, Y | 1 |
| Ferrara, F; Musto, P | 1 |
| Alcazar, O; Hu, Z; Lindner, D; Negrotto, S; Ng, KP; Rini, B; Saunthararajah, Y; Triozzi, P | 1 |
| Du, J; Gong, J; Guan, M; Hu, J; Hu, T; Jiang, H; Liu, W; Lu, Y; Sun, C; Sun, Y | 1 |
| Adachi, Y; Hizaki, K; Imai, K; Kato, N; Nakazawa, M; Sanchez, JV; Sasaki, S; Shinomura, Y; Sukawa, Y; Suzuki, H; Taniguchi, H; Tanuma, T; Yamamoto, H | 1 |
| Lee, CH; Lee, MK; Lee, SY; Old, L; Park, JH; Park, YM; Song, MH | 1 |
| Gamo, T; Habano, W; Otsuka, K; Ozawa, S; Sugai, T; Terashima, J; Wakabayashi, G | 1 |
| Au, SL; Ko, FC; Ng, IO; Ng, YL; Wong, CC; Wong, CM | 1 |
| Ding, Q; Ding, YB; Liu, XA; Liu, YX; Shi, JP; Wang, S; Xia, JG; Xia, TS; Zhao, Y | 1 |
| Fleurence, R; Kim, E; Knopf, K; Linnehan, JE; Pan, F; Peng, S | 1 |
| Sun, Y; Tang, B; Zhao, G; Zhao, R; Zhong, J; Zhu, N; Zhu, Y | 1 |
| Hamada, H; Hirai, S; Kato, K; Sakuragi, N; Takenouchi, M; Yagita, H | 1 |
| Auffret, M; Bibault, JE; Cambier, N; Lemahieu, JM; Quesnel, B; Rose, C | 1 |
| Dong, X; Korch, C; Meinkoth, JL | 1 |
| Bhatnagar, N; Guo, B; Li, X; Padi, SK; Tang, MS; Zhang, Q | 1 |
| Dong, ZM; Fang, XH; Ge, MH; Hu, FJ; Li, P; Ling, ZQ; Mao, WM; Zhao, X | 1 |
| Dubovsky, JA; Gao, Y; Mariusso, LF; Pinilla-Ibarz, JA; Powers, JJ; Sotomayor, EM | 1 |
| Alajez, NM; Bruce, J; Huang, SH; Hui, AB; Ito, E; Lenarduzzi, M; Liu, FF; O'Sullivan, B; Shi, W; Waldron, J; Xu, W; Yue, S | 1 |
| Baer, MR; Gojo, I | 1 |
| Brueckner, B; Hagemann, S; Heil, O; Lyko, F | 1 |
| Certa, U; Foser, S; Scott, R; Siegrist, F | 1 |
| Alva, AS; Aparicio, AM; Hahn, NM; Singal, R; Sonpavde, G; Yellapragada, S | 1 |
| Ge, B; Gunderson, KL; Koka, V; Lam, KC; Montpetit, A; Morcos, L; Pastinen, T; Pokholok, DK; Verlaan, DJ | 1 |
| Liu, HG; Liu, Y | 1 |
| Cullus, P; Erneux, C; Gromova, P; Rubin, BP; Thys, A; Vanderwinden, JM | 1 |
| Eling, TE; Kadowaki, M; Kamitani, H; Wade, PA; Watanabe, T; Yoshioka, H | 1 |
| Cheong, SC; Gan, CP; Hamid, S; Hor, SY; Ismail, SM; Saunders, N; Teo, SH; Wan Mustafa, WM; Zain, RB | 1 |
| Fraczek, JE; Rogiers, V; Tourwé, D; Vanhaecke, T; Vinken, M | 1 |
| Li, M; Li, XH; Sun, JZ; Wang, Y; Xu, WW; Yang, XX; Zhu, W | 1 |
| Li, K; Liang, J; Wu, Q; Zhang, J; Zhu, H | 1 |
| Hayashi, Y; Imai, T; Kikumori, T; Kiuchi, T; Kurebayashi, J; Murata, Y; Sassa, M; Watanabe, R | 1 |
| Morales-Ramírez, P; Rodríguez-Reyes, R | 1 |
| Morales, JC; Rodríguez-Vargas, JM; Ruiz-Magaña, MJ; Ruiz-Ruiz, C; Saldivia, MA; Schulze-Osthoff, K | 1 |
| Becker, K; Hapfelmeier, A; Höfler, H; Keller, G; Langer, R; Mutze, K; Novotny, A; Ott, K; Schumacher, F | 1 |
| Chen, J; Fan, H; Gu, D; Huang, H; Qiao, F; Su, X; Wei, X; Xu, Z | 1 |
| Hou, J; Huang, W; Li, Y; Liu, B; Lv, A; Xing, Y; Yan, X | 1 |
| Cartron, PF; Hervouet, E; Hulin, P; Vallette, FM | 1 |
| Auersperg, N; Cheng, JC; Leung, PC | 1 |
| Ahn, SY; Choi, Y; Jeon, M; Jung, AR; Kang, YA; Kim, DY; Kim, SD; Lee, JH; Lee, KH; Lee, SB; Lee, YJ; Lee, YS; Park, YH; Seol, M | 1 |
| Ichinomiya, S; Iwata, H; Okabe, H; Sato, H; Sekine, Y; Suzuki, R; Ueno, K; Yamada, R; Yanagihara, M; Yano, T | 1 |
| Aul, C; Baila, L; Beeldens, F; Coens, C; de Witte, T; Eckart Schaefer, H; Ganser, A; Germing, U; Giagounidis, A; Hagemeijer, A; Labar, B; Lübbert, M; Muus, P; Pflüger, KH; Platzbecker, U; Rüter, BH; Salih, HR; Selleslag, D; Suciu, S; Wijermans, PW | 1 |
| Esteller, M; Melo, SA; Simó-Riudalbas, L | 1 |
| Liu, J; Quan, F; Su, J; Wang, L; Wang, Y; Xu, W; Zhang, Y | 1 |
| Hattori, N; Kikuyama, M; Okochi-Takada, E; Ushijima, T; Wakabayashi, M; Yamashita, S | 1 |
| Amati, M; Neuzil, J; Nocchi, L; Saccucci, F; Santarelli, L; Tomasetti, M | 1 |
| Ahmed, AA; Bast, RC; Bornmann, WG; Chen, MY; Hennessey, V; Liao, WS; Lu, Z; Rosner, GL; Washington, MN; Yu, Y | 1 |
| Abel, PW; Deng, C; Gatalica, Z; Lin, MF; Tu, Y; Wang, B; Wang, J; Wolff, DW; Xie, Y; Yang, M | 1 |
| Bryan, J; Garcia-Manero, G; Jabbour, E; Kantarjian, H | 1 |
| Borges, KS; Carlotti, CG; Gomes, MV; Machado, HR; Moreno, DA; Queiroz, RG; Scrideli, CA; Tone, LG | 1 |
| Li, W; Matsumura, F; Vogel, CF; Wong, P; Wu, D | 1 |
| Shen, H; Suo, Y; Wang, H; Wang, X; Yin, R | 1 |
| Aucagne, R; Bastie, JN; Bataille, A; Delva, L; Droin, N; Fenaux, P; Hammann, A; Lagrange, B; Largeot, A; Losson, R; Martin, L; Paggetti, J; Solary, E; Yan, KP | 1 |
| Blanquart, C; Boutin, B; Fonteneau, JF; Grégoire, M; Gueugnon, F; Guillot, F; Leclercq, S; Padieu, M; Pouliquen, D; Rogel, A | 1 |
| Kong, Q; Li, L; Liu, X; Liu, Z; Mu, Y; Wang, Z; Wu, M; Zhang, X | 1 |
| Esmaeilpour, T; Rasooli, M; Talaei-Khozani, T; Tavakolinejad, S; Vojdani, Z | 1 |
| Ikezoe, T; Nishioka, C; Udaka, K; Yang, J; Yokoyama, A | 1 |
| Adams, S; Anderson, J; Basu, BP; Dalgleish, A; Hasan, F; Himoudi, N; Poon, E; Wallace, R; Williams, O; Wilson, N; Xue, SA; Yan, M | 1 |
| Buchner, D; Hatoum, HT; Kim, E; Lin, SJ | 1 |
| Günterová, J; Matoušová, M; Mertlíková-Kaiserová, H; Otmar, M; Tloušťová, E; Votruba, I | 1 |
| Jiao, Y; Li, P; Meng, Y; Wang, JX; Wang, QG; Zhang, ST; Zhu, ST | 1 |
| Kim, EJ; Kim, IY; Kim, SK; Kim, WJ; Kim, YJ; Kim, YW; Yoon, HY | 1 |
| An, HJ; Lee, H; Paik, SG | 1 |
| Biojone, C; Gomes, MV; Guimarães, FS; Joca, SR; Sales, AJ; Terceti, MS | 1 |
| Al-Sohaily, S; Cooper, WA; Kennedy, CW; Kohonen-Corish, MR; McCaughan, BC; Mladenova, DN; Pangon, L; Selinger, CI; Stirzaker, C | 1 |
| Califano, JA; Mithani, SK; Smith, IM | 1 |
| Heo, DS; Jang, JY; Jeon, YK; Kim, CW; Kim, TM; Kim, WY; Paik, JH | 1 |
| Bose, JR; Brenet, F; Curcio, TJ; Feldman, EJ; Gergis, US; Ippoliti, CM; Mayer, SA; Moh, M; Morawa, E; Ritchie, EK; Roboz, GJ; Scandura, JM; Villegas, L | 1 |
| Bao, L; Dunham, K; Lucas, K | 1 |
| Kim, DN; Lee, SK; Song, YJ | 1 |
| Jiang, P; Lee, W; Li, W; Xiang, Y; Yu, G; Zhang, Y | 1 |
| Hoshino, H; Moriya, Y; Okamoto, T; Suzuki, M; Tamura, H; Yoshida, S; Yoshino, I | 1 |
| Aurelian, L; Lee, KS; Li, B; Liu, J; Smith, CC | 1 |
| Adès, L; Auberger, P; Baran-Marszak, F; Boehrer, S; Cluzeau, T; de Botton, S; Eclache, V; Fenaux, P; Galluzzi, L; Gardin, C; Kroemer, G; Lainey, E; Leroy, C; Roudot, H; Sébert, M; Tailler, M; Thépot, S | 1 |
| Abdulhaq, H; Atem, FD; Costa, R; Haq, B; Latsko, J; Lister, J; Rossetti, JM; Sahovic, EA; Shadduck, RK; Zenati, M | 1 |
| Choi, CW; Jang, JH; Joo, YD; Kim, HG; Kim, SH; Kim, YK; Lee, JH; Min, YH; Park, E; Park, J; Park, S; Park, SK | 1 |
| Ayala-Ortega, E; Dávalos-Salas, M; Furlan-Magaril, M; González-Buendía, E; Recillas-Targa, F; Valdes-Quezada, C | 1 |
| Chen, HM; Du, W; Fang, JY; Hong, J; Tang, JT; Wang, JL; Wang, YC; Xiong, H; Zhao, SL | 1 |
| Hagemann, N; Hudson, K; Luo, S; Preuss, D | 1 |
| Gronemeyer, H; Hahn, WC; Kedinger, V; Khanwalkar, H; Kotova, I; Lund, P; Voltz, E | 1 |
| Kim, HY; Kuypers, FA; Kwiatkowski, J; Olivieri, NF; Saunthararajah, Y; Thayalasuthan, V; Trachtenberg, FL; Vichinsky, EP; Ware, RE | 1 |
| Advani, A; Copelan, E; Ebrahem, Q; Gu, X; Hu, Z; Kalaycio, M; Link, KA; Maciejewski, J; Mahfouz, RZ; Mulloy, JC; Negrotto, S; Ng, KP; Radivoyevitch, T; Saunthararajah, Y; Sekeres, M; Sobecks, R | 1 |
| Guo, CW; Jiang, ZZ; Li, P; Li, Q; Song, K | 1 |
| Li, Z; Wang, J; Wang, S; Yi, Z | 1 |
| Cai, X; Liu, Y; Sun, J; Yi, B; Zhang, H; Zhou, H | 1 |
| Al-Salihi, M; Alexander, A; Burnett, DM; Fitzpatrick, FA; Samlowski, WE; Yu, M | 1 |
| Fang, GA; Li, YW; Liu, XG; Qiu, L; Wang, YK; Yang, XC; Zhou, JH; Zhou, SQ | 1 |
| Bhattacharyya, B; Hallett, M; Han, ZG; Huang, J; Stefanska, B; Suderman, M; Szyf, M | 1 |
| Byrne, DJ; Dobrovic, A; Fox, SB; Huang, KT; Mikeska, T; Takano, EA | 1 |
| Bao, B; Rodriguez-Melendez, R; Zempleni, J | 1 |
| Nielsen, AL; Sølvsten, C | 1 |
| May, JM; Qiao, H | 1 |
| Kaminskyy, VO; Surova, OV; Vaculova, A; Zhivotovsky, B | 1 |
| Amengual, J; Bhagat, G; Kalac, M; Leshchenko, VV; Marchi, E; O'Connor, OA; Parekh, S; Scotto, L; Seshan, VE; Temkin, AM; Tycko, B; Ulahannan, N | 1 |
| Chen, J; Cui, Q; Lu, Z; Zhao, L | 1 |
| Accardi, R; Boffetta, P; Brennan, P; Calabrese, L; Chiesa, F; Creveaux, M; Cuenin, C; Curado, MP; Daudt, A; Fathallah, I; Gheit, T; Herceg, Z; Hussain, I; Koifman, S; Maffini, FA; Malfroy, M; Matos, E; Menezes, AM; Saulnier, A; Sebastian, S; Shahzad, N; Shukla, R; Siouda, M; Sylla, BS; Tommasino, M; Torrente, M; Vaissière, T; Wünsch-Filho, V; Yue, J; Zaridze, D | 1 |
| Achberger, S; Alcazar, O; Aldrich, W; Hu, Z; Negrotto, S; Saunthararajah, Y; Triozzi, P | 1 |
| Badran, AH; Comi, TJ; Furman, JL; Ghosh, I; Ma, AS; Porter, JR | 1 |
| Gao, XP; Gomes, I; Kishore, R; Malik, AB; Rajasingh, J; Siddiqui, MR; Thangavel, J | 1 |
| Li, G; Li, W; Li, X; Liao, Q; Ma, J; McCarthy, JB; Su, B; Tan, Y; Wang, W; Wu, M; Xiang, B; Xiong, W; Yang, J; Yi, M; Zhang, Z | 1 |
| Chen, JH; Hu, WX; Luo, SQ; Pei, JH; Xiao, HW; Zhong, Y | 1 |
| Abboud, CN; Cashen, AF; DiPersio, JF; Gao, F; Hassan, A; Klco, JM; Procknow, E; Stockerl-Goldstein, KE; Uy, GL; Vij, R; Welch, JS; Westervelt, P | 1 |
| Kumar, A; Prasada, KS; Rai, PS; Rao, BS; Satyamoorthy, K; Upadhya, R | 1 |
| Bordoni, RE; Buchner, D; Farrelly, E; Feinberg, BA; Gilmore, JW; Haislip, S; Jackson, JH; Kim, E | 1 |
| Maki, K; Mitani, K | 1 |
| Ades, L; Bouabdallah, K; Braun, T; de Renzis, B; Dreyfus, F; Droin, N; Fenaux, P; Fontenay, M; Gardin, C; Itzykson, R; Joly, B; Lafon, I; Laribi, K; Meurice, G; Oréar, C; Preudhomme, C; Recher, C; Renneville, A; Royer, B; Sanhes, L; Solary, E; Toma, A; Vekhoff, A; Vey, N | 1 |
| Mossman, D; Scott, RJ | 1 |
| Bodo, J; Gopalan, B; Guinta, K; Hsi, E; Jankowska, AM; Maciejewski, J; Mulloy, JC; Negrotto, S; Ng, KP; Saunthararajah, Y | 1 |
| Amato, E; Boninsegna, L; Dandrea, M; Debattisti, V; Falconi, M; Fumagalli, C; Malpeli, G; Pelosi, G; Scarpa, A | 1 |
| Costa, VL; Danielsen, SA; Eknaes, M; Henrique, R; Jerónimo, C; Lind, GE; Lothe, RA; Morais, A; Oliveira, J; Patrício, P; Teixeira, MR | 1 |
| Clark, SJ; Coolen, MW; Custodio, J; Esteller, M; Mayor, R; Muñoz, M; Peinado, MA | 1 |
| Castoro, R; Chung, W; El Ahdab, S; He, R; Issa, JP; Jelinek, J; Kantarjian, HM; Qin, T; Shu, J; Si, J; Wang, X; Zhang, N | 1 |
| Hao, T; Li, S; Li, Z; Yang, J; Zhang, H | 1 |
| Chen, JF; Dong, CX; Feng, DW; Guo, ZP; Wang, MF; Yang, LH; Zhagn, L; Zhang, JH; Zhang, RJ | 1 |
| Brown, KD; Darst, RP; Delmas, AL; Dyer, LM; Hakam, A; Izumchenko, EG; Kladde, MP; Monroe, M; Pardo, CE; Riggs, BM; Siegel, EM | 1 |
| Hu, CH; Wu, F | 1 |
| Shu, Y; Wang, B; Wang, J; Wang, JM; Zou, SQ | 1 |
| Han, T; Liu, Y; Shang, D; Tian, Y; Xu, X | 1 |
| Cronk, RJ; Lang, JM; McNeel, DG; Smith, HA | 1 |
| Ari, F; Colling, C; Dere, E; Honert, K; Kiechle, M; Krüger, A; Napieralski, R; Schmitt, M; Ulukaya, E | 1 |
| Atanackovic, D; Bartels, K; Bokemeyer, C; Cao, Y; Fuchs, G; Hegewisch-Becker, S; Hildebrandt, Y; Kloth, B; Kobbe, G; Kröger, N; Lajmi, N; Luetkens, T; Meyer, S; Platzbecker, U; Reinhard, H; Schilling, G; Schroeder, T | 1 |
| Endl, E; Felsberg, J; Hammes, J; Hartmann, W; Pietsch, T; von dem Knesebeck, A; Waha, A | 1 |
| Anderson, GJ; Chang, Y; Guo, M; Liu, G; Liu, Y; Nie, G; Ning, B; Su, X; Zhao, Y; Zheng, X | 1 |
| Bollard, CM; Copeland, A; Cruz, CR; Gerdemann, U; Heslop, HE; Horton, TM; Ku, S; Leen, AM; Rooney, CM; Shafer, JA; Sheehan, A; Tzou, B; Younes, A | 1 |
| Cho, YH; Choi, HS; Kim, SY; Lee, HG; Lee, JH; Yoon, SY | 1 |
| Chan, KW; Lockhart, S; McDonald, L; Rytting, M | 1 |
| Cui, XY; Gao, WF; Lin, YM; Ma, XT; Wang, N; Yang, BX; Yao, XR | 1 |
| Canter, DJ; Golovine, KV; Kolenko, VM; Kutikov, A; Makhov, PB; Matveev, VB; Roshchin, DA; Rybko, VA; Uzzo, RG | 1 |
| Jabbour, E; Kadia, TM; Kantarjian, H | 1 |
| Brodská, B; Holoubek, A | 1 |
| Chan, WC; Fang, WL; Hu, LY; Huang, KH; Kao, HW; Lai, CH; Li, SC; Liao, YL; Lin, WC; Tsai, KW; Wu, CW | 1 |
| Chang, X; Chen, J; Dai, D; Ma, J; Zhang, S; Zhi, Y | 1 |
| Chau, S; Foulks, JM; Hendrickson, TF; Ho, KK; Kanner, SB; McCullar, MV; Nix, RN; Parnell, KM; Saunders, M; Swierczek, K; Wright, K | 1 |
| Choi, CH; Lee, TB; Moon, YS | 1 |
| Tohyama, K | 2 |
| Chim, CS; Jin, DY; Liang, R; So, CC; Wong, KY; Yim, RL | 1 |
| Arpiainen, S; Holthöfer, H; Lehtonen, S; Ristola, M; Saleem, MA | 1 |
| Bianco-Miotto, T; Butler, LM; Centenera, MM; Chiam, K; Tilley, WD | 1 |
| Jung, G; Lim, SO; Quan, X | 1 |
| Biermann, K; Gillis, A; Looijenga, LH; Nettersheim, D; Schorle, H | 1 |
| Beach, CL; Fenaux, P; Gidwani, R; Khan, ZM; Pashos, CL | 1 |
| Abraham, J; Davie, J; Keller, C; Londhe, P; Zhu, B | 1 |
| Li, L; Liu, X; Tu, B; Wang, D; Wang, H; Wang, L; Zheng, Z; Zhu, WG | 1 |
| Chu, SH; Feng, DF; Ma, YB; Qiu, JH; Zhang, H; Zhu, ZA | 1 |
| Ahn Jo, S; Ahn, JH; Choi, EN; Oh, S; Sung, HY | 1 |
| Hong, X; Kalkanis, SN; Lemke, N; Nelson, K | 1 |
| Anant, S; Benbrook, DM; Lightfoot, S; Mills, WK; Natarajan, G; Queimado, L; Ramachandran, I; Ramalingam, S; Reis, A; Thavathiru, E; Zuna, R | 1 |
| Chen, DW; Liu, QY; Wang, HZ; Xie, LP; Zhang, RQ | 1 |
| Cai, W; Ekström, TJ; Karimi, M; Kiss, NB; Larsson, C; Pongratz, I; Rüegg, J; Swedenborg, E | 1 |
| Dou, LP; Lou, FD; Lu, XC; Wang, QS; Yu, L; Zhao, Y | 1 |
| Avraham, A; Bose, S; Evron, E; Gal-Yam, EN; Israeli, S; Kaufman, B; Rubinek, T; Shulman, M; Wolf, I; Zundelevich, A | 1 |
| Akahira, J; Hiroki, E; Ito, K; Miki, Y; Nagase, S; Sasano, H; Sugawara, J; Suzuki, F; Suzuki, T; Yaegashi, N | 1 |
| Fujii, T; Hayashi, M; Kanda, M; Kodera, Y; Nishikawa, Y; Nomoto, S; Okamura, Y; Sugimoto, H; Takeda, S; Yamada, S | 1 |
| Chen, HW; Lee, YM; Maurya, PK; Su, CM; Tzeng, CR | 1 |
| Bian, EB; Huang, C; Jin, Y; Li, J; Lv, XW; Ma, TT; Tao, H; Yang, JJ; Zhang, L | 1 |
| Brugger, W; Claus, R; Deschler, B; Döhner, H; Döhner, K; Galm, O; Ganser, A; Germing, U; Hackanson, B; Hagemeijer, A; Heil, G; Kuendgen, A; Lübbert, M; Platzbecker, U; Rethwisch, V; Rüter, BH; Schmid, M; Schmoor, C; Wijermans, PW | 1 |
| Dam, MA; Eskin, A; Kim, W; Konkankit, VV; Koya, RC; Liau, LM; Nelson, S; Prins, RM; Ribas, A | 1 |
| Rezvani, K | 1 |
| He, YL; Wang, JX; Yang, S; Zhang, ST; Zhu, ST | 1 |
| Barekati, Z; Bitzer, J; Grussenmeyer, T; Hartmann, N; Jenoe, P; Kohler, C; Lefkovits, I; Letzkus, M; Moes, S; Radpour, R; Schumacher, MM; Staedtler, F; Zhong, XY | 1 |
| Akpek, G; Cao, Q; Gojo, I; Rapoport, AP; Singh, SN | 1 |
| Chen, NN; Chen, XY; Fu, YS; Kong, QY; Li, H; Li, Y; Liu, J; Liu, ZL; Wu, ML | 1 |
| Gao, W; Singh, KP; Treas, J; Tyagi, T | 1 |
| Blanco-Fernández, A; Dempsey, E; Harvey, DJ; Madden, SF; Mariño, K; McCann, A; Peracaula, R; Pérez-Garay, M; Rudd, PM; Saldova, R; Struwe, WB; Watson, JA | 1 |
| Berkova, Z; Koblas, T; Leontovyč, I; Pektorova, L; Saudek, F; Zacharovova, K | 1 |
| Birch, L; Cheung, YY; Ho, SM; Morey, LM; Prins, GS; Tang, WY | 1 |
| Lei, YX; Wang, CX; Zhou, ZH | 1 |
| Cowan, LA; Talwar, S; Yang, AS | 1 |
| Bloomfield, CD; Blum, W; Garzon, R; Geyer, S; Klisovic, RB; Marcucci, G; Metzeler, KH; Walker, A | 1 |
| Engel, N; Rank, A | 1 |
| Carducci, MA; Herman, JG; Shabbeer, S; Simons, BW; Williams, SA | 1 |
| Cavalli, LR; da Costa Prando, E; Rainho, CA | 1 |
| Blanquart, C; Fonteneau, JF; Grégoire, M; Gueugnon, F; Panterne, C; Roulois, D | 1 |
| Amin, S; Mann, D; Mann, J; Oscier, D; Parker, AE; Walsh, M; Willmore, E; Wilson, C | 1 |
| Chan, KK; Covey, J; Desimone, J; Engelke, KJ; Lavelle, D; Ling, Y; Mahfouz, R; Negrotto, S; Ng, KP; Ruiz, MA; Saunthararajah, Y; Smith, N; Terse, P; Vaitkus, K | 1 |
| Hiraishi, T; Itoh, F; Maehata, T; Niwa, H; Oikawa, R; Oishi, Y; Sato, Y; Suzuki, H; Suzuki, M; Toyota, M; Watanabe, Y; Yoshida, Y | 1 |
| Byun, CJ; Jo, I; Jo, SA; Klug, M; Park, MH; Park, YJ; Rehli, M; Seo, J | 1 |
| Huang, C; Huang, S; Li, CR; Li, DJ; Wang, LF | 1 |
| Barišić, D; Bosnar, MH; Horvat, T; Mužinić, A; Zoldoš, V | 1 |
| Haugen, A; Mollerup, S; Skaug, V; Stangeland, L; Tekpli, X; Zienolddiny, S | 1 |
| Wang, HX; Wang, L; Zhao, J | 1 |
| Bosi, A; Buchi, F; Ferrari, G; Gozzini, A; Masala, E; Sanna, A; Santini, V; Spinelli, E | 1 |
| Chang, SC; Sun, CY; Wu, MS | 1 |
| Adamson, DC; Bigner, D; Bortoff, K; Di, C; Duncan, C; Fu, J; Gregory, S; Killela, P; Lin, N; McLendon, R; Truszkowski, P | 1 |
| Astudillo, A; Ballestar, E; Calvanese, V; Fernández, AF; Ferrero, C; Fraga, MF; Hernando, H; Huidobro, C; Mangas, C; Martínez-Camblor, P; Obaya, AJ; Parra-Blanco, A; Rodrigo, L; Rodríguez, RM; Suárez-Fernández, L; Urdinguio, RG | 1 |
| Kim, JH; Lee, YC; Lee, YS; Shin, H | 1 |
| Bai, T; Kobayashi, A; Matsuoka, T; Sasaki, N; Tanaka, J; Tanaka, T; Tanizaki, Y; Toujima, S; Utsunomiya, H; Utsunomiya, T; Yamamoto, M; Yukawa, K | 1 |
| Anoruo, N; Clark, AF; Mao, W; Rubin, JS; Wordinger, RJ | 1 |
| Bazzoli, F; Boland, CR; Daoud, Y; Fini, L; Fox, JG; Garcia, M; Gasbarrini, A; Genta, RM; Malfertheiner, P; Meyer, RL; Piazzi, G; Ricciardiello, L; Romano, M; Selgrad, M; Wex, T | 1 |
| Brown, R; Dai, W; Plumb, JA; Rizzo, S; Siddiq, A; Steele, NL; van der Zee, A; Walley, AJ; Wilhelm-Benartzi, CS; Zeller, C | 1 |
| Clouser, CL; Greggs, WM; Mansky, LM; Patterson, SE | 1 |
| Börner, C; Höllt, V; Kraus, J; Martella, E | 1 |
| Daaka, Y; Gersey, Z; Kim, WJ | 1 |
| Briggs, JE; Clouser, CL; Crankshaw, DL; Holtz, CM; Mansky, LM; Mullett, M; O'Sullivan, MG; Patterson, SE | 1 |
| He, D; Hong, S; Hu, G; Hu, Q; Qian, Y; Ren, G; Xiang, T; Zeng, Q; Zhu, J | 1 |
| Bothur, E; Brand, S; Garn, H; Kesper, DA; Kilic-Niebergall, E; Lohoff, M; Pfefferle, PI; Pinkenburg, O; Renz, H; Teich, R | 1 |
| Beijnen, JH; Derissen, EJ; Manson, ML; Schellens, JH; Wijermans, PW | 1 |
| Chunhua Zhao, R; Li, J; Liang, W; Xia, H | 1 |
| Brown, KW; Charlet, J; Diederich, M; Schnekenburger, M | 1 |
| Borthakur, G; Burger, J; Faderl, S; Feliu, J; Ferrajoli, A; Garcia-Manero, G; Huang, X; Jabbour, E; Kadia, T; Kantarjian, HM; Konopleva, M; Ravandi, F; Wang, X | 1 |
| Altenberger, C; Arns, BM; Babinsky, V; Döme, B; End-Pfützenreuter, A; Grin, Y; Heller, G; Klepetko, W; Lang, G; Minichsdorfer, C; Noll, C; Weinzierl, M; Ziegler, B; Zielinski, CC; Zöchbauer-Müller, S | 1 |
| Bermejo, JL; Campos, B; Chaisaingmongkol, J; Claus, R; Dyckhoff, G; Geiselhart, L; Herold-Mende, C; Herpel, E; Lasitschka, F; Oakes, CC; Plass, C; Popanda, O; Schmezer, P; Warta, R | 1 |
| Berglundh, T; Larsson, L; Rymo, L; Thorbert-Mros, S | 1 |
| Capalash, N; Parashar, G; Parashar, NC | 1 |
| Achberger, S; Alcazar, O; Aldrich, W; Ponnazhagan, S; Saunthararajah, Y; Triozzi, PL | 1 |
| Blancafort, P; Costa, J; Fenn, K; Huang, X; Lizardi, PM; Narayanaswamy, R; Sasaki, C; Szpakowski, S | 1 |
| Fan, LP; Fu, HY; Shen, JZ; Wu, DS; Xu, CB; Zhou, HR | 1 |
| Guo, LP; Li, LW; Li, XY; Lu, SX; Yu, XY; Zhou, Y | 1 |
| Terry, SY; Vallis, KA | 1 |
| Guan, XJ; Liang, H; Shao, XR | 1 |
| Guo, J; Guo, L; Han, X; Li, J; Qu, Q; Sun, HD; Tan, WH; Yi, TZ | 1 |
| Bendebury, A; Gravina, S; Gundry, M; Lee, M; Maslov, AY; Strogonova, N; Suh, Y; Tazearslan, C; Vijg, J | 1 |
| Li, QY; Liang, MM; Lu, KH; Lu, SS; Lu, YQ; Ning, SF; Xu, HY; Yang, XG | 1 |
| Cass, CE; Damaraju, VL; Mowles, D; Ng, A; Tong, Z; Yao, S; Young, JD | 1 |
| Isomura, H; Kanda, T; Kawashima, D; Kondo, Y; Murata, T; Saito, S; Sugimoto, A; Tsurumi, T | 1 |
| D'Costa, ZJ; Hibma, MH; Leong, CM; Matthews, C; Shields, J | 1 |
| Marks, PW | 1 |
| Hu, K; Kong, QR; Liu, ZH; Mu, YS; Wu, ML; Yin, Z; Zhao, ZP | 1 |
| Cui, YT; Dong, SW; He, Z; Liang, DC; Liang, SJ; Liu, YM; Wang, S; Wang, YG; Zhang, P; Zhong, RR | 1 |
| Cheung, KH; Holford, ME; Krauthammer, M; McCusker, JP | 1 |
| Agarwal, P; Axelsson, T; Ehrencrona, H; Göransson, H; Halldórsdóttir, AM; Isaksson, A; Jernberg-Wiklund, H; Kanduri, M; Mansouri, L; Marincevic, M; Rosenquist, R; Sander, B; Stamatopoulos, K | 1 |
| Gao, Y; Ping, B; Zhou, S | 1 |
| Ikehata, M; Iwakawa, S; Ueda, K | 1 |
| Beijnen, JH; Jansen, RS; Keizer, RJ; Rosing, H; Schellens, JH; Wijermans, PW | 1 |
| Bultmann, S; Elsaesser, J; Lahaye, T; Leonhardt, H; Morbitzer, R; Schmidt, CS; Spada, F; Thanisch, K | 1 |
| Chen, JJ; Chen, Y; Lin, DJ; Long, ZJ; Wu, X; Xiao, RZ; Xiong, MJ | 1 |
| Dai, X; Wang, Y; Zhang, F | 1 |
| Kelley, N; Tennis, MA; Vanscoyk, MM; Wilson, LA; Winn, RA | 1 |
| Xue, H; Zhao, C | 1 |
| Chang, YL; Hong, TM; Jou, YS; Lin, JC; Lin, TC; Wu, CT; Wu, JY; Wu, YY; Yang, PC | 1 |
| Liu, YP; Nie, XC; Takano, Y; Xia, P; Xing, YN; Xu, XY; Yang, X; Yu, M; Zheng, HC | 1 |
| Kim, H; Lee, BJ; Lee, KH; Park, K | 1 |
| Li, CL; Li, JF; Liu, BY; Nie, H; Qu, QL; Su, LP; Wang, M; Yan, M; Yu, YY; Zhu, ZG | 1 |
| Chie, EK; Kim, HJ; Kim, IA; Kim, IH; Kim, JH; Young, PD | 1 |
| Chen, XW; Chen, YX; Li, B; Li, CG; Li, YH; Wen, FQ; Zhang, ZX | 1 |
| Li, P; Meng, XY; Wang, YJ; Zhang, ST; Zhou, QZ; Zhu, ST | 1 |
| Blatt, K; Cerny-Reiterer, S; Ghanim, V; Hadzijusufovic, E; Heller, G; Herrmann, H; Karlic, H; Mirkina, I; Peter, B; Pickl, WF; Schuch, K; Valent, P; Zöchbauer-Müller, S | 1 |
| Chen, J; Gou, Z; Li, P; Liu, R; Wang, H; Wen, J; Zhao, G; Zheng, M; Zhu, Y | 1 |
| Ahuja, N; Baylin, SB; Beaty, R; Brock, MV; Cai, Y; Feller-Kopman, D; Harbom, KM; Harris, J; Issa, JP; Jang, YY; Li, H; Lin, YC; Matsui, W; Minn, I; Pappou, E; Rassool, FV; Robert, C; Sharkis, SJ; Shin, JJ; Stearns, V; Tsai, HC; Van Neste, L; Welm, AL; Yarmus, LB; Yen, RW; Zahnow, CA | 1 |
| Abdulrantam, F; Hendrianto, E; Pikir, BS; Susilowati, H | 1 |
| Liang, G; Liang, JF; Wu, LN; Xiao, H; Zhao, YZ; Zheng, HX | 1 |
| Aoyama, S; Danbara, M; Harigae, H; Higashihara, M; Nakano, H; Takahashi, S | 1 |
| Bardhan, K; Liu, K; McGaha, TL; Torres, CM; Yang, D; Zimmerman, M | 1 |
| Kim, J; Kim, YR; Lee, KA | 1 |
| Chiaratti, MR; de Araújo, RR; De Bem, TH; Meirelles, FV; Oliveira, Lde J; Perecin, F; Sangalli, JR; Smith, LC; Valim Pimentel, JR | 1 |
| Andreu-Vieyra, C; Han, H; Jones, PA; Liang, G; Noushmehr, H; Yang, X | 1 |
| Bickenbach, JR; Chinnathambi, S; Tomanek-Chalkley, A; Wiechert, S; Winter, MC | 1 |
| Ausserlechner, MJ; Fiegl, H; Geiger, K; Hagenbuchner, J; Kiechl-Kohlendorfer, U; Meister, B; Müller, T; Obexer, P; Rupp, M; Sergi, C | 1 |
| Bhatla, T; Brown, P; Burke, MJ; Carroll, WL; Morrison, DJ; Raetz, EA; Wang, J | 1 |
| Barter, MJ; Bui, C; Galler, M; Reynard, LN; Rowan, AD; Scott, JL; Xu, Y; Young, DA | 1 |
| Bang, YJ; Han, SW; Im, SA; Kim, HP; Kim, TY; Lee, KH; Oh, DY; Park, J; Song, SH; Yoon, YK; Yun, J | 1 |
| Chen, JW; Li, XF; Wang, LX; Wen, HY; Zhang, XY | 1 |
| Armstrong, RN; Baird, DM; Colyer, HA; Jones, RE; Mills, KI; Pettigrew, KA; Rea, IM; Zhang, SD | 1 |
| Cesano, A; Cohen, A; Cordeiro, JA; Hawtin, RE; Hogge, D; Lacayo, N; Rosen, DB | 1 |
| Aota, K; Azuma, M; Kani, K; Momota, Y; Motegi, K; Takano, H; Yamamura, Y; Yamanoi, T | 1 |
| Logan, PC; Mitchell, MD; Ponnampalam, AP; Steiner, M | 1 |
| Chen, CS; Huang, TH; Kuo, YC; Lai, IL; Lin, HY; Lin, SP; Niu, DM; Weng, YI | 1 |
| Cao, J; Fang, S; Huang, SF; Ren, GS; Wen, YA; Zhang, LP | 1 |
| Arnold, A; Berry, WA; Fang, F; Huang, T; Matei, D; Nephew, KP; Schilder, J; Shen, C; Zeng, Y | 1 |
| Blumenfeld, Z | 1 |
| Bai, T; Bai, Y; Du, Z; Gao, YT; Lou, C; Wang, FM; Wang, YJ; Yang, B; Zhang, Y | 1 |
| Bloomfield, CD; Blum, W; Byrd, JC; Caligiuri, MA; Chan, KK; Curfman, JP; Devine, SM; Eisfeld, AK; Garr, C; Garzon, R; Geyer, S; Grever, MR; Jacob, S; Kefauver, C; Klisovic, R; Marcucci, G; Perrotti, D; Santhanam, R; Schwind, S; Tarighat, SS; Walker, A; Wang, H; Whitman, S | 1 |
| Chen, JB; Li, Y; Liu, Q; Ren, GS; Song, JJ; Xiang, TX; Yang, L; Yang, ZS | 1 |
| He, G; Hu, X; Jin, S; Lu, C; Ruan, C; Sun, A; Wu, D; Zhang, X | 1 |
| Chang, C; He, Q; Li, X; Wu, L; Xu, F; Zhang, Y; Zhang, Z | 1 |
| Cho, BN; Cho, C; Kim, BH; Kim, YI; Lee, HK; Lee, SJ; Shim, J | 1 |
| Cao, H; Chen, XY; Fang, JY; Lu, YY; Shen, ZY; Wang, P; Wang, YC; Yu, J; Zhang, YJ; Zhu, JD | 1 |
| Parikh, SA; Tefferi, A | 2 |
| Bäck, M; Nagy, E | 1 |
| Du, WH; Hao, HS; Liu, Y; Qin, T; Ren, JJ; Wang, D; Zhao, XM; Zhu, HB | 1 |
| Fu, Y; Jiang, X; Jin, Y; Li, C; Lv, S; Qiao, M; Xu, H; Yuan, B | 1 |
| Hu, C; Jin, J; Tong, H; Wang, L; Zhuang, Z | 1 |
| Chen, H; Jin, F; Liu, C; Mao, XY; Wang, H; Wei, J; Yao, F; Zheng, HC | 1 |
| Ko, JL; Lee, H; Tang, SC; Wang, PH; Wu, CH | 1 |
| Guo, XL; Li, R; Song, JR; Tao, SF; Wei, LX; Wu, MC; Xu, Y; Zhang, CS; Zhang, SS | 1 |
| Deng, T; Liu, J; Luo, HS; Wang, FL; Xie, YS; Zhang, LJ; Zhang, Y | 1 |
| Autry, J; Borthakur, G; Boumber, Y; Castoro, R; Cortes, J; Estrov, Z; Faderl, S; Garcia-Manero, G; Issa, JP; Jabbour, E; Jorgensen, J; Kantarjian, H; Ravandi, F; Wen, S | 1 |
| de Almeida, IT; Milagre, I; Nunes, MJ; Pinheiro, A; Rivera, I; Rodrigues, E; Silva, MJ | 1 |
| Ayaki, M; Elanchezhian, R; Palsamy, P; Shinohara, T | 1 |
| Chen, R; Hu, Q; Ji, L; Liao, QP; Wang, YL; Xie, Y; Yu, L; Zhang, Y | 1 |
| Daudi, S; Kim, KM; Kim, MJ; Lee, SY; Miliotto, A; Odunsi, K; Old, L; Song, MH | 1 |
| Bilban, M; Egger, G; Hassler, MR; Klisaroska, A; Kollmann, K; Schiefer, AI; Sexl, V; Steiner, I | 1 |
| Andersson, BS; Champlin, RE; Li, Y; Murray, D; Nieto, Y; Valdez, BC; Wang, G | 1 |
| Ehemann, V; Geffers, R; Hoffmann, K; Kesselmeier, M; Longerich, T; Lorenzo Bermejo, J; Neumann, O; Pellegrino, R; Radlwimmer, B; Schemmer, P; Schirmacher, P | 1 |
| Arthur, C; Buckstein, R; Cermak, J; Chou, WC; Delaunay, J; Dmoszynska, A; Faderl, S; Gau, JP; Kantarjian, HM; Kuo, CY; Lysák, D; Mayer, J; Mazur, G; Minden, M; Oriol, A; Ravandi, F; Thomas, XG; Wierzbowska, A | 1 |
| Du, HY; Li, FX; Li, M; Li, XH; Sun, JZ; Wu, YS; Yang, XX; Zhu, W | 1 |
| Jang, JJ; Jung, N; Kang, GH; Kim, BH; Suh, KS; Won, JK | 1 |
| Dykema, KJ; Furge, KA; Staal, B; Vande Woude, GF; Zhang, YW | 1 |
| Bock, C; Do, H; Dobrovic, A; Mikeska, T | 1 |
| Choi, YH; Kang, HS; Kim, CG; Kim, GY; Kim, WJ; Shin, DY | 1 |
| Chen, XY; Guo, MZ; He, QY | 1 |
| Basu, PS; Mazumder-Indra, D; Mitra, S; Mondal, RK; Panda, CK; Roy, A; Roychoudhury, S | 1 |
| Chen, WF; Huang, F; Zha, J | 1 |
| Åkerström, G; Björklund, P; Carling, T; Choi, M; Fonseca, AL; Hellman, P; Kugelberg, J; Lifton, RP; Scholl, U; Starker, LF; Westin, G | 1 |
| Babiarova, K; Brabcova, E; Hainz, P; Krystofova, J; Kutinova, L; Musil, J; Nemeckova, S; Zurkova, K | 1 |
| Chan, SH; Chen, H; Cheung, FM; Chiu, PM; Chua, D; Hyytiainen, M; Kan, R; Keski-Oja, J; Ko, JM; Kwong, DL; Lee, AW; Lung, ML; Nicholls, JM; Stanbridge, EJ; Tao, Q; Tsao, SW; Wong, VC; Zabarovsky, ER | 1 |
| Chiao, JW; Hong, L; Huang, Y; Ma, X; Zou, Y | 1 |
| Ardekani, AM; Jeddi Tehrani, M; Soleymani Fard, S | 1 |
| Jones, V; Katiyar, SK; Prasad, R; Singh, T; Vaid, M | 1 |
| Howell, PM; Liu, S; Riker, AI | 1 |
| Kadota, Y; Kawakami, T; Nakaya, T; Sato, M; Suzuki, S; Yanagawa, M | 1 |
| Cluzeau, T; Fenaux, P | 1 |
| Choi, YH; Han, MH; Kang, HS; Kim, GY; Kim, WJ; Park, YS; Shin, DY; Yang, K | 1 |
| Cogdill, AP; Cooper, ZA; Ferrone, CR; Fiedler, A; Frederick, DT; Garber, HR; Rosenberg, L; Thayer, SP; Wargo, JA; Warshaw, AL | 1 |
| Clark, B; Lobie, PE; Steiner, M; Tang, JZ; Zhu, T | 1 |
| Korz, V; Meyer, K; Wang, H | 1 |
| Bloomfield, CD; Blum, W; Bundschuh, R; Byrd, JC; Caligiuri, MA; Curfman, J; Frankhouser, D; Garzon, R; Geyer, S; Grever, MR; Jacob, S; Klisovic, R; Marcucci, G; Metzeler, K; Murphy, M; Rodriguez, B; Tam, HH; Trimarchi, M; Walker, A; Whitman, SP; Wu, YZ; Yan, P | 1 |
| Hu, JP; Hu, WX; Li, J; Luo, SQ; Qu, Q; Ren, W; Zhang, JM; Zhong, Y | 1 |
| Ba, M; Kong, M; Liang, H; Ma, L; Wang, Y; Yu, Q; Yu, T | 1 |
| Aoki, D; Banno, K; Kisu, I; Kobayashi, Y; Masuda, K; Nomura, H; Susumu, N; Tominaga, E; Tsuji, K; Ueki, A; Yamagami, W; Yanokura, M | 1 |
| He, L; Ji, W; Yang, J; Zhao, X | 1 |
| Ernberg, I; Grigorieva, EV; Gubanova, NV; Haraldson, K; Kashuba, VI; Kharchenko, OA; Kondratov, AG; Kutsenko, OS; Mostovich, LA; Prudnikova, TY; Vavilov, PV; Zabarovsky, ER | 1 |
| Hanaoka, N; Kurimoto, M; Matsuoka, H; Murayama, T; Nakakuma, H; Sonoki, T; Uneda, S | 1 |
| Hotta, T; Kasai, M; Kobayashi, Y; Kondo, Y; Miyazaki, Y; Mukai, HY; Ogura, M; Ohnishi, K; Ohyashiki, K; Okamoto, S; Oki, Y; Tohyama, K; Tomita, A; Tomonaga, M; Uike, N; Watanabe, T; Yamamoto, K | 1 |
| Labhasetwar, V; Lu, S; Peetla, C; Vijayaraghavalu, S | 1 |
| Chen, HQ; Liang, Y; Ma, YL; Moyer, MP; Qin, HL; Shen, TY; Shi, CZ; Wang, F; Yang, YZ; Zhang, HZ; Zhang, P | 1 |
| Kraus, J | 1 |
| He, G; Li, H; Li, W; Ma, Y; Tan, G; Zhang, X | 1 |
| Chen, H; Fan, H; Peng, X; Qian, D; Qiao, F; Qiu, X; Su, X; Zhao, Z | 1 |
| Colon-Otero, G; Cooper, SJ; Copland, JA; Grebe, SK; Kang, KH; Marlow, LA; Menefee, ME; Perez, EA; Tun, HW; von Roemeling, CA | 1 |
| Chang, C; Huang, CK; Jiang, Q; Lai, KP; Lee, SO; Li, L; Liang, L; Lin, TH; Luo, J; Ma, Z; Niu, Y; Tian, J; Yamashita, S; Yeh, CR; Yeh, S | 1 |
| Hagiwara, K; Ito, H; Miyata, Y; Murate, T; Nagai, H; Ohashi, H | 1 |
| Bian, EB; Cheng, C; Huang, C; Li, J; Lv, XW; Ma, TT; Tao, H; Zhang, H | 1 |
| Babilonia, G; Bedell, V; Clark, J; Lamparska, K; Smith, SS; Yip, W | 1 |
| Chen, ZJ; Huang, XY; Liu, HQ; Sun, L; Wang, HY; Wang, Y; Wu, KL; Xu, ZY; Zhang, D | 1 |
| Fetterly, GJ; Ghoshal, S; Haese, JP; Karpf, AR; Thudium, KE; Wetzler, M | 1 |
| Brock, MV; Guo, M; Herman, JG; Liu, X; Zhan, Q; Zhang, X | 1 |
| Chang, CK; He, Q; Li, X; Song, LX; Wu, LY; Xu, L; Zhang, QX; Zhang, Y | 1 |
| Berg, E; Hummel, M; Joosten, M; Lenze, D; Leser, U; Seitz, V; Sommerfeld, A; Stein, H; Zimmermann, K | 1 |
| Brower, V | 1 |
| Dahlman-Wright, K; Gustafsson, JÅ; Putnik, M; Zhao, C | 1 |
| Damon, L; Franklin, J; Garcia-Manero, G; Greenberg, PL; Hu, K; Moore, M; Roboz, G; Yang, AS | 1 |
| Aydin, B; Gidener, S; Hocaoglu, N | 1 |
| Hibi, T; Hirata, K; Matsuzaki, J; Nishizawa, M; Saito, H; Saito, Y; Suzuki, H; Taya, T; Tsugawa, H | 1 |
| Fan, L; Fan, T; Gao, L; Li, R; Ling, Y; Wei, L; Wu, D; Zhang, C; Zhu, J | 1 |
| Colizzi, F; Coral, S; Covre, A; Dalla Santa, S; Fonsatti, E; Fratta, E; Maio, M; Nicolay, HJ; Parisi, G; Rizzo, A; Sigalotti, L | 1 |
| Castro, CC; Germano, RT; Magalhaes, SM; Pinheiro, RF; Sousa, JC | 1 |
| Chen, Y; Dai, F; Li, G; Li, R; Pan, X; Wang, L; Yang, J; Zhang, Y | 1 |
| Frick, K; Galili, N; Gross, CP; Guan, Y; Long, J; Ma, X; Raza, A; Wang, R; Xu, X; Zikria, J | 1 |
| Abe, E; Clyne, CD; Knower, KC; Miki, Y; Sasano, H; Simpson, ER; Suzuki, K; Takagi, K; To, SQ; Yang, Y | 1 |
| Baugh, JA; Levendale, A; Neary, R; Robinson, CM; Watson, CJ | 1 |
| Fetahu, ISh; Höbaus, J; Kallay, E; Khorchide, M; Manhardt, T | 1 |
| Bi, T; Che, X; Li, H; Liao, X; Zhang, D; Zhao, W | 1 |
| Bermejo, JL; Claus, R; Dienemann, H; Gu, L; Jacobsson, H; Meister, M; Muley, T; Peil, B; Plass, C; Risch, A; Sarkisyan, N; Scherf, DB | 1 |
| Han, T; Shang, D; Tian, Y; Xu, X | 1 |
| Godwin, AK; Guo, S; Liu, M | 1 |
| Li, G; Li, W; Li, X; Wang, W; Xiang, B; Yi, M | 1 |
| Bogachek, M; Cyr, AR; Domann, FE; Kulak, MV; Li, T; Price, DH; Spanheimer, PM; Weigel, RJ; Woodfield, GW | 1 |
| Di, W; Gu, L; Zhang, S; Zhu, J | 1 |
| Hou, CF; Luo, J; Ma, LM | 1 |
| Bao, L; Huang, XJ | 1 |
| Geng, J; Luo, H; Pu, Y; Wu, X; Xu, W; Yang, Z; Zhou, Z | 1 |
| Gore, SD; Suarez, L | 2 |
| Alazzouzi, H; Andretta, E; Arango, D; Bazzocco, S; Dopeso, H; Ferreira, AM; Gebert, J; Hernandez-Losa, J; Hofstra, RM; Landolfi, S; Macaya, I; Mariadason, JM; Mateo-Lozano, S; Mazzolini, R; Mooseker, MS; Ramón y Cajal, S; Reventós, J; Rodrigues, P; Schwartz, S; Suzuki, H; Woerner, SM; Yamamoto, H | 1 |
| Chang, C; Li, X; Xu, F; Yang, Y; Zhang, Q | 1 |
| Almgren, M; Baird, AM; Dockry, E; Ekström, TJ; Gray, SG; Hollywood, D; Meunier, A; Nikolaidis, G; O'Byrne, KJ; O'Kelly, F; Perry, AS | 1 |
| Sekeres, MA; Steensma, DP | 1 |
| Bess, MA; Chauhan, J; Clouser, CL; Dimick-Gray, S; Mansky, LM; Patterson, SE; van Oploo, JL; Zhou, D | 1 |
| Chang, C; Huang, CK; Lee, SO; Li, L; Liang, L; Luo, J; Niu, Y; Tian, J | 1 |
| Roboz, GJ | 1 |
| Camós, M; Colomer, D; Díaz, T; Díaz-Beyá, M; Esteve, J; Ferrer, G; Gel, B; Monzo, M; Navarro, A; Pratcorona, M; Rozman, M; Torrebadell, M | 1 |
| Accardi, R; Creveaux, M; Guillermier, S; Herceg, Z; Shukla, R; Siouda, M; Sylla, BS; Tommasino, M; Yue, J | 1 |
| Chen, XM; Ding, YB; Guo, LR; He, JL; Liu, XQ; Long, CL; Wang, YX; Xia, YY | 1 |
| Chung, D; Das, SK; Gao, F; Hemingway, J; Ma, X; Ostmann, AB; Rusie, A | 1 |
| De Preter, K; Decock, A; Hoebeeck, J; Ladenstein, R; Laureys, G; Noguera, R; Ongenaert, M; Schulte, JH; Speleman, F; Stallings, RL; Van Criekinge, W; Van Damme, A; Van Maerken, T; Van Peer, G; Vandesompele, J; Vermeulen, J | 1 |
| Cai, Z; Jin, Q; Li, Z; Liu, C; Tao, B; Yan, C | 1 |
| Ding, X; Fan, M; Huang, X; Liu, S; Liu, ZH; Wang, F; Wu, K; Wu, LY; Wu, Y; Xiong, L; Zhao, T; Zhao, Y; Zhu, LL | 1 |
| Botrugno, OA; Di Croce, L; Frigè, G; Gutierrez, A; Minucci, S; Pallavicini, I; Pelicci, P; Romanenghi, M; Santoro, F; Soncini, M | 1 |
| Deng, AC; Magro, CM; Sagransky, MJ | 1 |
| Chen, LH; Cheng, LY; Cherng, CG; Kao, GS; Su, CC; Tzeng, WY; Wang, CY; Yu, L | 1 |
| Aimiuwu, J; Chan, KK; Chu, BF; Grever, MR; Karpenko, MJ; Liu, Z; Otterson, GA; Villalona-Calero, MA | 1 |
| Chang, C; Fei, C; Gu, S; Guo, J; Li, X; Zhang, X; Zhang, Y; Zhao, Y | 1 |
| Gordiyuk, VV; Kashuba, EV; Kashuba, VI; Kondratov, AG; Kvasha, SM; Romanenko, AM; Rynditch, AV; Stoliar, LA; Zabarovsky, ER; Zgonnyk, YM | 1 |
| Hirano, T; Oga, H; Oka, K; Onda, K; Suzuki, R; Tanaka, S | 1 |
| Choi, JY; Hwang, S; Jo, I; Jo, SA; Kim, M; Kim, YJ; Lee, S; Pang, MG | 1 |
| Bhagat, TD; Bhattacharyya, S; Christopeit, M; Greally, JM; Maciejewski, JP; McDevitt, M; Melnick, AM; Mo, Y; Moliterno, A; Nischal, S; Pardanani, A; Sohal, D; Steidl, U; Suzuki, M; Verma, A; Will, B; Yu, Y; Zhou, L | 1 |
| Borthakur, G; Brandt, M; Cortes, J; Faderl, S; Garcia-Manero, G; Kantarjian, H; Liu-Dumlao, T; Pierce, S; Quintás-Cardama, A; Ravandi, F | 1 |
| Chen, Z; El-Rifai, W; Hu, TL; Peng, DF; Schneider, BG; Xu, ZK | 1 |
| Agresta, S; Amrein, PC; Attar, EC; Ballen, KK; Borger, DR; Burke, M; Chen, YB; Edmonds, KM; Emadi, A; Fathi, AT; Foster, J; Hill, C; Iafrate, AJ; Lopez, HU; Matulis, CR; Neuberg, DS; Sadrzadeh, H; Schenkein, DP; Stone, RM; Straley, KS; Yen, KE | 1 |
| Bracht, JR; Landweber, LF; Perlman, DH | 1 |
| Deng, N; Goh, LK; Gopalakrishnan, V; Huang, D; Ivanova, T; Lee, M; Liem, N; Luo, Q; Rozen, S; Tan, IB; Tan, P; Teh, BT; Wong, B; Wu, J; Wu, Y; Wu, YH; Yong, WP; Zhu, Y; Zouridis, H | 1 |
| Kang, S; Kim, B; Kim, SJ | 1 |
| Joeckel, TE; Lübbert, M | 1 |
| Kishimoto, M; Suemori, S; Tochigi, A; Tohyama, K; Tohyama, Y; Tsujioka, T; Uesugi, M; Yokoi, A | 1 |
| Ebrahem, Q; Mahfouz, RZ; Ng, KP; Saunthararajah, Y | 1 |
| Goldschmidt, H; Hose, D; Klein, B; Leonard, W; Moreaux, J; Rème, T; Requirand, G; Veyrune, JL | 1 |
| Cinar, MU; Fan, H; Hölker, M; Looft, C; Schellander, K; Tesfaye, D; Tholen, E; Zhang, R | 1 |
| Fan, R; Li, WY; Lin, GW; Wang, H; Wang, XQ; Wu, DP; Xu, Y | 1 |
| Chang, X; Chen, J; Dai, D; Li, Z; Lu, Y; Ma, J; Zhang, S; Zhi, Y | 1 |
| Abhyankar, S; Aljitawi, OS; Amin, M; Divine, C; Ganguly, S; McGuirk, JP | 1 |
| Dai, D; Deng, YF; Hu, MQ; Xu, YL; Zhang, L; Zhang, XQ; Zhang, XZ | 1 |
| Ganetsky, A | 1 |
| Baraty, C; Bianco, C; Castro, NP; Gonzales, M; Held, N; Karasawa, H; Rangel, MC; Rollman, K; Salomon, DS; Strizzi, L | 1 |
| Ao, L; Cao, J; Chen, HQ; Cui, ZH; Han, F; Jiang, X; Li, YH; Liu, JY; Liu, WB; Liu, Y; Yang, LJ | 1 |
| Chen, F; Fei, QL; Han, ZG; Huang, J; Li, YD; Liu, RF; Xu, X | 1 |
| Goodson, H; Helquist, P; Huegel, KL; Hulett, TW; Vaughan, KT; Wehrmann, ZT; Wiest, O | 1 |
| Almstedt, M; Claus, R; Hackanson, B; Lübbert, M; Pfeifer, D; Plass, C; Zucknick, M | 1 |
| Fang, HL; Jin, YT; Yu, ZC; Zhu, HB | 1 |
| Alberich-Jordà, M; Amabile, G; Avellino, R; Balastik, M; Delwel, R; Di Ruscio, A; DiRuscio, A; Ebralidze, AK; Figueroa, ME; Lowers, I; Melnick, A; Radomska, HS; Shapiro-Koss, C; Tenen, DG; Valk, PJ; Wouters, B; Ye, M; Zhang, H; Zhang, J | 1 |
| Kotamraju, S; Kutala, VK; Lakshmi, SV; Naushad, SM; Rao, DS; Reddy, CA; Saumya, K | 1 |
| Andry, G; De Martelar, V; Dom, G; Dumont, JE; Galdo, VC; Hébrant, A; Leteurtre, E; Libert, F; Maenhaut, C; Tarabichi, M; Tomás, G; van Staveren, WC | 1 |
| Beumer, JH; Buch, SC; Christner, S; Egorin, MJ; Kirkwood, JM; Lin, Y; Moschos, S; Tarhini, AA; Tawbi, HA | 1 |
| Bloomfield, CD; Blum, W; Byrd, JC; Caligiuri, MA; Chan, KK; Chen, CS; Dorrance, AM; Garzon, R; Hoellerbauer, P; Huang, X; Jacob, S; James Lee, L; Klisovic, RB; Marcucci, G; Mims, A; Mrózek, K; Perrotti, D; Santhanam, R; Schwind, S; Sun, J; Tarighat, SS; Walker, AR; Walker, C; Wang, H | 1 |
| Aimiuwu, J; Blum, W; Byrd, JC; Chan, KK; Chen, P; Garzon, R; Grever, MR; Klisovic, R; Liu, Z; Marcucci, G; Mims, A; Santhanam, R; Saradhi, UV; Schwind, S; Villalona-Calero, MA; Walker, A; Wang, H; Wang, J | 1 |
| Chen, ML; Feng, YQ; Liu, YL; Xing, XW; Yuan, BF; Zhou, X | 1 |
| Chen, PW; Li, H; Mellon, J; Niederkorn, JY; Sadegh, L | 1 |
| Cui, Q; Fu, H; Fu, S; Gu, Y; Hu, Y; Huang, H; Liu, L; Sheng, L; Shi, J; Tan, Y; Wu, K; Yu, X | 1 |
| Jiang, GY; Li, QC; Wang, EH; Xu, HT; Xu, K; Yang, LH; Zhang, XP; Zhao, HY | 1 |
| He, X; Huang, C; Huang, Y; Jin, Y; Li, J; Lv, XW; Miao, CG; Yang, YY; Zhang, L | 1 |
| Liu, J; Luo, HS; Wang, FL; Xie, YS; Zhang, LJ; Zhang, Y | 1 |
| Borden, EC; Fruehauf, JP; Haney, R; Jacobs, BS; Lindner, DJ; Tuthill, R; Wu, Y | 1 |
| Brooks, J; Cullo, A; Davies, J; Gonda, T; Hirsch, S; Kim, S; Ludwig, T; Olive, K; Quante, M; Salas, M; Shakya, R; Szabolcs, M; Tycko, B; Wang, TC | 1 |
| Cheriyath, V; Dermawan, JK; Labhasetwar, V; Vijayaraghavalu, S | 1 |
| Eisenhofer, G; Hagelgans, A; Lehnert, R; Menschikowski, M; Platzbecker, U; Schönefeldt, C; Siegert, G; Thiede, C; Vogel, M | 1 |
| Bernaudin, M; Carlotti, CG; Carosella, ED; Donadi, EA; Ferrone, S; Flajollet, S; Jensen, SS; Kristensen, BW; Lechapt-Zalcman, E; Moreau, P; Pancoto, JT; Poras, I; Simões, RT; Valable, S; Wastowski, IJ; Yaghi, L | 1 |
| Lau, KM; Li, KK; Mao, Y; Ng, HK; Pang, JC; Poon, WS; Wang, Y; Zhou, L | 1 |
| Gallacher, J; Kalogerou, M; Sampson, JR; Shen, MH; Yang, J | 1 |
| Chang, KW; Chiang, WF; Chu, TH; Gong, NR; Lin, SC; Liu, CJ; Wu, CH; Yang, CC | 1 |
| Brodsky, L; Chenchik, AA; Gudkov, AV; Komarova, EA; Leonova, KI; Lipchick, B; Novototskaya, L; Pal, M; Sen, GC | 1 |
| Hu, Q; Liao, QP; Yu, L | 1 |
| Chan, AK; Lau, KM; Li, KK; Mao, Y; Ng, HK; Pang, JC; Poon, WS; Shi, Z; Wang, Y; Yang, L; Zhou, L | 1 |
| Cortes, JE; Faderl, S; Fullmer, A; Garcia-Manero, G; Jabbour, E; Kantarjian, H; O'Brien, S; Ravandi, F; Wierda, W | 1 |
| Chen, Y; Leach, R; Qian, CN; Wang, K | 1 |
| Do, YR; Huh, J; Kim, DD; Kim, H; Kim, HJ; Kim, KH; Kim, MK; Kim, SH; Kim, T; Mun, YC; Yi, JH | 1 |
| Chi, SG; Lee, MG; Ryu, BK; Yoo, TH | 1 |
| Krishnadas, DK; Lucas, K; Shapiro, T | 1 |
| Byun, DW; Chun, SW; Jung, CH; Kang, SG; Kim, BY; Kim, CH; Kim, SJ; Kim, YJ; Ko, HJ; Mok, JO; Park, HK; Suh, KI; Yoo, MH | 1 |
| Carlson, K; Christos, PJ; Feldman, EJ; Ippoliti, C; Lagassa, CB; Ritchie, EK; Roboz, GJ; Rohan, SD; Scandura, JM | 1 |
| Biancardi, MN; Dumas, C; Earle Pope, C; Galiguis, J; Gómez, MC; Jenkins, JA; Wang, G | 1 |
| Chan, K; Covey, J; Ebrahem, Q; Engelke, KJ; Gu, X; Jankowska, A; Ling, Y; Maciejewski, J; Mahfouz, RZ; Radivoyevitch, T; Saunthararajah, Y; Sekeres, MA; Tabarroki, A; Terse, P; Tiu, R; Visconte, V | 1 |
| Erdmann-Gilmore, P; Hundal, J; Klco, JM; Lamprecht, TL; Ley, TJ; Lichti, CF; Magrini, V; Mardis, ER; Meyer, MR; Sarkaria, SM; Spencer, DH; Townsend, RR; Varghese, N; Walker, J; Wilson, RK; Wylie, T | 1 |
| Arimondo, PB; Ceccaldi, A; Champion, C; Daunay, A; Fourrière, L; Guieysse-Peugeot, AL; Lacomme, S; Moison, C; Senamaud-Beaufort, C; Tost, J | 1 |
| Armstrong, D; Beyrouthy, MJ; Biswal, BK; Christensen, BC; Hever-Jardine, MP; Marsit, CJ; Spinella, MJ; Tomlinson, CR | 1 |
| Labhasetwar, V; Vijayaraghavalu, S | 1 |
| Batte, K; Cantemir-Stone, CZ; Dakhlallah, D; Hitchcock, CL; Marsh, CB; Mikhail, A; Nana-Sinkam, SP; Nuovo, G; Piper, MG; Wang, Y; Wright, VP; Yan, P | 1 |
| Battistini, A; Belardelli, F; Fragale, A; Gabriele, L; Lucarini, V; Mattei, F; Sanchez, M; Scala, S; Schiavoni, G; Sestili, P; Sistigu, A; Spada, M; Spadaro, F | 1 |
| Gao, X; Han, D; Huang, H; Li, F; Ma, N; Qiao, Y; Wang, D; Wang, L; Wang, X; Wu, G; Xiang, Y; Zhang, G; Zhang, Y; Zhao, R; Zhou, J | 1 |
| Allen, PB; Baer, MR; Kleinberg, ME; Koka, R | 1 |
| Abildgaard, MO; Borre, M; Haldrup, C; Høyer, S; Kristensen, H; Parker, C; Strand, S; Sørensen, KD; Ulhøi, BP; Ørntoft, TF | 1 |
| Fan, EZ; Fang, JG; Lian, M; Wang, H; Wang, Q | 1 |
| Mikkelsen, JG; Nielsen, AL; Pedersen, FS; Wolf, G | 1 |
| Denman, CJ; Kopp, LM; Lee, DA; Ray, A; Senyukov, VS; Somanchi, SS; Zhu, S | 1 |
| Awad, M; Bomalaski, J; Coley, HM; Crook, T; Hatzimichael, E; Janczar, K; Langer, J; Lattanzio, L; Lo Nigro, C; O'Neil, K; Roncaroli, F; Singh, P; Syed, N; Szlosarek, P | 1 |
| Cui, L; Deng, H; Guo, J; Guo, Y; Liu, Z; Song, H; Sun, W; Xia, T; Xiao, B; Yu, X | 1 |
| Guan, H; Klapproth, K; Ushmorov, A; Weitzer, CD; Wirth, T; Xie, L | 1 |
| Champlin, R; Chen, J; Daver, N; de Lima, M; Garcia-Manero, G; Giralt, S; Jabbour, E; Kadia, T; Kantarjian, H; Khouri, I; Koca, E; Mathisen, MS; Oran, B; Parmar, S; Pierce, S; Popat, U; Rondon, G; Tanaka, M | 1 |
| Chen, J; Peng, L; Ren, G; Tan, C; Yang, Z | 1 |
| Ma, H; Wang, J; Zhu, Z | 1 |
| Atenafu, EG; Brandwein, JM; Craddock, KJ; Gupta, V; Kennedy, JA; Lipton, JH; Messner, HA; Minden, MD; Schimmer, AD; Schuh, AC; Yee, KW | 1 |
| Barros, SP; Moretti, AJ; Niculescu, MD; Offenbacher, S; Preisser, JS; Yu, N; Zhang, S; Zhou, J | 1 |
| Gao, Y; Geng, Y; Han, X; He, Z; Jia, W; Kong, Y; Li, D; Lian, H; Liao, C; Sun, J; Xu, Y; Zhang, P; Zhang, Y | 1 |
| Brewer, MA; Meng, F; Sun, G; Yu, Y; Zhong, M | 2 |
| Chen, H; Hardy, TM; Li, Y; Meeran, SM; Patel, SN; Tollefsbol, TO | 1 |
| Laska, MJ; Nexø, BA; Nissen, KK | 1 |
| Huang, ML; Lin, ZQ; Liu, LY; Lu, HW; Mo, SM; Yao, TT | 1 |
| Baylin, SB; Dai, C; Jones, PA; Liang, G; Pandiyan, K; Yang, X; You, JS; Zhou, XJ | 1 |
| Ambs, S; Calin, GA; Croce, CM; Esposito, D; Hudson, RS; Liu, CG; Prueitt, RL; Schetter, AJ; Stephens, RM; Van Roosbroeck, K; Volfovsky, N; Volinia, S; Yi, M | 1 |
| Agudo, G; Alonso, MA; Arozamena, J; Bolado-Carrancio, A; de la Vega, R; Delgado-Calle, J; Pérez-López, J; Riancho, JA; Rodríguez-Rey, JC; Sañudo, C | 1 |
| Cho, SH; Choi, Y; Joo, YD; Kim, DY; Kim, SD; Lee, JH; Lee, KH; Lee, SM; Lee, WS | 1 |
| Dong, Y; Huang, H; Li, Q; Ning, Y; Sun, Q; Xu, W; Zhang, W | 1 |
| Bang, SM; Cheong, JW; Kim, BS; Kim, CS; Kim, HJ; Kim, I; Kim, SY; Kim, YK; Lee, HG; Lee, JH; Lee, JO; Lee, YG; Min, YH; Mun, YC; Park, J; Park, S; Park, Y; Seong, CM; Yi, HG; Yoon, SS | 1 |
| Belch, A; Gelebart, P; Lai, R; Molavi, O; Wang, P; Zak, Z | 1 |
| Absalon, M; Blum, W; Broun, R; Davies, SM; Garzon, R; Marcucci, G; McMasters, R; Mo, J; Moscow, JA; O'Brien, M; Perentesis, JP; Phillips, CL; Schwind, S; Smolarek, T | 1 |
| Seiter, K | 1 |
| Chen, Y; Cui, X; Hu, H; Jiao, Y; Li, S; Lin, L; Lv, X; Song, E; Wang, M; Yao, H; Yu, F | 1 |
| Cao, HX; Feng, JF; Li, XY; Ma, R; Wu, JQ; Wu, JZ; Zhong, YJ | 1 |
| Gong, XL; Li, R; Wang, X; Wang, XM; Wang, Y; Wang, YZ; Yang, ZF | 1 |
| Brock, MV; Guo, M; Herman, JG; Licchesi, JD; Liu, X; Pei, X; Yang, Y; Yue, W; Zhang, X | 1 |
| Agarwal, C; Agarwal, R; Chan, D; Mateen, S; Raina, K | 1 |
| Camacho-Arroyo, I; García-Gómez, E; González-Arenas, A; Hansberg-Pastor, V; Peña-Ortiz, MA; Rodríguez-Dorantes, M | 1 |
| Cai, LL; Chang, C; Fan, H; Guo, B; Han, WD; Li, SX; Lin, J; Liu, Y; Lu, XC; Ran, HH; Wang, Y; Yang, B; Yang, Y; Zhai, B; Zhang, F; Zhang, L; Zhu, HL | 1 |
| Han, XP; Huang, WR; Jiang, MM; Jing, Y; Mei, JH; Wang, QS; Wang, SH; Yang, H; Yu, L; Zhang, SS; Zhu, HY | 1 |
| Cerdeira, AS; Husain, Z; Karumanchi, SA; Kopcow, HD; Lo, A; Rajakumar, A; Royle, CM; Sukhatme, VP; Thadhani, RI | 1 |
| Bloomfield, CD; Blum, W; Byrd, JC; Caligiuri, MA; Chan, KK; Garzon, R; Hoellerbauer, P; Huang, X; Klisovic, R; Lee, LJ; Lee, RJ; Marcucci, G; Mims, A; Muthusamy, N; Perrotti, D; Santhanam, R; Schwind, S; Walker, AR; Wang, H; Yu, B | 1 |
| Akkamsetty, Y; Callen, DF; Ho, K; Kumar, R; Lim, SP; Neilsen, PM; Prestidge, C; Suetani, RJ; Walther, DJ; Wang, W | 1 |
| Fialova, B; Kolar, Z; Langova, K; Paskova, L; Smesny Trtkova, K | 1 |
| Boucher, K; Burr, L; Davidson, C; Garrido-Laguna, I; Gilcrease, W; Jakubowski, L; Jones, D; McGregor, KA; Morrell, G; Olpin, JD; Sharma, S; Soldi, R; Wade, M; Weis, J | 1 |
| Antonicelli, F; Diederich, M; Doliwa, C; Dufer, J; Poplineau, M; Schnekenburger, M; Trussardi-Régnier, A | 1 |
| Ferrara, F | 1 |
| Matsumura, I; Morita, Y; Tanaka, H | 1 |
| Kiianitsa, K; Maizels, N | 1 |
| Brown, CO; Fitzgerald, MP; Goel, A; Salem, K; Schibler, J; Singh, N; Zhan, F | 1 |
| Arneth, BM; Fuessel, S; Hagelgans, A; Menschikowski, M; Nacke, B; Siegert, G; Wirth, MP | 1 |
| Kang, YH; Kuang, JY; Mai, L; Xie, QF; Xu, QH; Yang, L; Zhang, SQ | 1 |
| Peek, RM; Schneider, BG | 1 |
| Mori, A; Niwa, T; Tatematsu, M; Toyoda, T; Tsukamoto, T; Ushijima, T | 1 |
| Cao, Y; Chen, M; Li, Z; Qi, F; Qi, L; Zhang, H; Zu, X | 1 |
| Cai, L; Gong, P; Li, L; Ma, Y; Su, X; Tao, Q; Wang, Z; Zhao, P; Zheng, C; Zheng, M | 1 |
| Chen, SA; Chen, YC; Chen, YJ; Chung, CC; Kao, YH; Kuo, CC; Lien, GS | 1 |
| Bazzoli, F; Bianchi, P; Boland, CR; Ceccarelli, C; Chieco, P; D'Angelo, L; Fini, L; Garcia, M; Laghi, L; Malfertheiner, P; Paterini, P; Piazzi, G; Ricciardiello, L; Selgrad, M | 1 |
| Curran, MP | 1 |
| Choi, YH; Kim, GY; Kim, WJ; Shin, DY; Sung Kang, H; Yoo, YH | 1 |
| Ito, Y; Murrell, A; Nativio, R | 1 |
| Li, JY; Qian, SX; Zhu, Y | 1 |
| Cui, G; Fan, WS; Fu, XY; Guan, Z; Huang, K; Li, J; Li, LA; Li, YL; Meng, YG; Sun, L; Wang, SJ; Yan, ZF; Yang, YZ; You, YQ | 1 |
| Burgos-Morón, E; Calderón-Montaño, JM; Cortés, F; Domínguez, I; Helleday, T; López-Lázaro, M; Mateos, S; Orta, ML; Pastor, N | 1 |
| Chang, WY; Hyun, JW; Kang, KA; Kim, GY; Kim, HS; Kim, KC; Na, SY; Zhang, R | 1 |
| Barouhas, I; Bushinsky, DA; Favus, MJ; Fu, B; Liu, W; Shuboy, A; Wang, H; Wang, J; Zhou, D | 1 |
| Jing, Y; Sun, L; Yang, L; Yuan, L | 1 |
| Han, XA; Han, YP; Sun, EW; Zeng, HL | 1 |
| Boumber, Y; Fang, Z; Garcia-Manero, G; Gonzalez-Cervantes, EA; Kuang, SQ; Wei, Y; Yang, H; Zweidler-McKay, PA | 1 |
| Billings, S; Englehaupt, R; Hasrouni, E; Kalaycio, M; Liu, Y; Rogers, HJ; Saunthararajah, Y; Sekeres, MA; Tabarroki, A; Tiu, RV; Visconte, V | 1 |
| Guo, RD; Han, X; Li, ZJ; Tan, ZJ; Wang, YL | 1 |
| Côté, S; Momparler, LF; Momparler, RL | 1 |
| Akiyama, Y; Hashimoto, Y; Yuasa, Y | 1 |
| Beijnen, JH; Derissen, EJ; Schellens, JH | 1 |
| Bai, XF; Ding, Y; Gao, L; Gao, XN; Jiang, MM; Li, JX; Li, YH; Lu, XC; Luo, XF; Mei, ZY; Qu, C; Shi, JL; Wang, J; Wang, LL; Wang, LX; Xu, YH; Yao, YS; Yu, L; Zhou, JH; Zhou, MH | 1 |
| Glasow, A; Kortmann, RD; Patties, I | 1 |
| Chang, CK; Li, X; Song, LX; Wu, LY; Zhang, Y | 1 |
| Pan, Y; Shao, C; Xie, Y; Ye, S; Yuan, D | 1 |
| Beyer, C; Dees, C; Distler, A; Distler, JH; Distler, O; Funke, R; Lin, NY; Palumbo-Zerr, K; Schett, G; Schlottmann, I; Zerr, P | 1 |
| Brioli, A; Davies, FE; Johnson, DC; Kaiser, MF; Melchor, L; Mirabella, F; Morgan, GJ; Walker, BA; Wardell, CP; Wu, P | 1 |
| Dash, S; Feitelson, M; Han, C; Lim, K; Lu, D; Song, K; Wu, T; Zhang, J | 1 |
| Ellinger, J; Müller, SC; Schiffgen, M; Schmidt, DH; von Rücker, A | 1 |
| Baylin, SB; Bernards, R; Bruurs, L; Cai, Y; de Lint, K; de Rink, I; Geutjes, EJ; Mohammad, H; Roepman, P; van Blijswijk, J; Wang, W; Yu, LR | 1 |
| Liang, J; Lin, Z; Liu, L; Rao, Q; Xie, Q; Yao, T; Zheng, C | 1 |
| Berdeja, JG; Borthakur, G; Estrov, Z; Faderl, S; Gabrail, N; Garcia-Manero, G; Godley, LA; Jabbour, E; Kantarjian, H; Kassalow, L; Maddipoti, S; Nadeem, A; Yang, H | 1 |
| Cao, M; Lü, CX; Quan, XQ; Ruan, L; Shang, SS; Wang, G; Wu, XF; Xu, RD; Yan, FQ; Zhang, CT | 1 |
| Li, H; Lin, C; Ran, Y; Wang, Z; Yang, W; You, Y; Zhu, H | 1 |
| Bultmann, I; Conradi, A; Kretschmer, C; Sterner-Kock, A | 1 |
| Liu, Z; Zhang, L; Zhang, S; Zhang, W; Zhang, Y | 1 |
| He, HB; Huan, YJ; Kong, QR; Liu, SC; Liu, ZH; Wang, JY; Xie, BT; Zhou, Y; Zhu, J | 1 |
| Charalambous, C; Constantinou, AI; Papageorgis, P; Pitta, CA | 1 |
| Estey, EH | 1 |
| Bai, Y; Bao, ZS; Chen, Y; Wang, LJ; Yan, ZH; Zhang, QG; Zhang, W | 1 |
| Cai, X; Chen, K; Chen, Q; Huang, A; Li, S; Nie, D; Quan, H; Shan, X; Tang, N; Zhou, F; Zhou, Z | 1 |
| Greene, WK; Kees, UR; Welch, MD | 1 |
| Breda, L; Gambari, R; Rivella, S; Zuccato, C | 1 |
| Cortes, J; Garcia-Manero, G; Jabbour, E; Kadia, T; Kantarjian, H; Malik, A; O'Brien, S; Ravandi, F; Teng, A; Welch, MA | 1 |
| Abhyankar, S; Aljitawi, O; Bhalla, KN; Dutreix, C; Fiskus, W; Fleming, A; Ganguly, S; Kambhampati, S; McGuirk, JP; Reyes, R; Wick, J; Williams, CB | 1 |
| Brown, K; Gillespie, KM; Holly, JM; Jarrett, C; Perks, CM; Zeng, L | 1 |
| Dou, LP; Jing, Y; Mei, JH; Wang, QS; Yu, L | 1 |
| Fan, R; Gao, Y; He, Z; Jin, L; Lian, H; Liu, J; Sun, J; Sun, Y; Xu, Y; Zhang, T; Zhang, Y | 1 |
| Chen, SN; Gao, S; Han, Y; He, GS; Hu, XH; Jin, ZM; Qiu, HY; Sun, AN; Tang, XW; Wu, DP; Xu, Y | 1 |
| Ornstein, DL; Preis, M | 1 |
| Hinoda, Y; Morishige, A; Nakamura, M; Nishikawa, J; Oga, A; Okada, T; Saito, M; Sakai, K; Sakaida, I; Sasaki, K; Suehiro, Y; Zhang, Y | 1 |
| Bauer, RN; Brighton, LE; Carson, JL; Fry, RC; Jaspers, I; Müller, LL; Rager, JE; Smeester, L | 1 |
| Brenner, C; Cryderman, DE; Fagan, RL; Kopelovich, L; Wallrath, LL | 1 |
| Boison, D; Farrell, JM; Kaplan, DL; Lusardi, TA; Lytle, NK; Pritchard, EM; Sandau, US; Williams-Karnesky, RL | 1 |
| Dong, W; Jian, N; Jian, P; Jian, W; Jun, L; Li, P; Na, W; Pei-Fang, X; Wen-Li, Z; Xing, F; Yan-Fang, T | 1 |
| Guo, LH; He, JS; Li, H; Wang, F; Yu, J | 1 |
| Boffelli, D; Coppé, JP; Di Noia, JM; Heo, SJ; Lee, EL; Martin, DI; Muñoz, DP; Takayama, S | 1 |
| Alholle, A; Arrigoni, E; Avigad, S; Brini, AT; Dallol, A; Gharanei, S; Grimer, R; Hiruma, T; Kishida, T; Latif, F; Maher, ER; Vaiyapuri, S | 1 |
| Cheng, Y; Dong, M; Fan, X; Feng, X; Jin, Z; Meltzer, SJ; Mori, Y; Wang, L; Zhang, X; Zhao, Z | 1 |
| Ge, YL; Han, LL; Hou, L; Lin, DL; Ma, ZL; Wu, L; Zhou, MJ | 1 |
| Cai, L; Ren, J; Sun, W; Tan, Y; Turdi, S; Yang, X | 1 |
| Drews, M; Frycz, BA; Jagodziński, PP; Marciniak, R; Murawa, D; Murawa, P; Wysocki-Borejsza, M | 1 |
| Alp, E; Konac, E; Menevse, S; Yilmaz, A | 1 |
| Berger, A; Bitzer, M; Essmann, F; Fulda, S; Häcker, S; Johnstone, RW; Lauer, UM; Nuebling, T; Salih, HR; Schenk, M; Schulze-Osthoff, K; Sipos, B; Venturelli, S; Waibel, M; Weiland, T | 1 |
| Kone, BC; Kong, Q; Yu, Z | 1 |
| Hesson, LB; Liu, J; Nunez, AC; Patil, V; Pimanda, JE; Sloane, MA; Ward, RL | 1 |
| Gao, X; Jiang, M; Ning, Q; Wang, J; Wang, L; Yao, Y; Yu, L; Zhou, J | 1 |
| Jakt, LM; Nishikawa, S; Wong, YF | 1 |
| Bao, Y; Chen, H; Pan, Y; Shao, C; Ye, S; Yuan, D | 1 |
| Berger, F; Bertoni, F; Cavalli, F; Cogliatti, S; Forconi, F; Gaidano, G; Gattei, V; Kwee, I; Lucioni, M; Marasca, R; Mensah, AA; Orlandi, EM; Rinaldi, A; Rossi, D; Zucca, E | 1 |
| Borthakur, G; Brandt, M; Cornelison, AM; Cortes, J; Garcia-Manero, G; Ghanem, H; Jabbour, E; Kadia, T; Kantarjian, H; O'Brien, S; Ravandi, F | 1 |
| Anastasiadis, PZ; Andorfer, CA; Borges, S; Döppler, H; Geiger, XJ; Perez, EA; Storz, P; Sun, Z; Thompson, E | 1 |
| Cho, IH; Chowdhury, B; Cui, Y; Irudayaraj, J | 1 |
| Konac, E; Menevse, S; Sozen, S; Varol, N; Yilmaz, A | 1 |
| Choi, KH; Kim, HS; Lee, CK; Park, JK; Son, DC; Uh, KJ | 1 |
| Chik, F; Machnes, Z; Szyf, M | 1 |
| Chun, KH; Hwang, JA; Kim, SJ; Lee, YS; Ro, JY | 1 |
| Moon, JH; Sohn, SK | 1 |
| Chang, KH; Fang, X; Han, H; Huang, A; Jiang, Y; Li, Q; Padilla, S; Papayannopoulou, T; Qu, H; Song, CZ; Stamatoyannopoulos, J; Wang, H | 1 |
| Bonnac, L; Clouser, CL; Mansky, LM; Patterson, SE | 1 |
| Brodská, B; Holoubek, A; Kuželová, K; Otevřelová, P | 1 |
| Gao, L; Gao, X; Jiang, M; Li, J; Li, Y; Luo, X; Wang, L; Yao, Y; Yu, L; Zhou, J; Zhou, M | 1 |
| Belz, K; Fulda, S; Steinhart, L | 1 |
| Antonicelli, F; Brassart-Pasco, S; Diederich, M; Dufer, J; Kosciarz, A; Poplineau, M; Schnekenburger, M; Trussardi-Régnier, A | 1 |
| Han, H; Liang, G; Pandiyan, K; Yang, X | 1 |
| Iliakis, G; Moscariello, M | 1 |
| Peng, M; Rothstein, SJ; Yaish, MW | 1 |
| Ahmad, N; Ali, M; Kohli, K; Neupane, YR; Sabir, MD | 1 |
| Al-Nakhle, H; Bell, SM; Burns, PA; Cummings, M; Hanby, AM; Hughes, TA; Lane, S; Parker, MD; Smith, L; Speirs, V | 1 |
| Benedetti, D; Bomben, R; Caldana, C; D'Arena, G; Dal Bo, M; Del Poeta, G; Di Raimondo, F; Gaidano, G; Gattei, V; Hartmann, TN; Hutterer, E; Pozzato, G; Pozzo, F; Rossi, D; Rossi, FM; Tissino, E; Zaja, F; Zucchetto, A | 1 |
| Borodovsky, A; Brennan, C; Chan, TA; Fabius, AW; Huse, J; Pedraza, A; Riggins, GJ; Turcan, S; Viale, A | 1 |
| Chang, C; He, Q; Li, X; Song, L; Su, J; Wu, D; Wu, L; Xu, F; Zhang, Q; Zhang, X; Zhang, Z; Zhou, L | 1 |
| Jiang, DF; Xing, TJ; Xu, HT; Yu, WQ | 1 |
| Cassarino, MF; Cavagnini, F; Lasio, G; Losa, M; Pagliardini, L; Pecori Giraldi, F; Sesta, A | 1 |
| Angioli, R; Barbosa, A; Begum, S; Brait, M; de Graeff, P; Fazio, VM; Hoque, MO; Loyo, M; Maldonado, L; Marchionni, L; Noordhuis, M; Noordhuis, MG; Poeta, ML; Rabitti, C; Sidransky, D; van der Zee, AG; Wisman, GB | 1 |
| Cao, Z; Chen, S; Cheng, Y; Dong, M; Fan, X; Feng, X; Gao, Y; Jin, Z; Liu, J; Meltzer, SJ; Mori, Y; Wang, L; Yu, H; Zhang, X; Zhang, Y; Zhao, Z | 1 |
| Chuang, CK; Lenka, G; Ng, KF; Pang, ST; Weng, WH | 1 |
| Guo, H; He, X; Jiang, X; Wang, W; Zhao, N; Zhu, L | 1 |
| Guizzetti, M; Kusumo, H; Pandey, SC; Sakharkar, AJ; Zhang, X | 1 |
| Abe, K; Egawa, S; Fukushige, S; Horii, A; Kaneko, N; Karasawa, H; Miura, K; Mizuguchi, Y; Morishita, K; Motoi, F; Nagase, H; Saiki, Y; Sasaki, I; Sase, T; Shibata, C; Sunamura, M; Unno, M; Yamamura, A | 1 |
| Diagileva, OA; Dvirnyk, VN; Gemdzhian, ÉG; Glasko, EN; Kokhno, AV; Parovichnikova, EN; Platonova, TL | 1 |
| Borthakur, G; Cortes, J; DiNardo, CD; Faderl, S; Garcia-Manero, G; Jabbour, E; Kadia, T; Kantarjian, HM; Konopleva, M; Luthra, R; Patel, KP; Pemmaraju, N; Pierce, S; Ravandi, F | 1 |
| Bechelli, J; Becker, MW; Chen, R; Ifthikharuddin, JJ; Jordan, CT; Liesveld, JL; Minhajuddin, M; Mulford, D; O'Dwyer, K; Phillips, GL; Rosell, K; Walker, A | 1 |
| Chen, P; Chen, Y; He, Z; Peng, H; Zeng, H; Zhang, H; Zhang, Y | 1 |
| Cui, W; Huang, HQ; Li, N; Zhang, GS | 1 |
| Baer, MR; Bhatnagar, B; Chen, C; Duong, VH; Emadi, A; Gourdin, TS; Ning, Y; Sausville, EA; Tidwell, ML | 1 |
| Fu, LJ; Lou, XY; Qu, J; Qu, Q; Wu, LX; Zhan, M; Zhang, YW; Zhou, HH | 1 |
| Berenzon, D; Dralle, S; Ellis, LR; Isom, S; Klepin, HD; Lawrence, J; Lyerly, S; Manuel, M; Pardee, T; Powell, BL; Sliesoraitis, S; Tawfik, B | 1 |
| Cao, J; Chen, HQ; Han, F; Jiang, X; Li, YH; Liu, JY; Liu, WB; Liu, Y | 1 |
| Estevez, B; Han, DM; Lockshin, RA; Norouzi, M; Penaloza, CG; Zakeri, Z | 1 |
| Kladde, MP; Loose, DS; Nabilsi, NH; Peraza-Penton, AC; Poudyal, R; Ryder, DJ | 1 |
| Ames, RS; Bee, WT; Benowitz, A; Erickson-Miller, CL; Gore, ER; Kallal, L; Li, H; Montoute, MN; Pope, AJ; Wu, Z; Xie, W; Zappacosta, F; Zeng, X | 1 |
| Ikehata, M; Iwakawa, S; Ogawa, M; Tanaka, S; Ueda, K; Yamada, Y | 1 |
| Chang, Y; Chu, M; Gao, W; Guo, Y; Li, P; Zhang, K | 1 |
| Jiang, Z; Kuo, PY; Leshchenko, VV; Parekh, S; Thirukonda, VK | 1 |
| Merkel, DG; Nagler, A | 1 |
| Arthur, C; Berrak, E; Delaunay, J; Jones, M; Kantarjian, HM; Thomas, XG | 1 |
| Yang, E; Zhang, HS; Zou, QP | 1 |
| Barøy, T; Myklebost, O; Skårn, M; Stratford, EW | 1 |
| Bernasconi, MJ; Cogdill, AP; Gunda, V; Parangi, S; Wargo, JA | 1 |
| Cai, LL; Chi, XH; Li, SW; Lu, XC; Ran, HH; Wang, HT; Yang, B; Yang, Y; Yu, RL; Zhao, Y; Zhu, HL | 1 |
| Ashktorab, H; Brim, H; Brodeur, GM; Fatemi, M; Paul, TA; Shokrani, B | 1 |
| Banzhaf-Strathmann, J; Claus, R; Cruts, M; De Deyn, PP; Edbauer, D; Engelborghs, S; Mücke, O; Plass, C; Rentzsch, K; van Broeckhoven, C; van der Zee, J | 1 |
| Au, AY; Bull, CF; Fenech, MF; Hande, MP; Low, GK; Mayrhofer, G; O'Callaghan, NJ; Pickett, HA; Zeegers, D | 1 |
| Han, J; Heo, K; Hong, SH; Hwang, JA; Kim, DH; Kim, Y; Kim, YH; Lee, BB; Lee, YS; Park, SE; Shim, YM | 1 |
| Gaikazian, S; Kumar, R; Shah, D | 1 |
| Clifford, SC; Farwick, N; Frühwald, MC; Gerss, J; Hasselblatt, M; Kerl, K; Kreth, JH; Lechtape, B; Mühlisch, J; Plagemann, T; Richter, GH; Schlosser, S; Unland, R | 1 |
| Cho, YG; Han, J; Han, JY; Hong, SH; Hwang, JA; Kim, DH; Kim, Y; Kim, YH; Lee, J; Lee, YS; Shim, YM | 1 |
| Guo, QN; Huang, Y; Li, Y; Lv, Y; Meng, G | 1 |
| Green, BB; Kerr, DE | 1 |
| Bueso-Ramos, C; Cortes, J; Davanlou, M; DiNardo, C; Estecio, MR; Fang, Z; Garcia-Manero, G; Geng, QR; Kantarjian, H; Nguyen, M; Parmar, S; Pierce, S; Wei, Y; Yang, H | 1 |
| Gao, XN; Jiang, MM; Li, RS; Li, YH; Wang, J; Wang, LL; Wang, LX; Yao, YS; Yu, L; Zhou, JH; Zhou, MH | 1 |
| Dong, D; Lu, D; Ma, WJ; Tian, XJ; Wen, JX; Zhang, J; Zhou, Y | 1 |
| Maddox, SA; Schafe, GE; Watts, CS | 1 |
| Buchi, F; Gozzini, A; Masala, E; Rossi, A; Sanna, A; Santini, V; Spinelli, E; Valencia, A | 1 |
| Fang, JY; Jiang, N; Lu, W; Wang, H; Wang, X; Zhang, XF | 1 |
| Geng, CZ; Hou, SY; Liu, WH; Lü, WH; Sang, MX; Shan, BE; Xu, YY | 1 |
| Saunthararajah, Y | 1 |
| Delgado-Calle, J; Klein-Nulend, J; Riancho, JA | 1 |
| Liu, Q; Luo, C; Tao, J; Wang, Q; Wu, X; Xu, X; Zhang, Y | 1 |
| Cao, X; Chen, X; Liu, M; Tao, G; Xie, W; Zhou, F | 1 |
| Du, C; Hou, B; Huang, G; Huang, T; Mo, Y; Tian, F; Wang, S; Xiao, X; You, J; Yu, N; Zeng, X; Zhang, J; Zhang, Z; Zhao, W; Zhou, S; Zhou, X | 1 |
| Ikezoe, T; Nishioka, C; Nobumoto, A; Tsuda, M; Yang, J; Yokoyama, A | 1 |
| Han, L; Hu, Y; Li, X; Tao, H; Wang, J; Yang, B; Zhang, S | 1 |
| Araki, H; Baluchamy, S; Lavelle, D; Li, X; Mahmud, N; Petro, B; Quigley, JG; Suphangul, M; Taioli, S | 1 |
| Li, CS; Li, T; Liu, QY; Liu, WJ; Liu, ZS; Ren, JG; Yu, GZ; Zhang, J | 1 |
| Lübbert, M; Navada, SC; Silverman, LR; Steinmann, J | 1 |
| Kang, HJ; Kim, HS; Kim, J; Kim, N; Kim, SJ; Lee, JO; Lee, SK; Lee, YW; Moon, JW; Park, SH | 1 |
| Hu, RC; Liu, JJ; Liu, WE; Tan, SX; Tan, YL | 2 |
| Baylin, SS; Belinsky, SA; Liu, Y; Tellez, CS; Tessema, M; Van Neste, L; Yingling, CM | 1 |
| Ling, Y; Liu, Y; Lu, M; Xu, Y; Zhang, C; Zhou, T; Zhu, C; Zhu, J | 1 |
| Arroyo-Solera, I; Barnadas, A; Casanova, I; Céspedes, MV; Gallardo, A; León, X; López, M; López-Pousa, A; Mangues, MA; Mangues, R; Pavón, MA; Quer, M; Téllez-Gabriel, M | 1 |
| Fang, BZ; Fu, ZZ; Han, Y; He, GS; Jin, ZM; Liu, ZZ; Ma, X; Miao, M; Qiu, HY; Ruan, CG; Sun, AN; Tang, XW; Wang, XL; Wu, DP | 1 |
| Fandy, TE; Gore, SD; Jiemjit, A; Rhoden, P; Suarez, L; Thakar, M | 1 |
| Bi, J; Gao, M; Ma, T; Song, B; Wang, Y; Zhang, C; Zhou, Y | 1 |
| Li, Q; Ling, X; Ling, Y; Shi, X; Wang, Y | 1 |
| Bian, EB; Cheng, C; He, Y; Huang, C; Li, J; Ma, TT; Zhang, L | 1 |
| Azechi, T; Sato, F; Sudo, R; Wachi, H | 1 |
| Clarke, K; Qin, W; Sauter, ER; Weiland, T; Zhang, K | 1 |
| Chen, BB; Chen, XB; Li, J; Lü, HF; Luo, SX; Ma, YJ; Wang, XF | 1 |
| Klepfish, A; Lugassy, G; Mittelman, M; Shimoni, A; Silbershatz, I | 1 |
| Christensen, BC; David, JM; Lakshmikuttyamma, A; Owens, TA; Petrelli, NJ; Rajasekaran, AK; Selvakumar, P | 1 |
| Chen, CC; Chern, TR; Chuang, SH; Klemm, L; Lin, JH; Müschen, M; Tsai, CT; Yang, PM | 1 |
| Gallagher, RC; Liu, J; Samuel, K; Turner, ML | 1 |
| Chen, H; Geng, P; Huang, L; Jiang, W; Li, Y; Lin, X; Liu, J; Su, B; Wang, Y; Yao, J | 1 |
| Buer, J; Geffers, R; Kehrmann, J; Probst-Kepper, M; Steinmann, J; Tatura, R; Zeschnigk, M | 1 |
| Dong, L; Lei, H; Li, Z; Liu, C; Luo, M; Ma, Y; Shen, J; Song, W; Wang, F; Wang, Y; Yu, J; Zhang, J | 1 |
| Al-Ali, HK; Jaekel, N; Niederwieser, D | 1 |
| Driscoll, H; Duarte, C; Peterson, S; Sathyanarayana, P; Ufkin, ML; Yang, X | 1 |
| Dai, Q; Gu, Y; Guo, S; Pan, S; Yu, Y; Zhang, W; Zhao, F | 1 |
| Kearns, P; Leonard, SM; Perry, T; Woodman, CB | 1 |
| Blanchard, TG; Czinn, SJ; Guang, W; Kim, KC; Lillehoj, EP | 1 |
| Carroll, RJ; Chapkin, RS; Cho, Y; Davidson, LA; Lupton, JR; Turner, ND | 1 |
| Dong, QZ; Liu, Y; Miao, Y; Wang, EH; Wang, L; Wang, S; Xu, HT | 1 |
| Arthur, C; Berrak, E; Delaunay, J; Jones, M; Kantarjian, HM; Li, Y; Mayer, J; Mazur, G; Ravandi, F; Thomas, XG; Wierzbowska, A | 1 |
| Komandirov, MA; Sharifulina, SA; Uzdensky, AB | 1 |
| Brglez, V; Lambeau, G; Petan, T; Pucer, A; Pungerčar, J | 1 |
| Borges, S; Döppler, HR; Storz, P | 1 |
| Al-Rayyan, N; Cheng, A; Elbedewy, A; Ivanova, MM; Klinge, CM; Litchfield, LM; Radde, BN | 1 |
| Alt, J; Delahanty, G; Duvall, B; Ferraris, D; Huang, KC; Mistry, B; Redkar, S; Rojas, C; Rowbottom, C; Sanders, K; Schuck, E; Slusher, BB; Tsukamoto, T | 1 |
| Camilloni, G; Capitano, F; Deiana, C; Fragapane, P; Gaglio, D; Mastrodonato, A; Mele, A; Minicocci, E | 1 |
| Akers, SN; Batt, CA; Beck, A; Gnjatic, S; Griffiths, EA; James, SR; Karpf, AR; Lele, S; Matsuzaki, J; Mhawech-Fauceglia, P; Miliotto, A; Miller, A; Odunsi, K; Ritter, G; Tsuji, T; Zhang, W | 1 |
| Brüning, A; Buchholtz, ML; Jückstock, J; Mylonas, I | 1 |
| Chim, CS; Jin, DY; Kho, CS; Kwong, YL; Rosèn, A; Tse, E; Wang, LQ; Wong, KF | 1 |
| Barankiewicz, J; Bednarek, W; Boon, L; Gabrysiak, M; Golab, J; Hamblin, MR; Mroz, P; Muchowicz, A; Rygiel, T; Wachowska, M | 1 |
| Dolan, ME; Godley, LA; Moen, EL; Stark, AL; Zhang, W | 1 |
| Chan, MW; Chen, CJ; Lee, TC; Pu, YS; Wang, HH; Wu, MM | 1 |
| Bai, F; Bao, L; Chencheri, SC; Krishnadas, DK; Lucas, K | 1 |
| Deng, Z; Lin, J; Matsuda, K; Miki, T; Nakamura, Y; Shuin, T; Tanikawa, C | 1 |
| Gong, P; Li, J; Li, X; Lyu, X; Peng, H; Yao, K | 1 |
| Lin, L; Liu, PS; Ma, XP; Ma, YC; Wu, Y; Zhang, X | 1 |
| Chang, C; Guo, C; He, Q; Li, X; Song, L; Su, J; Wu, D; Wu, L; Xiao, C; Zhang, X; Zhang, Z; Zhou, L | 1 |
| Alhonen, L; Jantunen, E; Mäntymaa, P; Mustjoki, S; Pirnes-Karhu, S; Uimari, A | 1 |
| He, L; Mor, E; Shomron, N; Torchinsky, A | 1 |
| Beristain, AG; Hogg, K; Robinson, WP | 1 |
| Benmaamar, R | 1 |
| Shang, ZJ; Shen, H; Song, K; Xia, XY; Zhang, HZ; Zhu, F | 1 |
| Bai, SY; Jiao, F; Ma, Y; Wang, J; Wang, X; Yan, ZH; Yu, Y; Yue, Z | 1 |
| Chang, CM; Chang, WC; Hou, MF; Shiurba, R; Tsai, YT; Wang, JM; Wang, JY | 1 |
| Appleton, K; Brown, R; Gabra, H; Glasspool, RM; Gore, ME; Halford, SE; Hall, GD; Kaye, S; Mackean, M; McNeish, IA; Paul, J; Pledge, S; Rustin, GJ; Ullah, R; Walker, J; Wilson, RH | 1 |
| Cao, L; Gao, H; Gui, S; Li, P; Zhang, Y | 1 |
| Jiranek, WA; Maiti, A | 1 |
| Cha, HJ; Chang, HW; Choi, SH; Han, MW; Kim, SA; Kim, SW; Kim, SY; Lee, JC; Lee, WH; Min, YJ | 1 |
| Xiao, Z | 1 |
| Huang, L; Huang, P; Mo, D; Pan, S; Sun, R; Wu, J; Xu, J; Xu, Y | 1 |
| Flis, K; Flis, S; Gnyszka, A | 1 |
| Huang, S; Luo, M; Ning, Q; Qin, Y; Shao, S; Yuan, N; Zhang, X; Zhao, X; Zuo, X | 1 |
| Ahn, JH; Choi, EN; Choi, HJ; Ju, W; Kim, NH; Lyu, D; Sung, HY | 1 |
| Ali, A; Chen, Y; Dobi, A; Haffner, MC; Li, H; McLeod, DG; Petrovics, G; Ravindranath, L; Sesterhenn, IA; Sharad, S; Srinivasan, A; Srivastava, S; Yan, W; Yegnasubramanian, S | 1 |
| Chen, P; Chen, Y; He, SD; He, ZH; Liu, D; Yang, Y; Ye, JR; Zhu, YQ | 1 |
| Chen, LB; Guan, XX; Lu, XX; Tong, JD; Wang, JZ; Wang, Z; Zhang, YW; Zheng, Y | 1 |
| Bendtzen, K; Coco, M; Di Marco, R; Di Rosa, M; Fagone, P; Magro, G; Malaguarnera, L; Mammana, S; Mangano, K; Meroni, PL; Nicoletti, F; Quattrocchi, C | 1 |
| Jiang, R; Li, Y; Liu, Q; Luo, F; Wang, B; Xu, W; Xu, Y; Zhang, A; Zhao, Y | 1 |
| He, Y; Huang, C; Li, J; Long, XR | 1 |
| Abboud, CN; Cashen, AF; Dipersio, JF; Jacoby, M; Niu, H; Pusic, I; Schroeder, MA; Stockerl-Goldstein, KE; Uy, GL; Vij, R; Welch, JS; Westervelt, P | 1 |
| Bratcher, AP; Givvimani, S; James, D; Kundu, S; Metreveli, N; Narayanan, N; Pushpakumar, SB; Tyagi, SC | 1 |
| Poplutz, MK; Rink, L; Uciechowski, P; Wessels, I | 1 |
| Chang, C; Chen, Y; Hou, M; Li, X; Song, L; Song, Q; Su, J; Wu, D; Wu, L; Xu, F; Zhang, X; Zhang, Z; Zhou, L | 1 |
| Cui, L; Dong, Z; Guo, W; Guo, Y; Kuang, G; Shen, S; Wang, C | 1 |
| Daskalakis, M; Hackanson, B | 1 |
| Luo, JM; Sun, J; Zhang, XK | 1 |
| Cui, ZG; Feng, XQ; Guo, J; Liu, SG; Meng, FJ; Nie, SM; Shi, X; Su, Z; Zhang, L; Zhao, CT | 1 |
| Cinalli, T; Colaluca, K; Duong, HK; Rogers, HJ; Saunthararajah, Y; Sekeres, MA; Stein, BL; Tabarroki, A; Tiu, RV; Visconte, V | 1 |
| Arimany-Nardi, C; Errasti-Murugarren, E; Gorboulev, V; Koepsell, H; Martinez-Picado, J; Minuesa, G; Pastor-Anglada, M | 1 |
| De Vita, S; Ebert, BL; Garcia, M; Gavillet, M; Gerbaulet, A; Levine, RL; Mullally, A; Roers, A; Schneider, RK; Williams, DA; Wood, J | 1 |
| Du, H; Hu, X; Huang, J; Jiang, H; Xuan, H | 1 |
| Jin, R; Kim, H; Lee, DY; Renshu, L; Roh, MR; Yang, S; Yingji, S; Zhang, X; Zheng, Z | 1 |
| Dong, Z; Guo, W; Guo, Y; Kuang, G; Shen, S; Yang, Z; Zhang, M | 1 |
| Motevalli, A; Roberts, T; Slijepcevic, P; Virmouni, SA; Yasaei, H | 1 |
| Ao, L; Cao, J; Chen, H; Cui, Z; Dong, Y; Han, F; Liu, J; Liu, W; Ma, X; Shi, R; Zhang, H | 1 |
| Bernasconi, MJ; Frederick, DT; Gunda, V; Parangi, S; Wargo, JA | 1 |
| Dang, YH; Liu, P; Xing, B; Xu, FY; Xu, WJ | 1 |
| Geng, P; Liu, K; Yao, J; Zhang, J; Zhou, B; Zhu, W; Zhu, Y | 1 |
| De Bruyne, E; De Raeve, H; De Smedt, E; Lemaire, M; Maes, K; McClue, S; Menu, E; Van Valckenborgh, E; Vanderkerken, K | 1 |
| Bourke, MJ; Hawkins, NJ; Hesson, LB; Nunez, AC; Perera, D; Pimanda, JE; Sieber, OM; Sloane, MA; Ward, RL; Wong, JW | 1 |
| Bao, Z; Feng, Y; Guo, T; Jiang, C; Jiang, T; Li, M; Liu, Q; Sun, L; Wang, H; Yan, Z; Yang, X; Zhang, C; Zhang, Q | 1 |
| Cornelison, AM; Cortes, JE; Daver, N; Garcia-Manero, G; Jabbour, E; Kadia, T; Kantarjian, H; Ravandi, F; Teng, A | 1 |
| Schleiffenbaum, BE | 1 |
| Cinti, C; Gherardini, L; Grimaldi, S; Naldi, I; Pani, L; Pelosi, G; Taranta, M; Viglione, F | 1 |
| Chen, Z; Li, J; Sheng, X; Tan, L; Yang, L; Zhao, Q; Zhou, Y | 1 |
| Destro, MF; Duarte, CM; Nunes, FD; Xavier, FC | 1 |
| Dunn, J; Fan, Y; Hoffman, R; Jang, I; Jjingo, D; Jo, H; Jordan, IK; Kim, CW; Kim, D; Kim, S; Pan, C; Qiu, H; Son, DJ | 1 |
| Ao, X; He, WG; Huang, YN; Li, RJ; Li, WH; Liu, QL; Tang, YL; Xie, YC; Yang, HF; Zeng, XC; Zhang, GX; Zhang, L | 1 |
| Du, M; Su, XM; Xing, YJ; Zhang, T | 1 |
| Chan, MW; Chang, CB; Suen, JL; Sun, J; Tung, CH; Wu, SF | 1 |
| Bi, SQ; Fu, J; Lin, YD; Luo, B; Luo, GR; Shen, N; Xiao, SW; Xie, S; Xie, XX; Zhang, QM; Zhou, SF | 1 |
| Chen, PJ; Huang, GB; Li, B; Lou, YF; Luo, XY; Yu, XR; Zheng, DQ; Zou, ZZ | 1 |
| Bassett, RL; Desai, JR; Hwu, WJ; Ilagan, JL; Issa, JP; Jelinek, J; Papadopoulos, NE; Plimack, ER; Sharma, P; Vence, LM | 1 |
| Cao, Z; Chen, S; Cheng, Y; Dong, M; Fan, X; Feng, X; Gao, Y; Jin, Z; Liu, J; Meltzer, SJ; Mori, Y; Wang, L; Wu, W; Yu, H; Zhang, X; Zhao, Z | 1 |
| Gao, H; Gu, J; Ren, L; Wang, X; Zhang, Y | 1 |
| Burke, MJ; Cao, X; Ghodke-Puranik, Y; Lamba, JK; Lindgren, BR; Miller, JS; Pounds, S; Verneris, MR; Weigel, BJ | 1 |
| Fanger, G; Knox, S; Oronsky, B; Oronsky, N; Scicinski, J | 1 |
| Aparicio, S; Bullinger, L; Chaturvedi, A; Damm, F; Döhner, K; Ganser, A; Geffers, R; Heuser, M; Humphries, RK; Jyotsana, N; Lübbert, M; Schwarzer, A; Yap, D; Yun, H | 1 |
| Bennett, TE; Heckler, B; Jewett, C; Lukowiak, K; Schriner, EK; Sorg, BA; Todd, RP; Wyrick, K | 1 |
| Godley, LA; Jasielec, J; Saloura, V | 1 |
| Ahn, JH; Choi, EN; Ju, W; Lyu, D; Park, AK; Sung, HY | 1 |
| Hu, C; Jin, J; Li, K; Mei, C; Ren, Z; Tong, H; Vera, JC; Zhuang, Z | 1 |
| Abiko, Y; Arakawa, T; Kamino, Y; Kurashige, Y; Nagayasu, H; Nishimura, M; Saitoh, M; Sato, J; Uehara, O; Yoshida, K | 1 |
| Dawn, B; Elias, HK; Malik, AB; Rajasingh, J; Rajasingh, S; Simpson, AD; Sundivakkam, PK; Thangavel, J; Vogel, SM; Xuan, YT | 1 |
| Fu, B; Li, ZQ; Liu, D; Ma, H; Qi, MY; Wang, L; Wang, WT; Zhang, X; Zhang, YL | 1 |
| Cheng, C; Huang, X; Liu, Z; Sun, Y; Wang, G; Wang, S; Wu, J; Xia, J; Xie, A; Ye, P | 1 |
| Chen, ZW; Shi, KH; Tao, H; Xu, SS; Yang, JJ; Zhan, HY; Zhou, X | 1 |
| Fiegl, H; Fleischer, M; Hollmann, MW; Lirk, P; Weber, NC | 1 |
| Campbell, RR; Dang, D; Ono, K; Schmidt, BL; Viet, CT; Ye, Y | 1 |
| Chen, M; Fan, H; Feng, K; Fu, X; Guo, B; Han, W; Liu, Y; Lu, X; Nie, J; Shi, F; Wang, X; Wang, Y; Zhang, W; Zhang, Y; Zhu, H | 1 |
| Abba, MC; Cattaneo, ER; Coleman, RA; Garcia-Fabiani, MB; Gonzalez-Baro, MR; Lacunza, E; Montanaro, MA; Pellon-Maison, M; Quiroga, IY; Soler-Gerino, MC | 1 |
| Hou, Z; Li, L; Lu, L; Miao, Z; Ren, M; Wang, X; Yang, Y; Yao, Y; Yu, L; Zhang, B; Zhao, D | 1 |
| Dicato, M; Diederich, M; Gaigneaux, A; Ghelfi, J; Grandjenette, C; Henry, E; Karius, T; Schnekenburger, M | 1 |
| Chen, JY; Hong, CQ; Huang, P; Wu, MY; Wu, X; You, YJ; Zhang, F; Zhuang, YX | 1 |
| Bruederlein, S; Färbinger, J; Gehringer, F; Guan, H; Holzmann, K; Leithäuser, F; Möller, P; Ritz, O; Ushmorov, A; Vogel, MJ; Weitzer, CD; Wirth, T; Xie, L | 1 |
| Bivalacqua, T; Brait, M; Driscoll, T; Hoque, MO; Maldonado, L; Michailidi, C; Munari, E; Netto, GJ; Schoenberg, M; Schultz, L; Sidransky, D | 1 |
| Chen, Y; Duan, Y; Gu, X; Hao, J; Li, L; Liu, J; Liu, Z; Shen, Z; Wang, L; Wang, Y; Zhao, W | 1 |
| Cai, L; Chi, X; Li, S; Lu, X; Tuo, S; Wang, H; Wang, X; Wu, X; Yang, B; Yang, Y; Yu, R; Zhang, F; Zhu, H | 1 |
| Honda, H; Inaba, T; Nagamachi, A | 1 |
| Chan, HL; Chen, YY; Chuang, JJ; Dai, YC; Lin, WH; Lin, YL; Liu, YW | 1 |
| Jabbour, E | 1 |
| Fang, F; Li, M; Matei, D; Nephew, KP; Pilrose, J; Shen, C; Wang, Y; Wulfridge, P; Zuo, Q | 1 |
| Bredeson, C; Eid, JE; Frankel, P; Gojo, I; Goldberg, SL; Issa, JP; Kirschbaum, M; Kujawski, LA; Lubiniecki, GM; Marks, P; Sun, X; Tosolini, A; Yang, A | 1 |
| Jiang, Q; Xie, M; Xie, Y | 1 |
| Glazer, PM; Lu, Y; Turker, MS; Wajapeyee, N | 1 |
| He, HB; Huan, YJ; Kong, QR; Li, JY; Liu, ZH; Wang, HM; Wu, ZF; Xie, BT; Zhang, JG; Zhu, J | 1 |
| Kumari, D; Usdin, K | 2 |
| Birdwell, CE; Cvek, U; Kilgore, PC; Queen, KJ; Rollyson, P; Scott, RS; Trutschl, M | 1 |
| Deutsch, J; Frees, M; Laux, D; Leon-Ferre, R; Milhem, M; Smith, BJ; Xia, C | 1 |
| Benton, CB; Borthakur, G; Dara, S; Franklin, AR; Garcia-Manero, G; Jabbour, E; Kantarjian, H; Kwari, M; O'Brien, S; Pierce, SR; Ravandi, F; Rytting, M; Thomas, DA; Yang, H | 1 |
| Burgos-Morón, E; Calderón-Montaño, JM; Domínguez, I; Helleday, T; Höglund, A; López-lázaro, M; Orta, ML; Pastor, N; Ström, C; Visnes, T | 1 |
| Capobianco, E; Cinti, C; El Baroudi, M; La Sala, D | 1 |
| Duong, VH; Komrokji, RS; List, AF | 1 |
| Abdelhay, E; Binato, R; Cappelletti, P; Corrêa, S; Du Rocher, B; Ferreira, G; Mencalha, A; Pinto, LF; Soares-Lima, S | 1 |
| Hsieh, MM; Platner, C; Saunthararajah, Y; Tisdale, JF; Uchida, N | 1 |
| Hu, Z; Zhou, Y | 1 |
| Dass, R; De Porre, P; He, J; Thomas, X; Xiu, L | 1 |
| Bannert, S; Bender, S; Benner, A; Dreidax, D; Duffy, D; Ehemann, V; Fischer, M; Henrich, KO; Lindner, S; Oakes, CC; Pfister, S; Saadati, M; Schröder, C; Schulte, JH; Schwarzl, T; Westermann, F | 1 |
| Chen, G; Fan, Y; Jin, J; Li, L; Liu, Q; Tao, Q; Wang, L; Wang, Z; Xu, B; Ying, J; Zhang, L; Zhang, Q | 1 |
| Mjoli, PB; Poolman, T; Ray, DW; Singh, N; Sommer, P; Taylor, K | 1 |
| Domann, FE; Hudachek, DR; Vorrink, SU | 1 |
| Cao, JL; Peng, YN; Tang, LH; Wang, Y; Yan, M; Yu, LN; Zhou, XL | 1 |
| Hou, SY; Liu, WH; Sang, MX; Shan, BE; Zhang, C | 1 |
| Han, W; Li, X; Liu, L; Nie, J | 1 |
| Huang, Y; Rao, A | 1 |
| Gu, J; Guan, X; Huang, G; Lai, J; Song, W; Wang, Y; Xu, J; Yang, F; Zhang, W | 1 |
| Boureau, L; Cheishvili, D; Szyf, M | 1 |
| Bae, JH; Heo, K; Kim, JA; Kim, JG; Yang, K; Yi, JM | 1 |
| Han, J; Sui, N; Zhang, JJ | 1 |
| Asnaghi, L; Eberhart, CG; Enke, R; Handa, JT; Merbs, SL; Rajaii, F | 1 |
| Blagitko-Dorfs, N; Lübbert, M; Lyko, F; Maercker, C; Öz, S; Raddatz, G; Rius, M | 1 |
| Hoffman, BT; Hua, W; Ierardi, T; Lesslie, M; Mulvana, D | 1 |
| Milne, TA | 1 |
| Arakelian, A; Bhattacharya, B; Cheishvili, D; Chik, F; Hallett, M; Li, CC; Rabbani, SA; Suderman, M; Szyf, M | 1 |
| Akhondi, MM; Kazemnejad, S; Mohseni-Kouchesfehani, H; Rahimi, M; Soltanghoraei, H; Zarnani, AH | 1 |
| Mascarenhas, J | 1 |
| Busch, M; Dünker, N; Philippeit, C | 1 |
| Hantash, BM; Purandare, B; Teklemariam, T; Zhao, L | 1 |
| Braun-Prado, K; Camargo, AA; Chequin, A; Costa, ET; Costa, FF; Klassen, G; Klassen, LM; Manica, GC; Pedrosa, Fde O; Pereira, IT; Ramos, EA; Souza, EM | 1 |
| Bar-Natan, M; Bejar, R; Caughey, B; Chen, R; Ebert, BL; Garcia-Manero, G; Getz, G; Kantarjian, H; Lord, A; Neuberg, D; Pérez-Ladaga, A; Steensma, DP; Stevenson, K; Stojanov, P; Stone, RM; Wang, H; Zaneveld, J | 1 |
| Levine, A; Sun, Y; Yi, L | 1 |
| Kouraklis, G; Nebiker, CA; Tampaki, EC; Tampakis, A | 1 |
| Barrio-Real, L; Benedetti, LG; Cho, S; Engel, N; Kazanietz, MG; Sukumar, S; Tu, Y | 1 |
| Cao, Q; Das, SK; Diallo, A; Hawkins, GA; Jia, L; Mondal, AK; Parks, JS; Shi, H; Wang, X; Xue, B; Yu, L | 1 |
| Du, Y; Ji, C; Ji, M; Li, P; Lu, F; Ma, D; Ye, J | 1 |
| Baer, MR; Bhatnagar, B; Chen, Q; Duong, VH; Tidwell, ML; Vannorsdall, EJ; Zandberg, DP | 1 |
| Gopinath, KS; Kumar, A; Shivananda, S; Tiwari, A | 1 |
| Li, B; Li, Y; Lu, Z; Luo, H; Wang, Y; Wu, X; Xu, Z; Zhang, Z | 1 |
| Agrawal, R; Gomez-Pinilla, F; Tyagi, E; Ying, Z; Zhuang, Y | 1 |
| Choi, YW; Devanand, P; Kim, SI; Kim, SJ; Kim, WJ; Lim, IK; Ryu, MS; Sheen, SS; Yim, H | 1 |
| Brennan, K; Fedier, A; Hacker, NF; Heinzelmann-Schwarz, VA; Hitchins, MP; Jacob, F; Nixdorf, S; Ward, R | 1 |
| Aggarwal, NR; Chau, E; D'Alessio, FR; Florez, MA; Garibaldi, BT; Gibbs, KW; King, LS; Mandke, P; Mock, JR; Sidhaye, VK; Singer, BD; Tripathi, A; Yegnasubramanian, S | 1 |
| Sakata-Yanagimoto, M | 1 |
| Chao, MR; Chen, JL; Hsu, YW; Hu, CW; Yen, CC | 1 |
| Chan, MW; Fang, YC; Hsu, MM; Huang, PY; Lee, CI; Lee, YC | 1 |
| Li, B; Li, H; Sun, L; Ye, Z; Yuan, L; Zhang, J; Zhu, X | 1 |
| Adams, PD; Clark, W; Cole, JJ; Copland, M; Edwards, JR; Lund, K; McBryan, T; Pchelintsev, NA; VanderKraats, ND | 1 |
| Choi, Y; Joo, YD; Kim, DY; Kim, SD; Lee, JH; Lee, KH; Lee, SM; Lee, WS | 1 |
| Cao, L; Du, XJ; Fang, F; Feng, X; Hu, SY; Li, YH; Li, YP; Li, ZH; Lu, J; Ni, J; Pan, J; Su, GH; Sun, LC; Tao, YF; Wang, J; Wang, NN; Xiao, PF; Xu, LX; Xu, YY; Zhao, H; Zhao, WL | 1 |
| Claret, FX; Wang, S; Yang, H; Zhang, R | 1 |
| Ahn, JH; Ju, W; Sung, HY | 1 |
| Ghobrial, IM; Glavey, S; Jiang, B; Leleu, X; Manier, S; Mishima, Y; Reagan, M; Roccaro, AM; Sacco, A; Wang, YE; Zhang, W; Zhang, Y | 1 |
| Borthakur, G; Brandt, M; Cortes, J; Garcia-Manero, G; Huang, X; Issa, JP; Jabbour, E; Kantarjian, HM; Pierce, S; Ravandi, F | 1 |
| Jing, Y; Liu, SY; Niu, JH; Yang, H; Yu, L; Zhang, Q; Zhu, CY; Zhu, HY | 2 |
| Cui, GX; Wu, WZ; Zhang, YP | 1 |
| Fu, ZZ; Wang, J; Zheng, HF; Zhou, J | 1 |
| Li, HM; Zhang, R | 1 |
| Calvo, F; Daunay, A; Djaafri, I; Fauvel, F; Idbaih, A; Janin, A; Khayati, F; Lebbé, C; Menashi, S; Mourah, S; Podgorniak, MP; Sadoux, A; Setterblad, N; Soulier, J; Teixeira, L; Tost, J | 1 |
| Bai, Y; Jiang, X; Ren, G; Shi, H; Shi, Y; Wang, J; Wang, L; Zhang, X; Zhou, R | 1 |
| Lin, S; Luo, Y; Tang, S; Tian, J; Wei, L; Xie, M | 1 |
| Becker, N; Effenberger, K; Esteller, M; Hagmann, W; Izbicki, JR; Kemming, D; Kim, SZ; Lamszus, K; Pantel, K; Riethdorf, S; Risch, A; Sandoval, J; Uzunoglu, FG; Westphal, M; Wikman, H; Wrage, M | 1 |
| Araki, H; Koca, E; Mahmud, N; Park, Y; Petro, B; Rondelli, D; Saraf, S; Taioli, S; Yoshinaga, KG | 1 |
| Allen, RD; Chen, N; Reichert, AI; Veerappan, V | 1 |
| Katagiri, T; Lo, PH; Matsuda, K; Nakamura, Y; Tanikawa, C | 1 |
| Arizumi, T; Chishina, H; Hagiwara, S; Inoue, T; Kitai, S; Kudo, M; Minami, Y; Nishida, N; Sakurai, T; Takita, M; Ueshima, K; Yada, N | 1 |
| Araújo, ES; Krepischi, AC; Pereira, LV; Stabellini, R; Vasques, LR | 1 |
| Abdolhosseini, M; Benakanakere, M; Finoti, LS; Hosur, K; Kinane, DF | 1 |
| Achdjian, S; Dang, D; Katz, SG; Schmidt, BL; Viet, CT; Ye, Y | 1 |
| Fan, C; Jiang, G; Lin, X; Liu, Y; Miao, Y; Wang, E; Wang, L; Xu, X; Yu, J; Zhang, X; Zhang, Y | 1 |
| Buisine, MP; Copin, MC; Crépin, M; Leteurtre, E; Mariette, C; Porchet, N; Renaud, F; Stechly, L; Truant, S; Van Seuningen, I; Vincent, A | 1 |
| Agrawal, H; Chauhan, MS; Manik, RS; Palta, P; Saini, M; Selokar, NL; Singla, SK | 2 |
| Cen, J; Chen, Z; Gu, W; Hu, S; Qiu, G; Wang, R; Wei, J; Xiang, L; Xie, X | 1 |
| Borchardt, C; Clemens, D; Dirksen, U; Frühwald, MC; Kool, M; Unland, R | 1 |
| Chen, S; Fu, Z; Gao, S; Han, Y; Jin, Z; Ma, X; Qiu, H; Sun, A; Tang, X; Wu, D | 1 |
| Li, J; Liu, J; Su, C; Tong, X; Zheng, D; Zhou, Z | 1 |
| Du, XJ; Jun, W; Li, SY; Liu, Y; Shen, S; Sun, R; Wang, HX; Zhu, YH | 1 |
| Ahmad, N; Bhatnagar, A; Kohli, K; Kumar, N; Neupane, YR; Srivastava, M | 1 |
| Abler, LL; Altmann, HM; Hernandez, LL; Jarrard, DF; Keil, KP; Laporta, J; Vezina, CM; Yang, B | 1 |
| Cao, Y; Chen, H; Jiang, M; Jie, Z; Le, Z; Li, D; Li, Z; Liu, Y; Tan, S; Xiong, J; Zhang, G | 1 |
| Arango-Gonzalez, B; Biel, M; Carell, T; Ekström, PA; Farinelli, P; Michalakis, S; Paquet-Durand, F; Perera, A; Trifunovic, D; Wagner, M; Zrenner, E | 1 |
| Hattori, N; Takeshima, H; Ushijima, T; Wakabayashi, M; Yamashita, S | 1 |
| Kruger, A; Purcell, M; Tainsky, MA | 1 |
| Bak, YT; Choe, J; Joo, MK; Kim, HJ; Kim, JS; Kim, KH; Lee, BJ; Park, JJ; Yoo, HS | 1 |
| Choi, SK; Choi, SY; Hwang, SM; Jin, M; Kim, M; Lee, JH; Namkoong, E; Park, K; Park, MY; Shin, YH | 1 |
| Chang, L; El-Osta, A; Harikrishnan, KN; Hudson, JE; Kaspi, A; Khurana, I; Ooi, J; Porrello, ER; Sim, CB; Ziemann, M | 1 |
| Fan, JJ; Gao, Y; Li, HY; Li, Y; Ma, DM; Mai, L; Song, FZ; Wu, JY; Zeng, F; Zhang, J | 1 |
| Heldin, CH; Idås, O; Kahata, K; Moustakas, A; Tan, EJ; Thuault, S | 1 |
| Biondo, C; Catalano, T; Lentini, M; Teti, D; Venza, I; Venza, M; Visalli, M | 1 |
| Furusawa, H; Honma, M; Sugiyama, K; Takamune, M | 1 |
| Löwenberg, B; Ossenkoppele, G | 1 |
| Abdel-Wahab, O; Ahn, J; Armstrong, SA; Chiosis, G; Chung, YR; Dogan, A; Hricik, T; Intlekofer, A; Levine, RL; Lipson, D; Manshouri, T; McKenney, AS; Miller, VA; Nahas, M; Otto, GA; Pandey, S; Park, CY; Rampal, R; Rapaport, F; Stephens, PJ; van den Brink, MR; Verstovsek, S; Wang, K; Yelensky, R | 1 |
| Deng, C; Du, X; Geng, S; Lu, Z; Luo, C; Weng, J; Wu, P | 1 |
| Jiang, X | 1 |
| Cho, SG; Dong, SM; Hayward, SD; Kim, H; Kwon, HJ; Kwon, SH; Lee, HG; Lee, JH; Lee, JM; Park, JH; Park, PG; Yoon, H | 1 |
| Qiu, Z; Wang, YQ; Wu, JJ; Xin, YJ; Yu, B; Yuan, B; Zhou, WH | 1 |
| Greil, R; Pleyer, L | 1 |
| Feng, Q; Hou, M; Hou, Y; Li, G; Li, L; Liu, X; Min, Y; Ni, H; Peng, J; Qiu, J; Shao, L; Wang, Y; Xu, S; Yang, L; Zhang, X; Zhou, H | 1 |
| Chen, WZ; Chen, XY; Huang, SH; Liu, JM; Liu, ZL; Long, XH; Peng, AF; Zhang, ZH; Zhou, YF | 1 |
| Cui, Y; Jin, J; Luo, C; Qi, Y; Xu, B; Ying, JM; Zhang, L; Zhang, Q | 1 |
| Erba, HP | 1 |
| Wang, Z; Wilson, A; Xu, J | 1 |
| Fu, X; Han, W; Li, X; Mei, Q; Nie, J | 1 |
| Beyá, MD; Cordeiro, A; Díaz, T; Ferrer, G; Fuster, D; Martinez, A; Monzó, M; Navarro, A | 1 |
| Cui, FB; Ding, H; Li, RT; Liu, BR; Liu, Q; Qian, XP; Wang, HY; Wu, FL; Wu, PY; Yang, M; Yu, LX; Yue, GF | 1 |
| Han, L; Jiang, K; Kang, C; Liu, X; Ning, X; Shi, Z; Zhang, A; Zhang, Q | 1 |
| Chen, C; Chen, Z; Na, H; Ren, S; Sun, J; Wang, B; Yan, L; Zhu, Z; Zuo, Y | 1 |
| Bohannan, Z; Borthakur, G; Bueso-Ramos, C; Chang, KS; DiNardo, CD; Estécio, MR; Fang, Z; Garcia-Manero, G; Kantarjian, H; Kondo, K; Maddipoti, S; Pierce, SA; Stevenson, W; Wei, Y; Yang, H | 1 |
| Chen, G; Chen, H; Ding, B; Ye, X; Yin, L; Yin, M; Zhang, C; Zheng, Y; Zhou, X | 1 |
| Chen, C; Deng, Q; Dong, X; Jia, W; Nie, X; Xu, C; Xu, R; Zhang, M | 1 |
| Alholle, A; Bauer, J; Brini, AT; Gentle, D; Gharanei, S; Grimer, R; Jeys, L; Latif, F; Maher, ER; Niada, S; Slater, A; Sumathi, VP | 1 |
| Advani, A; Cooper, K; Copelan, E; Dean, R; Durkin, L; Earl, M; Englehaupt, R; Hamilton, B; Hobson, S; Hsi, E; Husseinzadeh, H; Juersivich, J; Kalaycio, M; Lichtin, A; Maciejewski, J; Mahfouz, R; Przychodzen, B; Radivoyevitch, T; Reu, F; Rump, M; Saunthararajah, Y; Sekeres, M; Sobecks, R; Tiu, R | 1 |
| Cao, Q; Diao, L; Dong, Z; Fan, F; Ge, J; Hu, K; Liu, X; Ma, D; Ma, X; Shen, C; Sun, A; Sun, X; Wang, C; Wang, P; Yang, Z; Zhao, X; Zhu, H; Zou, Y | 1 |
| Liu, X; Shen, Y; Sun, Q; Zhang, J; Zhou, N | 1 |
| Li, Q; Rao, L; Xu, Q; Yi, B; Zhang, D | 1 |
| Carter-Cooper, B; Emadi, A; Etemadi, A; Faramand, R; Ford, LA; Griffiths, EA; Lapidus, RG; Tolu, S; Wang, ES; Wetzler, M | 1 |
| Fang, Q; Gao, R; Hu, XY; Li, Y; Ma, D; Sun, J; Wang, JS; Wang, P | 1 |
| Klimek, V | 1 |
| Mukherjee, S; Ornstein, MC; Sekeres, MA | 1 |
| Anthony, S; Corre, A; Gong, M; Liu, J; Rehan, VK; Sakurai, R | 1 |
| Mahalingaiah, PK; Singh, KP; Treas, JN; Tyagi, T | 1 |
| De Bruyne, E; De Smedt, E; Hose, D; Kassambara, A; Klein, B; Maes, K; Menu, E; Moreaux, J; Seckinger, A; Van Valckenborgh, E; Vanderkerken, K | 1 |
| Brandwein, J; Brian, L; Chen, EX; Degelder, T; Egorin, MJ; Espinoza-Delgado, I; Gupta, V; Haines, P; Holleran, JL; How, J; McGill, S; Minden, MD; Piekarz, R; Schimmer, AD; Schuh, AC; Siu, LL; Stayner, LA; Wang, L; Webster, S; Wong, T; Yee, KW | 1 |
| Fang, Z; Guan, H; Li, F; Li, J; Li, Y; Mi, B; Tan, P; Wu, W; Zhang, Y | 1 |
| Damm, OS; Ehmcke, J; Gromoll, J; Kläver, R; Lahrmann, E; Redmann, K; Rohde, C; Sánchez, V; Sandhowe-Klaverkamp, R; Schlatt, S; Wistuba, J | 1 |
| Biankin, AV; Caldon, CE; Chang, DK; Colvin, EK; Henshall, SM; Mawson, A; Musgrove, EA; Pajic, M; Pinese, M; Scarlett, CJ; Susanto, JM; Sutherland, RL | 1 |
| Chao, X; Chengming, F; Chunkang, C; Juan, G; Shucheng, G; Xi, Z; Xiao, L; Youshan, Z | 1 |
| Chen, XJ; Li, YJ; Li, YY; Liu, ZY; Sun, ZL; Xie, WJ; Zhang, DS | 1 |
| Dunleavy, K; Jiang, Z; Kuo, PY; Leshchenko, VV; Overbey, J; Parekh, S; Weniger, MA; Wiestner, A; Wilson, WH | 1 |
| Bhatnagar, B; Blum, W; Devine, S; Garzon, R; Hofstetter, J; Kauffman, M; Klisovic, R; Marcucci, G; Phelps, MA; Ranganathan, P; Santhanam, R; Shacham, S; Vasu, S; Walker, A; Walsh, K; Yu, X | 1 |
| Kim, EJ; Kim, JS; Kim, SH; Kim, SM; Kim, SY; Lee, M | 1 |
| Chen, RL; Huang, BT; Li, BS; Zeng, QC; Zhao, WH | 1 |
| Dong, R; He, X; Li, J; Qiu, H; Wang, Y; Yu, J | 1 |
| ChuanYi, Z; Hui, L; Hui, Z; Wenting, Y; XuQun, H; Yiling, C | 1 |
| Adès, L; Berthon, C; Braun, T; Brechignac, S; Cherait, A; Fenaux, P; Gardin, C; Harel, S; Park, S; Quesnel, B; Rigal, M; Thépot, S; Willekens, C | 1 |
| Dehghani, M; Kianpour, S; Mokarram, P; Monabati, A; Mostafavi-Pour, Z; Torabinejad, S | 1 |
| Chen, Y; Ding, J; Duan, L; Gu, J; Hong, M; Li, J; Li, Y; Liu, P; Lu, H; Pan, L; Qian, S; Qiu, H; Shi, J; Wang, J; Wu, H; Xu, J; Xu, Y; Yu, K; Zhang, R; Zhang, S; Zhou, J; Zhou, S; Zhu, H; Zhu, Y | 1 |
| Cui, Y; Irudayaraj, J; Naz, A; Thompson, DH | 1 |
| Fu, C; Han, Y; Jin, Z; Ma, X; Qiu, H; Sun, A; Tang, X; Wang, J; Wang, P; Wu, D; Zheng, H; Zhou, J | 1 |
| Arichi, N; Chang, I; Dahiya, R; Deng, G; Fukuhara, S; Hiraki, M; Hirata, H; Majid, S; Mitsui, Y; Saini, S; Shahryari, V; Shiina, H; Tanaka, Y; Yamamura, S; Yasumoto, H | 1 |
| Ford, LA; Gandhi, S; Griffiths, EA; Gupta, N; Miller, A; Thompson, JE; Vigil, CE; Wang, ES; Wetzler, M | 1 |
| Borthakur, G; Brandt, M; Burger, J; Cortes, J; Faderl, S; Feliu, J; Ferrajoli, A; Garcia-Manero, G; Huang, X; Jabbour, E; Kadia, TM; Kantarjian, H; Konopleva, M; Pierce, S; Ravandi, F; Wang, X | 1 |
| Bian, YM; Liu, JH; Lu, DP; Xie, Y | 1 |
| Abdel-Wahab, O; Allione, B; Buchi, F; Droin, N; Figueroa, ME; Gioia, D; Lunghi, M; Masala, E; Meldi, K; Micol, JB; Poloni, A; Qin, T; Santini, V; Selimoglu-Buet, D; Solary, E; Sotzen, J | 1 |
| Cuvelier, N; Fernandez-Zapico, ME; Frommhold, A; Hahn, H; Johnsen, SA; Nitzki, F; Salinas-Riester, G; Tolosa, EJ | 1 |
| Chen, H; Gao, SM; Li, HY; Tang, LY; Wu, JB; Yang, JJ; Zheng, XQ | 1 |
| Chen, XH; Gao, L; Kong, PY; Liu, J; Liu, Y; Zhang, C; Zhang, X | 1 |
| Bohannan, Z; Cabrero, M; Garcia-Manero, G; Jabbour, E; Kantarjian, HM; Pierce, S; Ravandi, F | 1 |
| Falahi, F; Huisman, C; Karsten, G; Kok, K; Overkamp, J; Rots, MG; Schuuring, E; Terpstra, MM; van der Wijst, MG; van der Zee, AG; Wisman, GB | 1 |
| Cheng, H; Hu, X; Huang, C; Liu, J; Tang, G; Wang, J; Yang, J; Zhou, H | 1 |
| Chim, CS; Li, ZY; Wang, LQ; Wong, KY; Zhang, Q | 1 |
| Arthur, C; Delaunay, J; Dmoszynska, A; Kadia, TM; Kantarjian, H; Minden, M; Ravandi, F; Thomas, XG; Wierzbowska, A | 1 |
| Apprey, V; Devaney, JM; Furbert-Harris, P; Ittmann, M; Kwabi-Addo, B; Lee, NH; Olender, J; Wang, BD; Wang, S | 1 |
| Jiang, P; Lee, S; Lee, W; Xiang, Y; Yu, G; Zhang, C; Zhang, Y; Zhu, Z | 1 |
| Chen, M; Duan, F; Han, W; Li, X; Lu, X; Luo, G; Mei, Q; Wang, M | 1 |
| Chevassut, T; Cho, IH; Choudhury, SR; Chowdhury, B; Cooper, B; Cui, Y; Irudayaraj, J; Lossie, AC; McGovern, A | 1 |
| Brock, MV; Guo, M; Herman, JG; Li, X; Liang, P; Tao, Q; Yu, J | 1 |
| Ahrens, TD; Boerries, M; Busch, H; Follo, M; Hembach, S; Hoeppner, J; Hopt, UT; Lassmann, S; Ostendorp, J; Timme, S; Werner, M | 1 |
| Chang, CH; Chang, SC; Chen, CY; Chuu, CP; King, KL; Kung, HJ; Shiah, SG; Su, LC; Wen, HC | 1 |
| Jones, J; Martinez, S; Moraleda, JM; Quesada, MP; Rodríguez-Lozano, FJ | 1 |
| Chen, M; Fu, X; Han, W; Meng, Y; Nie, J; Wang, X; Wang, Y; Zhang, Y | 1 |
| DeSimone, J; Ibanez, V; Lavelle, D; Mahmud, N; Rivers, A; Ruiz, MA; Vaitkus, K | 1 |
| Chen, J; Dai, D; Xu, X; Zhang, C; Zhu, X | 1 |
| Jang, JH; Jung, CW; Jung, HA; Kim, M; Kim, S; Maeng, CH | 1 |
| Bin, H; Liang, W; Nan, W; Rui, T; Shuhai, Z; Wei, Z; Zhifang, M | 1 |
| Gao, L; Kang, HY; Li, MY; Wang, CB; Wang, LL; Wang, W; Wang, XR; Yu, L | 1 |
| Arimondo, PB; Besse, J; Bréand, S; Busato, F; Cussac, D; Davoine, E; De Vries, L; Deroide, A; Desjobert, C; Fournier, L; Lestienne, F; Novosad, N; Riond, J; Tost, J; Vispé, S | 1 |
| Hu, R; Huang, Y; Jiang, H; Lu, Y; Sun, Y; Wang, J; Yan, J; Yang, Y; Zhang, Y | 1 |
| Arcaro, KF; Chen, X; Furdui, CM; Liu, L; Mims, J; Punska, EC; Tsang, AW; Williams, KE; Zhao, W; Zhou, X | 1 |
| Abdel-Wahab, AH; Al Homssi, A; Al-Tel, T; Al-Tunaiji, H; El-Awady, RA; El-Serafi, A; Hersi, F; Saleh, EM; Suhail, M | 1 |
| Hong, JY; Jang, JH; Jung, CW; Jung, HA; Kim, HJ; Kim, JS; Kim, K; Kim, SH; Park, JS; Park, S; Seo, JY | 1 |
| Chang, YM; Khabele, D; Kim, JW; Schreiber, SL; Shamji, AF; Stewart, ML; Tamayo, P; Wang, S; Wilson, AJ | 1 |
| Liu, ZH; Luo, FY; Tang, CE; Xiao, S; Xiao, ZQ; Zhang, PF | 1 |
| Dunn, J; Jo, H; Simmons, R; Thabet, S | 1 |
| Chen, M; Dasgupta, C; Hu, XQ; Xiao, D; Yang, S; Zhang, L | 1 |
| Choi, JH; Kim, GJ; Kim, HS; Kim, J; Kim, N; Lee, HJ; Lee, JO; Lee, SK; Lee, YW; Moon, JW; Park, SH; Seo, JS | 1 |
| Cieslik, C; Döhner, K; Grishina, O; Hackanson, B; Lübbert, M; Lubrich, B; May, AM; Müller, MJ; Schmoor, C | 1 |
| Chang, C; Guo, J; Li, X; Shi, W; Wu, L; Xu, F | 1 |
| Lu, Q; Luo, Y; Shu, Y; Wang, Y; Xiao, R | 1 |
| Hoffman, R; Iancu-Rubin, C | 1 |
| He, H; Huan, Y; Liu, Z; Wang, H; Wu, Z; Zhang, J; Zhu, J | 1 |
| Abboud, CN; Cashen, AF; Choi, J; DiPersio, JF; Fiala, MA; Gao, F; Holt, M; Jacoby, MA; Pusic, I; Stockerl-Goldstein, KE; Uy, GL; Vij, R; Westervelt, P | 1 |
| Amoozgar, Z; Goldberg, MS; Huang, J; Orsulic, S; Saleh, MH; Wang, L; Xing, D | 1 |
| Huan, Y; Liu, Z; Song, X; Wu, Z; Zhang, J; Zhu, J | 1 |
| Fu, C; Han, Y; Jin, Z; Liu, H; Ma, L; Miao, M; Qiu, H; Tang, X; Wang, J; Wang, P; Wu, D; Yan, S; Zheng, H; Zhou, J | 1 |
| Liu, S; Molina, JR; Pang, J; Shen, N; Yan, F; Yang, P | 1 |
| Akers, SN; Barger, CJ; Karpf, AR; Link, PA; Mhawech-Fauceglia, P; Miller, A; Odunsi, K; Zhang, W | 1 |
| Bai, F; Cheerva, AC; Diller, L; George, RE; Krishnadas, DK; Lucas, KG; Shusterman, S; Sullivan, JE | 1 |
| Shi, J; Song, H; Sun, B; Wu, Y; Xu, M | 1 |
| Gu, W; Li, H; Li, X; Liu, H; Peng, T; Tang, Y | 1 |
| Barani, B; Dawn, B; Rajasingh, J; Rajasingh, S; Samanta, S; Thangavel, J; Xuan, YT | 1 |
| Chen, C; Huang, LP; Liu, H; Wang, XP | 1 |
| Ali, A; Itzykson, R; Loiseau, C | 1 |
| Dyrvig, M; Gøtzsche, CR; Lichota, J; Woldbye, DP | 1 |
| Ayupe, AC; Beckedorff, FC; Camargo, L; Reis, EM; Tahira, AC; Verjovski-Almeida, S | 1 |
| Ai, D; He, JL; Liu, YJ; Wang, CJ; Xue, FX; Xue, SS; Zhang, X; Zhu, Y | 1 |
| Hosokawa, M; Iwakawa, S; Tanaka, S; Ueda, K | 1 |
| Chen, J; Han, Y; Liang, J; Ruan, C; Tang, Y; Wu, D; Ye, C | 1 |
| Badar, T; Borthakur, G; Cortes, JE; Daver, N; Jabbour, E; Kantarjian, HM; Newberry, KJ; Pemmaraju, N; Pierce, SR; Ravandi, F; Verstovsek, S | 1 |
| Deng, ZQ; Guo, H; Lin, J; Ma, JC; Qian, J; Wen, XM; Yang, J; Yang, L; Yin, JY; Zhang, M; Zhang, YY; Zhu, XW | 1 |
| Hasegawa, T; Hirata, K; Isosaka, M; Kai, M; Kanda, T; Maruyama, R; Niinuma, T; Nishida, T; Nobuoka, T; Nojima, M; Shinomura, Y; Suzuki, H; Taguchi, T; Tokino, T; Yamamoto, E | 1 |
| Anantharam, V; Asaithambi, A; Ay, M; Harischandra, DS; Jin, H; Kanthasamy, A; Kanthasamy, AG | 1 |
| Hosokawa, M; Iwakawa, S; Ueda, K | 1 |
| Qi, X; Wang, W; Wu, M | 1 |
| Jackson, PN; Mata-Greenwood, E; Pearce, WJ; Zhang, L | 1 |
| Chen, Q; Guo, H; Lin, J; Qian, J; Wen, XM; Yang, J; Yang, L; Yao, DM; Zhang, YY; Zhou, JD | 1 |
| Chen, P; Chen, Y; He, SD; He, ZH; Liu, D; Ye, JR | 1 |
| Kobbe, G; Schroeder, T | 1 |
| Gorman, S; Hart, PH; McGonigle, TA; Ng, RL; Scott, NM | 1 |
| Bonnac, L; Landman, SR; Mansky, LM; Patterson, SE; Rawson, JM; Reilly, CS | 1 |
| Garcia-Manero, G; Goswami, M; Hasserjian, RP; Jabbour, EJ; Medeiros, LJ; Patel, KP; Peng, J; Tang, G; Wang, SA | 1 |
| Azab, M; Chung, W; Daver, N; Griffiths, EA; Hao, Y; Issa, JJ; Jabbour, E; Kantarjian, H; Lowder, JN; Naim, S; O'Connell, C; Oganesian, A; Rizzieri, D; Roboz, G; Stock, W; Taverna, P; Tibes, R; Walsh, K; Yee, K | 1 |
| Ford, LA; Freyer, CW; Griffiths, EA; Muppidi, MR; Portwood, S; Thompson, JE; Wang, ES; Wetzler, M | 1 |
| Evers, BM; Kim, JT; Lee, EY; Li, J; Song, J; Townsend, CM; Weiss, HL | 1 |
| Gao, N; Jiang, G; Wu, J; Xi, Q; Yang, Y; Ye, W; Zhang, B; Zhang, X | 1 |
| Barron, E; Dustin, LD; He, S; Hinton, DR; Ishikawa, K; Kase, S; Nazari Khanamiri, H; Spee, C; Wang, Z; Zhou, P | 1 |
| Cao, YB; DA, WM; Li, SW; Li, XH; Liu, B; Liu, ZY; Wu, XX; Wu, YM; Xu, LX; Yan, B; Yang, XL | 1 |
| Hu, GY; Li, QZ; Liao, YP; Liu, YX | 1 |
| Ağaoğlu, L; Akçay, A; Can, İ; Celkan, T; Doğru, Ö; Fırtına, S; Hatırnaz Ng, Ö; Karakaş, Z; Özbek, U; Sayitoğlu, M; Timur, Ç; Yıldırmak, Y | 1 |
| Danesh, A; De Carvalho, DD; Han, H; Jones, PA; Liang, G; Loo Yau, H; O'Brien, C; Pugh, TJ; Roulois, D; Shen, SY; Singhania, R; Wang, Y | 1 |
| Qin, Y; Tong, Y; Wan, L; Wang, C; Zhou, K; Zhou, Z; Zou, J | 1 |
| Li, M; Sun, LG; Tian, XY; Zhang, L | 1 |
| Antonios, JP; Everson, RG; Garrett, MC; Kruse, CA; Li, G; Li, N; Liau, LM; Lisiero, DN; Prins, RM; Scharnweber, R; Soto, H; Yong, WH | 1 |
| Bandura, AS; Horbacka, K; Horst, N; Jagodziński, PP; Krokowicz, P; Rawłuszko-Wieczorek, AA; Świderska, M | 1 |
| Deng, T; Li, D; Li, H; Li, Y | 1 |
| Ko, CY; Lai, HY; Li, CF; Pan, YC; Tsai, HH; Wang, JM; Wu, WC; Yen, CJ; Yuh, CH | 1 |
| Borthakur, G; Cortes, J; Daver, N; Diaz-Pines-Mateo, M; Dinardo, C; Estey, E; Garcia-Manero, G; Huang, X; Jabbour, E; Kadia, T; Kantarjian, H; Konopleva, M; O'Brien, S; Pemmaraju, N; Pierce, S; Ravandi, F; Verstovsek, S; Wang, X | 1 |
| Bai, W; Chen, Y; Gao, A | 1 |
| De Porre, P; Diels, J; Güntert, A; Lange, A; Tapprich, C; Thilakarathne, P; Tomeczkowski, J; Xiu, L | 1 |
| Almgren, M; Du, ZM; Ernberg, I; Hu, LF; Ignatyev, I; Kashuba, V; Moumad, K; Nawaz, I; Pavlova, TV; Zabarovsky, ER | 1 |
| Dou, MH; Hu, C; Huang, J; Jin, J; Li, Y; Lou, YJ; Luo, YW; Ma, LY; Mao, LP; Mei, C; Niu, LM; Ren, YL; Tong, HY; Wang, JH; Wei, JY; Xie, LL; Xu, GX; Ye, L; Ye, XN; Yu, WJ; Zhou, XP | 1 |
| Bhatt, VR; Ganti, AK; Hausmann, H; Maness, LJ; Yuan, J | 1 |
| Tan, H; Wang, C; Xie, B; Xu, J; Yu, B; Zheng, R | 1 |
| Carter, BZ; Dai, M; Ding, B; Jiang, L; Jiang, X; Liang, S; Liu, Q; Meng, F; Wang, Z; Ye, J; Yin, C; Yu, G; Zhang, Y; Zhao, Q; Zhong, Q | 1 |
| Chang, C; Chao, X; He, Q; Li, X; Song, L; Su, J; Wu, D; Wu, L; Xu, F; Zhang, Z; Zhao, Y; Zhou, L | 1 |
| Cha, S; Choi, SK; Choi, SY; Kim, M; Kim, N; Lee, JH; Namkoong, E; Park, K; Shin, YH | 1 |
| Aul, C; Baron, F; Becker, H; de Witte, T; Fiaccadori, V; Ganser, A; Germing, U; Giagounidis, A; Hagemeijer, A; Labar, B; Lübbert, M; Muus, P; Pflüger, KH; Platzbecker, U; Rüter, BH; Salih, HR; Schaefer, HE; Selleslag, D; Suciu, S; Wijermans, PW | 1 |
| Chen, X; Gao, L; Kim, YJ; Li, S; Liu, L; Zhao, Y | 1 |
| An, Y; Deng, H; Gao, F; Li, C; Ma, Y; Tong, J; Wang, D; Wang, X; Xu, X; Yamanaka, K; Yang, X; Zhao, Y; Zhu, Z | 1 |
| Chen, SN; Fu, JH; Gao, S; Han, Y; Hu, XH; Jin, ZM; Li, Z; Qiu, HY; Sun, AN; Tang, XW; Wu, DP; Xu, Y | 1 |
| Berdasco, M; Caba, O; Cabeza, L; Gónzalez, B; Melguizo, C; Ortiz, R; Perazzoli, G; Prados, J | 1 |
| Gopinadh, J; Klar, AS; Kleber, S; Renner, C; Wadle, A | 1 |
| Guttin, A; Ipas, H; Issartel, JP | 1 |
| Bu, JY; Cui, RJ; Du, YD; Huang, N; Li, D; Lin, P; Sun, H; Tang, JB; Xu, CY; Yang, ZK; Yu, XG | 1 |
| Diederich, M; Schnekenburger, M | 1 |
| Al-Kali, A; Alfakara, D; Hashmi, S; Hogan, W; Hook, C; Litzow, M; Patnaik, M; Subari, S; Zblewski, D | 1 |
| Li, J; Sheng, X; Tan, L; Wang, Z; Zhou, D; Zhou, Y | 1 |
| Dong, Y; Ji, T; Liang, J; Ma, Z; Xiao, Y; Yin, G | 1 |
| Ali, NA; Barnard, J; DeZern, A; Garcia-Manero, G; Gore, SD; Jabbour, E; Kantarjian, H; Komrokji, R; List, A; Maciejewski, JP; Nazha, A; Roboz, G; Sekeres, MA; Steensma, DP; Zeidan, AM; Zell, K; Zimmerman, C | 1 |
| Ito, S; Uchida, H | 1 |
| Benson, EA; Liu, Y; Matei, D; Nephew, KP; Skaar, TC | 1 |
| Eom, KS; Han, S; Hong, T; Jeon, S; Kim, HJ; Kim, YJ; Lee, J; Lee, S; Lee, SE; Min, CK; Park, GJ; Shin, SH; Yahng, SA; Yim, DS; Yoon, JH | 1 |
| Chen, F; Du, C; Ernberg, I; He, Q; Huang, G; Huang, T; Lan, Y; Lin, L; Matskova, L; Mo, Y; Murata, M; Wang, S; Wei, J; Wei, L; Xiao, X; Xie, Y; Zhang, Z; Zhou, X | 1 |
| Chim, CS; Rosèn, A; Wang, LQ; Wong, KY | 1 |
| Choi, CW; Do, YR; Jang, JH; Jeong, SH; Joo, YD; Kim, HG; Kim, I; Kim, SJ; Kim, SR; Kim, YJ; Kim, YK; Lee, JH; Lee, WS; Mun, YC; Na, SM; Park, SK; Yi, HG | 1 |
| Guan, RT; Guo, JX; Pan, JX; Zhang, XY; Zhong, JF; Zhou, YH | 1 |
| Clark, JD; Kingery, P; Li, W; Liang, D; Sahbaie, P; Shi, X; Sun, Y | 1 |
| Huan, YJ; Kong, QR; Li, JY; Liu, ZH; Wang, JY; Wu, ZF; Xie, BT; Xue, BH; Zhang, JG; Zhu, J | 1 |
| Issa, JP; Lowder, JN; Taverna, P | 1 |
| Ali, AM; Jacoby, M; Welch, JS | 1 |
| Chen, X; Gan, W; Han, X; Li, D; Lin, X; Liu, Y; Meng, X; Wang, L; Xiang, Z; Zhang, P | 1 |
| Becker, PS; Dean, C; Deeg, HJ; Estey, E; Hendrie, P; Mawad, R; Myint, H; Pagel, JM; Sandhu, V; Scott, B; Singer, JW; Walter, R; Wang, L; Wood, BL | 1 |
| Cai, Z; Chen, B; Du, X; He, G; Huang, X; Jin, J; Li, J; Li, X; Liang, H; Liu, T; Ruan, C; Shao, Z; Shen, Z; Wu, D; Xiao, Z; Yu, L | 1 |
| Banas, M; Cichy, J; Guzik, K; Koltun, M; Krzykawska-Serda, M; Kwitniewski, M; Majewski, P; Makarska, A; Marczynska, J | 1 |
| Borinstein, SC; Hawkins, AG; Laird, PW; Lawlor, ER; Martens, JR; Punj, V; Ryland, KE; Weisenberger, DJ | 1 |
| Itano, Y; Kondo, T; Okamoto, S; Ouchida, M; Suemori, S; Takahashi, K; Tohyama, K; Tohyama, Y; Tsujioka, T; Yokoi, A | 1 |
| Dai, Y; He, HS; Huang, DP; Huang, LQ; Jiang, YZ; Su, GP; Sun, ZM | 1 |
| Aul, C; Baron, F; Becker, H; Bogatyreva, L; de Witte, T; Ganser, A; Germing, U; Giagounidis, A; Hagemeijer, A; Huls, G; Labar, B; Lübbert, M; Marie, JP; Muus, P; Pflüger, KH; Platzbecker, U; Rüter, B; Salih, HR; Schaefer, HE; Selleslag, D; Suciu, S; van der Helm, L; Vellenga, E; Wijermans, PW | 1 |
| Deng, Y; Liu, D; Sheng, Y; Wang, H; Yang, F; Zhang, C; Zhang, T | 1 |
| Ackermann, S; Berthold, F; Dreidax, D; Engesser, A; Fischer, M; Henrich, KO; Hero, B; Hertwig, F; Ikram, F; Kahlert, Y; Kocak, H; Nürnberg, P; Roels, F; Volland, R; Westermann, F | 1 |
| Guo, C; Han, M; Jiang, Y; Liang, B; Lv, Z; Nie, J; Qian, Y; Wang, X; Wei, Y; Wu, J; Yang, Y; Zhang, J | 1 |
| He, C; Jiang, H; Xu, R; Zhao, X; Zhong, Z | 1 |
| Ding, L; Jin, LY; Kong, B; Lv, ZD; Wang, Y; Yang, ZC | 1 |
| Han, T; Liu, Y; Shang, D; Xu, X | 1 |
| DeZern, AE | 1 |
| Ema, A; Enomoto, T; Katoh, H; Kikuchi, M; Kojo, K; Kosaka, Y; Minatani, N; Sawanobori, M; Sengoku, N; Tanino, H; Ushiku, H; Waraya, M; Watanabe, M; Yamashita, K | 1 |
| Cui, MY; Gao, XZ; Li, WC; Wang, GN; Zhang, YR; Zhao, WG | 1 |
| Cook, N; Pannebakker, BA; Shuker, DM; Tauber, E | 1 |
| Ji, MH; Jia, M; Ju, LS; Sun, J; Sun, XR; Wang, ZY; Yang, JJ; Zhang, H | 1 |
| Avettand-Fenoel, V; Bouchat, S; Clumeck, N; Corazza, F; Darcis, G; De Wit, S; Delacourt, N; Gatot, JS; Kabeya, K; Kula, A; Melard, A; Pardons, M; Rohr, O; Rouzioux, C; Van Driessche, B; Van Lint, C; Vanhulle, C | 1 |
| Chang, E; Ganguly, S; Gocke, CD; Konig, H; Levis, M; Rajkhowa, T | 1 |
| Baggerly, K; Bast, RC; Bedi, A; Das, P; Fishman, D; Liu, J; Lu, Z; Mao, W; Marquez, RT; Wang, Y; Yang, H; Yu, Y | 1 |
| Mitchell, MD; Ponnampalam, AP; Vincent, ZL | 1 |
| Huang, YM; Xiao, HF; Xu, WQ | 1 |
| Lu, JH; Xu, M | 1 |
| Chen, J; Qiu, X; Wang, Z; You, Y; Zhang, Z | 1 |
| Bhatla, T; Burke, MJ; Carroll, WL; Lu, BY; Thanawala, SU; Zochowski, KC | 1 |
| Fenech, MF; François, M; Leifert, WR; Tellam, R | 1 |
| Chen, S; Qiu, H; Shen, H; Sun, A; Sun, Y; Wu, D; Xu, Y; Yang, Z | 1 |
| Gangat, N; Patnaik, MM; Tefferi, A | 1 |
| Barra, V; Cilluffo, D; Costa, G; Di Leonardo, A; Lentini, L | 1 |
| Al Ali, NH; Barnard, J; DeZern, AE; Garcia-Manero, G; Jabbour, EJ; Kantarjian, HM; Komrokji, RS; List, AF; Maciejewski, JP; Nazha, A; Roboz, GJ; Sekeres, MA; Steensma, DP; Zell, K; Zimmerman, C | 1 |
| Lin, T; Lv, J; Ma, Q; Martinez, SR; MataGreenwood, E; Song, M; Xiao, D; Xiong, F; Xu, Z; Zhang, L | 1 |
| Al-Kali, A; Baidoun, F; Elliott, M; Hashmi, S; Hogan, W; Hreh, M; Litzow, M; Patnaik, M; Subari, S | 1 |
| Fang, Q; Gao, R; Ma, D; Sun, J; Wang, JS; Wang, P | 1 |
| Cao, Y; Chen, Y; Huang, Y; Li, G; Liu, Z | 1 |
| Bu, HQ; Chen, L; Chen, ZQ; Chu, YQ; Fei, Y; Lin, SZ; Liu, DL; Pan, FP; Pan, J; Tang, J; Xu, LP; Yu, QJ; Zhang, H; Zhou, HK | 1 |
| Hsiao, YP; Hung, SJ; Liu, FT; Tang, SC; Yang, JH; Yeh, JI | 1 |
| Aburatani, H; Hattori, Y; Ichikawa, D; Kawakami, Y; Matsushita, M; Okamoto, S; Otsuka, Y; Ozawa, K; Suzuki, T; Tanaka, C; Tsutsumida, N; Uchiumi, A | 1 |
| Li, B; Li, D; Lian, C; Tang, B; Wang, K; Wang, M; Wang, X; Wang, Y; Xiao, T; Zhang, W; Zhang, Y; Zuo, Q | 1 |
| Bonnac, L; Clouser, CL; Daly, MB; Kim, B; Landman, SR; Mansky, LM; Patterson, SE; Rawson, JM; Reilly, CS; Xie, J | 1 |
| Gillard, BT; Greenwood, M; Greenwood, MP; Loh, SY; Murphy, D; Paton, JF | 1 |
| Fu, JX; Ju, SG; Li, J; Sun, Y; Wang, ZY; Yuan, YQ; Zhang, LY; Zhou, DM | 1 |
| Arceci, RJ; Elmoneim, AA; Heuston, E; Triche, T; Wai, DH | 1 |
| Bär, B; Blijlevens, NNM; Bremmers, MEJ; Cruijsen, M; Dolstra, H; Falkenburg, JHF; Hobo, W; Huls, G; Jansen, J; Kester, M; Schaap, NPM; van der Velden, WJFM; Woestenenk, R | 1 |
| Bakker, A; De Keulenaer, S; De Meester, E; De Meyer, T; Diddens, J; Frankl-Vilches, C; Galle, J; Sohnius-Wilhelmi, N; Steyaert, S; Van Criekinge, W; Van der Linden, A; Vanden Berghe, W | 1 |
| Bainschab, A; Greinix, HT; Krause, R; Quehenberger, F; Sill, H; Wölfler, A; Zebisch, A | 1 |
| Choi, MY; Kim, KH; Lee, JY; Lee, SM; Lee, WS | 1 |
| Chen, J; Chen, Y; Fu, H; Huangfu, Z; Liao, B; Qi, Y; Shen, J; Xu, C; Zhou, H | 1 |
| Cao, C; Chen, L; Chen, P; Tan, W; Yi, F; Zhang, X; Zhu, X | 1 |
| Blagitko-Dorfs, N; Collamat-Lai, G; Ford, LA; Griffiths, EA; James, SR; Karpf, AR; Lübbert, M; Matsuzaki, J; Naqash, R; Nemeth, MJ; Paluch, BE; Srivastava, P | 1 |
| Haase, H; Kessels, JE; Rink, L; Uciechowski, P; Wessels, I | 1 |
| Anaka, M; Behren, A; Cebon, J; Chueh, AC; Davalos-Salas, M; Jayachandran, A; Lo, PH; Molania, R; Prithviraj, P; Walkiewicz, M | 1 |
| Alexandrov, LB; Artiguenave, F; Auboeuf, D; Bernard, O; Braun, T; Chautard, E; Commes, T; Cowley, MJ; de Botton, S; Deleuze, JF; Dinger, ME; Droin, N; Fenaux, P; Figueroa, M; Gayevskiy, V; Itzykson, R; Jourdan, E; Koscielny, S; Meldi, K; Merlevede, J; Meyer, V; Morabito, M; Ogawa, S; Padron, E; Pata-Merci, N; Preudhomme, C; Qin, T; Quesnel, B; Selimoglu-Buet, D; Solary, E; Solier, S; Stratton, MR; Vainchenker, W; Yoshida, K | 1 |
| He, L; Liu, FZ; Wang, JS; Zhang, S; Zhu, HQ | 1 |
| Chen, P; Chen, Y; Kong, X; Luo, H; Peng, H; Shi, Z; Zeng, H; Zhang, H | 1 |
| Chang, C; He, Q; Li, X; Shi, W; Song, L; Su, J; Wu, D; Wu, L; Xiao, C; Xu, F; Zhang, Z; Zhou, L | 1 |
| Barraco, M; Clissa, C; Cocco, L; Finelli, C; Follo, MY; Mongiorgi, S; Parisi, S; Stanzani, M | 1 |
| Affinito, O; Belardo, C; Chiariotti, L; Cristino, L; De Novellis, V; Errico, F; Florio, E; Imperatore, R; Keller, S; Luongo, L; Maddaloni, G; Maione, S; Migliarini, S; Nuzzo, T; Pasqualetti, M; Pollegioni, L; Punzo, D; Sacchi, S; Sisalli, MJ; Usiello, A | 1 |
| Gao, D; Guo, M; Herman, JG | 1 |
| Al-Kali, A; Atallah, E; Azarnia, N; Baer, MR; Collins, R; Fenaux, P; Gaidano, G; Garcia-Manero, G; Godley, LA; Greenberg, P; Jabbour, E; Kambhampati, S; Kantarjian, H; Kreuzer, KA; Platzbecker, U; Roboz, GJ; Scott, BL; Sekeres, MA; Silverman, LR; Steensma, DP; Wilhelm, FE | 1 |
| Abolhassani, F; Aliakbari, F; Baazm, M; Barbarestani, M; Hajian, M; Khanlarkhani, N; Kharizinejad, E; Minaee Zanganeh, B; Mortezaee, K; Rastegar, T; Sajjadi, SM | 1 |
| Deng, C; Du, X; Geng, S; Huang, X; Li, M; Lu, Z; Tong, J; Weng, J; Wu, P; Yao, H | 1 |
| Ali, NA; Barnard, J; DeZern, AE; Garcia-Manero, G; Greenberg, MD; Jabbour, E; Kantarjian, HM; Komrokji, RS; List, AF; Maciejewski, JP; Nazha, A; Roboz, GJ; Sekeres, MA; Steensma, DP; Zell, K; Zimmerman, C | 1 |
| Agrawal, K; Brus, J; Dzubak, P; Hajduch, M; Hruby, M; Otmar, M; Policianova, O; Skopal, J; Stepanek, P; Svec, P | 1 |
| Almqvist, H; Artursson, P; Axelsson, H; Dan, C; Haraldsson, M; Jafari, R; Larsson, A; Lundbäck, T; Martinez Molina, D; Mateus, A; Nordlund, P | 1 |
| Adam, PJ; Blum, W; Borges, E; Bucci, D; Caligiuri, MA; Cheney, C; Gopalakrishnan, B; Groh, V; He, S; Heider, KH; Konopitzky, R; Kössl, C; Lozanski, G; Lucas, DM; Mani, R; Marcucci, G; Mo, X; Muthusamy, N; Rueter, B; Vasu, S; Whitman, SP; Yu, J | 1 |
| Hao, J; Kuang, X; Li, L; Liu, X; Wang, H; Wang, Y; Yang, J; Zeng, X; Zhang, T | 1 |
| Che, K; Li, J; Liu, M; Liu, X; Luo, B | 1 |
| Qiu, SC; Wang, YZ | 1 |
| Chen, ST; Hsieh, YY; Huang, TC; Jhan, JY; Lo, HL; Yang, PM | 1 |
| Arozamena, J; Berciano, MT; Delgado-Calle, J; Lafarga, M; May, T; Pérez-Campo, FM; Riancho, JA; Sañudo, C; Zauers, J | 1 |
| Moolmuang, B; Ruchirawat, M; Singhirunnusorn, P | 1 |
| Iwaisako, K; Kawashima, M; Kawata, Y; Kurebayashi, J; Nishimura, T; Noda, M; Shi, G; Toi, M; Yoshida, Y; Yoshikawa, K; Yuki, K | 1 |
| Chen, L; Han, W; Li, X; Liu, L; Mei, Q; Nie, J; Song, Y; Wu, X | 1 |
| Bao, Y; Chen, Z; Dong, H; Guo, Y; Li, K; Shen, K; Wang, Q; Yang, W; Yang, Y; Zhang, H | 1 |
| Anders, NM; Giovinazzo, H; Liu, J; Nelson, WG; Rudek, MA; Vaghasia, A; Wanjiku, T; Yegnasubramanian, S; Zhou, J | 1 |
| Barwick, BG; Bell, JS; Dwivedi, B; Kagey, JD; Kowalski, J; McCabe, MT; Vertino, PM | 1 |
| Ding, XL; Liang, G; Wang, K; Yang, X | 1 |
| Béhanzin, E; Bowen, D; Demolis, P; Flores, B; Gisselbrecht, C; Hudson, I; Moreau, A; Nieto, M; Pignatti, F; Salmonson, T; Stemplewski, H | 1 |
| Atagunduz, IK; Avsar, E; Deveci, B; Ferhanoglu, B; Geduk, A; Kara, O; Kurtoglu, E; Mehtap, O; Ozturk, E; Salim, O; Tiftik, EN; Tombak, A; Toptas, T; Tuglular, TF; Undar, L; Yucel, OK | 1 |
| Dong, W; Gu, W; Hua, X; Li, H; Lin, Y; Ling, Y; Wu, W; Xiang, L; Xie, X; Yan, F | 1 |
| Amankulor, N; Chan, T; Chang, Y; Choi, J; Deibert, C; Engh, J; Grandi, P; Kim, WJ; Kohanbash, G; Lotze, M; Okada, H; Park, Y; Pomerantz, A; Rao, A; Sette, P; Zhang, X | 1 |
| Dodd, S; Forest, J; Lukowiak, K; Sunada, H | 1 |
| Kanai, T; Kimura, M; Muramatsu, T; Nakaoka, T; Saito, H; Saito, Y; Sakai, K; Sato, T; Toshimitsu, K | 1 |
| Shan, W; Shi, H; Wu, R; Xue, B; Yang, X; Yu, L | 1 |
| Chen, YH; Ding, Y; Liang, AB; Luo, X; Wu, H | 1 |
| Lan, Q; Li, Z; Liu, H; Qu, M; Wang, Z; Xu, L; Yu, J; Zhang, S; Zhong, Q; Zhu, Q | 1 |
| Bai, J; Du, Z; Feng, X; Li, A; Liu, B; Luan, J; Song, J; Sun, X; Wang, H; Zhang, L | 1 |
| Chen, M; Han, W; Li, X; Liu, C; Nie, J; Zhang, Y | 1 |
| Kong, X; Liu, A; Liu, J; Liu, Y; Su, Y; Sun, P; Wang, X; You, D; Yuan, L; Zhang, D; Zhang, X | 1 |
| Chang, I; Dahiya, R; Deng, G; Fukuhara, S; Hashimoto, Y; Imai-Sumida, M; Kato, T; Majid, S; Mitsui, Y; Nakajima, K; Saini, S; Shiina, H; Shiina, M; Tanaka, Y; Wong, DK; Yamamura, S | 1 |
| Correard, F; Espitallier, F; Pisano, P; Pourroy, B; Savry, A; Villano, LG | 1 |
| Ansari, M; Fallah, S; Ghasemi, A | 1 |
| Alam, M; Avigan, D; Bouillez, A; Gali, R; Kharbanda, S; Kufe, D; Rajabi, H; Stone, R; Stroopinsky, D; Tagde, A | 1 |
| Amler, L; Bourgon, R; Frierson, H; Fu, L; Fuentes, E; Hampton, GM; Kabbarah, O; Lackner, MR; Lu, S; Moskaluk, C; Okrah, K; Penuel, E; Pirzkall, A; Qu, X; Rumpel, C; Sandmann, T; Tabernero, J; Walter, K; Wang, Y | 1 |
| Chen, G; Chen, T; Guo, W; Liu, Z; Sun, W; Tian, W; Xiao, J; Yu, M; Yuan, Z | 1 |
| Dasgupta, C; Gay, MS; Kanna, A; Li, Y; Zhang, L | 1 |
| Abraham, I; Fernandez-Zapico, ME; Patnaik, MM; Robertson, KD; Vincelette, ND; Yun, S | 1 |
| Dasgupta, C; Halavi, S; Hartman, RE; Li, Y; Ma, Q; Xiao, D; Zhang, L | 1 |
| Åstot, C; Bergström, T; Dorner, BG; Mahrhold, S; Rummel, A; Stern, D | 1 |
| Chen, P; Li, Q; Wu, X; Zhao, Y | 1 |
| Hu, W; Jiang, Q; Kong, X; Li, Y; Lv, C; Yang, L; Zhang, Y | 1 |
| Glasow, A; Kortmann, RD; Menzel, F; Patties, I | 1 |
| González-Pacanowska, D; Horváth, A; Pérez-Moreno, G; Requena, CE; Ruiz-Pérez, LM; Vértessy, BG; Vidal, AE | 1 |
| Colizzi, F; Dolcetti, R; Fratta, E; Montico, B; Rizzo, A; Sigalotti, L | 1 |
| Buschbeck, M; Diesch, J; Garz, AK; Götze, KS; Palau, A; Zwick, A | 1 |
| Ben-Shlomo, A; Cescato, R; Grotzky, A; Krause, T; Marincek, N; Meier, LP; Olariu, CI; Perren, A; Radojewski, P; Stettler, C; Taelman, VF; Walter, MA | 1 |
| Angriman, I; Basato, S; Brun, P; Castagliuolo, I; Castoro, C; Erroi, F; Scarpa, M | 1 |
| Drzewiecka, H; Dyszkiewicz, W; Gałęcki, B; Jagodziński, PP; Jarmołowska-Jurczyszyn, D; Kluk, A | 1 |
| Endo, D; Koji, T; Shibata, Y; Song, B; Song, N | 1 |
| Admon, A; Barnea, E; Kadosh, DM; Shraibman, B | 1 |
| Baek, A; Bear, HD; Damle, SR; Graham, LJ; Manjili, MH; Payne, KK; Terracina, KP | 1 |
| Allen, AR; Hauer-Jensen, M; Koturbash, I; Kutanzi, KR; Miousse, IR; Nelson, GA; Nzabarushimana, E; Pathak, R; Prior, S; Raber, J; Skinner, C; Tackett, AJ | 1 |
| Ek, F; Ek, S; Emruli, VK; Olsson, R | 1 |
| Chen, Y; Du, Q; Huang, Y; She, F; Wu, W | 1 |
| Hashimoto, S; Nakamura, M; Nishikawa, J; Okamoto, T; Saito, M; Sakai, K; Sakaida, I; Sasaki, S; Suehiro, Y; Yamasaki, T | 1 |
| Alvarez, M; Duarte, AD; Lazarini, M; Machado-Neto, JA; Niemann, FS; Pericole, FV; Saad, ST; Traina, F; Vieira, KP | 1 |
| Duan, S; Jiang, D; Shen, Y; Wang, H; Wang, J; Wang, Y; Xu, Y; Zhu, H | 1 |
| Ahn, H; Cerchietti, L; Elstrom, R; Furman, R; Leonard, J; Martin, P; Marullo, R; Patel, J; Pera, B; Ruan, J; Tang, T; Yang, SN | 1 |
| Gao, R; Groden, J; Kato, Y; Kaul, SC; Kaul, Z; Li, L; Wadhwa, R; Yu, Y; Zhang, Z | 1 |
| He, Y; Huang, C; Huang, K; Li, Z; Liu, H; Ye, G; Zhou, X | 1 |
| Ardiles, ÁO; Díaz, P; Elgueta, C; Estay, C; Lizana, PA; Muñoz, P | 1 |
| Fialova, B; Gursky, J; Kolar, Z; Langova, K; Luzna, P; Trtkova, KS | 1 |
| Clarke, PAG; Davis, R; Kwabi-Addo, B; Mumuni, S; Wang, S | 1 |
| Cheng, L; Hou, Y; Luo, T; Wang, F; Wang, H; Xu, J | 1 |
| Ahn, JS; Cho, YY; Chung, JS; Joo, YD; Kim, H; Kim, HJ; Kim, YS; Lee, HS; Lee, IH; Lee, SM; Lee, WS; Lee, YJ; Moon, JH; Park, SW; Shin, HJ; Sohn, SK | 1 |
| Creemers, SG; de Herder, WW; Dogan, F; Eekhoff, EM; Feelders, RA; Franssen, GJ; Hofland, LJ; Janssen, JA; Papathomas, TG; van der Valk, P; van Kemenade, FJ; van Koetsveld, PM | 1 |
| Gao, SL; Gao, SS; Guo, RW; Li, L; Zhai, XJ | 1 |
| Cao, T; Dawn, B; Patel, U; Rajasingh, J; Rajasingh, S; Samanta, S | 1 |
| Chen, S; Huang, W; Li, Y; Liu, R; Mao, X; Shi, W; Shuai, W; Wu, J; Ye, Z; Zhuang, L; Zuo, Z | 1 |
| Altman, J; Dinner, S; Frankfurt, O; Gao, J; Helenowski, I; McMahon, BJ; Stein, BL; Waisbren, J | 1 |
| Cao, Y; Gu, WY; Lin, Y; Qiu, GQ; Wang, ZL; Wu, HQ; Wu, W; Xie, XB | 1 |
| Baylin, SB; Charlet, J; Grønbæk, K; Jones, PA; Liang, G; Liu, M; Ohtani, H; Shen, H; Zhang, YW; Zhou, W; Ørskov, AD | 1 |
| Carosella, ED; Daunay, A; de Almeida, BS; Donadi, EA; Moreau, P; Poras, I; Simoes, RT; Tost, J; Yaghi, L | 1 |
| Barba, L; Bassoy, EY; Boehler, M; Calvo Tardón, M; Dietrich, PY; Jueliger, S; Marinari, E; Martinvalet, D; Pellegatta, S; Riccadonna, C; Taverna, P; Vuillefroy de Silly, R; Walker, PR; Yacoub Maroun, C | 1 |
| Cai, HL; Huang, HQ; Huang, ZJ; Li, GP; Liu, G; Luo, Q; Wei, B | 1 |
| Clozel, T; Elemento, O; Erdem, Z; Hassler, MR; Krzywinski, M; Robinson, BD; Shariat, SF; Xylinas, E; Zhuang, D | 1 |
| Chen, H; Jin, X; Jin, Z; Kim, KY; Roh, MR; Zheng, Z | 1 |
| Liu, H; Sun, Z; Tang, B; Tong, J; Zhang, L; Zhang, X; Zheng, C; Zhou, H; Zhu, X | 1 |
| Cheng, XB; Hirata, K; Koga, A; Kohi, S; Sato, N | 1 |
| Baer, MR; Bloomfield, CD; Blum, W; DeAngelo, DJ; Geyer, S; Hoke, E; Klisovic, R; Kohlschmidt, J; Kolitz, JE; Larson, RA; Marcucci, G; Mrózek, K; Powell, BL; Sanford, BL; Stock, W; Stone, RM; Uy, G; Wang, ES | 1 |
| Abel, GA; Davidoff, AJ; Gore, SD; Gross, CP; Hajime, U; Hu, X; Huntington, SF; Long, JB; Ma, X; Podoltsev, NA; Prebet, T; Wang, R; Zeidan, AM | 1 |
| Mahalingaiah, PK; Ponnusamy, L; Singh, KP | 1 |
| Cao, M; Hu, Y; Wu, H; Xue, X; Zhao, S | 1 |
| Gong, K; Jia, X; Liu, X; Shao, G; Xu, S; Yan, S; Yang, J; Zhang, C; Zhang, Z | 1 |
| Huang, X; Kong, G; Li, J; Li, Y; Liu, X; Wang, L; Wang, X; Wu, Y; Xu, H; Zhang, X; Zhang, Z; Zhu, W | 1 |
| Chang, CK; Guo, J; He, Q; Li, X; Song, LX; Su, JY; Tao, Y; Wu, D; Wu, LY; Xiao, C; Xu, F; Zhang, Z; Zhou, LY | 1 |
| Chim, CS; Li, ZH; Wang, LQ; Wong, KY | 1 |
| Aoyama, K; Choi, K; Hasegawa, N; Iseki, T; Isshiki, Y; Iwama, A; Kawajiri-Manako, C; Koide, S; Mimura, N; Muto, T; Nagao, Y; Nakaseko, C; Ohwada, C; Sakai, S; Sakaida, E; Shimizu, R; Starczynowski, DT; Takeda, Y; Takeuchi, M; Togasaki, E; Tsukamoto, S; Yokote, K | 1 |
| Li, D; Li, T; Liang, L; Liu, J; Nong, L; Qu, L; Zhang, B; Zhang, Z; Zheng, Y | 1 |
| Fan, Y; Feng, Y; Kelly, K; Li, C; Li, L; Mu, J; Oberst, M; Peng, W; Ren, G; Tao, Q; Xiang, T; Ying, Y | 1 |
| An, L; Jia, R; Li, T; Lin, S; Luo, Q; Ma, J; Nie, Q; Qiu, F; Wang, Z; Zhang, D; Zhang, L; Zhang, X | 1 |
| Eom, KS; Jeon, YW; Kim, DW; Kim, HJ; Kim, M; Kim, TM; Kim, YJ; Lee, JW; Lee, S; Lee, SE; Min, CK; Min, WS; Shin, SH; Yahng, SA; Yoon, JH | 1 |
| Bhasin, M; Burke, SD; Cavalli, RC; Cerdeira, AS; Karumanchi, SA; Kopcow, HD; Korkes, HA; Pernicone, E; Rajakumar, A; Roberts, DJ; Thadhani, RI | 1 |
| Anglard, P; Befort, K; Filliol, D; Fonteneau, M; Romieu, P; Zwiller, J | 1 |
| Chang, K; Feng, W; Hua, K; Jia, N; Li, Q; Tao, X; Wang, J; Wong, KK; Yu, Y | 1 |
| Alkema, NG; de Jong, S; Hoekman, RL; Klip, HG; Meersma, GJ; Tomar, T; van der Zee, AG; Wisman, GB | 1 |
| Byers, BL; Heninger, E; Jarrard, DF; Kircher, MR; Kosoff, D; Krueger, TE; Lang, JM; McNeel, DG; Sperger, JM; Thiede, SM; Yang, B | 1 |
| Al Ali, N; Barnard, J; Brown, F; DeZern, AE; Garcia-Manero, G; Hand, W; Komrokji, RS; Roboz, GJ; Sekeres, MA; Steensma, DP; Zeidan, AM; Zimmerman, C | 1 |
| Lu, SY; Wang, C; Wang, Z; Zhao, XH; Zhou, ZH | 1 |
| Huang, H; Huang, Z; Lin, J; Lin, X; Qiu, J; Shi, B; Wang, C; Wei, X; Wu, W; Zhang, L | 1 |
| Fang, LW; Hu, NB; Li, B; Luo, XP; Pan, LJ; Qin, TJ; Qu, SQ; Xiao, ZJ; Xu, ZF; Zhang, HL; Zhang, Y | 1 |
| Abedin, S; Platanias, LC | 1 |
| Gornicec, M; Sill, H; Stanzel, S; Wölfler, A; Zebisch, A | 1 |
| Beninati, C; Catalano, T; Teti, D; Venza, I; Venza, M; Visalli, M | 1 |
| Banelli, B; Barbagallo, C; Barbagallo, D; Di Mauro, S; Di Pietro, C; Magro, G; Maugeri, M; Purrello, F; Purrello, M; Ragusa, M; Romani, M | 1 |
| Chen, L; Gong, F; Guo, Y; Jin, J; Li, R; Ma, RZ; Niu, Y; Shi, X; Zhang, L; Zhang, X | 1 |
| Kim, MC; Kim, NY; Kim, Y | 1 |
| Cheong, JW; Chung, H; Jang, J; Kim, JS; Kim, SJ; Kim, Y; Lee, J; Min, YH; Park, H | 1 |
| Li, H; Luan, P; Peng, W; Wang, K; Xu, Y; Zhang, P; Zhuang, J | 1 |
| Cao, Q; Shi, H; Wang, X; Xue, B; Yu, L | 1 |
| Becker, H; Bissé, E; Bogatyreva, L; Claus, R; Ihorst, G; Lübbert, M; Sander, PN; Suciu, S; Wijermans, PW | 1 |
| Brock, G; Greene, RM; Mukhopadhyay, P; Pisano, MM; Rezzoug, F; Seelan, RS; Smolenkova, IA; Warner, DR | 1 |
| Greene, RM; Mukhopadhyay, P; Pisano, MM; Seelan, RS; Smolenkova, IA; Warner, DR | 1 |
| Han, ZB; Hao, J; Huang, C; Jia, Z; Jiang, W; Li, Y; Ren, H; Sun, Y; Wang, H; Wang, X; Xie, K; Yang, S; Zhao, T; Zheng, C | 1 |
| Abboud, CN; Baty, JD; Cashen, AF; DiPersio, JF; Duncavage, EJ; Fehniger, TA; Fronick, CC; Fulton, RS; Ghobadi, A; Graubert, TA; Hantel, A; Heath, SE; Jacoby, MA; Janke, MR; Khan, N; Knoebel, RW; Lee, YS; Ley, TJ; Link, DC; Luber, K; Miller, CA; O'Laughlin, M; Oh, ST; Petti, AA; Pusic, I; Romee, R; Schroeder, MA; Stock, W; Stockerl-Goldstein, KE; Sukhanova, MJ; Tandon, B; Tomasson, MH; Uy, GL; Vij, R; Walter, MJ; Wartman, LD; Welch, JS; Westervelt, P; Wilson, RK | 1 |
| Aoki, H; Harada, T; Kai, M; Kitajima, H; Maruyama, R; Nakase, H; Niinuma, T; Sasaki, Y; Sugai, T; Suzuki, H; Tokino, T; Toyota, M; Yamamoto, E | 1 |
| Chang, CK; Guo, J; He, Q; Li, X; Song, LX; Su, JY; Wu, D; Wu, LY; Xiao, C; Xu, F; Zhang, Z; Zhao, YS | 1 |
| Barat, C; Dental, C; Ouellet, M; Proust, A; Tremblay, MJ | 1 |
| Sidaway, P | 1 |
| Astolfi, A; Bertuccio, SN; Melchionda, F; Pession, A; Serravalle, S | 1 |
| Banati, RB; Kam, WW; Liu, GJ; Middleton, RJ | 1 |
| Gao, S; Hua, FL; Li, Y; Meng, YS | 1 |
| Swerev, TM; Ushmorov, A; Wirth, T | 1 |
| Arici, B; De Petro, G; Grossi, I; Portolani, N; Salvi, A | 1 |
| Du, W; Huang, JA; Lei, Z; Liu, Z; Qian, Q; Qin, H; Shen, D; Zeng, Y; Zhu, J | 1 |
| Choi, DR; Choi, Y; Chung, YJ; Goo, BK; Hur, EH; Jung, SH; Lee, JH; Moon, J | 1 |
| Abdelkarim, M; Blagitko-Dorfs, N; Bullinger, L; Döhner, K; Duyster, J; Gaidzik, VI; Hackanson, B; Hiller, JK; Lübbert, M; Schmidt-Salzmann, C; Schmoor, C; Yalcin, A | 1 |
| Kwok, TT; Tsang, TY; Yau, PL; Yeung, CL | 1 |
| Bae, H; Baek, J; Cho, Y; Kim, B; Kim, W; Ku, Y; Lee, G; Lee, Y; Rhyu, I; Ryoo, H; Seol, Y; Woo, K | 1 |
| Cashen, AF; DiPersio, JF; Duncavage, EJ; Fronick, CC; Fulton, RS; Gao, F; Jacoby, MA; Lee, YS; Ley, TJ; Link, DC; Miller, CA; O'Laughlin, M; Petti, AA; Tandon, B; Uy, GL; Walter, MJ; Wartman, LD; Welch, JS; Westervelt, P; Wilson, RK | 1 |
| Choi, YJ; Chung, CJ; Jung, JE; Kim, KH; Shin, S; Song, MJ | 1 |
| Gu, J; Huang, W; Mao, X; Wang, Y; Wang, Z; Xiao, M; Zhu, L | 1 |
| Hu, C; Jin, J; Lin, P; Lou, Y; Luo, Y; Ma, L; Mai, W; Mei, C; Meng, H; Qian, J; Qian, W; Ren, Y; Tong, H; Wei, J; Xie, L; Xu, G; Xu, W; Ye, L; Ye, X; Zhou, X | 1 |
| Dekan, S; Do, C; Gaba, A; Hsu, E; Kenner, L; Sczabolcs, M; Tycko, B; Wenzl, R; Yotova, I | 1 |
| Levine, AJ | 1 |
| Chen, YS; Chuang, PC; Huang, YH; Ko, JY; Lee, MS; Lian, WS; Sun, YC; Wang, FS; Weng, WT; Wu, SL | 1 |
| Bendinelli, P; Desiderio, MA; Maroni, P; Matteucci, E | 1 |
| Duan, Y; Han, X; Jia, Y; Liu, L; Lv, W; Ma, M; Wang, J; Wang, X; Wang, Y | 1 |
| Duan, W; Hou, X; Huang, F; Li, Y; Liu, T | 1 |
| Issa, JJ; Kropf, P; Sato, T | 1 |
| Costeas, PA; Marioli, D; Patmanidi, AL; Pierides, C; Sgourou, A; Spyridonidis, A; Stamou, P; Taraviras, S; Theofani, E; Vittoraki, A | 1 |
| Balestrieri, C; Bertoni, F; Leoni, C; Montagner, S; Monticelli, S; Polletti, S; Rinaldi, A | 1 |
| Bartolomei, MS; Bedalov, A; Carrette, LL; Dial, TO; Hasaka, T; Jadhav, A; Kesner, B; Lee, JT; Lessing, D; Maloney, DJ; Payer, B; Simeonov, A; Szanto, A; Theriault, J; Wei, C | 1 |
| Al Ali, N; Apuri, S; Komrokji, RS; Lancet, JE; List, AF; Padron, E | 1 |
| Chen, Y; Huang, J; Li, J; Li, Y; Lian, Y; Qian, S; Wu, Y; Xie, Y; Zhang, X; Zhao, H; Zhu, Y | 1 |
| Butter, R; Linnekamp, JF; Medema, JP; Spijker, R; van Laarhoven, HWM | 1 |
| Chen, M; Dasgupta, C; Hu, XQ; Huang, X; Xiao, D; Yang, S; Zhang, L | 1 |
| Hu, FH; Huang, WJ; Jen, J; Liao, SY; Lin, P; Lu, YH; Shieh, JM; Tang, YA; Wang, TW; Wang, YC; Wang, YJ; Yeh, YL | 1 |
| Amos-Landgraf, J; Bryan, JN; Esebua, M; Kumar, SR; May, TJ | 1 |
| Chen, J; Chen, SX; Huang, HT; Li, JG; Li, Q; Peng, Q; She, MR; Wei, SS; Xia, PF | 1 |
| Cho, SY; Kim, YI; Kim, YJ; Kwon, HS; Lee, HJ; Park, SW; Yang, HS | 1 |
| Chen, Z; Guan, W; Hao, S; Wang, H; Xu, H; Zhang, J | 1 |
| Artz, A; Churpek, JE; Godley, LA; Hantel, A; Khan, N; King, D; Knoebel, RW; Larson, RA; Liu, H; Odenike, O; Stock, W; Thirman, MJ | 1 |
| Bohl, SR; Bullinger, L; Claus, R; Döhner, H; Döhner, K; Dolnik, A; Gaidzik, VI; Hackanson, B; Jensen, T; Knudsen, S; Lang, KM; Lübbert, M; Paschka, P | 1 |
| Chang, CK; Guo, J; Li, X; Song, LL; Wu, D; Wu, LY; Xiao, C; Xu, F; Zhao, YS | 1 |
| Dombret, H; Gardin, C | 1 |
| Chen, Y; Huang, Z; Li, R; Li, Z; Liang, X; Lin, T; Liu, S; Ma, J; Shi, W; Tan, X; Wang, W; Ye, Z; Yu, C; Zhang, B; Zhang, H; Zhang, L; Zhang, Q; Zhao, X | 1 |
| Hu, L; Li, G; Shen, Q; Yao, Y; Zhang, X; Zhou, J | 1 |
| Chang, YW; Singh, KP | 1 |
| Li, JR; Li, SY; Sun, LL; Yang, SM; Yu, HB | 1 |
| Kim, M; Levine, LB; Li, J; Phillips, G; Roddy, JV; Walker, AR | 1 |
| Balleari, E; Bernal, T; Beyne-Rauzy, O; Bordessoule, D; Calabuig, M; Cametti, G; Campelo, MD; Cheze, S; Cony-Makhoul, P; Dreyfus, F; Fenaux, P; Fensterl, J; Ferrero, D; Gaidano, G; Germing, U; Gioia, D; Götze, K; Guerci-Bresler, A; Hamel, JF; Kaivers, J; Kelaidi, C; Komrokji, R; Kotsianidis, I; Müller-Thomas, C; Pane, F; Park, S; Ramos, F; Roboz, GJ; Rose, C; Sanna, A; Santini, V; Sanz, GF; Sapena, R; Sekeres, MA; Stamatoullas, A; Steensma, DP; Thépot, S; Toma, A; Vey, N; Wattel, E | 1 |
| Kim, EM; Manzar, GS; Zavazava, N | 1 |
| Bhalla, K; Boddu, PC; Cortes, JE; DiNardo, CD; Garcia-Manero, G; Jabbour, EJ; Jain, N; Kadia, TM; Kantarjian, HM; Konopleva, M; Ohanian, M; Pemmaraju, N; Pierce, S; Ravandi, F; Takahashi, K; Verstovsek, S; Wierda, WG | 1 |
| Chen, Q; Gu, J; Li, N; Li, S; Wang, W; Wang, X; Wang, Z; Zhao, G | 1 |
| Bosenberg, M; Micevic, G; Theodosakis, N | 1 |
| Cummings-Lorbetskie, C; Desaulniers, D; Parfett, C; Xiao, GH; Zhou, G | 1 |
| Anguita, E; Bernal, T; Bulnes, PD; Colado, E; Garay, MCG; Gil, AC; Lopez-Larrea, C; Marin, AM; Márquez-Kisinousky, L; Minguela, A; Mogorron, AV; Raneros, AB; Rodriguez, RM; Suarez-Alvarez, B; Vidal-Castiñeira, JR | 1 |
| Liu, Y; Luo, F; Tu, L; Wang, Y; Zhang, N; Zhao, M | 1 |
| Liao, A; Liu, Z; Wang, H; Wang, X | 1 |
| Ades, L; Al-Ali, H; Almeida, AM; Autzinger, EM; Bargay, J; Bonanad, S; Burgstaller, S; Costa, MJ; Deben, G; Diez-Campelo, M; Esteves, S; Falantes, JF; Fenaux, P; Garrido, A; Geissler, D; Greil, R; Itzykson, R; Krippl, P; Lang, A; Maurillo, L; Musto, P; Pedro, C; Pinto, R; Pleyer, L; Prebet, T; Ramos, F; Sekeres, MA; Shammo, J; Sperr, WR; Stauder, R; Thepot, S; Valent, P; Van De Loosdrecht, AA; Wetzel, J | 1 |
| Allen, B; Masternak, MM; Muller, MT; Pezone, A; Porcellini, A | 1 |
| Chen, X; Guo, Y; Jiang, X; Liang, L; Qi, G; Qin, M; Tang, Y; Zhong, K; Zou, X; Zou, Y | 1 |
| Chapuis, B; Chevalier, P; Doñate Puertas, R; Gadot, N; Janin, A; Julien, C; Lachuer, J; Méjat, A; Meugnier, E; Morel, E; Pirola, L; Rey, C; Rome, S; Romestaing, C; Scridon, A; Tronc, F; Valla, C | 1 |
| Golas, MM; Llamas Luceño, N; Sander, B; Yuan, J | 1 |
| Blednov, YA; Harris, RA; Mayfield, RD; Morikawa, H; Ponomarev, I; Stelly, CE | 1 |
| Bai, Y; Chang, D; Li, M; Liu, C; Lv, D; Sun, G; Zhang, X | 1 |
| Chen, P; Dong, X; Gu, L; Li, D; Shao, J; Xu, L; Yang, Y; Zhao, H | 1 |
| Guo, H; Li, XX; Lin, J; Ma, JC; Qian, J; Wen, XM; Yan, Y; Yang, L; Zhang, TJ; Zhang, W; Zhou, JD | 1 |
| Borghi, MO; Cantone, MC; Caraglia, M; Di Blasio, AM; Dicitore, A; Gaudenzi, G; Gelmini, G; Gentilini, D; Grassi, ES; Hofland, LJ; Misso, G; Pepe, D; Persani, L; Vitale, G | 1 |
| Jayaprakash, C; Radhakrishnan, R; Ray, S; Satyamoorthy, K | 1 |
| Crans, RAJ; Declerck, K; Diddens, J; Gerhäuser, C; Scherf, DB; Szarc Vel Szic, K; Vanden Berghe, W | 1 |
| Li, JJ; Liu, J; Wang, FJ; Xie, HT; Zeng, YY; Zhang, J | 1 |
| Huang, C; Wang, Q; Zhang, C; Zhao, L | 1 |
| Al-Kali, A; Begna, K; Elliott, M; Hogan, W; Litzow, M; McCullough, K; Nanah, R; Patnaik, M | 1 |
| Acun, T; Doberstein, N; Gemoll, T; Habermann, JK; Oztas, E; Ried, T; Thorns, C | 1 |
| Kurita, R; Onishi, Y; Tomita, T | 1 |
| He, PF; Lian, XY; Lin, J; Ma, JC; Qian, J; Wen, XM; Xu, ZJ; Yao, DM; Zhang, ZH; Zhou, JD | 1 |
| Borthakur, G; Cortes, J; Daver, N; Ferrajoli, A; Garcia-Manero, G; Kadia, T; Kantarjian, HM; Ohanian, M; Oran, B; Pemmaraju, N; Ragon, BK; Ravandi, F | 1 |
| Beyne-Rauzy, O; Braun, T; Chait, Y; Chretien, ML; Duchmann, M; Dumas, PY; Fenaux, P; Gruson, B; Guieze, R; Hirsch, P; Itzykson, R; Laribi, K; Legros, L; Micol, JB; Park, S; Pilorge, S; Platzbecker, U; Sahnes, L; Salanoubat, C; Sébert, M; Solary, E; Vey, N | 1 |
| Evers, BM; Kim, JT; Weiss, HL | 1 |
| Liu, P; Zhang, H; Zhou, S | 1 |
| Helleday, T; Henter, JI; Herold, N; Kutzner, J; Myrberg, IH; Olsen, TK; Paulin, CBJ; Rudd, SG; Sanjiv, K; Schaller, T | 1 |
| Jiang, Y; Jin, C; Li, M; Ouyang, Y; Tan, Z | 1 |
| Baguet, A; Demeret, C; Guenat, D; Jacquin, E; Morel, A; Mougin, C; Perrard, J; Prétet, JL | 1 |
| Chen, X; Duan, N; Li, Z; Song, T; Wang, K; Zhang, C; Zhang, Q; Zhang, W | 1 |
| Becker, PS; Buckley, SA; Chen, TL; Estey, EH; Halpern, AB; Hendrie, PC; Huebner, EM; Orlowski, KF; Othus, M; Percival, MM; Pogosova-Agadjanyan, EL; Scott, BL; Stirewalt, DL; Walter, RB | 1 |
| Leung, LK; Tan, W; Ye, L; Zhu, Z | 1 |
| Eslin, D; Glade Bender, JL; Glasser, CL; Lee, A; Marks, L; Modak, S | 1 |
| Ming, F; Sun, Q | 1 |
| Bai, M; Jiang, H; Jiang, T; Ma, Z; Sun, D; Weng, Y; Yang, X; Zheng, C | 1 |
| Li, RH; Liu, H; Wang, XP | 1 |
| Baker, K; Deeg, HJ; Festuccia, M; Gooley, TA; Sandmaier, BM; Scott, BL | 1 |
| Ji, Y; Lai, J; Li, Y; Qiao, X; Yan, P; Yin, F | 1 |
| Davidoff, AJ; Gore, SD; Hu, X; Huntington, SF; Long, JB; Ma, X; Podoltsev, NA; Wang, R; Zeidan, AM | 1 |
| Jiang, X; Li, R; Lu, Z; Sun, Y; Wang, X; Xiao, X; Xiao, Y; Xu, Q; Zhang, G | 1 |
| Hwang, JT; Jeong, JC; Kim, EJ; Lee, YK; Park, UH; Um, SJ | 1 |
| Goswami, M; Hourigan, CS; Lindblad, KE; Oetjen, KA | 1 |
| Fujita, M; Kaneda, M | 1 |
| Bai, F; Krishnadas, DK; Lucas, KG; Sundaram, K; Wang, Y | 1 |
| Fell, SM; Holmberg, J; Kogner, P; Li, S; Nyman, U; Schlisio, S; Shi, Y; Södersten, E; Surova, O; Toskas, K; Westerlund, I | 1 |
| Chen, M; Dong, L; Feng, K; Han, W; Jia, H; Li, X; Liu, L; Liu, Y; Mei, Q; Nie, J; Shi, L; Zhang, Y | 1 |
| Chen, JK; Ding, HF; Dong, Z; Fan, G; Guo, C; Huang, S; Pei, L; Shi, H; Wei, Q; Xiao, X | 1 |
| Apel, A; Arnason, J; Avigan, D; Bhargava, P; Clark, RA; Cole, L; Jain, S; Kufe, D; Kupper, TS; Leaf, RK; Nahas, M; Pyzer, A; Rosenblatt, J; Stroopinsky, D; Washington, A | 1 |
| Chen, K; Deng, M; Guo, X; Jiang, Z; Li, P; Shi, P; Xu, B; Zha, J; Zhang, L | 1 |
| D'Haese, PC; Godderis, L; Moonen, L; Poels, K; Vervaet, BA | 1 |
| Iizasa, H; Nakamura, M; Nishikawa, J; Saito, M; Sakai, K; Sakaida, I; Sasaki, S; Shimokuri, K; Suehiro, Y; Yamasaki, T; Yanagihara, M; Yoshiyama, H | 1 |
| Gore, SD; Komrokji, RS; Sekeres, MA; Stahl, M; Steensma, DP; Zeidan, AM | 1 |
| Abdelkarim, M; Becker, H; Bullinger, L; Claus, R; Döhner, K; Duyster, J; Gaidzik, VI; Hackanson, B; Kovarbasic, M; Lübbert, M; Pahl, HL; Schmidts, A; Wäsch, R; Wehrle, J; Yalcin, A | 1 |
| Nakagawa, H; Nobeyama, Y | 1 |
| Chan, GC; Chim, CS; Li, Z; Wong, KY | 1 |
| Ai, H; Chen, L; Mi, RH; Song, YP; Wang, P; Wei, XD; Yin, QS; Yuan, FF | 1 |
| Kaul, SC; Putri, JF; Sakamoto, K; Wadhwa, R; Widodo, N | 1 |
| Bian, E; Guo, Z; Li, G; Ma, CC; Wan, J; Zhao, B | 1 |
| Bai, G; Bao, Y; Chu, J; Eli, M; Wen, H | 1 |
| Binder, G; Broder, MS; Chang, E; Cogle, CR; McGuire, M; Papoyan, E; Reddy, SR | 1 |
| Cheong, JW; Kim, H; Kim, HJ; Kim, MK; Kim, YJ; Lee, GW; Lee, HS; Lee, JH; Lee, WS; Lim, SN; Sohn, SK; Yoon, SS | 1 |
| Boddu, P; Borthakur, G; Cortes, J; Daver, N; Garcia-Manero, G; Jabbour, E; Kadia, TM; Kantarjian, H; Pemmaraju, N; Pierce, S; Ravandi, F | 1 |
| Burns, KE; Finlay, G; Helsby, NA; Shepherd, P; Tingle, MD | 1 |
| Feng, S; Gao, J; Tong, H; Wen, S; Zhang, L; Zhou, H | 1 |
| Ambati, CR; Berg, S; Bhowmik, SK; Coarfa, C; Degener, S; Donepudi, SR; El-Zein, R; Gödde, D; Gu, F; Jin, F; Kaipparettu, BA; Karanam, B; Kavuri, SM; Kheradmand, F; Krishnapuram, R; Lerner, SP; Lotan, Y; Maity, S; Michailidis, G; Noldus, J; Piyarathna, DWB; Purwaha, P; Putluri, N; Putluri, V; Rajapakshe, K; Roghmann, F; Roth, S; Sreekumar, A; Störkel, S; Terris, MK; Thaiparambil, J; Vantaku, V; von Rundstedt, FC | 1 |
| Bade, R; Cui, J; Gong, K; Jia, X; Jiang, S; Liu, X; Liu, Y; Shao, G; Shi, R; Tian, X; Xie, W; Xu, W; Yan, S; Yang, J; Yang, Z; Zhang, M; Zhang, T | 1 |
| DeSimone, J; Engel, JD; Fada, S; Gordeuk, V; Gowhari, M; Hassan, J; Hsieh, M; Hsu, LL; Ibanez, V; Jacobberger, J; Krauz, L; Lavelle, D; Molokie, R; Ng, KP; Pacelli, D; Pacini, M; Phelps, M; Radivoyevitch, T; Ruiz, MA; Rump, M; Saraf, S; Saunthararajah, Y; Tisdale, JF; Woost, P | 1 |
| Arentsen-Peters, TCJM; Baruchel, A; Danen-van Oorschot, AA; de Haas, V; Fornerod, M; Larmonie, NSD; Obulkasim, A; Pieters, R; Reinhardt, D; Sonneveld, E; Trka, J; Valerio, D; van den Heuvel-Eibrink, MM; Zimmermann, M; Zwaan, CM | 1 |
| Binder, E; El Chaer, F; Emadi, A; Holtzman, N; Koka, M; Porter, NC; Rapoport, AP; Singh, ZN | 1 |
| Fu, S; Shi, H; Sun, L; Xiao, Y; Xu, K; Ye, W; Zhang, X | 1 |
| Deng, X; Hou, C; Liang, T; Wang, H; Zhu, L | 1 |
| Dodillet, H; Kreuzer, KA; Monsef, I; Skoetz, N | 1 |
| Abdollahi, M; Rahmani, S | 1 |
| Alvaro, F; Arceci, RJ; Arndt, C; Barnette, P; Boklan, J; Carpten, J; Cooper, T; Farrar, JE; Gooden, GC; Gore, L; Lee, D; Legendre, C; Liang, WS; Macy, ME; Martin, L; Meshinchi, S; Narendran, A; Pollard, J; Salhia, B; Triche, TJ; Wai, D | 1 |
| Ferrari, M; Hu, Z; Nizzero, S; Ramirez, MR; Shen, H; Shi, C; Wu, X; Zhang, G; Zhou, J | 1 |
| Cui, JK; Jiang, L; Li, Q; Luo, Y; Shi, W; Xiao, Y; You, Y; Zhong, ZD | 1 |
| Abboud, CN; Ali, AM; Cashen, AF; DiPersio, JF; Fehniger, TA; Gao, F; Ghobadi, A; Jacoby, MA; Oh, ST; Pusic, I; Romee, R; Schroeder, MA; Stockerl-Goldstein, KE; Uy, GL; Vij, R; Wartman, LD; Weisel, D; Welch, JS; Westervelt, P | 1 |
| Gao, Y; Gong, M; Kong, X; Ma, Y; Zhang, C | 1 |
| Hao, JX; Li, J; Wu, D; Zhang, M | 1 |
| Guo, R; Han, HH; Jiang, ZX; Liu, YF; Sun, H; Wang, M | 1 |
| Gabius, HJ; Gebert, J; Katzenmaier, EM; Kloor, M; Kopitz, J | 1 |
| Cao, YM; Gu, J; Ji, QH; Liao, T; Qu, N; Shi, RL; Sun, GH; Wang, Y; Wang, YJ; Wei, WJ; Wen, D; Yu, J; Zhang, L; Zhang, YS; Zhao, YX; Zhu, YX | 1 |
| Han, T; Hu, H; Jiao, F; Wang, LW; Zhuo, M | 1 |
| Cai, X; Dai, H; Ke, M; Liu, Z; Luo, H; Yan, M; Zeng, W | 1 |
| Flotho, C; Lübbert, M; Sommer, S | 1 |
| Cao, J; Chen, P; Chen, Y; He, SD; He, ZH; Liu, D; Ye, JR; Zeng, HH | 1 |
| Germing, U; Haas, R; Kobbe, G; Rautenberg, C; Schroeder, T | 1 |
| Chen, GD; Fan, GY; Li, ZG; Qian, DY; Wu, YL; You, KL | 1 |
| Bornhäuser, M; Bug, G; Germing, U; Geyh, S; Haas, R; Hopfer, O; Klein, S; Kobbe, G; Kondakci, M; Krüger, W; Nachtkamp, K; Platzbecker, U; Rautenberg, C; Schroeder, T; Steinmann, J | 1 |
| Baura, VA; Biembengut, IV; Chequin, A; Costa, FF; de O Pedrosa, F; de Souza, EM; Klassen, G; Klassen, LMB; Manica, GCM; Ramos, EAS; Toledo, MB | 1 |
| Fukuda, M; Hosokawa, M; Iwakawa, S; Masuda, A; Tanaka, S; Ueda, K | 1 |
| Mach, RL; Mach-Aigner, AR; Manfrão-Netto, JHC; Mello-de-Sousa, TM; Poças-Fonseca, MJ | 1 |
| Briot, T; Clavreul, A; Lagarce, F; Lautram, N; Roger, E; Verger, A | 1 |
| Guo, H; Li, X; Lian, H; Liu, T; Qiu, X; Qu, F; Yang, R; Zhao, X | 1 |
| Imués, MA; Piferrer, F; Ribas, L; Vanezis, K | 1 |
| Dombret, H; Itzykson, R | 1 |
| Odenike, O | 1 |
| Ahn, JS; Bae, SH; Cho, YY; Chung, JS; Kim, H; Kim, HJ; Kim, SH; Kim, YS; Kwon, JH; Lee, HS; Lee, IH; Lee, JH; Lee, SM; Lee, WS; Lee, YJ; Moon, JH; Park, SW; Shin, HJ; Sohn, SK; Song, IC | 1 |
| Azarnia, N; Fenaux, P; Fruchtman, SM; Garcia-Manero, G; Kantarjian, H; Komrokji, R; Nazha, A; Platzbecker, U; Prebet, T; Roboz, G; Santini, V; Sekeres, MA; Silverman, LR; Steensma, DP; Zbyszewski, PS | 1 |
| Attwood, K; Chatta, G; Granger, V; Gueron, G; Guru, K; Hu, Q; Johnson, C; Krishnan, N; McNally, L; Morrison, C; Pili, R; Rak, M; Ramakrishnan, S; Smit, E; Wang, D; Wang, J; Woloszynska-Read, A | 1 |
| Davidoff, AJ; Gore, SD; Hu, X; Huntington, SF; Ma, X; Podoltsev, NA; Stahl, M; Wang, R; Zeidan, AM | 1 |
| Guo, XZ; Huang, YQ; Pan, JX; Wu, SX; Zhang, XY | 1 |
| Carrette, LLG; Kelleher, RJ; Lee, JT; Ma, W; Press, W; Wang, CY; Wei, C | 1 |
| Fuchs, EJ | 1 |
| Amiot, M; Chiron, D; Descamps, G; Djamai, H; Gillardin, PS; Le Gouill, S; Lucani, B; Maiga, S; Moreau, P; Moreau-Aubry, A; Pellat-Deceunynck, C; Tessoulin, B | 1 |
| da Costa, NM; de Almeida Simão, T; Gonzaga, IM; Herceg, Z; Hernandez-Vargas, H; Nicolau, MC; Nicolau-Neto, P; Ribeiro Pinto, LF; Soares Lima, SC | 1 |
| Gao, R; Kalra, RS; Kaul, SC; Kaul, Z; Li, L; Wadhwa, R; Wang, J; Yu, Y; Zhang, Z | 1 |
| Andreeff, M; Benton, CB; Boddu, P; Borthakur, G; Cortes, J; Daver, N; DiNardo, CD; Garcia-Manero, G; Jabbour, EJ; Kadia, T; Kanagal-Shamanna, R; Kantarjian, H; Konopleva, M; Patel, K; Ravandi, F; Takahashi, K | 1 |
| Müller-Tidow, C; Schlenk, RF | 1 |
| Bittencourt, H; Cooper, TM; Dalla-Pozza, L; Fraser, C; Gaynon, P; Gore, L; Jones, P; Liang, G; Malvar, J; Messinger, Y; Place, AE; Salhia, B; Sposto, R; Sun, W; Triche, T; Wayne, AS; Yang, X | 1 |
| Deng, C; Du, X; Geng, S; Lai, P; Li, M; Lu, Z; Weng, J; Wu, P | 1 |
| Anand, V; Appunni, S; Khandelwal, M; Mathur, S; Seth, A; Sharma, A; Singh, P | 1 |
| Bowden, NA; Budden, T; van der Westhuizen, A | 1 |
| DU, Y; Jing, Y; Li, PF; Liu, M; Peng, CJ; Sun, JZ; Wang, ZH; Yao, YB; Zhou, HW; Zhou, MH | 1 |
| Bachmann, M; Mühl, H; Pfeilschifter, J | 1 |
| Darwish, HA; Diab, I; Helmy, MW; Motawi, TK; Noureldin, MH | 1 |
| Greene, RM; Mukhopadhyay, P; Pisano, MM; Seelan, RS | 1 |
| Chen, X; Huo, Y; Li, Y; Sun, J; Wang, T; Wang, W; Wu, J; Xi, W; Yang, A; Zheng, G | 1 |
| Abou Hussein, AK; Al-Kali, A; Elliott, M; Gangat, N; Hashmi, S; Hogan, W; Litzow, M; Patnaik, M; Zblewski, D | 1 |
| Bao, Y; He, Z; Li, Y; Lin, B; Sun, J; Sun, M; Sun, Y; Tao, W; Wang, Z; Zhao, D | 1 |
| Futaki, S; Hamamoto, H; Hayashi, M; Hirata, A; Kondo, Y; Maemura, K; Mizuno, Y; Otsuki, Y; Shibata, MA; Tanaka, Y; Taniguchi, K; Uchiyama, K | 1 |
| Chen, W; Lu, W; Qiu, Y; Wang, Y; Xu, R; Zhang, B; Zhang, Z | 1 |
| Bohl, SR; Bullinger, L; Rücker, FG | 1 |
| Brand, OJ; Jenkins, G; Knox, AJ; Pang, L; Pasini, A | 1 |
| Castelli, A; Conconi, A; Liscia, D; Mosca-Siez, ML; Patriarca, A; Riccomagno, P | 1 |
| Abu-Irmaileh, B; Al-Majawleh, M; Hamadneh, L; Hasan, M; Jarrar, Y; Shraim, S | 1 |
| Ma, Y; Shen, J; Wang, LX | 1 |
| Chen, P; Ge, J; Qiu, J; Wang, Q; Xu, L; Xu, Z; Yu, K; Zhuang, J | 1 |
| Choi, SD; Jeon, S; Jeong, D; Kim, H; Nam, GH; Ryu, A; Sunwoo, J | 1 |
| Gu, J; Liu, H; Wang, G; Xiong, C | 1 |
| Bär, BMAM; Evers, D; Gotthardt, M; van der Velden, WJFM | 1 |
| Arellano, M; Carlisle, JW | 1 |
| Cruijsen, M; Huls, G; Joosten, I; Koenen, HJPM; Landman, S; Urbano, PCM; van Erp, PEJ; van Rijssen, E | 1 |
| Chiu, JF; Huang, N; Li, G; Lin, W; Pei, X; Tao, T | 1 |
| Han, Y; Pan, T; Qi, J; Wu, D; Yang, L; You, T; Zhu, L | 1 |
| Chen, RA; Chen, Y; Ji, YR; Li, GH; Liu, C; Liu, L; Qin, WW; Wang, WQ; Zhou, NC | 1 |
| He, X; Li, S; Pei, L; Ren, G; Sun, R; Xiang, Q; Xiang, T | 1 |
| Fan, Y; Guo, F; Song, D; Sun, Q; Wang, J; Wang, L; Zhang, D; Zhang, Q; Zhang, W | 1 |
| Choi, DH; Choi, IA; Kim, HY; Lee, CS; Lee, J | 1 |
| Kiselev, P; Ma, X; Scott, BL; Steensma, DP; Sugrue, MM; Swern, AS | 1 |
| Konopleva, M; Letai, A | 1 |
| Advani, AS; Bixby, D; DeAngelo, DJ; Erba, HP; Faderl, S; Fathi, AT; Ho, PA; Jillella, A; Kovacsovics, TJ; Lancet, JE; Levy, MY; O'Meara, MM; Ravandi, F; Stein, AS; Stein, EM; Voellinger, J; Walter, RB | 1 |
| Ahn, JS; Ahn, SY; Bae, SH; Baek, DW; Cho, YY; Choi, Y; Kim, H; Kim, HJ; Lee, HS; Lee, SM; Lee, WS; Lee, YJ; Moon, JH; Park, SW; Shin, HJ; Sohn, SK; Song, IC | 1 |
| Cao, Y; Cen, JN; Dong, WM; Gu, WY; Lin, Y; Liu, Y; Xiang, LL; Xie, XB | 1 |
| Bian, XN; Fan, LY; Hu, SY; Kong, LJ; Li, J; Ling, J; Liu, H; Lu, J; Xiao, PF; Yao, YH | 1 |
| Al-Kali, A; Alkhateeb, HB; Almasri, J; Damlaj, M; Firwana, B; Murad, MH; Sonbol, MB; Wang, Z | 1 |
| Ali, A; Montoro, J; Raza, A; Yerlikaya, A | 1 |
| Beijnen, JH; Lucas, L; Oganesian, A; Roosendaal, J; Rosing, H; Schellens, JHM | 1 |
| Hunter, AM; Padron, E; Zhang, L | 1 |
| Das, M | 1 |
| An, R; Xu, H; Xue, Y; Zeng, X; Zhang, T; Zhang, Y | 1 |
| Al Yacoub, R; Cronin, TL; Griffiths, EA; Miller, A; Ontiveros, EP; Thompson, JE; Vachhani, P; Wang, ES; Zhang, F | 1 |
| Aldoss, I; Marcucci, G; Mei, M; Pullarkat, V | 1 |
| Cashen, AF | 1 |
| Albano, F; Anelli, L; Brunetti, C; Carluccio, P; Casieri, P; Coccaro, N; Cumbo, C; Impera, L; Minervini, A; Minervini, CF; Orsini, P; Parciante, E; Ricco, A; Specchia, G; Tota, G; Zagaria, A | 1 |
| Michaelis, LC | 1 |
| Beijnen, JH; Gebretensae, A; Lin, ZJ; Lucas, L; Oganesian, A; Roosendaal, J; Rosing, H; Schellens, JHM; Wang, K | 1 |
| de Witte, T | 1 |
| Huls, G; Kicinski, M; Lübbert, M; Suciu, S; Wijermans, P | 1 |
| Ravandi, F; Short, NJ | 1 |
| Al-Kali, A; Binder, M; Carr, R; Coston, T; Finke, CM; Gangat, N; Ketterling, RP; Lasho, TL; Litzow, M; Mangaonkar, AA; Pardanani, A; Patnaik, MM; Pophali, P; Tefferi, A; Vallapureddy, R; Zblewski, D | 1 |
| Chen, YY; Guo, SQ; Li, YH; Liu, S; Shi, R | 1 |
| Duchmann, M; Itzykson, R | 1 |
| Flaishon, L; Rowe, JM; Stone, A; Yakar, RB; Zukerman, T | 1 |
| Ossenkoppele, GJ; Santini, V | 1 |
| Davidoff, AJ; Giri, S; Gore, SD; Huntington, SF; Ma, X; Podoltsev, NA; Stahl, M; Wang, R; Zeidan, AM; Zhu, W | 1 |
| Amit, O; Avivi, I; Bar-On, Y; Gurion, R; Raanani, P; Ram, R; Wolach, O; Zuckerman, T | 1 |
| Agarwal, S; Friedel, A; Gopalakrishnan, S; Hayslip, J; Kirschbrown, W; Menon, R; Mensing, S; Potluri, J; Salem, AH | 1 |
| Al Malki, MM; Aldoss, I; Ali, H; Aribi, A; Forman, SJ; Khaled, S; Marcucci, G; Mei, M; Nakamura, R; O'Donnell, M; Pillai, R; Pullarkat, V; Salhotra, A; Sanchez, JF; Sandhu, K; Snyder, D; Stein, AS; Sun, W; Yang, D | 1 |
| Estey, EH; Percival, MM | 1 |
| Gattermann, N; Germing, U; Kaivers, J; Kobbe, G; Kündgen, A; Schroeder, T | 1 |
| Hattori, N; Iida, N; Kimura, K; Kono, Y; Nakata, Y; Sako, M; Takeshima, H; Ushijima, T | 1 |
| Angenendt, L; Bohnenberger, H; Buzovetsky, O; Cinatl, J; Comoglio, F; Ferreirós, N; Geisslinger, G; Hartmann, W; Kaderali, L; Keppler, OT; Knecht, KM; Michaelis, M; Mohr, S; Oellerich, T; Rothenburger, T; Scheich, S; Schliemann, C; Schneider, C; Serve, H; Ströbel, P; Thomas, D; Wardelmann, E; Wilke, A; Xiong, Y | 1 |
| Bailly, B; Braakman, J; Caekelbergh, K; Chevalier, P; Diels, J; Dierickx, D; Doyle, M; Geers, J; Malfait, B; Meers, S; Van Hoorenbeeck, S; Van Kouwenhove, M; Vande Broek, I | 1 |
| Cook, N; Pannebakker, BA; Parker, DJ; Shuker, DM; Tauber, E | 1 |
| Ellers, J; Kraaijeveld, K; Lammers, M; Mariën, J; Visser, M | 1 |
| Kong, R; Liu, Q; Qiu, HC; Wang, Y; Wu, DH; Wu, PF; Zhang, XL | 1 |
| Kuang, P; Liu, T; Qin, Y; Wu, Y; Zeng, Q | 1 |
| Alshareef, M; Cachia, D; Das, A; Henderson, F; Infinger, L; Lindhorst, SM; Martinez Santos, JL; Patel, SJ; Vandergrift, WA; Varma, AK | 1 |
| Dvořák Tomaštíková, E; Ercan, U; Finke, A; Krečmerová, M; Niezgodzki, I; Nowicka, A; Otmar, M; Pecinka, A; Poppenberger, B; Procházková, K; Rozhon, W; Schubert, I; Tokarz, B; Zwyrtková, J | 1 |
| Qin, B; Wang, L; Yu, J; Zayas, J | 1 |
| Chen, N; Cheng, L; Dai, L; Deng, H; Dong, Z; Fang, C; Fu, J; Ji, Y; Li, J; Liu, Y; Shi, G; Su, X; Wang, H; Wang, W; Yang, Y; Yu, Y; Zhang, H; Zhang, S | 1 |
| Sanz, GF | 1 |
| Choi, CW; Choi, H; Jeon, MJ; Kang, KW; Kim, BS; Kim, DS; Lee, BH; Lee, SR; Park, Y; Sung, HJ; Yu, ES | 1 |
| Demir, AM; Demirci, U; Umit, EG | 1 |
| Contieri, B; Duarte, BKL; Lazarini, M | 1 |
| Fang, T; Shu, HE | 1 |
| Antunovic, P; Cammenga, J; Deneberg, S; Derolf, ÅR; Eriksson, A; Höglund, M; Juliusson, G; Lazarevic, V; Lehmann, S; Lorenz, F; Möllgård, L; Ölander, E; Österroos, A; Uggla, B; Wennström, L | 1 |
| Hao, L; Liu, S; Wang, L; Yang, X; Zhang, Y; Zhao, Z | 1 |
| Carraway, HE; Chandhok, NS; Griffiths, EA; Prebet, T | 1 |
| Lu, A; Ring, BZ; Su, L; Tanaka, Y; Wang, W; Wang-Renault, SF; Weng, J | 1 |
| Anauate, AC; Arasaki, CH; Arruda Cardoso Smith, M; Artigiani, R; Assumpção, PP; Burbano, RR; Calcagno, DQ; Chen, ES; Demachki, S; Geraldis, JC; Gigek, CO; Krainer, J; Leal, MF; Lourenço, LG; Pabinger, S; Payão, SLM; Rasmussen, LT; Santos, LC; Wisnieski, F | 1 |
| Azizi, A; Dutta, R; Ediriwickrema, A; Gotlib, J; Greenberg, P; Iberri, D; Majeti, R; Mannis, G; Medeiros, B; Patel, SA; Shomali, W; Zhang, T | 1 |
| Naoe, T | 1 |
| Abd Elmageed, ZY; Ali, HEA; Buttolph, T; Carraway, HE; Cen, Y; Denvir, J; Fan, J; Fandy, TE; Malkaram, SA; Primerano, DA; Shatnawi, A | 1 |
| He, H; Huan, Y; Jiang, Y; Lv, X; Qu, J; Song, X; Wang, X | 1 |
| Liu, C; Shao, Z; Sun, Y; Wu, C | 1 |
| Beutel, G; Eder, M; Gabdoulline, R; Gohring, G; Heuser, M; Koenecke, C; Krauter, J; Markel, D; Schlegelberger, B; Shahswar, R; Stadler, M; Thol, F; Trummer, A | 1 |
| Baek, DW; Cho, HJ; Kim, J; Moon, JH; Sohn, SK | 1 |
| Carraway, H; Durkin, L; Grabowski, D; Gu, X; Hamilton, B; Hasipek, M; Hong, C; Hsi, ED; Jha, BK; Maciejewski, J; Patel, B; Radivoyevitch, T; Sakre, N; Saunthararajah, Y; Schuerger, C; Sobecks, R; Tohme, R; Tomlinson, B; Zidan, AM | 1 |
| Henrique, R; Jerónimo, C; Nunes, SP; Paramio, JM | 1 |
| Breccia, M; Colafigli, G; Di Prima, A; Diverio, D; Foà, R; Latagliata, R; Mancini, M; Martelli, M; Pepe, S; Scalzulli, E | 1 |
| Anderson, JT; Baker, SD; Buelow, DR; Gibson, AA; Goodwin, EA; Hu, S; Lamba, JK; Pounds, SB; Shi, L; Sparreboom, A | 1 |
| Cazzola, M | 1 |
| Demehri, S; Ghim, SJ; Ha, T; Jenson, AB; Joh, JJ; Khanal, S; Redman, RA; Strickley, JD | 1 |
| Deeg, JH; Guan, F; Li, H; Li, X; Pang, X; Wan, T; Wang, H; Wang, Y; Wu, J; Xie, C | 1 |
| Ajib, S; Bornhäuser, M; Bug, G; Crysandt, M; Dressler, S; Haas, R; Hausmann, A; Heidenreich, D; Hirschbühl, K; Hoepting, M; Jost, E; Kaivers, J; Klein, S; Kobbe, G; Koldehoff, M; Kordelas, L; Kriege, O; Müller, LP; Rautenberg, C; Schaffrath, J; Schmid, C; Schroeder, T; Schuler, E; Wagner-Drouet, EM; Wolff, D | 1 |
| Bai, J; Lian, X; Pei, Z; Song, Q; Wang, H; Wang, J; Zhang, B | 1 |
| Gangat, N; Tefferi, A | 1 |
| He, HS; Hua, JS; Li, F; Ma, IX; Wang, XH; Wang, XQ; Wu, M; Xie, YH; Yang, RY; Ye, XJ | 1 |
| Day, RC; Hampton, MB; Hore, TA; Kardailsky, O; Magrath, HE; Mayyas, IM; Morison, IM; O'Connor, KM; Weeks, RJ | 1 |
| de Vries, R; Joosten, I; Koenen, HJPM; Landman, S; van der Horst, C; van Erp, PEJ | 1 |
| Bachmaier, G; Berg, JL; Berghold, A; Geissler, K; Hatzl, S; Hoefler, G; Klymiuk, I; Mayer, MC; Perfler, B; Pichler, M; Pregartner, G; Reinisch, A; Sill, H; Strobl, H; Tierling, S; Uhl, B; Wölfler, A; Wurm, S; Zebisch, A | 1 |
| Bonifacio, G; Cao, X; Guerin, A; Latremouille-Viau, D; Sadek, I; Shi, S; Stein, EM; Wu, EQ | 1 |
| Chen, J; Dean, R; Dever, M; Fada, S; Hill, B; Jagadeesh, D; Lindner, D; Morrison, A; Parameswaran, N; Pohlman, B; Radivoyevitch, T; Robinson, S; Saunthararajah, Y; Smith, M | 1 |
| Du, X; Hu, N; Pan, L; Qin, T; Qu, S; Wang, B; Wang, X; Xiao, Z; Xu, Z | 1 |
| DiNardo, CD | 1 |
| Banks, J; Filicko-O'Hara, J; Jeurkar, C; Kasner, M; Keiffer, G; Leiby, BE; Palmisiano, N; Wilde, L | 1 |
| Dai, H; Kang, L; Li, Z; Ma, Y; Qu, C; Song, Y; Tang, X; Wu, D; Yin, J; Yu, L; Zhu, X | 1 |
| Diamantopoulos, PT; Viniou, NA | 1 |
| Breier, A; Elefantová, K; Janotka, Ľ; Kavcová, H; Messingerová, L; Šimoničová, K; Sulová, Z | 1 |
| Huang, S; Reich, NO; Sandoval, JE; Stillson, NJ; Yung, C | 1 |
| Deng, C; Du, X; Geng, S; Huang, X; Li, M; Weng, J; Wu, P; Xu, R | 1 |
| Chen, L; Liu, W; Wang, X; Zhou, Z | 1 |
| Byun, SY; Cho, JY; Cho, R; Hong, J; Hur, K; Kim, M; Kim, Y; Koh, Y; Ku, Y; Lee, Y; Lee, YS; Liu, J; Park, HM; Park, JH; Shin, DY; Shum, D; Yoon, SS | 1 |
| H Wei, A; Kipp, D | 1 |
| Chojecki, A | 1 |
| Liu, L; Luo, J; Mu, J; Zhang, M; Zhao, B | 1 |
| Al-Kali, A; Alkhateeb, H; Begna, KH; Elliott, MA; Foran, JM; Gangat, N; Guglielmelli, P; Hanson, CA; Litzow, MR; Mannelli, F; Palmer, JM; Pardanani, A; Patnaik, MM; Szuber, N; Tefferi, A; Vannucchi, AM | 1 |
| Bewersdorf, JP; Johnson, A; Lee, J; Schiffer, M; Zeidan, AM; Zhao, J | 1 |
| Cahill, K; Odenike, O; Patel, AA; Saygin, C | 1 |
| Abbas, HA; Chen, K; Futreal, A; Garcia-Manero, G; Im, JS; Jiang, X; Little, L; Reuben, A; Reville, PK; Sinson, JC; Yang, H | 1 |
| Azenkot, T; Jonas, BA; Moskoff, BN; Othman, TA; Tenold, ME | 1 |
| Bowen, D; Cargo, C; Culligan, D; Enright, H; Green, S; Ingram, W; Jones, GL; Kell, J; Killick, SB; Krishnamurthy, P; Kulasekararaj, A; Mills, J; Mufti, G; Payne, EM; Quek, L; Raghavan, M; Stanworth, SJ; Sternberg, A; Wiseman, DH | 1 |
| Bachmaier, G; Berg, JL; Berghold, A; Hatzl, S; Herzog, SA; Mayer, MC; Perfler, B; Reinisch, A; Sill, H; Wölfler, A; Zebisch, A | 1 |
| da Costa, MJG; Ebinger, M; Frühwald, MC; Gerss, J; Hasselblatt, M; Hauser, P; Hettmer, S; Jakob, M; Johann, P; Kerl, K; Kröncke, T; Nemes, K; Reinhard, H; Schüller, U; Sehested, A; Siebert, R; Steinbügl, M; Sumerauer, D; Tüchert, S; Witt, O | 1 |
| Bae, SB; Jang, GH; Ji, YS; Kim, CK; Kim, SH; Lim, SH; Park, SK; Won, JH; Yun, J | 1 |
| Lane, SW; Straube, J; Vu, T | 1 |
| Alvarado, Y; Daver, NG; DiNardo, CD; Kadia, TM; Kantarjian, HM; Konopleva, MY; Loghavi, S; Maiti, A; Ning, J; Ohanian, M; Qiao, W; Rausch, CR; Ravandi, F; Sasaki, K; Short, NJ; Takahashi, K; Venugopal, S; Yilmaz, M | 1 |
| Hansen, E; Xu, K | 1 |
| Hosokawa, M; Iwakawa, S; Ogawara, KI; Seiki, R | 1 |
| Amirinia, F; Asadi, N; Hodjat, M; Jourshari, PB | 1 |
| Al-Abri, M; Chan, SM; Chow, S; Hall, V; Rashedi, I; Tang, K; Tremblay-Lemay, R; Tsui, H | 1 |
| Lübbert, M; Ossenkoppele, GJ; Santini, V; Wierzbowska, A | 1 |
| Bantscheff, M; Baylin, SB; Benowitz, AB; Briand, J; Burt, C; Butlin, RJ; Campobasso, N; Carpenter, C; Chapman, P; Cheng, X; Cockerill, M; Eberl, HC; Fairweather, E; Foley, SW; Fosbenner, DT; Gilmartin, AG; Goldberg, K; Grandi, P; Graves, AP; Groy, A; Handler, JL; Heerding, D; Ho, T; Horton, JR; Jaworski, JP; Jones, PA; Jordan, AM; Jurewicz, AJ; Keenan, K; Kellner, WA; Kershaw, CS; King, BW; Kruger, RG; Li, M; Luengo, JI; McCabe, MT; McHugh, CF; McNulty, DE; Mebrahtu, M; Merrihew, S; Minthorn, E; Mohammad, HP; Muliaditan, M; Ogilvie, D; Pappalardi, MB; Patel, M; Pathuri, S; Prinjha, RK; Raoof, A; Romeril, SP; Rueda, L; Rutkowska, A; Sherk, C; Steidel, M; Stowell, A; Taylor, AN; Waddell, I; Werner, T; Wiseman, AK; Wong, K; Zhang, C; Zhang, X | 1 |
| Griffiths, EA | 1 |
| Fukuda-Kurahashi, Y; Kamachi, K; Kimura, S; Kurahashi, Y; Ureshino, H; Watanabe, T; Yamamoto, Y; Yoshida-Sakai, N | 1 |
| Chen, X; Liu, F; Rong, D; Tong, X; Wang, H; Xu, L | 1 |
| Gafter-Gvili, A; Gurion, R; Raanani, P; Sherban, A; Wolach, O | 1 |
| Baer, MR; Baylin, SB; Bentzen, SM; Duong, VH; Emadi, A; Kogan, AA; Lapidus, RG; Mi, T; Niyongere, S; O'Connell, CL; Rassool, FV; Youngblood, BA | 1 |
| Brunner, AM; Fell, G; Steensma, DP | 1 |
| Bassan, R; Candoni, A; De Bellis, E; Di Bona, E; Griguolo, D; Imbergamo, S; Lazzarotto, D; Leoncin, M; Liço, A; Lucchini, E; Mauro, E; Mosna, F; Palmieri, C; Poiani, M; Pravato, S; Stulle, M; Tanasi, I; Trentin, L; Zaja, F | 1 |
| Breier, A; Janotka, Ľ; Kavcová, H; Messingerova, L; Šimoničová, K; Sulová, Z | 1 |
| Brás, NF; Carell, T; Diehl, T; Mayer, RJ; Müller, M; Ofial, AR; Roos, WP; Sommermann, CC; Traube, FR; Zipse, H | 1 |
| Chen, H; de Claro, RA; Earp, J; Ehrlich, LA; Gehrke, BJ; Kim, N; Kitabi, E; Manning, ML; Norsworthy, KJ; Okusanya, OO; Pazdur, R; Subramaniam, S; Vallejo, J | 1 |
| Brasacchio, D; DiCorleto, C; Gamgee, J; Gasiorowski, R; Gregory, GP; Gruber, E; Hawkes, EA; Hogg, SJ; Jia, W; Jong, I; Kailainathan, G; Kats, LM; Kumar, B; Levy, S; Lewis, A; Luong, Q; Maher, B; Opat, S; Polekhina, G; Reynolds, J; Sabouri-Thompson, Z; Shortt, J; Skinner, H; So, J; Uhe, M; Vervoort, S; Waltham, M; Wong, J | 1 |
| Arora, S; Bachiashvili, K; Bathini, S; Bhatia, R; Di Stasi, A; Diamond, B; Godby, K; Gupta, U; Jamy, O; Oliver, JD; Rangaraju, S; Salzman, D; Vachhani, P; Worth, S; Zainaldin, C | 1 |
| Azab, M; Bewersdorf, JP; Brandwein, JM; Demeter, J; Döhner, H; Fenaux, P; Gercheva, L; Gobbi, M; Griffiths, EA; Hao, Y; Issa, JJ; Jedrzejczak, WW; Kantarjian, HM; Keer, H; Krauter, J; Mayer, J; Min, YH; Miyazaki, Y; Novák, J; Ojeda-Uribe, M; Robak, T; Roboz, GJ; Thomas, X; Yee, KWL; Yeh, SP; Zeidan, AM | 1 |
| Chen, RR; Jin, J; Li, L; Mai, WY; Meng, HT; Qian, JJ; Sun, JN; Tong, HY; Wang, LL; Xie, WZ; Ye, XJ; Yu, WJ; Zhang, Y; Zhu, HH; Zhu, LX | 1 |
| Corman, S; Epstein, RS; Joshi, N; Kale, H; Salimi, T; Wang, WJ; Zeidan, AM | 1 |
| Chu, HT; Fung, SH; Gill, H; Kwong, YL; Lee, E; Lee, P; Li, J; Liao, JJ; Miu, KK; Tse, E; Wang, Z; Yim, R; Yip, PK; Yung, Y | 1 |
| Betts, KA; Bui, CN; Chai, X; Choi, M; Kapustyan, T; LeBlanc, TW; Ma, E; Montez, M; Song, J; Yin, L | 1 |
| Kantarjian, H; Short, NJ | 1 |
| Cao, J; Chen, Y; Hu, J; Luo, L; Yang, T; Yang, X; Ye, Y; Zheng, J; Zheng, X; Zheng, Z | 1 |
| Huang, W; Lin, C; Lin, D; Lin, L; Xie, Y | 1 |
| Al Jammal, M; Al-Juhaishi, T; Al-Kindi, SG; Arora, S; Badhwar, A; Chahine, N; Chami, T; Hajjari, J; Heisler, AC; Hoit, BD; Janus, SE; Mously, H | 1 |
| Cross, M; Platzbecker, U; Stein, A | 1 |
| Sekeres, MA; Taylor, J | 1 |
| Chang, Z; Gao, B; Gong, K; Guo, G; Han, R; Jiang, S; Liu, X; Shao, G; Sun, K; Wang, P; Xu, W; Zhang, C; Zhu, H | 1 |
| Aumer, T; Gremmelmaier, CB; Kaiser, S; Pforr, JC; Runtsch, LS; Traube, FR; Yeşiltaç, GN | 1 |
| Usuki, K | 1 |
| Kiyokawa, N; Nakasato, K; Okita, H; Ueno-Yokohata, H | 1 |
| Antin, JH; Arihara, Y; Bashey, A; Brunner, AM; Cullen, N; Cutler, C; Davids, MS; DeAngelo, DJ; Flamand, Y; Galinsky, I; Garcia, JS; Ho, V; Jonas, BA; Keng, M; Koller, P; Leonard, R; Luskin, MR; Mendez, LM; Neuberg, D; Penter, L; Pfaff, K; Ritz, J; Robertson, T; Rodig, SJ; Savell, A; Soiffer, RJ; Stone, RM; Streicher, H; Tomlinson, BK; Wadleigh, M; Winer, ES; Wolff, JO; Wu, CJ | 1 |
| Mrozowicz, J; Samiec, M; Sawicki, S; Szmatoła, T; Witarski, W; Ząbek, T | 1 |
| Feld, J; Navada, SC; Silverman, LR; Tremblay, D | 1 |
| Anderson, D; Aya-Bonilla, C; Breese, EH; Brown, PA; Cheung, LC; Chiu, SK; Chua, GA; Cruickshank, MN; Faulk, KE; Ferrari, E; Ford, J; Guest, EM; Hesselman, MC; Hughes, AM; Jafari, R; Kees, UR; Kotecha, RS; Kuek, V; Kunold, E; Lock, RB; Loh, ML; Malinge, S; Oommen, J; Post, F; Singh, S | 1 |
| Amaro, DMC; Gagelmann, N; Gjærde, LK; Loh, KP; Lombardo, J; Meckstroth, S; Mir, N; Neuendorff, NR; Roy, M; Shih, YY; Singhal, S; Thibaud, V; Zhao, Y | 1 |
| Han, Y; Jiang, L; Jin, J; Lang, W; Li, K; Lin, P; Liu, X; Lu, C; Luo, Y; Ma, L; Mei, C; Ren, Y; Shen, C; Sun, J; Tong, H; Wang, L; Wang, Y; Xu, G; Yang, H; Yang, W; Ye, L; Ye, X; Zhang, H; Zhang, Q; Zhang, X; Zhou, X; Zhu, S | 1 |
| Bang, SY; Cho, BS; Cho, SG; Eom, KS; Kim, HJ; Kim, YJ; Kwag, D; Lee, JH; Lee, JW; Lee, S; Lee, SE; Min, CK; Min, GJ; Park, S; Park, SS; Yoon, JH | 1 |
| Baumann, J; Bender, M; Lübbert, M; Spindler, M; Throm, Y | 1 |
| Aboutaleb, N; Darzi, M; Golshahi, H; Kazemnejad, S; Manshori, M; Naderi, N | 1 |
| Al-Ali, HK; Becker, H; Brugger, W; Bug, G; Crysandt, M; De Wit, M; Döhner, H; Döhner, K; Duyster, J; Ganser, A; Giagounidis, A; Götze, KS; Grishina, O; Hackanson, B; Heil, G; Heuser, M; Krauter, J; Kündgen, A; Lübbert, M; May, AM; Müller-Tidow, C; Neubauer, A; Rummelt, C; Salih, HR; Schlenk, RF; Schmoor, C; Scholl, S; Wäsch, R | 1 |
| Ciernikova, S; Fridrichova, I; Kalinkova, L; Sevcikova, A; Stevurkova, V | 1 |
| de Graaf, IJ; Heemskerk, MHM; Kroonen, JS; Kumar, S; Remst, DFG; Vertegaal, ACO; Wouters, AK | 1 |
| Al Homsi, U; Al-Zaidan, L; Assami, L; Bedhiafi, T; Dermime, S; Elashi, AA; Elkord, E; Fernandes, Q; Hydrose, SP; Inchakalody, VP; Khan, AQ; Krishnankutty, R; Maalej, KM; Merhi, M; Mestiri, S; Moustafa, D; Raza, A; Sasidharan Nair, V; Taib, N; Taleb, S; Therachiyil, L; Uddin, S; Yoosuf, ZSKM | 1 |
| Aribi, A; Ball, B; Marcucci, G; Pullarkat, V; Salhotra, A; Stein, A | 1 |
| Furukawa, K; Higashimoto, K; Kaneko, K; Ohkawa, Y; Ohmi, Y; Soejima, H; Yamamoto, Y | 1 |
| Beechinor, R; Guglielmo, J; Jonas, BA; Kneen, R; Krackeler, ML; Leija, C; Moskoff, B; Pervitsky, V; Sawicky, D | 1 |
| Borlak, J; Liu, L; Tang, Z | 1 |
| Cooper, PR; Duncan, HF; Kearney, M; Smith, AJ | 1 |
| Anders, NM; Baker, SD; Garrison, DA; Kagan, AB; Rudek, MA; Webster, JA; Yegnasubramanian, S | 1 |
| Kavoosi, F; Sanaei, M | 1 |
| Brokinkel, B; Bunk, EC; Canisius, J; Eich, HT; Grauer, OM; Paulus, W; Senner, V; Spille, DC; Stummer, W; Thomas, C; Wagner, A | 1 |
| Fu, Y; Hu, M; Ji, J; Jiang, C; Li, L; Nie, Q; Xu, H; Zhang, B; Zhou, X | 1 |
| Alnimer, Y; Boron, J; Bouligny, IM; Doyel, M; Gor, J; Grant, S; Hang, Y; Ho, T; Maher, KR; Murray, G; Patel, T; Tran, V; Venn, C; Wages, NA; Zacholski, K | 1 |
| Asada, S; Chinen, T; Enomoto, Y; Fukagawa, T; Fukuyama, T; Goyama, S; Ishikawa, T; Isobe, T; Kato, K; Kitagawa, D; Kitamura, T; Nakanishi, M; Nannya, Y; Nishiyama, A; Saitoh, K; Sato, N; Satoh, H; Shimura, R; Soga, T; Tanaka, Y; Yabushita, T; Yamamoto, K | 1 |
| Montesinos, P; Sossa-Melo, C | 1 |
252 review(s) available for azacitidine and decitabine
| Article | Year |
|---|---|
Targeting DNA methylation with small molecules: what's next?
Topics: Animals; Antineoplastic Agents; DNA Methylation; DNA Modification Methylases; Drug Discovery; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Humans; Models, Molecular; Molecular Targeted Therapy; Neoplasms; Nucleosides | 2015 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Glucocorticoid receptors in human leukemias and related diseases.
Topics: Animals; Azacitidine; Cell Line; Cell Survival; Clone Cells; Decitabine; Dexamethasone; Drug Resistance; Glucocorticoids; Humans; Leukemia; Leukemia, Lymphoid; Lymphoma; Mice; Mutation; Phenotype; Prognosis; Receptors, Glucocorticoid | 1985 |
Azapyrimidine nucleosides: metabolism and inhibitory mechanisms.
Topics: Animals; Antineoplastic Agents; Azacitidine; Azauridine; Decitabine; DNA; Gastric Mucosa; Leukemia, Experimental; Mice; Rats; RNA, Ribosomal | 1985 |
DNA methylation and drug resistance in variants of C3H10T1/2 C1 8 cells.
Topics: Animals; Azacitidine; Cell Differentiation; Cell Line; Decitabine; DNA; Drug Resistance; Embryo, Mammalian; Gene Expression Regulation; Methylation; Mice; Muscles | 1986 |
Molecular, cellular and animal pharmacology of 5-aza-2'-deoxycytidine.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cell Cycle; Cell Differentiation; Decitabine; DNA; Drug Resistance; Gene Expression Regulation; Immunosuppressive Agents; Leukemia, Experimental; Mutagens | 1985 |
Thymidine as an anticancer agent, alone or in combination. A biochemical appraisal.
Topics: Animals; Antineoplastic Agents; Azacitidine; Cytarabine; Decitabine; Drug Therapy, Combination; Fluorouracil; Humans; Methotrexate; Neoplasms; Thymidine | 1982 |
DNA methylation in friend erythroleukemia cells: the effects of chemically induced differentiation and of treatment with inhibitors of DNA methylation.
Topics: 5-Methylcytosine; Animals; Azacitidine; Cell Differentiation; Cell Line; Cytosine; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA, Neoplasm; Friend murine leukemia virus; Gene Expression Regulation; Globins; Leukemia, Erythroblastic, Acute; Methylation; Mice | 1984 |
The effects of 5-azacytidine and 5-azadeoxycytidine on chromosome structure and function: implications for methylation-associated cellular processes.
Topics: Animals; Antineoplastic Agents; Azacitidine; Carcinogens; Chromosomes; Decitabine; DNA Replication; Humans; Methylation | 1995 |
5-Aza-2'-deoxycytidine (Decitabine) and 5-azacytidine in the treatment of acute myeloid leukemias and myelodysplastic syndromes: past, present and future trends.
Topics: Acute Disease; Antineoplastic Agents; Azacitidine; Decitabine; Humans; Leukemia, Myeloid; Myelodysplastic Syndromes | 1993 |
The relationship of DNA methylation to cancer.
Topics: 5-Methylcytosine; Azacitidine; CpG Islands; Cytosine; Decitabine; DNA Methylation; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Humans; Methyltransferases; Neoplasms | 1996 |
Pharmacological approach for optimization of the dose schedule of 5-Aza-2'-deoxycytidine (Decitabine) for the therapy of leukemia.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow Diseases; Cell Differentiation; Decitabine; Deoxycytidine Kinase; DNA Methylation; DNA, Neoplasm; Drug Administration Schedule; Drug Resistance, Neoplasm; Gene Expression Regulation, Leukemic; Genes, Tumor Suppressor; Hematopoiesis; Humans; Leukemia | 1997 |
Drug-induced DNA hypermethylation: a potential mediator of acquired drug resistance during cancer chemotherapy.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Azacitidine; Cells, Cultured; Cisplatin; Decitabine; DNA Methylation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Humans; Neoplasms; Topoisomerase II Inhibitors | 1997 |
Pharmacological approach for optimization of the dose schedule of 5-Aza-2'-deoxycytidine (Decitabine) for the therapy of leukemia.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Modification Methylases; Drug Administration Schedule; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Humans; Leukemia; Leukemia, Experimental | 1997 |
Chemoprotection against cytosine nucleoside analogs using the human cytidine deaminase gene.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cytarabine; Cytidine Deaminase; Decitabine; Deoxycytidine; Drug Resistance; Gemcitabine; Humans | 1999 |
P15INK4b gene methylation and myelodysplastic syndromes.
Topics: Acute Disease; Animals; Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow; Carrier Proteins; Cell Cycle; Cell Cycle Proteins; Cell Differentiation; Cell Transformation, Neoplastic; Chromosomes, Human, Pair 9; Clinical Trials, Phase II as Topic; Cyclin-Dependent Kinase Inhibitor p15; Cyclin-Dependent Kinase Inhibitor p16; Cyclin-Dependent Kinases; Decitabine; Disease Progression; DNA Methylation; Genes, p16; Genes, Tumor Suppressor; Hematopoiesis; Humans; Leukemia, Myeloid; Mice; Myelodysplastic Syndromes; Neoplasm Proteins; Precancerous Conditions; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Transforming Growth Factor beta; Tumor Suppressor Proteins | 1999 |
DNA methylation and cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; CpG Islands; Decitabine; DNA Methylation; DNA, Neoplasm; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Humans; Mutation; Neoplasms; Oncogenes | 2000 |
DNA methylation inhibitors in the treatment of leukemias, myelodysplastic syndromes and hemoglobinopathies: clinical results and possible mechanisms of action.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials as Topic; Decitabine; DNA Methylation; DNA Modification Methylases; Hemoglobinopathies; Humans; Leukemia; Myelodysplastic Syndromes | 2000 |
Evaluation of an inhibitor of DNA methylation, 5-aza-2'-deoxycytidine, for the treatment of lung cancer and the future role of gene therapy.
Topics: Animals; Antibiotics, Antineoplastic; Azacitidine; Carcinoma, Non-Small-Cell Lung; Decitabine; DNA Methylation; DNA Modification Methylases; Evaluation Studies as Topic; Forecasting; Genetic Therapy; Humans; Lung Neoplasms | 2000 |
Pharmacologic induction of fetal hemoglobin: raising the therapeutic bar in sickle cell disease.
Topics: Anemia, Sickle Cell; Azacitidine; Butyrates; Decitabine; Fetal Hemoglobin; Humans; Hydroxyurea | 2001 |
Evolving treatment options of myelodysplastic syndromes.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Middle Aged; Myelodysplastic Syndromes; Prognosis; Risk Factors | 2001 |
Targeting hypomethylation of DNA to achieve cellular differentiation in myelodysplastic syndromes (MDS).
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cytokines; Decitabine; DNA Methylation; DNA Modification Methylases; DNA, Neoplasm; Humans; Myelodysplastic Syndromes; Myeloid Cells; Prognosis; Quality of Life | 2001 |
[Chemotherapy and radiation therapy].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Azacitidine; Busulfan; Decitabine; Harringtonines; Homoharringtonine; Humans; Hydroxyurea; Leukemia, Myeloid, Chronic-Phase | 2001 |
Novel agents for the therapy of acute leukemia.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Azacitidine; Cysteine Endopeptidases; Cytosine; Decitabine; Dioxolanes; DNA Methylation; Humans; Leukemia; Multienzyme Complexes; Neovascularization, Pathologic; Proteasome Endopeptidase Complex | 2002 |
Review of the clinical experience with 5-azacytidine and 5-aza-2'-deoxycytidine in solid tumors.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials as Topic; Decitabine; DNA Methylation; Hematologic Agents; Hematologic Diseases; Humans; Neoplasms | 2002 |
5-Azacytidine and 5-aza-2'-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Methylation; DNA Modification Methylases; DNA, Neoplasm; Enzyme Inhibitors; Humans; Neoplasms | 2002 |
Reactivating the expression of methylation silenced genes in human cancer.
Topics: Antineoplastic Agents; Azacitidine; Decitabine; DNA Methylation; DNA Modification Methylases; DNA, Neoplasm; Enzyme Inhibitors; Gene Silencing; Genes, Tumor Suppressor; Histone Deacetylase Inhibitors; Humans; Neoplasms; Promoter Regions, Genetic | 2002 |
New drugs in acute myeloid leukemia.
Topics: Acute Disease; Adenine Nucleotides; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Arabinonucleosides; Azacitidine; Bevacizumab; Boronic Acids; Bortezomib; Clofarabine; Cytosine; Decitabine; Dioxolanes; Humans; Indoles; Leukemia, Myeloid; Phthalazines; Pyrazines; Pyridines; Pyrroles; Thionucleotides | 2002 |
Decitabine: 2'-deoxy-5-azacytidine, Aza dC, DAC, dezocitidine, NSC 127716.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cell Differentiation; Clinical Trials as Topic; Decitabine; DNA Methylation; Drugs, Investigational; Gene Expression Regulation; Humans; Leukemia; Transcriptional Activation | 2003 |
Therapies to increase fetal hemoglobin in sickle cell disease.
Topics: Anemia, Sickle Cell; Azacitidine; Butyrates; Cytokines; Decitabine; Drug Therapy, Combination; Fetal Hemoglobin; Humans; Hydroxyurea | 2003 |
Decitabine: 2'-deoxy-5-azacytidine, Aza dC, DAC, dezocitidine, NSC 127716.
Topics: Anemia, Sickle Cell; Antineoplastic Agents; Azacitidine; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Decitabine; Humans; Leukemia; Lung Neoplasms; Male; Prostatic Neoplasms | 2003 |
Inhibitors of DNA methylation in the treatment of hematological malignancies and MDS.
Topics: Acetylation; Azacitidine; Cytidine; Decitabine; DNA Methylation; Hematologic Neoplasms; Histones; Humans; Leukemia, Myeloid; Myelodysplastic Syndromes | 2003 |
Decitabine.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials as Topic; Decitabine; Drug Resistance, Neoplasm; Gene Silencing; Humans; Immune System | 2003 |
Hemoglobinopathies.
Topics: Animals; Azacitidine; Butyrates; Cerebral Hemorrhage; Decitabine; Disease Models, Animal; DNA Methylation; Globins; Hemoglobinopathies; Humans; Hydroxyurea; Mice; Stroke | 2003 |
DNA methylation in haematological malignancies: the role of decitabine.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials as Topic; Decitabine; DNA Methylation; Hematologic Neoplasms; Humans; Leukemia | 2003 |
[DNA methylation and cancer--DNA methylation as a target of cancer chemotherapy].
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; CpG Islands; Decitabine; DNA Methylation; Epigenesis, Genetic; Gene Silencing; Genes, Tumor Suppressor; Humans; Mice; Neoplasms; Point Mutation; Repressor Proteins | 2003 |
Decitabine: development of a DNA methyltransferase inhibitor for hematological malignancies.
Topics: Animals; Azacitidine; Clinical Trials as Topic; Decitabine; DNA Modification Methylases; Enzyme Inhibitors; Hematologic Neoplasms; Humans | 2003 |
Genomic surgery for lung cancer.
Topics: Animals; Antineoplastic Agents; Azacitidine; Chromatin Assembly and Disassembly; Decitabine; Depsipeptides; DNA Methylation; Gene Expression Regulation, Neoplastic; Genetic Engineering; Histone Deacetylases; Humans; Lung Neoplasms; Peptides, Cyclic | 2004 |
Demethylation of DNA by decitabine in cancer chemotherapy.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cell Cycle; Cell Differentiation; Decitabine; DNA Methylation; Gene Expression Regulation, Neoplastic; Gene Silencing; Hematologic Neoplasms; Humans | 2004 |
DNA hypo-methylating agents and sickle cell disease.
Topics: Anemia, Sickle Cell; Azacitidine; Decitabine; DNA Methylation; DNA Modification Methylases; Fetal Hemoglobin; Gene Deletion; Humans; Randomized Controlled Trials as Topic | 2004 |
The role of fetal hemoglobin-enhancing agents in thalassemia.
Topics: Azacitidine; Decitabine; Fetal Hemoglobin; Humans; Thalassemia; Treatment Outcome | 2004 |
Decitabine. MGI Pharma Inc/SuperGen Inc.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials as Topic; Decitabine; DNA Modification Methylases; Drug Evaluation, Preclinical; Humans; Neoplasms | 2004 |
Decitabine dosing schedules.
Topics: Azacitidine; Decitabine; Dose-Response Relationship, Drug; Drug Administration Routes; Drug Administration Schedule; Humans; Neoplasms; Treatment Outcome | 2005 |
Decitabine in myelodysplastic syndromes.
Topics: Azacitidine; Decitabine; DNA Methylation; DNA Modification Methylases; Drug Administration Schedule; Humans; Myelodysplastic Syndromes; Prognosis; Treatment Outcome | 2005 |
Decitabine in acute myeloid leukemia.
Topics: Acute Disease; Azacitidine; Decitabine; DNA Modification Methylases; Dose-Response Relationship, Drug; Epigenesis, Genetic; Humans; Leukemia, Myeloid | 2005 |
Decitabine in chronic leukemias.
Topics: Azacitidine; Chronic Disease; Combined Modality Therapy; Decitabine; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2005 |
Pharmacology of 5-Aza-2'-deoxycytidine (decitabine).
Topics: Animals; Azacitidine; Biotransformation; Decitabine; Humans; Leukemia; Treatment Outcome | 2005 |
5-azacytidine and decitabine monotherapies of myelodysplastic disorders.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials as Topic; Decitabine; DNA Modification Methylases; Humans; MEDLINE; Myelodysplastic Syndromes; Treatment Outcome | 2005 |
The epigenome as a molecular marker and target.
Topics: Azacitidine; Biomarkers, Tumor; Cell Cycle; Cell Transformation, Neoplastic; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Methyltransferase 3B; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Neoplasms; Protein Processing, Post-Translational | 2005 |
Conventional and new treatment options for myelofibrosis with myeloid metaplasia.
Topics: Androgens; Angiogenesis Inhibitors; Antineoplastic Agents; Azacitidine; Benzamides; Chronic Disease; Decitabine; Erythropoietin; Humans; Imatinib Mesylate; Piperazines; Primary Myelofibrosis; Pyrimidines; Quinolones; Recombinant Proteins | 2005 |
Epigenetic drugs: a longstanding story.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cell Differentiation; Decitabine; DNA Methylation; Drug Design; Drug Industry; Epigenesis, Genetic; History, 20th Century; Humans; Models, Chemical; Neoplasms; Pharmacogenetics; Prognosis; Time Factors | 2005 |
Epigenetic therapy of cancer with 5-aza-2'-deoxycytidine (decitabine).
Topics: Alleles; Animals; Antimetabolites, Antineoplastic; Azacitidine; Cell Line, Tumor; Cellular Senescence; Clinical Trials as Topic; Decitabine; Disease Models, Animal; DNA; DNA Methylation; Dose-Response Relationship, Drug; Epigenesis, Genetic; Gene Silencing; Genes, Tumor Suppressor; Humans; Models, Biological; Models, Chemical; Neoplasms; Phenotype; Phosphorylation; Prodrugs; S Phase; Time Factors | 2005 |
Clinical development of decitabine as a prototype for an epigenetic drug program.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Azacitidine; Clinical Trials as Topic; Decitabine; DNA Adducts; Enzyme Inhibitors; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Gene Silencing; Histone Deacetylase Inhibitors; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Neoplasms; Remission Induction; Time Factors; Treatment Outcome | 2005 |
Epigenetic treatment of hematopoietic malignancies: in vivo targets of demethylating agents.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Azacitidine; Cell Cycle Proteins; Cyclin-Dependent Kinase Inhibitor p15; Decitabine; DNA; DNA Methylation; DNA Modification Methylases; Epigenesis, Genetic; Gene Silencing; Hematologic Neoplasms; Herpesvirus 4, Human; Humans; Leukemia, Myeloid, Acute; Membrane Proteins; Models, Genetic; Neoplasms; Time Factors; Tumor Suppressor Proteins | 2005 |
An epigenetic approach to the treatment of advanced MDS; the experience with the DNA demethylating agent 5-aza-2'-deoxycytidine (decitabine) in 177 patients.
Topics: Adult; Aged; Aged, 80 and over; Azacitidine; Decitabine; DNA Modification Methylases; Epigenesis, Genetic; Europe; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction | 2005 |
In vivo effects of decitabine in myelodysplasia and acute myeloid leukemia: review of cytogenetic and molecular studies.
Topics: Acute Disease; Animals; Antimetabolites, Antineoplastic; Azacitidine; Chromosome Aberrations; Clinical Trials as Topic; Cyclin-Dependent Kinase Inhibitor p15; Decitabine; DNA Methylation; Epigenesis, Genetic; Humans; Leukemia, Myeloid; Mice; Myelodysplastic Syndromes | 2005 |
The hematopathological basis for studying effects of the demethylating agent 5-aza-2'-deoxycytidine (decitabine) in myelodysplasia.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow Examination; Cell Differentiation; Decitabine; DNA Methylation; DNA Modification Methylases; Humans; Myelodysplastic Syndromes | 2005 |
Methylation inhibitor therapy in the treatment of myelodysplastic syndrome.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Modification Methylases; Drug Administration Schedule; Drug Monitoring; Humans; Myelodysplastic Syndromes; Patient Selection; Treatment Outcome | 2005 |
Optimizing therapy with methylation inhibitors in myelodysplastic syndromes: dose, duration, and patient selection.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Modification Methylases; Drug Administration Schedule; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Patient Selection; Treatment Outcome | 2005 |
Inhibitors of DNA methylation: beyond myelodysplastic syndromes.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Decitabine; DNA Modification Methylases; Hematologic Neoplasms; Humans; Leukemia | 2005 |
DNA methylation and gene silencing in cancer.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Methylation; DNA Modification Methylases; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Neoplasms | 2005 |
Epigenetic therapy with decitabine for myelodysplasia and leukemia.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials as Topic; Decitabine; DNA Methylation; Epigenesis, Genetic; Humans; Leukemia; Myelodysplastic Syndromes | 2005 |
New strategies in chronic myeloid leukemia.
Topics: Angiogenesis Inhibitors; Azacitidine; Benzamides; Cancer Vaccines; Clinical Trials as Topic; Decitabine; Drug Resistance, Neoplasm; Farnesyl-Diphosphate Farnesyltransferase; Female; Harringtonines; Homoharringtonine; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Time Factors | 2006 |
Strategies for achieving transfusion independence in myelodysplastic syndromes.
Topics: Anemia; Antilymphocyte Serum; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Drug Costs; Erythrocyte Transfusion; Erythropoietin; Health Services Needs and Demand; Humans; Immunosuppressive Agents; Informed Consent; Myelodysplastic Syndromes; Nurse's Role; Oncology Nursing; Patient Education as Topic; Patient Selection; Quality of Life; Thalidomide; Treatment Outcome | 2007 |
The genomics of new drugs in sickle cell disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Azacitidine; Butyrates; Decitabine; Drug Resistance; Humans; Hydroxyurea; Nitric Oxide; Pharmacogenetics; Phenotype; Poloxamer; Polymorphism, Genetic; Sulfasalazine; Toxicogenetics | 2006 |
Decitabine--bedside to bench.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Methylation; Enzyme Inhibitors; Gene Silencing; Humans; Methyltransferases; Molecular Structure; Neoplasms | 2007 |
Induction of fetal hemoglobin in the treatment of sickle cell disease.
Topics: Anemia, Sickle Cell; Azacitidine; Butyrates; Decitabine; Fetal Hemoglobin; Gene Expression Regulation; Humans; Hydroxyurea | 2006 |
The role of decitabine in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Clinical Trials, Phase III as Topic; Decitabine; DNA Methylation; Drug Therapy, Combination; Humans; Myelodysplastic Syndromes | 2007 |
[Role of epigenetics in the carcinogenesis of head and neck carcinomas - possible new targeted therapy?].
Topics: Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Carcinoma, Squamous Cell; Cell Division; Decitabine; DNA Methylation; DNA Modification Methylases; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Genes, Suppressor; Otorhinolaryngologic Neoplasms; Promoter Regions, Genetic; Targeted Gene Repair; Tumor Cells, Cultured | 2007 |
A selective activity of DNMTi decitabine on AML1ETO positive cells?
Topics: Animals; Apoptosis; Azacitidine; Cell Line, Tumor; Cell Proliferation; Core Binding Factor Alpha 2 Subunit; Cyclin-Dependent Kinase Inhibitor p15; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Enzyme Inhibitors; Epigenesis, Genetic; Gene Expression Regulation, Leukemic; Humans; Leukemia, Promyelocytic, Acute; Oncogene Proteins, Fusion; RUNX1 Translocation Partner 1 Protein | 2007 |
Targeting the epigenome for the treatment of thoracic malignancies.
Topics: Animals; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Azacitidine; Cell Transformation, Neoplastic; Chromatin; Decitabine; Depsipeptides; Drug Evaluation, Preclinical; Epigenesis, Genetic; Humans; Lung Neoplasms | 2006 |
Risk-based management of myelodysplastic syndrome.
Topics: Anemia, Sideroblastic; Antilymphocyte Serum; Azacitidine; Benzoates; Decitabine; Deferasirox; DNA Modification Methylases; Enzyme Inhibitors; Erythropoietin; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Histone Deacetylase Inhibitors; Humans; Immunosuppressive Agents; Interleukin-11; Iron Chelating Agents; Lenalidomide; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Prognosis; Risk; Stem Cell Transplantation; Thalidomide; Triazoles | 2007 |
Myelodysplasia: the good, the fair and the ugly.
Topics: Antilymphocyte Serum; Antineoplastic Agents; Azacitidine; Bone Marrow Transplantation; Clinical Trials as Topic; Decitabine; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppression Therapy; Lenalidomide; Myelodysplastic Syndromes; Thalidomide | 2007 |
Recent experience with decitabine in MDS.
Topics: Azacitidine; Decitabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Myelodysplastic Syndromes; Treatment Outcome | 2007 |
DNA methylation as a therapeutic target in cancer.
Topics: Antineoplastic Agents; Azacitidine; Base Sequence; Clinical Trials as Topic; Decitabine; DNA Methylation; Gene Expression Regulation, Neoplastic; Humans; Models, Biological; Molecular Sequence Data; Neoplasms | 2007 |
DNA methyltransferases as targets for cancer therapy.
Topics: Antineoplastic Agents; Azacitidine; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Epigenesis, Genetic; Female; Gene Expression Regulation; Gene Silencing; Hematologic Neoplasms; Humans; Leukemia, Myeloid; Male; Myelodysplastic Syndromes; Transcriptional Activation | 2007 |
Use of hypomethylating agents in myelodysplastic syndromes.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Decitabine; DNA Methylation; DNA Modification Methylases; Histone Deacetylase Inhibitors; Humans; Myelodysplastic Syndromes; Randomized Controlled Trials as Topic | 2007 |
Decitabine and its role in the treatment of hematopoietic malignancies.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Methylation; DNA Modification Methylases; Hematologic Neoplasms; Humans | 2007 |
The use of hypomethylating agents in the treatment of hematologic malignancies.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials as Topic; Decitabine; DNA Methylation; Hematologic Neoplasms; Histone Deacetylase Inhibitors; Humans; Prognosis; Promoter Regions, Genetic; Quality of Life | 2007 |
DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Clinical Trials as Topic; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Modification Methylases; Drug Therapy, Combination; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes | 2008 |
Evaluating new treatment options for MDS.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials as Topic; Decitabine; Epigenesis, Genetic; Humans; Immunologic Factors; Lenalidomide; Myelodysplastic Syndromes; Survival Analysis; Thalidomide | 2007 |
Pharmacogenomics and therapeutics of hemoglobinopathies.
Topics: Azacitidine; Butyrates; Decitabine; Fetal Hemoglobin; Genome, Human; Hemoglobinopathies; Humans; Hydroxyurea; Pharmacogenetics; Polymorphism, Single Nucleotide | 2008 |
[Myelodysplastic syndrome].
Topics: alpha Catenin; Antineoplastic Agents; Azacitidine; Cholecalciferol; Cyclosporine; Decitabine; Drug Therapy, Combination; Humans; Immunosuppressive Agents; Lenalidomide; Myelodysplastic Syndromes; Prognosis; Thalidomide; Vitamin K 2; World Health Organization | 2008 |
Current status of epigenetic treatment in myelodysplastic syndromes.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Clinical Trials as Topic; Decitabine; DNA Methylation; Epigenesis, Genetic; Histone Deacetylase Inhibitors; Humans; Myelodysplastic Syndromes; Valproic Acid | 2008 |
DNA methyltransferase inhibitors: class effect or unique agents?
Topics: Azacitidine; Decitabine; DNA Modification Methylases; Humans; Myelodysplastic Syndromes; Treatment Outcome | 2008 |
Evolution of decitabine development: accomplishments, ongoing investigations, and future strategies.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials as Topic; Decitabine; Drug Evaluation, Preclinical; History, 20th Century; History, 21st Century; Humans; Myelodysplastic Syndromes | 2008 |
Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Methylation; DNA Modification Methylases; Enzyme Activation; Enzyme Inhibitors; Epigenesis, Genetic; Humans; Neoplasms | 2008 |
Review: recent clinical trials in epigenetic therapy.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials as Topic; Cytidine; Decitabine; DNA Methylation; Epigenesis, Genetic; Genetic Therapy; Histone Deacetylases; Humans; Myelodysplastic Syndromes | 2006 |
New drugs in acute myeloid leukemia.
Topics: Adenine Nucleotides; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Azacitidine; Clofarabine; Decitabine; Enzyme Inhibitors; fms-Like Tyrosine Kinase 3; Gemtuzumab; Humans; Leukemia, Myeloid, Acute | 2008 |
[Pathogenesis of and therapeutic progress for myelodysplastic syndromes].
Topics: Azacitidine; Clinical Trials as Topic; Decitabine; Deoxycytidine; DNA Methylation; Drug Design; Gene Targeting; Humans; Iron Chelating Agents; Lenalidomide; Myelodysplastic Syndromes; Thalidomide; Tumor Necrosis Factor-alpha | 2008 |
Demethylating agents in myeloid malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Clinical Trials as Topic; Decitabine; DNA Methylation; Epigenesis, Genetic; Gene Silencing; Humans; Leukemia; Myelodysplastic Syndromes; Risk; Treatment Outcome; Valproic Acid | 2008 |
Epigenetic therapy of leukemia: An update.
Topics: Acetylation; Antineoplastic Agents; Azacitidine; Decitabine; DNA Methylation; Enzyme Inhibitors; Epigenesis, Genetic; Histone Deacetylase Inhibitors; Histone Deacetylases; Histones; Humans; Leukemia; Neoplasms | 2009 |
Haemoglobin F modulation in childhood sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Azacitidine; Butyrates; Child; Clinical Trials as Topic; Decitabine; Fetal Hemoglobin; Humans; Hydroxyurea; Stroke; Young Adult | 2009 |
Are new agents really making a difference in MDS?
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Decitabine; Humans; Lenalidomide; Myelodysplastic Syndromes; Thalidomide; Treatment Outcome | 2008 |
Management of myelodysplastic syndromes: 2008 update.
Topics: Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Clinical Trials as Topic; Decitabine; Disease-Free Survival; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Hematinics; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Iron Chelating Agents; Lenalidomide; Myelodysplastic Syndromes; Survival Analysis; Thalidomide; Treatment Outcome | 2008 |
How I treat patients with myelodysplastic syndromes.
Topics: Acute Disease; Aged; Azacitidine; Chelation Therapy; Chromosome Deletion; Chromosomes, Human, Pair 5; Clinical Trials as Topic; Decitabine; Disease Progression; DNA Methylation; Erythropoietin; Hematopoietic Cell Growth Factors; Hematopoietic Stem Cell Transplantation; Humans; Iron Chelating Agents; Lenalidomide; Leukemia, Myeloid; Myelodysplastic Syndromes; Severity of Illness Index; Thalidomide; Transplantation, Homologous | 2009 |
Optimal sequencing of treatments for patients with myelodysplastic syndromes.
Topics: Azacitidine; Decitabine; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Myelodysplastic Syndromes; Thalidomide; Transplantation, Homologous | 2009 |
Epigenetic modifications: new therapeutic targets in primary myelofibrosis.
Topics: Acetylation; Animals; Azacitidine; Cell Proliferation; Decitabine; DNA Methylation; Gene Silencing; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Histone Deacetylase Inhibitors; Humans; Immune System; Primary Myelofibrosis | 2009 |
Epigenetic DNA-(cytosine-5-carbon) modifications: 5-aza-2'-deoxycytidine and DNA-demethylation.
Topics: 5-Methylcytosine; Animals; Antimetabolites, Antineoplastic; Azacitidine; Cell Cycle; Cytosine; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA-Cytosine Methylases; Epigenesis, Genetic; Gene Expression Regulation; Humans | 2009 |
5-azacitidine prolongs overall survival in patients with myelodysplastic syndrome--a systematic review and meta-analysis.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Humans; Middle Aged; Myelodysplastic Syndromes; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome | 2010 |
Novel biospecific agents for the treatment of myelodysplastic syndromes.
Topics: Arsenic Trioxide; Arsenicals; Azacitidine; Decitabine; Etanercept; Farnesyltranstransferase; Humans; Immunoglobulin G; Lenalidomide; Myelodysplastic Syndromes; Oxides; Receptors, Tumor Necrosis Factor; Thalidomide | 2003 |
Preventing autoimmunity by regulating regulatory T-cell induction.
Topics: Animals; Autoimmunity; Azacitidine; Decitabine; Diabetes Mellitus, Type 1; DNA Modification Methylases; Humans; Lymphocyte Activation; Mice; Mice, Inbred C57BL; Mice, Inbred NOD; T-Lymphocytes, Regulatory; Treatment Outcome | 2009 |
Decitabine versus 5-azacitidine for the treatment of myelodysplastic syndrome: adjusted indirect meta-analysis.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Humans; Myelodysplastic Syndromes; Randomized Controlled Trials as Topic; Treatment Outcome | 2010 |
[Management of anemia and bone marrow hypoplasia in the treatment of myeloid leukemia].
Topics: Anemia; Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow; Bone Marrow Diseases; Clinical Trials as Topic; Decitabine; Drug Design; Erythrocyte Transfusion; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid; Platelet Transfusion; Practice Guidelines as Topic | 2009 |
[Novel therapeutic agents for myelodysplastic syndrome].
Topics: Antineoplastic Agents; Azacitidine; Clinical Trials as Topic; Decitabine; Drug Discovery; Drug Therapy, Combination; Erythropoietin; Humans; Lenalidomide; Myelodysplastic Syndromes; Randomized Controlled Trials as Topic; Remission Induction; Thalidomide | 2009 |
Treatment of MDS: something old, something new, something borrowed...
Topics: Azacitidine; Benzoates; Blood Transfusion; Bone Marrow Diseases; Chromosome Deletion; Chromosomes, Human, Pair 5; Clinical Trials as Topic; Combined Modality Therapy; Decitabine; DNA-Cytosine Methylases; Glutathione; Hematinics; Humans; Hydrazines; Immunologic Factors; Lenalidomide; Myelodysplastic Syndromes; Pyrazoles; Randomized Controlled Trials as Topic; Receptors, Fc; Recombinant Fusion Proteins; Risk; Thalidomide; Thrombopoietin | 2009 |
Decitabine in the treatment of myelodysplastic syndromes.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials as Topic; Decitabine; DNA Methylation; Gene Silencing; Genes, Tumor Suppressor; Humans; Myelodysplastic Syndromes; Treatment Outcome | 2010 |
Maintenance therapy in acute myeloid leukemia revisited: will new agents rekindle an old interest?
Topics: Azacitidine; Benzenesulfonates; Decitabine; Enzyme Inhibitors; Humans; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Prenylation; Protein-Tyrosine Kinases; Pyridines; Sorafenib; Staurosporine | 2010 |
Decitabine.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Modification Methylases; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Primary Myelofibrosis; Stem Cell Transplantation; Transplantation, Homologous | 2010 |
Epigenetic therapy in myelodysplastic syndromes.
Topics: Acid Anhydride Hydrolases; Apoptosis Regulatory Proteins; Azacitidine; Calcium-Calmodulin-Dependent Protein Kinases; Clinical Trials as Topic; Cyclin-Dependent Kinase Inhibitor p15; Death-Associated Protein Kinases; Decitabine; DNA Methylation; Epigenesis, Genetic; Humans; Meta-Analysis as Topic; Myelodysplastic Syndromes; Neoplasm Proteins | 2010 |
Epigenetic changes in the myelodysplastic syndrome.
Topics: Acetylation; Acute Disease; Azacitidine; Cell Transformation, Neoplastic; Decitabine; DNA Methylation; Epigenesis, Genetic; Histone Deacetylase Inhibitors; Histone Deacetylases; Histones; Humans; Leukemia, Myeloid; Methylation; Myelodysplastic Syndromes; Neoplasms; Protein Processing, Post-Translational | 2010 |
Practical recommendations for hypomethylating agent therapy of patients with myelodysplastic syndromes.
Topics: Aged; Antibiotic Prophylaxis; Antifungal Agents; Azacitidine; Clinical Trials as Topic; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Drug Administration Schedule; Enzyme Inhibitors; Epigenesis, Genetic; Fatigue; Gastrointestinal Diseases; Hematopoietic Stem Cell Transplantation; Humans; Infusions, Intravenous; Injections, Subcutaneous; Mucositis; Myelodysplastic Syndromes; Pancytopenia; Patient Selection | 2010 |
High-risk myelodysplastic syndromes: chemotherapy, transplantation, and beyond.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Blood Transfusion; Clinical Trials as Topic; Combined Modality Therapy; Decitabine; DNA Methylation; DNA-Cytosine Methylases; Forecasting; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Multicenter Studies as Topic; Myelodysplastic Syndromes; Prognosis; Retrospective Studies; Risk; Transplantation Conditioning | 2010 |
[Epigenetic therapy in myelodysplastic syndromes (MDS). Treatment with DNA methyltransferase inhibitors].
Topics: Azacitidine; Decitabine; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Epigenesis, Genetic; Humans; Myelodysplastic Syndromes | 2010 |
Pharmacotherapy of myelodysplastic syndromes.
Topics: Azacitidine; Decitabine; DNA Methylation; Drug Approval; Erythropoietin; Humans; Iron Chelating Agents; Lenalidomide; Myelodysplastic Syndromes; Recombinant Proteins; Thalidomide; United States; United States Food and Drug Administration | 2010 |
Methods in DNA methylation profiling.
Topics: Azacitidine; Biomarkers; Chromatography, Affinity; Decitabine; DNA; DNA Methylation; DNA Modification Methylases; Epigenomics; Gene Expression Profiling; Mass Spectrometry; Microarray Analysis; Sequence Analysis, DNA | 2009 |
Therapy with azanucleosides for myelodysplastic syndromes.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Chromosomes, Human, Pair 7; Decitabine; Deoxycytidine; Disease Progression; DNA Methylation; Drug Therapy, Combination; Humans; Myelodysplastic Syndromes; Risk Assessment; Treatment Outcome | 2010 |
DNA methylation and cancer.
Topics: Animals; Antineoplastic Agents; Azacitidine; CpG Islands; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA, Neoplasm; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Gene Silencing; Genes, Tumor Suppressor; Humans; Neoplasms | 2010 |
Pharmacologic induction of fetal hemoglobin production.
Topics: Adult; Azacitidine; Decitabine; DNA Methylation; Enzyme Inhibitors; Fetal Hemoglobin; gamma-Globins; Gene Expression Regulation, Developmental; Hemoglobinopathies; Humans | 2010 |
Novel and emerging drugs for acute myeloid leukemia: pharmacology and therapeutic activity.
Topics: Adenine Nucleotides; Animals; Arabinonucleosides; Azacitidine; Benzamides; Clofarabine; Cytarabine; Cytosine; Daunorubicin; Decitabine; Dioxolanes; Farnesyltranstransferase; Histone Deacetylase Inhibitors; Humans; Hydrazines; Imatinib Mesylate; Leukemia, Myeloid, Acute; Liposomes; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Sulfonamides; TOR Serine-Threonine Kinases; Valproic Acid; Vascular Endothelial Growth Factor Receptor-1 | 2011 |
Hypomethylating agents and other novel strategies in myelodysplastic syndromes.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Methylation; Epoetin Alfa; Erythropoietin; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Lenalidomide; Myelodysplastic Syndromes; Prognosis; Recombinant Proteins; Thalidomide; Transplantation, Homologous | 2011 |
Hypomethylating agents for urologic cancers.
Topics: Antineoplastic Agents; Azacitidine; Clinical Trials as Topic; Decitabine; DNA Methylation; Humans; Treatment Outcome; Urologic Neoplasms | 2011 |
[Progress in research on DNA methylation and laryngeal carcinoma].
Topics: Acid Anhydride Hydrolases; Animals; Antimetabolites, Antineoplastic; Azacitidine; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cyclin-Dependent Kinase Inhibitor p16; Decitabine; DNA Methylation; Genes, p16; Humans; Laryngeal Neoplasms; Neoplasm Proteins; Tumor Suppressor Proteins | 2011 |
Therapeutic epigenetics: an emerging clinical approach to hematologic malignancies.
Topics: Azacitidine; Decitabine; DNA Methylation; Epigenesis, Genetic; Hematologic Neoplasms; Histone Deacetylase Inhibitors; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | 2005 |
Pharmacokinetic evaluation of decitabine for the treatment of leukemia.
Topics: Age Factors; Aged; Animals; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Methylation; Dose-Response Relationship, Drug; Drug Delivery Systems; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | 2011 |
[Hypomethylating agents for the treatment of myelodysplastic syndromes].
Topics: Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Methylation; Epigenesis, Genetic; Humans; Mutation; Myelodysplastic Syndromes | 2011 |
[Epigenetic therapy in myelodysplastic syndromes].
Topics: Azacitidine; Decitabine; Depsipeptides; DNA Methylation; DNA Modification Methylases; Drug Design; Drug Therapy, Combination; Epigenesis, Genetic; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Molecular Targeted Therapy; Myelodysplastic Syndromes; Randomized Controlled Trials as Topic; Vorinostat | 2011 |
Treatment of higher-risk myelodysplastic syndrome.
Topics: Algorithms; Antineoplastic Agents; Azacitidine; Combined Modality Therapy; Decitabine; DNA Methylation; Drug Therapy, Combination; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Humans; Lenalidomide; Myelodysplastic Syndromes; Patient Selection; Stem Cell Transplantation; Thalidomide | 2011 |
Failure of hypomethylating agent-based therapy in myelodysplastic syndromes.
Topics: Adenine Nucleotides; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Arabinonucleosides; Azacitidine; Clofarabine; Cytosine; Decitabine; Drug Resistance; Drug Substitution; Enzyme Inhibitors; Glutathione; Glycine; Humans; Myelodysplastic Syndromes; Stem Cell Transplantation; Sulfones; Treatment Failure | 2011 |
Epigenetic drug discovery: targeting DNA methyltransferases.
Topics: Antineoplastic Agents; Azacitidine; Decitabine; DNA Methylation; DNA Modification Methylases; Drug Discovery; Enzyme Inhibitors; Epigenesis, Genetic; Humans; Neoplasms | 2012 |
[Novel therapeutics for myelodysplastic syndromes].
Topics: Azacitidine; Decitabine; DNA Methylation; Humans; Lenalidomide; Myelodysplastic Syndromes; Thalidomide | 2011 |
Will DNA methylation inhibitors work in solid tumors? A review of the clinical experience with azacitidine and decitabine in solid tumors.
Topics: Azacitidine; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Modification Methylases; Dose-Response Relationship, Drug; Epigenesis, Genetic; Histone Deacetylase Inhibitors; Humans; Immunotherapy; Molecular Structure; Neoplasms | 2010 |
Epigenomics in hematopoietic transplantation: novel treatment strategies.
Topics: Azacitidine; Decitabine; DNA (Cytosine-5-)-Methyltransferases; Epigenomics; Graft vs Host Disease; Graft vs Leukemia Effect; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Histone Deacetylase Inhibitors; Humans; Immune Tolerance; Immunologic Factors; T-Lymphocytes, Regulatory | 2011 |
Optimizing hypomethylating agents in myelodysplastic syndromes.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Decitabine; DNA Methylation; Drug Administration Schedule; Epigenesis, Genetic; Histone Deacetylase Inhibitors; Humans; Immunomodulation; Myelodysplastic Syndromes; Patient Compliance; Treatment Failure | 2012 |
[Demethylating medication in myelodysplastic syndrome].
Topics: Age Factors; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Methylation; DNA Modification Methylases; Humans; Myelodysplastic Syndromes; Treatment Outcome | 2012 |
Decitabine for acute myeloid leukemia.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials as Topic; Decitabine; DNA Methylation; Dose-Response Relationship, Drug; Drug Monitoring; Female; Humans; Infusions, Intravenous; Injections, Intravenous; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Methyltransferases; Middle Aged; Pharmacovigilance; Remission Induction; Risk Adjustment; Treatment Outcome | 2012 |
[Decitabine for treatment of myelodysplastic syndrome in an elderly patient and review of literature].
Topics: Azacitidine; Decitabine; DNA Modification Methylases; Female; Humans; Middle Aged; Myelodysplastic Syndromes | 2012 |
Utility of DNA methyltransferase inhibitors for the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Decitabine; DNA Modification Methylases; Enzyme Inhibitors; Humans; Life Expectancy; Myelodysplastic Syndromes; Treatment Outcome | 2012 |
Chronic myelomonocytic leukemia: 2012 update on diagnosis, risk stratification, and management.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Marrow Examination; Chromosome Aberrations; Clinical Trials as Topic; Combined Modality Therapy; Decitabine; Diagnosis, Differential; Disease Management; Female; Genes, Neoplasm; Humans; Leukemia, Myelomonocytic, Chronic; Leukocyte Count; Male; Risk Assessment; Stem Cell Transplantation; Transplantation, Homologous | 2012 |
Antineoplastic activity of the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine in anaplastic large cell lymphoma.
Topics: Anaplastic Lymphoma Kinase; Animals; Antineoplastic Agents; Azacitidine; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p16; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Enzyme Inhibitors; Female; Gene Expression Regulation, Neoplastic; Humans; Lymphoma, Large-Cell, Anaplastic; Mice; Receptor Protein-Tyrosine Kinases; Transcriptome; Xenograft Model Antitumor Assays | 2012 |
DNA methylation biomarkers in cancer: progress towards clinical implementation.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Biomarkers, Tumor; Decitabine; DNA Methylation; Early Detection of Cancer; Genetic Markers; Humans; Neoplasms; Promoter Regions, Genetic | 2012 |
Myelodysplastic syndromes: therapy and outlook.
Topics: Algorithms; Azacitidine; Decitabine; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Myelodysplastic Syndromes | 2012 |
[New tools and treatments in myelodysplastic syndromes].
Topics: Antimetabolites, Antineoplastic; Azacitidine; Blood Transfusion; Cytogenetics; Decitabine; Flow Cytometry; Gene Expression Profiling; Humans; Immunologic Factors; Lenalidomide; Mutation; Myelodysplastic Syndromes; Prognosis; Thalidomide | 2013 |
Current treatment of acute myeloid leukemia.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Consolidation Chemotherapy; Cytarabine; Decitabine; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Precision Medicine; Stem Cell Transplantation | 2012 |
Primary cutaneous langerhans cell sarcoma: a report of four cases and review of the literature.
Topics: Aged; Aged, 80 and over; Antigens, CD; Antimetabolites, Antineoplastic; Azacitidine; Biomarkers, Tumor; Decitabine; Humans; Immunophenotyping; Langerhans Cell Sarcoma; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasms, Multiple Primary; Skin Neoplasms | 2013 |
Clinical results with the DNA hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in patients with myelodysplastic syndromes: an update.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Decitabine; DNA Methylation; Humans; Myelodysplastic Syndromes; Prognosis; Treatment Outcome | 2012 |
The role of decitabine for the treatment of acute myeloid leukemia.
Topics: Antineoplastic Agents; Azacitidine; Decitabine; DNA Modification Methylases; Humans; Leukemia, Myeloid, Acute | 2012 |
Can hypomethylating agents provide a platform for curative therapy in myelodysplastic syndromes?
Topics: Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Hematopoietic Stem Cell Transplantation; Humans; Myelodysplastic Syndromes; Risk Factors; Transplantation, Homologous | 2012 |
Conventional chemotherapy or hypomethylating agents for older patients with acute myeloid leukaemia?
Topics: Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Combined Modality Therapy; Comorbidity; Consolidation Chemotherapy; Decitabine; DNA Methylation; DNA-Cytosine Methylases; DNA, Neoplasm; Enzyme Inhibitors; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Middle Aged; Molecular Targeted Therapy; Multicenter Studies as Topic; Neoplasm Proteins; Prognosis; Randomized Controlled Trials as Topic; Remission Induction; Survival Rate; Treatment Outcome | 2014 |
Decitabine: a review of its use in older patients with acute myeloid leukaemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Azacitidine; Clinical Trials, Phase III as Topic; Decitabine; Drug Administration Schedule; Europe; Humans; Leukemia, Myeloid, Acute; Middle Aged; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Remission Induction; Treatment Outcome | 2013 |
Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Decitabine; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Epigenesis, Genetic; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Prognosis; Remission Induction; Treatment Outcome | 2013 |
Chronic myelomonocytic leukemia: 2013 update on diagnosis, risk stratification, and management.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Decision Trees; Decitabine; Diagnosis, Differential; DNA Methylation; Humans; Leukemia, Myelomonocytic, Chronic; Leukocytosis; Monocytes; Mutation; Practice Guidelines as Topic; Prognosis | 2013 |
When is the optimal timing for allogeneic transplantation in the case of MDS patients treated with hypomethylating agents?
Topics: Adult; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Hematopoietic Stem Cell Transplantation; Humans; Male; Myelodysplastic Syndromes; Prognosis; Survival Rate; Transplantation, Homologous; Treatment Outcome | 2013 |
The role of hypomethylating agents in myelodysplastic syndrome: changing the management paradigm.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials as Topic; Decitabine; DNA Modification Methylases; Drug Therapy, Combination; Histone Deacetylase Inhibitors; Humans; Myelodysplastic Syndromes; Prognosis; Stem Cell Transplantation | 2013 |
The euphoria of hypomethylating agents in MDS and AML: is it justified?
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Cytarabine; Decitabine; DNA Methylation; Endpoint Determination; Humans; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Patient Selection; Randomized Controlled Trials as Topic; Remission Induction; Survival Analysis; Treatment Outcome | 2013 |
Key clinical observations after 5-azacytidine and decitabine treatment of myelodysplastic syndromes suggest practical solutions for better outcomes.
Topics: Azacitidine; Cell Proliferation; Chromosome Aberrations; Decitabine; Disease-Free Survival; DNA-Cytosine Methylases; Enzyme Inhibitors; Gene Expression Regulation; Humans; Myelodysplastic Syndromes; S Phase; Survival Rate; Transcription Factors | 2013 |
Novel therapeutic strategies using hypomethylating agents in the treatment of myelodysplastic syndrome.
Topics: Azacitidine; Benzamides; Decitabine; DNA Methylation; Humans; Imatinib Mesylate; Lenalidomide; Molecular Targeted Therapy; Myelodysplastic Syndromes; Piperazines; Pyrimidines; Thalidomide | 2014 |
Clinical development of demethylating agents in hematology.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials as Topic; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Methyltransferase 3A; Epigenesis, Genetic; Humans; Leukemia, Myeloid, Acute; Mutation, Missense; Myelodysplastic Syndromes | 2014 |
The role of hypomethylating agents in the treatment of elderly patients with AML.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Cell Cycle; Clinical Trials as Topic; Decitabine; DNA Methylation; Humans; Leukemia, Myeloid, Acute; Retrospective Studies | 2014 |
Decitabine.
Topics: Animals; Antineoplastic Agents; Azacitidine; Decitabine; DNA Modification Methylases; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | 2014 |
Decitabine. Acute myeloid leukaemia: no progress.
Topics: Age Factors; Aged; Animals; Antimetabolites, Antineoplastic; Azacitidine; Cytarabine; Decitabine; Humans; Leukemia, Myeloid, Acute; Patient Selection; Risk Factors; Survival Analysis; Time Factors; Treatment Outcome | 2014 |
Episensitization: therapeutic tumor resensitization by epigenetic agents: a review and reassessment.
Topics: Animals; Antineoplastic Agents; Azacitidine; Azetidines; Benzamides; Decitabine; DNA Modification Methylases; Drug Resistance, Neoplasm; Epigenesis, Genetic; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Neoplasms; Nitro Compounds; Oxidative Stress; Pyridines; Vorinostat | 2014 |
The mechanistic role of DNA methylation in myeloid leukemogenesis.
Topics: Azacitidine; Clinical Trials as Topic; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Humans; Leukemia, Myeloid; Mutation | 2014 |
-7/7q- syndrome in myeloid-lineage hematopoietic malignancies: attempts to understand this complex disease entity.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Chromosome Deletion; Chromosomes, Human, Pair 7; Decitabine; Gene Expression Regulation, Neoplastic; Genetic Association Studies; Hematologic Neoplasms; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Myeloid Cells; Prognosis | 2015 |
Comparison between decitabine and azacitidine for the treatment of myelodysplastic syndrome: a meta-analysis with 1,392 participants.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Comparative Effectiveness Research; Decitabine; Humans; Myelodysplastic Syndromes; Publication Bias; Treatment Outcome | 2015 |
Update on the pharmacotherapy for myelodysplastic syndromes.
Topics: Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials as Topic; Decitabine; DNA Modification Methylases; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Lenalidomide; Myelodysplastic Syndromes; Prognosis; Remission Induction; Risk Assessment; Thalidomide | 2014 |
Decitabine, a new star in epigenetic therapy: the clinical application and biological mechanism in solid tumors.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Biomarkers, Tumor; Clinical Trials as Topic; Decitabine; DNA Methylation; Epigenesis, Genetic; Humans; Neoplasms; Prognosis | 2014 |
Connections between TET proteins and aberrant DNA modification in cancer.
Topics: 5-Methylcytosine; Azacitidine; Cytosine; Decitabine; Dioxygenases; DNA Methylation; DNA Modification Methylases; DNA-Binding Proteins; Hematologic Neoplasms; Humans; Isocitrate Dehydrogenase; Mixed Function Oxygenases; Molecular Targeted Therapy; Mutation; Neoplasms; Proto-Oncogene Proteins; Small Molecule Libraries | 2014 |
DNA demethylation and invasive cancer: implications for therapeutics.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Methylation; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Humans; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasms | 2015 |
Rationale for combination therapy in myelofibrosis.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Biphenyl Compounds; Clinical Trials as Topic; Decitabine; Drug Therapy, Combination; Gene Expression; Hematopoietic Stem Cells; Homeodomain Proteins; Humans; Hydroxamic Acids; Indoles; Janus Kinase 2; Mutation; Nitriles; Panobinostat; Primary Myelofibrosis; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Pyrimidines; Recombinant Proteins; Serum Amyloid P-Component | 2014 |
Histone deacetylase inhibitors and colorectal cancer: what is new?
Topics: Antineoplastic Agents; Azacitidine; Colorectal Neoplasms; Combined Modality Therapy; Decitabine; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Valproic Acid; Vorinostat | 2014 |
[TET2 dysregulation in hematologic malignancies].
Topics: Azacitidine; Cytosine; Decitabine; Dioxygenases; DNA-Binding Proteins; Enzyme Inhibitors; Epigenesis, Genetic; Genetic Predisposition to Disease; Hematologic Neoplasms; Humans; Methylation; Molecular Targeted Therapy; Multigene Family; Mutation; Neoplasm Proteins; Proto-Oncogene Proteins | 2014 |
[Research progress of epigenetic drug decitabine in AML].
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cell Transformation, Neoplastic; Decitabine; DNA Methylation; Epigenesis, Genetic; Humans; Leukemia, Myeloid, Acute | 2014 |
How I treat the older patient with acute myeloid leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Clinical Trials as Topic; Cytogenetic Analysis; Decitabine; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Molecular Targeted Therapy; Precision Medicine; Prognosis; Survival Analysis; Treatment Outcome | 2015 |
Digging deep into "dirty" drugs - modulation of the methylation machinery.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials as Topic; Decitabine; DNA Methylation; Epigenesis, Genetic; Histone Code; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Transcription, Genetic | 2015 |
Finding the optimal combination therapy for the treatment of newly diagnosed AML in older patients unfit for intensive therapy.
Topics: Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Critical Care; Cytarabine; Decitabine; Female; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Male; Organophosphates; Quinazolines; Quinolones | 2015 |
Decitabine: a promising epi-immunotherapeutic agent in solid tumors.
Topics: Animals; Azacitidine; Carcinogenesis; Clinical Trials as Topic; Decitabine; DNA Methylation; DNA Modification Methylases; Humans; Immunotherapy; Neoplasms; Tumor Escape | 2015 |
More is better: combination therapies for myelodysplastic syndromes.
Topics: Antineoplastic Agents; Azacitidine; Benzamides; Clinical Trials as Topic; Decitabine; Disease Progression; Drug Therapy, Combination; Gene Expression; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Pyrimidines; Thalidomide; Valproic Acid; Vorinostat | 2015 |
The role of epigenetics in the endothelial cell shear stress response and atherosclerosis.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Azacitidine; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Methyltransferase 3A; Endothelial Cells; Epigenesis, Genetic; Hemodynamics; Homeodomain Proteins; Humans; Kruppel-Like Transcription Factors; Mechanotransduction, Cellular; Mice; RNA, Small Interfering; Stress, Mechanical | 2015 |
Epigenetic mechanisms: An emerging role in pathogenesis and its therapeutic potential in systemic sclerosis.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Biomarkers; CD27 Ligand; CD40 Antigens; Decitabine; DNA Methylation; Epigenesis, Genetic; Extracellular Matrix; Fibrosis; Histone Deacetylase Inhibitors; Histones; Humans; MicroRNAs; Protein Processing, Post-Translational; Proto-Oncogene Protein c-fli-1; Scleroderma, Systemic; Signal Transduction | 2015 |
Role of epigenetic reprogramming in hematopoietic stem cell function.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cell Proliferation; Cellular Reprogramming; Chromatin; Cytokines; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Epigenesis, Genetic; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Hydroxamic Acids; Lithium Chloride; Valproic Acid | 2015 |
Managing patients with higher-risk myelodysplastic syndrome with stable disease on hypomethylating agents.
Topics: Antineoplastic Agents; Azacitidine; Decitabine; Disease Management; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Humans; Molecular Targeted Therapy; Myelodysplastic Syndromes; Risk Assessment; Treatment Outcome | 2015 |
New therapeutic approaches in myelodysplastic syndromes: Hypomethylating agents and lenalidomide.
Topics: Angiogenesis Inhibitors; Animals; Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials, Phase III as Topic; Decitabine; Humans; Lenalidomide; Myelodysplastic Syndromes; Randomized Controlled Trials as Topic; Thalidomide; Translational Research, Biomedical | 2015 |
Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow; Decitabine; Disease Management; Disease Progression; Hematopoietic Stem Cell Transplantation; Humans; Intercellular Signaling Peptides and Proteins; Karyotype; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Research Design; Thalidomide; Transplantation, Homologous | 2015 |
D-CAG (decitabine followed by cytarabine, aclarubicin, and G-CSF) for relapsed acute myeloid leukemia after hematopoietic cell transplantation.
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Combined Modality Therapy; Cytarabine; Decitabine; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Young Adult | 2016 |
Effect of Decitabine Combined with Unrelated Cord Blood Transplantation in an Adult Patient with -7/EVI1+ Acute Myeloid Leukemia: a Case Report and Literature Review.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Chromosome Deletion; Chromosomes, Human, Pair 7; Decitabine; DNA-Binding Proteins; Fetal Blood; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; MDS1 and EVI1 Complex Locus Protein; Proto-Oncogenes; Transcription Factors; Transplantation, Homologous; Treatment Outcome; Young Adult | 2015 |
[Research Advances on Pathogenesis of Myelodysplastic Syndrome].
Topics: Azacitidine; Bone Marrow; Cytokines; Decitabine; Hematopoietic Stem Cells; Humans; Immunophenotyping; Myelodysplastic Syndromes; Stromal Cells | 2015 |
Myelodysplastic syndromes: Contemporary review and how we treat.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Disease-Free Survival; Humans; Myelodysplastic Syndromes; Stem Cell Transplantation | 2016 |
The clinical value of aberrant epigenetic changes of DNA damage repair genes in human cancer.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Biomarkers, Tumor; Carcinogenesis; CpG Islands; Decitabine; DNA Damage; DNA Methylation; DNA Modification Methylases; DNA Repair; DNA Repair Enzymes; Drug Resistance, Neoplasm; Epigenesis, Genetic; Fluorouracil; Humans; Molecular Targeted Therapy; Neoplasms; Prognosis; Promoter Regions, Genetic; Tumor Suppressor Proteins | 2016 |
Targeting epigenetic pathways in acute myeloid leukemia and myelodysplastic syndrome: a systematic review of hypomethylating agents trials.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Methylation; Epigenesis, Genetic; Female; Humans; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Prognosis; Randomized Controlled Trials as Topic; Survival Rate; Treatment Outcome | 2016 |
Epimutational profile of hematologic malignancies as attractive target for new epigenetic therapies.
Topics: Acetylation; Antineoplastic Agents; Azacitidine; Decitabine; DNA Methylation; Epigenesis, Genetic; Female; Hematologic Neoplasms; Histones; Humans; Lymphoma, T-Cell, Cutaneous; Male; Myelodysplastic Syndromes; Protein Domains | 2016 |
A clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancers.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials as Topic; Decitabine; DNA Methylation; Drug Resistance, Neoplasm; Epigenesis, Genetic; Hematologic Neoplasms; Humans; Treatment Outcome | 2016 |
Macrophage polarization in response to epigenetic modifiers during infection and inflammation.
Topics: Animals; Azacitidine; Cardiovascular Diseases; Decitabine; Drug Therapy, Combination; Epigenesis, Genetic; Histone Deacetylase Inhibitors; Humans; Infections; Macrophages; Wounds and Injuries | 2017 |
The p53 protein plays a central role in the mechanism of action of epigentic drugs that alter the methylation of cytosine residues in DNA.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Cell Death; Cytosine; Decitabine; DNA Methylation; DNA, Neoplasm; Drug Resistance, Neoplasm; Epigenesis, Genetic; Humans; Mutation; Neoplasms; Tumor Suppressor Protein p53 | 2017 |
DNA Hypomethylating Drugs in Cancer Therapy.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Clinical Trials as Topic; Decitabine; DNA Demethylation; Humans; Neoplasms; Tumor Microenvironment | 2017 |
Clinical and biological effects of demethylating agents on solid tumours - A systematic review.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cytidine; Decitabine; DNA Methylation; Humans; Hydralazine; Immune System; Methylation; Neoplasms; Procaine; Treatment Outcome | 2017 |
Hypomethylating Agents as a Therapy for AML.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Methylation; Drug Therapy, Combination; Histone Deacetylase Inhibitors; Humans; Leukemia, Myeloid, Acute | 2017 |
Aberrant DNA methylation in melanoma: biomarker and therapeutic opportunities.
Topics: Azacitidine; Biomarkers, Tumor; Decitabine; DNA Methylation; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Humans; Melanoma; MicroRNAs; Prognosis | 2017 |
Promoter methylation of MGMT in oral carcinoma: A population-based study and meta-analysis.
Topics: Azacitidine; Biomarkers, Tumor; Carcinoma, Squamous Cell; Case-Control Studies; Cell Line, Tumor; Decitabine; DNA Methylation; Gene Expression Regulation, Neoplastic; Humans; India; Mouth Neoplasms; O(6)-Methylguanine-DNA Methyltransferase; Polymerase Chain Reaction; Promoter Regions, Genetic; Sensitivity and Specificity | 2017 |
Efficacy and safety of decitabine in treatment of elderly patients with acute myeloid leukemia: A systematic review and meta-analysis.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Humans; Leukemia, Myeloid, Acute; Male | 2017 |
Immunological effects of hypomethylating agents.
Topics: Animals; Antineoplastic Agents; Azacitidine; Biomarkers; Decitabine; Dendritic Cells; DNA Methylation; Epigenesis, Genetic; Gene Expression Regulation; Humans; Immunomodulation; Killer Cells, Natural; Leukemia, Myeloid, Acute; Mutation; Myelodysplastic Syndromes; T-Lymphocytes | 2017 |
The Role of Epigenetic Regulation in Epstein-Barr Virus-Associated Gastric Cancer.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Core Binding Factor Alpha 3 Subunit; CpG Islands; Decitabine; DNA Methylation; DNA, Viral; Epigenesis, Genetic; Epstein-Barr Virus Infections; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Viral; Herpesvirus 4, Human; Humans; MicroRNAs; RNA, Viral; Stomach Neoplasms; Tumor Protein p73 | 2017 |
A call for action: Increasing enrollment of untreated patients with higher-risk myelodysplastic syndromes in first-line clinical trials.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials as Topic; Decitabine; Humans; Myelodysplastic Syndromes; Patient Selection; Reproducibility of Results; Survival Analysis; Treatment Failure | 2017 |
Thrombopoietin mimetics for patients with myelodysplastic syndromes.
Topics: Adult; Azacitidine; Benzoates; Blood Transfusion; Decitabine; Female; Hemorrhage; Humans; Hydrazines; Lenalidomide; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Pyrazoles; Quality of Life; Randomized Controlled Trials as Topic; Receptors, Fc; Recombinant Fusion Proteins; Thalidomide; Thrombocytopenia; Thrombopoietin | 2017 |
Novel treatment opportunities for sulfur mustard-related cancers: genetic and epigenetic perspectives.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cancer Vaccines; Carcinogens; Chemical Warfare Agents; Decitabine; Epigenesis, Genetic; Genetic Therapy; Humans; Hydroxamic Acids; Mustard Gas; Neoplasms; Oncolytic Virotherapy; Vorinostat | 2017 |
DNA-hypomethylating agents as epigenetic therapy before and after allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and juvenile myelomonocytic leukemia.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Combined Modality Therapy; Decitabine; DNA Methylation; Epigenesis, Genetic; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myelomonocytic, Juvenile; Myelodysplastic Syndromes | 2018 |
Hypomethylating agents for treatment and prevention of relapse after allogeneic blood stem cell transplantation.
Topics: Allografts; Azacitidine; Decitabine; Drug Administration Schedule; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Recurrence; Retrospective Studies; Salvage Therapy; Secondary Prevention; Stem Cell Transplantation | 2018 |
How and when to decide between epigenetic therapy and chemotherapy in patients with AML.
Topics: Azacitidine; Chromosome Aberrations; Decision Making; Decitabine; Epigenesis, Genetic; Humans; Leukemia, Myeloid, Acute | 2017 |
Incorporating novel approaches in the management of MDS beyond conventional hypomethylating agents.
Topics: Allografts; Azacitidine; Decitabine; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Humans; Myelodysplastic Syndromes; Stem Cell Transplantation | 2017 |
Effects of 5-Aza-2'-deoxycytidine (decitabine) on gene expression.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Methylation; Gene Expression; Humans | 2018 |
Epigenetic therapy: azacytidine and decitabine in acute myeloid leukemia.
Topics: Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Decitabine; Epigenesis, Genetic; Gene Expression Regulation, Leukemic; Humans; Leukemia, Myeloid, Acute; Sulfonamides | 2018 |
How I treat older patients with acute myeloid leukemia.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Chromosome Aberrations; Cytarabine; Decitabine; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Hematopoietic Stem Cell Transplantation; Histone Deacetylase Inhibitors; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Prognosis; Remission Induction; Survival Rate; Transplantation, Homologous | 2018 |
Addition of histone deacetylase inhibitors does not improve prognosis in patients with myelodysplastic syndrome and acute myeloid leukemia compared with hypomethylating agents alone: A systematic review and meta-analysis of seven prospective cohort studie
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cohort Studies; Decitabine; Histone Deacetylase Inhibitors; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Prognosis; Prospective Studies; Treatment Outcome | 2018 |
BCL-2 inhibition in AML: an unexpected bonus?
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Decitabine; Humans; Leukemia, Myeloid, Acute; Proto-Oncogene Proteins c-bcl-2; Sulfonamides | 2018 |
A systematic review and network meta-analysis comparing azacitidine and decitabine for the treatment of myelodysplastic syndrome.
Topics: Azacitidine; Blood Transfusion; Decitabine; Humans; Mortality; Myelodysplastic Syndromes; Network Meta-Analysis; Quality of Life | 2018 |
Improving Treatment for Myelodysplastic Syndromes Patients.
Topics: Aging; Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Enzyme Inhibitors; Humans; Lenalidomide; Myelodysplastic Syndromes; Stem Cell Transplantation; Transplantation, Homologous | 2018 |
Current Management and Recent Advances in the Treatment of Chronic Myelomonocytic Leukemia.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Leukemia, Myelomonocytic, Chronic; Transplantation, Homologous | 2018 |
Hypomethylating agents in combination with venetoclax for acute myeloid leukemia: Update on clinical trial data and practical considerations for use.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials as Topic; Decitabine; Drug Administration Schedule; Drug Synergism; Humans; Leukemia, Myeloid, Acute; Practice Guidelines as Topic; Remission Induction; Sulfonamides; Survival Analysis; Treatment Outcome | 2019 |
Clinical update on hypomethylating agents.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Clinical Trials as Topic; Decitabine; DNA Methylation; Drug Administration Schedule; Drug Combinations; Gene Expression Regulation, Leukemic; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Uridine | 2019 |
Efficacy outcomes in the treatment of older or medically unfit patients with acute myeloid leukaemia: A systematic review and meta-analysis.
Topics: Age Factors; Aged; Antimetabolites, Antineoplastic; Azacitidine; Cytarabine; Decitabine; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Survival Analysis; Treatment Outcome | 2019 |
Hypomethylating agents in the treatment of acute myeloid leukemia: A guide to optimal use.
Topics: Azacitidine; Decitabine; DNA Methylation; Humans; Leukemia, Myeloid, Acute | 2019 |
Current treatment strategies for measurable residual disease in patients with acute myeloid leukemia.
Topics: Aminopyridines; Aniline Compounds; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Immunological; Azacitidine; Cytogenetic Analysis; Decitabine; Enzyme Inhibitors; Flow Cytometry; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Immunologic Factors; In Situ Hybridization, Fluorescence; Lenalidomide; Leukemia, Myeloid, Acute; Molecular Diagnostic Techniques; Neoplasm, Residual; Nivolumab; para-Aminobenzoates; Protein Kinase Inhibitors; Pyrazines; Pyrrolidines; Recombinant Fusion Proteins; Remission Induction; Transplantation, Homologous; Triazines; Triazoles | 2019 |
Novel therapies in low- and high-risk myelodysplastic syndrome.
Topics: Activin Receptors, Type II; Anemia; Antineoplastic Agents; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Decitabine; Erythrocyte Transfusion; Hematinics; Humans; Immunoglobulin Fc Fragments; Iron Chelating Agents; Lenalidomide; Myelodysplastic Syndromes; Oligonucleotides; Prognosis; Recombinant Fusion Proteins; Risk Assessment; Stem Cell Transplantation; Sulfonamides; Thalidomide; Thrombopoietin; Transplantation, Homologous | 2019 |
Hypomethylating agents for patients with myelodysplastic syndromes prior to hematopoietic stem cell transplantation: a systematic review and meta-analysis.
Topics: Allografts; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Disease-Free Survival; DNA Methylation; Hematopoietic Stem Cell Transplantation; Humans; Myelodysplastic Syndromes; Premedication; Survival Analysis; Treatment Outcome | 2019 |
Does early diagnosis and treatment of myelodysplastic syndromes make a difference?
Topics: Allografts; Azacitidine; Decitabine; Early Diagnosis; Hematinics; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Myelodysplastic Syndromes; Risk Factors | 2019 |
In MDS, is higher risk higher reward?
Topics: Aged; Allografts; Azacitidine; Clinical Trials as Topic; Decitabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Myelodysplastic Syndromes; Translational Research, Biomedical | 2019 |
Updates on DNA methylation modifiers in acute myeloid leukemia.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials as Topic; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA, Neoplasm; Enzyme Inhibitors; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Meta-Analysis as Topic; Molecular Targeted Therapy; Multicenter Studies as Topic; Neoplasm Proteins; Sulfonamides; Treatment Outcome | 2020 |
Advances in non-intensive chemotherapy treatment options for adults diagnosed with acute myeloid leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Benzimidazoles; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Decitabine; Gemtuzumab; Glycine; Humans; Leukemia, Myeloid, Acute; Male; Molecular Targeted Therapy; Phenylurea Compounds; Precision Medicine; Pyridines; Recurrence; Remission Induction; Staurosporine; Sulfonamides | 2020 |
＜Editors' Choice＞ How to improve outcomes of elderly patients with acute myeloid leukemia: era of excitement.
Topics: Aged; Aged, 80 and over; Aminopyridines; Aniline Compounds; Antineoplastic Agents; Arsenic Trioxide; Azacitidine; Benzimidazoles; Bridged Bicyclo Compounds, Heterocyclic; Decitabine; fms-Like Tyrosine Kinase 3; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Phenylurea Compounds; Precision Medicine; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Smoothened Receptor; Staurosporine; Sulfonamides; Survival Rate; Tretinoin; Triazines | 2020 |
Hypomethylating agent-based post-transplant strategies to maximize the outcome of high-risk acute myeloid leukemia after allogeneic stem cell transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Combined Modality Therapy; Decitabine; DNA Methylation; fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Postoperative Care; Transplantation, Homologous; Treatment Outcome | 2020 |
DNA Methylation as a Therapeutic Target for Bladder Cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Cell Line, Tumor; Decitabine; DNA Methylation; Epigenesis, Genetic; Humans; Urinary Bladder Neoplasms | 2020 |
Myelodysplastic Syndromes.
Topics: Azacitidine; Decitabine; Enzyme Inhibitors; Erythrocyte Transfusion; Genetic Predisposition to Disease; Humans; Leukemia, Myeloid, Acute; Mutation; Myelodysplastic Syndromes; Stem Cell Transplantation; Transplantation, Homologous; Watchful Waiting | 2020 |
Venetoclax-based chemotherapy in acute and chronic myeloid neoplasms: literature survey and practice points.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials, Phase III as Topic; Cytarabine; Decitabine; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Randomized Controlled Trials as Topic; Sulfonamides | 2020 |
Immune responses to azacytidine in animal models of inflammatory disorders: a systematic review.
Topics: Animals; Azacitidine; Decitabine; Immunity; Models, Animal; T-Lymphocytes, Regulatory | 2021 |
Factors affecting response to 5-azacytidine and prognosis of myelodysplastic syndrome. Is long-term survival a realistic goal?
Topics: Age Factors; Azacitidine; Decitabine; Disease-Free Survival; Humans; Myelodysplastic Syndromes; Risk Factors; Survival Rate | 2021 |
Hypomethylating agents in the treatment of chronic myelomonocytic leukemia: a meta-analysis and systematic review.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Humans; Leukemia, Myelomonocytic, Chronic; Treatment Outcome | 2021 |
Comparison of Azacitidine and Decitabine in Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Network Meta-analysis.
Topics: Age Factors; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Decitabine; Disease Management; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Odds Ratio; Prognosis; Treatment Outcome | 2021 |
Cedazuridine/decitabine: from preclinical to clinical development in myeloid malignancies.
Topics: Azacitidine; Decitabine; Humans; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Uridine | 2021 |
An evaluation of venetoclax in combination with azacitidine, decitabine, or low-dose cytarabine as therapy for acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Decitabine; Humans; Leukemia, Myeloid, Acute; Sulfonamides | 2021 |
Optimizing DNA hypomethylating therapy in acute myeloid leukemia and myelodysplastic syndromes.
Topics: Aged; Azacitidine; Decitabine; Genetic Therapy; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Treatment Outcome | 2021 |
Novel agents for myelodysplastic syndromes.
Topics: Azacitidine; Decitabine; Drug Approval; Humans; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; United States; United States Food and Drug Administration | 2021 |
The Clinical Value of Decitabine Monotherapy in Patients with Acute Myeloid Leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Decitabine; DNA; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Multicenter Studies as Topic; Remission Induction | 2022 |
Maintenance therapy with hypomethylating agents for patients with acute myeloid leukemia in first remission not eligible for allogeneic hematopoietic cell transplantation: A systematic review and meta-analysis.
Topics: Acute Disease; Azacitidine; Decitabine; Disease-Free Survival; Enzyme Inhibitors; Humans; Leukemia, Myeloid; Maintenance Chemotherapy; Randomized Controlled Trials as Topic; Recurrence; Remission Induction; Treatment Outcome | 2022 |
Different mechanisms of drug resistance to hypomethylating agents in the treatment of myelodysplastic syndromes and acute myeloid leukemia.
Topics: Aged; Azacitidine; Decitabine; Drug Resistance; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | 2022 |
Costs per patient achieving remission with venetoclax-based combinations in newly diagnosed patients with acute myeloid leukemia ineligible for intensive induction chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Decitabine; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Network Meta-Analysis; Quality of Life; Sulfonamides | 2022 |
Hypomethylating agents for the treatment of myelodysplastic syndromes and acute myeloid leukemia: Past discoveries and future directions.
Topics: Azacitidine; Decitabine; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | 2022 |
Reported Pericardial Toxicities Associated with Acute Myelogenous Leukemia Treatments: A Pharmacovigilance Analysis of the FDA Adverse Reporting Database.
Topics: Adolescent; Adult; Aminopyridines; Anthracyclines; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Cladribine; Cytarabine; Decitabine; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Pericarditis; Pharmacovigilance; Sulfonamides; Triazines; United States; United States Food and Drug Administration | 2022 |
How Azanucleosides Affect Myeloid Cell Fate.
Topics: Azacitidine; Decitabine; DNA Methylation; Myeloid Cells; RNA | 2022 |
Diagnosis and Treatment of Myelodysplastic Syndromes: A Review.
Topics: Antineoplastic Agents; Azacitidine; Decitabine; Erythropoietin; Female; Hematinics; Humans; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Neutropenia; Prognosis; Thrombocytopenia | 2022 |
Hypomethylating agent-based therapies in older adults with acute myeloid leukemia - A joint review by the Young International Society of Geriatric Oncology and European Society for Blood and Marrow Transplantation Trainee Committee.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Marrow; Decitabine; Humans; Leukemia, Myeloid, Acute; Quality of Life | 2023 |
Targeting DNA Methylation in Leukemia, Myelodysplastic Syndrome, and Lymphoma: A Potential Diagnostic, Prognostic, and Therapeutic Tool.
Topics: Azacitidine; Decitabine; DNA Methylation; Epigenesis, Genetic; Hematologic Neoplasms; Humans; Leukemia; Lymphoma; Myelodysplastic Syndromes; Prognosis | 2022 |
DNA methyltransferase inhibitor exposure-response: Challenges and opportunities.
Topics: Azacitidine; Decitabine; DNA; DNA Methylation; Enzyme Inhibitors; Humans; Leukemia, Myeloid, Acute; Methyltransferases | 2023 |
148 trial(s) available for azacitidine and decitabine
| Article | Year |
|---|---|
5-Aza-2'-deoxycytidine (NSC 127716) in non-seminomatous testicular cancer. Phase II from the EORTC Early Clinical Trials Cooperative Group and Genito-Urinary Group.
Topics: Adult; Antineoplastic Agents; Azacitidine; Decitabine; Drug Evaluation; Dysgerminoma; Humans; Male; Middle Aged; Testicular Neoplasms | 1992 |
Clinical trial on 5-aza-2'-deoxycytidine in patients with acute leukemia.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Agents; Azacitidine; Cell Cycle; Cell Differentiation; Child; Clinical Trials as Topic; Decitabine; DNA, Neoplasm; Drug Evaluation; Humans; Leukemia; Methylation; Research Design | 1985 |
The EORTC Early Clinical Trials Cooperative Group experience with 5-aza-2'-deoxycytidine (NSC 127716) in patients with colo-rectal, head and neck, renal carcinomas and malignant melanomas.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Azacitidine; Carcinoma, Squamous Cell; Clinical Trials as Topic; Decitabine; Female; Hematologic Diseases; Humans; Male; Melanoma; Middle Aged; Neoplasms | 1987 |
5-Aza-2'-deoxycytidine (Decitabine) induces trilineage response in unfavourable myelodysplastic syndromes.
Topics: Aged; Anemia, Refractory, with Excess of Blasts; Antigens, CD; Antigens, CD34; Azacitidine; Bone Marrow; Decitabine; Female; Humans; Male; Middle Aged; Remission Induction | 1993 |
In vitro and in vivo effects of 5-aza-2'-deoxycytidine (Decitabine) on clonogenic cells from acute myeloid leukemia patients.
Topics: Acute Disease; Antineoplastic Agents; Azacitidine; Decitabine; Drug Screening Assays, Antitumor; Humans; Leukemia, Myeloid; Remission Induction; Tumor Stem Cell Assay | 1993 |
Continuous infusion of low-dose 5-Aza-2'-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow; Decitabine; Erythrocyte Count; Female; Humans; Infusions, Intravenous; Leukocyte Count; Male; Middle Aged; Morbidity; Myelodysplastic Syndromes; Platelet Count; Prognosis; Risk Assessment; Survival Rate | 1997 |
A randomized phase II study on the effects of 5-Aza-2'-deoxycytidine combined with either amsacrine or idarubicin in patients with relapsed acute leukemia: an EORTC Leukemia Cooperative Group phase II study (06893).
Topics: Adolescent; Adult; Aged; Amsacrine; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Decitabine; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Survival Rate; Time Factors | 1997 |
Decitabine (5-Aza-2'-deoxycytidine; DAC) plus daunorubicin as a first line treatment in patients with acute myeloid leukemia: preliminary observations.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Marrow; Daunorubicin; Decitabine; Drug Administration Schedule; Female; Humans; Immunophenotyping; Infusions, Intravenous; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged | 1997 |
Studies of decitabine with allogeneic progenitor cell transplantation.
Topics: Adult; Antimetabolites, Antineoplastic; Azacitidine; Combined Modality Therapy; Decitabine; Drug Administration Schedule; Hematopoietic Stem Cell Transplantation; Humans; Infusions, Intravenous; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Middle Aged; Patient Selection; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pseudomonas Infections; Recurrence; Time Factors; Transplantation, Homologous | 1997 |
Decitabine studies in chronic and acute myelogenous leukemia.
Topics: Adult; Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow; Decitabine; Female; Fever; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged | 1997 |
Pilot phase I-II study on 5-aza-2'-deoxycytidine (Decitabine) in patients with metastatic lung cancer.
Topics: Adult; Antimetabolites, Antineoplastic; Azacitidine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Decitabine; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pilot Projects; Tumor Cells, Cultured | 1997 |
Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukemia.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Blast Crisis; Decitabine; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase; Male; Middle Aged | 1997 |
Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Methylation; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Patient Selection; Survival Rate; Treatment Outcome | 2000 |
A phase I trial of cisplatin plus decitabine, a new DNA-hypomethylating agent, in patients with advanced solid tumors and a follow-up early phase II evaluation in patients with inoperable non-small cell lung cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Azacitidine; Carcinoma, Non-Small-Cell Lung; Cisplatin; Decitabine; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged | 2000 |
Decitabine with allogeneic peripheral blood stem cell transplantation in the therapy of leukemia relapse following a prior transplant: results of a phase I study.
Topics: Adult; Antimetabolites, Antineoplastic; Azacitidine; Cohort Studies; Decitabine; Dose-Response Relationship, Drug; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Middle Aged; Recurrence; Remission Induction; Survival Analysis; Transplantation, Homologous; Treatment Outcome | 2001 |
Maintenance of elevated fetal hemoglobin levels by decitabine during dose interval treatment of sickle cell anemia.
Topics: Anemia, Sickle Cell; Azacitidine; Decitabine; DNA Modification Methylases; Fetal Hemoglobin; Humans; Injections, Subcutaneous; Leukocyte Count; Neutrophils; Reticulocyte Count; Time Factors | 2002 |
Phase II trial of cisplatin plus decitabine, a new DNA hypomethylating agent, in patients with advanced squamous cell carcinoma of the cervix.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Carcinoma, Squamous Cell; Cisplatin; Decitabine; Enzyme Inhibitors; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Survival Analysis; Uterine Cervical Neoplasms | 2002 |
Long-term follow-up of a phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Busulfan; Cyclophosphamide; Decitabine; Disease-Free Survival; Dose-Response Relationship, Drug; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Middle Aged; Survival Analysis; Transplantation Conditioning | 2003 |
Phase I trial of continuous infusion 5-aza-2'-deoxycytidine.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Biopsy; Decitabine; DNA Methylation; DNA, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Polymerase Chain Reaction | 2003 |
Effects of 5-aza-2'-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Azacitidine; Biomarkers; Blood Coagulation; Bone Marrow; Cell Adhesion; Cell Differentiation; Decitabine; DNA Methylation; Endothelium, Vascular; Erythrocytes; Female; Fetal Hemoglobin; Hematopoiesis; Humans; Inflammation; Laminin; Male; Middle Aged; Thrombospondins; Vascular Diseases | 2003 |
Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Cell Cycle Proteins; Cell Differentiation; Child; Child, Preschool; Cohort Studies; Cyclin-Dependent Kinase Inhibitor p15; Decitabine; DNA Methylation; DNA Modification Methylases; Dose-Response Relationship, Drug; Female; Gene Silencing; Hematologic Neoplasms; Humans; Karyotyping; Leukemia; Male; Methylation; Middle Aged; Myeloproliferative Disorders; Time Factors; Treatment Outcome; Tumor Suppressor Proteins | 2004 |
Nonclonal neutrophil responses after successful treatment of myelodysplasia with low-dose 5-aza-2'-deoxycytidine (decitabine).
Topics: Aged; Azacitidine; Cell Proliferation; Clone Cells; Decitabine; Female; Granulocytes; Humans; In Situ Hybridization, Fluorescence; Leukocyte Count; Leukopoiesis; Male; Myelodysplastic Syndromes; Neutropenia; Neutrophils | 2004 |
Evaluation of a 7-day continuous intravenous infusion of decitabine: inhibition of promoter-specific and global genomic DNA methylation.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Methylation; DNA Modification Methylases; Drug Administration Schedule; Drug Evaluation; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Promoter Regions, Genetic | 2005 |
Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Benzamides; Decitabine; DNA Methylation; DNA Modification Methylases; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines | 2005 |
Treatment of myelodysplastic syndrome with a DNA methyltransferase inhibitor: lack of evidence for induction of chromosomal instability.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Chromosomal Instability; Chromosome Deletion; Cytogenetic Analysis; Decitabine; Female; Follow-Up Studies; Humans; Male; Metaphase; Middle Aged; Monosomy; Myelodysplastic Syndromes | 2006 |
Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study.
Topics: Acute Disease; Aged; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Disease Progression; Disease-Free Survival; DNA Methylation; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Palliative Care; Quality of Life; Survival Rate | 2006 |
Superiority of prolonged low-dose azanucleoside administration? Results of 5-aza-2'-deoxycytidine retreatment in high-risk myelodysplasia patients.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Disease Progression; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Recurrence; Retreatment; Risk Factors; Survival Rate | 2006 |
Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Bayes Theorem; Bone Marrow Diseases; Chemical and Drug Induced Liver Injury; Cyclin-Dependent Kinase Inhibitor p15; Decitabine; DNA Methylation; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gene Expression Regulation; Gene Expression Regulation, Leukemic; Humans; Infusions, Intravenous; Injections, Subcutaneous; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm Proteins; Remission Induction; Risk; Treatment Outcome | 2007 |
Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia.
Topics: Acetylation; Adolescent; Adult; Aged; Aged, 80 and over; Azacitidine; Child; Child, Preschool; Decitabine; DNA Methylation; Epigenesis, Genetic; Histone Deacetylase Inhibitors; Histones; Humans; Leukemia; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Survival Analysis; Valproic Acid | 2006 |
Phase I trial of sequential low-dose 5-aza-2'-deoxycytidine plus high-dose intravenous bolus interleukin-2 in patients with melanoma or renal cell carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Carcinoma, Renal Cell; Decitabine; DNA Methylation; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Fetal Hemoglobin; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Humans; Injections, Intravenous; Injections, Subcutaneous; Interleukin-2; Kidney Neoplasms; Leukocytes, Mononuclear; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Predictive Value of Tests; Treatment Outcome | 2006 |
Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura.
Topics: Adult; Aged; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Azacitidine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Decitabine; DNA Modification Methylases; Esophageal Neoplasms; Female; Gene Expression Regulation, Neoplastic; Genes, p16; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Membrane Proteins; Mesothelioma; Middle Aged; Neoplasm Proteins; Pleural Neoplasms; Transcriptional Activation | 2006 |
Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Chromosome Aberrations; Chromosomes, Human, Pair 5; Chromosomes, Human, Pair 7; Decitabine; Drug Administration Schedule; Fatigue; Humans; Infusions, Intravenous; Injections, Subcutaneous; Male; Middle Aged; Multivariate Analysis; Myelodysplastic Syndromes; Prognosis; Risk Factors; Survival Analysis; Survival Rate; Treatment Outcome; Vomiting | 2007 |
Epigenetic regulation of Wnt-signaling pathway in acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; beta Catenin; Cell Line, Tumor; Child; Child, Preschool; Decitabine; Disease-Free Survival; DNA Methylation; Epigenesis, Genetic; Female; Follow-Up Studies; Gene Expression Regulation, Leukemic; Humans; Infant; Male; Middle Aged; Neoplasm Proteins; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Quercetin; Signal Transduction; Wnt Proteins | 2007 |
Chromatin-modifying agents permit human hematopoietic stem cells to undergo multiple cell divisions while retaining their repopulating potential.
Topics: Animals; Antigens, CD34; Azacitidine; Cell Division; Cells, Cultured; Chromatin; Cytokines; Decitabine; Enzyme Inhibitors; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Hydroxamic Acids; Mice; Mice, Inbred NOD; Mice, SCID; Thy-1 Antigens; Time Factors; Transplantation, Heterologous; Up-Regulation | 2007 |
The C/EBPdelta tumor suppressor is silenced by hypermethylation in acute myeloid leukemia.
Topics: Antimetabolites, Antineoplastic; Azacitidine; CCAAT-Enhancer-Binding Protein-delta; Chromatin Assembly and Disassembly; Decitabine; DNA Methylation; Female; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Gene Silencing; Humans; Leukemia, Myeloid, Acute; Male; Methyl-CpG-Binding Protein 2; Oligonucleotide Array Sequence Analysis; Promoter Regions, Genetic; Tumor Suppressor Proteins; U937 Cells | 2007 |
Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Benzamides; Blast Crisis; Decitabine; DNA Methylation; Female; Genes, abl; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Polymerase Chain Reaction; Pyrimidines; Survival Analysis; Treatment Outcome | 2007 |
Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cohort Studies; Decitabine; DNA Modification Methylases; Enzyme Inhibitors; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Risk; Treatment Outcome | 2007 |
Pharmacokinetics of decitabine administered as a 3-h infusion to patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Area Under Curve; Azacitidine; Bone Marrow; Chromatography, High Pressure Liquid; Decitabine; Drug Administration Schedule; Female; Half-Life; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Mass Spectrometry; Middle Aged; Myelodysplastic Syndromes; Sepsis; Tissue Distribution | 2008 |
Preferential cytogenetic response to continuous intravenous low-dose decitabine (DAC) administration in myelodysplastic syndrome with monosomy 7.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Chromosomes, Human, Pair 7; Decitabine; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Injections, Subcutaneous; Leukocyte Count; Monosomy; Myelodysplastic Syndromes; Randomized Controlled Trials as Topic; Remission Induction; Time Factors; Treatment Outcome | 2007 |
Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Brain Diseases; Decitabine; Fatigue; Humans; Infections; Leukemia, Myeloid, Acute; Maximum Tolerated Dose; Middle Aged; Neutropenia; Remission Induction; Treatment Failure; Valproic Acid | 2007 |
Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Azacitidine; Carboplatin; Cohort Studies; CpG Islands; Decitabine; DNA Methylation; DNA Modification Methylases; Female; Humans; Male; Middle Aged; Neoplasms | 2007 |
Induction of hypomethylation and molecular response after decitabine therapy in patients with chronic myelomonocytic leukemia.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Methylation; Female; Humans; Janus Kinase 2; Karyotyping; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Mutation; Nuclear Proteins; Nucleophosmin; Remission Induction | 2008 |
Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine.
Topics: Aged; Aged, 80 and over; Azacitidine; Decitabine; DNA Methylation; Humans; Middle Aged; Myelodysplastic Syndromes; Salvage Therapy; Treatment Failure; Treatment Outcome | 2008 |
Azacytidine causes complex DNA methylation responses in myeloid leukemia.
Topics: Antineoplastic Agents; Azacitidine; Cell Line, Tumor; Cytosine; Decitabine; DNA Methylation; Genome, Human; Humans; Leukemia, Myeloid; Myelodysplastic Syndromes; Oligonucleotide Array Sequence Analysis | 2008 |
Feasibility of allo-SCT after hypomethylating therapy with decitabine for myelodysplastic syndrome.
Topics: Adult; Aged; Azacitidine; Decitabine; Disease Progression; Female; Graft vs Host Disease; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Stem Cell Transplantation; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome | 2009 |
Assessment of ATRX expression in patients with myelodysplastic syndromes treated with decitabine.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Core Binding Factor Alpha 3 Subunit; Cytogenetic Analysis; Decitabine; DNA Helicases; Humans; Myelodysplastic Syndromes; Nuclear Proteins; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; X-linked Nuclear Protein | 2009 |
Non-intensive treatment with low-dose 5-aza-2'-deoxycytidine (DAC) prior to allogeneic blood SCT of older MDS/AML patients.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Combined Modality Therapy; Decitabine; Disease Progression; Dose-Response Relationship, Drug; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Risk Factors; Survival Rate; Transplantation Conditioning | 2009 |
Decitabine effect on tumor global DNA methylation and other parameters in a phase I trial in refractory solid tumors and lymphomas.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Blood Pressure; Cation Transport Proteins; Copper Transporter 1; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Modification Methylases; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Hydrogen-Ion Concentration; In Situ Nick-End Labeling; Ki-67 Antigen; Leukocytes, Mononuclear; Lymphoma; Male; Middle Aged; Neoplasms; Sex Factors; Treatment Outcome; Young Adult | 2009 |
Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Middle Aged; Myelodysplastic Syndromes; Outpatients; Treatment Outcome | 2009 |
Decitabine combined with fractionated gemtuzumab ozogamicin therapy in patients with relapsed or refractory acute myeloid leukemia.
Topics: Adult; Aged; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Decitabine; Female; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Salvage Therapy; Treatment Outcome | 2009 |
Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Survival Rate; Treatment Outcome | 2010 |
Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Cohort Studies; Decitabine; Disease-Free Survival; DNA Methylation; Female; Humans; Karyotyping; Leukemia, Myeloid, Acute; Male; MicroRNAs; Middle Aged; Remission Induction; Treatment Outcome | 2010 |
Phase I trial of low dose decitabine targeting DNA hypermethylation in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: dose-limiting myelosuppression without evidence of DNA hypomethylation.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Methylation; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neutropenia; Thrombocytopenia; Treatment Outcome | 2010 |
A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum-resistant, epithelial ovarian cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Carboplatin; Decitabine; DNA Methylation; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum Compounds | 2010 |
Phase I study of decitabine with doxorubicin and cyclophosphamide in children with neuroblastoma and other solid tumors: a Children's Oncology Group study.
Topics: Adolescent; Adult; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Caspase 8; Child; Child, Preschool; Cyclophosphamide; Decitabine; DNA Methylation; Doxorubicin; Female; Fetal Hemoglobin; Gene Expression Profiling; Humans; Infant; Male; Melanoma-Specific Antigens; Neoplasm Proteins; Neoplasms; Neuroblastoma | 2010 |
Decreased incidence of febrile episodes with antibiotic prophylaxis in the treatment of decitabine for myelodysplastic syndrome.
Topics: Adult; Aged; Antibiotic Prophylaxis; Antimetabolites, Antineoplastic; Appendicitis; Azacitidine; Decitabine; Drug Administration Schedule; Female; Fever; Fluoroquinolones; Hemorrhage; Hospitalization; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Neutropenia; Time Factors; Treatment Outcome | 2011 |
Hydralazine and magnesium valproate as epigenetic treatment for myelodysplastic syndrome. Preliminary results of a phase-II trial.
Topics: Adult; Aged; Azacitidine; Cytogenetic Analysis; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Modification Methylases; Epigenomics; Female; Histone Deacetylase Inhibitors; Humans; Hydralazine; Kaplan-Meier Estimate; Male; Middle Aged; Myelodysplastic Syndromes; Treatment Outcome; Valproic Acid; Young Adult | 2011 |
Decitabine in myelodysplastic syndromes and chronic myelomonocytic leukemia: Argentinian/South Korean multi-institutional clinical experience.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Argentina; Azacitidine; Decitabine; Drug Administration Schedule; Female; Humans; Injections, Intravenous; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Republic of Korea; Survival Analysis; Treatment Outcome; Young Adult | 2010 |
Phase I study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomas.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; CpG Islands; Decitabine; Disease Progression; DNA Methylation; Epigenesis, Genetic; Female; Humans; Hydroxamic Acids; Lymphoma, Non-Hodgkin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Promoter Regions, Genetic; Time Factors; Vorinostat | 2011 |
Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Rese
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Disease-Free Survival; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Palliative Care; Quality of Life; Treatment Outcome | 2011 |
Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Daunorubicin; Decitabine; Diarrhea; DNA Methylation; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fever; Humans; Infections; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Middle Aged; Nausea; Neutropenia; Treatment Outcome; Young Adult | 2011 |
A prospective multicenter observational study of decitabine treatment in Korean patients with myelodysplastic syndrome.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Prospective Studies; Republic of Korea; Transplantation, Homologous; Treatment Outcome; Young Adult | 2011 |
MicroRNA 345, a methylation-sensitive microRNA is involved in cell proliferation and invasion in human colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Biomarkers, Tumor; Blotting, Western; Cell Movement; Cell Proliferation; Chromatin Immunoprecipitation; Colorectal Neoplasms; CpG Islands; Decitabine; DNA Methylation; DNA Primers; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genes, bcl-2; Humans; Immunoenzyme Techniques; Luciferases; Lymphatic Metastasis; Male; MicroRNAs; Middle Aged; Neoplasm Invasiveness; Oligonucleotide Array Sequence Analysis; Prognosis; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured | 2011 |
Combination decitabine, arsenic trioxide, and ascorbic acid for the treatment of myelodysplastic syndrome and acute myeloid leukemia: a phase I study.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Azacitidine; Bone Marrow; Bone Marrow Cells; Cohort Studies; Decitabine; Dose-Response Relationship, Drug; Female; Gene Expression Profiling; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neovascularization, Pathologic; Oxides; Young Adult | 2011 |
Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Female; Gene Expression Regulation, Leukemic; Humans; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Mutation; Prognosis; Survival Analysis | 2011 |
A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Comorbidity; Decitabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prevalence; Treatment Outcome | 2012 |
Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients.
Topics: Adenine Nucleotides; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Azacitidine; Clofarabine; Consolidation Chemotherapy; Cytarabine; Decitabine; Female; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Treatment Outcome | 2012 |
Treatment of nuclear-donor cells or cloned zygotes with chromatin-modifying agents increases histone acetylation but does not improve full-term development of cloned cattle.
Topics: Acetylation; Animals; Azacitidine; Cattle; Cell Nucleus; Cells, Cultured; Chromatin Assembly and Disassembly; Cloning, Organism; Decitabine; Embryonic Development; Female; Histone Deacetylase Inhibitors; Histones; Hydralazine; Hydroxamic Acids; Nuclear Transfer Techniques; Pregnancy; Term Birth; Up-Regulation; Valproic Acid; Zygote | 2012 |
Epigenetic reprogramming reverses the relapse-specific gene expression signature and restores chemosensitivity in childhood B-lymphoblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Blast Crisis; Cell Line, Tumor; Child; Child, Preschool; Cohort Studies; Decitabine; DNA Methylation; Female; Gene Expression Regulation, Leukemic; Gene Silencing; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Leukemia, B-Cell; Male; Vorinostat | 2012 |
Epigenetic resensitization to platinum in ovarian cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Carboplatin; Decitabine; Disease-Free Survival; DNA Methylation; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms | 2012 |
Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Boronic Acids; Bortezomib; Cell Line, Tumor; Decitabine; Drug Evaluation, Preclinical; Female; Gene Expression Regulation, Leukemic; HEK293 Cells; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Pyrazines; Treatment Outcome; Validation Studies as Topic | 2012 |
A randomized study of decitabine versus conventional care for maintenance therapy in patients with acute myeloid leukemia in complete remission.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Humans; Leukemia, Myeloid, Acute; Middle Aged; Remission Induction | 2012 |
Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Choice Behavior; Cytarabine; Decision Making; Decitabine; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Neutropenia; Palliative Care; Patient Participation; Remission Induction; Risk Assessment; Risk Factors; Thrombocytopenia; Treatment Outcome | 2012 |
Phase I/II study of decitabine in patients with myelodysplastic syndrome: a multi-center study in Japan.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Dose-Response Relationship, Drug; Female; Humans; Japan; Male; Middle Aged; Myelodysplastic Syndromes; Treatment Outcome | 2012 |
Clinical outcome of treatment with a combined regimen of decitabine and aclacinomycin/cytarabine for patients with refractory acute myeloid leukemia.
Topics: Aclarubicin; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cell Survival; Cyclin-Dependent Kinase Inhibitor p15; Cytarabine; Decitabine; DNA Methylation; DNA Modification Methylases; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Leukemia, Myeloid, Acute; Leukocytes, Mononuclear; Male; Middle Aged; Recurrence; Remission Induction; Survival Analysis; Tumor Cells, Cultured; Young Adult | 2012 |
A randomized controlled trial of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving decitabine.
Topics: Aged; Aged, 80 and over; Azacitidine; Decitabine; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Platelet Count; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombopoietin; Treatment Outcome | 2013 |
Phase I study of 5-aza-2'-deoxycytidine in combination with valproic acid in non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Carcinoma, Non-Small-Cell Lung; Decitabine; Dose-Response Relationship, Drug; Drug Synergism; Female; Histone Deacetylase Inhibitors; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Treatment Outcome; Valproic Acid | 2013 |
Safety and efficacy of decitabine in combination with temozolomide in metastatic melanoma: a phase I/II study and pharmacokinetic analysis.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Dacarbazine; Decitabine; Disease-Free Survival; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Skin Neoplasms; Temozolomide | 2013 |
Scriptaid and 5-aza-2'deoxycytidine enhanced expression of pluripotent genes and in vitro developmental competence in interspecies black-footed cat cloned embryos.
Topics: Animals; Azacitidine; Cats; Cloning, Organism; Decitabine; Embryo Transfer; Epigenesis, Genetic; Felis; Gene Expression Regulation, Developmental; Hydroxylamines; Quinolines | 2012 |
Comparative analysis between azacitidine and decitabine for the treatment of myelodysplastic syndromes.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites; Azacitidine; Bone Marrow Examination; Decitabine; Disease-Free Survival; Female; Humans; Infection Control; Kaplan-Meier Estimate; Karyotyping; Male; Middle Aged; Myelodysplastic Syndromes; Neutropenia; Research Design; Retrospective Studies; Risk Assessment; Treatment Outcome; Young Adult | 2013 |
A phase I/II study of decitabine in combination with panitumumab in patients with wild-type (wt) KRAS metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Colorectal Neoplasms; Decitabine; DNA Methylation; DNA Modification Methylases; ErbB Receptors; Female; Humans; Male; Middle Aged; Mutation; Neoplasm Metastasis; Panitumumab; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins | 2013 |
Randomized open-label phase II study of decitabine in patients with low- or intermediate-risk myelodysplastic syndromes.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Injections, Subcutaneous; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Myelodysplastic Syndromes; Prognosis; Proportional Hazards Models; Risk Assessment; Severity of Illness Index; Survival Analysis; Treatment Outcome | 2013 |
Preclinical and phase I results of decitabine in combination with midostaurin (PKC412) for newly diagnosed elderly or relapsed/refractory adult patients with acute myeloid leukemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cell Line, Tumor; Cohort Studies; Decitabine; Drug Synergism; Female; Flow Cytometry; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Recurrence; Staurosporine | 2013 |
Decitabine can be safely reduced after achievement of best objective response in patients with myelodysplastic syndrome.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Survival Rate; Treatment Outcome | 2013 |
[Morphological evaluation of dysmyelopoiesis in decitabine-treated patients with myelodysplastic syndromes].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Myelodysplastic Syndromes; Myelopoiesis; Prospective Studies; Treatment Outcome; Young Adult | 2013 |
A phase I study of decitabine and rapamycin in relapsed/refractory AML.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Decitabine; Dose-Response Relationship, Drug; Drug Administration Routes; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Pilot Projects; Recurrence; Sirolimus | 2013 |
A post hoc sensitivity analysis of survival probabilities in a multinational phase III trial of decitabine in older patients with newly diagnosed acute myeloid leukemia.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Treatment Outcome | 2014 |
Multivariate and subgroup analyses of a randomized, multinational, phase 3 trial of decitabine vs treatment choice of supportive care or cytarabine in older patients with newly diagnosed acute myeloid leukemia and poor- or intermediate-risk cytogenetics.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Cytarabine; Cytogenetic Analysis; Decitabine; Female; Humans; Internationality; Leukemia, Myeloid, Acute; Male; Multivariate Analysis; Risk Factors; Treatment Outcome | 2014 |
Epigenetic potentiation of NY-ESO-1 vaccine therapy in human ovarian cancer.
Topics: Adult; Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cancer Vaccines; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Decitabine; DNA Methylation; Doxorubicin; Epigenesis, Genetic; Female; Gene Expression; Humans; Immunity, Humoral; Immunotherapy, Active; Long Interspersed Nucleotide Elements; Membrane Proteins; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Polyethylene Glycols; T-Lymphocyte Subsets; Treatment Outcome | 2014 |
A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer.
Topics: Adaptor Proteins, Signal Transducing; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Carboplatin; Decitabine; DNA Methylation; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; MutL Protein Homolog 1; Neoplasm Recurrence, Local; Nuclear Proteins; Ovarian Neoplasms; Platinum | 2014 |
A phase I dose escalation study of oral bexarotene in combination with intravenous decitabine in patients with AML.
Topics: Administration, Oral; Aged; Aged, 80 and over; Animals; Anticarcinogenic Agents; Antimetabolites, Antineoplastic; Azacitidine; Bexarotene; Decitabine; Drug Administration Schedule; Drug Therapy, Combination; Female; Gene Expression; Gene Expression Profiling; Humans; Injections, Intravenous; Leukemia, Promyelocytic, Acute; Male; Mice; Middle Aged; Receptors, Retinoic Acid; Recurrence; Retinoic Acid Receptor alpha; Retinoid X Receptor alpha; Tetrahydronaphthalenes; Tumor Cells, Cultured | 2014 |
A phase I study of decitabine with pegylated interferon α-2b in advanced melanoma: impact on DNA methylation and lymphocyte populations.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Decitabine; DNA Methylation; Female; Humans; Interferon alpha-2; Interferon-alpha; Leukocyte Count; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Neutropenia; Polyethylene Glycols; Recombinant Proteins; T-Lymphocyte Subsets | 2014 |
A therapeutic trial of decitabine and vorinostat in combination with chemotherapy for relapsed/refractory acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Child; Child, Preschool; Decitabine; Disease-Free Survival; DNA Methylation; Drug Resistance, Neoplasm; Humans; Hydroxamic Acids; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Secondary Prevention; Vorinostat; Young Adult | 2014 |
Low-dose decitabine-based chemoimmunotherapy for patients with refractory advanced solid tumors: a phase I/II report.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Carcinoma; Combined Modality Therapy; Cyclophosphamide; Decitabine; DNA Methylation; DNA Modification Methylases; Double-Blind Method; Doxorubicin; Female; Humans; Immunotherapy; Killer Cells, Natural; Lymphoma; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms; Prednisone; Prospective Studies; Survival Analysis; Vincristine | 2014 |
A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Decitabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Hydroxamic Acids; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Myelodysplastic Syndromes; Treatment Outcome; Vorinostat; Young Adult | 2014 |
Treatment of resistant metastatic melanoma using sequential epigenetic therapy (decitabine and panobinostat) combined with chemotherapy (temozolomide).
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Dacarbazine; Decitabine; DNA Modification Methylases; Dose-Response Relationship, Drug; Drug Monitoring; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Epigenomics; Eye Neoplasms; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Panobinostat; Skin Neoplasms; Temozolomide; Treatment Outcome | 2014 |
Safety and clinical activity of 5-aza-2'-deoxycytidine (decitabine) with or without Hyper-CVAD in relapsed/refractory acute lymphocytic leukaemia.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Marrow; Chemical and Drug Induced Liver Injury; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Decitabine; Dexamethasone; DNA Methylation; DNA, Neoplasm; Doxorubicin; Drug Administration Schedule; Female; Gastrointestinal Diseases; Humans; Hyperglycemia; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Methotrexate; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction; Salvage Therapy; Vincristine; Young Adult | 2014 |
Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bayes Theorem; Decitabine; Drug Administration Schedule; Female; Histone Deacetylase Inhibitors; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Treatment Outcome; Valproic Acid | 2015 |
Evaluation of noncytotoxic DNMT1-depleting therapy in patients with myelodysplastic syndromes.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Survival Analysis; Treatment Outcome | 2015 |
A phase I trial of two sequence-specific schedules of decitabine and vorinostat in patients with acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Decitabine; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Recurrence; Remission Induction; Retreatment; Treatment Outcome; Vorinostat | 2015 |
Efficacy and safety of decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin in newly diagnosed elderly patients with acute myeloid leukemia.
Topics: Aclarubicin; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Prospective Studies; Survival Analysis; Treatment Outcome | 2015 |
Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia.
Topics: Adenine Nucleotides; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Azacitidine; Clofarabine; Cytarabine; Decitabine; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Nausea; Remission Induction; Treatment Outcome | 2015 |
Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; beta-Thromboglobulin; Bone Marrow; Decitabine; DNA Methylation; DNA Mutational Analysis; DNA, Intergenic; Drug Resistance, Neoplasm; Enhancer Elements, Genetic; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genes, Neoplasm; Humans; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Neoplasm Proteins; Platelet Factor 4; Treatment Outcome | 2015 |
Discontinuation of hypomethylating agent therapy in patients with myelodysplastic syndromes or acute myelogenous leukemia in complete remission or partial response: retrospective analysis of survival after long-term follow-up.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Methylation; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Retrospective Studies; Survival Analysis; Treatment Outcome; Withholding Treatment | 2015 |
Decitabine improves outcomes in older patients with acute myeloid leukemia and higher blast counts.
Topics: Age Factors; Aged; Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow; Decitabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Survival Analysis; Treatment Outcome | 2015 |
An open-label, single-arm, phase I/II study of lower-dose decitabine based therapy in patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Carcinoma, Hepatocellular; Decitabine; Disease-Free Survival; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Modification Methylases; Female; Humans; Liver Neoplasms; Male; Middle Aged; Treatment Outcome | 2015 |
Low Dose Decitabine Combined with Taxol and Platinum Chemotherapy to Treat Refractory/Recurrent Ovarian Cancer: An Open-Label, Single-Arm, Phase I/II Study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Biomarkers, Tumor; Decitabine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Platinum; Recurrence; Safety | 2015 |
Mutations in the Spliceosomal Machinery Genes SRSF2, U2AF1, and ZRSR2 and Response to Decitabine in Myelodysplastic Syndrome.
Topics: Adult; Aged; Aged, 80 and over; Azacitidine; Decitabine; Female; Humans; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Nuclear Proteins; Prognosis; Ribonucleoproteins; RNA Splicing; Serine-Arginine Splicing Factors; Spliceosomes; Splicing Factor U2AF; Treatment Outcome | 2015 |
DECIDER: prospective randomized multicenter phase II trial of low-dose decitabine (DAC) administered alone or in combination with the histone deacetylase inhibitor valproic acid (VPA) and all-trans retinoic acid (ATRA) in patients >60 years with acute mye
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Clinical Protocols; Decitabine; Female; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Tretinoin; Valproic Acid | 2015 |
Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome.
Topics: Adult; Aged; Allografts; Antimetabolites, Antineoplastic; Azacitidine; Combined Modality Therapy; Decitabine; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Gastrointestinal Diseases; Graft vs Host Disease; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Male; Maximum Tolerated Dose; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Young Adult | 2015 |
A phase I trial combining decitabine/dendritic cell vaccine targeting MAGE-A1, MAGE-A3 and NY-ESO-1 for children with relapsed or therapy-refractory neuroblastoma and sarcoma.
Topics: Adolescent; Antigens, Neoplasm; Azacitidine; Cancer Vaccines; Cell Proliferation; Cells, Cultured; Child; Child, Preschool; Combined Modality Therapy; Decitabine; Dendritic Cells; Feasibility Studies; Female; Humans; Male; Melanoma-Specific Antigens; Membrane Proteins; Neoplasm Proteins; Neuroblastoma; Peptide Fragments; Recurrence; Sarcoma; T-Lymphocytes; Treatment Outcome | 2015 |
Low-Dose Decitabine for Patients With Thrombocytopenia Following Allogeneic Hematopoietic Stem Cell Transplantation: A Pilot Therapeutic Study.
Topics: Azacitidine; Blood Platelets; Bone Marrow Examination; China; Decitabine; Hematopoietic Stem Cell Transplantation; Humans; Pilot Projects; Platelet Count; Thrombocytopenia; Time Factors; Transplantation, Homologous; Treatment Outcome | 2015 |
Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Decitabine; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Myelodysplastic Syndromes; Neoplasm Staging; Prognosis | 2015 |
A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome.
Topics: Adult; Aged; Aged, 80 and over; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Decitabine; Female; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Sialic Acid Binding Ig-like Lectin 3 | 2016 |
Converging or Crossing Curves: Untie the Gordian Knot or Cut it? Appropriate Statistics for Non-Proportional Hazards in Decitabine DACO-016 Study (AML).
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Proportional Hazards Models; Statistics as Topic; Survival Rate; United States | 2015 |
Decitabine versus best supportive care in older patients with refractory anemia with excess blasts in transformation (RAEBt) - results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS St
Topics: Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Antimetabolites, Antineoplastic; Azacitidine; Blast Crisis; Decitabine; Disease-Free Survival; Female; Humans; Male; Middle Aged; Survival Rate | 2015 |
Carboplatin with Decitabine Therapy, in Recurrent Platinum Resistant Ovarian Cancer, Alters Circulating miRNAs Concentrations: A Pilot Study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Biomarkers, Tumor; Carboplatin; Decitabine; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Pilot Projects; Prognosis; Survival Rate; Young Adult | 2015 |
Model-based adaptive phase I trial design of post-transplant decitabine maintenance in myelodysplastic syndrome.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Combined Modality Therapy; Decitabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hematopoietic Stem Cell Transplantation; Humans; Maintenance Chemotherapy; Male; Middle Aged; Models, Biological; Myelodysplastic Syndromes; Research Design; Transplantation, Homologous; Treatment Outcome; Young Adult | 2015 |
Phase II study of tosedostat with cytarabine or decitabine in newly diagnosed older patients with acute myeloid leukaemia or high-risk MDS.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Female; Glycine; Humans; Hydroxamic Acids; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Survival Analysis; Treatment Outcome | 2016 |
Decitabine for Treatment of Myelodysplastic Syndromes in Chinese Patients: An Open-Label, Phase-3b Study.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Asian People; Azacitidine; China; Decitabine; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Myelodysplastic Syndromes; Research Design; Survival Rate; Treatment Outcome; Young Adult | 2015 |
Decitabine improves progression-free survival in older high-risk MDS patients with multiple autosomal monosomies: results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Disease Progression; Disease-Free Survival; Female; Germany; Humans; Leukemia; Male; Middle Aged; Monosomy; Myelodysplastic Syndromes; Risk Factors | 2016 |
Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial.
Topics: Aged; Azacitidine; Decitabine; Disease-Free Survival; DNA Methylation; Drug Administration Schedule; Europe; Female; Glycine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myelodysplastic Syndromes; Risk; Sulfones; Treatment Outcome | 2016 |
The efficacy of current prognostic models in predicting outcome of patients with myelodysplastic syndromes at the time of hypomethylating agent failure.
Topics: Adult; Azacitidine; Decitabine; Disease-Free Survival; Female; Humans; Male; Models, Biological; Myelodysplastic Syndromes; Predictive Value of Tests; Retrospective Studies; Survival Rate | 2016 |
Combinatorial epigenetic therapy in diffuse large B cell lymphoma pre-clinical models and patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cell Line, Tumor; Decitabine; DNA Methylation; Epigenesis, Genetic; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Treatment Outcome; Vorinostat | 2016 |
Maintenance therapy with decitabine in younger adults with acute myeloid leukemia in first remission: a phase 2 Cancer and Leukemia Group B Study (CALGB 10503).
Topics: Adolescent; Adult; Azacitidine; Decitabine; Disease-Free Survival; Female; Humans; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Male; Middle Aged; Remission Induction; Survival Rate; Young Adult | 2017 |
Elevated fetal haemoglobin is a predictor of better outcome in MDS/AML patients receiving 5-aza-2'-deoxycytidine (Decitabine).
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Biomarkers; Decitabine; Disease-Free Survival; DNA Methylation; Female; Fetal Hemoglobin; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Survival Analysis | 2017 |
TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Topics: 5-Methylcytosine; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Biomarkers, Tumor; Bone Marrow; Decitabine; Exome; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Prospective Studies; Risk Factors; Survival Rate; Tumor Suppressor Protein p53 | 2016 |
Evaluating the impact of genetic and epigenetic aberrations on survival and response in acute myeloid leukemia patients receiving epigenetic therapy.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Biomarkers, Tumor; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methyltransferase 3A; Epigenesis, Genetic; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Nucleophosmin; Survival Rate; Treatment Outcome | 2017 |
Mutational landscape and response are conserved in peripheral blood of AML and MDS patients during decitabine therapy.
Topics: Azacitidine; Blood Cells; Decitabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Mutation; Myelodysplastic Syndromes; Neoplasm Proteins | 2017 |
Minimal residual disease eradication with epigenetic therapy in core binding factor acute myeloid leukemia.
Topics: Adult; Aged; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Decitabine; Disease-Free Survival; Epigenesis, Genetic; Female; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm, Residual; Survival Rate; Translocation, Genetic; Vidarabine | 2017 |
Mitoxantrone, etoposide and cytarabine following epigenetic priming with decitabine in adults with relapsed/refractory acute myeloid leukemia or other high-grade myeloid neoplasms: a phase 1/2 study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Biomarkers; Cytarabine; Decitabine; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Neoplasm Grading; Recurrence; Treatment Outcome; Young Adult | 2017 |
Increased IFNγ
Topics: Animals; Antineoplastic Agents; Azacitidine; Cell Line, Tumor; Cytotoxicity, Immunologic; Decitabine; Disease Models, Animal; Disease Progression; DNA Methylation; Dose-Response Relationship, Drug; Epigenesis, Genetic; Female; Humans; Interferon-gamma; Lymphocyte Activation; Male; Mice; Neoplasms; Survival Analysis; T-Lymphocyte Subsets; T-Lymphocytes, Cytotoxic; Th1 Cells; Treatment Outcome; Xenograft Model Antitumor Assays | 2017 |
Oral tetrahydrouridine and decitabine for non-cytotoxic epigenetic gene regulation in sickle cell disease: A randomized phase 1 study.
Topics: Adult; Anemia, Sickle Cell; Azacitidine; Decitabine; Drug Therapy, Combination; Enzyme Inhibitors; Epigenesis, Genetic; Female; Fetal Hemoglobin; Gene Expression Regulation; Gene Silencing; Humans; Male; Middle Aged; Tetrahydrouridine; Treatment Outcome; Young Adult | 2017 |
A multicenter, randomized study of decitabine as epigenetic priming with induction chemotherapy in children with AML.
Topics: Adolescent; Azacitidine; Child; Child, Preschool; Cytarabine; Daunorubicin; Decitabine; DNA Methylation; Epigenesis, Genetic; Etoposide; Female; Humans; Induction Chemotherapy; Infant; Leukemia, Myeloid, Acute; Male; Promoter Regions, Genetic; Treatment Outcome | 2017 |
Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. best supportive care.
Topics: Antineoplastic Agents; Azacitidine; Decitabine; Drug Resistance, Neoplasm; Glycine; Humans; Kaplan-Meier Estimate; Myelodysplastic Syndromes; Prognosis; Sulfones; Treatment Outcome | 2017 |
A phase 1 study of azacitidine combined with chemotherapy in childhood leukemia: a report from the TACL consortium.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Child; Child, Preschool; Decitabine; Female; Humans; Infant; Leukemia, Myeloid, Acute; Male | 2018 |
Hypomethylating agents (HMAs) effect on myelodysplastic/myeloproliferative neoplasm unclassifiable (MDS/MPN-U): single institution experience.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Decitabine; DNA Methylation; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myelodysplastic-Myeloproliferative Diseases; Prognosis; Survival Rate | 2018 |
A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Benzodiazepines; Decitabine; Disease-Free Survival; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm, Residual; Pyrroles; Sialic Acid Binding Ig-like Lectin 3; Survival Rate | 2018 |
Response to hypomethylating agents improves long-term outcomes for lower-risk patients with myelodysplastic syndrome in case-matched cohorts.
Topics: Adult; Aged; Aged, 80 and over; Azacitidine; Decitabine; Disease-Free Survival; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Risk Factors; Survival Rate | 2018 |
Suboptimal response rates to hypomethylating agent therapy in chronic myelomonocytic leukemia; a single institutional study of 121 patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Azacitidine; Decitabine; Disease-Free Survival; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Survival Rate; Time Factors | 2019 |
[Efficacy and Safety of Decitabine Combined with Half-Course Pre-excitation for the Treatment of Elderly Patients with Acute Myeloid Leukemia].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Decitabine; Humans; Leukemia, Myeloid, Acute; Retrospective Studies; Treatment Outcome | 2019 |
[Comparison of the Curative Efficacy of Elderly Patients with High-Risk MDS and MDS-Transformed AML between Decitabine Combined with Low-Dose CEG Regimen and Decitabine Combined with Low-Dose CAG Regimen].
Topics: Aclarubicin; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Prospective Studies; Treatment Outcome | 2020 |
A pilot clinical trial of oral tetrahydrouridine/decitabine for noncytotoxic epigenetic therapy of chemoresistant lymphoid malignancies.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Epigenesis, Genetic; Humans; Lymphoma; Pilot Projects; Tetrahydrouridine | 2021 |
Phase I Clinical Trial of DNA Methyltransferase Inhibitor Decitabine and PARP Inhibitor Talazoparib Combination Therapy in Relapsed/Refractory Acute Myeloid Leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Decitabine; DNA; Humans; Leukemia, Myeloid, Acute; Methyltransferases; Phthalazines; Poly(ADP-ribose) Polymerase Inhibitors | 2022 |
FDA Approval Summary: Decitabine and Cedazuridine Tablets for Myelodysplastic Syndromes.
Topics: Adult; Azacitidine; Decitabine; Humans; Myelodysplastic Syndromes; Tablets; Treatment Outcome; Uridine | 2022 |
Integrated clinical and genomic evaluation of guadecitabine (SGI-110) in peripheral T-cell lymphoma.
Topics: Azacitidine; Decitabine; Genomics; Humans; Lymphoma, T-Cell, Peripheral; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Neutropenia; Treatment Outcome | 2022 |
Activity of decitabine combined with all-
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Decitabine; Humans; Leukemia, Myeloid, Acute; Tretinoin | 2023 |
Decitabine versus intensive chemotherapy induction for older patients with acute myeloid leukaemia: a futile but successful trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Decitabine; Humans; Leukemia, Myeloid, Acute; Remission Induction; Treatment Outcome | 2023 |
2773 other study(ies) available for azacitidine and decitabine
| Article | Year |
|---|---|
Synthesis and antitumor activity of fluorine-substituted 4-amino-2(1H)-pyridinones and their nucleosides. 3-Deazacytosines.
Topics: Animals; Antimetabolites, Antineoplastic; Cytosine; Drug Evaluation, Preclinical; Indicators and Reagents; Leukemia L1210; Magnetic Resonance Spectroscopy; Mass Spectrometry; Mice; Spectrophotometry; Structure-Activity Relationship | 1987 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Synergistic reduction of HIV-1 infectivity by 5-azacytidine and inhibitors of ribonucleotide reductase.
Topics: Anti-HIV Agents; Azacitidine; Dose-Response Relationship, Drug; Enzyme Inhibitors; HIV Infections; HIV-1; Humans; Microbial Sensitivity Tests; Molecular Structure; Ribonucleotide Reductases; Structure-Activity Relationship | 2016 |
Discovery of Reversible DNA Methyltransferase and Lysine Methyltransferase G9a Inhibitors with Antitumoral in Vivo Efficacy.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; DNA Modification Methylases; Drug Design; Enzyme Inhibitors; Histocompatibility Antigens; Histone-Lysine N-Methyltransferase; Humans; Mice; Molecular Docking Simulation; Protein Conformation; Xenograft Model Antitumor Assays | 2018 |
Template-directed interference footprinting of cytosine contacts in a protein-DNA complex: potent interference by 5-aza-2'-deoxycytidine.
Topics: Antineoplastic Agents; Azacitidine; Base Sequence; Cytosine; Decitabine; DNA; DNA-Binding Proteins; Electrophoresis, Polyacrylamide Gel; Molecular Sequence Data; Templates, Genetic; X-Ray Diffraction | 1992 |
Progressive stages of "transdifferentiation" from epidermal to mesenchymal phenotype induced by MyoD1 transfection, 5-aza-2'-deoxycytidine treatment, and selection for reduced cell attachment in the human keratinocyte line HaCaT.
Topics: Animals; Azacitidine; Cell Adhesion; Cell Differentiation; Cell Line; Clone Cells; Decitabine; Desmin; Filaggrin Proteins; Gene Expression Regulation; Genes, Switch; Humans; Keratinocytes; Mice; Mice, Nude; MyoD Protein; Myosins; Nuclear Proteins; Phenotype; Phosphoproteins; Transfection | 1992 |
Down-regulation of a member of the S100 gene family in mammary carcinoma cells and reexpression by azadeoxycytidine treatment.
Topics: Amino Acid Sequence; Antineoplastic Agents; Azacitidine; Base Sequence; Breast; Breast Neoplasms; Calcimycin; Calcium-Binding Proteins; Cell Cycle; Cell Line; Chromosome Banding; Decitabine; DNA; DNA Probes; DNA, Neoplasm; Female; Gene Expression; Humans; Molecular Sequence Data; Multigene Family; RNA; RNA, Messenger; RNA, Neoplasm; S100 Proteins; Sequence Homology, Nucleic Acid | 1992 |
Phenylacetate: a novel nontoxic inducer of tumor cell differentiation.
Topics: Adipose Tissue; Animals; Antineoplastic Agents; Azacitidine; Cell Differentiation; Cell Division; Cell Line; Cell Transformation, Neoplastic; Decitabine; Gene Expression; Genes, myc; Humans; Leukemia, Promyelocytic, Acute; Mice; Mice, Nude; Phenylacetates; RNA, Ribosomal | 1992 |
Synergistic cytotoxicity with 2'-deoxy-5-azacytidine and topotecan in vitro and in vivo.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Azacitidine; Camptothecin; Colorectal Neoplasms; Decitabine; DNA Topoisomerases, Type I; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Female; Lethal Dose 50; Methylation; Mice; Mice, Inbred BALB C; Topotecan; Tumor Cells, Cultured | 1992 |
Induction of gene amplification by 5-aza-2'-deoxycytidine.
Topics: Animals; Antineoplastic Agents; Aspartic Acid; Azacitidine; Blotting, Southern; Cell Line; Cricetinae; Decitabine; DNA; Dose-Response Relationship, Drug; Drug Resistance; Gene Amplification; Mesocricetus; Methylation; Phosphonoacetic Acid | 1992 |
Studies on the mechanism of the synergistic interaction between 2'-deoxy-5-azacytidine and cisplatin.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cisplatin; Decitabine; DNA, Neoplasm; Drug Resistance; Drug Synergism; Humans; Melanoma; Methylation; Mice; Sensitivity and Specificity; Tubercidin; Tumor Cells, Cultured | 1992 |
Potent inhibitors for the deamination of cytosine arabinoside and 5-aza-2'-deoxycytidine by human cytidine deaminase.
Topics: Antineoplastic Agents; Azacitidine; Azepines; Cytarabine; Cytidine; Cytidine Deaminase; Deamination; Decitabine; Humans; Kinetics; Pyrimidine Nucleosides; Tetrahydrouridine | 1992 |
Cytotoxicity of 5-aza-2'-deoxycytidine in a mammalian cell system.
Topics: Animals; Antineoplastic Agents; Azacitidine; Cell Cycle; Cells, Cultured; Chromosome Aberrations; Cricetinae; Cricetulus; Decitabine; DNA; Female; Methylation; Ovary | 1992 |
Production of thyroid tumours in mice by demethylating agents.
Topics: Animals; Azacitidine; Decitabine; DNA; Goiter; Methylation; Mice; Thyroid Neoplasms | 1992 |
Hemimethylation and hypersensitivity are early events in transcriptional reactivation of human inactive X-linked genes in a hamster x human somatic cell hybrid.
Topics: Animals; Azacitidine; Base Sequence; Chromatin; Cricetinae; Decitabine; Dinucleoside Phosphates; DNA; Dosage Compensation, Genetic; Genetic Linkage; Humans; Hybrid Cells; Hypoxanthine Phosphoribosyltransferase; Kinetics; Methylation; Molecular Sequence Data; RNA, Messenger; Transcription, Genetic; X Chromosome | 1992 |
Induction of erythroid differentiation and fetal hemoglobin production in human leukemic cells treated with phenylacetate.
Topics: Azacitidine; Cell Differentiation; Cell Division; Decitabine; Erythroid Precursor Cells; Fetal Hemoglobin; Humans; Hydroxyurea; Leukemia, Experimental; Phenylacetates; Tumor Cells, Cultured | 1992 |
Effects of 5-aza-2'-deoxycytidine and interferon-alpha on differentiation and oncogene expression in HL-60 myeloid leukemic cells.
Topics: Antineoplastic Agents; Azacitidine; Blotting, Northern; Cell Differentiation; Decitabine; DNA, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Interferon-alpha; Leukemia, Myeloid; Oncogenes; RNA, Neoplasm; Tumor Cells, Cultured | 1992 |
Flow cytometric detection of drugs altering the DNA methylation pattern.
Topics: Azacitidine; Base Sequence; beta-Galactosidase; Butyrates; Butyric Acid; Cell Cycle; Cell Transformation, Viral; Cells, Cultured; Decitabine; DNA, Bacterial; Escherichia coli; Flow Cytometry; Fluorometry; Gene Expression Regulation, Enzymologic; Humans; Kidney; Lac Operon; Methylation; Molecular Sequence Data; Transcription, Genetic | 1992 |
Phase II study of 5-aza-2'-deoxycytidine in advanced ovarian carcinoma. The EORTC Early Clinical Trials Group.
Topics: Adult; Aged; Antineoplastic Agents; Azacitidine; Carcinoma; Decitabine; Drug Evaluation; Female; Humans; Middle Aged; Ovarian Neoplasms | 1990 |
5-azacytidine and 5-azadeoxycytidine inhibit human immunodeficiency virus type 1 replication in vitro.
Topics: Antineoplastic Agents; Azacitidine; CD4 Antigens; Cell Line; Cells, Cultured; Decitabine; Fluorescent Antibody Technique; HIV-1; Humans; Virus Replication | 1990 |
Kinetochore formation in experimentally undercondensed chromosomes.
Topics: Animals; Azacitidine; Benzimidazoles; Bisbenzimidazole; Cells, Cultured; Chromosomes, Human; Decitabine; Epitopes; Heterochromatin; Humans; Immunohistochemistry; Male; Mice | 1990 |
Chromosome aberration induction in Chinese hamster ovary cells by restriction enzymes with different methylation sensitivity.
Topics: Animals; Azacitidine; Cell Line; Chromosome Aberrations; Cricetinae; Cytosine; Decitabine; Deoxyribonuclease HpaII; Deoxyribonucleases, Type II Site-Specific; DNA; Methylation; Substrate Specificity | 1990 |
Fragile sites induced by 5-azacytidine and 5-azadeoxycytidine in the murine genome.
Topics: Animals; Azacitidine; Chromosome Banding; Chromosome Fragile Sites; Chromosome Fragility; Decitabine; Mice | 1990 |
Synergistic cytotoxicity using 2'-deoxy-5-azacytidine and cisplatin or 4-hydroperoxycyclophosphamide with human tumor cells.
Topics: Antineoplastic Agents; Azacitidine; Cell Line; Cell Survival; Cisplatin; Computer Graphics; Cyclophosphamide; Decitabine; DNA, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Methylation; Tumor Cells, Cultured | 1990 |
The MHC class II deficiency syndrome: heterogeneity at the level of the response to 5-azadeoxycytidine.
Topics: Azacitidine; Cell Line, Transformed; Decitabine; DNA; Gene Expression Regulation; Genes, MHC Class II; HLA-D Antigens; Humans; Immunologic Deficiency Syndromes; Lymphocytes; Methylation; Promoter Regions, Genetic; Syndrome; Transcription, Genetic | 1990 |
Effect of 5-aza-2'-deoxycytidine and retinoic acid on differentiation and c-myc expression in HL-60 myeloid leukemic cells.
Topics: Antineoplastic Agents; Azacitidine; Cell Differentiation; Cell Division; Decitabine; Drug Synergism; Gene Expression; Humans; Proto-Oncogene Proteins c-myc; Tretinoin; Tumor Cells, Cultured | 1990 |
Induction of cytidine deaminase in HL-60 myeloid leukemic cells by 5-aza-2'-deoxycytidine.
Topics: Antineoplastic Agents; Azacitidine; Cell Differentiation; Cytidine Deaminase; Decitabine; DNA, Neoplasm; Enzyme Induction; Humans; Leukemia, Promyelocytic, Acute; Tumor Cells, Cultured | 1990 |
Comparison of antineoplastic activity of cytosine arabinoside and 5-aza-2'-deoxycytidine against human leukemic cells of different phenotype.
Topics: Antineoplastic Agents; Azacitidine; Cytarabine; Decitabine; DNA; Humans; Leukemia; Methylation; Phenotype; Tumor Cells, Cultured | 1990 |
Increased sensitivity of nontumorigenic fibroblasts expressing ras or myc oncogenes to malignant transformation induced by 5-aza-2'-deoxycytidine.
Topics: Animals; Azacitidine; Blotting, Northern; Cell Differentiation; Cell Line; Cell Survival; Cell Transformation, Neoplastic; Cocarcinogenesis; Decitabine; DNA; Genes, ras; Matrix Metalloproteinase 3; Metalloendopeptidases; Methylation; Mice; Mice, Nude; Neoplasm Metastasis; Proto-Oncogene Proteins c-myc; Proto-Oncogenes; RNA, Messenger | 1991 |
Potentiation of MyoD1 activity by 5-aza-2'-deoxycytidine.
Topics: Azacitidine; Blotting, Northern; Bone and Bones; Cell Differentiation; Cloning, Molecular; Decitabine; DNA; Fluorescent Antibody Technique; Gene Expression Regulation; Humans; Methylation; Muscles; MyoD Protein; Nuclear Proteins; Phosphoproteins; Transfection; Tumor Cells, Cultured | 1990 |
5-aza-2'-deoxycytidine in advanced or recurrent cancer of the uterine cervix.
Topics: Adult; Aged; Antineoplastic Agents; Azacitidine; Decitabine; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Uterine Cervical Neoplasms | 1991 |
Effects of 5-azacytidine and 5-aza-2-deoxycytidine on alphafetoprotein levels in mice.
Topics: alpha-Fetoproteins; Animals; Azacitidine; Carbon Tetrachloride; Decitabine; Drug Synergism; Immunodiffusion; Liver; Mice; Mice, Inbred C3H | 1990 |
The antileukaemic activity of 5-Aza-2 deoxycytidine (Aza-dC) in patients with relapsed and resistant leukaemia.
Topics: Acute Disease; Adult; Amsacrine; Antigens, CD; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Marrow; Decitabine; Drug Resistance; Female; Humans; Leukemia; Male; Middle Aged; Recurrence | 1991 |
DNA alkali-labile sites induced by incorporation of 5-aza-2'-deoxycytidine into DNA of mouse leukemia L1210 cells.
Topics: Alkalies; Animals; Antineoplastic Agents; Azacitidine; Cells, Cultured; Decitabine; DNA, Neoplasm; Hydrogen-Ion Concentration; Leukemia L1210; Mice | 1985 |
Inhibition of phytohemagglutinin-induced DNA synthesis and of adenosine deamination by 5-azacytidine and 5-aza-2'-deoxycytidine in intact human cells.
Topics: Adenosine; Antineoplastic Agents; Azacitidine; Cells, Cultured; Deamination; Decitabine; DNA; Humans; Lymphocytes; Phytohemagglutinins | 1985 |
Immunological concepts and the combination of cyclophosphamide with 5-aza-2'-deoxycytidine on L1210 in vivo.
Topics: Animals; Antineoplastic Agents; Azacitidine; Cell Survival; Cyclophosphamide; Decitabine; Drug Synergism; Drug Therapy, Combination; Leukemia L1210; Male; Mice; Mice, Inbred Strains; T-Lymphocytes, Regulatory | 1985 |
Induction of thymidine kinase activity in a spontaneously enzyme-deficient murine tumor cell line by exposure in vivo to the DNA-hypomethylating agent 5-aza-2'-deoxycytidine: implications for mechanisms of tumor progression.
Topics: Animals; Azacitidine; Cell Line; Decitabine; DNA; Enzyme Induction; Male; Methylation; Mice; Mice, Inbred DBA; Mutation; Neoplasms, Experimental; Thymidine Kinase | 1985 |
Levels and stability of DNA methylation in random surviving cell clones derived from a Chinese hamster cell line after prolonged treatment with 5-aza-2'-deoxycytidine.
Topics: Animals; Azacitidine; Cell Cycle; Cell Line; Cell Survival; Clone Cells; Cricetinae; Decitabine; Deoxycytidine; DNA; Female; Methylation; Ovary; Time Factors | 1986 |
Induction of differentiation and inhibition of DNA methylation in HL-60 myeloid leukemic cells by 5-AZA-2'-deoxycytidine.
Topics: Antineoplastic Agents; Azacitidine; Cell Differentiation; Cell Line; Decitabine; Dimethyl Sulfoxide; DNA; Dose-Response Relationship, Drug; Humans; Leukemia, Myeloid, Acute; Methylation; Superoxides | 1985 |
Arabinosyl-5-azacytosine: plasma kinetics and therapeutic response (L1210) in vitro and in vivo in mice.
Topics: Animals; Antineoplastic Agents; Azacitidine; Cells, Cultured; Decitabine; Kinetics; Leukemia L1210; Male; Mice; Mice, Inbred Strains | 1985 |
DNA methyltransferase levels in tumorigenic and nontumorigenic cells in culture.
Topics: 5-Methylcytosine; Animals; Azacitidine; Cattle; Cells, Cultured; Cricetinae; Cytosine; Decitabine; DNA; DNA (Cytosine-5-)-Methyltransferases; DNA, Neoplasm; Fibroblasts; Gene Expression Regulation; Humans; Mesocricetus; Methylation; Mice; Neoplasm Proteins; Neoplasms, Experimental; Rats | 1986 |
Sample preparation for the determination of 5-aza-2'-deoxycytidine in plasma by high-performance liquid chromatography.
Topics: Adolescent; Adult; Antineoplastic Agents; Azacitidine; Chromatography, High Pressure Liquid; Decitabine; Humans; Kinetics; Leukemia; Middle Aged; Spectrophotometry, Ultraviolet | 1985 |
Mechanism of action of 1-beta-D-arabinofuranosyl-5-azacytosine and its effects in L1210 mouse leukemia cells.
Topics: Animals; Antineoplastic Agents; Azacitidine; Bone Marrow; Bone Marrow Cells; Cell Division; Cell Line; Cell Survival; Cytarabine; Decitabine; Drug Evaluation, Preclinical; Kinetics; Leukemia L1210; Leukocyte Count; Male; Mice; Mice, Inbred DBA; Nucleosides; Phosphorylation; Thymidine | 1986 |
3-Deazauridine (NSC 126849): an interesting modulator of biochemical response.
Topics: 3-Deazauridine; Acute Disease; Animals; Antineoplastic Agents; Azacitidine; Cytarabine; Decitabine; Drug Evaluation; Drug Synergism; Galactosamine; Humans; Kinetics; Leukemia; Neoplasms; Thymidine; Uridine | 1986 |
Effects of 5-aza-2'-deoxycytidine on survival and cell cycle progression of L1210 leukemia cells.
Topics: Animals; Antineoplastic Agents; Azacitidine; Cell Cycle; Cell Survival; Cells, Cultured; Decitabine; DNA, Neoplasm; Leukemia L1210; Mice; Thymidine | 1986 |
Incorporation of 5-fluorodeoxycytidine and metabolites into nucleic acids of human MCF-7 breast carcinoma cells.
Topics: Azacitidine; Breast Neoplasms; Cell Line; Cell Survival; Decitabine; Deoxycytidine; Deoxyuridine; DNA, Neoplasm; Floxuridine; Humans; Methylation; RNA, Neoplasm; Tetrahydrouridine | 1986 |
Phase I and pharmacokinetic study of 5-aza-2'-deoxycytidine (NSC 127716) in cancer patients.
Topics: Adult; Aged; Azacitidine; Creatine; Decitabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Evaluation; Female; Humans; Kinetics; Leukocyte Count; Male; Metabolic Clearance Rate; Middle Aged; Neoplasm Recurrence, Local; Neoplasms; Platelet Count; Temperature; Time Factors | 1986 |
Delayed DNA methylation is an integral feature of DNA replication in mammalian cells.
Topics: Animals; Azacitidine; Cell Cycle; Cell Line; Cells, Cultured; Cricetinae; Decitabine; DNA; DNA Replication; Humans; Kinetics; Lymphocytes; Methylation; Mutation | 1986 |
Strong effects of 5-azacytidine on the in vitro lifespan of human diploid fibroblasts.
Topics: 5-Methylcytosine; Azacitidine; Cell Division; Cell Line; Cell Survival; Cytarabine; Cytosine; Decitabine; DNA; Fibroblasts; Humans; Methylation | 1986 |
Differences in DNA damage produced by incorporation of 5-aza-2'-deoxycytidine or 5,6-dihydro-5-azacytidine into DNA of mammalian cells.
Topics: Animals; Azacitidine; Cell Cycle; Cell Line; Decitabine; DNA; DNA Damage; DNA Replication; Humans; Hydrogen-Ion Concentration; Leukemia L1210; Lymphocytes; Mice | 1986 |
Methylation is an early and necessary step in the sporulation programme of the slime mold Physarum polycephalum.
Topics: Azacitidine; Decitabine; DNA, Fungal; Ethionine; Methylation; Physarum; S-Adenosylhomocysteine; Spores, Fungal | 1986 |
Interaction of deoxycytidine and deoxycytidine analogs in normal and leukemic human myeloid progenitor cells.
Topics: Azacitidine; Cell Division; Cell Line; Colony-Forming Units Assay; Cytarabine; Decitabine; Deoxycytidine; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid, Acute | 1986 |
5-AZA-2'-deoxycytidine synergistic action with thymidine on leukemic cells and interaction of 5-AZA-dCMP with dCMP deaminase.
Topics: Animals; Azacitidine; Cell Line; Cell Survival; DCMP Deaminase; Decitabine; Deoxycytosine Nucleotides; DNA, Neoplasm; Drug Synergism; Humans; Methylation; Mice; Nucleotide Deaminases; Thymidine; Thymine Nucleotides | 1986 |
In vitro transformation of primary rat tracheal epithelial cells by 5-azacytidine.
Topics: Animals; Azacitidine; Cell Transformation, Neoplastic; Cells, Cultured; Decitabine; DNA; Dose-Response Relationship, Drug; Epithelium; Male; Methylation; Methylnitronitrosoguanidine; Mutation; Rats; Rats, Inbred F344; Time Factors; Trachea | 1986 |
Antagonism of 5-aza-2'-deoxycytidine antileukemic activity by concomitant treatment with cytarabine.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Drug Interactions; Leukemia L1210; Male; Mice; Statistics as Topic | 1986 |
Growth inhibitory effects of 5-aza-2'-deoxycytidine in HL-60 promyelocytic leukemia cells resistant to differentiation induction.
Topics: Azacitidine; Cell Cycle; Cell Differentiation; Cell Division; Cell Line; Decitabine; Dimethyl Sulfoxide; Humans; Nitroblue Tetrazolium; Tretinoin | 1986 |
Differential inhibition of sister chromatid condensation induced by 5-azadeoxycytidine in human chromosomes.
Topics: Azacitidine; Bromodeoxyuridine; Chromatids; Decitabine; Depression, Chemical; Humans; Male; Metaphase; Sister Chromatid Exchange; Staining and Labeling | 1986 |
Effects of nucleoside analogs and sodium butyrate on recovery from potentially lethal X ray damage in human colon tumor cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Azacitidine; Butyrates; Butyric Acid; Cells, Cultured; Colon; Colonic Neoplasms; Decitabine; Humans; Radiation-Sensitizing Agents | 1987 |
Selection of metastatic variants with identifiable karyotypic changes from a nonmetastatic murine tumor after treatment with 2'-deoxy-5-azacytidine or hydroxyurea: implications for the mechanisms of tumor progression.
Topics: Animals; Azacitidine; Cell Division; Clone Cells; Decitabine; DNA; Female; Hydroxyurea; Karyotyping; Mammary Neoplasms, Experimental; Mathematics; Mice; Mice, Inbred CBA; Neoplasm Metastasis; Phenotype | 1987 |
DNA methylation alters chromatin structure and regulates Thy-1 expression in EL-4 T cells.
Topics: 5-Methylcytosine; Animals; Antigens, Surface; Azacitidine; Cell Line; Chromatin; Cytosine; Decitabine; DNA, Neoplasm; Ethyl Methanesulfonate; Gene Expression Regulation; Lymphoma; Methylation; Mice; Mice, Inbred C57BL; RNA, Messenger; T-Lymphocytes; Thy-1 Antigens | 1987 |
In vitro biochemical tests to evaluate the response to therapy of acute leukemia with cytosine arabinoside or 5-AZA-2'-deoxycytidine.
Topics: Adult; Azacitidine; Cells, Cultured; Child; Cytarabine; Cytidine Deaminase; Decitabine; Deoxycytidine Kinase; DNA Replication; DNA, Neoplasm; Drug Resistance; Humans; In Vitro Techniques; Infant; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Thymidine Kinase | 1987 |
Effect of 5-azacytidine and congeners on DNA methylation and expression of deoxycytidine kinase in the human lymphoid cell lines CCRF/CEM/0 and CCRF/CEM/dCk-1.
Topics: Azacitidine; Cell Line; Cytarabine; Decitabine; Deoxycytidine Kinase; DNA; DNA (Cytosine-5-)-Methyltransferases; Drug Resistance; Humans; Lymphoid Tissue; Methylation; Phosphotransferases | 1987 |
In situ augmentation of class I major histocompatibility antigen expression on immunogenic variants of a spontaneous murine mammary carcinoma.
Topics: Adenocarcinoma; Animals; Azacitidine; Decitabine; Female; Graft Rejection; Histocompatibility Antigens; Histocompatibility Antigens Class II; Mammary Neoplasms, Experimental; Methylnitronitrosoguanidine; Mice; Mice, Inbred C3H; Mice, Inbred CBA; Neoplasm Transplantation | 1987 |
Modulation of cell-mediated immunity with 5-azapyrimidine nucleosides.
Topics: Adjuvants, Immunologic; Animals; Azacitidine; Decitabine; Graft vs Host Reaction; Host vs Graft Reaction; Immunity, Cellular; Immunosuppressive Agents; In Vitro Techniques; Mice; Mice, Inbred Strains; Spleen; Transplantation, Homologous | 1987 |
Resistance of HL-60 promyelocytic leukemia cells to induction of differentiation and its reversal by combination treatment.
Topics: Antineoplastic Agents; Azacitidine; Cell Differentiation; Cell Line; Decitabine; Dimethyl Sulfoxide; Drug Synergism; Humans; Leukemia, Myeloid, Acute; Tretinoin | 1987 |
5-Azacytidine and 5-aza-2'-deoxycytidine behave as different antineoplastic agents in B16 melanoma.
Topics: Animals; Antineoplastic Agents; Azacitidine; Cell Survival; Cells, Cultured; Cytidine; Decitabine; Drug Resistance; Melanoma; Mice; Mutation; Uridine | 1987 |
Differential nuclear protein binding to 5-azacytosine-containing DNA as a potential mechanism for 5-aza-2'-deoxycytidine resistance.
Topics: 5-Methylcytosine; Animals; Azacitidine; Cell Line; Cell Nucleus; Cytarabine; Cytosine; Decitabine; DNA; DNA (Cytosine-5-)-Methyltransferases; DNA-Binding Proteins; Drug Resistance; Methylation; Mice | 1987 |
Effect of deoxycytidine on the metabolism and cytotoxicity of 5-aza-2'-deoxycytidine and arabinosyl 5-azacytosine in normal and leukemic human myeloid progenitor cells.
Topics: Acute Disease; Azacitidine; Bone Marrow; Decitabine; Deoxycytidine; Deoxycytosine Nucleotides; DNA, Neoplasm; Hematopoietic Stem Cells; Humans; Leukemia; Neoplastic Stem Cells | 1987 |
Gene reactivation: a tool for the isolation of mammalian DNA methylation mutants.
Topics: Animals; Antineoplastic Agents; Azacitidine; Cell Line; Cricetinae; Cricetulus; Decitabine; DNA; Ethyl Methanesulfonate; Female; Genes; Metallothionein; Methylation; Mutation; Nucleic Acid Hybridization; Ovary; Temperature; Thymidine Kinase | 1987 |
High degree of resistance to 5-aza-2'-deoxycytidine in L1210 cells in vitro associated with almost complete loss of deoxycytidine kinase activity.
Topics: 5-Methylcytosine; Animals; Azacitidine; Cell Line; Cells, Cultured; Cytosine; Decitabine; Deoxycytidine; Deoxycytidine Kinase; DNA (Cytosine-5-)-Methyltransferases; Drug Resistance; Leukemia L1210; Mice; Phosphorylation; Phosphotransferases | 1987 |
Regulated expression of tumor-specific and MHC class I antigens in an ultraviolet radiation-induced murine skin cancer.
Topics: Animals; Antigens, Neoplasm; Azacitidine; Decitabine; Gene Expression Regulation; H-2 Antigens; Histocompatibility Antigens; Interferon-gamma; Methylation; Mice; Neoplasms, Radiation-Induced; Skin Neoplasms; Ultraviolet Rays | 1988 |
Heritable high frequency modulation of antigen expression in neoplastic cells exposed to 5-aza-2'-deoxycytidine or hydroxyurea: analysis and implications.
Topics: Animals; Antigens, Neoplasm; Azacitidine; Decitabine; DNA, Neoplasm; Histocompatibility Antigens; Humans; Hydroxyurea; Mammary Neoplasms, Experimental; Melanoma, Experimental; Methylation; Mice; Tumor Cells, Cultured | 1988 |
Inhibition of condensation in the late-replicating X chromosome induced by 5-azadeoxycytidine in human lymphocyte cultures.
Topics: Azacitidine; Cells, Cultured; Decitabine; DNA Replication; Dosage Compensation, Genetic; Humans; Karyotyping; Lymphocytes; Metaphase; X Chromosome | 1988 |
Increased metallothionein gene expression in 5-aza-2'-deoxycytidine-induced resistance to cadmium cytotoxicity.
Topics: Animals; Azacitidine; Cadmium; Cell Line; Cell Survival; Decitabine; DNA; DNA Restriction Enzymes; Dose-Response Relationship, Drug; Drug Resistance; Gene Expression Regulation; Hydroxyurea; Kinetics; Liver; Metallothionein; Methylation; Nucleic Acid Hybridization; Rats; Rats, Inbred F344 | 1988 |
Variable DNA methylation changes during differentiation of human melanoma cells.
Topics: Aphidicolin; Azacitidine; Cell Differentiation; Cell Division; Chromatography, High Pressure Liquid; Cytarabine; Decitabine; Diterpenes; DNA; DNA, Neoplasm; Humans; Hydroxyurea; Methylation; Monophenol Monooxygenase; Tetradecanoylphorbol Acetate; Tumor Cells, Cultured | 1988 |
Effect of ageing on reactivation of the human X-linked HPRT locus.
Topics: Aging; Azacitidine; Decitabine; Dosage Compensation, Genetic; Female; Heterozygote; Humans; Hypoxanthine Phosphoribosyltransferase; Lesch-Nyhan Syndrome; Skin; X Chromosome | 1988 |
Capture and characterization of 5-aza-2'-deoxycytidine-treated C3H/10T1/2 cells prior to transformation.
Topics: Animals; Antineoplastic Agents; Azacitidine; Cell Division; Cell Transformation, Neoplastic; Cells, Cultured; Clone Cells; Decitabine; Mice; Mice, Inbred C3H; Nucleic Acid Hybridization; RNA | 1988 |
Comparison of the antileukaemic activity of 5 aza-2-deoxycytidine and arabinofuranosyl-cytosine in rats with myelocytic leukaemia.
Topics: Animals; Antineoplastic Agents; Azacitidine; Bone Marrow; Cell Cycle; Colony-Forming Units Assay; Cytarabine; Decitabine; DNA; Dose-Response Relationship, Drug; Female; Leukemia, Myeloid; Rats; Rats, Inbred BN; Time Factors | 1988 |
Preclinical antitumor activity of 5-aza-2'-deoxycytidine against human and neck cancer xenografts [corrected].
Topics: Animals; Antineoplastic Agents; Azacitidine; Decitabine; Drug Administration Schedule; Drug Screening Assays, Antitumor; Female; Head and Neck Neoplasms; Mice; Mice, Nude; Neoplasm Transplantation | 1988 |
DNA methylation and differentiation.
Topics: Animals; Azacitidine; Cell Differentiation; Decitabine; DNA; Gene Expression Regulation; Humans; In Vitro Techniques; Methylation | 1989 |
Gene structure and transcription in mouse cells with extensively demethylated DNA.
Topics: 5-Methylcytosine; Animals; Azacitidine; Chromatin; Clone Cells; Cytosine; Decitabine; DNA; Gene Expression Regulation; Methylation; Mice; Transcription, Genetic | 1989 |
Immunological characteristics of immunogenic variants induced in the MCA-F murine fibrosarcoma using 1-methyl-3-nitro-1-nitrosoguanidine, 5-aza-2'-deoxycytidine, or ultraviolet radiation.
Topics: Animals; Azacitidine; Cross Reactions; Decitabine; Female; Fibrosarcoma; H-2 Antigens; Methylnitronitrosoguanidine; Mice; Mice, Inbred C3H; Phenotype; Tumor Cells, Cultured; Ultraviolet Rays | 1989 |
Differential effects of 5-azacytidine and 5-azadeoxycytidine on cytotoxicity, DNA-strand breaking and repair of X-ray-induced DNA damage in HeLa cells.
Topics: Antineoplastic Agents; Azacitidine; Cell Survival; Decitabine; DNA Damage; DNA Repair; DNA, Single-Stranded; HeLa Cells; Humans; Nucleosides | 1989 |
Preclinical evaluation of hematopoietic toxicity of antileukemic agent, 5-aza-2'-deoxycytidine.
Topics: Animals; Antineoplastic Agents; Azacitidine; Bone Marrow; Bone Marrow Cells; Cell Count; Colony-Forming Units Assay; Decitabine; DNA; Dogs; Granulocytes; Hematopoiesis; Infusions, Intravenous; Leukocyte Count; Male; Mice; Platelet Count | 1989 |
5-Aza-2'-deoxycytidine as inducer of differentiation and growth inhibition in mouse neuroblastoma cells.
Topics: Acetylcholinesterase; Animals; Azacitidine; Cell Differentiation; Cell Division; Cell Survival; Decitabine; DNA; Methylation; Mice; Neuroblastoma; Tumor Cells, Cultured | 1989 |
Activation and demethylation of the intracisternal A particle genes by 5-azacytidine.
Topics: Animals; Azacitidine; Cell Line; Dealkylation; Decitabine; Gene Expression Regulation; Genes, Intracisternal A-Particle; Methylation; Mice; Microscopy, Electron; Proto-Oncogenes; RNA, Messenger | 1989 |
5-Azadeoxycytidine induced undercondensation in the giant X chromosomes of Microtus agrestis.
Topics: Animals; Arvicolinae; Azacitidine; Cell Line; Decitabine; DNA Replication; Female; Fibroblasts; Heterochromatin; Karyotyping; Metaphase; Translocation, Genetic; X Chromosome | 1989 |
Increased frequencies of sister chromatid exchanges at common fragile sites (1)(q42) and (19)(q13).
Topics: Azacitidine; Bromodeoxyuridine; Cells, Cultured; Chromosome Banding; Chromosome Fragile Sites; Chromosome Fragility; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 19; Decitabine; Humans; Karyotyping; Sister Chromatid Exchange | 1989 |
Electron microscopic characterisation of retrovirus and retrovirus-like particles induced by demethylating agents (5-azacytidine and 5-azadeoxycytidine) in Syrian hamster (Mesocricetus auratus) cells.
Topics: Animals; Antineoplastic Agents; Azacitidine; Cell Line; Cells, Cultured; Cricetinae; Decitabine; Kidney; Mesocricetus; Microscopy, Electron; Retroviridae; Tumor Cells, Cultured | 1989 |
2-Aminopurine as a probe for mismatch repair in mammalian cells and its relationship to DNA methylation.
Topics: 2-Aminopurine; Adenine; Animals; Azacitidine; Cell Line; Clone Cells; Cricetinae; Cricetulus; Decitabine; DNA; DNA Repair; DNA Replication; Female; Methylation; Molecular Probes; Ovary | 1989 |
Maintenance of DNA methylation level in SV40-infected human fibroblasts during their in vitro limited proliferative life span.
Topics: 5-Methylcytosine; Azacitidine; Base Composition; Cell Division; Cell Transformation, Viral; Cytosine; Decitabine; DNA; Humans; In Vitro Techniques; Methylation; Simian virus 40 | 1989 |
Mechanism of action of 5-AZA-dC: induced DNA hypomethylation does not lead to aberrant gene expression in human leukemic CEM cells.
Topics: Antineoplastic Agents; Azacitidine; Cell Line; Decitabine; DNA Damage; DNA, Neoplasm; Gene Expression; Humans; Kinetics; Methylation; Neoplasm Proteins; Precursor Cell Lymphoblastic Leukemia-Lymphoma; RNA, Neoplasm | 1989 |
Chemotherapy of L1210 and L1210/ARA-C leukemia with 5-aza-2'-deoxycytidine and 3-deazauridine.
Topics: 3-Deazauridine; Animals; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cell Line; Cytarabine; Decitabine; Drug Interactions; Drug Resistance; Drug Screening Assays, Antitumor; Leukemia L1210; Male; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Tumor Cells, Cultured | 1989 |
5-Aza-2'-deoxycytidine as a differentiation inducer in acute myeloid leukaemias and myelodysplastic syndromes of the elderly.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Azacitidine; Bone Marrow; Cell Differentiation; Decitabine; Drug Evaluation; Female; Humans; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Neoplastic Stem Cells | 1989 |
The antileukaemic activity of 5-Aza-2-deoxycytidine (Aza-dC) in patients with relapsed acute leukaemia.
Topics: Antineoplastic Agents; Azacitidine; Bone Marrow; Decitabine; Drug Evaluation; Humans; Leukemia, Myeloid, Acute; Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1989 |
Comparison of the in vitro cytotoxicity (L1210) of 5-aza-2'-deoxycytidine with its therapeutic and toxic effects in mice.
Topics: Animals; Antineoplastic Agents; Azacitidine; Cell Survival; Cells, Cultured; Decitabine; Dose-Response Relationship, Drug; Kinetics; Leukemia L1210; Mice | 1985 |
Tetrahydrouridine, cytidine analogues, and hemoglobin F.
Topics: Agranulocytosis; Animals; Azacitidine; Cytidine Deaminase; Decitabine; Fetal Hemoglobin; Gene Expression Regulation; Globins; Granulocytes; Papio; Tetrahydrouridine; Uridine | 1985 |
Delayed methylation and the matrix bound DNA methylase.
Topics: Animals; Azacitidine; Binding Sites; Cell Nucleus; Decitabine; DNA; DNA (Cytosine-5-)-Methyltransferases; In Vitro Techniques; L Cells; Methylation; Methyltransferases; Mice; Time Factors | 1985 |
The effect of 5-azacytidine and its analogues on blast cell renewal in acute myeloblastic leukemia.
Topics: Azacitidine; Cell Division; Culture Media; Decitabine; Dose-Response Relationship, Drug; Humans; Leukemia, Myeloid, Acute; Neoplastic Stem Cells; Phenotype; Stem Cells | 1985 |
Nuclear matrix-associated DNA methylase.
Topics: Ammonium Sulfate; Animals; Antineoplastic Agents; Azacitidine; Carcinoma, Krebs 2; Cell Nucleus; Decitabine; DNA (Cytosine-5-)-Methyltransferases; Kinetics; L Cells; Methylation; Methyltransferases; Mice; Solubility | 1985 |
Experimental chemotherapy (L1210) with 5-aza-2'-deoxycytidine in combination with pyran copolymer (MVE-4), an immune adjuvant.
Topics: Adjuvants, Immunologic; Animals; Antibody Formation; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Decitabine; Leukemia L1210; Mice; Mice, Inbred Strains; Pyran Copolymer | 1985 |
Comparison of the antileukemic activity of 5-AZA-2'-deoxycytidine, 1-beta-D-arabinofuranosylcytosine and 5-azacytidine against L1210 leukemia.
Topics: Animals; Antineoplastic Agents; Azacitidine; Cytarabine; Decitabine; DNA, Neoplasm; Leukemia L1210; Male; Methylation; Mice; Mice, Inbred BALB C; Mice, Inbred DBA | 1984 |
Effects of 5-aza-2'-deoxycytidine in combination with the biochemical modulator thymidine or the immune modulator pyran copolymer on L1210 leukemia-bearing mice.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Body Weight; Decitabine; Leukemia L1210; Male; Mice; Polymers; Pyran Copolymer; Thymidine; Time Factors | 1984 |
Cellular differentiation, cytidine analogs and DNA methylation.
Topics: Adipose Tissue; Animals; Azacitidine; Cell Differentiation; Cells, Cultured; Cytarabine; Cytidine; Decitabine; Deoxycytidine; DNA; DNA (Cytosine-5-)-Methyltransferases; Methylation; Methyltransferases; Mice; Muscles; Structure-Activity Relationship | 1980 |
5-Aza-2'-deoxycytidine: preclinical studies in mice.
Topics: Animals; Azacitidine; Biotransformation; Cell-Free System; Decitabine; DNA; Hematopoiesis; Male; Mice; Phosphorylation; Spleen; Time Factors | 1980 |
Kinetics of 5-aza-2'-deoxycytidine phosphorylation in mouse spleen and L1210 leukemic cell extracts.
Topics: Animals; Azacitidine; Binding, Competitive; Cell-Free System; Decitabine; Deoxycytidine Kinase; Deoxyribonucleosides; Kinetics; Leukemia L1210; Mice; Nucleosides; Phosphorylation; Spleen | 1980 |
Transformation and metabolic effects of 5-aza-2'-deoxycytidine in mice.
Topics: Animals; Antineoplastic Agents; Azacitidine; Biotransformation; Cell-Free System; Cyclic AMP; Cytidine Deaminase; Decitabine; Deoxycytidine Kinase; DNA; Female; Liver; Mice; Spleen | 1980 |
High-performance liquid chromatographic analysis of chemical stability of 5-aza-2'-deoxycytidine.
Topics: Azacitidine; Chromatography, High Pressure Liquid; Decitabine; Drug Stability; Kinetics | 1981 |
Dose- and schedule-dependent activation and drug synergism between thymidine and 5-aza-2'-deoxycytidine in a human promyelocytic leukemia cell line.
Topics: Animals; Antineoplastic Agents; Azacitidine; Biological Transport; Cell Line; Cell Survival; Chromatography, High Pressure Liquid; Decitabine; DNA; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Humans; Leukemia L1210; Leukemia, Myeloid, Acute; Mice; Thymidine; Time Factors | 1982 |
Inhibition of DNA methyltransferase and induction of Friend erythroleukemia cell differentiation by 5-azacytidine and 5-aza-2'-deoxycytidine.
Topics: Animals; Azacitidine; Cell Differentiation; Cell Line; Cell Survival; Decitabine; Dimethyl Sulfoxide; DNA (Cytosine-5-)-Methyltransferases; DNA Replication; Kinetics; Leukemia, Experimental; Methyltransferases; Mice | 1982 |
Phase I study on 5-aza-2'-deoxycytidine in children with acute leukemia.
Topics: Acute Disease; Adolescent; Antineoplastic Agents; Azacitidine; Child; Child, Preschool; Cytarabine; Decitabine; Dose-Response Relationship, Drug; Drug Evaluation; Hematopoietic System; Humans; Leukemia; Male | 1981 |
Synergistic effect of cis-dichlorodiammineplatinum and 5-aza-2'-deoxycytidine on mouse leukemic cells in vivo and in vitro.
Topics: Animals; Azacitidine; Cell Division; Cisplatin; Decitabine; DNA, Neoplasm; Drug Synergism; In Vitro Techniques; Leucine; Leukemia L1210; Leukemia, Experimental; Male; Mice; Mice, Inbred Strains; RNA, Neoplasm | 1982 |
Cell cycle-specific reactivation of an inactive X-chromosome locus by 5-azadeoxycytidine.
Topics: Animals; Azacitidine; Cell Division; Decitabine; DNA; Female; Genes; Humans; Hybrid Cells; Hypoxanthine Phosphoribosyltransferase; Interphase; Methylation; Mice; Sex Chromosomes; X Chromosome | 1982 |
Toxicology in mice of the antileukemic agent 5-aza-2'-deoxycytidine.
Topics: Animals; Antineoplastic Agents; Azacitidine; Blood Cells; Decitabine; Female; Lethal Dose 50; Male; Mice; Mice, Inbred BALB C; Mice, Inbred DBA | 1981 |
The effect of 5-azadeoxycytidine on cell growth and DNA methylation.
Topics: Animals; Azacitidine; Cell Division; Cell Line; Cricetinae; Decitabine; DNA Replication; Methylation; Mice; Time Factors | 1982 |
Inhibitory effects of 5-azapyrimidine nucleosides on cellular immunity.
Topics: Animals; Antineoplastic Agents; Azacitidine; Decitabine; Female; Graft Survival; Immunity, Cellular; Male; Mice; Mice, Inbred A; Rats; Rats, Inbred Lew; Skin Transplantation | 1982 |
Combinational chemotherapy of L1210 and L1210/ARA-C leukemia with 5-AZA-2'-deoxycytidine and beta-2'-deoxythioguanosine.
Topics: Animals; Antineoplastic Agents; Azacitidine; Decitabine; Deoxyguanosine; Drug Evaluation; Drug Therapy, Combination; Leukemia L1210; Male; Mice; Thionucleosides | 1982 |
Plasma and cerebrospinal fluid pharmacokinetics of 5-Aza-2'-deoxycytidine in rabbits and dogs.
Topics: Animals; Antineoplastic Agents; Azacitidine; Blood Proteins; Chromatography, High Pressure Liquid; Decitabine; Dogs; Female; Half-Life; Kinetics; Male; Protein Binding; Rabbits | 1983 |
Kinetics of deamination of 5-aza-2'-deoxycytidine and cytosine arabinoside by human liver cytidine deaminase and its inhibition by 3-deazauridine, thymidine or uracil arabinoside.
Topics: 3-Deazauridine; Adult; Arabinofuranosyluracil; Azacitidine; Cytarabine; Cytidine Deaminase; Cytosine; Decitabine; Humans; Kinetics; Liver; Nucleoside Deaminases; Substrate Specificity; Thymidine | 1983 |
Inhibition of DNA methylation in L1210 leukemic cells by 5-aza-2'-deoxycytidine as a possible mechanism of chemotherapeutic action.
Topics: 5-Methylcytosine; Animals; Antineoplastic Agents; Azacitidine; Cytosine; Decitabine; DNA; DNA (Cytosine-5-)-Methyltransferases; Dose-Response Relationship, Drug; Leukemia L1210; Male; Methylation; Mice | 1983 |
5-aza-2'-deoxycytidine therapy in patients with acute leukemia inhibits DNA methylation.
Topics: Azacitidine; Cell Line; Decitabine; DNA, Neoplasm; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Methylation | 1984 |
5-Aza-2'-deoxycytidine induces terminal differentiation of leukemic blasts from patients with acute myeloid leukemias.
Topics: Azacitidine; Cell Differentiation; Cells, Cultured; Decitabine; Humans; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Neoplastic Stem Cells | 1984 |
Effects of the alpha-D-anomer of 5-aza-2'-deoxycytidine on L1210 mouse leukemic cells in vitro and in vivo.
Topics: Animals; Azacitidine; Cell Division; Decitabine; Deoxycytidine Kinase; DNA Replication; Drug Evaluation, Preclinical; Isomerism; Leukemia L1210; Mice; Transcription, Genetic | 1984 |
Cell cycle effects and cellular pharmacology of 5-aza-2'-deoxycytidine.
Topics: Animals; Azacitidine; Cell Cycle; Cell Line; Cell Survival; Decitabine; DNA Replication; Female; Mammary Neoplasms, Experimental; Mice; Mutation; Thioguanine | 1984 |
DNA methylation in 5-aza-2'-deoxycytidine-resistant variants of C3H 10T1/2 C18 cells.
Topics: Animals; Azacitidine; Cell Line; Cytosine; Decitabine; DNA; Drug Resistance; Kinetics; Methylation; Mice; Mice, Inbred C3H | 1984 |
Effects of dose and duration of exposure on 5-aza-2'-deoxycytidine cytotoxicity for L1210 leukemia in vitro.
Topics: Animals; Azacitidine; Cell Division; Cell Survival; Clone Cells; Decitabine; Kinetics; Leukemia L1210; Mice; Time Factors | 1984 |
Antileukemic activity of 5-aza-2'-deoxycytidine and cytarabine against intracerebral L1210 murine leukemia.
Topics: Animals; Azacitidine; Brain Neoplasms; Cytarabine; Decitabine; Dose-Response Relationship, Drug; Kinetics; Leukemia L1210; Male; Mice; Mice, Inbred Strains | 1984 |
Induction of cholinergic and adrenergic differentiation in N-18 cells by differentiation agents and DNA demethylating agents.
Topics: Acetylcholine; Antineoplastic Agents; Azacitidine; Cell Differentiation; Choline O-Acetyltransferase; Culture Media, Conditioned; Decitabine; DNA, Neoplasm; Methylation; Neurons; RNA, Messenger; Sympathetic Nervous System; Tumor Cells, Cultured; Tyrosine 3-Monooxygenase | 1993 |
Antiproliferative effects and DNA hypomethylation by 5-aza-2'-deoxycytidine in human neuroblastoma cell lines.
Topics: Antigens, Differentiation; Antineoplastic Agents; Azacitidine; Brain Neoplasms; Cell Division; Decitabine; Deoxycytidine; Deoxycytidine Kinase; DNA-Cytosine Methylases; DNA, Neoplasm; Humans; Methylation; Neuroblastoma; Tumor Cells, Cultured | 1993 |
Exemption of satellite DNA from demethylation in immortalized differentiated derivatives of F9 mouse embryonal carcinoma cells.
Topics: Animals; Antineoplastic Agents; Azacitidine; Carcinoma, Embryonal; Cell Differentiation; Cell Division; Cell Line; Cell Line, Transformed; Collagen; Decitabine; DNA, Neoplasm; DNA, Satellite; Embryo, Mammalian; Endoderm; Glyceraldehyde-3-Phosphate Dehydrogenases; Kinetics; Methylation; Mice; Pseudogenes; Repetitive Sequences, Nucleic Acid; Restriction Mapping; RNA, Messenger; Stem Cells; Tumor Cells, Cultured | 1994 |
Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2'-deoxycytidine.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Azacitidine; Base Sequence; Cell Line; Cytotoxicity, Immunologic; Decitabine; DNA Primers; Female; Gene Expression Regulation, Neoplastic; Glyceraldehyde-3-Phosphate Dehydrogenases; Humans; Lymphocytes; Lymphocytes, Tumor-Infiltrating; Melanocytes; Melanoma; Melanoma-Specific Antigens; Molecular Sequence Data; Neoplasm Metastasis; Neoplasm Proteins; Neoplasms; Polymerase Chain Reaction; RNA, Neoplasm; Tumor Cells, Cultured | 1994 |
Regulation of folate-binding protein gene expression by DNA methylation in methotrexate-resistant KB cells.
Topics: Azacitidine; Blotting, Southern; Carrier Proteins; Decitabine; DNA, Neoplasm; Drug Resistance; Folate Receptors, GPI-Anchored; Gene Expression Regulation, Neoplastic; Humans; KB Cells; Methotrexate; Methylation; Receptors, Cell Surface; Transcription, Genetic | 1994 |
5-Aza-2'-deoxycytidine induces growth inhibition and upregulation of epidermal growth factor receptor on human epithelial cancer cells.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antineoplastic Agents; Azacitidine; Carcinoma, Squamous Cell; Cell Division; Decitabine; Endocytosis; ErbB Receptors; Humans; KB Cells; Tumor Cells, Cultured; Up-Regulation | 1994 |
S-adenosyl-L-homocysteine: a non-cytotoxic hypomethylating agent.
Topics: Azacitidine; Cell Membrane Permeability; Cells, Cultured; Decitabine; DNA; DNA Modification Methylases; DNA Replication; Fibroblasts; Humans; L-Lactate Dehydrogenase; Methylation; Mitochondria; S-Adenosylhomocysteine; Tetrazolium Salts | 1994 |
Enhancement of the antileukemic activity of 5-aza-2'-deoxycytidine by cyclopentenyl cytosine in HL-60 leukemic cells.
Topics: Antineoplastic Agents; Azacitidine; Cell Division; Cytidine; Cytidine Deaminase; Decitabine; Deoxycytosine Nucleotides; DNA, Neoplasm; Drug Synergism; Humans; Leukemia, Experimental; Tumor Cells, Cultured | 1994 |
Toxicity of 5-aza-2'-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation.
Topics: Animals; Antineoplastic Agents; Azacitidine; Blotting, Southern; Cell Division; Cell Survival; Cells, Cultured; Crosses, Genetic; Decitabine; DNA; DNA (Cytosine-5-)-Methyltransferases; Embryo, Mammalian; Female; Fibroblasts; Genotype; Heterozygote; Kinetics; Mice; Mutagens; Mutation; Pregnancy; Stem Cells | 1994 |
Transfection of wild-type deoxycytidine kinase (dck) cDNA into an AraC- and DAC-resistant rat leukemic cell line of clonal origin fully restores drug sensitivity.
Topics: Animals; Azacitidine; Base Sequence; Cytarabine; Decitabine; Deoxycytidine Kinase; DNA, Complementary; Drug Resistance; Leukemia, Experimental; Molecular Sequence Data; Phosphorylation; Rats; Recombinant Fusion Proteins; RNA, Messenger; Transfection; Tumor Cells, Cultured | 1995 |
Synergistic and additive combinations of several antitumor drugs and other agents with the potent alkylating agent adozelesin.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aphidicolin; Azacitidine; Benzofurans; Caffeine; Cell Survival; CHO Cells; Cisplatin; Cricetinae; Cricetulus; Cyclohexanecarboxylic Acids; Cyclohexenes; Decitabine; Deoxyadenosines; DNA; Dose-Response Relationship, Drug; Drug Synergism; Duocarmycins; Indoles; Melanoma, Experimental; Melphalan; Mutagens; Organoplatinum Compounds; Pentoxifylline; Tumor Cells, Cultured | 1995 |
Pharmacologic activation of expression of immunodominant viral antigens: a new strategy for the treatment of Epstein-Barr-virus-associated malignancies.
Topics: Adult; Antigens, Viral; Azacitidine; Base Sequence; Burkitt Lymphoma; Decitabine; DNA-Binding Proteins; DNA, Neoplasm; DNA, Viral; Epstein-Barr Virus Nuclear Antigens; Gene Expression Regulation, Viral; Herpesviridae Infections; Herpesvirus 4, Human; Humans; Immunodominant Epitopes; Lymphoma, B-Cell; Methylation; Molecular Sequence Data; Polymerase Chain Reaction; Tumor Cells, Cultured; Tumor Virus Infections; Viral Matrix Proteins; Virus Activation | 1995 |
Transcriptional regulation of the mts1 gene in human lymphoma cells: the role of DNA-methylation.
Topics: Azacitidine; Decitabine; DNA Modification Methylases; Gene Expression Regulation; Humans; Lymphoma; Methylation; Neoplasm Metastasis; Restriction Mapping; Transcription, Genetic; Tumor Cells, Cultured | 1995 |
Cell death and cell cycle perturbation in the developmental toxicity of the demethylating agent, 5-aza-2'-deoxycytidine.
Topics: Animals; Azacitidine; Cell Cycle; Cell Death; Decitabine; DNA; Dose-Response Relationship, Drug; Female; Flow Cytometry; Limb Deformities, Congenital; Mice; Pregnancy; Teratogens | 1994 |
Suppression of intestinal neoplasia by DNA hypomethylation.
Topics: Adenomatous Polyposis Coli; Animals; Azacitidine; Decitabine; DNA Modification Methylases; Heterozygote; Intestinal Polyps; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Models, Biological; Suppression, Genetic; Time Factors | 1995 |
Demethylation of the estrogen receptor gene in estrogen receptor-negative breast cancer cells can reactivate estrogen receptor gene expression.
Topics: Antineoplastic Agents; Azacitidine; Base Sequence; Breast Neoplasms; Cytosine; Decitabine; DNA, Neoplasm; Gene Expression; Gene Expression Regulation, Neoplastic; Guanine; Humans; Methylation; Molecular Sequence Data; Receptors, Estrogen; RNA, Messenger; Tumor Cells, Cultured | 1995 |
De novo induced mutations in the deoxycytidine kinase (dck) gene in rat leukemic clonal cell lines confer resistance to cytarabine (AraC) and 5-aza-2'-deoxycytidine (DAC).
Topics: Animals; Antineoplastic Agents; Azacitidine; Blotting, Southern; Cell Line; Cytarabine; Decitabine; Deoxycytidine Kinase; Drug Resistance; Gene Expression; Kinetics; Leukemia, Experimental; Polymerase Chain Reaction; Polymorphism, Genetic; Rats; Restriction Mapping; Time Factors; Transcription, Genetic; Tumor Cells, Cultured | 1995 |
In vitro-induced resistance to the deoxycytidine analogues cytarabine (AraC) and 5-aza-2'-deoxycytidine (DAC) in a rat model for acute myeloid leukemia is mediated by mutations in the deoxycytidine kinase (dck) gene.
Topics: Animals; Antineoplastic Agents; Azacitidine; Base Sequence; Chromosome Aberrations; Cytarabine; Decitabine; Deoxycytidine Kinase; Drug Resistance; In Situ Hybridization, Fluorescence; Leukemia, Myeloid, Acute; Molecular Sequence Data; Point Mutation; Polymorphism, Single-Stranded Conformational; Rats; Translocation, Genetic; Tumor Cells, Cultured | 1995 |
Biological and molecular studies on Syrian hamster intracisternal R-type particles.
Topics: Animals; Azacitidine; Cell Line; Cricetinae; Decitabine; Gene Expression Regulation; Mesocricetus; Microscopy, Electron; Molecular Probes; Retroviridae; RNA, Viral | 1995 |
CDKN2 gene silencing in lung cancer by DNA hypermethylation and kinetics of p16INK4 protein induction by 5-aza 2'deoxycytidine.
Topics: Azacitidine; Base Sequence; Carrier Proteins; Cyclin-Dependent Kinase Inhibitor p16; Decitabine; DNA; DNA Modification Methylases; Enzyme Inhibitors; Gene Expression Regulation; Humans; Lung Neoplasms; Methylation; Molecular Sequence Data; Protein Kinase Inhibitors; Tumor Cells, Cultured | 1995 |
5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers.
Topics: 5-Methylcytosine; Alleles; Azacitidine; Base Sequence; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Carrier Proteins; Chromosomes, Human, Pair 9; CpG Islands; Cyclin-Dependent Kinase Inhibitor p16; Cytosine; Decitabine; DNA, Neoplasm; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Glioma; Head and Neck Neoplasms; Humans; Lung Neoplasms; Methylation; Molecular Sequence Data; Neoplasm Proteins; Neoplasms; Sequence Deletion; Transcription, Genetic; Tumor Cells, Cultured | 1995 |
2'-deoxy-5-azacytidine increases binding of cisplatin to DNA by a mechanism independent of DNA hypomethylation.
Topics: Azacitidine; Cisplatin; Decitabine; DNA; DNA Damage; Drug Synergism; Humans; Methylation; Plasmids; Spectrophotometry, Atomic | 1993 |
Inactivation of a tumor suppressor function in immortal Syrian hamster cells by N-methyl-N'-nitro-N-nitrosoguanidine and by 5-aza-2'-deoxycytidine.
Topics: Animals; Antineoplastic Agents; Azacitidine; Cell Adhesion; Cell Division; Cell Line; Cell Transformation, Neoplastic; Cells, Cultured; Cricetinae; Decitabine; Embryo, Mammalian; Epidermal Growth Factor; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Insulin; Mesocricetus; Methylnitronitrosoguanidine; Mice; Mice, Nude; Phenotype; Platelet-Derived Growth Factor | 1993 |
5-Aza-2'-Deoxycytidine and DNA Methyltransferase Inhibitors in the Treatment of Myeloid Leukemias and Myelodysplastic Syndromes: Biological Aspects and Clinical Results. Proceedings of a workshop. Rome, Italy, November 3, 1991.
Topics: Animals; Antineoplastic Agents; Azacitidine; Decitabine; Humans; Leukemia, Myeloid; Myelodysplastic Syndromes | 1993 |
Interaction of 5-aza-2'-deoxycytidine with amsacrine or 1,25-dihydroxyvitamin D3 on HL-60 myeloid leukemic cells and inhibitors of cytidine deaminase.
Topics: Amsacrine; Antineoplastic Agents; Azacitidine; Calcitriol; Decitabine; Drug Interactions; Drug Screening Assays, Antitumor; Humans; Leukemia, Myeloid; Time Factors; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1993 |
5-Aza-2'-deoxycytidine: cell differentiation and DNA methylation.
Topics: Antineoplastic Agents; Azacitidine; Cartilage; Cell Differentiation; Cell Line; Decitabine; DNA; Gene Expression Regulation; Methylation; Muscle Proteins; MyoD Protein; Phenotype | 1993 |
Pilot study of 5-aza-2'-deoxycytidine (Decitabine) in the treatment of poor prognosis acute myelogenous leukemia patients: preliminary results.
Topics: Aged; Antineoplastic Agents; Azacitidine; Decitabine; Female; Humans; Immunophenotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Pilot Projects; Prognosis; Remission Induction | 1993 |
Preliminary results with 5-aza-2'-deoxycytidine (DAC)-containing chemotherapy in patients with relapsed or refractory acute leukemia. The EORTC Leukemia Cooperative Group.
Topics: Acute Disease; Adolescent; Adult; Aged; Amsacrine; Antineoplastic Agents; Azacitidine; Decitabine; Female; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction | 1993 |
Effects of 5-aza-2'-deoxycytidine on differentiation and oncogene expression in the human monoblastic leukemia cell line U-937.
Topics: Antigens, Surface; Antineoplastic Agents; Azacitidine; Cell Adhesion; Cell Differentiation; Cell Division; Decitabine; DNA; Gene Expression Regulation, Neoplastic; Genes, fos; Genes, myc; Humans; Leukemia, Monocytic, Acute; Macrophages; Methylation; Monocytes; Tumor Cells, Cultured | 1993 |
Role of deoxycytidine kinase in an in vitro model for AraC- and DAC-resistance: substrate-enzyme interactions with deoxycytidine, 1-beta-D-arabinofuranosylcytosine and 5-aza-2'-deoxycytidine.
Topics: Acute Disease; Animals; Antineoplastic Agents; Azacitidine; Binding, Competitive; Cytarabine; Decitabine; Deoxycytidine; Deoxycytidine Kinase; Drug Resistance; In Vitro Techniques; Kinetics; Leukemia, Myeloid; Rats; Rats, Inbred BN; Tumor Cells, Cultured | 1993 |
Hemidemethylation is sufficient for chromatin relaxation and transcriptional activation of methylated aprt gene in mouse P19 embryonal carcinoma cell line.
Topics: Adenine Phosphoribosyltransferase; Animals; Antineoplastic Agents; Azacitidine; Chromatin; Decitabine; Enzyme Activation; Gene Expression Regulation, Enzymologic; Methylation; Mice; Teratoma; Transcription, Genetic; Tumor Cells, Cultured | 1993 |
Utility of the murine erythroleukemic cell (MELC) in assessing mechanisms of action of DNA-active developmental toxicants: application to 5-fluorouracil.
Topics: Animals; Azacitidine; Cell Cycle; Cell Survival; Culture Techniques; Cyclophosphamide; Decitabine; DNA; Fetus; Fluorouracil; Leukemia, Erythroblastic, Acute; Mice; Teratogens; Thymidylate Synthase; Toxicology; Tumor Cells, Cultured | 1993 |
Evaluation of the antineoplastic activity of adozelesin alone and in combination with 5-aza-2'-deoxycytidine and cytosine arabinoside on DLD-1 human colon carcinoma cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Benzofurans; Carcinoma, Squamous Cell; Cell Division; Colonic Neoplasms; Cyclohexanecarboxylic Acids; Cyclohexenes; Cytarabine; Decitabine; DNA, Neoplasm; Drug Screening Assays, Antitumor; Duocarmycins; Humans; Indoles; Lung Neoplasms; Time Factors; Tumor Cells, Cultured | 1993 |
The effect of 5-azacytidine (5-aza-CR) and its analogue on cell differentiation and DNA methylation of HL-60 cells.
Topics: Antineoplastic Agents; Azacitidine; Cell Differentiation; Decitabine; DNA-Cytosine Methylases; DNA-Directed RNA Polymerases; DNA, Neoplasm; Humans; Leukemia, Promyelocytic, Acute; Methylation; Tumor Cells, Cultured | 1993 |
Cytotoxic activity and mechanism of action of 5-Aza-2'-deoxycytidine in human CML cells.
Topics: Antineoplastic Agents; Azacitidine; Blast Crisis; Cytarabine; Decitabine; DNA, Neoplasm; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Time Factors; Tumor Cells, Cultured | 1993 |
5-Aza deoxyCytidine-induced inhibition of differentiation of spermatogonia into spermatocytes in the mouse.
Topics: Animals; Antispermatogenic Agents; Azacitidine; Cell Differentiation; Decitabine; DNA; DNA Modification Methylases; Isotope Labeling; Male; Methylation; Mice; Spermatocytes; Spermatogenesis; Spermatogonia | 1995 |
Specific induction of uncoiling in NORs of human acrocentric chromosomes by 5-azacytidine and 5-azadeoxicytidine.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Azacitidine; Cells, Cultured; Chromosomes; Decitabine; DNA, Satellite; Female; Humans; Lymphocytes; Microscopy, Electron; Nucleolus Organizer Region | 1995 |
Silencing of p16/CDKN2 expression in human gliomas by methylation and chromatin condensation.
Topics: Astrocytoma; Azacitidine; Base Sequence; Brain Chemistry; Brain Neoplasms; Carrier Proteins; Chromatin; Cyclin-Dependent Kinase Inhibitor p16; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA, Neoplasm; Gene Expression Regulation, Neoplastic; Glioblastoma; Glioma; Humans; Methylation; Molecular Sequence Data; Neoplasm Proteins; Regulatory Sequences, Nucleic Acid; RNA, Messenger; RNA, Neoplasm; Tumor Cells, Cultured | 1996 |
Promoter-specific modulation of insulin-like growth factor II genomic imprinting by inhibitors of DNA methylation.
Topics: Animals; Animals, Newborn; Astrocytes; Azacitidine; Cells, Cultured; Decitabine; DNA Modification Methylases; Embryo, Mammalian; Enzyme Inhibitors; Gene Expression Regulation; Genomic Imprinting; Humans; Insulin-Like Growth Factor II; Methylation; Mice; Promoter Regions, Genetic | 1996 |
The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Azacitidine; Base Sequence; Decitabine; Dinucleoside Phosphates; DNA; DNA Modification Methylases; DNA Primers; DNA Probes; DNA, Neoplasm; Enzyme Inhibitors; Genome, Human; Humans; Male; Melanoma; Melanoma-Specific Antigens; Methylation; Molecular Sequence Data; Neoplasm Proteins; Neoplasms; Polymerase Chain Reaction; Promoter Regions, Genetic; RNA, Messenger; T-Lymphocytes, Cytotoxic; Transcription, Genetic; Tumor Cells, Cultured | 1996 |
Induction of MAGE genes in lymphoid cells by the demethylating agent 5-aza-2'-deoxycytidine.
Topics: Amino Acid Sequence; Antigens, Neoplasm; Azacitidine; Base Sequence; Dealkylation; Decitabine; DNA Modification Methylases; Enzyme Inhibitors; Gene Expression Regulation; Humans; Interleukin-2; Lymphocyte Activation; Lymphocytes; Melanoma-Specific Antigens; Molecular Sequence Data; Neoplasm Proteins | 1996 |
Monoclonal antibodies against recombinant-MAGE-1 protein identify a cross-reacting 72-kDa antigen which is co-expressed with MAGE-1 protein in melanoma cells.
Topics: Animals; Antibodies, Monoclonal; Antigens, Neoplasm; Azacitidine; Cross Reactions; Decitabine; Immunohistochemistry; Melanoma; Mice; Mice, Inbred BALB C; Neoplasm Proteins; Recombinant Proteins; RNA, Messenger; Tumor Cells, Cultured | 1996 |
Expression of MAGE genes in human colorectal carcinoma.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Azacitidine; Base Sequence; Colorectal Neoplasms; Decitabine; Gene Expression Regulation, Neoplastic; Humans; Melanoma-Specific Antigens; Molecular Sequence Data; Neoplasm Proteins; Tumor Cells, Cultured | 1996 |
Teratogenic effects of the demethylating agent 5-aza-2'-deoxycytidine in the Swiss Webster mouse.
Topics: Analysis of Variance; Animals; Azacitidine; Cleft Palate; Decitabine; DNA Damage; DNA Modification Methylases; Dose-Response Relationship, Drug; Embryonic and Fetal Development; Enzyme Inhibitors; Female; Gene Expression Regulation, Developmental; Gestational Age; Hindlimb; Injections, Intraperitoneal; Mice; Pregnancy; Ribs; Spine; Teratogens | 1996 |
Chromosome 11p15.5 regional imprinting: comparative analysis of KIP2 and H19 in human tissues and Wilms' tumors.
Topics: Adult; Alleles; Azacitidine; Base Sequence; Cell Line; Child; Chromosomes, Human, Pair 11; Cyclin-Dependent Kinase Inhibitor p57; Decitabine; DNA Methylation; DNA Modification Methylases; DNA Primers; Enzyme Inhibitors; Female; Fetus; Gene Expression Regulation; Genes, Tumor Suppressor; Genomic Imprinting; Heterozygote; Humans; Infant, Newborn; Kidney Neoplasms; Male; Muscle Proteins; Nuclear Proteins; RNA, Long Noncoding; RNA, Messenger; RNA, Untranslated; Wilms Tumor | 1996 |
Altered expression of annexin II in human B-cell lymphoma cell lines.
Topics: Alkaline Phosphatase; Annexin A2; Azacitidine; B-Lymphocytes; Cell Nucleus; Decitabine; DNA Modification Methylases; Enzyme Inhibitors; Gene Expression; Humans; Immune Sera; Leukemia, Erythroblastic, Acute; Lymphoma, B-Cell; Phosphorylation; RNA, Messenger; Tumor Cells, Cultured | 1996 |
Methylated CpG points identified within MAGE-1 promoter are involved in gene repression.
Topics: Antigens, Neoplasm; Azacitidine; Decitabine; DNA Methylation; Gene Expression Regulation, Neoplastic; Humans; Melanoma-Specific Antigens; Neoplasm Proteins; Promoter Regions, Genetic; Transcription Factors; Transcription, Genetic; Tumor Cells, Cultured | 1996 |
Reversal of loss of imprinting in tumor cells by 5-aza-2'-deoxycytidine.
Topics: Azacitidine; Choriocarcinoma; Colorectal Neoplasms; Decitabine; DNA Methylation; DNA Modification Methylases; Genomic Imprinting; Humans; Insulin-Like Growth Factor II; Muscle Proteins; RNA, Long Noncoding; RNA, Untranslated; Tumor Cells, Cultured | 1997 |
Continuous infusion of low-dose 5-Aza-2'-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome.
Topics: Acute Disease; Aged; Aged, 80 and over; Anemia, Refractory; Anemia, Refractory, with Excess of Blasts; Antineoplastic Agents; Azacitidine; Decitabine; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Pancytopenia | 1997 |
Frequent aberrant methylation of p16INK4a in primary rat lung tumors.
Topics: Amino Acid Sequence; Animals; Azacitidine; Base Sequence; Carrier Proteins; Cloning, Molecular; CpG Islands; Cyclin-Dependent Kinase Inhibitor p16; Decitabine; Disease Models, Animal; DNA Methylation; Exons; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Humans; Lung Neoplasms; Molecular Sequence Data; Proteins; Rats; Rats, Inbred F344; Sequence Analysis, DNA; Sequence Deletion; Sequence Homology, Amino Acid; Tumor Cells, Cultured; Tumor Suppressor Protein p14ARF | 1997 |
Effect of methyltransferase inhibitors on the regulation of baculovirus protein synthesis.
Topics: Animals; Azacitidine; Cell Line; Decitabine; Enzyme Inhibitors; Gene Expression Regulation, Viral; Hemagglutinin Glycoproteins, Influenza Virus; Methyltransferases; Nucleopolyhedroviruses; Occlusion Body Matrix Proteins; Spodoptera; Tubercidin; Viral Nonstructural Proteins; Viral Proteins; Viral Structural Proteins | 1995 |
Mutagenicity of 5-aza-2'-deoxycytidine is mediated by the mammalian DNA methyltransferase.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Dinucleoside Phosphates; DNA Methylation; Methyltransferases; Mice; Mice, Inbred C57BL; Mice, Transgenic; Models, Chemical; Models, Genetic; Mutagenesis; Mutagens | 1997 |
Alternative promoters of gene MAGE4a.
Topics: Alternative Splicing; Amino Acid Sequence; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Azacitidine; Base Sequence; Cloning, Molecular; Decitabine; DNA-Binding Proteins; DNA, Neoplasm; Exons; Gene Expression Regulation, Neoplastic; Humans; Male; Melanoma; Molecular Sequence Data; Neoplasm Proteins; Placenta; Promoter Regions, Genetic; Restriction Mapping; Rhabdomyosarcoma; RNA, Messenger; Sequence Analysis, DNA; Testis; Tumor Cells, Cultured | 1997 |
Activation of the retinoic acid receptor beta gene by 5-aza-2'-deoxycytidine in human DLD-1 colon carcinoma cells.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Azacitidine; Blotting, Northern; Blotting, Southern; Cell Line; Colonic Neoplasms; Decitabine; DNA Methylation; Exons; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Humans; Receptors, Retinoic Acid; Tretinoin; Tumor Stem Cell Assay | 1997 |
5-Azadeoxycytidine-induced chromatin remodeling of the inactive X-linked HPRT gene promoter occurs prior to transcription factor binding and gene reactivation.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Cell Line; Chromatin; Cricetinae; Decitabine; Gene Expression Regulation, Enzymologic; Humans; Hybrid Cells; Hypoxanthine Phosphoribosyltransferase; Kinetics; Male; Polymerase Chain Reaction; Promoter Regions, Genetic; Restriction Mapping; RNA, Messenger; Transcription Factors; Transcription, Genetic; X Chromosome | 1997 |
Deletional, mutational, and methylation analyses of CDKN2 (p16/MTS1) in primary and metastatic prostate cancer.
Topics: Aged; Azacitidine; Carrier Proteins; Chromosome Deletion; Cyclin-Dependent Kinase Inhibitor p16; Decitabine; DNA Methylation; DNA Modification Methylases; DNA Mutational Analysis; DNA, Neoplasm; Gene Expression; Heterozygote; Humans; Male; Middle Aged; Neoplasm Metastasis; Polymerase Chain Reaction; Prostatic Neoplasms; Sequence Analysis, DNA; Tumor Cells, Cultured | 1997 |
Preferential induction of chromosome 1 multibranched figures and whole-arm deletions in a human pro-B cell line treated with 5-azacytidine or 5-azadeoxycytidine.
Topics: Antimetabolites, Antineoplastic; Azacitidine; B-Lymphocytes; Cell Line; Centromere; Chromosome Deletion; Chromosomes, Human, Pair 1; Decitabine; Gene Rearrangement; Hematopoietic Stem Cells; Humans; Time Factors | 1997 |
Expression of MAGE and BAGE genes in Japanese breast cancers.
Topics: Antigens, Neoplasm; Azacitidine; Breast Neoplasms; Decitabine; DNA Modification Methylases; Gene Expression Regulation, Neoplastic; Humans; Japan; Melanoma-Specific Antigens; Neoplasm Proteins; Tumor Cells, Cultured | 1997 |
Transcriptional defects underlie loss of E-cadherin expression in breast cancer.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Breast Neoplasms; Cadherins; Cloning, Molecular; Decitabine; DNA Methylation; DNA-Binding Proteins; Gene Expression Regulation, Neoplastic; Humans; Promoter Regions, Genetic; Trans-Activators; Transcription Factor AP-2; Transcription Factors; Transcription, Genetic; Tumor Cells, Cultured | 1997 |
Expression of MAGE genes in ocular melanoma during progression from primary to metastatic disease.
Topics: Antigens, Neoplasm; Azacitidine; Clone Cells; Decitabine; Disease Progression; Eye Neoplasms; Gene Expression Regulation, Neoplastic; Humans; Melanoma; Melanoma-Specific Antigens; Neoplasm Metastasis; Neoplasm Proteins; Tumor Cells, Cultured | 1997 |
Epigenetic silencing of RNA polymerase I transcription: a role for DNA methylation and histone modification in nucleolar dominance.
Topics: Azacitidine; Brassica; Butyrates; Butyric Acid; Cell Nucleolus; Cytosine; Decitabine; DNA Methylation; Enzyme Inhibitors; Gene Expression Regulation, Plant; Genes, Dominant; Histones; Hydroxamic Acids; Polyploidy; RNA Polymerase I; RNA, Ribosomal; Transcription, Genetic | 1997 |
DNA demethylation and pericentromeric rearrangements of chromosome 1.
Topics: Adult; Azacitidine; B-Lymphocytes; Burkitt Lymphoma; Cell Line; Cell Line, Transformed; Centromere; Chromosome Aberrations; Chromosome Disorders; Chromosomes, Human, Pair 1; Decitabine; DNA Methylation; DNA, Satellite; Face; Fibroblasts; Heterochromatin; Humans; Immunologic Deficiency Syndromes; Male; Stem Cells; Tumor Cells, Cultured | 1997 |
Counter-selection for over-expressed human CD44s in primary tumors versus lung metastases in a mouse fibrosarcoma model.
Topics: 3T3 Cells; Animals; Antigens, CD; Antimetabolites, Antineoplastic; Azacitidine; Cell Line, Transformed; Cell Survival; Cell Transformation, Neoplastic; Decitabine; Fibrosarcoma; Genes, ras; Humans; Hyaluronan Receptors; Lung Neoplasms; Mice; Mice, Nude; Neoplasm Metastasis; Oncogene Proteins v-sis; Oncogenes; Retroviridae Proteins, Oncogenic; Transfection | 1997 |
Role of estrogen receptor gene demethylation and DNA methyltransferase.DNA adduct formation in 5-aza-2'deoxycytidine-induced cytotoxicity in human breast cancer cells.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Breast Neoplasms; Decitabine; DNA Adducts; DNA Methylation; DNA Modification Methylases; Humans; Receptors, Estrogen; Tumor Cells, Cultured | 1997 |
Inhibition of DNA methylation by 5-aza-2'-deoxycytidine suppresses the growth of human tumor cell lines.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Cell Division; Cyclin-Dependent Kinase Inhibitor p16; Decitabine; DNA Methylation; DNA Modification Methylases; G1 Phase; Gene Expression; Humans; Mice; Mice, Nude; Neoplasms; Rats; Rats, Nude; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 1998 |
Two members of the human MAGEB gene family located in Xp21.3 are expressed in tumors of various histological origins.
Topics: Alternative Splicing; Amino Acid Sequence; Azacitidine; Base Sequence; Decitabine; DNA, Complementary; Exons; Gene Expression; Humans; Molecular Sequence Data; Neoplasm Proteins; Neoplasms; Sequence Homology, Amino Acid; Sequence Homology, Nucleic Acid; Tumor Cells, Cultured; X Chromosome | 1997 |
Independent induction of senescence by p16INK4a and p21CIP1 in spontaneously immortalized human fibroblasts.
Topics: 5-Methylcytosine; Azacitidine; Cell Division; Cell Line, Transformed; Cellular Senescence; CpG Islands; Cyclin-Dependent Kinase Inhibitor p16; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Cytosine; Decitabine; DNA Methylation; DNA, Complementary; Gene Expression Regulation; Genes, p16; Genes, p53; Germ-Line Mutation; Humans; Li-Fraumeni Syndrome | 1998 |
Effect of 5-aza-2'-deoxycytidine and vitamin D3 analogs on growth and differentiation of human myeloid leukemic cells.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cell Differentiation; Cholecalciferol; Decitabine; Dose-Response Relationship, Drug; Drug Interactions; HL-60 Cells; Humans; In Vitro Techniques; Leukemia, Myeloid | 1998 |
Differentially expressed genes associated with 5-Aza-2'-deoxycytidine-induced hindlimb defects in the Swiss Webster mouse.
Topics: Animals; Azacitidine; Cloning, Molecular; Decitabine; Female; Gene Expression Regulation, Developmental; Hindlimb; Mice; Molecular Sequence Data; Polymerase Chain Reaction; Pregnancy; Teratogens; Up-Regulation | 1998 |
Methylation-mediated regulation of the glutathione S-transferase P1 gene in human breast cancer cells.
Topics: Azacitidine; Blotting, Southern; Breast Neoplasms; CpG Islands; Decitabine; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Female; Gene Expression Regulation, Neoplastic; Glutathione S-Transferase pi; Glutathione Transferase; Humans; Isoenzymes; Neoplasm Proteins; Promoter Regions, Genetic; Receptors, Estrogen; RNA, Messenger; Transcription, Genetic; Tumor Cells, Cultured | 1998 |
Expression of D-type cyclins in normal and neoplastic rat pituitary.
Topics: Animals; Apoptosis; Azacitidine; Cell Cycle; Cyclin D1; Cyclin D2; Cyclin D3; Cyclins; Decitabine; Fibroblast Growth Factor 2; Gene Expression Regulation, Neoplastic; Immunohistochemistry; Mice; Pituitary Gland; Pituitary Neoplasms; Polymerase Chain Reaction; Rats; RNA-Directed DNA Polymerase; RNA, Messenger; Transfection; Tumor Cells, Cultured | 1998 |
Maintenance of hypomethylation status and preferential expression of exogenous human MDR1/PGY1 gene in mouse L cells by YAC mediated transfer.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Azacitidine; Cell Survival; Chromosomes, Artificial, Yeast; Clone Cells; Decitabine; Dinucleoside Phosphates; DNA Methylation; DNA Modification Methylases; Drug Resistance, Multiple; Enzyme Inhibitors; Exons; Gene Amplification; Genetic Markers; Humans; L Cells; Mice; Promoter Regions, Genetic; Recombinant Proteins; Restriction Mapping; Transcriptional Activation; Transfection; Tumor Stem Cell Assay; Vincristine | 1997 |
Structure and methylation-based silencing of a gene (DBCCR1) within a candidate bladder cancer tumor suppressor region at 9q32-q33.
Topics: Amino Acid Sequence; Azacitidine; Base Sequence; Blotting, Northern; Blotting, Southern; Carcinoma, Transitional Cell; Cell Cycle Proteins; Chromosomes, Artificial, Yeast; Chromosomes, Human, Pair 9; CpG Islands; Decitabine; DNA Methylation; DNA, Complementary; Exons; Gene Deletion; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Humans; Introns; Molecular Sequence Data; Nerve Tissue Proteins; Polymorphism, Single-Stranded Conformational; Proteins; RNA, Messenger; Sequence Analysis, DNA; Tumor Suppressor Proteins; Urinary Bladder Neoplasms; Urothelium | 1998 |
The role of epigenetics in cancer. DNA Methylation, Imprinting and the Epigenetics of Cancer--an American Association for Cancer Research Special Conference. Las Croabas, Puerto Rico, 12-16 1997 December.
Topics: Azacitidine; Decitabine; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Genomic Imprinting; Humans; Neoplasms; Societies, Scientific; United States | 1998 |
Epigenetic control of programmed cell death: inhibition by 5-azacytidine of 1,25-dihydroxyvitamin D3-induced programmed cell death in C6.9 glioma cells.
Topics: Animals; Apoptosis; Azacitidine; Calcitriol; Decitabine; DNA Fragmentation; DNA Modification Methylases; Enzyme Inhibitors; Genes, myc; Glioma; Rats; Sphingosine; Tumor Cells, Cultured | 1998 |
Effect of Cladribine, fludarabine, and 5-aza-deoxycytidine on S-adenosylmethionine (SAM) and nucleotides pools in stimulated human lymphocytes.
Topics: Adenine Nucleotides; Adenine Phosphoribosyltransferase; Antineoplastic Agents; Azacitidine; Cells, Cultured; Cladribine; Cytidine Triphosphate; Decitabine; Guanine Nucleotides; Humans; Kinetics; Lymphocyte Activation; Lymphocytes; NAD; Ribonucleotides; S-Adenosylmethionine; Uracil Nucleotides; Vidarabine | 1998 |
Does 2-chlorodeoxyadenosine contribute to alteration of DNA methyltransferase activity?
Topics: Adenosylhomocysteinase; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Azacitidine; Cladribine; Decitabine; DNA (Cytosine-5-)-Methyltransferases; Hydrolases; Kinetics; Leukemia L1210; Mice; Tumor Cells, Cultured; Vidarabine | 1998 |
Induction of XIST expression from the human active X chromosome in mouse/human somatic cell hybrids by DNA demethylation.
Topics: Animals; Azacitidine; Decitabine; DNA; DNA Methylation; DNA Modification Methylases; Dosage Compensation, Genetic; Enzyme Inhibitors; Genes; Humans; Hybrid Cells; Mice; RNA, Long Noncoding; RNA, Untranslated; Transcription Factors; X Chromosome | 1998 |
Induction of transforming growth factor-beta receptor type II expression in estrogen receptor-positive breast cancer cells through SP1 activation by 5-aza-2'-deoxycytidine.
Topics: Activin Receptors, Type I; Antimetabolites, Antineoplastic; Azacitidine; Base Sequence; Breast Neoplasms; Decitabine; Female; Humans; Insulin-Like Growth Factor II; Molecular Sequence Data; Mutation; Promoter Regions, Genetic; Protein Serine-Threonine Kinases; Receptor, Transforming Growth Factor-beta Type I; Receptor, Transforming Growth Factor-beta Type II; Receptors, Estrogen; Receptors, Transforming Growth Factor beta; Repressor Proteins; Sp1 Transcription Factor; Transforming Growth Factor beta; Tumor Cells, Cultured | 1998 |
Methylation of the 5' CpG island of the FHIT gene is closely associated with transcriptional inactivation in esophageal squamous cell carcinomas.
Topics: Acid Anhydride Hydrolases; Antimetabolites, Antineoplastic; Azacitidine; Base Sequence; Carcinoma, Squamous Cell; CpG Islands; Decitabine; DNA Methylation; DNA, Neoplasm; Esophageal Neoplasms; Exons; Gene Deletion; Gene Expression Regulation, Neoplastic; Humans; Molecular Sequence Data; Neoplasm Proteins; Polymerase Chain Reaction; Polymorphism, Single-Stranded Conformational; Proteins; Transcriptional Activation; Tumor Cells, Cultured | 1998 |
Demethylation of the progesterone receptor CpG island is not required for progesterone receptor gene expression.
Topics: Azacitidine; CpG Islands; Decitabine; DNA Methylation; DNA Modification Methylases; Estradiol; Estrogen Antagonists; Fulvestrant; Gene Expression Regulation; Histone Acetyltransferases; Humans; Nuclear Receptor Coactivator 1; Receptors, Estrogen; Receptors, Progesterone; Receptors, Steroid; Transcription Factors; Tumor Cells, Cultured | 1998 |
Drug resistance to 5-aza-2'-deoxycytidine, 2',2'-difluorodeoxycytidine, and cytosine arabinoside conferred by retroviral-mediated transfer of human cytidine deaminase cDNA into murine cells.
Topics: 3T3 Cells; Animals; Antimetabolites; Antimetabolites, Antineoplastic; Azacitidine; Colony-Forming Units Assay; Cytarabine; Cytidine Deaminase; Decitabine; Deoxycytidine; DNA, Complementary; Drug Resistance; Enzyme Inhibitors; Fibroblasts; Gemcitabine; Gene Transfer Techniques; Genetic Vectors; Humans; Mice; Phenotype; Retroviridae; Tetrahydrouridine | 1998 |
DNA methylation regulates p27kip1 expression in rodent pituitary cell lines.
Topics: Animals; Azacitidine; Cell Cycle Proteins; Cell Line; Cyclin-Dependent Kinase Inhibitor p27; Cyclin-Dependent Kinases; Decitabine; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Genes, Tumor Suppressor; Humans; Mice; Microtubule-Associated Proteins; Pituitary Gland; Pituitary Neoplasms; Rats; RNA, Messenger; Sequence Alignment; Tumor Cells, Cultured; Tumor Suppressor Proteins | 1998 |
Frequent alteration of CDKN2 (p16(INK4A)/MTS1) expression in human primary prostate carcinomas.
Topics: Adenocarcinoma; Animals; Azacitidine; Blotting, Western; Cyclin-Dependent Kinase Inhibitor p16; Decitabine; Gene Expression Regulation, Neoplastic; Genes, p16; Genes, Retinoblastoma; Humans; Male; Mice; Mice, Nude; Neoplasm Proteins; Neoplasm Transplantation; Polymerase Chain Reaction; Polymorphism, Single-Stranded Conformational; Prostatic Hyperplasia; Prostatic Neoplasms; Retinoblastoma Protein; RNA, Messenger; RNA, Neoplasm; Transcription, Genetic; Tumor Cells, Cultured | 1997 |
Altered methylation of the human MDR1 promoter is associated with acquired multidrug resistance.
Topics: Antimetabolites, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Azacitidine; Blotting, Southern; Daunorubicin; Decitabine; Dinucleoside Phosphates; DNA Methylation; Drug Resistance, Multiple; Epirubicin; Exons; Humans; Introns; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, T-Cell; Promoter Regions, Genetic; Restriction Mapping; Transcription, Genetic; Tumor Cells, Cultured; Verapamil | 1997 |
Phenylacetate in chemoprevention: in vitro and in vivo suppression of 5-aza-2'-deoxycytidine-induced carcinogenesis.
Topics: 3T3 Cells; Animals; Anticarcinogenic Agents; Azacitidine; Carcinogens; Cell Division; Cell Transformation, Neoplastic; Chemoprevention; Clone Cells; Collagen; Decitabine; DNA Methylation; Drug Combinations; Female; Genes, ras; Laminin; Mice; Mice, Nude; Neoplasm Invasiveness; Neoplasms, Experimental; Phenylacetates; Proteoglycans | 1995 |
Expression of BAGE, GAGE, and MAGE genes in human gastric carcinoma.
Topics: Aged; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA, Neoplasm; Female; Gastric Mucosa; Gene Expression Regulation, Neoplastic; Genes, Neoplasm; Humans; Male; Melanoma-Specific Antigens; Middle Aged; Neoplasm Proteins; Stomach; Stomach Neoplasms; Tumor Cells, Cultured | 1996 |
Involvement of DNA methylation in binding of a highly repetitive DNA component to nuclear scaffold proteins from rat liver.
Topics: Animals; Antigens, Nuclear; Azacitidine; Cell Line; CpG Islands; Decitabine; DNA; DNA Methylation; DNA-Binding Proteins; Gene Expression Regulation; Liver; Nuclear Proteins; Procainamide; Protein Binding; Rats; Repetitive Sequences, Nucleic Acid | 1998 |
Demethylation by 5-aza-2'-deoxycytidine of specific 5-methylcytosine sites in the promoter region of the retinoic acid receptor beta gene in human colon carcinoma cells.
Topics: 5-Methylcytosine; Adenocarcinoma; Antimetabolites, Antineoplastic; Azacitidine; Base Sequence; Colonic Neoplasms; CpG Islands; Cytosine; Decitabine; DNA Methylation; DNA Primers; DNA, Neoplasm; Humans; Molecular Sequence Data; Polymerase Chain Reaction; Promoter Regions, Genetic; Receptors, Retinoic Acid; Tumor Cells, Cultured | 1998 |
The p16 (CDKN2A) gene is involved in the growth of neuroblastoma cells and its expression is associated with prognosis of neuroblastoma patients.
Topics: Azacitidine; Cell Division; Cyclin-Dependent Kinase Inhibitor p16; Decitabine; DNA Modification Methylases; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Humans; Neuroblastoma; Prognosis; Tumor Cells, Cultured | 1998 |
Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer.
Topics: Adaptor Proteins, Signal Transducing; Azacitidine; Carrier Proteins; Cell Cycle Proteins; CpG Islands; Cyclin-Dependent Kinase Inhibitor p15; Cyclin-Dependent Kinase Inhibitor p16; Decitabine; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; MutL Protein Homolog 1; Neoplasm Proteins; Neoplasms; Nuclear Proteins; Promoter Regions, Genetic; Tissue Inhibitor of Metalloproteinase-3; Transcriptional Activation; Tumor Cells, Cultured; Tumor Suppressor Proteins | 1999 |
Prolonged upregulation of the expression of HLA class I antigens and costimulatory molecules on melanoma cells treated with 5-aza-2'-deoxycytidine (5-AZA-CdR).
Topics: Alleles; Antigens, Neoplasm; Azacitidine; Blotting, Western; CD58 Antigens; Decitabine; Flow Cytometry; Histocompatibility Antigens Class I; Humans; Intercellular Adhesion Molecule-1; Melanoma; Melanoma-Specific Antigens; Neoplasm Proteins; Reverse Transcriptase Polymerase Chain Reaction; Time Factors; Tumor Cells, Cultured; Up-Regulation | 1999 |
Effect of CpG methylation on expression of the mouse imprinted gene Mest.
Topics: Animals; Azacitidine; Base Sequence; Chromosome Mapping; Cloning, Molecular; CpG Islands; Decitabine; DNA; DNA Methylation; Embryo, Mammalian; Female; Genomic Imprinting; Kidney; Male; Mice; Molecular Sequence Data; Proteins; Spermatozoa; Transcription, Genetic | 1999 |
Differential expression of MHC class II genes in lung tumour cell lines.
Topics: Actins; Adenocarcinoma; Antibodies, Monoclonal; Azacitidine; Blotting, Northern; Carcinoma, Large Cell; Carcinoma, Squamous Cell; Decitabine; Densitometry; Enzyme Inhibitors; Fluorescent Antibody Technique; Gene Expression; Genes, MHC Class II; Genes, myc; HLA-DP Antigens; HLA-DQ Antigens; HLA-DR Antigens; Humans; Interferon-gamma; Lung Neoplasms; Proto-Oncogene Mas; RNA, Messenger; Tumor Cells, Cultured | 1998 |
A role for DNA methylation in gastrulation and somite patterning.
Topics: Abnormalities, Drug-Induced; Amino Acid Sequence; Animals; Azacitidine; Body Patterning; Decitabine; DNA Methylation; Gastrula; Gene Expression Regulation, Developmental; Gene Expression Regulation, Enzymologic; Humans; Methyltransferases; Molecular Sequence Data; Muscles; Notochord; RNA, Messenger; Sequence Homology, Amino Acid; Somites; Zebrafish | 1999 |
Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggest a suppressor role in kidney, brain, and other human cancers.
Topics: Azacitidine; Brain Neoplasms; CpG Islands; Decitabine; DNA Methylation; Humans; Kidney Neoplasms; Tissue Inhibitor of Metalloproteinase-3 | 1999 |
Re-expression of endogenous p16ink4a in oral squamous cell carcinoma lines by 5-aza-2'-deoxycytidine treatment induces a senescence-like state.
Topics: Azacitidine; beta-Galactosidase; Carcinoma, Squamous Cell; Cellular Senescence; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Cyclin-Dependent Kinase Inhibitor p16; Cyclin-Dependent Kinases; Decitabine; DNA Methylation; DNA Modification Methylases; Gene Expression Regulation, Neoplastic; Gene Transfer Techniques; Humans; Mouth Neoplasms; Mutation; Phosphorylation; Promoter Regions, Genetic; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Recombinant Proteins; Retinoblastoma Protein; Retroviridae; Tumor Cells, Cultured | 1998 |
5-Aza-2'-deoxycytidine is chemopreventive in a 4-(methyl-nitrosamino)-1-(3-pyridyl)-1-butanone-induced primary mouse lung tumor model.
Topics: Animals; Anticarcinogenic Agents; Azacitidine; Carcinogens; Decitabine; Lung Neoplasms; Male; Mice; Mice, Inbred A; Mice, Inbred C3H; Nitrosamines | 1999 |
Hypomethylation of the metastasis-associated S100A4 gene correlates with gene activation in human colon adenocarcinoma cell lines.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Azacitidine; Colonic Neoplasms; Decitabine; DNA Methylation; Gene Expression Regulation; HT29 Cells; Humans; Neoplasm Metastasis; S100 Calcium-Binding Protein A4; S100 Proteins; Transcriptional Activation; Tumor Cells, Cultured | 1998 |
Association of K-ras mutations with p16 methylation in human colon cancer.
Topics: Azacitidine; Cells, Cultured; Colonic Neoplasms; Decitabine; DNA Methylation; DNA Modification Methylases; DNA Mutational Analysis; Enzyme Inhibitors; Genes, p16; Genes, ras; Humans; Mutation; Restriction Mapping; Reverse Transcriptase Polymerase Chain Reaction; Tumor Cells, Cultured | 1999 |
Methylation of CpG in a small region of the hMLH1 promoter invariably correlates with the absence of gene expression.
Topics: Adaptor Proteins, Signal Transducing; Azacitidine; Base Pair Mismatch; Carcinoma; Carrier Proteins; Colorectal Neoplasms; Colorectal Neoplasms, Hereditary Nonpolyposis; CpG Islands; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Mutational Analysis; DNA Repair; DNA, Neoplasm; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Humans; Microsatellite Repeats; MutL Protein Homolog 1; Neoplasm Proteins; Nuclear Proteins; Promoter Regions, Genetic; RNA, Messenger; RNA, Neoplasm; Tumor Cells, Cultured | 1999 |
Acetylated histones are associated with FMR1 in normal but not fragile X-syndrome cells.
Topics: Acetylation; Acetyltransferases; Azacitidine; Cells, Cultured; Chromatin; Decitabine; DNA; Enzyme Inhibitors; Fragile X Mental Retardation Protein; Fragile X Syndrome; Histone Acetyltransferases; Histones; Humans; Hydroxamic Acids; Male; Nerve Tissue Proteins; Protein Binding; RNA-Binding Proteins; Saccharomyces cerevisiae Proteins; Transcription, Genetic | 1999 |
Repression of the IL-6 gene is associated with hypermethylation.
Topics: Azacitidine; Decitabine; DNA Methylation; Gene Expression Regulation; Humans; Interleukin-1; Interleukin-6; Recombinant Proteins; Restriction Mapping; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 1999 |
Hypermethylation of the DAP-kinase CpG island is a common alteration in B-cell malignancies.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Azacitidine; Burkitt Lymphoma; Calcium-Calmodulin-Dependent Protein Kinases; CpG Islands; Death-Associated Protein Kinases; Decitabine; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Humans; Interferon-gamma; Leukemia; Lymphocytes; Lymphoma, T-Cell; Tumor Cells, Cultured | 1999 |
Characterization of the GAGE genes that are expressed in various human cancers and in normal testis.
Topics: Amino Acid Sequence; Animals; Antigens, Neoplasm; Azacitidine; Base Sequence; Chromosome Mapping; Cloning, Molecular; COS Cells; Decitabine; Exons; Gene Expression Regulation, Neoplastic; Gene Library; Humans; Male; Melanoma; Molecular Sequence Data; Multigene Family; Neoplasm Proteins; Neoplasms; Recombinant Proteins; Sequence Alignment; Sequence Homology, Amino Acid; Sequence Homology, Nucleic Acid; Testis; Transcriptional Activation; Transfection; Tumor Cells, Cultured; X Chromosome | 1999 |
Association of 5' CpG demethylation and altered chromatin structure in the promoter region with transcriptional activation of the multidrug resistance 1 gene in human cancer cells.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Azacitidine; Chromatin; Clone Cells; Decitabine; Dinucleoside Phosphates; DNA Methylation; Drug Resistance, Neoplasm; Gene Amplification; Genes, MDR; Humans; Promoter Regions, Genetic; Transcriptional Activation; Tumor Cells, Cultured | 1999 |
DNA methylation of retinoic acid receptor beta in breast cancer and possible therapeutic role of 5-aza-2'-deoxycytidine.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Breast Neoplasms; Cell Division; Decitabine; DNA Methylation; Female; Humans; Receptors, Retinoic Acid; Tumor Cells, Cultured | 1999 |
Roles of cell division and gene transcription in the methylation of CpG islands.
Topics: Azacitidine; Cell Division; CpG Islands; Cyclin-Dependent Kinase Inhibitor p16; Decitabine; DNA Methylation; DNA-Binding Proteins; Exons; Eye Proteins; Gene Expression Regulation; Homeodomain Proteins; Models, Genetic; MyoD Protein; Paired Box Transcription Factors; PAX6 Transcription Factor; Promoter Regions, Genetic; Proto-Oncogene Proteins c-abl; Repressor Proteins; Transcription, Genetic; Tumor Cells, Cultured | 1999 |
5-AZA-2'-deoxycytidine-induced dysmorphogenesis in the rat.
Topics: Abnormalities, Drug-Induced; Animals; Azacitidine; Bone and Bones; Decitabine; Ectromelia; Female; Fetal Weight; Hindlimb; Pregnancy; Rats; Rats, Sprague-Dawley; Skull; Species Specificity | 1999 |
DNA methylation is the primary silencing mechanism for a set of germ line- and tumor-specific genes with a CpG-rich promoter.
Topics: Azacitidine; CpG Islands; Decitabine; DNA Methylation; DNA, Neoplasm; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Male; Neoplasm Proteins; Promoter Regions, Genetic; Spermatozoa; Testis; Tissue Distribution; Tumor Cells, Cultured | 1999 |
Synergistic effect of histone hyperacetylation and DNA demethylation in the reactivation of the FMR1 gene.
Topics: Acetylation; Azacitidine; Base Sequence; Cell Line; Decitabine; DNA Methylation; DNA Primers; Enzyme Inhibitors; Fragile X Mental Retardation Protein; Fragile X Syndrome; Histone Deacetylase Inhibitors; Histones; Humans; Male; Nerve Tissue Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA-Binding Proteins | 1999 |
Inhibition of DNA methyltransferase stimulates the expression of signal transducer and activator of transcription 1, 2, and 3 genes in colon tumor cells.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Azacitidine; Cell Division; Cell Nucleus; Colonic Neoplasms; Decitabine; DNA Modification Methylases; DNA-Binding Proteins; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; HT29 Cells; Humans; Interferon alpha-2; Interferon-alpha; Interferon-beta; Interferon-gamma; Interferons; Recombinant Proteins; Signal Transduction; STAT1 Transcription Factor; STAT2 Transcription Factor; STAT3 Transcription Factor; Trans-Activators | 1999 |
Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Blast Crisis; Decitabine; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Remission Induction; Salvage Therapy; Survival Analysis | 1999 |
Correlation between growth control, neoplastic potential and endogenous connexin43 expression in HeLa cell lines: implications for tumor progression.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Cell Division; Clone Cells; Coculture Techniques; Connexin 43; Decitabine; Disease Progression; DNA Methylation; Fibroblasts; Gap Junctions; Gene Expression Regulation, Neoplastic; Gene Silencing; HeLa Cells; Humans; Mice; Mice, Nude; Neoplasm Proteins; Neoplasm Transplantation; Recombinant Fusion Proteins; RNA, Messenger; RNA, Neoplasm; Tetracycline; Transcriptional Activation; Transfection | 2000 |
Mechanism for inactivation of the KIP family cyclin-dependent kinase inhibitor genes in gastric cancer cells.
Topics: Azacitidine; Butyric Acid; CDC2 Protein Kinase; Cell Cycle Proteins; Cyclin-Dependent Kinase Inhibitor p27; Cyclin-Dependent Kinase Inhibitor p57; Decitabine; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Microtubule-Associated Proteins; Nuclear Proteins; Restriction Mapping; Reverse Transcriptase Polymerase Chain Reaction; Stomach Neoplasms; Transcription, Genetic; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2000 |
DNA methylator and mismatch repair phenotypes are not mutually exclusive in colorectal cancer cell lines.
Topics: Azacitidine; Base Pair Mismatch; Colorectal Neoplasms; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Ligases; DNA Methylation; DNA Methyltransferase 3A; DNA Methyltransferase 3B; DNA Repair; Humans; Phenotype; Retroviridae; Tumor Cells, Cultured | 2000 |
Activation of the MN/CA9 gene is associated with hypomethylation in human renal cell carcinoma cell lines.
Topics: Antigens, Neoplasm; Azacitidine; Base Sequence; Carcinoma, Renal Cell; CpG Islands; Decitabine; DNA Methylation; DNA, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Kidney Neoplasms; Molecular Sequence Data; Tumor Cells, Cultured | 2000 |
p16/MTS1/INK4A suppresses prostate cancer by both pRb dependent and independent pathways.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cell Division; Cellular Senescence; Cyclin-Dependent Kinase Inhibitor p16; Decitabine; Gene Expression Regulation, Neoplastic; Humans; Male; Prostatic Neoplasms; Retinoblastoma Protein | 2000 |
Evidence of epigenetic changes affecting the chromatin state of the retinoic acid receptor beta2 promoter in breast cancer cells.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Breast; Breast Neoplasms; Cell Line; Chromatin; CpG Islands; Decitabine; DNA Methylation; Enzyme Inhibitors; Epithelial Cells; Female; Gene Expression Regulation; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Promoter Regions, Genetic; Receptors, Estrogen; Receptors, Retinoic Acid; Tretinoin; Tumor Cells, Cultured | 2000 |
Heterogeneous expression of the SSX cancer/testis antigens in human melanoma lesions and cell lines.
Topics: Adult; Antibodies, Monoclonal; Antibody Specificity; Azacitidine; Caco-2 Cells; Cell Nucleus; Child; Decitabine; DNA Modification Methylases; Gene Expression Regulation, Neoplastic; HeLa Cells; Humans; Immunohistochemistry; K562 Cells; Male; Melanoma; Microscopy, Fluorescence; Neoplasm Proteins; Recombinant Fusion Proteins; Repressor Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Neoplasm; Sequence Deletion; Testis; Tumor Cells, Cultured | 2000 |
Methylation of class II trans-activator promoter IV: a novel mechanism of MHC class II gene control.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Base Sequence; Choriocarcinoma; Decitabine; DNA Methylation; DNA Modification Methylases; Gene Expression Regulation; Genes, MHC Class II; Humans; Interferon-gamma; Molecular Sequence Data; Nuclear Proteins; Promoter Regions, Genetic; Trans-Activators; Transcription, Genetic; Trophoblasts; Tumor Cells, Cultured | 2000 |
High frequency of hypermethylation at the 14-3-3 sigma locus leads to gene silencing in breast cancer.
Topics: 14-3-3 Proteins; Azacitidine; Breast; Breast Neoplasms; Cell Cycle Proteins; Cell Line; Cell Line, Transformed; Cell Transformation, Neoplastic; CpG Islands; Decitabine; DNA Methylation; DNA Repair; Epithelial Cells; Female; G2 Phase; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Neoplasm Proteins; Protein Biosynthesis; Proteins; Radiation Tolerance; Recombinant Fusion Proteins; RNA, Messenger; RNA, Neoplasm; Transcription, Genetic; Transfection; Tumor Cells, Cultured; Tyrosine 3-Monooxygenase | 2000 |
Methylation of the neutral endopeptidase gene promoter in human prostate cancers.
Topics: Azacitidine; Decitabine; DNA Methylation; DNA, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Male; Neprilysin; Promoter Regions, Genetic; Prostatic Neoplasms; Tumor Cells, Cultured | 2000 |
Loss of imprinting and elevated expression of wild-type p73 in human gastric adenocarcinoma.
Topics: Adenocarcinoma; Alleles; Azacitidine; Culture Media, Serum-Free; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Decitabine; DNA-Binding Proteins; DNA, Neoplasm; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Genomic Imprinting; HL-60 Cells; Humans; Mutation; Nuclear Proteins; Polymorphism, Single-Stranded Conformational; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Stomach Neoplasms; Tumor Cells, Cultured; Tumor Protein p73; Tumor Suppressor Protein p53; Tumor Suppressor Proteins; U937 Cells | 2000 |
Quantitation of inhibition of DNA methylation of the retinoic acid receptor beta gene by 5-Aza-2'-deoxycytidine in tumor cells using a single-nucleotide primer extension assay.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Methylation; DNA Primers; Gene Expression Regulation; Humans; Polymerase Chain Reaction; Promoter Regions, Genetic; Receptors, Retinoic Acid; Tumor Cells, Cultured | 2000 |
PAX6 methylation and ectopic expression in human tumor cells.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Blotting, Western; Colonic Neoplasms; CpG Islands; Decitabine; DNA Methylation; DNA-Binding Proteins; Exons; Eye Proteins; Gene Expression Regulation, Neoplastic; Homeodomain Proteins; Humans; Paired Box Transcription Factors; PAX6 Transcription Factor; Promoter Regions, Genetic; Repressor Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Transcription, Genetic; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2000 |
Methylation of specific CpG sites in the promoter region could significantly down-regulate p16(INK4a) expression in gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Blotting, Northern; Blotting, Southern; Carrier Proteins; CpG Islands; Cyclin-Dependent Kinase Inhibitor p16; Decitabine; DNA Methylation; Down-Regulation; Female; Humans; Immunohistochemistry; Male; Middle Aged; Models, Genetic; Mutagens; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sequence Analysis, DNA; Stomach Neoplasms; Sulfites; Tumor Cells, Cultured | 2000 |
Epigenetic regulation of the MGMT and hMSH6 DNA repair genes in cells resistant to methylating agents.
Topics: Alkylating Agents; Antimetabolites, Antineoplastic; Azacitidine; Blotting, Western; CpG Islands; Cytosine; Decitabine; DNA Methylation; DNA Repair; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gene Silencing; Humans; Luciferases; Methylnitrosourea; O(6)-Methylguanine-DNA Methyltransferase; Plasmids; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sequence Analysis, DNA; Transcription, Genetic; Transfection; Tumor Cells, Cultured | 2000 |
Inhibition of the interferon-gamma/signal transducers and activators of transcription (STAT) pathway by hypermethylation at a STAT-binding site in the p21WAF1 promoter region.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Blotting, Southern; Cell Division; CpG Islands; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Decitabine; DNA Methylation; DNA Mutational Analysis; DNA-Binding Proteins; Dose-Response Relationship, Drug; Genes, Reporter; Humans; Interferon-gamma; Luciferases; Muscle Neoplasms; Muscle, Skeletal; Polymorphism, Genetic; Promoter Regions, Genetic; Response Elements; Rhabdomyosarcoma; Signal Transduction; STAT1 Transcription Factor; Time Factors; Trans-Activators; Transfection; Tumor Cells, Cultured; Up-Regulation | 2000 |
Frequent alteration of p63 expression in human primary bladder carcinomas.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA-Binding Proteins; Gene Deletion; Gene Expression Regulation, Neoplastic; Genes, p53; Genes, Tumor Suppressor; Humans; Membrane Proteins; Mutation; Phosphoproteins; Polymorphism, Single-Stranded Conformational; Promoter Regions, Genetic; Protein Isoforms; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Trans-Activators; Transcription Factors; Transcription, Genetic; Tumor Cells, Cultured; Tumor Suppressor Proteins; Urinary Bladder; Urinary Bladder Neoplasms | 2000 |
Regulation of the promoter activity of interferon regulatory factor-7 gene. Activation by interferon snd silencing by hypermethylation.
Topics: Azacitidine; Base Sequence; Cloning, Molecular; CpG Islands; Decitabine; DNA; DNA Methylation; DNA-Binding Proteins; Gene Silencing; Humans; Interferon Regulatory Factor-7; Interferon-alpha; Interferon-Stimulated Gene Factor 3; Interferon-Stimulated Gene Factor 3, gamma Subunit; Introns; Molecular Sequence Data; Mutation; Oligodeoxyribonucleotides; Promoter Regions, Genetic; Protein Binding; Response Elements; Transcription Factors; Transcriptional Activation; Tumor Cells, Cultured | 2000 |
Regional methylation of the 5' end CpG island of BRCA1 is associated with reduced gene expression in human somatic cells.
Topics: Azacitidine; Breast Neoplasms; Cell Line; Cervix Uteri; Chromosomal Proteins, Non-Histone; CpG Islands; Decitabine; DNA Methylation; DNA-Binding Proteins; Female; Gene Expression Regulation; Gene Silencing; Genes, BRCA1; Germ Cells; Humans; Kidney; Male; Methyl-CpG-Binding Protein 2; Promoter Regions, Genetic; Repressor Proteins; Transcriptional Activation; Transfection | 2000 |
Hypermethylation of the p16 (Ink4a) promoter in B6C3F1 mouse primary lung adenocarcinomas and mouse lung cell lines.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Azacitidine; Carrier Proteins; Cell Division; CpG Islands; Cyclin-Dependent Kinase Inhibitor p16; Decitabine; DNA Methylation; DNA Modification Methylases; DNA Mutational Analysis; DNA, Neoplasm; Female; Gene Expression; Genes, Tumor Suppressor; Immunohistochemistry; Loss of Heterozygosity; Lung Neoplasms; Mice; Mice, Inbred A; Mice, Inbred C3H; Mice, Inbred C57BL; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; Tumor Cells, Cultured | 2000 |
Inactivation of the 14-3-3 sigma gene is associated with 5' CpG island hypermethylation in human cancers.
Topics: 14-3-3 Proteins; Adenocarcinoma; Alleles; Animals; Azacitidine; Biomarkers, Tumor; Cell Cycle; CpG Islands; Decitabine; DNA Methylation; DNA, Neoplasm; Electrophoresis, Polyacrylamide Gel; Exonucleases; Exoribonucleases; Fluorescence; G2 Phase; Gene Expression; Gene Silencing; Genes, p53; Humans; Mice; Mice, SCID; Neoplasm Proteins; Neoplasm Transplantation; Nucleic Acid Conformation; Polymerase Chain Reaction; Polymorphism, Single-Stranded Conformational; Protein Biosynthesis; Proteins; Stomach Neoplasms; Sulfites; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2000 |
Increased cell proliferation and R.Msp1 fragmentation induced by 5-aza-2'-deoxycytidine in rat testes related to the gene imprinting mechanism.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Cell Division; Decitabine; DNA Fragmentation; DNA Methylation; Male; Rats; Rats, Wistar; Testis | 2000 |
Epigenetic alterations in methylation in oral squamous cell carcinoma cell lines detected by two-dimensional gel electrophoresis.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Carcinoma, Squamous Cell; Decitabine; DNA Methylation; DNA, Neoplasm; Electrophoresis, Gel, Two-Dimensional; Humans; Mouth Neoplasms; Restriction Mapping; Tumor Cells, Cultured | 2000 |
2-deoxy 5-azacytidine and fetal hemoglobin induction in sickle cell anemia.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Azacitidine; Blood Cell Count; Cohort Studies; Decitabine; Erythrocyte Count; Female; Fetal Hemoglobin; Globins; Humans; Hydroxyurea; Male; Middle Aged; Neutrophils; Platelet Count; Reticulocytes | 2000 |
Retroviral expression in embryonic stem cells and hematopoietic stem cells.
Topics: Adoptive Transfer; Animals; Azacitidine; Cell Differentiation; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Flow Cytometry; Gene Expression Regulation, Viral; Gene Silencing; Genetic Vectors; Hematopoietic Stem Cells; Mice; Mice, Inbred C57BL; Mice, Transgenic; Proviruses; Recombinant Fusion Proteins; Retroviridae; Stem Cells; Terminal Repeat Sequences | 2000 |
Evidence that silencing of the HPRT promoter by DNA methylation is mediated by critical CpG sites.
Topics: Alleles; Animals; Azacitidine; Base Sequence; Cell Line; Cloning, Molecular; CpG Islands; Cricetinae; Decitabine; DNA Methylation; Gene Silencing; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hybrid Cells; Hydroxamic Acids; Hypoxanthine Phosphoribosyltransferase; Molecular Sequence Data; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sequence Analysis, DNA; X Chromosome | 2001 |
Lack of phosphotyrosine phosphatase SHP-1 expression in malignant T-cell lymphoma cells results from methylation of the SHP-1 promoter.
Topics: Azacitidine; Base Sequence; Decitabine; DNA Methylation; DNA Modification Methylases; Gene Expression; Humans; Intracellular Signaling Peptides and Proteins; Janus Kinase 3; Lymphoma; Lymphoma, T-Cell, Cutaneous; Phosphorylation; Promoter Regions, Genetic; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Protein Tyrosine Phosphatases; Protein-Tyrosine Kinases; Skin Neoplasms; Tetradecanoylphorbol Acetate; Transcription, Genetic; Tumor Cells, Cultured | 2000 |
Resistance to TRAIL-induced apoptosis in primitive neuroectodermal brain tumor cells correlates with a loss of caspase-8 expression.
Topics: Adult; Antimetabolites, Antineoplastic; Apoptosis; Apoptosis Regulatory Proteins; Azacitidine; Carrier Proteins; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspase 8; Caspase 9; Caspases; Child; Cycloheximide; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Drug Resistance; Enzyme Induction; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Humans; Intracellular Signaling Peptides and Proteins; Jurkat Cells; Membrane Glycoproteins; Neoplasm Proteins; Neuroectodermal Tumors, Primitive; Protein Synthesis Inhibitors; Receptors, Tumor Necrosis Factor; Recombinant Proteins; RNA, Messenger; RNA, Neoplasm; TNF-Related Apoptosis-Inducing Ligand; Transcription, Genetic; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 2000 |
Decitabine (5-Aza-2'-deoxycytidine) decreased DNA methylation and expression of MDR-1 gene in K562/ADM cells.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Azacitidine; Binding Sites; CpG Islands; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA, Neoplasm; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gene Expression Regulation, Leukemic; Genes, MDR; Humans; K562 Cells; Neoplasm Proteins; Promoter Regions, Genetic; Repressor Proteins; Transcription Factors | 2000 |
Inactivation of the human androgen receptor gene is associated with CpG hypermethylation in uterine endometrial cancer.
Topics: Alleles; Antimetabolites, Antineoplastic; Azacitidine; CpG Islands; Decitabine; DNA Methylation; Endometrial Neoplasms; Endometrium; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Immunohistochemistry; Receptors, Androgen; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2000 |
Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Azacitidine; Base Pair Mismatch; Carboplatin; Carrier Proteins; Cisplatin; Colonic Neoplasms; Dacarbazine; Decitabine; DNA Methylation; DNA Repair; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Nude; MutL Protein Homolog 1; Neoplasm Proteins; Nuclear Proteins; Ovarian Neoplasms; Promoter Regions, Genetic; Temozolomide; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2000 |
Trans-regulated silencing and reactivation of TP53 tumor suppressor gene in malignant transformation and its reversion.
Topics: Animals; Azacitidine; Cell Transformation, Neoplastic; Chromosomes, Human, Pair 11; Decitabine; DNA Methylation; DNA Modification Methylases; Gene Expression Regulation, Neoplastic; Gene Silencing; Genes, p53; Humans; Mice; Transcriptional Activation; Transfection; Tumor Cells, Cultured; X-Rays | 2000 |
5-Aza-2'-deoxycytidine leads to down-regulation of aberrant p16INK4A RNA transcripts and restores the functional retinoblastoma protein pathway in hepatocellular carcinoma cell lines.
Topics: Azacitidine; Base Sequence; Blotting, Western; Carcinoma, Hepatocellular; Carrier Proteins; Cell Line; Cyclin-Dependent Kinase Inhibitor p16; Decitabine; DNA Methylation; Down-Regulation; Humans; Jurkat Cells; Molecular Sequence Data; Mutation; Promoter Regions, Genetic; Retinoblastoma Protein; RNA, Neoplasm; Signal Transduction; Transcription, Genetic; Tumor Cells, Cultured | 2000 |
Epigenetic regulation of androgen receptor gene expression in human prostate cancers.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Base Sequence; Binding Sites; Cyclic AMP Response Element-Binding Protein; Decitabine; Dinucleoside Phosphates; DNA Methylation; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Male; Polymerase Chain Reaction; Promoter Regions, Genetic; Prostatic Neoplasms; Receptors, Androgen; Tumor Cells, Cultured | 2000 |
Biallelic inactivation of retinoic acid receptor beta2 gene by epigenetic change in breast cancer.
Topics: Alleles; Azacitidine; Breast Neoplasms; Chromosomes, Human, Pair 3; Decitabine; DNA Methylation; DNA, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Loss of Heterozygosity; Promoter Regions, Genetic; Receptors, Retinoic Acid; Tumor Cells, Cultured; Up-Regulation | 2001 |
Loss of Fas (CD95/APO-1) expression by antigen-specific cytotoxic T cells is reversed by inhibiting DNA methylation.
Topics: Animals; Apoptosis; Azacitidine; Clone Cells; Decitabine; DNA Methylation; Enzyme Inhibitors; Fas Ligand Protein; fas Receptor; Female; Flow Cytometry; Gene Expression Regulation; HLA-C Antigens; Immunotherapy, Adoptive; Membrane Glycoproteins; Mice; Mice, Inbred DBA; Recombinant Fusion Proteins; T-Lymphocytes, Cytotoxic; Transfection; Tumor Cells, Cultured | 2000 |
Sensitization by 5-aza-2'-deoxycytidine of leukaemia cells with MLL abnormalities to induction of differentiation by all-trans retinoic acid and 1alpha,25-dihydroxyvitamin D3.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Calcitriol; Cell Differentiation; Chromosome Breakage; Chromosomes, Human, Pair 11; Decitabine; DNA Methylation; DNA-Binding Proteins; Histone-Lysine N-Methyltransferase; Humans; Leukemia; Myeloid-Lymphoid Leukemia Protein; Proto-Oncogenes; Transcription Factors; Tretinoin; Tumor Cells, Cultured | 2001 |
Experimental condensation inhibition in constitutive and facultative heterochromatin of mammalian chromosomes.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Cell Line; Chromosomes, Human; Decitabine; DNA Methylation; DNA Modification Methylases; Evolution, Molecular; Gene Silencing; Heterochromatin; Humans; Karyotyping; Lymphocytes; Molecular Conformation; Sex Chromosomes | 2000 |
Induction of MAGE-3 expression in lung and esophageal cancer cells.
Topics: Adenocarcinoma; Anti-Bacterial Agents; Antibiotics, Antineoplastic; Antigens, Neoplasm; Azacitidine; Carcinoma, Non-Small-Cell Lung; Decitabine; Depsipeptides; DNA Modification Methylases; Enzyme Inhibitors; Esophageal Neoplasms; Histone Deacetylase Inhibitors; Humans; Immunohistochemistry; Lung Neoplasms; Melanoma; Neoplasm Proteins; Peptides, Cyclic; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured | 2001 |
Identification of a novel member of the snail/Gfi-1 repressor family, mlt 1, which is methylated and silenced in liver tumors of SV40 T antigen transgenic mice.
Topics: Amino Acid Sequence; Animals; Antigens, Polyomavirus Transforming; Antimetabolites, Antineoplastic; Azacitidine; Base Sequence; Decitabine; DNA Methylation; DNA-Binding Proteins; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Genome, Human; Humans; Liver Neoplasms, Experimental; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Molecular Sequence Data; Neuroblastoma; Open Reading Frames; Promoter Regions, Genetic; Repressor Proteins; RNA, Messenger; Snail Family Transcription Factors; Transcription Factors; Zinc Fingers | 2001 |
Association of acetylated histones with paternally expressed genes in the Prader--Willi deletion region.
Topics: Acetylation; Alleles; Antimetabolites, Antineoplastic; Autoantigens; Azacitidine; Decitabine; Gene Deletion; Gene Expression Regulation; Histones; Humans; Polymerase Chain Reaction; Prader-Willi Syndrome; Ribonucleoproteins, Small Nuclear; snRNP Core Proteins | 2001 |
Resistance to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in neuroblastoma cells correlates with a loss of caspase-8 expression.
Topics: Amino Acid Chloromethyl Ketones; Apoptosis; Apoptosis Regulatory Proteins; Azacitidine; Caspase 10; Caspase 8; Caspase 9; Caspase Inhibitors; Caspases; Cysteine Proteinase Inhibitors; Decitabine; Dose-Response Relationship, Drug; Enzyme Inhibitors; GPI-Linked Proteins; Humans; Jurkat Cells; Membrane Glycoproteins; Methylation; Neuroblastoma; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor; Receptors, Tumor Necrosis Factor, Member 10c; Reverse Transcriptase Polymerase Chain Reaction; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor Decoy Receptors; Tumor Necrosis Factor-alpha | 2001 |
DNA methyltransferase inhibition enhances apoptosis induced by histone deacetylase inhibitors.
Topics: Acetylation; Apoptosis; Azacitidine; Decitabine; DNA Modification Methylases; Drug Synergism; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Lung Neoplasms; Oligopeptides; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2001 |
Unbalanced expression of HLA-A and -B antigens: a specific feature of cutaneous melanoma and other non-hemopoietic malignancies reverted by IFN-gamma.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Azacitidine; Base Sequence; Cells, Cultured; Decitabine; DNA, Complementary; Down-Regulation; Flow Cytometry; HLA-A Antigens; HLA-B Antigens; Humans; Interferon-gamma; Leukocytes, Mononuclear; Melanoma; Molecular Sequence Data; Neoplasms; Phenotype; Recombinant Proteins; Ribonucleases; RNA, Messenger; Sequence Homology, Nucleic Acid; Skin Neoplasms; Tumor Cells, Cultured; Up-Regulation | 2001 |
Analysis of the ANA gene as a candidate for the chromosome 21q oral cancer susceptibility locus.
Topics: Azacitidine; Cell Cycle Proteins; Chromosomes, Human, Pair 21; Decitabine; DNA Methylation; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Gene Silencing; Genetic Predisposition to Disease; Humans; Loss of Heterozygosity; Mutation; Polymerase Chain Reaction; Polymorphism, Single-Stranded Conformational; Proteins; RNA, Messenger; Tumor Cells, Cultured | 2001 |
Activation of the p53 DNA damage response pathway after inhibition of DNA methyltransferase by 5-aza-2'-deoxycytidine.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cell Survival; Colonic Neoplasms; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Decitabine; DNA Damage; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; G1 Phase; Gene Expression Regulation; HT29 Cells; Humans; Mutation; RNA, Messenger; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2001 |
Association of deletions and translocation of the reduced folate carrier gene with profound loss of gene expression in methotrexate-resistant K562 human erythroleukemia cells.
Topics: 5' Untranslated Regions; Antimetabolites, Antineoplastic; Azacitidine; Biological Transport; Carrier Proteins; Decitabine; DNA Methylation; Drug Resistance, Neoplasm; Gene Deletion; Gene Expression Regulation, Neoplastic; Genes, Reporter; Histones; Humans; Hydroxamic Acids; In Situ Hybridization, Fluorescence; K562 Cells; Karyotyping; Leukemia, Erythroblastic, Acute; Membrane Proteins; Membrane Transport Proteins; Methotrexate; Promoter Regions, Genetic; Reduced Folate Carrier Protein; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Translocation, Genetic | 2001 |
Silencing of the caspase-1 gene occurs in murine and human renal cancer cells and causes solid tumor growth in vivo.
Topics: Animals; Apoptosis; Azacitidine; Caspase 1; Cell Division; Coloring Agents; Decitabine; DNA Methylation; DNA, Complementary; Enzyme Inhibitors; fas Receptor; Gene Silencing; Genetic Vectors; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Kidney Neoplasms; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Plasmids; Reverse Transcriptase Polymerase Chain Reaction; Tetrazolium Salts; Thiazoles; Time Factors; Transfection; Tumor Cells, Cultured | 2001 |
Elevation of breast carcinoma Nm23-H1 metastasis suppressor gene expression and reduced motility by DNA methylation inhibition.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Breast Neoplasms; Carcinoma, Ductal, Breast; Cell Movement; CpG Islands; Decitabine; DNA Methylation; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Humans; Monomeric GTP-Binding Proteins; Neoplasm Metastasis; NM23 Nucleoside Diphosphate Kinases; Nucleoside-Diphosphate Kinase; Promoter Regions, Genetic; Transcription Factors; Transfection; Tumor Cells, Cultured | 2001 |
5' CpG island methylation of the FHIT gene is correlated with loss of gene expression in lung and breast cancer.
Topics: Acid Anhydride Hydrolases; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Biomarkers, Tumor; Blotting, Northern; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; CpG Islands; Decitabine; DNA Methylation; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Loss of Heterozygosity; Lung Neoplasms; Male; Middle Aged; Neoplasm Proteins; Protein Biosynthesis; Proteins; RNA, Messenger | 2001 |
Loss of expression of a new member of the DNAJ protein family confers resistance to chemotherapeutic agents used in the treatment of ovarian cancer.
Topics: Amino Acid Sequence; Azacitidine; Base Sequence; Chromosome Mapping; Cisplatin; Cloning, Molecular; Decitabine; DNA, Neoplasm; Down-Regulation; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Heat-Shock Proteins; HSP40 Heat-Shock Proteins; Humans; In Situ Hybridization, Fluorescence; Loss of Heterozygosity; Molecular Sequence Data; Ovarian Neoplasms; Oximes; Paclitaxel; Piperazines; Reverse Transcriptase Polymerase Chain Reaction; Sequence Homology, Amino Acid; Topotecan; Transfection; Tumor Cells, Cultured | 2001 |
Regulation of the intestinal mucin MUC2 gene expression in vivo: evidence for the role of promoter methylation.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Blotting, Northern; Colorectal Neoplasms; CpG Islands; Decitabine; DNA Methylation; Enzyme Inhibitors; Epithelial Cells; Gene Expression Regulation; Goblet Cells; Humans; Immunohistochemistry; In Situ Hybridization; Intestinal Mucosa; Mice; Mice, Nude; Models, Genetic; Mucin-2; Mucins; Neoplasm Transplantation; Promoter Regions, Genetic; RNA; Tumor Cells, Cultured | 2001 |
Transcriptional silencing of Cyclooxygenase-2 by hyper-methylation of the 5' CpG island in human gastric carcinoma cells.
Topics: Azacitidine; Blotting, Southern; Carcinoma; Chromosome Mapping; CpG Islands; Cyclooxygenase 2; Decitabine; DNA Methylation; Enzyme Induction; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Isoenzymes; Membrane Proteins; Promoter Regions, Genetic; Prostaglandin-Endoperoxide Synthases; Stomach Neoplasms; Transcription, Genetic; Tumor Cells, Cultured | 2001 |
Cytosine methylation represses glutathione S-transferase P1 (GSTP1) gene expression in human prostate cancer cells.
Topics: Azacitidine; Base Sequence; Cytosine; Decitabine; DNA Methylation; Enzyme Inhibitors; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Gene Silencing; Glutathione S-Transferase pi; Glutathione Transferase; HeLa Cells; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Isoenzymes; Male; Molecular Sequence Data; Plasmids; Promoter Regions, Genetic; Prostatic Neoplasms; Transfection; Tumor Cells, Cultured | 2001 |
Promoter hypermethylation: a common cause of reduced p16(INK4a) expression in uveal melanoma.
Topics: Adult; Aged; Aged, 80 and over; Azacitidine; CpG Islands; Cyclin-Dependent Kinase Inhibitor p16; Decitabine; DNA Methylation; DNA, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Male; Melanoma; Middle Aged; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured; Uveal Neoplasms | 2001 |
DNA methylation regulates placental lactogen I gene expression.
Topics: Animals; Azacitidine; Cells, Cultured; CpG Islands; Decitabine; DNA Methylation; Enzyme Inhibitors; Gene Expression Regulation; Hydroxamic Acids; Placental Lactogen; Promoter Regions, Genetic; Rats; Rats, Inbred BUF; RNA, Messenger; Tissue Distribution; Transcriptional Activation | 2001 |
Activation of the maternally preset program of apoptosis by microinjection of 5-aza-2'-deoxycytidine and 5-methyl-2'-deoxycytidine-5'-triphosphate in Xenopus laevis embryos.
Topics: Animals; Apoptosis; Azacitidine; Decitabine; Deoxycytidine; DNA Fragmentation; DNA Methylation; DNA Modification Methylases; Embryo, Nonmammalian; Female; In Situ Nick-End Labeling; Microinjections; Oocytes; Proto-Oncogene Proteins c-bcl-2; Xenopus laevis | 2001 |
Loss of mismatch repair activity in simian virus 40 large T antigen-immortalized BPH-1 human prostatic epithelial cell line.
Topics: Adaptor Proteins, Signal Transducing; Adenosine Triphosphatases; Antigens, Polyomavirus Transforming; Azacitidine; Base Pair Mismatch; Blotting, Western; Carrier Proteins; Cell Line; Decitabine; DNA Methylation; DNA Repair; DNA Repair Enzymes; DNA-Binding Proteins; Down-Regulation; Epithelial Cells; Exons; Fungal Proteins; Gene Deletion; Humans; Male; Mismatch Repair Endonuclease PMS2; Models, Biological; Multidrug Resistance-Associated Proteins; Mutation; MutL Protein Homolog 1; MutL Proteins; MutS Homolog 2 Protein; MutS Homolog 3 Protein; Neoplasm Proteins; Nuclear Proteins; Nucleic Acid Heteroduplexes; Prostate; Proto-Oncogene Proteins; Reverse Transcriptase Polymerase Chain Reaction; Saccharomyces cerevisiae Proteins | 2001 |
Antineoplastic action of 5-aza-2'-deoxycytidine and histone deacetylase inhibitor and their effect on the expression of retinoic acid receptor beta and estrogen receptor alpha genes in breast carcinoma cells.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Breast Neoplasms; Decitabine; Enzyme Inhibitors; Estrogen Receptor alpha; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Receptors, Estrogen; Receptors, Retinoic Acid; Tumor Cells, Cultured | 2001 |
Reversion of transcriptional repression of Sp1 by 5 aza-2' deoxycytidine restores TGF-beta type II receptor expression in the pancreatic cancer cell line MIA PaCa-2.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Azacitidine; Cell Division; Chloramphenicol O-Acetyltransferase; Decitabine; DNA Modification Methylases; DNA, Complementary; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Genetic Vectors; Humans; Pancreatic Neoplasms; Plicamycin; Promoter Regions, Genetic; Protein Serine-Threonine Kinases; Receptor, Transforming Growth Factor-beta Type II; Receptors, Transforming Growth Factor beta; RNA, Messenger; Sp1 Transcription Factor; Transcriptional Activation; Transfection; Transforming Growth Factor beta; Tumor Cells, Cultured | 2001 |
Methylation-dependent silencing of the reduced folate carrier gene in inherently methotrexate-resistant human breast cancer cells.
Topics: Acetylation; Antimetabolites, Antineoplastic; Azacitidine; Biological Transport; Breast Neoplasms; Carrier Proteins; CpG Islands; Decitabine; Dipyridamole; DNA Methylation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Female; Folic Acid Antagonists; Gene Silencing; Histone Deacetylases; Histones; Humans; Ion Pumps; Membrane Transport Proteins; Methotrexate; Promoter Regions, Genetic; Reduced Folate Carrier Protein | 2001 |
Promoter hypermethylation of MGMT is associated with protein loss in gastric carcinoma.
Topics: Alleles; Antimetabolites, Antineoplastic; Azacitidine; Blotting, Western; Carcinoma; CpG Islands; Decitabine; DNA Methylation; Enzyme Inhibitors; Genes, p53; Humans; Mutation; O(6)-Methylguanine-DNA Methyltransferase; Polymorphism, Single-Stranded Conformational; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; Stomach Neoplasms; Transcription, Genetic; Tumor Cells, Cultured | 2001 |
Molecular mechanisms for aberrant expression of the human breast cancer specific gene 1 in breast cancer cells: control of transcription by DNA methylation and intronic sequences.
Topics: Amino Acid Motifs; Azacitidine; Base Sequence; Binding Sites; Breast Neoplasms; CpG Islands; Decitabine; DNA Methylation; Enzyme Inhibitors; Exons; gamma-Synuclein; Humans; Introns; Models, Genetic; Molecular Sequence Data; Neoplasm Metastasis; Neoplasm Proteins; Nerve Tissue Proteins; Promoter Regions, Genetic; Time Factors; Transcription Factor AP-1; Transcription, Genetic; Transcriptional Activation; Transfection; Tumor Cells, Cultured | 2001 |
Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2'-deoxycytidine.
Topics: Adult; Aged; Aged, 80 and over; Anemia, Refractory; Anemia, Refractory, with Excess of Blasts; Anemia, Sideroblastic; Antimetabolites, Antineoplastic; Azacitidine; Chromosome Aberrations; Chromosome Disorders; Decitabine; Drug Administration Schedule; Female; Humans; In Situ Hybridization, Fluorescence; Karyotyping; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Risk; Survival Rate | 2001 |
Autoreactive murine Th1 and Th2 cells kill syngeneic macrophages and induce autoantibodies.
Topics: Animals; Autoantibodies; Azacitidine; Cell Death; Clone Cells; Coculture Techniques; Decitabine; DNA Methylation; Enzyme Inhibitors; Interferon-gamma; Interleukin-4; Interleukin-6; Macrophages, Peritoneal; Mice; Mice, Inbred Strains; Th1 Cells; Th2 Cells; Tumor Necrosis Factor-alpha | 2001 |
Hypermethylation of CpG islands in the mouse asparagine synthetase gene: relationship to asparaginase sensitivity in lymphoma cells. Partial methylation in normal cells.
Topics: Animals; Asparaginase; Aspartate-Ammonia Ligase; Azacitidine; Base Sequence; Blotting, Northern; CpG Islands; Decitabine; DNA; DNA Modification Methylases; DNA Primers; Gene Amplification; Liver; Lymphoma; Methylation; Mice; Mice, Inbred C3H; Molecular Sequence Data; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sequence Homology, Nucleic Acid; Spleen; Tumor Cells, Cultured | 2001 |
Histone deacetylase and DNA methyltransferase in human prostate cancer.
Topics: Azacitidine; Cell Line; CpG Islands; Decitabine; DNA Methylation; DNA Modification Methylases; Dose-Response Relationship, Drug; Histone Deacetylases; Humans; Immunohistochemistry; Male; Prostatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Spectrometry, Fluorescence; Tumor Cells, Cultured; Up-Regulation | 2001 |
CpG methylation of promoter region inactivates E-cadherin gene in renal cell carcinoma.
Topics: Azacitidine; Cadherins; Carcinoma, Renal Cell; Cells, Cultured; CpG Islands; Decitabine; DNA Methylation; DNA Primers; DNA, Neoplasm; Enzyme Inhibitors; Gene Silencing; Humans; Immunoenzyme Techniques; Kidney Neoplasms; Neoplasm Staging; Polymerase Chain Reaction; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; RNA, Neoplasm; Transcription, Genetic | 2001 |
Hypermethylation of the tumor necrosis factor receptor superfamily 6 (APT1, Fas, CD95/Apo-1) gene promoter at rel/nuclear factor kappaB sites in prostatic carcinoma.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Methylation; DNA Mutational Analysis; DNA Primers; DNA, Neoplasm; fas Receptor; Flow Cytometry; Gene Expression; Humans; Immunoenzyme Techniques; In Vitro Techniques; Male; Middle Aged; NF-kappa B; Oncogene Proteins v-rel; Promoter Regions, Genetic; Prostatic Neoplasms; Receptors, Tumor Necrosis Factor; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Thiolester Hydrolases; Urinary Bladder Neoplasms | 2001 |
Epigenetic regulation of the KAI1 metastasis suppressor gene in human prostate cancer cell lines.
Topics: Adenocarcinoma; Antigens, CD; Azacitidine; Base Sequence; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Gene Silencing; Genes, Tumor Suppressor; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Kangai-1 Protein; Male; Membrane Glycoproteins; Molecular Sequence Data; Neoplasm Metastasis; Neoplasm Proteins; Polymerase Chain Reaction; Promoter Regions, Genetic; Prostatic Hyperplasia; Prostatic Neoplasms; Proto-Oncogene Proteins; Sulfites; Tumor Cells, Cultured | 2001 |
DNA hypermethylation is a mechanism for loss of expression of the HLA class I genes in human esophageal squamous cell carcinomas.
Topics: Azacitidine; Carcinoma, Squamous Cell; Chromosomes, Human, Pair 6; CpG Islands; Decitabine; DNA Methylation; DNA Modification Methylases; DNA Primers; DNA, Neoplasm; Down-Regulation; Esophageal Neoplasms; Gene Deletion; Genes, MHC Class I; Histocompatibility Antigens Class I; Humans; Immunoenzyme Techniques; Loss of Heterozygosity; Microsatellite Repeats; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2001 |
E-cadherin expression is commonly downregulated by CpG island hypermethylation in esophageal carcinoma cells.
Topics: Azacitidine; Cadherins; Carcinoma; CpG Islands; Decitabine; DNA Methylation; DNA Modification Methylases; Down-Regulation; Enzyme Inhibitors; Esophageal Neoplasms; Humans; Promoter Regions, Genetic; RNA, Neoplasm; Transcription, Genetic; Tumor Cells, Cultured | 2001 |
Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells.
Topics: Acetylation; Azacitidine; Breast Neoplasms; CpG Islands; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Drug Synergism; Enzyme Inhibitors; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Fulvestrant; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Receptors, Estrogen; RNA, Messenger; Tumor Cells, Cultured | 2001 |
Demethylation by 5-aza-2'-deoxycytidine (5-azadC) of p16INK4A gene results in downregulation of vascular endothelial growth factor expression in human lung cancer cell lines.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cell Division; Decitabine; DNA Methylation; DNA Modification Methylases; Dose-Response Relationship, Drug; Down-Regulation; Endothelial Growth Factors; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Genes, Dominant; Genes, p16; Humans; Interleukin-8; Kinetics; Lung Neoplasms; Lymphokines; Promoter Regions, Genetic; Protein Isoforms; RNA, Neoplasm; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2001 |
Selection of drug-resistant transduced cells with cytosine nucleoside analogs using the human cytidine deaminase gene.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow Cells; Colony-Forming Units Assay; Cytarabine; Cytidine Deaminase; Decitabine; Deoxycytidine; DNA Modification Methylases; Drug Evaluation; Drug Resistance; Enzyme Inhibitors; Flow Cytometry; Gene Transfer Techniques; Genetic Vectors; Green Fluorescent Proteins; Humans; Leukemia; Luminescent Proteins; Retroviridae; Transgenes | 2001 |
Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Azacitidine; Bone Neoplasms; Caspase 3; Caspase 8; Caspase 9; Caspases; Decitabine; DNA Modification Methylases; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Induction; Gene Transfer Techniques; Humans; Membrane Glycoproteins; Methylation; Neoplasm Proteins; Receptors, Tumor Necrosis Factor; RNA, Messenger; Sarcoma, Ewing; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 2001 |
CpG hypermethylation of the promoter region inactivates the estrogen receptor-beta gene in patients with prostate carcinoma.
Topics: Azacitidine; Decitabine; DNA Methylation; DNA Modification Methylases; Estrogen Receptor beta; Gene Expression Regulation; Humans; Male; Neoplasms, Hormone-Dependent; Promoter Regions, Genetic; Prostatic Hyperplasia; Prostatic Neoplasms; Receptors, Estrogen; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured | 2001 |
Rexpression of HLA class I antigens and restoration of antigen-specific CTL response in melanoma cells following 5-aza-2'-deoxycytidine treatment.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Methylation; Epitopes, T-Lymphocyte; Genes, MHC Class I; HLA-A Antigens; HLA-B Antigens; Humans; Melanoma; T-Lymphocytes, Cytotoxic; Tumor Cells, Cultured | 2001 |
Reduced expression of syndecan-1 affects metastatic potential and clinical outcome in patients with colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Azacitidine; Chi-Square Distribution; Colorectal Neoplasms; Decitabine; Female; Humans; Immunohistochemistry; In Situ Hybridization; Intestinal Mucosa; Lymphatic Metastasis; Male; Membrane Glycoproteins; Methylation; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Proteoglycans; RNA, Messenger; RNA, Neoplasm; Survival Analysis; Syndecan-1; Syndecans; Tumor Cells, Cultured | 2001 |
5-Aza-2'-deoxycytidine induces histone hyperacetylation of mouse centromeric heterochromatin by a mechanism independent of DNA demethylation.
Topics: Acetylation; Animals; Azacitidine; Cell Line; Centromere; Chromosomal Proteins, Non-Histone; Decitabine; DNA Methylation; DNA Modification Methylases; DNA-Binding Proteins; Heterochromatin; Histone Deacetylase 2; Histone Deacetylases; Histones; Methyl-CpG-Binding Protein 2; Mice; Protein Transport; Repressor Proteins; Transfection | 2001 |
Diminished expression of S100A2, a putative tumor suppressor, at early stage of human lung carcinogenesis.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Base Sequence; Biomarkers, Tumor; Bronchi; Carcinoma, Non-Small-Cell Lung; Cell Line, Transformed; Cell Transformation, Neoplastic; Chemotactic Factors; Decitabine; Epithelial Cells; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mice; Mice, Nude; Molecular Sequence Data; Neoplasm Staging; Oligonucleotide Array Sequence Analysis; Rats; RNA, Neoplasm; S100 Proteins; Transplantation, Heterologous; Tumor Cells, Cultured | 2001 |
CpG methylation as a basis for breast tumor-specific loss of NES1/kallikrein 10 expression.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Biomarkers, Tumor; Breast Neoplasms; CpG Islands; Decitabine; DNA Methylation; Exons; Gene Expression Regulation, Neoplastic; Humans; Introns; Kallikreins; Luciferases; Promoter Regions, Genetic; RNA, Messenger | 2001 |
Methylation in hMLH1 promoter interferes with its binding to transcription factor CBF and inhibits gene expression.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Azacitidine; Binding Sites; Carrier Proteins; CCAAT-Binding Factor; Colorectal Neoplasms; CpG Islands; Decitabine; DNA Methylation; DNA, Neoplasm; Electrophoresis, Polyacrylamide Gel; Gene Expression Regulation; Gene Expression Regulation, Neoplastic; Gene Silencing; Genes, Reporter; Humans; Luciferases; MutL Protein Homolog 1; Neoplasm Proteins; Nuclear Proteins; Promoter Regions, Genetic; Protein Binding; Recombinant Fusion Proteins; Transcription, Genetic; Transfection; Tumor Cells, Cultured | 2001 |
Glypican-3 expression is silenced in human breast cancer.
Topics: Azacitidine; Breast; Breast Neoplasms; Carcinoma, Hepatocellular; Decitabine; DNA Methylation; DNA, Neoplasm; Dosage Compensation, Genetic; Epithelial Cells; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Genes, Tumor Suppressor; Glypicans; Heparan Sulfate Proteoglycans; Humans; Liver Neoplasms; Loss of Heterozygosity; Neoplasm Proteins; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; Tumor Cells, Cultured; Tumor Stem Cell Assay; X Chromosome | 2001 |
The 5-lipoxygenase promoter is regulated by DNA methylation.
Topics: Arachidonate 5-Lipoxygenase; Azacitidine; Base Sequence; CpG Islands; Decitabine; DNA Methylation; DNA Primers; Enzyme Induction; Enzyme Inhibitors; HeLa Cells; HL-60 Cells; Humans; Lipoxygenase Inhibitors; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; U937 Cells | 2002 |
Hypermethylation in human cancers of the RIZ1 tumor suppressor gene, a member of a histone/protein methyltransferase superfamily.
Topics: Animals; Azacitidine; Base Sequence; Cloning, Molecular; CpG Islands; Decitabine; DNA Methylation; DNA-Binding Proteins; DNA, Neoplasm; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Gene Silencing; Genes, Tumor Suppressor; Histone Methyltransferases; Histone-Lysine N-Methyltransferase; Humans; Methyltransferases; Molecular Sequence Data; Neoplasms; Nuclear Proteins; Promoter Regions, Genetic; Protein Methyltransferases; Rats; Retinoblastoma Protein; RNA, Messenger; Transcription Factors; Zinc Fingers | 2001 |
Methylation-mediated silencing of TMS1/ASC is accompanied by histone hypoacetylation and CpG island-localized changes in chromatin architecture.
Topics: Acetylation; Antimetabolites, Antineoplastic; Azacitidine; Binding Sites; CARD Signaling Adaptor Proteins; Cells, Cultured; Chromatin; CpG Islands; Cytoskeletal Proteins; Decitabine; Deoxyribonuclease I; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Enzyme Inhibitors; Fibroblasts; Gene Silencing; Histones; Humans; Hydroxamic Acids; Models, Genetic; Polymerase Chain Reaction; Precipitin Tests; Proteins; Reverse Transcriptase Polymerase Chain Reaction; Sequence Analysis, DNA | 2002 |
Potential of 5-aza-2'-deoxycytidine (Decitabine) a potent inhibitor of DNA methylation for therapy of advanced non-small cell lung cancer.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Carcinoma, Non-Small-Cell Lung; Decitabine; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; Female; Humans; Lung Neoplasms; Male; Middle Aged | 2001 |
Reexpression of a cluster of silenced transgenes is associated with their rearrangement.
Topics: Animals; Azacitidine; Clone Cells; Decitabine; DNA Methylation; Gene Expression Regulation, Neoplastic; Gene Rearrangement; Gene Silencing; Lac Operon; Mice; Multigene Family; Phosphoglycerate Kinase; Recombinant Fusion Proteins; Transfection; Transgenes; Tumor Cells, Cultured | 2001 |
Expression of the Hypermethylated in Cancer gene (HIC-1) is associated with good outcome in human breast cancer.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Breast Neoplasms; Carcinoma; Chromosome Deletion; Chromosomes, Human, Pair 17; Cohort Studies; Decitabine; DNA Methylation; Enzyme Inhibitors; Female; Follow-Up Studies; Gene Deletion; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Silencing; Genes, p53; Humans; Kruppel-Like Transcription Factors; Loss of Heterozygosity; Neoplasm Proteins; Prognosis; Prospective Studies; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Survival Analysis; Transcription Factors; Tumor Cells, Cultured | 2001 |
Increased expression of unmethylated CDKN2D by 5-aza-2'-deoxycytidine in human lung cancer cells.
Topics: Azacitidine; Blotting, Southern; Blotting, Western; Cell Cycle Proteins; Cell Survival; CpG Islands; Cyclin-Dependent Kinase Inhibitor p16; Cyclin-Dependent Kinase Inhibitor p19; Decitabine; DNA Methylation; DNA Modification Methylases; Gene Expression Regulation, Neoplastic; Gene Silencing; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Lung Neoplasms; Polymerase Chain Reaction; Promoter Regions, Genetic; RNA, Messenger; Tumor Cells, Cultured | 2001 |
Cooperativity between DNA methyltransferases in the maintenance methylation of repetitive elements.
Topics: Animals; Azacitidine; Base Sequence; Cell Line; CpG Islands; Decitabine; DNA; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Methyltransferase 3A; DNA Methyltransferase 3B; Enzyme Inhibitors; Kinetics; Long Interspersed Nucleotide Elements; Mice; Mice, Knockout; Repetitive Sequences, Nucleic Acid | 2002 |
Characterization of XAGE-1b, a short major transcript of cancer/testis-associated gene XAGE-1, induced in melanoma metastasis.
Topics: Amino Acid Sequence; Animals; Antigens, Neoplasm; Azacitidine; Base Sequence; Blotting, Northern; Chromosome Mapping; Cloning, Molecular; Decitabine; Disease Progression; DNA Modification Methylases; DNA Primers; DNA, Complementary; DNA, Neoplasm; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Humans; Male; Melanoma; Molecular Sequence Data; Neoplasm Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Testis; Transfection; Tumor Cells, Cultured | 2002 |
Aberrant methylation and histone deacetylation of cyclooxygenase 2 in gastric cancer.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Cyclooxygenase 2; Cytosine; Decitabine; DNA; DNA Methylation; Enzyme Inhibitors; Gastric Mucosa; Gene Silencing; Histone Deacetylases; Histones; Humans; Hydroxamic Acids; Immunohistochemistry; Isoenzymes; Membrane Proteins; Methylation; Polymorphism, Single-Stranded Conformational; Precipitin Tests; Promoter Regions, Genetic; Prostaglandin-Endoperoxide Synthases; Reverse Transcriptase Polymerase Chain Reaction; Stomach Neoplasms; Sulfites; Transcription, Genetic; Tumor Cells, Cultured | 2002 |
Inhibition of dna methylation by 5-aza-2'-deoxycytidine correlates with induction of K562 cells differentiation.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Butyric Acid; Cell Differentiation; CpG Islands; Cytosine; Decitabine; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Humans; K562 Cells | 2000 |
Evidence of inhibition of DNA methylation by fludarabine.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Azacitidine; Cell Line; Cell Survival; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Vidarabine | 2000 |
Frequent allelic losses on the short arm of chromosome 1 and decreased expression of the p73 gene at 1p36.3 in squamous cell carcinoma of the oral cavity.
Topics: Azacitidine; Carcinoma, Squamous Cell; Chromosomes, Human, Pair 1; Decitabine; DNA-Binding Proteins; Female; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Genotype; Humans; Loss of Heterozygosity; Male; Microsatellite Repeats; Mouth Neoplasms; Nuclear Proteins; Phenotype; Physical Chromosome Mapping; Polymorphism, Single-Stranded Conformational; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sequence Deletion; Tumor Cells, Cultured; Tumor Protein p73; Tumor Suppressor Proteins | 2002 |
Reduced expression of insulin-like growth factor binding protein-3 and its promoter hypermethylation in human hepatocellular carcinoma.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Base Sequence; Blotting, Northern; Carcinoma, Hepatocellular; Chromosomes, Human, Pair 7; Decitabine; DNA Methylation; DNA, Complementary; Humans; Insulin-Like Growth Factor Binding Protein 3; Liver Neoplasms; Loss of Heterozygosity; Mannosephosphates; Molecular Sequence Data; Mutation; Oligonucleotide Array Sequence Analysis; Polymerase Chain Reaction; Polymorphism, Single-Stranded Conformational; Promoter Regions, Genetic; Receptor, IGF Type 2; Reverse Transcriptase Polymerase Chain Reaction; RNA; Tumor Cells, Cultured | 2002 |
Somatic recombination: a major genotoxic effect of two pyrimidine antimetabolitic chemotherapeutic drugs in Drosophila melanogaster.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Cytarabine; Decitabine; Drosophila melanogaster; Female; Male; Molecular Structure; Mutagenicity Tests; Recombination, Genetic | 2002 |
Effect of 5-Aza-2'-deoxycytidine on the P16 tumor suppressor gene in hepatocellular carcinoma cell line HepG2.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Carcinogenicity Tests; Carcinoma, Hepatocellular; Cell Cycle; Cyclin-Dependent Kinase Inhibitor p16; Decitabine; DNA Methylation; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; RNA, Messenger; Tumor Cells, Cultured | 2001 |
Dietary selenite and azadeoxycytidine treatments affect dimethylhydrazine-induced aberrant crypt formation in rat colon and DNA methylation in HT-29 cells.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Azacitidine; Carcinogens; Colon; Colorectal Neoplasms; Decitabine; Dimethylhydrazines; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; HT29 Cells; Humans; Injections, Intraperitoneal; Male; Rats; Rats, Inbred F344; Sodium Selenite | 2002 |
Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor.
Topics: Azacitidine; Binding Sites; Cell Differentiation; Cell Line; Cell Nucleus; Cell Transformation, Neoplastic; Cloning, Molecular; CpG Islands; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Methyltransferase 3A; Exons; Gene Expression; Gene Silencing; Histone Deacetylases; Humans; Leukemia, Promyelocytic, Acute; Mutation; Neoplasm Proteins; Oncogene Proteins, Fusion; Promoter Regions, Genetic; Receptors, Retinoic Acid; Recombinant Fusion Proteins; Transcription Factors; Tretinoin; Tumor Cells, Cultured; Zinc | 2002 |
Analysis of gene induction in human fibroblasts and bladder cancer cells exposed to the methylation inhibitor 5-aza-2'-deoxycytidine.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Carcinoma, Transitional Cell; CpG Islands; Decitabine; DNA Methylation; Fibroblasts; Gene Expression Regulation; Gene Expression Regulation, Neoplastic; Humans; Promoter Regions, Genetic; Transcriptional Activation; Urinary Bladder Neoplasms | 2002 |
Lack of a consistent relationship between demethylation of the CD44 promoter and CD44 expression.
Topics: Animals; Azacitidine; Butyric Acid; CpG Islands; Decitabine; DNA Methylation; Flow Cytometry; Gene Expression Regulation; Hyaluronan Receptors; Mice; Promoter Regions, Genetic; Proto-Oncogene Proteins c-jun; Transcription, Genetic; Tumor Cells, Cultured | 2002 |
Variable promoter region CpG island methylation of the putative tumor suppressor gene Connexin 26 in breast cancer.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Breast Neoplasms; Connexin 26; Connexins; CpG Islands; Decitabine; DNA Methylation; Female; Humans; Polymorphism, Single-Stranded Conformational; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sequence Analysis, DNA; Sulfites; Transcription, Genetic; Tumor Cells, Cultured | 2002 |
High prevalence of decreased expression of KAI1 metastasis suppressor in human oral carcinogenesis.
Topics: Aged; Alleles; Antigens, CD; Azacitidine; Carcinoma, Squamous Cell; Chromosomes, Human, Pair 11; Decitabine; DNA Methylation; DNA Modification Methylases; DNA Mutational Analysis; DNA, Neoplasm; Enzyme Inhibitors; Epithelium; Female; Gene Expression Regulation, Neoplastic; Humans; Immunoenzyme Techniques; Kangai-1 Protein; Male; Membrane Glycoproteins; Middle Aged; Mouth Neoplasms; Neoplasm Metastasis; Polymerase Chain Reaction; Polymorphism, Single-Stranded Conformational; Proto-Oncogene Proteins; RNA, Messenger; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2002 |
p16INK4a loss and sensitivity in KSHV associated primary effusion lymphoma.
Topics: Adenoviridae; Azacitidine; Blotting, Western; CpG Islands; Cyclin-Dependent Kinase Inhibitor p16; Cyclin-Dependent Kinases; Decitabine; DNA Methylation; DNA Primers; Down-Regulation; Gene Deletion; Herpesvirus 8, Human; Humans; Lymphoma, B-Cell; Mutation; Polymerase Chain Reaction; Retinoblastoma Protein; RNA, Neoplasm; Sarcoma, Kaposi; Signal Transduction; Transcription, Genetic; Transfection; Tumor Cells, Cultured | 2002 |
Differentiation therapy for myelodysplastic syndrome.
Topics: Azacitidine; Cell Differentiation; Decitabine; DNA Modification Methylases; Enzyme Inhibitors; Histone Deacetylase Inhibitors; HL-60 Cells; Humans; Myelodysplastic Syndromes; Tretinoin | 2002 |
Silencing of GSTP1 gene by CpG island DNA hypermethylation in HBV-associated hepatocellular carcinomas.
Topics: Adult; Azacitidine; Blotting, Western; Carcinoma, Hepatocellular; CpG Islands; Decitabine; DNA Methylation; DNA, Neoplasm; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Gene Silencing; Glutathione S-Transferase pi; Glutathione Transferase; Hepatitis B; Humans; Isoenzymes; Liver Neoplasms; Male; Middle Aged; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured | 2002 |
5-Aza-2'-deoxycytidine-induced cytotoxicity and limb reduction defects in the mouse.
Topics: Animals; Azacitidine; Basic Helix-Loop-Helix Transcription Factors; Cell Death; Cell Division; Decitabine; Extremities; Immunohistochemistry; Limb Deformities, Congenital; Mice; Teratogens; Transcription Factors | 2002 |
Cell division is required for de novo methylation of CpG islands in bladder cancer cells.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Carcinoma, Transitional Cell; Cell Division; CpG Islands; Cyclin-Dependent Kinase Inhibitor p16; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Methyltransferase 3A; Down-Regulation; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Genes, p16; Humans; Kinetics; RNA, Messenger; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2002 |
Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Blotting, Northern; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cells, Cultured; Decitabine; DNA Methylation; DNA Modification Methylases; DNA, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Middle Aged; Phosphoric Monoester Hydrolases; Promoter Regions, Genetic; PTEN Phosphohydrolase; RNA, Messenger; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2002 |
Hypertonicity induction of melanoma antigen, a tumor-associated antigen.
Topics: Antigens, Neoplasm; Antimetabolites, Antineoplastic; Azacitidine; Dactinomycin; Decitabine; Gene Expression Regulation; Humans; Hypertonic Solutions; Melanoma-Specific Antigens; Neoplasm Proteins; Protein Synthesis Inhibitors; RNA Stability; Sodium Chloride; Tumor Cells, Cultured; Up-Regulation | 2002 |
DNA methylation dominates transcriptional silencing of Pax5 in terminally differentiated B cell lines.
Topics: Animals; Azacitidine; B-Lymphocytes; Decitabine; DNA Methylation; DNA-Binding Proteins; Gene Expression Regulation; Gene Silencing; Hydroxamic Acids; Mice; PAX5 Transcription Factor; Promoter Regions, Genetic; Transcription Factors | 2002 |
Cytotoxic activity of 2',2'-difluorodeoxycytidine, 5-aza-2'-deoxycytidine and cytosine arabinoside in cells transduced with deoxycytidine kinase gene.
Topics: 3T3 Cells; Animals; Azacitidine; Cell Death; Cell Line; Cytarabine; Cytidine Deaminase; Decitabine; Deoxycytidine; Deoxycytidine Kinase; DNA, Complementary; Dose-Response Relationship, Drug; Gemcitabine; Genetic Vectors; Humans; Mice; Phenotype; Phosphorylation; Retroviridae; Thymidine Kinase; Tumor Cells, Cultured | 2002 |
Tropomyosin-1, a novel suppressor of cellular transformation is downregulated by promoter methylation in cancer cells.
Topics: Antibiotics, Antineoplastic; Azacitidine; Breast Neoplasms; Chromatin; Decitabine; DNA Methylation; Down-Regulation; Drosophila Proteins; Enzyme Inhibitors; Fibroblasts; Histone Deacetylases; Humans; Hydroxamic Acids; Immunoblotting; Microscopy, Fluorescence; Promoter Regions, Genetic; Tropomyosin; Tumor Cells, Cultured | 2002 |
DNA hypomethylating agents 5-aza-2'-deoxycytidine and valproate increase neuronal 5-lipoxygenase mRNA.
Topics: Animals; Arachidonate 5-Lipoxygenase; Azacitidine; Cells, Cultured; Cerebellum; Decitabine; DNA Methylation; Neurons; Rats; RNA, Messenger; Valproic Acid | 2002 |
Remodeling of DNA methylation and phenotypic and transcriptional changes in synthetic Arabidopsis allotetraploids.
Topics: Arabidopsis; Azacitidine; Chromatin; Crosses, Genetic; Cytosine; Decitabine; DNA Methylation; DNA-Cytosine Methylases; DNA, Complementary; Evolution, Molecular; Gene Expression Regulation; Gene Silencing; Phenotype; Polymorphism, Restriction Fragment Length; Polyploidy; RNA, Messenger | 2002 |
Complex relationships between 5-aza-dC induced DNA demethylation and chromosome compaction at mitosis.
Topics: Azacitidine; Bromodeoxyuridine; Cell Cycle; Chromosomes; Decitabine; DNA; DNA Methylation; Immunohistochemistry; Mitosis; Staining and Labeling | 2002 |
Tumour specific promoter region methylation of the human homologue of the Drosophila Roundabout gene DUTT1 (ROBO1) in human cancers.
Topics: Animals; Azacitidine; Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Chromosomes, Human, Pair 3; CpG Islands; Decitabine; DNA Methylation; DNA Mutational Analysis; DNA, Neoplasm; Drosophila melanogaster; Drosophila Proteins; Female; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Humans; Kidney Neoplasms; Loss of Heterozygosity; Lung Neoplasms; Mutation, Missense; Nerve Tissue Proteins; Promoter Regions, Genetic; Receptors, Immunologic; Roundabout Proteins; Sequence Homology, Nucleic Acid; Tumor Cells, Cultured | 2002 |
Progressive aberrant methylation of the RASSF1A gene in simian virus 40 infected human mesothelial cells.
Topics: Alleles; Azacitidine; Cell Line, Transformed; Cell Transformation, Viral; Cocarcinogenesis; CpG Islands; Decitabine; DNA Methylation; DNA, Neoplasm; Gene Expression Regulation; Gene Silencing; Genes, Tumor Suppressor; Humans; Hydroxamic Acids; Mesothelioma; Neoplasm Proteins; Polymerase Chain Reaction; Promoter Regions, Genetic; Simian virus 40; Tumor Suppressor Proteins | 2002 |
Inactivation of O6-methylguanine-DNA methyltransferase by promoter CpG island hypermethylation in gastric cancers.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Carcinoma; CpG Islands; Decitabine; DNA Methylation; DNA Modification Methylases; DNA Primers; Down-Regulation; Enzyme Inhibitors; Humans; Microsatellite Repeats; Mutation; Neoplasm Invasiveness; Neoplasm Staging; O(6)-Methylguanine-DNA Methyltransferase; Prognosis; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sequence Analysis, DNA; Stomach; Stomach Neoplasms; Sulfites; Survival Rate; Transcription, Genetic; Tumor Cells, Cultured | 2002 |
In vitro and in vivo activity and cross resistance profiles of novel ruthenium (II) organometallic arene complexes in human ovarian cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Azacitidine; Calcium Channel Blockers; Carboplatin; Cisplatin; Decitabine; Drug Design; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Edetic Acid; Female; Humans; Ligands; Mice; Mice, Nude; Neoplasm Proteins; Organometallic Compounds; Ovarian Neoplasms; Ruthenium Compounds; Structure-Activity Relationship; Verapamil; Xenograft Model Antitumor Assays | 2002 |
Differential expression of FEZ1/LZTS1 gene in lung cancers and their cell cultures.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Azacitidine; Blotting, Western; Carcinoma, Large Cell; Carcinoma, Squamous Cell; Chromosomes, Human, Pair 8; CpG Islands; Decitabine; DNA Modification Methylases; DNA-Binding Proteins; DNA, Neoplasm; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Loss of Heterozygosity; Lung Neoplasms; Nerve Tissue Proteins; Polymorphism, Single-Stranded Conformational; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2002 |
Reduced expression of the insulin-induced protein 1 and p41 Arp2/3 complex genes in human gastric cancers.
Topics: Actin-Related Protein 2-3 Complex; Actins; Adult; Aged; Aged, 80 and over; Azacitidine; Decitabine; DNA Methylation; DNA, Neoplasm; Female; Gene Expression; Humans; Intracellular Signaling Peptides and Proteins; Male; Membrane Proteins; Middle Aged; Proteins; Reverse Transcriptase Polymerase Chain Reaction; Stomach Neoplasms; Tumor Cells, Cultured | 2002 |
SNPs in the CpG island of NAP1L2: a possible link between DNA methylation and neural tube defects?
Topics: Animals; Azacitidine; Cell Line; CpG Islands; Decitabine; DNA; DNA Methylation; DNA Modification Methylases; DNA Mutational Analysis; Enzyme Inhibitors; Female; Gene Expression Regulation; Genetic Linkage; Humans; Lac Operon; Male; Mice; Nerve Tissue Proteins; Neural Tube Defects; Polymorphism, Single Nucleotide; Promoter Regions, Genetic; Proteins; X Chromosome | 2002 |
Expression spectrum and methylation-dependent regulation of melanoma antigen-encoding gene family members in pancreatic cancer cells.
Topics: Adult; Aged; Antigens, Neoplasm; Azacitidine; Culture Techniques; Decitabine; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Female; Gene Expression; Gene Expression Regulation; Humans; Male; Melanoma; Middle Aged; Pancreatic Neoplasms; Tumor Cells, Cultured; Up-Regulation | 2002 |
DNA methylation down-regulates CDX1 gene expression in colorectal cancer cell lines.
Topics: Animals; Azacitidine; Base Sequence; Blotting, Western; Cloning, Molecular; Colorectal Neoplasms; Cosmids; CpG Islands; Decitabine; DNA Methylation; Down-Regulation; Enzyme Inhibitors; HeLa Cells; Humans; Mice; Molecular Sequence Data; Plasmids; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; Sulfites; Transfection; Tumor Cells, Cultured | 2002 |
Selective down-regulation of tyrosinase family gene TYRP1 by inhibition of the activity of melanocyte transcription factor, MITF.
Topics: Acetamides; Azacitidine; Binding Sites; Blotting, Northern; Cells, Cultured; Cycloheximide; Decitabine; DNA-Binding Proteins; Down-Regulation; Electrophoretic Mobility Shift Assay; Gene Expression Regulation; Humans; Hydroxamic Acids; Luciferases; Melanocytes; Membrane Glycoproteins; Microphthalmia-Associated Transcription Factor; Monophenol Monooxygenase; Mutation; Oxidoreductases; Promoter Regions, Genetic; Protein Binding; Recombinant Fusion Proteins; Regulatory Sequences, Nucleic Acid; RNA, Messenger; Sequence Deletion; Transcription Factors; Tumor Cells, Cultured | 2002 |
Quantitative analysis of DNA demethylation and transcriptional reactivation of the FMR1 gene in fragile X cells treated with 5-azadeoxycytidine.
Topics: Azacitidine; Base Sequence; Cell Line; CpG Islands; Decitabine; DNA; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Fragile X Mental Retardation Protein; Fragile X Syndrome; Humans; Male; Molecular Sequence Data; Nerve Tissue Proteins; Promoter Regions, Genetic; RNA-Binding Proteins; RNA, Messenger; Sequence Analysis, DNA | 2002 |
Estrogen receptor alpha-mediated silencing of caveolin gene expression in neuronal cells.
Topics: Animals; Azacitidine; Brain; Butadienes; Caveolin 1; Caveolins; Cell Line; Decitabine; Enzyme Activation; Enzyme Inhibitors; Estradiol; Estrogen Receptor alpha; Gene Expression Regulation; Gene Silencing; Genes, Reporter; Humans; Hydroxamic Acids; Methylation; Mice; Mitogen-Activated Protein Kinases; Molecular Sequence Data; Neurons; Nitriles; Promoter Regions, Genetic; Receptors, Estrogen; RNA, Messenger; Transcription, Genetic | 2002 |
In TH2 cells the Il4 gene has a series of accessibility states associated with distinctive probabilities of IL-4 production.
Topics: Acetylation; Animals; Azacitidine; Cells, Cultured; Decitabine; DNA Methylation; DNA Modification Methylases; Gene Expression; Green Fluorescent Proteins; Histones; Interleukin-13; Interleukin-4; Luminescent Proteins; Mice; Mice, Inbred C57BL; Mice, Transgenic; Th1 Cells; Th2 Cells; Transcription Factors | 2002 |
5-aza-2'-deoxycytidine-induced expression of functional cancer testis antigens in human renal cell carcinoma: immunotherapeutic implications.
Topics: Antibodies, Monoclonal; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Azacitidine; Blotting, Western; Carcinoma, Renal Cell; Decitabine; Electrophoresis, Polyacrylamide Gel; Eye Proteins; Humans; Immunotherapy; Kidney Neoplasms; Melanoma-Specific Antigens; Membrane Proteins; Mitogen-Activated Protein Kinases; Neoplasm Proteins; Precipitin Tests; Protein Biosynthesis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Time Factors; Tumor Cells, Cultured | 2002 |
Role of DNA methylation in transcription of human endogenous retrovirus in the pathogenesis of systemic lupus erythematosus.
Topics: Adult; Azacitidine; Cells, Cultured; Clone Cells; Decitabine; DNA Methylation; DNA Primers; Endogenous Retroviruses; Female; Gene Products, gag; Humans; Leukocytes, Mononuclear; Lupus Erythematosus, Systemic; Middle Aged; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Viral; Transcription, Genetic | 2002 |
MYEOV, a gene at 11q13, is coamplified with CCND1, but epigenetically inactivated in a subset of esophageal squamous cell carcinomas.
Topics: Azacitidine; Blotting, Northern; Blotting, Southern; Carcinoma, Squamous Cell; Chromosomes, Human, Pair 11; Cyclin D1; Decitabine; DNA Methylation; Esophageal Neoplasms; Gene Amplification; Gene Silencing; Humans; Neoplasm Proteins; Oncogene Proteins; Proto-Oncogene Proteins; Tumor Cells, Cultured | 2002 |
Histone modifications depict an aberrantly heterochromatinized FMR1 gene in fragile x syndrome.
Topics: Acetylation; Alleles; Azacitidine; Decitabine; DNA Methylation; Fragile X Mental Retardation Protein; Fragile X Syndrome; Heterochromatin; Histones; Humans; Lysine; Nerve Tissue Proteins; RNA-Binding Proteins; Transcriptional Activation; Trinucleotide Repeats; Tumor Cells, Cultured | 2002 |
Characterization and enrichment of cardiomyocytes derived from human embryonic stem cells.
Topics: 1-Methyl-3-isobutylxanthine; Azacitidine; Cell Differentiation; Cell Size; Decitabine; Diltiazem; Dimethyl Sulfoxide; Dose-Response Relationship, Drug; Embryo, Mammalian; Gene Expression Regulation; Humans; Immunohistochemistry; Isoproterenol; Ki-67 Antigen; Myocardium; Myosin Heavy Chains; Phenylephrine; Stem Cells; Time Factors; Tretinoin; Troponin I | 2002 |
Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2'-deoxycytidine (decitabine) treatment.
Topics: Adult; Aged; Azacitidine; Cell Cycle Proteins; Cell Survival; Cyclin-Dependent Kinase Inhibitor p15; Cyclin-Dependent Kinase Inhibitor p16; Decitabine; Disease Progression; DNA Methylation; DNA Modification Methylases; Female; Genes, Tumor Suppressor; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Treatment Outcome; Tumor Suppressor Proteins | 2002 |
Inhibition of HhaI DNA (Cytosine-C5) methyltransferase by oligodeoxyribonucleotides containing 5-aza-2'-deoxycytidine: examination of the intertwined roles of co-factor, target, transition state structure and enzyme conformation.
Topics: Azacitidine; Base Sequence; Decitabine; DNA Methylation; DNA-Cytosine Methylases; Electrophoresis, Polyacrylamide Gel; Enzyme Inhibitors; Oligodeoxyribonucleotides; Protein Conformation | 2002 |
Crucial role of DNA methylation in determination of clonally distributed killer cell Ig-like receptor expression patterns in NK cells.
Topics: 5' Untranslated Regions; Azacitidine; Cells, Cultured; Clone Cells; Conserved Sequence; CpG Islands; Decitabine; Dinucleotide Repeats; DNA Methylation; DNA Modification Methylases; Down-Regulation; Enzyme Inhibitors; Gene Silencing; Histone Deacetylase Inhibitors; Humans; Jurkat Cells; Killer Cells, Natural; Kinetics; Multigene Family; Receptors, Immunologic; Receptors, KIR; Transcription, Genetic; Tumor Cells, Cultured | 2002 |
Deregulation of caspase 8 and 10 expression in pediatric tumors and cell lines.
Topics: Azacitidine; Carrier Proteins; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspase 10; Caspase 8; Caspase 9; Caspases; Child; Decitabine; DNA Methylation; Enzyme Inhibitors; Gene Amplification; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Genes, myc; Genes, Tumor Suppressor; Humans; Hydroxamic Acids; Intracellular Signaling Peptides and Proteins; Neoplasm Proteins; Neoplasms; RNA, Messenger; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2002 |
Antineoplastic action of 5-aza-2'-deoxycytidine and phenylbutyrate on human lung carcinoma cells.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Methylation; DNA, Neoplasm; Drug Synergism; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Humans; Lung Neoplasms; Phenylbutyrates; Tumor Cells, Cultured | 2002 |
Re-expression of p16 gene in the myeloma cell line U266 induced by synergy of sodium butyrate and 5-Aza-2'-deoxycytidine.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Blotting, Western; Butyrates; Cell Cycle; Cell Division; Cyclin-Dependent Kinase Inhibitor p16; Decitabine; Drug Synergism; Gene Expression; Humans; Multiple Myeloma; Reverse Transcriptase Polymerase Chain Reaction; Tumor Cells, Cultured | 2002 |
An ACF1-ISWI chromatin-remodeling complex is required for DNA replication through heterochromatin.
Topics: 3T3 Cells; Adenosine Triphosphatases; Animals; Aphidicolin; Azacitidine; Cells, Cultured; Centromere; Chromatin; Chromosomal Proteins, Non-Histone; Decitabine; DNA; DNA Replication; DNA-Cytosine Methylases; Enzyme Inhibitors; Gene Deletion; Green Fluorescent Proteins; HeLa Cells; Heterochromatin; Humans; Luminescent Proteins; Mice; Nuclear Proteins; Protamines; Recombinant Fusion Proteins; RNA, Small Interfering; S Phase; Transcription Factors; Tumor Cells, Cultured | 2002 |
Histone H3-lysine 9 methylation is associated with aberrant gene silencing in cancer cells and is rapidly reversed by 5-aza-2'-deoxycytidine.
Topics: Acetylation; Antimetabolites, Antineoplastic; Azacitidine; Culture Techniques; Cyclin-Dependent Kinase Inhibitor p16; Decitabine; DNA Methylation; Gene Silencing; Histones; Humans; Lysine; Methylation; Precipitin Tests; Tumor Cells, Cultured; Tumor Suppressor Protein p14ARF; Urinary Bladder Neoplasms | 2002 |
Induction of TRAG-3 expression in A549 lung adenocarcinoma cell line by 5-aza-2' deoxyazacytidine.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Lung Neoplasms; Neoplasm Proteins; Reverse Transcriptase Polymerase Chain Reaction; Tumor Cells, Cultured | 2002 |
Synergistic antineoplastic action of DNA methylation inhibitor 5-AZA-2'-deoxycytidine and histone deacetylase inhibitor depsipeptide on human breast carcinoma cells.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Breast Neoplasms; Decitabine; DNA Methylation; DNA Primers; Drug Combinations; Drug Synergism; Enzyme Inhibitors; Female; Gelsolin; Gene Expression Regulation, Neoplastic; Gene Silencing; Genes, Tumor Suppressor; Histone Deacetylase Inhibitors; Humans; In Vitro Techniques; Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Serpins; Tumor Cells, Cultured | 2003 |
Critical role of histone methylation in tumor suppressor gene silencing in colorectal cancer.
Topics: Adaptor Proteins, Signal Transducing; Azacitidine; Carrier Proteins; Colorectal Neoplasms; Cyclin-Dependent Kinase Inhibitor p16; Decitabine; DNA Methylation; Enzyme Inhibitors; Gene Silencing; Genes, Tumor Suppressor; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Lysine; Methylation; MutL Protein Homolog 1; Neoplasm Proteins; Nuclear Proteins; O(6)-Methylguanine-DNA Methyltransferase; Precipitin Tests; Promoter Regions, Genetic; Tumor Cells, Cultured | 2003 |
[The re-expression of p15(INK4B) gene in leukemia cells induced by in vitro DNA methyltransferase and histone deacetylase inhibition].
Topics: Azacitidine; Cell Cycle Proteins; Cyclin-Dependent Kinase Inhibitor p15; Cyclin-Dependent Kinase Inhibitor p16; Decitabine; DNA Methylation; Enzyme Inhibitors; Gene Expression; Histone Deacetylase Inhibitors; Humans; In Vitro Techniques; Leukemia; Methyltransferases; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2002 |
Characteristic promoter hypermethylation signatures in male germ cell tumors.
Topics: Azacitidine; Cell Line, Tumor; CpG Islands; Decitabine; DNA Methylation; DNA Repair; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Gene Silencing; Genes, Tumor Suppressor; Humans; Male; Neoplasms, Germ Cell and Embryonal; Promoter Regions, Genetic; Repressor Proteins; RNA, Messenger | 2002 |
Pharmacologic unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma.
Topics: Azacitidine; Base Sequence; Carcinoma, Squamous Cell; CpG Islands; Decitabine; DNA Methylation; Down-Regulation; Enzyme Inhibitors; Esophageal Neoplasms; Gene Expression Regulation, Neoplastic; Gene Silencing; Genes, Tumor Suppressor; Humans; Hydroxamic Acids; Molecular Sequence Data; Oligonucleotide Array Sequence Analysis; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; Tumor Cells, Cultured | 2002 |
Dependence of histone modifications and gene expression on DNA hypermethylation in cancer.
Topics: Acetylation; Adaptor Proteins, Signal Transducing; Azacitidine; Carrier Proteins; Colorectal Neoplasms; Decitabine; DNA Methylation; DNA Modification Methylases; Gene Expression Regulation, Neoplastic; Gene Silencing; Histone Deacetylase Inhibitors; Histone Deacetylases; Histones; Humans; Hydroxamic Acids; Methylation; MutL Protein Homolog 1; Neoplasm Proteins; Nuclear Proteins; Promoter Regions, Genetic; Transcription, Genetic; Tumor Cells, Cultured | 2002 |
Decitabine has promising clinical activity in chronic myeloid leukemia.
Topics: Antineoplastic Agents; Azacitidine; Benzamides; Clinical Trials, Phase I as Topic; Decitabine; DNA Modification Methylases; Enzyme Inhibitors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Treatment Failure | 2002 |
JunB gene expression is inactivated by methylation in chronic myeloid leukemia.
Topics: Azacitidine; Computer Systems; CpG Islands; Decitabine; DNA Methylation; DNA Mutational Analysis; DNA, Complementary; DNA, Neoplasm; Gene Expression Regulation, Leukemic; Genes, jun; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm Proteins; Promoter Regions, Genetic; Proto-Oncogene Proteins c-jun; Reverse Transcriptase Polymerase Chain Reaction | 2003 |
The human telomerase RNA gene (hTERC) is regulated during carcinogenesis but is not dependent on DNA methylation.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cell Division; Cell Line; Decitabine; DNA Methylation; Gene Expression Regulation, Neoplastic; HeLa Cells; Humans; Neoplasms; Polymorphism, Genetic; Promoter Regions, Genetic; Protein Conformation; Reverse Transcriptase Polymerase Chain Reaction; RNA; Sarcoma; Sulfites; Telomerase; Tumor Cells, Cultured | 2002 |
Hypermethylation-mediated regulation of CD44 gene expression in human neuroblastoma.
Topics: Azacitidine; Bone Marrow Neoplasms; CpG Islands; Decitabine; DNA Methylation; DNA Modification Methylases; Exons; Gene Amplification; Gene Expression Regulation; Gene Silencing; Humans; Hyaluronan Receptors; Immunohistochemistry; N-Myc Proto-Oncogene Protein; Neoplasm Staging; Neuroblastoma; Nuclear Proteins; Oncogene Proteins; Promoter Regions, Genetic; Tumor Cells, Cultured | 2003 |
[Apoptosis and re-expression of p16 gene in the myeloma cell line U266 induced by synergy of histone deacetylase inhibitor and demethylating agent].
Topics: Annexin A5; Apoptosis; Azacitidine; Blotting, Western; Cell Cycle; Cyclin-Dependent Kinase Inhibitor p16; Decitabine; DNA Modification Methylases; DNA, Neoplasm; Drug Synergism; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Humans; Multiple Myeloma; Phenylbutyrates; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured | 2002 |
[Inhibitory effect on proliferation of KG1a cell line by methyltransferase inhibitors].
Topics: Azacitidine; Cell Cycle Proteins; Cell Differentiation; Cell Division; Cell Line; Cyclin-Dependent Kinase Inhibitor p15; Cyclin-Dependent Kinase Inhibitor p16; Decitabine; DNA Methylation; DNA Modification Methylases; Dose-Response Relationship, Drug; Enzyme Inhibitors; Genes, Tumor Suppressor; Humans; Leukemia, Myeloid; Tumor Suppressor Proteins | 2002 |
Methylation status of promoters and expression of MUC2 and MUC5AC mucins in pancreatic cancer cells.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Azacitidine; Base Sequence; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA, Neoplasm; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Humans; Molecular Sequence Data; Mucin 5AC; Mucin-2; Mucins; Neoplasm Invasiveness; Neoplasm Proteins; Pancreas; Pancreatic Neoplasms; Promoter Regions, Genetic; RNA, Messenger; RNA, Neoplasm | 2003 |
Role of DNA methylation in the suppression of Apaf-1 protein in human leukaemia.
Topics: Apoptosis; Apoptotic Protease-Activating Factor 1; Azacitidine; Cytosine; Decitabine; DNA Methylation; Humans; Leukemia; Polymerase Chain Reaction; Promoter Regions, Genetic; Proteins; Reference Values; Sequence Analysis, DNA; Tumor Cells, Cultured; Ultraviolet Rays | 2003 |
HLA-G gene repression is reversed by demethylation.
Topics: Azacitidine; Blotting, Southern; Blotting, Western; Decitabine; DNA Methylation; Dose-Response Relationship, Drug; Enzyme Inhibitors; Flow Cytometry; Histocompatibility Antigens Class I; Histone Deacetylases; HLA Antigens; HLA-G Antigens; Humans; Immunohistochemistry; Reverse Transcriptase Polymerase Chain Reaction; Time Factors; Transcription, Genetic; Tumor Cells, Cultured | 2003 |
On the use of DNA methylation inhibitors and the reversal of transcriptional silencing.
Topics: Azacitidine; Decitabine; DNA Methylation; DNA-Cytosine Methylases; Enzyme Inhibitors; Gene Silencing; Humans; Leukemia, Myeloid, Acute; Transcription, Genetic | 2003 |
Hypomethylation of the synuclein gamma gene CpG island promotes its aberrant expression in breast carcinoma and ovarian carcinoma.
Topics: Azacitidine; Breast Neoplasms; CpG Islands; Decitabine; DNA Methylation; Epithelial Cells; Exons; Female; Gene Expression Regulation, Neoplastic; Humans; Nerve Tissue Proteins; Ovarian Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Synucleins; Tumor Cells, Cultured | 2003 |
Immortalization of bovine capillary endothelial cells by hTERT alone involves inactivation of endogenous p16INK4A/pRb.
Topics: Animals; Azacitidine; Cattle; Cell Line, Transformed; Cells, Cultured; Cellular Senescence; Cyclin-Dependent Kinase Inhibitor p16; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Modification Methylases; DNA-Binding Proteins; Endothelium, Vascular; Enzyme Inhibitors; Humans; Retinoblastoma Protein; Telomerase; Telomere; Transfection | 2003 |
Effects of 5-aza-2'-deoxycytidine on matrix metalloproteinase expression and pancreatic cancer cell invasiveness.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA, Neoplasm; Enzyme Inhibitors; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Matrix Metalloproteinases; Methylation; Neoplasm Invasiveness; Pancreatic Neoplasms; Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured | 2003 |
A systematic profile of DNA methylation in human cancer cell lines.
Topics: 5-Methylcytosine; Azacitidine; Cluster Analysis; CpG Islands; Cytosine; Decitabine; DNA Methylation; DNA, Neoplasm; Genes, Tumor Suppressor; Germ-Line Mutation; Humans; Neoplasms; Oligonucleotide Array Sequence Analysis; Tumor Cells, Cultured | 2003 |
Preclinical evaluation of antineoplastic activity of inhibitors of DNA methylation (5-aza-2'-deoxycytidine) and histone deacetylation (trichostatin A, depsipeptide) in combination against myeloid leukemic cells.
Topics: Acetylation; Acute Disease; Anti-Bacterial Agents; Antibiotics, Antineoplastic; Azacitidine; Cell Division; Decitabine; Depsipeptides; DNA Methylation; DNA Replication; DNA, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Histones; HL-60 Cells; Humans; Hydroxamic Acids; Leukemia, Myeloid; Neoplasm Proteins; Peptides, Cyclic; Protein Processing, Post-Translational; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2003 |
Inactivation of deoxycytidine kinase and overexpression of P-glycoprotein in AraC and daunorubicin double resistant leukemic cell lines.
Topics: 2-Chloroadenosine; Alternative Splicing; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Azacitidine; Biological Transport; Buthionine Sulfoximine; Calcium Channel Blockers; Cytarabine; Daunorubicin; Decitabine; Deoxyadenosines; Deoxycytidine Kinase; DNA Mutational Analysis; DNA, Neoplasm; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Glutathione; Humans; Idarubicin; Leukemia; Methotrexate; Neoplasm Proteins; Rats; Reverse Transcriptase Polymerase Chain Reaction; Tumor Cells, Cultured; Verapamil | 2003 |
Detection of hypermethylated RIZ1 gene in primary tumor, mouth, and throat rinsing fluid, nasopharyngeal swab, and peripheral blood of nasopharyngeal carcinoma patient.
Topics: Azacitidine; Carcinoma; Case-Control Studies; Decitabine; DNA; DNA Methylation; DNA-Binding Proteins; Histone-Lysine N-Methyltransferase; Humans; Mouth; Nasopharyngeal Neoplasms; Nuclear Proteins; Pharynx; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sensitivity and Specificity; Sulfites; Transcription Factors; Transcription, Genetic; Tumor Cells, Cultured | 2003 |
Interaction of 5-aza-2'-deoxycytidine and depsipeptide on antineoplastic activity and activation of 14-3-3sigma, E-cadherin and tissue inhibitor of metalloproteinase 3 expression in human breast carcinoma cells.
Topics: 14-3-3 Proteins; Antineoplastic Agents; Azacitidine; Biomarkers, Tumor; Breast Neoplasms; Cadherins; Cell Line, Tumor; Decitabine; Depsipeptides; DNA; DNA Modification Methylases; Dose-Response Relationship, Drug; Drug Synergism; Exonucleases; Exoribonucleases; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Humans; Inhibitory Concentration 50; Neoplasm Proteins; Peptides, Cyclic; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tissue Inhibitor of Metalloproteinase-3; Tumor Stem Cell Assay | 2003 |
Inactivation of hMLH1 and hMSH2 by promoter methylation in primary non-small cell lung tumors and matched sputum samples.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Alleles; Azacitidine; Carcinoma, Non-Small-Cell Lung; Carrier Proteins; Decitabine; DNA Methylation; DNA-Binding Proteins; Female; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; MutL Protein Homolog 1; MutS Homolog 2 Protein; Neoplasm Proteins; Nuclear Proteins; Promoter Regions, Genetic; Proto-Oncogene Proteins; RNA, Messenger; Sputum | 2003 |
Promoter hypermethylation of DLC-1, a candidate tumor suppressor gene, in several common human cancers.
Topics: Adenocarcinoma; Azacitidine; Base Sequence; Breast Neoplasms; Carcinoma, Hepatocellular; Colonic Neoplasms; CpG Islands; Decitabine; DNA Methylation; DNA, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; GTPase-Activating Proteins; Humans; Liver Neoplasms; Male; Molecular Sequence Data; Neoplasm Proteins; Neoplasms; Promoter Regions, Genetic; Prostatic Neoplasms; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2003 |
Induction of a senescent-like phenotype does not confer the ability of bovine immortal cells to support the development of nuclear transfer embryos.
Topics: Animals; Apoptosis; Azacitidine; Bromodeoxyuridine; Butyrates; Cattle; Cell Differentiation; Cell Division; Cell Line; Cellular Senescence; Decitabine; DNA Methylation; Embryonic and Fetal Development; Enzyme Inhibitors; Epithelial Cells; Female; Histone Deacetylase Inhibitors; Hydroxamic Acids; In Vitro Techniques; Mammary Glands, Animal; Nuclear Transfer Techniques; Oocytes; Phenotype; Ploidies | 2003 |
Upregulation of galectin-7 in murine lymphoma cells is associated with progression toward an aggressive phenotype.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Disease Progression; Female; Galectins; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Lymphoma, T-Cell; Male; Mice; Mice, Inbred C57BL; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Transplantation; Neoplasms, Radiation-Induced; Oligonucleotide Array Sequence Analysis; RNA, Messenger; RNA, Neoplasm; Specific Pathogen-Free Organisms; Thymus Neoplasms; Tumor Cells, Cultured | 2003 |
Methylation of cyclin D2 is observed frequently in pancreatic cancer but is also an age-related phenomenon in gastrointestinal tissues.
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Azacitidine; Cell Line, Tumor; Cyclin D2; Cyclins; Decitabine; Digestive System; DNA Methylation; Female; Humans; Male; Middle Aged; Pancreatic Juice; Pancreatic Neoplasms; Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA; Transfection | 2003 |
Susceptibility to postnatal growth retardation induced by 5-AZA-2'-deoxycytidine in utero: gender specificity and correlation with reduced insulin-like growth factor 1.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Blood Glucose; Body Weight; Corticosterone; Decitabine; Depression, Chemical; Energy Metabolism; Female; Growth Disorders; Insulin-Like Growth Factor I; Mice; Pregnancy; Sex Characteristics | 2003 |
Hypermethylation of the gene promoter and enhancer region can regulate Fas expression and sensitivity in colon carcinoma.
Topics: Apoptosis; Azacitidine; Caco-2 Cells; Colonic Neoplasms; CpG Islands; Decitabine; DNA Methylation; DNA Modification Methylases; DNA, Neoplasm; Enhancer Elements, Genetic; fas Receptor; Gene Expression Regulation, Neoplastic; HCT116 Cells; HT29 Cells; Humans; Promoter Regions, Genetic; Sensitivity and Specificity | 2003 |
DNA hypermethylation near the transcription start site of collagen alpha2(I) gene occurs in both cancer cell lines and primary colorectal cancers.
Topics: Azacitidine; Base Sequence; Collagen Type I; Colorectal Neoplasms; Decitabine; DNA Methylation; DNA, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Intestinal Mucosa; Polymerase Chain Reaction; RNA, Messenger; Transcription Initiation Site; Transcriptional Activation; Tumor Cells, Cultured | 2003 |
Five new human cancer-germline genes identified among 12 genes expressed in spermatogonia.
Topics: Animals; Azacitidine; Decitabine; DNA Methylation; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Neoplasms; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; Spermatogonia; Transcription, Genetic; Tumor Cells, Cultured; X Chromosome | 2003 |
Methylation-regulated expression of HLA class I antigens in melanoma.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Methylation; Genes, MHC Class I; HLA Antigens; HLA-A Antigens; HLA-B Antigens; Humans; Melanoma; Tumor Cells, Cultured; Up-Regulation | 2003 |
Hypermethylation of death-associated protein (DAP) kinase CpG island is frequent not only in B-cell but also in T- and natural killer (NK)/T-cell malignancies.
Topics: Antibodies, Monoclonal; Apoptosis; Apoptosis Regulatory Proteins; Azacitidine; B-Lymphocytes; Calcium-Calmodulin-Dependent Protein Kinases; CpG Islands; Death-Associated Protein Kinases; Decitabine; DNA Methylation; Enzyme Induction; fas Receptor; Gene Expression Regulation, Neoplastic; Hematologic Neoplasms; Humans; Jurkat Cells; Killer Cells, Natural; Leukemia-Lymphoma, Adult T-Cell; Lymphoma, B-Cell; Lymphoma, T-Cell; Neoplasm Proteins; Neoplastic Stem Cells; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; T-Lymphocytes | 2003 |
Cytosine methylation occurs in a CDC48 homologue and a MADS-box gene during adventitious shoot induction in Petunia leaf explants.
Topics: Amino Acid Sequence; Azacitidine; Cloning, Molecular; Culture Techniques; Cytosine; Decitabine; DNA Methylation; DNA, Plant; Gene Expression Regulation, Plant; MADS Domain Proteins; Microscopy, Electron, Scanning; Molecular Sequence Data; Petunia; Phylogeny; Plant Leaves; Plant Shoots; Sequence Analysis, DNA; Sequence Homology, Amino Acid | 2003 |
Reactivation of tumor suppressor genes by the cardiovascular drugs hydralazine and procainamide and their potential use in cancer therapy.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Breast Neoplasms; Cell Cycle; Cyclin-Dependent Kinase Inhibitor p16; Decitabine; DNA Methylation; Enzyme Inhibitors; Female; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Head and Neck Neoplasms; Humans; Hydralazine; Mice; Mice, Nude; Procainamide; Receptors, Estrogen; Receptors, Retinoic Acid; Tumor Cells, Cultured; Uterine Cervical Neoplasms | 2003 |
Epigenetic characteristics and development of embryos cloned from donor cells treated by trichostatin A or 5-aza-2'-deoxycytidine.
Topics: Acetylation; Animals; Azacitidine; Blastocyst; Cattle; Cloning, Organism; Decitabine; DNA Methylation; DNA Modification Methylases; Embryonic and Fetal Development; Enzyme Inhibitors; Epigenesis, Genetic; Female; Fibroblasts; Gene Expression Regulation, Developmental; Histone Deacetylase Inhibitors; Histones; Hydroxamic Acids; Nuclear Transfer Techniques | 2003 |
E-cadherin expression is silenced by DNA methylation in cervical cancer cell lines and tumours.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Blotting, Western; Cadherins; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Enzyme Inhibitors; Female; Humans; Molecular Sequence Data; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Tumor Cells, Cultured; Uterine Cervical Neoplasms | 2003 |
5-Aza-2'-deoxycytidine (decitabine) treatment of hematopoietic malignancies: a multimechanism therapeutic approach?
Topics: Aged; Aged, 80 and over; Azacitidine; Decitabine; DNA Methylation; Female; Gene Expression Regulation; Hematologic Neoplasms; Humans; Male; Middle Aged; Neoplasm Proteins | 2003 |
DNA mismatch repair genes in renal cell carcinoma.
Topics: Azacitidine; Base Pair Mismatch; Blotting, Western; Carcinoma, Renal Cell; Decitabine; DNA Modification Methylases; DNA Repair; DNA, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Immunohistochemistry; Kidney Neoplasms; Male; Neoplasm Proteins; Reverse Transcriptase Polymerase Chain Reaction; Tumor Cells, Cultured | 2003 |
Alterations of BLU, a candidate tumor suppressor gene on chromosome 3p21.3, in human nasopharyngeal carcinoma.
Topics: Adult; Aged; Azacitidine; Base Sequence; Carcinoma; Chromosomes, Human, Pair 3; CpG Islands; Cytoskeletal Proteins; Decitabine; DNA Methylation; DNA Primers; Enzyme Inhibitors; Genes, Tumor Suppressor; Humans; Middle Aged; Molecular Sequence Data; Mutagens; Mutation; Nasopharyngeal Neoplasms; Polymerase Chain Reaction; Promoter Regions, Genetic; Protein Biosynthesis; Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sequence Analysis, DNA; Sulfites; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2003 |
Role of hMLH1 promoter hypermethylation in drug resistance to 5-fluorouracil in colorectal cancer cell lines.
Topics: Adaptor Proteins, Signal Transducing; Antimetabolites, Antineoplastic; Azacitidine; Base Pair Mismatch; Blotting, Western; Carrier Proteins; Cloning, Molecular; Colorectal Neoplasms; Cyclin-Dependent Kinase Inhibitor p16; Decitabine; DNA Methylation; DNA Repair; Drug Resistance, Neoplasm; Enzyme Inhibitors; Fluorouracil; Humans; Immunoblotting; Kruppel-Like Transcription Factors; Microsatellite Repeats; MutL Protein Homolog 1; Neoplasm Proteins; Nuclear Proteins; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Time Factors; Transcription Factors; Transcriptional Activation; Tumor Cells, Cultured | 2003 |
Silencing of mouse Aprt is a gradual process in differentiated cells.
Topics: Adenine Phosphoribosyltransferase; Alleles; Animals; Azacitidine; Binding Sites; Blotting, Southern; Cell Differentiation; Cell Line; Cloning, Molecular; CpG Islands; Decitabine; DNA Methylation; Gene Silencing; In Situ Hybridization, Fluorescence; Mice; Models, Genetic; Phenotype; Reverse Transcriptase Polymerase Chain Reaction; Sp1 Transcription Factor; Sulfites; Time Factors; Transfection | 2003 |
Transcriptional silencing of the DLC-1 tumor suppressor gene by epigenetic mechanism in gastric cancer cells.
Topics: Acetylation; Acetyltransferases; Alleles; Azacitidine; Blotting, Northern; Blotting, Southern; CpG Islands; Decitabine; DNA Methylation; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Gene Silencing; Genes, Tumor Suppressor; GTPase-Activating Proteins; Histone Acetyltransferases; Histones; Humans; Hydroxamic Acids; Neoplasm Proteins; Protein Processing, Post-Translational; RNA, Messenger; RNA, Neoplasm; Saccharomyces cerevisiae Proteins; Stomach Neoplasms; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2003 |
The heparan sulfate proteoglycan GPC3 is a potential lung tumor suppressor.
Topics: Adenocarcinoma; Animals; Apoptosis; Azacitidine; Cell Line, Tumor; Decitabine; Enzyme Inhibitors; Gene Expression Profiling; Genes, Tumor Suppressor; Glypicans; Humans; Hydroxamic Acids; Lung Neoplasms; Membrane Proteins; Mice; Neoplasm Proteins; Oligonucleotide Array Sequence Analysis; Respiratory Mucosa; Smoking; Tumor Suppressor Proteins | 2003 |
Epigenetic silencing of multiple interferon pathway genes after cellular immortalization.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cell Division; CpG Islands; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Down-Regulation; Fibroblasts; Gene Silencing; Humans; Interferons; Oligonucleotide Array Sequence Analysis; Oligonucleotides; Phenotype; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; Up-Regulation | 2003 |
Aberrant methylation of the vascular endothelial growth factor receptor-1 gene in prostate cancer.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Methylation; Enzyme Inhibitors; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Male; Oligonucleotide Array Sequence Analysis; Polymerase Chain Reaction; Promoter Regions, Genetic; Prostatic Hyperplasia; Prostatic Neoplasms; Sulfites; Tumor Cells, Cultured; Vascular Endothelial Growth Factor Receptor-1 | 2003 |
Forced expression of the H11 heat shock protein can be regulated by DNA methylation and trigger apoptosis in human cells.
Topics: Apoptosis; Azacitidine; Caspases; Cell Line, Tumor; Decitabine; DNA Methylation; Heat-Shock Proteins; Hot Temperature; Humans; MAP Kinase Kinase Kinase 1; Mitogen-Activated Protein Kinases; Molecular Chaperones; p38 Mitogen-Activated Protein Kinases; Protein Serine-Threonine Kinases | 2003 |
Expression profiling reveals that methylation of TIMP3 is involved in uveal melanoma development.
Topics: Azacitidine; Biomarkers, Tumor; Decitabine; Disease Progression; DNA Methylation; DNA Modification Methylases; DNA Probes; Down-Regulation; Enzyme Inhibitors; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Immunoenzyme Techniques; Liver Neoplasms; Melanoma; Neoplasm Proteins; Oligonucleotide Array Sequence Analysis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Tissue Inhibitor of Metalloproteinase-3; Tissue Inhibitor of Metalloproteinases; Tumor Cells, Cultured; Uveal Neoplasms | 2003 |
Promoter hypomethylation of a novel cancer/testis antigen gene CAGE is correlated with its aberrant expression and is seen in premalignant stage of gastric carcinoma.
Topics: Antigens, Nuclear; Antimetabolites, Antineoplastic; Azacitidine; Base Sequence; Biomarkers, Tumor; CpG Islands; DEAD-box RNA Helicases; Decitabine; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Humans; Hydroxamic Acids; Methylation; Molecular Sequence Data; Neoplasm Staging; Nuclear Proteins; Oligonucleotide Probes; Precancerous Conditions; Promoter Regions, Genetic; Stomach Neoplasms; Transcription Factors; Tumor Cells, Cultured | 2003 |
Down-regulation of FEZ1/LZTS1 gene with frequent loss of heterozygosity in oral squamous cell carcinomas.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Azacitidine; Carcinoma, Squamous Cell; Decitabine; Disease Progression; DNA Methylation; DNA Modification Methylases; DNA-Binding Proteins; DNA, Neoplasm; Down-Regulation; Enzyme Inhibitors; Female; Gene Expression Regulation, Neoplastic; Humans; Leucine Zippers; Loss of Heterozygosity; Male; Microsatellite Repeats; Middle Aged; Mouth Neoplasms; Nerve Tissue Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2003 |
Epigenetic inactivation of laminin-5-encoding genes in lung cancers.
Topics: Azacitidine; Carcinoid Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cell Adhesion Molecules; Cell Line, Tumor; CpG Islands; Decitabine; DNA; DNA Methylation; Humans; Kalinin; Laminin; Lung Neoplasms; Lymphocytes; Methylation; Models, Genetic; Mouth Mucosa; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; Sequence Analysis, DNA; Sulfites; Transcription, Genetic; Tumor Cells, Cultured | 2003 |
Decreased methylation and transcription repressor Sp3 up-regulated human monoamine oxidase (MAO) B expression during Caco-2 differentiation.
Topics: Antioxidants; Azacitidine; Base Sequence; Blotting, Northern; Blotting, Western; Caco-2 Cells; Cell Differentiation; Cell Nucleus; CpG Islands; Decitabine; DNA Methylation; DNA-Binding Proteins; Enzyme Inhibitors; Gene Expression Regulation; Genes, Reporter; HeLa Cells; Humans; Luciferases; Methylation; Molecular Sequence Data; Monoamine Oxidase; Promoter Regions, Genetic; Protein Binding; Protein Isoforms; Protein Structure, Tertiary; Signal Transduction; Software; Sp1 Transcription Factor; Sp3 Transcription Factor; Sulfites; Time Factors; Transcription Factors; Transcriptional Activation; Transfection; Up-Regulation | 2003 |
Decitabine induces cell cycle arrest at the G1 phase via p21(WAF1) and the G2/M phase via the p38 MAP kinase pathway.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Carrier Proteins; Cell Cycle; Cell Division; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Decitabine; DNA Methylation; Dose-Response Relationship, Drug; G1 Phase; Kinetics; Leukemia, Lymphoid; Mitosis; Multiple Myeloma; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Tumor Cells, Cultured | 2003 |
Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers.
Topics: Alleles; Animals; Azacitidine; Breast Neoplasms; CpG Islands; Decitabine; DNA Methylation; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Genes, Tumor Suppressor; Humans; Mice; Promoter Regions, Genetic; rho GTP-Binding Proteins; Tumor Cells, Cultured | 2003 |
Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Blast Crisis; Decitabine; DNA Modification Methylases; Drug Administration Schedule; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged | 2003 |
Transcriptional regulation of mouse delta-opioid receptor gene by CpG methylation: involvement of Sp3 and a methyl-CpG-binding protein, MBD2, in transcriptional repression of mouse delta-opioid receptor gene in Neuro2A cells.
Topics: Animals; Azacitidine; Blotting, Western; Cell Line; Cell Line, Tumor; CpG Islands; Decitabine; DNA; DNA Methylation; DNA-Binding Proteins; Drosophila; Genes, Reporter; Histone Deacetylases; Mice; Plasmids; Polymerase Chain Reaction; Promoter Regions, Genetic; Receptors, Opioid, delta; Reverse Transcriptase Polymerase Chain Reaction; RNA; RNA, Messenger; Sp3 Transcription Factor; Transcription Factors; Transcription, Genetic; Transfection | 2003 |
Aberrant promoter methylation of the transcription factor genes PAX5 alpha and beta in human cancers.
Topics: Azacitidine; Breast Neoplasms; Carcinoma, Squamous Cell; CpG Islands; Decitabine; DNA Methylation; DNA-Binding Proteins; Gene Expression; Humans; Lung Neoplasms; Microsatellite Repeats; PAX5 Transcription Factor; Promoter Regions, Genetic; Transcription Factors; Tumor Cells, Cultured | 2003 |
Lsh-deficient murine embryonal fibroblasts show reduced proliferation with signs of abnormal mitosis.
Topics: Animals; Azacitidine; Cell Cycle; Cell Division; Cells, Cultured; Centrosome; Decitabine; DNA Helicases; Embryo, Mammalian; Fibroblasts; Mice; Mitosis; Spindle Apparatus | 2003 |
Epigenetic down-regulation of death-associated protein kinase in lung cancers.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Azacitidine; Blotting, Western; Calcium-Calmodulin-Dependent Protein Kinases; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cells, Cultured; CpG Islands; Death-Associated Protein Kinases; Decitabine; DNA; DNA Methylation; Down-Regulation; Enzyme Inhibitors; Epithelial Cells; Exons; Gene Silencing; Genetic Techniques; Humans; Lung Neoplasms; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sequence Analysis, DNA; Sulfites; Time Factors; Tumor Cells, Cultured | 2003 |
Interleukin 12-based immunotherapy improves the antitumor effectiveness of a low-dose 5-Aza-2'-deoxycitidine treatment in L1210 leukemia and B16F10 melanoma models in mice.
Topics: Animals; Antigens; Antigens, Ly; Antigens, Surface; Antimetabolites, Antineoplastic; Antineoplastic Agents; Azacitidine; CD4 Antigens; CD8 Antigens; Cell Line, Tumor; Cell Survival; Decitabine; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Hemoglobins; Immunotherapy; Interferon-gamma; Interleukin-12; Interleukin-4; Lectins, C-Type; Lymph Nodes; Lymphocytes; Melanoma; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Mice, SCID; Models, Genetic; Neutrophils; NK Cell Lectin-Like Receptor Subfamily B; Protein Biosynthesis; Proteins; Time Factors | 2003 |
In vitro efficacy of combined treatment depends on the underlying mechanism of resistance in imatinib-resistant Bcr-Abl-positive cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Azacitidine; Base Sequence; Benzamides; Cell Division; Cell Line, Tumor; Decitabine; DNA, Neoplasm; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxides; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2004 |
Silencing of CDX2 expression in colon cancer via a dominant repression pathway.
Topics: Adenoma; Azacitidine; Blotting, Western; CDX2 Transcription Factor; Cell Division; Colonic Neoplasms; Cytoplasm; Decitabine; DNA Methylation; Enzyme Inhibitors; Gene Expression; Gene Expression Regulation, Neoplastic; Gene Silencing; Histone Deacetylase Inhibitors; Homeodomain Proteins; Humans; Hydroxamic Acids; Immunohistochemistry; Methyltransferases; Mutation; Mutation, Missense; Phenotype; Phosphatidylinositol 3-Kinases; Rectal Neoplasms; Trans-Activators; Transcription, Genetic | 2003 |
Molecular cloning and characterization of human acid sensing ion channel (ASIC)2 gene promoter.
Topics: Acid Sensing Ion Channels; Azacitidine; Base Sequence; Binding Sites; Brain; Cloning, Molecular; CpG Islands; Decitabine; DNA; DNA Methylation; DNA-Binding Proteins; Gene Expression Regulation, Neoplastic; Glioma; Humans; Luciferases; Membrane Potentials; Membrane Proteins; Molecular Sequence Data; Mutation; Nerve Tissue Proteins; Patch-Clamp Techniques; Promoter Regions, Genetic; Recombinant Fusion Proteins; RNA-Binding Proteins; RNA, Messenger; Sequence Analysis, DNA; Sodium Channels; Sp1 Transcription Factor; Transcription Factors; Transcription Initiation Site; Transfection; Tumor Cells, Cultured | 2003 |
Clinicopathological significance and molecular regulation of maspin expression in ductal adenocarcinoma of the pancreas.
Topics: Acetylation; Aged; Azacitidine; Carcinoma, Pancreatic Ductal; Decitabine; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Female; Gene Silencing; Genes, Tumor Suppressor; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Immunoenzyme Techniques; Lymphatic Metastasis; Male; Middle Aged; Pancreatic Neoplasms; Promoter Regions, Genetic; Proteins; Serpins; Tumor Cells, Cultured; Up-Regulation | 2003 |
The histone code regulating expression of the imprinted mouse Igf2r gene.
Topics: Acetylation; Alleles; Animals; Azacitidine; Decitabine; DNA Methylation; Enzyme Inhibitors; Female; Gene Expression Regulation; Gene Silencing; Genomic Imprinting; Histones; Hydroxamic Acids; Male; Mice; Pregnancy; Receptor, IGF Type 2 | 2003 |
Demethylation of the human telomerase catalytic subunit (hTERT) gene promoter reduced hTERT expression and telomerase activity and shortened telomeres.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cell Division; Cellular Senescence; Decitabine; DNA Methylation; DNA-Binding Proteins; Down-Regulation; Gene Expression Regulation, Neoplastic; Humans; Neoplasms; Promoter Regions, Genetic; Proto-Oncogene Proteins c-myc; RNA, Messenger; Telomerase; Telomere; Transcription, Genetic; Tumor Cells, Cultured | 2003 |
Epigenetic inactivation of RASSF1A in head and neck cancer.
Topics: Azacitidine; Carcinoma; Cell Line, Tumor; Decitabine; DNA; DNA Methylation; Down-Regulation; Head and Neck Neoplasms; Humans; Microsatellite Repeats; Papillomaviridae; Point Mutation; Polymerase Chain Reaction; Promoter Regions, Genetic; Protein Isoforms; RNA; Sequence Analysis, DNA; Sulfites; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2003 |
Down-regulation of a novel actin-binding molecule, skeletrophin, in malignant melanoma.
Topics: Actins; Amino Acid Sequence; Azacitidine; Blotting, Northern; Blotting, Western; Cloning, Molecular; Decitabine; DNA, Complementary; Down-Regulation; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Melanoma; Microfilament Proteins; Molecular Sequence Data; Neoplasm Proteins; Precipitin Tests; Reverse Transcriptase Polymerase Chain Reaction; Staining and Labeling; Transfection; Tumor Cells, Cultured; Two-Hybrid System Techniques; Ubiquitin-Protein Ligases; Yeasts | 2003 |
Reduced expression of oestrogen receptor beta in invasive breast cancer and its re-expression using DNA methyl transferase inhibitors in a cell line model.
Topics: Age Factors; Azacitidine; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chi-Square Distribution; Decitabine; DNA Methylation; DNA Modification Methylases; Estrogen Receptor beta; Female; Gene Silencing; Humans; Immunohistochemistry; Lymphatic Metastasis; Neoplasm Recurrence, Local; Receptors, Estrogen; Reverse Transcriptase Polymerase Chain Reaction; Tumor Cells, Cultured; Uterine Cervical Dysplasia | 2003 |
Upregulation of the truncated basic hair keratin 1(hHb1-DeltaN) in carcinoma cells by Epstein-Barr virus (EBV).
Topics: Azacitidine; Blotting, Northern; Blotting, Western; CpG Islands; Cysteine Proteinase Inhibitors; Decitabine; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Fluorescent Antibody Technique; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Herpesvirus 4, Human; Humans; Keratins; Leupeptins; Oligonucleotide Array Sequence Analysis; Protein Biosynthesis; Reverse Transcriptase Polymerase Chain Reaction; Stomach Neoplasms; Tumor Cells, Cultured; Up-Regulation | 2003 |
Downregulation of ID4 by promoter hypermethylation in gastric adenocarcinoma.
Topics: Adenocarcinoma; Azacitidine; Cell Line; Decitabine; DNA Methylation; DNA Modification Methylases; DNA-Binding Proteins; Down-Regulation; Drug Synergism; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Gene Silencing; Helix-Loop-Helix Motifs; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Inhibitor of Differentiation Proteins; Microsatellite Repeats; Promoter Regions, Genetic; Stomach Neoplasms; Transcription Factors | 2003 |
Methylation-associated silencing of the thrombospondin-1 gene in human neuroblastoma.
Topics: Animals; Azacitidine; Cell Division; Cell Line, Tumor; CpG Islands; Decitabine; DNA Methylation; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Neuroblastoma; Promoter Regions, Genetic; Thrombospondin 1; Transcription, Genetic; Transplantation, Heterologous | 2003 |
Functional and molecular characterization of the epithelioid to round transition in human colorectal cancer LoVo cells.
Topics: Azacitidine; Cell Aggregation; Cell Culture Techniques; Cell Movement; Cell Transformation, Neoplastic; Colonic Neoplasms; Decitabine; Gene Expression Regulation, Neoplastic; Genetic Variation; Humans; Intestinal Mucosa; RNA, Messenger; Transcription, Genetic; Tumor Cells, Cultured | 2003 |
Role of promoter methylation in regulation of the mammalian heparanase gene.
Topics: Animals; Azacitidine; Cell Line, Tumor; CpG Islands; Decitabine; DNA Methylation; Glucuronidase; Humans; Hydroxamic Acids; Promoter Regions, Genetic; Rats | 2003 |
Epigenetic inactivation of RASSF1A candidate tumor suppressor gene at 3p21.3 in brain tumors.
Topics: Azacitidine; Brain Neoplasms; Cell Line, Tumor; Chromosomes, Human, Pair 3; CpG Islands; Decitabine; DNA Methylation; Genes, Tumor Suppressor; Glioma; Humans; Medulloblastoma; Neoplasm Proteins; Promoter Regions, Genetic; Tumor Suppressor Proteins | 2003 |
Inhibition of DNA methylation and histone deacetylation prevents murine lung cancer.
Topics: Alleles; Animals; Antimetabolites, Antineoplastic; Azacitidine; Cytosine; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Drug Synergism; Enzyme Inhibitors; Female; Gene Dosage; Histone Deacetylase Inhibitors; Histones; Lung Neoplasms; Male; Mice; Mice, Inbred A; Phenylbutyrates | 2003 |
Promoter methylation of cyclin D2 gene in gastric carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Carcinoma; Cell Line, Tumor; CpG Islands; Cyclin D2; Cyclins; Decitabine; DNA Methylation; Gene Expression Regulation, Neoplastic; Humans; Middle Aged; Models, Genetic; Polymerase Chain Reaction; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Stomach Neoplasms | 2003 |
Comment on "Chromosomal instability and tumors promoted by DNA hypomethylation" and "Induction of tumors in nice by genomic hypomethylation".
Topics: Animals; Azacitidine; Chromosomal Instability; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Genes, APC; Humans; Incidence; Intestinal Neoplasms; Mice; Neoplasms; Point Mutation; Time Factors | 2003 |
A novel histone deacetylase inhibitor, scriptaid, enhances expression of functional estrogen receptor alpha (ER) in ER negative human breast cancer cells in combination with 5-aza 2'-deoxycytidine.
Topics: Acetylation; Antimetabolites, Antineoplastic; Azacitidine; Breast Neoplasms; Cell Division; Decitabine; DNA Modification Methylases; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Estrogen Receptor alpha; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxylamines; Inhibitory Concentration 50; Quinolines; Receptors, Estrogen; Receptors, Progesterone; RNA, Messenger; Tumor Cells, Cultured | 2003 |
Demethylation of host-cell DNA at the site of avian retrovirus integration.
Topics: Agar; Animals; Azacitidine; Cell Line; Cell Line, Tumor; CpG Islands; Cricetinae; Decitabine; DNA Methylation; Enzyme Inhibitors; Genes, src; Histone Deacetylases; Hydroxamic Acids; Mesocricetus; Models, Genetic; Molecular Sequence Data; Protein Synthesis Inhibitors; Retroviridae; Sulfites; Terminal Repeat Sequences; Transcription, Genetic; Virus Integration | 2003 |
Hypermethylation of retrotransposons in the liverwort Marchantia paleacea var. diptera.
Topics: Amino Acid Sequence; Azacitidine; Culture Media; Decitabine; DNA Methylation; DNA, Plant; Gene Expression; Hepatophyta; Molecular Sequence Data; Plants; Retroelements | 2004 |
Genetic and epigenetic alterations of DLC-1 gene in hepatocellular carcinoma.
Topics: Azacitidine; Base Sequence; Carcinoma, Hepatocellular; cdc42 GTP-Binding Protein; Cell Line, Tumor; CpG Islands; Decitabine; DNA Methylation; Gene Expression Regulation, Neoplastic; Gene Silencing; GTPase-Activating Proteins; Humans; Liver Neoplasms; Loss of Heterozygosity; Molecular Sequence Data; rac1 GTP-Binding Protein; Reverse Transcriptase Polymerase Chain Reaction; rhoA GTP-Binding Protein; RNA, Messenger; Tumor Suppressor Proteins | 2003 |
Restoration of insulin-like growth factor binding protein-related protein 1 has a tumor-suppressive activity through induction of apoptosis in human prostate cancer.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Caspase 3; Caspases; Cell Division; Cell Line, Tumor; Culture Media, Conditioned; Decitabine; DNA, Complementary; Humans; Insulin-Like Growth Factor Binding Proteins; Insulin-Like Growth Factor I; Male; Prostatic Neoplasms; RNA, Messenger; Transfection | 2003 |
Epigenetic inactivation of TSLC1 gene in nasopharyngeal carcinoma.
Topics: Adult; Aged; Animals; Azacitidine; Base Sequence; Cell Adhesion Molecule-1; Cell Adhesion Molecules; Chromosomes, Human, Pair 11; Decitabine; DNA Methylation; DNA Modification Methylases; DNA Primers; DNA, Neoplasm; Enzyme Inhibitors; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Genes, Tumor Suppressor; Humans; Immunoglobulins; Loss of Heterozygosity; Male; Membrane Proteins; Mice; Microsatellite Repeats; Middle Aged; Molecular Sequence Data; Mutation; Nasopharyngeal Neoplasms; Nasopharynx; Promoter Regions, Genetic; Proteins; Reverse Transcriptase Polymerase Chain Reaction; Sequence Deletion; Transplantation, Heterologous; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2003 |
DNA methylation controls the responsiveness of hepatoma cells to leukemia inhibitory factor.
Topics: Animals; Azacitidine; Carcinoma, Hepatocellular; Decitabine; DNA Methylation; DNA-Binding Proteins; Interleukin-6; Leukemia Inhibitory Factor; Leukemia Inhibitory Factor Receptor alpha Subunit; Liver Neoplasms; Promoter Regions, Genetic; Rats; Receptors, Cytokine; Receptors, OSM-LIF; RNA, Messenger; Signal Transduction; STAT3 Transcription Factor; Trans-Activators | 2003 |
Resetting the histone code at CDKN2A in HNSCC by inhibition of DNA methylation.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Carcinoma, Squamous Cell; Decitabine; DNA Methylation; Gene Silencing; Genes, p16; Head and Neck Neoplasms; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids | 2003 |
Epigenetic silencing of the HIC-1 gene in human medulloblastomas.
Topics: Adolescent; Adult; Antimetabolites, Antineoplastic; Azacitidine; Blotting, Northern; Cerebellar Neoplasms; Child; Child, Preschool; Cystine; Decitabine; Epigenesis, Genetic; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Glycine; Humans; Infant; Loss of Heterozygosity; Male; Medulloblastoma; Methylation; Middle Aged; Molecular Sequence Data; Myogenic Regulatory Factors; Polymerase Chain Reaction; Polymorphism, Single-Stranded Conformational; RNA, Messenger; Sulfites; Tumor Cells, Cultured | 2003 |
Plakoglobin is a new target gene of histone deacetylase in human fibrosarcoma HT1080 cells.
Topics: Azacitidine; beta Catenin; Cell Line, Tumor; Chromatin; Chromatin Assembly and Disassembly; Cytoskeletal Proteins; Decitabine; Desmoplakins; DNA-Binding Proteins; Enzyme Inhibitors; Fibrosarcoma; gamma Catenin; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genes, Reporter; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Lymphoid Enhancer-Binding Factor 1; Oligonucleotide Array Sequence Analysis; Promoter Regions, Genetic; RNA, Messenger; Trans-Activators; Transcription Factors; Transcriptional Activation | 2004 |
Proteomic analysis of pancreatic ductal carcinoma cells treated with 5-aza-2'-deoxycytidine.
Topics: Actin Depolymerizing Factors; Azacitidine; Carcinoma, Pancreatic Ductal; Cell Division; Contractile Proteins; Cyclin-Dependent Kinase Inhibitor p16; Cyclophilin A; Cystatin B; Cystatins; Decitabine; DNA Methylation; Humans; Mass Spectrometry; Microfilament Proteins; Pancreatic Neoplasms; Profilins; Promoter Regions, Genetic; Proteomics; Rosaniline Dyes; Superoxide Dismutase; Tumor Cells, Cultured | 2003 |
Hypermethylation of the Ink4b locus in murine myeloid leukemia and increased susceptibility to leukemia in p15(Ink4b)-deficient mice.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Blotting, Southern; Blotting, Western; Cell Cycle Proteins; CpG Islands; Cyclin-Dependent Kinase Inhibitor p15; Cyclin-Dependent Kinase Inhibitor p16; Decitabine; DNA Methylation; Exons; Gene Deletion; Genotype; Introns; Leukemia, Myeloid, Acute; Mice; Mice, Transgenic; Phenotype; Retroviridae; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Time Factors; Tumor Suppressor Proteins | 2003 |
Identification of tumour-specific epigenetic events in medulloblastoma development by hypermethylation profiling.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Carcinoma; Carcinoma, Large Cell; Case-Control Studies; Caspase 8; Caspases; Cell Adhesion Molecule-1; Cell Adhesion Molecules; Cell Cycle Proteins; Cerebellum; Child; Child, Preschool; Cohort Studies; Cyclin-Dependent Kinase Inhibitor p15; Cyclin-Dependent Kinase Inhibitor p16; Decitabine; DNA Methylation; DNA Modification Methylases; DNA-Binding Proteins; Gene Silencing; Genes, Tumor Suppressor; Histone-Lysine N-Methyltransferase; Humans; Immunoglobulins; Infant; Infant, Newborn; Kruppel-Like Transcription Factors; Medulloblastoma; Membrane Proteins; Middle Aged; Nuclear Proteins; Promoter Regions, Genetic; Proteins; Reverse Transcriptase Polymerase Chain Reaction; Tissue Inhibitor of Metalloproteinase-3; Transcription Factors; Transcription, Genetic; Tumor Cells, Cultured; Tumor Protein p73; Tumor Suppressor Protein p14ARF; Tumor Suppressor Proteins | 2004 |
Expression of the p16INK4a gene and methylation pattern of CpG sites in the promoter region in rat tumor cell lines.
Topics: Adenocarcinoma; Animals; Azacitidine; CpG Islands; Cyclin-Dependent Kinase Inhibitor p16; Decitabine; DNA Methylation; Fibroblasts; Gene Silencing; Histiocytoma, Benign Fibrous; Lung Neoplasms; Neoplasms; Osteosarcoma; Promoter Regions, Genetic; Rats; RNA, Messenger; Sulfites; TATA Box; Tumor Cells, Cultured | 2004 |
CHFR-associated early G2/M checkpoint defects in breast cancer cells.
Topics: Azacitidine; Blotting, Western; Breast Neoplasms; Cell Cycle Proteins; CpG Islands; Decitabine; DNA Methylation; Enzyme Inhibitors; Female; Flow Cytometry; G2 Phase; Gene Expression Regulation, Neoplastic; Humans; Mitosis; Mitotic Index; Neoplasm Proteins; Poly-ADP-Ribose Binding Proteins; Tumor Cells, Cultured; Ubiquitin-Protein Ligases | 2004 |
Identification of HRK as a target of epigenetic inactivation in colorectal and gastric cancer.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Azacitidine; Biomarkers, Tumor; Cell Line, Tumor; Cell Separation; Chromatin; Colorectal Neoplasms; CpG Islands; Decitabine; Depsipeptides; DNA Methylation; Doxorubicin; Flow Cytometry; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Models, Genetic; Neuropeptides; Oligopeptides; Polymerase Chain Reaction; Precipitin Tests; Reverse Transcriptase Polymerase Chain Reaction; Stomach Neoplasms; Sulfites | 2003 |
Hepatocyte growth factor activator inhibitor 2/placental bikunin (HAI-2/PB) gene is frequently hypermethylated in human hepatocellular carcinoma.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Carcinoma, Hepatocellular; Cell Division; Cell Line, Tumor; CpG Islands; Decitabine; DNA Methylation; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Liver Neoplasms; Membrane Glycoproteins; Oligonucleotide Array Sequence Analysis; Reverse Transcriptase Polymerase Chain Reaction; Transfection; Trypsin Inhibitor, Kunitz Soybean | 2003 |
[The study of 5-Aza-2'-deoxycytidine on transcription regulation of p16/CDKN2 gene demethylation in RKO human colorectal cell line].
Topics: Antimetabolites, Antineoplastic; Azacitidine; Base Sequence; Blotting, Western; Cell Line, Tumor; Colorectal Neoplasms; Decitabine; DNA Methylation; DNA Modification Methylases; Genes, p16; Humans; Immunohistochemistry; Molecular Sequence Data; RNA, Messenger; Transcription, Genetic | 2003 |
5-aza-2'-deoxycytidine activates the p53/p21Waf1/Cip1 pathway to inhibit cell proliferation.
Topics: Antioxidants; Azacitidine; Binding Sites; Blotting, Western; Cell Differentiation; Cell Division; Cell Line, Tumor; Cell Survival; Comet Assay; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Decitabine; DNA Damage; DNA Methylation; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Luciferases; Models, Genetic; Mutagenesis, Site-Directed; Oncogene Proteins, Viral; Polymerase Chain Reaction; Promoter Regions, Genetic; Repressor Proteins; Sulfites; Time Factors; Transfection; Tumor Suppressor Protein p53 | 2004 |
Limited gene activation in tumor and normal epithelial cells treated with the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine.
Topics: Antigens, Neoplasm; Antimetabolites, Antineoplastic; Azacitidine; Cell Line, Tumor; Decitabine; DNA Methylation; DNA Modification Methylases; Epithelial Cells; Gene Expression Regulation; Humans; Melanocytes; Melanoma; Melanoma-Specific Antigens; Multigene Family; Neoplasm Proteins; Transcriptional Activation | 2004 |
5-Aza-2'-deoxycytidine stimulates inducible nitric oxide synthase induction in C6 astrocytoma cells.
Topics: Animals; Animals, Newborn; Antimetabolites, Antineoplastic; Astrocytes; Astrocytoma; Azacitidine; Blotting, Northern; Cells, Cultured; Decitabine; DNA Methylation; DNA Modification Methylases; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Induction; Gene Expression; Interferon Regulatory Factor-1; Interferons; Interleukin-1; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Nitric Oxide Synthase; Phosphoproteins; Rats; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Time Factors; Tumor Necrosis Factor-alpha | 2004 |
Continuous zebularine treatment effectively sustains demethylation in human bladder cancer cells.
Topics: Azacitidine; Cytidine; Decitabine; DNA; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Enzyme Inhibitors; Gene Silencing; Genes, p16; Humans; Pyrimidine Nucleosides; Urinary Bladder Neoplasms | 2004 |
Expression and regulation of tumor suppressor gene maspin in human bladder cancer.
Topics: Adult; Aged; Azacitidine; Carcinoma, Transitional Cell; Cell Line, Tumor; Cytoplasm; Decitabine; DNA Methylation; Female; Gene Expression Regulation, Neoplastic; Genes, Reporter; Genes, Tumor Suppressor; Histones; Humans; Hydroxamic Acids; Immunohistochemistry; Luciferases; Male; Middle Aged; Promoter Regions, Genetic; Protein Biosynthesis; Proteins; Reverse Transcriptase Polymerase Chain Reaction; Serpins; Transcriptional Activation; Urinary Bladder Neoplasms | 2004 |
5-Aza-2'-deoxycitydine induces demethylation and up-regulates transcription of p16INK4A gene in human gastric cancer cell lines.
Topics: Azacitidine; Cell Line, Tumor; Decitabine; DNA Methylation; Enzyme Inhibitors; Flow Cytometry; Gene Expression; Genes, p16; Genes, Tumor Suppressor; Humans; Reverse Transcriptase Polymerase Chain Reaction; Stomach Neoplasms; Transcription, Genetic; Up-Regulation | 2004 |
The absence of p53 is critical for the induction of apoptosis by 5-aza-2'-deoxycytidine.
Topics: Animals; Apoptosis; Azacitidine; Decitabine; G1 Phase; Mice; Mitosis; Tumor Suppressor Protein p53 | 2004 |
Disruption of cell-type-specific methylation at the Maspin gene promoter is frequently involved in undifferentiated thyroid cancers.
Topics: Adenoma; Azacitidine; Cell Line, Tumor; Decitabine; DNA Methylation; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Humans; Promoter Regions, Genetic; Proteins; RNA, Messenger; Serpins; Thyroid Gland; Thyroid Neoplasms | 2004 |
5-Aza-2'-deoxycytidine and paclitaxel inhibit inducible nitric oxide synthase activation in fibrosarcoma cells.
Topics: Animals; Azacitidine; Cell Line, Tumor; Decitabine; Dose-Response Relationship, Drug; Enzyme Inhibitors; Fibrosarcoma; Mice; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Paclitaxel | 2004 |
Role of the DNA methyltransferase variant DNMT3b3 in DNA methylation.
Topics: Alternative Splicing; Animals; Azacitidine; Blotting, Southern; Blotting, Western; CpG Islands; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Methyltransferase 3A; DNA Methyltransferase 3B; Embryo, Mammalian; Enzyme Inhibitors; Exons; HCT116 Cells; Humans; Isoenzymes; Mice; Mice, Knockout; NIH 3T3 Cells; Reverse Transcriptase Polymerase Chain Reaction; RNA; RNA, Messenger; Stem Cells; Sulfites | 2004 |
Epigenetic control of mouse Oct-4 gene expression in embryonic stem cells and trophoblast stem cells.
Topics: Animals; Azacitidine; Cell Lineage; Chromatin; Decitabine; DNA Methylation; DNA-Binding Proteins; Embryo, Mammalian; Enzyme Inhibitors; Gene Expression Regulation; Gene Silencing; Genes, Reporter; Heterozygote; Hydroxamic Acids; Liver; Luciferases; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Models, Genetic; NIH 3T3 Cells; Octamer Transcription Factor-3; Placenta; Polymerase Chain Reaction; Precipitin Tests; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; Stem Cells; Sulfites; Transcription Factors; Trophoblasts | 2004 |
Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas.
Topics: Adult; Aged; Aged, 80 and over; Azacitidine; Decitabine; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Female; Gene Expression Regulation, Neoplastic; Genes, ras; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Male; Melanoma; Middle Aged; Mutation; Promoter Regions, Genetic; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-raf; Signal Transduction; Skin Neoplasms; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2004 |
A simple method for estimating global DNA methylation using bisulfite PCR of repetitive DNA elements.
Topics: Alu Elements; Azacitidine; Cell Line, Tumor; CpG Islands; Decitabine; DNA; DNA Methylation; Humans; Long Interspersed Nucleotide Elements; Mutation; Polymerase Chain Reaction; Repetitive Sequences, Nucleic Acid; Reproducibility of Results; Sensitivity and Specificity; Sequence Analysis, DNA; Sulfites | 2004 |
Modification of hematopoietic stem cell fate by 5aza 2'deoxycytidine and trichostatin A.
Topics: Adult; Antigens, CD34; Antimetabolites, Antineoplastic; Azacitidine; Cell Division; Cells, Cultured; Decitabine; Hematopoietic Stem Cells; Humans; Hydroxamic Acids; In Vitro Techniques; Methylation; Phenotype; Protein Synthesis Inhibitors; Thy-1 Antigens | 2004 |
[Effect of inhibitors for demethylation and histone deacetylase on proliferation of cell line K562 and expression of tumor related genes].
Topics: Azacitidine; Cell Cycle; Cell Division; Decitabine; DNA Methylation; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; K562 Cells | 2004 |
Cancer chemotherapy targeted at reactivating the expression of epigenetically inactivated genes.
Topics: Antineoplastic Agents; Azacitidine; Clinical Trials as Topic; Decitabine; DNA Methylation; DNA, Viral; Enzyme Inhibitors; Gene Expression; Gene Silencing; Gene Targeting; Herpesvirus 4, Human; Humans; Neoplasms; Promoter Regions, Genetic | 2004 |
DNA methylation as an epigenetic regulator of neural 5-lipoxygenase expression: evidence in human NT2 and NT2-N cells.
Topics: Arachidonate 5-Lipoxygenase; Azacitidine; Cell Differentiation; Cell Line; CpG Islands; Decitabine; DNA Methylation; Epigenesis, Genetic; Gene Expression Regulation, Developmental; Humans; Neurons; Promoter Regions, Genetic; RNA, Messenger; Teratocarcinoma; Valproic Acid | 2004 |
Human PinX1, a potent telomerase inhibitor, is not involved in human gastrointestinal tract carcinoma.
Topics: Azacitidine; Carcinoma; Cell Cycle Proteins; Cell Line, Tumor; CpG Islands; Decitabine; DNA Methylation; Gastrointestinal Neoplasms; Gene Expression; Humans; Mutation, Missense; Polymorphism, Genetic; Promoter Regions, Genetic; RNA, Messenger; Sequence Analysis, DNA; Telomerase; Tumor Suppressor Proteins | 2004 |
Epigenetic modifications affect Dnmt3L expression.
Topics: Animals; Azacitidine; Base Sequence; Binding Sites; Cell Line; Chlorocebus aethiops; COS Cells; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Embryo, Mammalian; Epigenesis, Genetic; Epithelial Cells; Gene Expression Regulation; Hydroxamic Acids; Luciferases; Mice; Molecular Sequence Data; NIH 3T3 Cells; Promoter Regions, Genetic; Recombinant Fusion Proteins; RNA, Messenger; Sp1 Transcription Factor; Stem Cells; Thymus Gland | 2004 |
Transplacental exposure to the DNA demethylating agent, 5-AZA-CdR, affects the sexual behavior of CD-1 male mice.
Topics: Animals; Azacitidine; Decitabine; DNA Methylation; Female; Male; Maternal-Fetal Exchange; Mice; Pregnancy; Reaction Time; Sexual Behavior, Animal | 2004 |
Hypermethylation of the 5' CpG island of the FHIT gene is associated with hyperdiploid and translocation-negative subtypes of pediatric leukemia.
Topics: Acid Anhydride Hydrolases; Adolescent; Antimetabolites, Antineoplastic; Azacitidine; B-Lymphocytes; Child; Child, Preschool; Chromosomes, Human, Pair 12; Chromosomes, Human, Pair 21; CpG Islands; Decitabine; Diploidy; DNA Methylation; DNA, Neoplasm; Female; Gene Deletion; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Myeloid; Male; Neoplasm Proteins; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Promoter Regions, Genetic; T-Lymphocytes; Translocation, Genetic; Tumor Cells, Cultured | 2004 |
Hypermethylation and transcriptional downregulation of the carboxyl-terminal modulator protein gene in glioblastomas.
Topics: Adaptor Proteins, Signal Transducing; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Azacitidine; Carrier Proteins; Cell Line, Tumor; Decitabine; DNA Methylation; Down-Regulation; Gene Deletion; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Hydroxamic Acids; Membrane Proteins; Mutation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Thiolester Hydrolases; Transcription, Genetic | 2004 |
MDR1 promoter hypermethylation in MCF-7 human breast cancer cells: changes in chromatin structure induced by treatment with 5-Aza-cytidine.
Topics: Acetylation; Antibiotics, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Azacitidine; Breast Neoplasms; Chromatin; Chromatin Immunoprecipitation; Decitabine; DNA Methylation; DNA Modification Methylases; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Promoter Regions, Genetic; RNA, Messenger; Transcriptional Activation; Tumor Cells, Cultured | 2004 |
Hypermethylation and silencing of the putative tumor suppressor Tazarotene-induced gene 1 in human cancers.
Topics: Antineoplastic Agents; Azacitidine; Cell Division; Cell Line, Tumor; Decitabine; DNA Methylation; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Gene Silencing; Genes, Tumor Suppressor; Humans; Membrane Proteins; Neoplasms; Promoter Regions, Genetic; Protein Biosynthesis; Proteins; Receptors, Retinoic Acid; Tretinoin | 2004 |
Enhancement of antineoplastic action of 5-aza-2'-deoxycytidine by phenylbutyrate on L1210 leukemic cells.
Topics: Animals; Antineoplastic Agents; Azacitidine; Cell Cycle Proteins; Cell Division; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p15; Decitabine; DNA; DNA Replication; Drug Synergism; Genes, Tumor Suppressor; HL-60 Cells; Humans; Leukemia; Male; Mice; Phenylbutyrates; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Tumor Suppressor Proteins | 2004 |
Effects of demethylating agent 5-aza-2(')-deoxycytidine and histone deacetylase inhibitor FR901228 on maspin gene expression in oral cancer cell lines.
Topics: Antineoplastic Agents; Azacitidine; Cell Line, Tumor; CpG Islands; Decitabine; Depsipeptides; DNA Methylation; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Humans; Mouth Neoplasms; Peptides, Cyclic; Proteins; RNA, Messenger; Serpins; Transcription, Genetic | 2004 |
5-aza-2'-deoxycytidine restores the E-cadherin system in E-cadherin-silenced cancer cells and reduces cancer metastasis.
Topics: Azacitidine; Blotting, Western; Cadherins; Calcium; Cell Line, Tumor; Cell Movement; Decitabine; DNA Primers; Gene Silencing; Humans; Neoplasm Metastasis; Polymerase Chain Reaction | 2004 |
Hypermethylation of the PTEN gene in ovarian cancer cell lines.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Methylation; DNA Modification Methylases; DNA, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Ovarian Neoplasms; Phosphoric Monoester Hydrolases; Promoter Regions, Genetic; RNA, Messenger; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2004 |
Demethylation of the synuclein gamma gene CpG island in primary gastric cancers and gastric cancer cell lines.
Topics: Adult; Aged; Aged, 80 and over; Azacitidine; Cell Division; Cell Line, Tumor; CpG Islands; Decitabine; Disease Progression; DNA Methylation; DNA, Complementary; Exons; Female; Gastric Mucosa; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Neoplasm Metastasis; Nerve Tissue Proteins; Polymorphism, Single-Stranded Conformational; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Stomach Neoplasms; Sulfites; Synucleins; Time Factors | 2004 |
The tumor suppressor gene WWOX at FRA16D is involved in pancreatic carcinogenesis.
Topics: Adenocarcinoma; Alleles; Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Separation; Cell Transformation, Neoplastic; Decitabine; DNA Methylation; DNA Mutational Analysis; DNA, Complementary; Exons; Flow Cytometry; Genes, Tumor Suppressor; Humans; Loss of Heterozygosity; Oxidoreductases; Pancreatic Neoplasms; Promoter Regions, Genetic; Protein Structure, Tertiary; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Transfection; Tumor Suppressor Proteins; WW Domain-Containing Oxidoreductase | 2004 |
Folic acid-mediated inhibition of serum-induced activation of EGFR promoter in colon cancer cells.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Blotting, Western; Cell Line, Tumor; Cells, Cultured; Colonic Neoplasms; Culture Media, Serum-Free; Decitabine; DNA Methylation; DNA Primers; ErbB Receptors; Folic Acid; Humans; Luciferases; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; Tetrahydrofolates; Transfection | 2004 |
Evaluation of antineoplastic action of 5-aza-2'-deoxycytidine (Dacogen) and docetaxel (Taxotere) on human breast, lung and prostate carcinoma cell lines.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Breast Neoplasms; Cadherins; Cell Line, Tumor; Decitabine; DNA; Docetaxel; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Female; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Humans; Lung Neoplasms; Male; Prostatic Neoplasms; Proteins; Serpins; Taxoids; Time Factors | 2004 |
Aberrant expression of the maspin gene associated with epigenetic modification in melanoma cells.
Topics: Azacitidine; Cell Line, Tumor; Decitabine; DNA Methylation; Genes, Tumor Suppressor; Humans; Immunohistochemistry; Melanoma; Polymerase Chain Reaction; Promoter Regions, Genetic; Proteins; Serpins | 2004 |
Promoter methylation inhibits APC gene expression by causing changes in chromatin conformation and interfering with the binding of transcription factor CCAAT-binding factor.
Topics: Adenomatous Polyposis Coli Protein; Azacitidine; CCAAT-Binding Factor; Cell Line, Tumor; Chromatin; Colorectal Neoplasms; CpG Islands; Decitabine; DNA Methylation; Gene Expression Regulation, Neoplastic; Genes, APC; Humans; Luciferases; Promoter Regions, Genetic; Protein Conformation; RNA, Messenger; Transfection; Up-Regulation | 2004 |
MEIS 1 expression is downregulated through promoter hypermethylation in AML1-ETO acute myeloid leukemias.
Topics: Acute Disease; Adult; Azacitidine; Bone Marrow; Case-Control Studies; Cell Line, Tumor; Core Binding Factor Alpha 2 Subunit; Decitabine; DNA Methylation; Down-Regulation; Homeodomain Proteins; Humans; Hydroxamic Acids; Leukemia, Myeloid; Myeloid Ecotropic Viral Integration Site 1 Protein; Neoplasm Proteins; Oncogene Proteins, Fusion; Promoter Regions, Genetic; RNA, Messenger; RUNX1 Translocation Partner 1 Protein; Transcription Factors | 2004 |
Methylation in the core-promoter region of the chondromodulin-I gene determines the cell-specific expression by regulating the binding of transcriptional activator Sp3.
Topics: 5-Methylcytosine; Azacitidine; Binding Sites; Blotting, Western; Bone and Bones; Cartilage; Cell Line, Tumor; Chondrocytes; Chromatin; CpG Islands; Cytosine; Decitabine; DNA Methylation; DNA-Binding Proteins; Genes, Reporter; Humans; Intercellular Signaling Peptides and Proteins; Luciferases; Membrane Proteins; Precipitin Tests; Promoter Regions, Genetic; Protein Binding; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; RNA, Messenger; RNA, Small Interfering; Sp1 Transcription Factor; Sp3 Transcription Factor; Sulfites; Thymine; Transcription Factors; Transcription, Genetic | 2004 |
The candidate tumor suppressor gene BLU, located at the commonly deleted region 3p21.3, is an E2F-regulated, stress-responsive gene and inactivated by both epigenetic and genetic mechanisms in nasopharyngeal carcinoma.
Topics: Alleles; Animals; Azacitidine; Base Sequence; Carcinoma; Cell Line; Cell Line, Tumor; Cell Transformation, Viral; Chromosomes, Human, Pair 3; CpG Islands; Decitabine; DNA Methylation; Enzyme Inhibitors; Epigenesis, Genetic; Gene Deletion; Gene Expression Regulation, Neoplastic; Gene Silencing; Genes, Tumor Suppressor; Humans; Mice; Mice, Nude; Molecular Sequence Data; Nasopharyngeal Neoplasms; Promoter Regions, Genetic; Protein Binding; Stress, Physiological; Tumor Suppressor Proteins | 2004 |
DNA methylation profiles of lymphoid and hematopoietic malignancies.
Topics: Age Factors; Antimetabolites, Antineoplastic; Azacitidine; Cell Line, Tumor; Decitabine; DNA Methylation; DNA, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Humans; Leukemia; Logistic Models; Lymphoma; Male; Middle Aged; Multiple Myeloma; Promoter Regions, Genetic; Sex Factors | 2004 |
Gamma-catenin expression is reduced or absent in a subset of human non-small cell lung cancers, and its re-expression inhibits cell growth.
Topics: Azacitidine; beta Catenin; Carcinoma, Non-Small-Cell Lung; Cell Division; Cell Line, Tumor; Cytoskeletal Proteins; Decitabine; Desmoplakins; DNA Modification Methylases; gamma Catenin; Humans; Hydroxamic Acids; Lung Neoplasms; Neoplasm Proteins; Trans-Activators | 2004 |
Antineoplastic action of 5-aza-2'-deoxycytidine (Dacogen) and depsipeptide on Raji lymphoma cells.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cadherins; Cell Division; Chromatin; Colony-Forming Units Assay; Decitabine; Depsipeptides; DNA Methylation; DNA Modification Methylases; Drug Combinations; Drug Synergism; Gene Expression Regulation, Neoplastic; Gene Silencing; Histone Deacetylase Inhibitors; Humans; In Vitro Techniques; Lymphoma; Reverse Transcriptase Polymerase Chain Reaction; RNA, Neoplasm; Tumor Cells, Cultured | 2004 |
Regulation of Chk2 gene expression in lymphoid malignancies: involvement of epigenetic mechanisms in Hodgkin's lymphoma cell lines.
Topics: Acetylation; Apoptosis; Azacitidine; Butyrates; Cell Line, Tumor; Checkpoint Kinase 2; Decitabine; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Histones; Hodgkin Disease; Humans; Hydroxamic Acids; Lymphoma; Methylation; Protein Serine-Threonine Kinases; RNA, Messenger | 2004 |
Promoter hypermethylation silences cyclooxygenase-2 (Cox-2) and regulates growth of human hepatocellular carcinoma cells.
Topics: Azacitidine; Base Sequence; Carcinoma, Hepatocellular; Cell Division; Cell Line, Tumor; Cell Survival; Cyclooxygenase 2; Decitabine; Dinoprostone; DNA Methylation; DNA, Neoplasm; Gene Silencing; Humans; Isoenzymes; Liver Neoplasms; Membrane Proteins; Promoter Regions, Genetic; Prostaglandin-Endoperoxide Synthases | 2004 |
Frequent silencing of low density lipoprotein receptor-related protein 1B (LRP1B) expression by genetic and epigenetic mechanisms in esophageal squamous cell carcinoma.
Topics: Acetylation; Antimetabolites, Antineoplastic; Azacitidine; Carcinoma, Squamous Cell; Cell Division; Cell Line, Tumor; CpG Islands; Decitabine; DNA Methylation; Esophageal Neoplasms; Gene Deletion; Gene Expression Regulation, Neoplastic; Gene Silencing; Histones; Humans; Nucleic Acid Hybridization; Receptors, LDL; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2004 |
The IL-12Rbeta2 gene functions as a tumor suppressor in human B cell malignancies.
Topics: Animals; Azacitidine; B-Lymphocytes; Chronic Disease; Decitabine; DNA Modification Methylases; Genes, Tumor Suppressor; Humans; Interleukin-12; Leukemia, B-Cell; Lymphoproliferative Disorders; Mice; Mice, Inbred NOD; Mice, SCID; Palatine Tonsil; Receptors, Interleukin; Receptors, Interleukin-12 | 2004 |
Progesterone receptor gene inactivation and CpG island hypermethylation in human leukemia cancer cells.
Topics: Azacitidine; Case-Control Studies; CpG Islands; Decitabine; DNA Methylation; DNA Modification Methylases; DNA Primers; Gene Silencing; HL-60 Cells; Humans; Jurkat Cells; K562 Cells; Oligonucleotides, Antisense; Polymerase Chain Reaction; Protein Isoforms; Receptors, Progesterone; Repressor Proteins; RNA, Messenger | 2004 |
Expression of the human myotonic dystrophy kinase-related Cdc42-binding kinase gamma is regulated by promoter DNA methylation and Sp1 binding.
Topics: Amino Acid Sequence; Animals; Azacitidine; Base Sequence; Blotting, Northern; cdc42 GTP-Binding Protein; Cell Line; Cell Line, Tumor; COS Cells; Cytoplasm; Decitabine; DNA; DNA Methylation; Genes, Reporter; Genetic Variation; Genetic Vectors; Glutathione Transferase; GTP Phosphohydrolases; HeLa Cells; Humans; Hydroxamic Acids; Luciferases; Models, Genetic; Molecular Sequence Data; Myotonin-Protein Kinase; Precipitin Tests; Promoter Regions, Genetic; Protein Binding; Protein Isoforms; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein-Tyrosine Kinases; Recombinant Fusion Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sequence Analysis, DNA; Sequence Homology, Amino Acid; Sp1 Transcription Factor; Transcription, Genetic; Transfection | 2004 |
Reduced expression of small GTPases and hypermethylation of the folate binding protein gene in cisplatin-resistant cells.
Topics: Antineoplastic Agents; Azacitidine; Carboplatin; Carrier Proteins; Cell Survival; Cisplatin; Decitabine; DNA Methylation; Down-Regulation; Drug Resistance, Neoplasm; Endocytosis; Folate Receptors, GPI-Anchored; Folic Acid; Gene Expression Regulation, Neoplastic; Humans; Immunoblotting; Methotrexate; Monomeric GTP-Binding Proteins; Receptors, Cell Surface; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured | 2004 |
Less frequent promoter hypermethylation of DLC-1 gene in primary breast cancers.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Base Sequence; Breast Neoplasms; Cell Line, Tumor; Decitabine; DNA Methylation; DNA Primers; DNA, Neoplasm; Female; Gene Frequency; Gene Silencing; GTPase-Activating Proteins; Humans; Neoplasm Invasiveness; Polymerase Chain Reaction; Promoter Regions, Genetic; Tumor Suppressor Proteins | 2004 |
Myelodysplasia, megakaryocytes, and methylation.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Methylation; DNA Modification Methylases; Humans; Megakaryocytes; Myelodysplastic Syndromes | 2004 |
The effects of 5-aza-2'-deoxycytidine (Decitabine) on the platelet count in patients with intermediate and high-risk myelodysplastic syndromes.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Female; Humans; Male; Megakaryocytes; Middle Aged; Myelodysplastic Syndromes; Platelet Count; Risk Factors; Survival Rate; Thrombopoietin; Treatment Outcome | 2004 |
Formation of mitoxantrone adducts in human tumor cells: potentiation by AN-9 and DNA methylation.
Topics: Azacitidine; Butyrates; Cell Line, Tumor; Decitabine; DNA Adducts; DNA Methylation; Humans; Mitoxantrone; Molecular Structure; Proteins; RNA; Time Factors | 2004 |
Epigenetic modification regulates both expression of tumor-associated genes and cell cycle progressing in human colon cancer cell lines: Colo-320 and SW1116.
Topics: Acetylation; Azacitidine; Butyrates; Cell Cycle; Cell Line, Tumor; Cell Survival; Colonic Neoplasms; Decitabine; DNA; DNA Methylation; Gene Expression Regulation, Neoplastic; Genes, APC; Genes, p16; Histones; Humans; Hydroxamic Acids | 2004 |
Methylation-associated silencing of the heat shock protein 47 gene in human neuroblastoma.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Cell Line, Tumor; Collagen Type I; Collagen Type IV; Decitabine; DNA Methylation; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Heat-Shock Proteins; HSP47 Heat-Shock Proteins; Humans; Mice; Mice, Nude; Neuroblastoma; Oligonucleotide Array Sequence Analysis; Promoter Regions, Genetic; Up-Regulation | 2004 |
Microarray analysis of gene regulation in the Hepa1c1c7 cell line following exposure to the DNA methylation inhibitor 5-aza-2'-deoxycytidine and 2,3,7,8-tetrachlorodibenzo-p-dioxin.
Topics: Animals; Azacitidine; Carcinoma, Hepatocellular; Cell Line, Tumor; Decitabine; DNA Modification Methylases; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Mice; Oligonucleotide Array Sequence Analysis; Polychlorinated Dibenzodioxins | 2004 |
Epigenetic regulation of MDR1 gene in breast cancer: CpG methylation status dominates the stable maintenance of a silent gene.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Azacitidine; Breast Neoplasms; Chromatin; CpG Islands; Decitabine; DNA Methylation; DNA Modification Methylases; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Humans; Promoter Regions, Genetic | 2004 |
HER-2, gp100, and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T cells.
Topics: Animals; Antigen Presentation; Antigens, Neoplasm; Azacitidine; Brain Neoplasms; Cell Line, Tumor; Chlorocebus aethiops; COS Cells; Decitabine; DNA Methylation; Epitopes, T-Lymphocyte; Gene Expression Regulation, Neoplastic; Glioblastoma; gp100 Melanoma Antigen; Humans; Interferon-gamma; Melanoma-Specific Antigens; Membrane Glycoproteins; Neoplasm Proteins; Receptor, ErbB-2; RNA, Messenger; T-Lymphocytes, Cytotoxic | 2004 |
5-aza-2'-deoxycytidine upregulates caspase-9 expression cooperating with p53-induced apoptosis in human lung cancer cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Caspase 9; Caspases; Cell Line, Tumor; Decitabine; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Tumor Suppressor Protein p53 | 2004 |
DNA hypomethylation induced by non-genotoxic carcinogens in mouse and rat colon.
Topics: Animals; Azacitidine; Carcinogens; Chenodeoxycholic Acid; Cholic Acid; Colon; Colonic Neoplasms; Decitabine; Deoxycholic Acid; DNA; DNA Methylation; Dose-Response Relationship, Drug; Female; Lithocholic Acid; Male; Mice; Rats; Rats, Inbred F344; Rutin; Time Factors | 2004 |
Epigenetic silencing of the immunoglobulin heavy-chain gene in classical Hodgkin lymphoma-derived cell lines contributes to the loss of immunoglobulin expression.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Burkitt Lymphoma; Cell Line, Tumor; Decitabine; DNA Methylation; Down-Regulation; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Gene Silencing; Hodgkin Disease; Humans; Immunoglobulin Heavy Chains; Octamer Transcription Factor-2; Promoter Regions, Genetic; Trans-Activators; Transcription Factors; Transcription, Genetic | 2004 |
Apoptotic speck protein-like, a highly homologous protein to apoptotic speck protein in the pyrin domain, is silenced by DNA methylation and induces apoptosis in human hepatocellular carcinoma.
Topics: Amino Acid Sequence; Annexin A5; Apoptosis; Azacitidine; Carcinoma, Hepatocellular; CARD Signaling Adaptor Proteins; Caspase 3; Caspases; Cytoskeletal Proteins; Decitabine; DNA Methylation; Enzyme Activation; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Liver Neoplasms; Molecular Sequence Data; Protein Structure, Tertiary; Proteins; Pyrin; Sequence Homology, Amino Acid; Tumor Cells, Cultured | 2004 |
Silencing of the hypoxia-inducible cell death protein BNIP3 in pancreatic cancer.
Topics: Adenocarcinoma; Apoptosis; Azacitidine; Cell Hypoxia; CpG Islands; Decitabine; DNA Methylation; Gene Expression Regulation, Neoplastic; Gene Silencing; Glucose Transport Proteins, Facilitative; Humans; Insulin-Like Growth Factor Binding Protein 3; Membrane Proteins; Monosaccharide Transport Proteins; Pancreas; Pancreatic Neoplasms; Promoter Regions, Genetic; Proto-Oncogene Proteins; Tumor Cells, Cultured | 2004 |
Demethylating agent 5-aza-2'-deoxycytidine enhances expression of TNFRI and promotes TNF-mediated apoptosis in vitro and in vivo.
Topics: Animals; Antigens, CD; Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Cell Line, Tumor; Cell Separation; CpG Islands; Decitabine; DNA Fragmentation; Flow Cytometry; Humans; In Situ Nick-End Labeling; Melanoma; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Necrosis; Neoplasm Transplantation; Promoter Regions, Genetic; Receptors, Tumor Necrosis Factor; Receptors, Tumor Necrosis Factor, Type I; Recombinant Proteins; Ribonucleases; RNA; Time Factors; Tumor Necrosis Factor-alpha | 2004 |
Enhanced sensitivity of prostate cancer DU145 cells to cisplatinum by 5-aza-2'-deoxycytidine.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Azacitidine; Cell Line, Tumor; Cisplatin; Decitabine; DNA Methylation; Drug Synergism; Flow Cytometry; Humans; Male; Microscopy, Fluorescence; Prostatic Neoplasms; Time Factors | 2004 |
Prevalent hyper-methylation of the CDH13 gene promoter in malignant B cell lymphomas.
Topics: Azacitidine; Cadherins; Cell Line, Tumor; CpG Islands; Decitabine; DNA Methylation; Gene Expression; Humans; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Prognosis; Promoter Regions, Genetic; RNA, Messenger | 2004 |
The frequent expression of cancer/testis antigens provides opportunities for immunotherapeutic targeting of sarcoma.
Topics: Antibodies, Neoplasm; Antigens, Neoplasm; Autoantigens; Azacitidine; Cell Line, Tumor; Decitabine; DNA Methylation; HLA-A2 Antigen; Humans; Immunohistochemistry; Immunotherapy; Interferon-gamma; Membrane Proteins; Neoplasm Proteins; Polymerase Chain Reaction; Sarcoma | 2004 |
Reduced expression of MYO18B, a candidate tumor-suppressor gene on chromosome arm 22q, in ovarian cancer.
Topics: Azacitidine; Carcinoma, Endometrioid; Case-Control Studies; Chromosomes, Human, Pair 22; Cystadenocarcinoma, Mucinous; Cystadenocarcinoma, Serous; Decitabine; DNA Methylation; DNA Mutational Analysis; Female; Genes, Tumor Suppressor; Humans; Hydroxamic Acids; Mutation, Missense; Myosin Heavy Chains; Ovarian Neoplasms; Ovary; Promoter Regions, Genetic; Tumor Cells, Cultured | 2004 |
CpG hypermethylation of MDR1 gene contributes to the pathogenesis and progression of human prostate cancer.
Topics: Aged; Aged, 80 and over; Apoptosis; Azacitidine; Base Sequence; Cell Division; CpG Islands; Decitabine; Disease Progression; DNA Methylation; Gene Expression Regulation, Neoplastic; Gene Silencing; Genes, MDR; Humans; Male; Middle Aged; Molecular Sequence Data; Promoter Regions, Genetic; Prostatic Hyperplasia; Prostatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2004 |
Favorable neuroblastoma genes and molecular therapeutics of neuroblastoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Azacitidine; Boronic Acids; Caspases; Decitabine; DNA; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Mice; Mice, Nude; Mice, SCID; Neoplasm Proteins; Neuroblastoma; Phenylbutyrates; Proteasome Inhibitors; Transplantation, Heterologous; Tumor Cells, Cultured | 2004 |
[Effect of 5-aza-2'-deoxycytidine on cell of high-risk patients with myelodysplastic syndrome in vitro].
Topics: Azacitidine; Cell Cycle Proteins; Cell Line; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p15; Decitabine; DNA Methylation; DNA Methyltransferase 3A; DNA Modification Methylases; Humans; Myelodysplastic Syndromes; RNA, Messenger; Tumor Suppressor Proteins | 2004 |
Methylation profiles of thirty four promoter-CpG islands and concordant methylation behaviours of sixteen genes that may contribute to carcinogenesis of astrocytoma.
Topics: Adolescent; Adult; Antigens, Neoplasm; Astrocytoma; Azacitidine; Brain Neoplasms; Cadherins; Carcinoma, Hepatocellular; Child; CpG Islands; Cyclin-Dependent Kinase Inhibitor p16; Decitabine; DNA Methylation; DNA-Binding Proteins; Epigenesis, Genetic; Female; Genes, Tumor Suppressor; Glioma; Humans; Liver Neoplasms; Male; Melanoma-Specific Antigens; Middle Aged; Neoplasm Proteins; Nuclear Proteins; Promoter Regions, Genetic; Sex Factors; Tumor Cells, Cultured; Tumor Protein p73; Tumor Suppressor Proteins | 2004 |
Downregulation of connexin 26 in human lung cancer is related to promoter methylation.
Topics: Actins; Antimetabolites, Antineoplastic; Azacitidine; Blotting, Northern; Blotting, Southern; Carcinoma, Squamous Cell; Cell Line, Tumor; Connexin 26; Connexins; Decitabine; DNA Methylation; DNA Modification Methylases; DNA, Neoplasm; Down-Regulation; Enzyme Inhibitors; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Glyceraldehyde-3-Phosphate Dehydrogenases; Humans; Immunohistochemistry; Lung Neoplasms; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; Sequence Analysis, DNA | 2005 |
Methylation-regulated expression of cancer testis antigens in primary effusion lymphoma: immunotherapeutic implications.
Topics: Antigens, Neoplasm; Azacitidine; Blotting, Western; Cell Line, Tumor; Decitabine; DNA Methylation; Humans; Immunoprecipitation; Immunotherapy; Lymphoma, B-Cell; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Time Factors; Up-Regulation | 2005 |
Cell type-specific regulation of the TGF-beta-responsive alpha2(I) collagen gene by CpG methylation.
Topics: Animals; Azacitidine; Base Sequence; Cell Line; Collagen Type I; CpG Islands; Decitabine; DNA Methylation; DNA Modification Methylases; DNA-Binding Proteins; Gene Expression Regulation; Genes, Reporter; Histones; Humans; Molecular Sequence Data; Promoter Regions, Genetic; Sequence Alignment; Smad Proteins; Sp1 Transcription Factor; Trans-Activators; Transcription, Genetic; Transforming Growth Factor beta | 2005 |
Reactivation of SYK expression by inhibition of DNA methylation suppresses breast cancer cell invasiveness.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Breast; Breast Neoplasms; Carcinoma, Ductal; Carcinoma, Intraductal, Noninfiltrating; Cell Proliferation; Decitabine; DNA Methylation; DNA Modification Methylases; Enzyme Precursors; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Intracellular Signaling Peptides and Proteins; Neoplasm Invasiveness; Phenotype; Protein-Tyrosine Kinases; Stilbenes; Syk Kinase | 2005 |
Silencing of the retinoid response gene TIG1 by promoter hypermethylation in nasopharyngeal carcinoma.
Topics: Animals; Azacitidine; Cells, Cultured; Decitabine; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Mediator Complex; Mice; Nasopharyngeal Neoplasms; Nasopharynx; Promoter Regions, Genetic; Receptors, Retinoic Acid; Retinoids; Reverse Transcriptase Polymerase Chain Reaction; Transcription Factors; Transplantation, Heterologous | 2005 |
Genome-wide demethylation destabilizes CTG.CAG trinucleotide repeats in mammalian cells.
Topics: Animals; Azacitidine; CHO Cells; CpG Islands; Cricetinae; Decitabine; DNA Methylation; Genome, Human; Humans; Hydralazine | 2004 |
Methylation-associated silencing of the Wnt antagonist SFRP1 gene in human ovarian cancers.
Topics: Adult; Aged; Azacitidine; Decitabine; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Intercellular Signaling Peptides and Proteins; Membrane Proteins; Middle Aged; Ovarian Neoplasms; Promoter Regions, Genetic; Proto-Oncogene Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Wnt Proteins | 2004 |
Aberrant methylation of HIN-1 (high in normal-1) is a frequent event in many human malignancies.
Topics: Adult; Azacitidine; Child; Cytokines; Decitabine; DNA Methylation; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Male; Neoplasms; Promoter Regions, Genetic; RNA, Messenger; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2005 |
Expression and regulation of MIM (Missing In Metastasis), a novel putative metastasis suppressor gene, and MIM-B, in bladder cancer cell lines.
Topics: Azacitidine; Clone Cells; Decitabine; DNA Methylation; Down-Regulation; Genes, Tumor Suppressor; Humans; Microfilament Proteins; Neoplasm Invasiveness; Neoplasm Proteins; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured; Urinary Bladder; Urinary Bladder Neoplasms | 2004 |
Distinct effects on gene expression of chemical and genetic manipulation of the cancer epigenome revealed by a multimodality approach.
Topics: Algorithms; Apoptosis; Azacitidine; Cell Division; Cell Line, Tumor; Cluster Analysis; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Methyltransferase 3B; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Gene Silencing; Genome; Humans; Hydroxamic Acids; Metallothionein; Methyltransferases; Neoplasms; Oligonucleotide Array Sequence Analysis; Promoter Regions, Genetic; Reproducibility of Results; RNA, Messenger; Transcriptional Activation | 2004 |
Epigenetic regulation of 11 beta-hydroxysteroid dehydrogenase type 2 expression.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 2; Animals; Azacitidine; Base Sequence; Blood Pressure; Cell Line, Tumor; CpG Islands; Decitabine; DNA; DNA Methylation; Enzyme Inhibitors; Epigenesis, Genetic; Humans; Hydrocortisone; Hydroxamic Acids; Hypertension; Molecular Sequence Data; Procainamide; Promoter Regions, Genetic; Rats; Rats, Wistar; Receptors, Glucocorticoid; Transcription Factors; Transcription, Genetic | 2004 |
Loss of maspin expression is associated with development and progression of gastric carcinoma with p53 abnormality.
Topics: Adenoma; Azacitidine; Decitabine; Disease Progression; DNA Methylation; Gastric Mucosa; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Humans; Immunoenzyme Techniques; Mouth Neoplasms; Neoplasm Invasiveness; Neoplasm Staging; Promoter Regions, Genetic; Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Serpins; Stomach Neoplasms; Tumor Suppressor Protein p53 | 2004 |
[Methylation of mismatch repair gene (MMR) in primary hepatocellular carcinoma].
Topics: Adaptor Proteins, Signal Transducing; Azacitidine; Base Pair Mismatch; Carcinoma, Hepatocellular; Carrier Proteins; Cell Line, Tumor; Decitabine; DNA Methylation; DNA Modification Methylases; DNA Repair; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; MutL Protein Homolog 1; MutL Proteins; Neoplasm Proteins; Nuclear Proteins; RNA, Messenger | 2004 |
Oncogene regulation of tumor suppressor genes in tumorigenesis.
Topics: Animals; Azacitidine; Cells, Cultured; Decitabine; DNA Methylation; DNA Modification Methylases; Fibroblasts; Gene Expression Regulation, Neoplastic; Genes, src; Genes, Tumor Suppressor; Microarray Analysis; Oncogenes; Promoter Regions, Genetic; Rats | 2005 |
The in vitro and in vivo effects of re-expressing methylated von Hippel-Lindau tumor suppressor gene in clear cell renal carcinoma with 5-aza-2'-deoxycytidine.
Topics: Adenocarcinoma, Clear Cell; Animals; Antimetabolites, Antineoplastic; Azacitidine; Cytidine; Decitabine; Disease Models, Animal; DNA Methylation; Gene Silencing; Humans; Kidney Neoplasms; Mice; Pyrimidine Nucleosides; Reverse Transcriptase Polymerase Chain Reaction; Transfection; Transplantation, Heterologous; Tumor Cells, Cultured; Tumor Suppressor Proteins; Ubiquitin-Protein Ligases; Von Hippel-Lindau Tumor Suppressor Protein | 2004 |
Hypermethylation of growth arrest DNA damage-inducible gene 45 beta promoter in human hepatocellular carcinoma.
Topics: Apoptosis; Azacitidine; Binding Sites; Blotting, Northern; Carcinoma, Hepatocellular; Cell Line, Tumor; Cloning, Molecular; CpG Islands; Decitabine; DNA; DNA Damage; DNA Methylation; DNA, Complementary; Dose-Response Relationship, Drug; Down-Regulation; Enzyme-Linked Immunosorbent Assay; GADD45 Proteins; Genes, p53; Genes, Reporter; Genetic Vectors; Humans; Intracellular Signaling Peptides and Proteins; Liver; Liver Neoplasms; Luciferases; Mutation; Plasmids; Polymerase Chain Reaction; Promoter Regions, Genetic; Proteins; Sulfites; Transfection; Tumor Suppressor Protein p53 | 2004 |
Induction of gene expression by 5-Aza-2'-deoxycytidine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) but not epithelial cells by DNA-methylation-dependent and -independent mechanisms.
Topics: Acute Disease; Apoptosis; Azacitidine; Base Sequence; Cell Division; Decitabine; DNA Methylation; DNA Primers; Epithelial Cells; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Myeloid; Myelodysplastic Syndromes; Polymerase Chain Reaction | 2005 |
Effects of DNA methylation inhibitor on down-regulation of ribonuclease inhibitor expression in cancer cell lines.
Topics: Azacitidine; Breast Neoplasms; Cell Line, Tumor; Colonic Neoplasms; Decitabine; DNA Methylation; DNA Modification Methylases; Down-Regulation; Female; Humans; Male; Nerve Tissue Proteins; Prostatic Neoplasms; RNA, Messenger; Stomach Neoplasms | 2004 |
Issues regarding study design for initial clinical trials using decitabine.
Topics: Azacitidine; Clinical Protocols; Clinical Trials as Topic; Decitabine; Humans; Patient Selection; Research Design | 2004 |
Inactivation of the hMSH3 mismatch repair gene in bladder cancer.
Topics: Azacitidine; Base Pair Mismatch; Biomarkers, Tumor; Carcinoma, Transitional Cell; Cell Line, Tumor; CpG Islands; Decitabine; DNA Methylation; DNA Mutational Analysis; DNA Repair Enzymes; DNA-Binding Proteins; Female; Humans; Male; MutS Homolog 3 Protein; Urinary Bladder Neoplasms | 2004 |
Establishment of a detection system for demethylating agents using an endogenous promoter CpG island.
Topics: Azacitidine; Blotting, Southern; Cell Line, Tumor; Chemistry Techniques, Analytical; CpG Islands; Decitabine; DNA Methylation; DNA Modification Methylases; DNA Primers; Gene Components; Genes; Genetic Markers; Humans; Microscopy, Fluorescence; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction | 2004 |
Silencing of the maternally imprinted tumor suppressor ARHI contributes to follicular thyroid carcinogenesis.
Topics: Adenocarcinoma, Follicular; Adenoma; Antimetabolites, Antineoplastic; Azacitidine; Base Sequence; Decitabine; DNA Primers; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Genes, Tumor Suppressor; Genomic Imprinting; Humans; Loss of Heterozygosity; Reverse Transcriptase Polymerase Chain Reaction; rho GTP-Binding Proteins; Thyroid Neoplasms | 2005 |
Silencing the critics: new studies move closer to answering epigenetic questions.
Topics: Acetylation; Adaptor Proteins, Signal Transducing; Animals; Antimetabolites, Antineoplastic; Azacitidine; Carrier Proteins; Decitabine; DNA Methylation; DNA, Neoplasm; Enzyme Inhibitors; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Histones; Humans; Mutation; MutL Protein Homolog 1; Neoplasm Proteins; Neoplasms; Nuclear Proteins; Phenotype | 2004 |
[Growth and gene expression of leukemia cell after treated with methylation inhibitor 5-aza-2'-deoxycytidine].
Topics: Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Cell Cycle Proteins; Cell Proliferation; Cell Transformation, Neoplastic; Cyclin-Dependent Kinase Inhibitor p15; Decitabine; DNA Methylation; DNA Modification Methylases; Gene Expression Regulation, Neoplastic; HL-60 Cells; Humans; K562 Cells; RNA, Messenger; Tumor Suppressor Proteins | 2004 |
DNA methylation affects cell proliferation, cortisol secretion and steroidogenic gene expression in human adrenocortical NCI-H295R cells.
Topics: Adrenal Cortex; Azacitidine; Bucladesine; Cell Line; Cell Proliferation; Decitabine; DNA Methylation; Gene Expression Regulation; Humans; Hydrocortisone | 2004 |
Epigenetic inactivation of TFPI-2 as a common mechanism associated with growth and invasion of pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Azacitidine; Base Sequence; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Decitabine; DNA Primers; Glycoproteins; Humans; Hydroxamic Acids; Loss of Heterozygosity; Oligonucleotide Array Sequence Analysis; Pancreatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Transplantation, Heterologous | 2005 |
Methylation and acetylation characteristics of cloned bovine embryos from donor cells treated with 5-aza-2'-deoxycytidine.
Topics: Acetylation; Animals; Azacitidine; Blastocyst; Cattle; Cells, Cultured; Cloning, Organism; Decitabine; DNA Methylation; Enzyme Inhibitors; Female; Fertilization in Vitro; Fibroblasts; Oocytes; Totipotent Stem Cells | 2005 |
Intratumor heterogeneity of cancer/testis antigens expression in human cutaneous melanoma is methylation-regulated and functionally reverted by 5-aza-2'-deoxycytidine.
Topics: Antigens, Neoplasm; Azacitidine; Cell Line, Tumor; Decitabine; DNA Methylation; HLA-B Antigens; Humans; Melanoma; Neoplasm Proteins; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; Skin Neoplasms | 2004 |
5-Aza-2'-deoxycytidine induces p21WAF expression by demethylation of p73 leading to p53-independent apoptosis in myeloid leukemia.
Topics: Apoptosis; Azacitidine; Blotting, Western; Caspase 3; Caspases; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; CpG Islands; Cyclin-Dependent Kinase Inhibitor p21; Cytochromes c; Decitabine; DNA Methylation; DNA-Binding Proteins; Epithelial Cells; Flow Cytometry; G1 Phase; Genes, Tumor Suppressor; HeLa Cells; HL-60 Cells; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Leukocytes, Mononuclear; Membrane Potentials; Microscopy, Fluorescence; Mitochondria; Myelodysplastic Syndromes; Nuclear Proteins; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; RNA; RNA, Messenger; Sulfites; Time Factors; Transfection; Tumor Protein p73; Tumor Suppressor Protein p53; Tumor Suppressor Proteins; U937 Cells; Up-Regulation | 2005 |
Restoration of expression of transforming growth factor-beta type II receptor in murine renal cell carcinoma (renca) cells by 5-Aza-2'-deoxycytidine.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Carcinoma, Renal Cell; Cell Line, Tumor; Decitabine; DNA Methylation; Kidney Neoplasms; Mice; Promoter Regions, Genetic; Protein Serine-Threonine Kinases; Receptor, Transforming Growth Factor-beta Type II; Receptors, Transforming Growth Factor beta; RNA, Messenger; Transforming Growth Factor beta; Transforming Growth Factor beta1 | 2005 |
Hypermethylation of the death-associated protein kinase promoter attenuates the sensitivity to TRAIL-induced apoptosis in human non-small cell lung cancer cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Apoptosis Regulatory Proteins; Azacitidine; Calcium-Calmodulin-Dependent Protein Kinases; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cloning, Molecular; Coloring Agents; Death-Associated Protein Kinases; Decitabine; DNA Fragmentation; DNA Methylation; DNA, Complementary; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fas Ligand Protein; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Lung Neoplasms; Membrane Glycoproteins; Polymerase Chain Reaction; Promoter Regions, Genetic; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tetrazolium Salts; Thiazoles; Time Factors; TNF-Related Apoptosis-Inducing Ligand; Treatment Outcome; Tumor Necrosis Factor-alpha | 2004 |
Growth delay of human pancreatic cancer cells by methylase inhibitor 5-aza-2'-deoxycytidine treatment is associated with activation of the interferon signalling pathway.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Azacitidine; Cisplatin; Decitabine; Deoxycytidine; DNA Methylation; DNA Modification Methylases; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Interferon-gamma; Interferons; Pancreatic Neoplasms; Signal Transduction | 2005 |
Expression of aquaporin-5 in and fluid secretion from immortalized human salivary gland ductal cells by treatment with 5-aza-2'-deoxycytidine: a possibility for improvement of xerostomia in patients with Sjögren's syndrome.
Topics: Aquaporin 5; Aquaporins; Azacitidine; Base Sequence; Cell Line, Transformed; Cell Membrane; CpG Islands; Decitabine; DNA Methylation; Gene Expression Regulation; Genes, Reporter; Humans; Membrane Proteins; Molecular Sequence Data; Promoter Regions, Genetic; Salivary Glands; Sjogren's Syndrome; Xerostomia | 2005 |
Hypermethylation of the promoter region is associated with the loss of MEG3 gene expression in human pituitary tumors.
Topics: Azacitidine; Base Sequence; CpG Islands; Decitabine; DNA Methylation; Exons; Humans; Loss of Heterozygosity; Molecular Sequence Data; Mutation; Pituitary Neoplasms; Promoter Regions, Genetic; Proteins; RNA, Long Noncoding | 2005 |
In vivo haematopoietic activity is induced in neurosphere cells by chromatin-modifying agents.
Topics: Animals; Azacitidine; Chromatin; Decitabine; Diploidy; Genes, bcl-2; Green Fluorescent Proteins; Hematopoiesis; Hematopoietic Stem Cells; Humans; Hydroxamic Acids; In Vitro Techniques; Karyotyping; Mice; Mice, Inbred C57BL; Mice, Transgenic; Multipotent Stem Cells; Neurons; Spheroids, Cellular | 2005 |
Epigenetic regulation of protein phosphatase 2A (PP2A), lymphotactin (XCL1) and estrogen receptor alpha (ER) expression in human breast cancer cells.
Topics: Acetylation; Azacitidine; Breast Neoplasms; Chemokines, C; Decitabine; DNA Methylation; DNA Modification Methylases; Epigenesis, Genetic; Estrogen Receptor alpha; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Lymphokines; Oligonucleotide Array Sequence Analysis; Phosphoprotein Phosphatases; Protein Phosphatase 2; Receptors, Progesterone; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Sialoglycoproteins; Tumor Cells, Cultured | 2004 |
Microarray analysis of gene expression in metastatic gastric cancer cells after incubation with the methylation inhibitor 5-aza-2'-deoxycytidine.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Azacitidine; CpG Islands; Decitabine; DNA Methylation; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Neoplasm Proteins; Oligonucleotide Array Sequence Analysis; Promoter Regions, Genetic; Stomach Neoplasms; Tumor Cells, Cultured | 2004 |
Epigenetic and genetic alterations of p33ING1b in ovarian cancer.
Topics: Adenocarcinoma, Clear Cell; Antimetabolites, Antineoplastic; Azacitidine; Carcinoma, Endometrioid; Case-Control Studies; Cell Cycle Proteins; CpG Islands; Cystadenocarcinoma, Mucinous; Cystadenocarcinoma, Serous; Decitabine; DNA Methylation; DNA-Binding Proteins; Female; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Humans; Immunoenzyme Techniques; Inhibitor of Growth Protein 1; Intracellular Signaling Peptides and Proteins; Loss of Heterozygosity; Mutation; Nuclear Proteins; Ovarian Neoplasms; Ovary; Promoter Regions, Genetic; Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2005 |
Characterization of {gamma}-aminobutyric acid type A receptor-associated protein, a novel tumor suppressor, showing reduced expression in breast cancer.
Topics: Adaptor Proteins, Signal Transducing; Apoptosis Regulatory Proteins; Azacitidine; Breast Neoplasms; Cell Growth Processes; Cell Line, Tumor; Decitabine; DNA Methylation; DNA Mutational Analysis; Down-Regulation; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Humans; Microtubule-Associated Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Subcellular Fractions; Transfection; Up-Regulation | 2005 |
Methylation of the gamma-catenin gene is associated with poor prognosis of renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Azacitidine; Carcinoma, Renal Cell; CpG Islands; Cytoskeletal Proteins; Decitabine; Desmoplakins; Disease Progression; DNA Methylation; DNA, Neoplasm; Enzyme Inhibitors; Female; gamma Catenin; Humans; Kidney; Kidney Neoplasms; Male; Middle Aged; Mutation; Prognosis; Promoter Regions, Genetic; Survival Rate | 2005 |
Regulation of replication at the R/G chromosomal band boundary and pericentromeric heterochromatin of mammalian cells.
Topics: Animals; Azacitidine; Cell Line; Centromere; Chromosome Banding; Decitabine; DNA; DNA Replication; Female; HeLa Cells; Heterochromatin; Histones; Humans; Interphase; Mice; Mitosis; S Phase | 2005 |
Aberrant methylation and silencing of the BNIP3 gene in colorectal and gastric cancer.
Topics: Acetylation; Azacitidine; Base Sequence; Blotting, Western; Cell Line, Tumor; Colorectal Neoplasms; CpG Islands; Decitabine; DNA Methylation; DNA Modification Methylases; DNA, Neoplasm; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Gene Silencing; Histone Deacetylases; Histones; Humans; Membrane Proteins; Microscopy, Confocal; Microscopy, Fluorescence; Proto-Oncogene Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Neoplasm; Sequence Analysis, DNA; Stomach Neoplasms | 2005 |
Increased heparanase expression is caused by promoter hypomethylation and up-regulation of transcriptional factor early growth response-1 in human prostate cancer.
Topics: Aged; Aged, 80 and over; Azacitidine; Base Sequence; Cell Line, Tumor; CpG Islands; Decitabine; DNA Methylation; DNA Modification Methylases; DNA-Binding Proteins; Early Growth Response Protein 1; Enzyme Inhibitors; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Glucuronidase; Humans; Immediate-Early Proteins; Male; Middle Aged; Promoter Regions, Genetic; Prostatic Hyperplasia; Prostatic Neoplasms; Regression Analysis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sequence Analysis, DNA; Transcription Factors; Up-Regulation | 2005 |
Enhancement of antineoplastic action of 5-aza-2'-deoxycytidine by zebularine on L1210 leukemia.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Cell Line, Tumor; Cytidine; Cytidine Deaminase; Decitabine; DNA Methylation; Dose-Response Relationship, Drug; Drug Interactions; Humans; Leukemia L1210; Male; Mice; Pyrimidine Nucleosides; Reverse Transcriptase Polymerase Chain Reaction; Tumor Stem Cell Assay | 2005 |
Aberrant methylation of Reprimo in lung cancer.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cell Cycle; Cell Cycle Proteins; Cell Transformation, Neoplastic; Decitabine; DNA Methylation; Genes, p53; Glycoproteins; Humans; Lung Neoplasms; Lymphocytes; Reverse Transcriptase Polymerase Chain Reaction; Tumor Cells, Cultured | 2005 |
Silencing of the thrombomodulin gene in human malignant melanoma.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cells, Cultured; CpG Islands; Decitabine; DNA Methylation; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Melanocytes; Melanoma; Polymerase Chain Reaction; Promoter Regions, Genetic; RNA, Messenger; Skin Neoplasms; Thrombomodulin | 2005 |
Epigenetic silencing of cellular retinol-binding proteins in nasopharyngeal carcinoma.
Topics: Adult; Aged; Animals; Azacitidine; CpG Islands; Decitabine; DNA Methylation; DNA, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Middle Aged; Nasopharyngeal Neoplasms; Nasopharynx; Promoter Regions, Genetic; Retinoids; Retinol-Binding Proteins; Retinol-Binding Proteins, Cellular; Transplantation, Heterologous; Tumor Cells, Cultured | 2005 |
Role of histone deacetylation in cell-specific expression of endothelial nitric-oxide synthase.
Topics: Azacitidine; Decitabine; DNA Methylation; HeLa Cells; Histone Deacetylase 1; Histone Deacetylase Inhibitors; Histone Deacetylases; Histones; Humans; Hydroxamic Acids; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Promoter Regions, Genetic; Sp1 Transcription Factor | 2005 |
De novo DNA methyltransferases Dnmt3a and Dnmt3b primarily mediate the cytotoxic effect of 5-aza-2'-deoxycytidine.
Topics: Animals; Apoptosis; Azacitidine; Cell Death; Cell Differentiation; Cell Line; COS Cells; Decitabine; DNA; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Adducts; DNA Fragmentation; DNA Methyltransferase 3A; DNA Methyltransferase 3B; DNA Modification Methylases; Dose-Response Relationship, Drug; Embryo, Mammalian; Immunoblotting; Lentivirus; Mice; Mice, Knockout; Microscopy, Fluorescence; Mutation; Stem Cells | 2005 |
Sequential 5-Aza 2'-deoxycytidine/depsipeptide FK228 treatment induces tissue factor pathway inhibitor 2 (TFPI-2) expression in cancer cells.
Topics: Azacitidine; Base Sequence; Cell Line, Tumor; Decitabine; Depsipeptides; DNA Primers; Esophageal Neoplasms; Glycoproteins; Humans; Lung Neoplasms | 2005 |
Differential epigenetic modifications in the FMR1 gene of the fragile X syndrome after reactivating pharmacological treatments.
Topics: Acetylation; Acetylcarnitine; Azacitidine; Cell Line; Chromatin Immunoprecipitation; Decitabine; DNA Methylation; Epigenesis, Genetic; Exons; Fragile X Mental Retardation Protein; Fragile X Syndrome; Histones; Humans; Male; Nerve Tissue Proteins; Polymerase Chain Reaction; Promoter Regions, Genetic; RNA-Binding Proteins | 2005 |
Frequent silencing of DBC1 is by genetic or epigenetic mechanisms in non-small cell lung cancers.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Carcinoma, Non-Small-Cell Lung; Cell Cycle Proteins; Chromosomes, Human, Pair 9; CpG Islands; Decitabine; DNA; DNA Methylation; Epigenesis, Genetic; Female; Gene Deletion; Gene Silencing; Humans; Male; Nerve Tissue Proteins; Promoter Regions, Genetic; Tumor Suppressor Proteins | 2005 |
Release of methyl CpG binding proteins and histone deacetylase 1 from the Estrogen receptor alpha (ER) promoter upon reactivation in ER-negative human breast cancer cells.
Topics: Acetylation; Azacitidine; Breast Neoplasms; Chromatin; Chromatin Immunoprecipitation; Chromosomal Proteins, Non-Histone; CpG Islands; Decitabine; DNA Methylation; DNA-Binding Proteins; Estrogen Receptor alpha; Female; Gene Expression Regulation, Neoplastic; Histone Deacetylase 1; Histone Deacetylase Inhibitors; Histone Deacetylases; Histones; Humans; Methyl-CpG-Binding Protein 2; Promoter Regions, Genetic; Repressor Proteins; Transcription Factors; Tumor Cells, Cultured | 2005 |
Genetic and epigenetic alterations of the candidate tumor-suppressor gene MYO18B, on chromosome arm 22q, in colorectal cancer.
Topics: Acetylation; Azacitidine; Base Sequence; Cell Proliferation; Chromosomes, Human, Pair 22; Colorectal Neoplasms; Decitabine; DNA Primers; Humans; Immunoprecipitation; Mutation; Myosins; Tumor Suppressor Proteins | 2005 |
Co-culture of human CD34+ cells with mesenchymal stem cells increases the survival of CD34+ cells against the 5-aza-deoxycytidine- or trichostatin A-induced cell death.
Topics: Antigens, CD34; Apoptosis; Azacitidine; Cell Differentiation; Cell Proliferation; Cell Size; Cell Survival; Cells, Cultured; Coculture Techniques; Decitabine; Hematopoietic Stem Cells; Humans; Hydroxamic Acids; Mesenchymal Stem Cells; Tissue Engineering | 2005 |
Epigenetic up-regulation of C-C chemokine receptor 7 and C-X-C chemokine receptor 4 expression in melanoma cells.
Topics: Acetylation; Antimetabolites, Antineoplastic; Azacitidine; Cell Movement; Decitabine; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Melanoma; Receptors, CCR7; Receptors, Chemokine; Receptors, CXCR4; RNA, Messenger; Skin Neoplasms; Tumor Cells, Cultured; Up-Regulation | 2005 |
Activation of p53/p21Waf1/Cip1 pathway by 5-aza-2'-deoxycytidine inhibits cell proliferation, induces pro-apoptotic genes and mitogen-activated protein kinases in human prostate cancer cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Cell Cycle Proteins; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Decitabine; DNA Damage; Gene Expression Regulation, Neoplastic; Genes, p53; Humans; Male; Prostatic Neoplasms; Signal Transduction; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2005 |
Methylthioadenosine phosphorylase gene is silenced by promoter hypermethylation in human lymphoma cell line DHL-9: another mechanism of enzyme deficiency.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Base Sequence; Decitabine; DNA Methylation; Gene Silencing; Humans; Lymphoma; Molecular Sequence Data; Polymerase Chain Reaction; Promoter Regions, Genetic; Purine-Nucleoside Phosphorylase; Reverse Transcriptase Polymerase Chain Reaction; Tumor Cells, Cultured | 2005 |
Methylation of the CA9 promoter can modulate expression of the tumor-associated carbonic anhydrase IX in dense carcinoma cell lines.
Topics: Antigens, Neoplasm; Antimetabolites, Antineoplastic; Azacitidine; Biomarkers, Tumor; Carbonic Anhydrase IX; Carbonic Anhydrases; Carcinoma; Carcinoma, Renal Cell; Colonic Neoplasms; Decitabine; DNA Methylation; Female; Fibroblasts; Gene Expression Regulation, Neoplastic; HeLa Cells; Humans; Isoenzymes; Kidney Neoplasms; Promoter Regions, Genetic; Tumor Cells, Cultured; Uterine Cervical Neoplasms | 2005 |
Valproic acid, in combination with all-trans retinoic acid and 5-aza-2'-deoxycytidine, restores expression of silenced RARbeta2 in breast cancer cells.
Topics: Azacitidine; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Chromatin Immunoprecipitation; Decitabine; DNA Primers; Enzyme Inhibitors; Histone Deacetylases; Histones; Humans; Receptors, Retinoic Acid; Reverse Transcriptase Polymerase Chain Reaction; RNA; RNA, Messenger; Time Factors; Tretinoin; Valproic Acid | 2005 |
Aberrant promoter methylation in human DAB2 interactive protein (hDAB2IP) gene in gastrointestinal tumour.
Topics: Azacitidine; Cell Line, Tumor; Decitabine; DNA Methylation; Gastrointestinal Neoplasms; Humans; Hydroxamic Acids; Promoter Regions, Genetic; ras GTPase-Activating Proteins; Sequence Analysis, DNA | 2005 |
Discovery of aberrant expression of R-RAS by cancer-linked DNA hypomethylation in gastric cancer using microarrays.
Topics: Azacitidine; Base Sequence; Cell Line, Tumor; Cell Survival; Cluster Analysis; CpG Islands; Decitabine; DNA Methylation; Gene Expression Regulation, Neoplastic; Genome, Human; GTP Phosphohydrolases; Humans; Hydroxamic Acids; Introns; Molecular Sequence Data; Oligonucleotide Array Sequence Analysis; ras Proteins; RNA Interference; RNA, Small Interfering; Stomach Neoplasms; Transcriptional Activation | 2005 |
Altered expression of topoisomerase IIalpha contributes to cross-resistant to etoposide K562/MX2 cell line by aberrant methylation.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Azacitidine; Blotting, Northern; Carubicin; Cell Line, Tumor; CpG Islands; Decitabine; DNA Methylation; DNA Topoisomerases, Type II; DNA-Binding Proteins; Drug Resistance, Neoplasm; Etoposide; Flow Cytometry; Humans; Immunoblotting; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2005 |
Epigenetic silencing of the protocadherin family member PCDH-gamma-A11 in astrocytomas.
Topics: Astrocytoma; Azacitidine; Base Sequence; Brain; Cadherins; Cell Line, Tumor; CpG Islands; Decitabine; DNA Methylation; Exons; Gene Silencing; Humans; Methylation; Molecular Sequence Data; Oligonucleotide Array Sequence Analysis; Protocadherins; Reverse Transcriptase Polymerase Chain Reaction; Sulfites; Transcription, Genetic | 2005 |
Histone deacetylase inhibitors decrease DNA methyltransferase-3B messenger RNA stability and down-regulate de novo DNA methyltransferase activity in human endometrial cells.
Topics: Azacitidine; Cell Line, Tumor; Decitabine; DNA (Cytosine-5-)-Methyltransferases; Down-Regulation; Endometrial Neoplasms; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; RNA, Messenger | 2005 |
Reversible conversion of immortal human cells from telomerase-positive to telomerase-negative cells.
Topics: Acetylation; Azacitidine; Cell Line, Transformed; Cell Line, Tumor; Cell Transformation, Viral; Chromatin; Decitabine; DNA Methylation; DNA-Binding Proteins; Fibroblasts; Humans; Hydroxamic Acids; Oncogene Proteins, Viral; Polymorphism, Restriction Fragment Length; Promoter Regions, Genetic; Repressor Proteins; Telomerase; Telomere | 2005 |
The essential role of histone H3 Lys9 di-methylation and MeCP2 binding in MGMT silencing with poor DNA methylation of the promoter CpG island.
Topics: Azacitidine; Cell Line, Tumor; Chromosomal Proteins, Non-Histone; CpG Islands; Decitabine; DNA Methylation; DNA-Binding Proteins; Gene Expression; Gene Silencing; Histones; Humans; Hydroxamic Acids; Lysine; Methyl-CpG-Binding Protein 2; O(6)-Methylguanine-DNA Methyltransferase; Polymerase Chain Reaction; Promoter Regions, Genetic; Repressor Proteins; Transcription Factors | 2005 |
TWIST2 demonstrates differential methylation in immunoglobulin variable heavy chain mutated and unmutated chronic lymphocytic leukemia.
Topics: Antimetabolites, Antineoplastic; Azacitidine; B-Lymphocytes; Decitabine; DNA Methylation; DNA Modification Methylases; Gene Expression Regulation, Leukemic; Gene Expression Regulation, Neoplastic; Helix-Loop-Helix Motifs; Humans; Immunoglobulin Heavy Chains; Immunoglobulin Variable Region; Leukemia, Lymphocytic, Chronic, B-Cell; Prognosis; Promoter Regions, Genetic; Repressor Proteins; Somatic Hypermutation, Immunoglobulin; Transcription Factors; Treatment Outcome; Twist-Related Protein 1 | 2005 |
Loss of caspase-1 gene expression in human gastric carcinomas and cell lines.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Carcinoma; Caspase 1; Decitabine; DNA Methylation; Female; Gene Expression Profiling; Histones; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Prognosis; Stomach Neoplasms; Survival Analysis; Tumor Cells, Cultured | 2005 |
Ras-mediated loss of the pro-apoptotic response protein Par-4 is mediated by DNA hypermethylation through Raf-independent and Raf-dependent signaling cascades in epithelial cells.
Topics: Agar; Alleles; Animals; Apoptosis; Apoptosis Regulatory Proteins; Azacitidine; Blotting, Northern; Blotting, Western; Butadienes; Cell Line; Cell Line, Tumor; Cell Transformation, Neoplastic; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Methyltransferase 3A; DNA, Complementary; Down-Regulation; Enzyme Inhibitors; Epithelial Cells; Female; Fibroblasts; Flavonoids; Genetic Vectors; Humans; Intracellular Signaling Peptides and Proteins; Mice; Mutation; NIH 3T3 Cells; Nitriles; Ovary; Phosphatidylinositol 3-Kinases; Polymerase Chain Reaction; raf Kinases; Rats; RNA; RNA, Messenger; Signal Transduction; Up-Regulation | 2005 |
Structural and functional preservation of specific sequences of DNA and mRNA in apoptotic bodies from ES cells.
Topics: Animals; Apoptosis; Azacitidine; Biotinylation; Blotting, Northern; Blotting, Southern; Blotting, Western; Cell Differentiation; Cell Proliferation; Chromatin; Decitabine; Deoxyribonuclease I; DNA; DNA Methylation; Dose-Response Relationship, Drug; Embryo, Mammalian; Flow Cytometry; Mice; Microscopy, Electron; Models, Genetic; Propidium; Protein Biosynthesis; Protein Conformation; RNA, Messenger; Stem Cells; Time Factors; Tretinoin | 2005 |
[Analysis of the methylation in the promoter of LRP15 gene and its expression].
Topics: Azacitidine; Decitabine; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Gene Expression Regulation; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; K562 Cells; Neoplasm Proteins; Polymerase Chain Reaction; Promoter Regions, Genetic | 2005 |
Activation of CMV promoter-controlled glycosyltransferase and beta -galactosidase glycogenes by butyrate, tricostatin A, and 5-aza-2'-deoxycytidine.
Topics: Animals; Azacitidine; beta-Galactosidase; Butyrates; Cell Line, Tumor; Cricetinae; Cricetulus; Cytomegalovirus; Decitabine; DNA Modification Methylases; Drug Synergism; Enzyme Activation; Gene Expression Regulation, Enzymologic; Gene Silencing; Glycosyltransferases; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Promoter Regions, Genetic; RNA, Messenger | 2005 |
RASSF1A suppresses the c-Jun-NH2-kinase pathway and inhibits cell cycle progression.
Topics: Azacitidine; Cell Growth Processes; Cell Line, Tumor; Decitabine; G1 Phase; Humans; JNK Mitogen-Activated Protein Kinases; Lung Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-jun; RNA, Small Interfering; Transfection; Tumor Suppressor Proteins | 2005 |
Methylation of CpG islands in the rat 7-dehydrocholesterol reductase promoter suppresses transcriptional activation.
Topics: Animals; Azacitidine; Base Sequence; Carcinoma, Hepatocellular; CpG Islands; Decitabine; DNA Methylation; Gene Expression Regulation, Enzymologic; Gene Silencing; Humans; Liver Neoplasms; Luciferases; Molecular Sequence Data; Oxidoreductases Acting on CH-CH Group Donors; Promoter Regions, Genetic; Rats; Transcription, Genetic; Transcriptional Activation; Tumor Cells, Cultured | 2005 |
Inhibition of chromatin condensation prevents transgene silencing in a neural progenitor cell line transplanted to the rat brain.
Topics: Animals; Azacitidine; Brain; Brain Tissue Transplantation; Cell Line, Transformed; Chromatin Assembly and Disassembly; Decitabine; Enzyme Inhibitors; Female; Gene Silencing; Heterochromatin; Hydroxamic Acids; Rats; Rats, Sprague-Dawley; Stem Cell Transplantation; Stem Cells; Transgenes | 2005 |
Aberrant CpG island hypermethylation profile is associated with atypical and anaplastic meningiomas.
Topics: Adult; Aged; Azacitidine; CpG Islands; Decitabine; DNA Methylation; Female; Humans; Male; Meningioma; Middle Aged; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction | 2005 |
CpG methylation at promoter site -140 inactivates TGFbeta2 receptor gene in prostate cancer.
Topics: Azacitidine; CpG Islands; Decitabine; DNA Methylation; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Male; Promoter Regions, Genetic; Prostatic Neoplasms; Protein Serine-Threonine Kinases; Receptor, Transforming Growth Factor-beta Type II; Receptors, Transforming Growth Factor beta; RNA, Messenger; Tumor Cells, Cultured | 2005 |
Silencing of the Tropomyosin-1 gene by DNA methylation alters tumor suppressor function of TGF-beta.
Topics: Azacitidine; Base Sequence; Breast Neoplasms; Cell Line, Tumor; Decitabine; DNA Methylation; Exons; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Genes, Tumor Suppressor; Humans; Introns; Molecular Sequence Data; Neoplasm Metastasis; Promoter Regions, Genetic; RNA, Messenger; Transforming Growth Factor beta; Tropomyosin | 2005 |
5-Aza-deoxycytidine induces selective degradation of DNA methyltransferase 1 by a proteasomal pathway that requires the KEN box, bromo-adjacent homology domain, and nuclear localization signal.
Topics: Anaphase-Promoting Complex-Cyclosome; Animals; Antimetabolites, Antineoplastic; Aphidicolin; Azacitidine; Catalytic Domain; Cell Nucleus; Cells, Cultured; Cysteine Proteinase Inhibitors; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Replication; Humans; Mice; Mutation; Nuclear Localization Signals; Phosphorylation; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Structure, Tertiary; Rats; Ubiquitin; Ubiquitin-Protein Ligase Complexes | 2005 |
Expression and methylation status of the FHIT gene in acute myeloid leukemia and myelodysplastic syndrome.
Topics: Acid Anhydride Hydrolases; Acute Disease; Azacitidine; Bone Marrow; Cell Cycle Proteins; Cyclin-Dependent Kinase Inhibitor p15; Decitabine; DNA Methylation; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Humans; Leukemia, Myeloid; Myelodysplastic Syndromes; Neoplasm Proteins; Recurrence; RNA, Messenger; Tumor Suppressor Proteins | 2005 |
Insensitivity to transforming growth factor-beta results from promoter methylation of cognate receptors in human prostate cancer cells (LNCaP).
Topics: Azacitidine; Chromatin Immunoprecipitation; CpG Islands; Decitabine; DNA Methylation; Humans; Male; Phosphorylation; Promoter Regions, Genetic; Prostatic Neoplasms; Receptors, Transforming Growth Factor beta; Transforming Growth Factor beta; Tumor Cells, Cultured; Up-Regulation | 2005 |
Distribution of the chromatin protein DEK distinguishes active and inactive CD21/CR2 gene in pre- and mature B lymphocytes.
Topics: Azacitidine; B-Lymphocytes; Cell Differentiation; Cell Line; Chromatin; Chromosomal Proteins, Non-Histone; Decitabine; Gene Expression Regulation; Humans; Oncogene Proteins; Poly-ADP-Ribose Binding Proteins; Promoter Regions, Genetic; Receptors, Complement 3d | 2005 |
Resistance to Fas-mediated apoptosis is restored by cycloheximide through the downregulation of cellular FLIPL in NK/T-cell lymphoma.
Topics: Antibodies, Monoclonal; Apoptosis; Apoptosis Regulatory Proteins; Azacitidine; Calcium-Calmodulin-Dependent Protein Kinases; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspases; Cell Proliferation; Cell Survival; Cycloheximide; Death-Associated Protein Kinases; Decitabine; Down-Regulation; Enzyme Activation; Etoposide; fas Receptor; Humans; Intracellular Signaling Peptides and Proteins; Jurkat Cells; Killer Cells, Natural; Lymphoma, T-Cell, Peripheral; Protein Synthesis Inhibitors | 2005 |
Antileukemia activity of the combination of 5-aza-2'-deoxycytidine with valproic acid.
Topics: Antibiotics, Antineoplastic; Apoptosis; Azacitidine; Cell Line, Tumor; Decitabine; DNA Primers; Drug Synergism; Gene Expression Regulation, Neoplastic; HL-60 Cells; Humans; Leukemia, T-Cell; Reverse Transcriptase Polymerase Chain Reaction; Valproic Acid | 2005 |
Interleukin 6 supports the maintenance of p53 tumor suppressor gene promoter methylation.
Topics: Apoptosis; Azacitidine; Base Sequence; Cell Cycle; Cell Line, Tumor; Cytidine; Decitabine; Deoxycytidine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Gene Silencing; Genes, p53; Humans; Interleukin-6; Molecular Sequence Data; Multiple Myeloma; Promoter Regions, Genetic; Sulfites; Tumor Suppressor Protein p53 | 2005 |
[5-Aza-2'-deoxycytidine enhances differentiation and apoptosis induced by phenylbutyrate in Kasumi-1 cells].
Topics: Acute Disease; Apoptosis; Azacitidine; CD11b Antigen; CD13 Antigens; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Decitabine; Dose-Response Relationship, Drug; Drug Synergism; Humans; Leukemia, Myeloid; Phenylbutyrates | 2005 |
The controversial denouement of vertebrate DNA methylation research.
Topics: Animals; Azacitidine; Decitabine; DNA Methylation; DNA Modification Methylases; Dosage Compensation, Genetic; Gene Expression Regulation, Developmental; Genomic Imprinting; Neoplasms; Vertebrates | 2005 |
Multiple markers for melanoma progression regulated by DNA methylation: insights from transcriptomic studies.
Topics: Animals; Azacitidine; Biomarkers, Tumor; Cell Cycle Proteins; Decitabine; Disease Progression; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Epigenesis, Genetic; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Melanoma, Experimental; Mice; Mice, Nude; Oligonucleotide Array Sequence Analysis; RNA, Messenger; RNA, Neoplasm; Skin Neoplasms; Transplantation, Heterologous; Tumor Cells, Cultured | 2005 |
Hyperacetylation enhances the growth-inhibitory effect of all-trans retinoic acid by the restoration of retinoic acid receptor beta expression in head and neck squamous carcinoma (HNSCC) cells.
Topics: Acetylation; Antineoplastic Agents; Azacitidine; Carcinoma, Squamous Cell; Cell Line, Tumor; Decitabine; DNA Methylation; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Lysine; Promoter Regions, Genetic; Receptors, Retinoic Acid; Tretinoin | 2005 |
Aberrant methylation of the Human Hedgehog interacting protein (HHIP) gene in pancreatic neoplasms.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Azacitidine; Carrier Proteins; Decitabine; DNA Methylation; DNA Modification Methylases; DNA, Neoplasm; Epithelial Cells; Gene Expression Regulation, Neoplastic; Humans; Membrane Glycoproteins; Pancreas; Pancreatic Ducts; Pancreatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Tumor Cells, Cultured | 2005 |
Methylation silencing of the Apaf-1 gene in acute leukemia.
Topics: 5' Untranslated Regions; Antimetabolites, Antineoplastic; Apoptotic Protease-Activating Factor 1; Azacitidine; Cell Line, Tumor; CpG Islands; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Gene Expression Regulation, Neoplastic; Gene Silencing; Genes, Tumor Suppressor; Histone Deacetylase Inhibitors; HL-60 Cells; Humans; Jurkat Cells; K562 Cells; Leukemia, Myeloid, Acute; Promoter Regions, Genetic; Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; U937 Cells | 2005 |
Contribution of epigenetic silencing of tumor necrosis factor-related apoptosis inducing ligand receptor 1 (DR4) to TRAIL resistance and ovarian cancer.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Apoptosis Regulatory Proteins; Azacitidine; Cell Line, Tumor; Decitabine; Drug Resistance, Neoplasm; Epigenesis, Genetic; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Immunohistochemistry; Membrane Glycoproteins; Oligonucleotide Array Sequence Analysis; Ovarian Neoplasms; Polymerase Chain Reaction; Promoter Regions, Genetic; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor-alpha | 2005 |
Granulocyte-macrophage colony-stimulating factor induces de novo methylation of the p15 CpG island in hematopoietic cells.
Topics: Azacitidine; Base Sequence; Cell Differentiation; Cell Line, Tumor; Cells, Cultured; CpG Islands; Cyclin-Dependent Kinase Inhibitor p15; Decitabine; DNA Methylation; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cells; Humans; Hydroxamic Acids; Molecular Sequence Data; Myeloid Cells; Sequence Analysis, DNA | 2005 |
Epigenetic down-regulation of CDKN1C/p57KIP2 in pancreatic ductal neoplasms identified by gene expression profiling.
Topics: Adenocarcinoma, Mucinous; Adenocarcinoma, Papillary; Azacitidine; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cluster Analysis; Cyclin-Dependent Kinase Inhibitor p57; Decitabine; Down-Regulation; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Hydroxamic Acids; Immunohistochemistry; Oligonucleotide Array Sequence Analysis; Pancreatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction | 2005 |
Promoter characterization of Semaphorin SEMA3F, a tumor suppressor gene.
Topics: Azacitidine; Base Sequence; Blotting, Southern; Cell Line, Tumor; Computational Biology; CpG Islands; Decitabine; DNA Methylation; DNA Primers; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Luciferases; Membrane Proteins; Molecular Sequence Data; Nerve Tissue Proteins; Plasmids; Polymerase Chain Reaction; Promoter Regions, Genetic; RNA | 2005 |
Genetic and epigenetic alterations of RB2/p130 tumor suppressor gene in human sporadic retinoblastoma: implications for pathogenesis and therapeutic approach.
Topics: Azacitidine; Base Sequence; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Decitabine; DNA Methylation; DNA Mutational Analysis; DNA Primers; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Humans; Immunohistochemistry; Molecular Sequence Data; Proteins; Retinal Neoplasms; Retinoblastoma; Retinoblastoma-Like Protein p130 | 2005 |
Introduction: emerging role of epigenetic therapy: focus on decitabine.
Topics: Azacitidine; Decitabine; DNA Modification Methylases; Epigenesis, Genetic; Humans; Neoplasms; Treatment Outcome | 2005 |
Epigenetic-mediated upregulation of progesterone receptor B gene in endometrial cancer cell lines.
Topics: Adenocarcinoma; Azacitidine; Cell Line, Tumor; Decitabine; DNA Methylation; Endometrial Neoplasms; Enzyme Inhibitors; Epigenesis, Genetic; Female; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Polymerase Chain Reaction; Receptors, Progesterone; RNA, Messenger; Up-Regulation | 2005 |
5-Aza-2'-deoxycytidine (decitabine) can relieve p21WAF1 repression in human acute myeloid leukemia by a mechanism involving release of histone deacetylase 1 (HDAC1) without requiring p21WAF1 promoter demethylation.
Topics: Acylation; Azacitidine; Chromatin Assembly and Disassembly; Cyclin-Dependent Kinase Inhibitor p21; Decitabine; DNA Methylation; Enzyme Inhibitors; Histone Deacetylase 1; Histone Deacetylase Inhibitors; Histone Deacetylases; Histones; Humans; Hydroxamic Acids; K562 Cells; Leukemia, Myeloid, Acute; Neoplasm Proteins; Promoter Regions, Genetic; Protein Processing, Post-Translational; Tumor Suppressor Protein p53 | 2006 |
Induction of HLA-G expression in a melanoma cell line OCM-1A following the treatment with 5-aza-2'-deoxycytidine.
Topics: Azacitidine; Calreticulin; Cell Line, Tumor; Choriocarcinoma; Decitabine; Gene Expression Regulation, Neoplastic; Histocompatibility Antigens Class I; HLA Antigens; HLA-G Antigens; Humans; Melanoma; Methylation; Promoter Regions, Genetic; Transcription, Genetic | 2005 |
Differential promotion of glutamate transporter expression and function by glucocorticoids in astrocytes from various brain regions.
Topics: Adrenal Cortex Hormones; Amino Acid Transport System X-AG; Animals; Astrocytes; Azacitidine; Blotting, Western; Brain; Central Nervous System; Cerebellum; Corticosterone; Decitabine; Detergents; Dexamethasone; DNA Methylation; DNA Modification Methylases; DNA Primers; Dose-Response Relationship, Drug; Fluorescent Dyes; Glucocorticoids; Immunohistochemistry; Kainic Acid; Ligands; Luciferases; Membrane Microdomains; Mifepristone; Neuroglia; Rats; Rats, Sprague-Dawley; Receptors, Mineralocorticoid; Reverse Transcriptase Polymerase Chain Reaction; Time Factors; Transfection; Up-Regulation | 2005 |
Characterization of DNA demethylation effects induced by 5-Aza-2'-deoxycytidine in patients with myelodysplastic syndrome.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Enzyme Inhibitors; HCT116 Cells; Humans; Jurkat Cells; Myelodysplastic Syndromes | 2005 |
P-cadherin overexpression is an indicator of clinical outcome in invasive breast carcinomas and is associated with CDH3 promoter hypomethylation.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Azacitidine; Biomarkers, Tumor; Blotting, Western; Breast Neoplasms; Cadherins; Cell Line, Tumor; Decitabine; DNA Methylation; Female; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Ki-67 Antigen; Middle Aged; Neoplasm Invasiveness; Predictive Value of Tests; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Analysis; Tumor Suppressor Protein p53 | 2005 |
Inactivation of monocarboxylate transporter MCT3 by DNA methylation in atherosclerosis.
Topics: Aorta; Atherosclerosis; Azacitidine; Biological Transport; Cell Proliferation; Cells, Cultured; CpG Islands; Decitabine; DNA Methylation; Humans; Lactic Acid; Membrane Transport Proteins; Monocarboxylic Acid Transporters; Muscle, Smooth, Vascular; Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Symporters | 2005 |
Conditional expression of the CTCF-paralogous transcriptional factor BORIS in normal cells results in demethylation and derepression of MAGE-A1 and reactivation of other cancer-testis genes.
Topics: Animals; Antigens, Neoplasm; Azacitidine; Base Sequence; Cell Line, Tumor; Decitabine; DNA Methylation; DNA-Binding Proteins; Fibroblasts; Gene Expression Regulation, Neoplastic; Genetic Vectors; Humans; Immunohistochemistry; Melanoma-Specific Antigens; Molecular Sequence Data; Neoplasm Proteins; Nucleic Acid Conformation; Promoter Regions, Genetic; Protein Binding; Retroviridae; RNA, Small Interfering; Transcriptional Activation; Transfection | 2005 |
The role of T-fimbrin in the response to DNA damage: silencing of T-fimbrin by small interfering RNA sensitizes human liver cancer cells to DNA-damaging agents.
Topics: Actins; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Azacitidine; Carcinogens; Cell Cycle; Cell Line, Tumor; Cell Separation; Cytoskeleton; Decitabine; DNA Damage; DNA Methylation; Etoposide; Flow Cytometry; G2 Phase; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Immunoblotting; Liver Neoplasms; Membrane Glycoproteins; Microfilament Proteins; Microscopy, Fluorescence; Protein Isoforms; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; RNA, Small Interfering; Time Factors; Transfection; Ultraviolet Rays | 2005 |
5-aza-2'-deoxycytidine sensitizes hepatoma and pancreatic cancer cell lines.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Azacitidine; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Decitabine; DNA; DNA Methylation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fluorouracil; HeLa Cells; Humans; Liver Neoplasms; Pancreatic Neoplasms; Prognosis; Time Factors; Treatment Outcome; Trypan Blue | 2005 |
Hypermethylation of the RUNX3 gene in hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Azacitidine; Carcinoma, Hepatocellular; Decitabine; DNA Methylation; DNA, Neoplasm; Female; Humans; Liver Neoplasms; Male; Middle Aged; Promoter Regions, Genetic | 2005 |
Approaches to the reactivation of hemoglobin F as a treatment for sickle cell disease.
Topics: Acetylation; Anemia, Sickle Cell; Azacitidine; Clinical Trials as Topic; CpG Islands; Decitabine; Disease Management; DNA Methylation; Erythrocytes, Abnormal; Fetal Hemoglobin; Gene Silencing; Globins; Hemoglobin, Sickle; Histone Deacetylase Inhibitors; Humans; Hydroxyurea; Phenylbutyrates; Protein Processing, Post-Translational; Up-Regulation | 2004 |
The retinoic acid synthesis gene ALDH1a2 is a candidate tumor suppressor in prostate cancer.
Topics: Aldehyde Dehydrogenase; Aldehyde Dehydrogenase 1 Family; Azacitidine; Base Sequence; Cell Line, Tumor; Decitabine; DNA Methylation; Enzyme Inhibitors; Gene Expression Profiling; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Humans; Isoenzymes; Male; Molecular Sequence Data; Neoplastic Stem Cells; Promoter Regions, Genetic; Prostate; Prostatic Neoplasms; Retinal Dehydrogenase; Tretinoin | 2005 |
GADD45 deregulation in cancer: frequently methylated tumor suppressors and potential therapeutic targets.
Topics: Amino Acid Sequence; Antimetabolites, Antineoplastic; Azacitidine; Cell Cycle Proteins; Cell Line; Cell Line, Tumor; CpG Islands; Decitabine; DNA Methylation; DNA Modification Methylases; Gene Expression Regulation, Neoplastic; Humans; Models, Biological; Molecular Sequence Data; Neoplasms; Nuclear Proteins; Prognosis; Promoter Regions, Genetic; Sequence Homology, Amino Acid; Tumor Suppressor Proteins | 2005 |
The stress-responsive gene GADD45G is a functional tumor suppressor, with its response to environmental stresses frequently disrupted epigenetically in multiple tumors.
Topics: Antigens, Differentiation; Antimetabolites, Antineoplastic; Azacitidine; Base Sequence; Cell Cycle Proteins; Cell Line; Cell Line, Tumor; Cell Proliferation; CpG Islands; Decitabine; DNA Methylation; DNA Modification Methylases; Gene Expression Regulation, Neoplastic; HeLa Cells; HL-60 Cells; Hot Temperature; HT29 Cells; Humans; Intracellular Signaling Peptides and Proteins; K562 Cells; Mutation; Neoplasms; Nuclear Proteins; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; Tumor Suppressor Proteins | 2005 |
Cytogenetic and expression profiles associated with transformation to androgen-resistant prostate cancer.
Topics: Androgens; Azacitidine; Cell Line, Tumor; Chromosome Aberrations; Chromosomes, Human, Pair 13; Chromosomes, Human, Pair 2; Decitabine; Disease Progression; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Methyltransferase 3A; Gene Expression; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Male; Methyltransferases; Nucleic Acid Hybridization; Oligonucleotide Array Sequence Analysis; Prostatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Spectral Karyotyping | 2006 |
Trapped in action: direct visualization of DNA methyltransferase activity in living cells.
Topics: Animals; Azacitidine; Cell Nucleus; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Replication; Fluorescence Recovery After Photobleaching; Green Fluorescent Proteins; Humans; Mice; Photochemistry; Recombinant Fusion Proteins | 2005 |
Multi-gene epigenetic silencing of tumor suppressor genes in T-cell lymphoma cells; delayed expression of the p16 protein upon reversal of the silencing.
Topics: Adult; Anaplastic Lymphoma Kinase; Azacitidine; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p15; Decitabine; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Epigenesis, Genetic; Gene Expression Regulation, Leukemic; Gene Silencing; Humans; Lymphoma, T-Cell, Cutaneous; Promoter Regions, Genetic; Protein Biosynthesis; Protein-Tyrosine Kinases; Receptor Protein-Tyrosine Kinases; Skin Neoplasms; Time Factors; Tumor Suppressor Protein p14ARF | 2006 |
Epigenetic repression of RASSF1A but not CASP8 in supratentorial PNET (sPNET) and atypical teratoid/rhabdoid tumors (AT/RT) of childhood.
Topics: Adolescent; Adult; Azacitidine; Brain Neoplasms; Caspase 8; Caspases; Child; Child, Preschool; CpG Islands; Decitabine; DNA Methylation; Epigenesis, Genetic; Female; Gene Silencing; Humans; Hydroxamic Acids; Infant; Male; Neuroectodermal Tumors, Primitive; Promoter Regions, Genetic; Rhabdoid Tumor; Teratoma; Tumor Suppressor Proteins | 2006 |
Decitabine activates specific caspases downstream of p73 in myeloid leukemia.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Caspase 3; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Decitabine; DNA Methylation; DNA-Binding Proteins; Enzyme Activation; Humans; Leukemia, Myeloid, Acute; Nuclear Proteins; Promoter Regions, Genetic; Tumor Protein p73; Tumor Suppressor Proteins | 2005 |
Potentiation of in vitro ara-C cytotoxicity by ribonucleotide reductase inhibitors, cyclin-dependent kinase modulators and the DNA repair inhibitor aphidicolin in paediatric acute myeloid leukaemia.
Topics: Antimetabolites, Antineoplastic; Aphidicolin; Azacitidine; Child; Cyclin-Dependent Kinases; Cytarabine; Decitabine; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Leukemia, Myeloid, Acute; Leukocytes, Mononuclear; Nucleic Acid Synthesis Inhibitors; Ribonucleotide Reductases | 2005 |
Reversal of hypermethylation and reactivation of p16INK4a, RARbeta, and MGMT genes by genistein and other isoflavones from soy.
Topics: Anticarcinogenic Agents; Antineoplastic Agents; Azacitidine; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p16; Decitabine; DNA Methylation; Dose-Response Relationship, Drug; Esophageal Neoplasms; Genistein; Glycine max; Humans; Hydroxamic Acids; Isoflavones; Isothiocyanates; O(6)-Methylguanine-DNA Methyltransferase; Receptors, Retinoic Acid; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sulfites; Sulfoxides; Tea; Thiocyanates | 2005 |
Activator protein 2alpha status determines the chemosensitivity of cancer cells: implications in cancer chemotherapy.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Breast Neoplasms; Cell Line, Tumor; Decitabine; DNA Methylation; Gene Silencing; Humans; Mice; Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; RNA, Small Interfering; Transcription Factor AP-2 | 2005 |
The cell cycle checkpoint gene Rad9 is a novel oncogene activated by 11q13 amplification and DNA methylation in breast cancer.
Topics: Azacitidine; Base Sequence; Breast Neoplasms; Breast Neoplasms, Male; Cell Cycle Proteins; Cell Growth Processes; Cell Line, Tumor; Chromosomes, Human, Pair 11; Cyclin D1; Decitabine; DNA Methylation; Female; Gene Amplification; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Introns; Male; Middle Aged; Molecular Sequence Data; RNA, Messenger | 2005 |
Expression and methylation pattern of TSLC1 cascade genes in lung carcinomas.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Carcinoma; Carcinoma, Non-Small-Cell Lung; Cell Adhesion Molecule-1; Cell Adhesion Molecules; Decitabine; DNA Methylation; Gene Expression Regulation, Neoplastic; Humans; Immunoglobulins; Lung Neoplasms; Membrane Proteins; Microfilament Proteins; Nuclear Proteins; Oligonucleotide Array Sequence Analysis; Transcription Factors; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2006 |
[Inhibitory effect of 5-Aza-2'-deoxycytidine on human nasopharyngeal carcinoma xenograft in nude mice].
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis Regulatory Proteins; Azacitidine; Calcium-Calmodulin-Dependent Protein Kinases; Cell Line, Tumor; Cell Proliferation; Death-Associated Protein Kinases; Decitabine; DNA Methylation; DNA Modification Methylases; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Nasopharyngeal Neoplasms; Neoplasm Transplantation; RNA, Messenger | 2005 |
Decitabine: a historical review of the development of an epigenetic drug.
Topics: Anemia, Sickle Cell; Azacitidine; Decitabine; DNA Modification Methylases; Drug Design; Epigenesis, Genetic; History, 20th Century; History, 21st Century; Humans; Myelodysplastic Syndromes; Transplantation Conditioning | 2005 |
DNA methylation in the treatment of hematologic malignancies.
Topics: Azacitidine; Decitabine; DNA Methylation; Enzyme Inhibitors; Hematologic Neoplasms; Humans | 2005 |
Antimitogenic and chemosensitizing effects of the methylation inhibitor zebularine in ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cell Growth Processes; Cell Line, Tumor; Cisplatin; Cytidine; Decitabine; DNA Methylation; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Genes, Tumor Suppressor; Humans; Ovarian Neoplasms | 2005 |
Comparison of biological effects of non-nucleoside DNA methylation inhibitors versus 5-aza-2'-deoxycytidine.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Carcinoma, Transitional Cell; Catechin; Cell Line, Tumor; Colorectal Neoplasms; Cytidine; Decitabine; Deoxycytidine; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Female; Gene Silencing; HT29 Cells; Humans; Hydralazine; Male; Procainamide; Prostatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction | 2005 |
Butyrates and decitabine cooperate to induce histone acetylation and granulocytic maturation of t(8;21) acute myeloid leukemia blasts.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Butyrates; Cell Differentiation; Cell Line, Tumor; Cell Transformation, Neoplastic; Decitabine; DNA Modification Methylases; Epigenesis, Genetic; Gene Silencing; Granulocytes; Histone Deacetylase Inhibitors; Humans; Leukemia, Myeloid, Acute; Mannose; Translocation, Genetic | 2005 |
Molecular inhibition of histone deacetylation results in major enhancement of the production of IL-1beta in response to LPS.
Topics: Acetylation; Azacitidine; Decidua; Decitabine; DNA Methylation; Enzyme Inhibitors; Female; Histones; Humans; Hydroxamic Acids; In Vitro Techniques; Interleukin-1; Interleukin-10; Pregnancy; Tumor Necrosis Factor-alpha | 2006 |
Hypermethylation of 18S and 28S ribosomal DNAs predicts progression-free survival in patients with ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Azacitidine; Cell Line, Tumor; Decitabine; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA, Ribosomal; Female; Gene Expression Regulation, Neoplastic; Humans; Middle Aged; Multivariate Analysis; Ovarian Neoplasms; Prognosis; RNA, Ribosomal, 18S; RNA, Ribosomal, 28S; Survival Analysis | 2005 |
Functional epigenetics identifies a protocadherin PCDH10 as a candidate tumor suppressor for nasopharyngeal, esophageal and multiple other carcinomas with frequent methylation.
Topics: Azacitidine; Cadherins; Carcinoma; Cell Movement; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Methyltransferase 3B; Epigenesis, Genetic; Esophageal Neoplasms; Gene Silencing; Genes, Tumor Suppressor; Humans; Nasopharyngeal Neoplasms; Promoter Regions, Genetic; Protocadherins; Sequence Deletion; Transcription, Genetic | 2006 |
Phenotypic and functional changes of human melanoma xenografts induced by DNA hypomethylation: immunotherapeutic implications.
Topics: Animals; Antibody Formation; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Methylation; Female; Gene Expression; Histocompatibility Antigens Class I; HLA-A1 Antigen; HLA-A2 Antigen; Humans; Immunotherapy; Melanoma-Specific Antigens; Melanoma, Experimental; Membrane Proteins; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Proteins; Tumor Cells, Cultured; Vaccination; Xenograft Model Antitumor Assays | 2006 |
CpG methylation of the PAI-1 gene 5'-flanking region is inversely correlated with PAI-1 mRNA levels in human cell lines.
Topics: 5' Flanking Region; Azacitidine; Carcinoma, Squamous Cell; CpG Islands; Decitabine; DNA; DNA Methylation; DNA Modification Methylases; Dose-Response Relationship, Drug; Gene Expression Regulation, Neoplastic; Gene Silencing; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Mouth Neoplasms; Plasminogen Activator Inhibitor 1; RNA, Messenger; Sequence Analysis, DNA; Time Factors; U937 Cells | 2005 |
Clinical experience with decitabine in North American patients with myelodysplastic syndrome.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Clinical Trials as Topic; Decitabine; DNA Modification Methylases; Dose-Response Relationship, Drug; Drug Administration Schedule; Histone Deacetylase Inhibitors; Humans; Myelodysplastic Syndromes; North America; Valproic Acid | 2005 |
The methyltransferase inhibitor 5-aza-2-deoxycytidine induces apoptosis via induction of 15-lipoxygenase-1 in colorectal cancer cells.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Arachidonate 15-Lipoxygenase; Azacitidine; Blotting, Western; Caspase 3; Caspases; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Decitabine; DNA Fragmentation; DNA Primers; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Gene Silencing; Genes, Tumor Suppressor; Humans; RNA, Small Interfering; Time Factors; Transcription, Genetic; Up-Regulation | 2005 |
Quantification of outpatient management and hospitalization of patients with high-risk myelodysplastic syndrome treated with low-dose decitabine.
Topics: Aged; Aged, 80 and over; Ambulatory Care; Antineoplastic Agents; Azacitidine; Case-Control Studies; Decitabine; DNA Modification Methylases; Female; Humans; Length of Stay; Male; Matched-Pair Analysis; Middle Aged; Myelodysplastic Syndromes; Quality of Life; Retrospective Studies; Survival Analysis | 2005 |
5-Aza-2'-deoxycytidine induces retinoic acid receptor-beta(2) demethylation and growth inhibition in esophageal squamous carcinoma cells.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Decitabine; DNA Methylation; DNA Modification Methylases; Esophageal Neoplasms; Esophagus; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Receptors, Retinoic Acid; RNA, Messenger | 2005 |
Epigenetic processes play a major role in B-cell-specific gene silencing in classical Hodgkin lymphoma.
Topics: Azacitidine; B-Lymphocytes; Cell Line, Tumor; Decitabine; DNA Methylation; Down-Regulation; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Gene Silencing; Hodgkin Disease; Humans; Promoter Regions, Genetic; Reed-Sternberg Cells; Transcription Factors | 2006 |
Effects of 5-aza-2'-deoxycytidine on proliferation, differentiation and p15/INK4b regulation of human hematopoietic progenitor cells.
Topics: Antigens, CD34; Azacitidine; Cell Differentiation; Cell Proliferation; Cells, Cultured; Cyclin-Dependent Kinase Inhibitor p15; Decitabine; Dose-Response Relationship, Drug; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Humans; In Vitro Techniques; Male; Muramidase | 2006 |
Loss of interleukin-2-dependency in HTLV-I-infected T cells on gene silencing of thioredoxin-binding protein-2.
Topics: Acetylation; Azacitidine; Carrier Proteins; Cell Line, Tumor; Cell Transformation, Viral; Chromatin Immunoprecipitation; CpG Islands; Decitabine; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Gene Expression Regulation, Viral; Gene Silencing; Histone Deacetylase Inhibitors; Histones; Human T-lymphotropic virus 1; Humans; Hydroxamic Acids; Interleukin-2; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; T-Lymphocytes; Thioredoxins; Transcription, Genetic; Vorinostat | 2006 |
BRCA1 promoter methylation in sporadic breast cancer is associated with reduced BRCA1 copy number and chromosome 17 aneusomy.
Topics: Aneuploidy; Antimetabolites, Antineoplastic; Azacitidine; BRCA1 Protein; Breast; Breast Neoplasms; Cell Line, Tumor; Chromosomes, Human, Pair 17; Decitabine; DNA Methylation; Female; Gene Dosage; Gene Expression; Genes, BRCA1; Humans; Hydroxamic Acids; Lymphocytes; Middle Aged; Promoter Regions, Genetic; RNA, Messenger | 2005 |
Loss of the tissue-specific proapoptotic BH3-only protein Nbk/Bik is a unifying feature of renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Apoptosis; Apoptosis Regulatory Proteins; Azacitidine; Carcinoma, Renal Cell; Cell Line, Tumor; Decitabine; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Female; Gene Deletion; Gene Expression Regulation, Neoplastic; Humans; Kidney Neoplasms; Loss of Heterozygosity; Male; Membrane Proteins; Middle Aged; Mitochondrial Proteins; RNA, Messenger; Transfection; Tumor Suppressor Proteins | 2006 |
Aberrant promoter methylation of EDNRB in lung cancer in Taiwan.
Topics: Azacitidine; Decitabine; DNA Methylation; Down-Regulation; Female; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Promoter Regions, Genetic; Receptor, Endothelin B; Sequence Analysis, DNA; Taiwan | 2006 |
Site-specific DNA methylation by a complex of PU.1 and Dnmt3a/b.
Topics: Animals; Azacitidine; Chromatin Immunoprecipitation; Cyclin-Dependent Kinase Inhibitor p16; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Methyltransferase 3A; DNA Methyltransferase 3B; Histone Deacetylase Inhibitors; Histone Deacetylases; Hydroxamic Acids; Immunoprecipitation; Mice; NIH 3T3 Cells; Promoter Regions, Genetic; Proto-Oncogene Proteins; Trans-Activators; Transcription, Genetic | 2006 |
Inhibition of DNA methylation sensitizes glioblastoma for tumor necrosis factor-related apoptosis-inducing ligand-mediated destruction.
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Azacitidine; Caspase 8; Caspases; Decitabine; DNA Methylation; DNA Modification Methylases; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Glioblastoma; Histocompatibility Antigens Class I; Humans; Intracellular Signaling Peptides and Proteins; Male; Membrane Glycoproteins; Mice; Mice, Nude; Middle Aged; Phosphoproteins; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor; Signal Transduction; TNF-Related Apoptosis-Inducing Ligand; Transplantation, Heterologous; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 2005 |
Chemical genomic screening for methylation-silenced genes in gastric cancer cell lines using 5-aza-2'-deoxycytidine treatment and oligonucleotide microarray.
Topics: Adult; Aged; Aged, 80 and over; Azacitidine; Cell Line, Tumor; Decitabine; Delta-5 Fatty Acid Desaturase; DNA Methylation; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Genomics; Humans; Male; Middle Aged; Oligonucleotide Array Sequence Analysis; Stomach Neoplasms; Up-Regulation | 2006 |
RAS-mediated epigenetic inactivation of OPCML in oncogenic transformation of human ovarian surface epithelial cells.
Topics: Azacitidine; Cell Adhesion Molecules; Cell Line, Transformed; Cell Transformation, Neoplastic; CpG Islands; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Epigenesis, Genetic; Epithelial Cells; Female; Gene Silencing; Genes, ras; GPI-Linked Proteins; Humans; Ovarian Neoplasms; Ovary; Promoter Regions, Genetic; Proto-Oncogene Proteins p21(ras); RNA, Small Interfering; Signal Transduction | 2006 |
Homozygous deletion and reduced expression of the DOCK8 gene in human lung cancer.
Topics: Azacitidine; Base Sequence; Cell Line, Tumor; Cloning, Molecular; Decitabine; DNA Methylation; DNA Modification Methylases; Down-Regulation; Epithelial Cells; Gene Deletion; Gene Expression Regulation, Neoplastic; Guanine Nucleotide Exchange Factors; Histone Deacetylase Inhibitors; Homozygote; Humans; Hydroxamic Acids; Lung Neoplasms; Molecular Sequence Data; Transfection | 2006 |
A novel mechanism for acquired cisplatin-resistance: suppressed translation of death-associated protein kinase mRNA is insensitive to 5-aza-2'-deoxycitidine and trichostatin in cisplatin-resistant cervical squamous cancer cells.
Topics: Antineoplastic Agents; Apoptosis Regulatory Proteins; Azacitidine; Calcium-Calmodulin-Dependent Protein Kinases; Carcinoma, Squamous Cell; Cell Line, Tumor; Cisplatin; Death-Associated Protein Kinases; Decitabine; DNA Methylation; DNA Modification Methylases; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Hydroxamic Acids; Promoter Regions, Genetic; Protein Biosynthesis; Protein Synthesis Inhibitors; RNA, Messenger; Uterine Cervical Neoplasms | 2006 |
Inhibition of DNA methyltransferase activity prevents tumorigenesis in a mouse model of prostate cancer.
Topics: Animals; Antigens, Viral, Tumor; Antimetabolites, Antineoplastic; Azacitidine; Cell Growth Processes; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Enzyme Activation; Enzyme Inhibitors; Gene Expression; Humans; Male; Mice; Mice, Inbred C57BL; Prostate; Prostatic Neoplasms; Transgenes | 2006 |
Alterations of the Wnt signaling pathway during the neoplastic progression of Barrett's esophagus.
Topics: Adenocarcinoma; Azacitidine; Barrett Esophagus; beta Catenin; Cell Division; Cell Line, Tumor; CpG Islands; Decitabine; Disease Progression; DNA Methylation; DNA, Neoplasm; Esophageal Neoplasms; Gene Expression Regulation; Gene Expression Regulation, Neoplastic; Gene Silencing; Genes, APC; Humans; Intercellular Signaling Peptides and Proteins; Membrane Proteins; Mucous Membrane; Neoplasm Proteins; Precancerous Conditions; Promoter Regions, Genetic; RNA, Messenger; RNA, Neoplasm; RNA, Small Interfering; Signal Transduction; Transfection; Wnt Proteins; Wnt2 Protein | 2006 |
Regulation of high molecular weight-melanoma associated antigen (HMW-MAA) gene expression by promoter DNA methylation in human melanoma cells.
Topics: Antigens, Neoplasm; Azacitidine; Decitabine; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Humans; Lymphocytes; Melanoma; Promoter Regions, Genetic; Tumor Cells, Cultured | 2006 |
The dioxin receptor is silenced by promoter hypermethylation in human acute lymphoblastic leukemia through inhibition of Sp1 binding.
Topics: Azacitidine; Base Sequence; Cell Line, Tumor; Chromatin Immunoprecipitation; CpG Islands; Decitabine; DNA Methylation; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Molecular Sequence Data; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Promoter Regions, Genetic; Protein Binding; Receptors, Aryl Hydrocarbon; Sp1 Transcription Factor | 2006 |
Epigenetic suppression of secreted frizzled related protein 1 (SFRP1) expression in human breast cancer.
Topics: Acetylation; Azacitidine; Breast; Breast Neoplasms; Cell Line; Cell Line, Tumor; Decitabine; DNA Methylation; Down-Regulation; Epigenesis, Genetic; Genes, Tumor Suppressor; Histones; Humans; Hydroxamic Acids; Intracellular Signaling Peptides and Proteins; Polymerase Chain Reaction; Promoter Regions, Genetic; Proteins; Reverse Transcriptase Polymerase Chain Reaction; Sequence Analysis, DNA | 2006 |
[The synergistic inhibitory effect of 5-aza-2-deoxycytidine and Tamoxifen on estrogen receptor alpha negative breast cancer cell lines in vitro].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Breast Neoplasms; Cell Line, Tumor; Decitabine; Drug Synergism; Estrogen Receptor alpha; Female; Gene Expression Regulation, Neoplastic; Humans; Middle Aged; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tamoxifen | 2005 |
Epigenetic regulation of the tumor suppressor gene TCF21 on 6q23-q24 in lung and head and neck cancer.
Topics: Animals; Azacitidine; Basic Helix-Loop-Helix Transcription Factors; Cell Cycle; Cell Line, Tumor; Chromosomes, Human, Pair 6; Decitabine; DNA Methylation; Dose-Response Relationship, Drug; Epigenesis, Genetic; Gene Expression Regulation; Gene Silencing; Genome; Head and Neck Neoplasms; Humans; Immunohistochemistry; Loss of Heterozygosity; Luciferases; Lung; Lung Neoplasms; Mice; Mice, Nude; Models, Genetic; Neoplasm Transplantation; Open Reading Frames; Plasmids; Promoter Regions, Genetic; Retroviridae; Reverse Transcriptase Polymerase Chain Reaction; Sulfites; Time Factors; Transfection | 2006 |
Promoter hypermethylation of FANCF plays an important role in the occurrence of ovarian cancer through disrupting Fanconi anemia-BRCA pathway.
Topics: Animals; Azacitidine; Cell Line, Tumor; Cell Proliferation; Decitabine; DNA Methylation; Fanconi Anemia; Fanconi Anemia Complementation Group F Protein; Female; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Ovarian Neoplasms; Ovary; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction | 2006 |
CpG island methylation and expression of the secreted frizzled-related protein gene family in chronic lymphocytic leukemia.
Topics: Azacitidine; Cell Transformation, Neoplastic; CpG Islands; Decitabine; DNA Methylation; Dose-Response Relationship, Drug; Gene Expression Profiling; Gene Silencing; Humans; Intercellular Signaling Peptides and Proteins; Leukemia, Lymphocytic, Chronic, B-Cell; Membrane Proteins; Proto-Oncogene Proteins; Signal Transduction; Wnt Proteins | 2006 |
De novo induction of a cancer/testis antigen by 5-aza-2'-deoxycytidine augments adoptive immunotherapy in a murine tumor model.
Topics: Animals; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Azacitidine; Chromatin; CpG Islands; Decitabine; DNA Methylation; Gene Expression Profiling; Humans; Immunotherapy, Adoptive; Lung Neoplasms; Mammary Neoplasms, Animal; Mice; Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Transplantation, Heterologous; Tumor Cells, Cultured | 2006 |
Tumor-specific expression of the novel cytochrome P450 enzyme, CYP2W1.
Topics: Adrenal Gland Neoplasms; Animals; Arachidonic Acid; Azacitidine; Blotting, Western; Catalysis; Cell Line; Cell Line, Tumor; Cloning, Molecular; Colon; Colonic Neoplasms; CpG Islands; Cytochrome P-450 Enzyme System; Cytochrome P450 Family 2; Decitabine; DNA Methylation; Exons; Gene Expression Regulation; Gene Expression Regulation, Neoplastic; Humans; Introns; Mixed Function Oxygenases; Protein Folding; Protein Isoforms; Rats; RNA, Messenger; Transfection | 2006 |
Expression of Lea in gastric cancer cell lines depends on FUT3 expression regulated by promoter methylation.
Topics: Antigens, Neoplasm; Azacitidine; Cell Line, Tumor; Decitabine; DNA Methylation; DNA Primers; Fucosyltransferases; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Luciferases; Plasmids; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; Stomach Neoplasms | 2006 |
Wnt signaling activation and WIF-1 silencing in nasopharyngeal cancer cell lines.
Topics: Adaptor Proteins, Signal Transducing; Azacitidine; Blotting, Western; Carcinoma; Carrier Proteins; Cell Line, Tumor; Decitabine; DNA Methylation; DNA, Complementary; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Nasopharyngeal Neoplasms; Promoter Regions, Genetic; Repressor Proteins; Reverse Transcriptase Polymerase Chain Reaction; Sequence Analysis, DNA; Signal Transduction; Transfection; Wnt Proteins | 2006 |
Epigenetic inactivation of Wnt inhibitory factor-1 plays an important role in bladder cancer through aberrant canonical Wnt/beta-catenin signaling pathway.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Base Sequence; beta Catenin; Carcinoma, Transitional Cell; Carrier Proteins; Cell Line, Tumor; Cyclin D1; Decitabine; DNA Modification Methylases; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Humans; Middle Aged; Molecular Sequence Data; Proto-Oncogene Proteins c-myc; Repressor Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Signal Transduction; Urinary Bladder Neoplasms; Wnt Proteins | 2006 |
Current therapy of sickle cell disease.
Topics: Acetamides; Anemia, Sickle Cell; Azacitidine; Butyrates; Decitabine; Erythrocyte Transfusion; Humans; Hydroxyurea; Nitric Oxide; Trityl Compounds | 2006 |
Discovery of novel methylation biomarkers in cervical carcinoma by global demethylation and microarray analysis.
Topics: Azacitidine; Biomarkers, Tumor; Cell Line, Tumor; Cervix Uteri; CpG Islands; Decitabine; DNA Methylation; DNA, Neoplasm; Enzyme Inhibitors; Female; Gene Expression Regulation, Neoplastic; Genes, Neoplasm; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Microarray Analysis; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; Up-Regulation; Uterine Cervical Neoplasms | 2006 |
Expansion of human umbilical cord blood SCID-repopulating cells using chromatin-modifying agents.
Topics: Animals; Antigens, CD34; Azacitidine; Cells, Cultured; Chromatin; Cord Blood Stem Cell Transplantation; Cytokines; Decitabine; Hematopoietic Stem Cells; Humans; Hydroxamic Acids; Mice; Mice, Inbred NOD; Mice, SCID; Severe Combined Immunodeficiency; Thy-1 Antigens; Transplantation, Heterologous | 2006 |
Inhibition of DNA methylation increases follistatin expression and secretion in the human adrenocortical cell line NCI-H295R.
Topics: Adrenal Cortex; Azacitidine; Cell Line; Decitabine; DNA Methylation; Dose-Response Relationship, Drug; Enzyme Inhibitors; Follistatin; Gene Expression Regulation; Humans; Peptides; Protein Isoforms; RNA, Messenger | 2006 |
Trisomy 19 as the sole chromosomal abnormality in proliferative chronic myelomonocytic leukemia.
Topics: Aged; Azacitidine; Chromosome Aberrations; Chromosomes, Human, Pair 19; Cytarabine; Cytogenetic Analysis; Daunorubicin; Decitabine; Dose-Response Relationship, Drug; Fatal Outcome; Female; Humans; Hydroxyurea; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Phenotype; Steroids; Treatment Outcome | 2006 |
Accurate quantification of DNA methylation using combined bisulfite restriction analysis coupled with the Agilent 2100 Bioanalyzer platform.
Topics: Azacitidine; Cell Line, Tumor; CpG Islands; Decitabine; DNA Methylation; DNA Restriction Enzymes; Electrophoresis, Microchip; Humans; Molecular Diagnostic Techniques; Neoplasms; Polymerase Chain Reaction; Reproducibility of Results; Sulfites | 2006 |
Aberrant methylation of the eyes absent 4 gene in ulcerative colitis-associated dysplasia.
Topics: Azacitidine; Biomarkers; Cell Line; Chronic Disease; Colitis, Ulcerative; Colonic Neoplasms; Colonic Polyps; Decitabine; Humans; Hydroxamic Acids; Methylation; Polymerase Chain Reaction; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Trans-Activators | 2006 |
Methylation of the human papillomavirus-18 L1 gene: a biomarker of neoplastic progression?
Topics: Azacitidine; Biomarkers, Tumor; Capsid Proteins; Cervix Uteri; Decitabine; DNA Methylation; DNA Modification Methylases; DNA-Binding Proteins; DNA, Viral; Enzyme Inhibitors; Female; HeLa Cells; Humans; Oncogene Proteins, Viral; Papillomaviridae; Proviruses; Regulatory Elements, Transcriptional; Uterine Cervical Neoplasms; Viral Proteins | 2006 |
PDLIM4 repression by hypermethylation as a potential biomarker for prostate cancer.
Topics: Aged; Azacitidine; Biomarkers, Tumor; Cell Line, Tumor; Cyclooxygenase 2; Decitabine; DNA Methylation; DNA Modification Methylases; DNA-Binding Proteins; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Glutathione S-Transferase pi; Humans; LIM Domain Proteins; Male; Membrane Proteins; Microfilament Proteins; Middle Aged; Nerve Tissue Proteins; Polymerase Chain Reaction; Prostatic Neoplasms | 2006 |
High-frequency promoter hypermethylation of the deleted in liver cancer-1 gene in multiple myeloma.
Topics: Azacitidine; Base Sequence; Bone Marrow; Decitabine; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Female; GTPase-Activating Proteins; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Male; Middle Aged; Molecular Sequence Data; Multiple Myeloma; Neoplasm Proteins; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Tumor Cells, Cultured; Tumor Suppressor Proteins; Up-Regulation | 2006 |
Epigenetic inactivation of the Wnt antagonist DICKKOPF-1 (DKK-1) gene in human colorectal cancer.
Topics: Adaptor Proteins, Signal Transducing; Adenomatous Polyposis Coli Protein; Animals; Antimetabolites, Antineoplastic; Azacitidine; Carrier Proteins; Cell Transformation, Neoplastic; Colon; Colorectal Neoplasms; CpG Islands; Decitabine; DNA Methylation; Epigenesis, Genetic; Epithelium; Genes, Tumor Suppressor; Humans; Intercellular Signaling Peptides and Proteins; Mice; Mice, Nude; Neoplasm Transplantation; Promoter Regions, Genetic; Repressor Proteins; Signal Transduction; Transplantation, Heterologous; Wnt Proteins | 2006 |
New agents in the treatment of MDS.
Topics: Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials, Phase III as Topic; Decitabine; Enzyme Inhibitors; Humans; Indoles; Lenalidomide; Myelodysplastic Syndromes; Predictive Value of Tests; Thalidomide; Treatment Outcome | 2005 |
The miscarriage-associated HLA-G -725G allele influences transcription rates in JEG-3 cells.
Topics: Abortion, Spontaneous; Alleles; Azacitidine; Decitabine; DNA-Cytosine Methylases; Female; Haplotypes; Histocompatibility Antigens Class I; HLA Antigens; HLA-G Antigens; Humans; Interferon-beta; Mutagenesis, Site-Directed; Polymorphism, Single Nucleotide; Pregnancy; Promoter Regions, Genetic; Transcription, Genetic; Tumor Cells, Cultured | 2006 |
Functional diversity of DNA methyltransferase inhibitors in human cancer cell lines.
Topics: Azacitidine; Catechin; Cell Line, Tumor; Cytidine; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Enzyme Inhibitors; Humans; Indoles; Jurkat Cells; Phthalimides; Procaine; Propionates; Tryptophan | 2006 |
p21Waf1/Cip1 plays a critical role in modulating senescence through changes of DNA methylation.
Topics: Azacitidine; Cell Line; Cell Proliferation; Cellular Senescence; Cyclin-Dependent Kinase Inhibitor p16; Cyclin-Dependent Kinase Inhibitor p21; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Methyltransferase 3A; Gene Expression Regulation; Humans; Promoter Regions, Genetic; RNA Interference; Signal Transduction | 2006 |
Effect of methylation-associated silencing of the death-associated protein kinase gene on nasopharyngeal carcinoma.
Topics: Adult; Aged; Animals; Apoptosis Regulatory Proteins; Azacitidine; Base Sequence; Calcium-Calmodulin-Dependent Protein Kinases; Cell Cycle; Cell Growth Processes; Cell Line, Tumor; Death-Associated Protein Kinases; Decitabine; DNA Methylation; Female; Gene Silencing; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Molecular Sequence Data; Nasopharyngeal Neoplasms; Polymerase Chain Reaction; Promoter Regions, Genetic; RNA, Messenger; Xenograft Model Antitumor Assays | 2006 |
Characterization of decomposition products and preclinical and low dose clinical pharmacokinetics of decitabine (5-aza-2'-deoxycytidine) by a new liquid chromatography/tandem mass spectrometry quantification method.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Blood Chemical Analysis; Chromatography, High Pressure Liquid; Decitabine; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Humans; Male; Metabolic Clearance Rate; Rats; Rats, Sprague-Dawley; Spectrometry, Mass, Electrospray Ionization; Spectrophotometry, Ultraviolet | 2006 |
Drug therapy for myelodysplastic syndrome: building evidence for action.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Methylation; DNA Modification Methylases; Humans; Myelodysplastic Syndromes | 2006 |
Aberrant methylation and deacetylation of deleted in liver cancer-1 gene in prostate cancer: potential clinical applications.
Topics: Acetylation; Adult; Aged; Aged, 80 and over; Azacitidine; Base Sequence; Blotting, Southern; Blotting, Western; Chromatin Immunoprecipitation; Decitabine; DNA Methylation; Down-Regulation; Enzyme Inhibitors; Gene Deletion; GTPase-Activating Proteins; Humans; Male; Middle Aged; Molecular Sequence Data; Promoter Regions, Genetic; Prostate; Prostatic Hyperplasia; Prostatic Neoplasms; RNA, Messenger; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2006 |
Effect of 5-aza-2'-deoxycytidine (Dacogen) on covalent histone modifications of chromatin associated with the epsilon-, gamma-, and beta-globin promoters in Papio anubis.
Topics: Animals; Azacitidine; Base Sequence; Chromatin; Chromatin Immunoprecipitation; Decitabine; DNA Primers; Globins; Histones; Papio; Promoter Regions, Genetic | 2006 |
Lactate dehydrogenase-B is silenced by promoter hypermethylation in human prostate cancer.
Topics: Amino Acid Sequence; Azacitidine; Base Sequence; Bone Neoplasms; Decitabine; DNA Methylation; DNA Modification Methylases; DNA, Neoplasm; Electrophoresis, Gel, Two-Dimensional; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Isoenzymes; L-Lactate Dehydrogenase; Male; Molecular Sequence Data; Promoter Regions, Genetic; Prostatic Neoplasms; Proteomics; Tumor Cells, Cultured | 2006 |
Irinotecan inactivation is modulated by epigenetic silencing of UGT1A1 in colon cancer.
Topics: Azacitidine; Camptothecin; Cell Line, Tumor; CpG Islands; Decitabine; DNA Methylation; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Glucuronides; Glucuronosyltransferase; HCT116 Cells; HT29 Cells; Humans; Hydroxamic Acids; Irinotecan | 2006 |
GnT-V expression and metastatic phenotypes in macrophage-melanoma fusion hybrids is down-regulated by 5-Aza-dC: evidence for methylation sensitive, extragenic regulation of GnT-V transcription.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Base Sequence; Consensus Sequence; Decitabine; DNA Methylation; Down-Regulation; Gene Expression Regulation, Neoplastic; Macrophages, Peritoneal; Melanoma, Experimental; Mice; Mice, Inbred DBA; Molecular Sequence Data; N-Acetylglucosaminyltransferases; Neoplasm Metastasis; Phenotype; Promoter Regions, Genetic; Recombinant Fusion Proteins; Transcription, Genetic | 2006 |
Oncogenic HRAS suppresses clusterin expression through promoter hypermethylation.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Cell Line, Transformed; Clusterin; Decitabine; DNA Methylation; Genes, ras; Genes, Suppressor; Hydroxamic Acids; Promoter Regions, Genetic; Rats; Signal Transduction | 2006 |
A single nucleotide polymorphism chip-based method for combined genetic and epigenetic profiling: validation in decitabine therapy and tumor/normal comparisons.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Blotting, Southern; Decitabine; DNA Methylation; DNA, Neoplasm; Epigenesis, Genetic; Gene Dosage; Humans; Kidney Neoplasms; Leukemia, Myeloid, Acute; Oligonucleotide Array Sequence Analysis; Polymorphism, Single Nucleotide; Reproducibility of Results; Sulfites; Wilms Tumor | 2006 |
Silenced tumor suppressor genes reactivated by DNA demethylation do not return to a fully euchromatic chromatin state.
Topics: Adaptor Proteins, Signal Transducing; Azacitidine; Carrier Proteins; Cell Line, Tumor; Chromatin; Colorectal Neoplasms; Decitabine; DNA Methylation; Gene Silencing; Genes, Tumor Suppressor; HCT116 Cells; Histones; Humans; Intercellular Signaling Peptides and Proteins; Membrane Proteins; MutL Protein Homolog 1; Nuclear Proteins; Promoter Regions, Genetic | 2006 |
PGP9.5 methylation in diffuse-type gastric cancer.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Base Sequence; Cell Line, Tumor; Decitabine; DNA Methylation; Genes, Tumor Suppressor; Humans; Molecular Sequence Data; Oligonucleotide Array Sequence Analysis; Promoter Regions, Genetic; Stomach Neoplasms; Ubiquitin Thiolesterase | 2006 |
Gene promoter hypermethylation in mouse lung tumors.
Topics: Animals; Azacitidine; Biomarkers, Tumor; Cadherins; CpG Islands; Decitabine; DNA Methylation; DNA Modification Methylases; DNA, Neoplasm; Estrogen Receptor alpha; Gene Silencing; Genes, Neoplasm; Humans; Lung Neoplasms; Mice; Promoter Regions, Genetic; Receptors, Progesterone; TCF Transcription Factors; Transcription Factor 7-Like 1 Protein | 2006 |
5-Aza-2'-deoxycytidine and IFN-gamma cooperate to sensitize for TRAIL-induced apoptosis by upregulating caspase-8.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Azacitidine; Caspase 8; Caspases; Cell Line, Tumor; Cell Survival; Cerebellar Neoplasms; Decitabine; Gene Expression Regulation, Enzymologic; Humans; Interferon-gamma; Medulloblastoma; Membrane Glycoproteins; Neuroblastoma; Recombinant Proteins; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor-alpha | 2006 |
Altered nuclear receptor corepressor expression attenuates vitamin D receptor signaling in breast cancer cells.
Topics: Azacitidine; Breast Neoplasms; Calcitriol; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cholecalciferol; Decitabine; Female; Humans; Hydroxamic Acids; Nuclear Proteins; Nuclear Receptor Co-Repressor 1; Receptors, Calcitriol; Repressor Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Structure-Activity Relationship; Time Factors; Tumor Cells, Cultured | 2006 |
Methylation status of the Ep-CAM promoter region in human breast cancer cell lines and breast cancer tissue.
Topics: Antigens, Neoplasm; Azacitidine; Breast; Breast Neoplasms; Cell Adhesion Molecules; Cell Line, Tumor; Colon; CpG Islands; Decitabine; DNA Methylation; Epithelial Cell Adhesion Molecule; Female; Gene Expression Regulation, Neoplastic; Humans; Intestinal Mucosa; Promoter Regions, Genetic; RNA, Messenger | 2007 |
Imprinting at the SMPD1 locus: implications for acid sphingomyelinase-deficient Niemann-Pick disease.
Topics: Adult; Animals; Azacitidine; Beckwith-Wiedemann Syndrome; Cells, Cultured; Chlorocebus aethiops; Chromosomes, Human, Pair 11; COS Cells; Decitabine; DNA Methylation; Genomic Imprinting; Heterozygote; Humans; Male; Mutation; Niemann-Pick Diseases; Pedigree; Polymorphism, Single Nucleotide; Reverse Transcriptase Polymerase Chain Reaction; Sequence Analysis, DNA; Sphingomyelin Phosphodiesterase; Transfection | 2006 |
Lytic induction and apoptosis of Epstein-Barr virus-associated gastric cancer cell line with epigenetic modifiers and ganciclovir.
Topics: Apoptosis; Azacitidine; Cell Line, Tumor; Decitabine; DNA Methylation; DNA Modification Methylases; Ganciclovir; Herpesvirus 4, Human; Humans; Hydroxamic Acids; Protein Processing, Post-Translational; Signal Transduction; Stomach Neoplasms; Virus Activation | 2007 |
Nickel ions increase histone H3 lysine 9 dimethylation and induce transgene silencing.
Topics: Animals; Azacitidine; Blotting, Western; Carcinoma; Cell Line; Cell Line, Tumor; Cell Survival; Chromatin Immunoprecipitation; Decitabine; DNA Methylation; Dose-Response Relationship, Drug; Electrophoresis, Polyacrylamide Gel; Enzyme Inhibitors; Epigenesis, Genetic; Fibroblasts; Gene Silencing; Histones; Humans; Kinetics; Lung Neoplasms; Lysine; Methyltransferases; Mice; Nickel; Trace Elements; Transgenes | 2006 |
Sequential gene expression changes in cancer cell lines after treatment with the demethylation agent 5-Aza-2'-deoxycytidine.
Topics: Azacitidine; Carcinoma, Hepatocellular; Decitabine; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Neoplasm Proteins; Tumor Cells, Cultured | 2006 |
Epigenetic inactivation of Betaig-h3 gene in human cancer cells.
Topics: Azacitidine; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; CpG Islands; Decitabine; DNA Methylation; Epigenesis, Genetic; Extracellular Matrix Proteins; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Genes, Reporter; Humans; Luciferases; Lung Neoplasms; Male; Neoplasms; Promoter Regions, Genetic; Prostatic Neoplasms; Transforming Growth Factor beta | 2006 |
Analysis of genes upregulated by the demethylating agent 5-aza-2'-deoxycytidine in gastric cancer cell lines.
Topics: Azacitidine; Base Sequence; Cell Line, Tumor; Cell Proliferation; Decitabine; DNA, Complementary; Gene Expression Regulation, Neoplastic; Genome, Human; Humans; Methylation; Oligonucleotide Array Sequence Analysis; RNA, Messenger; Stomach Neoplasms; Sulfates; Time Factors; Up-Regulation | 2006 |
Promoter demethylation and histone acetylation mediate gene expression of MAGE-A1, -A2, -A3, and -A12 in human cancer cells.
Topics: Acetylation; Antigens, Neoplasm; Azacitidine; Blotting, Western; Cell Line, Tumor; Corynebacterium; Decitabine; DNA Methylation; DNA Modification Methylases; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Histone Deacetylases; Histones; Humans; Hydroxamic Acids; Melanoma-Specific Antigens; Neoplasm Proteins; Neoplasms; Promoter Regions, Genetic | 2006 |
Aberrant DNA demethylation in promoter region and aberrant expression of mRNA of PAX4 gene in hematologic malignancies.
Topics: Azacitidine; Cell Line; Cell Proliferation; Decitabine; DNA Methylation; Gene Expression Profiling; Homeodomain Proteins; Humans; Lymphadenitis; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Paired Box Transcription Factors; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sensitivity and Specificity | 2006 |
Identification of novel target genes by an epigenetic reactivation screen of renal cancer.
Topics: Adult; Aged; Azacitidine; Base Sequence; Carcinoma, Renal Cell; Cell Line, Tumor; Collagen Type I; Collagen Type I, alpha 1 Chain; Decitabine; DNA Methylation; Epigenesis, Genetic; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Hydroxamic Acids; Insulin-Like Growth Factor Binding Protein 1; Insulin-Like Growth Factor Binding Protein 3; Kidney Neoplasms; Male; Middle Aged; Molecular Sequence Data; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; RNA, Neoplasm; Up-Regulation | 2006 |
DNA methylation changes after 5-aza-2'-deoxycytidine therapy in patients with leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Methylation; Dose-Response Relationship, Drug; Female; Genes, p53; Homeodomain Proteins; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; RNA, Long Noncoding; RNA, Untranslated | 2006 |
[Transcription regulation of 5-Aza-2'-deoxycytidine on maspin gene demethylation in RKO human colorectal cell line].
Topics: Azacitidine; Cell Line, Tumor; CpG Islands; Decitabine; DNA Methylation; Gene Expression Regulation, Neoplastic; Humans; Serpins; Transcription, Genetic | 2006 |
DNA mismatch repair as an effector for promoting phorbol ester-induced apoptotic DNA damage and cell killing: implications in tumor promotion.
Topics: Apoptosis; Azacitidine; Base Pair Mismatch; Cell Line, Tumor; CpG Islands; Decitabine; DNA; DNA Damage; DNA Repair; DNA-Binding Proteins; Humans; Methylation; Neoplasms; Phorbol Esters; Protein Kinase C; Protein Kinase Inhibitors; Reactive Oxygen Species | 2006 |
Differential regulation of the alcohol dehydrogenase 1B (ADH1B) and ADH1C genes by DNA methylation and histone deacetylation.
Topics: Alcohol Dehydrogenase; Azacitidine; Carcinoma, Hepatocellular; Cell Line, Tumor; Decitabine; DNA Methylation; Enzyme Inhibitors; Epigenesis, Genetic; Gene Expression Regulation, Enzymologic; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Liver Neoplasms; Promoter Regions, Genetic | 2006 |
Decitabine: in myelodysplastic syndromes.
Topics: Antimetabolites, Antineoplastic; Area Under Curve; Azacitidine; Clinical Trials as Topic; Decitabine; Humans; Molecular Structure; Myelodysplastic Syndromes; Treatment Outcome | 2006 |
Decitabine in myelodysplastic syndromes: viewpoints.
Topics: Antimetabolites, Antineoplastic; Area Under Curve; Azacitidine; Clinical Trials as Topic; Decitabine; Humans; Molecular Structure; Myelodysplastic Syndromes; Treatment Outcome | 2006 |
Second complete remission in an elderly patient with acute myeloid leukemia retreated with decitabine.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Humans; Leukemia, Myeloid, Acute; Male; Recurrence; Remission Induction; Time Factors | 2006 |
Regulation of myofibroblast transdifferentiation by DNA methylation and MeCP2: implications for wound healing and fibrogenesis.
Topics: Animals; Azacitidine; Cell Differentiation; CpG Islands; Decitabine; DNA Methylation; Epigenesis, Genetic; Fibroblasts; Hepatocytes; Humans; I-kappa B Proteins; Liver; Liver Cirrhosis; Male; Methyl-CpG-Binding Protein 2; Mice; Models, Genetic; NF-KappaB Inhibitor alpha; Promoter Regions, Genetic; Rats; Rats, Sprague-Dawley; Repressor Proteins; RNA, Messenger; Transcription, Genetic; Wound Healing | 2007 |
Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells.
Topics: Azacitidine; Cell Line, Tumor; Chromatin; CpG Islands; Decitabine; DNA Methylation; DNA-Binding Proteins; Down-Regulation; Epigenesis, Genetic; Histone Deacetylase Inhibitors; Humans; MicroRNAs; Phenylbutyrates; Promoter Regions, Genetic; Proto-Oncogene Mas; Proto-Oncogene Proteins c-bcl-6 | 2006 |
Restoration of tamoxifen sensitivity in estrogen receptor-negative breast cancer cells: tamoxifen-bound reactivated ER recruits distinctive corepressor complexes.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Breast Neoplasms; Cell Line, Tumor; Decitabine; DNA (Cytosine-5-)-Methyltransferases; Drug Synergism; Estrogen Antagonists; Estrogen Receptor alpha; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Mi-2 Nucleosome Remodeling and Deacetylase Complex; Promoter Regions, Genetic; Repressor Proteins; RNA, Messenger; Sin3 Histone Deacetylase and Corepressor Complex; Tamoxifen | 2006 |
Effect of histone deacetylase inhibitor LAQ824 on antineoplastic action of 5-Aza-2'-deoxycytidine (decitabine) on human breast carcinoma cells.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Colony-Forming Units Assay; Decitabine; DNA; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Female; Flow Cytometry; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Inhibitory Concentration 50; Neoplastic Stem Cells; S Phase; Time Factors | 2006 |
Differentially methylated alleles in a distinct region of the human interleukin-1alpha promoter are associated with allele-specific expression of IL-1alpha in CD4+ T cells.
Topics: Alleles; Animals; Azacitidine; CD4-Positive T-Lymphocytes; CpG Islands; Decitabine; DNA Methylation; Enzyme Inhibitors; Gene Expression Regulation; Humans; Interleukin-1; Lymphocytes; Mice; Promoter Regions, Genetic | 2006 |
5-Aza-2'-deoxycytidine-mediated reductions in G9A histone methyltransferase and histone H3 K9 di-methylation levels are linked to tumor suppressor gene reactivation.
Topics: Azacitidine; Cell Line, Tumor; Decitabine; Enzyme Inhibitors; Genes, Tumor Suppressor; Histone Methyltransferases; Histone-Lysine N-Methyltransferase; Histones; Humans; Methylation; Protein Methyltransferases; Reverse Transcriptase Polymerase Chain Reaction | 2007 |
Multiple mechanisms underlie the aberrant expression of the human kallikrein 6 gene in breast cancer.
Topics: Antineoplastic Agents; Azacitidine; Breast Neoplasms; Calcitriol; Cell Line, Tumor; Decitabine; Disease Progression; DNA Methylation; Female; Gene Expression Regulation, Neoplastic; Humans; Hydroxamic Acids; Kallikreins; Promoter Regions, Genetic; Transcription, Genetic | 2006 |
The epigenetic basis for the aberrant expression of kallikreins in human cancers.
Topics: Azacitidine; Breast Neoplasms; Cell Line, Tumor; CpG Islands; Decitabine; Epigenesis, Genetic; Female; Gene Expression Regulation, Neoplastic; Humans; Kallikreins; Male; Neoplasms; Ovarian Neoplasms; Prostatic Neoplasms | 2006 |
Overcoming resistance to interferon-induced apoptosis of renal carcinoma and melanoma cells by DNA demethylation.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Azacitidine; Blotting, Western; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Modification Methylases; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Interferon-alpha; Interferon-beta; Interferons; Intracellular Signaling Peptides and Proteins; Kidney Neoplasms; Melanoma, Experimental; Mice; Mice, Nude; Neoplasm Proteins; Polymerase Chain Reaction; Transplantation, Heterologous; Up-Regulation | 2006 |
Synergic antiproliferative effect of DNA methyltransferase inhibitor in combination with anticancer drugs in gastric carcinoma.
Topics: Antineoplastic Agents; Apoptosis; Azacitidine; Cell Line, Tumor; Cell Proliferation; Decitabine; DNA Modification Methylases; Drug Synergism; Enzyme Inhibitors; Flow Cytometry; Gene Expression; Humans; Reverse Transcriptase Polymerase Chain Reaction; Stomach Neoplasms | 2006 |
RUNX3 is frequently inactivated by dual mechanisms of protein mislocalization and promoter hypermethylation in breast cancer.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Breast Neoplasms; Cell Line, Tumor; Core Binding Factor Alpha 3 Subunit; Decitabine; DNA Methylation; Gene Expression Regulation, Neoplastic; Gene Targeting; Genes, Tumor Suppressor; Humans; Hydroxamic Acids; Promoter Regions, Genetic | 2006 |
Genome-wide analysis of epigenetic silencing identifies BEX1 and BEX2 as candidate tumor suppressor genes in malignant glioma.
Topics: Azacitidine; Brain Neoplasms; Decitabine; DNA Methylation; Gene Expression; Gene Expression Profiling; Gene Silencing; Genes, Tumor Suppressor; Genome, Human; Glioma; Histones; Humans; Hydroxamic Acids; Nerve Tissue Proteins; Promoter Regions, Genetic | 2006 |
Estrogen receptor-alpha methylation predicts melanoma progression.
Topics: Age Factors; Azacitidine; Decitabine; Disease Progression; DNA Methylation; DNA, Neoplasm; Estrogen Receptor alpha; Female; Gene Silencing; Humans; Hydroxamic Acids; Male; Melanoma; Middle Aged; Neoplasm Staging; Promoter Regions, Genetic; Sex Factors | 2006 |
Methylation of neutral endopeptidase 24.11 promoter in rat hepatocellular carcinoma.
Topics: Animals; Azacitidine; Base Sequence; Cell Line, Tumor; CpG Islands; Decitabine; DNA Methylation; DNA Modification Methylases; Gene Expression Regulation, Neoplastic; Liver Neoplasms, Experimental; Male; Molecular Sequence Data; Neprilysin; Oligonucleotide Array Sequence Analysis; Promoter Regions, Genetic; Rats; Rats, Inbred F344; RNA, Messenger; Transcription, Genetic | 2006 |
[Disfigurement of p16INK4A gene expression in development of ovarian cancer and the mechanism].
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p16; Decitabine; DNA Methylation; Female; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Nude; Neoplasm Seeding; Ovarian Neoplasms; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Time Factors; Tumor Burden; Xenograft Model Antitumor Assays | 2006 |
PML-RARalpha and AML1-ETO translocations are rarely associated with methylation of the RARbeta2 promoter.
Topics: Antineoplastic Agents; Azacitidine; Core Binding Factor Alpha 2 Subunit; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Drug Resistance, Neoplasm; Gene Expression Regulation, Leukemic; Histone Deacetylases; HL-60 Cells; Humans; K562 Cells; Leukemia, Promyelocytic, Acute; Oncogene Proteins, Fusion; Promoter Regions, Genetic; Receptors, Retinoic Acid; RNA, Messenger; RNA, Neoplasm; RUNX1 Translocation Partner 1 Protein; Translocation, Genetic; Tretinoin; U937 Cells | 2006 |
Methylation mediated silencing of TMS1/ASC gene in prostate cancer.
Topics: Aged; Aged, 80 and over; Azacitidine; CARD Signaling Adaptor Proteins; Cell Line, Tumor; Chromatin Immunoprecipitation; CpG Islands; Cytoskeletal Proteins; Decitabine; DNA Methylation; DNA Modification Methylases; DNA, Neoplasm; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Gene Silencing; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Male; Middle Aged; Promoter Regions, Genetic; Prostatic Hyperplasia; Prostatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction | 2006 |
Regulation of DNA methylation on the expression of the FHIT gene contributes to cervical carcinoma cell tumorigenesis.
Topics: Acid Anhydride Hydrolases; Apoptosis; Azacitidine; Cell Proliferation; Cells, Cultured; Decitabine; DNA Methylation; DNA Modification Methylases; Endothelium, Vascular; Enzyme Inhibitors; Female; Flow Cytometry; G1 Phase; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Neoplasm Proteins; Reverse Transcriptase Polymerase Chain Reaction; Umbilical Veins; Uterine Cervical Neoplasms | 2006 |
Identification of novel genes associated with astrocytoma progression using suppression subtractive hybridization and real-time reverse transcription-polymerase chain reaction.
Topics: Adenosine Triphosphatases; Antimetabolites, Antineoplastic; Apolipoproteins; Apolipoproteins D; Astrocytoma; Azacitidine; Biomarkers, Tumor; Brain Neoplasms; Cation Transport Proteins; Cell Adhesion Molecules, Neuronal; Decitabine; Disease Progression; DNA Methylation; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Silencing; Genes, Tumor Suppressor; Glycoproteins; Guanine Nucleotide Exchange Factors; Histone Deacetylases; Humans; Hydroxamic Acids; Membrane Transport Proteins; Nerve Tissue Proteins; Nuclear Proteins; Nucleic Acid Hybridization; Oligonucleotide Array Sequence Analysis; Protein Synthesis Inhibitors; Proteins; Reverse Transcriptase Polymerase Chain Reaction | 2006 |
Localized methylation in the key regulator gene endothelin-1 is associated with cell type-specific transcriptional silencing.
Topics: Animals; Azacitidine; Cells, Cultured; Chondrocytes; CpG Islands; Decitabine; DNA Methylation; Endothelin-1; Fibroblasts; Gene Expression Profiling; Gene Silencing; Genes, Regulator; Mice; Oligonucleotide Array Sequence Analysis; Transcription, Genetic | 2006 |
Restoration of shp1 expression by 5-AZA-2'-deoxycytidine is associated with downregulation of JAK3/STAT3 signaling in ALK-positive anaplastic large cell lymphoma.
Topics: Anaplastic Lymphoma Kinase; Apoptosis; Azacitidine; Base Sequence; Blotting, Western; Cell Cycle; Cell Line; Decitabine; DNA Primers; Down-Regulation; Doxorubicin; Humans; Intracellular Signaling Peptides and Proteins; Janus Kinase 3; Lymphoma, Large B-Cell, Diffuse; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Protein Tyrosine Phosphatases; Protein-Tyrosine Kinases; Receptor Protein-Tyrosine Kinases; Signal Transduction; STAT3 Transcription Factor | 2006 |
Further studies on aberrant gene expression associated with arsenic-induced malignant transformation in rat liver TRL1215 cells.
Topics: Animals; Arsenic; Arsenites; Azacitidine; Blotting, Western; Carcinogens; Cell Cycle; Cell Line; Cell Transformation, Neoplastic; Dealkylation; Decitabine; DNA, Neoplasm; Gene Expression; Gene Expression Regulation, Developmental; Gene Expression Regulation, Neoplastic; Growth; Intercellular Signaling Peptides and Proteins; Liver Neoplasms; Rats; Reverse Transcriptase Polymerase Chain Reaction; Stress, Physiological | 2006 |
Epigenetic inactivation of the dioxin-responsive cytochrome P4501A1 gene in human prostate cancer.
Topics: Azacitidine; Chromatin; CpG Islands; Cytochrome P-450 CYP1A1; Decitabine; Dioxins; DNA Methylation; DNA, Neoplasm; Enhancer Elements, Genetic; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Male; Prostatic Neoplasms; Response Elements | 2006 |
Epigenomic profiling reveals novel and frequent targets of aberrant DNA methylation-mediated silencing in malignant glioma.
Topics: Azacitidine; Brain Neoplasms; Cell Cycle Proteins; Cell Growth Processes; Cell Line, Tumor; Decitabine; DNA Methylation; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Silencing; Glioblastoma; Humans; Hydroxamic Acids; Up-Regulation | 2006 |
Epigenetic regulation of human trophoblastic cell migration and invasion.
Topics: Azacitidine; Cadherins; Cell Line, Tumor; Cell Movement; Choriocarcinoma; Decitabine; Desmoplakins; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Methyltransferase 3A; DNA Methyltransferase 3B; Epigenesis, Genetic; Female; gamma Catenin; Humans; Promoter Regions, Genetic; Trophoblasts | 2006 |
Downregulation of RUNX3 and TES by hypermethylation in glioblastoma.
Topics: Azacitidine; Brain; Core Binding Factor Alpha 3 Subunit; Cytoskeletal Proteins; Decitabine; DNA Methylation; Gene Expression Regulation, Neoplastic; Glioblastoma; Homeodomain Proteins; Humans; LIM Domain Proteins; Oligonucleotide Array Sequence Analysis; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; RNA-Binding Proteins; Sequence Analysis, DNA; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2007 |
The expression of metastasis suppressor MIM/MTSS1 is regulated by DNA methylation.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cell Line, Tumor; Cloning, Molecular; Cosmids; CpG Islands; Decitabine; DNA Methylation; Gene Expression Regulation, Neoplastic; Hedgehog Proteins; Humans; Microfilament Proteins; Neoplasm Proteins; Plasmids; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Trans-Activators; Transfection; Up-Regulation; Urinary Bladder Neoplasms | 2006 |
Role of cyclic nucleotides in fetal hemoglobin induction in cultured CD34+ cells.
Topics: Adenylyl Cyclases; Antigens, CD34; Antisickling Agents; Azacitidine; Butyrates; Colforsin; Cyclic AMP; Cyclic GMP; Decitabine; Enzyme Inhibitors; Erythroid Cells; Fetal Hemoglobin; Humans; Hydroxyurea; K562 Cells; Monocytes; RNA, Messenger | 2006 |
Expression profiling identifies three pathways altered in cellular immortalization: interferon, cell cycle, and cytoskeleton.
Topics: Azacitidine; Cell Cycle; Cell Line, Tumor; Cellular Senescence; Cytoskeleton; Decitabine; DNA Methylation; Down-Regulation; Enzyme Inhibitors; Epigenesis, Genetic; Female; Fibroblasts; Gene Expression Profiling; Genes, p53; Humans; Interferon Regulatory Factor-7; Interferon-alpha; Interferon-beta; Li-Fraumeni Syndrome; Male; Oligonucleotide Array Sequence Analysis; Reverse Transcriptase Polymerase Chain Reaction; Up-Regulation | 2006 |
Identification of DNMT1 (DNA methyltransferase 1) hypomorphs in somatic knockouts suggests an essential role for DNMT1 in cell survival.
Topics: Animals; Azacitidine; Cell Line; Cell Survival; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Genetic Engineering; Humans; Mice; RNA Interference | 2006 |
Regulation of Cdx2 expression by promoter methylation, and effects of Cdx2 transfection on morphology and gene expression of human esophageal epithelial cells.
Topics: Azacitidine; Base Sequence; Bile Acids and Salts; CDX2 Transcription Factor; Decitabine; DNA Methylation; DNA Primers; Epithelial Cells; Esophagus; Gene Expression Regulation; Homeodomain Proteins; Humans; Immunohistochemistry; Molecular Sequence Data; Polymerase Chain Reaction; Promoter Regions, Genetic; Transfection | 2007 |
Inhibitors of DNA methylation and histone deacetylation independently relieve AML1/ETO-mediated lysozyme repression.
Topics: Acetylation; Azacitidine; Cell Line, Tumor; Chromatin Assembly and Disassembly; Core Binding Factor Alpha 2 Subunit; CpG Islands; Decitabine; DNA Methylation; Enzyme Inhibitors; Gene Expression Regulation, Enzymologic; Gene Silencing; Histone Acetyltransferases; Histones; Humans; Hydroxamic Acids; Muramidase; Protein Processing, Post-Translational; RNA, Small Interfering; U937 Cells; Up-Regulation | 2006 |
Promoter hypomethylation and reactivation of MAGE-A1 and MAGE-A3 genes in colorectal cancer cell lines and cancer tissues.
Topics: Antigens, Neoplasm; Antimetabolites, Antineoplastic; Azacitidine; Cell Line, Tumor; Colorectal Neoplasms; Decitabine; DNA Methylation; DNA, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Melanoma-Specific Antigens; Neoplasm Proteins; Promoter Regions, Genetic; RNA, Messenger; Stomach Neoplasms | 2006 |
Methylation status of a single CpG locus 3 bases upstream of TATA-box of receptor activator of nuclear factor-kappaB ligand (RANKL) gene promoter modulates cell- and tissue-specific RANKL expression and osteoclastogenesis.
Topics: Animals; Azacitidine; Bone Marrow Cells; CpG Islands; Decitabine; DNA Methylation; Gene Expression Regulation; Mice; Models, Biological; Osteoblasts; Osteoclasts; Promoter Regions, Genetic; RANK Ligand; Receptors, Calcitriol; RNA, Messenger; Stromal Cells | 2007 |
Hypermethylation of Cyclin D2 is associated with loss of mRNA expression and tumor development in prostate cancer.
Topics: Adenocarcinoma; Adult; Aged; Azacitidine; Cell Line, Tumor; Cell Transformation, Neoplastic; Cyclin D2; Cyclins; Decitabine; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Promoter Regions, Genetic; Prostatic Hyperplasia; Prostatic Intraepithelial Neoplasia; Prostatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Transcription, Genetic | 2006 |
An EBF3-mediated transcriptional program that induces cell cycle arrest and apoptosis.
Topics: Apoptosis; Azacitidine; Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Chromosomes, Human, Pair 10; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Decitabine; DNA Methylation; Epigenesis, Genetic; Female; Gene Deletion; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Humans; Hydroxamic Acids; Intracellular Signaling Peptides and Proteins; Male; Microtubule-Associated Proteins; Neoplasm Proteins; Neoplasms; Promoter Regions, Genetic; Recombinant Fusion Proteins; Transcription, Genetic | 2006 |
Epigenetic modulation of endogenous tumor suppressor expression in lung cancer xenografts suppresses tumorigenicity.
Topics: Acid Anhydride Hydrolases; Animals; Apoptosis; Azacitidine; Carcinoma, Non-Small-Cell Lung; Caspases; Cyclin-Dependent Kinase Inhibitor p16; Decitabine; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Epigenesis, Genetic; Female; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Lung Neoplasms; Mice; Mice, Nude; Neoplasm Proteins; Oxidoreductases; Promoter Regions, Genetic; Transgenes; Transplantation, Heterologous; Tumor Cells, Cultured; Tumor Suppressor Proteins; WW Domain-Containing Oxidoreductase | 2007 |
High-resolution mapping of DNA methylation in human genome using oligonucleotide tiling array.
Topics: Acetylation; Azacitidine; Binding Sites; Cell Line, Tumor; Colorectal Neoplasms; Computational Biology; Decitabine; DNA Methylation; Gene Expression Regulation, Neoplastic; Genetic Predisposition to Disease; Genome, Human; HCT116 Cells; Histones; Homeodomain Proteins; Humans; Microarray Analysis; Oligonucleotide Probes; Sequence Analysis, DNA | 2007 |
Epigenetic allele silencing unveils recessive RYR1 mutations in core myopathies.
Topics: Alleles; Animals; Azacitidine; Base Sequence; Case-Control Studies; Cells, Cultured; CpG Islands; Decitabine; DNA Methylation; DNA Primers; Epigenesis, Genetic; Female; Fetus; Gene Silencing; Genes, Recessive; Genomic Imprinting; Humans; Hydroxamic Acids; Male; Mice; Mice, Inbred C57BL; Muscle, Skeletal; Myoblasts, Skeletal; Myopathy, Central Core; Pedigree; Point Mutation; Polymorphism, Single Nucleotide; Ryanodine Receptor Calcium Release Channel; Tissue Distribution | 2006 |
DNA methylation-dependent silencing of CST6 in human breast cancer cell lines.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Breast Neoplasms; Cell Line, Tumor; Cell Transformation, Neoplastic; CpG Islands; Cystatin M; Cystatins; Decitabine; DNA Methylation; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Promoter Regions, Genetic | 2006 |
Epigenetic cancer therapy makes headway.
Topics: Acetylation; Animals; Antineoplastic Agents; Azacitidine; Decitabine; DNA Methylation; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Histone Deacetylases; Humans; Hydroxamic Acids; Methyltransferases; Neoplasms; Randomized Controlled Trials as Topic; Valproic Acid; Vorinostat | 2006 |
Reversal of p15/INK4b hypermethylation in AML1/ETO-positive and -negative myeloid leukemia cell lines.
Topics: Azacitidine; Core Binding Factor Alpha 2 Subunit; Cyclin-Dependent Kinase Inhibitor p15; Decitabine; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Leukemia, Myeloid; Oncogene Proteins, Fusion; RUNX1 Translocation Partner 1 Protein; Transcription, Genetic; Tumor Cells, Cultured | 2007 |
5-Aza-2'-deoxycytidine and depsipeptide synergistically induce expression of BIK (BCL2-interacting killer).
Topics: Acetylation; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Azacitidine; Cell Line, Tumor; Decitabine; Depsipeptides; DNA Methylation; DNA Modification Methylases; Drug Synergism; Histones; Humans; Membrane Proteins; Mitochondrial Proteins; Oligonucleotide Array Sequence Analysis; Promoter Regions, Genetic; RNA, Messenger; Up-Regulation | 2006 |
Alteration of DNA methylation status in K562 and MCF-7 cancer cell lines by nucleoside analogues.
Topics: Azacitidine; Breast Neoplasms; Cadherins; Cell Line, Tumor; Cladribine; Decitabine; DNA Methylation; Estrogen Receptor alpha; Genes, APC; Genes, BRCA1; Humans; K562 Cells; Nucleosides; Promoter Regions, Genetic; PTEN Phosphohydrolase; Vidarabine | 2006 |
DNA methyltransferase inhibitors coordinately induce expression of the human reelin and glutamic acid decarboxylase 67 genes.
Topics: Acetylation; Azacitidine; Cell Adhesion Molecules, Neuronal; Cells, Cultured; Cytidine; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; Dose-Response Relationship, Drug; Doxorubicin; Enzyme Inhibitors; Extracellular Matrix Proteins; Gene Expression Regulation; Glutamate Decarboxylase; Histones; Humans; Isoenzymes; Methyl-CpG-Binding Protein 2; Nerve Tissue Proteins; Reelin Protein; RNA, Messenger; Serine Endopeptidases | 2007 |
Efficacy of DNA hypomethylating capacities of 5-aza-2'-deoxycytidine and its alpha anomer.
Topics: Antimetabolites; Apoptosis; Azacitidine; Blotting, Southern; Blotting, Western; Cell Line, Tumor; Decitabine; DNA Methylation; DNA Probes; Humans; Isomerism | 2007 |
Alterations of the tumor suppressor gene ARLTS1 in ovarian cancer.
Topics: ADP-Ribosylation Factors; Apoptosis; Azacitidine; Breast Neoplasms; Cell Proliferation; Decitabine; Down-Regulation; Female; Genes, Tumor Suppressor; Humans; Ovarian Neoplasms | 2006 |
Interleukin-6 contributes to growth in cholangiocarcinoma cells by aberrant promoter methylation and gene expression.
Topics: 5-Methylcytosine; Azacitidine; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell Line, Tumor; Cholangiocarcinoma; Decitabine; DNA Methylation; ErbB Receptors; Humans; Interleukin-6; Promoter Regions, Genetic | 2006 |
Decitabine (Dacogen) for myelodysplastic syndromes.
Topics: Azacitidine; Decitabine; Humans; Myelodysplastic Syndromes | 2006 |
Methylation of the mouse DIx5 and Osx gene promoters regulates cell type-specific gene expression.
Topics: Animals; Azacitidine; Cell Differentiation; Cell Line; CpG Islands; Decitabine; DNA Methylation; Epigenesis, Genetic; Gene Expression Regulation; Homeodomain Proteins; Mice; Osteoblasts; Osteogenesis; Promoter Regions, Genetic; Sp7 Transcription Factor; Transcription Factors | 2006 |
Correlation between the single-site CpG methylation and expression silencing of the XAF1 gene in human gastric and colon cancers.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Apoptosis Regulatory Proteins; Azacitidine; Cell Line, Tumor; Colonic Neoplasms; CpG Islands; Decitabine; DNA Methylation; DNA, Neoplasm; Down-Regulation; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Hydroxamic Acids; Intracellular Signaling Peptides and Proteins; Male; Middle Aged; Neoplasm Proteins; Promoter Regions, Genetic; Protein Synthesis Inhibitors; RNA, Messenger; Stomach Neoplasms | 2006 |
Mullerian Inhibiting Substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancer.
Topics: Animals; Anti-Mullerian Hormone; Apoptosis; Azacitidine; Cell Line, Tumor; Decitabine; Drug Resistance, Neoplasm; Female; Glycoproteins; Humans; Immunoglobulin G; Melphalan; Mice; Mice, Nude; Ovarian Neoplasms; Paclitaxel; Receptors, Peptide; Receptors, Transforming Growth Factor beta; Testicular Hormones; Xenograft Model Antitumor Assays | 2006 |
Decitabine.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Methylation; Drug Approval; Humans; Myelodysplastic Syndromes; United States; United States Food and Drug Administration | 2006 |
Reprimo methylation is a potential biomarker of Barrett's-Associated esophageal neoplastic progression.
Topics: Adenocarcinoma; Aged; Azacitidine; Barrett Esophagus; Carcinoma, Squamous Cell; Cell Cycle Proteins; Cell Line, Tumor; Decitabine; Disease Progression; DNA Methylation; Esophageal Diseases; Esophageal Neoplasms; Female; Genetic Markers; Glycoproteins; Humans; Male; Middle Aged; Polymerase Chain Reaction; Precancerous Conditions | 2006 |
Relationship of aberrant DNA hypermethylation of CHFR with sensitivity to taxanes in endometrial cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cisplatin; Decitabine; DNA Methylation; Docetaxel; Doxorubicin; Drug Screening Assays, Antitumor; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Proteins; Paclitaxel; Poly-ADP-Ribose Binding Proteins; Promoter Regions, Genetic; Taxoids; Ubiquitin-Protein Ligases | 2007 |
[Effect of spleen tyrosine kinase expression re-activation by inhibition of DNA methylation on oncogenesis growth of gastric cancer].
Topics: Animals; Azacitidine; Cell Line, Tumor; CpG Islands; Decitabine; DNA Methylation; Female; Gene Expression; Humans; Intracellular Signaling Peptides and Proteins; Male; Mice; Mice, Nude; Promoter Regions, Genetic; Protein-Tyrosine Kinases; Stomach Neoplasms; Syk Kinase | 2006 |
Epigenetic silencing of novel tumor suppressors in malignant melanoma.
Topics: Animals; Azacitidine; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; CpG Islands; Decitabine; DNA Methylation; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Gene Silencing; Genetic Predisposition to Disease; Homeodomain Proteins; Humans; Intracellular Signaling Peptides and Proteins; Male; Melanoma; Melanoma, Experimental; Mice; Mice, Nude; Protein-Tyrosine Kinases; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Syk Kinase; Transfection; Transplantation, Heterologous; Tumor Suppressor Proteins | 2006 |
Low-dose decitabine and high-risk MDS.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Female; Gene Expression Regulation, Leukemic; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Methylation; Myelodysplastic Syndromes; Neoplasm Proteins; Protein Processing, Post-Translational; Randomized Controlled Trials as Topic; Remission Induction; Risk Factors | 2006 |
Igf-2r expression regulated by epigenetic modification and the locus of gene imprinting disrupted in cloned cattle.
Topics: Animals; Azacitidine; Brain; Cattle; Cell Line; Cloning, Organism; CpG Islands; Decitabine; DNA; DNA Methylation; Epigenesis, Genetic; Female; Fetal Heart; Gene Expression; Gene Expression Regulation, Developmental; Genomic Imprinting; Hydroxamic Acids; Introns; Liver; Lung; Male; Molecular Sequence Data; Nuclear Transfer Techniques; Receptor, IGF Type 2; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sequence Analysis, DNA | 2007 |
Downregulation and CpG island hypermethylation of NES1/hK10 gene in the pathogenesis of human gastric cancer.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cell Line, Transformed; Cell Line, Tumor; CpG Islands; Decitabine; DNA Methylation; Down-Regulation; Gene Expression Regulation, Neoplastic; Genetic Predisposition to Disease; Humans; In Situ Hybridization; Kallikreins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Stomach Neoplasms | 2007 |
Trichostatin A and 5-aza-2'-deoxycytidine switch S1P from an inhibitor to a stimulator of motility through epigenetic regulation of S1P receptors.
Topics: Azacitidine; Cell Line, Tumor; Cell Movement; Decitabine; DNA Methylation; Epigenesis, Genetic; Gene Expression Regulation; Humans; Hydroxamic Acids; Lysophospholipids; Melanoma; Nerve Tissue Proteins; Receptors, Lysophospholipid; Receptors, Lysosphingolipid; RNA-Binding Proteins; RNA, Messenger; Sphingosine | 2007 |
A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Azacitidine; Breast Neoplasms; Carcinoma, Adenosquamous; Carcinoma, Squamous Cell; Cathepsin K; Cathepsins; Colonic Neoplasms; CpG Islands; Cyclin A; Cyclin A1; Decitabine; DNA Methylation; DNA Modification Methylases; DNA-Binding Proteins; Epigenesis, Genetic; Female; Gene Expression Profiling; Humans; Lung Neoplasms; Male; Middle Aged; MSX1 Transcription Factor; Oligonucleotide Array Sequence Analysis; Promoter Regions, Genetic; Prostatic Neoplasms; Transcription Factors; Tumor Cells, Cultured | 2006 |
Effect of combined therapy with low-dose 5-aza-2'-deoxycytidine and irinotecan on colon cancer cell line HCT-15.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Azacitidine; Camptothecin; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Cyclin-Dependent Kinase Inhibitor p16; Decitabine; DNA Methylation; Drug Therapy, Combination; Gene Expression Regulation, Neoplastic; Humans; In Situ Nick-End Labeling; Intracellular Signaling Peptides and Proteins; Irinotecan; Male; Membrane Proteins; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Proteins; Promoter Regions, Genetic; Proto-Oncogene Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Tumor Suppressor Protein p14ARF | 2007 |
[Expression of S100A2 in secondarily radioresistant pancreatic cancer cells and significance thereof].
Topics: Azacitidine; Cell Cycle; Cell Line, Tumor; Cell Survival; Chemotactic Factors; Decitabine; Down-Regulation; Fluorescent Antibody Technique; Gene Expression Regulation, Neoplastic; Humans; Pancreatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; S100 Proteins | 2006 |
Inhibition of breast cancer cell growth in vitro and in vivo: effect of restoration of Wwox expression.
Topics: Adenoviridae; Azacitidine; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Decitabine; Disease Progression; DNA Methylation; DNA, Complementary; Down-Regulation; Gene Expression Regulation, Neoplastic; Humans; In Vitro Techniques; Neoplasm Proteins; Oxidoreductases; RNA Interference; Time Factors; Tumor Suppressor Proteins; WW Domain-Containing Oxidoreductase | 2007 |
Decitabine and vitamin D3 differentially affect hematopoietic transcription factors to induce monocytic differentiation.
Topics: Azacitidine; CD11b Antigen; Cell Differentiation; Cholecalciferol; Decitabine; Humans; Lipopolysaccharide Receptors; Models, Biological; Monocytes; Plicamycin; Sp1 Transcription Factor; Transcription Factors; Transcription, Genetic; U937 Cells | 2007 |
Differentiation-specific association of HP1alpha and HP1beta with chromocentres is correlated with clustering of TIF1beta at these sites.
Topics: Animals; Azacitidine; Blotting, Western; Cell Differentiation; Cell Line, Tumor; Cell Nucleus; Centromere; Chromobox Protein Homolog 5; Chromosomal Proteins, Non-Histone; Decitabine; DNA Methylation; Enzyme Inhibitors; Green Fluorescent Proteins; Histone Deacetylase Inhibitors; Hydroxamic Acids; Immunohistochemistry; Microscopy, Confocal; Nuclear Proteins; Protein Subunits; Recombinant Fusion Proteins; Signal Transduction; Transcription Factors | 2007 |
Inhibition of histone deacetylation does not block resilencing of p16 after 5-aza-2'-deoxycytidine treatment.
Topics: Acetylation; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cell Cycle; Cell Line, Tumor; Chromatin; Cyclin-Dependent Kinase Inhibitor p16; Cyclin-Dependent Kinase Inhibitor p21; Decitabine; DNA Methylation; Dose-Response Relationship, Drug; Fibroblasts; Histone Deacetylase Inhibitors; Histones; Humans; Neoplasms; Phenylbutyrates | 2007 |
Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Disease-Free Survival; DNA Modification Methylases; Female; Humans; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Survival Rate; Treatment Outcome | 2007 |
Insulin-like growth factor binding protein-related protein 1 (IGFBP-rP1) has potential tumour-suppressive activity in human lung cancer.
Topics: Adenocarcinoma; Apoptosis; Azacitidine; Carcinoma, Squamous Cell; Cell Line, Tumor; Decitabine; DNA Methylation; DNA Modification Methylases; DNA, Neoplasm; Epithelial Cells; Humans; Immunohistochemistry; Insulin-Like Growth Factor Binding Proteins; Lung; Lung Neoplasms; Microarray Analysis; Neoplasm Staging; Transfection; Tumor Suppressor Proteins | 2007 |
Epigenetic silencing of CYP24 in tumor-derived endothelial cells contributes to selective growth inhibition by calcitriol.
Topics: Animals; Azacitidine; Base Sequence; Calcitriol; Decitabine; DNA Methylation; Endothelial Cells; Epigenesis, Genetic; Gene Silencing; Mice; Molecular Sequence Data; Promoter Regions, Genetic; Receptors, Calcitriol; Signal Transduction; Steroid Hydroxylases; Tetrazolium Salts; Thiazoles; Vitamin D3 24-Hydroxylase | 2007 |
Identification of candidate methylation-responsive genes in ovarian cancer.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cell Line, Tumor; CpG Islands; Decitabine; DNA Methylation; Epigenesis, Genetic; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genes, Neoplasm; Humans; Ovarian Neoplasms | 2007 |
Downregulation of TSLC1 and DAL-1 expression occurs frequently in breast cancer.
Topics: Azacitidine; Breast Neoplasms; Carcinoma; Cell Adhesion; Cell Adhesion Molecule-1; Cell Adhesion Molecules; Cell Line, Tumor; Decitabine; DNA Methylation; Epigenesis, Genetic; Female; Gene Expression Regulation, Neoplastic; Humans; Immunoglobulins; Membrane Proteins; Microfilament Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA; Sulfites; Tumor Suppressor Proteins | 2007 |
Characterization of in vitro and in vivo hypomethylating effects of decitabine in acute myeloid leukemia by a rapid, specific and sensitive LC-MS/MS method.
Topics: Acute Disease; Antimetabolites, Antineoplastic; Azacitidine; Cell Line, Tumor; Chromatography, Liquid; Clinical Trials, Phase I as Topic; Decitabine; Deoxycytidine; Deoxyguanosine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Humans; Leukemia, Myeloid; Tandem Mass Spectrometry | 2007 |
Genetic redundancy in human cervical carcinoma cells: identification of cells with "normal" properties.
Topics: Animals; Azacitidine; Butyrates; Cardiovirus Infections; Decitabine; DNA Methylation; Encephalomyocarditis virus; Female; HeLa Cells; Histone Deacetylase Inhibitors; Human papillomavirus 18; Humans; Immunocompromised Host; Interferon Regulatory Factor-1; Interferon-beta; Interferon-Stimulated Gene Factor 3, gamma Subunit; Mice; Mice, Nude; Papillomavirus Infections; Tumor Necrosis Factor-alpha; Uterine Cervical Neoplasms | 2007 |
Dual role of DNA methylation inside and outside of CTCF-binding regions in the transcriptional regulation of the telomerase hTERT gene.
Topics: Azacitidine; Binding Sites; CCCTC-Binding Factor; Cell Line; Decitabine; DNA Methylation; DNA-Binding Proteins; Down-Regulation; Exons; Gene Expression Regulation; Humans; Promoter Regions, Genetic; Repressor Proteins; Telomerase; Transcription, Genetic | 2007 |
Promoter methylation status of the Cyclin D2 gene is associated with poor prognosis in human epithelial ovarian cancer.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cell Line, Tumor; Cyclin D2; Cyclins; Decitabine; DNA Methylation; Enzyme Inhibitors; Female; Humans; Hydroxamic Acids; Immunohistochemistry; Ovarian Neoplasms; Prognosis; Promoter Regions, Genetic; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2007 |
Evidence that tumor necrosis factor-related apoptosis-inducing ligand induction by 5-Aza-2'-deoxycytidine sensitizes human breast cancer cells to adriamycin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Azacitidine; Breast Neoplasms; Cell Line, Tumor; Decitabine; Down-Regulation; Doxorubicin; Drug Synergism; Enzyme Activation; Histone Deacetylase 1; Histone Deacetylases; Humans; Proto-Oncogene Proteins c-akt; RNA, Small Interfering; TNF-Related Apoptosis-Inducing Ligand; Transfection | 2007 |
The Escherichia coli protein YjjG is a house-cleaning nucleotidase in vivo.
Topics: Azacitidine; Bromodeoxyuridine; Decitabine; Deoxyuridine; DNA Damage; Escherichia coli; Escherichia coli Proteins; Fluorouracil; Models, Biological; Molecular Structure; Mutation; N-Glycosyl Hydrolases; Nucleotidases; Orotic Acid; Substrate Specificity; Thymidine Monophosphate; Uridine | 2007 |
MAGE-A9 mRNA and protein expression in bladder cancer.
Topics: Antibodies, Monoclonal; Antigens, Neoplasm; Azacitidine; Benzamides; Cell Line, Tumor; Decitabine; Gene Expression; Histone Deacetylase Inhibitors; Humans; Immunohistochemistry; Male; Neoplasm Proteins; Phenylbutyrates; Protein Isoforms; Pyridines; RNA, Messenger; Testicular Neoplasms; Urinary Bladder Neoplasms | 2007 |
[Methylation of P15INK4B gene in patients with myelodysplastic syndromes and demethylating effects of drugs].
Topics: Arsenic Trioxide; Arsenicals; Azacitidine; Cyclin-Dependent Kinase Inhibitor p15; Decitabine; Disease Progression; DNA Methylation; Genetic Predisposition to Disease; Humans; Leukemia; Myelodysplastic Syndromes; Oxides | 2007 |
Hypermethylation of Ron proximal promoter associates with lack of full-length Ron and transcription of oncogenic short-Ron from an internal promoter.
Topics: Azacitidine; Cells, Cultured; CpG Islands; Decitabine; DNA Methylation; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Erythroblastic, Acute; Lung Neoplasms; Promoter Regions, Genetic; Receptor Protein-Tyrosine Kinases; Transcription, Genetic; Transgenes | 2007 |
Downregulation of connexin 43 in nasopharyngeal carcinoma cells is related to promoter methylation.
Topics: Azacitidine; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Connexin 43; Decitabine; DNA Methylation; DNA Modification Methylases; Down-Regulation; Fluoresceins; Gap Junctions; Gene Expression Regulation, Neoplastic; Humans; Isoquinolines; Nasopharyngeal Neoplasms; Promoter Regions, Genetic | 2007 |
Epigenetic silencing of HSulf-1 in ovarian cancer:implications in chemoresistance.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Azacitidine; Cell Line, Tumor; Chromatin; Cisplatin; CpG Islands; Decitabine; DNA Methylation; Drug Resistance, Neoplasm; Enzyme Inhibitors; Epigenesis, Genetic; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Histone Deacetylase Inhibitors; Humans; Middle Aged; Ovarian Neoplasms; Sulfotransferases | 2007 |
Xeroderma pigmentosum group C gene expression is predominantly regulated by promoter hypermethylation and contributes to p53 mutation in lung cancers.
Topics: Aged; Azacitidine; Base Sequence; Blotting, Western; Cell Line, Tumor; CpG Islands; Decitabine; DNA Methylation; DNA-Binding Proteins; Female; Gene Expression Regulation, Neoplastic; Humans; Luciferases; Lung Neoplasms; Male; Middle Aged; Molecular Sequence Data; Mutation; Promoter Regions, Genetic; Proto-Oncogene Proteins c-mdm2; Recombinant Fusion Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Smoking; Transfection; Tumor Suppressor Protein p53 | 2007 |
Discovery of epigenetically silenced genes in acute myeloid leukemias.
Topics: alpha Catenin; Azacitidine; Carrier Proteins; CpG Islands; Decitabine; DNA Methylation; Epigenesis, Genetic; Genes, Tumor Suppressor; Humans; Hydroxamic Acids; Leukemia, Myeloid, Acute; Reverse Transcriptase Polymerase Chain Reaction; Vorinostat | 2007 |
SGNE1/7B2 is epigenetically altered and transcriptionally downregulated in human medulloblastomas.
Topics: Azacitidine; Base Sequence; Cell Line, Tumor; Cell Proliferation; Cerebellar Neoplasms; CpG Islands; Decitabine; DNA Methylation; DNA Modification Methylases; Down-Regulation; Enzyme Inhibitors; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Medulloblastoma; Molecular Sequence Data; Neuroendocrine Secretory Protein 7B2; Reverse Transcriptase Polymerase Chain Reaction; Sequence Analysis, DNA; Transcription, Genetic | 2007 |
Methylation patterns of IGFBP7 in colon cancer cell lines are associated with levels of gene expression.
Topics: Azacitidine; Cell Line, Tumor; Colonic Neoplasms; CpG Islands; Decitabine; DNA Methylation; Enzyme Inhibitors; Gene Expression; Humans; Immunohistochemistry; Insulin-Like Growth Factor Binding Proteins; Reverse Transcriptase Polymerase Chain Reaction | 2007 |
Methylation status of genes upregulated by demethylating agent 5-aza-2'-deoxycytidine in hepatocellular carcinoma.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Carcinoma, Hepatocellular; Carrier Proteins; Caveolin 1; Cell Line, Tumor; Decitabine; DNA Methylation; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Humans; Kruppel-Like Factor 6; Kruppel-Like Transcription Factors; LIM Domain Proteins; Liver Neoplasms; Microfilament Proteins; Muscle Proteins; Myosin Light Chains; Neoplasm Proteins; Promoter Regions, Genetic; Proto-Oncogene Proteins; Reverse Transcriptase Polymerase Chain Reaction | 2006 |
[SHP-1 gene's methylation status of Daudi lymphoma cell and the demethylation effect of 5-aza-2'-deoxycytidine].
Topics: Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Cell Line, Tumor; Cell Proliferation; Decitabine; DNA Methylation; Dose-Response Relationship, Drug; Humans; Lymphoma; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2006 |
Aberrant DNA methylation of the Src kinase Hck, but not of Lyn, in Philadelphia chromosome negative acute lymphocytic leukemia.
Topics: Azacitidine; CpG Islands; Decitabine; DNA Methylation; Humans; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Promoter Regions, Genetic; Proto-Oncogene Proteins c-hck; src-Family Kinases | 2007 |
Epigenetic regulation of Nanog gene in embryonic stem and trophoblast stem cells.
Topics: 5' Flanking Region; Acetylation; Animals; Azacitidine; Base Sequence; Cell Line; Decitabine; DNA Methylation; DNA Primers; DNA-Binding Proteins; Embryonic Stem Cells; Epigenesis, Genetic; Histones; Homeodomain Proteins; Hydroxamic Acids; Mice; Mice, Inbred C57BL; Nanog Homeobox Protein; NIH 3T3 Cells; Octamer Transcription Factor-3; Pluripotent Stem Cells; Promoter Regions, Genetic; Trophoblasts | 2007 |
Covalent modification of DNA regulates memory formation.
Topics: Animals; Azacitidine; Behavior, Animal; Cell Adhesion Molecules, Neuronal; Conditioning, Classical; Decitabine; DNA; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Enzyme Inhibitors; Extracellular Matrix Proteins; Fear; Gene Expression Regulation, Enzymologic; Hippocampus; Male; Memory; Models, Biological; Nerve Tissue Proteins; Phosphoprotein Phosphatases; Rats; Rats, Sprague-Dawley; Reelin Protein; Reverse Transcriptase Polymerase Chain Reaction; Serine Endopeptidases | 2007 |
5-AZA-2'-deoxycytidine in cancer immunotherapy: a mouse to man story.
Topics: Animals; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Humans; Immunotherapy, Adoptive; Melanoma; Mice; Xenograft Model Antitumor Assays | 2007 |
Epigenetic inactivation of EGFR by CpG island hypermethylation in cancer.
Topics: Antineoplastic Agents; Azacitidine; Breast Neoplasms; Cell Line; Cell Line, Tumor; Decitabine; Dinucleoside Phosphates; DNA Methylation; DNA Primers; Epigenesis, Genetic; ErbB Receptors; Female; Gefitinib; Genetic Therapy; Humans; Organ Specificity; Quinazolines; Restriction Mapping; Reverse Transcriptase Polymerase Chain Reaction | 2006 |
Silencing of tissue factor pathway inhibitor-2 gene in malignant melanomas.
Topics: Azacitidine; Cell Line, Tumor; Cells, Cultured; CpG Islands; Decitabine; DNA Methylation; Gene Expression Regulation; Gene Silencing; Glycoproteins; Humans; Immunohistochemistry; Melanoma; Neoplasm Metastasis; Oligonucleotide Array Sequence Analysis; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; Ultraviolet Rays | 2007 |
Transcriptional reactivation of murine cytomegalovirus ie gene expression by 5-aza-2'-deoxycytidine and trichostatin A in latently infected cells despite lack of methylation of the major immediate-early promoter.
Topics: Animals; Azacitidine; Decitabine; DNA Methylation; DNA, Viral; Enzyme Inhibitors; Gene Expression Regulation, Viral; Genes, Immediate-Early; Hydroxamic Acids; Immediate-Early Proteins; Mice; Models, Animal; Muromegalovirus; Promoter Regions, Genetic; Proviruses; Transcription, Genetic; Virus Activation | 2007 |
Epigenetic regulation of human alpha1d-adrenergic receptor gene expression: a role for DNA methylation in Sp1-dependent regulation.
Topics: Azacitidine; Base Sequence; Cell Line, Tumor; Chromatin; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Gene Expression Regulation; Gene Silencing; Humans; Immunoprecipitation; Molecular Sequence Data; Mutagenesis, Site-Directed; Promoter Regions, Genetic; Protein Binding; Receptors, Adrenergic, alpha-1; Recombinant Fusion Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sequence Analysis, DNA; Sp1 Transcription Factor; Sulfites; Transcription, Genetic | 2007 |
The tumor suppressor Wnt inhibitory factor 1 is frequently methylated in nasopharyngeal and esophageal carcinomas.
Topics: Adaptor Proteins, Signal Transducing; Animals; Azacitidine; Biomarkers, Tumor; Carcinoma; Cell Line; Cell Line, Tumor; Cell Proliferation; Decitabine; DNA Methylation; Down-Regulation; Esophageal Neoplasms; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Nasopharyngeal Neoplasms; Promoter Regions, Genetic; Repressor Proteins; Tumor Suppressor Proteins; Wnt1 Protein | 2007 |
Stress chaperones, mortalin, and pex19p mediate 5-aza-2' deoxycytidine-induced senescence of cancer cells by DNA methylation-independent pathway.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Biomarkers; Biomarkers, Tumor; Cell Line, Tumor; Cellular Senescence; Chromatin; Chromatin Assembly and Disassembly; Cyclin-Dependent Kinase Inhibitor p16; Decitabine; DNA Methylation; DNA Modification Methylases; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Gene Silencing; Genes, p53; Heat-Shock Proteins; HSP70 Heat-Shock Proteins; Humans; Lipoproteins; Membrane Proteins; Molecular Chaperones; Osteosarcoma; Tumor Suppressor Proteins | 2007 |
Differentiation-promoting drugs up-regulate NKG2D ligand expression and enhance the susceptibility of acute myeloid leukemia cells to natural killer cell-mediated lysis.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bryostatins; Cell Differentiation; Cell Line, Tumor; Cholecalciferol; Cytotoxicity, Immunologic; Decitabine; Flow Cytometry; GPI-Linked Proteins; Humans; Hydroxamic Acids; Intercellular Signaling Peptides and Proteins; Killer Cells, Natural; Leukemia, Myeloid; Reverse Transcriptase Polymerase Chain Reaction; Tretinoin; Up-Regulation | 2007 |
Lysyl oxidase-like 2 expression is increased in colon and esophageal tumors and associated with less differentiated colon tumors.
Topics: Adult; Aged; Aged, 80 and over; Amino Acid Oxidoreductases; Azacitidine; Blotting, Western; Cell Differentiation; Cell Line; Colonic Neoplasms; CpG Islands; Decitabine; DNA Primers; Esophageal Neoplasms; Female; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Loss of Heterozygosity; Male; Middle Aged; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction | 2007 |
Frequent inactivation of SPARC by promoter hypermethylation in colon cancers.
Topics: Azacitidine; Cell Line, Tumor; Colonic Neoplasms; CpG Islands; Decitabine; DNA Methylation; DNA, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Oligonucleotide Array Sequence Analysis; Osteonectin; Prognosis; Promoter Regions, Genetic; Survival Analysis | 2007 |
5-aza-2'-deoxycytidine delays androgen-independent disease and improves survival in the transgenic adenocarcinoma of the mouse prostate mouse model of prostate cancer.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Azacitidine; Castration; Combined Modality Therapy; Decitabine; Disease Models, Animal; Male; Mice; Mice, Transgenic; Neoplasms, Hormone-Dependent; Prostatic Neoplasms | 2007 |
Epigenetic combination therapy as a tumor-selective treatment approach for hepatocellular carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Decitabine; DNA Methylation; DNA Modification Methylases; Drug Screening Assays, Antitumor; Epigenesis, Genetic; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Liver Neoplasms; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Vorinostat | 2007 |
Clonogenic acute myelogenous leukemia cells are heterogeneous with regard to regulation of differentiation and effect of epigenetic pharmacological targeting.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Azacitidine; Cell Cycle; Cell Differentiation; Cell Proliferation; Decitabine; DNA, Mitochondrial; Enzyme Inhibitors; Epigenesis, Genetic; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Phenylbutyrates; Thymidine; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2007 |
Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells.
Topics: Annexin A5; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Azacitidine; Cell Cycle; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Decitabine; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Humans; Hydroxamic Acids; Methylation; Pancreatic Neoplasms; Vorinostat | 2007 |
DNA methylation regulates tissue-specific expression of Shank3.
Topics: Animals; Azacitidine; Brain; Carrier Proteins; Cells, Cultured; CpG Islands; Decitabine; DNA Methylation; Embryo, Mammalian; Enzyme Inhibitors; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Neoplastic; Green Fluorescent Proteins; Heart; Hippocampus; Humans; Lymphocytes; Methionine; Microfilament Proteins; Nerve Tissue Proteins; Neurons; Rats; RNA, Small Interfering; Tissue Distribution; Transfection | 2007 |
Overlapping roles of the methylated DNA-binding protein MBD1 and polycomb group proteins in transcriptional repression of HOXA genes and heterochromatin foci formation.
Topics: Azacitidine; Chromatin Assembly and Disassembly; Decitabine; DNA Methylation; DNA-Binding Proteins; Enzyme Inhibitors; Gene Silencing; HeLa Cells; Heterochromatin; Homeodomain Proteins; Humans; Ligases; Mutation; Polycomb Repressive Complex 1; Polycomb-Group Proteins; Repressor Proteins; RNA, Small Interfering; Transcription Factors; Transcription, Genetic; Ubiquitin-Protein Ligases | 2007 |
Down-regulation of IL-7Ralpha expression in human T cells via DNA methylation.
Topics: Azacitidine; CD8-Positive T-Lymphocytes; Cytokines; Decitabine; DNA Methylation; Down-Regulation; Gene Expression Regulation; Humans; Immunologic Memory; Jurkat Cells; Promoter Regions, Genetic; Receptors, Interleukin-7; T-Lymphocytes | 2007 |
Methylation of Ras association domain family protein 1, isoform A correlated with proliferation and drug resistance in hepatocellular carcinoma cell line SMMC-7721.
Topics: Animals; Antineoplastic Agents; Azacitidine; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Decitabine; DNA Methylation; DNA Modification Methylases; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enzyme Inhibitors; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Liver Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Mitomycin; Neoplastic Stem Cells; Transfection; Tumor Suppressor Proteins | 2007 |
Epigenetic and functional analysis of IGFBP3 and IGFBPrP1 in cellular immortalization.
Topics: Azacitidine; Blotting, Western; Cell Division; Cell Line, Transformed; Cell Proliferation; Cell Transformation, Neoplastic; Cluster Analysis; Decitabine; Epigenesis, Genetic; Gene Expression; Gene Expression Profiling; Humans; Insulin-Like Growth Factor Binding Protein 3; Insulin-Like Growth Factor Binding Protein 4; Insulin-Like Growth Factor Binding Proteins; Interferon-alpha; Li-Fraumeni Syndrome; Oligonucleotide Array Sequence Analysis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2007 |
High-resolution analysis of 3p deletion in neuroblastoma and differential methylation of the SEMA3B tumor suppressor gene.
Topics: Adolescent; Antineoplastic Agents; Azacitidine; Base Sequence; Cell Differentiation; Cell Line; Cell Line, Tumor; Child; Child, Preschool; Chromosome Breakage; Chromosome Deletion; Chromosomes, Human, Pair 3; CpG Islands; Decitabine; DNA Methylation; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Humans; Infant; Membrane Glycoproteins; Molecular Sequence Data; Neuroblastoma; Nucleic Acid Hybridization; Reverse Transcriptase Polymerase Chain Reaction; Semaphorins; Tretinoin | 2007 |
LOXL1 and LOXL4 are epigenetically silenced and can inhibit ras/extracellular signal-regulated kinase signaling pathway in human bladder cancer.
Topics: Amino Acid Oxidoreductases; Azacitidine; Cell Line, Tumor; Cytoplasm; Decitabine; DNA Methylation; Epigenesis, Genetic; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; MAP Kinase Signaling System; Mutation; Neoplastic Stem Cells; Protein-Lysine 6-Oxidase; ras Proteins; Urinary Bladder Neoplasms | 2007 |
Tissue factor pathway inhibitor-2 as a frequently silenced tumor suppressor gene in hepatocellular carcinoma.
Topics: Azacitidine; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Decitabine; DNA Methylation; Epigenesis, Genetic; Gene Expression Profiling; Gene Silencing; Genes, Tumor Suppressor; Glycoproteins; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Immunohistochemistry; Liver Neoplasms; Neoplasm Invasiveness; Promoter Regions, Genetic; Serine Proteinase Inhibitors | 2007 |
Epigenetic regulation (DNA methylation, histone modifications) of the 11p15 mucin genes (MUC2, MUC5AC, MUC5B, MUC6) in epithelial cancer cells.
Topics: Acylation; Azacitidine; Chromosomes, Human, Pair 11; Decitabine; DNA Methylation; Epigenesis, Genetic; Epithelial Cells; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Molecular Sequence Data; Mucin 5AC; Mucin-2; Mucin-5B; Mucin-6; Mucins; Neoplasms; Tumor Cells, Cultured | 2007 |
Transcriptional silencing of the TMS1/ASC tumour suppressor gene by an epigenetic mechanism in hepatocellular carcinoma cells.
Topics: Acetylation; Antimetabolites, Antineoplastic; Azacitidine; Carcinoma, Hepatocellular; CARD Signaling Adaptor Proteins; Cell Line, Tumor; Cytoskeletal Proteins; Decitabine; DNA Methylation; Enzyme Inhibitors; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Gene Silencing; Genes, Tumor Suppressor; Histones; Humans; Hydroxamic Acids; Liver Neoplasms; Methylation; Promoter Regions, Genetic; RNA, Messenger; RNA, Neoplasm; Transcription, Genetic | 2007 |
Genetic and epigenetic alterations of LTF at 3p21.3 in nasopharyngeal carcinoma.
Topics: Azacitidine; Base Sequence; Carcinoma; Cell Line, Tumor; Chromosomes, Human, Pair 3; CpG Islands; Decitabine; DNA Methylation; DNA Modification Methylases; DNA Mutational Analysis; Down-Regulation; Enzyme Inhibitors; Epigenesis, Genetic; Exons; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Lactoferrin; Loss of Heterozygosity; Male; Middle Aged; Molecular Sequence Data; Mutation; Nasopharyngeal Neoplasms; Polymorphism, Single-Stranded Conformational; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2006 |
Global genomic methylation levels in the liver and gonads of the three-spine stickleback (Gasterosteus aculeatus) after exposure to hexabromocyclododecane and 17-beta oestradiol.
Topics: Animals; Azacitidine; Carcinogens; Decitabine; Deoxycytidine; DNA; Estradiol; Female; Gonads; Hydrocarbons, Brominated; Liver; Male; Methylation; Smegmamorpha | 2008 |
Identification of epigenetically silenced genes in tumor endothelial cells.
Topics: Azacitidine; Caco-2 Cells; Clusterin; Colonic Neoplasms; Decitabine; DNA Methylation; DNA Modification Methylases; Endothelial Cells; Epigenesis, Genetic; Fibrillin-1; Fibrillins; Gene Expression Regulation, Neoplastic; Gene Silencing; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Microfilament Proteins; Neovascularization, Pathologic; Oxidoreductases Acting on Sulfur Group Donors; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; Thioredoxins | 2007 |
Promoter methylation of PARG1, a novel candidate tumor suppressor gene in mantle-cell lymphomas.
Topics: Azacitidine; Cell Line, Tumor; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 14; Decitabine; Disease Progression; DNA Methylation; DNA, Neoplasm; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Silencing; Genes, Tumor Suppressor; GTPase-Activating Proteins; Humans; Lymphoma, Mantle-Cell; Neoplasm Proteins; Oligonucleotide Array Sequence Analysis; Polymerase Chain Reaction; Promoter Regions, Genetic; Transcription, Genetic; Translocation, Genetic | 2007 |
Trichostatin A, sodium butyrate, and 5-aza-2'-deoxycytidine alter the expression of glucocorticoid receptor alpha and beta isoforms in Hut-78 T- and Raji B-lymphoma cell lines.
Topics: Antineoplastic Agents; Azacitidine; Blotting, Western; Butyrates; Cell Line, Tumor; Decitabine; Electrophoresis, Polyacrylamide Gel; Enzyme Inhibitors; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Humans; Hydroxamic Acids; Lymphoma; Polymerase Chain Reaction; Receptors, Glucocorticoid; Reverse Transcription | 2007 |
Epigenetic regulation of leptin affects MMP-13 expression in osteoarthritic chondrocytes: possible molecular target for osteoarthritis therapeutic intervention.
Topics: Acetylation; Adult; Aged; Aged, 80 and over; Analysis of Variance; Azacitidine; Blotting, Western; Cartilage, Articular; Case-Control Studies; Chondrocytes; Decitabine; DNA Methylation; DNA Modification Methylases; Female; Gene Expression; Gene Expression Regulation; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Knee Joint; Leptin; Male; Matrix Metalloproteinase 13; Matrix Metalloproteinase 3; Matrix Metalloproteinase 9; Middle Aged; Osteoarthritis; Promoter Regions, Genetic; RNA Interference; RNA, Small Interfering | 2007 |
Tumor suppressor activity of CCAAT/enhancer binding protein alpha is epigenetically down-regulated in head and neck squamous cell carcinoma.
Topics: Azacitidine; Carcinoma, Squamous Cell; CCAAT-Enhancer-Binding Protein-alpha; Cell Differentiation; Cell Line, Tumor; Decitabine; DNA Methylation; Down-Regulation; Epigenesis, Genetic; Gene Deletion; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Head and Neck Neoplasms; Humans; Loss of Heterozygosity; Neoplasm Metastasis; Transfection | 2007 |
Transcriptional activation of steroidogenic factor-1 by hypomethylation of the 5' CpG island in endometriosis.
Topics: Aromatase; Aromatase Inhibitors; Azacitidine; Blotting, Western; Cells, Cultured; Chromatin; CpG Islands; Decitabine; DNA Methylation; Endometriosis; Enzyme Inhibitors; Female; Genes, Reporter; Homeodomain Proteins; Humans; Immunoprecipitation; Luciferases; Plasmids; Receptors, Cytoplasmic and Nuclear; Reverse Transcriptase Polymerase Chain Reaction; RNA; Steroidogenic Factor 1; Transcription Factors; Transcriptional Activation; Transfection | 2007 |
Diverse histone modifications on histone 3 lysine 9 and their relation to DNA methylation in specifying gene silencing.
Topics: Acetylation; Animals; Azacitidine; Cell Line, Tumor; Chromatin Immunoprecipitation; CpG Islands; Decitabine; DNA Methylation; DNA Modification Methylases; Gene Expression Regulation; Gene Silencing; Histones; Hydroxamic Acids; Leukemia L1210; Lysine; Methylation; Mice; Mice, Inbred DBA; Oligonucleotide Array Sequence Analysis; Protein Processing, Post-Translational | 2007 |
Association of DNA methylation and epigenetic inactivation of RASSF1A and beta-catenin with metastasis in small bowel carcinoid tumors.
Topics: Azacitidine; beta Catenin; Blotting, Western; Carcinoid Tumor; Cell Line, Tumor; CpG Islands; Decitabine; DNA Methylation; DNA Mutational Analysis; Enterochromaffin Cells; Epigenesis, Genetic; Humans; Immunohistochemistry; Intestinal Neoplasms; Neoplasm Metastasis; Promoter Regions, Genetic; Tumor Suppressor Proteins | 2006 |
Short hairpin RNA causes the methylation of transforming growth factor-beta receptor II promoter and silencing of the target gene in rat hepatic stellate cells.
Topics: Animals; Azacitidine; Base Sequence; Cell Line; CpG Islands; Decitabine; DNA Methylation; Gene Silencing; Liver; Molecular Sequence Data; Nucleotides; Promoter Regions, Genetic; Protein Serine-Threonine Kinases; Rats; Receptor, Transforming Growth Factor-beta Type II; Receptors, Transforming Growth Factor beta; RNA, Small Interfering; Sequence Analysis, DNA; Sequence Homology, Nucleic Acid; Transcription, Genetic | 2007 |
[Expression of ER alpha in chemically induced MDA-MB-435 cells and its responsiveness to endocrine].
Topics: Animals; Azacitidine; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Decitabine; DNA Modification Methylases; Enzyme Inhibitors; Estrogen Receptor alpha; Female; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Ovariectomy; Receptors, Progesterone; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Trefoil Factor-1; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2006 |
[Demethylation of estrogen receptor gene and its re-expression in estrogen receptor-negative breast].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Azacitidine; Base Sequence; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Decitabine; DNA Methylation; Estrogen Receptor alpha; Female; Gene Expression Regulation, Neoplastic; Humans; Promoter Regions, Genetic; Receptors, Progesterone; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Selective Estrogen Receptor Modulators; Tamoxifen | 2006 |
Functional up-regulation of human leukocyte antigen class I antigens expression by 5-aza-2'-deoxycytidine in cutaneous melanoma: immunotherapeutic implications.
Topics: Azacitidine; Cell Line, Tumor; Decitabine; Fluorescent Antibody Technique, Indirect; Gene Expression Regulation, Neoplastic; gp100 Melanoma Antigen; Histocompatibility Antigens Class I; Humans; Immunotherapy; Interferon-gamma; Melanoma; Membrane Glycoproteins; Reverse Transcriptase Polymerase Chain Reaction; Skin Neoplasms; T-Lymphocytes, Cytotoxic; Up-Regulation | 2007 |
Down-regulation of PU.1 by methylation of distal regulatory elements and the promoter is required for myeloma cell growth.
Topics: Apoptosis; Azacitidine; Base Sequence; Cell Growth Processes; Cell Line, Tumor; Decitabine; DNA Methylation; Down-Regulation; Gene Expression Regulation, Neoplastic; Humans; Introns; Molecular Sequence Data; Multiple Myeloma; Prognosis; Promoter Regions, Genetic; Proto-Oncogene Proteins; Regulatory Elements, Transcriptional; Trans-Activators; Up-Regulation | 2007 |
[Effect of adenomatous polyposis coli(APC) promoter methylation on gene transcription in lung cancer cell lines].
Topics: Adenocarcinoma; Adenomatous Polyposis Coli Protein; Azacitidine; Carcinoma, Large Cell; Cell Line, Tumor; CpG Islands; Decitabine; DNA Methylation; Genes, APC; Humans; Lung Neoplasms; Promoter Regions, Genetic; Small Cell Lung Carcinoma; Transcription, Genetic | 2007 |
Potential advantages of DNA methyltransferase 1 (DNMT1)-targeted inhibition for cancer therapy.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Azacitidine; Cell Line, Tumor; Cell Proliferation; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Damage; DNA Methylation; DNA Methyltransferase 3B; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; RNA, Small Interfering; Stomach Neoplasms; Transfection | 2007 |
Epigenetic deregulation of multiple S100 gene family members by differential hypomethylation and hypermethylation events in medulloblastoma.
Topics: Adolescent; Adult; Azacitidine; Cell Line, Tumor; Cerebellar Neoplasms; Cerebellum; Child; Child, Preschool; Decitabine; DNA Methylation; DNA Modification Methylases; Epigenesis, Genetic; Female; Gene Expression Regulation, Neoplastic; Humans; Infant; Male; Medulloblastoma; S100 Proteins | 2007 |
Adverse effects of 5-aza-2'-deoxycytidine on spermatogenesis include reduced sperm function and selective inhibition of de novo DNA methylation.
Topics: Animals; Azacitidine; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Genotype; Infertility, Male; Male; Mice; Spermatogenesis; Spermatozoa | 2007 |
PU.1 is dispensable to block erythroid differentiation in Friend erythroleukemia cells.
Topics: Acetamides; Animals; Azacitidine; Cell Differentiation; Decitabine; Drug Resistance; Erythroid Cells; Friend murine leukemia virus; GATA1 Transcription Factor; Genes, myc; Leukemia, Erythroblastic, Acute; Leukemia, Experimental; Mice; Proto-Oncogene Proteins; RNA, Small Interfering; Trans-Activators; Tumor Cells, Cultured | 2008 |
De novo protein synthesis is required for lytic cycle reactivation of Epstein-Barr virus, but not Kaposi's sarcoma-associated herpesvirus, in response to histone deacetylase inhibitors and protein kinase C agonists.
Topics: Azacitidine; Blotting, Northern; Cell Line; Cycloheximide; Decitabine; DNA-Binding Proteins; Enzyme Inhibitors; Gene Expression; Herpesvirus 4, Human; Herpesvirus 8, Human; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Immediate-Early Proteins; Protein Biosynthesis; Protein Kinase C; Protein Synthesis Inhibitors; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Viral; Tetradecanoylphorbol Acetate; Trans-Activators; Viral Proteins; Virus Activation | 2007 |
PRTFDC1, a possible tumor-suppressor gene, is frequently silenced in oral squamous-cell carcinomas by aberrant promoter hypermethylation.
Topics: Azacitidine; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Chromosomes, Human, Pair 10; CpG Islands; Decitabine; DNA Methylation; Gene Silencing; Genes, Tumor Suppressor; Humans; Mouth Neoplasms; Nucleic Acid Hybridization; Promoter Regions, Genetic; RNA, Messenger | 2007 |
Suppression of DPYD expression in RKO cells via DNA methylation in the regulatory region of the DPYD promoter: a potentially important epigenetic mechanism regulating DPYD expression.
Topics: Azacitidine; Base Sequence; Cell Line, Tumor; Colorectal Neoplasms; Decitabine; Dihydrouracil Dehydrogenase (NADP); DNA Methylation; DNA Primers; DNA, Neoplasm; Epigenesis, Genetic; Gene Expression Regulation, Enzymologic; Humans; Hydroxamic Acids; Promoter Regions, Genetic; RNA, Messenger; RNA, Neoplasm; Sp1 Transcription Factor; Suppression, Genetic | 2007 |
Delivery of 5-aza-2'-deoxycytidine to cells using oligodeoxynucleotides.
Topics: Antineoplastic Agents; Azacitidine; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p16; Decitabine; DNA Methylation; Dose-Response Relationship, Drug; Drug Delivery Systems; Epigenesis, Genetic; Genetic Therapy; Humans; Models, Chemical; Myelodysplastic Syndromes; Oligonucleotides; Triazines; Urinary Bladder Neoplasms | 2007 |
Effects of chromatin-modifying agents on CD34+ cells from patients with idiopathic myelofibrosis.
Topics: Antigens, CD34; Antimetabolites, Antineoplastic; Azacitidine; Cell Movement; Chromatin; Decitabine; DNA (Cytosine-5-)-Methyltransferases; Hematopoietic Stem Cells; Homozygote; Humans; Hydroxamic Acids; Mutation; Primary Myelofibrosis; Protein Synthesis Inhibitors; Receptors, CXCR4; Stem Cells | 2007 |
Epigenetic regulation of microRNA-370 by interleukin-6 in malignant human cholangiocytes.
Topics: Azacitidine; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell Line, Tumor; Cell Proliferation; Cholangiocarcinoma; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Epigenesis, Genetic; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Interleukin-6; MAP Kinase Kinase Kinases; MicroRNAs; Proto-Oncogene Proteins | 2008 |
Promoter methylation regulates estrogen receptor 2 in human endometrium and endometriosis.
Topics: Adult; Azacitidine; Cells, Cultured; CpG Islands; Decitabine; DNA Methylation; Endometriosis; Endometrium; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Gene Expression Regulation; Humans; Promoter Regions, Genetic; Receptors, Progesterone; RNA, Messenger; Stromal Cells | 2007 |
Ornithine decarboxylase antizyme upregulates DNA-dependent protein kinase and enhances the nonhomologous end-joining repair of DNA double-strand breaks in human oral cancer cells.
Topics: Antigens, Nuclear; Azacitidine; Cadherins; Carrier Proteins; Cell Cycle Proteins; Cell Line; Cell Line, Tumor; Cell Nucleus; Decitabine; DNA Breaks, Double-Stranded; DNA Repair; DNA-Activated Protein Kinase; DNA-Binding Proteins; G1 Phase; Gamma Rays; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Histones; Humans; Keratinocytes; Ku Autoantigen; Mouth Neoplasms; Proteins; Transfection; Up-Regulation | 2007 |
Effect of cytarabine and decitabine in combination in human leukemic cell lines.
Topics: Annexin A5; Antimetabolites, Antineoplastic; Azacitidine; Cytarabine; Decitabine; DNA Methylation; DNA, Neoplasm; HL-60 Cells; Humans; Reverse Transcriptase Polymerase Chain Reaction | 2007 |
Regulation and expression of human CYP7B1 in prostate: overexpression of CYP7B1 during progression of prostatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Azacitidine; Cell Line, Tumor; Cytochrome P-450 Enzyme System; Cytochrome P450 Family 7; Decitabine; DNA Methylation; Enzyme Inhibitors; Estrogen Receptor beta; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Male; Middle Aged; Prostatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Statistics, Nonparametric; Steroid Hydroxylases | 2007 |
Re-expression of RASSF1A by 5-Aza-CdR induced demethylation of the promoter region in human biliary tract carcinoma cells.
Topics: Azacitidine; Biliary Tract Neoplasms; Blotting, Western; Cell Line, Tumor; Decitabine; DNA Methylation; Gene Expression Regulation, Neoplastic; Humans; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Suppressor Proteins | 2007 |
Decitabine dosage in myelodysplastic syndromes.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Injections, Subcutaneous; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Randomized Controlled Trials as Topic; Remission Induction; Treatment Outcome | 2007 |
Reversal of methylation silencing of Apo2L/TRAIL receptor 1 (DR4) expression overcomes resistance of SK-MEL-3 and SK-MEL-28 melanoma cells to interferons (IFNs) or Apo2L/TRAIL.
Topics: Apoptosis; Azacitidine; Cell Line, Tumor; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Interferons; Melanoma; Receptors, TNF-Related Apoptosis-Inducing Ligand; TNF-Related Apoptosis-Inducing Ligand | 2008 |
An epigenetic disorder may cause aberrant expression of aromatase gene in endometriotic stromal cells.
Topics: Aromatase; Azacitidine; Cells, Cultured; CpG Islands; Decitabine; DNA Methylation; Endometriosis; Epigenesis, Genetic; Estradiol; Female; Gene Expression Regulation, Enzymologic; Humans; Ovarian Diseases; Promoter Regions, Genetic; RNA, Messenger; Stromal Cells; Uterine Diseases | 2008 |
Dynamic DNA methylation reprogramming: active demethylation and immediate remethylation in the male pronucleus of bovine zygotes.
Topics: Animals; Azacitidine; Cattle; Decitabine; DNA Methylation; Embryonic Development; Enzyme Inhibitors; Epigenesis, Genetic; Gene Expression Regulation, Developmental; Histones; Male; Models, Biological; Parthenogenesis; Rabbits; Spermatozoa; Zygote | 2007 |
Hydroxycarbamide in combination with azacitidine or decitabine is antagonistic on DNA methylation inhibition.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Aphidicolin; Azacitidine; Cell Cycle; Decitabine; DNA Methylation; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Humans; Hydroxyurea; Tumor Cells, Cultured | 2007 |
The synergistic effect of 5-aza-2'-deoxycytidine and 5-fluorouracil on drug-resistant tumors.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Azacitidine; Calcium-Calmodulin-Dependent Protein Kinases; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Cyclin-Dependent Kinase Inhibitor p16; Death-Associated Protein Kinases; Decitabine; DNA Methylation; Drug Resistance, Neoplasm; Drug Synergism; Fluorouracil; Humans; Mice; Mice, Nude; Reverse Transcriptase Polymerase Chain Reaction; Tumor Suppressor Protein p14ARF; Up-Regulation; Xenograft Model Antitumor Assays | 2006 |
The interferon-alpha responsive gene TMEM7 suppresses cell proliferation and is downregulated in human hepatocellular carcinoma.
Topics: Amino Acid Sequence; Animals; Azacitidine; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Decitabine; DNA Methylation; Epigenesis, Genetic; Gene Silencing; Genes, Tumor Suppressor; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Immunohistochemistry; Interferon-alpha; Liver Neoplasms; Male; Mice; Mice, Nude; Molecular Sequence Data; Neoplasm Invasiveness; Promoter Regions, Genetic; Sequence Homology, Amino Acid | 2007 |
Oral decitabine reactivates expression of the methylated gamma-globin gene in Papio anubis.
Topics: Administration, Oral; Animals; Azacitidine; Decitabine; DNA Methylation; DNA Modification Methylases; Fetal Hemoglobin; Gene Expression Regulation; Gene Silencing; Globins; Papio anubis | 2007 |
Epigenetic modulation of estrogen receptor-alpha by pRb family proteins: a novel mechanism in breast cancer.
Topics: Azacitidine; Breast Neoplasms; CCAAT-Enhancer-Binding Proteins; Cell Line, Tumor; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; E1A-Associated p300 Protein; Estrogen Receptor alpha; Humans; Promoter Regions, Genetic; Retinoblastoma Protein; Retinoblastoma-Like Protein p107; Retinoblastoma-Like Protein p130; Ubiquitin-Protein Ligases | 2007 |
Monocytic skin nodules in chronic myelomonocytic leukemia: clinical response to decitabine therapy.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Modification Methylases; Female; Humans; Leukemia, Myelomonocytic, Chronic; Monocytes; Skin Diseases | 2007 |
High expressions of neuronatin isoforms in favorable neuroblastoma.
Topics: Azacitidine; Cell Line, Tumor; Decitabine; DNA Methylation; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Genomic Imprinting; Humans; Infant; Membrane Proteins; Nerve Tissue Proteins; Neuroblastoma; Oligonucleotide Array Sequence Analysis; Prognosis; Protein Isoforms; RNA, Messenger; Up-Regulation | 2007 |
Decitabine up-regulates S100A2 expression and synergizes with IFN-gamma to kill uveal melanoma cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Chemotactic Factors; Decitabine; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Interferon-alpha; Interferon-gamma; Melanoma; S100 Proteins; Tumor Cells, Cultured; Uveal Neoplasms | 2007 |
Effects of 5-aza-2'-deoxycytidine on the gene expression profile during embryogenesis of the Ascidian ciona intestinalis: a microarray analysis.
Topics: Animals; Azacitidine; Ciona intestinalis; Decitabine; Embryo, Nonmammalian; Enzyme Inhibitors; Gene Expression Profiling; Gene Expression Regulation, Developmental; Oligonucleotide Array Sequence Analysis | 2007 |
5-Aza-2'-deoxycytidine increases the expression of anti-angiogenic vascular endothelial growth factor 189b variant in human lung microvascular endothelial cells.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Blotting, Western; Capillaries; Cell Line; Decitabine; Endothelial Cells; Humans; Indicators and Reagents; Lung; Reverse Transcriptase Polymerase Chain Reaction; Stimulation, Chemical; Vascular Endothelial Growth Factor A | 2008 |
Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML).
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cytogenetic Analysis; Decitabine; Female; Humans; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Multicenter Studies as Topic; Prognosis; Randomized Controlled Trials as Topic; Survival Rate; Treatment Outcome | 2008 |
DNA methylation and histone acetylation work in concert to regulate memory formation and synaptic plasticity.
Topics: Acetylation; Animals; Azacitidine; Chromatin; Conditioning, Psychological; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Enzyme Inhibitors; Epigenesis, Genetic; Fear; Histone Deacetylase Inhibitors; Histone Deacetylases; Histones; Memory; Neuronal Plasticity; Rats | 2008 |
Epigenetic dysregulation of Wnt signaling pathway in multiple myeloma.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Aged, 80 and over; Azacitidine; Base Sequence; beta Catenin; Cell Line, Tumor; Decitabine; DNA Methylation; DNA, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Intercellular Signaling Peptides and Proteins; Male; Middle Aged; Molecular Sequence Data; Multiple Myeloma; Neoplasm Proteins; Phosphorylation; Protein Processing, Post-Translational; Recombinant Proteins; Signal Transduction; Wnt Proteins | 2007 |
Trichostatin A and 5 Aza-2' deoxycytidine decrease estrogen receptor mRNA stability in ER positive MCF7 cells through modulation of HuR.
Topics: 3' Untranslated Regions; Antigens, Surface; Azacitidine; Base Sequence; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Decitabine; ELAV Proteins; ELAV-Like Protein 1; Enzyme Inhibitors; Epigenesis, Genetic; Estrogen Receptor alpha; Estrogen Receptor Modulators; Female; Humans; Hydroxamic Acids; Immunoprecipitation; Molecular Sequence Data; Oligonucleotide Array Sequence Analysis; Reverse Transcriptase Polymerase Chain Reaction; RNA Stability; RNA-Binding Proteins; RNA, Messenger; Transfection | 2008 |
Downregulation of microRNAs-143 and -145 in B-cell malignancies.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Burkitt Lymphoma; Cell Line, Tumor; Cell Survival; Decitabine; Down-Regulation; Gene Expression Regulation, Neoplastic; Humans; Hydroxamic Acids; Leukemia, Lymphocytic, Chronic, B-Cell; Lymph Nodes; Lymphoma, B-Cell; MicroRNAs; RNA, Neoplasm; Tumor Cells, Cultured | 2007 |
Gene induction and apoptosis in human hepatocellular carci-noma cells SMMC-7721 exposed to 5-aza-2'-deoxycytidine.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; CpG Islands; Decitabine; DNA Modification Methylases; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Transcriptional Activation | 2007 |
Transbuccal delivery of 5-aza-2 -deoxycytidine: effects of drug concentration, buffer solution, and bile salts on permeation.
Topics: Animals; Azacitidine; Bile Acids and Salts; Buffers; Cheek; Chromatography, High Pressure Liquid; Decitabine; Mouth Mucosa; Osmolar Concentration; Permeability; Swine | 2007 |
The N-methyl-D-aspartate receptor type 2A is frequently methylated in human colorectal carcinoma and suppresses cell growth.
Topics: Azacitidine; Carcinoma; Cell Proliferation; Colorectal Neoplasms; Decitabine; DNA Methylation; DNA Modification Methylases; Humans; Immunohistochemistry; Promoter Regions, Genetic; Receptors, N-Methyl-D-Aspartate; Tissue Array Analysis | 2008 |
[The role of secreted Wnt-antagonist genes hypermethylation in early detection of colorectal tumor].
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenoma; Adult; Aged; Azacitidine; Cell Line, Tumor; Colorectal Neoplasms; Decitabine; DNA Methylation; Enzyme Inhibitors; Female; Gene Expression Regulation, Neoplastic; Glycoproteins; HCT116 Cells; Humans; Hydroxamic Acids; Intestinal Mucosa; Intracellular Signaling Peptides and Proteins; Male; Middle Aged; Repressor Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2007 |
Combining epigenetic and cytotoxic therapy in the treatment of solid tumors.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Clinical Trials as Topic; CpG Islands; Decitabine; DNA Methylation; Drug Resistance, Neoplasm; Epigenesis, Genetic; Humans; Mice; Models, Genetic; Neoplasms | 2007 |
Downregulation of several fibulin genes in prostate cancer.
Topics: Aged; Azacitidine; Calcium-Binding Proteins; Cell Line, Tumor; Decitabine; DNA Methylation; Down-Regulation; Extracellular Matrix Proteins; Gene Dosage; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Male; Middle Aged; Prostatic Neoplasms; Proteoglycans; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2007 |
Inducible expression of a prostate cancer-testis antigen, SSX-2, following treatment with a DNA methylation inhibitor.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Neoplasm; Antibody Specificity; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Methylation; Gene Expression Regulation, Neoplastic; Humans; Immunoblotting; Immunoglobulin G; Male; Membrane Proteins; Middle Aged; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Repressor Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2007 |
ZIC1 gene expression is controlled by DNA and histone methylation in mesenchymal proliferations.
Topics: Animals; Azacitidine; Base Sequence; Cell Proliferation; Decitabine; DNA Methylation; DNA Modification Methylases; Fibromatosis, Aggressive; Gene Expression Regulation; Histones; Humans; Mesoderm; Methylation; Mice; Molecular Sequence Data; NIH 3T3 Cells; Promoter Regions, Genetic; Transcription Factors | 2007 |
DNA methylation state is preserved in the sperm-derived pronucleus of the pig zygote.
Topics: Animals; Azacitidine; Cell Nucleus; CpG Islands; Decitabine; DNA; DNA Methylation; Epigenesis, Genetic; Immunohistochemistry; Male; Methylation; Mice; Polymerase Chain Reaction; Spermatozoa; Swine; Zygote | 2007 |
Genetic and epigenetic changes in the common 1p36 deletion in neuroblastoma tumours.
Topics: Adaptor Proteins, Signal Transducing; Azacitidine; Cell Line, Tumor; Chromosome Deletion; Chromosomes, Human, Pair 1; Class I Phosphatidylinositol 3-Kinases; Decitabine; DNA Methylation; DNA Mutational Analysis; DNA-Binding Proteins; DNA, Neoplasm; Exons; Genetic Variation; Histones; Humans; Hydroxamic Acids; Mutation; Neuroblastoma; Phosphatidylinositol 3-Kinases; Polymorphism, Genetic; Retinol-Binding Proteins, Cellular; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Transcription Factors; Transcription, Genetic; Tumor Suppressor Proteins; Up-Regulation | 2007 |
Epigenetic inactivation of microRNA gene hsa-mir-9-1 in human breast cancer.
Topics: Azacitidine; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; CpG Islands; Decitabine; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Genes, Tumor Suppressor; Humans; MicroRNAs; RNA, Neoplasm; Tumor Cells, Cultured | 2008 |
Modulation of HLA-G expression.
Topics: Azacitidine; Base Sequence; Cell Hypoxia; Cell Line, Tumor; Decitabine; Enzyme Inhibitors; Epigenesis, Genetic; Flow Cytometry; Gene Expression; Gene Expression Regulation; Histocompatibility Antigens Class I; HLA Antigens; HLA-G Antigens; Hot Temperature; Humans; Molecular Sequence Data; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Transcription, Genetic; Valproic Acid | 2007 |
Promoter methylation is associated with the age-dependent loss of N-cadherin in the rat kidney.
Topics: Aging; Animals; Azacitidine; Base Sequence; Cadherins; Cells, Cultured; Cytosine; Decitabine; DNA; DNA Methylation; Enzyme Inhibitors; Gene Expression Regulation; Guanine; Kidney; Liver; Male; Molecular Sequence Data; Promoter Regions, Genetic; Rats; Rats, Inbred F344 | 2008 |
Metastatic suppressor genes inactivated by aberrant methylation in gastric cancer.
Topics: Azacitidine; Decitabine; DNA Methylation; DNA, Neoplasm; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Genetic Testing; Humans; Lymph Nodes; Lymphatic Metastasis; Receptor-Like Protein Tyrosine Phosphatases, Class 5; RNA, Messenger; Stomach Neoplasms | 2007 |
p300 expression repression by hypermethylation associated with tumour invasion and metastasis in oesophageal squamous cell carcinoma.
Topics: Azacitidine; Carcinoma, Squamous Cell; Decitabine; DNA Methylation; DNA, Neoplasm; E1A-Associated p300 Protein; Esophageal Neoplasms; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Lymphatic Metastasis; Male; Neoplasm Invasiveness; Neoplasm Proteins; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm | 2007 |
Increased iodine uptake in thyroid carcinoma after treatment with sodium butyrate and decitabine (5-Aza-dC).
Topics: Acetylation; Azacitidine; Blotting, Western; Butyrates; Cell Line, Tumor; Decitabine; DNA Methylation; Drug Therapy, Combination; Epigenesis, Genetic; Humans; Iodine Radioisotopes; Polymerase Chain Reaction; RNA, Messenger; Sodium Iodide; Symporters; Thyroid Neoplasms | 2007 |
An ATM- and Rad3-related (ATR) signaling pathway and a phosphorylation-acetylation cascade are involved in activation of p53/p21Waf1/Cip1 in response to 5-aza-2'-deoxycytidine treatment.
Topics: Acetylation; Ataxia Telangiectasia Mutated Proteins; Azacitidine; Base Sequence; Cell Cycle Proteins; Cell Line; Cyclin-Dependent Kinase Inhibitor p21; Decitabine; DNA Damage; DNA Primers; Humans; Mutagenesis, Site-Directed; Phosphorylation; Promoter Regions, Genetic; Protein Serine-Threonine Kinases; Replication Protein A; Signal Transduction; Tumor Suppressor Protein p53; Ubiquitination | 2008 |
The Cables gene on chromosome 18q is silenced by promoter hypermethylation and allelic loss in human colorectal cancer.
Topics: Adenocarcinoma; Azacitidine; Carrier Proteins; Cell Line, Tumor; Cell Proliferation; Chromosomes, Human, Pair 18; Colorectal Neoplasms; Cyclins; Decitabine; DNA Methylation; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Loss of Heterozygosity; Mutation; Phosphoproteins; Promoter Regions, Genetic | 2007 |
Regulation of the CLDN3 gene in ovarian cancer cells.
Topics: Azacitidine; Binding Sites; Cell Line, Tumor; Claudin-3; Claudin-4; CpG Islands; Decitabine; DNA Methylation; Female; Humans; Hydroxamic Acids; Membrane Proteins; Mutagenesis, Site-Directed; Ovarian Neoplasms; Promoter Regions, Genetic; RNA, Messenger; Sp1 Transcription Factor; Sp3 Transcription Factor | 2007 |
DNA methylation inhibitor 5-Aza-2'-deoxycytidine induces reversible genome-wide DNA damage that is distinctly influenced by DNA methyltransferases 1 and 3B.
Topics: Ataxia Telangiectasia Mutated Proteins; Azacitidine; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Checkpoint Kinase 1; Decitabine; DNA; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Damage; DNA Methylation; DNA Methyltransferase 3B; DNA-Binding Proteins; Enzyme Inhibitors; Genetic Markers; Genome, Human; Histones; Humans; Neoplasms; Protein Binding; Protein Kinases; Protein Serine-Threonine Kinases; Tumor Suppressor Proteins | 2008 |
Epigenetic silencing of telomerase and a non-alkylating agent as a novel therapeutic approach for glioma.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Brain Neoplasms; Cell Line, Tumor; Cellular Senescence; Decitabine; DNA Methylation; Dose-Response Relationship, Drug; Down-Regulation; Drug Resistance, Neoplasm; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Gene Silencing; Glioma; Humans; Methyltransferases; Paclitaxel; RNA, Messenger; Telomerase | 2008 |
DNA methyltransferase 3B (DNMT3B) mutations in ICF syndrome lead to altered epigenetic modifications and aberrant expression of genes regulating development, neurogenesis and immune function.
Topics: Abnormalities, Multiple; Acetylation; Azacitidine; B-Lymphocytes; Case-Control Studies; Cell Line, Transformed; Cell Transformation, Viral; Cells, Cultured; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Methyltransferase 3B; Enzyme Inhibitors; Epigenesis, Genetic; Female; Gene Expression Profiling; Gene Expression Regulation, Developmental; Genes, Recessive; Histones; Humans; Hydroxamic Acids; Immunologic Deficiency Syndromes; Intellectual Disability; Male; Mutation; Neurons; Oligonucleotide Array Sequence Analysis; Promoter Regions, Genetic; Time Factors | 2008 |
Hypomethylation and aberrant expression of the glioma pathogenesis-related 1 gene in Wilms tumors.
Topics: Adolescent; Adult; Aged; Azacitidine; Base Sequence; Child; Decitabine; DNA Methylation; Female; Gene Dosage; Gene Expression Regulation, Neoplastic; Gene Silencing; Genes, Tumor Suppressor; Humans; Immunohistochemistry; Kidney Neoplasms; Male; Membrane Proteins; Middle Aged; Molecular Sequence Data; Neoplasm Proteins; Nerve Tissue Proteins; RNA, Messenger; Transcriptional Activation; Wilms Tumor | 2007 |
CpG methylation plays a vital role in determining tissue- and cell-specific expression of the human cell-death-inducing DFF45-like effector A gene through the regulation of Sp1/Sp3 binding.
Topics: Apoptosis Regulatory Proteins; Azacitidine; Base Sequence; Binding Sites; Cell Line; Cell Line, Tumor; Chromatin; CpG Islands; Decitabine; DNA Methylation; Exons; Gene Expression; Gene Expression Regulation; Humans; Molecular Sequence Data; Promoter Regions, Genetic; RNA Interference; Sp1 Transcription Factor; Sp3 Transcription Factor; Tissue Distribution | 2008 |
Alpha anomer of 5-aza-2'-deoxycytidine down-regulates hTERT mRNA expression in human leukemia HL-60 cells.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA; DNA Methylation; Dose-Response Relationship, Drug; Down-Regulation; HL-60 Cells; Humans; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; S-Adenosylhomocysteine; S-Adenosylmethionine; Stereoisomerism; Telomerase | 2008 |
The effects of nucleoside analogues on promoter methylation of selected tumor suppressor genes in MCF-7 and MDA-MB-231 breast cancer cell lines.
Topics: Antineoplastic Agents; Azacitidine; Breast Neoplasms; Cell Line, Tumor; Cladribine; Decitabine; DNA Methylation; DNA, Neoplasm; Female; Genes, APC; Genes, BRCA1; Genes, Tumor Suppressor; Humans; Nucleosides; Promoter Regions, Genetic; PTEN Phosphohydrolase; Receptors, Retinoic Acid; Vidarabine | 2007 |
Effects of 5-Aza-CdR on cell proliferation of breast cancer cell line MDA-MB-435S and expression of maspin gene.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Decitabine; Female; Humans; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Serpins | 2007 |
Epigenetic memory of an active gene state depends on histone H3.3 incorporation into chromatin in the absence of transcription.
Topics: Animals; Azacitidine; Blotting, Western; Chromatin; Chromatin Immunoprecipitation; Decitabine; DNA Methylation; DNA Modification Methylases; Embryo, Nonmammalian; Enzyme Inhibitors; Epigenesis, Genetic; Gene Expression Regulation, Developmental; Histones; Models, Biological; Mutation; MyoD Protein; Nuclear Transfer Techniques; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; Transcription, Genetic; Xenopus; Xenopus Proteins | 2008 |
Genome-wide demethylation promotes triplet repeat instability independently of homologous recombination.
Topics: Adenine Phosphoribosyltransferase; Animals; Azacitidine; CHO Cells; Cricetinae; Cricetulus; Decitabine; DNA Methylation; DNA Primers; Genomic Instability; Recombination, Genetic; Reverse Transcriptase Polymerase Chain Reaction; Trinucleotide Repeats | 2008 |
DNA demethylation and histone deacetylation inhibition co-operate to re-express estrogen receptor beta and induce apoptosis in prostate cancer cell-lines.
Topics: Apoptosis; Azacitidine; Cell Line, Tumor; Cell Proliferation; Decitabine; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Estrogen Receptor alpha; Estrogen Receptor beta; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Receptors, Androgen; Receptors, Progesterone | 2008 |
Drugs affecting prelamin A processing: effects on heterochromatin organization.
Topics: Acetylcysteine; Adult; Antimetabolites, Antineoplastic; Azacitidine; Cell Nucleus; Cells, Cultured; Chromatin Assembly and Disassembly; Decitabine; DNA-Binding Proteins; Enzyme Inhibitors; Farnesyltranstransferase; Fibroblasts; Heterochromatin; Humans; Lamin Type A; Membrane Proteins; Methionine; Nuclear Lamina; Nuclear Proteins; Protein Precursors; Protein Prenylation | 2008 |
Genome-wide transcriptional response to 5-aza-2'-deoxycytidine and trichostatin a in multiple myeloma cells.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Methylation; DNA Modification Methylases; DNA, Neoplasm; Enzyme Inhibitors; Epigenesis, Genetic; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genes, Neoplasm; Genome, Human; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Multiple Myeloma; Transcription, Genetic; Tumor Cells, Cultured | 2008 |
Myelodysplastic syndromes: introduction.
Topics: Azacitidine; Decitabine; Hematopoietic Stem Cell Transplantation; Humans; Intercellular Signaling Peptides and Proteins; Lenalidomide; Myelodysplastic Syndromes; Thalidomide | 2008 |
DNA hypomethylation circuit of the mouse oocyte-specific histone H1foo gene in female germ cell lineage.
Topics: Animals; Azacitidine; Blastocyst; Cell Lineage; Cells, Cultured; Decitabine; DNA; DNA Methylation; Embryonic Stem Cells; Enzyme Inhibitors; Female; Fertilization; Histones; Luciferases; Luminescent Agents; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Oocytes; Oogenesis; Proteins; RNA, Messenger | 2008 |
Regulation of demethylation and re-expression of RASSF1A gene in gastric cancer cell lines by combined treatment of 5-Aza-CdR and NaB.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Butyrates; Cell Line, Tumor; Decitabine; DNA Methylation; Drug Therapy, Combination; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Humans; Stomach Neoplasms; Tumor Suppressor Proteins | 2008 |
Epigenetic-based treatments emphasize the biologic differences of core-binding factor acute myeloid leukemias.
Topics: Adult; Azacitidine; Biomarkers, Tumor; Chromatin Assembly and Disassembly; Chromosome Inversion; Chromosomes, Human, Pair 16; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Core Binding Factor Alpha 2 Subunit; Decitabine; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Epigenesis, Genetic; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Leukemia, Myeloid, Acute; Mutation; Oligonucleotide Array Sequence Analysis; Oncogene Proteins, Fusion; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RUNX1 Translocation Partner 1 Protein; Translocation, Genetic; Tumor Cells, Cultured; U937 Cells | 2008 |
Differential epigenetic regulation of Aiolos expression in human tumoral cell lines and primary cells.
Topics: Acetylation; Antineoplastic Agents; Azacitidine; Cell Culture Techniques; Cell Line, Tumor; Chromatin; CpG Islands; Decitabine; DNA Methylation; Drug Combinations; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Histone Acetyltransferases; Histones; Humans; Hydroxamic Acids; Ikaros Transcription Factor; Jurkat Cells; Neoplasms; Promoter Regions, Genetic; Transcription Factors; Transcriptional Activation; U937 Cells | 2008 |
Simultaneous determination of decitabine and vorinostat (Suberoylanalide hydroxamic acid, SAHA) by liquid chromatography tandem mass spectrometry for clinical studies.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Chromatography, High Pressure Liquid; Decitabine; Freezing; Humans; Hydroxamic Acids; Reference Standards; Reproducibility of Results; Solutions; Tandem Mass Spectrometry; Vorinostat | 2008 |
The DNA demethylating agent 5-aza-2'-deoxycytidine activates NY-ESO-1 antigenicity in orthotopic human glioma.
Topics: Adoptive Transfer; Analysis of Variance; Animals; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Asian People; Azacitidine; Blotting, Western; Brain Neoplasms; Chromosome Mapping; CpG Islands; Decitabine; DNA Methylation; Flow Cytometry; Gene Expression Regulation, Neoplastic; Glioma; Histocompatibility Antigens Class I; Humans; Kaplan-Meier Estimate; Male; Membrane Proteins; Mice; Mice, Inbred NOD; Mice, SCID; Microarray Analysis; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; T-Lymphocytes, Cytotoxic; Testis; Transplantation, Heterologous; Up-Regulation | 2008 |
Effects of cellular differentiation, chromosomal integration and 5-aza-2'-deoxycytidine treatment on human papillomavirus-16 DNA methylation in cultured cell lines.
Topics: Azacitidine; Cell Differentiation; Decitabine; DNA Methylation; Epithelial Cells; Extrachromosomal Inheritance; Female; Human papillomavirus 16; Humans; Oncogene Proteins, Viral; Papillomavirus E7 Proteins; Repressor Proteins; Tumor Cells, Cultured; Uterine Cervical Dysplasia; Uterine Cervical Neoplasms; Virus Integration | 2008 |
5-Aza-2'-deoxycytidine suppresses human renal carcinoma cell growth in a xenograft model via up-regulation of the connexin 32 gene.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Carcinoma, Renal Cell; Cell Line, Tumor; Connexins; Decitabine; Female; Gap Junction beta-1 Protein; Humans; Mice; Mice, Nude; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Up-Regulation; Xenograft Model Antitumor Assays | 2008 |
ER alpha negative breast cancer cells restore response to endocrine therapy by combination treatment with both HDAC inhibitor and DNMT inhibitor.
Topics: Animals; Azacitidine; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; Enzyme Inhibitors; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogens; Female; Flow Cytometry; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Mice; Receptors, Progesterone; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tamoxifen; Trefoil Factor-1; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2008 |
Epigenetic silencing of maspin expression occurs early in the conversion of keratocytes to fibroblasts.
Topics: Azacitidine; Base Sequence; Blotting, Western; Cell Differentiation; Cells, Cultured; Corneal Stroma; Decitabine; DNA Methylation; DNA Modification Methylases; Down-Regulation; Enzyme Inhibitors; Epigenesis, Genetic; Eye Proteins; Fibroblasts; Gene Silencing; Humans; Hydroxamic Acids; Molecular Sequence Data; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Serpins | 2008 |
Pharmacological inhibition of DNA methylation induces proinvasive and prometastatic genes in vitro and in vivo.
Topics: Animals; Azacitidine; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Decitabine; DNA Methylation; DNA Modification Methylases; gamma-Synuclein; Gene Silencing; Humans; Mice; Neoplasm Metastasis; Neoplasm Proteins; Promoter Regions, Genetic; Receptors, CXCR4; Urokinase-Type Plasminogen Activator | 2008 |
Clinical effectiveness of decitabine in severe sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Azacitidine; Decitabine; DNA Modification Methylases; Enzyme Inhibitors; Female; Humans; Middle Aged; Treatment Outcome | 2008 |
Analysis of protein domains and Rett syndrome mutations indicate that multiple regions influence chromatin-binding dynamics of the chromatin-associated protein MECP2 in vivo.
Topics: 3T3 Cells; Amino Acid Sequence; Animals; Azacitidine; Blotting, Western; Cell Nucleus; Chromatin; Decitabine; DNA Methylation; Epigenesis, Genetic; Fluorescent Antibody Technique; Kinetics; Methyl-CpG-Binding Protein 2; Mice; Molecular Sequence Data; Mutation; Protein Binding; Protein Isoforms; Protein Transport; Rett Syndrome | 2008 |
Inhibition of DNA methyltransferase activity upregulates Fyn tyrosine kinase expression in Hut-78 T-lymphoma cells.
Topics: Azacitidine; Cell Line, Tumor; CpG Islands; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Humans; Lymphoma; Promoter Regions, Genetic; Proto-Oncogene Proteins c-fyn; Up-Regulation | 2008 |
Histone hyperacetylation occurs on promoters of lytic cycle regulatory genes in Epstein-Barr virus-infected cell lines which are refractory to disruption of latency by histone deacetylase inhibitors.
Topics: Acetylation; Animals; Azacitidine; Butyrates; Callithrix; Cell Line; Chromatin Immunoprecipitation; Decitabine; DNA Modification Methylases; DNA, Viral; Enzyme Inhibitors; Herpesvirus 4, Human; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Phosphorylation; Promoter Regions, Genetic; Protein Binding; Tetradecanoylphorbol Acetate; Valproic Acid; Virus Activation; Virus Latency | 2008 |
SIRT1 inhibition alleviates gene silencing in Fragile X mental retardation syndrome.
Topics: Alleles; Azacitidine; Base Sequence; Cell Line; Decitabine; DNA Methylation; DNA Primers; Enzyme Inhibitors; Female; Fragile X Mental Retardation Protein; Fragile X Syndrome; Gene Silencing; Histones; Humans; Hydroxamic Acids; Models, Biological; Mutation; Naphthalenes; Niacinamide; Promoter Regions, Genetic; Pyrones; Sirtuin 1; Sirtuins; Trinucleotide Repeat Expansion | 2008 |
Epigenetic silencing of AXIN2/betaTrCP and deregulation of p53-mediated control lead to wild-type beta-catenin nuclear accumulation in lung tumorigenesis.
Topics: Active Transport, Cell Nucleus; Axin Protein; Azacitidine; beta Catenin; beta-Transducin Repeat-Containing Proteins; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Nucleus; Cytoskeletal Proteins; Decitabine; DNA Methylation; Epigenesis, Genetic; Gene Silencing; Humans; Hydroxamic Acids; Lung Neoplasms; Prognosis; Promoter Regions, Genetic; Tumor Suppressor Protein p53; Vorinostat | 2008 |
Cell type-specific activation of the cytomegalovirus promoter by dimethylsulfoxide and 5-aza-2'-deoxycytidine.
Topics: Acetylation; Animals; Azacitidine; beta-Galactosidase; Cattle; Cell Line; Coumarins; Cricetinae; Cytomegalovirus; Decitabine; Dimethyl Sulfoxide; DNA Methylation; Dose-Response Relationship, Drug; Gene Expression Regulation, Viral; Histones; I-kappa B Kinase; Imidazoles; N-Acetylglucosaminyltransferases; p38 Mitogen-Activated Protein Kinases; Promoter Regions, Genetic; Protein Biosynthesis; Pyridines; Time Factors; Transcription, Genetic; Up-Regulation | 2008 |
The novel gene LRP15 is regulated by DNA methylation and confers increased efficiency of DNA repair of ultraviolet-induced DNA damage.
Topics: Animals; Azacitidine; Base Sequence; Cell Proliferation; Chlorocebus aethiops; Comet Assay; COS Cells; Cyclin B; Cyclin B1; Decitabine; DNA Damage; DNA Methylation; DNA Repair; Gene Expression Regulation, Neoplastic; HeLa Cells; Humans; Hydroxamic Acids; Molecular Sequence Data; Neoplasm Proteins; RNA, Messenger; Ultraviolet Rays | 2008 |
Methylation silencing of transforming growth factor-beta receptor type II in rat prostate cancers.
Topics: Adenocarcinoma; Animals; Azacitidine; Cell Line, Tumor; Decitabine; DNA Methylation; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Gene Silencing; Histones; Humans; Male; Oligonucleotide Array Sequence Analysis; Prostatic Neoplasms; Protein Serine-Threonine Kinases; Rats; Rats, Inbred F344; Receptor, Transforming Growth Factor-beta Type II; Receptors, Transforming Growth Factor beta; Up-Regulation | 2008 |
Epigenetic and HIF-1 regulation of stanniocalcin-2 expression in human cancer cells.
Topics: Azacitidine; Base Sequence; Cell Hypoxia; Cell Line, Tumor; CpG Islands; Decitabine; DNA Methylation; Gene Expression Regulation, Neoplastic; Gene Silencing; Glycoproteins; Humans; Hydralazine; Hypoxia-Inducible Factor 1, alpha Subunit; Intercellular Signaling Peptides and Proteins; Molecular Sequence Data; Promoter Regions, Genetic; RNA Interference; Transcriptional Activation | 2008 |
Induction of MHC class I-related chain B (MICB) by 5-aza-2'-deoxycytidine.
Topics: Azacitidine; CD8-Positive T-Lymphocytes; Cell Line; Cytotoxicity, Immunologic; Decitabine; DNA Damage; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Histocompatibility Antigens Class I; Humans; Killer Cells, Natural; Lymphocyte Activation; NK Cell Lectin-Like Receptor Subfamily K; Promoter Regions, Genetic; Receptors, Immunologic; Receptors, Natural Killer Cell; Transcription, Genetic | 2008 |
[Hypermethylation and regulation of expression of secreted frizzled-related protein genes in colorectal tumor].
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenoma; Adult; Aged; Azacitidine; Biomarkers, Tumor; Colonic Neoplasms; Colorectal Neoplasms; Decitabine; DNA Methylation; DNA Modification Methylases; Eye Proteins; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; HCT116 Cells; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Intercellular Signaling Peptides and Proteins; Male; Membrane Proteins; Middle Aged; RNA, Messenger | 2007 |
Inhibition of cytidine deaminase by zebularine enhances the antineoplastic action of 5-aza-2'-deoxycytidine.
Topics: 3T3 Cells; Animals; Antineoplastic Agents; Azacitidine; Cytidine; Cytidine Deaminase; Decitabine; Drug Synergism; Enzyme Inhibitors; Leukemia, Experimental; Male; Mice; Mice, Inbred BALB C; Mice, Inbred DBA | 2009 |
DNA methylation and histone modifications cause silencing of Wnt antagonist gene in human renal cell carcinoma cell lines.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Blotting, Western; Carcinoma, Renal Cell; Cell Line, Tumor; CpG Islands; Decitabine; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Gene Silencing; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Immunohistochemistry; Immunoprecipitation; Kidney Neoplasms; Membrane Proteins; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Wnt Proteins | 2008 |
Progressive silencing of p14ARF in oesophageal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Barrett Esophagus; Base Sequence; Cell Line; Decitabine; Disease Progression; Epithelial Cells; Esophageal Neoplasms; Female; Gene Silencing; Histones; Humans; Male; Methylation; Middle Aged; Molecular Sequence Data; Survival Rate; Tumor Suppressor Protein p14ARF | 2009 |
Reduced T-cadherin expression and promoter methylation are associated with the development and progression of hepatocellular carcinoma.
Topics: Adult; Aged; Azacitidine; Cadherins; Carcinoma, Hepatocellular; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Decitabine; Disease Progression; DNA Methylation; DNA Modification Methylases; Down-Regulation; Enzyme Inhibitors; Female; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Promoter Regions, Genetic; Tumor Suppressor Proteins | 2008 |
Genistein mediated histone acetylation and demethylation activates tumor suppressor genes in prostate cancer cells.
Topics: Acetylation; Anticarcinogenic Agents; Antimetabolites, Antineoplastic; Azacitidine; Blotting, Western; Cell Line, Tumor; Chromatin Immunoprecipitation; Chromones; CpG Islands; Decitabine; Deubiquitinating Enzyme CYLD; Down-Regulation; Electrophoretic Mobility Shift Assay; Enzyme Inhibitors; Forkhead Box Protein O3; Forkhead Transcription Factors; Gene Expression Regulation; Gene Expression Regulation, Neoplastic; Genes, p53; Genes, Tumor Suppressor; Genistein; Histones; Humans; Hydroxamic Acids; Male; Methylation; Morpholines; NF-kappa B; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phytoestrogens; Prostatic Neoplasms; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Reverse Transcriptase Polymerase Chain Reaction; Sirtuin 1; Sirtuins; Tumor Suppressor Proteins; Up-Regulation | 2008 |
Oct4 is epigenetically regulated by methylation in normal placenta and gestational trophoblastic disease.
Topics: Azacitidine; Cell Line, Tumor; Decitabine; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Epigenesis, Genetic; Exons; Female; Gene Expression Regulation, Neoplastic; Gestational Trophoblastic Disease; Humans; Hydroxamic Acids; Octamer Transcription Factor-3; Placenta; Pregnancy; Promoter Regions, Genetic; RNA, Messenger | 2008 |
Selective POTE paralogs on chromosome 2 are expressed in human embryonic stem cells.
Topics: Amino Acid Sequence; Antigens, Neoplasm; Azacitidine; Brain; Cell Differentiation; Cell Lineage; Cells, Cultured; Chromosome Mapping; Chromosomes, Human, Pair 2; Cloning, Molecular; Decitabine; DNA Methylation; Embryonic Stem Cells; Fetus; Gene Expression; Humans; Male; Molecular Sequence Data; Multigene Family; Protein Isoforms; Sequence Homology, Amino Acid; Testis | 2008 |
Epigenetic remodeling during arsenical-induced malignant transformation.
Topics: Acetylation; Arsenicals; Azacitidine; Cell Line; Cell Line, Tumor; Cell Transformation, Neoplastic; Decitabine; Environmental Exposure; Histones; Humans; Hydroxamic Acids; Lung Neoplasms; Oligonucleotide Array Sequence Analysis; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; Skin Neoplasms; Teratogens; Urinary Bladder Neoplasms; Urothelium | 2008 |
Importance of dose-schedule of 5-aza-2'-deoxycytidine for epigenetic therapy of cancer.
Topics: Animals; Antineoplastic Agents; Azacitidine; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor Proteins; Decitabine; DNA Methylation; Dose-Response Relationship, Drug; Drug Administration Schedule; Epigenesis, Genetic; Genomic Imprinting; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Mice; Neoplasms, Experimental; Tumor Stem Cell Assay | 2008 |
SPARC promoter hypermethylation in colorectal cancers can be reversed by 5-Aza-2'deoxycytidine to increase SPARC expression and improve therapy response.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; CpG Islands; Decitabine; DNA Methylation; Fluorouracil; HT29 Cells; Humans; Osteonectin; Promoter Regions, Genetic | 2008 |
[Analysis of in vitro anti-leukemia effect of 5-aza-2'-deoxycitydine].
Topics: Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Calgranulin A; Calgranulin B; Cell Proliferation; Cell Transformation, Neoplastic; Decitabine; HL-60 Cells; Humans; RNA, Messenger | 2008 |
Decitabine-induced demethylation of 5' CpG island in GADD45A leads to apoptosis in osteosarcoma cells.
Topics: Animals; Apoptosis; Azacitidine; Blotting, Western; Bone Neoplasms; Cell Cycle Proteins; CpG Islands; Decitabine; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Humans; Immunoenzyme Techniques; Male; Mice; Mice, Nude; Nuclear Proteins; Osteoblasts; Osteosarcoma; RNA, Small Interfering; Transplantation, Heterologous; Tumor Cells, Cultured | 2008 |
[Epigenetic regulation of expression of retinoic acid receptor beta gene in leukemia cell].
Topics: Acetylation; Adult; Aged; Azacitidine; Chromatin Immunoprecipitation; CpG Islands; Decitabine; DNA Methylation; Epigenesis, Genetic; Gene Expression Regulation, Leukemic; Histones; Humans; Leukemia; Middle Aged; Receptors, Retinoic Acid; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tretinoin; U937 Cells; Valproic Acid | 2007 |
Reprogramming epigenetic silencing: artificial transcription factors synergize with chromatin remodeling drugs to reactivate the tumor suppressor mammary serine protease inhibitor.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Chromatin Assembly and Disassembly; Decitabine; Gene Silencing; Genes, Tumor Suppressor; Humans; Hydroxamic Acids; Models, Biological; Serine Proteinase Inhibitors; Serpins; Transcription Factors; Tumor Cells, Cultured; Vorinostat | 2008 |
DNA methylation controls Foxp3 gene expression.
Topics: Adoptive Transfer; Animals; Azacitidine; CD4-Positive T-Lymphocytes; Decitabine; DNA Methylation; DNA-Binding Proteins; Enzyme Inhibitors; Flow Cytometry; Forkhead Transcription Factors; Gene Expression Regulation; Lymphocyte Activation; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Knockout; Mice, Transgenic; Ovalbumin; Receptors, Antigen, T-Cell; Regulatory Sequences, Nucleic Acid; T-Lymphocytes, Regulatory; Transforming Growth Factor beta | 2008 |
Investigation of transcriptional gene silencing and mechanism induced by shRNAs targeted to RUNX3 in vitro.
Topics: Azacitidine; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Core Binding Factor Alpha 3 Subunit; Decitabine; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; RNA, Messenger; RNA, Small Interfering; Stomach Neoplasms; Time Factors; Transcription, Genetic; Transfection | 2008 |
Generalized granuloma annulare as an initial manifestation of chronic myelomonocytic leukemia: a report of 2 cases.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Diagnosis, Differential; Fatal Outcome; Granuloma Annulare; Humans; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; PUVA Therapy | 2008 |
2'-Deoxy-N4-[2-(4-nitrophenyl)ethoxycarbonyl]-5-azacytidine: a novel inhibitor of DNA methyltransferase that requires activation by human carboxylesterase 1.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Carboxylic Ester Hydrolases; Cell Line, Tumor; Decitabine; DNA Methylation; DNA-Cytosine Methylases; Dose-Response Relationship, Drug; Enzyme Inhibitors; Gene Silencing; Humans; Inhibitor of Differentiation Proteins; Liver Neoplasms; Prodrugs; RNA, Messenger; Time Factors | 2008 |
TLS-ERG leukemia fusion protein deregulates cyclin-dependent kinase 1 and blocks terminal differentiation of myeloid progenitor cells.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; CDC2 Protein Kinase; Cell Differentiation; Decitabine; Epigenesis, Genetic; Granulocyte Colony-Stimulating Factor; Hydroxamic Acids; Interleukin-3; Mice; Myeloid Progenitor Cells; Oncogene Proteins; Oncogene Proteins, Fusion; Protein Structure, Tertiary; Protein Synthesis Inhibitors; Proto-Oncogene Protein c-ets-1; RNA-Binding Protein FUS; Transcription Factors; Transcriptional Regulator ERG | 2008 |
The human receptor tyrosine kinase Axl gene--promoter characterization and regulation of constitutive expression by Sp1, Sp3 and CpG methylation.
Topics: Amino Acid Motifs; Axl Receptor Tyrosine Kinase; Azacitidine; Cell Line, Tumor; Colorectal Neoplasms; CpG Islands; Decitabine; DNA Methylation; Enzyme Induction; Gene Expression Regulation, Neoplastic; Genes, Reporter; HeLa Cells; Humans; Mutagenesis, Site-Directed; Neoplasm Proteins; Oncogene Proteins; Promoter Regions, Genetic; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; Recombinant Fusion Proteins; RNA Interference; RNA, Small Interfering; Sp1 Transcription Factor; Sp3 Transcription Factor | 2008 |
Demethylating agent 5-aza-2'-deoxycytidine enhances susceptibility of bladder transitional cell carcinoma to Cisplatin.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Azacitidine; Carcinoma, Transitional Cell; Cell Line, Tumor; Cisplatin; Decitabine; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Urinary Bladder Neoplasms | 2008 |
DACT3 is an epigenetic regulator of Wnt/beta-catenin signaling in colorectal cancer and is a therapeutic target of histone modifications.
Topics: Adaptor Proteins, Signal Transducing; Adenosine; Adenosylhomocysteinase; Apoptosis; Azacitidine; beta Catenin; Colorectal Neoplasms; Decitabine; Dishevelled Proteins; DNA Methylation; DNA Modification Methylases; Down-Regulation; Enzyme Inhibitors; Epigenesis, Genetic; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; HCT116 Cells; Histone Deacetylase Inhibitors; Histone Deacetylases; Histones; Humans; Hydroxamic Acids; Oligonucleotide Array Sequence Analysis; Phosphoproteins; Promoter Regions, Genetic; Reproducibility of Results; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Transfection; Wnt Proteins | 2008 |
Deoxyribonucleic acid methyltransferase 3B promotes epigenetic silencing through histone 3 chromatin modifications in pituitary cells.
Topics: Animals; Azacitidine; Cells, Cultured; Chromatin; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methyltransferase 3B; Epigenesis, Genetic; Gene Silencing; Histone Deacetylase Inhibitors; Histone Deacetylases; Histones; Humans; Hydroxamic Acids; Male; Mice; Pituitary Gland; Protein Processing, Post-Translational; Up-Regulation | 2008 |
Hypermethylation-modulated downregulation of claudin-7 expression promotes the progression of colorectal carcinoma.
Topics: Azacitidine; Cell Line, Tumor; Claudins; Colorectal Neoplasms; Decitabine; Disease Progression; DNA Methylation; Down-Regulation; Gene Expression; Humans; Lymph Nodes; Lymphatic Metastasis; Membrane Proteins; Methylation; Neoplasm Staging; Promoter Regions, Genetic | 2008 |
Genetic and epigenetic inactivation of T-cadherin in human hepatocellular carcinoma cells.
Topics: Acetylation; Adult; Aged; Anticarcinogenic Agents; Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Blotting, Western; Cadherins; Carcinoma, Hepatocellular; Cell Cycle; Cell Proliferation; Decitabine; DNA Methylation; DNA Modification Methylases; Down-Regulation; Epigenesis, Genetic; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Immunohistochemistry; Liver Neoplasms; Loss of Heterozygosity; Male; Middle Aged; Promoter Regions, Genetic; Proto-Oncogene Proteins c-jun; Reverse Transcriptase Polymerase Chain Reaction; Up-Regulation | 2008 |
Hypermethylation of the Keap1 gene in human lung cancer cell lines and lung cancer tissues.
Topics: Azacitidine; Binding Sites; Cell Line, Tumor; CpG Islands; Decitabine; DNA Methylation; DNA Modification Methylases; Down-Regulation; Enzyme Inhibitors; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Humans; Intracellular Signaling Peptides and Proteins; Kelch-Like ECH-Associated Protein 1; Lung Neoplasms | 2008 |
Increased pre-implantation development of cloned bovine embryos treated with 5-aza-2'-deoxycytidine and trichostatin A.
Topics: Animals; Azacitidine; Blastocyst; Cattle; Cloning, Organism; Decitabine; Drug Therapy, Combination; Embryonic Development; Enzyme Inhibitors; Hydroxamic Acids; Nuclear Transfer Techniques | 2008 |
ssDNA-binding protein 2 is frequently hypermethylated and suppresses cell growth in human prostate cancer.
Topics: Adenocarcinoma; Aged; Azacitidine; Base Sequence; Biomarkers, Tumor; Cell Cycle; Cell Proliferation; Decitabine; DNA Methylation; DNA Mutational Analysis; DNA-Binding Proteins; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Molecular Sequence Data; Neoplasm Staging; Prostatic Hyperplasia; Prostatic Neoplasms; Tumor Cells, Cultured | 2008 |
Down-regulation of hedgehog-interacting protein through genetic and epigenetic alterations in human hepatocellular carcinoma.
Topics: Aged; Azacitidine; Carcinoma, Hepatocellular; Carrier Proteins; Cell Line, Tumor; Cell Proliferation; Decitabine; DNA Methylation; Down-Regulation; Epistasis, Genetic; Female; Gene Expression Regulation, Neoplastic; Hepatoblastoma; Humans; Liver Neoplasms; Loss of Heterozygosity; Male; Membrane Glycoproteins; Middle Aged; Veratrum Alkaloids | 2008 |
HDAC inhibitors act with 5-aza-2'-deoxycytidine to inhibit cell proliferation by suppressing removal of incorporated abases in lung cancer cells.
Topics: Azacitidine; Cell Line, Tumor; Cell Proliferation; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Humans; Lung Neoplasms; Models, Theoretical; Tumor Cells, Cultured | 2008 |
Epigenetic inheritance of DNA methylation limits activation-induced expression of FOXP3 in conventional human CD25-CD4+ T cells.
Topics: Arthritis, Juvenile; Azacitidine; CD4-Positive T-Lymphocytes; Cells, Cultured; Cytokines; Decitabine; DNA Methylation; DNA Modification Methylases; Female; Forkhead Transcription Factors; Gene Expression Regulation; Humans; Interleukin-2 Receptor alpha Subunit; Lymphocyte Activation; Male; Synovial Fluid; T-Lymphocytes, Regulatory; Transforming Growth Factor beta | 2008 |
Incubation with somatostatin, 5-aza decitabine and trichostatin up-regulates somatostatin receptor expression in prostate cancer cells.
Topics: Azacitidine; Cell Line, Tumor; Decitabine; DNA Methylation; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Male; Prostatic Neoplasms; Receptors, Somatostatin; RNA, Messenger; Somatostatin; Up-Regulation | 2008 |
CHD5, a tumor suppressor gene deleted from 1p36.31 in neuroblastomas.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Cell Line, Tumor; Chromosomes, Human, Pair 1; Colony-Forming Units Assay; Decitabine; DNA Helicases; DNA Methylation; DNA Mutational Analysis; DNA, Antisense; Down-Regulation; Gene Deletion; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Humans; Mice; Mice, Nude; Neoplastic Stem Cells; Nerve Tissue Proteins; Neuroblastoma; Predictive Value of Tests; Prognosis; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; Risk Factors; RNA, Messenger; Transfection; Transplantation, Heterologous; Up-Regulation | 2008 |
Histone H3 (lys-9) deacetylation is associated with transcriptional silencing of E-cadherin in colorectal cancer cell lines.
Topics: Acetylation; Antigens, CD; Azacitidine; Cadherins; Cell Line, Tumor; Chromatin Immunoprecipitation; Colorectal Neoplasms; Decitabine; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Gene Silencing; Histone Deacetylase Inhibitors; Histone Deacetylases; Histones; Humans; Hydroxamic Acids; Polymerase Chain Reaction; Promoter Regions, Genetic; RNA, Messenger; Transcription, Genetic | 2008 |
5-Aza-2'-deoxycytidine restores proapoptotic function of p53 in cancer cells resistant to p53-induced apoptosis.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Apoptosis Regulatory Proteins; Azacitidine; Cell Cycle; Cell Proliferation; Decitabine; DNA Modification Methylases; Gene Expression Regulation, Neoplastic; HCT116 Cells; Humans; Neoplasms; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; RNA Interference; Time Factors; Tumor Suppressor Protein p53 | 2008 |
Mammalian target of rapamycin pathway inhibition enhances the effects of 5-aza-dC on suppressing cell proliferation in human gastric cancer cell lines.
Topics: Adaptor Proteins, Signal Transducing; Azacitidine; Base Sequence; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p27; Decitabine; Down-Regulation; Humans; Methylation; Phosphatidylinositol 3-Kinases; Phosphoproteins; Phosphorylation; Protein Kinases; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Ribosomal Protein S6 Kinases, 70-kDa; Signal Transduction; Stomach Neoplasms; TOR Serine-Threonine Kinases; Transcription, Genetic; Up-Regulation | 2008 |
Downmodulation of dimethyl transferase activity enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in prostate cancer cells.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Blotting, Western; Caspase 8; Cell Line, Tumor; Cell Proliferation; Decitabine; Dose-Response Relationship, Drug; Down-Regulation; Drug Resistance, Neoplasm; Flow Cytometry; Humans; Male; Prostatic Neoplasms; Receptors, TNF-Related Apoptosis-Inducing Ligand; TNF-Related Apoptosis-Inducing Ligand | 2008 |
Analysis of the methylation status of genes up-regulated by the demethylating agent, 5-aza-2'-deoxycytidine, in esophageal squamous cell carcinoma.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Carcinoma, Squamous Cell; Cathepsin L; Cathepsins; Cell Cycle Proteins; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cysteine Endopeptidases; Decitabine; DNA Methylation; DNA Modification Methylases; Esophageal Neoplasms; Esophagus; Fatty Acid-Binding Proteins; Gene Expression Regulation, Neoplastic; Humans; Neoplasm Proteins; Nuclear Proteins; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2008 |
[Methylation of PTPRG gene and its regulation in gastric cancer].
Topics: Azacitidine; Cell Line, Tumor; Decitabine; DNA Methylation; DNA Modification Methylases; Gene Expression Regulation, Neoplastic; Humans; Lymph Nodes; Lymphatic Metastasis; Receptor-Like Protein Tyrosine Phosphatases, Class 5; RNA, Messenger; Stomach Neoplasms | 2008 |
Role of myofibroblasts in innate chemoresistance of pancreatic carcinoma--epigenetic downregulation of caspases.
Topics: Animals; Apoptosis; Azacitidine; Carcinoma, Pancreatic Ductal; Caspases; Cell Line, Tumor; Cell Nucleus; Coculture Techniques; Decitabine; Deoxycytidine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; Down-Regulation; Drug Resistance, Neoplasm; Epigenesis, Genetic; Etoposide; Female; Fibroblasts; Gemcitabine; Humans; Mice; Mice, SCID; Pancreatic Neoplasms; STAT1 Transcription Factor; Transfection | 2008 |
Molecular and biologic characterization and drug sensitivity of pan-histone deacetylase inhibitor-resistant acute myeloid leukemia cells.
Topics: Acetylation; Animals; Antineoplastic Agents; Apoptosis; Azacitidine; Benzoquinones; Cell Differentiation; Cell Proliferation; Decitabine; DNA-Binding Proteins; Drug Resistance, Neoplasm; Enzyme Inhibitors; Heat Shock Transcription Factors; Histone Deacetylase Inhibitors; HL-60 Cells; HSP70 Heat-Shock Proteins; HSP90 Heat-Shock Proteins; Humans; Hydroxamic Acids; Indoles; Lactams, Macrocyclic; Leukemia, Myeloid, Acute; Mice; Mice, Inbred NOD; Neoplasm Proteins; Panobinostat; S Phase; Transcription Factors; Tubulin; Vorinostat | 2008 |
DNA hypermethylation regulates the expression of members of the Mu-class glutathione S-transferases and glutathione peroxidases in Barrett's adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Barrett Esophagus; Cell Transformation, Neoplastic; CpG Islands; Decitabine; Disease Progression; DNA Methylation; DNA, Neoplasm; Down-Regulation; Epigenesis, Genetic; Esophageal Neoplasms; Gene Expression Regulation, Enzymologic; Glutathione Peroxidase; Glutathione Transferase; Humans; Hydroxamic Acids; Middle Aged; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Tumor Cells, Cultured | 2009 |
Epigenetic identification of ubiquitin carboxyl-terminal hydrolase L1 as a functional tumor suppressor and biomarker for hepatocellular carcinoma and other digestive tumors.
Topics: Azacitidine; Biomarkers, Tumor; Carcinoma, Hepatocellular; Caspases; Cell Division; Cell Line, Tumor; Cell Proliferation; CpG Islands; Decitabine; Digestive System Neoplasms; DNA Methylation; Epigenesis, Genetic; G2 Phase; Gene Silencing; Humans; Hydroxamic Acids; Liver Neoplasms; Promoter Regions, Genetic; RNA, Messenger; Transfection; Tumor Suppressor Protein p53; Tumor Suppressor Proteins; Ubiquitin Thiolesterase | 2008 |
Epigenetic mechanisms involved in differential MDR1 mRNA expression between gastric and colon cancer cell lines and rationales for clinical chemotherapy.
Topics: ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Azacitidine; Cell Line, Tumor; Colonic Neoplasms; Decitabine; DNA Methylation; DNA, Neoplasm; Enzyme Inhibitors; Epigenesis, Genetic; Gene Expression Profiling; Histones; Humans; Hydroxamic Acids; RNA, Messenger; Sequence Analysis, DNA; Stomach Neoplasms | 2008 |
Promoter methylation of the bone morphogenetic protein-6 gene in association with adult T-cell leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Azacitidine; Base Sequence; Bone Morphogenetic Protein 6; Bone Morphogenetic Proteins; Decitabine; DNA Methylation; Female; Gene Expression Regulation, Leukemic; Gene Silencing; Humans; Leukemia-Lymphoma, Adult T-Cell; Male; Middle Aged; Molecular Sequence Data; Promoter Regions, Genetic; RNA, Messenger; Sequence Analysis, DNA; Sulfites | 2008 |
Alleviation of myelodysplastic syndrome-associated skin rush after treatment with decitabine.
Topics: Aged; Anemia, Refractory; Antimetabolites, Antineoplastic; Azacitidine; Blood Transfusion; Chromosome Deletion; Chromosomes, Human, Y; Decitabine; Exanthema; Humans; Male | 2008 |
Complete cytogenetic remission after decitabine treatment in a patient with secondary AML harbouring high p15INK4b gene methylation and high global DNA methylation.
Topics: Azacitidine; Cyclin-Dependent Kinase Inhibitor p15; Cytogenetics; Decitabine; DNA Methylation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Treatment Outcome | 2009 |
Epigenetic mechanisms and Sp1 regulate mitochondrial citrate carrier gene expression.
Topics: Acetylation; Animals; Anion Transport Proteins; Azacitidine; Base Sequence; Cell Line; Decitabine; DNA Methylation; Epigenesis, Genetic; Gene Expression; Genes, Reporter; Histones; Humans; Hydroxamic Acids; Mice; Mitochondrial Proteins; Organic Anion Transporters; Promoter Regions, Genetic; Rats; Sp1 Transcription Factor | 2008 |
[Effect of decitabine combined with Trichostatin A on MDS cell line SKM-1 in vitro].
Topics: Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Decitabine; Drug Synergism; fas Receptor; Humans; Hydroxamic Acids; Inhibitor of Apoptosis Proteins; Microtubule-Associated Proteins; Myelodysplastic Syndromes; Survivin | 2008 |
LRRC3B, encoding a leucine-rich repeat-containing protein, is a putative tumor suppressor gene in gastric cancer.
Topics: Acetylation; Animals; Azacitidine; Base Sequence; Blotting, Southern; Cell Line, Tumor; Chromatin Immunoprecipitation; Decitabine; DNA Methylation; DNA Primers; Down-Regulation; Gene Silencing; Genes, Tumor Suppressor; Histones; Humans; Hydroxamic Acids; Immunohistochemistry; Male; Mice; Mice, Nude; Neoplasm Proteins; Reverse Transcriptase Polymerase Chain Reaction; Stomach Neoplasms | 2008 |
Decitabine as "bridge therapy" to a MUD transplant in relapsed AML postautologous stem cell transplantation.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Female; Follow-Up Studies; Histocompatibility Testing; Humans; Leukemia, Myeloid, Acute; Living Donors; Middle Aged; Recurrence; Stem Cell Transplantation; Time Factors; Transplantation, Autologous; Treatment Outcome | 2008 |
Treatment of ovarian cancer cell lines with 5-aza-2'-deoxycytidine upregulates the expression of cancer-testis antigens and class I major histocompatibility complex-encoded molecules.
Topics: Antigens, Neoplasm; Antimetabolites, Antineoplastic; Azacitidine; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Decitabine; DNA Methylation; Female; Flow Cytometry; Gene Expression; Histocompatibility Antigens Class I; Humans; Ovarian Neoplasms; Polymerase Chain Reaction; Up-Regulation | 2009 |
Nonsteroidal anti-inflammatory drug-activated gene (NAG-1/GDF15) expression is increased by the histone deacetylase inhibitor trichostatin A.
Topics: Azacitidine; Cell Line, Tumor; Decitabine; Early Growth Response Protein 1; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Glioblastoma; Growth Differentiation Factor 15; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Neoplasm Proteins; RNA, Messenger; RNA, Neoplasm; RNA, Small Interfering; Sp1 Transcription Factor; Up-Regulation | 2008 |
Identification of candidate tumor suppressor genes inactivated by promoter methylation in melanoma.
Topics: Azacitidine; Carrier Proteins; Cell Line, Tumor; Colonic Neoplasms; CpG Islands; Decitabine; DNA Methylation; Esophageal Neoplasms; Gene Expression Profiling; Gene Silencing; Genes, Tumor Suppressor; Glioma; Heat-Shock Proteins; Humans; Hydroxamic Acids; Intracellular Signaling Peptides and Proteins; Melanoma; Membrane Proteins; Microfilament Proteins; Neuropeptides; Nuclear Proteins; Oligonucleotide Array Sequence Analysis; Phosphoprotein Phosphatases; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction | 2009 |
Promoter CpG methylation of oestrogen receptors in leukaemia.
Topics: Antibiotics, Antineoplastic; Azacitidine; Case-Control Studies; Cell Line, Tumor; CpG Islands; Decitabine; DNA; DNA Methylation; HL-60 Cells; Humans; Jurkat Cells; K562 Cells; Leukemia; Promoter Regions, Genetic; Receptors, Estrogen; RNA, Messenger; RNA, Neoplasm; U937 Cells | 2009 |
Histone deacetylase inhibitor scriptaid induces cell cycle arrest and epigenetic change in colon cancer cells.
Topics: Apoptosis; Azacitidine; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Decitabine; DNA Methylation; Enzyme Inhibitors; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Genes, p16; Histone Deacetylase Inhibitors; Humans; Hydroxylamines; Promoter Regions, Genetic; Quinolines | 2008 |
Epigenetic silencing of LRRC3B in colorectal cancer.
Topics: Azacitidine; Cell Line, Tumor; Colorectal Neoplasms; Decitabine; DNA Methylation; Enzyme Inhibitors; Epigenesis, Genetic; Gene Silencing; Genes, Tumor Suppressor; Genetic Markers; Humans; In Vitro Techniques; Microarray Analysis; Neoplasm Proteins; Polymerase Chain Reaction | 2009 |
PCFT/SLC46A1 promoter methylation and restoration of gene expression in human leukemia cells.
Topics: Azacitidine; Cell Line, Tumor; CpG Islands; Decitabine; DNA Methylation; Gene Expression; Gene Expression Regulation, Leukemic; Gene Silencing; Humans; Leukemia; Membrane Transport Proteins; Promoter Regions, Genetic; Proton-Coupled Folate Transporter | 2008 |
Aberrant methylation of candidate tumor suppressor genes in neuroblastoma.
Topics: Azacitidine; Child; Child, Preschool; Decitabine; DNA Methylation; Epigenesis, Genetic; Genes, Tumor Suppressor; Genome; Humans; Hydroxamic Acids; Infant; Neuroblastoma; Polymerase Chain Reaction; RNA, Messenger | 2009 |
Demethylating agent 5-aza-2'-deoxycytidine activates HLA-G expression in human leukemia cell lines.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Blotting, Western; Cell Line, Tumor; Decitabine; Flow Cytometry; Gene Expression Regulation, Neoplastic; Histocompatibility Antigens Class I; HLA Antigens; HLA-G Antigens; Humans; Leukemia; Reverse Transcriptase Polymerase Chain Reaction | 2009 |
Abnormal DNA methylation of CD133 in colorectal and glioblastoma tumors.
Topics: AC133 Antigen; Animals; Antigens, CD; Antineoplastic Agents; Azacitidine; Brain Neoplasms; Caco-2 Cells; Carcinoma; Colorectal Neoplasms; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Female; Gene Deletion; Gene Expression Regulation, Neoplastic; Glioblastoma; Glycoproteins; HCT116 Cells; HT29 Cells; Humans; Mice; Mice, Nude; Peptides; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2008 |
Comparative epigenomics of human and mouse mammary tumors.
Topics: Animals; Azacitidine; Breast Neoplasms; Cell Cycle Proteins; Cell Line, Tumor; Databases, Genetic; Decitabine; DNA Methylation; DNA Modification Methylases; Epigenesis, Genetic; Gene Expression Regulation; Gene Silencing; Genes, Tumor Suppressor; Glycoproteins; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Mammary Neoplasms, Animal; Mice; Oligonucleotide Array Sequence Analysis; Polymerase Chain Reaction; Structure-Activity Relationship; Tissue Inhibitor of Metalloproteinase-3 | 2009 |
5-Aza-2'-deoxycytidine reactivates expression of RUNX3 by deletion of DNA methyltransferases leading to caspase independent apoptosis in colorectal cancer Lovo cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Caspase 3; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Core Binding Factor Alpha 3 Subunit; Decitabine; DNA Damage; DNA Methyltransferase 3A; DNA Modification Methylases; Dose-Response Relationship, Drug; Down-Regulation; Enzyme Activation; Humans | 2009 |
Hypoxic silencing of tumor suppressor RUNX3 by histone modification in gastric cancer cells.
Topics: Acetylation; Azacitidine; Cell Hypoxia; Cell Line, Tumor; Core Binding Factor Alpha 3 Subunit; Decitabine; Disease Progression; DNA Methylation; Down-Regulation; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Gene Silencing; Genes, Tumor Suppressor; Histocompatibility Antigens; Histone Deacetylase 1; Histone Deacetylase Inhibitors; Histone Deacetylases; Histone-Lysine N-Methyltransferase; Humans; Hydroxamic Acids; Methylation; Neoplasm Proteins; Protein Processing, Post-Translational; Recombinant Fusion Proteins; Stomach Neoplasms; Transcription, Genetic | 2009 |
Retinoic acid receptor beta2 re-expression and growth inhibition in thyroid carcinoma cell lines after 5-aza-2'-deoxycytidine treatment.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Carcinoma; Cell Line, Tumor; Cell Proliferation; Decitabine; DNA Methylation; Gene Expression Regulation, Neoplastic; Humans; Organ Specificity; Promoter Regions, Genetic; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Retinoic Acid Receptor gamma; Thyroid Gland; Thyroid Neoplasms; Transfection | 2008 |
Loss of MLL5 results in pleiotropic hematopoietic defects, reduced neutrophil immune function, and extreme sensitivity to DNA demethylation.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Bacterial Infections; Blepharitis; Cell Differentiation; Decitabine; DNA Methylation; Genotype; Hematopoiesis; Hematopoietic Stem Cells; Histone-Lysine N-Methyltransferase; Homozygote; Mice; Mice, Knockout; Myeloid-Lymphoid Leukemia Protein; Neutrophils | 2009 |
Epigenetic silencing of the interferon regulatory factor ICSBP/IRF8 in human multiple myeloma.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cell Line, Tumor; Decitabine; DNA Methylation; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Interferon Regulatory Factors; Multiple Myeloma; Neoplasm Proteins; Promoter Regions, Genetic | 2008 |
Mechanisms of resistance to 5-aza-2'-deoxycytidine in human cancer cell lines.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Blotting, Western; Cell Line, Tumor; Decitabine; DNA; DNA Damage; DNA Methylation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Humans; Inhibitory Concentration 50; Loss of Heterozygosity; Reverse Transcriptase Polymerase Chain Reaction | 2009 |
The aberrant promoter methylation of BMP3b and BMP6 in malignant pleural mesotheliomas.
Topics: Azacitidine; Bone Morphogenetic Protein 6; Cell Line, Tumor; Decitabine; DNA Methylation; Enzyme Inhibitors; Gene Expression; Growth Differentiation Factor 10; Humans; Japan; Mesothelioma; Pleural Neoplasms; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; United States | 2008 |
Involvement of epigenetic mechanisms in the regulation of secreted phospholipase A2 expressions in Jurkat leukemia cells.
Topics: Antimetabolites, Antineoplastic; Azacitidine; CpG Islands; Decitabine; DNA Methylation; Enzyme-Linked Immunosorbent Assay; Epigenesis, Genetic; Gene Expression Regulation, Enzymologic; Gene Silencing; Group II Phospholipases A2; Humans; Interferon-gamma; Jurkat Cells; Phospholipases A2, Secretory; Reverse Transcriptase Polymerase Chain Reaction; Sulfites; Transcription Factors; U937 Cells | 2008 |
Synergistic effect of 5-Aza-2'-deoxycytidine and genistein in combination against leukemia.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cyclin-Dependent Kinase Inhibitor p57; Decitabine; DNA Methylation; DNA, Neoplasm; Drug Synergism; Genistein; HL-60 Cells; Humans; Leukemia; Leukemia L1210; Male; Mice; Promoter Regions, Genetic | 2008 |
Reactivation of IGFBP7 by DNA demethylation inhibits human colon cancer cell growth in vitro.
Topics: Azacitidine; Cell Cycle; Cell Division; Cell Line, Tumor; Cell Movement; Colonic Neoplasms; Decitabine; DNA; DNA Methylation; G1 Phase; Humans; Insulin-Like Growth Factor Binding Proteins; Neoplasm Invasiveness; RNA, Messenger; Transcription, Genetic | 2008 |
Methylation of WTH3, a possible drug resistant gene, inhibits p53 regulated expression.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Azacitidine; Cell Line, Tumor; Decitabine; DNA Methylation; Doxorubicin; Drug Resistance, Multiple; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Genes, p53; Humans; Promoter Regions, Genetic; rab GTP-Binding Proteins; RNA, Small Interfering; Transgenes | 2008 |
The property of methylated APC gene promotor and its influence on lung cancer cell line.
Topics: Adenomatous Polyposis Coli Protein; Azacitidine; Binding Sites; Cell Line, Tumor; CpG Islands; Decitabine; DNA Methylation; Gene Silencing; Genes, APC; Humans; Lung Neoplasms; Polymerase Chain Reaction; Promoter Regions, Genetic | 2009 |
[Myelodysplastic syndromes: therapeutic advances and promising future].
Topics: Antineoplastic Agents; Azacitidine; Decitabine; Forecasting; Humans; Lenalidomide; Myelodysplastic Syndromes; Thalidomide | 2008 |
p53-inducible ribonucleotide reductase (p53R2/RRM2B) is a DNA hypomethylation-independent decitabine gene target that correlates with clinical response in myelodysplastic syndrome/acute myelogenous leukemia.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cell Cycle Proteins; Cell Line, Tumor; CpG Islands; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; G1 Phase; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Ribonucleotide Reductases; Tumor Suppressor Protein p53 | 2008 |
Timing is everything: order of administration of 5-aza 2' deoxycytidine, trichostatin A and tamoxifen changes estrogen receptor mRNA expression and cell sensitivity.
Topics: Azacitidine; Cell Line, Tumor; Decitabine; Drug Administration Schedule; Estrogen Receptor Modulators; Humans; Hydroxamic Acids; Receptors, Estrogen; RNA, Messenger; Tamoxifen | 2009 |
Aberrant methylation of ADAMTS1 in non-small cell lung cancer.
Topics: ADAM Proteins; ADAMTS1 Protein; Adult; Aged; Aged, 80 and over; Azacitidine; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chi-Square Distribution; Decitabine; DNA Methylation; Female; Humans; Lung Neoplasms; Male; Middle Aged; Reverse Transcriptase Polymerase Chain Reaction | 2008 |
Synergistic induction of NY-ESO-1 antigen expression by a novel histone deacetylase inhibitor, valproic acid, with 5-aza-2'-deoxycytidine in glioma cells.
Topics: Antigens, Neoplasm; Azacitidine; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Decitabine; DNA Methylation; Drug Synergism; Enzyme Inhibitors; Gene Expression; Glioma; Histone Deacetylase Inhibitors; Histones; Humans; Immunotherapy; Membrane Proteins; Oligonucleotide Array Sequence Analysis; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; Valproic Acid | 2009 |
The presence of a methylation fingerprint of Helicobacter pylori infection in human gastric mucosae.
Topics: Azacitidine; Cell Line, Tumor; CpG Islands; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Epigenesis, Genetic; Gastric Mucosa; Genetic Predisposition to Disease; Helicobacter Infections; Helicobacter pylori; Humans; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sulfites | 2009 |
Regulation of the leucocyte chemoattractant receptor FPR in glioblastoma cells by cell differentiation.
Topics: Animals; Azacitidine; Brain Neoplasms; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Chemotaxis; Decitabine; DNA Modification Methylases; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Methylation; Mice; Mice, Nude; Neoplasm Transplantation; Promoter Regions, Genetic; Receptors, Formyl Peptide; Transplantation, Heterologous; Tumor Suppressor Protein p53 | 2009 |
DNA methyltransferase inhibitor 5-aza-CdR enhances the radiosensitivity of gastric cancer cells.
Topics: Apoptosis; Azacitidine; Cell Division; Cell Line, Tumor; Cell Proliferation; Decitabine; DNA Modification Methylases; Enzyme Inhibitors; G2 Phase; Humans; Radiation-Sensitizing Agents; Stomach Neoplasms | 2009 |
Promoter methylation blocks FES protein-tyrosine kinase gene expression in colorectal cancer.
Topics: Azacitidine; Base Sequence; Cell Line, Tumor; Colorectal Neoplasms; CpG Islands; Decitabine; DNA Methylation; Down-Regulation; Gene Expression Regulation, Neoplastic; Humans; Molecular Sequence Data; Promoter Regions, Genetic; Proto-Oncogene Mas; Proto-Oncogene Proteins c-fes | 2009 |
[Effects of 5-Aza-2'-deoxycytidine and trichostatin A on DNA methylation and expression of hMLH1 in ovarian cancer cell line COC1/DDP].
Topics: Adaptor Proteins, Signal Transducing; Antimetabolites, Antineoplastic; Azacitidine; Cell Line, Tumor; Cell Proliferation; Cisplatin; Decitabine; DNA Methylation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; MutL Protein Homolog 1; Nuclear Proteins; Ovarian Neoplasms; Promoter Regions, Genetic; RNA, Messenger | 2008 |
[5-aza-2'-deoxycytidine induces changes of histone H3-lysine 9 methylation in bladder tumor cells].
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cell Line, Tumor; Cell Survival; Core Binding Factor Alpha 3 Subunit; Decitabine; DNA Methylation; Dose-Response Relationship, Drug; Histones; Humans; Lysine; Methylation; Promoter Regions, Genetic; Time Factors; Urinary Bladder Neoplasms | 2008 |
[Hypomethylation of 5'CpG island of insulin-like growth factor binding protein-related protein 1 is associated with its overexpression in colorectal cancer].
Topics: Adult; Aged; Aged, 80 and over; Azacitidine; Cell Line, Tumor; Colorectal Neoplasms; CpG Islands; Decitabine; DNA Methylation; Female; Gene Expression Regulation, Neoplastic; Humans; Insulin-Like Growth Factor Binding Proteins; Male; Middle Aged; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Transcription, Genetic | 2008 |
Hypomethylating drugs convert HA-1-negative solid tumors into targets for stem cell-based immunotherapy.
Topics: Acetylation; Antigens, Neoplasm; Azacitidine; Cell Line, Tumor; CpG Islands; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA, Neoplasm; Gene Expression Regulation, Neoplastic; Gene Silencing; Histones; Humans; Hydroxamic Acids; Immunotherapy; Minor Histocompatibility Antigens; Neoplasm Proteins; Neoplasms; Oligopeptides; Promoter Regions, Genetic; Protein Processing, Post-Translational; RNA, Messenger; RNA, Neoplasm; T-Lymphocytes, Cytotoxic; Transcription, Genetic | 2009 |
Epigenetic control of differential expression of specific ERG isoforms in acute T-lymphoblastic leukemia.
Topics: Azacitidine; Base Sequence; CpG Islands; Decitabine; DNA Methylation; DNA Primers; Epigenesis, Genetic; Exons; Oncogene Proteins; Polymerase Chain Reaction; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Protein Isoforms; Trans-Activators; Transcriptional Regulator ERG | 2009 |
Epigenetic regulation of Foxp3 expression in regulatory T cells by DNA methylation.
Topics: Animals; Autoimmune Diseases; Azacitidine; Cell Differentiation; Cell Line, Tumor; Cells, Cultured; Colitis; Decitabine; DNA Methylation; Epigenesis, Genetic; Female; Forkhead Transcription Factors; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Knockout; Mice, SCID; T-Lymphocytes, Regulatory | 2009 |
Epigenetic therapy upregulates the tumor suppressor microRNA-126 and its host gene EGFL7 in human cancer cells.
Topics: Antineoplastic Agents; Azacitidine; Calcium-Binding Proteins; Cell Line, Tumor; Decitabine; EGF Family of Proteins; Endothelial Growth Factors; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Humans; Male; MicroRNAs; Neoplasms; Phenylbutyrates; Promoter Regions, Genetic; Prostatic Neoplasms; Up-Regulation; Urinary Bladder Neoplasms | 2009 |
Inhibition of DNA methyltransferase activates tumor necrosis factor alpha-induced monocytic differentiation in acute myeloid leukemia cells.
Topics: Acetylation; Acute Disease; Azacitidine; Cell Differentiation; Chromatin; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Enzyme Inhibitors; Histones; Humans; Leukemia, Myeloid; Monocytes; NF-kappa B; NF-kappa B p50 Subunit; Promoter Regions, Genetic; Receptors, Tumor Necrosis Factor, Type I; Receptors, Tumor Necrosis Factor, Type II; Transcription Factor RelA; Tumor Necrosis Factor-alpha; U937 Cells | 2009 |
Promoter CpG methylation in cancer cells contributes to the regulation of MUC4.
Topics: Acetylation; Azacitidine; Cell Line, Tumor; CpG Islands; Decitabine; DNA Methylation; DNA Modification Methylases; DNA, Neoplasm; Enzyme Inhibitors; Epigenesis, Genetic; Histone Deacetylase Inhibitors; Histone Deacetylases; Histones; Humans; Hydroxamic Acids; Mucin-4; Neoplasms; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2009 |
Decitabine is an effective treatment of idiopathic myelofibrosis.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Modification Methylases; Humans; Male; Primary Myelofibrosis; Treatment Outcome | 2009 |
Cancer prevention: epigenetics steps up to the plate.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cell Transformation, Neoplastic; Chemoprevention; Cytidine; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Enzyme Inhibitors; Epigenesis, Genetic; Humans; Models, Biological; Neoplasms | 2008 |
[5-Aza-CdR regulates the expression of RASSF1A gene in human gastric cancer cell line and inhibits the growth of cells].
Topics: Azacitidine; Cell Line, Tumor; Decitabine; DNA Methylation; Gene Expression Regulation, Neoplastic; Humans; Stomach Neoplasms; Tumor Suppressor Proteins | 2009 |
Down-regulation of Rap1GAP via promoter hypermethylation promotes melanoma cell proliferation, survival, and migration.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cell Growth Processes; Cell Line, Tumor; Cell Movement; Cell Survival; Decitabine; DNA Methylation; Down-Regulation; Extracellular Signal-Regulated MAP Kinases; Focal Adhesions; Gene Expression Regulation, Neoplastic; GTPase-Activating Proteins; Humans; Melanoma; Phosphorylation; Promoter Regions, Genetic; rap1 GTP-Binding Proteins; Transfection | 2009 |
Antitumor effects of a combined 5-aza-2'deoxycytidine and valproic acid treatment on rhabdomyosarcoma and medulloblastoma in Ptch mutant mice.
Topics: Acetylation; Animals; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Gene Expression; Gene Silencing; Histone Deacetylase Inhibitors; Histone Deacetylases; Histones; Medulloblastoma; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Muscle, Skeletal; Patched Receptors; Patched-1 Receptor; Receptors, Cell Surface; Rhabdomyosarcoma; Valproic Acid | 2009 |
Decitabine-induced effusions.
Topics: Azacitidine; Decitabine; Female; Humans; Middle Aged; Myelodysplastic Syndromes; Pleural Effusion | 2009 |
Possible involvement of activation of P53/P21 and demethylation of RUNX 3 in the cytotoxicity against Lovo cells induced by 5-Aza-2'-deoxycytidine.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Caspase 3; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Core Binding Factor Alpha 3 Subunit; Cyclin-Dependent Kinase Inhibitor p21; Decitabine; DNA Damage; DNA Methyltransferase 3A; DNA Modification Methylases; Dose-Response Relationship, Drug; Enzyme Activation; Enzyme Inhibitors; Humans; Matrix Metalloproteinase 2; Tumor Suppressor Protein p53 | 2009 |
Differential CpG island methylation of murine adenine nucleotide translocase genes.
Topics: Animals; Azacitidine; CpG Islands; Decitabine; DNA; DNA Methylation; DNA Modification Methylases; DNA Restriction Enzymes; Fibroblasts; Gene Expression; Genes; Isoenzymes; Male; Mice; Mitochondrial ADP, ATP Translocases; NIH 3T3 Cells; Promoter Regions, Genetic; Sulfites | 2009 |
Synergy of 5-aza-2'-deoxycytidine (DAC) and paclitaxel in both androgen-dependent and -independent prostate cancer cell lines.
Topics: Androgens; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Azacitidine; Caspases; Cell Cycle; Cell Division; Cell Line, Tumor; Decitabine; Flow Cytometry; Humans; Male; Mitochondria; Oxidoreductases; Paclitaxel; Prostatic Neoplasms; Tetrazolium Salts; Up-Regulation | 2009 |
Study of 5-Aza-CdR on transcription regulation of RASSF1A gene in the BIU87 cell line.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cell Survival; Decitabine; DNA Methylation; DNA Modification Methylases; Dose-Response Relationship, Drug; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Humans; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Transcription, Genetic; Tumor Suppressor Proteins; Urinary Bladder Neoplasms | 2009 |
The developmental potential of mouse somatic cell nuclear-transferred oocytes treated with trichostatin A and 5-aza-2'-deoxycytidine.
Topics: Animals; Azacitidine; Blastocyst; Decitabine; DNA Methylation; Embryo Transfer; Embryonic Development; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Histone Deacetylases; Hydroxamic Acids; Methyltransferases; Mice; Nuclear Transfer Techniques; Oocytes | 2009 |
Aberrant promoter methylation of SPARC in ovarian cancer.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cell Proliferation; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Methyltransferase 3A; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Osteonectin; Ovarian Neoplasms; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Analysis; Tumor Cells, Cultured | 2009 |
Myc sensitizes p53-deficient cancer cells to the DNA-damaging effects of the DNA methyltransferase inhibitor decitabine.
Topics: Aneuploidy; Animals; Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Blotting, Western; Burkitt Lymphoma; Cell Cycle; Decitabine; DNA Damage; DNA Methylation; DNA Modification Methylases; DNA, Neoplasm; Embryo, Mammalian; Epstein-Barr Virus Infections; Fibroblasts; Herpesvirus 4, Human; Humans; Kidney; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Transgenic; Mutation; Proto-Oncogene Proteins c-myc; Tumor Suppressor Protein p53 | 2009 |
DNA hypomethylation therapies and hemoglobin disorders. [An interview with Hassana Fathallah by H&O].
Topics: Anemia, Sickle Cell; Antineoplastic Agents; Azacitidine; beta-Thalassemia; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Enzyme Inhibitors; Fetal Hemoglobin; Histone Acetyltransferases; Humans; Hydroxyurea | 2008 |
The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Cytidine; Decitabine; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Myeloid, Acute | 2009 |
DNA demethylation protects from cleavable complex stabilization and DNA strand breakage induced by the topoisomerase type I inhibitor camptothecin.
Topics: Animals; Azacitidine; Camptothecin; CHO Cells; Comet Assay; Cricetinae; Cricetulus; Decitabine; DNA Breaks; DNA Methylation; DNA Topoisomerases, Type I; Electrophoresis, Gel, Pulsed-Field; Enzyme Inhibitors; Epigenesis, Genetic; Topoisomerase I Inhibitors | 2009 |
New agents for the treatment of AML recent study findings.
Topics: Adenine Nucleotides; Antineoplastic Agents; Arabinonucleosides; Azacitidine; Carbazoles; Clofarabine; Decitabine; Enzyme Inhibitors; Furans; Humans; Hydrazines; Immunotherapy; Lenalidomide; Leukemia, Myeloid, Acute; Quinolones; Staurosporine; Sulfonamides; Thalidomide | 2008 |
Future research directions for the treatment of AML.
Topics: Antineoplastic Agents; Azacitidine; Biomedical Research; Carbazoles; Carboplatin; Cytarabine; Daunorubicin; Decitabine; Enzyme Inhibitors; Etoposide; Flavonoids; Furans; Humans; Leukemia, Myeloid, Acute; Mitoxantrone; Piperidines; Quinolones; Staurosporine; Topotecan; Tretinoin | 2008 |
Inactivation of the MAL gene in breast cancer is a common event that predicts benefit from adjuvant chemotherapy.
Topics: Azacitidine; Base Sequence; Breast Neoplasms; Cell Line; Cell Movement; Chemotherapy, Adjuvant; CpG Islands; Decitabine; DNA Methylation; Epigenesis, Genetic; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Immunoenzyme Techniques; Lasers; Membrane Microdomains; Membrane Transport Proteins; Middle Aged; Molecular Sequence Data; Myelin and Lymphocyte-Associated Proteolipid Proteins; Myelin Proteins; Prognosis; Promoter Regions, Genetic; Proteolipids; Reverse Transcriptase Polymerase Chain Reaction; Survival Rate; Wound Healing | 2009 |
Stem-cell-like glioma cells are resistant to TRAIL/Apo2L and exhibit down-regulation of caspase-8 by promoter methylation.
Topics: AC133 Antigen; Antigens, CD; Azacitidine; Caspase 3; Caspase 7; Caspase 8; Cell Death; Cycloheximide; Decitabine; DNA Methylation; Down-Regulation; Drug Resistance, Neoplasm; Glioma; Glycoproteins; Humans; Peptides; Poly(ADP-ribose) Polymerases; Promoter Regions, Genetic; Protein Synthesis Inhibitors; RNA, Messenger; Stem Cells; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured | 2009 |
A systematic assessment of radiation dose enhancement by 5-Aza-2'-deoxycytidine and histone deacetylase inhibitors in head-and-neck squamous cell carcinoma.
Topics: Acetylation; Apoptosis; Azacitidine; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Decitabine; DNA Methylation; Enzyme Inhibitors; Gene Silencing; Head and Neck Neoplasms; Histone Deacetylase Inhibitors; Histones; Humans; Radiation Tolerance; Radiation-Sensitizing Agents; Reverse Transcriptase Polymerase Chain Reaction; Tumor Stem Cell Assay | 2009 |
BTG3 tumor suppressor gene promoter demethylation, histone modification and cell cycle arrest by genistein in renal cancer.
Topics: Anticarcinogenic Agents; Azacitidine; Cell Cycle; Cell Cycle Proteins; Cell Survival; Chromatin; Chromatin Immunoprecipitation; Decitabine; DNA Methylation; DNA Modification Methylases; DNA-Binding Proteins; Enzyme Inhibitors; Genes, Tumor Suppressor; Genistein; Histones; Humans; Kidney Neoplasms; Promoter Regions, Genetic; Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured | 2009 |
5-AZA-2'-deoxycytidine (5-AZA-CdR) leads to down-regulation of Dnmt1o and gene expression in preimplantation mouse embryos.
Topics: Animals; Azacitidine; beta Catenin; Blastocyst; Cadherins; Connexins; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Down-Regulation; Embryonic Development; Female; Gene Expression Regulation, Developmental; Mice; Mutagens; Teratogens | 2009 |
Unique methylation pattern of oncostatin m receptor gene in cancers of colorectum and other digestive organs.
Topics: Acetylation; Azacitidine; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Decitabine; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Epigenesis, Genetic; Gastrointestinal Tract; Histone Deacetylase Inhibitors; Histone Deacetylases; Histones; Humans; Hydroxamic Acids; Oncostatin M Receptor beta Subunit; Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Tumor Suppressor Protein p53 | 2009 |
Decitabine, differently from DNMT1 silencing, exerts its antiproliferative activity through p21 upregulation in malignant pleural mesothelioma (MPM) cells.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cell Cycle; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Gene Silencing; Humans; Neoplasms, Mesothelial; Pleural Neoplasms; Up-Regulation | 2009 |
Integrative analysis of epigenetic modulation in melanoma cell response to decitabine: clinical implications.
Topics: Apoptosis; Azacitidine; Biomarkers, Tumor; Cell Line, Tumor; Cell Proliferation; Computational Biology; Decitabine; DNA Damage; Drug Resistance, Neoplasm; Epigenesis, Genetic; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Melanoma | 2009 |
Androgen receptor CpG island methylation status in human leukemia cancer cells.
Topics: Adolescent; Adult; Azacitidine; Cell Line, Tumor; Child; CpG Islands; Decitabine; DNA Methylation; Female; Humans; Leukemia; Male; Middle Aged; Receptors, Androgen; RNA, Messenger | 2009 |
6-Thioguanine perturbs cytosine methylation at the CpG dinucleotide site by DNA methyltransferases in vitro and acts as a DNA demethylating agent in vivo.
Topics: Azacitidine; Cytosine; Decitabine; Dinucleoside Phosphates; DNA; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA-Cytosine Methylases; Humans; Jurkat Cells; Oligodeoxyribonucleotides; Tandem Mass Spectrometry; Thioguanine | 2009 |
Combined inhibition of DNA methylation and histone acetylation enhances gene re-expression and drug sensitivity in vivo.
Topics: Acetylation; Adaptor Proteins, Signal Transducing; Animals; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Gene Expression Regulation, Neoplastic; Histone Acetyltransferases; Humans; Hydroxamic Acids; Melanoma-Specific Antigens; Mice; Mice, Nude; MutL Protein Homolog 1; Neoplasm Proteins; Nuclear Proteins; Ovarian Neoplasms; Sulfonamides; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2009 |
The characterization of DNA methylation-mediated regulation of bovine placental lactogen and bovine prolactin-related protein-1 genes.
Topics: Animals; Azacitidine; Cattle; Cell Line; Decitabine; DNA Methylation; DNA Primers; Epigenesis, Genetic; Female; Gonadotropins, Pituitary; Luciferases; Placental Lactogen; Reverse Transcriptase Polymerase Chain Reaction; Sequence Analysis, DNA; Trophoblasts | 2009 |
RA induces the neural-like cells generated from epigenetic modified NIH/3T3 cells.
Topics: Animals; Azacitidine; Cell Differentiation; Decitabine; DNA Methylation; Epigenesis, Genetic; Flow Cytometry; Gene Expression Profiling; Gene Expression Regulation; Immunohistochemistry; Intermediate Filament Proteins; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Mice; Nerve Tissue Proteins; Nestin; Neurons; NIH 3T3 Cells; Octamer Transcription Factor-3; Phosphopyruvate Hydratase; Proto-Oncogene Proteins c-myc; Reverse Transcriptase Polymerase Chain Reaction; SOXB1 Transcription Factors; Tretinoin | 2010 |
The comet assay: a sensitive method for detecting DNA damage in individual cells.
Topics: Apoptosis; Azacitidine; Cell Line, Tumor; Comet Assay; Decitabine; DNA Damage; DNA Repair; Dose-Response Relationship, Drug; Ethidium; Fluorescent Dyes; Humans; Hydrogen-Ion Concentration; Lung Neoplasms; Microscopy, Fluorescence; Mutagenicity Tests; Sensitivity and Specificity; Small Cell Lung Carcinoma | 2009 |
Epigenetic regulation of c-ROS receptor tyrosine kinase expression in malignant gliomas.
Topics: Astrocytoma; Azacitidine; Decitabine; Disease Progression; DNA Methylation; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Microarray Analysis; Promoter Regions, Genetic; Proto-Oncogene Mas; Receptor Protein-Tyrosine Kinases; RNA, Messenger; Tumor Cells, Cultured; Up-Regulation | 2009 |
Epigenetic silencing of EphA1 expression in colorectal cancer is correlated with poor survival.
Topics: Azacitidine; Cell Line, Tumor; Colon; Colorectal Neoplasms; CpG Islands; Decitabine; DNA Methylation; Epigenesis, Genetic; Gene Silencing; Humans; Immunohistochemistry; Polymerase Chain Reaction; Promoter Regions, Genetic; Receptor, EphA1 | 2009 |
Panobinostat treatment depletes EZH2 and DNMT1 levels and enhances decitabine mediated de-repression of JunB and loss of survival of human acute leukemia cells.
Topics: Azacitidine; Cell Survival; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA-Binding Proteins; Drug Combinations; Enhancer of Zeste Homolog 2 Protein; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; K562 Cells; Leukemia, Myeloid, Acute; Panobinostat; Polycomb Repressive Complex 2; Promoter Regions, Genetic; Repressor Proteins; Transcription Factors | 2009 |
Discovery of novel hypermethylated genes in prostate cancer using genomic CpG island microarrays.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Bone Morphogenetic Protein 7; Cell Line, Tumor; CpG Islands; Decitabine; DNA Methylation; Down-Regulation; Epigenesis, Genetic; Gene Expression; Gene Silencing; Genes, Tumor Suppressor; Genetic Markers; Homeodomain Proteins; Humans; Male; Oligonucleotide Array Sequence Analysis; Prostatic Neoplasms; Transcription Factors | 2009 |
Differential expression of stromal cell-derived factor 1 in human brain microvascular endothelial cells and pericytes involves histone modifications.
Topics: Azacitidine; Blood-Brain Barrier; Brain; Capillaries; Cells, Cultured; Chemokine CXCL12; Chromatin; Chromatin Immunoprecipitation; Decitabine; DNA Methylation; DNA Modification Methylases; Gene Expression; Gene Silencing; Histones; Humans; Pericytes; Promoter Regions, Genetic | 2009 |
Repeated responses of an elderly patient with high-risk myelodysplastic syndrome to sequential therapy with tipifarnib, 5-azacitidine, and decitabine.
Topics: Aged; Anemia, Refractory, with Excess of Blasts; Azacitidine; Benzene; Decitabine; DNA (Cytosine-5-)-Methyltransferases; Drug Therapy, Combination; Farnesyltranstransferase; Histone Deacetylase Inhibitors; Humans; Male; Occupational Exposure; Platelet Count; Quinolones; Thalidomide; Valproic Acid | 2009 |
Synergistic effect of trichostatin A and 5-aza-2'-deoxycytidine on growth inhibition of pancreatic endocrine tumour cell lines: a proteomic study.
Topics: Analysis of Variance; Apoptosis; Azacitidine; Carcinoma, Pancreatic Ductal; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Decitabine; Drug Synergism; Endocrine Gland Neoplasms; Enzyme Inhibitors; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Hydroxamic Acids; Pancreatic Neoplasms | 2009 |
5-Aza-2'-deoxycytidine is a potent inhibitor of DNA methyltransferase 3B and induces apoptosis in human endometrial cancer cell lines with the up-regulation of hMLH1.
Topics: Adaptor Proteins, Signal Transducing; Apoptosis; Azacitidine; Cell Line, Tumor; Cell Survival; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methyltransferase 3B; DNA Repair; DNA Repair Enzymes; Endometrial Neoplasms; Female; Humans; MutL Protein Homolog 1; Nuclear Proteins; Up-Regulation | 2010 |
Successful induction therapy with decitabine in refractory childhood acute lymphoblastic leukemia.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Child; Decitabine; Female; Humans; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Treatment Outcome | 2009 |
Promoter CpG island hypermethylation- and H3K9me3 and H3K27me3-mediated epigenetic silencing targets the deleted in colon cancer (DCC) gene in colorectal carcinogenesis without affecting neighboring genes on chromosomal region 18q21.
Topics: Azacitidine; Cell Line, Tumor; Chromosomes, Human, Pair 18; Colonic Neoplasms; CpG Islands; DCC Receptor; Decitabine; DNA Methylation; Epigenesis, Genetic; Histones; Humans; Hydroxamic Acids; Oxidoreductases, N-Demethylating; Promoter Regions, Genetic; Receptors, Cell Surface; Tumor Suppressor Proteins | 2009 |
Lysyl oxidase-like 2 promotes migration in noninvasive breast cancer cells but not in normal breast epithelial cells.
Topics: Amino Acid Oxidoreductases; Azacitidine; Blotting, Western; Breast Neoplasms; Catalysis; Cell Line; Cell Line, Tumor; Decitabine; Gene Expression Regulation, Enzymologic; Humans; Hydroxamic Acids; Immunohistochemistry; Mammary Glands, Human; Neoplasm Metastasis; Reverse Transcriptase Polymerase Chain Reaction | 2009 |
Epigenetic modifications of the Estrogen receptor beta gene in epithelial ovarian cancer cells.
Topics: Azacitidine; Cell Growth Processes; Cell Line, Tumor; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Enzyme Inhibitors; Estrogen Receptor beta; Female; Histone Acetyltransferases; Humans; Hydroxamic Acids; Ovarian Neoplasms; Promoter Regions, Genetic | 2009 |
DNA methylation inhibits p53-mediated survivin repression.
Topics: Azacitidine; Decitabine; DNA Methylation; Endometrial Neoplasms; Female; Humans; Inhibitor of Apoptosis Proteins; Microtubule-Associated Proteins; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; Survivin; Tumor Suppressor Protein p53 | 2009 |
Growth inhibition of human cancer cells by 5-aza-2'-deoxycytidine does not correlate with its effects on INK4a/ARF expression or initial promoter methylation status.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Blotting, Western; Breast Neoplasms; Cell Cycle; Cell Proliferation; Colorectal Neoplasms; Cyclin-Dependent Kinase Inhibitor p16; Decitabine; DNA Methylation; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Polymerase Chain Reaction; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Suppressor Protein p14ARF | 2009 |
Durable clinical and cytogenetic remission in an elderly patient with relapsed acute myeloid leukemia treated with low-dose lenalidomide.
Topics: Acute Disease; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Azacitidine; Blood Transfusion; Chromosome Deletion; Chromosomes, Human, Pair 5; Decitabine; Humans; Lenalidomide; Leukemia, Myeloid; Male; Neoplasm Recurrence, Local; Remission Induction; Thalidomide | 2009 |
[Effect of a methylation inhibitor 5-aza-2'-deoxycytidine on SHP-1 gene expression, proliferation and apoptosis in K562 cells].
Topics: Apoptosis; Azacitidine; Cell Proliferation; Decitabine; DNA Methylation; Gene Expression Regulation, Leukemic; Humans; K562 Cells; Protein Tyrosine Phosphatase, Non-Receptor Type 6 | 2009 |
Epigenetic reversal of acquired resistance to 5-fluorouracil treatment.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Base Sequence; Cell Line, Tumor; Colorectal Neoplasms; CpG Islands; Decitabine; DNA Methylation; Drug Resistance, Neoplasm; Epigenomics; Fluorouracil; Gene Expression Regulation, Neoplastic; Gene Order; Humans; Mice; Mice, Nude; Molecular Sequence Data; Nucleoside-Phosphate Kinase; Promoter Regions, Genetic; RNA Stability; Uridine; Xenograft Model Antitumor Assays | 2009 |
Recent advances in low- and intermediate-1-risk myelodysplastic syndrome: developing a consensus for optimal therapy.
Topics: Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Blood Transfusion; Clinical Trials as Topic; Consensus; Decitabine; Humans; Lenalidomide; Middle Aged; Myelodysplastic Syndromes; Prognosis; Risk Factors; Thalidomide | 2008 |
Wnt signaling pathway is epigenetically regulated by methylation of Wnt antagonists in acute myeloid leukemia.
Topics: Adult; Aged; Ataxia Telangiectasia Mutated Proteins; Azacitidine; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Decitabine; DNA Methylation; Epigenesis, Genetic; Female; Genes, bcl-1; Humans; Intercellular Signaling Peptides and Proteins; Leukemia, Myeloid, Acute; Male; Membrane Proteins; Middle Aged; Prognosis; Promoter Regions, Genetic; Protein Serine-Threonine Kinases; Signal Transduction; Wnt Proteins | 2009 |
Quantitation of DNA methylation by melt curve analysis.
Topics: Algorithms; Antimetabolites, Antineoplastic; Azacitidine; Cell Line, Tumor; Colorectal Neoplasms; Cyclin-Dependent Kinase Inhibitor p16; Decitabine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; DNA, Neoplasm; Esophageal Neoplasms; Hot Temperature; Humans; Immunohistochemistry; Nucleic Acid Denaturation; Oligonucleotides; Polymerase Chain Reaction; Promoter Regions, Genetic; Tissue Inhibitor of Metalloproteinase-3; Tumor Suppressor Proteins | 2009 |
GSTP1 determines cis-platinum cytotoxicity in gastric adenocarcinoma MGC803 cells: regulation by promoter methylation and extracellular regulated kinase signaling.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Azacitidine; Cell Line, Tumor; Cisplatin; CpG Islands; Decitabine; DNA Methylation; Drug Resistance, Neoplasm; Enzyme Induction; Gene Expression Regulation, Neoplastic; Glutathione S-Transferase pi; Humans; Inactivation, Metabolic; MAP Kinase Signaling System; Mitogen-Activated Protein Kinases; Neoplasm Proteins; Promoter Regions, Genetic; RNA, Messenger; RNA, Neoplasm; Stomach Neoplasms; Transcription, Genetic | 2009 |
Treatment of chronic lymphocytic leukemia with a hypomethylating agent induces expression of NXF2, an immunogenic cancer testis antigen.
Topics: Adult; Aged; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Azacitidine; B7-1 Antigen; B7-2 Antigen; Blotting, Western; CD40 Antigens; Cell Line; Decitabine; DNA Methylation; DNA Modification Methylases; Enzyme-Linked Immunosorbent Assay; Female; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Immunoglobulin G; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Reverse Transcriptase Polymerase Chain Reaction; Transfection; Tumor Cells, Cultured | 2009 |
Epigenetic down-regulation of BIM expression is associated with reduced optimal responses to imatinib treatment in chronic myeloid leukaemia.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Azacitidine; Bcl-2-Like Protein 11; Benzamides; Cell Proliferation; Decitabine; DNA Methylation; DNA Modification Methylases; Dose-Response Relationship, Drug; Down-Regulation; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Epigenesis, Genetic; Female; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Membrane Proteins; Middle Aged; Piperazines; Promoter Regions, Genetic; Proto-Oncogene Proteins; Pyrimidines; RNA, Messenger; RNA, Neoplasm; Tumor Cells, Cultured | 2009 |
Inhibitors of poly ADP-ribose polymerase (PARP) induce apoptosis of myeloid leukemic cells: potential for therapy of myeloid leukemia and myelodysplastic syndromes.
Topics: Apoptosis; Azacitidine; Benzamides; Butyrates; Cell Cycle; Cell Line; Cell Line, Tumor; Cell Survival; Decitabine; DNA Modification Methylases; DNA Repair; Drug Synergism; Flow Cytometry; Fluorescent Antibody Technique; Fluorobenzenes; Histone Acetyltransferases; HL-60 Cells; Humans; Hydroxamic Acids; Immunohistochemistry; K562 Cells; Leukemia, Myeloid; Myelodysplastic Syndromes; Phenanthrenes; Phthalazines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Pyridines; U937 Cells | 2009 |
Dynamic changes in DNA methylation during multistep rat lung carcinogenesis induced by 3-methylcholanthrene and diethylnitrosamine.
Topics: Animals; Azacitidine; Cell Line; Cocarcinogenesis; Cyclin-Dependent Kinase Inhibitor p15; Cyclin-Dependent Kinase Inhibitor p16; Decitabine; Diethylnitrosamine; DNA Methylation; Female; Immunohistochemistry; Lung; Lung Neoplasms; Male; Methylcholanthrene; Microdissection; Rats; Rats, Wistar; Reverse Transcriptase Polymerase Chain Reaction | 2009 |
Epigenetic hierarchy governing Nestin expression.
Topics: Acetylation; Animals; Azacitidine; Carcinoma, Embryonal; Cell Line; Chromatin; Chromatin Immunoprecipitation; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Embryonic Stem Cells; Enhancer Elements, Genetic; Epigenesis, Genetic; Histones; Hydroxamic Acids; Intermediate Filament Proteins; Introns; Mice; Nerve Tissue Proteins; Nestin; Promoter Regions, Genetic; Transcription, Genetic; Tretinoin | 2009 |
Proliferating cell nuclear antigen is protected from degradation by forming a complex with MutT Homolog2.
Topics: Acetylation; Azacitidine; Blotting, Western; Cell Cycle; Cell Line; Cell Line, Tumor; Decitabine; Deoxyguanine Nucleotides; Fluorescence Resonance Energy Transfer; Humans; Hydrogen Peroxide; Immunoprecipitation; Luminescent Proteins; Microscopy, Confocal; Oxidants; Phosphoric Diester Hydrolases; Proliferating Cell Nuclear Antigen; Protein Binding; Pyrophosphatases; Recombinant Fusion Proteins; RNA Interference; Thymidine; Transfection; Ultraviolet Rays | 2009 |
LINE-1 methylation in plasma DNA as a biomarker of activity of DNA methylation inhibitors in patients with solid tumors.
Topics: Antigens, Neoplasm; Antimetabolites, Antineoplastic; Azacitidine; Biomarkers, Tumor; Cell Line, Tumor; Cheek; Decitabine; DNA Methylation; DNA Modification Methylases; DNA, Neoplasm; Humans; Long Interspersed Nucleotide Elements; Melanoma-Specific Antigens; Mouth Mucosa; Neoplasm Proteins; Neoplasms; Promoter Regions, Genetic; Saliva; Sequence Analysis, DNA | 2009 |
Blockade of MEK signaling potentiates 5-Aza-2'-deoxycytidine-induced apoptosis and upregulation of p21(waf1) in acute myelogenous leukemia cells.
Topics: Acetylation; Aged; Apoptosis; Azacitidine; Benzimidazoles; Blotting, Western; Cell Proliferation; Chromatin Immunoprecipitation; Cyclin-Dependent Kinase Inhibitor p21; Decitabine; DNA Modification Methylases; Drug Synergism; Enzyme Inhibitors; Flow Cytometry; Gene Expression Regulation; Histone Deacetylase Inhibitors; Histone Deacetylases; Histones; Humans; Leukemia, Myeloid; MAP Kinase Kinase 1; Middle Aged; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Signal Transduction; Transfection; Tumor Cells, Cultured | 2009 |
CpG hypermethylation of collagen type I alpha 2 contributes to proliferation and migration activity of human bladder cancer.
Topics: Adult; Aged; Aged, 80 and over; Azacitidine; Biomarkers, Tumor; Cell Adhesion; Cell Movement; Cell Proliferation; Collagen; Collagen Type I; CpG Islands; Decitabine; DNA Methylation; Down-Regulation; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Immunoblotting; Immunoenzyme Techniques; Male; Middle Aged; Oligonucleotide Array Sequence Analysis; Promoter Regions, Genetic; Prostatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured; Urinary Bladder; Urinary Bladder Neoplasms | 2009 |
Glucocorticoid receptor alpha and beta variant expression is associated with ASF/SF2 splicing factor upregulation in HT-29 colon cancer and MCF-7 breast carcinoma cells.
Topics: Azacitidine; Breast Neoplasms; Butyrates; Colonic Neoplasms; Decitabine; Enzyme Inhibitors; HT29 Cells; Humans; Hydroxamic Acids; Nuclear Proteins; Receptors, Glucocorticoid; RNA-Binding Proteins; Serine-Arginine Splicing Factors | 2009 |
Additive effects of 5-aza-2'-deoxycytidine and irradiation on clonogenic survival of human medulloblastoma cell lines.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cell Line, Tumor; Cell Survival; Combined Modality Therapy; Decitabine; Dose-Response Relationship, Radiation; Humans; Medulloblastoma; Radiation Tolerance; Radiotherapy Dosage; Radiotherapy, Conformal | 2009 |
Quantification of regional DNA methylation by liquid chromatography/tandem mass spectrometry.
Topics: Azacitidine; Base Sequence; Cell Line, Tumor; Chromatography, High Pressure Liquid; Decitabine; Deoxycytidine; DNA; DNA Methylation; Humans; Promoter Regions, Genetic; Reproducibility of Results; Tandem Mass Spectrometry | 2009 |
c-Myc regulates the coordinated transcription of brain disease-related PDCD10-SERPINI1 bidirectional gene pair.
Topics: Apoptosis Regulatory Proteins; Azacitidine; Cell Line, Tumor; Chromatin Immunoprecipitation; Decitabine; DNA Methylation; Electrophoretic Mobility Shift Assay; Enzyme Inhibitors; Glioblastoma; Humans; Membrane Proteins; Molecular Sequence Data; Mutagenesis, Site-Directed; Neuroblastoma; Neuropeptides; Neuroserpin; Promoter Regions, Genetic; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-myc; Serpins; Transcriptional Activation | 2009 |
Expression level and DNA methylation status of glutathione-S-transferase genes in normal murine prostate and TRAMP tumors.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Azacitidine; Cell Line, Tumor; CpG Islands; Decitabine; DNA Methylation; Drug Combinations; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Gene Silencing; Glutathione S-Transferase pi; Glutathione Transferase; Hydroxamic Acids; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Neoplasm Metastasis; Prostate; Prostatic Neoplasms; RNA, Messenger | 2009 |
T-lymphocyte maturation-associated protein gene as a candidate metastasis suppressor for head and neck squamous cell carcinomas.
Topics: Adult; Aged; Aged, 80 and over; Azacitidine; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cell Line, Tumor; Decitabine; Female; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Heterozygote; Humans; Male; Membrane Transport Proteins; Middle Aged; Mutation; Myelin and Lymphocyte-Associated Proteolipid Proteins; Myelin Proteins; Neoplasm Metastasis; Proteolipids; RNA, Messenger | 2009 |
Quantitative evaluation of DNA methylation by optimization of a differential-high resolution melt analysis protocol.
Topics: Azacitidine; Cell Line, Tumor; CpG Islands; Decitabine; DNA Methylation; DNA Primers; DNA, Neoplasm; Genes, bcl-2; Humans; Nucleic Acid Denaturation; Polymerase Chain Reaction; Telomerase; Urinary Bladder Neoplasms | 2009 |
Interaction of TFAP2C with the estrogen receptor-alpha promoter is controlled by chromatin structure.
Topics: Acetylation; Azacitidine; Breast Neoplasms; Cell Line, Tumor; Chromatin; Chromatin Immunoprecipitation; CpG Islands; Decitabine; DNA Methylation; Enzyme Inhibitors; Estrogen Receptor alpha; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Histones; Humans; Hydroxamic Acids; Lysine; Promoter Regions, Genetic; Protein Binding; Reverse Transcriptase Polymerase Chain Reaction; Transcription Factor AP-2 | 2009 |
Effects of a novel DNA methyltransferase inhibitor zebularine on human breast cancer cells.
Topics: Adenocarcinoma; Apoptosis Regulatory Proteins; Azacitidine; Breast Neoplasms; Cell Cycle Proteins; Cell Line, Tumor; Chromatin Immunoprecipitation; Cytidine; Cytidine Deaminase; Decitabine; DNA (Cytosine-5-)-Methyltransferases; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Inhibitors; Female; Gene Expression Regulation, Neoplastic; Humans; Hydroxamic Acids; Neoplasm Proteins; Receptors, Estrogen; S Phase; Tumor Stem Cell Assay; Vorinostat | 2010 |
The combination effect of sodium butyrate and 5-Aza-2'-deoxycytidine on radiosensitivity in RKO colorectal cancer and MCF-7 breast cancer cell lines.
Topics: Azacitidine; Breast Neoplasms; Butyrates; Cell Line, Tumor; Colorectal Neoplasms; Decitabine; DNA Methylation; Enzyme Inhibitors; Female; Histone Deacetylase Inhibitors; Humans; Radiation Dosage; Radiation-Sensitizing Agents | 2009 |
CpG island methylation affects accessibility of the proximal BRCA1 promoter to transcription factors.
Topics: Adenocarcinoma; Azacitidine; BRCA1 Protein; Breast Neoplasms; Cell Line, Tumor; Chromatin Immunoprecipitation; CpG Islands; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Female; Gene Expression Regulation, Neoplastic; Genes, BRCA1; Humans; Hydroxamic Acids; Neoplasm Proteins; Promoter Regions, Genetic; Protein Binding; RNA, Messenger; Transcription Factors; Transcription, Genetic | 2010 |
Chemical decomposition of 5-aza-2'-deoxycytidine (Decitabine): kinetic analyses and identification of products by NMR, HPLC, and mass spectrometry.
Topics: Azacitidine; Chromatography, High Pressure Liquid; Decitabine; DNA Modification Methylases; Enzyme Inhibitors; Gas Chromatography-Mass Spectrometry; Half-Life; Hydrogen-Ion Concentration; Kinetics; Magnetic Resonance Spectroscopy; Spectrophotometry, Ultraviolet; Temperature; Time Factors | 2009 |
Treatment with demethylating agent, 5-aza-2'-deoxycytidine enhances therapeutic HPV DNA vaccine potency.
Topics: Animals; Azacitidine; CD8-Positive T-Lymphocytes; Decitabine; Female; Gene Expression; Humans; Mice; Papillomavirus Vaccines; Survival Analysis; Vaccines, DNA | 2009 |
Camptothecin-induced cell proliferation inhibition and apoptosis enhanced by DNA methyltransferase inhibitor, 5-aza-2'-deoxycytidine.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Azacitidine; Camptothecin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Decitabine; DNA (Cytosine-5-)-Methyltransferases; Drug Synergism; Electrophoresis, Gel, Two-Dimensional; Enzyme-Linked Immunosorbent Assay; Galectin 1; Humans; Reverse Transcriptase Polymerase Chain Reaction; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2009 |
Cord blood stem cell expansion is permissive to epigenetic regulation and environmental cues.
Topics: Adult; Animals; Antigens, CD34; Azacitidine; Cell Culture Techniques; Cell Division; Cells, Cultured; Cord Blood Stem Cell Transplantation; Cytokines; Decitabine; Enzyme Inhibitors; Epigenesis, Genetic; Fetal Blood; Hematopoietic Stem Cells; Humans; Hydroxamic Acids; Mice; Mice, Inbred NOD; Mice, SCID; Thy-1 Antigens; Transplantation, Heterologous; Transplantation, Homologous | 2009 |
Frequent loss of cystatin E/M expression implicated in the progression of prostate cancer.
Topics: Acetylation; Animals; Azacitidine; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Chromatin; Cystatin M; Decitabine; Disease Progression; DNA Methylation; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Immunohistochemistry; Male; Mice; Mice, Nude; Neoplasms, Experimental; Prostatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Transplantation, Heterologous | 2009 |
Chromatin remodeling at Alu repeats by epigenetic treatment activates silenced microRNA-512-5p with downregulation of Mcl-1 in human gastric cancer cells.
Topics: Alu Elements; Apoptosis; Azacitidine; Cell Line, Tumor; Chromatin Assembly and Disassembly; Chromosomes, Human, Pair 19; Decitabine; DNA Methylation; DNA Polymerase II; DNA Polymerase III; Down-Regulation; Epigenesis, Genetic; Histone Deacetylase Inhibitors; Humans; MicroRNAs; Myeloid Cell Leukemia Sequence 1 Protein; Phenylbutyrates; Proto-Oncogene Proteins c-bcl-2; Stomach Neoplasms | 2009 |
Epigenetic silencing of TTF-1/NKX2-1 through DNA hypermethylation and histone H3 modulation in thyroid carcinomas.
Topics: Azacitidine; Base Sequence; Carcinoma, Papillary; Cell Line, Tumor; Chromatin Immunoprecipitation; CpG Islands; Decitabine; DNA Methylation; DNA Primers; Epigenesis, Genetic; Gene Expression Profiling; Gene Silencing; Histones; Humans; Hydroxamic Acids; Nuclear Proteins; RNA, Messenger; RNA, Neoplasm; Thyroid Gland; Thyroid Neoplasms; Thyroid Nuclear Factor 1; Transcription Factors | 2009 |
Targeting DNA methylation.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials as Topic; Decitabine; DNA Methylation; DNA Modification Methylases; Epigenesis, Genetic; Humans; Myelodysplastic Syndromes; Neoplasms | 2009 |
DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation.
Topics: Adenosine; Azacitidine; Blotting, Western; Cell Line; Cell Line, Tumor; Decitabine; DNA Methylation; DNA-Binding Proteins; Enhancer of Zeste Homolog 2 Protein; Enzyme Inhibitors; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Histones; Humans; Keratin-7; Methylation; Molecular Structure; Oligonucleotide Array Sequence Analysis; Polycomb Repressive Complex 2; Reverse Transcriptase Polymerase Chain Reaction; Transcription Factors | 2009 |
Re-differentiation of thyroid carcinoma cell lines treated with 5-Aza-2'-deoxycytidine and retinoic acid.
Topics: Azacitidine; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Colony-Forming Units Assay; Decitabine; Fluorescent Antibody Technique; Gene Expression Regulation, Neoplastic; Humans; Organ Specificity; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Retinoic Acid Receptor gamma; Symporters; Thyroid Neoplasms; Tretinoin | 2009 |
Epigenetic modifiers exacerbate oxidative stress in renal proximal tubule cells.
Topics: Animals; Antifungal Agents; Antimetabolites, Antineoplastic; Azacitidine; Cell Survival; Cells, Cultured; Decitabine; Hydroxamic Acids; Kidney Tubules, Proximal; Mice; Oxidative Stress; Reactive Oxygen Species | 2009 |
Distinct roles for histone methyltransferases G9a and GLP in cancer germ-line antigen gene regulation in human cancer cells and murine embryonic stem cells.
Topics: Animals; Antigens, Neoplasm; Azacitidine; Cell Line; Cell Line, Tumor; Decitabine; DNA Methylation; Embryonic Stem Cells; Gene Expression; Gene Expression Regulation; Histocompatibility Antigens; Histone Deacetylase Inhibitors; Histone Deacetylases; Histone-Lysine N-Methyltransferase; Humans; Hydroxamic Acids; Mice; Mice, Knockout | 2009 |
Use of epigenetic modification to induce FOXP3 expression in naïve T cells.
Topics: Animals; Azacitidine; Blotting, Western; CD4-Positive T-Lymphocytes; Decitabine; DNA Modification Methylases; Forkhead Transcription Factors; Gene Expression Regulation; Humans; Immunophenotyping; Interleukin-2 Receptor alpha Subunit; Mice; Mice, Inbred BALB C; Spleen; T-Lymphocytes; T-Lymphocytes, Regulatory | 2009 |
Genomic screening for genes silenced by DNA methylation revealed an association between RASD1 inactivation and dexamethasone resistance in multiple myeloma.
Topics: Antineoplastic Agents; Azacitidine; Cell Line, Tumor; Cell Survival; Decitabine; Dexamethasone; DNA Methylation; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Silencing; Genetic Testing; Humans; Models, Biological; Multiple Myeloma; Oligonucleotide Array Sequence Analysis; ras Proteins | 2009 |
Xenoestrogen-induced epigenetic repression of microRNA-9-3 in breast epithelial cells.
Topics: Azacitidine; Breast; Cell Line, Tumor; Cells, Cultured; CpG Islands; Decitabine; Diethylstilbestrol; DNA Methylation; Epigenesis, Genetic; Epithelial Cells; Fluorescent Antibody Technique; Gene Expression; Gene Expression Profiling; Gene Regulatory Networks; Humans; Hydroxamic Acids; MicroRNAs; Models, Biological; Oligonucleotide Array Sequence Analysis; Reverse Transcriptase Polymerase Chain Reaction; Transfection | 2009 |
DNA methylation regulates constitutive expression of Stat6 regulatory genes SOCS-1 and SHP-1 in colon cancer cells.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Caco-2 Cells; Colonic Neoplasms; Decitabine; DNA Methylation; Gene Expression Regulation, Neoplastic; HT29 Cells; Humans; Interleukin-4; Phenotype; Protein Tyrosine Phosphatase, Non-Receptor Type 6; STAT6 Transcription Factor; Suppressor of Cytokine Signaling 1 Protein; Suppressor of Cytokine Signaling Proteins | 2009 |
Epigenetic regulation of HIV-1 latency by cytosine methylation.
Topics: Azacitidine; CD4-Positive T-Lymphocytes; CpG Islands; Cytosine; Decitabine; DNA Methylation; DNA-Binding Proteins; Epigenesis, Genetic; HIV-1; Humans; Jurkat Cells; NF-kappa B; Promoter Regions, Genetic; Repressor Proteins; RNA, Small Interfering; Transfection; Virus Latency | 2009 |
Alteration of transcriptional profile in human bronchial epithelial cells induced by cigarette smoke condensate.
Topics: Animals; Azacitidine; Blotting, Northern; Bronchi; Cell Differentiation; Cell Line; Cell Survival; Cell Transformation, Neoplastic; Decitabine; Epithelial Cells; Flow Cytometry; Gene Expression Profiling; Humans; Mice; Nicotiana; Oligonucleotide Array Sequence Analysis; Reverse Transcriptase Polymerase Chain Reaction; Transcription, Genetic | 2009 |
Transcriptional activation of the gamma-globin gene in baboons treated with decitabine and in cultured erythroid progenitor cells involves different mechanisms.
Topics: Age Factors; Animals; Azacitidine; Carrier Proteins; Cells, Cultured; Chromatin Immunoprecipitation; Decitabine; DNA Methylation; Erythroid Precursor Cells; Fetal Blood; Fetal Hemoglobin; gamma-Globins; Gestational Age; Nuclear Proteins; Papio anubis; Phlebotomy; Promoter Regions, Genetic; Protein Isoforms; Protein Processing, Post-Translational; RNA, Messenger; SUMO-1 Protein; Transcription, Genetic | 2009 |
Frequent methylation of RASSF1A in synovial sarcoma and the anti-tumor effects of 5-aza-2'-deoxycytidine against synovial sarcoma cell lines.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Cell Line, Tumor; Cell Proliferation; Cell Survival; Decitabine; DNA Methylation; Dose-Response Relationship, Drug; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Inhibitory Concentration 50; Mice; Mice, Inbred BALB C; Mice, Nude; Microscopy, Fluorescence; Reverse Transcriptase Polymerase Chain Reaction; Sarcoma, Synovial; Time Factors; Tumor Burden; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2010 |
15-hydroxyprostaglandin dehydrogenase is down-regulated in gastric cancer.
Topics: Azacitidine; Cell Line, Tumor; Cell Proliferation; CpG Islands; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Decitabine; Dinoprostone; DNA Methylation; Down-Regulation; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Hydroxyprostaglandin Dehydrogenases; Immunohistochemistry; Interleukin-1beta; Nitrobenzenes; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Stomach Neoplasms; Sulfonamides; Transfection | 2009 |
Diet-induced up-regulation of gene expression in adipocytes without changes in DNA methylation.
Topics: 3T3-L1 Cells; Adaptor Proteins, Signal Transducing; Adipocytes, White; Adipose Tissue, White; Animals; Antimetabolites, Antineoplastic; Azacitidine; Cell Size; CpG Islands; Decitabine; Dietary Fats; DNA Methylation; Gene Expression; Intercellular Signaling Peptides and Proteins; Leptin; Male; Mice; Mice, Inbred C57BL; Obesity; Promoter Regions, Genetic; Proteins; Up-Regulation | 2009 |
[Detection of O6-methylguanine-DNA methyltransferase promoter methylation in chemotherapy for glioma].
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Azacitidine; Brain Neoplasms; Cell Line, Tumor; CpG Islands; Dacarbazine; Decitabine; DNA Methylation; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Glioma; Humans; Male; Middle Aged; Nimustine; O(6)-Methylguanine-DNA Methyltransferase; Promoter Regions, Genetic; Survival Rate; Temozolomide; Young Adult | 2009 |
IGFBP7 is a p53-responsive gene specifically silenced in colorectal cancer with CpG island methylator phenotype.
Topics: Adenocarcinoma; Adenoma; Azacitidine; Cell Line, Tumor; Cellular Senescence; Colorectal Neoplasms; Consensus Sequence; CpG Islands; Decitabine; DNA Methylation; DNA, Neoplasm; Gene Silencing; Genes, p53; Histones; Humans; Insulin-Like Growth Factor Binding Proteins; Neoplasm Proteins; Phenotype; Proto-Oncogene Proteins B-raf; Recombinant Fusion Proteins; Tumor Stem Cell Assay; Tumor Suppressor Protein p53 | 2010 |
iTRAQ-coupled 2-D LC-MS/MS analysis of protein profile associated with HBV-modulated DNA methylation.
Topics: Azacitidine; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Chromatography, Liquid; Decitabine; DNA; DNA Methylation; DNA Modification Methylases; Gene Expression Regulation, Neoplastic; Hepatitis B virus; Humans; Liver Neoplasms; Proteome; Reverse Transcriptase Polymerase Chain Reaction; Tandem Mass Spectrometry | 2009 |
14-3-3sigma gene silencing during melanoma progression and its role in cell cycle control and cellular senescence.
Topics: 14-3-3 Proteins; Antineoplastic Agents; Azacitidine; Biomarkers, Tumor; Cell Cycle; Cell Line, Tumor; Cell Movement; Cellular Senescence; CpG Islands; Decitabine; Disease Progression; DNA Methylation; Down-Regulation; Exonucleases; Exoribonucleases; Gene Expression; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Melanoma; Neoplasm Metastasis; Neoplasm Proteins; Phenylbutyrates; RNA, Messenger | 2009 |
RUNX3 gene methylation in epithelial ovarian cancer tissues and ovarian cancer cell lines.
Topics: Azacitidine; Cell Line, Tumor; Core Binding Factor Alpha 3 Subunit; CpG Islands; Decitabine; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Female; Gene Expression Regulation, Neoplastic; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Promoter Regions, Genetic; RNA, Messenger | 2009 |
Effects of 5-Aza-CdR on the proliferation of human breast cancer cell line MCF-7 and on the expression of Apaf-1 gene.
Topics: Apoptosis; Apoptotic Protease-Activating Factor 1; Azacitidine; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Decitabine; DNA (Cytosine-5-)-Methyltransferases; Female; Humans; RNA, Messenger | 2009 |
Repression of induced apoptosis in the 2-cell bovine embryo involves DNA methylation and histone deacetylation.
Topics: 5-Methylcytosine; Animals; Apoptosis; Azacitidine; Blastocyst; Carbonyl Cyanide m-Chlorophenyl Hydrazone; Cattle; Cytosine; Decitabine; DNA Fragmentation; DNA Methylation; Histone Deacetylase Inhibitors; Histone Deacetylases; Histones; Hydroxamic Acids | 2009 |
Homologous recombination but not nucleotide excision repair plays a pivotal role in tolerance of DNA-protein cross-links in mammalian cells.
Topics: Animals; Ataxia Telangiectasia; Azacitidine; Base Sequence; BRCA2 Protein; Cell Cycle Proteins; Cell Line; Chromosomes; Cricetinae; Cross-Linking Reagents; Decitabine; Deoxyribonucleotides; DNA; DNA Breaks, Double-Stranded; DNA Repair; Escherichia coli; Fanconi Anemia Complementation Group D2 Protein; Formaldehyde; Histones; Humans; Molecular Weight; Mutation; Proteasome Endopeptidase Complex; Proteins; Rad51 Recombinase; Recombination, Genetic | 2009 |
Three epigenetic drugs up-regulate homeobox gene Rhox5 in cancer cells through overlapping and distinct molecular mechanisms.
Topics: Animals; Arsenic Trioxide; Arsenicals; Azacitidine; Benzamides; Cell Line, Tumor; Decitabine; DNA Modification Methylases; Epigenesis, Genetic; Genes, Homeobox; Growth Inhibitors; Histone Deacetylase Inhibitors; Homeodomain Proteins; Humans; Male; Mice; Oxides; Pyridines; Transcription Factors; Up-Regulation | 2009 |
Preclinical antileukemia activity of JNJ-26481585, a potent second-generation histone deacetylase inhibitor.
Topics: Antineoplastic Agents; Azacitidine; Decitabine; Drug Evaluation, Preclinical; Drug Synergism; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Leukemia; Tumor Cells, Cultured | 2010 |
Clinical implications of gene expression profiling in myelodysplastic syndromes: recognition of ribosomal and translational gene dysregulation and development of predictive assays.
Topics: Antigens, CD34; Azacitidine; Cell Proliferation; Decitabine; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lenalidomide; Myelodysplastic Syndromes; Protein Biosynthesis; Ribosomes; Thalidomide | 2009 |
Involvement of DNA hypermethylation in down-regulation of the zinc transporter ZIP8 in cadmium-resistant metallothionein-null cells.
Topics: Animals; Azacitidine; Cadmium; Cation Transport Proteins; Cells, Cultured; CpG Islands; Decitabine; DNA Methylation; DNA Modification Methylases; Epigenesis, Genetic; Gene Silencing; Metallothionein; Mice; Mice, Knockout; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2009 |
Methylation-associated silencing of S100A4 expression in human epidermal cancers.
Topics: Azacitidine; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; beta Catenin; Biopsy; Cadherins; Cell Line, Tumor; Decitabine; DNA Methylation; Down-Regulation; Enzyme Inhibitors; Epidermis; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Introns; Neoplasms, Glandular and Epithelial; S100 Calcium-Binding Protein A4; S100 Proteins; Skin Neoplasms; Transcription Factor 4; Transcription Factors; Wnt Proteins | 2009 |
Epigenetic silencing of death receptor 4 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in gliomas.
Topics: Apoptosis; Azacitidine; Cell Line, Tumor; Decitabine; DNA Methylation; Drug Resistance, Neoplasm; Gene Silencing; Glioma; Humans; Promoter Regions, Genetic; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor; RNA, Small Interfering; TNF-Related Apoptosis-Inducing Ligand | 2009 |
Clinical roundtable monograph. Overall survival and maintenance of MDS patients.
Topics: Azacitidine; Clinical Trials, Phase III as Topic; Decitabine; Disease-Free Survival; DNA Modification Methylases; Humans; Myelodysplastic Syndromes; Randomized Controlled Trials as Topic | 2009 |
A 64-year-old male with fever and persistent lung infiltrate.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cryptogenic Organizing Pneumonia; Decitabine; Humans; Male; Middle Aged | 2009 |
DNA methyltransferase inhibition induces mouse embryonic stem cell differentiation into endothelial cells.
Topics: Angiopoietin-1; Animals; Antigens, CD; Azacitidine; Basic Helix-Loop-Helix Transcription Factors; Bone Morphogenetic Protein 4; Cadherins; Cell Differentiation; Cell Line; Cells, Cultured; CpG Islands; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Down-Regulation; Embryonic Stem Cells; Endothelial Cells; Gene Expression; Mice; Neovascularization, Physiologic; Octamer Transcription Factor-3; Promoter Regions, Genetic; Receptor, TIE-2; Up-Regulation; Vascular Endothelial Growth Factor A; von Willebrand Factor | 2010 |
Loss of human ribosomal gene CpG methylation enhances cryptic RNA polymerase II transcription and disrupts ribosomal RNA processing.
Topics: Azacitidine; Cell Nucleolus; Cell Proliferation; Cell Survival; CpG Islands; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Methyltransferase 3B; DNA, Ribosomal; Enzyme Inhibitors; HCT116 Cells; Humans; Kinetics; RNA Polymerase II; RNA Processing, Post-Transcriptional; RNA Stability; RNA, Ribosomal; Transcription, Genetic | 2009 |
Atypical presentations of Sweet's syndrome in patients with MDS/AML receiving combinations of hypomethylating agents with histone deacetylase inhibitors.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Decitabine; Diagnosis, Differential; Fatal Outcome; Female; Histone Deacetylase Inhibitors; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Sweet Syndrome; Treatment Outcome | 2009 |
Activation of HLA-G expression by 5-aza-2 - deoxycytidine in malignant hematopoetic cells isolated from leukemia patients.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Blotting, Western; Decitabine; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Gene Expression Regulation, Leukemic; Hematopoietic Stem Cells; Histocompatibility Antigens Class I; HLA Antigens; HLA-G Antigens; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Stem Cell Transplantation | 2009 |
[Effect of 5-Aza-dC on FHIT gene expression in hepatocellular carcinoma cell line HepG2].
Topics: Acid Anhydride Hydrolases; Azacitidine; Cell Proliferation; Decitabine; DNA Methylation; DNA Modification Methylases; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Neoplasm Proteins; RNA, Messenger | 2009 |
Clinical roundtable monograph. Choosing an appropriate therapy for lower-risk MDS in the community setting.
Topics: Azacitidine; Decitabine; DNA Modification Methylases; Drug Administration Schedule; Humans; Myelodysplastic Syndromes | 2009 |
5-Aza-2'-deoxycytidine sensitizes busulfan-resistant myeloid leukemia cells by regulating expression of genes involved in cell cycle checkpoint and apoptosis.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Azacitidine; Blotting, Western; Busulfan; Cell Line, Tumor; Cell Separation; Decitabine; Drug Resistance, Neoplasm; Flow Cytometry; Gene Expression; Gene Expression Regulation, Neoplastic; Genes, cdc; Humans; In Situ Nick-End Labeling; Leukemia, Myeloid; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction | 2010 |
Frequent epigenetic inactivation of the receptor tyrosine kinase EphA5 by promoter methylation in human breast cancer.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Base Sequence; Biomarkers, Tumor; Breast; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating; Cell Line, Tumor; Decitabine; DNA Methylation; Epigenesis, Genetic; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Middle Aged; Molecular Sequence Data; Neoplasm Staging; Receptor, EphA5; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; RNA, Messenger | 2010 |
LARG at chromosome 11q23 has functional characteristics of a tumor suppressor in human breast and colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chromosome Deletion; Chromosome Mapping; Chromosomes, Human, Pair 11; Colorectal Neoplasms; Decitabine; DNA Methylation; Female; Guanine Nucleotide Exchange Factors; Humans; Hydroxamic Acids; Male; Nucleic Acid Hybridization; Promoter Regions, Genetic; Protein Synthesis Inhibitors; Rho Guanine Nucleotide Exchange Factors; Transfection; Tumor Suppressor Proteins | 2009 |
Case records of the Massachusetts General Hospital. Case 28-2009. A 68-year-old man with fatigue, cough, and peripheral-blood monocytosis.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow; Bone Marrow Examination; Combined Modality Therapy; Cough; Decitabine; Diagnosis, Differential; Fatigue; Humans; Leukemia, Myeloid, Acute; Leukocytosis; Male; Monocytes; Stem Cell Transplantation | 2009 |
[Effects of 5-Aza-2'-deoxycytidine and trichostatin A on P16, hMLH1 and MGMT genes and DNA methylation in human gastric cancer cells].
Topics: Adaptor Proteins, Signal Transducing; Antimetabolites, Antineoplastic; Azacitidine; Cell Line, Tumor; Decitabine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Genes, p16; Humans; Hydroxamic Acids; MutL Protein Homolog 1; Nuclear Proteins; Promoter Regions, Genetic; Stomach Neoplasms; Tumor Suppressor Proteins | 2009 |
Impaired active demethylation of the paternal genome in pronuclear-stage rat zygotes produced by in vitro fertilization or intracytoplasmic sperm injection.
Topics: Animals; Azacitidine; Decitabine; DNA Methylation; Enzyme Inhibitors; Female; Fertilization in Vitro; Genome; Hydroxamic Acids; Male; Oocytes; Protein Synthesis Inhibitors; Rats; Rats, Sprague-Dawley; Sperm Injections, Intracytoplasmic; Zygote | 2010 |
MeCP2/H3meK9 are involved in IL-6 gene silencing in pancreatic adenocarcinoma cell lines.
Topics: Adenocarcinoma; Azacitidine; CCAAT-Enhancer-Binding Protein-alpha; Cell Line, Tumor; Chromatin Immunoprecipitation; Decitabine; DNA; DNA Methylation; Gene Silencing; Humans; Hydroxamic Acids; Interleukin-6; Methyl-CpG-Binding Protein 2; NF-kappa B; Pancreatic Neoplasms | 2009 |
Tamoxifen epigenetically modulates CXCL12 expression in MCF-7 breast cancer cells.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Azacitidine; Breast Neoplasms; Cell Line, Tumor; Chemokine CXCL12; Cytosine; Decitabine; DNA Methylation; Epigenesis, Genetic; Female; Gene Expression Regulation, Neoplastic; Humans; Sequence Analysis, DNA; Tamoxifen | 2010 |
Correction of the abnormal trafficking of primary myelofibrosis CD34+ cells by treatment with chromatin-modifying agents.
Topics: Animals; Antigens, CD34; Azacitidine; Bone Marrow; Chromatin; Decitabine; Down-Regulation; Humans; Hydroxamic Acids; Mice; Mice, Inbred NOD; Mice, SCID; Primary Myelofibrosis; Receptors, CXCR4; Spleen | 2009 |
Wnt antagonist gene DKK2 is epigenetically silenced and inhibits renal cancer progression through apoptotic and cell cycle pathways.
Topics: Adult; Aged; Apoptosis; Azacitidine; Carcinoma, Renal Cell; Cell Cycle; Chromatin Immunoprecipitation; Decitabine; Disease Progression; Female; Gene Silencing; Humans; Hydroxamic Acids; Intercellular Signaling Peptides and Proteins; Kidney Neoplasms; Male; Middle Aged; Wnt Proteins | 2009 |
Epigenetic therapies move into new territory, but how exactly do they work?
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Decitabine; DNA Methylation; DNA Modification Methylases; DNA-Binding Proteins; Drug Synergism; Enhancer of Zeste Homolog 2 Protein; Enzyme Inhibitors; Epigenesis, Genetic; Histone Deacetylase Inhibitors; Humans; Myelodysplastic Syndromes; Polycomb Repressive Complex 2; Randomized Controlled Trials as Topic; Survival Analysis; Transcription Factors; Transplantation, Heterologous | 2009 |
Efficient readout of posttranslational codes on the 50-residue tail of histone H3 by high-resolution MS/MS.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA (Cytosine-5-)-Methyltransferases; HeLa Cells; Histones; Humans; Methylation; Protein Processing, Post-Translational; Serine Endopeptidases; Tandem Mass Spectrometry | 2010 |
Development of a novel output value for quantitative assessment in methylated DNA immunoprecipitation-CpG island microarray analysis.
Topics: Azacitidine; Cell Line, Tumor; CpG Islands; Decitabine; DNA Methylation; DNA Modification Methylases; Epigenesis, Genetic; Humans; Immunoprecipitation; Oligonucleotide Array Sequence Analysis; Stomach Neoplasms | 2009 |
Demonstration of all-or-none loss of imprinting in mRNA expression in single cells.
Topics: Alleles; Azacitidine; Cell Cycle Proteins; Cells, Cultured; Decitabine; Gene Expression; Genomic Imprinting; Humans; Hydroxamic Acids; RNA, Messenger; Transcription Factors; Trophoblasts; Tumor Suppressor Proteins | 2009 |
DNA methyltransferase inhibitors increase baculovirus-mediated gene expression in mammalian cells when applied before infection.
Topics: Animals; Azacitidine; Baculoviridae; Cell Line; CHO Cells; Cricetinae; Cricetulus; Cytosine; Decitabine; DNA (Cytosine-5-)-Methyltransferases; Enzyme Inhibitors; Gene Expression Regulation; Genetic Vectors; Humans | 2010 |
[Reversion transcriptional expression of DAPK in bladder cancer T24 cells 5-aza-2'-deoxycytidine].
Topics: Apoptosis Regulatory Proteins; Azacitidine; Calcium-Calmodulin-Dependent Protein Kinases; Cell Line, Tumor; Death-Associated Protein Kinases; Decitabine; DNA Methylation; DNA Modification Methylases; Humans; Promoter Regions, Genetic; RNA, Messenger; Transcriptional Activation; Urinary Bladder Neoplasms | 2009 |
[Up-regulation of major histocompatibility complex class I-related molecules A (MICA) induced by 5-aza-2'-deoxycytidine].
Topics: Ataxia Telangiectasia Mutated Proteins; Azacitidine; Caffeine; Carcinoma, Hepatocellular; Cell Cycle Proteins; Cell Line; Cell Membrane; Decitabine; DNA Damage; DNA-Binding Proteins; Flow Cytometry; Hep G2 Cells; Hepatocytes; Histocompatibility Antigens Class I; Humans; Liver Neoplasms; Protein Serine-Threonine Kinases; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Tumor Suppressor Proteins; Up-Regulation | 2009 |
Promoter histone H3 lysine 9 di-methylation is associated with DNA methylation and aberrant expression of p16 in gastric cancer cells.
Topics: Acetylation; Azacitidine; Blotting, Western; Chromatin Immunoprecipitation; Cyclin-Dependent Kinase Inhibitor p16; Decitabine; DNA Methylation; DNA Modification Methylases; DNA, Neoplasm; Enzyme Inhibitors; Gene Silencing; Histone Deacetylase Inhibitors; Histone Deacetylases; Histones; Humans; Hydroxamic Acids; Immunoprecipitation; Lysine; Polymerase Chain Reaction; Promoter Regions, Genetic; Stomach Neoplasms; Tumor Cells, Cultured | 2009 |
Fluorescence polarization combined capillary electrophoresis immunoassay for the sensitive detection of genomic DNA methylation.
Topics: Azacitidine; Cell Line, Tumor; Decitabine; DNA; DNA Methylation; Electrophoresis, Capillary; Enzyme Inhibitors; Fluorescence Polarization Immunoassay; Fluorescent Dyes; Genome, Human; Humans; Lasers; Methyltransferases | 2009 |
Human T-cell leukemia virus type I-mediated repression of PDZ-LIM domain-containing protein 2 involves DNA methylation but independent of the viral oncoprotein tax.
Topics: Adult; Animals; Antimetabolites, Antineoplastic; Azacitidine; Cell Line, Transformed; Cell Survival; Cell Transformation, Viral; Cells, Cultured; Decitabine; DNA Methylation; Gene Products, tax; Host-Pathogen Interactions; Human T-lymphotropic virus 1; Humans; Jurkat Cells; Leukemia-Lymphoma, Adult T-Cell; LIM Domain Proteins; Mice; Microfilament Proteins; T-Lymphocytes | 2009 |
Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Chromosome Aberrations; Chromosomes, Human, Pair 5; Decitabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Treatment Outcome | 2009 |
Expression and mutation analysis of TIG1 (tazarotene-induced gene 1) in human gastric cancer.
Topics: Azacitidine; Cell Line, Tumor; Chromosomes, Human, Pair 3; CpG Islands; Decitabine; DNA Methylation; Humans; Membrane Proteins; Mutation; RNA, Messenger; Stomach Neoplasms | 2009 |
Gene silencing of MIR22 in acute lymphoblastic leukaemia involves histone modifications independent of promoter DNA methylation.
Topics: Azacitidine; CpG Islands; Decitabine; DNA Methylation; DNA, Neoplasm; Epigenesis, Genetic; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Silencing; Genes, Neoplasm; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; MicroRNAs; Polymerase Chain Reaction; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Promoter Regions, Genetic; Tumor Cells, Cultured | 2010 |
Azacytidine inhibits RNA methylation at DNMT2 target sites in human cancer cell lines.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Blotting, Western; Colonic Neoplasms; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Humans; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; RNA, Transfer, Amino Acyl; Tumor Cells, Cultured | 2009 |
Epigenetics: methylation-associated repression of heparan sulfate 3-O-sulfotransferase gene expression contributes to the invasive phenotype of H-EMC-SS chondrosarcoma cells.
Topics: Azacitidine; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chondrosarcoma; CpG Islands; Decitabine; DNA Methylation; Enzyme Repression; HeLa Cells; Heparan Sulfate Proteoglycans; Heparitin Sulfate; HL-60 Cells; Humans; Neoplasm Invasiveness; Sulfotransferases; Up-Regulation | 2010 |
Real-time PCR analysis of genes encoding tumor antigens in esophageal tumors and a cancer vaccine.
Topics: Aged; Antigens, Neoplasm; Azacitidine; Cancer Vaccines; Carcinoma, Squamous Cell; Clone Cells; Decitabine; DNA Modification Methylases; Epithelial Cells; Esophageal Neoplasms; Female; Gene Expression Profiling; Humans; Male; Middle Aged; Neoplasm Proteins; Reverse Transcriptase Polymerase Chain Reaction | 2009 |
Regulation of EP receptors in non-small cell lung cancer by epigenetic modifications.
Topics: Acetylation; Antineoplastic Agents; Azacitidine; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Chromatin Assembly and Disassembly; CpG Islands; Decitabine; DNA Methylation; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Lung Neoplasms; Phenylbutyrates; Receptors, Prostaglandin E; RNA, Messenger; Tumor Cells, Cultured; Vorinostat | 2009 |
Effects of decitabine on the expression of selected endogenous control genes in human breast cancer cells.
Topics: Azacitidine; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Decitabine; DNA (Cytosine-5-)-Methyltransferases; Docetaxel; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Genes, Neoplasm; Humans; Taxoids | 2010 |
Induction of Foxp3 demethylation increases regulatory CD4+CD25+ T cells and prevents the occurrence of diabetes in mice.
Topics: Animals; Azacitidine; Base Sequence; CD4-Positive T-Lymphocytes; Decitabine; Diabetes Mellitus, Type 1; Female; Forkhead Transcription Factors; Humans; Interleukin-2 Receptor alpha Subunit; Lymphocyte Activation; Male; Methylation; Mice; Mice, Inbred C57BL; Mice, Inbred NOD; Molecular Sequence Data; T-Lymphocytes, Regulatory; Thymus Gland; Treatment Outcome | 2009 |
FOXE1 is a target for aberrant methylation in cutaneous squamous cell carcinoma.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Carcinoma, Squamous Cell; Decitabine; DNA Methylation; DNA, Neoplasm; Female; Forkhead Transcription Factors; Genetic Predisposition to Disease; Humans; Male; Middle Aged; Neoplasm Proteins; Promoter Regions, Genetic; RNA, Messenger; RNA, Neoplasm; Skin Neoplasms | 2010 |
Role of histone modifications and DNA methylation in the regulation of O6-methylguanine-DNA methyltransferase gene expression in human stomach cancer cells.
Topics: Acetylation; Azacitidine; Cell Line, Tumor; Decitabine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Gene Expression Regulation, Neoplastic; Histones; Humans; Hydroxamic Acids; Promoter Regions, Genetic; Stomach Neoplasms; Tumor Suppressor Proteins | 2010 |
Genomic screening for genes upregulated by demethylation revealed novel targets of epigenetic silencing in breast cancer.
Topics: Adaptor Proteins, Signal Transducing; Azacitidine; Biomarkers, Tumor; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Chemokines; Chromatin Immunoprecipitation; Decitabine; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Silencing; Genome, Human; Humans; Intercellular Signaling Peptides and Proteins; Nerve Growth Factors; Netrins; Oligonucleotide Array Sequence Analysis; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured; Ubiquitin Thiolesterase; Up-Regulation | 2010 |
DNA demethylation at specific CpG sites in the IL1B promoter in response to inflammatory cytokines in human articular chondrocytes.
Topics: Azacitidine; Cartilage, Articular; Cells, Cultured; Chondrocytes; CpG Islands; Cytokines; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Humans; Interleukin-1beta; Matrix Metalloproteinase 13; Matrix Metalloproteinase 3; Oncostatin M; Osteoarthritis, Hip; Promoter Regions, Genetic; RNA, Messenger; Tumor Necrosis Factor-alpha | 2009 |
Impact of DNA demethylation of the G0S2 gene on the transcription of G0S2 in squamous lung cancer cell lines with or without nuclear receptor agonists.
Topics: Azacitidine; Cell Cycle Proteins; Cell Line, Tumor; Chromatin Immunoprecipitation; Decitabine; DNA Methylation; DNA Modification Methylases; Gene Expression Regulation, Neoplastic; Humans; Hydroxamic Acids; Lung Neoplasms; Neoplasms, Squamous Cell; Peroxisome Proliferator-Activated Receptors; Pioglitazone; Thiazolidinediones; Transcription, Genetic; Tretinoin | 2009 |
Reexpression of epigenetically silenced AML tumor suppressor genes by SUV39H1 inhibition.
Topics: Apoptosis; Azacitidine; Cadherins; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p15; Decitabine; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Humans; Leukemia, Myeloid, Acute; Methyltransferases; Promoter Regions, Genetic; Repressor Proteins; RNA Interference | 2010 |
Generation of antigen-presenting cells from tumor-infiltrated CD11b myeloid cells with DNA demethylating agent 5-aza-2'-deoxycytidine.
Topics: Animals; Antigen-Presenting Cells; Antimetabolites, Antineoplastic; Azacitidine; Blotting, Western; Cancer Vaccines; CD11b Antigen; Cell Differentiation; Cell Separation; Cytokines; Decitabine; Female; Flow Cytometry; Immunotherapy; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Myeloid Cells; Neoplasms, Experimental; Reverse Transcriptase Polymerase Chain Reaction | 2010 |
Epigenetic mechanisms modulate thyroid transcription factor 1-mediated transcription of the surfactant protein B gene.
Topics: Adenosine Triphosphatases; Animals; Azacitidine; Cell Line; Chromatin; CpG Islands; Decitabine; DNA Helicases; DNA Methylation; Epigenesis, Genetic; Epithelial Cells; Female; Humans; Lung; Male; Mice; Nuclear Proteins; Promoter Regions, Genetic; Pulmonary Surfactant-Associated Protein B; Rats; Thyroid Nuclear Factor 1; Transcription Factors; Transcription, Genetic; Transcriptional Activation | 2010 |
Fas expression in metastatic osteosarcoma cells is not regulated by CpG island methylation.
Topics: Azacitidine; Cell Line, Tumor; Cell Survival; CpG Islands; Decitabine; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Fas Ligand Protein; fas Receptor; Gene Expression Regulation, Neoplastic; Humans; Introns; Neoplasm Metastasis; Osteosarcoma; Promoter Regions, Genetic | 2009 |
5'-AZA induces Ngn3 expression and endocrine differentiation in the PANC-1 human ductal cell line.
Topics: Azacitidine; Basic Helix-Loop-Helix Transcription Factors; Cell Differentiation; Cell Line; Cell Transdifferentiation; Decitabine; DNA Modification Methylases; Humans; Islets of Langerhans; Nerve Tissue Proteins; Pancreatic Ducts; Transcription Factors | 2010 |
Killer cell immunoglobulin-like receptor expression induction on neonatal CD8(+) T cells in vitro and following congenital infection with Trypanosoma cruzi.
Topics: Antibodies, Monoclonal; Antigens, CD; Azacitidine; CD3 Complex; CD8-Positive T-Lymphocytes; Chagas Disease; Decitabine; DNA Modification Methylases; Enzyme Inhibitors; Female; Fetal Blood; Humans; Immunophenotyping; Infant, Newborn; Infant, Newborn, Diseases; Interleukin-2; NK Cell Lectin-Like Receptor Subfamily C; Pregnancy; Receptors, Antigen, T-Cell, alpha-beta; Receptors, KIR; Receptors, KIR2DL1; Receptors, KIR2DL2; Receptors, KIR2DL3; Receptors, KIR3DL1; T-Lymphocyte Subsets; Trypanosoma cruzi | 2010 |
Defective interleukin-4/Stat6 activity correlates with increased constitutive expression of negative regulators SOCS-3, SOCS-7, and CISH in colon cancer cells.
Topics: Azacitidine; Caco-2 Cells; Decitabine; DNA Methylation; HT29 Cells; Humans; Interleukin-4; Neoplasms; Nuclear Proteins; Phosphorylation; Promoter Regions, Genetic; RNA, Messenger; Signal Transduction; STAT6 Transcription Factor; Suppressor of Cytokine Signaling 3 Protein; Suppressor of Cytokine Signaling Proteins; Up-Regulation | 2009 |
Increased CXCR4 expression in AsPC1 pancreatic carcinoma cells with RNA interference-mediated knockdown of DNMT1 and DNMT3B.
Topics: Azacitidine; Cell Line, Tumor; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Methyltransferase 3B; DNA, Neoplasm; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Pancreatic Neoplasms; Promoter Regions, Genetic; Receptors, CXCR4; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Sequence Analysis, DNA | 2010 |
Combinatorial pharmacologic approaches target EZH2-mediated gene repression in breast cancer cells.
Topics: Adenosine; Antigens, Neoplasm; Azacitidine; Breast Neoplasms; Cell Line; Cell Line, Tumor; Chromatin Immunoprecipitation; Cluster Analysis; CpG Islands; Decitabine; DNA Methylation; DNA-Binding Proteins; Enhancer of Zeste Homolog 2 Protein; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Immunoblotting; Methylation; Neoplasm Proteins; Oligonucleotide Array Sequence Analysis; Polycomb Repressive Complex 2; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Transcription Factors | 2009 |
[Effects of 5-aza-2'-deoxycytidine on the amount of exosomes and secreted immuno-associated proteins by hepatoma cells].
Topics: Antigens, Neoplasm; Antimetabolites, Antineoplastic; Azacitidine; Carcinoma, Hepatocellular; Decitabine; DNA Methylation; DNA Modification Methylases; Exosomes; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Histocompatibility Antigens Class I; HSP70 Heat-Shock Proteins; Humans; Liver Neoplasms; Membrane Proteins; RNA, Messenger; Tumor Suppressor Protein p53; Up-Regulation | 2009 |
Mechanism of DNA replication-dependent transcriptional activation of the acetylcholinesterase gene in the Ciona intestinalis embryo.
Topics: Acetylcholinesterase; Animals; Animals, Genetically Modified; Anti-Bacterial Agents; Aphidicolin; Azacitidine; Base Sequence; Ciona intestinalis; Decitabine; DNA Methylation; DNA Replication; Embryo, Nonmammalian; Models, Biological; Molecular Sequence Data; MyoD Protein; Transcriptional Activation | 2009 |
High DNA methyltransferase 3B expression mediates 5-aza-deoxycytidine hypersensitivity in testicular germ cell tumors.
Topics: Ataxia Telangiectasia Mutated Proteins; Azacitidine; Cell Cycle Proteins; Cell Line, Tumor; Cisplatin; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Methyltransferase 3B; DNA-Binding Proteins; Dose-Response Relationship, Drug; Genes, Tumor Suppressor; Histones; Humans; Male; Neoplasms, Germ Cell and Embryonal; Phosphorylation; Protein Serine-Threonine Kinases; RNA, Small Interfering; Testicular Neoplasms; Tumor Suppressor Proteins | 2009 |
A DNA methyltransferase inhibitor and all-trans retinoic acid reduce oral cavity carcinogenesis induced by the carcinogen 4-nitroquinoline 1-oxide.
Topics: 4-Nitroquinoline-1-oxide; Animals; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Carcinogens; Carcinoma, Squamous Cell; Cyclin-Dependent Kinase Inhibitor p16; Cyclooxygenase 2; Decitabine; DNA Modification Methylases; Female; Immunoenzyme Techniques; Mice; Mice, Inbred C57BL; Mouth Mucosa; Mouth Neoplasms; Proliferating Cell Nuclear Antigen; Proto-Oncogene Proteins c-myb; Receptors, Retinoic Acid; Retinoids; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tretinoin | 2009 |
Silencing of claudin-11 is associated with increased invasiveness of gastric cancer cells.
Topics: Azacitidine; Biomarkers, Tumor; Cell Line, Tumor; Cell Movement; Claudins; Decitabine; DNA Methylation; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Neoplasm Invasiveness; Nerve Tissue Proteins; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; RNA, Small Interfering; Stomach Neoplasms | 2009 |
Direct and transgenerational impact on Daphnia magna of chemicals with a known effect on DNA methylation.
Topics: Animals; Azacitidine; Daphnia; Decitabine; DNA; DNA Methylation; Dose-Response Relationship, Drug; Epigenesis, Genetic; Genistein; Inhibitory Concentration 50; Mutagens; Oxazoles; Toxicity Tests, Acute; Toxicity Tests, Chronic | 2010 |
Resistance to 5-aza-2'-deoxycytidine in genic regions compared to non-genic repetitive sequences.
Topics: 3T3 Cells; Animals; Azacitidine; Clusterin; CpG Islands; Decitabine; Dipeptidases; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Epigenesis, Genetic; GPI-Linked Proteins; Homeodomain Proteins; Mice; Octamer Transcription Factor-3; Period Circadian Proteins; Repetitive Sequences, Nucleic Acid; Transcription Factors | 2010 |
Decitabine treatment of patients with higher-risk myelodysplastic syndromes.
Topics: Antineoplastic Agents; Azacitidine; Clinical Trials as Topic; Decitabine; Humans; Myelodysplastic Syndromes | 2009 |
Global demethylation of rat chondrosarcoma cells after treatment with 5-aza-2'-deoxycytidine results in increased tumorigenicity.
Topics: Animals; Azacitidine; Cell Line, Tumor; Chondrosarcoma; Cytokines; Decitabine; DNA Methylation; Epigenesis, Genetic; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Long Interspersed Nucleotide Elements; Mice; Microsatellite Repeats; Midkine; Neoplasm Invasiveness; Oligonucleotide Array Sequence Analysis; Rats; Sequence Analysis, DNA; SOXB1 Transcription Factors; Xenograft Model Antitumor Assays | 2009 |
Epigenetic silencing of CRABP2 and MX1 in head and neck tumors.
Topics: Azacitidine; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cell Line, Tumor; CpG Islands; Decitabine; DNA Methylation; Epigenesis, Genetic; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; GTP-Binding Proteins; Head and Neck Neoplasms; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Myxovirus Resistance Proteins; Oligonucleotide Array Sequence Analysis; Prognosis; Receptors, Retinoic Acid; Reverse Transcriptase Polymerase Chain Reaction; Tissue Array Analysis | 2009 |
Chemotherapeutic drug-induced ABCG2 promoter demethylation as a novel mechanism of acquired multidrug resistance.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Azacitidine; Cell Line, Tumor; Cell Proliferation; Cytidine; Decitabine; DNA Methylation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Jurkat Cells; K562 Cells; Neoplasm Proteins; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction | 2009 |
Neutrophilic eccrine hidradenitis associated with decitabine.
Topics: Adult; Anti-Infective Agents; Anti-Inflammatory Agents; Antimetabolites, Antineoplastic; Azacitidine; Dapsone; Decitabine; Female; Hidradenitis; Humans; Myelodysplastic Syndromes; Prednisolone | 2010 |
Growth-inhibiting effects of arsenic trioxide plus epigenetic therapeutic agents on leukemia cell lines.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Azacitidine; Cell Proliferation; Cell Survival; Decitabine; DNA Methylation; DNA Modification Methylases; DNA, Neoplasm; Drug Antagonism; Drug Synergism; Electrophoresis, Capillary; Growth Inhibitors; Histone Deacetylase Inhibitors; HL-60 Cells; Humans; Hydroxamic Acids; K562 Cells; Leukemia; Oxides; U937 Cells; Valproic Acid | 2010 |
[Effect of 5-Aza-CdR on expression and methylation of E-cadherin gene in human colon carcinoma cells].
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cadherins; Cell Proliferation; Colonic Neoplasms; Decitabine; DNA Methylation; Gene Expression Regulation, Neoplastic; HT29 Cells; Humans; RNA, Messenger | 2010 |
Promoter hypermethylation of FBXO32, a novel TGF-beta/SMAD4 target gene and tumor suppressor, is associated with poor prognosis in human ovarian cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Animals; Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Case-Control Studies; Cell Line, Tumor; Cell Proliferation; Cisplatin; Decitabine; DNA Methylation; Down-Regulation; Drug Resistance, Neoplasm; Epigenesis, Genetic; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Mice; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Muscle Proteins; Ovarian Neoplasms; Prognosis; Promoter Regions, Genetic; Proportional Hazards Models; SKP Cullin F-Box Protein Ligases; Smad4 Protein; Taiwan; Transforming Growth Factor beta; Young Adult | 2010 |
SLIT2 attenuation during lung cancer progression deregulates beta-catenin and E-cadherin and associates with poor prognosis.
Topics: Azacitidine; beta Catenin; beta-Transducin Repeat-Containing Proteins; Cadherins; Carcinoma, Non-Small-Cell Lung; Cell Movement; Decitabine; Disease Progression; DNA Methylation; Gene Knockdown Techniques; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Immunohistochemistry; Intercellular Signaling Peptides and Proteins; Lung Neoplasms; Nerve Tissue Proteins; Oncogene Protein v-akt; Prognosis; Promoter Regions, Genetic; Receptors, Immunologic; RNA, Messenger; Roundabout Proteins | 2010 |
Involvement of epigenetically silenced microRNA-181c in gastric carcinogenesis.
Topics: 3' Untranslated Regions; Azacitidine; Cell Line, Tumor; Cell Proliferation; CpG Islands; Decitabine; DNA Methylation; Gene Silencing; Humans; MicroRNAs; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Receptor, Notch4; Receptors, Notch; Stomach Neoplasms | 2010 |
DNA methylation and its involvement in carboxylesterase 1A1 (CES1A1) gene expression.
Topics: Azacitidine; Base Sequence; Carboxylesterase; Cell Line; Decitabine; DNA Methylation; Gene Expression; Humans; Hydrolysis; Kidney; Liver; Molecular Sequence Data; Nitrophenols; RNA, Messenger; Transcriptional Activation | 2010 |
Myelodysplastic syndromes: emerging therapies, survival, and alternative outcomes.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Early Diagnosis; Humans; Myelodysplastic Syndromes; Outcome Assessment, Health Care; Survival | 2009 |
Alternative dosing schedules for methylation inhibitors in MDS treatment.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Drug Administration Schedule; Humans; Methylation; Myelodysplastic Syndromes | 2009 |
Myelodysplastic syndromes: health care management considerations.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cooperative Behavior; Cost Control; Decitabine; Drug Costs; Humans; Managed Care Programs; Myelodysplastic Syndromes; Quality of Health Care; Survival | 2009 |
Vitamin D stimulates apoptosis in gastric cancer cells in synergy with trichostatin A /sodium butyrate-induced and 5-aza-2'-deoxycytidine-induced PTEN upregulation.
Topics: Acetylation; Apoptosis; Azacitidine; Butyrates; Cell Line, Tumor; Decitabine; Early Growth Response Protein 1; Gene Knockdown Techniques; Histones; Humans; Hydroxamic Acids; p300-CBP Transcription Factors; Promoter Regions, Genetic; PTEN Phosphohydrolase; Stomach Neoplasms; Up-Regulation; Vitamin D | 2010 |
Induction of apoptosis of non-small cell lung cancer by a methylated oligonucleotide targeting survivin gene.
Topics: Apoptosis; Azacitidine; Carcinoma, Non-Small-Cell Lung; Caspase 3; Cell Line, Tumor; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Modification Methylases; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Inhibitor of Apoptosis Proteins; Lung Neoplasms; Microtubule-Associated Proteins; Oligonucleotides; Reverse Transcriptase Polymerase Chain Reaction; Survivin; Transfection | 2010 |
Regulation of human endogenous retrovirus-K expression in melanomas by CpG methylation.
Topics: Azacitidine; Biomarkers, Tumor; Cell Line, Tumor; CpG Islands; Decitabine; DNA Methylation; Endogenous Retroviruses; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Viral; Gene Silencing; Humans; Melanoma; Promoter Regions, Genetic; RNA Splicing; Sequence Analysis, RNA; Sulfites; Terminal Repeat Sequences; Viral Envelope Proteins | 2010 |
Aberrant methylation impairs low density lipoprotein receptor-related protein 1B tumor suppressor function in gastric cancer.
Topics: Animals; Azacitidine; Cell Growth Processes; Cell Line, Tumor; Chi-Square Distribution; Decitabine; DNA Methylation; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Nude; Receptors, LDL; Reverse Transcriptase Polymerase Chain Reaction; ROC Curve; Statistics, Nonparametric; Stomach Neoplasms; Tumor Stem Cell Assay; Xenograft Model Antitumor Assays | 2010 |
The novel human endogenous retrovirus-related gene, psiTPTE22-HERV, is silenced by DNA methylation in cancers.
Topics: Azacitidine; Blotting, Western; Chromosomes, Human, Pair 22; Cytoplasm; Decitabine; DNA Methylation; DNA Modification Methylases; Endogenous Retroviruses; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Gene Expression Regulation; Gene Silencing; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Membrane Proteins; Neoplasms; Open Reading Frames; PTEN Phosphohydrolase; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Transcription, Genetic | 2010 |
Differential regulation of the dioxin-induced Cyp1a1 and Cyp1b1 genes in mouse hepatoma and fibroblast cell lines.
Topics: Animals; Aryl Hydrocarbon Hydroxylases; Azacitidine; Carcinoma, Hepatocellular; Cell Line; Cytochrome P-450 CYP1A1; Cytochrome P-450 CYP1B1; Decitabine; Dioxins; Enzyme Induction; Fibroblasts; Gene Expression Regulation, Enzymologic; Hybrid Cells; Hydroxamic Acids; Liver Neoplasms; Mice; Receptors, Aryl Hydrocarbon; RNA, Messenger | 2010 |
Epigenetic mediated transcriptional activation of PARP-1 participates in silica-associated malignant transformation of human bronchial epithelial cells.
Topics: Animals; Azacitidine; Bronchial Neoplasms; Cell Transformation, Neoplastic; Cells, Cultured; Decitabine; Enzyme Activation; Epigenesis, Genetic; Epithelial Cells; Female; Humans; Male; Mice; Mice, Inbred BALB C; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Silicon Dioxide; Transcriptional Activation | 2010 |
A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines.
Topics: Acute Disease; Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Blotting, Western; Cell Cycle; Cell Line; Cell Line, Tumor; Cell Survival; Decitabine; DNA Damage; DNA Methylation; Dose-Response Relationship, Drug; Flow Cytometry; Gene Expression; HL-60 Cells; Humans; Leukemia, Myeloid; Oligonucleotide Array Sequence Analysis; Protein Biosynthesis; Repressor Proteins | 2010 |
Epigenetically regulated clonal heritability of CTA expression profiles in human melanoma.
Topics: Antigens, Neoplasm; Antimetabolites, Antineoplastic; Azacitidine; Cell Division; Clone Cells; Cloning, Molecular; Decitabine; DNA Methylation; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Humans; Inheritance Patterns; Melanoma; Neoplasm Proteins; Promoter Regions, Genetic; Tumor Cells, Cultured | 2010 |
Molecular genetic and epigenetic analysis of NCX2/SLC8A2 at 19q13.3 in human gliomas.
Topics: Adolescent; Adult; Aged; Azacitidine; Brain Neoplasms; Cell Line, Tumor; Child; Child, Preschool; Chromosomes, Human, Pair 19; CpG Islands; Decitabine; DNA Methylation; Enzyme Inhibitors; Epigenesis, Genetic; Female; Genes, Tumor Suppressor; Glioma; Humans; Loss of Heterozygosity; Male; Middle Aged; Polymorphism, Single Nucleotide; Sequence Analysis, DNA; Young Adult | 2010 |
TWIST1 hypermethylation is observed frequently in colorectal tumors and its overexpression is associated with unfavorable outcomes in patients with colorectal cancer.
Topics: Adenoma; Adult; Aged; Aged, 80 and over; Azacitidine; Case-Control Studies; Cell Line, Tumor; Chromosome Mapping; Colorectal Neoplasms; Decitabine; DNA Methylation; Female; Gene Expression Regulation, Neoplastic; Humans; Hydroxamic Acids; Intestinal Mucosa; Linear Models; Male; Middle Aged; Nuclear Proteins; Polymerase Chain Reaction; Prognosis; Sequence Analysis, DNA; Statistics, Nonparametric; Twist-Related Protein 1 | 2010 |
Changes in chromatin structure and methylation of the human interleukin-1beta gene during monopoiesis.
Topics: Azacitidine; Calcitriol; Cell Differentiation; Cell Line, Tumor; Chromatin Assembly and Disassembly; Cytokines; Decitabine; DNA; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Gene Expression; Gene Expression Regulation, Leukemic; Histone Deacetylase Inhibitors; HL-60 Cells; Humans; Hydroxamic Acids; Interleukin-1beta; Lipopolysaccharide Receptors; Lipopolysaccharides; Micrococcal Nuclease; Monocytes; Myelopoiesis; Promoter Regions, Genetic | 2010 |
Genome-wide methylation and expression profiling identifies promoter characteristics affecting demethylation-induced gene up-regulation in melanoma.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Cell Line, Tumor; CpG Islands; Decitabine; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Epigenesis, Genetic; Female; Gene Expression Profiling; Genome, Human; Humans; Male; Melanoma; Middle Aged; Promoter Regions, Genetic; Tumor Suppressor Proteins; Up-Regulation | 2010 |
DNA methylation-dependent repression of PDZ-LIM domain-containing protein 2 in colon cancer and its role as a potential therapeutic target.
Topics: Animals; Azacitidine; Cell Adhesion; Cell Growth Processes; Cell Line, Tumor; Colorectal Neoplasms; Decitabine; DNA Methylation; DNA Modification Methylases; Female; HCT116 Cells; HT29 Cells; Humans; LIM Domain Proteins; Mice; Mice, SCID; Microfilament Proteins; NF-kappa B; Transplantation, Heterologous; Up-Regulation | 2010 |
Osteopontin regulates human glioma cell invasiveness and tumor growth in mice.
Topics: Animals; Antineoplastic Agents; Azacitidine; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Decitabine; Electrophoresis, Polyacrylamide Gel; Glioma; Humans; Immunohistochemistry; Matrix Metalloproteinase 2; Mice; Mice, Nude; Neoplasm Invasiveness; Osteopontin; Reverse Transcriptase Polymerase Chain Reaction; Vimentin; Xenograft Model Antitumor Assays | 2010 |
Epigenetic regulation affects N-myc downstream-regulated gene 1 expression indirectly in pancreatic cancer cells.
Topics: Azacitidine; Cell Cycle Proteins; CpG Islands; Decitabine; DNA Methylation; DNA Modification Methylases; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Intracellular Signaling Peptides and Proteins; Pancreatic Neoplasms; Promoter Regions, Genetic; Tumor Cells, Cultured | 2010 |
Epigenetic repression of PDZ-LIM domain-containing protein 2: implications for the biology and treatment of breast cancer.
Topics: Animals; Azacitidine; Base Sequence; Breast Neoplasms; Cell Line, Tumor; Decitabine; DNA Methylation; DNA Modification Methylases; DNA Primers; Enzyme Inhibitors; Epigenesis, Genetic; Female; Humans; LIM Domain Proteins; Mice; Mice, SCID; Microfilament Proteins; NF-kappa B; Promoter Regions, Genetic; Receptors, Estrogen; Tumor Stem Cell Assay | 2010 |
Differential epigenetic regulation of BDNF and NT-3 genes by trichostatin A and 5-aza-2'-deoxycytidine in Neuro-2a cells.
Topics: Acetylation; Animals; Azacitidine; Brain-Derived Neurotrophic Factor; Cell Line, Tumor; Chromatin Immunoprecipitation; CpG Islands; Decitabine; DNA Methylation; DNA Modification Methylases; Epigenesis, Genetic; Exons; Histones; Hydroxamic Acids; Mice; Nerve Growth Factors; Neurons; Promoter Regions, Genetic | 2010 |
Inhibition of DNA methyltransferase induces G2 cell cycle arrest and apoptosis in human colorectal cancer cells via inhibition of JAK2/STAT3/STAT5 signalling.
Topics: Apoptosis; Azacitidine; Cell Cycle; Cell Line, Tumor; Colorectal Neoplasms; Decitabine; DNA Methylation; DNA Modification Methylases; G2 Phase; Gene Expression Regulation, Enzymologic; Humans; Janus Kinase 2; Protein Tyrosine Phosphatase, Non-Receptor Type 6; STAT3 Transcription Factor; STAT5 Transcription Factor; Transcription, Genetic | 2009 |
Porcupine expression is associated with the expression of S100P and other cancer-related molecules in non-small cell lung carcinoma.
Topics: Acyltransferases; Azacitidine; Calcium-Binding Proteins; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Decitabine; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Membrane Proteins; Neoplasm Proteins; RNA Interference; RNA, Messenger; Time Factors; Transcriptional Activation | 2010 |
DNA methylation and carcinogenesis of PRDM5 in cervical cancer.
Topics: Azacitidine; Cell Line, Tumor; CpG Islands; Decitabine; DNA Methylation; DNA Modification Methylases; DNA-Binding Proteins; Female; Gene Expression Regulation, Neoplastic; Genetic Predisposition to Disease; HeLa Cells; Humans; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Transcription Factors; Uterine Cervical Neoplasms | 2010 |
Valproic acid in the complex therapy of malignant tumors.
Topics: Acetylation; Angiogenesis Inhibitors; Apoptosis; Azacitidine; Cell Cycle; Clinical Trials as Topic; Combined Modality Therapy; Decitabine; Drug Repositioning; Drug Resistance, Neoplasm; Drug Synergism; Drug Therapy, Combination; Epilepsy; Histone Deacetylase Inhibitors; Histone Deacetylases; Histones; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasms; Topoisomerase II Inhibitors; Tumor Suppressor Protein p53; Valproic Acid | 2010 |
Identification of hypermethylated genes associated with cisplatin resistance in human cancers.
Topics: Algorithms; Azacitidine; Calcium-Binding Proteins; Carcinoma, Squamous Cell; Cell Cycle; Cell Growth Processes; Cell Line, Tumor; Cisplatin; Decitabine; DNA Methylation; Drug Resistance, Neoplasm; Gene Knockdown Techniques; Gene Silencing; Humans; KB Cells; Neoplasm Proteins; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; RNA, Small Interfering; Transcription, Genetic; Up-Regulation | 2010 |
Promoter hypermethylation in MLL-r infant acute lymphoblastic leukemia: biology and therapeutic targeting.
Topics: Azacitidine; Cell Line, Tumor; Child; Child, Preschool; Cohort Studies; CpG Islands; Decitabine; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Female; Gene Rearrangement; Gene Silencing; Genome-Wide Association Study; Histone-Lysine N-Methyltransferase; Humans; Infant; Male; Myeloid-Lymphoid Leukemia Protein; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Promoter Regions, Genetic | 2010 |
Establishment and characterization of multi-drug resistant, prostate carcinoma-initiating stem-like cells from human prostate cancer cell lines 22RV1.
Topics: Acetylation; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Azacitidine; Biomarkers, Tumor; Cell Line, Tumor; Cell Proliferation; CpG Islands; Decitabine; DNA Methylation; DNA Modification Methylases; Drug Resistance, Neoplasm; Enzyme Inhibitors; Epigenesis, Genetic; Histones; Humans; Male; Methylation; Mice; Mice, Nude; Neoplasm Proteins; Neoplastic Stem Cells; Promoter Regions, Genetic; Prostatic Neoplasms; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-kit; Time Factors; Tumor Burden | 2010 |
Rapid determination of AKAP12 promoter methylation levels in peripheral blood using methylation-sensitive high resolution melting (MS-HRM) analysis: application in colorectal cancer.
Topics: A Kinase Anchor Proteins; Azacitidine; Case-Control Studies; Cell Cycle Proteins; Cell Line, Tumor; Colorectal Neoplasms; Decitabine; DNA Methylation; Humans; Linear Models; Nucleic Acid Denaturation; Polymerase Chain Reaction; Promoter Regions, Genetic; Reproducibility of Results; Time Factors | 2010 |
Methylation of PARP-1 promoter involved in the regulation of benzene-induced decrease of PARP-1 mRNA expression.
Topics: Azacitidine; Benzene; Carcinogens; Cell Line; Decitabine; DNA Methylation; Drug Synergism; Enzyme Inhibitors; Epigenesis, Genetic; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Methyltransferases; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Promoter Regions, Genetic; RNA, Messenger | 2010 |
Antineoplastic effects of decitabine, an inhibitor of DNA promoter methylation, in adrenocortical carcinoma cells.
Topics: Adrenocortical Carcinoma; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Methylation; Drug Screening Assays, Antitumor; Humans; Tumor Cells, Cultured | 2010 |
Sequential loss of cell cycle checkpoint control contributes to malignant transformation of murine embryonic fibroblasts induced by 20-methylcholanthrene.
Topics: Aneuploidy; Animals; Antimetabolites; Azacitidine; Carcinogens; Cell Cycle; Cell Cycle Proteins; Cell Line; Cell Proliferation; Cell Transformation, Neoplastic; Chromosome Aberrations; Decitabine; DNA Damage; DNA Methylation; Embryo, Mammalian; Epigenesis, Genetic; Fibroblasts; Gene Expression Regulation, Neoplastic; Genotype; Gestational Age; Methylcholanthrene; Mice; Phenotype; Phosphorylation; Signal Transduction | 2010 |
Pancreatic cancer DNMT1 expression and sensitivity to DNMT1 inhibitors.
Topics: Azacitidine; Catechin; Cell Line, Tumor; Cell Proliferation; Chromosomes, Human, Pair 19; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Drug Resistance, Neoplasm; Gene Dosage; Humans; Mutation; Pancreatic Neoplasms; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins | 2010 |
BORIS (CTCFL) is not expressed in most human breast cell lines and high grade breast carcinomas.
Topics: Alternative Splicing; Azacitidine; Breast Neoplasms; Carcinoma; CCCTC-Binding Factor; Cell Line, Tumor; Decitabine; DNA-Binding Proteins; Exons; Fibroblasts; Gene Expression Regulation, Neoplastic; Humans; Polymerase Chain Reaction; Repressor Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tissue Distribution | 2010 |
Progression to metastatic stage in a cellular model of prostate cancer is associated with methylation of the androgen receptor gene and transcriptional suppression of the insulin-like growth factor-I receptor gene.
Topics: Androgen Antagonists; Androgens; Azacitidine; Blotting, Western; CpG Islands; Decitabine; Dihydrotestosterone; Disease Progression; DNA Methylation; DNA Modification Methylases; Down-Regulation; Enzyme Inhibitors; Flutamide; Gene Expression Regulation, Neoplastic; Humans; Male; Promoter Regions, Genetic; Prostatic Neoplasms; Receptor, IGF Type 1; Receptors, Androgen; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Transcription, Genetic; Tumor Cells, Cultured | 2010 |
Targeting of 5-aza-2'-deoxycytidine residues by chromatin-associated DNMT1 induces proteasomal degradation of the free enzyme.
Topics: Animals; Aphidicolin; Azacitidine; Cell Line; Chromatin; Decitabine; DNA; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Methyltransferase 3A; Enzyme Inhibitors; Mice; Proteasome Endopeptidase Complex | 2010 |
Hypomethylating agent induction therapy followed by hematopoietic cell transplantation is feasible in patients with myelodysplastic syndromes.
Topics: Azacitidine; Decitabine; Enzyme Inhibitors; Female; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; HLA Antigens; Humans; Male; Myelodysplastic Syndromes; Neoadjuvant Therapy; Recurrence; Retrospective Studies; Survival Rate; Transplantation Chimera | 2010 |
Upregulation of DNA methyltransferase-mediated gene silencing, anchorage-independent growth, and migration of colon cancer cells by interleukin-6.
Topics: Azacitidine; Carcinogenicity Tests; Carcinoma; Cell Line, Tumor; Cell Movement; Cell Transformation, Neoplastic; Colitis; Colonic Neoplasms; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Down-Regulation; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Gene Silencing; Genes, Tumor Suppressor; Humans; Immunohistochemistry; Inflammation Mediators; Interleukin-6; Neoplasm Metastasis; Promoter Regions, Genetic; Up-Regulation | 2010 |
Functional modulation of IGF-binding protein-3 expression in melanoma.
Topics: Apoptosis; Azacitidine; Base Sequence; Caspase 3; Cell Division; Cell Line, Tumor; Cell Survival; Chromatin; Decitabine; DNA Methylation; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Insulin-Like Growth Factor Binding Protein 3; Insulin-Like Growth Factor Binding Proteins; Melanoma; Molecular Sequence Data; Promoter Regions, Genetic; RNA, Messenger; Skin Neoplasms | 2010 |
5-Aza-2'-deoxycytidine treatment induces skeletal myogenic differentiation of mouse dental pulp stem cells.
Topics: Adipogenesis; Animals; Azacitidine; Cell Differentiation; Cells, Cultured; Decitabine; Dental Pulp; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Female; Mesenchymal Stem Cells; Mice; Mice, Inbred C57BL; Muscle Development; Muscle Fibers, Skeletal; MyoD Protein; Myosin Heavy Chains; Osteogenesis; Transfection | 2010 |
Quantitative assessment of AKAP12 promoter methylation in colorectal cancer using methylation-sensitive high resolution melting: Correlation with Duke's stage.
Topics: A Kinase Anchor Proteins; Azacitidine; Base Sequence; Biomarkers, Tumor; Blotting, Western; Cell Cycle Proteins; Cell Line, Tumor; Colorectal Neoplasms; Decitabine; DNA Methylation; DNA Modification Methylases; DNA Primers; DNA, Neoplasm; Enzyme Inhibitors; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Molecular Sequence Data; Neoplasm Staging; Polymerase Chain Reaction; Prognosis; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; Sequence Analysis, DNA; Transition Temperature | 2010 |
Altered DNA methylation is associated with docetaxel resistance in human breast cancer cells.
Topics: Antineoplastic Agents; Azacitidine; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Docetaxel; Drug Resistance, Neoplasm; Humans; Inhibitory Concentration 50; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Taxoids; Tetrazolium Salts; Thiazoles; Time Factors | 2010 |
Modulation of E-cadherin expression by K-Ras; involvement of DNA methyltransferase-3b.
Topics: Azacitidine; Cadherins; Cell Communication; Cell Line, Tumor; Cell Movement; CpG Islands; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Methyltransferase 3B; Genes, ras; Humans; Male; Promoter Regions, Genetic; Prostatic Neoplasms | 2010 |
The DNA demethylating agent 5-aza-2'-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells.
Topics: Antigens, Neoplasm; Antimetabolites, Antineoplastic; Azacitidine; Cell Line, Tumor; Chromosomes, Human, X; Decitabine; DNA Methylation; DNA, Neoplasm; Gene Expression Regulation, Leukemic; Genes, X-Linked; HL-60 Cells; Humans; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Melanoma-Specific Antigens; Membrane Proteins; Multiple Myeloma; Neoplasm Proteins; RNA, Messenger; RNA, Neoplasm; U937 Cells | 2010 |
Expression, epigenetic regulation, and humoral immunogenicity of cancer-testis antigens in chronic myeloid leukemia.
Topics: Adult; Aged; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Azacitidine; Benzamides; Decitabine; Disease-Free Survival; Drug Resistance, Neoplasm; Epigenesis, Genetic; Female; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Immunity, Humoral; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm, Residual; Piperazines; Pyrimidines | 2010 |
NGX6 gene mediated by promoter methylation as a potential molecular marker in colorectal cancer.
Topics: Age Factors; Aged; Azacitidine; Biomarkers, Tumor; Chi-Square Distribution; Cloning, Molecular; Colorectal Neoplasms; CpG Islands; Decitabine; DNA Methylation; DNA Modification Methylases; Down-Regulation; Enzyme Inhibitors; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; HT29 Cells; Humans; Male; Membrane Proteins; Middle Aged; Neoplasm Staging; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; Transcription, Genetic; Transfection; Tumor Suppressor Proteins | 2010 |
In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia.
Topics: Adoptive Transfer; Animals; Azacitidine; CD4-Positive T-Lymphocytes; Cells, Cultured; Combined Modality Therapy; Decitabine; DNA Modification Methylases; Enzyme Inhibitors; Flow Cytometry; Forkhead Transcription Factors; Gene Expression; Graft vs Host Disease; Graft vs Leukemia Effect; Humans; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Knockout; Reverse Transcriptase Polymerase Chain Reaction; Survival Rate; T-Lymphocytes, Regulatory | 2010 |
Management of myelodysplastic syndromes in the geriatric patient.
Topics: Aged; Anemia; Antineoplastic Agents; Azacitidine; Decitabine; Erythrocyte Transfusion; Erythropoietin; Humans; Iron Chelating Agents; Lenalidomide; Myelodysplastic Syndromes; Neutropenia; Thalidomide; Thrombocytopenia | 2009 |
Myelodysplastic syndrome: An update on diagnosis and therapy.
Topics: Antineoplastic Agents; Azacitidine; Cytogenetic Analysis; Decitabine; Flow Cytometry; Histone Deacetylase Inhibitors; Humans; Immunohistochemistry; Lenalidomide; Myelodysplastic Syndromes; Prognosis; Severity of Illness Index; Thalidomide | 2009 |
Advances in the management of acute myeloid leukemia in older adult patients.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Humans; Leukemia, Myeloid, Acute; Middle Aged; Nurse's Role; Nursing Assessment; Oncology Nursing; Patient Education as Topic; Practice Guidelines as Topic; Prognosis; Quality of Life; Social Support; Stem Cell Transplantation | 2010 |
Hypermethylation of the progesterone receptor A in constitutive antiprogestin-resistant mouse mammary carcinomas.
Topics: Animals; Apoptosis; Azacitidine; Cell Culture Techniques; Cell Line, Tumor; Coculture Techniques; Decitabine; DNA Methylation; DNA Modification Methylases; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Hormone Antagonists; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mifepristone; Mitosis; Neoplasm Transplantation; Promoter Regions, Genetic; Receptors, Glucocorticoid; Receptors, Progesterone; Transplantation, Heterologous; Tumor Burden | 2011 |
S110, a 5-Aza-2'-deoxycytidine-containing dinucleotide, is an effective DNA methylation inhibitor in vivo and can reduce tumor growth.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Cell Line, Tumor; Cell Proliferation; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Down-Regulation; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Models, Biological; Neoplasms; Oligonucleotides; Treatment Outcome; Tumor Burden; Xenograft Model Antitumor Assays | 2010 |
Demethylating agent 5-aza-2-deoxycytidine enhances susceptibility of breast cancer cells to anticancer agents.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Blotting, Western; Breast Neoplasms; Cell Proliferation; Decitabine; DNA Methylation; DNA Modification Methylases; Doxorubicin; Drug Synergism; Enzyme Inhibitors; Female; Flow Cytometry; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Paclitaxel; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured | 2010 |
[No correlation between the sensitivity to 5-aza-dC and the global DNA methylation level in hepatocellular carcinoma cells].
Topics: Azacitidine; Carcinoma, Hepatocellular; Caspase 3; Decitabine; DNA Methylation; DNA Modification Methylases; Hep G2 Cells; Humans | 2010 |
Epigenetic mechanisms of promigratory chemokine CXCL14 regulation in human prostate cancer cells.
Topics: Adenocarcinoma; Azacitidine; Base Sequence; Cell Line, Tumor; Cell Movement; Chemokines, CXC; Decitabine; DNA Methylation; Down-Regulation; Gene Expression Regulation, Neoplastic; Humans; Male; Molecular Sequence Data; Promoter Regions, Genetic; Prostatic Neoplasms; RNA, Messenger | 2010 |
Seladin-1 expression is regulated by promoter methylation in adrenal cancer.
Topics: Adrenal Gland Neoplasms; Azacitidine; Carcinoma; Cell Line, Tumor; Decitabine; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Epigenesis, Genetic; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Nerve Tissue Proteins; Oxidoreductases Acting on CH-CH Group Donors; Polymerase Chain Reaction; Promoter Regions, Genetic; RNA, Messenger; Time Factors | 2010 |
Effect of 5-aza-2'-deoxycytidine on immune-associated proteins in exosomes from hepatoma.
Topics: Antigens, Neoplasm; Azacitidine; Blotting, Western; Carcinoma, Hepatocellular; Centrifugation, Density Gradient; Decitabine; DNA Modification Methylases; Enzyme Inhibitors; Exosomes; Hep G2 Cells; HLA Antigens; HSP70 Heat-Shock Proteins; Humans; Liver Neoplasms; Membrane Proteins; Microscopy, Immunoelectron; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Suppressor Protein p53; Up-Regulation | 2010 |
Early growth response-1 induces and enhances vascular endothelial growth factor-A expression in lung cancer cells.
Topics: Adenocarcinoma; Animals; Azacitidine; Cell Line, Tumor; Decitabine; Early Growth Response Protein 1; Enzyme Inhibitors; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation, Neoplastic; Genes, ras; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Lung Neoplasms; Promoter Regions, Genetic; Repressor Proteins; RNA Interference; Vascular Endothelial Growth Factor A | 2010 |
Hypermethylation downregulates Runx3 gene expression and its restoration suppresses gastric epithelial cell growth by inducing p27 and caspase3 in human gastric cancer.
Topics: Adult; Aged; Apoptosis; Azacitidine; Blotting, Western; Caspase 3; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Core Binding Factor Alpha 3 Subunit; CpG Islands; Cyclin-Dependent Kinase Inhibitor p27; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Down-Regulation; Enzyme Inhibitors; Epithelial Cells; Female; Gastric Mucosa; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Intracellular Signaling Peptides and Proteins; Male; Middle Aged; Neoplasm Staging; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Stomach Neoplasms; Time Factors; Up-Regulation; Young Adult | 2010 |
Histone methylation is a critical regulator of the abnormal expression of POU5F1 and RASSF1A in testis cancer cell lines.
Topics: Azacitidine; Decitabine; Gene Silencing; Histones; Humans; Lysine; Male; Methylation; Octamer Transcription Factor-3; Proto-Oncogene Mas; Testicular Neoplasms; Tumor Suppressor Proteins | 2011 |
Decitabine maintains hematopoietic precursor self-renewal by preventing repression of stem cell genes by a differentiation-inducing stimulus.
Topics: Animals; Azacitidine; Cell Differentiation; Cell Lineage; Cell Proliferation; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; Down-Regulation; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cells; Homeodomain Proteins; Humans; Mice; Proto-Oncogene Proteins; Repressor Proteins; RNA, Small Interfering; Time Factors; Trans-Activators | 2010 |
Nucleoside drugs induce cellular differentiation by caspase-dependent degradation of stem cell factors.
Topics: Azacitidine; Carcinoma, Embryonal; Caspase 7; Caspase Inhibitors; Cell Differentiation; Cell Line, Tumor; Cytarabine; Decitabine; DNA Damage; DNA Methylation; Enzyme Inhibitors; Humans; JNK Mitogen-Activated Protein Kinases; Neurons; Octamer Transcription Factor-3; Polycomb-Group Proteins; Protein Processing, Post-Translational; Protein Stability; Repressor Proteins; Stem Cell Factor | 2010 |
DNA methylation of interferon regulatory factors in gastric cancer and noncancerous gastric mucosae.
Topics: Aged; Azacitidine; Cell Line, Tumor; Decitabine; DNA Methylation; DNA, Neoplasm; Down-Regulation; Female; Gastric Mucosa; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Interferon Regulatory Factor-1; Interferon Regulatory Factors; Male; Middle Aged; Stomach Neoplasms | 2010 |
Up-regulation of connexin 32 gene by 5-aza-2'-deoxycytidine enhances vinblastine-induced cytotoxicity in human renal carcinoma cells via the activation of JNK signalling.
Topics: Azacitidine; Carcinoma, Renal Cell; Cell Proliferation; Connexins; Decitabine; Deoxycytidine; Down-Regulation; Enzyme Activation; Gap Junction beta-1 Protein; Gene Expression Regulation, Neoplastic; Humans; JNK Mitogen-Activated Protein Kinases; Kidney Neoplasms; Signal Transduction; Transcriptional Activation; Up-Regulation; Vinblastine | 2010 |
3-Deazauridine enhances the antileukemic action of 5-aza-2'-deoxycytidine and targets drug-resistance due to deficiency in deoxycytidine kinase.
Topics: 3-Deazauridine; Animals; Azacitidine; Cell Line, Tumor; Decitabine; Deoxycytidine Kinase; Drug Resistance, Neoplasm; Drug Synergism; Humans; Leukemia L1210; Male; Mice; Reverse Transcriptase Polymerase Chain Reaction | 2011 |
Promoter hypomethylation contributes to the expression of MUC3A in cancer cells.
Topics: 5' Flanking Region; Azacitidine; Carcinoma; Cell Line, Tumor; Decitabine; DNA Methylation; Gene Expression; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Hydroxamic Acids; Mucin-3; RNA, Messenger | 2010 |
Feasibility of therapy with hypomethylating agents in patients with renal insufficiency.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Humans; Kaplan-Meier Estimate; Kidney; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Middle Aged; Myelodysplastic Syndromes; Renal Insufficiency | 2010 |
Putative tumour-suppressor gene DAB2 is frequently down regulated by promoter hypermethylation in nasopharyngeal carcinoma.
Topics: Adaptor Proteins, Signal Transducing; Adolescent; Adult; Aged; Aged, 80 and over; Animals; Apoptosis Regulatory Proteins; Azacitidine; Carcinoma; Cell Adhesion; Cell Line, Tumor; Cell Proliferation; Decitabine; DNA Methylation; DNA Modification Methylases; Down-Regulation; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Genes, Tumor Suppressor; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Immunohistochemistry; Male; Mice; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Transplantation; Polymerase Chain Reaction; Promoter Regions, Genetic; Proto-Oncogene Proteins c-fos; RNA, Messenger; Time Factors; Transfection; Tumor Suppressor Proteins; Young Adult | 2010 |
Chronic prenatal hypoxia induces epigenetic programming of PKC{epsilon} gene repression in rat hearts.
Topics: Animals; Azacitidine; Blotting, Western; Decitabine; DNA Methylation; DNA Modification Methylases; Epigenesis, Genetic; Female; Fetal Heart; Fetal Hypoxia; Gene Expression Regulation, Enzymologic; Male; Methylation; Pregnancy; Promoter Regions, Genetic; Protein Kinase C-epsilon; Rats; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sp1 Transcription Factor | 2010 |
Downregulation of WIF-1 by hypermethylation in astrocytomas.
Topics: Adaptor Proteins, Signal Transducing; Astrocytoma; Azacitidine; beta Catenin; Cell Line, Tumor; Decitabine; DNA Methylation; Down-Regulation; Gene Expression Regulation, Neoplastic; Humans; Promoter Regions, Genetic; Repressor Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Wnt Proteins | 2010 |
Epigenetic alterations differ in phenotypically distinct human neuroblastoma cell lines.
Topics: Acetylation; Azacitidine; Cell Line, Tumor; Cell Proliferation; Cell Shape; Chromatin Immunoprecipitation; Decitabine; DNA Methylation; DNA Modification Methylases; Dose-Response Relationship, Drug; Enzyme Inhibitors; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Genotype; Histone Deacetylase Inhibitors; Histones; Humans; Neuroblastoma; Phenotype; Polymerase Chain Reaction; Promoter Regions, Genetic; Thrombospondin 1; Transfection; Valproic Acid | 2010 |
Wnt antagonist DKK1 acts as a tumor suppressor gene that induces apoptosis and inhibits proliferation in human renal cell carcinoma.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Apoptosis Regulatory Proteins; Azacitidine; Blotting, Western; Carcinoma, Renal Cell; Caspase 3; Cell Proliferation; Chromatin Immunoprecipitation; Cyclin-Dependent Kinase Inhibitor p21; Decitabine; DNA Methylation; Epigenesis, Genetic; Female; Genes, Tumor Suppressor; Humans; Hydroxamic Acids; Immunoenzyme Techniques; Intercellular Signaling Peptides and Proteins; Kidney Neoplasms; Male; Promoter Regions, Genetic; Proto-Oncogene Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Wnt Proteins | 2011 |
Effect of 5-aza-2-deoxycytidine microinjecting into hippocampus and prelimbic cortex on acquisition and retrieval of cocaine-induced place preference in C57BL/6 mice.
Topics: Animals; Azacitidine; Behavior, Animal; Catheterization; Cocaine; Conditioning, Psychological; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Enzyme Inhibitors; Hippocampus; Male; Memory; Mice; Mice, Inbred C57BL; Microinjections; Substance-Related Disorders | 2010 |
Epigenetically altered wound healing in keloid fibroblasts.
Topics: Acetylation; Azacitidine; Black or African American; Cell Division; Cells, Cultured; Culture Media; Decitabine; Dermis; DNA Methylation; Enzyme Inhibitors; Epigenesis, Genetic; Fibroblasts; Fibrosis; Gene Expression Profiling; Gene Silencing; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Insulin-Like Growth Factor Binding Protein 5; Intercellular Signaling Peptides and Proteins; Keloid; Membrane Proteins; Oligonucleotide Array Sequence Analysis; Wound Healing | 2010 |
Demethylation of a LINE-1 antisense promoter in the cMet locus impairs Met signalling through induction of illegitimate transcription.
Topics: Antimetabolites, Antineoplastic; Antisense Elements (Genetics); Azacitidine; Blotting, Western; Chromatin Immunoprecipitation; Decitabine; DNA Methylation; Gene Expression; Gene Expression Regulation, Neoplastic; Genetic Loci; HCT116 Cells; HL-60 Cells; Humans; Long Interspersed Nucleotide Elements; Promoter Regions, Genetic; Proto-Oncogene Mas; Proto-Oncogene Proteins c-met; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Transcription, Genetic; Transfection | 2010 |
Active loss of DNA methylation in two-cell stage goat embryos.
Topics: 5-Methylcytosine; Animals; Azacitidine; Decitabine; DNA; DNA Methylation; DNA Modification Methylases; Embryo, Mammalian; Enzyme Inhibitors; Female; Goats; Histones; Immunohistochemistry; Lysine; Male; Methylation; Zygote | 2010 |
Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Humans; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Prognosis; Treatment Failure; Treatment Outcome | 2010 |
Epigenetic regulation of vitamin D 24-hydroxylase/CYP24A1 in human prostate cancer.
Topics: Azacitidine; Calcitriol; Cell Line, Tumor; Decitabine; DNA Methylation; Down-Regulation; Epigenesis, Genetic; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Male; Promoter Regions, Genetic; Prostatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Steroid Hydroxylases; Vitamin D3 24-Hydroxylase | 2010 |
Long-term stability of demethylation after transient exposure to 5-aza-2'-deoxycytidine correlates with sustained RNA polymerase II occupancy.
Topics: Azacitidine; Cell Line, Tumor; CpG Islands; Decitabine; DNA Methylation; Gene Expression Regulation, Neoplastic; Gene Silencing; Genes, Tumor Suppressor; Humans; Promoter Regions, Genetic; RNA Polymerase II | 2010 |
The functional significance of microRNA-145 in prostate cancer.
Topics: Apoptosis; Azacitidine; Cell Cycle; Cell Line, Tumor; Decitabine; DNA Methylation; Down-Regulation; Gene Silencing; Genistein; Humans; Hydroxamic Acids; Male; Microarray Analysis; MicroRNAs; Prostatic Neoplasms; TNF-Related Apoptosis-Inducing Ligand; Up-Regulation | 2010 |
Exploiting drug repositioning for discovery of a novel HIV combination therapy.
Topics: Anti-HIV Agents; Azacitidine; Decitabine; Deoxycytidine; Drug Interactions; Drug Therapy, Combination; Gemcitabine; HIV; HIV Infections; Humans; Mutation | 2010 |
Demethylation by 5-aza-2'-deoxycytidine in colorectal cancer cells targets genomic DNA whilst promoter CpG island methylation persists.
Topics: Acetylation; Apoptosis; Azacitidine; Biomarkers, Tumor; Blotting, Western; Cell Proliferation; Cells, Cultured; Colorectal Neoplasms; CpG Islands; Decitabine; DNA Methylation; DNA Modification Methylases; DNA, Neoplasm; Enzyme Inhibitors; Epigenesis, Genetic; Fibroblasts; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genome, Human; Histone Deacetylase Inhibitors; Histone Deacetylases; Histones; Humans; Hydroxamic Acids; Immunoenzyme Techniques; Oligonucleotide Array Sequence Analysis; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2010 |
BORIS/CTCFL expression is insufficient for cancer-germline antigen gene expression and DNA hypomethylation in ovarian cell lines.
Topics: Antigens, Neoplasm; Azacitidine; Cell Line, Tumor; Decitabine; DNA Methylation; DNA-Binding Proteins; Epigenesis, Genetic; Female; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Organ Specificity; Ovarian Neoplasms; Promoter Regions, Genetic; Transcription Initiation Site | 2010 |
Function and regulatory mechanisms of the candidate tumor suppressor receptor protein tyrosine phosphatase gamma (PTPRG) in breast cancer cells.
Topics: Animals; Azacitidine; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; CpG Islands; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Decitabine; DNA Methylation; Extracellular Signal-Regulated MAP Kinases; Female; Hydroxamic Acids; Intracellular Signaling Peptides and Proteins; Mice; Phosphorylation; Receptor-Like Protein Tyrosine Phosphatases, Class 5 | 2010 |
Epigenetic regulation of miR-196b expression in gastric cancer.
Topics: Azacitidine; Base Sequence; Cell Line, Tumor; CpG Islands; Decitabine; DNA Methylation; DNA Primers; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; MicroRNAs; Polymerase Chain Reaction; Promoter Regions, Genetic; Stomach Neoplasms; Transcription, Genetic | 2010 |
Validation of a novel statistical model for assessing the synergy of combined-agent cancer chemoprevention.
Topics: Algorithms; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Chemoprevention; Decitabine; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Synergism; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Models, Statistical; Neoplasms; Vorinostat | 2010 |
Epigenetic inactivation of the tumor suppressor gene RIZ1 in hepatocellular carcinoma involves both DNA methylation and histone modifications.
Topics: Acetylation; Azacitidine; Carcinoma, Hepatocellular; Cell Line, Tumor; Decitabine; DNA Methylation; DNA-Binding Proteins; Epigenesis, Genetic; Genes, Tumor Suppressor; Histone-Lysine N-Methyltransferase; Histones; Humans; Hydroxamic Acids; Liver Neoplasms; Nuclear Proteins; Promoter Regions, Genetic; RNA, Messenger; Transcription Factors | 2010 |
MAD2 downregulation in hypoxia is independent of promoter hypermethylation.
Topics: Antigens, Neoplasm; Azacitidine; Calcium-Binding Proteins; Carbonic Anhydrase IX; Carbonic Anhydrases; Cell Cycle Proteins; Cell Hypoxia; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Decitabine; DNA Methylation; Down-Regulation; Humans; Mad2 Proteins; Promoter Regions, Genetic; Repressor Proteins | 2010 |
Identification of novel methylation markers in hepatocellular carcinoma using a methylation array.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Carcinoma, Hepatocellular; Cell Line, Tumor; CpG Islands; Decitabine; DNA Methylation; Gene Expression Profiling; GPI-Linked Proteins; Homeodomain Proteins; Humans; Interferon Regulatory Factors; Liver Neoplasms; Neuropeptide Y; Oligonucleotide Array Sequence Analysis; Promoter Regions, Genetic; Receptors, Tumor Necrosis Factor, Member 10c; Tumor Necrosis Factor Decoy Receptors | 2010 |
[The relationship between the TSLC1 silencing and DNA methylation in human lung cancer cells].
Topics: Azacitidine; Cell Adhesion Molecule-1; Cell Adhesion Molecules; Cell Line, Tumor; Decitabine; DNA Methylation; Gene Silencing; Humans; Immunoglobulins; Lung Neoplasms; Promoter Regions, Genetic; Tumor Suppressor Proteins | 2010 |
MeCP2 binds cooperatively to its substrate and competes with histone H1 for chromatin binding sites.
Topics: Animals; AT Rich Sequence; Azacitidine; BALB 3T3 Cells; Binding Sites; Binding, Competitive; Chromatin; Decitabine; DNA; DNA Methylation; Enzyme Inhibitors; Fluorescence Polarization; Green Fluorescent Proteins; Histones; Humans; Methyl-CpG-Binding Protein 2; Mice; Microscopy, Atomic Force; Microscopy, Electron; Microscopy, Fluorescence; Mutation; Nucleosomes; Protein Binding; Protein Multimerization | 2010 |
Combinations of DNA methyltransferase and histone deacetylase inhibitors induce DNA damage in small cell lung cancer cells: correlation of resistance with IFN-stimulated gene expression.
Topics: Apoptosis; Azacitidine; Benzamides; Cell Cycle; Cell Line, Tumor; Cell Survival; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Damage; DNA Methylation; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Indoles; Interferons; Lung Neoplasms; Panobinostat; Phosphorylation; Pyrimidines; Small Cell Lung Carcinoma | 2010 |
Screening for methylation-silenced genes in acute myeloid leukemia HL-60 cell line by a quantitative proteomic approach.
Topics: Azacitidine; Decitabine; DNA Methylation; DNA Modification Methylases; Electrophoresis, Gel, Two-Dimensional; Gene Expression Profiling; Gene Silencing; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Proteome; Proteomics; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2010 |
Promoter hypermethylation of progesterone receptor isoform B (PR-B) in adenomyosis and its rectification by a histone deacetylase inhibitor and a demethylation agent.
Topics: Azacitidine; Cells, Cultured; Decitabine; DNA Modification Methylases; Endometriosis; Endometrium; Enzyme Inhibitors; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Methylation; Promoter Regions, Genetic; Receptors, Progesterone; Stromal Cells | 2010 |
Fetal globin gene inducers: novel agents and new potential.
Topics: alpha-Globins; Antimetabolites, Antineoplastic; Azacitidine; beta-Thalassemia; Butyrates; Clinical Trials as Topic; Decitabine; Fetal Hemoglobin; Humans; Mutation; Quantitative Trait Loci; Transcriptional Activation | 2010 |
Decitabine increases fetal hemoglobin in Papio anubis by increasing γ-globin gene transcription.
Topics: Animals; Azacitidine; beta-Globins; Chromatography, High Pressure Liquid; Decitabine; DNA Methylation; epsilon-Globins; Fetal Hemoglobin; gamma-Globins; Papio; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Time Factors; Transcription, Genetic | 2010 |
Chromatin remodeling is required for gene reactivation after decitabine-mediated DNA hypomethylation.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cell Line, Tumor; Chromatin Assembly and Disassembly; Colonic Neoplasms; Decitabine; DNA Methylation; Gene Expression Regulation, Neoplastic; Gene Silencing; Green Fluorescent Proteins; Humans; Transfection; Transgenes | 2010 |
Olfactomedin 4 is a novel target gene of retinoic acids and 5-aza-2'-deoxycytidine involved in human myeloid leukemia cell growth, differentiation, and apoptosis.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Apoptosis; Azacitidine; Blotting, Western; Cell Cycle Proteins; Cell Differentiation; Cell Proliferation; Decitabine; DNA Methylation; Electrophoretic Mobility Shift Assay; Gene Expression; Gene Expression Regulation, Neoplastic; Granulocyte Colony-Stimulating Factor; HL-60 Cells; Humans; Immunohistochemistry; Leukemia, Myeloid; Myeloid Cells; Phosphoproteins; Response Elements; Reverse Transcriptase Polymerase Chain Reaction; Tretinoin | 2010 |
Identification of GPX3 epigenetically silenced by CpG methylation in human esophageal squamous cell carcinoma.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Carcinoma, Squamous Cell; Cell Line, Tumor; CpG Islands; Decitabine; DNA Methylation; Down-Regulation; Esophageal Neoplasms; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Glutathione Peroxidase; Humans; Male; Middle Aged; Promoter Regions, Genetic; Tumor Suppressor Proteins | 2011 |
Epigenetic silencing of beta-spectrin, a TGF-beta signaling/scaffolding protein in a human cancer stem cell disorder: Beckwith-Wiedemann syndrome.
Topics: Animals; Azacitidine; Base Sequence; Beckwith-Wiedemann Syndrome; Blotting, Western; Decitabine; DNA Methylation; Enzyme Inhibitors; Epigenesis, Genetic; Epigenomics; Gene Expression Profiling; Hep G2 Cells; Heterozygote; Humans; Insulin-Like Growth Factor II; Mice; Mice, Knockout; Neoplastic Stem Cells; Oligonucleotide Array Sequence Analysis; Phenotype; Promoter Regions, Genetic; Spectrin; Tumor Cells, Cultured | 2010 |
Mechanistic insights on the inhibition of c5 DNA methyltransferases by zebularine.
Topics: Animals; Azacitidine; Base Sequence; Cytidine; Decitabine; DNA; DNA (Cytosine-5-)-Methyltransferases; Enzyme Inhibitors; Humans; Methylation; Mice | 2010 |
Aberrant demethylation of the recoverin gene is involved in the aberrant expression of recoverin in cancer cells.
Topics: Azacitidine; Cell Line, Tumor; Decitabine; DNA Methylation; DNA Modification Methylases; Exons; Gene Expression Regulation, Neoplastic; Humans; Lung; Melanoma; Neoplasms; Promoter Regions, Genetic; Recoverin; Skin; Small Cell Lung Carcinoma | 2010 |
The effect of DNA methylation inhibitor 5-Aza-2'-deoxycytidine on human endometrial stromal cells.
Topics: Azacitidine; Cell Line; Decidua; Decitabine; DNA Methylation; Endometrium; Estradiol; Female; Humans; Medroxyprogesterone Acetate; Microarray Analysis; Stromal Cells | 2010 |
Aberrant methylation of the RIZ1 gene in myelodysplastic syndrome and acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Base Sequence; Decitabine; DNA Methylation; DNA-Binding Proteins; Female; Gene Expression; Histone-Lysine N-Methyltransferase; HL-60 Cells; Humans; Leukemia, Myeloid; Male; Middle Aged; Molecular Sequence Data; Myelodysplastic Syndromes; Nuclear Proteins; Polymerase Chain Reaction; Promoter Regions, Genetic; Sequence Analysis, DNA; Transcription Factors; U937 Cells; Young Adult | 2011 |
Sequential treatment of CD34+ cells from patients with primary myelofibrosis with chromatin-modifying agents eliminate JAK2V617F-positive NOD/SCID marrow repopulating cells.
Topics: Animals; Antigens, CD34; Antimetabolites, Antineoplastic; Antineoplastic Agents; Azacitidine; Bone Marrow; Cells, Cultured; Chromatin; Decitabine; Hematopoietic Stem Cells; Humans; Hydroxamic Acids; Immunoblotting; Interleukin Receptor Common gamma Subunit; Janus Kinase 2; Mice; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Mutation; Primary Myelofibrosis; Protein Synthesis Inhibitors; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Vorinostat | 2010 |
Restoring the functional immunogenicity of chronic lymphocytic leukemia using epigenetic modifiers.
Topics: Acetylation; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Methylation; Drug Synergism; Epigenomics; Histones; Humans; Hydroxamic Acids; Immunophenotyping; L-Lactate Dehydrogenase; Leukemia, Lymphocytic, Chronic, B-Cell; Male; T-Lymphocytes; Testis; Th1 Cells; Tumor Cells, Cultured | 2011 |
Gene expression profiling of myelodysplastic CD34+ hematopoietic stem cells treated in vitro with decitabine.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antigens, CD34; Antimetabolites, Antineoplastic; Azacitidine; Cluster Analysis; Decitabine; DNA Methylation; Female; Gene Expression; Gene Expression Profiling; Hematopoietic Stem Cells; Humans; Integrin beta1; Male; Middle Aged; Myelodysplastic Syndromes; Oligonucleotide Array Sequence Analysis; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; Young Adult | 2011 |
Functional and epigenetic characterization of the KRT19 gene in renal cell neoplasms.
Topics: Azacitidine; Carcinoma, Renal Cell; Cell Line, Tumor; Decitabine; DNA Methylation; Epigenesis, Genetic; Female; Gene Expression Regulation, Neoplastic; Humans; Keratin-19; Kidney; Kidney Neoplasms; Male; Middle Aged; Promoter Regions, Genetic | 2011 |
Resilience to social stress coincides with functional DNA methylation of the Crf gene in adult mice.
Topics: Analysis of Variance; Animals; Antidepressive Agents, Tricyclic; Avoidance Learning; Azacitidine; Cell Line, Tumor; Corticotropin-Releasing Hormone; Cyclic AMP; Decitabine; DNA Methylation; Enzyme Inhibitors; Gene Expression Regulation; Genetic Vectors; Green Fluorescent Proteins; Imipramine; Injections, Intraventricular; Male; Mice; Mice, Inbred C57BL; Microdissection; Naphthalenes; Neuroblastoma; Neurons; Oxepins; Paraventricular Hypothalamic Nucleus; RNA Interference; RNA, Messenger; Stress, Psychological | 2010 |
Reduced methyl-CpG protein binding contributing to miR-184 expression in umbilical cord blood CD4+ T-cells.
Topics: Azacitidine; CD4-Positive T-Lymphocytes; CpG Islands; Decitabine; DNA Methylation; Fetal Blood; Humans; Interferon-gamma; Methyl-CpG-Binding Protein 2; MicroRNAs; NFATC Transcription Factors | 2011 |
Equitoxic doses of 5-azacytidine and 5-aza-2'deoxycytidine induce diverse immediate and overlapping heritable changes in the transcriptome.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Gene Expression Profiling; Gene Expression Regulation; HL-60 Cells; Humans; MicroRNAs; RNA, Messenger | 2010 |
Epigenetic silencing of somatostatin in gastric cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Azacitidine; Biomarkers, Tumor; Cell Line, Tumor; Decitabine; DNA Methylation; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Humans; Hydroxamic Acids; Methylation; Predictive Value of Tests; Reproducibility of Results; RNA, Messenger; Somatostatin; Stomach Neoplasms | 2011 |
Chromatin-modifying agents increase transcription of CYP46A1, a key player in brain cholesterol elimination.
Topics: Analysis of Variance; Azacitidine; Blotting, Western; Cholesterol; Cholesterol 24-Hydroxylase; Decitabine; DNA Modification Methylases; Dose-Response Relationship, Drug; Electrophoretic Mobility Shift Assay; HEK293 Cells; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Neurons; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; Sp1 Transcription Factor; Sp3 Transcription Factor; Steroid Hydroxylases | 2010 |
DNA methyltransferase inhibition may limit cancer cell growth by disrupting ribosome biogenesis.
Topics: Azacitidine; Cell Proliferation; CpG Islands; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Enzyme Inhibitors; Gene Silencing; Genes, rRNA; Genes, Tumor Suppressor; Genomic Imprinting; HCT116 Cells; Humans; Neoplasms; Repetitive Sequences, Nucleic Acid; Ribosomes | 2011 |
Prodrugs of aza nucleosides based on proton transfer reaction.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cytarabine; Decitabine; Drug Design; Hydrogen Bonding; Kinetics; Myelodysplastic Syndromes; Nucleosides; Prodrugs; Protons; Thermodynamics | 2010 |
Cell line-dependent variability in HIV activation employing DNMT inhibitors.
Topics: Azacitidine; Decitabine; DNA Modification Methylases; Enzyme Inhibitors; Genes, Reporter; Green Fluorescent Proteins; HIV; Humans; Hydroxamic Acids; Jurkat Cells; Tumor Necrosis Factor-alpha; Virus Activation; Virus Latency | 2010 |
Fused-core silica column ultra-performance liquid chromatography-ion trap tandem mass spectrometry for determination of global DNA methylation status.
Topics: Azacitidine; Cell Line, Tumor; Chromatography, High Pressure Liquid; Decitabine; Deoxycytidine; Deoxyguanosine; DNA; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Enzyme Inhibitors; Humans; Silicon Dioxide; Tandem Mass Spectrometry | 2011 |
Epigenetic regulation on the 5'-proximal CpG island of human porcine endogenous retrovirus subgroup A receptor 2/GPR172B.
Topics: Animals; Azacitidine; Cell Culture Techniques; CpG Islands; Decitabine; DNA Methylation; Endogenous Retroviruses; Epigenomics; Gene Expression Regulation, Viral; HEK293 Cells; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Receptors, Virus; Swine | 2011 |
Azacytidine impairs NK cell reactivity while decitabine augments NK cell responsiveness toward stimulation.
Topics: Azacitidine; Cell Line; Cell Proliferation; Cytotoxicity, Immunologic; Decitabine; Humans; Immunity, Innate; Interferon-gamma; Killer Cells, Natural | 2011 |
Epigenetic modifiers influence lineage commitment of human bone marrow stromal cells: Differential effects of 5-aza-deoxycytidine and trichostatin A.
Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Azacitidine; Bone Marrow Cells; Bone Regeneration; Cell Differentiation; Cell Lineage; Cells, Cultured; Chondrogenesis; Core Binding Factor Alpha 1 Subunit; Decitabine; DNA Methylation; Epigenesis, Genetic; Female; Gene Expression; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Male; Middle Aged; Osteogenesis; Stromal Cells | 2011 |
Down-regulation of tumor suppressor A kinase anchor protein 12 in human hepatocarcinogenesis by epigenetic mechanisms.
Topics: A Kinase Anchor Proteins; Azacitidine; Carcinoma, Hepatocellular; Cell Cycle Proteins; Cell Line, Tumor; Decitabine; Down-Regulation; Epigenesis, Genetic; Humans; Liver Neoplasms; MicroRNAs; Promoter Regions, Genetic; Protein Array Analysis | 2010 |
Aberrantly silenced promoters retain a persistent memory of the silenced state after long-term reactivation.
Topics: Adenine Phosphoribosyltransferase; Animals; Azacitidine; Cell Line, Tumor; Chromatin Immunoprecipitation; CpG Islands; Decitabine; DNA Methylation; DNA Modification Methylases; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Histones; Hydroxamic Acids; Lysine; Methylation; Mice; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; Time Factors | 2011 |
Loss of heterozygosity and DNA methylation affect germline fibroblast growth factor receptor 4 polymorphism to direct allelic selection in breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Animals; Azacitidine; Breast Neoplasms; Carcinoma, Ductal, Breast; Cell Line, Tumor; Decitabine; DNA Methylation; Female; Germ-Line Mutation; Humans; Loss of Heterozygosity; Mice; Mice, SCID; Middle Aged; Polymorphism, Single Nucleotide; Receptor, Fibroblast Growth Factor, Type 4; Selection, Genetic; Xenograft Model Antitumor Assays | 2010 |
Effects of MEK and DNMT inhibitors on arsenic-treated human uroepithelial cells in relation to Cyclin-D1 and p16.
Topics: Arsenic Poisoning; Arsenites; Azacitidine; Blotting, Western; Butadienes; Cell Cycle; Cells, Cultured; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p16; Decitabine; DNA Modification Methylases; Dose-Response Relationship, Drug; Environmental Exposure; Humans; MAP Kinase Kinase Kinases; Neoplasm Proteins; Nitriles; Reverse Transcriptase Polymerase Chain Reaction; Urologic Neoplasms; Urothelium | 2011 |
Sustained exposure to the DNA demethylating agent, 2'-deoxy-5-azacytidine, leads to apoptotic cell death in chronic myeloid leukemia by promoting differentiation, senescence, and autophagy.
Topics: Aging; Antimetabolites, Antineoplastic; Apoptosis; Autophagy; Azacitidine; Cell Differentiation; Cell Line, Tumor; Cell Survival; Decitabine; DNA Methylation; Drug Synergism; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2011 |
High IGSF4 expression in pediatric M5 acute myeloid leukemia with t(9;11)(p22;q23).
Topics: Adolescent; Azacitidine; Blotting, Western; Cell Adhesion Molecule-1; Cell Adhesion Molecules; Cell Line, Tumor; Child; Child, Preschool; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 9; Decitabine; DNA Methylation; Enzyme Inhibitors; Female; Gene Expression Profiling; Gene Expression Regulation, Leukemic; HL-60 Cells; Humans; Immunoglobulins; Infant; Infant, Newborn; Leukemia, Monocytic, Acute; Male; Oligonucleotide Array Sequence Analysis; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Survival Analysis; Translocation, Genetic | 2011 |
[Study on promoter methylation status of E-cadherin gene in nasopharyngeal carcinoma cell lines].
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cadherins; Cell Line, Tumor; Cell Movement; Cell Proliferation; Decitabine; DNA Methylation; Down-Regulation; Gene Expression Regulation, Neoplastic; Humans; Nasopharyngeal Neoplasms; Neoplasm Invasiveness; Promoter Regions, Genetic | 2010 |
Demethylation of E-cadherin gene in nasopharyngeal carcinoma could serve as a potential therapeutic strategy.
Topics: Azacitidine; Biomarkers, Tumor; Cadherins; CpG Islands; Decitabine; DNA Modification Methylases; Down-Regulation; Humans; Methylation; Nasopharyngeal Neoplasms; Promoter Regions, Genetic; Transcription, Genetic; Tumor Cells, Cultured | 2011 |
TFPI-2 is a putative tumor suppressor gene frequently inactivated by promoter hypermethylation in nasopharyngeal carcinoma.
Topics: Azacitidine; Carcinoma; Cell Line, Tumor; Cell Proliferation; Decitabine; DNA Methylation; Epigenesis, Genetic; Flow Cytometry; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Glycoproteins; Humans; Nasopharyngeal Neoplasms; Promoter Regions, Genetic; RNA, Messenger | 2010 |
Pattern of hypomethylating agents use among elderly patients with myelodysplastic syndromes.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Methylation; DNA Modification Methylases; Female; Humans; Male; Myelodysplastic Syndromes; Survival Rate; Treatment Outcome | 2011 |
Analysis of genome-wide methylation and gene expression induced by 5-aza-2'-deoxycytidine identifies BCL2L10 as a frequent methylation target in acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Cells, Cultured; Decitabine; DNA Methylation; Epigenomics; Female; Gene Expression Regulation, Leukemic; Gene Frequency; Genome, Human; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Promoter Regions, Genetic; Proto-Oncogene Proteins c-bcl-2; Young Adult | 2010 |
Down-regulation of serum/glucocorticoid regulated kinase 1 in colorectal tumours is largely independent of promoter hypermethylation.
Topics: Azacitidine; Blotting, Western; Cell Line, Tumor; Colorectal Neoplasms; CpG Islands; Decitabine; DNA Methylation; Down-Regulation; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; HCT116 Cells; HT29 Cells; Humans; Immediate-Early Proteins; Polymorphism, Single Nucleotide; Promoter Regions, Genetic; Protein Serine-Threonine Kinases; Receptors, Glucocorticoid; Reverse Transcriptase Polymerase Chain Reaction | 2010 |
Claudin-7 down-regulation is an important feature in oral squamous cell carcinoma.
Topics: Adult; Aged; Azacitidine; Carcinoma, Squamous Cell; Cell Line, Tumor; Claudins; Decitabine; Down-Regulation; Female; Humans; Immunohistochemistry; Male; Membrane Proteins; Middle Aged; Mouth Neoplasms; RNA, Messenger | 2010 |
Premature senescence induced by DNA demethylating agent (Decitabine) as therapeutic option for malignant pleural mesothelioma.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cellular Senescence; Decitabine; DNA Methylation; Humans; Mesothelioma; Pleural Neoplasms | 2011 |
Chronic exposure to cigarette smoke condensate in vitro induces epithelial to mesenchymal transition-like changes in human bronchial epithelial cells, BEAS-2B.
Topics: Azacitidine; Bronchi; Cells, Cultured; Cytoskeleton; Decitabine; DNA Methylation; Epithelial Cells; Epithelial-Mesenchymal Transition; Gene Expression Profiling; Glucosides; Humans; Hydroxamic Acids; Intercellular Junctions; Nicotiana; Smoke | 2011 |
Epigenetic regulation of CD133 and tumorigenicity of CD133 positive and negative endometrial cancer cells.
Topics: AC133 Antigen; Animals; Antigens, CD; Azacitidine; Cell Transformation, Neoplastic; Decitabine; Endometrial Neoplasms; Epigenomics; Female; Glycoproteins; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasm Transplantation; Neoplastic Stem Cells; Peptides | 2010 |
Successful resolution of acute myelogenous leukemia-associated hemophagocytic lymphohistiocytosis with decitabine.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Humans; Leukemia, Myeloid, Acute; Lymphohistiocytosis, Hemophagocytic; Male; Treatment Outcome | 2011 |
Production of cloned calves by combination treatment of both donor cells and early cloned embryos with 5-aza-2/-deoxycytidine and trichostatin A.
Topics: Animals; Azacitidine; Blastocyst; Cattle; Cloning, Organism; Decitabine; Embryo Transfer; Embryonic Development; Female; Hydroxamic Acids; Nuclear Transfer Techniques; Pregnancy; Pregnancy Outcome | 2011 |
Decitabine-induced apoptosis is derived by Puma and Noxa induction in chronic myeloid leukemia cell line as well as in PBL and is potentiated by SAHA.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Azacitidine; Cells, Cultured; Decitabine; Drug Evaluation, Preclinical; Drug Synergism; Gene Expression Regulation, Leukemic; Humans; Hydroxamic Acids; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocytes; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Up-Regulation; Vorinostat | 2011 |
Down-regulation of VEZT gene expression in human gastric cancer involves promoter methylation and miR-43c.
Topics: 3' Untranslated Regions; Azacitidine; Base Sequence; Carrier Proteins; Cell Line; Cell Line, Tumor; Decitabine; DNA Methylation; DNA Modification Methylases; Down-Regulation; Gene Expression Regulation, Neoplastic; Genes, Reporter; HEK293 Cells; Humans; Luciferases; Membrane Proteins; MicroRNAs; Promoter Regions, Genetic; Stomach Neoplasms | 2011 |
[Expression, genetic and epigenetic alterations of LTF gene in nasopharyngeal carcinoma cell lines].
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cell Line, Tumor; Decitabine; DNA Methylation; Epigenesis, Genetic; Gene Deletion; Humans; Lactoferrin; Loss of Heterozygosity; Nasopharyngeal Neoplasms; Nasopharyngitis; Promoter Regions, Genetic; RNA, Messenger | 2010 |
Aberrant methylation accounts for cell adhesion-related gene silencing during 3-methylcholanthrene and diethylnitrosamine induced multistep rat lung carcinogenesis associated with overexpression of DNA methyltransferases 1 and 3a.
Topics: Animals; Azacitidine; Cadherins; Cell Adhesion; Cell Adhesion Molecules; Cell Transformation, Neoplastic; Decitabine; Diethylnitrosamine; Disease Models, Animal; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Methyltransferase 3A; DNA Methyltransferase 3B; Enzyme Inhibitors; Female; Gene Silencing; Immunoglobulins; Lung Neoplasms; Male; Methylcholanthrene; Rats; Rats, Wistar; Tissue Inhibitor of Metalloproteinase-3; Up-Regulation | 2011 |
Promoter hypermethylation of cyclooxygenase-2 gene in esophageal squamous cell carcinoma.
Topics: Azacitidine; Carcinoma, Squamous Cell; Cell Line, Tumor; Cyclooxygenase 2; Decitabine; Dinoprostone; DNA Methylation; Esophageal Neoplasms; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Promoter Regions, Genetic; RNA, Messenger; Sequence Analysis, DNA | 2011 |
5-Aza-2'-deoxycytidine increases sialyl Lewis X on MUC1 by stimulating β-galactoside:α2,3-sialyltransferase 6 gene.
Topics: Azacitidine; beta-Galactoside alpha-2,3-Sialyltransferase; Cell Adhesion; Cell Line, Tumor; Decitabine; DNA Methylation; E-Selectin; Enzyme Inhibitors; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Glycogen; Glycosylation; Humans; Immobilized Proteins; Molecular Weight; Mucin-1; Oligosaccharides; Sialyl Lewis X Antigen; Sialyltransferases; Transcriptional Activation | 2011 |
Role of PTEN promoter methylation in tamoxifen-resistant breast cancer cells.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Apoptosis; Azacitidine; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Drug Resistance, Neoplasm; Enzyme Activation; Female; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Oncogene Protein v-akt; Phosphatidylinositol 3-Kinases; Promoter Regions, Genetic; PTEN Phosphohydrolase; S-Adenosylmethionine; Tamoxifen; Tumor Burden; Xenograft Model Antitumor Assays | 2011 |
5-Aza-2'-deoxycytidine and interleukin-1 cooperate to regulate matrix metalloproteinase-3 gene expression.
Topics: Azacitidine; Colonic Neoplasms; Decitabine; DNA Methylation; DNA Modification Methylases; Drug Synergism; Gene Expression Regulation; HCT116 Cells; HeLa Cells; Humans; Inflammation Mediators; Interleukin-1; Matrix Metalloproteinase 3; Promoter Regions, Genetic; Proto-Oncogene Proteins c-jun; Transcription Factors; Transcriptional Activation | 2011 |
Aberrant methylation of heparan sulfate glucosamine 3-O-sulfotransferase 2 genes as a biomarker in colorectal cancer.
Topics: Azacitidine; Biomarkers, Tumor; Cell Cycle Proteins; Cell Line, Tumor; Colorectal Neoplasms; Core Binding Factor Alpha 3 Subunit; Cyclin-Dependent Kinase Inhibitor p16; Decitabine; DNA Methylation; Gene Expression Regulation, Neoplastic; Genes, p16; HCT116 Cells; Humans; Neoplasm Proteins; Poly-ADP-Ribose Binding Proteins; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; Sulfotransferases; Ubiquitin-Protein Ligases | 2010 |
(-)-Epigallocatechin-3-gallate reactivates silenced tumor suppressor genes, Cip1/p21 and p16INK4a, by reducing DNA methylation and increasing histones acetylation in human skin cancer cells.
Topics: Acetylation; Anticarcinogenic Agents; Azacitidine; Catechin; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Genes, p16; Histone Deacetylases; Histones; Humans; Hydroxamic Acids; Skin Neoplasms; Transcriptional Activation | 2011 |
Chromatin-modifying drugs induce miRNA-153 expression to suppress Irs-2 in glioblastoma cell lines.
Topics: Azacitidine; Cell Line, Tumor; Chromatin; Decitabine; Glioblastoma; Humans; Insulin Receptor Substrate Proteins; MicroRNAs; Phenylbutyrates | 2011 |
Alphabet soup: RAEB, HMA, DOE, and AFOP.
Topics: Anemia, Refractory, with Excess of Blasts; Antimetabolites, Antineoplastic; Azacitidine; Biopsy; Bronchoscopy; Cryptogenic Organizing Pneumonia; Decitabine; Diagnosis, Differential; Drug Therapy, Combination; Glucocorticoids; Heart Transplantation; Humans; Male; Methylprednisolone; Middle Aged; Pulmonary Fibrosis; Tomography, X-Ray Computed | 2010 |
Re-expression of ARHI (DIRAS3) induces autophagy in breast cancer cells and enhances the inhibitory effect of paclitaxel.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Autophagy; Azacitidine; Blotting, Western; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Decitabine; Gene Expression Regulation, Neoplastic; Green Fluorescent Proteins; Humans; Hydroxamic Acids; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Microscopy, Electron, Transmission; Microscopy, Fluorescence; Paclitaxel; Reverse Transcriptase Polymerase Chain Reaction; rho GTP-Binding Proteins; RNA Interference; Transplantation, Heterologous | 2011 |
Epigenetic mechanisms for silencing glutathione S-transferase m2 expression by hypermethylated specificity protein 1 binding in lung cancer.
Topics: Aged; Azacitidine; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Decitabine; DNA Methylation; Enzyme Inhibitors; Epigenesis, Genetic; Female; Glutathione Transferase; Humans; Lung Neoplasms; Male; Sp1 Transcription Factor | 2011 |
[Effect and mechanism of DNMT inhibitor on the reversal of multidrug resistance in human colon cancer cell line sw620/L-OHP].
Topics: ATP Binding Cassette Transporter, Subfamily B; Azacitidine; Cell Line, Tumor; Colonic Neoplasms; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Modification Methylases; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Membrane Proteins; Multidrug Resistance-Associated Proteins; Proto-Oncogene Proteins | 2010 |
Aberrant methylation frequency of TNFRSF10C promoter in pancreatic cancer cell lines.
Topics: Apoptosis; Azacitidine; Decitabine; Disease Progression; DNA Methylation; Epigenesis, Genetic; Gene Expression; GPI-Linked Proteins; Humans; Hydroxamic Acids; Pancreatic Neoplasms; Promoter Regions, Genetic; Receptors, Tumor Necrosis Factor, Member 10c; Restriction Mapping; Sequence Analysis, DNA; Tumor Cells, Cultured; Tumor Necrosis Factor Decoy Receptors | 2011 |
Silence of HIN-1 expression through methylation of its gene promoter in gastric cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Cell Line, Tumor; Cytokines; Decitabine; DNA Methylation; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Male; Middle Aged; Promoter Regions, Genetic; Stomach Neoplasms; Tumor Suppressor Proteins | 2011 |
GPR54 is a target for suppression of metastasis in endometrial cancer.
Topics: Animals; Azacitidine; Cell Line; Cell Line, Tumor; Decitabine; DNA Methylation; Endometrial Neoplasms; Enzyme Inhibitors; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Kisspeptins; Mice; Mice, Nude; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Oligonucleotide Array Sequence Analysis; Prognosis; Receptors, G-Protein-Coupled; Receptors, Kisspeptin-1; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2011 |
Hypomethylating agents for the treatment of acute myeloid leukemia in the elderly: for all, none, or which patients?
Topics: Aged; Antineoplastic Agents; Azacitidine; Clinical Trials as Topic; Decitabine; DNA Methylation; DNA Modification Methylases; Humans; Leukemia, Myeloid, Acute; Middle Aged; Treatment Outcome | 2011 |
Correlation between T-cadherin gene expression and aberrant methylation of T-cadherin promoter in human colon carcinoma cells.
Topics: Azacitidine; Blotting, Western; Cadherins; Colonic Neoplasms; CpG Islands; Decitabine; DNA Methylation; Gene Expression Regulation, Neoplastic; Humans; Promoter Regions, Genetic; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured | 2012 |
Noncytotoxic differentiation treatment of renal cell cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Azacitidine; Carcinoma, Renal Cell; Cell Differentiation; Cell Line, Tumor; Cell Survival; Cellular Senescence; Cytotoxins; Decitabine; DNA Damage; Humans; Kidney Neoplasms; Mice; Mice, Nude; Xenograft Model Antitumor Assays | 2011 |
Quantitative assessment of AKAP12 promoter methylation in human prostate cancer using methylation-sensitive high-resolution melting: correlation with Gleason score.
Topics: A Kinase Anchor Proteins; Azacitidine; Cell Cycle Proteins; Cell Line, Tumor; Decitabine; DNA Methylation; DNA Modification Methylases; Humans; Male; Mitogens; Promoter Regions, Genetic; Prostatic Hyperplasia; Prostatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction | 2011 |
Epigenetic inactivation of calcium-sensing receptor in colorectal carcinogenesis.
Topics: Adenocarcinoma; Adenoma; Antineoplastic Agents, Alkylating; Azacitidine; Caco-2 Cells; Cell Survival; Colonic Neoplasms; CpG Islands; Decitabine; DNA Methylation; DNA, Neoplasm; Gene Expression; Gene Silencing; Humans; Hydroxamic Acids; Receptors, Calcium-Sensing; RNA, Messenger; Tissue Array Analysis | 2011 |
Expression of the human cancer/testis antigen NY-SAR-35 is activated by CpG island hypomethylation.
Topics: Antigens, Neoplasm; Azacitidine; Base Sequence; Biotechnology; Cell Line, Tumor; Cloning, Molecular; CpG Islands; Decitabine; DNA Methylation; DNA Primers; Female; Gene Expression; Humans; Male; Promoter Regions, Genetic; RNA, Neoplasm; Testis; Transfection | 2011 |
Involvement of promoter methylation in the regulation of Pregnane X receptor in colon cancer cells.
Topics: Azacitidine; Caco-2 Cells; Carcinoma; Cell Line, Tumor; Colonic Neoplasms; Cytochrome P-450 CYP3A; Decitabine; DNA Methylation; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; HCT116 Cells; HT29 Cells; Humans; Pregnane X Receptor; Promoter Regions, Genetic; Receptors, Calcitriol; Receptors, Steroid | 2011 |
Transcriptional repressive H3K9 and H3K27 methylations contribute to DNMT1-mediated DNA methylation recovery.
Topics: Azacitidine; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Gene Silencing; Genetic Loci; GTPase-Activating Proteins; HCT116 Cells; HeLa Cells; Histones; Humans; Lysine; Stochastic Processes; Transcription, Genetic; Tumor Suppressor Proteins | 2011 |
Reactivation of Syk gene by AZA suppresses metastasis but not proliferation of breast cancer cells.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Decitabine; DNA Methylation; DNA, Neoplasm; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; Mice; Mice, Nude; Polymerase Chain Reaction; Protein-Tyrosine Kinases; Syk Kinase | 2012 |
Economic analysis of decitabine versus best supportive care in the treatment of intermediate- and high-risk myelodysplastic syndromes from a US payer perspective.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Decitabine; Disease-Free Survival; Drug Administration Schedule; Drug Costs; Humans; Leukemia, Myeloid, Acute; Markov Chains; Models, Economic; Myelodysplastic Syndromes; Patient Care; Randomized Controlled Trials as Topic; Risk; United States | 2010 |
Interleukin-6 expression was regulated by epigenetic mechanisms in response to influenza virus infection or dsRNA treatment.
Topics: Azacitidine; Base Sequence; Binding Sites; Cell Line, Tumor; CpG Islands; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Electrophoretic Mobility Shift Assay; Enzyme Inhibitors; Epigenesis, Genetic; Gene Expression; HEK293 Cells; Host-Pathogen Interactions; Humans; Influenza A Virus, H5N1 Subtype; Interleukin-6; Molecular Sequence Data; Promoter Regions, Genetic; Protein Binding; RNA Interference; RNA, Double-Stranded; Transcription Factors | 2011 |
Epigenetic modulation enhances the therapeutic effect of anti-IL-13R(alpha)2 antibody in human mesothelioma xenografts.
Topics: Animals; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Azacitidine; Cell Line, Tumor; Combined Modality Therapy; Decitabine; Drug Synergism; Epigenesis, Genetic; Female; HCT116 Cells; Humans; Immunotherapy; Interleukin-13 Receptor alpha2 Subunit; Mesothelioma; Mice; Mice, Inbred BALB C; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Xenograft Model Antitumor Assays | 2011 |
Acute myocarditis induced by hypomethylating agents.
Topics: Acute Disease; Anemia, Refractory, with Excess of Blasts; Azacitidine; Decitabine; Humans; Middle Aged; Myocarditis; Troponin | 2011 |
Histone deacetylase inhibitors upregulate Rap1GAP and inhibit Rap activity in thyroid tumor cells.
Topics: Adenocarcinoma, Follicular; Azacitidine; Butyrates; Carcinoma; Carcinoma, Papillary; Cell Line, Tumor; Decitabine; DNA Methylation; Drug Screening Assays, Antitumor; Drug Synergism; Gene Expression Regulation, Neoplastic; GTPase-Activating Proteins; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Neoplasm Proteins; rap GTP-Binding Proteins; rap1 GTP-Binding Proteins; RNA, Small Interfering; Thyroid Neoplasms; Up-Regulation | 2011 |
Downregulation of miR-205 and miR-31 confers resistance to chemotherapy-induced apoptosis in prostate cancer cells.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Apoptosis Regulatory Proteins; Azacitidine; Cell Line, Tumor; Decitabine; DNA Methylation; DNA Modification Methylases; Down-Regulation; Drug Resistance, Neoplasm; E2F6 Transcription Factor; Humans; Male; Mice; MicroRNAs; Promoter Regions, Genetic; Prostatic Neoplasms | 2010 |
Hypermethylation-modulated down-regulation of CDH1 expression contributes to the progression of esophageal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antigens, CD; Azacitidine; Cadherins; Carcinoma, Squamous Cell; Cell Adhesion; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Shape; Cell Survival; Decitabine; DNA Methylation; DNA Modification Methylases; Down-Regulation; Esophageal Neoplasms; Female; Humans; Male; Methylation; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Promoter Regions, Genetic; Transcription, Genetic | 2011 |
Epigenetic repolarization of T lymphocytes from chronic lymphocytic leukemia patients using 5-aza-2'-deoxycytidine.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cell Polarity; Cell Proliferation; Cells, Cultured; Decitabine; DNA Methylation; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Epigenesis, Genetic; Gene Expression Regulation, Leukemic; Humans; Interferon-gamma; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Activation; STAT1 Transcription Factor; T-Lymphocytes; Th2 Cells | 2011 |
MiR-218 suppresses nasopharyngeal cancer progression through downregulation of survivin and the SLIT2-ROBO1 pathway.
Topics: 3' Untranslated Regions; Adult; Aged; Azacitidine; Base Sequence; Cell Line; Cell Line, Tumor; Connexin 43; Decitabine; Disease Progression; DNA Methylation; Down-Regulation; Female; Gene Expression Regulation, Neoplastic; HEK293 Cells; Humans; Inhibitor of Apoptosis Proteins; Intercellular Signaling Peptides and Proteins; Male; MicroRNAs; Middle Aged; Molecular Sequence Data; Nasopharyngeal Neoplasms; Nerve Tissue Proteins; Receptors, Immunologic; Reverse Transcriptase Polymerase Chain Reaction; Roundabout Proteins; Signal Transduction; Survivin | 2011 |
Novel agents for the treatment of acute myeloid leukemia in the older patient.
Topics: Adenine Nucleotides; Age Factors; Aged; Antineoplastic Agents; Arabinonucleosides; Azacitidine; Clofarabine; Cytosine; Decitabine; Disease-Free Survival; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Middle Aged; Prognosis; Quinolones; Thalidomide | 2011 |
Azacytidine and decitabine induce gene-specific and non-random DNA demethylation in human cancer cell lines.
Topics: Azacitidine; Chromatin; CpG Islands; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Methyltransferase 3B; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Gene Knockout Techniques; Genes, Neoplasm; Genome, Human; HCT116 Cells; HL-60 Cells; Humans; Leukemia, Myeloid; Oligonucleotide Array Sequence Analysis; Protein Binding; Transcription Factors; Tumor Suppressor Proteins | 2011 |
Interferon-alpha induces reversible DNA demethylation of the interferon-induced transmembrane protein-3 core promoter in human melanoma cells.
Topics: Azacitidine; Biomarkers, Pharmacological; Cell Growth Processes; Cell Line, Tumor; Chemotactic Factors; Decitabine; DNA Methylation; DNA Modification Methylases; Gene Expression Regulation, Neoplastic; Humans; Interferon-alpha; Melanoma; Membrane Proteins; Promoter Regions, Genetic; RNA-Binding Proteins; S100 Proteins; Transforming Growth Factor beta; Transgenes | 2011 |
Genome-wide assessment of imprinted expression in human cells.
Topics: Alleles; Azacitidine; Cell Line; Decitabine; Fibroblasts; Gene Expression Profiling; Gene Expression Regulation; Genome, Human; Genomic Imprinting; Genomics; Humans | 2011 |
ENDOGLIN/CD105 is expressed in KIT positive cells in the gut and in gastrointestinal stromal tumours.
Topics: Animals; Antigens, CD; Antigens, CD34; Azacitidine; Benzamides; Cell Line, Tumor; Decitabine; DNA Methylation; Endoglin; Endothelium, Vascular; Gastrointestinal Stromal Tumors; Gastrointestinal Tract; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Interstitial Cells of Cajal; Mice; Mice, Transgenic; Piperazines; Platelet Endothelial Cell Adhesion Molecule-1; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Cell Surface; RNA, Messenger; Signal Transduction | 2012 |
DNA methylation-mediated silencing of nonsteroidal anti-inflammatory drug-activated gene (NAG-1/GDF15) in glioma cell lines.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Azacitidine; Brain Neoplasms; Cell Growth Processes; Cell Line, Tumor; Decitabine; DNA Methylation; Early Growth Response Protein 1; Gene Expression Regulation, Neoplastic; Gene Silencing; Glioblastoma; Growth Differentiation Factor 15; Humans; Hydroxamic Acids; Promoter Regions, Genetic; Sulindac; Transfection | 2012 |
Valproic acid: growth inhibition of head and neck cancer by induction of terminal differentiation and senescence.
Topics: Antineoplastic Agents; Azacitidine; Carcinoma, Squamous Cell; Cell Culture Techniques; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Cellular Senescence; Decitabine; Head and Neck Neoplasms; Histone Deacetylase Inhibitors; Humans; Squamous Cell Carcinoma of Head and Neck; Tretinoin; Valproic Acid | 2012 |
Synergetic effects of DNA demethylation and histone deacetylase inhibition in primary rat hepatocytes.
Topics: Albumins; Animals; Azacitidine; Biomarkers; CDC2 Protein Kinase; Cell Cycle; Cell Proliferation; Cell Shape; Cells, Cultured; Decitabine; DNA; DNA Methylation; Drug Synergism; Epidermal Growth Factor; Hepatocytes; Histone Deacetylase Inhibitors; Hydroxamic Acids; Rats | 2012 |
Aberrant CpG island hypermethylation and down-regulation of Oct-6 mRNA expression in human hepatocellular carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Carcinoma, Hepatocellular; Cell Line, Tumor; CpG Islands; Decitabine; DNA Methylation; DNA, Neoplasm; Dose-Response Relationship, Drug; Down-Regulation; Enzyme Inhibitors; Epigenesis, Genetic; Female; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Male; Middle Aged; Octamer Transcription Factor-6; RNA, Messenger | 2011 |
Changes in the levels of DNA methylation in testis and liver of SD rats neonatally exposed to 5-aza-2'-deoxycytidine and cadmium.
Topics: Animals; Animals, Newborn; Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Base Sequence; Body Weight; Cadmium Chloride; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Drug Therapy, Combination; Enzyme Inhibitors; Female; Liver; Male; Molecular Sequence Data; Organ Size; Promoter Regions, Genetic; Rats; Rats, Sprague-Dawley; Sperm Count; Testis; Tumor Suppressor Protein p53 | 2011 |
Aberrant promoter methylation in overexpression of CITED1 in papillary thyroid cancer.
Topics: Adult; Aged; Apoptosis Regulatory Proteins; Azacitidine; Carcinoma; Carcinoma, Papillary; Cell Line, Tumor; CpG Islands; Decitabine; DNA Methylation; Female; Gene Expression Regulation; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Mutation; Nuclear Proteins; Promoter Regions, Genetic; Thyroid Cancer, Papillary; Thyroid Neoplasms; Trans-Activators; Transcription Factors | 2011 |
The in vivo induction of sister chromatid exchange by the demethylating agent 5-aza-2'-deoxycytidine.
Topics: Animals; Azacitidine; Cell Death; Decitabine; Male; Methylation; Mice; Mice, Inbred BALB C; Mitotic Index; Sister Chromatid Exchange | 2011 |
The DNA methyltransferase inhibitors zebularine and decitabine induce mitochondria-mediated apoptosis and DNA damage in p53 mutant leukemic T cells.
Topics: Apoptosis; Azacitidine; Caspase 9; Cell Cycle; Cell Line, Tumor; Cytidine; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Damage; Genes, p53; Humans; Leukemia, T-Cell; Mitochondria; Mutation; Reactive Oxygen Species; T-Lymphocytes | 2012 |
DNA methyltransferase 1 as a predictive biomarker and potential therapeutic target for chemotherapy in gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Biomarkers, Tumor; Carcinoma; Cisplatin; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Methyltransferase 3B; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Male; Middle Aged; Molecular Targeted Therapy; Multivariate Analysis; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Stomach Neoplasms; Treatment Outcome; Tumor Stem Cell Assay | 2011 |
Clinical significance of expression of Hint1 and potential epigenetic mechanism in gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Cell Line, Tumor; Decitabine; Epigenesis, Genetic; Epstein-Barr Virus Infections; Female; Gastric Mucosa; Gene Expression Regulation, Neoplastic; Helicobacter Infections; Hep G2 Cells; Humans; Male; Middle Aged; Neoplasm Staging; Nerve Tissue Proteins; Stomach Neoplasms | 2011 |
Inhibition of p53-p21 pathway promotes the differentiation of rat bone marrow mesenchymal stem cells into cardiomyocytes.
Topics: Animals; Apoptosis; Azacitidine; Benzothiazoles; Bone Marrow Cells; Cell Proliferation; Cells, Cultured; Cyclin-Dependent Kinase Inhibitor p21; Decitabine; Down-Regulation; Leukocyte Common Antigens; Male; Mesenchymal Stem Cells; Myocytes, Cardiac; Rats; Rats, Sprague-Dawley; Toluene; Tumor Suppressor Protein p53 | 2011 |
Proximity ligation in situ assay for monitoring the global DNA methylation in cells.
Topics: Azacitidine; Cell Line; Cell Line, Tumor; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Enzyme Inhibitors; Epigenomics; Humans; Microscopy, Fluorescence; Proliferating Cell Nuclear Antigen; Protein Binding; Protein Interaction Mapping; RNA Interference | 2011 |
Inhibition of p53 represses E-cadherin expression by increasing DNA methyltransferase-1 and promoter methylation in serous borderline ovarian tumor cells.
Topics: Azacitidine; Cadherins; Carcinoma; Cell Line, Tumor; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Methyltransferase 3A; DNA Methyltransferase 3B; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Neoplasm Invasiveness; Ovarian Neoplasms; Phosphatidylinositol 3-Kinases; Promoter Regions, Genetic; Proto-Oncogene Proteins c-akt; Tumor Suppressor Protein p53 | 2011 |
Feasibility of hypomethylating agents followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome.
Topics: Adult; Aged; Azacitidine; Decitabine; Disease-Free Survival; DNA Methylation; Feasibility Studies; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Male; Middle Aged; Myelodysplastic Syndromes; Neutrophils; Risk; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome | 2012 |
A demethylating agent enhances chemosensitivity to vinblastine in a xenograft model of renal cell carcinoma.
Topics: Animals; Antineoplastic Agents; Azacitidine; Carcinoma, Renal Cell; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Decitabine; DNA Methylation; DNA Modification Methylases; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Promoter Regions, Genetic; Proteomics; Vinblastine; Xenograft Model Antitumor Assays | 2011 |
DNMT3B gene amplification predicts resistance to DNA demethylating drugs.
Topics: Antineoplastic Agents; Azacitidine; Cell Line, Tumor; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Methyltransferase 3B; Drug Resistance, Neoplasm; Gene Amplification; Humans; In Situ Hybridization, Fluorescence; RNA, Messenger | 2011 |
The effects of 5-aza-2'- deoxycytidine and trichostatin A on gene expression and DNA methylation status in cloned bovine blastocysts.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Blastocyst; Cattle; Cloning, Organism; Decitabine; DNA Methylation; Female; Fertilization in Vitro; Gene Expression; Histone Deacetylase Inhibitors; Hydroxamic Acids; Nuclear Transfer Techniques | 2011 |
Methylation silencing of angiopoietin-like 4 in rat and human mammary carcinomas.
Topics: Angiopoietin-Like Protein 4; Angiopoietins; Animals; Azacitidine; Breast Neoplasms; Cell Line, Tumor; Decitabine; DNA Methylation; Female; Gene Silencing; Hydroxamic Acids; Mammary Glands, Animal; Mammary Neoplasms, Animal; Oligonucleotide Array Sequence Analysis; Rats; Rats, Inbred F344; Rats, Sprague-Dawley | 2011 |
Thrombomodulin is silenced in malignant mesothelioma by a poly(ADP-ribose) polymerase-1-mediated epigenetic mechanism.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Cell Line; Decitabine; DNA Methylation; Epithelium; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Male; Mesothelioma; Middle Aged; Neoplasm Proteins; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Promoter Regions, Genetic; Thrombomodulin | 2011 |
Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2/M arrest, and autophagy.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Autophagy; Azacitidine; Cell Division; Cell Line, Tumor; Cell Proliferation; Decitabine; Drug Synergism; Drug Therapy, Combination; Epigenomics; Female; G2 Phase; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Genomic Imprinting; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Mice; Mice, Inbred BALB C; Mice, Nude; Ovarian Neoplasms; Transplantation, Heterologous; Vorinostat | 2011 |
Epigenetic repression of regulator of G-protein signaling 2 promotes androgen-independent prostate cancer cell growth.
Topics: Androgens; Animals; Azacitidine; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; CpG Islands; Decitabine; DNA Methylation; Down-Regulation; Epigenomics; Epithelial Cells; HEK293 Cells; Humans; Male; Mice; Mice, Nude; Promoter Regions, Genetic; Prostate; Prostatic Neoplasms; Receptors, Androgen; Receptors, G-Protein-Coupled; RGS Proteins; RNA, Small Interfering | 2012 |
Abnormal methylation of histone deacetylase genes: implications on etiology and epigenetic therapy of astrocytomas.
Topics: Adult; Antimetabolites, Antineoplastic; Astrocytoma; Azacitidine; Brain; Brain Neoplasms; Child; Colony-Forming Units Assay; Decitabine; DNA Methylation; DNA, Neoplasm; Epigenesis, Genetic; Histone Deacetylase 6; Histone Deacetylases; Humans; Polymerase Chain Reaction; Repressor Proteins; Tumor Cells, Cultured | 2011 |
Suppression of WIF-1 through promoter hypermethylation causes accelerated proliferation of the aryl hydrocarbon receptor (AHR) overexpressing MCF10AT1 breast cancer cells.
Topics: Adaptor Proteins, Signal Transducing; Antimetabolites, Antineoplastic; Azacitidine; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Decitabine; Estrogen Receptor alpha; Female; Gene Expression Regulation, Neoplastic; Humans; Methylation; Promoter Regions, Genetic; Receptors, Aryl Hydrocarbon; Repressor Proteins; Reverse Transcriptase Polymerase Chain Reaction; TCF Transcription Factors | 2011 |
Ultra-performance liquid chromatography/tandem mass spectrometry for accurate quantification of global DNA methylation in human sperms.
Topics: Azacitidine; Chromatography, High Pressure Liquid; Decitabine; Deoxycytidine; Deoxyguanosine; DNA; DNA Methylation; Hep G2 Cells; Humans; Male; Reproducibility of Results; Sensitivity and Specificity; Spermatozoa; Tandem Mass Spectrometry | 2011 |
Transcription intermediary factor 1γ is a tumor suppressor in mouse and human chronic myelomonocytic leukemia.
Topics: Aged; Aged, 80 and over; Aging; Animals; Antimetabolites, Antineoplastic; Azacitidine; Base Sequence; Cell Differentiation; Decitabine; DNA Methylation; Female; Gene Expression Regulation, Leukemic; Genes, Tumor Suppressor; Hematopoiesis; Hematopoietic Stem Cells; Humans; Leukemia, Myelomonocytic, Chronic; Male; Mice; Mice, Knockout; Middle Aged; Molecular Sequence Data; Neoplasm Proteins; Promoter Regions, Genetic; Receptor, Macrophage Colony-Stimulating Factor; Specific Pathogen-Free Organisms; Transcription Factors | 2011 |
A 5-aza-2'-deoxycytidine/valproate combination induces cytotoxic T-cell response against mesothelioma.
Topics: Animals; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cell Line, Tumor; Cell Proliferation; Decitabine; DNA Modification Methylases; Drug Synergism; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Membrane Proteins; Mesothelioma; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Pleural Neoplasms; T-Lymphocytes, Cytotoxic; Valproic Acid; Vorinostat | 2011 |
Effect of trichostatin A and 5-Aza-2'-deoxycytidine on transgene reactivation and epigenetic modification in transgenic pig fibroblast cells.
Topics: Acetylation; Animals; Animals, Genetically Modified; Azacitidine; Cell Shape; Cell Survival; Cells, Cultured; Cytomegalovirus; Decitabine; DNA Methylation; Epigenesis, Genetic; Fibroblasts; Gene Expression Regulation; Green Fluorescent Proteins; Histone Deacetylase Inhibitors; Histones; Hydroxamic Acids; Methyltransferases; Promoter Regions, Genetic; Swine; Transgenes | 2011 |
Cardiomyocyte marker expression in a human lymphocyte cell line using mouse cardiomyocyte extract.
Topics: Actins; Animals; Azacitidine; B-Lymphocytes; Biomarkers; Cell Extracts; Cell Membrane Permeability; Cell Transdifferentiation; Decitabine; Flow Cytometry; Humans; Hydroxamic Acids; Immunohistochemistry; Mice; Myocytes, Cardiac; Myosin Heavy Chains; Troponin T | 2011 |
Simultaneous inhibition of DNA methyltransferase and histone deacetylase induces p53-independent apoptosis via down-regulation of Mcl-1 in acute myelogenous leukemia cells.
Topics: Apoptosis; Azacitidine; Benzamides; Blotting, Western; Cell Cycle; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Decitabine; DNA Modification Methylases; Drug Therapy, Combination; Enzyme Inhibitors; Epigenomics; Flow Cytometry; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Humans; Leukemia, Myeloid, Acute; Mutation, Missense; Myeloid Cell Leukemia Sequence 1 Protein; Proto-Oncogene Proteins c-bcl-2; Pyridines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2011 |
Increased PRAME antigen-specific killing of malignant cell lines by low avidity CTL clones, following treatment with 5-Aza-2'-Deoxycytidine.
Topics: Antibody Affinity; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Azacitidine; Cell Line, Tumor; Cytotoxicity, Immunologic; Decitabine; HL-60 Cells; HLA-A2 Antigen; Humans; Immunotherapy, Adoptive; K562 Cells; Neoplasms; T-Lymphocytes, Cytotoxic; Transfection | 2011 |
Use of hypomethylating agents and associated care in patients with myelodysplastic syndromes: a claims database study.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Female; Humans; Insurance Claim Review; Male; Myelodysplastic Syndromes | 2011 |
2´-deoxy-5,6-dihydro-5-azacytidine - a less toxic alternative of 2´-deoxy-5-azacytidine: a comparative study of hypomethylating potential.
Topics: Apoptosis; Azacitidine; Decitabine; DNA Methylation; Gene Expression Regulation; Genetic Loci; Genome, Human; Humans; Molecular Structure; RNA, Messenger; Thrombospondin 1 | 2011 |
Epigenetic inactivation of the SFRP1 gene in esophageal squamous cell carcinoma.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Carcinoma, Squamous Cell; Cell Line, Tumor; Decitabine; DNA Methylation; Esophageal Neoplasms; Gene Silencing; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Intercellular Signaling Peptides and Proteins; Membrane Proteins | 2011 |
EFEMP1 as a novel DNA methylation marker for prostate cancer: array-based DNA methylation and expression profiling.
Topics: Aged; Aged, 80 and over; Azacitidine; Biomarkers, Tumor; Cell Line, Tumor; CpG Islands; Decitabine; DNA Methylation; DNA Modification Methylases; Epigenomics; Extracellular Matrix Proteins; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Promoter Regions, Genetic; Prostatic Hyperplasia; Prostatic Neoplasms; Reproducibility of Results | 2011 |
Silencing of BNIP3 results from promoter methylation by DNA methyltransferase 1 induced by the mitogen-activated protein kinase pathway.
Topics: Azacitidine; Butadienes; Cell Hypoxia; Cell Line, Tumor; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Epigenesis, Genetic; Genes, Reporter; Humans; Luciferases, Renilla; MAP Kinase Signaling System; Membrane Proteins; Mitogen-Activated Protein Kinases; Nitriles; Promoter Regions, Genetic; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Transcription, Genetic | 2011 |
Antidepressant-like effect induced by systemic and intra-hippocampal administration of DNA methylation inhibitors.
Topics: Animals; Antidepressive Agents; Azacitidine; Behavior, Animal; Brain-Derived Neurotrophic Factor; Decitabine; Depression; Disease Models, Animal; DNA Methylation; Hindlimb Suspension; Hippocampus; Imipramine; Male; Mice; Rats; Swimming | 2011 |
Loss of special AT-rich binding protein 1 expression is a marker of poor survival in lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Blotting, Western; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; Chromatin Immunoprecipitation; Cohort Studies; Decitabine; DNA Methylation; Epigenesis, Genetic; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Immunoenzyme Techniques; Lung Neoplasms; Male; Matrix Attachment Region Binding Proteins; Middle Aged; Neoplasm Staging; Prognosis; Tissue Array Analysis | 2011 |
Use of integrative epigenetic and cytogenetic analyses to identify novel tumor-suppressor genes in malignant melanoma.
Topics: Adult; Aged; Aged, 80 and over; Azacitidine; Cell Line, Tumor; Cell Proliferation; Comparative Genomic Hybridization; Decitabine; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Epigenesis, Genetic; Female; Gene Deletion; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Genomics; Humans; Male; Melanoma; Middle Aged; Oligonucleotide Array Sequence Analysis; Skin Neoplasms; Transfection | 2011 |
MicroRNA-146a downregulates NFκB activity via targeting TRAF6 and functions as a tumor suppressor having strong prognostic implications in NK/T cell lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Apoptosis; Azacitidine; Cell Line, Tumor; Cell Proliferation; Child; Decitabine; DNA Methylation; DNA Modification Methylases; Down-Regulation; Drug Synergism; Etoposide; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Humans; Kaplan-Meier Estimate; Lymphoma, Extranodal NK-T-Cell; MicroRNAs; Middle Aged; NF-kappaB-Inducing Kinase; Prognosis; Promoter Regions, Genetic; Protein Serine-Threonine Kinases; Signal Transduction; TNF Receptor-Associated Factor 6; Treatment Outcome; Young Adult | 2011 |
MAGE-A1, MAGE-A3, and NY-ESO-1 can be upregulated on neuroblastoma cells to facilitate cytotoxic T lymphocyte-mediated tumor cell killing.
Topics: Antigens, Neoplasm; Azacitidine; Cell Line, Tumor; Decitabine; Humans; Interferon-gamma; Melanoma-Specific Antigens; Membrane Proteins; Neoplasm Proteins; Neuroblastoma; T-Lymphocytes, Cytotoxic; Up-Regulation | 2011 |
The role of promoter methylation in Epstein-Barr virus (EBV) microRNA expression in EBV-infected B cell lines.
Topics: Azacitidine; B-Lymphocytes; Cell Line; Decitabine; DNA Methylation; DNA Modification Methylases; Gene Expression Regulation, Viral; Gene Silencing; Herpesvirus 4, Human; Humans; MicroRNAs; Promoter Regions, Genetic; RNA, Viral; Viral Proteins | 2011 |
Decreased expression of protease-activated receptor 4 in human gastric cancer.
Topics: Aged; Azacitidine; Cell Line, Tumor; Decitabine; DNA Modification Methylases; Down-Regulation; Female; Gastric Mucosa; Gene Expression; Gene Expression Regulation, Neoplastic; Genetic Association Studies; Humans; Male; Methylation; Middle Aged; Promoter Regions, Genetic; Receptors, Thrombin; Sequence Analysis, DNA; Stomach Neoplasms | 2011 |
Aberrant methylation of N-methyl-D-aspartate receptor type 2B (NMDAR2B) in non-small cell carcinoma.
Topics: Adult; Aged; Azacitidine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; Decitabine; DNA Methylation; Female; Gene Expression Regulation, Neoplastic; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Neoplasm Proteins; Neoplasm Staging; Pneumonectomy; Prognosis; Proportional Hazards Models; Receptors, N-Methyl-D-Aspartate; RNA, Messenger; RNA, Neoplasm; Sampling Studies | 2011 |
The Levels of H11/HspB8 DNA methylation in human melanoma tissues and xenografts are a critical molecular marker for 5-Aza-2'-deoxycytidine therapy.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Cell Cycle; Decitabine; DNA Methylation; Female; Heat-Shock Proteins; Humans; Melanocytes; Melanoma; Mice; Mice, Inbred BALB C; Molecular Chaperones; Phosphatidylinositol 3-Kinases; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-akt; Xenograft Model Antitumor Assays | 2011 |
Hypomethylating agents reactivate FOXO3A in acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Apoptosis; Apoptosis Regulatory Proteins; Azacitidine; Bcl-2-Like Protein 11; Cell Line, Tumor; Checkpoint Kinase 1; Checkpoint Kinase 2; Decitabine; DNA Methylation; DNA Repair; Female; Forkhead Box Protein O3; Forkhead Transcription Factors; Histones; Humans; Leukemia, Myeloid, Acute; Male; Membrane Proteins; Middle Aged; Phosphorylation; Protein Kinases; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins | 2011 |
Activity of azacitidine in chronic myelomonocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Female; Humans; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Retrospective Studies | 2011 |
Gain of DNA methylation is enhanced in the absence of CTCF at the human retinoblastoma gene promoter.
Topics: Azacitidine; Binding Sites; CCCTC-Binding Factor; Cell Line, Tumor; Decitabine; DNA Methylation; DNA, Neoplasm; Down-Regulation; Genes, Reporter; Genes, Retinoblastoma; Glioma; HeLa Cells; Humans; Hydroxamic Acids; K562 Cells; Mutation; Nucleic Acid Conformation; Promoter Regions, Genetic; Repressor Proteins; Sequence Analysis, DNA; Transgenes | 2011 |
Changes in global gene expression in response to chemical and genetic perturbation of chromatin structure.
Topics: Arabidopsis; Arabidopsis Proteins; Azacitidine; Chromatin; Decitabine; DNA Damage; DNA Methylation; DNA Transposable Elements; DNA-Binding Proteins; Gene Expression Profiling; Mutation; Oligonucleotide Array Sequence Analysis; Seedlings; Substrate Specificity; Transcription Factors; Transcription, Genetic; Up-Regulation | 2011 |
Transformation-dependent silencing of tumor-selective apoptosis-inducing TRAIL by DNA hypermethylation is antagonized by decitabine.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Cell Line, Transformed; Cell Line, Tumor; Cell Transformation, Neoplastic; Decitabine; DNA Methylation; Down-Regulation; Enzyme Inhibitors; Epigenesis, Genetic; Gene Expression Regulation; Gene Silencing; HeLa Cells; Humans; Interferons; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Proto-Oncogene Proteins p21(ras); Signal Transduction; TNF-Related Apoptosis-Inducing Ligand; Xenograft Model Antitumor Assays | 2011 |
A pilot study of subcutaneous decitabine in β-thalassemia intermedia.
Topics: Adult; Antimetabolites, Antineoplastic; Azacitidine; beta-Thalassemia; Cell Differentiation; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Erythrocytes; Female; gamma-Globins; Gene Expression Regulation; Hemoglobins; Humans; Injections, Subcutaneous; Male; Middle Aged; Pilot Projects; Prognosis; Young Adult | 2011 |
p53 independent epigenetic-differentiation treatment in xenotransplant models of acute myeloid leukemia.
Topics: Animals; Antineoplastic Agents; Apoptosis; Azacitidine; Blotting, Western; Cell Differentiation; Cytarabine; Decitabine; DNA Damage; Electrophoresis, Polyacrylamide Gel; Epigenesis, Genetic; Genes, p53; Humans; Leukemia, Myeloid, Acute; Mice; Phosphorylation; Transplantation, Heterologous | 2011 |
Heparan sulfate D-glucosaminyl 3-O-sulfotransferase-3B1, a novel epithelial-mesenchymal transition inducer in pancreatic cancer.
Topics: Azacitidine; Base Sequence; Cell Line, Tumor; Chromatin Immunoprecipitation; Decitabine; Endothelial Cells; Epithelial-Mesenchymal Transition; Heparitin Sulfate; Histones; Humans; Hydroxamic Acids; Methylation; Pancreatic Neoplasms; RNA, Messenger; Sequence Analysis, DNA; Snail Family Transcription Factors; Sulfotransferases; Transcription Factors; Transcriptional Activation | 2011 |
The effect of decitabine on megakaryocyte maturation and platelet release.
Topics: Animals; Azacitidine; Blood Platelets; Bone Marrow Cells; Cell Differentiation; Cell Line; Decitabine; DNA Methylation; Fetal Blood; Humans; In Vitro Techniques; Megakaryocytes; Mice; Myelodysplastic Syndromes; Platelet Count; Polyploidy; Thrombocytopenia; Thrombopoiesis; Up-Regulation | 2011 |
[High glucose induce the demethylation of CTGF promoter and gene expression].
Topics: Azacitidine; Cell Line; Connective Tissue Growth Factor; CpG Islands; Decitabine; DNA Methylation; Dose-Response Relationship, Drug; Enzyme Inhibitors; Gene Expression Regulation; Glucose; Humans; Mesangial Cells; Promoter Regions, Genetic | 2011 |
The depletion of DNA methyltransferase-1 and the epigenetic effects of 5-aza-2'deoxycytidine (decitabine) are differentially regulated by cell cycle progression.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cell Cycle Checkpoints; Cell Line, Tumor; CpG Islands; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Damage; DNA Methylation; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; HCT116 Cells; Humans; Melanoma-Specific Antigens; S Phase; Tumor Suppressor Protein p53 | 2011 |
[Promoter methylation status of hPer3 gene in AML patients and the in vitro effect of decitabine on the status].
Topics: Adolescent; Adult; Aged; Azacitidine; Cell Proliferation; Decitabine; DNA Methylation; Female; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Period Circadian Proteins; Promoter Regions, Genetic; U937 Cells; Young Adult | 2011 |
Definition of the landscape of promoter DNA hypomethylation in liver cancer.
Topics: Aged; Azacitidine; Breast Neoplasms; Carcinoma, Hepatocellular; Decitabine; DNA Methylation; DNA-Binding Proteins; Female; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Ovarian Neoplasms; Promoter Regions, Genetic | 2011 |
Aberrant DNA methylation but not mutation of CITED4 is associated with alteration of HIF-regulated genes in breast cancer.
Topics: Azacitidine; Breast Neoplasms; Cell Line, Tumor; Decitabine; DNA Methylation; Enzyme Inhibitors; Female; Gene Expression Regulation, Neoplastic; Glucose Transporter Type 1; HCT116 Cells; HL-60 Cells; Humans; Hydroxamic Acids; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; K562 Cells; Mutation; Neoplasm Invasiveness; Polymorphism, Genetic; Promoter Regions, Genetic; RNA, Messenger; Transcription Factors | 2011 |
Cytosine methylation in miR-153 gene promoters increases the expression of holocarboxylase synthetase, thereby increasing the abundance of histone H4 biotinylation marks in HEK-293 human kidney cells.
Topics: 3' Untranslated Regions; Azacitidine; Binding Sites; Biotinylation; Carbon-Nitrogen Ligases; Cytosine; Decitabine; DNA Methylation; Epigenomics; Gene Expression Regulation; HEK293 Cells; Histones; Humans; Kidney; MicroRNAs; Promoter Regions, Genetic | 2012 |
FMR1 CGG repeat lengths mediate different regulation of reporter gene expression in comparative transient and locus specific integration assays.
Topics: 5' Untranslated Regions; Azacitidine; Base Sequence; Decitabine; DNA Primers; Female; Fragile X Mental Retardation Protein; Fragile X Syndrome; Gene Expression Regulation; Gene Silencing; Genes, Reporter; HEK293 Cells; Humans; Male; Mutation; RNA, Messenger; Transfection; Trinucleotide Repeat Expansion; Trinucleotide Repeats | 2011 |
CpG methylation at the USF-binding site mediates cell-specific transcription of human ascorbate transporter SVCT2 exon 1a.
Topics: Azacitidine; CCAAT-Binding Factor; Cell Line; Cell Line, Tumor; CpG Islands; Decitabine; Dinucleoside Phosphates; Exons; Humans; Methylation; Promoter Regions, Genetic; Sodium-Coupled Vitamin C Transporters; Upstream Stimulatory Factors | 2011 |
Combined inhibition of DNA methyltransferase and histone deacetylase restores caspase-8 expression and sensitizes SCLC cells to TRAIL.
Topics: Azacitidine; Blotting, Western; Caspase 8; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methyltransferase 3A; DNA Methyltransferase 3B; Enzyme Inhibitors; Fluorescent Antibody Technique; Histone Deacetylases; Humans; Inhibitor of Apoptosis Proteins; Lung Neoplasms; Membrane Potential, Mitochondrial; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Small Cell Lung Carcinoma; Survivin; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured; Valproic Acid | 2011 |
HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL.
Topics: Acetylation; Animals; Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Cell Line, Tumor; Decitabine; DNA Methylation; Drug Synergism; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Indoles; Lymphoma, Large B-Cell, Diffuse; Mice; Mice, SCID; Panobinostat; Xenograft Model Antitumor Assays | 2011 |
Aberrant methylation of RASSF2A in human pancreatic ductal adenocarcinoma and its relation to clinicopathologic features.
Topics: Adult; Aged; Aged, 80 and over; Azacitidine; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cell Line; China; CpG Islands; Decitabine; DNA Methylation; DNA Modification Methylases; Down-Regulation; Enzyme Inhibitors; Female; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Promoter Regions, Genetic; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Time Factors; Tumor Suppressor Proteins | 2012 |
Inactivation of the putative suppressor gene DOK1 by promoter hypermethylation in primary human cancers.
Topics: Adult; Aged; Azacitidine; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p16; Decitabine; DNA Methylation; DNA-Binding Proteins; Female; Genes, Tumor Suppressor; Head and Neck Neoplasms; Humans; Male; Middle Aged; Phosphoproteins; Promoter Regions, Genetic; Risk Factors; RNA-Binding Proteins; Tumor Suppressor Proteins | 2012 |
Epigenetic regulation by decitabine of melanoma differentiation in vitro and in vivo.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Base Sequence; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p16; Cyclin-Dependent Kinase Inhibitor Proteins; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Epigenesis, Genetic; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Mice, Nude; Promoter Regions, Genetic; Proto-Oncogene Proteins B-raf; Sequence Analysis, DNA; SOX9 Transcription Factor; Tetrahydrouridine; Tumor Suppressor Protein p53; Up-Regulation | 2012 |
Evaluating the global CpG methylation status of native DNA utilizing a bipartite split-luciferase sensor.
Topics: Azacitidine; Biosensing Techniques; CpG Islands; Decitabine; DNA; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Genome, Human; HeLa Cells; Humans; Luciferases; Protein Structure, Tertiary; Zinc Fingers | 2011 |
Improvement of cardiac function in mouse myocardial infarction after transplantation of epigenetically-modified bone marrow progenitor cells.
Topics: Animals; Azacitidine; Bone Marrow Cells; Cell Differentiation; Decitabine; Endothelial Cells; Epigenesis, Genetic; Gene Expression Regulation; Heart; Hydroxamic Acids; Inflammation; Male; Mice; Mice, Inbred C57BL; Myocardial Infarction; Myocytes, Cardiac; Neovascularization, Physiologic; Pluripotent Stem Cells; Stem Cell Transplantation; Stem Cells; Ventricular Dysfunction, Left | 2011 |
NOR1 is an HSF1- and NRF1-regulated putative tumor suppressor inactivated by promoter hypermethylation in nasopharyngeal carcinoma.
Topics: Azacitidine; Base Sequence; Cell Line, Tumor; Decitabine; DNA Methylation; Humans; Membrane Transport Proteins; Molecular Sequence Data; Nasopharyngeal Neoplasms; Promoter Regions, Genetic; Tumor Suppressor Proteins | 2011 |
The association between non-Hodgkin lymphoma and methylation of p73.
Topics: Adult; Antimetabolites, Antineoplastic; Azacitidine; Blotting, Western; Decitabine; DNA Methylation; DNA-Binding Proteins; Dose-Response Relationship, Drug; Female; Gene Expression Regulation, Neoplastic; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Nuclear Proteins; Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; Tumor Cells, Cultured; Tumor Protein p73; Tumor Suppressor Proteins; Young Adult | 2011 |
γ-radiation induces cellular sensitivity and aberrant methylation in human tumor cell lines.
Topics: Ataxia Telangiectasia Mutated Proteins; Azacitidine; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Survival; Decitabine; DNA Breaks; DNA Methylation; DNA-Binding Proteins; Gamma Rays; Genes, p16; Humans; Hydroxamic Acids; Neoplasms; Promoter Regions, Genetic; Protein Serine-Threonine Kinases; Radiation Tolerance; Tumor Suppressor Proteins | 2011 |
Hematologic outcomes of myelodysplastic syndromes treatment with hypomethylating agents in community practice.
Topics: Aged; Aged, 80 and over; Azacitidine; Decitabine; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Female; Hemoglobins; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Neutrophils; Odds Ratio; Platelet Count; Retrospective Studies; Treatment Outcome | 2011 |
Long term transcriptional reactivation of epigenetically silenced genes in colorectal cancer cells requires DNA hypomethylation and histone acetylation.
Topics: Acetylation; Azacitidine; Cell Line, Tumor; Chromatin Immunoprecipitation; Colorectal Neoplasms; Decitabine; DNA Methylation; Epigenesis, Genetic; Gene Silencing; Histones; Humans; Real-Time Polymerase Chain Reaction; Transcriptional Activation | 2011 |
CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal hematopoietic precursors.
Topics: Antineoplastic Agents; Azacitidine; Base Sequence; Cell Lineage; CpG Islands; Decitabine; DNA Methylation; DNA Primers; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid, Acute; Polymerase Chain Reaction; Promoter Regions, Genetic | 2012 |
Methylation-associated down-regulation of RASSF1A and up-regulation of RASSF1C in pancreatic endocrine tumors.
Topics: Adult; Aged; Azacitidine; Case-Control Studies; Cell Line, Tumor; CpG Islands; Decitabine; DNA Methylation; Down-Regulation; Exons; Female; Gene Expression Regulation, Neoplastic; Humans; Linear Models; Male; Middle Aged; Pancreatic Neoplasms; Protein Isoforms; Reverse Transcriptase Polymerase Chain Reaction; Sequence Analysis, DNA; Statistics, Nonparametric; Tumor Suppressor Proteins; Up-Regulation | 2011 |
TCF21 and PCDH17 methylation: An innovative panel of biomarkers for a simultaneous detection of urological cancers.
Topics: Adult; Aged; Aged, 80 and over; Azacitidine; Basic Helix-Loop-Helix Transcription Factors; Biomarkers; Cadherins; Carcinoma, Renal Cell; Case-Control Studies; Cell Line, Tumor; Decitabine; DNA Methylation; Epigenesis, Genetic; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Hydroxamic Acids; Male; Middle Aged; Promoter Regions, Genetic; Prostatic Neoplasms; ROC Curve; Sensitivity and Specificity; Urinary Bladder Neoplasms | 2011 |
Dynamics of bivalent chromatin domains upon drug induced reactivation and resilencing in cancer cells.
Topics: Azacitidine; Chromatin; Chromosomes, Human, Pair 2; Chromosomes, Human, Pair 3; Colonic Neoplasms; CpG Islands; Decitabine; DNA Methylation; Gene Expression Regulation, Neoplastic; Gene Silencing; HCT116 Cells; Histones; Humans; Hydroxamic Acids; Inhibin-beta Subunits; Jumonji Domain-Containing Histone Demethylases; Time Factors; Transcriptional Activation | 2011 |
Mechanisms of resistance to decitabine in the myelodysplastic syndrome.
Topics: Aged; Aged, 80 and over; Azacitidine; Chromosome Aberrations; CpG Islands; Cytidine Deaminase; Decitabine; Deoxycytidine Kinase; DNA Methylation; Drug Resistance; Female; Gene Expression Regulation; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Reverse Transcriptase Polymerase Chain Reaction; Sequence Analysis, DNA | 2011 |
Promoter hypermethylation of DNA damage response genes in hepatocellular carcinoma.
Topics: Adaptor Proteins, Signal Transducing; Azacitidine; Carcinoma, Hepatocellular; Cell Cycle Proteins; Cell Line, Tumor; CpG Islands; Decitabine; DNA Damage; DNA Methylation; DNA Modification Methylases; DNA Repair; DNA Repair Enzymes; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Glutathione S-Transferase pi; Hep G2 Cells; Humans; Liver Neoplasms; Male; MutL Protein Homolog 1; Neoplasm Proteins; Nuclear Proteins; Poly-ADP-Ribose Binding Proteins; Prognosis; Promoter Regions, Genetic; RNA, Messenger; Tumor Suppressor Proteins; Ubiquitin-Protein Ligases | 2012 |
[Effects of decitabine on biological behavior of U266 cells].
Topics: Apoptosis; Azacitidine; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Decitabine; Humans; Multiple Myeloma | 2011 |
WIF1 is a frequent target for epigenetic silencing in squamous cell carcinoma of the cervix.
Topics: Adaptor Proteins, Signal Transducing; Azacitidine; Blotting, Western; Carcinoma, Squamous Cell; Cell Line; Cervix Uteri; CpG Islands; Decitabine; DNA Methylation; Epigenesis, Genetic; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Immunoenzyme Techniques; Promoter Regions, Genetic; Repressor Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Uterine Cervical Neoplasms | 2011 |
[Reversal effect of 5-Aza-dc on cisplatin-resistance in human NSCLC cells in vitro].
Topics: Adaptor Proteins, Signal Transducing; Antimetabolites, Antineoplastic; Azacitidine; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cisplatin; Decitabine; DNA Methylation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Humans; Lung Neoplasms; MutL Protein Homolog 1; Nuclear Proteins; Promoter Regions, Genetic; RNA, Messenger | 2011 |
Identification of methylation profile of HOX genes in extrahepatic cholangiocarcinoma.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Bile Duct Neoplasms; Biomarkers, Tumor; Cholangiocarcinoma; Decitabine; DNA Methylation; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Genes, Homeobox; Humans; Microarray Analysis | 2011 |
5-aza-2'-deoxycytidine enhances susceptibility of renal cell carcinoma to paclitaxel by decreasing LEF1/phospho-β-catenin expression.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; beta Catenin; Blotting, Western; Carcinoma, Renal Cell; Decitabine; Drug Synergism; Humans; Immunohistochemistry; Kidney Neoplasms; Lymphoid Enhancer-Binding Factor 1; Mice; Paclitaxel; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Transfection; Xenograft Model Antitumor Assays | 2011 |
Expression and immunotherapeutic targeting of the SSX family of cancer-testis antigens in prostate cancer.
Topics: Adenocarcinoma; Amino Acid Sequence; Animals; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Azacitidine; Cancer Vaccines; Cell Line, Tumor; Decitabine; Epitopes; Female; Gene Expression Regulation, Neoplastic; HLA-A2 Antigen; HLA-DR1 Antigen; Humans; Immunotherapy; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Molecular Sequence Data; Molecular Targeted Therapy; Multigene Family; Neoplasm Metastasis; Neoplasm Proteins; Prostatic Neoplasms; Repressor Proteins; Sequence Alignment; Sequence Homology, Amino Acid; T-Cell Antigen Receptor Specificity | 2011 |
Modulation of protein expression levels and DNA methylation status of breast cancer metastasis genes by anthracycline-based chemotherapy and the demethylating agent decitabine.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Breast Neoplasms; Cell Line, Tumor; Decitabine; DNA Methylation; Female; Gene Expression Regulation, Neoplastic; Humans; Neoplasm Invasiveness; Plasminogen Activator Inhibitor 1; Urokinase-Type Plasminogen Activator | 2011 |
Cancer-testis antigen expression and its epigenetic modulation in acute myeloid leukemia.
Topics: Aged; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Azacitidine; Biomarkers; Bone Marrow Cells; Case-Control Studies; Cell Line, Tumor; Decitabine; DNA Methylation; Epigenomics; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Immunotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Proteins; Repressor Proteins; Reverse Transcriptase Polymerase Chain Reaction; Up-Regulation | 2011 |
Frequent epigenetic inactivation of the chaperone SGNE1/7B2 in human gliomas.
Topics: 5' Untranslated Regions; Apoptosis; Astrocytoma; Azacitidine; Base Sequence; Brain Neoplasms; Cell Line, Tumor; CpG Islands; Decitabine; DNA Methylation; Epigenesis, Genetic; Exons; Gene Expression Regulation, Neoplastic; Humans; Neuroendocrine Secretory Protein 7B2; Promoter Regions, Genetic; Sequence Analysis, DNA; Transcription, Genetic | 2012 |
5-aza-2'-deoxycytidine activates iron uptake and heme biosynthesis by increasing c-Myc nuclear localization and binding to the E-boxes of transferrin receptor 1 (TfR1) and ferrochelatase (Fech) genes.
Topics: Active Transport, Cell Nucleus; Animals; Azacitidine; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Cell Line, Tumor; Cell Nucleus; CpG Islands; Decitabine; Enzyme Inhibitors; Erythroid Cells; Ferrochelatase; Heme; Humans; Iron; Mice; Proto-Oncogene Proteins c-myc; Receptors, Transferrin; Response Elements | 2011 |
Improving T-cell therapy for relapsed EBV-negative Hodgkin lymphoma by targeting upregulated MAGE-A4.
Topics: Antigens, Neoplasm; Antimetabolites, Antineoplastic; Azacitidine; Cell Line, Tumor; Decitabine; Epigenesis, Genetic; Epitopes; Feasibility Studies; Herpesvirus 4, Human; Hodgkin Disease; Humans; Immunotherapy, Adoptive; Molecular Targeted Therapy; Neoplasm Proteins; Recurrence; T-Lymphocytes; Up-Regulation | 2011 |
Successful allogeneic stem-cell transplantation in a patient with myelodysplastic syndrome with hemodialysis-dependent end-stage renal disease.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Diabetic Nephropathies; Humans; Kidney Failure, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Renal Dialysis; Risk; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous | 2011 |
Clonal cytogenetic abnormalities after tyrosine kinase inhibitor therapy in Ph+ ALL resolution after decitabine therapy.
Topics: Azacitidine; Benzamides; Child, Preschool; Chromosome Aberrations; Decitabine; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm, Residual; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Stem Cell Transplantation | 2012 |
HSPB8 is methylated in hematopoietic malignancies and overexpression of HSPB8 exhibits antileukemia effect.
Topics: Azacitidine; Decitabine; DNA Methylation; Gene Expression Regulation, Neoplastic; Heat-Shock Proteins; Hematologic Neoplasms; HL-60 Cells; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphoma; Molecular Chaperones; Protein Serine-Threonine Kinases; Tumor Cells, Cultured | 2012 |
Reversal of epigenetic silencing of AP-2alpha results in increased zinc uptake in DU-145 and LNCaP prostate cancer cells.
Topics: Azacitidine; Base Sequence; Cation Transport Proteins; Cell Line, Tumor; Chromatin Immunoprecipitation; Decitabine; DNA Methylation; DNA Primers; Epigenesis, Genetic; Gene Silencing; Humans; Male; Promoter Regions, Genetic; Prostatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Transcription Factor AP-2; Transcription, Genetic; Zinc | 2011 |
Generation of reactive oxygen species during apoptosis induced by DNA-damaging agents and/or histone deacetylase inhibitors.
Topics: Antineoplastic Agents; Apoptosis; Azacitidine; Butyrates; Caspase 3; Cell Line, Tumor; Cytostatic Agents; Dactinomycin; Decitabine; DNA Damage; Drug Synergism; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Poly(ADP-ribose) Polymerases; Reactive Oxygen Species; Vorinostat | 2011 |
Epigenetic regulation of miR-34b and miR-129 expression in gastric cancer.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cell Line, Tumor; CpG Islands; Decitabine; DNA Methylation; DNA, Neoplasm; Down-Regulation; Epigenomics; Gene Expression Regulation, Neoplastic; Gene Silencing; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; MicroRNAs; Polymerase Chain Reaction; RNA, Neoplasm; Stomach Neoplasms | 2011 |
Down-regulation of CXCL12 by DNA hypermethylation and its involvement in gastric cancer metastatic progression.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cell Line, Transformed; Cell Line, Tumor; Chemokine CXCL12; Decitabine; Disease Progression; DNA Methylation; Down-Regulation; Female; Gene Expression Regulation, Neoplastic; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Grading; Receptors, CXCR; Receptors, CXCR4; Stomach Neoplasms | 2012 |
Histone H4 deacetylation down-regulates catalase gene expression in doxorubicin-resistant AML subline.
Topics: Acetylation; Azacitidine; Catalase; Cell Line, Tumor; Decitabine; DNA Modification Methylases; Down-Regulation; Doxorubicin; Drug Resistance; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Protein Modification, Translational | 2012 |
Epigenetic inactivation of the MIR34B/C in multiple myeloma.
Topics: Azacitidine; Base Sequence; Decitabine; Disease Progression; DNA Methylation; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; MicroRNAs; Molecular Sequence Data; Multiple Myeloma; Primary Cell Culture; Recurrence; Tumor Cells, Cultured | 2011 |
Transcription of nephrin-Neph3 gene pair is synergistically activated by WT1 and NF-κB and silenced by DNA methylation.
Topics: Azacitidine; Cells, Cultured; Decitabine; DNA Methylation; Humans; Immunoglobulins; In Vitro Techniques; Kidney; Membrane Proteins; NF-kappa B; Nitriles; Podocytes; RNA Interference; RNA, Messenger; Sulfones; Transcription, Genetic; Tumor Necrosis Factor-alpha; WT1 Proteins | 2012 |
GSTP1 DNA methylation and expression status is indicative of 5-aza-2'-deoxycytidine efficacy in human prostate cancer cells.
Topics: Azacitidine; Biomarkers, Tumor; Cell Death; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cytidine; Decitabine; DNA Methylation; Dose-Response Relationship, Drug; Drug Discovery; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Gene Silencing; Glutathione S-Transferase pi; Humans; Male; Promoter Regions, Genetic; Prostate-Specific Antigen; Prostatic Neoplasms; Time Factors | 2011 |
Reactive oxygen species downregulate catalase expression via methylation of a CpG island in the Oct-1 promoter.
Topics: Acetylcysteine; Azacitidine; Carcinoma, Hepatocellular; Catalase; Cell Line, Tumor; CpG Islands; Decitabine; DNA Methylation; Down-Regulation; Enzyme Activation; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Neoplasm Invasiveness; Octamer Transcription Factor-1; Promoter Regions, Genetic; Reactive Oxygen Species | 2011 |
The seminoma cell line TCam-2 is sensitive to HDAC inhibitor depsipeptide but tolerates various other chemotherapeutic drugs and loss of NANOG expression.
Topics: Apoptosis; Azacitidine; Cell Differentiation; Cell Line, Tumor; Decitabine; Depsipeptides; Down-Regulation; Drug Resistance, Neoplasm; Endoderm; Gene Knockdown Techniques; Histone Deacetylase Inhibitors; Histone Deacetylases; Homeodomain Proteins; Humans; Male; Nanog Homeobox Protein; Octamer Transcription Factor-3; Seminoma; SOXF Transcription Factors; Testicular Neoplasms; Transcription Factor AP-2; Tranylcypromine; Tretinoin; Up-Regulation | 2011 |
A cost-effectiveness analysis of using azacitidine vs. decitabine in treating patients with myelodysplastic syndromes.
Topics: Aged; Azacitidine; Cost-Benefit Analysis; Decitabine; Enzyme Inhibitors; Female; Humans; Male; Myelodysplastic Syndromes; Outcome Assessment, Health Care; United States | 2012 |
CIITA is silenced by epigenetic mechanisms that prevent the recruitment of transactivating factors in rhabdomyosarcoma cells.
Topics: Acetylation; Azacitidine; Cell Line, Tumor; Chromatin Immunoprecipitation; Decitabine; Epigenesis, Genetic; Flow Cytometry; Gene Expression Profiling; Gene Silencing; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Interferon-gamma; Nuclear Proteins; Promoter Regions, Genetic; Rhabdomyosarcoma; Signal Transduction; Trans-Activators | 2012 |
5-Aza-2'-deoxycytidine reactivates gene expression via degradation of pRb pocket proteins.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cell Line, Tumor; Colonic Neoplasms; Decitabine; DNA Methylation; Gene Expression Regulation, Neoplastic; Gene Silencing; Histones; Humans; Lung Neoplasms; Osteosarcoma; Phosphorylation; Protein Phosphatase 2; Proto-Oncogene Proteins c-mdm2; Retinoblastoma Protein; Retinoblastoma-Like Protein p107; Retinoblastoma-Like Protein p130 | 2012 |
Effect of 5-Aza-2'-deoxycytidine on SLC22A18 in glioma U251 cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Cell Cycle Checkpoints; Cell Line, Tumor; Decitabine; DNA Methylation; G1 Phase; Glioma; Humans; Organic Cation Transport Proteins; RNA, Messenger; S Phase | 2012 |
Amyloid protein-mediated differential DNA methylation status regulates gene expression in Alzheimer's disease model cell line.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Azacitidine; Cell Line, Tumor; CpG Islands; Decitabine; Discoidin Domain Receptors; DNA Methylation; Epigenesis, Genetic; Gene Expression Regulation; Humans; Mutation; Nuclear Cap-Binding Protein Complex; Promoter Regions, Genetic; Receptor Protein-Tyrosine Kinases; Receptors, Mitogen | 2011 |
Heparanase expression is associated with histone modifications in glioblastoma.
Topics: Azacitidine; Base Sequence; Cell Line, Tumor; CpG Islands; Decitabine; DNA Modification Methylases; Epigenesis, Genetic; Gene Expression; Gene Expression Regulation, Neoplastic; Glioblastoma; Glucuronidase; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Molecular Sequence Data; NF-kappa B p50 Subunit; Promoter Regions, Genetic; Protein Processing, Post-Translational; Transcription Factor RelA | 2012 |
Wnt inhibitory factor 1 induces apoptosis and inhibits cervical cancer growth, invasion and angiogenesis in vivo.
Topics: Adaptor Proteins, Signal Transducing; Animals; Apoptosis; Azacitidine; beta Catenin; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cervix Uteri; Decitabine; DNA Methylation; Down-Regulation; Epigenesis, Genetic; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Immunoenzyme Techniques; Mice; Mice, Nude; Neoplasm Invasiveness; Neovascularization, Pathologic; Promoter Regions, Genetic; Real-Time Polymerase Chain Reaction; Repressor Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Uterine Cervical Neoplasms; Wnt Proteins | 2012 |
Decitabine, independent of apoptosis, exerts its cytotoxic effects on cell growth in melanoma cells.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Cell Differentiation; Cell Division; Cell Proliferation; Decitabine; DNA Methylation; Dose-Response Relationship, Drug; G2 Phase; Melanoma; Mice; Tumor Cells, Cultured | 2011 |
Epigenetic regulation of glucose transporter 4 by estrogen receptor β.
Topics: Adipocytes; Animals; Azacitidine; Cell Nucleus; Cells, Cultured; CpG Islands; Decitabine; DNA Methylation; DNA Modification Methylases; Epigenesis, Genetic; Estrogen Receptor alpha; Estrogen Receptor beta; Gene Knockout Techniques; Glucose Transporter Type 4; Liver X Receptors; Mice; Orphan Nuclear Receptors; Promoter Regions, Genetic; Protein Binding; Protein Isoforms; Sp1 Transcription Factor; Transcription, Genetic | 2011 |
[Silence mechanism of WT1 gene in leukemic cell line U937].
Topics: Azacitidine; Decitabine; DNA Methylation; Gene Silencing; Histones; HL-60 Cells; Humans; Hydroxamic Acids; K562 Cells; Promoter Regions, Genetic; U937 Cells; WT1 Proteins | 2011 |
Epigenetic silencing of the tumor suppressor klotho in human breast cancer.
Topics: Acetylation; Azacitidine; Base Sequence; Breast; Breast Neoplasms; Cell Line, Tumor; CpG Islands; Decitabine; DNA Methylation; Female; Gene Silencing; Glucuronidase; Histones; Humans; Klotho Proteins; Promoter Regions, Genetic; Tumor Suppressor Proteins | 2012 |
MicroRNA-34b functions as a potential tumor suppressor in endometrial serous adenocarcinoma.
Topics: Adenocarcinoma; Apoptosis; Azacitidine; Cell Cycle; Cell Division; Cell Line, Tumor; Decitabine; DNA Methylation; Endometrial Neoplasms; Female; Genes, Tumor Suppressor; Humans; Immunohistochemistry; MicroRNAs; Neoplasm Invasiveness; Neoplasm Metastasis; Oligonucleotide Array Sequence Analysis; Promoter Regions, Genetic; Proto-Oncogene Mas; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction | 2012 |
Identification of the A kinase anchor protein 12 (AKAP12) gene as a candidate tumor suppressor of hepatocellular carcinoma.
Topics: A Kinase Anchor Proteins; Adult; Aged; Apoptosis; Azacitidine; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Decitabine; DNA Methylation; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Humans; Immunoenzyme Techniques; Liver Neoplasms; Male; Middle Aged; Oligonucleotide Array Sequence Analysis; Polymorphism, Single Nucleotide; Prognosis; Promoter Regions, Genetic; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate | 2012 |
MicroRNA regulation via DNA methylation during the morula to blastocyst transition in mice.
Topics: Animals; Azacitidine; Decitabine; DNA Methylation; DNA Modification Methylases; Embryo, Mammalian; Embryonic Development; Enzyme Inhibitors; Epigenesis, Genetic; Gene Expression Regulation, Developmental; Mice; MicroRNAs | 2012 |
MeCP2 controls the expression of RASAL1 in the hepatic fibrosis in rats.
Topics: Animals; Azacitidine; Cell Proliferation; Decitabine; DNA Methylation; Gene Knockdown Techniques; Hepatic Stellate Cells; Liver Cirrhosis; Male; Methyl-CpG-Binding Protein 2; Myofibroblasts; ras GTPase-Activating Proteins; Rats; Rats, Sprague-Dawley; RNA, Messenger; RNA, Small Interfering | 2011 |
Decitabine immunosensitizes human gliomas to NY-ESO-1 specific T lymphocyte targeting through the Fas/Fas ligand pathway.
Topics: Antigens, Neoplasm; Azacitidine; Brain Neoplasms; Cell Death; Cell Line, Tumor; Coculture Techniques; Cytokines; Decitabine; Fas Ligand Protein; fas Receptor; Glioma; Histocompatibility Antigens Class I; Humans; Membrane Proteins; Molecular Targeted Therapy; Retroviridae; Signal Transduction; T-Lymphocytes; Transduction, Genetic; Up-Regulation | 2011 |
MAGE: the spell is broken.
Topics: Antigens, Neoplasm; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Hodgkin Disease; Humans; Immunotherapy, Adoptive; Neoplasm Proteins; T-Lymphocytes | 2011 |
Aberrant methylation of the 3q25 tumor suppressor gene PTX3 in human esophageal squamous cell carcinoma.
Topics: Antimetabolites, Antineoplastic; Azacitidine; C-Reactive Protein; Carcinoma, Squamous Cell; Cell Line, Tumor; Chromosomes, Human, Pair 3; Decitabine; DNA Methylation; Down-Regulation; Esophageal Neoplasms; Gene Expression Regulation, Neoplastic; Humans; Promoter Regions, Genetic; Serum Amyloid P-Component | 2011 |
Integrated epigenetics of human breast cancer: synoptic investigation of targeted genes, microRNAs and proteins upon demethylation treatment.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Biomarkers, Tumor; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Decitabine; DNA Methylation; Electrophoresis, Gel, Two-Dimensional; Epigenesis, Genetic; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; MicroRNAs; Oligonucleotide Array Sequence Analysis; Promoter Regions, Genetic; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2011 |
Durable complete remission after single agent decitabine in AML relapsing in extramedullary sites after allo-SCT.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Humans; Leukemia, Myeloid, Acute; Leukemic Infiltration; Male; Middle Aged; Recurrence; Remission Induction; Stem Cell Transplantation; Transplantation, Homologous | 2012 |
CRABP-II- and FABP5-independent all-trans retinoic acid resistance in COLO 16 human cutaneous squamous cancer cells.
Topics: Antineoplastic Agents; Azacitidine; Carcinoma, Squamous Cell; Cell Line, Tumor; Cytochrome P-450 Enzyme System; Decitabine; DNA Methylation; Drug Resistance, Neoplasm; Fatty Acid-Binding Proteins; Humans; PPAR delta; Receptors, Retinoic Acid; Retinoic Acid 4-Hydroxylase; Skin Neoplasms; Tretinoin | 2012 |
DNA demethylation by 5-aza-2-deoxycytidine treatment abrogates 17 beta-estradiol-induced cell growth and restores expression of DNA repair genes in human breast cancer cells.
Topics: Apoptosis; Azacitidine; Breast Neoplasms; Cell Cycle; Cell Growth Processes; Decitabine; DNA Methylation; DNA Mismatch Repair; DNA Repair; Drug Interactions; Epigenesis, Genetic; Estradiol; Female; Gene Expression Regulation, Neoplastic; Humans; Promoter Regions, Genetic | 2012 |
5-AZA-2'-deoxycytidine induced demethylation influences N-glycosylation of secreted glycoproteins in ovarian cancer.
Topics: Azacitidine; Carcinoma, Ovarian Epithelial; Decitabine; Female; Glycoproteins; Glycosylation; Glycosyltransferases; Humans; Methylation; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Polysaccharides | 2011 |
The effect of epigenetic factors on differentiation of pancreatic progenitor cells into insulin-producing cells.
Topics: Azacitidine; Azepines; C-Peptide; Cell Culture Techniques; Cell Differentiation; Decitabine; Epigenesis, Genetic; Humans; Hydroxamic Acids; Immunohistochemistry; Insulin-Secreting Cells; Islets of Langerhans; Keratin-19; Models, Biological; Models, Genetic; Pancreas; Pyrroles; Quinazolines; Stem Cells; Transcription Factors | 2011 |
Neonatal exposure to estradiol/bisphenol A alters promoter methylation and expression of Nsbp1 and Hpcal1 genes and transcriptional programs of Dnmt3a/b and Mbd2/4 in the rat prostate gland throughout life.
Topics: Animals; Animals, Newborn; Azacitidine; Base Sequence; Benzhydryl Compounds; Calcium-Binding Proteins; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Methyltransferase 3A; DNA Methyltransferase 3B; DNA Primers; DNA-Binding Proteins; Estradiol; Gene Expression; HMGN Proteins; Male; Nerve Tissue Proteins; Phenols; Promoter Regions, Genetic; Prostate; Rats; Rats, Sprague-Dawley; RNA, Small Interfering | 2012 |
Analysis of aberrant methylation in DNA repair genes during malignant transformation of human bronchial epithelial cells induced by cadmium.
Topics: Animals; Azacitidine; Blotting, Western; Bronchi; Cadmium Chloride; Carcinogens; Cell Line, Transformed; Cell Proliferation; Cell Transformation, Neoplastic; Chromatography, High Pressure Liquid; Decitabine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Enzyme Inhibitors; Epithelial Cells; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Nude; Promoter Regions, Genetic; Real-Time Polymerase Chain Reaction; Time Factors | 2012 |
DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methyltransferase 3A; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation | 2012 |
Progression of prostate carcinogenesis and dietary methyl donors: temporal dependence.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Cell Transformation, Neoplastic; Choline; Decitabine; Diet; Disease Progression; DNA Methylation; Folic Acid; Homocysteine; Humans; Male; Methionine; Mice; Mice, Nude; Prostatic Neoplasms; Tumor Cells, Cultured; Vitamin B 6 | 2012 |
Evidence of epigenetic regulation of the tumor suppressor gene cluster flanking RASSF1 in breast cancer cell lines.
Topics: Acetylation; Azacitidine; Breast Neoplasms; Cell Line; Cell Line, Tumor; Chromosomes, Human, Pair 3; Decitabine; Epigenesis, Genetic; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Genes, Tumor Suppressor; Histones; Humans; Hydroxamic Acids; Lysine; Multigene Family; Promoter Regions, Genetic; Tumor Suppressor Proteins | 2011 |
Downregulation of MUC1 expression and its recognition by CD8⁺ T cells on the surface of malignant pleural mesothelioma cells treated with HDACi.
Topics: Antigens, Neoplasm; Azacitidine; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Decitabine; Down-Regulation; Drug Therapy, Combination; Flow Cytometry; Histone Deacetylase Inhibitors; Humans; Kinetics; Membrane Proteins; Mesothelioma; Mucin-1; Real-Time Polymerase Chain Reaction; RNA; Statistics, Nonparametric; Valproic Acid | 2012 |
Cross-talk between DNA methylation and active histone modifications regulates aberrant expression of ZAP70 in CLL.
Topics: Azacitidine; B-Lymphocytes; Blotting, Western; Cell Line; Chromatin; Chromatin Immunoprecipitation; Decitabine; DNA Methylation; Epigenesis, Genetic; Gene Expression Regulation, Leukemic; Gene Silencing; Histone Deacetylase Inhibitors; Histones; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes, Mononuclear; Promoter Regions, Genetic; Signal Transduction; Transcription Initiation Site; ZAP-70 Protein-Tyrosine Kinase | 2012 |
Effects of tetrahydrouridine on pharmacokinetics and pharmacodynamics of oral decitabine.
Topics: Administration, Oral; Animals; Antimetabolites; Antimetabolites, Antineoplastic; Area Under Curve; Azacitidine; Biological Availability; Decitabine; DNA Damage; DNA Methylation; Drug Interactions; Female; Hematopoietic Stem Cells; Inactivation, Metabolic; Injections, Intravenous; Injections, Subcutaneous; Mice; Papio anubis; Tetrahydrouridine | 2012 |
Hypermethylation of Sox17 gene is useful as a molecular diagnostic application in early gastric cancer.
Topics: Aged; Azacitidine; Biomarkers, Tumor; Cell Line, Tumor; CpG Islands; Decitabine; Disease Progression; DNA Methylation; Early Detection of Cancer; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Risk; SOXF Transcription Factors; Stomach Neoplasms | 2012 |
DNA methylation of the 5'-untranslated region at +298 and +351 represses BACE1 expression in mouse BV-2 microglial cells.
Topics: 5' Untranslated Regions; Amyloid Precursor Protein Secretases; Animals; Aspartic Acid Endopeptidases; Azacitidine; Cell Line; CpG Islands; Decitabine; DNA Methylation; DNA Modification Methylases; Gene Expression; Gene Expression Regulation; Genes, Reporter; HEK293 Cells; Humans; Mice; Microglia | 2012 |
[Effect of 5-Aza-CdR on biological activity and inhibitor of DNA binding 4 gene expression in human erythroleukemia cell line K562].
Topics: Apoptosis; Azacitidine; Cell Cycle; Cell Proliferation; Decitabine; DNA Methylation; Gene Expression; Humans; Inhibitor of Differentiation Proteins; K562 Cells | 2011 |
Epigenetic modulation of the HeLa cell membrane N-glycome.
Topics: Antineoplastic Agents; Azacitidine; Butyrates; Carbohydrate Sequence; Cytidine; Decitabine; DNA Methylation; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Glycomics; HeLa Cells; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Molecular Sequence Data; Polysaccharides | 2012 |
DNA methylation of the CYP1A1 enhancer is associated with smoking-induced genetic alterations in human lung.
Topics: Aged; Azacitidine; Cell Line; Cytochrome P-450 CYP1A1; Decitabine; DNA Methylation; Enhancer Elements, Genetic; Female; Gene Expression Regulation, Neoplastic; Humans; Lung; Lung Neoplasms; Male; Middle Aged; RNA, Messenger; Smoking | 2012 |
[Treatment of two chronic myelomonocytic leukemia patients with Decitabine].
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Female; Humans; Leukemia, Myelomonocytic, Chronic | 2011 |
Proteomic analysis identifies differentially expressed proteins in AML1/ETO acute myeloid leukemia cells treated with DNMT inhibitors azacitidine and decitabine.
Topics: Azacitidine; Core Binding Factor Alpha 2 Subunit; Decitabine; DNA Modification Methylases; Enzyme Inhibitors; Humans; Leukemia, Myeloid, Acute; Oncogene Proteins, Fusion; Proteomics; RUNX1 Translocation Partner 1 Protein | 2012 |
Suppression of Klotho expression by protein-bound uremic toxins is associated with increased DNA methyltransferase expression and DNA hypermethylation.
Topics: Animals; Azacitidine; Cell Line; CpG Islands; Cresols; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Gene Expression; Glucuronidase; Humans; Indican; Kidney; Klotho Proteins; Mice; Protein Binding; Sulfuric Acid Esters; Toxins, Biological; Uremia | 2012 |
Deletion or epigenetic silencing of AJAP1 on 1p36 in glioblastoma.
Topics: Azacitidine; Brain Neoplasms; Cell Adhesion Molecules; Cell Movement; Cell Proliferation; Decitabine; DNA Methylation; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; RNA, Small Interfering | 2012 |
A DNA methylation signature associated with aberrant promoter DNA hypermethylation of DNMT3B in human colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Azacitidine; Colorectal Neoplasms; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Methyltransferase 3B; Down-Regulation; Enzyme Inhibitors; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Gene Knockout Techniques; HCT116 Cells; HT29 Cells; Humans; Male; Middle Aged; Promoter Regions, Genetic; Transfection | 2012 |
Change in gene expression profiles of secreted frizzled-related proteins (SFRPs) by sodium butyrate in gastric cancers: induction of promoter demethylation and histone modification causing inhibition of Wnt signaling.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Azacitidine; beta Catenin; Butyrates; Cell Line, Tumor; Cell Proliferation; Decitabine; DNA Methylation; DNA Modification Methylases; Down-Regulation; Epigenesis, Genetic; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genes, Reporter; Histone Deacetylase Inhibitors; Histones; Humans; Intercellular Signaling Peptides and Proteins; Male; Membrane Proteins; Middle Aged; Promoter Regions, Genetic; Stomach Neoplasms; Transfection; Wnt Signaling Pathway | 2012 |
Demethylation restores SN38 sensitivity in cells with acquired resistance to SN38 derived from human cervical squamous cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis Regulatory Proteins; Azacitidine; Calcium-Calmodulin-Dependent Protein Kinases; Camptothecin; Carcinoma, Squamous Cell; Cell Line, Tumor; Cisplatin; Dealkylation; Death-Associated Protein Kinases; Decitabine; DNA Modification Methylases; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Promoter Regions, Genetic; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Transcription, Genetic; Uterine Cervical Neoplasms | 2012 |
SFRP1 promoter methylation and expression in human trabecular meshwork cells.
Topics: Aged; Aged, 80 and over; Azacitidine; Cells, Cultured; Decitabine; DNA Methylation; DNA Modification Methylases; DNA Primers; Enzyme Inhibitors; Female; Gene Expression Regulation; Glaucoma, Open-Angle; Humans; Intercellular Signaling Peptides and Proteins; Male; Membrane Proteins; Middle Aged; Promoter Regions, Genetic; Real-Time Polymerase Chain Reaction; Trabecular Meshwork | 2012 |
Epigenetic regulation of Delta-Like1 controls Notch1 activation in gastric cancer.
Topics: Animals; Azacitidine; Basic Helix-Loop-Helix Transcription Factors; Calcium-Binding Proteins; Cell Differentiation; Cell Line, Tumor; Decitabine; DNA Methylation; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Helicobacter Infections; Helicobacter pylori; Homeodomain Proteins; Humans; Intercellular Signaling Peptides and Proteins; Jagged-1 Protein; Membrane Proteins; Mice; Promoter Regions, Genetic; Receptor, Notch1; Serrate-Jagged Proteins; Signal Transduction; Stomach Neoplasms; Transcription Factor HES-1 | 2011 |
Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Azacitidine; Cell Line, Tumor; Cisplatin; Collagen Type I; Collagen Type I, alpha 1 Chain; CpG Islands; Decitabine; DNA Methylation; Drug Resistance, Neoplasm; Epigenomics; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Hydroxamic Acids; Midkine; MutL Protein Homolog 1; Nerve Growth Factors; Nuclear Proteins; Oligonucleotide Array Sequence Analysis; Ovarian Neoplasms; Proteins; Reverse Transcriptase Polymerase Chain Reaction; Sulfonamides | 2012 |
Discovery of drugs that possess activity against feline leukemia virus.
Topics: Adenine; Animals; Antiviral Agents; Azacitidine; Cat Diseases; Cats; Decitabine; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Leukemia Virus, Feline; Leukemia, Feline; Organophosphonates; Pyrrolidinones; Raltegravir Potassium; Retroviridae Infections; Tenofovir; Tumor Virus Infections | 2012 |
Regulation of opioid and cannabinoid receptor genes in human neuroblastoma and T cells by the epigenetic modifiers trichostatin A and 5-aza-2'-deoxycytidine.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cell Line, Tumor; Decitabine; Epigenesis, Genetic; Humans; Hydroxamic Acids; Jurkat Cells; Neuroblastoma; Real-Time Polymerase Chain Reaction; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Receptors, Opioid, mu; T-Lymphocytes | 2012 |
Rap1GAP regulates renal cell carcinoma invasion.
Topics: Azacitidine; Cadherins; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Movement; Decitabine; DNA Methylation; Gene Expression Regulation, Neoplastic; GTPase-Activating Proteins; Humans; Integrins; Kidney Neoplasms; Neoplasm Invasiveness; Promoter Regions, Genetic; RNA, Small Interfering; Transfection | 2012 |
Activity of a novel combined antiretroviral therapy of gemcitabine and decitabine in a mouse model for HIV-1.
Topics: Animals; Anti-HIV Agents; Azacitidine; Body Weight; Cells, Cultured; Chemical and Drug Induced Liver Injury; Decitabine; Deoxycytidine; Drug Combinations; Drug Synergism; Female; Flow Cytometry; Gemcitabine; HIV-1; Humans; Liver; Lymph Nodes; Mice; Mice, Inbred C57BL; Murine Acquired Immunodeficiency Syndrome; Proviruses; Spleen; T-Lymphocytes; Transfection | 2012 |
Protocadherin8 is a functional tumor suppressor frequently inactivated by promoter methylation in nasopharyngeal carcinoma.
Topics: Apoptosis; Azacitidine; Cadherins; Cell Adhesion; Cell Movement; Cell Proliferation; Decitabine; DNA Methylation; Female; Gene Expression Regulation, Neoplastic; Humans; Hydroxamic Acids; Male; Middle Aged; Nasopharyngeal Neoplasms; Prognosis; Promoter Regions, Genetic; Protocadherins; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured; Tumor Suppressor Proteins; Wound Healing | 2012 |
DNA methylation of TH1/TH2 cytokine genes affects sensitization and progress of experimental asthma.
Topics: Animals; Asthma; Azacitidine; CD4-Positive T-Lymphocytes; Cytokines; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Epigenesis, Genetic; Female; Interferon-gamma; Mice; Mice, Inbred BALB C; Mice, SCID; Promoter Regions, Genetic; Th1 Cells; Th2 Cells | 2012 |
5-Aza-2'-deoxycytidine increases the sensitivity of human bone marrow mesenchymal stem cells to chemotherapeutic agents by demethylation of p73.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Blotting, Western; Cell Differentiation; Cell Survival; Cells, Cultured; Decitabine; DNA Methylation; DNA-Binding Proteins; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Immunophenotyping; Mesenchymal Stem Cells; Nuclear Proteins; Reverse Transcriptase Polymerase Chain Reaction; Tumor Protein p73; Tumor Suppressor Proteins | 2012 |
DNA demethylation increases sensitivity of neuroblastoma cells to chemotherapeutic drugs.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Azacitidine; Cell Culture Techniques; Cell Line, Tumor; Cell Survival; Decitabine; DNA Methylation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Epigenesis, Genetic; Humans; Neuroblastoma; Reverse Transcriptase Polymerase Chain Reaction | 2012 |
Genome-wide miRNA expression profiling identifies miR-9-3 and miR-193a as targets for DNA methylation in non-small cell lung cancers.
Topics: Antineoplastic Agents; Azacitidine; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Decitabine; DNA Methylation; Female; Gene Expression Profiling; Gene Silencing; Humans; Hydroxamic Acids; Lung; Lung Neoplasms; Male; MicroRNAs; Middle Aged; Molecular Targeted Therapy; Oligonucleotide Array Sequence Analysis | 2012 |
Epigenetic screen of human DNA repair genes identifies aberrant promoter methylation of NEIL1 in head and neck squamous cell carcinoma.
Topics: Aged; Azacitidine; Carcinoma, Squamous Cell; Cell Line, Tumor; CpG Islands; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Glycosylases; DNA Methylation; DNA Repair; Epigenesis, Genetic; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Head and Neck Neoplasms; Humans; Keratinocytes; Male; Middle Aged; Promoter Regions, Genetic; Reference Values; Squamous Cell Carcinoma of Head and Neck | 2012 |
Influence of epigenetic modifications of the interleukin-10 promoter on IL10 gene expression.
Topics: Acetylation; Adenine; Azacitidine; B-Lymphocytes; Cell Line; Chromatin; CpG Islands; Decitabine; DNA Methylation; DNA Modification Methylases; Epigenesis, Genetic; Escherichia coli; Gene Expression Regulation; Genotype; Guanine; Histone Deacetylase Inhibitors; Histones; Humans; Interleukin-10; Lipopolysaccharides; Methylation; Polymorphism, Genetic; Promoter Regions, Genetic; RNA, Messenger; Transcription, Genetic | 2012 |
Curcumin causes promoter hypomethylation and increased expression of FANCF gene in SiHa cell line.
Topics: Azacitidine; Base Sequence; Cell Line, Tumor; Cell Survival; Curcumin; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA-Cytosine Methylases; DNA, Complementary; Epigenesis, Genetic; Fanconi Anemia Complementation Group F Protein; Humans; Inhibitory Concentration 50; Promoter Regions, Genetic; Resveratrol; Sequence Analysis, DNA; Stilbenes; Transcription, Genetic | 2012 |
Differential effects of low-dose decitabine on immune effector and suppressor responses in melanoma-bearing mice.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Cell Line, Tumor; Combined Modality Therapy; Cytokines; Decitabine; Dose-Response Relationship, Drug; Female; Humans; Immunotherapy; Interleukin-2; Killer Cells, Natural; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Oligodeoxyribonucleotides; Toll-Like Receptor 9 | 2012 |
Sequence-specific biosensors report drug-induced changes in epigenetic silencing in living cells.
Topics: Azacitidine; Base Sequence; Binding Sites; Blotting, Western; Decitabine; DNA; DNA Methylation; Dose-Response Relationship, Drug; Enzyme Inhibitors; HeLa Cells; Humans; Inteins; Luciferases; Luminescent Measurements; Molecular Sequence Data; Promoter Regions, Genetic; Recombinant Fusion Proteins; Reproducibility of Results; Retroelements; Transfection; Zinc Fingers | 2012 |
Methylation of secreted frizzled related protein gene in acute leukemia patients in China.
Topics: Adaptor Proteins, Signal Transducing; Adolescent; Adult; Aged; Aged, 80 and over; Azacitidine; Cell Line, Tumor; China; CpG Islands; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Methyltransferase 3A; DNA Methyltransferase 3B; Enzyme Inhibitors; Eye Proteins; Female; Frizzled Receptors; Humans; Intercellular Signaling Peptides and Proteins; Jurkat Cells; Leukemia; Male; Membrane Proteins; Middle Aged; Promoter Regions, Genetic; Proto-Oncogene Proteins; RNA, Messenger; Wnt Signaling Pathway; Young Adult | 2011 |
[Mechanism of loss of human esophageal cancer-related gene 4 (ECRG4) gene expression in esophageal squamous cell carcinoma cell line EC9706].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Azacitidine; Carcinoma, Squamous Cell; Cell Line, Tumor; CpG Islands; Decitabine; DNA Methylation; Epigenesis, Genetic; Esophageal Neoplasms; Exons; Gene Expression Regulation, Neoplastic; Humans; Mutation; Neoplasm Proteins; Oxides; Promoter Regions, Genetic; RNA, Messenger; Tumor Suppressor Proteins | 2011 |
Relationship between chromatin structure and sensitivity to molecularly targeted auger electron radiation therapy.
Topics: Analysis of Variance; Azacitidine; Cell Line, Tumor; Chromatin; Decitabine; DNA Damage; Electrons; Epidermal Growth Factor; ErbB Receptors; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Pentetic Acid; Radiation Tolerance; Radiopharmaceuticals; Radiotherapy; Sodium Chloride; Vorinostat | 2012 |
[The clinical research of treatment by decitabine moderate or high-risk myelodysplastic syndrome patients].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes | 2011 |
DNMT inhibitors and HDAC inhibitors regulate E-cadherin and Bcl-2 expression in endometrial carcinoma in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Azacitidine; Cadherins; Carcinoma; Cell Cycle Checkpoints; Cell Line, Tumor; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Endometrial Neoplasms; Enzyme Inhibitors; Female; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Humans; Mice; Mice, Nude; Promoter Regions, Genetic; Proto-Oncogene Proteins c-bcl-2; Transplantation, Heterologous; Valproic Acid | 2012 |
5-aza-2'-deoxycytidine-induced genome rearrangements are mediated by DNMT1.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Cell Proliferation; Cells, Cultured; Cytidine Deaminase; Decitabine; DNA; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Damage; DNA Methylation; DNA Repair; Down-Regulation; Fibroblasts; Gene Rearrangement; Histones; Mice; Mice, Transgenic; Mutagenesis; Mutation | 2012 |
Methylation characteristics and developmental potential of Guangxi Bama minipig (Sus scrofa domestica) cloned embryos from donor cells treated with trichostatin A and 5-aza-2'-deoxycytidine.
Topics: Animals; Azacitidine; Blastocyst; Cell Cycle; Cells, Cultured; Cloning, Organism; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Embryo Culture Techniques; Embryonic Development; Enzyme Inhibitors; Fibroblasts; Flow Cytometry; Gene Expression Regulation, Developmental; Histone Deacetylase 1; Histone Deacetylase Inhibitors; Hydroxamic Acids; Insulin-Like Growth Factor II; Kidney; Nuclear Transfer Techniques; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Swine; Swine, Miniature | 2013 |
Role of human nucleoside transporters in the uptake and cytotoxicity of azacitidine and decitabine.
Topics: Animals; Azacitidine; Carbon Radioisotopes; Decitabine; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Gemcitabine; Humans; Membrane Transport Proteins; Oocytes; Saccharomyces cerevisiae; Tritium; Xenopus | 2012 |
Epigenetic histone modification of Epstein-Barr virus BZLF1 promoter during latency and reactivation in Raji cells.
Topics: Azacitidine; Cell Line; Decitabine; DNA Modification Methylases; DNA-Binding Proteins; Enhancer of Zeste Homolog 2 Protein; Epigenesis, Genetic; Gene Expression Regulation, Viral; Gene Silencing; Herpesvirus 4, Human; Histone Deacetylase Inhibitors; Histone-Lysine N-Methyltransferase; Histones; Humans; Polycomb Repressive Complex 2; Promoter Regions, Genetic; Trans-Activators; Transcription Factors; Virus Latency | 2012 |
Screening of drugs to counteract human papillomavirus 16 E6 repression of E-cadherin expression.
Topics: Antiviral Agents; Azacitidine; Cadherins; Cyclin-Dependent Kinase Inhibitor p21; Decitabine; DNA Methylation; Doxorubicin; HCT116 Cells; Humans; Indoles; Oncogene Proteins, Viral; Repressor Proteins; Tamoxifen | 2012 |
Position effect variegation and epigenetic modification of a transgene in a pig model.
Topics: Animals; Animals, Genetically Modified; Azacitidine; Cell Line; Chromatin Assembly and Disassembly; Chromosomal Position Effects; Cytomegalovirus; Decitabine; DNA Methylation; Enzyme Inhibitors; Genetic Variation; Green Fluorescent Proteins; Histone Deacetylase Inhibitors; Histones; Hydroxamic Acids; Promoter Regions, Genetic; Swine; Transgenes | 2012 |
Decreased expression of retinoblastoma protein-interacting zinc-finger gene 1 in human esophageal squamous cell cancer by DNA methylation.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Base Sequence; Carcinoma, Squamous Cell; Cell Line, Tumor; Decitabine; DNA Methylation; DNA-Binding Proteins; Drug Screening Assays, Antitumor; Esophageal Neoplasms; Gene Expression Regulation, Neoplastic; Gene Silencing; Histone-Lysine N-Methyltransferase; Humans; Molecular Sequence Data; Nuclear Proteins; RNA, Messenger; Transcription Factors | 2012 |
A semantic web framework to integrate cancer omics data with biological knowledge.
Topics: Azacitidine; Database Management Systems; Decitabine; Drug Resistance, Neoplasm; Epigenomics; Gene Expression Profiling; Gene Ontology; Gene Regulatory Networks; Humans; Internet; Melanoma; Semantics; Transcription Factors; Translational Research, Biomedical | 2012 |
Mantle cell lymphoma displays a homogenous methylation profile: a comparative analysis with chronic lymphocytic leukemia.
Topics: Apoptosis Regulatory Proteins; Azacitidine; Cell Division; Cell Line, Tumor; CpG Islands; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA, Neoplasm; Female; Gene Expression Regulation, Leukemic; Gene Expression Regulation, Neoplastic; Genes, Homeobox; Genes, Immunoglobulin; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Immunoglobulin Heavy Chains; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Male; Neoplasm Proteins; Sequence Analysis, DNA; Transcription Factors | 2012 |
Different involvement of DNA methylation and histone deacetylation in the expression of solute-carrier transporters in 4 colon cancer cell lines.
Topics: Azacitidine; Cell Line, Tumor; Colonic Neoplasms; CpG Islands; Decitabine; DNA Methylation; DNA Modification Methylases; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Membrane Transport Proteins; Real-Time Polymerase Chain Reaction; RNA, Messenger | 2012 |
Decitabine triphosphate levels in peripheral blood mononuclear cells from patients receiving prolonged low-dose decitabine administration: a pilot study.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Chromatography, Liquid; Decitabine; Humans; Leukocytes, Mononuclear; Myelodysplastic Syndromes; Pilot Projects; Tandem Mass Spectrometry | 2012 |
Targeted transcriptional activation of silent oct4 pluripotency gene by combining designer TALEs and inhibition of epigenetic modifiers.
Topics: Animals; Azacitidine; Cells, Cultured; Decitabine; DNA Methylation; Embryonic Stem Cells; Enzyme Inhibitors; Epigenesis, Genetic; HEK293 Cells; Humans; Mice; Neural Stem Cells; Octamer Transcription Factor-3; Plasmids; Promoter Regions, Genetic; Trans-Activators; Transcriptional Activation; Valproic Acid | 2012 |
[Decitabine inhibits cell proliferation and induces apoptosis of all-trans retinoid acid-resistant acute promyelocytic leukemia NB4-R2 cell line].
Topics: Apoptosis; Azacitidine; Cell Line, Tumor; Cell Proliferation; Decitabine; Drug Resistance, Neoplasm; Humans; Leukemia, Promyelocytic, Acute; Tretinoin | 2012 |
5-Aza-2'-deoxycytidine induced growth inhibition of leukemia cells through modulating endogenous cholesterol biosynthesis.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cell Line, Tumor; Cell Proliferation; Cholesterol; Decitabine; Dipeptidyl Peptidase 4; DNA Methylation; Epigenesis, Genetic; Farnesyl-Diphosphate Farnesyltransferase; Gene Expression Regulation, Neoplastic; Geranyltranstransferase; HL-60 Cells; Humans; Jurkat Cells; K562 Cells; Mass Spectrometry; Melanoma; Proteomics; RNA, Small Interfering | 2012 |
Methylation of Wnt7a is modulated by DNMT1 and cigarette smoke condensate in non-small cell lung cancer.
Topics: Azacitidine; Carcinoma, Non-Small-Cell Lung; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Epithelial Cells; Lung; Lung Neoplasms; Phenotype; Promoter Regions, Genetic; Smoke; Smoking; Wnt Proteins | 2012 |
A simple method for high-throughput quantification of genome-wide DNA methylation by fluorescence polarization.
Topics: Azacitidine; Bacteriophage lambda; Base Sequence; CpG Islands; Decitabine; Deoxyribonuclease HpaII; DNA Methylation; DNA, Viral; Fluorescence Polarization; Genome, Human; HEK293 Cells; High-Throughput Nucleotide Sequencing; Humans; Receptors, GABA-A; Restriction Mapping; Sensitivity and Specificity | 2012 |
TROP2 is epigenetically inactivated and modulates IGF-1R signalling in lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Animals; Antigens, Neoplasm; Azacitidine; Base Sequence; Cell Adhesion Molecules; Cell Line, Tumor; Decitabine; Disease Models, Animal; Epigenesis, Genetic; Female; Gene Expression; Gene Expression Regulation; Gene Silencing; Histocytochemistry; Humans; Immunohistochemistry; Lung Neoplasms; Male; Mice; Middle Aged; Models, Biological; Molecular Sequence Data; Receptor, IGF Type 1; Signal Transduction | 2012 |
The roles of REIC gene and its encoding product in gastric carcinoma.
Topics: Adaptor Proteins, Signal Transducing; Apoptosis; Azacitidine; beta Catenin; Biomarkers, Tumor; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chemokines; Cyclin D2; Cyclin E; Decitabine; Gastric Mucosa; Humans; Intercellular Signaling Peptides and Proteins; Neoplasm Invasiveness; Proto-Oncogene Proteins c-akt; Pseudopodia; Ribosomal Protein S6 Kinases, 70-kDa; RNA Interference; RNA, Messenger; RNA, Small Interfering; Stomach Neoplasms; TOR Serine-Threonine Kinases; Wiskott-Aldrich Syndrome Protein Family | 2012 |
Identification of methylation-dependent regulatory elements for intergenic miRNAs in human H4 cells.
Topics: Azacitidine; Cell Line, Tumor; Decitabine; DNA Methylation; DNA Modification Methylases; DNA, Intergenic; Gene Expression Regulation; Humans; MicroRNAs; Oligonucleotide Array Sequence Analysis; Regulatory Elements, Transcriptional; Sequence Analysis, DNA | 2012 |
microRNA-155 is downregulated in gastric cancer cells and involved in cell metastasis.
Topics: 3' Untranslated Regions; Azacitidine; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Proliferation; Decitabine; DNA Methylation; Down-Regulation; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; HEK293 Cells; Humans; MicroRNAs; Neoplasm Invasiveness; Neoplasm Metastasis; Smad2 Protein; Stomach Neoplasms | 2012 |
DNMT (DNA methyltransferase) inhibitors radiosensitize human cancer cells by suppressing DNA repair activity.
Topics: Azacitidine; Caspase 3; Catechin; Cell Line, Tumor; Cytidine; Decitabine; Disulfides; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Breaks, Double-Stranded; DNA Methyltransferase 3A; DNA Methyltransferase 3B; DNA Repair; Enzyme Induction; Gene Expression Regulation, Neoplastic; Glioblastoma; Histones; Humans; Hydralazine; Inhibitory Concentration 50; Lung Neoplasms; Neoplasm Proteins; Radiation-Sensitizing Agents; Tumor Stem Cell Assay; Tyrosine | 2012 |
[Effect of methylation inhibitor on EphB4 gene expression, proliferation and apoptosis in CEM cells].
Topics: Apoptosis; Azacitidine; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Decitabine; DNA Methylation; DNA Modification Methylases; Humans; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Receptor, EphB4; RNA, Messenger | 2012 |
Promoter methylation regulates cigarette smoke-stimulated cyclooxygenase-2 expression in esophageal squamous cell carcinoma.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Carcinoma, Squamous Cell; Cell Line, Tumor; Cyclooxygenase 2; Decitabine; DNA Methylation; Esophageal Neoplasms; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Promoter Regions, Genetic; Smoking | 2012 |
5-azacytidine and decitabine exert proapoptotic effects on neoplastic mast cells: role of FAS-demethylation and FAS re-expression, and synergism with FAS-ligand.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Base Sequence; Cell Line, Tumor; CpG Islands; Decitabine; DNA Methylation; DNA, Neoplasm; Drug Synergism; Fas Ligand Protein; fas Receptor; Female; Humans; Leukemia, Mast-Cell; Male; Mast Cells; Mastocytosis, Systemic; Methylation; Middle Aged; Molecular Sequence Data; Neoplasm Proteins; Point Mutation; Promoter Regions, Genetic; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-kit; RNA, Small Interfering | 2012 |
Epigenetic modification of TLRs in leukocytes is associated with increased susceptibility to Salmonella enteritidis in chickens.
Topics: Animals; Avian Proteins; Azacitidine; Bacterial Load; Base Sequence; Chickens; Cytokines; Decitabine; DNA Primers; Epigenesis, Genetic; Genetic Predisposition to Disease; Hydroxamic Acids; Leukocytes; Poultry Diseases; Salmonella enteritidis; Salmonella Infections, Animal; Toll-Like Receptors | 2012 |
Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Bone Marrow Cells; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Transformation, Neoplastic; Decitabine; DNA Damage; DNA Methylation; DNA Modification Methylases; Gene Silencing; Humans; Leukemia; Mice; Molecular Sequence Data; Neoplastic Stem Cells; Promoter Regions, Genetic; Signal Transduction; Tumor Cells, Cultured | 2012 |
Reversin increase the plasticity of bone marrow-derived mesenchymal stem cell for generation of cardiomyocyte in vitro.
Topics: Animals; Antigens, CD34; Azacitidine; Biomarkers; Bone Marrow Cells; Cardiac Myosins; Cell Dedifferentiation; Cell Transdifferentiation; Cells, Cultured; Decitabine; GATA4 Transcription Factor; Male; Mesenchymal Stem Cells; Morpholines; Myocytes, Cardiac; Myosin Light Chains; Proto-Oncogene Proteins c-kit; Purines; Rabbits; Reverse Transcriptase Polymerase Chain Reaction | 2012 |
[Therapeutic effect of in vitro 5-aza-2'-deoxycytidine combined with imatinib on gastrointestinal stromal tumor].
Topics: Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Benzamides; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Decitabine; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Pyrimidines | 2012 |
The differentiating and apoptotic effects of 2-aza-5'-deoxycytidine are dependent on the PU.1 expression level in PU.1-transgenic K562 cells.
Topics: Apoptosis; Azacitidine; beta-Globins; Cell Differentiation; Cyclin B1; Decitabine; DNA Damage; Erythroid Cells; Gene Expression; Gene Knockdown Techniques; Histones; Humans; K562 Cells; Proto-Oncogene Proteins; Trans-Activators; Transgenes | 2012 |
Decitabine and vorinostat cooperate to sensitize colon carcinoma cells to Fas ligand-induced apoptosis in vitro and tumor suppression in vivo.
Topics: Adaptor Proteins, Signal Transducing; Adoptive Transfer; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Azacitidine; bcl-X Protein; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Colonic Neoplasms; Decitabine; Fas Ligand Protein; Gene Expression Regulation, Neoplastic; Humans; Hydroxamic Acids; Membrane Proteins; Mice; Mitochondrial Proteins; Neoplasm Metastasis; Neoplasms, Experimental; Proto-Oncogene Proteins; Tumor Escape; Vorinostat | 2012 |
Refractory anemia with ring sideroblasts associated with marked thrombocytosis harboring cytogenetic abnormality dup(2)(p15p22) treated with decitabine.
Topics: Anemia, Refractory; Anemia, Sideroblastic; Antimetabolites, Antineoplastic; Azacitidine; Chromosome Duplication; Chromosomes, Human, Pair 2; Decitabine; Humans; Male; Middle Aged; Thrombocytosis | 2012 |
Gene reactivation by 5-aza-2'-deoxycytidine-induced demethylation requires SRCAP-mediated H2A.Z insertion to establish nucleosome depleted regions.
Topics: Adenosine Triphosphatases; Azacitidine; Cell Line, Tumor; Chromatin Assembly and Disassembly; Decitabine; DNA Methylation; DNA Modification Methylases; Epigenesis, Genetic; Gene Expression Regulation; Gene Knockdown Techniques; Histones; Humans; Nucleosomes; Promoter Regions, Genetic; Transcriptional Activation | 2012 |
Treatment with the cancer drugs decitabine and doxorubicin induces human skin keratinocytes to express Oct4 and the OCT4 regulator mir-145.
Topics: Antineoplastic Agents; Azacitidine; Cell Proliferation; Cells, Cultured; Decitabine; DNA Methylation; Doxorubicin; Gene Expression Regulation; Humans; Keratinocytes; MicroRNAs; Octamer Transcription Factor-3; Skin | 2012 |
[5-aza-2'-deoxycytidine-induced inhibition of CDH13 expression and its inhibitory effect on methylation status in human colon cancer cells in vitro and on growth of xenograft in nude mice].
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Cadherins; Cell Proliferation; Decitabine; DNA Methylation; HCT116 Cells; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; RNA, Messenger; Tumor Burden | 2012 |
FOXO3/FKHRL1 is activated by 5-aza-2-deoxycytidine and induces silenced caspase-8 in neuroblastoma.
Topics: Apoptosis; Ataxia Telangiectasia Mutated Proteins; Azacitidine; Base Sequence; Caspase 8; Cell Cycle Proteins; Cell Line, Tumor; Cell Nucleus; Cyclic AMP Response Element-Binding Protein; Decitabine; DNA Methylation; DNA-Binding Proteins; Drug Screening Assays, Antitumor; Enzyme Activation; Enzyme Induction; Forkhead Box Protein O3; Forkhead Transcription Factors; Gene Expression Regulation, Neoplastic; Gene Silencing; HEK293 Cells; Humans; Neuroblastoma; Phosphorylation; Protein Serine-Threonine Kinases; Signal Transduction; TNF-Related Apoptosis-Inducing Ligand; Tumor Suppressor Proteins | 2012 |
cAMP response element-binding (CREB) recruitment following a specific CpG demethylation leads to the elevated expression of the matrix metalloproteinase 13 in human articular chondrocytes and osteoarthritis.
Topics: Azacitidine; Base Sequence; Calcium; Chondrocytes; CpG Islands; Cyclic AMP Response Element-Binding Protein; Decitabine; DNA Methylation; DNA Modification Methylases; DNA Primers; Enzyme Inhibitors; Humans; In Vitro Techniques; Matrix Metalloproteinase 13; Osteoarthritis; Promoter Regions, Genetic; RNA, Small Interfering; Up-Regulation | 2012 |
Gene silencing of EREG mediated by DNA methylation and histone modification in human gastric cancers.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Azacitidine; Cell Line, Tumor; Cetuximab; CpG Islands; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Methyltransferase 3B; Epidermal Growth Factor; Epigenesis, Genetic; Epiregulin; ErbB Receptors; Gene Knockdown Techniques; Gene Silencing; Histones; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Promoter Regions, Genetic; RNA, Messenger; RNA, Neoplasm; RNA, Small Interfering; Stomach Neoplasms; Xenograft Model Antitumor Assays | 2012 |
[A case report of undifferentiated connective tissue disease associated myelodysplastic].
Topics: Azacitidine; Connective Tissue Diseases; Decitabine; Humans; Immunosuppressive Agents; Male; Middle Aged; Myelodysplastic Syndromes; Thalidomide | 2012 |
Differential TERT promoter methylation and response to 5-aza-2'-deoxycytidine in acute myeloid leukemia cell lines: TERT expression, telomerase activity, telomere length, and cell death.
Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Cell Death; Cell Line, Tumor; CpG Islands; Decitabine; DNA Methylation; Female; Gene Expression Regulation, Neoplastic; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Male; Promoter Regions, Genetic; Telomerase; Telomere; U937 Cells | 2012 |
Assessing signaling pathways associated with in vitro resistance to cytotoxic agents in AML.
Topics: Adenine Nucleotides; Adolescent; Adult; Aged; Arabinonucleosides; Azacitidine; Child; Child, Preschool; Clofarabine; Cytotoxins; Decitabine; Drug Resistance, Neoplasm; Humans; Leukemia, Myeloid, Acute; Middle Aged; Models, Biological; Signal Transduction; Tumor Cells, Cultured | 2012 |
DNA demethylating agent decitabine increases AQP5 expression and restores salivary function.
Topics: Aging; Animals; Aquaporin 5; Azacitidine; Cell Membrane Permeability; Decitabine; DNA Methylation; DNA Modification Methylases; Female; Gene Expression Regulation; Mice; Mice, Inbred C57BL; Models, Animal; Promoter Regions, Genetic; Saliva; Salivary Glands; Salivation; Specific Pathogen-Free Organisms; Xerostomia | 2012 |
Cell cycle regulation of human endometrial stromal cells during decidualization.
Topics: Azacitidine; Cell Cycle; Cell Cycle Checkpoints; Cell Cycle Proteins; Cell Line; Cyclic AMP; Decidua; Decitabine; DNA Methylation; Endometrium; Estradiol; Female; G1 Phase; Gene Expression; Humans; Medroxyprogesterone Acetate; Polymerase Chain Reaction; Progestins; Resting Phase, Cell Cycle; Stromal Cells; Up-Regulation | 2012 |
Activation of silenced tumor suppressor genes in prostate cancer cells by a novel energy restriction-mimetic agent.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cell Line, Tumor; Decitabine; Deoxyglucose; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Gene Expression Regulation, Neoplastic; Gene Silencing; Genes, Tumor Suppressor; Humans; Male; Prostate; Prostatic Neoplasms; Transcriptional Activation | 2012 |
Silencing of PCDH10 in hepatocellular carcinoma via de novo DNA methylation independent of HBV infection or HBX expression.
Topics: Azacitidine; Cadherins; Carcinoma, Hepatocellular; CpG Islands; Decitabine; DNA Methylation; DNA Modification Methylases; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Hep G2 Cells; Hepatitis B virus; Humans; Liver; Liver Neoplasms; Male; Middle Aged; Promoter Regions, Genetic; Protocadherins; RNA, Messenger; Trans-Activators; Viral Regulatory and Accessory Proteins | 2013 |
Epigenetics and vitrification of embryos: one step forward and many raised equivocal questions.
Topics: Animals; Azacitidine; Decitabine; DNA Methylation; Embryonic Development; RNA, Long Noncoding; RNA, Untranslated | 2012 |
Aberrant methylation of SPARC in human hepatocellular carcinoma and its clinical implication.
Topics: Azacitidine; Carcinoma, Hepatocellular; Cell Line, Tumor; Decitabine; DNA Methylation; Humans; Liver Neoplasms; Osteonectin; Prognosis; RNA, Messenger | 2012 |
Epigenetic inactivation of PLCD1 in chronic myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Azacitidine; Biomarkers, Tumor; Bone Marrow Cells; CpG Islands; Decitabine; DNA Methylation; Female; G1 Phase Cell Cycle Checkpoints; Gene Expression Regulation, Neoplastic; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Phospholipase C delta; Promoter Regions, Genetic; RNA, Messenger; Tumor Suppressor Proteins; Young Adult | 2012 |
A patient with acute megakaryoblastic leukaemia who achieved CRi after decitabine treatment.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Female; Humans; Leukemia, Megakaryoblastic, Acute; Middle Aged; Remission Induction; Treatment Outcome | 2012 |
Over-expression of RPL23 in myelodysplastic syndromes is associated with apoptosis resistance of CD34+ cells and predicts poor prognosis and distinct response to CHG chemotherapy or decitabine.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Azacitidine; Cell Transformation, Neoplastic; Cytarabine; Decitabine; Female; Gene Expression Regulation, Neoplastic; Granulocyte Colony-Stimulating Factor; Harringtonines; Homoharringtonine; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Predictive Value of Tests; Prognosis; Ribosomal Proteins; Risk Factors; Treatment Outcome; Young Adult | 2012 |
Transcriptional silencing of the inhibin-α gene in human gastric carcinoma cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Carcinoma; Cell Line, Tumor; Cell Proliferation; Cell Survival; Decitabine; DNA Methylation; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Inhibins; Loss of Heterozygosity; Promoter Regions, Genetic; Sequence Analysis, DNA; Stomach Neoplasms; Transcription, Genetic | 2012 |
CTHRC1 is upregulated by promoter demethylation and transforming growth factor-β1 and may be associated with metastasis in human gastric cancer.
Topics: Apoptosis; Azacitidine; Blotting, Western; Cell Line, Tumor; Cell Movement; Cell Survival; Decitabine; DNA Methylation; Extracellular Matrix Proteins; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Metaplasia; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Stomach Neoplasms; Transforming Growth Factor beta1; Up-Regulation | 2012 |
Epigenetic regulation of 5-lipoxygenase in the phenotypic plasticity of valvular interstitial cells associated with aortic valve stenosis.
Topics: Aortic Valve; Aortic Valve Stenosis; Arachidonate 5-Lipoxygenase; Azacitidine; Decitabine; DNA Methylation; Epigenesis, Genetic; Gene Expression Regulation, Enzymologic; Humans; Leukotrienes; Phenotype; Promoter Regions, Genetic; Transcription, Genetic | 2012 |
Effect of 5-aza-2'-deoxycytidine on methylation of the putative imprinted control region of H19 during the in vitro development of vitrified bovine two-cell embryos.
Topics: Animals; Azacitidine; Cattle; Cells, Cultured; Cleavage Stage, Ovum; Decitabine; DNA Methylation; Drug Evaluation, Preclinical; Embryo Culture Techniques; Embryo, Mammalian; Embryonic Development; Enzyme Inhibitors; Gene Expression Regulation, Developmental; Genomic Imprinting; Locus Control Region; RNA, Long Noncoding; RNA, Untranslated; Vitrification | 2012 |
Development and validation of a liquid chromatography-tandem mass spectrometry method for quantification of decitabine in rat plasma.
Topics: Animals; Azacitidine; Chromatography, High Pressure Liquid; Decitabine; Male; Molecular Structure; Rats; Rats, Sprague-Dawley; Tandem Mass Spectrometry | 2012 |
Hypoxia-inducible factor-1α expression indicates poor prognosis in myelodysplastic syndromes.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Biomarkers; Bone Marrow; Bone Marrow Cells; Decitabine; Disease Progression; Female; Hemoglobins; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Immunohistochemistry; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Myelodysplastic Syndromes; Prognosis; Treatment Outcome; Young Adult | 2012 |
MTA1 expression correlates significantly with ER-alpha methylation in breast cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Decitabine; DNA Methylation; Estrogen Receptor alpha; Female; Gene Expression Regulation, Neoplastic; Histone Deacetylases; Humans; Mammary Glands, Human; Methylation; Middle Aged; Neoplasm Staging; Repressor Proteins; Trans-Activators | 2012 |
Nickel-induced epithelial-mesenchymal transition by reactive oxygen species generation and E-cadherin promoter hypermethylation.
Topics: Acetylcysteine; Antigens, Differentiation; Azacitidine; Bronchi; Cadherins; Cell Line, Transformed; Decitabine; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Fibronectins; Free Radical Scavengers; Gene Expression Regulation; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Intercellular Junctions; Nickel; Pulmonary Fibrosis; Reactive Oxygen Species; Respiratory Mucosa | 2012 |
Anti-tumor effect of 5-aza-2'-deoxycytidine by inhibiting telomerase activity in hepatocellular carcinoma cells.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Carcinoma, Hepatocellular; Cell Line, Tumor; Decitabine; DNA Methylation; Gene Expression; Humans; Liver Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Telomerase | 2012 |
5-Aza-2'-deoxycytidine induces cytotoxicity in BGC-823 cells via DNA methyltransferase 1 and 3a independent of p53 status.
Topics: Apoptosis; Azacitidine; Cell Growth Processes; Cell Line, Tumor; Cell Survival; Core Binding Factor Alpha 3 Subunit; Cyclin-Dependent Kinase Inhibitor p21; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Damage; DNA Methylation; DNA Methyltransferase 3A; Dose-Response Relationship, Drug; Enzyme Activation; Humans; Lung Neoplasms; Stomach Neoplasms; Tumor Suppressor Protein p53 | 2012 |
Demethylation of the coding region triggers the activation of the human testis-specific PDHA2 gene in somatic tissues.
Topics: Azacitidine; Base Sequence; Binding Sites; Cell Line; CpG Islands; Decitabine; DNA Methylation; Epigenesis, Genetic; Gene Expression Regulation, Enzymologic; Humans; Male; Molecular Sequence Data; Open Reading Frames; Organ Specificity; Polymerase Chain Reaction; Promoter Regions, Genetic; Protein Binding; Pyruvate Dehydrogenase (Lipoamide); RNA Polymerase II; RNA, Messenger; Sequence Analysis, DNA; Sequence Deletion; Sp1 Transcription Factor; Testis; Transcription Initiation Site | 2012 |
Promoter demethylation of Keap1 gene in human diabetic cataractous lenses.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Azacitidine; Cataract; Cells, Cultured; CpG Islands; Decitabine; Diabetes Complications; DNA Methylation; Humans; Intracellular Signaling Peptides and Proteins; Kelch-Like ECH-Associated Protein 1; Lens, Crystalline; Middle Aged; Oxidative Stress; Promoter Regions, Genetic | 2012 |
5-aza-2'-deoxycytidine improves the sensitivity of endometrial cancer cells to progesterone therapy.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Apoptosis; Azacitidine; Carcinoma; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Decitabine; Drug Synergism; Drug Therapy, Combination; Endometrial Neoplasms; Female; Humans; Medroxyprogesterone Acetate; Neoplasm Invasiveness; Receptors, Progesterone | 2012 |
A novel cancer/testis antigen KP-OVA-52 identified by SEREX in human ovarian cancer is regulated by DNA methylation.
Topics: Antibodies, Neoplasm; Antigens, Neoplasm; Azacitidine; Cell Line, Tumor; Decitabine; DNA Methylation; Female; Gene Library; Humans; Male; Ovarian Neoplasms; Recombinant Fusion Proteins; RNA, Messenger; Testicular Neoplasms | 2012 |
Epigenetic modifiers enhance the synergistic cytotoxicity of combined nucleoside analog-DNA alkylating agents in lymphoma cell lines.
Topics: Antineoplastic Agents, Alkylating; Ataxia Telangiectasia Mutated Proteins; Azacitidine; Busulfan; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Checkpoint Kinase 2; Cytotoxins; Decitabine; Deoxycytidine; DNA (Cytosine-5-)-Methyltransferases; DNA Methyltransferase 3A; DNA Methyltransferase 3B; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Epigenesis, Genetic; Gemcitabine; Hematopoietic Stem Cell Transplantation; Humans; Hydroxamic Acids; Lymphoma; Melphalan; Protein Serine-Threonine Kinases; Transplantation Conditioning; Transplantation, Homologous; Tumor Suppressor Proteins | 2012 |
Methylome analysis and integrative profiling of human HCCs identify novel protumorigenic factors.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Blood Proteins; Carcinoma, Hepatocellular; Carrier Proteins; Case-Control Studies; Cell Line, Tumor; Comparative Genomic Hybridization; CpG Islands; Decitabine; DNA Methylation; Down-Regulation; Female; Gene Expression Profiling; Gene Silencing; Genes, Tumor Suppressor; Glycoproteins; Humans; Liver; Liver Neoplasms; Male; Middle Aged; Period Circadian Proteins; Promoter Regions, Genetic; Young Adult | 2012 |
Aberrant methylation and downregulation of sall3 in human hepatocellular carcinoma.
Topics: Azacitidine; Carcinoma, Hepatocellular; Cell Line, Tumor; CpG Islands; Decitabine; DNA Methylation; Dose-Response Relationship, Drug; Down-Regulation; Gene Expression Regulation, Neoplastic; Homeodomain Proteins; Humans; Liver Neoplasms; Models, Genetic; Promoter Regions, Genetic; RNA, Messenger; Transcription Factors; Transcription, Genetic | 2012 |
Pharmacological unmasking microarray approach-based discovery of novel DNA methylation markers for hepatocellular carcinoma.
Topics: Azacitidine; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Line, Tumor; CpG Islands; Decitabine; DNA Methylation; Down-Regulation; Female; Hep G2 Cells; Humans; Hydroxamic Acids; Liver; Liver Neoplasms; Male; Middle Aged; Oligonucleotide Array Sequence Analysis; Promoter Regions, Genetic; Survival Analysis | 2012 |
Cancer-type regulation of MIG-6 expression by inhibitors of methylation and histone deacetylation.
Topics: Adaptor Proteins, Signal Transducing; Azacitidine; Base Sequence; Blotting, Western; Cell Line, Tumor; Chromatin Immunoprecipitation; CpG Islands; Decitabine; DNA Modification Methylases; DNA Primers; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Luciferases; Microarray Analysis; Molecular Sequence Data; Plasmids; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; Sequence Analysis, DNA; Tumor Suppressor Proteins | 2012 |
Anti-invasive effects of decitabine, a DNA methyltransferase inhibitor, through tightening of tight junctions and inhibition of matrix metalloproteinase activities in AGS human gastric carcinoma cells.
Topics: Antineoplastic Agents; Azacitidine; Cell Line, Tumor; Cell Movement; Claudins; Decitabine; DNA Modification Methylases; Gene Expression; Humans; Lipopolysaccharides; Matrix Metalloproteinases, Secreted; Proto-Oncogene Proteins c-akt; Stomach Neoplasms; Tight Junctions | 2012 |
XAF1 is frequently methylated in human esophageal cancer.
Topics: Adaptor Proteins, Signal Transducing; Aged; Apoptosis Regulatory Proteins; Azacitidine; Biomarkers, Tumor; Blotting, Western; Carcinoma, Squamous Cell; Cell Line, Tumor; Chi-Square Distribution; China; Decitabine; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Epigenesis, Genetic; Esophageal Neoplasms; Female; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Intracellular Signaling Peptides and Proteins; Logistic Models; Male; Middle Aged; Multivariate Analysis; Neoplasm Proteins; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction | 2012 |
Inactivation of SLIT2-ROBO1/2 pathway in premalignant lesions of uterine cervix: clinical and prognostic significances.
Topics: Azacitidine; Cell Line, Tumor; Decitabine; DNA Methylation; Female; Gene Silencing; Humans; Immunohistochemistry; Intercellular Signaling Peptides and Proteins; Nerve Tissue Proteins; Precancerous Conditions; Prognosis; Promoter Regions, Genetic; Receptors, Immunologic; Roundabout Proteins; Uterine Cervical Neoplasms | 2012 |
[The comparison of short-term efficacies between decitabine and HA regimen for MDS/AML patients].
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Decitabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Treatment Outcome | 2012 |
Comprehensive DNA methylation analysis of benign and malignant adrenocortical tumors.
Topics: Adenoma; Adrenal Cortex; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Azacitidine; Cell Line, Tumor; CpG Islands; Decitabine; DNA Methylation; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Genes, Neoplasm; Genome-Wide Association Study; Humans; Oligonucleotide Array Sequence Analysis; Promoter Regions, Genetic | 2012 |
Immunization with WT1-derived peptides by tattooing inhibits the growth of TRAMP-C2 prostate tumor in mice.
Topics: Adjuvants, Immunologic; Animals; Antibodies, Monoclonal; Antineoplastic Agents; Azacitidine; Cancer Vaccines; Cell Line, Tumor; Decitabine; Injections, Intradermal; Male; Mice; Mice, Inbred BALB C; Poly I-C; Prostatic Neoplasms; Tattooing; Transforming Growth Factor beta; Vaccines, Subunit; WT1 Proteins | 2012 |
LTBP-2 confers pleiotropic suppression and promotes dormancy in a growth factor permissive microenvironment in nasopharyngeal carcinoma.
Topics: Azacitidine; Carcinoma; Cell Line, Tumor; Cell Movement; Cell Transformation, Neoplastic; Decitabine; DNA Methylation; Down-Regulation; Gene Expression Regulation, Neoplastic; Humans; Hydroxamic Acids; Latent TGF-beta Binding Proteins; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neovascularization, Pathologic; Promoter Regions, Genetic; Tumor Microenvironment; Tumor Suppressor Proteins; Vascular Endothelial Growth Factor A | 2012 |
Effect of phenylhexyl isothiocyanate on aberrant histone H3 methylation in primary human acute leukemia.
Topics: Acetylation; Acute Disease; Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Case-Control Studies; Child; Decitabine; DNA Methylation; Female; Histone Deacetylase Inhibitors; Histone-Lysine N-Methyltransferase; Histones; Humans; Hydroxamic Acids; Isothiocyanates; Leukemia; Male; Middle Aged; Protein Processing, Post-Translational; Young Adult | 2012 |
Prostaglandin E2 induces growth inhibition, apoptosis and differentiation in T and B cell-derived acute lymphoblastic leukemia cell lines (CCRF-CEM and Nalm-6).
Topics: Antineoplastic Agents; Apoptosis; Azacitidine; Caspase 3; Cell Cycle; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Decitabine; Dinoprostone; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Flow Cytometry; Humans; Hydroxamic Acids; Inhibitory Concentration 50; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 2012 |
Grape seed proanthocyanidins reactivate silenced tumor suppressor genes in human skin cancer cells by targeting epigenetic regulators.
Topics: Antineoplastic Agents; Azacitidine; Blotting, Western; Carcinoma, Squamous Cell; Cell Line, Tumor; Decitabine; DNA Methylation; Gene Silencing; Genes, Tumor Suppressor; Grape Seed Extract; Histone Acetyltransferases; Humans; Immunoblotting; Proanthocyanidins; Real-Time Polymerase Chain Reaction; Skin Neoplasms | 2012 |
Up-regulation of miR-182 expression after epigenetic modulation of human melanoma cells.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cell Line, Tumor; CpG Islands; Decitabine; DNA Methylation; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Melanoma; MicroRNAs; Oligonucleotide Array Sequence Analysis; Skin; Skin Neoplasms; Up-Regulation | 2013 |
Gene expression of mesoderm-specific transcript is upregulated as preadipocytes differentiate to adipocytes in vitro.
Topics: 1-Methyl-3-isobutylxanthine; 3T3 Cells; Adipocytes; Adipogenesis; Animals; Azacitidine; Cells, Cultured; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Decitabine; Dexamethasone; DNA Methylation; Female; Gene Expression Regulation; Glucocorticoids; Insulin; Isoquinolines; Mice; Mice, Inbred C57BL; Phosphodiesterase Inhibitors; Proteins; Sulfonamides; Up-Regulation | 2012 |
Decitabine, a DNA methyltransferase inhibitor, induces apoptosis in human leukemia cells through intracellular reactive oxygen species generation.
Topics: Acetylcysteine; Apoptosis; Azacitidine; Baculoviral IAP Repeat-Containing 3 Protein; Caspases; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Decitabine; Down-Regulation; Enzyme Inhibitors; Humans; Inhibitor of Apoptosis Proteins; Leukemia; Membrane Potential, Mitochondrial; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; Ubiquitin-Protein Ligases; X-Linked Inhibitor of Apoptosis Protein | 2012 |
Targeting the MAGE A3 antigen in pancreatic cancer.
Topics: Adenocarcinoma; Antigens, Neoplasm; Azacitidine; Cell Line, Tumor; Chromatin Assembly and Disassembly; Cytokines; Decitabine; Deoxycytidine; DNA Methylation; Gemcitabine; Humans; Hydroxamic Acids; Immunotherapy; Male; Neoplasm Proteins; Pancreas; Pancreatic Neoplasms; Receptors, Antigen, T-Cell; T-Lymphocytes; Testis; Valproic Acid | 2012 |
14-3-3σ mediates G2-M arrest produced by 5-aza-2'-deoxycytidine and possesses a tumor suppressor role in endometrial carcinoma cells.
Topics: 14-3-3 Proteins; Azacitidine; Biomarkers, Tumor; Cell Growth Processes; Cell Line, Tumor; Cell Survival; Decitabine; DNA Methylation; Endometrial Neoplasms; Exonucleases; Exoribonucleases; Female; G2 Phase Cell Cycle Checkpoints; Genes, Tumor Suppressor; Humans; M Phase Cell Cycle Checkpoints; Transfection | 2012 |
Stress induced hippocampal mineralocorticoid and estrogen receptor β gene expression and long-term potentiation in male adult rats is sensitive to early-life stress experience.
Topics: Age Factors; Animals; Azacitidine; Corticosterone; Cyclofenil; Decitabine; Dentate Gyrus; DNA Methylation; DNA Modification Methylases; Eplerenone; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Gene Expression; Hippocampus; Long-Term Potentiation; Male; Maternal Deprivation; Mineralocorticoid Receptor Antagonists; Promoter Regions, Genetic; Rats; Rats, Wistar; Receptors, Androgen; Receptors, Glucocorticoid; Receptors, Mineralocorticoid; Spironolactone; Stress, Psychological; Testosterone; Up-Regulation | 2013 |
Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Biomarkers, Tumor; Cell Line, Tumor; Decitabine; DNA Methylation; DNA, Neoplasm; Female; Gene Expression Profiling; Genome, Human; Humans; Leukemia, Myeloid, Acute; Male; Oligonucleotide Array Sequence Analysis; Polymerase Chain Reaction; Promoter Regions, Genetic | 2012 |
The effects of promoter methylation on downregulation of DAZAP2 in multiple myeloma cell lines.
Topics: Animals; Azacitidine; Cell Line, Tumor; Chlorocebus aethiops; COS Cells; Decitabine; DNA Methylation; DNA Modification Methylases; Down-Regulation; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Multiple Myeloma; Polymerase Chain Reaction; Promoter Regions, Genetic; RNA-Binding Proteins; Sequence Analysis, DNA; Transcription, Genetic | 2012 |
5'-Aza-dC sensitizes paraquat toxic effects on PC12 cell.
Topics: Animals; Apoptosis; Azacitidine; Cell Survival; Cytochromes c; Decitabine; DNA Methylation; DNA Modification Methylases; Dopaminergic Neurons; Herbicides; Mitochondrial Proteins; Paraquat; PC12 Cells; Proto-Oncogene Proteins c-bcl-2; Rats; Reactive Oxygen Species | 2012 |
Association of epigenetic inactivation of the WRN gene with anticancer drug sensitivity in cervical cancer cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Azacitidine; Camptothecin; Carcinoma, Squamous Cell; Cell Line, Tumor; Decitabine; DNA Methylation; Epigenesis, Genetic; Exodeoxyribonucleases; Female; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; RecQ Helicases; RNA, Small Interfering; Topoisomerase I Inhibitors; Uterine Cervical Neoplasms; Werner Syndrome Helicase | 2012 |
[Effects of 5-Aza-2'-deoxycitydine and trichostatin A on expression and methylation of CHFR in human laryngreal carcinoma cell line].
Topics: Azacitidine; Cell Cycle Proteins; Decitabine; DNA Methylation; Gene Expression; Hep G2 Cells; Humans; Hydroxamic Acids; Laryngeal Neoplasms; Methylation; Neoplasm Proteins; Poly-ADP-Ribose Binding Proteins; Promoter Regions, Genetic; Ubiquitin-Protein Ligases | 2012 |
The TCF4/β-catenin pathway and chromatin structure cooperate to regulate D-glucuronyl C5-epimerase expression in breast cancer.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; beta Catenin; Breast Neoplasms; Carbohydrate Epimerases; Chromatin; Decitabine; DNA Methylation; Epigenesis, Genetic; Female; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; MCF-7 Cells; Promoter Regions, Genetic; Protein Processing, Post-Translational; Transcription Factor 4; Transcription Factors; Transcription, Genetic; Wnt Signaling Pathway | 2012 |
Pretreatment of leukemic cells with low-dose decitabine markedly enhances the cytotoxicity of gemtuzumab ozogamicin.
Topics: Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Azacitidine; Decitabine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gemtuzumab; Humans; Leukemia; Neoplasm Recurrence, Local; Tumor Cells, Cultured | 2013 |
Epigenetic modulation of the biophysical properties of drug-resistant cell lipids to restore drug transport and endocytic functions.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Azacitidine; Biological Transport; Breast Neoplasms; Cell Membrane; Decitabine; DNA Methylation; Doxorubicin; Drug Delivery Systems; Drug Resistance, Neoplasm; Endocytosis; Epigenesis, Genetic; Epigenomics; Female; Humans; Lipid Metabolism; MCF-7 Cells | 2012 |
SP1 mediates the link between methylation of the tumour suppressor miR-149 and outcome in colorectal cancer.
Topics: Azacitidine; Base Sequence; Cell Proliferation; Chi-Square Distribution; Colorectal Neoplasms; CpG Islands; Decitabine; DNA Methylation; DNA Modification Methylases; Down-Regulation; Enzyme Inhibitors; Female; Gene Expression Profiling; Gene Knockdown Techniques; Gene Silencing; HCT116 Cells; HT29 Cells; Humans; Kaplan-Meier Estimate; Male; MicroRNAs; Middle Aged; Molecular Sequence Data; Multivariate Analysis; Neoplasm Invasiveness; Oligonucleotide Array Sequence Analysis; Polymerase Chain Reaction; Prognosis; Proportional Hazards Models; Risk Assessment; Risk Factors; Signal Transduction; Sp1 Transcription Factor; Time Factors; Transfection | 2013 |
Expression and functions of μ-opioid receptors and cannabinoid receptors type 1 in T lymphocytes.
Topics: Analgesics, Opioid; Animals; Azacitidine; Cannabinoids; Cyclic AMP; Decitabine; Humans; Hydroxamic Acids; Interleukin-2; Interleukin-4; Jurkat Cells; Lymphocyte Activation; Mice; Neuroimmunomodulation; Receptor, Cannabinoid, CB1; Receptors, Opioid, mu; Signal Transduction; T-Lymphocytes | 2012 |
Genomic methylation profiling combined with gene expression microarray reveals the aberrant methylation mechanism involved in nasopharyngeal carcinoma taxol resistance.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Azacitidine; Carcinoma; Cell Line, Tumor; Decitabine; DNA Methylation; Drug Resistance, Neoplasm; Gene Expression Profiling; Genomics; Humans; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Oligonucleotide Array Sequence Analysis; Paclitaxel | 2012 |
Enforced expression of RASAL1 suppresses cell proliferation and the transformation ability of gastric cancer cells.
Topics: Aged; Azacitidine; Cell Line, Tumor; Cell Movement; Cell Proliferation; Decitabine; DNA Methylation; Dose-Response Relationship, Drug; Epigenesis, Genetic; Epstein-Barr Virus Infections; Female; Gene Expression Regulation, Neoplastic; GTPase-Activating Proteins; Helicobacter Infections; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Male; Middle Aged; ras GTPase-Activating Proteins; Stomach Neoplasms | 2012 |
Reexpression of tumor suppressor, sFRP1, leads to antitumor synergy of combined HDAC and methyltransferase inhibitors in chemoresistant cancers.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Azacitidine; Breast Neoplasms; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Survival; Decitabine; Depsipeptides; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Glycoproteins; Histone Deacetylase Inhibitors; Humans; Intracellular Signaling Peptides and Proteins; Kidney Neoplasms; Methyltransferases; Recombinant Proteins; Tumor Suppressor Proteins | 2012 |
New therapy targeting differential androgen receptor signaling in prostate cancer stem/progenitor vs. non-stem/progenitor cells.
Topics: Animals; Azacitidine; Curcumin; Decitabine; Disease Models, Animal; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Neoplastic Stem Cells; Orchiectomy; Prostatic Neoplasms; Receptors, Androgen; Signal Transduction; Xenograft Model Antitumor Assays | 2013 |
PROX1 overexpression inhibits protein kinase C beta II transcription through promoter DNA methylation.
Topics: Animals; Azacitidine; Cell Proliferation; Decitabine; DNA Methylation; Down-Regulation; Gene Expression Profiling; HCT116 Cells; HeLa Cells; Homeodomain Proteins; Humans; Indoles; Male; Mice; Mice, Inbred BALB C; Oligonucleotide Array Sequence Analysis; Promoter Regions, Genetic; Protein Kinase C; Protein Kinase C beta; Sp1 Transcription Factor; Tumor Suppressor Proteins | 2012 |
DNMT1-mediated PTEN hypermethylation confers hepatic stellate cell activation and liver fibrogenesis in rats.
Topics: Animals; Azacitidine; Cell Line; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Gene Knockdown Techniques; Gene Silencing; Hepatic Stellate Cells; Liver Cirrhosis, Experimental; Male; MAP Kinase Signaling System; Phosphatidylinositol 3-Kinases; Promoter Regions, Genetic; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Rats; Rats, Sprague-Dawley; Up-Regulation | 2012 |
2'-Deoxyriboguanylurea, the primary breakdown product of 5-aza-2'-deoxyribocytidine, is a mutagen, an epimutagen, an inhibitor of DNA methyltransferases and an inducer of 5-azacytidine-type fragile sites.
Topics: Azacitidine; Base Sequence; Cell Line, Tumor; Chromosome Fragile Sites; Decitabine; Deoxyribose; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Modification Methylases; DNA-Cytosine Methylases; Enzyme Inhibitors; Guanidines; Humans; Molecular Sequence Data; Mutagenesis; Mutagens; Oligodeoxyribonucleotides | 2012 |
Increased cleavage rate of human nuclear transfer embryos after 5-aza-2'-deoxycytidine treatment.
Topics: 5-Methylcytosine; Adult; Azacitidine; China; Decitabine; DNA Methylation; DNA Modification Methylases; Ectogenesis; Enzyme Inhibitors; Female; Fertilization in Vitro; Humans; Infertility; Kinetics; Male; Microscopy, Confocal; Microscopy, Fluorescence; Mitosis; Nuclear Transfer Techniques; Sperm Injections, Intracytoplasmic; Zygote | 2012 |
Synergism between clofarabine and decitabine through p53R2: a pharmacodynamic drug-drug interaction modeling.
Topics: Adenine Nucleotides; Arabinonucleosides; Azacitidine; Blotting, Western; Cell Cycle Proteins; Cell Line, Tumor; Cell Survival; Clofarabine; Decitabine; Drug Synergism; Humans; Protein Biosynthesis; Ribonucleotide Reductases | 2012 |
CDX2 serves as a Wnt signaling inhibitor and is frequently methylated in lung cancer.
Topics: Azacitidine; CDX2 Transcription Factor; Cell Line, Tumor; Cell Proliferation; Decitabine; DNA Methylation; G1 Phase; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Homeodomain Proteins; Humans; Lung Neoplasms; Promoter Regions, Genetic; Wnt Signaling Pathway | 2012 |
Histone acetylation and DNA demethylation of T cells result in an anaplastic large cell lymphoma-like phenotype.
Topics: Azacitidine; B-Lymphocytes; Cell Line, Tumor; Cluster Analysis; Decitabine; DNA Methylation; Epigenesis, Genetic; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Silencing; Histones; Humans; Hydroxamic Acids; Inhibitor of Differentiation Protein 2; Lymphoma, Large-Cell, Anaplastic; Phenotype; Promoter Regions, Genetic; T-Lymphocytes; Transcription Factors | 2013 |
Improving the outlook for myelodysplastic syndrome.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Biomarkers, Tumor; Decitabine; Disease Progression; DNA Methylation; Enzyme Inhibitors; Epigenesis, Genetic; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Methyltransferases; Molecular Targeted Therapy; Myelodysplastic Syndromes; Phosphoproteins; Point Mutation; Prognosis; Ribonucleoprotein, U2 Small Nuclear; Risk Assessment; RNA Splicing; RNA Splicing Factors; Spliceosomes; Thalidomide | 2012 |
Global identification of genes regulated by estrogen signaling and demethylation in MCF-7 breast cancer cells.
Topics: Azacitidine; Breast Neoplasms; Cell Cycle Proteins; Cell Line, Tumor; Decitabine; DNA Methylation; DNA Modification Methylases; Epigenesis, Genetic; Estradiol; Estrogens; Female; Gene Expression Regulation, Neoplastic; Humans; Intracellular Signaling Peptides and Proteins; LIM Domain Proteins; Promoter Regions, Genetic; Proteins; Signal Transduction; Transcriptome | 2012 |
Could decitabine treatment impair memory functions in humans?
Topics: Azacitidine; Decitabine; DNA Methylation; Enzyme Inhibitors; Humans; Memory Disorders | 2012 |
Development of a novel microRNA promoter microarray for ChIP-on-chip assay to identify epigenetically regulated microRNAs.
Topics: Azacitidine; Cell Line, Tumor; Chromatin Immunoprecipitation; Decitabine; DNA Modification Methylases; Down-Regulation; Epigenesis, Genetic; Histones; Humans; MicroRNAs; Oligonucleotide Array Sequence Analysis; Promoter Regions, Genetic; Stomach Neoplasms | 2012 |
Decreased PADI4 mRNA association with global hypomethylation in hepatocellular carcinoma during HBV exposure.
Topics: Adult; Aged; Azacitidine; Carcinoma, Hepatocellular; Cell Line, Tumor; Decitabine; DNA Methylation; DNA Modification Methylases; Female; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Hepatitis B; Hepatitis B virus; Histone Deacetylase Inhibitors; Host-Pathogen Interactions; Humans; Hydrolases; Hydroxamic Acids; Immunohistochemistry; Liver Neoplasms; Long Interspersed Nucleotide Elements; Male; Middle Aged; Protein-Arginine Deiminase Type 4; Protein-Arginine Deiminases; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Analysis | 2013 |
Epigenetic remodelling of gene expression profiles of neoplastic and normal tissues: immunotherapeutic implications.
Topics: Animals; Antigens, Neoplasm; Azacitidine; Cell Line, Tumor; Cell Transformation, Neoplastic; Decitabine; DNA Methylation; Epigenesis, Genetic; Epigenomics; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Immunotherapy; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Promoter Regions, Genetic; Receptors, G-Protein-Coupled; Signal Transduction | 2012 |
Case report of isochromosome 17q in acute myeloid leukemia with myelodysplasia-related changes after treatment with a hypomethylating agent.
Topics: Azacitidine; Cell Transformation, Neoplastic; Chromosomes, Human, Pair 17; Decitabine; DNA Methylation; Fatal Outcome; Humans; Isochromosomes; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes | 2012 |
5-aza-2'-Deoxycytidine enhances the radiosensitivity of breast cancer cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Breast Neoplasms; Cell Cycle; Cell Proliferation; Colony-Forming Units Assay; Decitabine; DNA Methylation; Female; Gene Expression Regulation, Neoplastic; Humans; Radiation Tolerance; Radiation-Sensitizing Agents; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured | 2013 |
The impact of hypomethylating agents on the cost of care and survival of elderly patients with myelodysplastic syndromes.
Topics: Aged; Aged, 80 and over; Azacitidine; Decitabine; Drug Costs; Enzyme Inhibitors; Female; Humans; Male; Myelodysplastic Syndromes; SEER Program | 2012 |
Epigenetic mechanisms regulate the prostaglandin E receptor 2 in breast cancer.
Topics: Adipose Tissue; Azacitidine; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Cell Line, Tumor; CpG Islands; Decitabine; DNA Methylation; Epigenesis, Genetic; Female; Fibroblasts; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Promoter Regions, Genetic; Receptors, Prostaglandin E, EP2 Subtype; Reference Values; Stromal Cells | 2012 |
Hypoxia-induced DNA hypermethylation in human pulmonary fibroblasts is associated with Thy-1 promoter methylation and the development of a pro-fibrotic phenotype.
Topics: Actins; Azacitidine; Cell Hypoxia; Cell Line; Collagen Type I; Collagen Type III; Decitabine; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Fibroblasts; Flow Cytometry; Gene Expression Regulation; Humans; Lung; Myofibroblasts; Phenotype; Promoter Regions, Genetic; Pulmonary Fibrosis; Real-Time Polymerase Chain Reaction; RNA, Messenger; Thy-1 Antigens; Time Factors | 2012 |
Epigenetic regulation of the 1,25-dihydroxyvitamin D3 24-hydroxylase (CYP24A1) in colon cancer cells.
Topics: Azacitidine; Caco-2 Cells; Cell Line, Tumor; Colonic Neoplasms; Decitabine; DNA Methylation; DNA Modification Methylases; Epigenesis, Genetic; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; HT29 Cells; Humans; Steroid Hydroxylases; Vitamin D3 24-Hydroxylase | 2013 |
Frequent silencing of protocadherin 8 by promoter methylation, a candidate tumor suppressor for human gastric cancer.
Topics: Apoptosis; Azacitidine; Cadherins; Cell Line, Tumor; Cell Movement; Cell Proliferation; Decitabine; DNA Methylation; Female; Gastric Mucosa; Gene Expression Regulation, Neoplastic; Gene Silencing; Genes, Tumor Suppressor; Humans; Lymphatic Metastasis; Male; Middle Aged; Promoter Regions, Genetic; Protocadherins; RNA, Messenger; Stomach Neoplasms; Up-Regulation | 2012 |
Epigenetic screen identifies genotype-specific promoter DNA methylation and oncogenic potential of CHRNB4.
Topics: Azacitidine; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Decitabine; DNA Methylation; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Genetic Predisposition to Disease; Genotype; Humans; Lung Neoplasms; Nerve Tissue Proteins; Polymorphism, Single Nucleotide; Promoter Regions, Genetic; Receptors, Nicotinic | 2013 |
Gene expression profiling of the synergy of 5-aza-2'-deoxycytidine and paclitaxel against renal cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Biomarkers, Tumor; Blotting, Western; Carcinoma, Renal Cell; Decitabine; Drug Synergism; Gene Expression Profiling; Humans; Kidney Neoplasms; Oligonucleotide Array Sequence Analysis; Paclitaxel; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Tumor Cells, Cultured | 2012 |
Transcriptional regulation of hTREX84 in human cancer cells.
Topics: Azacitidine; Base Sequence; Breast Neoplasms; Cell Cycle Proteins; Cell Line, Tumor; Cell Transformation, Neoplastic; Decitabine; DNA-Binding Proteins; Exons; Female; Gene Expression Regulation, Neoplastic; Humans; Molecular Sequence Data; Nuclear Proteins; Ovarian Neoplasms; Promoter Regions, Genetic; RNA-Binding Proteins; Sequence Analysis, DNA; Sulfites; Transcription Factor RelA; Transcription, Genetic | 2012 |
[Effect of DNA hypermethylation on NOR1 promoter activity and expression].
Topics: Azacitidine; Base Sequence; Cell Line, Tumor; CpG Islands; Decitabine; DNA Methylation; DNA Modification Methylases; DNA-Cytosine Methylases; Epigenesis, Genetic; Gene Silencing; HL-60 Cells; Humans; Membrane Transport Proteins; Molecular Sequence Data; Nasopharyngeal Neoplasms; Promoter Regions, Genetic; RNA, Messenger | 2012 |
Transcriptional regulation of the GPX1 gene by TFAP2C and aberrant CpG methylation in human breast cancer.
Topics: Azacitidine; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Chromatin Immunoprecipitation; CpG Islands; Decitabine; DNA Methylation; Dose-Response Relationship, Drug; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Glutathione Peroxidase; Glutathione Peroxidase GPX1; Humans; MCF-7 Cells; Oligonucleotide Array Sequence Analysis; Promoter Regions, Genetic; Protein Binding; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Sequence Analysis, DNA; tert-Butylhydroperoxide; Transcription Factor AP-2; Transcription, Genetic | 2013 |
Epigenetic silencing of DKK2 and Wnt signal pathway components in human ovarian carcinoma.
Topics: Animals; Azacitidine; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Decitabine; DNA Methylation; Epigenesis, Genetic; Female; Gene Expression Regulation, Neoplastic; Humans; Intercellular Signaling Peptides and Proteins; Mice; Neoplasm Invasiveness; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Wnt Signaling Pathway | 2012 |
[Effect of proliferation inhibition and PTEN gene expression induced by decitabine combined with daunorubicin on HL-60 cell line].
Topics: Azacitidine; Cell Proliferation; Daunorubicin; Decitabine; HL-60 Cells; Humans; PTEN Phosphohydrolase | 2012 |
[Effective treatment of myelodysplastic syndromes-refractory anemia with excess blasts type II by decitabine: a case report].
Topics: Anemia, Refractory, with Excess of Blasts; Azacitidine; Decitabine; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Treatment Outcome | 2012 |
Methylation mediated silencing of miR-23b expression and its role in glioma stem cells.
Topics: Antineoplastic Agents; Azacitidine; Brain Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Decitabine; Down-Regulation; Epigenesis, Genetic; Gene Silencing; Glioma; Humans; Methylation; MicroRNAs; Neoplastic Stem Cells; Promoter Regions, Genetic; Temozolomide | 2012 |
Cp-jeez! Aza-natomy!
Topics: Antimetabolites, Antineoplastic; Azacitidine; Biomarkers, Tumor; Decitabine; DNA Methylation; Female; Gene Expression Profiling; Genome, Human; Humans; Leukemia, Myeloid, Acute; Male | 2012 |
Brush border myosin Ia inactivation in gastric but not endometrial tumors.
Topics: Azacitidine; Base Sequence; Blotting, Western; Decitabine; DNA Methylation; DNA Primers; Endometrial Neoplasms; Female; Humans; Microscopy, Confocal; Microvilli; Mutation; Myosin Heavy Chains; Myosin Type I; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; Stomach Neoplasms | 2013 |
Aberrant promoter methylation of Dab2 gene in myelodysplastic syndrome.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Apoptosis Regulatory Proteins; Azacitidine; Cell Line; Decitabine; DNA Methylation; Down-Regulation; Female; Humans; Karyotyping; Male; Middle Aged; Myelodysplastic Syndromes; Polymerase Chain Reaction; Promoter Regions, Genetic; Risk Factors; Sequence Analysis, DNA; Tumor Suppressor Proteins | 2012 |
Gemcitabine reactivates epigenetically silenced genes and functions as a DNA methyltransferase inhibitor.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cell Line, Tumor; CpG Islands; Decitabine; Deoxycytidine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Enzyme Stability; Epigenesis, Genetic; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Silencing; Histone Deacetylase 1; Humans; Promoter Regions, Genetic; Tumor Suppressor Proteins; Vascular Endothelial Growth Factor Receptor-1 | 2012 |
Boulevard of broken dreams: drug approval for older adults with acute myeloid leukemia.
Topics: Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Modification Methylases; Drug Approval; Humans; Leukemia, Myeloid, Acute; Randomized Controlled Trials as Topic; United States; United States Food and Drug Administration | 2012 |
Anti-HIV-1 activity of resveratrol derivatives and synergistic inhibition of HIV-1 by the combination of resveratrol and decitabine.
Topics: Anti-HIV Agents; Azacitidine; Decitabine; Dose-Response Relationship, Drug; Drug Synergism; HIV-1; Humans; Molecular Structure; Resveratrol; Stilbenes | 2012 |
Targeting the unique methylation pattern of androgen receptor (AR) promoter in prostate stem/progenitor cells with 5-aza-2'-deoxycytidine (5-AZA) leads to suppressed prostate tumorigenesis.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Decitabine; DNA Methylation; DNA, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Neoplasm Proteins; Neoplasm Transplantation; Neoplastic Stem Cells; Promoter Regions, Genetic; Prostatic Neoplasms; Receptors, Androgen; Transplantation, Heterologous | 2012 |
Acute myeloid leukemia with translocation (8;16)(p11;p13) and MYST3-CREBBP rearrangement harbors a distinctive microRNA signature targeting RET proto-oncogene.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Azacitidine; Biomarkers, Tumor; Chromosomes, Human, Pair 16; Chromosomes, Human, Pair 8; Cluster Analysis; CREB-Binding Protein; Decitabine; DNA Methylation; DNA, Neoplasm; Female; Flow Cytometry; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Gene Rearrangement; Histone Acetyltransferases; Humans; Leukemia, Myeloid, Acute; Male; MicroRNAs; Middle Aged; Oligonucleotide Array Sequence Analysis; Oncogene Proteins, Fusion; Polymerase Chain Reaction; Prognosis; Proto-Oncogene Mas; Proto-Oncogene Proteins c-ret; Translocation, Genetic; Tumor Cells, Cultured; Young Adult | 2013 |
Transcriptional regulation of the human tumor suppressor DOK1 by E2F1.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Azacitidine; Cell Line; Cell Line, Tumor; Cell Proliferation; Chromatin Assembly and Disassembly; Decitabine; DNA Damage; DNA Methylation; DNA-Binding Proteins; E2F1 Transcription Factor; Etoposide; Gene Silencing; HEK293 Cells; Humans; Methyltransferases; Phosphoproteins; Response Elements; RNA-Binding Proteins; Transcriptional Activation | 2012 |
5-aza-2'-deoxycytidine leads to reduced embryo implantation and reduced expression of DNA methyltransferases and essential endometrial genes.
Topics: Animals; Azacitidine; Blotting, Western; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Methyltransferase 3A; DNA Methyltransferase 3B; Embryo Implantation; Endometrium; Estrogen Receptor alpha; Female; Homeobox A10 Proteins; Homeodomain Proteins; Immunohistochemistry; Male; Mice; Pregnancy; Receptors, Progesterone | 2012 |
Epigenetic changes through DNA methylation contribute to uterine stromal cell decidualization.
Topics: Animals; Azacitidine; CpG Islands; Decidua; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Methyltransferase 3A; Epigenesis, Genetic; Female; Mice; Pregnancy; Pregnancy, Animal; Promoter Regions, Genetic; Stromal Cells; Uterus | 2012 |
Genome-wide promoter methylation analysis in neuroblastoma identifies prognostic methylation biomarkers.
Topics: Azacitidine; Biomarkers, Tumor; Cell Line, Tumor; Chromogranins; Databases, Genetic; Decitabine; DNA Methylation; Epigenomics; Gene Expression Regulation, Neoplastic; Genome, Human; GTP-Binding Protein alpha Subunits, Gs; HCT116 Cells; High-Throughput Nucleotide Sequencing; Humans; Neuroblastoma; Promoter Regions, Genetic; Risk Factors; Sequence Analysis, DNA; Survival Analysis | 2012 |
5-aza-CdR induces the demethylation of Syk promoter in nasopharyngeal carcinoma cell.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Base Sequence; Blotting, Western; Cell Line, Tumor; Decitabine; DNA Methylation; DNA Primers; Humans; Intracellular Signaling Peptides and Proteins; Nasopharyngeal Neoplasms; Promoter Regions, Genetic; Protein-Tyrosine Kinases; Real-Time Polymerase Chain Reaction; RNA, Messenger; Syk Kinase | 2012 |
DNA demethylation regulates the expression of miR-210 in neural progenitor cells subjected to hypoxia.
Topics: Animals; Azacitidine; Blotting, Western; Cell Hypoxia; Cells, Cultured; Decitabine; DNA Methylation; DNA Modification Methylases; Female; Hypoxia-Inducible Factor 1; MicroRNAs; Neural Stem Cells; Polymerase Chain Reaction; Pregnancy; Rats; Rats, Wistar | 2012 |
The DNA demethylating agent decitabine activates the TRAIL pathway and induces apoptosis in acute myeloid leukemia.
Topics: Apoptosis; Azacitidine; Cell Line, Tumor; Decitabine; DNA Methylation; Histone Deacetylase Inhibitors; Humans; Leukemia, Myeloid, Acute; Promoter Regions, Genetic; Signal Transduction; TNF-Related Apoptosis-Inducing Ligand | 2013 |
Neonatal isolation decreases cued fear conditioning and frontal cortical histone 3 lysine 9 methylation in adult female rats.
Topics: Acoustic Stimulation; Age Factors; Animals; Animals, Newborn; Azacitidine; Behavior, Animal; Cerebral Cortex; Conditioning, Psychological; Corticosterone; Cues; Decitabine; DNA Modification Methylases; Dose-Response Relationship, Drug; Down-Regulation; Estradiol; Fear; Female; Histone Deacetylase Inhibitors; Histones; Light; Lysine; Maternal Deprivation; Methylation; Photic Stimulation; Rats; Rats, Sprague-Dawley; Reflex, Startle; Stress, Psychological; Valproic Acid | 2012 |
Methylation of the p73 gene in patients with myelodysplastic syndromes: correlations with apoptosis and prognosis.
Topics: Adult; Aged; Apoptosis; Azacitidine; Bone Marrow Cells; Cells, Cultured; Cytarabine; Decitabine; DNA Methylation; DNA-Binding Proteins; Female; Humans; Male; Middle Aged; Myelodysplastic-Myeloproliferative Diseases; Nuclear Proteins; Prognosis; Promoter Regions, Genetic; Survival; Tumor Protein p73; Tumor Suppressor Proteins | 2013 |
Alterations of the WNT7A gene in clear cell renal cell carcinomas.
Topics: Adult; Aged; Azacitidine; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Decitabine; DNA Methylation; Down-Regulation; Epigenesis, Genetic; Female; Genetic Markers; Humans; Loss of Heterozygosity; Male; Microsatellite Repeats; Middle Aged; Wnt Proteins; Young Adult | 2012 |
Decitabine, a DNA methyltransferase inhibitor, reduces P-glycoprotein mRNA and protein expressions and increases drug sensitivity in drug-resistant MOLT4 and Jurkat cell lines.
Topics: Antimetabolites, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Azacitidine; Cell Line, Tumor; Decitabine; DNA (Cytosine-5-)-Methyltransferases; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans | 2012 |
Histone H3 lysine 27 and 9 hypermethylation within the Bad promoter region mediates 5-Aza-2'-deoxycytidine-induced Leydig cell apoptosis: implications of 5-Aza-2'-deoxycytidine toxicity to male reproduction.
Topics: Animals; Apoptosis; Azacitidine; bcl-Associated Death Protein; CpG Islands; Decitabine; Enhancer of Zeste Homolog 2 Protein; Epigenesis, Genetic; Histones; Leydig Cells; Male; Mice; Polycomb Repressive Complex 2; Promoter Regions, Genetic; Reproduction | 2013 |
Methylome profiling reveals distinct alterations in phenotypic and mutational subgroups of myeloproliferative neoplasms.
Topics: Adult; Aged; Aged, 80 and over; Azacitidine; Cell Line, Tumor; Decitabine; Dioxygenases; DNA Methylation; DNA-Binding Proteins; Female; Humans; Janus Kinase 2; Male; Middle Aged; Mutation; Polycythemia Vera; Primary Myelofibrosis; Proto-Oncogene Proteins; Repressor Proteins; Thrombocythemia, Essential | 2013 |
Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia.
Topics: Acute Disease; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Decitabine; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Epigenesis, Genetic; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid; Male; Multivariate Analysis; Mutation; Prognosis; Remission Induction; Survival Analysis; Treatment Outcome | 2012 |
Silencing of glutathione peroxidase 3 through DNA hypermethylation is associated with lymph node metastasis in gastric carcinomas.
Topics: Azacitidine; Case-Control Studies; Cell Line, Tumor; Decitabine; DNA Methylation; Fluorescent Antibody Technique; Gene Expression Regulation, Enzymologic; Gene Silencing; Glutathione Peroxidase; Humans; Lymphatic Metastasis; Promoter Regions, Genetic; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Stomach Neoplasms | 2012 |
Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; DNA Mutational Analysis; Female; Glutarates; Granulocyte Precursor Cells; Humans; Idarubicin; Isocitrate Dehydrogenase; Leukemia, Myeloid; Male; Middle Aged; Mutation; Prospective Studies; Time Factors | 2012 |
Cytosine methylation and hydroxymethylation mark DNA for elimination in Oxytricha trifallax.
Topics: Azacitidine; Cytosine; Decitabine; DNA Methylation; DNA, Protozoan; Enzyme Inhibitors; Gene Rearrangement; High-Throughput Nucleotide Sequencing; Mass Spectrometry; Molecular Sequence Data; Oxytricha; Sequence Analysis, DNA | 2012 |
Methylation subtypes and large-scale epigenetic alterations in gastric cancer.
Topics: Animals; Azacitidine; Cell Proliferation; Chromosomal Instability; Cluster Analysis; CpG Islands; Decitabine; DNA Methylation; Epigenesis, Genetic; Epigenomics; Gastric Mucosa; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Mice; Neoplasm Transplantation; Phenotype; Stomach Neoplasms | 2012 |
Differential promoter methylation and histone modification contribute to the brain specific expression of the mouse Mbu-1 gene.
Topics: Animals; Apoptosis Regulatory Proteins; Azacitidine; Brain; Cell Line, Tumor; Chromatin Immunoprecipitation; CpG Islands; Decitabine; DNA Methylation; DNA-Binding Proteins; Epigenesis, Genetic; Histones; Mice; Nerve Tissue Proteins; Nuclear Proteins; Promoter Regions, Genetic | 2012 |
Effects of DNA methyltransferase inhibitors (DNMTIs) on MDS-derived cell lines.
Topics: Azacitidine; Cell Cycle; Cell Division; Cell Line; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Damage; DNA Methylation; Dose-Response Relationship, Drug; Enzyme Inhibitors; Gene Expression Profiling; HL-60 Cells; Humans; In Vitro Techniques; Inhibitory Concentration 50; Myelodysplastic Syndromes | 2013 |
High cytidine deaminase expression in the liver provides sanctuary for cancer cells from decitabine treatment effects.
Topics: Animals; Antimetabolites; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytidine Deaminase; Decitabine; Humans; Leukemia, Myeloid; Liver; Liver Neoplasms; Mice; Mice, Knockout; Tetrahydrouridine; Transplantation, Heterologous; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2012 |
Development of gene expression-based score to predict sensitivity of multiple myeloma cells to DNA methylation inhibitors.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Biomarkers, Tumor; Cell Line, Tumor; Decitabine; DNA Methylation; DNA Modification Methylases; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Multiple Myeloma; Predictive Value of Tests; Prognosis | 2012 |
Sulforaphane causes a major epigenetic repression of myostatin in porcine satellite cells.
Topics: 3' Untranslated Regions; Animals; Azacitidine; Base Sequence; Cells, Cultured; Decitabine; DNA (Cytosine-5-)-Methyltransferases; Epigenesis, Genetic; Follistatin; Gene Expression Regulation; Histone Deacetylase Inhibitors; Hydroxamic Acids; Isothiocyanates; MicroRNAs; Molecular Sequence Data; MyoD Protein; Myostatin; Promoter Regions, Genetic; Satellite Cells, Skeletal Muscle; Signal Transduction; Sulfoxides; Swine; Thiocyanates | 2012 |
Methylation of Wnt antagonist genes: a useful prognostic marker for myelodysplastic syndrome.
Topics: Adaptor Proteins, Signal Transducing; Adolescent; Adult; Aged; Aged, 80 and over; Azacitidine; beta Catenin; Bone Marrow Cells; Cell Cycle; Cell Line; Cell Nucleus; Chemokines; Cytoplasm; Decitabine; DNA Methylation; Eye Proteins; Female; Humans; Intercellular Signaling Peptides and Proteins; Kaplan-Meier Estimate; Male; Membrane Proteins; Middle Aged; Myelodysplastic Syndromes; Prognosis; Promoter Regions, Genetic; Proto-Oncogene Proteins; Real-Time Polymerase Chain Reaction; Severity of Illness Index; Wnt Proteins; Wnt Signaling Pathway; Young Adult | 2013 |
Association of NDRG1 gene promoter methylation with reduced NDRG1 expression in gastric cancer cells and tissue specimens.
Topics: Azacitidine; Base Sequence; Cell Cycle Proteins; Cell Differentiation; Cell Line, Tumor; Decitabine; DNA Methylation; Down-Regulation; Exons; Gene Expression Regulation, Neoplastic; Genes, Neoplasm; Histones; Humans; Intracellular Signaling Peptides and Proteins; Molecular Sequence Data; Mutation; Promoter Regions, Genetic; RNA, Messenger; Stomach Neoplasms | 2013 |
Decitabine in patients with relapsed acute myeloid leukemia (AML) after allogeneic stem cell transplantation (allo-SCT).
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Chemotherapy, Adjuvant; Cohort Studies; Decitabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Retrospective Studies; Transplantation, Homologous; Young Adult | 2013 |
[Methylation of FHIT gene promoter region in DNA from plasma of patients with myelodysplastic syndromes and demethylating effect of decitabine].
Topics: Acid Anhydride Hydrolases; Adult; Aged; Azacitidine; Decitabine; DNA; DNA Methylation; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm Proteins; Promoter Regions, Genetic | 2012 |
Regulation of human Cripto-1 expression by nuclear receptors and DNA promoter methylation in human embryonal and breast cancer cells.
Topics: Azacitidine; Binding Sites; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Embryonal; Cell Movement; Decitabine; DNA Methylation; DNA Modification Methylases; Dose-Response Relationship, Drug; Embryonal Carcinoma Stem Cells; Female; Gene Expression Regulation, Developmental; Gene Expression Regulation, Neoplastic; Genes, Reporter; GPI-Linked Proteins; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Intercellular Signaling Peptides and Proteins; Luciferases; MCF-7 Cells; Neoplasm Invasiveness; Neoplasm Proteins; Nuclear Receptor Subfamily 6, Group A, Member 1; Promoter Regions, Genetic; Receptors, Cytoplasmic and Nuclear; RNA Interference; RNA, Messenger; Time Factors; Tissue Array Analysis; Transcription, Genetic; Transfection; Tretinoin; Valproic Acid | 2013 |
ANKRD18A as a novel epigenetic regulation gene in lung cancer.
Topics: Ankyrin Repeat; Azacitidine; Decitabine; DNA Methylation; DNA Modification Methylases; Down-Regulation; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Promoter Regions, Genetic | 2012 |
Down-regulation of miR-517a and miR-517c promotes proliferation of hepatocellular carcinoma cells via targeting Pyk2.
Topics: Azacitidine; Base Sequence; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Decitabine; DNA Modification Methylases; Down-Regulation; Focal Adhesion Kinase 2; G2 Phase Cell Cycle Checkpoints; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Liver Neoplasms; MicroRNAs; Multigene Family; Oligonucleotide Array Sequence Analysis; RNA Interference; Transcriptome | 2013 |
Quantitative comparison of the efficacy of various compounds in lowering intracellular cholesterol levels in Niemann-Pick type C fibroblasts.
Topics: Azacitidine; beta-Cyclodextrins; Cells, Cultured; Child; Child, Preschool; Chloroquine; Chlorpromazine; Cholesterol; Decitabine; Dose-Response Relationship, Drug; Drug Synergism; Female; Fibroblasts; Humans; Hydroxamic Acids; Indoles; Intracellular Space; Male; Microscopy, Fluorescence; Mutation; Niemann-Pick Disease, Type C; Panobinostat; Sirolimus; Vorinostat | 2012 |
Decitabine induces very early in vivo DNA methylation changes in blasts from patients with acute myeloid leukemia.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Cluster Analysis; CpG Islands; Decitabine; DNA Methylation; Epigenesis, Genetic; Female; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid, Acute; Male | 2013 |
[Effects of 5-Aza-2-deoxycytidine on DNA methylation of anti-oncogenes in non-small cell lung cancer cells].
Topics: Antimetabolites, Antineoplastic; Azacitidine; Carcinoma, Non-Small-Cell Lung; Cell Differentiation; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p16; Decitabine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Gene Expression Regulation, Neoplastic; Humans; Intercellular Signaling Peptides and Proteins; Lung Neoplasms; Lymphatic Metastasis; Male; Membrane Proteins; Neoplasm Staging; RNA, Messenger; Tumor Suppressor Proteins | 2012 |
C/EBPγ deregulation results in differentiation arrest in acute myeloid leukemia.
Topics: Animals; Azacitidine; CCAAT-Enhancer-Binding Proteins; Cell Differentiation; Cells, Cultured; Chromatin Immunoprecipitation; Decitabine; DNA Methylation; DNA Modification Methylases; Epigenesis, Genetic; Gene Expression Regulation, Leukemic; Genes, Reporter; Granulocyte Colony-Stimulating Factor; Granulocytes; Humans; Leukemia, Myeloid, Acute; Luciferases, Renilla; Mice; Mice, Inbred C57BL; Mice, Knockout; Myeloid Cells; Neutrophils; Oligonucleotide Array Sequence Analysis; Promoter Regions, Genetic; Protein Binding; Stem Cells; Up-Regulation | 2012 |
Oxidative stress in coronary artery disease: epigenetic perspective.
Topics: Adult; Aged; Aged, 80 and over; Azacitidine; Cell Line; Coronary Artery Disease; Decitabine; DNA Methylation; Endothelial Cells; Epigenesis, Genetic; Female; Ferredoxin-NADP Reductase; Folic Acid; Glutathione S-Transferase pi; Glycine Hydroxymethyltransferase; Homocysteine; Humans; Hydroxamic Acids; Male; Malondialdehyde; Membrane Proteins; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Oxidative Stress; Promoter Regions, Genetic; Protein Carbonylation; Proto-Oncogene Proteins; Superoxide Dismutase; Young Adult | 2013 |
5-aza-2'-deoxycytidine has minor effects on differentiation in human thyroid cancer cell lines, but modulates genes that are involved in adaptation in vitro.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Carcinoma; Cell Differentiation; Cell Line, Tumor; Cell Movement; Cell Survival; Decitabine; Gene Expression Regulation, Neoplastic; Humans; Hydroxamic Acids; Oligonucleotide Array Sequence Analysis; Thyroid Gland; Thyroid Neoplasms; Vorinostat | 2013 |
Increased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: a novel epigenetic-targeting approach in acute myeloid leukemia.
Topics: Animals; Azacitidine; Blotting, Western; Cell Line, Tumor; Decitabine; Epigenesis, Genetic; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Leukemia, Myeloid, Acute; Mice; Mice, Inbred NOD; Mice, SCID; MicroRNAs; Phenylbutyrates; Up-Regulation | 2013 |
In vivo quantification of active decitabine-triphosphate metabolite: a novel pharmacoanalytical endpoint for optimization of hypomethylating therapy in acute myeloid leukemia.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Modification Methylases; Humans; Leukemia, Myeloid, Acute; Mice; Mice, Inbred C57BL; Polyphosphates | 2013 |
Preparation of a hyper-cross-linked polymer monolithic column and its application to the sensitive determination of genomic DNA methylation.
Topics: Azacitidine; Cell Line, Tumor; Cross-Linking Reagents; Decitabine; DNA; DNA Methylation; HeLa Cells; Humans; Polymers | 2013 |
Epigenetic regulation of CXCR4 expression by the ocular microenvironment.
Topics: Animals; Anterior Chamber; Antimetabolites, Antineoplastic; Azacitidine; Cecum; Cell Line, Tumor; Decitabine; Down-Regulation; Epigenesis, Genetic; Flow Cytometry; Gene Expression; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Histone Deacetylases; Histones; Hydroxamic Acids; Injections; Injections, Subcutaneous; Lysine; Methylation; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Promoter Regions, Genetic; Receptors, CXCR4; Reverse Transcriptase Polymerase Chain Reaction; Spleen; Up-Regulation | 2013 |
Decitabine facilitates the generation and immunosuppressive function of regulatory γδT cells derived from human peripheral blood mononuclear cells.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cells, Cultured; Decitabine; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunotherapy, Adoptive; Receptors, Antigen, T-Cell, gamma-delta; T-Lymphocytes, Regulatory | 2013 |
Abnormal hypermethylation and clinicopathological significance of Axin gene in lung cancer.
Topics: Adenocarcinoma; Axin Protein; Azacitidine; Base Sequence; Blotting, Western; Carcinoma, Large Cell; Carcinoma, Squamous Cell; Cell Adhesion; Cell Movement; Cell Proliferation; Decitabine; DNA Methylation; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Molecular Sequence Data; Neoplasm Staging; Promoter Regions, Genetic; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured | 2013 |
MeCP2 modulates the canonical Wnt pathway activation by targeting SFRP4 in rheumatoid arthritis fibroblast-like synoviocytes in rats.
Topics: Animals; Arthritis, Rheumatoid; Azacitidine; beta Catenin; Cell Proliferation; Cells, Cultured; Cyclin D1; Decitabine; DNA Methylation; Down-Regulation; Fibroblasts; Fibronectins; Male; Methyl-CpG-Binding Protein 2; Proto-Oncogene Proteins; Rats; Rats, Sprague-Dawley; RNA Interference; RNA, Messenger; RNA, Small Interfering; Synovial Membrane; Wnt Signaling Pathway | 2013 |
Cytotoxicity of 5-Aza-2'-deoxycytidine against gastric cancer involves DNA damage in an ATM-P53 dependent signaling pathway and demethylation of P16(INK4A).
Topics: Androstadienes; Antimetabolites, Antineoplastic; Ataxia Telangiectasia Mutated Proteins; Azacitidine; Cell Cycle Proteins; Cell Line, Tumor; Comet Assay; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Breaks, Double-Stranded; DNA Damage; DNA Methyltransferase 3A; DNA Methyltransferase 3B; DNA-Binding Proteins; Dose-Response Relationship, Drug; Down-Regulation; G2 Phase Cell Cycle Checkpoints; Humans; Protein Serine-Threonine Kinases; Signal Transduction; Stomach Neoplasms; Time Factors; Tumor Suppressor Protein p53; Tumor Suppressor Proteins; Wortmannin | 2013 |
Thrombospondin-1 expression in melanoma is blocked by methylation and targeted reversal by 5-Aza-deoxycytidine suppresses angiogenesis.
Topics: Animals; Azacitidine; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Decitabine; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Humans; Melanoma; Methylation; Mice; Neovascularization, Pathologic; Promoter Regions, Genetic; Xenograft Model Antitumor Assays | 2013 |
Hypomethylating therapy in an aggressive stroma-rich model of pancreatic carcinoma.
Topics: Animals; Azacitidine; Carcinoma, Pancreatic Ductal; Decitabine; DNA Methylation; Female; Humans; Male; Mice; Mice, Transgenic; Pancreatic Neoplasms; Stromal Cells | 2013 |
Highly synergistic effect of sequential treatment with epigenetic and anticancer drugs to overcome drug resistance in breast cancer cells is mediated via activation of p21 gene expression leading to G2/M cycle arrest.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Breast Neoplasms; Carcinogens; Cell Cycle Checkpoints; Cell Division; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; Doxorubicin; Drug Resistance, Neoplasm; Drug Synergism; Epigenesis, Genetic; Epigenomics; Female; G2 Phase; Genes, Tumor Suppressor; Humans; Hydroxamic Acids; Internationality; MCF-7 Cells; Vorinostat | 2013 |
Aberrant methylation of the M-type phospholipase A(2) receptor gene in leukemic cells.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Methylation; Female; Genes, Tumor Suppressor; Genetic Predisposition to Disease; Humans; Jurkat Cells; Leukemia; Male; Middle Aged; Myelodysplastic Syndromes; Receptors, Phospholipase A2; U937 Cells; Young Adult | 2012 |
Human leukocyte antigen-G is frequently expressed in glioblastoma and may be induced in vitro by combined 5-aza-2'-deoxycytidine and interferon-γ treatments: results from a multicentric study.
Topics: Acetylation; Aged; Antigen Presentation; Azacitidine; beta 2-Microglobulin; Biopsy; Brain Neoplasms; Cell Line, Tumor; Chromatin Assembly and Disassembly; Decitabine; DNA Methylation; Female; Glioblastoma; HLA-G Antigens; Humans; Interferon-gamma; Male; Middle Aged; Paraffin Embedding; Prognosis; Promoter Regions, Genetic; Survival Analysis; Transcription, Genetic; Up-Regulation | 2013 |
MiR-383 is downregulated in medulloblastoma and targets peroxiredoxin 3 (PRDX3).
Topics: Adolescent; Adult; Apoptosis; Azacitidine; Cell Cycle; Cell Line, Tumor; Cell Survival; Cerebellar Neoplasms; Child; Child, Preschool; Decitabine; Down-Regulation; Enzyme Inhibitors; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Hydroxamic Acids; Male; Medulloblastoma; MicroRNAs; Peroxiredoxin III; RNA Interference; Young Adult | 2013 |
Renal tumours in a Tsc1+/- mouse model show epigenetic suppression of organic cation transporters Slc22a1, Slc22a2 and Slc22a3, and do not respond to metformin.
Topics: Animals; Azacitidine; Blotting, Western; Catecholamine Plasma Membrane Transport Proteins; Decitabine; Disease Models, Animal; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Histone Deacetylases; Hypoglycemic Agents; Immunohistochemistry; Kidney; Kidney Neoplasms; Mechanistic Target of Rapamycin Complex 1; Metformin; Mice; Mice, Knockout; Multiprotein Complexes; Organic Cation Transport Proteins; Organic Cation Transporter 2; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; TOR Serine-Threonine Kinases; Tuberous Sclerosis; Tuberous Sclerosis Complex 1 Protein; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2013 |
miR-370 modulates insulin receptor substrate-1 expression and inhibits the tumor phenotypes of oral carcinoma.
Topics: Azacitidine; Carcinogenesis; Carcinoma, Squamous Cell; Cell Adhesion; Cell Culture Techniques; Cell Line, Tumor; Cell Movement; Cells, Cultured; Decitabine; DNA Modification Methylases; Down-Regulation; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Insulin Receptor Substrate Proteins; Keratinocytes; MicroRNAs; Mouth Neoplasms; Neoplasm Invasiveness; Neoplasm Staging; Oncogene Protein v-akt; RNA, Small Interfering; TOR Serine-Threonine Kinases | 2013 |
p53 cooperates with DNA methylation and a suicidal interferon response to maintain epigenetic silencing of repeats and noncoding RNAs.
Topics: Actins; Animals; Azacitidine; Computational Biology; Decitabine; DNA Methylation; Epigenetic Repression; Interferon Type I; Mice; Microarray Analysis; Repetitive Sequences, Nucleic Acid; RNA, Untranslated; Sequence Analysis, RNA; Tumor Suppressor Protein p53 | 2013 |
[Methylation of matrix metalloproteinases-2 promoter in endometrial cancer invasion].
Topics: Azacitidine; Decitabine; DNA Methylation; Endometrial Neoplasms; Female; Gene Expression Regulation, Neoplastic; Humans; Matrix Metalloproteinase 2; Neoplasm Invasiveness; Promoter Regions, Genetic; RNA, Messenger; Tumor Cells, Cultured | 2012 |
MIR-137 suppresses growth and invasion, is downregulated in oligodendroglial tumors and targets CSE1L.
Topics: Adult; Aged; Azacitidine; Brain Neoplasms; Bromodeoxyuridine; Cell Line, Tumor; Cell Proliferation; Cellular Apoptosis Susceptibility Protein; Child; Cohort Studies; Collagen; Decitabine; Down-Regulation; Drug Combinations; Enzyme Inhibitors; Female; Gene Expression Regulation, Neoplastic; Humans; Hydroxamic Acids; Kaplan-Meier Estimate; Laminin; Male; MicroRNAs; Middle Aged; Oligodendroglioma; Proteoglycans | 2013 |
Prognostic factors associated with disease progression and overall survival in patients with myelodysplastic syndromes treated with decitabine.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Disease Progression; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Odds Ratio; Prognosis; Retrospective Studies; Risk Factors; Treatment Outcome | 2013 |
DNA methylation is associated with transcription of Snail and Slug genes.
Topics: Azacitidine; Cell Line, Tumor; Decitabine; DNA Methylation; DNA Modification Methylases; Epithelial-Mesenchymal Transition; Gene Silencing; Humans; Induced Pluripotent Stem Cells; Snail Family Transcription Factors; Transcription Factors; Transcription, Genetic | 2013 |
Genome-wide single-nucleotide polymorphism array-based karyotyping in myelodysplastic syndrome and chronic myelomonocytic leukemia and its impact on treatment outcomes following decitabine treatment.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Chromosome Mapping; Decitabine; Drug Resistance, Neoplasm; Female; Genome, Human; Humans; Karyotyping; Leukemia, Myelomonocytic, Chronic; Male; Microarray Analysis; Middle Aged; Myelodysplastic Syndromes; Polymorphism, Single Nucleotide; Prognosis; Treatment Outcome | 2013 |
CD81 is a candidate tumor suppressor gene in human gastric cancer.
Topics: Apoptosis; Azacitidine; Base Sequence; Blotting, Western; Cell Cycle; Cell Line, Tumor; Decitabine; Disease Progression; DNA Methylation; Down-Regulation; G1 Phase Cell Cycle Checkpoints; Gene Expression Regulation, Neoplastic; Humans; Molecular Sequence Data; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Stomach Neoplasms; Tetraspanin 28; Tumor Suppressor Proteins | 2013 |
Complete remission following decitabine/dendritic cell vaccine for relapsed neuroblastoma.
Topics: Azacitidine; Cancer Vaccines; Child; Decitabine; Dendritic Cells; Hematopoietic Stem Cell Transplantation; Humans; Male; Neuroblastoma; Recurrence; Remission Induction | 2013 |
DNA methylation of RUNX3 in papillary thyroid cancer.
Topics: Azacitidine; Biomarkers, Tumor; Carcinoma; Carcinoma, Papillary; Cell Line, Tumor; Core Binding Factor Alpha 3 Subunit; Decitabine; DNA Methylation; Gene Expression; Humans; Thyroid Cancer, Papillary; Thyroid Neoplasms | 2012 |
Decitabine in patients with newly diagnosed and relapsed acute myeloid leukemia.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cohort Studies; Decitabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Treatment Outcome | 2013 |
Increased CDA expression/activity in males contributes to decreased cytidine analog half-life and likely contributes to worse outcomes with 5-azacytidine or decitabine therapy.
Topics: Animals; Azacitidine; Cytarabine; Cytidine; Cytidine Deaminase; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; Female; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Myeloid, Acute; Male; Mice; Myelodysplastic Syndromes; Polymorphism, Single Nucleotide; Survival Analysis; Treatment Outcome | 2013 |
Genomic impact of transient low-dose decitabine treatment on primary AML cells.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Cells, Cultured; CpG Islands; Decitabine; DNA Methylation; Dose-Response Relationship, Drug; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Genome, Human; Humans; Leukemia, Myeloid, Acute; Mice; Microarray Analysis; Primary Cell Culture; Time Factors | 2013 |
DNA methylation associated with polycomb repression in retinoic acid receptor β silencing.
Topics: Azacitidine; Cell Line, Tumor; Chromatin; CpG Islands; Decitabine; DNA Methylation; Enzyme Inhibitors; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Gene Silencing; Histones; Humans; Neoplasms; Promoter Regions, Genetic; Receptors, Retinoic Acid | 2013 |
Acute hypersensitivity of pluripotent testicular cancer-derived embryonal carcinoma to low-dose 5-aza deoxycytidine is associated with global DNA Damage-associated p53 activation, anti-pluripotency and DNA demethylation.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Carcinoma, Embryonal; Cell Line, Tumor; Decitabine; DNA Damage; DNA Methylation; Down-Regulation; Gene Expression Regulation, Neoplastic; Humans; Male; Testicular Neoplasms; Tumor Suppressor Protein p53 | 2012 |
Efficacy of decitabine-loaded nanogels in overcoming cancer drug resistance is mediated via sustained DNA methyltransferase 1 (DNMT1) depletion.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Blotting, Western; Breast Neoplasms; Cell Cycle; Cell Proliferation; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; Drug Delivery Systems; Drug Resistance, Neoplasm; Epigenomics; Female; Gene Expression Regulation, Neoplastic; Humans; Nanogels; Polyethylene Glycols; Polyethyleneimine; Tumor Cells, Cultured | 2013 |
Epigenetic regulation of miR-17~92 contributes to the pathogenesis of pulmonary fibrosis.
Topics: Animals; Azacitidine; Cells, Cultured; Decitabine; Disease Models, Animal; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Epigenomics; Fibroblasts; Gene Expression; Humans; Idiopathic Pulmonary Fibrosis; Mice; Mice, Inbred C57BL; MicroRNAs; Real-Time Polymerase Chain Reaction; Repressor Proteins; RNA, Long Noncoding | 2013 |
IRF-8 controls melanoma progression by regulating the cross talk between cancer and immune cells within the tumor microenvironment.
Topics: Animals; Azacitidine; CD4 Lymphocyte Count; Chemokines; Decitabine; Dendritic Cells; Disease Progression; Humans; Interferon Regulatory Factors; Interleukin-17; Interleukins; Lung Neoplasms; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Mice, Knockout; Receptor Cross-Talk; Receptors, Chemokine; Spleen; T-Lymphocytes; Tumor Microenvironment; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor B; Vascular Endothelial Growth Factor Receptor-2 | 2012 |
MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine.
Topics: Animals; Antineoplastic Agents; Apoptosis; Azacitidine; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cisplatin; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; Drug Resistance, Neoplasm; Epigenesis, Genetic; Female; Hep G2 Cells; Humans; Mice; Mice, Nude; MicroRNAs; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Xenograft Model Antitumor Assays | 2014 |
Scedosporium apiospermum soft tissue infection as the initial presentation of acute myeloid leukemia: a case report.
Topics: Aged, 80 and over; Amputation, Surgical; Antifungal Agents; Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow; Decitabine; Diagnosis, Differential; Disease Progression; Fatal Outcome; Female; Humans; Leg Ulcer; Leukemia, Myeloid, Acute; Mycoses; Pancytopenia; Pyrimidines; Scedosporium; Soft Tissue Infections; Triazoles; Voriconazole | 2013 |
Prognostic significance of aberrantly silenced ANPEP expression in prostate cancer.
Topics: Aged; Aged, 80 and over; Azacitidine; Biomarkers, Tumor; CD13 Antigens; Cell Line, Tumor; Decitabine; Disease-Free Survival; DNA Methylation; Epigenesis, Genetic; Gene Silencing; Humans; Male; Middle Aged; Neovascularization, Pathologic; Promoter Regions, Genetic; Prostatectomy; Prostatic Neoplasms; Sequence Analysis, DNA | 2013 |
Antagonism between gene therapy and epigenetic therapy on human laryngeal carcinoma tumor-bearing mice.
Topics: Animals; Azacitidine; Cadherins; Decitabine; DNA Modification Methylases; Epigenesis, Genetic; Genes, p53; Genetic Therapy; Humans; Laryngeal Neoplasms; Male; Mice; Mice, Inbred BALB C; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2013 |
Epigenetic marking and repression of porcine endogenous retroviruses.
Topics: Animals; Azacitidine; Cell Line; Decitabine; DNA Methylation; DNA, Viral; Down-Regulation; Endogenous Retroviruses; Enzyme Inhibitors; Epigenetic Repression; Gene Expression Regulation, Viral; Histone Deacetylase Inhibitors; Histones; Hydroxamic Acids; Male; Mice; Primary Cell Culture; Proviruses; RNA, Messenger; RNA, Viral; Swine; Swine Diseases; Swine, Miniature; Up-Regulation | 2013 |
Decitabine has a biphasic effect on natural killer cell viability, phenotype, and function under proliferative conditions.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cell Growth Processes; Cell Line, Tumor; Cell Survival; Cytotoxicity, Immunologic; Decitabine; DNA Methylation; Humans; K562 Cells; Killer Cells, Natural; Leukemia, Myeloid, Acute; Natural Cytotoxicity Triggering Receptor 2; Phenotype; Receptors, KIR; Receptors, Natural Killer Cell; RNA, Messenger; Transcription, Genetic | 2013 |
Epigenetic status of argininosuccinate synthetase and argininosuccinate lyase modulates autophagy and cell death in glioblastoma.
Topics: Apoptosis; Arginine; Argininosuccinate Lyase; Argininosuccinate Synthase; Autophagy; Azacitidine; Central Nervous System Neoplasms; Chloroquine; CpG Islands; Decitabine; DNA Methylation; Epigenomics; Glioblastoma; Humans; Hydrolases; Polyethylene Glycols; RNA Interference; RNA, Small Interfering; Stilbenes; Tumor Cells, Cultured; Up-Regulation | 2013 |
MicroRNA-195 and microRNA-378 mediate tumor growth suppression by epigenetical regulation in gastric cancer.
Topics: Azacitidine; Cell Cycle; Cell Line, Tumor; Cell Proliferation; CpG Islands; Cyclin-Dependent Kinase 6; Decitabine; DNA Methylation; Down-Regulation; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Humans; MicroRNAs; Promoter Regions, Genetic; Signal Transduction; Stomach Neoplasms; Vascular Endothelial Growth Factor A | 2013 |
Decitabine represses translocated MYC oncogene in Burkitt lymphoma.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Burkitt Lymphoma; Cell Line, Tumor; Cell Proliferation; Decitabine; DNA Modification Methylases; Dose-Response Relationship, Drug; Epigenetic Repression; Gene Expression Regulation, Neoplastic; Humans; Immunoglobulin M; Inhibitor of Differentiation Protein 2; NF-kappa B; Proto-Oncogene Proteins c-myc; Transcription, Genetic; Transfection; Translocation, Genetic; Up-Regulation | 2013 |
Allogeneic hematopoietic stem cell transplantation versus hypomethylating agents in patients with myelodysplastic syndrome: a retrospective case-control study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Modification Methylases; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Research Design; Retrospective Studies; Severity of Illness Index; Survival Rate; Time Factors; Transplantation, Homologous; Treatment Outcome | 2013 |
Epigenetic inactivation of ADAMTS9 via promoter methylation in multiple myeloma.
Topics: ADAM Proteins; ADAMTS9 Protein; Adult; Aged; Azacitidine; Cell Line, Tumor; Cell Proliferation; CpG Islands; Decitabine; DNA Methylation; Down-Regulation; Female; Humans; Hydroxamic Acids; Male; Middle Aged; Multiple Myeloma; Promoter Regions, Genetic; RNA Interference; RNA, Small Interfering; S Phase Cell Cycle Checkpoints | 2013 |
Label-free real-time detection of DNA methylation based on quartz crystal microbalance measurement.
Topics: Azacitidine; Cyclin-Dependent Kinase Inhibitor p16; Decitabine; DNA; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Primase; Gold; Hep G2 Cells; HT29 Cells; Humans; Immobilized Nucleic Acids; Quartz Crystal Microbalance Techniques; Receptor, Galanin, Type 2 | 2013 |
Treatment outcomes following leukemic transformation in Philadelphia-negative myeloproliferative neoplasms.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Cell Transformation, Neoplastic; Combined Modality Therapy; Cytarabine; Decitabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Myeloproliferative Disorders; Philadelphia Chromosome; Registries; Survival Analysis; Transplantation, Homologous; Treatment Outcome; Young Adult | 2013 |
Epigenetic regulation of TNFA expression in periodontal disease.
Topics: Adult; Azacitidine; Biopsy; Campylobacter rectus; Cell Culture Techniques; Cell Line; Chronic Periodontitis; CpG Islands; Cross-Sectional Studies; Decitabine; DNA Methylation; DNA Modification Methylases; Epigenesis, Genetic; Female; Gene Expression Regulation; Gingivitis; Humans; Luciferases; Luminescent Agents; Male; Middle Aged; Monocytes; Osteoclasts; Promoter Regions, Genetic; RNA, Messenger; Transcription, Genetic; Transfection; Tumor Necrosis Factor-alpha; Young Adult | 2013 |
An HPLC-MS/MS method for simultaneous determination of decitabine and its valyl prodrug valdecitabine in rat plasma.
Topics: Animals; Azacitidine; Chromatography, High Pressure Liquid; Decitabine; Linear Models; Male; Prodrugs; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Sensitivity and Specificity; Solid Phase Extraction; Tandem Mass Spectrometry; Valine | 2013 |
Anticancer efficacy of cisplatin and trichostatin A or 5-aza-2'-deoxycytidine on ovarian cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Blotting, Western; Cell Adhesion; Cell Movement; Cell Proliferation; Cisplatin; Decitabine; Epigenesis, Genetic; Epithelial-Mesenchymal Transition; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Mice; Mice, Inbred C3H; Mice, SCID; Ovarian Neoplasms; Spheroids, Cellular; Tumor Cells, Cultured | 2013 |
Epigenetic reactivation of estrogen receptor-α (ERα) by genistein enhances hormonal therapy sensitivity in ERα-negative breast cancer.
Topics: Animals; Anticarcinogenic Agents; Antineoplastic Agents, Hormonal; Azacitidine; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; Drug Resistance, Neoplasm; Drug Synergism; Epigenesis, Genetic; Estradiol; Estrogen Receptor alpha; Female; Gene Expression; Genistein; Histone Deacetylase 1; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Mice; Mice, Nude; Mice, Transgenic; Proliferating Cell Nuclear Antigen; Promoter Regions, Genetic; Tamoxifen; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
(Some) cellular mechanisms influencing the transcription of human endogenous retrovirus, HERV-Fc1.
Topics: Azacitidine; Cell Line, Tumor; CpG Islands; Decitabine; DNA Methylation; Endogenous Retroviruses; Epigenesis, Genetic; Gene Expression Regulation; Humans; Hydroxamic Acids; Promoter Regions, Genetic; Retroelements; Terminal Repeat Sequences; Transcription, Genetic | 2013 |
5-Aza-2'-deoxycytidine may influence the proliferation and apoptosis of cervical cancer cells via demethylation in a dose- and time-dependent manner.
Topics: Apoptosis; Apoptotic Protease-Activating Factor 1; Azacitidine; Cell Growth Processes; Cell Line, Tumor; Decitabine; DNA Methylation; Female; Gene Expression Regulation, Neoplastic; HeLa Cells; Humans; Tumor Suppressor Proteins; Uterine Cervical Neoplasms | 2013 |
Functional DNA demethylation is accompanied by chromatin accessibility.
Topics: Azacitidine; Cell Line, Tumor; Chromatin; Decitabine; DNA Methylation; Genes, Tumor Suppressor; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Promoter Regions, Genetic; Vorinostat | 2013 |
Transcription signatures encoded by ultraconserved genomic regions in human prostate cancer.
Topics: Adenocarcinoma; Aged; Azacitidine; Case-Control Studies; Cell Line, Tumor; Conserved Sequence; Decitabine; Epigenesis, Genetic; Gene Expression; Gene Expression Regulation, Neoplastic; Genome, Human; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Male; Metribolone; Middle Aged; Oligonucleotide Array Sequence Analysis; Prostate; Prostatic Neoplasms; RNA, Messenger; RNA, Neoplasm; RNA, Untranslated; Testosterone Congeners; Transcriptome | 2013 |
Role of BMPs in the regulation of sclerostin as revealed by an epigenetic modifier of human bone cells.
Topics: Adaptor Proteins, Signal Transducing; Azacitidine; Bone Morphogenetic Proteins; Cell Line; Decitabine; DNA Methylation; DNA Modification Methylases; Epigenesis, Genetic; Gene Expression Profiling; Genetic Markers; Humans; Oligonucleotide Array Sequence Analysis; Osteoblasts; Osteoporotic Fractures; Signal Transduction | 2013 |
Comparison of 7-day azacitidine and 5-day decitabine for treating myelodysplastic syndrome.
Topics: Adult; Aged; Aged, 80 and over; Azacitidine; Blood Transfusion; Combined Modality Therapy; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Drug Evaluation; Enzyme Inhibitors; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Survival Rate; Treatment Outcome; Young Adult | 2013 |
5-Aza-2'-deoxycytidine inhibited PDGF-induced rat airway smooth muscle cell phenotypic switching.
Topics: Airway Remodeling; Animals; Asthma; Azacitidine; Becaplermin; Biomarkers; Cell Cycle; Cell Movement; Cell Proliferation; Cell Survival; Cells, Cultured; Culture Techniques; Cytoskeleton; Decitabine; Disease Models, Animal; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; Down-Regulation; Enzyme Inhibitors; Muscle Contraction; Muscle, Smooth; Phenotype; Proliferating Cell Nuclear Antigen; Proto-Oncogene Proteins c-sis; Rats; Rats, Sprague-Dawley; Transcription, Genetic | 2013 |
Gene methylation and silencing of SOCS3 in mantle cell lymphoma.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Azacitidine; Cell Line, Tumor; Cyclin D1; Decitabine; DNA Methylation; Gene Expression Regulation, Neoplastic; Gene Silencing; Genetic Vectors; Humans; Lentivirus; Lymphoma, Mantle-Cell; Neoplasm Proteins; Prognosis; Recombinant Fusion Proteins; Signal Transduction; STAT3 Transcription Factor; Suppressor of Cytokine Signaling 3 Protein; Suppressor of Cytokine Signaling Proteins; Transcription Factor RelA; Transduction, Genetic; Treatment Outcome | 2013 |
Low dose decitabine in very high risk relapsed or refractory acute myeloid leukaemia in children and young adults.
Topics: Adolescent; Adult; Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow; Child; Child, Preschool; Combined Modality Therapy; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; Drug Evaluation; Female; Humans; Leukemia, Myeloid, Acute; Male; MicroRNAs; Neoplasm Proteins; Neutropenia; Remission Induction; RNA, Neoplasm; Salvage Therapy; Stem Cell Transplantation; Transplantation, Homologous; Treatment Outcome | 2013 |
Myelodysplasia: new approaches.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials as Topic; Decitabine; Disease Progression; Female; Granulocyte Colony-Stimulating Factor; Humans; Immunologic Factors; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Randomized Controlled Trials as Topic; Stem Cell Transplantation | 2013 |
The overexpression of hypomethylated miR-663 induces chemotherapy resistance in human breast cancer cells by targeting heparin sulfate proteoglycan 2 (HSPG2).
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Apoptosis; Azacitidine; Breast Neoplasms; Cell Line, Tumor; Cyclophosphamide; Decitabine; DNA Methylation; DNA, Neoplasm; Docetaxel; Down-Regulation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Heparan Sulfate Proteoglycans; Humans; Methylation; MicroRNAs; Neoplasm Proteins; RNA, Neoplasm; Taxoids | 2013 |
Blockade of DNA methylation enhances the therapeutic effect of gefitinib in non-small cell lung cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Azacitidine; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; CpG Islands; Decitabine; DNA Methylation; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Promoter Regions, Genetic; Protein Kinase Inhibitors; Quinazolines | 2013 |
A DNA methyltransferase inhibitor, 5-aza-2'-deoxycytidine, exacerbates neurotoxicity and upregulates Parkinson's disease-related genes in dopaminergic neurons.
Topics: 1-Methyl-4-phenylpyridinium; alpha-Synuclein; Animals; Apoptosis; Azacitidine; Cell Survival; Cells, Cultured; CpG Islands; Decitabine; DNA Methylation; DNA Modification Methylases; Dopaminergic Neurons; Enzyme Inhibitors; Gene Expression Regulation; Humans; Mice; Oxidopamine; Promoter Regions, Genetic; Rats; Rotenone | 2013 |
Epigenetic regulation of the Wnt signaling inhibitor DACT2 in human hepatocellular carcinoma.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Animals; Apoptosis; Azacitidine; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; beta Catenin; Carcinogenesis; Carcinoma, Hepatocellular; Carrier Proteins; Cell Line, Tumor; Cell Proliferation; Decitabine; Epigenesis, Genetic; Female; G2 Phase Cell Cycle Checkpoints; Heterografts; Humans; Liver Neoplasms; Male; Methylation; Mice, Nude; Middle Aged; Neoplasm Proteins; Polymorphism, Single Nucleotide; Promoter Regions, Genetic; Transcription Factor 4; Transcription Factors; Wnt Signaling Pathway | 2013 |
Demethylation demystification.
Topics: Animals; Azacitidine; Decitabine; Gene Expression Regulation, Leukemic; Humans; Leukemia, Myeloid, Acute | 2013 |
Silibinin synergizes with histone deacetylase and DNA methyltransferase inhibitors in upregulating E-cadherin expression together with inhibition of migration and invasion of human non-small cell lung cancer cells.
Topics: Antioxidants; Azacitidine; Blotting, Western; Cadherins; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Decitabine; Drug Synergism; Enzyme Inhibitors; Epigenesis, Genetic; Gene Silencing; Histone Deacetylase Inhibitors; Homeodomain Proteins; Humans; Hydroxamic Acids; Neoplasm Invasiveness; Silybin; Silymarin; Transcription Factors; Up-Regulation; Zinc Finger E-box-Binding Homeobox 1 | 2013 |
The role of DNA methylation and histone acetylation in the regulation of progesterone receptor isoforms expression in human astrocytoma cell lines.
Topics: Acetylation; Astrocytoma; Azacitidine; Cell Line, Tumor; Cell Proliferation; Cell Survival; Decitabine; DNA Methylation; Gene Expression Regulation, Neoplastic; Histones; Humans; Hydroxamic Acids; Neoplasm Grading; Protein Isoforms; Receptors, Progesterone | 2013 |
[Curative effect of decitabine combined with cytokine-induced killer cells in two elderly patients with acute myeloid leukemia].
Topics: Aged, 80 and over; Azacitidine; Cytokine-Induced Killer Cells; Decitabine; Humans; Immunotherapy, Adoptive; Leukemia, Myeloid, Acute; Male; Treatment Outcome | 2013 |
[Clinical observation of decitabine-treating patients with myelodysplastic syndrome and acute myeloid leukemia].
Topics: Adult; Aged; Aged, 80 and over; Azacitidine; Decitabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Survival Rate; Treatment Outcome; Young Adult | 2013 |
Conversion of peripheral blood NK cells to a decidual NK-like phenotype by a cocktail of defined factors.
Topics: Angiogenic Proteins; Azacitidine; CD56 Antigen; Cell Line, Transformed; Cell Movement; Cytoplasmic Granules; Decidua; Decitabine; Female; GPI-Linked Proteins; Human Umbilical Vein Endothelial Cells; Humans; Immunophenotyping; Killer Cells, Natural; Receptors, IgG; Receptors, KIR | 2013 |
Targeted delivery of microRNA-29b by transferrin-conjugated anionic lipopolyplex nanoparticles: a novel therapeutic strategy in acute myeloid leukemia.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Cell Line, Tumor; Combined Modality Therapy; Decitabine; DNA (Cytosine-5-)-Methyltransferases; Down-Regulation; Gene Expression; Gene Expression Regulation, Leukemic; Gene Knockdown Techniques; Gene Transfer Techniques; Humans; Leukemia, Myeloid, Acute; Linoleic Acid; Male; Mice; Mice, Inbred NOD; Mice, SCID; MicroRNAs; Nanoparticles; Phosphatidylethanolamines; Polyethylene Glycols; RNA Interference; Transferrin; Xenograft Model Antitumor Assays | 2013 |
Development of a novel cell-based assay system EPISSAY for screening epigenetic drugs and liposome formulated decitabine.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Azacitidine; Breast; Carrier Proteins; Cells, Cultured; Cytomegalovirus; Decitabine; DNA Methylation; Drug Screening Assays, Antitumor; Epigenesis, Genetic; Gene Expression Regulation; Genes, Reporter; Genetic Vectors; Humans; Hydroxamic Acids; Luminescent Proteins; Nitroreductases; Plasmids; Promoter Regions, Genetic; Red Fluorescent Protein; Repressor Proteins; RNA, Messenger; Unilamellar Liposomes; Vorinostat | 2013 |
Effect of histone deacetylase and DNA methyltransferase inhibitors on the expression of the androgen receptor gene in androgen-independent prostate cancer cell lines.
Topics: 5' Untranslated Regions; Acetylation; Androgens; Azacitidine; Butyric Acid; Cell Line, Tumor; Cell Survival; Decitabine; DNA; DNA Methylation; Histone Deacetylase Inhibitors; Histone Deacetylases; Histones; Humans; Male; Methyltransferases; Promoter Regions, Genetic; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen | 2013 |
Epigenetically induced changes in nuclear textural patterns and gelatinase expression in human fibrosarcoma cells.
Topics: Azacitidine; Biomarkers, Tumor; Cell Line, Tumor; Cell Nucleus; Chromatin; Chromatin Assembly and Disassembly; Decitabine; Disease Progression; DNA Methylation; Epigenesis, Genetic; Fibrosarcoma; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Image Cytometry; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Matrix Metalloproteinase Inhibitors; Neoplasm Metastasis; Neoplasm Proteins | 2013 |
[Molecular target therapy for myelodysplastic syndrome].
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cytokines; Decitabine; Epigenesis, Genetic; Histone Deacetylase Inhibitors; Humans; Lenalidomide; Molecular Targeted Therapy; Myelodysplastic Syndromes; Thalidomide; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A | 2012 |
A rapid and sensitive assay for DNA-protein covalent complexes in living cells.
Topics: Azacitidine; Camptothecin; Cell Line; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Adducts; DNA Topoisomerases, Type I; DNA-Binding Proteins; Humans; Immunoassay; Nuclear Proteins; Topoisomerase I Inhibitors | 2013 |
Scavenger receptor class A member 3 (SCARA3) in disease progression and therapy resistance in multiple myeloma.
Topics: Antineoplastic Agents; Azacitidine; Boronic Acids; Bortezomib; Cell Line; Cell Line, Tumor; Decitabine; Dexamethasone; Disease Progression; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Heat-Shock Proteins; Humans; Hydrogen Peroxide; Hydroxamic Acids; Multiple Myeloma; Oligonucleotide Array Sequence Analysis; Oxidants; Prognosis; Pyrazines; Radiation, Ionizing; Reverse Transcriptase Polymerase Chain Reaction; Scavenger Receptors, Class A | 2013 |
Deregulated expression of urokinase and its inhibitor type 1 in prostate cancer cells: role of epigenetic mechanisms.
Topics: Adenocarcinoma; Azacitidine; Cell Line, Tumor; Decitabine; DNA Methylation; DNA, Neoplasm; Down-Regulation; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Male; Neoplasm Invasiveness; Plasminogen Activator Inhibitor 1; Prostate; Prostatic Neoplasms; Urokinase-Type Plasminogen Activator | 2013 |
[Small interfering RNA targeting to hepatitis B virus X gene and 5-aza-2'-deoxycytidineon inhibited growth of the subcutaneous implanted tumor of hepatocellular carcinoma in nude mice].
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Methylation; Genes, p16; Hep G2 Cells; Humans; Liver Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; RNA, Small Interfering; Trans-Activators; Viral Regulatory and Accessory Proteins | 2012 |
Gastric cancer prevention by demethylation.
Topics: Adenocarcinoma; Animals; Azacitidine; Decitabine; DNA-Cytosine Methylases; Helicobacter Infections; Helicobacter pylori; Male; Stomach Neoplasms | 2013 |
Prevention of Helicobacter pylori-induced gastric cancers in gerbils by a DNA demethylating agent.
Topics: Adenocarcinoma; Animals; Azacitidine; Carcinogens; Decitabine; Disease Models, Animal; DNA Methylation; DNA-Cytosine Methylases; Drug Evaluation, Preclinical; Gene Expression Regulation, Neoplastic; Gerbillinae; Helicobacter Infections; Helicobacter pylori; Male; Methylnitrosourea; Stomach Neoplasms | 2013 |
5-Aza-2'-deoxycytidine enhances maspin expression and inhibits proliferation, migration, and invasion of the bladder cancer T24 cell line.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Cell Line, Tumor; Cell Movement; Cell Proliferation; Decitabine; DNA Methylation; DNA Modification Methylases; Humans; RNA, Messenger; Serpins; Urinary Bladder Neoplasms | 2013 |
Lipid-polymer nanoparticles encapsulating doxorubicin and 2'-deoxy-5-azacytidine enhance the sensitivity of cancer cells to chemical therapeutics.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Azacitidine; Cell Line, Tumor; Cell Proliferation; Decitabine; Doxorubicin; Drug Delivery Systems; Drug Synergism; Epigenesis, Genetic; Genes, Tumor Suppressor; Humans; Lactic Acid; Nanocapsules; Phosphatidylethanolamines; Polyethylene Glycols; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer | 2013 |
Heart failure and angiotensin II modulate atrial Pitx2c promotor methylation.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Azacitidine; Cell Line, Tumor; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Drug Interactions; Enzyme Inhibitors; Heart Atria; Heart Failure; Homeobox Protein PITX2; Homeodomain Proteins; Isoproterenol; Losartan; Male; Promoter Regions, Genetic; Rats; RNA; Transcription Factors | 2013 |
Van-Gogh-like 2 antagonises the canonical WNT pathway and is methylated in colorectal cancers.
Topics: Aged; Azacitidine; beta Catenin; Caco-2 Cells; Cell Growth Processes; Cell Line, Tumor; Colorectal Neoplasms; Decitabine; DNA Methylation; Female; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; HCT116 Cells; HT29 Cells; Humans; Intracellular Signaling Peptides and Proteins; Male; Membrane Proteins; Microsatellite Instability; Mutation; Promoter Regions, Genetic; Proto-Oncogene Proteins B-raf; RNA, Messenger; Wnt Proteins; Wnt Signaling Pathway | 2013 |
Decitabine, a DNA methyltransferases inhibitor, induces cell cycle arrest at G2/M phase through p53-independent pathway in human cancer cells.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Blotting, Western; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Decitabine; Enzyme Inhibitors; Flow Cytometry; G2 Phase Cell Cycle Checkpoints; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; HCT116 Cells; Humans; Lung Neoplasms; M Phase Cell Cycle Checkpoints; RNA, Small Interfering; Stomach Neoplasms; Tumor Suppressor Protein p53; Up-Regulation | 2013 |
Induced DNA demethylation can reshape chromatin topology at the IGF2-H19 locus.
Topics: Azacitidine; CCCTC-Binding Factor; Cell Cycle Proteins; Cell Line, Tumor; Chromatin; Chromosomal Proteins, Non-Histone; Cohesins; Decitabine; DNA Methylation; Down-Regulation; Enhancer Elements, Genetic; Enzyme Inhibitors; Gene Expression; Genetic Loci; Genomic Imprinting; Histones; Humans; Insulin-Like Growth Factor II; Methylation; Mucoproteins; Neoplasm Proteins; Nucleosomes; Polycomb Repressive Complex 2; Promoter Regions, Genetic; Repressor Proteins; RNA, Long Noncoding; Transcription Factors | 2013 |
[Interpretation of decitabine treatment for elderly patients with acute myeloid leukemia: the multicenter, open-label, phase III clinical trial (registered trial DACO-016)].
Topics: Azacitidine; Clinical Trials, Phase III as Topic; Decitabine; Humans; Leukemia, Myeloid, Acute; Multicenter Studies as Topic | 2013 |
STAT3 acetylation-induced promoter methylation is associated with downregulation of the ARHI tumor-suppressor gene in ovarian cancer.
Topics: Acetylation; Adult; Azacitidine; Cell Line, Tumor; Cell Proliferation; Chromatin Immunoprecipitation; CpG Islands; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Female; Gene Expression Regulation, Neoplastic; Humans; Ovarian Neoplasms; Promoter Regions, Genetic; rho GTP-Binding Proteins; STAT3 Transcription Factor | 2013 |
5-Aza-2'-deoxycytidine causes replication lesions that require Fanconi anemia-dependent homologous recombination for repair.
Topics: Animals; Azacitidine; Cell Line; Chromatids; Cricetinae; Cricetulus; Decitabine; DNA Breaks; DNA Replication; DNA-Activated Protein Kinase; Enzyme Inhibitors; Fanconi Anemia Complementation Group G Protein; Leupeptins; Proteasome Inhibitors; Recombinational DNA Repair | 2013 |
Oxidative stress causes epigenetic alteration of CDX1 expression in colorectal cancer cells.
Topics: Azacitidine; Colorectal Neoplasms; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Enzyme Activation; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Gene Silencing; Histone Deacetylase 1; Homeodomain Proteins; HT29 Cells; Humans; Hydrogen Peroxide; Oxidative Stress; Promoter Regions, Genetic; Reactive Oxygen Species; RNA, Messenger; Serine; Time Factors | 2013 |
Epigenetic regulation of BMP2 by 1,25-dihydroxyvitamin D3 through DNA methylation and histone modification.
Topics: Animals; Azacitidine; Bone Morphogenetic Protein 2; Decitabine; DNA Methylation; Epigenesis, Genetic; Female; Histones; Hypercalciuria; Male; Promoter Regions, Genetic; Protein Binding; Protein Processing, Post-Translational; Rats; Rats, Sprague-Dawley; Receptors, Calcitriol; Response Elements; Transcription, Genetic; Vitamin D | 2013 |
Acute graft-versus-host disease in a nonhematopoietic stem cell transplantation candidate treated with decitabine followed by granulocyte colony-stimulating factor-primed peripheral blood stem cells infusion: a special entity of the disease?
Topics: Acute Disease; Antineoplastic Agents; Azacitidine; Combined Modality Therapy; Decitabine; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Transplantation Conditioning | 2014 |
[Effects of decitabine on proliferation and apoptosis of NB4 and K562 cells].
Topics: Apoptosis; Azacitidine; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Decitabine; Humans; K562 Cells | 2013 |
Epigenetic inactivation of Notch-Hes pathway in human B-cell acute lymphoblastic leukemia.
Topics: Apoptosis; Azacitidine; B-Lymphocytes; Basic Helix-Loop-Helix Transcription Factors; Blood Cells; Bone Marrow; Calcium-Binding Proteins; Cell Line, Tumor; Cell Lineage; Cell Proliferation; Decitabine; DNA Methylation; Epigenesis, Genetic; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Gene Silencing; Hematopoiesis; Histones; Humans; Hydroxamic Acids; Intercellular Signaling Peptides and Proteins; Jagged-1 Protein; Leukemia, B-Cell; Membrane Proteins; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Receptor, Notch3; Receptors, Notch; Repressor Proteins; Serrate-Jagged Proteins; Signal Transduction; T-Lymphocytes; Transcription, Genetic; Vorinostat | 2013 |
Successful use of very low dose subcutaneous decitabine to treat high-risk myelofibrosis with Sweet syndrome that was refractory to 5-azacitidine.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Dose-Response Relationship, Drug; Humans; Injections, Subcutaneous; Male; Middle Aged; Primary Myelofibrosis; Risk Factors; Sweet Syndrome; Treatment Outcome | 2014 |
[Effect of 5-aza-2'-deoxycytidine on growth and methylation of RUNX3 gene in human pancreatic cancer cell line MiaPaca2].
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cell Line, Tumor; Cell Proliferation; Core Binding Factor Alpha 3 Subunit; Decitabine; DNA Methylation; Dose-Response Relationship, Drug; Gene Expression Regulation, Neoplastic; Humans; Pancreatic Neoplasms; RNA, Messenger | 2013 |
Epigenetic action of decitabine (5-aza-2'-deoxycytidine) is more effective against acute myeloid leukemia than cytotoxic action of cytarabine (ARA-C).
Topics: Acute Disease; Aged; Antimetabolites, Antineoplastic; Azacitidine; Cell Line, Tumor; Cell Survival; Cytarabine; Decitabine; DNA Methylation; Dose-Response Relationship, Drug; Drug Approval; HL-60 Cells; Humans; Leukemia, Myeloid; Middle Aged; Remission Induction; Survival Analysis; Treatment Outcome; United States; United States Food and Drug Administration | 2013 |
Multiple-to-multiple relationships between microRNAs and target genes in gastric cancer.
Topics: Azacitidine; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; Decitabine; DNA Methylation; Gene Expression Regulation, Neoplastic; Humans; Intercellular Signaling Peptides and Proteins; Methyl-CpG-Binding Protein 2; MicroRNAs; Nerve Tissue Proteins; Promoter Regions, Genetic; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Stomach Neoplasms; Transfection | 2013 |
Concise drug review: azacitidine and decitabine.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials, Phase III as Topic; Decitabine; Drug Approval; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes | 2013 |
Low dose decitabine treatment induces CD80 expression in cancer cells and stimulates tumor specific cytotoxic T lymphocyte responses.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; B7-1 Antigen; Cell Line, Tumor; Cell Proliferation; Decitabine; DNA Methylation; Dose-Response Relationship, Drug; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Interferon-gamma; Interleukin-2; K562 Cells; Mice; Mice, Inbred C57BL; Neoplasms, Experimental; Oligonucleotide Array Sequence Analysis; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; T-Lymphocytes; T-Lymphocytes, Cytotoxic; Tumor Burden; U937 Cells | 2013 |
Inhibitory effects of epigenetic modulators and differentiation inducers on human medulloblastoma cell lines.
Topics: Antineoplastic Agents; Azacitidine; Cell Line, Tumor; Cell Proliferation; Cerebellar Neoplasms; Decitabine; DNA Breaks, Double-Stranded; Dose-Response Relationship, Drug; Epigenesis, Genetic; Humans; Medulloblastoma; Neoplasm Grading; Tretinoin; Tumor Stem Cell Assay; Valproic Acid | 2013 |
[p15(INK4B) methylation on prognosis and response to decitabine in patients with MDS].
Topics: Adult; Aged; Azacitidine; Cyclin-Dependent Kinase Inhibitor p15; Decitabine; DNA Methylation; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Survival Rate; Treatment Outcome | 2013 |
Role of DNA methylation in long-term low-dose γ-rays induced adaptive response in human B lymphoblast cells.
Topics: Adaptation, Physiological; Azacitidine; B-Lymphocytes; Cell Line; Cell Proliferation; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Dose-Response Relationship, Radiation; Gamma Rays; Gene Expression Regulation; Heterochromatin; Humans; Radiation Tolerance | 2013 |
The Wnt antagonists DKK1 and SFRP1 are downregulated by promoter hypermethylation in systemic sclerosis.
Topics: Adult; Aged; Animals; Azacitidine; Case-Control Studies; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Down-Regulation; Enzyme Inhibitors; Epigenesis, Genetic; Female; Fibroblasts; Humans; Intercellular Signaling Peptides and Proteins; Leukocytes, Mononuclear; Male; Membrane Proteins; Mice; Middle Aged; Promoter Regions, Genetic; Scleroderma, Systemic; Wnt Signaling Pathway; Young Adult | 2014 |
Global methylation analysis identifies prognostically important epigenetically inactivated tumor suppressor genes in multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Azacitidine; Chromosome Aberrations; Decitabine; Disease Progression; DNA Methylation; Epigenesis, Genetic; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Humans; Male; Middle Aged; Multiple Myeloma; Osteonectin; Phenotype; Prognosis; Transforming Growth Factor beta1; Tumor Suppressor Proteins | 2013 |
Epigenetic regulation of MicroRNA-122 by peroxisome proliferator activated receptor-gamma and hepatitis b virus X protein in hepatocellular carcinoma cells.
Topics: Azacitidine; Carcinoma, Hepatocellular; Decitabine; Epigenesis, Genetic; Hep G2 Cells; Hepatitis C; Humans; Liver Neoplasms; Methyltransferases; MicroRNAs; Phenylbutyrates; PPAR gamma; Promoter Regions, Genetic; Repressor Proteins; Trans-Activators; Viral Regulatory and Accessory Proteins | 2013 |
Epigenetic regulation of microRNA expression in renal cell carcinoma.
Topics: Azacitidine; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Decitabine; DNA Methylation; DNA Modification Methylases; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Gene Silencing; Histone Deacetylases; Histones; Humans; Hydroxamic Acids; Kidney Neoplasms; MicroRNAs; Promoter Regions, Genetic; RNA; Vorinostat | 2013 |
The NuRD complex cooperates with DNMTs to maintain silencing of key colorectal tumor suppressor genes.
Topics: Apoptosis; Autoantigens; Azacitidine; Colorectal Neoplasms; Decitabine; DNA (Cytosine-5-)-Methyltransferases; Epigenesis, Genetic; Gene Expression; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Genes, Tumor Suppressor; HCT116 Cells; Histone Deacetylase 1; Histone Deacetylase 2; Humans; Mi-2 Nucleosome Remodeling and Deacetylase Complex; Promoter Regions, Genetic; Protein Binding; Wnt Proteins | 2014 |
Inhibition of DNA methyltransferases, histone deacetylases and lysine-specific demethylase-1 suppresses the tumorigenicity of the ovarian cancer ascites cell line SKOV3.
Topics: Acetylation; Animals; Ascites; Azacitidine; Cadherins; Carcinogenesis; Cell Movement; Decitabine; DNA Methylation; DNA Modification Methylases; Female; Histone Deacetylase Inhibitors; Histone Deacetylases; Histone Demethylases; Histones; Humans; Hydroxamic Acids; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Matrix Metalloproteinase Inhibitors; Mice; Mice, Inbred C3H; Mice, SCID; Neoplasm Invasiveness; Neoplasm Metastasis; Nuclear Proteins; Ovarian Neoplasms; Spheroids, Cellular; Tumor Cells, Cultured; Twist-Related Protein 1 | 2013 |
Exploration of tumor-suppressive microRNAs silenced by DNA hypermethylation in cervical cancer.
Topics: Azacitidine; Cell Line, Tumor; Decitabine; DNA Methylation; Enzyme Inhibitors; Female; Gene Expression Profiling; Gene Silencing; Humans; Microarray Analysis; MicroRNAs; Real-Time Polymerase Chain Reaction; Uterine Cervical Neoplasms | 2013 |
FOXP3 demethylation as a means of identifying quantitative defects in regulatory T cells in acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adult; Aged; Atherosclerosis; Azacitidine; Biomarkers; CD4 Antigens; Cells, Cultured; Cholesterol, LDL; Decitabine; DNA Modification Methylases; Down-Regulation; Female; Flow Cytometry; Forkhead Transcription Factors; Humans; Interferon-gamma; Interleukin-10; Interleukin-2 Receptor alpha Subunit; Male; Methylation; Middle Aged; T-Lymphocytes, Regulatory; Transforming Growth Factor beta1; Troponin I; Up-Regulation | 2013 |
Promoter hypermethylation contributes to the frequent suppression of the CDK10 gene in human nasopharyngeal carcinomas.
Topics: Azacitidine; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cell Survival; CpG Islands; Cyclin-Dependent Kinases; Decitabine; DNA Methylation; Down-Regulation; G1 Phase Cell Cycle Checkpoints; Gene Expression Regulation, Neoplastic; Humans; Nasopharyngeal Neoplasms; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference | 2013 |
Latent transforming growth factor β-binding protein 4 is downregulated in esophageal cancer via promoter methylation.
Topics: Azacitidine; Base Sequence; Binding Sites; Carcinoma; Cell Line, Tumor; Cell Movement; Decitabine; Disease Progression; DNA Methylation; Down-Regulation; Esophageal Neoplasms; Gene Expression Regulation, Neoplastic; Gene Order; Humans; Latent TGF-beta Binding Proteins; Neoplasm Staging; Promoter Regions, Genetic; Protein Binding; Transcription Factors; Transforming Growth Factor beta1 | 2013 |
Epigenetic modifications during sex change repress gonadotropin stimulation of cyp19a1a in a teleost ricefield eel (Monopterus albus).
Topics: Acetylation; Amino Acid Sequence; Animals; Aromatase; Azacitidine; Base Sequence; CpG Islands; Cyclic AMP; Decitabine; DNA Methylation; Eels; Enzyme Inhibitors; Epigenesis, Genetic; Female; Fish Proteins; Gene Expression; Gonadotropins; Hermaphroditic Organisms; Histones; Male; Methylation; Molecular Sequence Data; Ovary; Reverse Transcriptase Polymerase Chain Reaction; Sex Determination Processes; Testis | 2013 |
Treating cloned embryos, but not donor cells, with 5-aza-2'-deoxycytidine enhances the developmental competence of porcine cloned embryos.
Topics: Abattoirs; Animals; Azacitidine; Blastocyst; Blastomeres; Cells, Cultured; Cloning, Organism; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Down-Regulation; Ectogenesis; Embryo Culture Techniques; Enzyme Inhibitors; Epigenesis, Genetic; Female; Fetus; Fibroblasts; Gene Expression Regulation, Developmental; In Vitro Oocyte Maturation Techniques; Male; Nuclear Transfer Techniques; RNA, Messenger; Sus scrofa | 2013 |
Reversal of ER-β silencing by chromatin modifying agents overrides acquired tamoxifen resistance.
Topics: Active Transport, Cell Nucleus; Antineoplastic Agents, Hormonal; Apoptosis; Azacitidine; Breast Neoplasms; Cell Survival; Chromatin Assembly and Disassembly; Decitabine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Estrogen Receptor beta; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; MCF-7 Cells; Tamoxifen; Time Factors; Transfection | 2013 |
Hypermethylation of testis derived transcript gene promoter significantly correlates with worse outcomes in glioblastoma patients.
Topics: Azacitidine; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cytoskeletal Proteins; Decitabine; DNA Methylation; Glioblastoma; Humans; LIM Domain Proteins; Promoter Regions, Genetic; RNA-Binding Proteins; Treatment Outcome | 2013 |
Hepatitis C virus core protein epigenetically silences SFRP1 and enhances HCC aggressiveness by inducing epithelial-mesenchymal transition.
Topics: Acetylation; Animals; Azacitidine; beta Catenin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Decitabine; Disease Models, Animal; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; Epigenesis, Genetic; Epithelial-Mesenchymal Transition; Gene Expression Regulation; Gene Knockdown Techniques; Gene Silencing; Histones; Humans; Hydroxamic Acids; Intercellular Signaling Peptides and Proteins; Liver Neoplasms; Membrane Proteins; Promoter Regions, Genetic; Tumor Burden; Viral Core Proteins; Wnt Proteins; Xenograft Model Antitumor Assays | 2014 |
Hypomethylation of the CTGF gene locus is a common feature of paediatric pre-B acute lymphoblastic leukaemia.
Topics: Azacitidine; Cells, Cultured; Child; Connective Tissue Growth Factor; CpG Islands; Decitabine; DNA Methylation; Gene Expression Regulation, Leukemic; Humans; Hydroxamic Acids; Jurkat Cells; Neoplasm Proteins; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Real-Time Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Sequence Analysis, DNA | 2013 |
Combining gene therapy and fetal hemoglobin induction for treatment of β-thalassemia.
Topics: Antisickling Agents; Azacitidine; beta-Globins; beta-Thalassemia; Decitabine; Fetal Hemoglobin; Genetic Therapy; Genetic Vectors; Humans; Hydroxyurea; Lentivirus; Retroviridae; Thalidomide | 2013 |
Retrospective analysis of prognostic factors associated with response and overall survival by baseline marrow blast percentage in patients with myelodysplastic syndromes treated with decitabine.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow; Decitabine; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Retrospective Studies; Treatment Outcome | 2013 |
Insulin-like growth factor binding protein-3 (IGFBP-3) plays a role in the anti-tumorigenic effects of 5-Aza-2'-deoxycytidine (AZA) in breast cancer cells.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Breast Neoplasms; Cell Death; Cell Proliferation; Cell Transformation, Neoplastic; Decitabine; DNA Methylation; Epigenesis, Genetic; Estrogen Receptor alpha; Female; Gene Silencing; Humans; Insulin-Like Growth Factor Binding Protein 3; MCF-7 Cells; RNA, Small Interfering; Transcription Factor AP-2; Tumor Suppressor Protein p53 | 2013 |
[Clinical efficacy of decitabine plus improved CAG chemotherapy and haplo-identical donor peripheral lymphocyte infusion regimen on elderly patients with high risk myelodysplastic syndrome and acute myeloid leukemia].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Decitabine; Female; Haploidy; Humans; Leukemia, Myeloid, Acute; Lymphocyte Transfusion; Lymphocytes; Male; Middle Aged; Myelodysplastic Syndromes; Treatment Outcome | 2013 |
A carrier-mediated prodrug approach to improve the oral absorption of antileukemic drug decitabine.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Caco-2 Cells; Chromatography, High Pressure Liquid; Decitabine; Humans; Male; Models, Biological; Prodrugs; Rats; Rats, Sprague-Dawley; Tandem Mass Spectrometry | 2013 |
[5-day decitabine for treatment of myelodysplastic syndromes with complex karyotype abnormalities and acute myeloid leukemia].
Topics: Adult; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Female; Humans; Karyotype; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Treatment Outcome | 2013 |
The different faces of myelodysplasia in peripheral blood granulocytes.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Chemotherapy, Adjuvant; Decitabine; Female; Granulocytes; Hematopoiesis; Humans; Leukemia, Myeloid, Acute; Neoplasms, Second Primary; Ovarian Neoplasms; Remission Induction | 2014 |
Identification of genes specifically methylated in Epstein-Barr virus-associated gastric carcinomas.
Topics: Aged; Azacitidine; Carcinoma; Cell Line, Tumor; Cytoskeletal Proteins; Decitabine; DNA Methylation; DNA-Binding Proteins; DNA, Neoplasm; Epstein-Barr Virus Infections; Female; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Homeodomain Proteins; Humans; Hydroxamic Acids; Male; Microfilament Proteins; Middle Aged; Neoplasm Proteins; Nerve Tissue Proteins; Nuclear Proteins; Oncogene Proteins; Promoter Regions, Genetic; Protein Serine-Threonine Kinases; Real-Time Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Stomach Neoplasms; Transcription Factors; Tumor Protein p73; Tumor Suppressor Proteins | 2013 |
DNA methylation in nasal epithelial cells from smokers: identification of ULBP3-related effects.
Topics: Adult; Azacitidine; Decitabine; DNA Methylation; Epithelial Cells; Female; GPI-Linked Proteins; Humans; Influenza A virus; Influenza, Human; Intercellular Signaling Peptides and Proteins; Male; Nasal Mucosa; Smoking; Suppressor of Cytokine Signaling 3 Protein; Suppressor of Cytokine Signaling Proteins; Transcriptome | 2013 |
Laccaic acid A is a direct, DNA-competitive inhibitor of DNA methyltransferase 1.
Topics: Aminoquinolines; Anthraquinones; Azacitidine; Azo Compounds; Base Sequence; Breast Neoplasms; Decitabine; DNA; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Replication; Enzyme Inhibitors; Female; Fluorometry; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Molecular Sequence Data; Oligonucleotide Array Sequence Analysis; Pyrimidines; Reproducibility of Results; Signal Transduction; Transition Temperature | 2013 |
Epigenetic changes induced by adenosine augmentation therapy prevent epileptogenesis.
Topics: Adenosine; Adenosine Kinase; Animals; Anticonvulsants; Azacitidine; Base Sequence; Brain; CpG Islands; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Drug Implants; Epigenesis, Genetic; Epilepsy; Male; Mice; Mossy Fibers, Hippocampal; Rats; Rats, Sprague-Dawley; Sequence Analysis, DNA | 2013 |
The promoter of miR-663 is hypermethylated in Chinese pediatric acute myeloid leukemia (AML).
Topics: Adolescent; Azacitidine; Bone Marrow; Cell Line, Tumor; Child; Child, Preschool; China; Decitabine; DNA Methylation; Female; Genes, Tumor Suppressor; Humans; Infant; Leukemia, Myeloid, Acute; Male; MicroRNAs; Promoter Regions, Genetic; Sequence Analysis, DNA; Transcription, Genetic | 2013 |
The Tumor Suppressor Roles of miR-433 and miR-127 in Gastric Cancer.
Topics: 3' Untranslated Regions; Adult; Aged; Aged, 80 and over; Azacitidine; Cell Line, Tumor; Cell Movement; Cell Proliferation; Decitabine; Down-Regulation; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Hydroxamic Acids; Male; MicroRNAs; Middle Aged; Neoplasm Staging; ras Proteins; Stomach Neoplasms | 2013 |
Activation-induced cytidine deaminase (AID) is necessary for the epithelial-mesenchymal transition in mammary epithelial cells.
Topics: Animals; Azacitidine; Blotting, Western; Breast Neoplasms; Cell Line; Cell Line, Tumor; Cell Movement; CpG Islands; Cytidine Deaminase; Decitabine; DNA Methylation; Epithelial Cells; Epithelial-Mesenchymal Transition; Gene Expression Regulation; Genetic Complementation Test; HEK293 Cells; Humans; Mammary Glands, Human; Matrix Metalloproteinases; Mice; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Transforming Growth Factor beta; Tumor Necrosis Factor-alpha | 2013 |
RASSF2 methylation is a strong prognostic marker in younger age patients with Ewing sarcoma.
Topics: Adolescent; Azacitidine; Cell Line, Tumor; Cells, Cultured; Child; Child, Preschool; Cohort Studies; Decitabine; DNA Methylation; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Humans; Prognosis; Real-Time Polymerase Chain Reaction; Sarcoma, Ewing; Tumor Suppressor Proteins | 2013 |
Endoglin promoter hypermethylation identifies a field defect in human primary esophageal cancer.
Topics: Adenocarcinoma; Aged; Antigens, CD; Antimetabolites, Antineoplastic; Azacitidine; Biomarkers, Tumor; Carcinoma, Squamous Cell; Case-Control Studies; Decitabine; DNA Methylation; Endoglin; Esophageal Neoplasms; Esophagus; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Staging; Prognosis; Promoter Regions, Genetic; Real-Time Polymerase Chain Reaction; Receptors, Cell Surface; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; ROC Curve; Tumor Cells, Cultured | 2013 |
Aberrant NDRG1 methylation associated with its decreased expression and clinicopathological significance in breast cancer.
Topics: Azacitidine; Breast Neoplasms; Cell Cycle Proteins; Cell Differentiation; Cell Line, Tumor; CpG Islands; Decitabine; DNA Methylation; Epigenesis, Genetic; Female; Gene Expression Regulation, Neoplastic; Humans; Intracellular Signaling Peptides and Proteins; Neoplasm Metastasis; Promoter Regions, Genetic | 2013 |
Inhibition of DNA methylation attenuates low-dose cadmium-induced cardiac contractile and intracellular Ca(2+) anomalies.
Topics: Animals; Azacitidine; Biomechanical Phenomena; Cadmium; Calcium; Cells, Cultured; Cytokines; Decitabine; DNA Methylation; Drug Administration Schedule; Environmental Pollutants; Enzyme Inhibitors; Female; Heart; Male; Mice; Mice, Inbred C57BL; Myocardial Contraction; Myocardium; Random Allocation | 2013 |
Expression of 17β-hydroxysteroid dehydrogenase type 1 in gastric cancer.
Topics: Aged; Azacitidine; Cell Line, Tumor; Decitabine; DNA Methylation; Estradiol; Estradiol Dehydrogenases; Estrone; Female; Humans; Male; Methylation; Stomach Neoplasms; Up-Regulation | 2013 |
The DNA methyl transferase inhibitor, 5'-aza-2-deoxycitidine, enhances the apoptotic effect of Mevastatin in human leukemia HL-60 cells.
Topics: Apoptosis; Azacitidine; Caspases; Decitabine; DNA Modification Methylases; DNA Replication; Drug Synergism; Enzyme Activation; Enzyme-Linked Immunosorbent Assay; HL-60 Cells; Humans; L-Lactate Dehydrogenase; Leukemia; Lovastatin; Methylation; Microscopy, Fluorescence; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2014 |
Differential induction of apoptosis and senescence by the DNA methyltransferase inhibitors 5-azacytidine and 5-aza-2'-deoxycytidine in solid tumor cells.
Topics: Apoptosis; Azacitidine; Cell Line, Tumor; Cell Proliferation; Cellular Senescence; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Breaks, Double-Stranded; DNA Methylation; Hep G2 Cells; Humans; Neoplasms; Tumor Suppressor Protein p53 | 2013 |
Aldosterone reprograms promoter methylation to regulate αENaC transcription in the collecting duct.
Topics: Aldosterone; Animals; Azacitidine; Cell Line; Cells, Cultured; Cytosine; Decitabine; Dioxygenases; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Methyltransferase 3B; DNA-Binding Proteins; Endodeoxyribonucleases; Epithelial Sodium Channels; Kidney Tubules, Collecting; Mice; Promoter Regions, Genetic; Proto-Oncogene Proteins; Sp1 Transcription Factor; Transcription, Genetic | 2013 |
Reassembly of nucleosomes at the MLH1 promoter initiates resilencing following decitabine exposure.
Topics: Adaptor Proteins, Signal Transducing; Azacitidine; Cell Line, Tumor; Chromatin Assembly and Disassembly; CpG Islands; Decitabine; DNA Methylation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; MutL Protein Homolog 1; Nuclear Proteins; Nucleosomes; Promoter Regions, Genetic | 2013 |
Increased PRAME-specific CTL killing of acute myeloid leukemia cells by either a novel histone deacetylase inhibitor chidamide alone or combined treatment with decitabine.
Topics: Aminopyridines; Antigens, Neoplasm; Apoptosis; Azacitidine; Benzamides; Blotting, Western; Cell Cycle; Cell Line, Tumor; Decitabine; Flow Cytometry; Histone Deacetylase Inhibitors; HLA-A Antigens; Humans; Leukemia, Myeloid, Acute; Reverse Transcriptase Polymerase Chain Reaction; T-Lymphocytes, Cytotoxic | 2013 |
Prolonged treatment with DNMT inhibitors induces distinct effects in promoters and gene-bodies.
Topics: Azacitidine; Decitabine; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Humans; Intranuclear Inclusion Bodies; Microarray Analysis; Promoter Regions, Genetic; Time Factors; Tumor Cells, Cultured | 2013 |
Long-term cadmium exposure leads to the enhancement of lymphocyte proliferation via down-regulating p16 by DNA hypermethylation.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; B-Lymphocytes; Cadmium; Cell Line, Transformed; Cell Proliferation; Cell Transformation, Neoplastic; CpG Islands; Cyclin-Dependent Kinase Inhibitor p16; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Gene Expression Regulation; Granulocyte-Macrophage Progenitor Cells; Humans; Rats; RNA, Messenger; Time Factors | 2013 |
Promoter methylation patterns in Richter syndrome affect stem-cell maintenance and cell cycle regulation and differ from de novo diffuse large B-cell lymphoma.
Topics: Azacitidine; Cell Cycle; Cell Transformation, Neoplastic; Cluster Analysis; Decitabine; Disease Progression; DNA Methylation; Epigenesis, Genetic; Epigenomics; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genome-Wide Association Study; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Large B-Cell, Diffuse; Neoplastic Stem Cells; Oncostatin M; Promoter Regions, Genetic; Reproducibility of Results | 2013 |
Pharmacologic reversion of epigenetic silencing of the PRKD1 promoter blocks breast tumor cell invasion and metastasis.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating; Carcinoma, Lobular; Cell Movement; Cell Proliferation; Decitabine; DNA Methylation; Epigenesis, Genetic; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Immunoenzyme Techniques; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasm Invasiveness; Promoter Regions, Genetic; Protein Kinase C; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tissue Array Analysis; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2013 |
Real-time dynamics of methyl-CpG-binding domain protein 3 and its role in DNA demethylation by fluorescence correlation spectroscopy.
Topics: 5-Methylcytosine; Azacitidine; Cell Hypoxia; Cytosine; Decitabine; DNA; DNA Modification Methylases; DNA-Binding Proteins; HeLa Cells; Humans; Single-Cell Analysis; Spectrometry, Fluorescence | 2013 |
DNA methyltransferase inhibitor-mediated apoptosis in the Wnt/β-catenin signal pathway in a renal cell carcinoma cell line.
Topics: Apoptosis; Azacitidine; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Decitabine; DNA Fragmentation; DNA Methylation; DNA Modification Methylases; Epigenesis, Genetic; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Glycoproteins; Humans; Intracellular Signaling Peptides and Proteins; Wnt Signaling Pathway | 2013 |
Epigenetic changes of lentiviral transgenes in porcine stem cells derived from embryonic origin.
Topics: Animals; Azacitidine; Biomarkers; Blastocyst; Cell Differentiation; Cells, Cultured; Decitabine; DNA Methylation; Embryonic Stem Cells; Epigenesis, Genetic; Feeder Cells; Genetic Vectors; Germ Layers; Green Fluorescent Proteins; Humans; Lentivirus; Mice; Pluripotent Stem Cells; Swine; Transgenes | 2013 |
Synergistic anti-breast cancer effect of a combined treatment with the methyl donor S-adenosyl methionine and the DNA methylation inhibitor 5-aza-2'-deoxycytidine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Breast Neoplasms; Cell Line, Tumor; Decitabine; DNA Methylation; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Humans; Matrix Metalloproteinase 2; MCF-7 Cells; S-Adenosylmethionine; Urokinase-Type Plasminogen Activator | 2014 |
Galectin-7 is epigenetically-regulated tumor suppressor in gastric cancer.
Topics: Aged; Animals; Azacitidine; Cell Growth Processes; Cell Line, Tumor; Cell Movement; CpG Islands; Decitabine; DNA Methylation; Epigenomics; Female; Galectins; Genes, Tumor Suppressor; Heterografts; Humans; Male; Mice; Mice, Nude; Middle Aged; Promoter Regions, Genetic; RNA, Messenger; Stomach Neoplasms | 2013 |
Transcriptional environment and chromatin architecture interplay dictates globin expression patterns of heterospecific hybrids derived from undifferentiated human embryonic stem cells or from their erythroid progeny.
Topics: Adult; Animals; Azacitidine; beta-Globins; Carrier Proteins; Cell Differentiation; Cell Line, Tumor; Cells, Cultured; Chromatin; Decitabine; DNA-Binding Proteins; Embryo, Mammalian; Embryonic Stem Cells; epsilon-Globins; Erythroblasts; Erythroid Cells; Fibroblasts; gamma-Globins; Gene Expression Regulation, Developmental; Globins; Humans; Hybrid Cells; Mice; Nuclear Proteins; Oligonucleotide Array Sequence Analysis; Repressor Proteins; RNA Interference; Time Factors; Transcriptome | 2013 |
Characterization of permeability, stability and anti-HIV-1 activity of decitabine and gemcitabine divalerate prodrugs.
Topics: Anti-HIV Agents; Azacitidine; Biological Availability; Caco-2 Cells; Cell Proliferation; Decitabine; Deoxycytidine; Drug Stability; Gemcitabine; Half-Life; HEK293 Cells; HIV-1; Humans; Hydrogen-Ion Concentration; Permeability; Prodrugs | 2014 |
Combined treatment with low concentrations of decitabine and SAHA causes cell death in leukemic cell lines but not in normal peripheral blood lymphocytes.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Azacitidine; Cells, Cultured; Decitabine; Dose-Response Relationship, Drug; Humans; Hydroxamic Acids; Leukemia; Lymphocytes; Vorinostat | 2013 |
The cancer‑testis antigen NXF2 is activated by the hypomethylating agent decitabine in acute leukemia cells in vitro and in vivo.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Blotting, Western; Case-Control Studies; CpG Islands; Decitabine; DNA Methylation; Female; Humans; In Vitro Techniques; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Nucleocytoplasmic Transport Proteins; Promoter Regions, Genetic; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA-Binding Proteins; RNA, Messenger; Tumor Cells, Cultured | 2013 |
Smac mimetic and demethylating agents synergistically trigger cell death in acute myeloid leukemia cells and overcome apoptosis resistance by inducing necroptosis.
Topics: Apoptosis; Autocrine Communication; Azacitidine; Caspases; Cell Line, Tumor; Decitabine; DNA Fragmentation; DNA Methylation; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; Humans; Leukemia, Myeloid, Acute; Mitochondria; Mitochondrial Proteins; Necrosis; Oligopeptides; Paracrine Communication; Tumor Necrosis Factor-alpha | 2013 |
The DNA hypomethylating agent, 5-aza-2'-deoxycytidine, enhances tumor cell invasion through a transcription-dependent modulation of MMP-1 expression in human fibrosarcoma cells.
Topics: Azacitidine; Cell Line, Tumor; Cell Movement; Chromatin Assembly and Disassembly; Decitabine; DNA Methylation; Fibrosarcoma; Gene Expression Regulation, Neoplastic; Humans; Matrix Metalloproteinase 1; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Matrix Metalloproteinase Inhibitors; Neoplasm Invasiveness; Promoter Regions, Genetic; Sp1 Transcription Factor; Sp3 Transcription Factor | 2015 |
Synergistic re-activation of epigenetically silenced genes by combinatorial inhibition of DNMTs and LSD1 in cancer cells.
Topics: Azacitidine; Cell Line, Tumor; Clorgyline; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Drug Synergism; Enzyme Inhibitors; Gene Silencing; Histone Demethylases; Histones; Humans; Transcriptional Activation; Up-Regulation | 2013 |
Effects of chromatin decondensation on alternative NHEJ.
Topics: Animals; Azacitidine; Cell Cycle; Cell Line; Chromatin; Chromosomal Instability; Cytosine; Decitabine; DNA Breaks, Double-Stranded; DNA End-Joining Repair; DNA Ligases; DNA Methylation; Gene Expression Regulation; Humans; Hypotonic Solutions; Mice; Translocation, Genetic | 2013 |
Global DNA methylation analysis using methyl-sensitive amplification polymorphism (MSAP).
Topics: Arabidopsis; Azacitidine; Base Sequence; Cytidine; Decitabine; DNA Methylation; DNA, Plant; Polymerase Chain Reaction; Polymorphism, Genetic; Seeds | 2014 |
Lipid drug conjugate nanoparticle as a novel lipid nanocarrier for the oral delivery of decitabine: ex vivo gut permeation studies.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Drug Carriers; Kinetics; Nanoparticles; Permeability; Stearic Acids; Surface-Active Agents | 2013 |
Regulation of estrogen receptor β1 expression in breast cancer by epigenetic modification of the 5' regulatory region.
Topics: 5' Untranslated Regions; Acetylation; Azacitidine; Breast Neoplasms; Cell Line, Tumor; CpG Islands; Decitabine; DNA Methylation; Down-Regulation; Enzyme Inhibitors; Epigenesis, Genetic; Estrogen Receptor beta; Female; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Loss of Heterozygosity; Promoter Regions, Genetic; RNA, Messenger | 2013 |
CD49d is overexpressed by trisomy 12 chronic lymphocytic leukemia cells: evidence for a methylation-dependent regulation mechanism.
Topics: Azacitidine; B-Lymphocytes; Cell Proliferation; Cells, Cultured; Chromosomes, Human, Pair 12; Decitabine; Disease Progression; Gene Expression Regulation, Leukemic; Humans; Integrin alpha4; Leukemia, Lymphocytic, Chronic, B-Cell; Methylation; Sequence Analysis, DNA; Signal Transduction; Survival Analysis; Trisomy | 2013 |
Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Brain Neoplasms; Cell Differentiation; Cell Growth Processes; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Female; Glioma; Heterografts; Humans; Isocitrate Dehydrogenase; Mice; Mice, SCID; Mutation | 2013 |
Cytogenetic response based on revised IPSS cytogenetic risk stratification and minimal residual disease monitoring by FISH in MDS patients treated with low-dose decitabine.
Topics: Abnormal Karyotype; Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Chromosome Aberrations; Cytogenetic Analysis; Decitabine; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; In Situ Hybridization, Fluorescence; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm, Residual; Prognosis; Risk Assessment; Survival Rate | 2013 |
Methylation regulation of liver-specific microRNA-122 expression and its effects on the proliferation and apoptosis of hepatocellular carcinoma cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Decitabine; DNA Methylation; Gene Expression Regulation, Neoplastic; Hepatocytes; Humans; Liver; Liver Neoplasms; MicroRNAs; Promoter Regions, Genetic | 2013 |
AZA-deoxycytidine stimulates proopiomelanocortin gene expression and ACTH secretion in human pituitary ACTH-secreting tumors.
Topics: ACTH-Secreting Pituitary Adenoma; Adrenocorticotropic Hormone; Azacitidine; Corticotropin-Releasing Hormone; Decitabine; DNA Methylation; Gene Expression Regulation; Humans; In Vitro Techniques; Pituitary Neoplasms; Pro-Opiomelanocortin | 2014 |
Association of promoter methylation of VGF and PGP9.5 with ovarian cancer progression.
Topics: Adult; Aged; Azacitidine; Base Sequence; Cohort Studies; Decitabine; Disease Progression; DNA Methylation; DNA Primers; Female; Humans; Middle Aged; Nerve Growth Factors; Ovarian Neoplasms; Promoter Regions, Genetic; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; Ubiquitin Thiolesterase | 2013 |
MAL hypermethylation is a tissue-specific event that correlates with MAL mRNA expression in esophageal carcinoma.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Azacitidine; Barrett Esophagus; Carcinoma, Squamous Cell; Case-Control Studies; Decitabine; DNA Methylation; Esophageal Neoplasms; Esophagus; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Myelin and Lymphocyte-Associated Proteolipid Proteins; Neoplasm Grading; Prognosis; Promoter Regions, Genetic; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; ROC Curve; Tumor Cells, Cultured | 2013 |
Aberrant expression of the PRAC gene in prostate cancer.
Topics: Androgen Antagonists; Androgens; Antimetabolites, Antineoplastic; Azacitidine; Biomarkers, Tumor; Cell Line, Tumor; Decitabine; Dihydrotestosterone; Flutamide; Gene Expression Regulation, Neoplastic; Humans; Male; Nuclear Proteins; Prostatic Neoplasms | 2013 |
Inhibiting cardiac allograft rejection with interleukin-35 therapy combined with decitabine treatment in mice.
Topics: Allografts; Animals; Azacitidine; CD8-Positive T-Lymphocytes; Decitabine; Enzyme Inhibitors; Genetic Therapy; Graft Rejection; Heart Transplantation; HEK293 Cells; Humans; Interleukins; Mice; Mice, Inbred BALB C; Plasmids; T-Lymphocytes, Regulatory; Transplantation Tolerance | 2013 |
Regulation of DNA methylation by ethanol induces tissue plasminogen activator expression in astrocytes.
Topics: Animals; Antimetabolites, Antineoplastic; Astrocytes; Azacitidine; Blotting, Western; Cells, Cultured; Central Nervous System Depressants; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Methyltransferase 3A; Enzyme-Linked Immunosorbent Assay; Ethanol; Female; Gene Expression Regulation; Pregnancy; Rats; Rats, Sprague-Dawley; RNA; RNA, Messenger; Tissue Plasminogen Activator | 2014 |
Suppressed expression of NDRG2 correlates with poor prognosis in pancreatic cancer.
Topics: Azacitidine; Cell Line, Tumor; Decitabine; DNA Methylation; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Hydroxamic Acids; Immunohistochemistry; Male; Middle Aged; Negative Staining; Pancreatic Neoplasms; Prognosis; Promoter Regions, Genetic; Tumor Suppressor Proteins | 2013 |
Lack of association of IDH1, IDH2 and DNMT3A mutations with outcome in older patients with acute myeloid leukemia treated with hypomethylating agents.
Topics: Azacitidine; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methyltransferase 3A; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Mutation; Prognosis; Treatment Outcome | 2014 |
Protective effect of demethylation treatment on cigarette smoke extract-induced mouse emphysema model.
Topics: Animals; Apoptosis; Azacitidine; Decitabine; Disease Models, Animal; DNA-Binding Proteins; Electron Transport Complex IV; Emphysema; Lung; Male; Methylation; Mice; Mice, Inbred BALB C; Mitochondria; Mitochondrial Proteins; RNA, Messenger; Smoking; Transcription Factors | 2013 |
Effect of 5- AZn-2 '-deoxycytidine on proliferation of human lung adenocarcinoma cell line A549 in vitro.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Cell Line, Tumor; Cell Proliferation; Cell Shape; Decitabine; Humans; Lung Neoplasms; Malondialdehyde; Superoxide Dismutase | 2013 |
Ten-day decitabine as initial therapy for newly diagnosed patients with acute myeloid leukemia unfit for intensive chemotherapy.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Retrospective Studies; Time Factors; Treatment Outcome | 2014 |
Different involvement of promoter methylation in the expression of organic cation/carnitine transporter 2 (OCTN2) in cancer cell lines.
Topics: Animals; Azacitidine; Base Sequence; Cell Line, Tumor; Cell Survival; Chlorocebus aethiops; COS Cells; CpG Islands; Decitabine; DNA Methylation; Gene Expression Regulation, Neoplastic; Genes, Reporter; Genome, Human; Humans; Luciferases; Molecular Sequence Data; Neoplasms; Organic Cation Transport Proteins; Organoplatinum Compounds; Oxaliplatin; Polymerase Chain Reaction; Promoter Regions, Genetic; RNA, Messenger; Solute Carrier Family 22 Member 5; Transcription, Genetic | 2013 |
Efficacy of the hypomethylating agents as frontline, salvage, or consolidation therapy in adults with acute myeloid leukemia (AML).
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Comorbidity; Consolidation Chemotherapy; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Damage; DNA Methylation; DNA, Neoplasm; Drug Evaluation; Female; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Proteins; Proportional Hazards Models; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Rate | 2014 |
LHX6 acts as a novel potential tumour suppressor with epigenetic inactivation in lung cancer.
Topics: Animals; Apoptosis; Azacitidine; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cell Proliferation; Decitabine; DNA Methylation; Down-Regulation; Epigenesis, Genetic; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Gene Silencing; Humans; LIM-Homeodomain Proteins; Lung Neoplasms; Mice; Mice, Nude; Nerve Tissue Proteins; Signal Transduction; Transcription Factors; Transcription, Genetic; Tumor Suppressor Proteins; Wound Healing | 2013 |
Sex-dependent regulation of cytochrome P450 family members Cyp1a1, Cyp2e1, and Cyp7b1 by methylation of DNA.
Topics: Animals; Azacitidine; Cell Survival; Cytochrome P-450 CYP1A1; Cytochrome P-450 CYP2E1; Cytochrome P450 Family 7; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Estradiol; Female; Male; Mice; Mice, Inbred C57BL; Real-Time Polymerase Chain Reaction; Steroid Hydroxylases; Sulfites | 2014 |
Local depletion of DNA methylation identifies a repressive p53 regulatory region in the NEK2 promoter.
Topics: Azacitidine; Base Sequence; Binding Sites; Cell Cycle; Cell Proliferation; Decitabine; DNA; DNA Methylation; Dose-Response Relationship, Drug; Gene Expression Regulation; HCT116 Cells; Humans; NIMA-Related Kinases; Nucleosomes; Promoter Regions, Genetic; Protein Serine-Threonine Kinases; RNA, Messenger; Transcription, Genetic; Tumor Suppressor Protein p53 | 2013 |
Development of phenotypic screening assays for γ-globin induction using primary human bone marrow day 7 erythroid progenitor cells.
Topics: Anemia, Sickle Cell; Azacitidine; Bone Marrow Cells; Butyric Acid; Cell Survival; Decitabine; DNA Modification Methylases; Drug Evaluation, Preclinical; Enzyme-Linked Immunosorbent Assay; Epigenesis, Genetic; Erythroid Precursor Cells; gamma-Globins; Histone Deacetylase Inhibitors; Humans; Primary Cell Culture; Transcriptional Activation | 2013 |
Different effects of epigenetic modifiers on the cytotoxicity induced by 5-fluorouracil, irinotecan or oxaliplatin in colon cancer cells.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Camptothecin; Cell Line, Tumor; Colonic Neoplasms; Decitabine; DNA; DNA Modification Methylases; Drug Synergism; Epigenesis, Genetic; Fluorouracil; HCT116 Cells; Histone Deacetylase Inhibitors; HT29 Cells; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin | 2014 |
Androgen receptor is negatively correlated with the methylation-mediated transcriptional repression of miR-375 in human prostate cancer cells.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cell Line, Tumor; Decitabine; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Male; MicroRNAs; Promoter Regions, Genetic; Prostatic Neoplasms; Receptors, Androgen; RNA Interference; RNA, Small Interfering; Transcriptional Activation | 2014 |
Integrative genomic analysis of temozolomide resistance in diffuse large B-cell lymphoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Azacitidine; Cell Line, Tumor; Dacarbazine; Decitabine; Disease Models, Animal; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Silencing; Genomics; Humans; Lymphoma, Large B-Cell, Diffuse; Promoter Regions, Genetic; Temozolomide; Transcription Factors; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2014 |
[Effect of the methylation enzyme inhibitors of 5-aza-2-deoxycytidine on the TGF-beta/smad signal transduction pathway in human keloid fibroblasts].
Topics: Apoptosis; Azacitidine; Cell Proliferation; Cells, Cultured; Decitabine; Enzyme Inhibitors; Female; Fibroblasts; Humans; Keloid; Male; Signal Transduction; Smad2 Protein; Smad3 Protein; Smad7 Protein; Transforming Growth Factor beta | 2013 |
Epigenetic regulation and functional characterization of microRNA-142 in mesenchymal cells.
Topics: Azacitidine; Base Pairing; Base Sequence; Cell Line, Tumor; Cell Movement; Cell Proliferation; CpG Islands; Decitabine; DNA Methylation; Epigenesis, Genetic; Gene Expression Profiling; Gene Expression Regulation; Gene Silencing; Humans; MicroRNAs; Molecular Sequence Data; Osteosarcoma; Promoter Regions, Genetic; RNA Precursors; RNA, Antisense; Transcription, Genetic; Tumor Stem Cell Assay | 2013 |
Potential role of 5-aza-2'-deoxycytidine induced MAGE-A4 expression in immunotherapy for anaplastic thyroid cancer.
Topics: Antigens, Neoplasm; Azacitidine; Cell Line, Tumor; CpG Islands; Decitabine; DNA Methylation; Gene Expression; Humans; Immunotherapy; Indoles; MAP Kinase Signaling System; Melanoma; Neoplasm Proteins; Promoter Regions, Genetic; Proto-Oncogene Proteins B-raf; Sulfonamides; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms | 2013 |
Successful management of acute myeloid leukemia transformed from myelodysplastic syndromes in an elderly patient aged over 80 years old by ultralow dose decitabine combined with amifostine and autologous CIK cells.
Topics: Aged, 80 and over; Amifostine; Azacitidine; Cells, Cultured; Combined Modality Therapy; Cytokine-Induced Killer Cells; Decitabine; Disease Management; Disease Progression; Drug Therapy, Combination; Humans; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Transplantation, Autologous | 2014 |
Epigenetic silencing of CHD5, a novel tumor-suppressor gene, occurs in early colorectal cancer stages.
Topics: Adenoma; Azacitidine; Black or African American; Cell Line, Tumor; Cell Movement; Cell Proliferation; Colorectal Neoplasms; Decitabine; DNA Helicases; DNA Methylation; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Gene Silencing; Genes, Tumor Suppressor; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Nerve Tissue Proteins; Promoter Regions, Genetic; Vorinostat | 2014 |
Promoter DNA methylation regulates progranulin expression and is altered in FTLD.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Animals; Azacitidine; Brain; Cell Line; CpG Islands; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Methyltransferase 3A; Enzyme Inhibitors; Female; Frontotemporal Lobar Degeneration; Gene Expression Regulation; HEK293 Cells; Humans; Intercellular Signaling Peptides and Proteins; Male; Mice; Middle Aged; Parkinson Disease; Progranulins; Promoter Regions, Genetic; RNA, Messenger | 2013 |
Folate deficiency induces dysfunctional long and short telomeres; both states are associated with hypomethylation and DNA damage in human WIL2-NS cells.
Topics: Azacitidine; Biomarkers; Chromosomal Instability; Cytokinesis; Decitabine; Diet; DNA Damage; DNA Methylation; Folic Acid; Folic Acid Deficiency; Humans; Telomerase; Telomere; Uracil | 2014 |
HOXA11 hypermethylation is associated with progression of non-small cell lung cancer.
Topics: Azacitidine; Carcinoma, Non-Small-Cell Lung; Cell Growth Processes; Cell Line, Tumor; Cell Movement; Decitabine; Disease Progression; DNA Methylation; Female; Homeodomain Proteins; Humans; Lung Neoplasms; Male; Middle Aged; Paraffin Embedding; Promoter Regions, Genetic; Transfection | 2013 |
A rare case of acquired haemophilia in a patient with chronic myelomonocytic leukaemia successfully treated with decitabine.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Hemophilia A; Humans; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Treatment Outcome | 2014 |
Epigenetic repression of the dopamine receptor D4 in pediatric tumors of the central nervous system.
Topics: Apoptosis; Azacitidine; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Central Nervous System Neoplasms; Child; Chromatin Assembly and Disassembly; Decitabine; Dose-Response Relationship, Drug; Epigenesis, Genetic; Female; Humans; Hydroxamic Acids; Male; Medulloblastoma; Neuroectodermal Tumors, Primitive; Receptors, Dopamine D4; Sulfites; Tumor Cells, Cultured | 2014 |
Epigenetic inactivation of heparan sulfate (glucosamine) 3-O-sulfotransferase 2 in lung cancer and its role in tumorigenesis.
Topics: Adult; Azacitidine; Carcinogenesis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Proliferation; Decitabine; DNA Methylation; Female; Gene Knockdown Techniques; Gene Silencing; Humans; Lung Neoplasms; Male; Neoplasm Invasiveness; Phenotype; Prognosis; Promoter Regions, Genetic; Proportional Hazards Models; Sulfotransferases | 2013 |
Epigenetic regulation of the pro-apoptosis gene TSSC3 in human osteosarcoma cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Bone Neoplasms; Caspase 3; Cell Line, Tumor; Decitabine; DNA Methylation; Dose-Response Relationship, Drug; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Nuclear Proteins; Osteosarcoma; Promoter Regions, Genetic; Up-Regulation | 2014 |
Epigenetic contribution to individual variation in response to lipopolysaccharide in bovine dermal fibroblasts.
Topics: Acetylation; Animals; Azacitidine; Cattle; Decitabine; DNA Methylation; Epigenesis, Genetic; Female; Fibroblasts; Gene Expression Regulation; Hydroxamic Acids; Immunity, Innate; Interleukins; Lipopolysaccharides; Oligonucleotide Array Sequence Analysis; Real-Time Polymerase Chain Reaction; RNA; Serum Amyloid A Protein; Tumor Necrosis Factor-alpha | 2014 |
Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; B7-H1 Antigen; Biomarkers, Tumor; Cohort Studies; CTLA-4 Antigen; Decitabine; DNA Methylation; Female; Flow Cytometry; Humans; Immunoenzyme Techniques; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Leukocytes, Mononuclear; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Programmed Cell Death 1 Ligand 2 Protein; Programmed Cell Death 1 Receptor; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Tumor Cells, Cultured | 2014 |
Demethylating agent decitabine induces autologous cancer testis antigen specific cytotoxic T lymphocytes in vivo.
Topics: Animals; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Azacitidine; Cell Line, Tumor; Decitabine; Flow Cytometry; Humans; Male; Mice; Mice, Inbred BALB C; T-Lymphocytes, Cytotoxic | 2013 |
Reduced expression of Slit2 in renal cell carcinoma.
Topics: Aged; Azacitidine; Carcinoma, Renal Cell; Cell Line, Tumor; Decitabine; DNA Methylation; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; HEK293 Cells; HeLa Cells; Humans; Intercellular Signaling Peptides and Proteins; Jurkat Cells; Kidney Neoplasms; Male; Middle Aged; Nerve Tissue Proteins | 2014 |
DNA methyltransferase activity is required for memory-related neural plasticity in the lateral amygdala.
Topics: Acoustic Stimulation; Amygdala; Animals; Azacitidine; Decitabine; DNA Modification Methylases; Enzyme Inhibitors; Fear; Male; Memory; Mental Recall; Neuronal Plasticity; Phthalimides; Rats; Rats, Sprague-Dawley; Tryptophan | 2014 |
Redistribution of H3K27me3 and acetylated histone H4 upon exposure to azacitidine and decitabine results in de-repression of the AML1/ETO target gene IL3.
Topics: Acetylation; Apoptosis; Azacitidine; Cell Line, Tumor; Cell Survival; Chromatin Assembly and Disassembly; Core Binding Factor Alpha 2 Subunit; Decitabine; DNA Modification Methylases; Gene Silencing; Histones; Humans; Interleukin-3; Leukemia, Myeloid, Acute; Methylation; Promoter Regions, Genetic; Proto-Oncogene Proteins; RUNX1 Translocation Partner 1 Protein; Transcription Factors | 2014 |
Effect of inhibition of MEK pathway on 5-aza-deoxycytidine-suppressed pancreatic cancer cell proliferation.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Decitabine; DNA Methylation; Genes, Tumor Suppressor; Humans; MAP Kinase Signaling System; Pancreatic Neoplasms; Promoter Regions, Genetic; Protein Kinase Inhibitors | 2013 |
Expressions of MAGE-A9 and MAGE-A11 in breast cancer and their expression mechanism.
Topics: Adult; Antigens, Neoplasm; Azacitidine; Breast Neoplasms; Cell Line, Tumor; Decitabine; DNA Modification Methylases; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Middle Aged; Neoplasm Proteins; Receptors, Estrogen | 2014 |
Nitric oxide is involved in the down-regulation of SOST expression induced by mechanical loading.
Topics: Adaptor Proteins, Signal Transducing; Azacitidine; Bone and Bones; Bone Morphogenetic Proteins; Cell Line; Culture Media, Conditioned; Decitabine; DNA Methylation; Down-Regulation; Genetic Markers; Humans; Nitric Oxide; Osteoblasts; Pulsatile Flow; Signal Transduction; Stress, Mechanical; Transcription, Genetic; Transfection | 2014 |
Identification of hypermethylation in hepatocyte cell adhesion molecule gene promoter region in bladder carcinoma.
Topics: Azacitidine; Base Sequence; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; CpG Islands; Decitabine; DNA Methylation; DNA Primers; Flow Cytometry; Fluorescent Antibody Technique; Humans; Polymerase Chain Reaction; Promoter Regions, Genetic; Proteins; Urinary Bladder Neoplasms | 2013 |
Methylation of OPCML promoter in ovarian cancer tissues predicts poor patient survival.
Topics: Adult; Age Factors; Aged; Azacitidine; Biomarkers; Cell Adhesion Molecules; Cell Line, Tumor; Decitabine; DNA Methylation; Enzyme Inhibitors; Female; GPI-Linked Proteins; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Promoter Regions, Genetic; Real-Time Polymerase Chain Reaction; RNA; Sequence Analysis, DNA | 2014 |
Cytochrome b5 reductase 2 is a novel candidate tumor suppressor gene frequently inactivated by promoter hypermethylation in human nasopharyngeal carcinoma.
Topics: Adult; Aged; Animals; Azacitidine; Biomarkers, Tumor; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cytochrome-B(5) Reductase; Decitabine; DNA Methylation; Female; Genes, Tumor Suppressor; Humans; Male; Mice; Mice, Inbred BALB C; Middle Aged; Nasopharyngeal Neoplasms; Promoter Regions, Genetic | 2014 |
Downregulation of miR-217 correlates with resistance of Ph(+) leukemia cells to ABL tyrosine kinase inhibitors.
Topics: Animals; Antineoplastic Agents; Azacitidine; Cell Survival; Dasatinib; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Methyltransferase 3A; Down-Regulation; Drug Resistance, Neoplasm; Female; Gene Expression; Gene Expression Regulation, Leukemic; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Philadelphia Chromosome; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Xenograft Model Antitumor Assays | 2014 |
Demethylation of miR-9-3 and miR-193a genes suppresses proliferation and promotes apoptosis in non-small cell lung cancer cell lines.
Topics: Antibiotics, Antineoplastic; Apoptosis; Azacitidine; Base Sequence; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Decitabine; DNA Methylation; Down-Regulation; Doxorubicin; Humans; Lung Neoplasms; MicroRNAs; Myeloid Cell Leukemia Sequence 1 Protein; NF-kappa B; Oligonucleotides, Antisense; Promoter Regions, Genetic; Sequence Alignment; Up-Regulation | 2013 |
Differential effects of epigenetic modifiers on the expansion and maintenance of human cord blood stem/progenitor cells.
Topics: Animals; Antigens, CD34; Azacitidine; Cell Proliferation; Cells, Cultured; Decitabine; DNA Methylation; Epigenesis, Genetic; Fetal Blood; Gene Expression; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Mice; Mice, Inbred NOD; Mice, SCID; Thy-1 Antigens; Transplantation, Heterologous; Valproic Acid | 2014 |
5-Aza-2<-deoxycytidine induces hepatoma cell apoptosis via enhancing methionine adenosyltransferase 1A expression and inducing S-adenosylmethionine production.
Topics: Apoptosis; Azacitidine; bcl-2-Associated X Protein; Carcinoma, Hepatocellular; Caspase 3; Cell Line, Tumor; Decitabine; DNA Methylation; Down-Regulation; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Methionine Adenosyltransferase; Proto-Oncogene Proteins c-bcl-2; S-Adenosylmethionine; Up-Regulation | 2013 |
Identification of novel hypermethylated genes and demethylating effect of vincristine in colorectal cancer.
Topics: Aged; Antineoplastic Agents, Phytogenic; Azacitidine; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; CpG Islands; Decitabine; DNA Methylation; DNA Modification Methylases; Epigenesis, Genetic; Female; Gene Expression; Gene Expression Regulation, Neoplastic; Genes, Neoplasm; Humans; Male; Middle Aged; RNA, Messenger; Sequence Analysis, DNA; Vincristine | 2014 |
Promoter methylation-mediated downregulation of PRDM5 contributes to the development of lung squamous cell carcinoma.
Topics: Adult; Aged; Animals; Azacitidine; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Decitabine; DNA Methylation; DNA-Binding Proteins; Down-Regulation; Female; Humans; Lung Neoplasms; Male; Mice; Middle Aged; Promoter Regions, Genetic; Transcription Factors | 2014 |
Genome-wide unmasking of epigenetically silenced genes in lung adenocarcinoma from smokers and never smokers.
Topics: Adenocarcinoma; Azacitidine; Cell Line, Tumor; CpG Islands; Decitabine; Disease Progression; DNA Methylation; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Gene Silencing; Genome-Wide Association Study; Humans; Lung Neoplasms; Promoter Regions, Genetic; Reproducibility of Results; Smoking | 2014 |
Promoter methylation‑associated silencing of p27kip1 gene with metastasis in esophageal squamous cell carcinoma.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Carcinoma, Squamous Cell; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p27; Decitabine; DNA Methylation; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Gene Expression Regulation; Gene Silencing; Humans; Lymphatic Metastasis; Male; Promoter Regions, Genetic; RNA, Messenger | 2014 |
High RAB25 expression is associated with good clinical outcome in patients with locally advanced head and neck squamous cell carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Carcinoma, Squamous Cell; Cell Line; Cell Line, Tumor; Cell Movement; Cisplatin; Decitabine; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Keratinocytes; Male; Middle Aged; Prognosis; rab GTP-Binding Proteins; RNA, Messenger; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome | 2013 |
[Lower risk myelodysplastic syndrome patients with transfusion dependent treated by dose-reduced decitabine].
Topics: Adult; Aged; Aged, 80 and over; Azacitidine; Blood Transfusion; Decitabine; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Treatment Outcome; Young Adult | 2013 |
Decitabine induces delayed reactive oxygen species (ROS) accumulation in leukemia cells and induces the expression of ROS generating enzymes.
Topics: Antimetabolites, Antineoplastic; Antioxidants; Apoptosis; Azacitidine; Caspases; Cell Cycle Checkpoints; Cell Line, Tumor; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Leukemic; Gene Knockdown Techniques; Humans; Leukemia; Matrix Metalloproteinases; Oxidation-Reduction; Reactive Oxygen Species; Transcriptional Activation; Tumor Suppressor Protein p53 | 2014 |
RASSF10 is epigenetically inactivated and induces apoptosis in lung cancer cell lines.
Topics: Apoptosis; Azacitidine; Blotting, Western; Cell Culture Techniques; Cell Line, Tumor; Decitabine; DNA Methylation; Epigenesis, Genetic; Gene Knockdown Techniques; Humans; Lung Neoplasms; Microscopy, Fluorescence; RNA, Small Interfering; Transfection; Tumor Suppressor Proteins | 2014 |
Down-regulation of thyroid hormone receptor β1 gene expression in gastric cancer involves promoter methylation.
Topics: Azacitidine; Cell Line; Cell Line, Tumor; Decitabine; DNA Methylation; Down-Regulation; Enzyme Inhibitors; Female; Gene Expression Regulation, Neoplastic; Humans; Lymphatic Metastasis; Male; Middle Aged; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; Stomach Neoplasms; Thyroid Hormone Receptors beta | 2014 |
SOCS1 hypermethylation mediated by DNMT1 is associated with lipopolysaccharide-induced inflammatory cytokines in macrophages.
Topics: Animals; Azacitidine; Blotting, Western; Cell Line; Cytokines; Decitabine; DNA Methylation; Epigenesis, Genetic; Inflammation; Macrophage Activation; Macrophages; Mice; Reverse Transcriptase Polymerase Chain Reaction; RNA, Small Interfering; Signal Transduction; Suppressor of Cytokine Signaling 1 Protein; Suppressor of Cytokine Signaling Proteins | 2014 |
5-aza-2'-Deoxycytidine, a DNA methyltransferase inhibitor, facilitates the inorganic phosphorus-induced mineralization of vascular smooth muscle cells.
Topics: Alkaline Phosphatase; Aorta; Azacitidine; Blotting, Western; Cell Differentiation; Cells, Cultured; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Humans; Muscle, Smooth, Vascular; Phosphorus; Real-Time Polymerase Chain Reaction; RNA; Vascular Calcification | 2014 |
Methylation and miRNA effects of resveratrol on mammary tumors vs. normal tissue.
Topics: Animals; Azacitidine; Breast; Breast Neoplasms; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Methyltransferase 3B; Down-Regulation; Estrogens; Female; MicroRNAs; Rats; Rats, Inbred ACI; Resveratrol; Stilbenes | 2014 |
[Effects of 5-Aza-dC on 5-Fu chemosensitivity by modulating TIP30 gene expression in human colorectal cancer cells].
Topics: Acetyltransferases; Antimetabolites, Antineoplastic; Azacitidine; Cell Proliferation; CpG Islands; Decitabine; DNA Methylation; Drug Resistance, Neoplasm; Fluorouracil; Gene Expression Regulation, Neoplastic; HCT116 Cells; Humans; Inhibitory Concentration 50; RNA, Messenger; Transcription Factors | 2013 |
[Decitabine treatment in myelodysplastic syndromes--results of a compassionate patient program in Israel].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Compassionate Use Trials; Decitabine; Disease-Free Survival; Female; Humans; Israel; Male; Middle Aged; Myelodysplastic Syndromes; Survival Rate; Treatment Outcome | 2013 |
Epigenetic silencing of Na,K-ATPase β 1 subunit gene ATP1B1 by methylation in clear cell renal cell carcinoma.
Topics: Azacitidine; Carcinoma, Renal Cell; Cell Line, Tumor; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Methyltransferase 3A; Epigenesis, Genetic; Humans; Kidney Neoplasms; Promoter Regions, Genetic; RNA, Messenger; Sodium-Potassium-Exchanging ATPase; Von Hippel-Lindau Tumor Suppressor Protein | 2014 |
AID downregulation is a novel function of the DNMT inhibitor 5-aza-deoxycytidine.
Topics: Animals; Azacitidine; Cytidine Deaminase; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; Down-Regulation; Enzyme Inhibitors; Heterografts; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Molecular Docking Simulation | 2014 |
Use of IL3 and chromatin-modifying reagents valproic acid and 5-aza-2'-deoxycytidine to affect mobilized peripheral blood CD34+ cell fate decisions.
Topics: Aged; Antigens, CD34; Azacitidine; Blood Cells; Cell Differentiation; Cells, Cultured; Chromatin; Colony-Forming Units Assay; Decitabine; Flow Cytometry; Hematopoietic Stem Cells; Humans; Interleukin-3; Male; Middle Aged; Valproic Acid | 2014 |
Enhancement of radiosensitivity by 5-Aza-CdR through activation of G2/M checkpoint response and apoptosis in osteosarcoma cells.
Topics: 14-3-3 Proteins; Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Biomarkers, Tumor; Bone Neoplasms; Cell Division; Cell Line, Tumor; Checkpoint Kinase 2; Death-Associated Protein Kinases; Decitabine; Exoribonucleases; G2 Phase; Gene Expression Regulation, Neoplastic; Humans; Osteosarcoma; Radiation Tolerance | 2014 |
Impact of 5-aza-2'-deoxycytidine and epigallocatechin-3-gallate for induction of human regulatory T cells.
Topics: Azacitidine; Catechin; Decitabine; Forkhead Transcription Factors; Humans; Male; Methylation; Oligonucleotide Array Sequence Analysis; T-Lymphocytes, Regulatory | 2014 |
DNA methylation downregulated mir-10b acts as a tumor suppressor in gastric cancer.
Topics: Aged; Azacitidine; Cell Line, Tumor; Cell Movement; Cell Proliferation; CpG Islands; Decitabine; DNA Methylation; Epigenesis, Genetic; Female; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Guanine Nucleotide Exchange Factors; Humans; Hydroxamic Acids; Male; MicroRNAs; Middle Aged; Real-Time Polymerase Chain Reaction; Stomach Neoplasms; T-Lymphoma Invasion and Metastasis-inducing Protein 1 | 2015 |
miR-125a regulates cell cycle, proliferation, and apoptosis by targeting the ErbB pathway in acute myeloid leukemia.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Cell Cycle; Cell Proliferation; CpG Islands; Decitabine; Gene Expression Regulation, Leukemic; Hematopoiesis; Humans; Leukemia, Myeloid, Acute; Mice; Mice, Inbred NOD; MicroRNAs; Oncogene Proteins v-erbB; Signal Transduction | 2014 |
Small activating RNA restores the activity of the tumor suppressor HIC-1 on breast cancer.
Topics: Adult; Apoptosis; Azacitidine; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Decitabine; Down-Regulation; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Kruppel-Like Transcription Factors; Oligonucleotide Array Sequence Analysis; RNA; Tissue Array Analysis; Transcriptome; Up-Regulation | 2014 |
Sequential treatment with cytarabine and decitabine has an increased anti-leukemia effect compared to cytarabine alone in xenograft models of childhood acute myeloid leukemia.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Gene Expression Profiling; Humans; Leukemia, Myeloid, Acute; Mice; Mice, Inbred NOD; Mice, SCID; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2014 |
Genetic regulation of MUC1 expression by Helicobacter pylori in gastric cancer cells.
Topics: Azacitidine; Binding Sites; Cell Line, Tumor; CpG Islands; Decitabine; DNA Methylation; Enzyme Inhibitors; Gene Expression Regulation; Helicobacter pylori; Host-Pathogen Interactions; Humans; Immunoblotting; Mucin-1; Promoter Regions, Genetic; Protein Binding; Reverse Transcriptase Polymerase Chain Reaction; STAT3 Transcription Factor; Stomach Neoplasms; Up-Regulation | 2014 |
Colon cancer cell apoptosis is induced by combined exposure to the n-3 fatty acid docosahexaenoic acid and butyrate through promoter methylation.
Topics: Acetylation; Antimetabolites, Antineoplastic; Apoptosis; Apoptosis Regulatory Proteins; Azacitidine; Bcl-2-Like Protein 11; Butyrates; Cell Line, Tumor; Colonic Neoplasms; Death-Associated Protein Kinases; Decitabine; DNA Methylation; DNA Modification Methylases; Docosahexaenoic Acids; HCT116 Cells; Histones; Humans; Linoleic Acid; Lymphotoxin beta Receptor; Membrane Proteins; Promoter Regions, Genetic; Proto-Oncogene Proteins; Receptors, Tumor Necrosis Factor, Member 25; Transcription, Genetic | 2014 |
Kaiso interacts with p120-catenin to regulate β-catenin expression at the transcriptional level.
Topics: Azacitidine; beta Catenin; Blotting, Western; Catenins; Cell Line, Tumor; CpG Islands; Decitabine; Delta Catenin; DNA Methylation; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Promoter Regions, Genetic; Protein Binding; Reverse Transcriptase Polymerase Chain Reaction; Transcription Factors; Transcription, Genetic; Up-Regulation | 2014 |
Epigenetic regulation of death of crayfish glial cells but not neurons induced by photodynamic impact.
Topics: Action Potentials; Animals; Apoptosis; Astacoidea; Azacitidine; Decitabine; DNA Methylation; Enzyme Inhibitors; Epigenesis, Genetic; Histone Deacetylase Inhibitors; Hydroxamic Acids; In Vitro Techniques; Indoles; Lasers; Mechanoreceptors; Necrosis; Neuroglia; Organometallic Compounds; Photic Stimulation; Photosensitizing Agents; Valproic Acid | 2014 |
Secreted phospholipases A₂are differentially expressed and epigenetically silenced in human breast cancer cells.
Topics: Azacitidine; Breast Neoplasms; Cell Line; Cell Line, Tumor; CpG Islands; Decitabine; DNA Methylation; Epigenesis, Genetic; Female; Gene Expression Profiling; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Group II Phospholipases A2; Group III Phospholipases A2; Group X Phospholipases A2; Humans; Hydroxamic Acids; MCF-7 Cells; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction | 2014 |
A combination treatment with DNA methyltransferase inhibitors and suramin decreases invasiveness of breast cancer cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Decitabine; DNA Methylation; Enzyme Inhibitors; Female; Humans; Immunoblotting; Immunohistochemistry; Immunoprecipitation; Mice; Mice, Nude; Neoplasm Invasiveness; Phthalimides; Reverse Transcriptase Polymerase Chain Reaction; Suramin; Tryptophan; Xenograft Model Antitumor Assays | 2014 |
5-Aza-2-deoxycytidine and trichostatin A increase COUP-TFII expression in antiestrogen-resistant breast cancer cell lines.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Breast Neoplasms; COUP Transcription Factor II; CpG Islands; Decitabine; DNA Methylation; Drug Resistance, Neoplasm; Estrogen Receptor beta; Estrogen Receptor Modulators; Female; Humans; Hydroxamic Acids; MCF-7 Cells; Real-Time Polymerase Chain Reaction | 2014 |
Design, synthesis, and pharmacological evaluation of fluorinated tetrahydrouridine derivatives as inhibitors of cytidine deaminase.
Topics: Animals; Azacitidine; Biological Availability; Cytidine Deaminase; Decitabine; Drug Design; Drug Stability; Enzyme Inhibitors; Excitatory Postsynaptic Potentials; Fluorine; Gastric Juice; Macaca mulatta; Models, Molecular; Molecular Conformation; Structure-Activity Relationship; Tetrahydrouridine | 2014 |
Learning induced epigenetic modifications in the ventral striatum are necessary for long-term memory.
Topics: Analysis of Variance; Animals; Avoidance Learning; Azacitidine; Corpus Striatum; Decitabine; DNA Methylation; Dose-Response Relationship, Drug; Epigenesis, Genetic; Histone Deacetylase Inhibitors; Histone Deacetylases; Hydroxamic Acids; Male; Memory; Mice; Reaction Time; Vorinostat | 2014 |
Epigenetic silencing of the LDOC1 tumor suppressor gene in ovarian cancer cells.
Topics: Adult; Aged; Aged, 80 and over; Azacitidine; Biomarkers, Tumor; Cell Line; Decitabine; DNA Methylation; DNA Modification Methylases; DNA Primers; Enzyme Inhibitors; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Genes, Tumor Suppressor; Humans; Middle Aged; Ovarian Neoplasms; Promoter Regions, Genetic; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction | 2014 |
Epigenetic inactivation of mir-34b/c in addition to mir-34a and DAPK1 in chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Azacitidine; Blood Cells; Bone Marrow Cells; Cell Line, Tumor; Death-Associated Protein Kinases; Decitabine; DNA Methylation; Epigenesis, Genetic; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; MicroRNAs; Middle Aged; Polymerase Chain Reaction | 2014 |
5-Aza-2'-deoxycytidine potentiates antitumour immune response induced by photodynamic therapy.
Topics: Animals; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Azacitidine; Carcinoma, Lewis Lung; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Decitabine; Disease Models, Animal; Female; Flow Cytometry; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Photochemotherapy; Reverse Transcriptase Polymerase Chain Reaction | 2014 |
The role of gene body cytosine modifications in MGMT expression and sensitivity to temozolomide.
Topics: Antineoplastic Agents, Alkylating; Azacitidine; Cell Line, Tumor; CpG Islands; Cytosine; Dacarbazine; Decitabine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Polymorphism, Single Nucleotide; Promoter Regions, Genetic; Quantitative Trait Loci; Temozolomide; Tumor Suppressor Proteins | 2014 |
Long-term low-dose exposure of human urothelial cells to sodium arsenite activates lipocalin-2 via promoter hypomethylation.
Topics: Acute-Phase Proteins; Arsenites; Azacitidine; Cell Culture Techniques; Cell Line; Cell Proliferation; Chromatin Immunoprecipitation; Culture Media, Serum-Free; Decitabine; DNA Methylation; Dose-Response Relationship, Drug; Environmental Pollutants; Gene Silencing; Genome-Wide Association Study; Humans; Lipocalin-2; Lipocalins; Mutagenesis, Site-Directed; NF-kappa B; Promoter Regions, Genetic; Protein Binding; Proto-Oncogene Proteins; Sodium Compounds; Time Factors; Urinary Bladder Neoplasms; Urothelium | 2014 |
Decitabine facilitates immune recognition of sarcoma cells by upregulating CT antigens, MHC molecules, and ICAM-1.
Topics: Antigens, Neoplasm; Antimetabolites, Antineoplastic; Azacitidine; Cell Line, Tumor; Decitabine; HLA Antigens; Humans; Intercellular Adhesion Molecule-1; Melanoma-Specific Antigens; Membrane Proteins; Neoplasm Proteins; Sarcoma; T-Lymphocytes, Cytotoxic; Up-Regulation | 2014 |
Downregulation of the tumor suppressor HSPB7, involved in the p53 pathway, in renal cell carcinoma by hypermethylation.
Topics: Antineoplastic Agents; Azacitidine; Base Sequence; Carcinoma, Renal Cell; Cell Line, Tumor; Decitabine; DNA Methylation; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; HEK293 Cells; HSP27 Heat-Shock Proteins; Humans; Kidney Neoplasms; Molecular Sequence Data; Oligonucleotide Array Sequence Analysis; Signal Transduction; Tumor Suppressor Protein p53 | 2014 |
Aberrant CpG island methylation of PTEN is an early event in nasopharyngeal carcinoma and a potential diagnostic biomarker.
Topics: Azacitidine; Base Sequence; Biomarkers, Tumor; Carcinoma; Cell Line, Tumor; CpG Islands; Decitabine; DNA Methylation; Down-Regulation; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Mutation; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Promoter Regions, Genetic; PTEN Phosphohydrolase; RNA, Messenger; Sequence Analysis, DNA | 2014 |
Aberrant methylation of RASSF2A in tumors and plasma of patients with epithelial ovarian cancer.
Topics: Azacitidine; Biomarkers, Tumor; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Decitabine; DNA Methylation; Female; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Promoter Regions, Genetic; RNA, Messenger; Tumor Suppressor Proteins | 2014 |
[Clinical analysis of neutrophil suppression caused by decitabine for the treatment of myelodysplastic syndromes].
Topics: Adult; Aged; Aged, 80 and over; Agranulocytosis; Azacitidine; Decitabine; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Neutrophils; Young Adult | 2014 |
Spermidine/spermine N(1)-acetyltransferase activity associates with white blood cell count in myeloid leukemias.
Topics: Acetyltransferases; Animals; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Humans; Leukemia, Myeloid; Leukocyte Count; Male; Mice; Mice, Inbred C57BL; Polyamines | 2014 |
MicroRNA-34a is dispensable for p53 function as teratogenesis inducer.
Topics: Abnormalities, Drug-Induced; Animals; Azacitidine; Decitabine; Dose-Response Relationship, Drug; Drug Resistance; Female; Fetal Development; Gene Expression Profiling; Gene Expression Regulation, Developmental; Heterozygote; Limb Buds; Limb Deformities, Congenital; Male; Mice, Inbred ICR; Mice, Knockout; MicroRNAs; Pregnancy; Rats, Sprague-Dawley; Teratogens; Tumor Suppressor Protein p53; Up-Regulation | 2014 |
Activation of endocrine-related gene expression in placental choriocarcinoma cell lines following DNA methylation knock-down.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 2; Aromatase; Azacitidine; Cell Line, Tumor; Choriocarcinoma; CpG Islands; Decitabine; DNA Methylation; DNA-Binding Proteins; Female; Gene Expression Regulation, Neoplastic; Humans; Leptin; Placenta; Pregnancy; Promoter Regions, Genetic; Receptors, Glucocorticoid; TEA Domain Transcription Factors; Transcription Factors; Uterine Neoplasms | 2014 |
Epigenetic modification boosts ovarian cancer vaccination.
Topics: Antigens, Neoplasm; Azacitidine; Cancer Vaccines; Carcinoma, Ovarian Epithelial; Combined Modality Therapy; Decitabine; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Epigenesis, Genetic; Female; Gene Expression Regulation, Neoplastic; Humans; Membrane Proteins; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Treatment Outcome | 2014 |
Correlation of deregulated like-acetylglucosaminyl transferase and aberrant α-dystroglycan expression with human tongue cancer metastasis.
Topics: Azacitidine; Carcinoma, Squamous Cell; Cell Adhesion; Cell Line, Tumor; Cell Movement; Decitabine; DNA Methylation; DNA Modification Methylases; Dystroglycans; Enzyme Inhibitors; Epigenesis, Genetic; Female; Gene Expression Regulation, Neoplastic; Glycosylation; Humans; Immunohistochemistry; Laminin; Lymphatic Metastasis; Male; Middle Aged; N-Acetylglucosaminyltransferases; Neoplasm Invasiveness; Neoplasm Staging; Plasmids; Promoter Regions, Genetic; Tongue Neoplasms; Transfection | 2014 |
DNA methylation of heparanase promoter influences its expression and associated with the progression of human breast cancer.
Topics: Azacitidine; Breast Neoplasms; Carcinogenesis; Cell Proliferation; Decitabine; Disease Progression; DNA Methylation; Gene Expression Regulation, Neoplastic; Glucuronidase; Humans; MCF-7 Cells; Neoplasm Invasiveness; Promoter Regions, Genetic | 2014 |
Function of DNA methyltransferase 3a in lead (Pb(2+) )-Induced Cyclooxygenase-2 gene.
Topics: Azacitidine; Cell Line, Tumor; Cyclooxygenase 2; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Methyltransferase 3A; DNA Methyltransferase 3B; E2F1 Transcription Factor; Environmental Pollutants; Humans; Lead; NF-kappa B; Promoter Regions, Genetic; Protein Kinase Inhibitors; Real-Time Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Transcriptome | 2015 |
The Wnt/β-catenin signaling pathway is involved in the antitumor effect of fulvestrant on rat prolactinoma MMQ cells.
Topics: Animals; Antineoplastic Agents, Hormonal; Azacitidine; beta Catenin; Cell Line, Tumor; Cell Proliferation; Decitabine; Estradiol; Estrogen Receptor alpha; Extracellular Matrix Proteins; Fulvestrant; Intercellular Signaling Peptides and Proteins; Pituitary Neoplasms; Prolactinoma; Rats; Wnt Signaling Pathway | 2014 |
Inhibition of Methicillin-resistant Staphylococcus aureus-induced cytokines mRNA production in human bone marrow derived mesenchymal stem cells by 1,25-dihydroxyvitamin D3.
Topics: Azacitidine; Bacterial Proteins; Bone Marrow Cells; Calcitriol; Cell Differentiation; Cells, Cultured; Cytokines; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Gene Silencing; HEK293 Cells; Histones; Humans; Mesenchymal Stem Cells; Methicillin-Resistant Staphylococcus aureus; NF-kappa B; RNA, Messenger; Toll-Like Receptors | 2014 |
Development of TRAIL resistance by radiation-induced hypermethylation of DR4 CpG island in recurrent laryngeal squamous cell carcinoma.
Topics: Aged; Apoptosis; Azacitidine; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; CpG Islands; Decitabine; DNA Methylation; Dose-Response Relationship, Radiation; Epigenesis, Genetic; Female; Flow Cytometry; Gene Silencing; Humans; Immunohistochemistry; Laryngeal Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Oligonucleotide Array Sequence Analysis; Receptors, TNF-Related Apoptosis-Inducing Ligand; Reverse Transcriptase Polymerase Chain Reaction; TNF-Related Apoptosis-Inducing Ligand | 2014 |
[Decitabine in myelodysplastic syndromes: the current status and future].
Topics: Azacitidine; Decitabine; Humans; Myelodysplastic Syndromes | 2014 |
Kaposi's sarcoma-associated herpesvirus (KSHV) vIL-6 promotes cell proliferation and migration by upregulating DNMT1 via STAT3 activation.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cell Line; Cell Movement; Cell Proliferation; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Endothelial Cells; Epigenesis, Genetic; Herpesvirus 8, Human; Host-Pathogen Interactions; Humans; Interleukin-6; Signal Transduction; STAT3 Transcription Factor; Viral Proteins | 2014 |
DNA methyltransferase inhibitors improve the effect of chemotherapeutic agents in SW48 and HT-29 colorectal cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Azacitidine; Cell Cycle; Cell Line, Tumor; Colorectal Neoplasms; Cytidine; Decitabine; DNA Damage; DNA-Cytosine Methylases; Enzyme Inhibitors; Fluorouracil; Humans; Membrane Potential, Mitochondrial; Organoplatinum Compounds; Oxaliplatin | 2014 |
Breast cancer cells are arrested at different phases of the cell cycle following the re-expression of ARHI.
Topics: Apoptosis; Azacitidine; Breast Neoplasms; CDC2 Protein Kinase; Cell Line, Tumor; Cell Proliferation; Checkpoint Kinase 1; Cyclin B1; Cyclin D1; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Cyclin-Dependent Kinases; Decitabine; Female; G2 Phase Cell Cycle Checkpoints; Genetic Vectors; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Methyltransferases; Protein Kinases; rho GTP-Binding Proteins; RNA Interference; RNA, Small Interfering; S Phase Cell Cycle Checkpoints; Transfection; Tumor Suppressor Protein p53 | 2014 |
Aberrant DNA methylation in the IFITM1 promoter enhances the metastatic phenotype in an intraperitoneal xenograft model of human ovarian cancer.
Topics: Animals; Antigens, Differentiation; Azacitidine; Biomarkers, Tumor; Cell Line, Tumor; Decitabine; DNA Methylation; Female; Humans; Injections, Intraperitoneal; Mice; Mice, Inbred BALB C; Neoplasm Metastasis; Ovarian Neoplasms; Ovary; Promoter Regions, Genetic; Xenograft Model Antitumor Assays | 2014 |
Methylation of the PMEPA1 gene, a negative regulator of the androgen receptor in prostate cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Base Sequence; Black or African American; Cell Line, Tumor; CpG Islands; Decitabine; DNA Methylation; Gene Expression; Humans; Introns; Male; Membrane Proteins; Middle Aged; Molecular Sequence Data; Prostatic Neoplasms; Receptors, Androgen; RNA, Messenger; White People | 2014 |
Dual effects of cigarette smoke extract on proliferation of endothelial progenitor cells and the protective effect of 5-aza-2'-deoxycytidine on EPCs against the damage caused by CSE.
Topics: Animals; Azacitidine; Biomarkers; Cell Proliferation; Cell Shape; Cells, Cultured; Cytoprotection; Decitabine; Endothelial Progenitor Cells; Flow Cytometry; Mice, Inbred C57BL; Smoking; Time Factors | 2014 |
Integrated analysis of DNA methylation and mRNA expression profiling reveals candidate genes associated with cisplatin resistance in non-small cell lung cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Azacitidine; Carcinoma, Non-Small-Cell Lung; Cell Cycle Checkpoints; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cisplatin; Decitabine; DNA Methylation; Drug Resistance, Neoplasm; Epigenesis, Genetic; Gene Expression Profiling; GPI-Linked Proteins; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Lung Neoplasms; RNA, Messenger | 2014 |
Hypomethylating agent 5-aza-2'-deoxycytidine (DAC) ameliorates multiple sclerosis in mouse models.
Topics: Animals; Anti-Inflammatory Agents; Azacitidine; Cytokines; Decitabine; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Mice; Multiple Sclerosis; T-Lymphocytes, Regulatory | 2014 |
The acquisition of cancer stem cell-like properties and neoplastic transformation of human keratinocytes induced by arsenite involves epigenetic silencing of let-7c via Ras/NF-κB.
Topics: Animals; Arsenites; Azacitidine; Cell Line; Cell Transformation, Neoplastic; Decitabine; Epigenesis, Genetic; Gene Silencing; Humans; Keratinocytes; Mice; Mice, Nude; MicroRNAs; Neoplastic Stem Cells; NF-kappa B; ras Proteins; Sodium Compounds | 2014 |
MicroRNA-148a is silenced by hypermethylation and interacts with DNA methyltransferase 1 in hepatocellular carcinogenesis.
Topics: Azacitidine; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; CpG Islands; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Enzyme Inhibitors; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Liver Neoplasms; MicroRNAs; Promoter Regions, Genetic | 2014 |
Epigenetic regulation of aortic remodeling in hyperhomocysteinemia.
Topics: Acetylcholine; Adenosylhomocysteinase; Animals; Aorta; Azacitidine; Collagen; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Endothelium, Vascular; Epigenesis, Genetic; Extracellular Matrix Proteins; Gene Expression Regulation, Enzymologic; Homocystinuria; Hyperhomocysteinemia; Hypertension; Male; Matrix Metalloproteinase 9; Methylenetetrahydrofolate Reductase (NADPH2); Mice; Mice, Inbred C57BL; Mice, Knockout; Nitroprusside; Phenylephrine; Tissue Inhibitor of Metalloproteinase-1; Ultrasonography; Vascular Resistance | 2014 |
Regulation of the Interleukin-6 gene expression during monocytic differentiation of HL-60 cells by chromatin remodeling and methylation.
Topics: Azacitidine; Cell Differentiation; Chromatin Assembly and Disassembly; Decitabine; DNA Methylation; DNA Modification Methylases; Gene Expression Regulation; Histone Deacetylase Inhibitors; HL-60 Cells; Humans; Hydroxamic Acids; Inflammation Mediators; Interleukin-6; Lipopolysaccharides; Monocytes; Promoter Regions, Genetic | 2014 |
Decitabine of reduced dosage in Chinese patients with myelodysplastic syndrome: a retrospective analysis.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Asian People; Azacitidine; China; Cyclin-Dependent Kinase Inhibitor p15; Decitabine; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Treatment Outcome | 2014 |
Decreased expression of RASSF1A and up-regulation of RASSF1C is associated with esophageal squamous cell carcinoma.
Topics: Adult; Aged; Azacitidine; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Decitabine; DNA Methylation; Esophageal Neoplasms; Exons; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Promoter Regions, Genetic; RNA, Messenger; Tumor Suppressor Proteins | 2014 |
[Effect of arsenic trioxide and 5-aza-2'-deoxycytidine on SHP-1, JAK3, TYK2 gene expression in K562 cells].
Topics: Arsenic Trioxide; Arsenicals; Azacitidine; Decitabine; DNA Methylation; Gene Expression Regulation, Leukemic; Humans; Janus Kinase 3; K562 Cells; Oxides; Protein Tyrosine Phosphatase, Non-Receptor Type 6; TYK2 Kinase | 2014 |
Effect of 5-aza-2'-deoxycytidine combined with trichostatin A on RPMI-8226 cell proliferation, apoptosis and DLC-1 gene expression.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Cell Line, Tumor; Cell Proliferation; Decitabine; Gene Expression; GTPase-Activating Proteins; Humans; Hydroxamic Acids; Multiple Myeloma; Tumor Suppressor Proteins | 2014 |
Ruxolitinib in combination with DNA methyltransferase inhibitors: clinical responses in patients with symptomatic myelofibrosis with cytopenias and elevated blast(s) counts.
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Decitabine; DNA Modification Methylases; Fatigue; Female; Follow-Up Studies; Humans; Male; Middle Aged; Nitriles; Primary Myelofibrosis; Pyrazoles; Pyrimidines; Remission Induction; Treatment Outcome | 2015 |
Nucleoside transporters and human organic cation transporter 1 determine the cellular handling of DNA-methyltransferase inhibitors.
Topics: Animals; Azacitidine; Biological Transport; Cell Survival; Cytidine; Decitabine; DNA Modification Methylases; Dogs; HeLa Cells; Humans; Madin Darby Canine Kidney Cells; Nucleoside Transport Proteins; Oocytes; Organic Cation Transporter 1; Xenopus laevis | 2014 |
Loss of function of TET2 cooperates with constitutively active KIT in murine and human models of mastocytosis.
Topics: Animals; Azacitidine; Blotting, Western; Bone Marrow Cells; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Dasatinib; Decitabine; Dioxygenases; Disease Models, Animal; DNA-Binding Proteins; Drug Therapy, Combination; Enzyme Inhibitors; Esophagus; Gastric Mucosa; Humans; Mast Cells; Mastocytosis, Systemic; Mice, Knockout; Mice, Transgenic; Mutation, Missense; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-kit; Pyrimidines; RNA Interference; Skin; Stomach; Thiazoles | 2014 |
Down-regulation of CD9 by methylation decreased bortezomib sensitivity in multiple myeloma.
Topics: Azacitidine; Base Sequence; Boronic Acids; Bortezomib; Cell Line, Tumor; Decitabine; DNA Methylation; Dose-Response Relationship, Drug; Down-Regulation; Drug Interactions; Drug Resistance, Neoplasm; Humans; Multiple Myeloma; Pyrazines; Tetraspanin 29 | 2014 |
Downregulation of glutathione peroxidase 3 is associated with lymph node metastasis and prognosis in cervical cancer.
Topics: Azacitidine; CpG Islands; Decitabine; DNA Methylation; Female; Gene Expression Regulation, Neoplastic; Glutathione Peroxidase; HeLa Cells; Humans; Lymphatic Metastasis; Prognosis; Promoter Regions, Genetic; Uterine Cervical Neoplasms | 2014 |
Aberrant methylation and decreased expression of the TGF-β/Smad target gene FBXO32 in esophageal squamous cell carcinoma.
Topics: Adult; Aged; Azacitidine; Calmodulin-Binding Proteins; Carcinoma, Squamous Cell; Cell Growth Processes; Decitabine; DNA Methylation; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Gene Silencing; Humans; Hydroxamic Acids; Immunohistochemistry; Male; Middle Aged; Muscle Proteins; Promoter Regions, Genetic; RNA, Messenger; SKP Cullin F-Box Protein Ligases; Smad Proteins; Transforming Growth Factor beta; Up-Regulation | 2014 |
The effect of chemotherapeutic agents on telomere length maintenance in breast cancer cell lines.
Topics: Antineoplastic Agents; Azacitidine; Breast Neoplasms; Cell Line, Tumor; Decitabine; DNA; DNA Methylation; Epigenesis, Genetic; Female; Histones; Humans; Hydroxamic Acids; MCF-7 Cells; Methyltransferases; Promoter Regions, Genetic; Shelterin Complex; Telomere; Telomere Homeostasis; Telomere-Binding Proteins | 2014 |
Epigenetic regulation of sox30 is associated with testis development in mice.
Topics: Animals; Azacitidine; Cell Line; CpG Islands; Decitabine; DNA Methylation; Epigenesis, Genetic; Gene Expression Regulation, Developmental; Male; Mice; Organ Specificity; Sertoli Cells; SOX Transcription Factors; Spatio-Temporal Analysis; Testis | 2014 |
A potential role for immunotherapy in thyroid cancer by enhancing NY-ESO-1 cancer antigen expression.
Topics: Animals; Antigens, Neoplasm; Azacitidine; Cell Line, Tumor; Coculture Techniques; Cytoplasm; Decitabine; Gene Expression Regulation; Gene Expression Regulation, Neoplastic; Granzymes; Humans; Immunotherapy; Interferon-gamma; Lymphocytes; Membrane Proteins; Methylation; Mice; Mice, SCID; Neoplasm Metastasis; Polymerase Chain Reaction; Receptors, Antigen, T-Cell; RNA, Messenger; Thyroid Neoplasms | 2014 |
Effect of microinjecting of 5-aza-2-deoxycytidine into ventrolateral orbital cortex on depressive-like behavior in rats.
Topics: Animals; Azacitidine; Decitabine; Depression; DNA Methylation; DNA Modification Methylases; Male; Microinjections; Motor Activity; Prefrontal Cortex; Rats, Sprague-Dawley | 2014 |
A new tumor suppressor LncRNA ADAMTS9-AS2 is regulated by DNMT1 and inhibits migration of glioma cells.
Topics: ADAM Proteins; ADAMTS9 Protein; Adult; Aged; Azacitidine; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; Female; Glioma; Humans; Male; Middle Aged; Neoplasm Invasiveness; RNA, Antisense; RNA, Long Noncoding; RNA, Small Interfering; Tumor Suppressor Proteins | 2014 |
The role of DNA damage and repair in decitabine-mediated apoptosis in multiple myeloma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Azacitidine; Blotting, Western; Decitabine; Disease Models, Animal; DNA Damage; DNA Repair; Flow Cytometry; Fluorescent Antibody Technique; Homologous Recombination; Humans; Hydroxamic Acids; Mice; Mice, Inbred C57BL; Multiple Myeloma; Real-Time Polymerase Chain Reaction | 2014 |
Epigenetic inactivation of the candidate tumor suppressor USP44 is a frequent and early event in colorectal neoplasia.
Topics: Adenoma; Adolescent; Adult; Aged; Aged, 80 and over; Aneuploidy; Antimetabolites, Antineoplastic; Azacitidine; Cell Line, Tumor; Colon; Colorectal Neoplasms; CpG Islands; Decitabine; Epigenesis, Genetic; Gene Expression; Genes, Tumor Suppressor; Humans; Intestinal Mucosa; Male; Middle Aged; Oligonucleotide Array Sequence Analysis; Polymorphism, Single Nucleotide; Rectum; Ubiquitin Thiolesterase; Ubiquitin-Specific Proteases; Young Adult | 2014 |
Integrated analysis using methylation and gene expression microarrays reveals PDE4C as a prognostic biomarker in human glioma.
Topics: Adult; Aged; Azacitidine; Biomarkers, Tumor; Cell Line, Tumor; Cell Movement; Cyclic Nucleotide Phosphodiesterases, Type 4; Decitabine; DNA Methylation; Epigenesis, Genetic; Female; Gene Expression Regulation, Neoplastic; Genetic Predisposition to Disease; Glioma; Humans; Male; Middle Aged; Promoter Regions, Genetic; Survival Analysis; Tumor Suppressor Protein p53 | 2014 |
The effect of decitabine dose modification and myelosuppression on response and survival in patients with myelodysplastic syndromes.
Topics: Acute Disease; Aged; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Disease Progression; Dose-Response Relationship, Drug; Female; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Outcome Assessment, Health Care; Proportional Hazards Models; Retrospective Studies | 2015 |
[CME myelodysplasia - a frequent hematologic neoplasia in the elderly].
Topics: Aged, 80 and over; Anemia, Aplastic; Azacitidine; Bone Marrow; Bone Marrow Examination; Cell Proliferation; Cell Transformation, Neoplastic; Decitabine; Diagnosis, Differential; Disease Progression; Hematopoiesis; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Prognosis; Thalidomide | 2014 |
Novel epigenetic target therapy for prostate cancer: a preclinical study.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Cell Line, Tumor; Chromatography, High Pressure Liquid; Decitabine; Epigenesis, Genetic; Humans; Male; Mass Spectrometry; Mice; Mice, Inbred BALB C; Prostatic Neoplasms | 2014 |
Promoter hypermethylation influences the suppressive role of maternally expressed 3, a long non-coding RNA, in the development of epithelial ovarian cancer.
Topics: Azacitidine; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Proliferation; Decitabine; DNA Methylation; Epigenesis, Genetic; Female; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Ovary; Promoter Regions, Genetic; RNA, Long Noncoding; Tumor Suppressor Protein p53 | 2014 |
Epigenetic repression of HOXB cluster in oral cancer cell lines.
Topics: Azacitidine; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cell Line, Tumor; Decitabine; DNA Methylation; Epigenetic Repression; Genes, Homeobox; Homeodomain Proteins; Humans; Mouth Neoplasms; Polymerase Chain Reaction; Transcription Factors | 2014 |
News products to avoid.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Azacitidine; Decitabine; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Everolimus; Ferrosoferric Oxide; Gefitinib; Hematinics; Humans; Imidazoles; Indazoles; Oxonic Acid; Pyridines; Quinazolines; Risk Assessment; Risk Factors; Sirolimus; Tegafur | 2014 |
Flow-dependent epigenetic DNA methylation regulates endothelial gene expression and atherosclerosis.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Azacitidine; Decitabine; Disease Models, Animal; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Endothelial Cells; Epigenesis, Genetic; Gene Expression Regulation; Homeodomain Proteins; Human Umbilical Vein Endothelial Cells; Humans; Kruppel-Like Transcription Factors; Mice; Mice, Inbred C57BL; Mice, Knockout; Phosphoproteins; Plaque, Atherosclerotic; Promoter Regions, Genetic; Regional Blood Flow; RNA, Messenger; Stress, Mechanical; Transcription Factors | 2014 |
Differential expression of stromal aromatase in obese females is regulated by DNA methylation.
Topics: Adipose Tissue; Aromatase; Azacitidine; Cell Culture Techniques; Cells, Cultured; CpG Islands; Decitabine; DNA Methylation; Enzyme Activation; Female; Humans; Obesity; Promoter Regions, Genetic; RNA, Messenger | 2014 |
Aberrant promoter DNA methylation inhibits bone morphogenetic protein 2 expression and contributes to drug resistance in breast cancer.
Topics: Azacitidine; Bone Morphogenetic Protein 2; Breast Neoplasms; Decitabine; DNA Methylation; Drug Resistance, Neoplasm; Female; Gene Expression; Humans; MCF-7 Cells; Neoplasm Staging; Promoter Regions, Genetic; Real-Time Polymerase Chain Reaction; RNA Interference; RNA, Messenger; RNA, Small Interfering | 2014 |
Low-dose 5-aza-2'-deoxycytidine pretreatment inhibits experimental autoimmune encephalomyelitis by induction of regulatory T cells.
Topics: Animals; Azacitidine; Decitabine; DNA Modification Methylases; Encephalomyelitis, Autoimmune, Experimental; Female; Forkhead Transcription Factors; Mice, Inbred C57BL; Mice, Transgenic; Mycobacterium tuberculosis; Myelin-Oligodendrocyte Glycoprotein; Spinal Cord; Spleen; T-Lymphocytes, Regulatory | 2014 |
MAGED4 expression in glioma and upregulation in glioma cell lines with 5-aza-2'-deoxycytidine treatment.
Topics: Antigens, Neoplasm; Antimetabolites, Antineoplastic; Azacitidine; Biomarkers, Tumor; Cell Line, Tumor; CpG Islands; Decitabine; DNA Methylation; Gene Expression Regulation, Neoplastic; Glioma; Humans; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Up-Regulation | 2014 |
Combination of gefitinib and DNA methylation inhibitor decitabine exerts synergistic anti-cancer activity in colon cancer cells.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Azacitidine; Cell Line, Tumor; Cell Survival; Colonic Neoplasms; Decitabine; DNA Methylation; Dose-Response Relationship, Drug; Drug Synergism; Gefitinib; Humans; Intracellular Signaling Peptides and Proteins; Neoplasm Proteins; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; TOR Serine-Threonine Kinases | 2014 |
Temporal evolution in caveolin 1 methylation levels during human esophageal carcinogenesis.
Topics: Adenocarcinoma; Area Under Curve; Azacitidine; Barrett Esophagus; Carcinoma, Squamous Cell; Caveolin 1; Cell Line, Tumor; Decitabine; Disease Progression; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Esophageal Neoplasms; Gene Expression Regulation, Neoplastic; Humans; Promoter Regions, Genetic; RNA, Messenger; ROC Curve; Time Factors | 2014 |
Demethylation of the miR-146a promoter by 5-Aza-2'-deoxycytidine correlates with delayed progression of castration-resistant prostate cancer.
Topics: Animals; Apoptosis; Azacitidine; Cell Line, Tumor; Cell Proliferation; Decitabine; Disease Progression; DNA Methylation; Humans; Male; Methyltransferases; Mice; MicroRNAs; Promoter Regions, Genetic; Prostatic Neoplasms, Castration-Resistant; Xenograft Model Antitumor Assays | 2014 |
Impact of MLL5 expression on decitabine efficacy and DNA methylation in acute myeloid leukemia.
Topics: Aged; Aged, 80 and over; Animals; Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow Cells; Cells, Cultured; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Methyltransferase 3A; DNA-Binding Proteins; Drug Administration Schedule; Female; Gene Expression; Humans; Leukemia, Myeloid, Acute; Male; Mice; Middle Aged; Promoter Regions, Genetic; RNA, Messenger; Survival Analysis | 2014 |
Enhanced memory persistence is blocked by a DNA methyltransferase inhibitor in the snail Lymnaea stagnalis.
Topics: Animals; Astacoidea; Azacitidine; Decitabine; DNA Methylation; DNA Modification Methylases; Immersion; Lymnaea; Memory, Long-Term; Methamphetamine; Odorants; Serotonin | 2014 |
Aberrant hypomethylation-mediated AGR2 overexpression induces an aggressive phenotype in ovarian cancer cells.
Topics: Animals; Azacitidine; Cell Line, Tumor; Decitabine; DNA Methylation; Female; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Inbred BALB C; Mucoproteins; Neoplasm Metastasis; Neoplasms, Experimental; Oligonucleotide Array Sequence Analysis; Oncogene Proteins; Ovarian Neoplasms; Promoter Regions, Genetic; Proteins | 2014 |
Sequential combination of decitabine and idarubicin synergistically enhances anti-leukemia effect followed by demethylating Wnt pathway inhibitor promoters and downregulating Wnt pathway nuclear target.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Azacitidine; Cell Nucleus; Cell Proliferation; Decitabine; Down-Regulation; Drug Synergism; Humans; Idarubicin; In Situ Nick-End Labeling; Leukemia; Methylation; Mice; Mice, Inbred NOD; Mice, SCID; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; U937 Cells; Wnt Proteins | 2014 |
HBD-2 is downregulated in oral carcinoma cells by DNA hypermethylation, and increased expression of hBD-2 by DNA demethylation and gene transfection inhibits cell proliferation and invasion.
Topics: Azacitidine; beta-Defensins; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cells, Cultured; Decitabine; DNA Methylation; Gene Expression Regulation, Neoplastic; Humans; Keratinocytes; Mouth; Mouth Neoplasms | 2014 |
Combinatorial therapy with acetylation and methylation modifiers attenuates lung vascular hyperpermeability in endotoxemia-induced mouse inflammatory lung injury.
Topics: Acetylation; Acute Lung Injury; Animals; Azacitidine; Blotting, Western; Capillary Permeability; Cell Proliferation; Cell Survival; Chromatin Immunoprecipitation; Decitabine; Disease Models, Animal; Drug Therapy, Combination; Endothelial Cells; Endotoxemia; Enzyme Inhibitors; Flow Cytometry; Fluorescent Antibody Technique; Hydroxamic Acids; In Situ Nick-End Labeling; Inflammation; Lung; Male; Methylation; Mice; Mice, Inbred C57BL; Real-Time Polymerase Chain Reaction | 2014 |
HSPC117 is regulated by epigenetic modification and is involved in the migration of JEG-3 cells.
Topics: Azacitidine; Cell Line, Tumor; Cell Movement; Decitabine; Epigenesis, Genetic; Histones; Humans; Hydroxamic Acids; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Methylation; Proteins; RNA, Messenger; Tissue Inhibitor of Metalloproteinase-1 | 2014 |
'Default' generated neonatal regulatory T cells are hypomethylated at conserved non-coding sequence 2 and promote long-term cardiac allograft survival.
Topics: Adoptive Transfer; Animals; Animals, Newborn; Azacitidine; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Methyltransferase 3B; Forkhead Transcription Factors; Graft Survival; Heart Transplantation; Immunophenotyping; Male; Mice; Mice, Knockout; Mice, Transgenic; Receptors, Antigen, T-Cell; T-Lymphocytes, Regulatory; Transplantation, Homologous; Untranslated Regions | 2014 |
DNMT3A silencing RASSF1A promotes cardiac fibrosis through upregulation of ERK1/2.
Topics: Actins; Animals; Animals, Newborn; Azacitidine; Cells, Cultured; Collagen Type I; Collagen Type I, alpha 1 Chain; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methyltransferase 3A; Fibroblasts; Fibrosis; Gene Silencing; Isoproterenol; Male; MAP Kinase Signaling System; Myocardium; Rats; Rats, Sprague-Dawley; RNA, Messenger; Tumor Suppressor Proteins | 2014 |
Lidocaine and ropivacaine, but not bupivacaine, demethylate deoxyribonucleic acid in breast cancer cells in vitro.
Topics: Amides; Anesthetics, Local; Antimetabolites, Antineoplastic; Azacitidine; Breast Neoplasms; Bupivacaine; Cell Survival; Decitabine; DNA Methylation; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Synergism; Epigenesis, Genetic; Female; Humans; Lidocaine; MCF-7 Cells; Ropivacaine; Tumor Cells, Cultured | 2014 |
Demethylating drugs as novel analgesics for cancer pain.
Topics: Analgesics, Opioid; Animals; Antineoplastic Agents; Azacitidine; Carcinoma, Squamous Cell; Cytidine; Decitabine; Disease Models, Animal; DNA Methylation; Heterografts; Humans; Immunohistochemistry; In Situ Hybridization; Mice; Mouth Neoplasms; Neurons; Pain; Receptors, Opioid, mu; Reverse Transcriptase Polymerase Chain Reaction; Transduction, Genetic; Trigeminal Ganglion | 2014 |
Methylation of PRDM2, PRDM5 and PRDM16 genes in lung cancer cells.
Topics: Azacitidine; Cell Line, Tumor; Cell Proliferation; Decitabine; DNA Methylation; DNA Modification Methylases; DNA-Binding Proteins; Dose-Response Relationship, Drug; Enzyme Inhibitors; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Histone-Lysine N-Methyltransferase; Humans; Lung Neoplasms; Nuclear Proteins; Promoter Regions, Genetic; RNA, Messenger; Time Factors; Transcription Factors | 2014 |
Glycerol-3-phosphate acyltranferase-2 behaves as a cancer testis gene and promotes growth and tumorigenicity of the breast cancer MDA-MB-231 cell line.
Topics: Animals; Azacitidine; Breast Neoplasms; Carcinogenesis; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Computer Simulation; Decitabine; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Gene Silencing; Glycerol-3-Phosphate O-Acyltransferase; Humans; Male; Mice; RNA, Small Interfering; Testis | 2014 |
Methylation pattern of H19 exon 1 is closely related to preeclampsia and trophoblast abnormalities.
Topics: Adult; Azacitidine; Cell Line, Tumor; Cell Movement; Cell Proliferation; Decitabine; DNA Methylation; Exons; Female; Gene Expression Regulation, Neoplastic; Humans; Placenta; Pre-Eclampsia; Pregnancy; RNA, Long Noncoding; RNA, Messenger; Trophoblasts; Young Adult | 2014 |
5-aza-2'-deoxycytidine-mediated c-myc Down-regulation triggers telomere-dependent senescence by regulating human telomerase reverse transcriptase in chronic myeloid leukemia.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cell Cycle Proteins; Cell Line, Tumor; Cellular Senescence; Decitabine; DNA Damage; Down-Regulation; Epigenesis, Genetic; Gene Expression Regulation, Leukemic; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Promoter Regions, Genetic; Protein Binding; Proto-Oncogene Proteins c-myc; Telomerase; Telomere Shortening; Transcription, Genetic | 2014 |
Clinical importance and therapeutic implication of E-cadherin gene methylation in human ovarian cancer.
Topics: Adult; Aged; Azacitidine; Cadherins; Cell Line, Tumor; Cell Movement; Decitabine; DNA Methylation; Enzyme Inhibitors; Female; Gene Expression Regulation, Neoplastic; Humans; Middle Aged; Molecular Targeted Therapy; Ovarian Neoplasms; Promoter Regions, Genetic; Young Adult | 2014 |
FOXO1 downregulation contributes to the oncogenic program of primary mediastinal B-cell lymphoma.
Topics: Apoptosis; Azacitidine; Cell Line, Tumor; Decitabine; DNA Methylation; Down-Regulation; Epigenomics; Forkhead Box Protein O1; Forkhead Transcription Factors; Humans; Lymphoma, B-Cell; Mediastinal Neoplasms; Signal Transduction | 2014 |
An epigenetic marker panel for recurrence risk prediction of low grade papillary urothelial cell carcinoma (LGPUCC) and its potential use for surveillance after transurethral resection using urine.
Topics: Adult; Aged; Aged, 80 and over; Azacitidine; Biomarkers, Tumor; Case-Control Studies; Cyclin A1; Cyclin D2; Decitabine; DNA Methylation; Epigenesis, Genetic; Female; Genetic Predisposition to Disease; Humans; Hydroxamic Acids; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Predictive Value of Tests; Promoter Regions, Genetic; Urinary Bladder Neoplasms | 2014 |
[Comparative analysis of decitabine combined with DAG regimen and other regimens in treatment of refractory/relapsed acute myeloid leukemia].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Decitabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Treatment Outcome; Young Adult | 2014 |
Ultra-low-dose decitabine combined with autologous cytokine-induced killer cells for elderly patients with acute myeloid leukemia transformed from myelodysplastic syndrome.
Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Biomarkers, Tumor; Combined Modality Therapy; Cytokine-Induced Killer Cells; Decitabine; Humans; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Transplantation, Autologous; Treatment Outcome | 2014 |
Downregulation of glutathione S-transferase M1 protein in N-butyl-N-(4-hydroxybutyl)nitrosamine-induced mouse bladder carcinogenesis.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Blotting, Western; Body Weight; Butylhydroxybutylnitrosamine; Carcinogens; Cell Line, Tumor; Coloring Agents; Decitabine; Down-Regulation; Electrophoresis, Gel, Two-Dimensional; Female; Glutathione Transferase; Humans; Immunohistochemistry; Mice; Mice, Inbred C57BL; Mucous Membrane; Real-Time Polymerase Chain Reaction; RNA, Messenger; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Urinary Bladder; Urinary Bladder Neoplasms | 2014 |
Treating myelodysplastic syndrome when hypomethylating agents stop working.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Humans; Myelodysplastic Syndromes | 2014 |
Decitabine reactivated pathways in platinum resistant ovarian cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Carboplatin; Cell Line, Tumor; Decitabine; DNA Methylation; Drug Resistance, Neoplasm; Drug Synergism; Female; Gene Expression; Gene Expression Profiling; Humans; Ovarian Neoplasms | 2014 |
Silencing of the DNA mismatch repair gene MLH1 induced by hypoxic stress in a pathway dependent on the histone demethylase LSD1.
Topics: Adaptor Proteins, Signal Transducing; Azacitidine; Cell Hypoxia; Co-Repressor Proteins; Colonic Neoplasms; Decitabine; DNA Modification Methylases; Gene Silencing; HeLa Cells; Histone Demethylases; Humans; MCF-7 Cells; MutL Protein Homolog 1; Nerve Tissue Proteins; Nuclear Proteins | 2014 |
Epigenetic modification agents improve genomic methylation reprogramming in porcine cloned embryos.
Topics: Animals; Azacitidine; Cellular Reprogramming; Cloning, Organism; Decitabine; DNA Methylation; Embryo Culture Techniques; Embryonic Development; Epigenesis, Genetic; Fertilization in Vitro; Gene Expression; Histone Deacetylase Inhibitors; Hydroxamic Acids; Nuclear Transfer Techniques; Swine | 2014 |
Polycomb group complexes are recruited to reactivated FMR1 alleles in Fragile X syndrome in response to FMR1 transcription.
Topics: Alleles; Azacitidine; Cell Line; Decitabine; Enhancer of Zeste Homolog 2 Protein; Enzyme Inhibitors; Fragile X Mental Retardation Protein; Fragile X Syndrome; Gene Expression Regulation; Histones; Humans; Lymphocytes; Male; Naphthalenes; Polycomb Repressive Complex 2; Pyrones; RNA, Messenger; RNA, Small Interfering; Sirtuin 1; Transcription, Genetic | 2014 |
Genome-wide DNA methylation as an epigenetic consequence of Epstein-Barr virus infection of immortalized keratinocytes.
Topics: Azacitidine; Cell Line, Transformed; Chromatin; CpG Islands; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Enzyme Inhibitors; Epigenesis, Genetic; Gene Expression Profiling; Genome, Human; Herpesvirus 4, Human; Host-Pathogen Interactions; Humans; Keratinocytes; Mouth Mucosa; Promoter Regions, Genetic; Virus Latency | 2014 |
The PARP inhibitor Olaparib disrupts base excision repair of 5-aza-2'-deoxycytidine lesions.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Cell Line, Tumor; Cricetinae; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Adducts; DNA Breaks, Double-Stranded; DNA Repair; DNA-Binding Proteins; Enzyme Inhibitors; Humans; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Recombinational DNA Repair; X-ray Repair Cross Complementing Protein 1 | 2014 |
Pathway landscapes and epigenetic regulation in breast cancer and melanoma cell lines.
Topics: Azacitidine; Breast Neoplasms; Cell Line, Tumor; Decitabine; Down-Regulation; Epigenesis, Genetic; Female; Gene Regulatory Networks; Genes, Neoplasm; Humans; Melanoma; Signal Transduction; Transcription, Genetic; Up-Regulation | 2014 |
ABCB1 regulation through LRPPRC is influenced by the methylation status of the GC -100 box in its promoter.
Topics: Adult; Aged; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Azacitidine; Benzamides; Cell Line, Tumor; Decitabine; DNA Methylation; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Proteins; Piperazines; Promoter Regions, Genetic; Pyrimidines | 2014 |
Decitabine suspends human CD34+ cell differentiation and proliferation during lentiviral transduction.
Topics: Animals; Antigens, CD34; Antimetabolites, Antineoplastic; Azacitidine; Cell Differentiation; Cell Proliferation; Decitabine; DNA (Cytosine-5-)-Methyltransferases; Gene Expression; Genetic Vectors; Graft Survival; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Lentivirus; Male; Mice; Mice, Inbred NOD; Mice, SCID; Primary Cell Culture; Transduction, Genetic; Transplantation, Heterologous | 2014 |
Genome-wide demethylation by 5-aza-2'-deoxycytidine alters the cell fate of stem/progenitor cells.
Topics: Animals; Azacitidine; Cdh1 Proteins; Cell Differentiation; Cells, Cultured; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Enzyme Inhibitors; Epithelial Cells; Gene Expression; Genome; Hair Cells, Auditory, Inner; Keratin-8; Mice; Myosin Heavy Chains; Myosin VIIa; Myosins; Reverse Transcriptase Polymerase Chain Reaction; Saccule and Utricle; Stem Cells | 2015 |
Decitabine reduces transfusion dependence in older patients with acute myeloid leukemia: results from a post hoc analysis of a randomized phase III study.
Topics: Acute Disease; Aged; Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Decitabine; Disease-Free Survival; Erythrocyte Transfusion; Humans; Leukemia, Myeloid; Multivariate Analysis; Outcome Assessment, Health Care; Platelet Transfusion; Randomized Controlled Trials as Topic; Remission Induction | 2015 |
p19-INK4d inhibits neuroblastoma cell growth, induces differentiation and is hypermethylated and downregulated in MYCN-amplified neuroblastomas.
Topics: Adolescent; Adult; Antimetabolites, Antineoplastic; Azacitidine; Cell Differentiation; Cell Line, Tumor; Child; Child, Preschool; Cyclin-Dependent Kinase Inhibitor p19; Decitabine; DNA Methylation; Epigenesis, Genetic; Female; Gene Expression Regulation, Neoplastic; Humans; Infant; Infant, Newborn; Male; N-Myc Proto-Oncogene Protein; Neoplasm Staging; Nervous System Neoplasms; Neuroblastoma; Neurons; Nuclear Proteins; Oncogene Proteins; Signal Transduction; Survival Analysis; Tretinoin | 2014 |
Interferon regulatory factor 8 functions as a tumor suppressor in renal cell carcinoma and its promoter methylation is associated with patient poor prognosis.
Topics: Azacitidine; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Movement; Decitabine; DNA Methylation; DNA Modification Methylases; Down-Regulation; Female; G2 Phase Cell Cycle Checkpoints; Genes, Tumor Suppressor; HEK293 Cells; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Interferon Regulatory Factors; Kidney Neoplasms; M Phase Cell Cycle Checkpoints; Male; Prognosis; Promoter Regions, Genetic | 2014 |
The N-terminal transactivation domain of the glucocorticoid receptor mediates apoptosis of human small cell lung cancer cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Cell Line, Tumor; CpG Islands; Decitabine; DNA Methylation; Humans; Lung Neoplasms; Mifepristone; Promoter Regions, Genetic; Protein Structure, Tertiary; Receptors, Glucocorticoid; Small Cell Lung Carcinoma; Transcriptional Activation | 2014 |
Epigenetic determinants of CYP1A1 induction by the aryl hydrocarbon receptor agonist 3,3',4,4',5-pentachlorobiphenyl (PCB 126).
Topics: Aryl Hydrocarbon Receptor Nuclear Translocator; Azacitidine; Chromatin; CpG Islands; Cytochrome P-450 CYP1A1; Decitabine; DNA Methylation; Epigenesis, Genetic; HeLa Cells; Hep G2 Cells; Humans; Hydroxamic Acids; Polychlorinated Biphenyls; Promoter Regions, Genetic; Receptors, Aryl Hydrocarbon; RNA, Messenger | 2014 |
Increased methylation of the MOR gene proximal promoter in primary sensory neurons plays a crucial role in the decreased analgesic effect of opioids in neuropathic pain.
Topics: Animals; Azacitidine; Cell Line, Tumor; CpG Islands; Decitabine; Disease Models, Animal; Dose-Response Relationship, Drug; Enzyme Inhibitors; Ganglia, Spinal; Gene Expression Regulation; Hyperalgesia; Methylation; Mice; Morphine; Neuralgia; Neuroblastoma; Pain Measurement; Pain Threshold; Promoter Regions, Genetic; Receptors, Opioid, mu; Sensory Receptor Cells; Spinal Cord | 2014 |
Low-dose decitabine induces MAGE-A expression and inhibits invasion via suppression of NF-κB2 and MMP2 in Eca109 cells.
Topics: Antigens, Neoplasm; Antimetabolites, Antineoplastic; Azacitidine; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Decitabine; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; Matrix Metalloproteinase 2; Neoplasm Invasiveness; Neoplasm Proteins; NF-kappa B p52 Subunit | 2014 |
TAp73 and ΔNp73 have opposing roles in 5-aza-2'-deoxycytidine-induced apoptosis in breast cancer cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Base Sequence; Cell Line, Tumor; Decitabine; DNA Methylation; DNA-Binding Proteins; Female; G1 Phase; Gene Expression Regulation, Neoplastic; Humans; Mammary Glands, Human; Molecular Sequence Data; Nuclear Proteins; Promoter Regions, Genetic; Protein Isoforms; Signal Transduction; Transcription, Genetic; Tumor Protein p73; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2014 |
Combination effect of epigenetic regulation and ionizing radiation in colorectal cancer cells.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Azacitidine; Cell Line, Tumor; Colorectal Neoplasms; Combined Modality Therapy; Decitabine; DNA Methylation; Epigenesis, Genetic; Female; G1 Phase; HCT116 Cells; Humans; Mice; Mice, SCID; Radiation Tolerance; Radiation, Ionizing | 2014 |
Okadaic acid blocks the effects of 5-aza-2-deoxycytidine on consolidation, acquisition and retrieval of morphine-induced place preference in rats.
Topics: Animals; Azacitidine; CA1 Region, Hippocampal; Cerebral Cortex; Conditioning, Psychological; Decitabine; Disease Models, Animal; DNA Modification Methylases; Enzyme Inhibitors; Male; Memory; Morphine; Morphine Dependence; Narcotics; Okadaic Acid; Rats, Sprague-Dawley; Reward; Spatial Behavior | 2014 |
Decitabine and SAHA-induced apoptosis is accompanied by survivin downregulation and potentiated by ATRA in p53-deficient cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Cell Line, Tumor; Decitabine; Down-Regulation; Drug Synergism; G2 Phase Cell Cycle Checkpoints; HL-60 Cells; Humans; Hydroxamic Acids; Inhibitor of Apoptosis Proteins; Lymphocytes; M Phase Cell Cycle Checkpoints; Reactive Oxygen Species; Survivin; Tretinoin; Tumor Suppressor Protein p53; Vorinostat | 2014 |
The demethylating agent 5-Aza reduces the growth, invasiveness, and clonogenicity of uveal and cutaneous melanoma.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Cell Line, Tumor; Cell Movement; Cell Proliferation; Colony-Forming Units Assay; Decitabine; DNA Modification Methylases; DNA, Neoplasm; Humans; Melanoma; Melanoma, Cutaneous Malignant; Mice; Neoplasms, Experimental; Skin Neoplasms; Uveal Neoplasms | 2014 |
Quantitative determination of decitabine incorporation into DNA and its effect on mutation rates in human cancer cells.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cell Line, Tumor; Decitabine; DNA, Neoplasm; Humans; Mutation Rate; Scintillation Counting | 2014 |
Development and validation of a HILIC-MS/MS method for quantification of decitabine in human plasma by using lithium adduct detection.
Topics: Azacitidine; Chromatography, High Pressure Liquid; Decitabine; Drug Stability; Humans; Hydrophobic and Hydrophilic Interactions; Linear Models; Lithium; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry | 2014 |
MLL5 expression as a biomarker for DNA hypermethylation and sensitivity to epigenetic therapy.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA-Binding Proteins; Female; Humans; Leukemia, Myeloid, Acute; Male; RNA, Messenger | 2014 |
Synergistic effects of combined DNA methyltransferase inhibition and MBD2 depletion on breast cancer cells; MBD2 depletion blocks 5-aza-2'-deoxycytidine-triggered invasiveness.
Topics: Azacitidine; Breast Neoplasms; Decitabine; DNA Methylation; DNA Modification Methylases; DNA-Binding Proteins; Enzyme Inhibitors; Female; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Molecular Targeted Therapy; Neoplasm Invasiveness; Promoter Regions, Genetic | 2014 |
Comparative evaluation of cardiac markers in differentiated cells from menstrual blood and bone marrow-derived stem cells in vitro.
Topics: Adult; Azacitidine; Biomarkers; Blood Cells; Bone Marrow Cells; Cell Differentiation; Decitabine; Female; Fibroblast Growth Factor 2; Humans; Menstruation; Myocytes, Cardiac; Stem Cells; Young Adult | 2014 |
Epigenetic control of trefoil factor family (TFF) peptide expression in human retinoblastoma cell lines.
Topics: Azacitidine; Base Sequence; Cell Line, Tumor; Decitabine; DNA Methylation; DNA Primers; Epigenesis, Genetic; Female; Humans; Male; Peptide Fragments; Peptides; Phenylbutyrates; Polymerase Chain Reaction; Promoter Regions, Genetic; Retinoblastoma; Trefoil Factor-1; Trefoil Factor-2; Trefoil Factor-3; Tumor Suppressor Proteins | 2014 |
Inhibition of DNA methylation enhances HLA-G expression in human mesenchymal stem cells.
Topics: Adipose Tissue; Azacitidine; Bone Marrow Cells; Decitabine; DNA Methylation; Epigenesis, Genetic; HLA-G Antigens; Humans; Mesenchymal Stem Cells; Primary Cell Culture; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Valproic Acid | 2014 |
Fibronectin affects transient MMP2 gene expression through DNA demethylation changes in non-invasive breast cancer cell lines.
Topics: Azacitidine; Base Sequence; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Decitabine; DNA Methylation; Fibronectins; Gene Expression Regulation, Neoplastic; Humans; Matrix Metalloproteinase 2; Molecular Sequence Data; Neoplasm Invasiveness; Promoter Regions, Genetic; Time Factors; Transcriptional Activation | 2014 |
TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients.
Topics: Aged; Animals; Azacitidine; Biomarkers, Tumor; Bone Marrow Transplantation; Decitabine; Dioxygenases; DNA Methylation; DNA Modification Methylases; DNA-Binding Proteins; Enzyme Inhibitors; Female; Gene Frequency; Genotype; Humans; Kaplan-Meier Estimate; Logistic Models; Male; Mice, Knockout; Mutation; Myelodysplastic Syndromes; Proto-Oncogene Proteins; Repressor Proteins; Transplantation Chimera; Treatment Outcome; Tumor Suppressor Protein p53 | 2014 |
Selected drugs that inhibit DNA methylation can preferentially kill p53 deficient cells.
Topics: Animals; Anticarcinogenic Agents; Azacitidine; Catechin; Cell Line, Tumor; Cell Proliferation; Cytidine; Decitabine; DNA Methylation; Humans; Lung Neoplasms; Mice; Mice, Inbred C57BL; Mice, Knockout; Mutation; Neoplasm Transplantation; Phthalimides; Tryptophan; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2014 |
Subtype-specific overexpression of the Rac-GEF P-REX1 in breast cancer is associated with promoter hypomethylation.
Topics: Azacitidine; Breast Neoplasms; Cell Line, Tumor; Decitabine; DNA Methylation; DNA Modification Methylases; Female; Gene Expression; Gene Expression Regulation, Neoplastic; Guanine Nucleotide Exchange Factors; Humans; Kaplan-Meier Estimate; Promoter Regions, Genetic; Proto-Oncogene Proteins c-vav | 2014 |
Inhibiting DNA Methylation by 5-Aza-2'-deoxycytidine ameliorates atherosclerosis through suppressing macrophage inflammation.
Topics: Animals; Atherosclerosis; Azacitidine; Cell Adhesion; Cell Movement; Cells, Cultured; Decitabine; DNA Methylation; Endoplasmic Reticulum Stress; Lipids; Liver X Receptors; Macrophages; Male; Mice; Mice, Knockout; Orphan Nuclear Receptors; Plaque, Atherosclerotic; PPAR gamma; Promoter Regions, Genetic; Random Allocation; Rats | 2014 |
SMG1 acts as a novel potential tumor suppressor with epigenetic inactivation in acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Apoptosis; Azacitidine; Bone Marrow; Cell Line, Tumor; Decitabine; DNA Methylation; DNA, Neoplasm; Down-Regulation; Female; Gene Expression Regulation, Leukemic; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Male; Middle Aged; Neoplasm Proteins; Phosphatidylinositol 3-Kinases; Promoter Regions, Genetic; Protein Serine-Threonine Kinases; RNA Interference; RNA, Messenger; RNA, Neoplasm; TOR Serine-Threonine Kinases; Tumor Suppressor Proteins; Young Adult | 2014 |
Lack of objective response of myelodysplastic syndromes and acute myeloid leukemia to decitabine after failure of azacitidine.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Survival Rate; Treatment Failure | 2015 |
MicroRNA-125a reduces proliferation and invasion of oral squamous cell carcinoma cells by targeting estrogen-related receptor α: implications for cancer therapeutics.
Topics: Amino Acid Sequence; Animals; Apoptosis; Azacitidine; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Decitabine; Estrogen Receptor alpha; Female; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Molecular Sequence Data; Mouth Neoplasms; Neoplasm Invasiveness; Neoplasm Transplantation; Plasmids; Protein Binding; Sequence Homology, Amino Acid | 2014 |
Epigenetic silencing of miRNA-9 is correlated with promoter-proximal CpG island hypermethylation in gastric cancer in vitro and in vivo.
Topics: Adult; Aged; Animals; Azacitidine; Cell Line, Tumor; CpG Islands; Decitabine; DNA Methylation; Epigenesis, Genetic; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; MicroRNAs; Middle Aged; Promoter Regions, Genetic; Stomach Neoplasms; Xenograft Model Antitumor Assays | 2014 |
Interactive actions of Bdnf methylation and cell metabolism for building neural resilience under the influence of diet.
Topics: Animals; Anxiety; Azacitidine; Brain; Brain-Derived Neurotrophic Factor; Cell Line, Tumor; Decitabine; Diet, Fat-Restricted; Disease Models, Animal; Enzyme Inhibitors; Fatty Acids, Omega-3; Female; Male; Maze Learning; Methylation; Mice; Neuroblastoma; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Pregnancy; Prenatal Exposure Delayed Effects; Rats; Rats, Sprague-Dawley; Transcription Factors | 2015 |
Inhibition of bladder cancer invasion by Sp1-mediated BTG2 expression via inhibition of DNA methyltransferase 1.
Topics: Azacitidine; Chromatin Assembly and Disassembly; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methyltransferase 3A; Enzyme Inhibitors; Gene Knockdown Techniques; Humans; Immediate-Early Proteins; Introns; Neoplasm Invasiveness; Promoter Regions, Genetic; Sp1 Transcription Factor; Tumor Suppressor Proteins; Up-Regulation; Urinary Bladder Neoplasms | 2014 |
Expression of GBGT1 is epigenetically regulated by DNA methylation in ovarian cancer cells.
Topics: Azacitidine; Cell Line, Tumor; Decitabine; DNA Methylation; Female; Gene Expression Regulation, Neoplastic; Humans; N-Acetylgalactosaminyltransferases; Ovarian Neoplasms; Ovary; Promoter Regions, Genetic | 2014 |
Regulatory T cell DNA methyltransferase inhibition accelerates resolution of lung inflammation.
Topics: Acute Lung Injury; Adoptive Transfer; Animals; Azacitidine; Cells, Cultured; Chemotaxis, Leukocyte; Decitabine; Disease Models, Animal; DNA Modification Methylases; Enzyme Inhibitors; Forkhead Transcription Factors; Homeodomain Proteins; Influenza A Virus, H1N1 Subtype; Lipopolysaccharides; Lung; Mice, Inbred C57BL; Mice, Knockout; Phenotype; Pneumonia; T-Lymphocytes, Regulatory; Time Factors | 2015 |
Trace analysis of methylated and hydroxymethylated cytosines in DNA by isotope-dilution LC-MS/MS: first evidence of DNA methylation in Caenorhabditis elegans.
Topics: 5-Methylcytosine; Animals; Azacitidine; Cadmium; Caenorhabditis elegans; Chromatography, Liquid; Cytosine; Decitabine; Deoxycytidine; DNA; DNA Methylation; Isotope Labeling; Online Systems; Reproducibility of Results; Solid Phase Extraction; Tandem Mass Spectrometry | 2015 |
FT-IR microspectrometry reveals the variation of membrane polarizability due to epigenomic effect on epithelial ovarian cancer.
Topics: Azacitidine; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Membrane; Chromatography, High Pressure Liquid; CpG Islands; Decitabine; Deoxycytidine Monophosphate; DNA Methylation; DNA, Ribosomal; Epigenomics; Female; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Spectroscopy, Fourier Transform Infrared | 2014 |
Induction of a specific CD8+ T-cell response to cancer/testis antigens by demethylating pre-treatment against osteosarcoma.
Topics: Animals; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Blotting, Western; Bone Neoplasms; CD8-Positive T-Lymphocytes; Cell Proliferation; Decitabine; Female; Flow Cytometry; Humans; Immunotherapy; Membrane Proteins; Mice; Mice, SCID; Neoplasm Proteins; Osteosarcoma; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; T-Lymphocytes, Cytotoxic; Tumor Cells, Cultured | 2014 |
DNMT inhibitors reverse a specific signature of aberrant promoter DNA methylation and associated gene silencing in AML.
Topics: Azacitidine; Cell Line, Tumor; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Gene Silencing; High-Throughput Nucleotide Sequencing; Humans; Leukemia, Myeloid, Acute; Promoter Regions, Genetic; Sequence Analysis, RNA | 2014 |
Clinical outcome after failure of hypomethylating therapy for myelodysplastic syndrome.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Modification Methylases; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Patient Outcome Assessment; Salvage Therapy; Treatment Failure; Young Adult | 2015 |
Zinc finger protein 382 is downregulated by promoter hypermethylation in pediatric acute myeloid leukemia patients.
Topics: Acute Disease; Azacitidine; Cell Line, Tumor; Child; Decitabine; DNA Methylation; DNA-Binding Proteins; Down-Regulation; Enzyme Inhibitors; Female; Gene Expression Regulation, Leukemic; HL-60 Cells; Humans; Jurkat Cells; K562 Cells; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Neoplasm, Residual; Prognosis; Promoter Regions, Genetic; Proportional Hazards Models; Reverse Transcriptase Polymerase Chain Reaction; Transcription Factors; U937 Cells | 2014 |
Involvement of microRNA-24 and DNA methylation in resistance of nasopharyngeal carcinoma to ionizing radiation.
Topics: Animals; Azacitidine; Carcinoma; Cell Line, Tumor; Cell Proliferation; Cluster Analysis; Decitabine; Disease Models, Animal; DNA Methylation; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Histones; Humans; Male; Mice; MicroRNAs; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Radiation Tolerance; Radiation, Ionizing; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
DNA hypomethylation-mediated overexpression of carbonic anhydrase 9 induces an aggressive phenotype in ovarian cancer cells.
Topics: Animals; Azacitidine; Carbonic Anhydrases; Carcinoma, Ovarian Epithelial; Decitabine; DNA Methylation; Female; Gene Expression Regulation, Neoplastic; Humans; Mice; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasms, Experimental; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Phenotype; Promoter Regions, Genetic; RNA, Messenger | 2014 |
Global epigenetic regulation of microRNAs in multiple myeloma.
Topics: Apoptosis; Azacitidine; beta-Transducin Repeat-Containing Proteins; Cell Line, Tumor; Cell Proliferation; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA-Binding Proteins; E2F3 Transcription Factor; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Multiple Myeloma; RNA, Messenger; Transcription Factors | 2014 |
Combining DNA methyltransferase and histone deacetylase inhibition to treat acute myeloid leukemia/myelodysplastic syndrome: achievements and challenges.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Clinical Trials as Topic; Decitabine; DNA Modification Methylases; Drug Administration Schedule; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Research Design; Treatment Failure; Valproic Acid | 2015 |
[Clinical efficacy of decitabine combined with modified CAG regimen for relapsed-refractory acute myeloid leukemia with AML1-ETO⁺].
Topics: Aclarubicin; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Core Binding Factor Alpha 2 Subunit; Cytarabine; Decitabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Oncogene Proteins, Fusion; Recurrence; Retrospective Studies; RUNX1 Translocation Partner 1 Protein; Treatment Outcome; Young Adult | 2014 |
[Comparison of clinical efficacy between decitabine combined with CAG regimen and CAG regimen alone in patients with intermediate to high-risk myelodysplastic syndromes].
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Disease-Free Survival; Granulocyte Colony-Stimulating Factor; Humans; Myelodysplastic Syndromes; Remission Induction; Treatment Outcome | 2014 |
[Effect of decitabine on immune regulation in patients with acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation].
Topics: Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Graft vs Leukemia Effect; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Quality of Life; T-Lymphocytes, Cytotoxic; T-Lymphocytes, Regulatory; Transplantation, Homologous | 2014 |
A novel tumor suppressor function of Kindlin-3 in solid cancer.
Topics: Animals; Azacitidine; Breast Neoplasms; Cell Adhesion; Cell Line, Tumor; Cell Proliferation; Decitabine; DNA Methylation; Female; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Heterografts; Humans; Integrin beta3; Melanoma; Membrane Proteins; Mice; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Transplantation; Phosphorylation; RNA Interference; RNA, Messenger; RNA, Small Interfering; Talin | 2014 |
[Significance of expression and promoter methylation of LITAF gene in B-cell lymphoma].
Topics: Adult; Azacitidine; Cell Line, Tumor; CpG Islands; Decitabine; DNA Methylation; Gene Silencing; Humans; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Nuclear Proteins; Polymerase Chain Reaction; Promoter Regions, Genetic; Transcription Factors | 2014 |
Effects of 5-aza-2'-deoxycytidine and trichostatin A on high glucose- and interleukin-1β-induced secretory mediators from human retinal endothelial cells and retinal pigment epithelial cells.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Dose-Response Relationship, Drug; Endothelial Cells; Epithelial Cells; Eye Proteins; Gene Expression; Glucose; Humans; Hydroxamic Acids; Intercellular Adhesion Molecule-1; Interleukin-1beta; Matrix Metalloproteinase 2; Nerve Growth Factors; Primary Cell Culture; Retina; Retinal Pigments; RNA, Messenger; Serpins; Vascular Endothelial Growth Factor A | 2014 |
Identification of HERC5 and its potential role in NSCLC progression.
Topics: Azacitidine; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chromosome Deletion; Chromosomes, Human, Pair 4; Decitabine; DNA Copy Number Variations; DNA Methylation; Gene Expression Regulation, Neoplastic; Humans; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; Promoter Regions, Genetic; Survival Analysis | 2015 |
Ex vivo expansion of human mobilized peripheral blood stem cells using epigenetic modifiers.
Topics: Adult; Animals; Antigens, CD34; Azacitidine; Blood Cells; Bone Marrow Cells; Cell Count; Cell Division; Cells, Cultured; Chromatin Assembly and Disassembly; Colony-Forming Units Assay; Cytokines; Decitabine; DNA Methylation; Epigenesis, Genetic; Fetal Blood; Graft Survival; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Heterografts; Humans; Hydroxamic Acids; Immunomagnetic Separation; Infant, Newborn; Mice; Mice, Inbred NOD; Mice, SCID; Peripheral Blood Stem Cell Transplantation; Transcription, Genetic | 2015 |
HSI2/VAL1 PHD-like domain promotes H3K27 trimethylation to repress the expression of seed maturation genes and complex transgenes in Arabidopsis seedlings.
Topics: Arabidopsis; Arabidopsis Proteins; Azacitidine; Decitabine; DNA Methylation; Enzyme Inhibitors; Gene Expression; Gene Expression Regulation, Plant; Genes, Reporter; Glutathione Transferase; Histones; Homeodomain Proteins; Plants, Genetically Modified; Repressor Proteins; Seedlings; Seeds; Transgenes | 2014 |
Identification of novel epigenetically inactivated gene PAMR1 in breast carcinoma.
Topics: Azacitidine; Breast Neoplasms; Cell Line, Tumor; Decitabine; DNA Methylation; DNA Modification Methylases; Down-Regulation; Epigenesis, Genetic; Female; Gene Expression; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Humans; Mammary Glands, Human; Organ Specificity; Promoter Regions, Genetic; Serine Proteases | 2015 |
Identification of epigenetically inactivated genes in human hepatocellular carcinoma by integrative analyses of methylation profiling and pharmacological unmasking.
Topics: Aged; Azacitidine; Biopsy, Needle; Carcinoma, Hepatocellular; Case-Control Studies; Decitabine; DNA Methylation; Epigenesis, Genetic; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Hydroxamic Acids; Liver Neoplasms; Male; Middle Aged; Reference Values; Sampling Studies; Tumor Cells, Cultured | 2014 |
Stability of XIST repression in relation to genomic imprinting following global genome demethylation in a human cell line.
Topics: Apoptosis Regulatory Proteins; Azacitidine; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Methyltransferase 3B; DNA-Binding Proteins; Epigenetic Repression; Gene Knockout Techniques; Genome; Genome, Human; Genomic Imprinting; HCT116 Cells; Humans; In Situ Hybridization, Fluorescence; Insulin-Like Growth Factor II; Microarray Analysis; Polymorphism, Single Nucleotide; Proteins; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA-Binding Proteins; RNA, Long Noncoding | 2014 |
TLR2 promoter hypermethylation creates innate immune dysbiosis.
Topics: Animals; Azacitidine; Bacteroidaceae Infections; Cell Culture Techniques; Chronic Periodontitis; CpG Islands; Decitabine; Disease Models, Animal; DNA Methylation; DNA Modification Methylases; Dysbiosis; Epigenesis, Genetic; Epithelial Cells; Genetic Predisposition to Disease; Gingiva; Host-Pathogen Interactions; Humans; Immunity, Innate; Inflammation Mediators; Interleukin-1beta; Mice; Mice, Inbred BALB C; Porphyromonas gingivalis; Toll-Like Receptor 2 | 2015 |
Decitabine rescues cisplatin resistance in head and neck squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Azacitidine; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cisplatin; Decitabine; DNA Methylation; Drug Resistance, Neoplasm; Female; Head and Neck Neoplasms; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Transcriptome; Xenograft Model Antitumor Assays; Young Adult | 2014 |
Promoter methylation-mediated silencing of β-catenin enhances invasiveness of non-small cell lung cancer and predicts adverse prognosis.
Topics: Aged; Azacitidine; beta Catenin; Cadherins; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Membrane; Decitabine; DNA Methylation; Female; Gene Silencing; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Prognosis; Promoter Regions, Genetic; Wnt Signaling Pathway | 2014 |
MUC5AC hypomethylation is a predictor of microsatellite instability independently of clinical factors associated with colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Azacitidine; Cell Line, Tumor; Colorectal Neoplasms; CpG Islands; Decitabine; DNA Methylation; Female; Gene Expression Regulation, Neoplastic; HCT116 Cells; HT29 Cells; Humans; Immunohistochemistry; Male; Microsatellite Instability; Middle Aged; Mucin 5AC; Mutation; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); ras Proteins; Reverse Transcriptase Polymerase Chain Reaction; Tumor Suppressor Protein p53 | 2015 |
Treatment of buffalo (Bubalus bubalis) donor cells with trichostatin A and 5-aza-2'-deoxycytidine alters their growth characteristics, gene expression and epigenetic status and improves the in vitro developmental competence, quality and epigenetic status
Topics: Acetylation; Animals; Apoptosis; Azacitidine; Blastocyst; Buffaloes; Cells, Cultured; Cloning, Organism; Decitabine; DNA Methylation; DNA Modification Methylases; Ectogenesis; Embryo Culture Techniques; Enzyme Inhibitors; Epigenesis, Genetic; Female; Gene Expression Regulation, Developmental; Histone Deacetylase Inhibitors; Histones; Hydroxamic Acids; India; Methylation; Protein Processing, Post-Translational | 2016 |
Retinoic acid receptor-β gene reexpression and biological activity in SHI-1 cells after combined treatment with 5-aza-2'-deoxycytidine and all-trans retinoic acid.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Azacitidine; Cell Differentiation; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p16; Decitabine; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Monocytic, Acute; Receptors, Retinoic Acid; Tretinoin | 2015 |
Analysis of the antiproliferative effects of 3-deazaneoplanocin A in combination with standard anticancer agents in rhabdoid tumor cell lines.
Topics: Adenosine; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Azacitidine; Cell Line, Tumor; Cell Proliferation; Decitabine; Doxorubicin; Enhancer of Zeste Homolog 2 Protein; Epigenesis, Genetic; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Hydroxamic Acids; Molecular Targeted Therapy; Polycomb Repressive Complex 2; Rhabdoid Tumor; Vorinostat | 2015 |
[The clinical efficacy of the patients of acute myeloid leukemia and myelodysplastic syndromes treated with decitabine alone, combined with half or one couse of CAG regimen].
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | 2014 |
Efficacy and side-effects of decitabine in treatment of atypical chronic myeloid leukemia.
Topics: Adult; Anemia; Antimetabolites, Antineoplastic; Azacitidine; Chromosome Aberrations; Decitabine; Fatal Outcome; Female; Humans; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Male; Middle Aged; Remission Induction; Thrombocytopenia; Treatment Outcome | 2015 |
Combination therapy with epigenetic-targeted and chemotherapeutic drugs delivered by nanoparticles to enhance the chemotherapy response and overcome resistance by breast cancer stem cells.
Topics: Aldehyde Dehydrogenase; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Azacitidine; Breast Neoplasms; Caspase 9; Cell Line, Tumor; Chemistry, Pharmaceutical; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Methyltransferase 3B; Dose-Response Relationship, Drug; Doxorubicin; Drug Carriers; Drug Resistance, Neoplasm; Epigenesis, Genetic; Female; Gene Expression Regulation, Neoplastic; Humans; Mice, Inbred NOD; Mice, SCID; Nanomedicine; Nanoparticles; Neoplastic Stem Cells; Polyesters; Polyethylene Glycols; Spheroids, Cellular; Technology, Pharmaceutical; Time Factors; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
Lipid based nanocarrier system for the potential oral delivery of decitabine: formulation design, characterization, ex vivo, and in vivo assessment.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Azacitidine; Chemistry, Pharmaceutical; Decitabine; Drug Carriers; Drug Design; Drug Liberation; Drug Stability; Excipients; Lipids; Male; Microscopy, Electron, Transmission; Nanoparticles; Particle Size; Rats; Surface Properties | 2014 |
Androgen receptor DNA methylation regulates the timing and androgen sensitivity of mouse prostate ductal development.
Topics: Analysis of Variance; Animals; Azacitidine; Base Sequence; Decitabine; Dihydrotestosterone; DNA Methylation; DNA Primers; Gene Expression Regulation, Developmental; Homeodomain Proteins; Immunohistochemistry; Immunoprecipitation; In Situ Hybridization; In Vitro Techniques; Male; Mice; Models, Biological; Molecular Sequence Data; Organogenesis; Prostate; Real-Time Polymerase Chain Reaction; Receptors, Androgen; Sequence Analysis, DNA; Signal Transduction; Transcription Factors | 2014 |
Methylation-associated silencing of miR-495 inhibit the migration and invasion of human gastric cancer cells by directly targeting PRL-3.
Topics: Azacitidine; Cell Line, Tumor; Cell Movement; Decitabine; DNA Methylation; Gene Silencing; Genes, Tumor Suppressor; Humans; MicroRNAs; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Promoter Regions, Genetic; Protein Tyrosine Phosphatases; Sequence Analysis, DNA; Stomach Neoplasms | 2015 |
DNA methylation and differential gene regulation in photoreceptor cell death.
Topics: Animals; Apoptosis Regulatory Proteins; Azacitidine; Cell Death; Cells, Cultured; Chromatin; Decitabine; Disease Models, Animal; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Methyltransferase 3A; Epigenesis, Genetic; Eye Proteins; Humans; In Situ Nick-End Labeling; Mice; Mutation; Nerve Tissue Proteins; Photoreceptor Cells, Vertebrate; Rats; Retinitis Pigmentosa; Tissue Culture Techniques | 2014 |
Identification of coexistence of DNA methylation and H3K27me3 specifically in cancer cells as a promising target for epigenetic therapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Benzamides; Cell Proliferation; Decitabine; DNA Methylation; Enhancer of Zeste Homolog 2 Protein; Enzyme Inhibitors; Epigenesis, Genetic; Female; Gene Expression Regulation, Neoplastic; HCT116 Cells; Histone Deacetylase Inhibitors; Histones; Humans; Indoles; Insulin-Like Growth Factor Binding Proteins; Intercellular Signaling Peptides and Proteins; Male; MCF-7 Cells; Membrane Proteins; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Polycomb Repressive Complex 2; Promoter Regions, Genetic; Pyridines; Pyridones; Xenograft Model Antitumor Assays | 2015 |
Gene expression profiling of replicative and induced senescence.
Topics: Azacitidine; Cell Line, Tumor; Cellular Senescence; Cyclin A2; Decitabine; Doxorubicin; Gene Expression; Gene Expression Profiling; Humans; Hydrogen Peroxide; Interleukin-1; Sequence Analysis, RNA | 2014 |
CpG island promoter hypermethylation of Ras association domain family 1A gene contributes to gastric carcinogenesis.
Topics: Azacitidine; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; CpG Islands; Decitabine; DNA Methylation; Gene Expression; Gene Silencing; Humans; Neoplasm Staging; Promoter Regions, Genetic; Stomach Neoplasms; Tumor Suppressor Proteins | 2015 |
Epigenetic modulation of the muscarinic type 3 receptor in salivary epithelial cells.
Topics: Amino Acid Sequence; Azacitidine; Base Sequence; Blotting, Western; Cell Line; CpG Islands; Decitabine; DNA Methylation; DNA Primers; Epigenesis, Genetic; Epithelial Cells; Gene Expression Regulation; Humans; Microscopy, Confocal; Molecular Sequence Data; Receptor, Muscarinic M3; Reverse Transcriptase Polymerase Chain Reaction; Salivary Glands; Sequence Analysis, DNA | 2015 |
Dynamic changes in the cardiac methylome during postnatal development.
Topics: Animals; Animals, Newborn; Azacitidine; Cell Cycle Checkpoints; Cell-Penetrating Peptides; Decitabine; DNA Methylation; Epigenesis, Genetic; Gene Expression Regulation, Developmental; Heart; Male; Mice; Mice, Inbred C57BL; Mice, Inbred ICR; Myocardium; Myocytes, Cardiac; Signal Transduction | 2015 |
MiR-335 inhibits migration of breast cancer cells through targeting oncoprotein c-Met.
Topics: Azacitidine; Breast Neoplasms; Cell Movement; Cell Proliferation; Decitabine; Female; Gene Expression Regulation, Neoplastic; Hepatocyte Growth Factor; Humans; MCF-7 Cells; MicroRNAs; Neoplasm Invasiveness; Proto-Oncogene Proteins c-met | 2015 |
The high mobility group A2 protein epigenetically silences the Cdh1 gene during epithelial-to-mesenchymal transition.
Topics: Antigens, CD; Azacitidine; Breast Neoplasms; Cadherins; CCCTC-Binding Factor; Cell Line, Tumor; Cell Movement; Cells, Cultured; CpG Islands; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Methyltransferase 3A; Epithelial-Mesenchymal Transition; Female; Gene Silencing; HMGA2 Protein; Humans; Promoter Regions, Genetic; Repressor Proteins; Transforming Growth Factor beta | 2015 |
Epigenetic regulation of p14ARF and p16INK4A expression in cutaneous and uveal melanoma.
Topics: Adult; Azacitidine; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p16; Decitabine; DNA Methylation; Epigenesis, Genetic; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Histone Deacetylases; Humans; Melanoma; Promoter Regions, Genetic; Tumor Suppressor Protein p14ARF; Uveal Neoplasms | 2015 |
Human DNA methyltransferase gene-transformed yeasts display an inducible flocculation inhibited by 5-aza-2'-deoxycytidine.
Topics: Azacitidine; Culture Media; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methyltransferase 3A; DNA Methyltransferase 3B; Drug Evaluation, Preclinical; Enzyme Inhibitors; Flocculation; Galactokinase; Glucose; Humans; Mannose-Binding Lectins; Promoter Regions, Genetic; RNA, Messenger; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Transformation, Genetic | 2015 |
Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms.
Topics: Animals; Azacitidine; Benzodioxoles; Blotting, Western; Colony-Forming Units Assay; Decitabine; Exome; Flow Cytometry; Hematologic Neoplasms; High-Throughput Nucleotide Sequencing; Humans; Janus Kinase 2; Leukemia, Myeloid, Acute; Mice; Mutation, Missense; Myeloproliferative Disorders; Nitriles; Purines; Pyrazoles; Pyrimidines; Tumor Suppressor Protein p53 | 2014 |
The hENT1 and DCK genes underlie the decitabine response in patients with myelodysplastic syndrome.
Topics: Adult; Aged; Aged, 80 and over; Apoptosis; Azacitidine; Decitabine; Deoxycytidine Kinase; Down-Regulation; Drug Resistance; Enzyme Inhibitors; Equilibrative Nucleoside Transporter 1; Humans; Male; Middle Aged; Myelodysplastic Syndromes; RNA, Messenger | 2015 |
[Effects of 5-aza-2-deoxycytidine on methylation status of RECK gene and cancer cell invasion in tongue cancer SCC-4 cells].
Topics: Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Methylation; GPI-Linked Proteins; Humans; Methylation; Neoplasm Invasiveness; RNA, Messenger; Tongue Neoplasms | 2014 |
Hypermethylation of the interferon regulatory factor 5 promoter in Epstein-Barr virus-associated gastric carcinoma.
Topics: Azacitidine; Burkitt Lymphoma; Cell Line, Tumor; CpG Islands; Decitabine; DNA Methylation; Epigenesis, Genetic; Herpesvirus 4, Human; Humans; Interferon Regulatory Factors; Promoter Regions, Genetic; Sequence Analysis, DNA; Stomach Neoplasms; Virus Latency | 2015 |
Tet1-mediated DNA demethylation regulates neuronal cell death induced by oxidative stress.
Topics: Animals; Apoptosis; Azacitidine; Brain Ischemia; Brain-Derived Neurotrophic Factor; Cells, Cultured; Decitabine; DNA Methylation; DNA-Binding Proteins; Gene Expression Regulation; Glucuronidase; Hydrogen Peroxide; Klotho Proteins; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Neurons; Oxidative Stress; Proto-Oncogene Proteins; RNA Interference; RNA, Messenger; RNA, Small Interfering | 2015 |
Low-dose decitabine promotes megakaryocyte maturation and platelet production in healthy controls and immune thrombocytopenia.
Topics: Adolescent; Adult; Aged; Azacitidine; Base Sequence; Blood Platelets; Case-Control Studies; Cell Differentiation; CpG Islands; Decitabine; DNA Methylation; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Flow Cytometry; Humans; Male; Megakaryocytes; Middle Aged; Molecular Sequence Data; Promoter Regions, Genetic; Purpura, Thrombocytopenic, Idiopathic; Thrombocytopenia; TNF-Related Apoptosis-Inducing Ligand; Young Adult | 2015 |
Demethylation-mediated miR-129-5p up-regulation inhibits malignant phenotype of osteogenic osteosarcoma by targeting Homo sapiens valosin-containing protein (VCP).
Topics: Adenosine Triphosphatases; Azacitidine; Carcinogenesis; Cell Cycle Proteins; Cell Line, Tumor; Decitabine; DNA Methylation; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; MicroRNAs; Osteosarcoma; Signal Transduction; Valosin Containing Protein | 2015 |
Hypermethylation of the 16q23.1 tumor suppressor gene ADAMTS18 in clear cell renal cell carcinoma.
Topics: ADAM Proteins; ADAMTS Proteins; Adult; Aged; Azacitidine; Carcinoma, Renal Cell; Cell Line, Tumor; Chromosomes, Human, Pair 16; CpG Islands; Decitabine; Disease-Free Survival; DNA Methylation; Down-Regulation; HEK293 Cells; Humans; Male; Middle Aged; Sequence Analysis, DNA | 2015 |
Mitochondrial DNA inheritance in the human fungal pathogen Cryptococcus gattii.
Topics: Ammonium Chloride; Azacitidine; Canada; Cryptococcus gattii; Cryptococcus neoformans; Decitabine; DNA, Fungal; DNA, Mitochondrial; Genes, Mitochondrial; Humans; Ubiquitination | 2015 |
Epigenetic regulation of microRNA expression in Hodgkin lymphoma.
Topics: Azacitidine; Cell Line, Tumor; Cluster Analysis; Decitabine; DNA Methylation; Epigenesis, Genetic; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Silencing; Hodgkin Disease; Humans; Lymph Nodes; MicroRNAs; Promoter Regions, Genetic; Reproducibility of Results; Transcriptome | 2015 |
Gelatinases-stimuli nanoparticles encapsulating 5-fluorouridine and 5-aza-2'-deoxycytidine enhance the sensitivity of gastric cancer cells to chemical therapeutics.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Azacitidine; Cell Line, Tumor; Cell Proliferation; Chemistry, Pharmaceutical; Decitabine; DNA Methylation; Dose-Response Relationship, Drug; Drug Stability; Enzyme Activation; Epigenesis, Genetic; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Nanoparticles; Stomach Neoplasms; Time Factors; Transcription Factor AP-2 | 2015 |
DNMT1 and EZH2 mediated methylation silences the microRNA-200b/a/429 gene and promotes tumor progression.
Topics: Adenosine; Animals; Antineoplastic Agents; Azacitidine; Cell Line, Tumor; Decitabine; Disease Progression; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Enhancer of Zeste Homolog 2 Protein; Gene Expression Regulation, Neoplastic; Gene Silencing; Glioblastoma; Histones; Humans; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Polycomb Repressive Complex 2; Stomach Neoplasms; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
DAC can restore expression of NALP1 to suppress tumor growth in colon cancer.
Topics: Adaptor Proteins, Signal Transducing; Animals; Apoptosis Regulatory Proteins; Azacitidine; Blotting, Western; Cell Death; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; CpG Islands; Decitabine; Female; Gene Expression Regulation, Neoplastic; Humans; Intestinal Mucosa; Male; Mice, Nude; Middle Aged; Neoplasm Staging; NLR Proteins; RNA, Messenger; Survival Analysis; Tissue Array Analysis | 2015 |
RUNX3 promoter hypermethylation is frequent in leukaemia cell lines and associated with acute myeloid leukaemia inv(16) subtype.
Topics: Adult; Aged; Azacitidine; Cell Line, Tumor; Chromosome Inversion; Core Binding Factor Alpha 3 Subunit; Decitabine; DNA Methylation; Gene Expression Regulation, Leukemic; Humans; Leukemia, Myeloid, Acute; Middle Aged; Promoter Regions, Genetic; Transcriptional Activation | 2015 |
MiR-376a and histone deacetylation 9 form a regulatory circuitry in hepatocellular carcinoma.
Topics: Azacitidine; Carcinoma, Hepatocellular; Cell Line, Tumor; Decitabine; Down-Regulation; Epigenesis, Genetic; Histone Deacetylases; Humans; Liver Neoplasms; MicroRNAs; Mutation; Repressor Proteins | 2015 |
Downregulation of HTATIP2 expression is associated with promoter methylation and poor prognosis in glioma.
Topics: Acetyltransferases; Antimetabolites, Antineoplastic; Azacitidine; Binding Sites; Brain Neoplasms; Cell Line, Tumor; Decitabine; DNA Methylation; Down-Regulation; Female; Gene Expression Regulation, Neoplastic; Glioma; HEK293 Cells; Humans; Male; Middle Aged; Prognosis; Promoter Regions, Genetic; Sp1 Transcription Factor; Transcription Factors | 2015 |
Genome-wide DNA methylation profiling of recurrent and non-recurrent chordomas.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Bone Neoplasms; Cell Line, Tumor; Chordoma; Decitabine; DNA Methylation; Female; Gene Expression; Genome; Humans; Male; Middle Aged; Recurrence | 2015 |
Aberrant hypermethylation of aldehyde dehydrogenase 2 promoter upstream sequence in rats with experimental myocardial infarction.
Topics: Aldehyde Dehydrogenase; Aldehyde Dehydrogenase, Mitochondrial; Animals; Azacitidine; Base Sequence; Blotting, Western; CpG Islands; Decitabine; DNA Methylation; Male; Mitochondrial Proteins; Molecular Sequence Data; Myocardial Infarction; Promoter Regions, Genetic; Rats, Sprague-Dawley; Real-Time Polymerase Chain Reaction; Reproducibility of Results; RNA, Messenger; Transcription Factors | 2015 |
DNA methylation in Cosmc promoter region and aberrantly glycosylated IgA1 associated with pediatric IgA nephropathy.
Topics: Adolescent; Azacitidine; B-Lymphocytes; Case-Control Studies; Child; CpG Islands; Decitabine; DNA Methylation; Down-Regulation; Female; Glomerulonephritis, IGA; Glycosylation; Humans; Immunoglobulin A; Interleukin-4; Male; Molecular Chaperones; Promoter Regions, Genetic; RNA, Messenger | 2015 |
Effect of 5-Aza-2'-deoxycytidine on odontogenic differentiation of human dental pulp cells.
Topics: Azacitidine; Biomarkers; Cell Differentiation; Cell Proliferation; Cells, Cultured; Decitabine; Dental Pulp; DNA (Cytosine-5-)-Methyltransferases; Enzyme Inhibitors; Humans; Up-Regulation | 2015 |
Presence of isocitrate dehydrogenase mutations may predict clinical response to hypomethylating agents in patients with acute myeloid leukemia.
Topics: Age Factors; Aged; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Modification Methylases; Female; Genotype; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Male; Mutation; Odds Ratio; Prognosis; Remission Induction; Retrospective Studies; Sex Factors | 2015 |
Downregulation of HO-1 promoted apoptosis induced by decitabine via increasing p15INK4B promoter demethylation in myelodysplastic syndrome.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Apoptosis; Azacitidine; Cell Line, Tumor; Child; Cyclin-Dependent Kinase Inhibitor p15; Decitabine; DNA Methylation; Down-Regulation; Enzyme Inhibitors; Female; Heme Oxygenase-1; Humans; Male; Middle Aged; Mitochondria; Myelodysplastic Syndromes; Promoter Regions, Genetic; S Phase Cell Cycle Checkpoints; Young Adult | 2015 |
Myelodysplastic syndromes (MDS).
Topics: Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Humans; Immunologic Factors; Karyotyping; Lenalidomide; Myelodysplastic Syndromes; Thalidomide | 2015 |
Perinatal nicotine exposure suppresses PPARγ epigenetically in lung alveolar interstitial fibroblasts.
Topics: Animals; Azacitidine; Base Sequence; Cells, Cultured; Decitabine; Disease Models, Animal; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Down-Regulation; Epigenesis, Genetic; Female; Fibroblasts; Fibronectins; Humans; Lung; Methyl-CpG-Binding Protein 2; Molecular Sequence Data; Nicotine; PPAR gamma; Pregnancy; Promoter Regions, Genetic; Pulmonary Alveoli; Rats; RNA, Messenger; Smoking; Up-Regulation | 2015 |
Potentiation of growth inhibition and epigenetic modulation by combination of green tea polyphenol and 5-aza-2'-deoxycytidine in human breast cancer cells.
Topics: Azacitidine; Breast Neoplasms; Catechin; Cell Proliferation; Cell Survival; Decitabine; DNA Methylation; Epigenesis, Genetic; Female; Gene Expression Regulation, Neoplastic; Histones; Humans; MCF-7 Cells; Plant Extracts; Random Amplified Polymorphic DNA Technique; Tea | 2015 |
In vivo treatment with epigenetic modulating agents induces transcriptional alterations associated with prognosis and immunomodulation in multiple myeloma.
Topics: Animals; Antineoplastic Agents; Azacitidine; Cell Line, Tumor; Computational Biology; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Epigenesis, Genetic; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Mice, Inbred C57BL; Molecular Targeted Therapy; Multiple Myeloma; Transcription, Genetic; Treatment Outcome | 2015 |
Decitabine represses osteoclastogenesis through inhibition of RANK and NF-κB.
Topics: Animals; Azacitidine; Bone Resorption; Cell Differentiation; Cell Line; Cells, Cultured; Decitabine; DNA Methylation; DNA Modification Methylases; Female; Mice, Inbred C57BL; NF-kappa B; Osteoclasts; RANK Ligand; Signal Transduction; Transcription Factor AP-1 | 2015 |
[Clinical resarch of decitabine combined with modified CAG regimen for treatment of relapsed or refractory acute myeloid leukemia].
Topics: Aclarubicin; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Retrospective Studies; Treatment Outcome; Young Adult | 2015 |
Direct but no transgenerational effects of decitabine and vorinostat on male fertility.
Topics: Animals; Azacitidine; Decitabine; DNA Methylation; Endocrine Disruptors; Epididymis; Fertility; Flow Cytometry; Hydroxamic Acids; Male; Mice; Mice, Inbred C57BL; Spermatozoa; Testis; Vorinostat | 2015 |
The epigenetic agents suberoylanilide hydroxamic acid and 5‑AZA‑2' deoxycytidine decrease cell proliferation, induce cell death and delay the growth of MiaPaCa2 pancreatic cancer cells in vivo.
Topics: Animals; Antineoplastic Agents; Azacitidine; Blotting, Western; Cell Death; Cell Line, Tumor; Cell Proliferation; Decitabine; Disease Models, Animal; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Vorinostat | 2015 |
Decitabine treatment could ameliorate primary iron-overload in myelodysplastic syndrome patients.
Topics: Aged; Aged, 80 and over; Azacitidine; Bone Morphogenetic Protein 2; Decitabine; DNA Methylation; DNA Modification Methylases; Female; Ferritins; GPI-Linked Proteins; Hemochromatosis Protein; Hemoglobins; Humans; Iron Overload; Male; Middle Aged; Myelodysplastic Syndromes | 2015 |
BCL2 promotor methylation and miR-15a/16-1 upregulation is associated with sanguinarine-induced apoptotic death in rat HSC-T6 cells.
Topics: Animals; Apoptosis; Azacitidine; Benzophenanthridines; Cell Line; Cell Survival; Decitabine; Down-Regulation; Isoquinolines; Membrane Potential, Mitochondrial; Methylation; MicroRNAs; Promoter Regions, Genetic; Proto-Oncogene Proteins c-bcl-2; Rats; Reactive Oxygen Species; Up-Regulation | 2015 |
Harnessing Noxa demethylation to overcome Bortezomib resistance in mantle cell lymphoma.
Topics: Animals; Antineoplastic Agents; Azacitidine; Bortezomib; Cell Line, Tumor; Cell Survival; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Drug Resistance, Neoplasm; Epigenesis, Genetic; Female; Humans; Lymphoma, Mantle-Cell; Mice; Mice, Nude; Neoplasm Transplantation; Oligonucleotide Array Sequence Analysis; Promoter Regions, Genetic; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Real-Time Polymerase Chain Reaction; Recurrence | 2015 |
Decitabine priming enhances the antileukemic effects of exportin 1 (XPO1) selective inhibitor selinexor in acute myeloid leukemia.
Topics: Active Transport, Cell Nucleus; Animals; Antineoplastic Agents; Azacitidine; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Decitabine; DNA Methylation; DNA Modification Methylases; Exportin 1 Protein; Forkhead Box Protein O3; Forkhead Transcription Factors; Humans; Hydrazines; Karyopherins; Leukemia, Myeloid, Acute; Mice; Mice, Inbred NOD; Mice, SCID; Receptors, Cytoplasmic and Nuclear; Triazoles; Tumor Cells, Cultured; Up-Regulation | 2015 |
Radioresistance in a human laryngeal squamous cell carcinoma cell line is associated with DNA methylation changes and topoisomerase II α.
Topics: Antigens, Neoplasm; Azacitidine; Carcinoma, Squamous Cell; Cell Line, Tumor; CpG Islands; Decitabine; DNA Methylation; DNA Topoisomerases, Type II; DNA-Binding Proteins; Epigenesis, Genetic; Head and Neck Neoplasms; Humans; Laryngeal Neoplasms; Promoter Regions, Genetic; Radiation Tolerance; Squamous Cell Carcinoma of Head and Neck; Transcription, Genetic | 2015 |
Decitabine plus thalidomide yields more sustained survival rates than decitabine monotherapy for risk-tailored elderly patients with myelodysplastic syndrome.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Decitabine; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm Staging; Prognosis; Prospective Studies; Risk Factors; Survival Rate; Thalidomide | 2015 |
Frequent Loss of NISCH Promotes Tumor Proliferation and Invasion in Ovarian Cancer via Inhibiting the FAK Signal Pathway.
Topics: Azacitidine; Cell Line, Tumor; Cell Proliferation; Decitabine; DNA Methylation; Down-Regulation; Female; Focal Adhesion Kinase 1; Humans; Imidazoline Receptors; Intracellular Signaling Peptides and Proteins; Loss of Heterozygosity; Neoplasm Invasiveness; Neoplasm Transplantation; Ovarian Neoplasms; Promoter Regions, Genetic; Signal Transduction | 2015 |
miR-491-5p functions as a tumor suppressor by targeting JMJD2B in ERα-positive breast cancer.
Topics: 3' Untranslated Regions; Adult; Aged; Azacitidine; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Decitabine; DNA Methylation; Estrogen Receptor alpha; Female; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Humans; Jumonji Domain-Containing Histone Demethylases; MCF-7 Cells; MicroRNAs; Middle Aged | 2015 |
Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacitidine failure.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Disease Progression; Female; Humans; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Retrospective Studies; Risk Factors; Treatment Failure; Treatment Outcome | 2015 |
Methylation of Integrin α4 and E-Cadherin Genes in Human Prostate Cancer.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Biomarkers, Tumor; Cadherins; CpG Islands; Decitabine; DNA Methylation; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Integrin alpha4; Male; Promoter Regions, Genetic; Prostatic Hyperplasia; Prostatic Neoplasms; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured | 2015 |
Decitabine nanoconjugate sensitizes human glioblastoma cells to temozolomide.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Apoptosis; Azacitidine; Biocompatible Materials; Boron Compounds; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Decitabine; DNA Methylation; Drug Delivery Systems; Drug Synergism; Glioblastoma; Humans; Hydrogen-Ion Concentration; Hydrolysis; Kinetics; Lactic Acid; Magnetic Resonance Spectroscopy; Methacrylates; Methylmethacrylates; Micelles; Nanoconjugates; Polyethylene Glycols; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Spectrometry, Fluorescence; Temozolomide | 2015 |
[Retrospective efficacy analysis of decitabine bridging allogeneic hematopoietic stem cell transplantation on the treatment of myelodysplastic syndrome].
Topics: Azacitidine; Decitabine; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Myelodysplastic Syndromes; Retrospective Studies; Transplantation, Homologous | 2015 |
Inactivation of bone morphogenetic protein 2 may predict clinical outcome and poor overall survival for renal cell carcinoma through epigenetic pathways.
Topics: Aged; Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Bone Morphogenetic Protein 2; Carcinoma, Renal Cell; Cell Line, Tumor; Decitabine; DNA Methylation; Down-Regulation; Female; Gene Expression Regulation, Neoplastic; Genes, cdc; Humans; Kidney Neoplasms; Kidney Tubules; Male; Middle Aged; Neoplasm Proteins; Nephrectomy; Promoter Regions, Genetic; Recombinant Fusion Proteins; RNA, Messenger; RNA, Neoplasm; Transfection; Treatment Outcome | 2015 |
Comparison of epigenetic versus standard induction chemotherapy for newly diagnosed acute myeloid leukemia patients ≥60 years old.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Cytarabine; Decitabine; Epigenesis, Genetic; Female; fms-Like Tyrosine Kinase 3; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Middle Aged; Mutation; Nuclear Proteins; Nucleophosmin; Remission Induction; Retrospective Studies; Survival Analysis; Treatment Outcome | 2015 |
Epigenetic modification and preliminary investigation of the mechanism of the immune evasion of HL-60 cells.
Topics: Antimetabolites, Antineoplastic; Azacitidine; B7-1 Antigen; CD40 Antigens; CpG Islands; Decitabine; DNA Methylation; Dose-Response Relationship, Drug; Epigenesis, Genetic; HL-60 Cells; Humans; Hydroxamic Acids; Interferon-gamma; Nuclear Proteins; Promoter Regions, Genetic; Sequence Analysis, DNA; Trans-Activators; Tumor Escape; Vorinostat | 2015 |
Overexpression of mutant Ptch in rhabdomyosarcomas is associated with promoter hypomethylation and increased Gli1 and H3K4me3 occupancy.
Topics: Animals; Azacitidine; CpG Islands; Decitabine; DNA Methylation; Embryonic Development; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Gestational Age; Heterozygote; Histones; Kruppel-Like Transcription Factors; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Knockout; Models, Genetic; Mutation; Neoplasm Proteins; Patched Receptors; Patched-1 Receptor; Polymorphism, Single Nucleotide; Promoter Regions, Genetic; Protein Processing, Post-Translational; Receptors, Cell Surface; Rhabdomyosarcoma; Signal Transduction; Zinc Finger Protein GLI1 | 2015 |
Methylated alteration of SHP1 complements mutation of JAK2 tyrosine kinase in patients with myeloproliferative neoplasm.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Base Sequence; Blotting, Western; Case-Control Studies; Decitabine; DNA Methylation; Epigenomics; Humans; Janus Kinase 2; Molecular Sequence Data; Mutation; Myeloproliferative Disorders; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; STAT3 Transcription Factor; Tumor Cells, Cultured | 2015 |
Decitabine as a conditioning regimen in haploidentical stem cell transplantation for refractory acute myeloid leukaemia.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Nucleophosmin; Transplantation Conditioning; Treatment Outcome; Young Adult | 2015 |
Prolonged re-expression of the hypermethylated gene EPB41L3 using artificial transcription factors and epigenetic drugs.
Topics: Antineoplastic Agents; Azacitidine; Cell Line, Tumor; Decitabine; DNA Methylation; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Histone Code; Histone Deacetylases; Humans; Hydroxamic Acids; Microfilament Proteins; RNA, Messenger; Transcription Factors | 2015 |
[Effects of decitabine against acute T lymphoblastic leukemia cell line Molt4].
Topics: Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Caspase 3; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Decitabine; DNA Methylation; Humans; Lactoferrin; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Promoter Regions, Genetic | 2015 |
Infrequent DNA methylation of miR-9-1 and miR-9-3 in multiple myeloma.
Topics: Azacitidine; Biomarkers, Tumor; Case-Control Studies; Cell Line, Tumor; Decitabine; Disease Progression; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Genetic Predisposition to Disease; Humans; MicroRNAs; Multiple Myeloma; Phenotype; Promoter Regions, Genetic; Recurrence; Treatment Outcome | 2015 |
Genome-wide differentially methylated genes in prostate cancer tissues from African-American and Caucasian men.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Black or African American; Cell Line, Tumor; Decitabine; DNA Methylation; Gene Expression Regulation, Neoplastic; Genome, Human; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Male; Organ Specificity; Promoter Regions, Genetic; Prostatic Neoplasms; White People | 2015 |
Increased expression of protease-activated receptor 4 and Trefoil factor 2 in human colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cell Line, Tumor; Cell Movement; Colorectal Neoplasms; Decitabine; Disease Progression; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Microarray Analysis; Neoplasm Invasiveness; Peptides; Polymerase Chain Reaction; Receptors, Thrombin; Trefoil Factor-2 | 2015 |
The hypomethylating agent Decitabine causes a paradoxical increase in 5-hydroxymethylcytosine in human leukemia cells.
Topics: 5-Methylcytosine; Azacitidine; Catalytic Domain; Chromatography, High Pressure Liquid; CpG Islands; Cytosine; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA-Binding Proteins; Enzyme-Linked Immunosorbent Assay; HL-60 Cells; Humans; Immunohistochemistry; Leukemia, Myeloid, Acute; MCF-7 Cells; Microscopy, Fluorescence; Mixed Function Oxygenases; Protein Binding; Proto-Oncogene Proteins; Spectrometry, Fluorescence; Tandem Mass Spectrometry | 2015 |
Epigenetic silencing of BCL6B inactivates p53 signaling and causes human hepatocellular carcinoma cell resist to 5-FU.
Topics: Aged; Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Carcinoma, Hepatocellular; Cell Proliferation; Decitabine; DNA Methylation; DNA Modification Methylases; Drug Resistance, Neoplasm; Early Growth Response Protein 1; Enzyme Inhibitors; Female; Fluorouracil; G1 Phase Cell Cycle Checkpoints; Gene Expression Regulation, Neoplastic; Gene Silencing; Hep G2 Cells; Humans; Liver Neoplasms; Male; Middle Aged; Promoter Regions, Genetic; Repressor Proteins; RNA Interference; Signal Transduction; Time Factors; Transfection; Tumor Suppressor Protein p53 | 2015 |
Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine.
Topics: Acetylation; Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Azacitidine; Benzamides; Carcinoma, Squamous Cell; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cell Survival; Decitabine; Depsipeptides; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Damage; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Pyridines; Transcriptome; Vorinostat | 2015 |
Elevation of soluble guanylate cyclase suppresses proliferation and survival of human breast cancer cells.
Topics: Animals; Apoptosis; Azacitidine; Bradykinin; Breast Neoplasms; Cell Cycle; Cell Proliferation; Cell Survival; Cyclic GMP; Decitabine; DNA Methylation; Female; Guanylate Cyclase; Humans; MCF-7 Cells; Mice; Mice, Nude; Nitric Oxide; Nitroprusside; Promoter Regions, Genetic; Receptors, Cytoplasmic and Nuclear; Soluble Guanylyl Cyclase | 2015 |
Novel aberrant genetic and epigenetic events in Friedreich's ataxia.
Topics: Antioxidants; Apoptosis; Azacitidine; Brain-Derived Neurotrophic Factor; Caspase 3; Cells, Cultured; Decitabine; Deferiprone; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Epigenesis, Genetic; Frataxin; Friedreich Ataxia; Gene Expression Profiling; Humans; Iron Chelating Agents; Iron-Binding Proteins; MicroRNAs; Neuregulin-1; Oxidative Stress; Periodontal Ligament; Pyridones; Superoxide Dismutase; Ubiquinone | 2015 |
Hydroxymethylcytosine and demethylation of the γ-globin gene promoter during erythroid differentiation.
Topics: 5-Methylcytosine; Animals; Animals, Newborn; Antineoplastic Agents; Ascorbic Acid; Azacitidine; Bone Marrow Cells; Cell Differentiation; Cells, Cultured; Cytosine; Decitabine; Dioxygenases; DNA Methylation; Erythroid Cells; gamma-Globins; Histone Demethylases; Humans; Hydroxyurea; Liver; Papio anubis; Promoter Regions, Genetic; Tranylcypromine | 2015 |
Downregulation of A disintegrin and metallopeptidase with thrombospondin motif type 1 by DNA hypermethylation in human gastric cancer.
Topics: ADAM Proteins; ADAMTS1 Protein; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Base Sequence; Case-Control Studies; Cell Line, Tumor; Cell Movement; Collagen; Decitabine; DNA Methylation; Drug Combinations; Epigenesis, Genetic; Female; Humans; Laminin; Lymphatic Metastasis; Male; Middle Aged; Molecular Sequence Data; Proteoglycans; RNA, Messenger; Stomach Neoplasms; Tumor Burden | 2015 |
Platelet response during the second cycle of decitabine treatment predicts response and survival for myelodysplastic syndrome patients.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Biomarkers, Tumor; Blood Platelets; Decitabine; Disease-Free Survival; DNA Modification Methylases; Female; Humans; Male; Myelodysplastic Syndromes; Platelet Count; Retrospective Studies; Treatment Outcome | 2015 |
The androgen receptor plays a suppressive role in epithelial- mesenchymal transition of human prostate cancer stem progenitor cells.
Topics: Azacitidine; Cell Line, Tumor; Cell Self Renewal; Chromans; Chromones; Decitabine; Drug Synergism; Epithelial-Mesenchymal Transition; Humans; Male; Morpholines; Neoplastic Stem Cells; Prostatic Neoplasms; Receptors, Androgen; Signal Transduction; Vitamin E | 2015 |
[Clinical Significance of ID4 Gene Mehtylation in Demethylation-Treated MDS Cell Line and 2 MDS Patients].
Topics: Anemia, Aplastic; Azacitidine; Bone Marrow; Cell Line; Decitabine; DNA Methylation; Gene Expression; Genes, Tumor Suppressor; Humans; Inhibitor of Differentiation Proteins; Myelodysplastic Syndromes; Polymerase Chain Reaction; Promoter Regions, Genetic | 2015 |
Consequences of combining siRNA-mediated DNA methyltransferase 1 depletion with 5-aza-2'-deoxycytidine in human leukemic KG1 cells.
Topics: Azacitidine; Cell Line, Tumor; Cell Proliferation; CpG Islands; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Damage; DNA Methylation; DNA Methyltransferase 3A; DNA Methyltransferase 3B; DNA-Binding Proteins; G2 Phase Cell Cycle Checkpoints; Histones; Humans; Leukemia; Nuclear Proteins; Phosphorylation; Promoter Regions, Genetic; RNA Interference; RNA, Small Interfering; Tumor Protein p73; Tumor Suppressor Proteins | 2015 |
Sevoflurane attenuate hypoxia-induced VEGF level in tongue squamous cell carcinoma cell by upregulating the DNA methylation states of the promoter region.
Topics: Azacitidine; Base Sequence; Carcinoma, Squamous Cell; Cell Hypoxia; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Proliferation; Decitabine; DNA Methylation; Gene Expression Regulation, Neoplastic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Methyl Ethers; Molecular Sequence Data; Promoter Regions, Genetic; Protein Transport; Sevoflurane; Tongue Neoplasms; Up-Regulation; Vascular Endothelial Growth Factor A | 2015 |
Analysis of DNA methylation and gene expression in radiation-resistant head and neck tumors.
Topics: Azacitidine; Cell Line, Tumor; CpG Islands; Cyclin D2; Decitabine; DNA Methylation; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Kruppel-Like Factor 4; Promoter Regions, Genetic; Radiation Tolerance | 2015 |
Epigenetics and miRNA as predictive markers and targets for lung cancer chemotherapy.
Topics: Antibiotics, Antineoplastic; Azacitidine; Biomarkers, Tumor; Blotting, Western; Cell Line, Tumor; Cell Survival; Decitabine; DNA Methylation; DNA Modification Methylases; Doxorubicin; Drug Resistance, Neoplasm; Epigenesis, Genetic; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Lung Neoplasms; MicroRNAs; Oligonucleotide Array Sequence Analysis; Reverse Transcriptase Polymerase Chain Reaction | 2015 |
KRAS Genomic Status Predicts the Sensitivity of Ovarian Cancer Cells to Decitabine.
Topics: Animals; Azacitidine; Biomarkers, Tumor; Cystadenocarcinoma, Serous; Decitabine; Drug Resistance, Neoplasm; Female; Genes, ras; Humans; Mice; Mice, Nude; Mice, Transgenic; Mutation; Ovarian Neoplasms; Prognosis; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2015 |
Kank1 reexpression induced by 5-Aza-2'-deoxycytidine suppresses nasopharyngeal carcinoma cell proliferation and promotes apoptosis.
Topics: Adaptor Proteins, Signal Transducing; Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Blotting, Western; Carcinoma; Cell Line, Tumor; Cell Proliferation; Cytoskeletal Proteins; Decitabine; DNA Methylation; Gene Expression Regulation, Neoplastic; Humans; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Real-Time Polymerase Chain Reaction; Tumor Suppressor Proteins | 2015 |
Hypoxia Represses ER-α Expression and Inhibits Estrogen-Induced Regulation of Ca2+-Activated K+ Channel Activity and Myogenic Tone in Ovine Uterine Arteries: Causal Role of DNA Methylation.
Topics: Acetylcysteine; Animals; Azacitidine; Decitabine; DNA Methylation; Estradiol; Estrogen Receptor alpha; Female; Gene Expression Regulation; Hypoxia; Large-Conductance Calcium-Activated Potassium Channel alpha Subunits; Pregnancy; Pregnancy Complications; Progesterone; Promoter Regions, Genetic; Reactive Oxygen Species; Sheep; Uterine Artery; Vascular Resistance | 2015 |
Promoter hypermethylation of membrane type 3 matrix metalloproteinase is associated with cell migration in colorectal adenocarcinoma.
Topics: Adenocarcinoma; Aged; Azacitidine; Cell Line, Tumor; Cell Movement; Colorectal Neoplasms; Decitabine; DNA Methylation; Down-Regulation; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Matrix Metalloproteinase 16; Promoter Regions, Genetic; Real-Time Polymerase Chain Reaction; RNA Interference; RNA, Small Interfering | 2015 |
[Functional study of hENT1 on SKM-1 cell resistance to decitabine].
Topics: Apoptosis; Azacitidine; Caspase 3; Cell Line; Decitabine; DNA Methylation; Drug Resistance; Equilibrative Nucleoside Transporter 1; Humans; Lentivirus; Myelodysplastic Syndromes | 2015 |
Epigenetic Modification of Cloned Embryos Improves Nanog Reprogramming in Pigs.
Topics: Animals; Azacitidine; Cellular Reprogramming; Cloning, Organism; Decitabine; DNA Methylation; Embryonic Development; Epigenesis, Genetic; Gene Expression Regulation, Developmental; Homeodomain Proteins; Hydroxamic Acids; Sus scrofa; Transcription Factors | 2015 |
Decitabine Enhances Lymphocyte Migration and Function and Synergizes with CTLA-4 Blockade in a Murine Ovarian Cancer Model.
Topics: Animals; Antineoplastic Agents; Ascitic Fluid; Azacitidine; CD8-Positive T-Lymphocytes; Cell Movement; Cell Transformation, Neoplastic; CTLA-4 Antigen; Cytokines; Decitabine; Female; Gene Expression Regulation, Neoplastic; Humans; Immunotherapy; Killer Cells, Natural; Lymph Nodes; Lymphocytes, Tumor-Infiltrating; Mice; Ovarian Neoplasms; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2015 |
Epigenetic Modification Agents Improve Gene-Specific Methylation Reprogramming in Porcine Cloned Embryos.
Topics: Animals; Azacitidine; Cells, Cultured; Cellular Reprogramming; Decitabine; DNA Methylation; Embryo Culture Techniques; Embryonic Development; Enzyme Inhibitors; Epigenesis, Genetic; Fertilization in Vitro; Gene Expression Regulation, Developmental; Histone Deacetylase Inhibitors; Hydroxamic Acids; Nuclear Transfer Techniques; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Swine | 2015 |
[Therapeutic efficacies of decitabine application prior to hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia].
Topics: Azacitidine; Decitabine; Disease-Free Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Recurrence; Remission Induction; Retrospective Studies; Survival Rate; Transplantation, Homologous | 2015 |
The DNA Methyltransferase DNMT1 and Tyrosine-Protein Kinase KIT Cooperatively Promote Resistance to 5-Aza-2'-deoxycytidine (Decitabine) and Midostaurin (PKC412) in Lung Cancer Cells.
Topics: Animals; Antigens, CD; Azacitidine; Cadherins; Cell Line, Tumor; Cell Proliferation; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Proto-Oncogene Proteins c-kit; Staurosporine | 2015 |
DNA hypomethylation-mediated activation of Cancer/Testis Antigen 45 (CT45) genes is associated with disease progression and reduced survival in epithelial ovarian cancer.
Topics: Aged; Antigens, Neoplasm; Azacitidine; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Decitabine; Disease Progression; DNA Methylation; Epigenesis, Genetic; Female; Gene Expression Regulation, Neoplastic; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Promoter Regions, Genetic; RNA, Messenger | 2015 |
DNA Methylation of the EphA5 Promoter Is Associated with Rat Congenital Hypothyroidism.
Topics: Animals; Azacitidine; Congenital Hypothyroidism; Decitabine; DNA Methylation; Hippocampus; Neurons; Promoter Regions, Genetic; Rats; Rats, Sprague-Dawley; Receptor, EphA5 | 2015 |
Hypermethylation of the HLA-G promoter is associated with preeclampsia.
Topics: Adult; Azacitidine; Case-Control Studies; Cell Line; CpG Islands; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Enzyme Inhibitors; Epigenesis, Genetic; Female; Genetic Association Studies; Genetic Predisposition to Disease; HLA-G Antigens; Humans; Phenotype; Placenta; Pre-Eclampsia; Pregnancy; Promoter Regions, Genetic; RNA Interference; Transfection; Trophoblasts | 2015 |
Epigenetic modifiers reduce inflammation and modulate macrophage phenotype during endotoxemia-induced acute lung injury.
Topics: Acute Lung Injury; Animals; Azacitidine; Decitabine; Drug Combinations; Endotoxemia; Epigenesis, Genetic; Histone Deacetylases; Humans; Hydroxamic Acids; Inflammation; Lipopolysaccharides; Macrophages; Methyltransferases; Mice; Sepsis; Signal Transduction | 2015 |
[The Role of 5-Aza-CdR on Methylation of Promoter in RASSF1A Gene in Endometrial Carcinoma].
Topics: Azacitidine; Cell Line, Tumor; CpG Islands; Decitabine; DNA Methylation; Endometrial Neoplasms; Female; Humans; Polymerase Chain Reaction; Promoter Regions, Genetic; RNA, Messenger; Tumor Suppressor Proteins | 2015 |
Epigenetic regulation of Dnmt3a and Arc gene expression after electroconvulsive stimulation in the rat.
Topics: Animals; Azacitidine; Brain; Cytoskeletal Proteins; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Methyltransferase 3A; Enzyme Inhibitors; Epigenesis, Genetic; Male; Nerve Tissue Proteins; Promoter Regions, Genetic; Rats; Rats, Sprague-Dawley; Transcranial Direct Current Stimulation | 2015 |
Global analysis of biogenesis, stability and sub-cellular localization of lncRNAs mapping to intragenic regions of the human genome.
Topics: Alpha-Amanitin; Azacitidine; Cell Line, Tumor; Dactinomycin; Decitabine; DNA Modification Methylases; Gene Expression Profiling; Genome, Human; HeLa Cells; Humans; Introns; MCF-7 Cells; Nucleic Acid Synthesis Inhibitors; Oligonucleotide Array Sequence Analysis; Reverse Transcriptase Polymerase Chain Reaction; RNA Polymerase II; RNA Stability; RNA, Antisense; RNA, Long Noncoding | 2015 |
Metabolomic analysis revealed the role of DNA methylation in the balance of arachidonic acid metabolism and endothelial activation.
Topics: Animals; Arachidonic Acids; Azacitidine; Decitabine; DNA Methylation; Gene Expression Regulation, Enzymologic; HEK293 Cells; Human Umbilical Vein Endothelial Cells; Humans; Intramolecular Oxidoreductases; Kidney; Lipocalins; Liver; Male; Metabolomics; Mice; Thromboxane-A Synthase | 2015 |
Effects of Decitabine on Invasion and Exosomal Expression of miR-200c and miR-141 in Oxaliplatin-Resistant Colorectal Cancer Cells.
Topics: Antineoplastic Agents; Azacitidine; Cell Line, Tumor; Cell Movement; Colorectal Neoplasms; Decitabine; DNA Methylation; DNA Modification Methylases; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Exosomes; Humans; MicroRNAs; Neoplasm Invasiveness; Organoplatinum Compounds; Oxaliplatin | 2015 |
Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Blast Crisis; Decitabine; Female; Humans; Leukemia, Myeloid, Accelerated Phase; Male; Middle Aged; Primary Myelofibrosis; Prospective Studies; Remission Induction; Survival Analysis; Treatment Outcome | 2015 |
The 5' flanking region of miR-378 is hypomethylated in acute myeloid leukemia.
Topics: 5' Flanking Region; Adult; Aged; Antineoplastic Agents; Azacitidine; Decitabine; DNA Methylation; Female; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; MicroRNAs; Middle Aged; Prognosis; Real-Time Polymerase Chain Reaction | 2015 |
A Screen for Epigenetically Silenced microRNA Genes in Gastrointestinal Stromal Tumors.
Topics: Azacitidine; Cell Line, Tumor; Cell Proliferation; CpG Islands; Decitabine; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; MicroRNAs; Neoplasm Proteins; Phenylbutyrates; Receptor, Platelet-Derived Growth Factor beta; RNA, Neoplasm | 2015 |
Molecular cloning, epigenetic regulation, and functional characterization of Prkd1 gene promoter in dopaminergic cell culture models of Parkinson's disease.
Topics: Animals; Azacitidine; Cells, Cultured; Chromatin Immunoprecipitation; Cloning, Molecular; Decitabine; Dopaminergic Neurons; Epigenesis, Genetic; Gene Deletion; Gene Expression Regulation; Humans; Mice; Molecular Sequence Data; Parkinson Disease; Primary Cell Culture; Promoter Regions, Genetic; Protein Kinase C; RNA, Small Interfering; Tyrosine 3-Monooxygenase | 2015 |
Cellular Uptake of Decitabine by Equilibrative Nucleoside Transporters in HCT116 Cells.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Carrier Proteins; Colorectal Neoplasms; Decitabine; DNA Methylation; Equilibrative Nucleoside Transporter 1; Gene Expression; HCT116 Cells; Humans; Melanoma-Specific Antigens; Real-Time Polymerase Chain Reaction; RNA, Messenger; Thioinosine; Uridine | 2015 |
Effect of DR4 promoter methylation on the TRAIL-induced apoptosis in lung squamous carcinoma cell.
Topics: Adult; Aged; Aged, 80 and over; Apoptosis; Azacitidine; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Decitabine; DNA Methylation; Female; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Promoter Regions, Genetic; Receptors, TNF-Related Apoptosis-Inducing Ligand; TNF-Related Apoptosis-Inducing Ligand | 2015 |
Endothelial glucocorticoid receptor promoter methylation according to dexamethasone sensitivity.
Topics: 5' Untranslated Regions; Azacitidine; Cells, Cultured; Decitabine; Dexamethasone; DNA Methylation; DNA Modification Methylases; Gene Expression Regulation; Glucocorticoids; Human Umbilical Vein Endothelial Cells; Humans; Nitric Oxide Synthase Type III; Plasminogen Activator Inhibitor 1; Promoter Regions, Genetic; Protein Isoforms; Receptors, Glucocorticoid; RNA, Messenger; Transcription, Genetic | 2015 |
GPX3 promoter is methylated in chronic myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Azacitidine; Case-Control Studies; Decitabine; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Epigenesis, Genetic; Female; Fusion Proteins, bcr-abl; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Glutathione Peroxidase; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Staging; Promoter Regions, Genetic; RNA, Messenger; Young Adult | 2015 |
Decitabine enhances stem cell antigen-1 expression in cigarette smoke extract-induced emphysema in animal model.
Topics: Animals; Antigens, Ly; Azacitidine; Cells, Cultured; Decitabine; Emphysema; Endothelial Progenitor Cells; Gene Expression Regulation; Male; Membrane Proteins; Mice, Inbred C57BL; Models, Animal; Smoke; Tobacco Products; Treatment Outcome | 2016 |
First Steps Towards Successful Post-Transplantation Therapy for Myeloid Malignancies after Allogeneic Blood Stem Cell Transplantation.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Male; Myelodysplastic Syndromes | 2015 |
Reduced immune responses in chimeric mice engrafted with bone marrow cells from mice with airways inflammation.
Topics: Administration, Intranasal; Adoptive Transfer; Animals; Azacitidine; Bone Marrow Cells; Bronchoalveolar Lavage Fluid; Cell Count; Decitabine; Dendritic Cells; Disease Models, Animal; DNA Modification Methylases; Female; Fluorescein-5-isothiocyanate; Fluorescent Dyes; Immunoglobulin E; Immunoglobulin G; Inflammation; Lipopolysaccharides; Lymph Nodes; Mice, Inbred C57BL; Organic Chemicals; Ovalbumin; Radiation Chimera; Respiratory Hypersensitivity; Skin | 2015 |
Lack of mutational hot spots during decitabine-mediated HIV-1 mutagenesis.
Topics: Azacitidine; Cell Line; Decitabine; HIV Infections; HIV-1; Humans; Mutagenesis; Mutation; Mutation Rate | 2015 |
Myelodysplastic syndromes following therapy with hypomethylating agents (HMAs): development of acute erythroleukemia may not influence assessment of treatment response.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Biopsy; Bone Marrow; Chromosome Aberrations; Decitabine; DNA Methylation; Female; Humans; In Situ Hybridization, Fluorescence; Leukemia, Erythroblastic, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Survival Analysis; Treatment Outcome; Young Adult | 2016 |
Decitabine and Sorafenib Therapy in FLT-3 ITD-Mutant Acute Myeloid Leukemia.
Topics: Azacitidine; Cell Line, Tumor; Decitabine; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Middle Aged; Mutation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Survival Analysis | 2015 |
Differential expression and tumorigenic function of neurotensin receptor 1 in neuroendocrine tumor cells.
Topics: Azacitidine; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Proliferation; Decitabine; DNA Methylation; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Immunohistochemistry; Lentivirus; Neoplasm Invasiveness; Neuroendocrine Tumors; Promoter Regions, Genetic; Receptors, Neurotensin; Reverse Transcriptase Polymerase Chain Reaction; RNA, Small Interfering | 2015 |
Anticancer drugs induce hypomethylation of the acetylcholinesterase promoter via a phosphorylated-p38-DNMT1-AChE pathway in apoptotic hepatocellular carcinoma cells.
Topics: Acetylcholinesterase; Antineoplastic Agents; Apoptosis; Azacitidine; Carcinoma, Hepatocellular; Cell Line, Tumor; Cisplatin; CpG Islands; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Gene Expression Regulation, Neoplastic; GPI-Linked Proteins; Humans; Liver Neoplasms; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Promoter Regions, Genetic; RNA, Small Interfering; Signal Transduction | 2015 |
Inhibition of DNA Methylation and Methyl-CpG-Binding Protein 2 Suppresses RPE Transdifferentiation: Relevance to Proliferative Vitreoretinopathy.
Topics: Azacitidine; Blotting, Western; Cell Movement; Cell Transdifferentiation; Cells, Cultured; Decitabine; DNA; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Epithelial-Mesenchymal Transition; Gene Expression Regulation; Humans; Immunohistochemistry; Methyl-CpG-Binding Protein 2; Phosphorylation; Real-Time Polymerase Chain Reaction; Retinal Pigment Epithelium; Vitreoretinopathy, Proliferative | 2015 |
[Clinical Efficacy of Decitabine Combined with CAG Regimen for Myelodysplastic Syndrome-RAEB and Refractory Acute Myeloid Leukemia].
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Granulocyte Colony-Stimulating Factor; Humans; Karyotype; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Pancytopenia; Recurrence; Remission Induction; Retrospective Studies; Survival Rate; Treatment Outcome | 2015 |
[Effect of Decitabine on Megakaryocyte Culture of Steroid-resistant ITP Patients].
Topics: Azacitidine; Bone Marrow; Bone Marrow Cells; Decitabine; Drug Resistance; Flow Cytometry; Hematopoietic Stem Cells; Humans; Inosine Triphosphate; Megakaryocytes; Stem Cells; Steroids | 2015 |
A Possible Role for WNT5A Hypermethylation in Pediatric Acute Lymphoblastic Leukemia.
Topics: Adolescent; Azacitidine; Cell Line, Tumor; Child; Child, Preschool; Decitabine; DNA Methylation; Female; Gene Expression Regulation, Neoplastic; Humans; Infant; Infant, Newborn; Jurkat Cells; Male; Neoplasm Proteins; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Promoter Regions, Genetic; RNA, Messenger; RNA, Neoplasm; Wnt Signaling Pathway; Wnt-5a Protein | 2015 |
DNA-Demethylating Agents Target Colorectal Cancer Cells by Inducing Viral Mimicry by Endogenous Transcripts.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antimetabolites, Antineoplastic; Azacitidine; Cells, Cultured; Colorectal Neoplasms; DEAD-box RNA Helicases; Decitabine; DNA Methylation; Endogenous Retroviruses; Humans; Interferon Regulatory Factor-7; Interferon-Induced Helicase, IFIH1; Mice; Receptors, Retinoic Acid; RNA, Double-Stranded; Signal Transduction | 2015 |
Targeting the Sonic Hedgehog-Gli1 Pathway as a Potential New Therapeutic Strategy for Myelodysplastic Syndromes.
Topics: Adolescent; Adult; Aged; Animals; Azacitidine; Cell Line, Tumor; Cell Survival; Cyclin-Dependent Kinase Inhibitor p15; Decitabine; DNA Methylation; DNA Modification Methylases; Female; Gene Expression Regulation, Neoplastic; Hedgehog Proteins; Humans; Male; Mice; Middle Aged; Myelodysplastic Syndromes; Neoplasm Transplantation; Prognosis; Promoter Regions, Genetic; Signal Transduction; Transcription Factors; Young Adult; Zinc Finger Protein GLI1 | 2015 |
Epigenetic Regulation of miR-129-2 Leads to Overexpression of PDGFRa and FoxP1 in Glioma Cells.
Topics: Adult; Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Blotting, Western; Brain Neoplasms; Cell Proliferation; Chromatin Assembly and Disassembly; Decitabine; DNA Methylation; Epigenesis, Genetic; Forkhead Transcription Factors; Gene Expression Regulation, Neoplastic; Glioma; Humans; MicroRNAs; Real-Time Polymerase Chain Reaction; Receptor, Platelet-Derived Growth Factor alpha; Repressor Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured | 2015 |
Efficacy of systemic adoptive transfer immunotherapy targeting NY-ESO-1 for glioblastoma.
Topics: Animals; Antigens, Neoplasm; Azacitidine; Cell Line, Tumor; Decitabine; Disease Models, Animal; Glioblastoma; Humans; Immunotherapy, Adoptive; Mice; T-Lymphocytes | 2016 |
Effect of DNA methylation profile on OATP3A1 and OATP4A1 transcript levels in colorectal cancer.
Topics: Aged; Azacitidine; Butyric Acid; Caco-2 Cells; Colorectal Neoplasms; Decitabine; DNA Methylation; Down-Regulation; Estrone; Female; HCT116 Cells; Humans; Male; Middle Aged; Organic Anion Transporters; Promoter Regions, Genetic; RNA, Messenger | 2015 |
MiR-143 and miR-135 inhibitors treatment induces skeletal myogenic differentiation of human adult dental pulp stem cells.
Topics: Adult; Adult Stem Cells; Azacitidine; Cell Differentiation; Cells, Cultured; Decitabine; Dental Pulp; Humans; MicroRNAs; Molar, Third; Muscle Development; Muscle, Skeletal; Myoblasts; Oligonucleotides, Antisense; Transfection; Young Adult | 2015 |
HMDB and 5-AzadC Combination Reverses Tumor Suppressor CCAAT/Enhancer-Binding Protein Delta to Strengthen the Death of Liver Cancer Cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Azacitidine; Blotting, Western; Carcinoma, Hepatocellular; CCAAT-Enhancer-Binding Protein-delta; Cell Line, Tumor; Cells, Cultured; Decitabine; E2F1 Transcription Factor; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Immunohistochemistry; Ketones; Liver Neoplasms; Mice, Inbred NOD; Mice, SCID; Oligonucleotide Array Sequence Analysis; Propane; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
Cross talk between poly(ADP-ribose) polymerase 1 methylation and oxidative stress involved in the toxic effect of anatase titanium dioxide nanoparticles.
Topics: Antioxidants; Azacitidine; Cell Line, Tumor; Cell Survival; Decitabine; Dose-Response Relationship, Drug; Humans; L-Lactate Dehydrogenase; Methylation; Methyltransferases; Nanoparticles; Oxidative Stress; Poly(ADP-ribose) Polymerases; Promoter Regions, Genetic; Reactive Oxygen Species; Thioctic Acid; Titanium | 2015 |
Integrin α9 gene promoter is hypermethylated and downregulated in nasopharyngeal carcinoma.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Blotting, Western; Carcinoma; Case-Control Studies; Cell Proliferation; Cells, Cultured; Decitabine; DNA Methylation; Gene Expression Regulation, Neoplastic; Humans; Integrin alpha Chains; Integrins; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Nasopharynx; Promoter Regions, Genetic; Real-Time Polymerase Chain Reaction; Wnt Proteins | 2015 |
Epigenetic priming with decitabine followed by low-dose idarubicin/cytarabine has an increased anti-leukemic effect compared to traditional chemotherapy in high-risk myeloid neoplasms.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Chromosome Aberrations; Cytarabine; Decitabine; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Epigenesis, Genetic; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Recurrence; Remission Induction; Treatment Outcome | 2016 |
Activity of single-agent decitabine in atypical chronic myeloid leukemia.
Topics: Administration, Intravenous; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Middle Aged; Transplantation, Homologous | 2016 |
The hypomethylating agent decitabine prior to chemotherapy improves the therapy efficacy in refractory/relapsed acute myeloid leukemia patients.
Topics: Aclarubicin; Adolescent; Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cell Line, Tumor; Cytarabine; Decitabine; Disease-Free Survival; Female; Harringtonines; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Treatment Outcome; Young Adult | 2015 |
Efficacy and toxicity of decitabine versus CHG regimen (low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor) in patients with higher risk myelodysplastic syndrome: a retrospective study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Female; Granulocyte Colony-Stimulating Factor; Harringtonines; Homoharringtonine; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Retrospective Studies; Treatment Outcome; Young Adult | 2016 |
Epigenetic alteration of the purinergic type 7 receptor in salivary epithelial cells.
Topics: Adenosine Triphosphate; Azacitidine; Base Sequence; Cell Line; CpG Islands; Decitabine; DNA Methylation; Epigenesis, Genetic; Epithelial Cells; Humans; Molecular Sequence Data; Purinergic P2X Receptor Agonists; Receptors, Purinergic P2X7; RNA, Messenger; Salivary Glands | 2015 |
SUVH1, a Su(var)3-9 family member, promotes the expression of genes targeted by DNA methylation.
Topics: Arabidopsis; Arabidopsis Proteins; Azacitidine; Decitabine; DNA Methylation; Epigenesis, Genetic; Gene Expression Regulation, Plant; Gene Silencing; Genes, Reporter; Heterochromatin; Histones; Isoenzymes; Luciferases; Methyltransferases; Seedlings; Transgenes | 2016 |
Hypermethylation of the Keap1 gene inactivates its function, promotes Nrf2 nuclear accumulation, and is involved in arsenite-induced human keratinocyte transformation.
Topics: Antioxidants; Arsenites; Azacitidine; Blotting, Western; Cell Nucleus; Cell Proliferation; Cell Transformation, Neoplastic; Cells, Cultured; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Methyltransferase 3A; Humans; Intracellular Signaling Peptides and Proteins; Kelch-Like ECH-Associated Protein 1; Keratinocytes; NF-E2-Related Factor 2; Promoter Regions, Genetic; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Teratogens | 2015 |
Decitabine in the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndromes, Which Combined with Complex Karyotype Respectively.
Topics: Abnormal Karyotype; Aclarubicin; Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Child; Child, Preschool; Cytarabine; Decitabine; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Hematuria; Humans; Induction Chemotherapy; Infections; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Survival Rate; Treatment Outcome; Young Adult | 2015 |
Temozolomide Resistance in Glioblastoma Cell Lines: Implication of MGMT, MMR, P-Glycoprotein and CD133 Expression.
Topics: AC133 Antigen; Antigens, CD; Antineoplastic Agents, Alkylating; ATP Binding Cassette Transporter, Subfamily B, Member 1; Azacitidine; Cell Line, Tumor; Dacarbazine; Decitabine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Epigenesis, Genetic; Gene Expression; Gene Expression Regulation, Neoplastic; Glioblastoma; Glycoproteins; Guanine; Humans; Inhibitory Concentration 50; Peptides; Promoter Regions, Genetic; Temozolomide; Tumor Suppressor Proteins | 2015 |
Treatment with 5-Aza-2'-Deoxycytidine Induces Expression of NY-ESO-1 and Facilitates Cytotoxic T Lymphocyte-Mediated Tumor Cell Killing.
Topics: Antigens, Neoplasm; Azacitidine; Breast Neoplasms; Cell Line, Tumor; Decitabine; Female; HLA-A2 Antigen; Humans; Immunotherapy; Interferon-gamma; MCF-7 Cells; Membrane Proteins; Microscopy, Fluorescence; Multiple Myeloma; Peptides; Real-Time Polymerase Chain Reaction; Receptors, Antigen, T-Cell; T-Lymphocytes, Cytotoxic; Up-Regulation | 2015 |
Exosomal MicroRNAs in Tumoral U87 MG Versus Normal Astrocyte Cells.
Topics: Aniline Compounds; Astrocytes; Azacitidine; Benzylidene Compounds; Biological Transport; Cell Line, Tumor; Decitabine; Exosomes; Gene Expression Profiling; Gene Expression Regulation; Glioblastoma; Humans; Hypoxia; MicroRNAs; Models, Biological; Phenotype | 2015 |
DNA methylation inhibitor, decitabine, promotes MGC803 gastric cancer cell migration and invasion via the upregulation of NEDD4‑1.
Topics: Azacitidine; Cell Line, Tumor; Cell Movement; Cell Proliferation; Decitabine; DNA Methylation; Endosomal Sorting Complexes Required for Transport; Humans; Nedd4 Ubiquitin Protein Ligases; Neoplasm Invasiveness; Stomach Neoplasms; Ubiquitin-Protein Ligases; Up-Regulation | 2015 |
Perspectives in Medicinal Chemistry: DNA Methylation and Demethylation Mechanisms as Therapeutic Targets?
Topics: Azacitidine; Chemistry, Pharmaceutical; Decitabine; DNA Glycosylases; DNA Methylation; Endodeoxyribonucleases; Epigenesis, Genetic; Humans; Neoplasms | 2016 |
Hypomethylating agents are effective in shrinking splenomegaly in patients with chronic myelomonocytic leukemia.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Methylation; Female; Humans; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Retrospective Studies; Splenomegaly; Treatment Outcome | 2016 |
[Reversal effect of 5-aza-2-deoxycytidine on the maternally expressed gene 3 promoter hypermethylation and its inhibitory effect on the proliferation of epithelial ovarian cancer cells].
Topics: Antimetabolites, Antineoplastic; Azacitidine; Carcinoma, Ovarian Epithelial; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Decitabine; DNA Methylation; Female; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Promoter Regions, Genetic; RNA, Messenger | 2015 |
[5-aza-2'-deoxycytidine suppresses the growth of human lung adenocarcinoma cells in nude mouse xenograft models and its effect on methylation status and expression of TFPI-2 gene].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Antimetabolites, Antineoplastic; Azacitidine; Cell Proliferation; Decitabine; Disease Models, Animal; DNA Methylation; Gene Expression Regulation, Neoplastic; Glycoproteins; Heterografts; Humans; Lung Neoplasms; Mice; Mice, Nude; Random Allocation; RNA, Messenger | 2015 |
Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides.
Topics: Aged; Antineoplastic Agents; Azacitidine; Databases, Factual; Decitabine; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Research Design; Risk Factors; Survival Analysis | 2016 |
Differential regulation of expression of RNA-editing enzymes, ADAR1 and ADAR2, by 5-aza-2'-deoxycytidine and trichostatin A in human neuronal SH-SY5Y cells.
Topics: Adenosine Deaminase; Azacitidine; Cell Line, Tumor; Decitabine; DNA Modification Methylases; Epigenesis, Genetic; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Neurons; RNA-Binding Proteins; RNA, Messenger | 2015 |
Epigenetic downregulation of the ISG15-conjugating enzyme UbcH8 impairs lipolysis and correlates with poor prognosis in nasopharyngeal carcinoma.
Topics: Adenosine Triphosphatases; Apoptosis; Azacitidine; Blotting, Western; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cytokines; Decitabine; DNA Methylation; Down-Regulation; Enzyme Inhibitors; Epigenesis, Genetic; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; HEK293 Cells; Humans; Kaplan-Meier Estimate; Lipase; Lipid Droplets; Lipolysis; Nasopharyngeal Neoplasms; Prognosis; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Ubiquitin-Conjugating Enzymes; Ubiquitins; Valosin Containing Protein | 2015 |
Epigenetic silencing of tumor suppressor miR-3151 contributes to Chinese chronic lymphocytic leukemia by constitutive activation of MADD/ERK and PIK3R2/AKT signaling pathways.
Topics: 3' Untranslated Regions; Adult; Aged; Aged, 80 and over; Apoptosis; Asian People; Azacitidine; Binding Sites; Cell Line, Tumor; Cell Proliferation; China; Death Domain Receptor Signaling Adaptor Proteins; Decitabine; DNA Methylation; DNA Modification Methylases; Enzyme Activation; Enzyme Inhibitors; Epigenesis, Genetic; Extracellular Signal-Regulated MAP Kinases; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Guanine Nucleotide Exchange Factors; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; MicroRNAs; Middle Aged; Myeloid Cell Leukemia Sequence 1 Protein; Phosphatidylinositol 3-Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; RNA Interference; Signal Transduction; Transfection | 2015 |
A prospective, multicenter, observational study of long-term decitabine treatment in patients with myelodysplastic syndrome.
Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Antibiotic Prophylaxis; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Febrile Neutropenia; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Remission Induction; Republic of Korea; Risk Factors; Time Factors; Treatment Outcome; Young Adult | 2015 |
[Expression and Promoter CpG Island Methylation Status of miR-34b in Leukemia Cell Lines and Their Clinical Significance].
Topics: Azacitidine; Cell Proliferation; Child; CpG Islands; Decitabine; DNA Methylation; HL-60 Cells; Humans; K562 Cells; Leukemia; MicroRNAs; Promoter Regions, Genetic; Real-Time Polymerase Chain Reaction; Transfection | 2015 |
DNA Methylation Modulates Nociceptive Sensitization after Incision.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Edema; Epigenesis, Genetic; Gene Expression Regulation; Hindlimb; Male; Mice; Mice, Inbred C57BL; Nociception; Pain Measurement; Real-Time Polymerase Chain Reaction; Receptors, Opioid, mu; Signal Transduction; Wounds, Penetrating | 2015 |
Alteration of the DNA methylation status of donor cells impairs the developmental competence of porcine cloned embryos.
Topics: Animals; Azacitidine; Blastocyst; Cell Nucleus; Cells, Cultured; Cellular Reprogramming; Cloning, Organism; Decitabine; Deoxycytosine Nucleotides; DNA Methylation; Embryo Culture Techniques; Embryonic Development; Fertilization in Vitro; Fibroblasts; Genome; Oocytes; Swine | 2016 |
Will next-generation agents deliver on the promise of epigenetic hypomethylation therapy?
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cytidine Deaminase; Decitabine; DNA Methylation; DNA Modification Methylases; Drug Design; Drug Resistance, Neoplasm; Drug Stability; Enzyme Inhibitors; Epigenesis, Genetic; Half-Life; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Randomized Controlled Trials as Topic | 2015 |
Hand-foot syndrome following decitabine.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Hand-Foot Syndrome; Humans; Male; Middle Aged | 2016 |
Correlation between the germline methylation status in ERβ promoter and the risk in prostate cancer: a prospective study.
Topics: Aged; Aged, 80 and over; Azacitidine; Case-Control Studies; Cell Line, Tumor; Decitabine; DNA Methylation; Enzyme Inhibitors; Estrogen Receptor beta; Gene Expression Regulation, Neoplastic; Genetic Predisposition to Disease; Humans; Male; Middle Aged; Promoter Regions, Genetic; Prospective Studies; Prostatic Neoplasms | 2016 |
Chlorin e6-mediated photodynamic effect diminishes therapeutic potential of 5-aza-2'-deoxycytidine-based whole-tumour-cell vaccine in mice bearing squamous cell carcinoma SCCVII.
Topics: Animals; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Azacitidine; Cancer Vaccines; Carcinoma, Squamous Cell; Cell Line, Tumor; Chlorophyllides; Decitabine; DNA Methylation; Enzyme-Linked Immunosorbent Assay; Kaplan-Meier Estimate; Male; Mice; Mice, Inbred C3H; Photochemotherapy; Photosensitizing Agents; Porphyrins; Transplantation, Homologous | 2015 |
Promoter Methylation Analysis Reveals That KCNA5 Ion Channel Silencing Supports Ewing Sarcoma Cell Proliferation.
Topics: Azacitidine; Bone Neoplasms; Cell Line, Tumor; Cell Proliferation; CpG Islands; Decitabine; DNA Methylation; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Humans; Kv1.5 Potassium Channel; Promoter Regions, Genetic; Sarcoma, Ewing | 2016 |
Five-aza-2'-deoxycytidine-induced hypomethylation of cholesterol 25-hydroxylase gene is responsible for cell death of myelodysplasia/leukemia cells.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow Cells; Cell Death; Cell Line, Tumor; Cell Proliferation; Decitabine; DNA Methylation; Epigenesis, Genetic; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Gene Knockout Techniques; HL-60 Cells; Humans; Leukemia; Myelodysplastic Syndromes; Promoter Regions, Genetic; RNA, Small Interfering; Signal Transduction; Steroid Hydroxylases; Transcriptome | 2015 |
Methylation of tumor suppressor gene CDH13 and SHP1 promoters and their epigenetic regulation by the UHRF1/PRMT5 complex in endometrial carcinoma.
Topics: Azacitidine; Cadherins; CCAAT-Enhancer-Binding Proteins; Cell Line, Tumor; Decitabine; DNA Methylation; Endometrial Neoplasms; Female; Genes, Tumor Suppressor; Humans; Hydroxamic Acids; Middle Aged; Promoter Regions, Genetic; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Protein-Arginine N-Methyltransferases; RNA, Messenger; Ubiquitin-Protein Ligases; Up-Regulation | 2016 |
Transcription factor activating protein 2 beta (TFAP2B) mediates noradrenergic neuronal differentiation in neuroblastoma.
Topics: Adolescent; Adrenergic Neurons; Adult; Azacitidine; Cell Cycle; Cell Differentiation; Cell Line, Tumor; Child; Child, Preschool; CpG Islands; Decitabine; DNA Methylation; Dopamine beta-Hydroxylase; Down-Regulation; Gene Knockdown Techniques; Humans; Infant; Infant, Newborn; N-Myc Proto-Oncogene Protein; Neuroblastoma; Nuclear Proteins; Oncogene Proteins; Prognosis; Promoter Regions, Genetic; Repressor Proteins; RNA, Small Interfering; Transcription Factor AP-2; Tretinoin; Tyrosine 3-Monooxygenase; Up-Regulation; Young Adult | 2016 |
A novel quantification method for the total demethylation potential of aquatic sample extracts from Bohai Bay using the EGFP reporter gene.
Topics: Azacitidine; Base Sequence; Decitabine; DNA Methylation; Epigenesis, Genetic; Fluorescence; Green Fluorescent Proteins; Hep G2 Cells; Humans; Molecular Sequence Data; Oceans and Seas; Plasmids; Promoter Regions, Genetic; Toxicity Tests; Water Pollutants, Chemical | 2015 |
Demethylation of miR-10b plays a suppressive role in ccRCC cells.
Topics: Azacitidine; Carcinoma, Renal Cell; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; CpG Islands; Decitabine; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Humans; Kidney Neoplasms; MicroRNAs; Neoplasm Invasiveness; Nuclear Proteins; Phenylbutyrates; Promoter Regions, Genetic; Time Factors; Transfection; Twist-Related Protein 1 | 2015 |
Down-regulation of BRMS1 by DNA hypermethylation and its association with metastatic progression in triple-negative breast cancer.
Topics: Adult; Azacitidine; Cell Line, Tumor; Cell Movement; Decitabine; Disease Progression; DNA Methylation; DNA Modification Methylases; Down-Regulation; Enzyme Inhibitors; Epigenesis, Genetic; Female; Gene Expression Regulation, Neoplastic; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Invasiveness; Repressor Proteins; RNA Interference; RNA, Messenger; Transfection; Triple Negative Breast Neoplasms | 2015 |
Decitabine induces G2/M cell cycle arrest by suppressing p38/NF-κB signaling in human renal clear cell carcinoma.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Carcinoma, Renal Cell; Carrier Proteins; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Decitabine; Dose-Response Relationship, Drug; Down-Regulation; G2 Phase Cell Cycle Checkpoints; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Kidney Neoplasms; Membrane Proteins; NF-kappa B; Nuclear Proteins; Oligonucleotide Array Sequence Analysis; p38 Mitogen-Activated Protein Kinases; Signal Transduction; Ubiquitin Thiolesterase | 2015 |
Nine years without a new FDA-approved therapy for MDS: how can we break through the impasse?
Topics: Algorithms; Azacitidine; Clinical Trials as Topic; Decitabine; Drug Approval; Drug Industry; Humans; Karyotyping; Lenalidomide; Methylation; Mutation; Myelodysplastic Syndromes; Prognosis; Risk Assessment; Thalidomide; United States; United States Food and Drug Administration | 2015 |
Epigenetic regulation of ZEB1-RAB25/ESRP1 axis plays a critical role in phenylbutyrate treatment-resistant breast cancer.
Topics: Antineoplastic Agents; Azacitidine; Breast Neoplasms; Cell Line, Tumor; Decitabine; Drug Resistance, Neoplasm; Epigenesis, Genetic; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Hydroxamic Acids; Immunohistochemistry; MCF-7 Cells; Phenylbutyrates; rab GTP-Binding Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA-Binding Proteins; Signal Transduction; Trastuzumab; Zinc Finger E-box-Binding Homeobox 1 | 2016 |
Inhibitor of DNA binding 4 functions as a tumor suppressor and is targetable by 5-aza-2'-deoxycytosine with potential therapeutic significance in Burkitt's lymphoma.
Topics: Apoptosis; Azacitidine; Burkitt Lymphoma; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Decitabine; DNA Methylation; Gene Expression Regulation, Neoplastic; Gene Silencing; Genes, Tumor Suppressor; Humans; Inhibitor of Differentiation Proteins; Promoter Regions, Genetic | 2016 |
DNA Methylation and Sex Allocation in the Parasitoid Wasp Nasonia vitripennis.
Topics: Animals; Azacitidine; Decitabine; Diptera; DNA Methylation; Epigenesis, Genetic; Female; Genome, Insect; Male; Sex Determination Processes; Sex Ratio; Wasps | 2015 |
Hypermethylation of Hippocampal Synaptic Plasticity-Related genes is Involved in Neonatal Sevoflurane Exposure-Induced Cognitive Impairments in Rats.
Topics: Anesthetics, Inhalation; Animals; Animals, Newborn; Azacitidine; Brain-Derived Neurotrophic Factor; Cell Adhesion Molecules, Neuronal; Cognition Disorders; Conditioning, Psychological; Decitabine; Dendritic Spines; DNA Methylation; DNA Modification Methylases; Extracellular Matrix Proteins; Fear; Hippocampus; Male; Maze Learning; Methyl Ethers; Methyl-CpG-Binding Protein 2; Nerve Tissue Proteins; Neuronal Plasticity; Pyramidal Cells; Rats; Rats, Sprague-Dawley; Reelin Protein; RNA, Messenger; Serine Endopeptidases; Sevoflurane | 2016 |
Sequential treatment with 5-aza-2'-deoxycytidine and deacetylase inhibitors reactivates HIV-1.
Topics: Azacitidine; CD4-Positive T-Lymphocytes; Cells, Cultured; Decitabine; Enzyme Inhibitors; Histone Deacetylase Inhibitors; HIV-1; Humans; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Viral; Virus Activation | 2016 |
The combination of FLT3 and DNA methyltransferase inhibition is synergistically cytotoxic to FLT3/ITD acute myeloid leukemia cells.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Azacitidine; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Decitabine; DNA Modification Methylases; Drug Synergism; Enzyme Inhibitors; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Tumor Cells, Cultured | 2016 |
NDN is an imprinted tumor suppressor gene that is downregulated in ovarian cancers through genetic and epigenetic mechanisms.
Topics: Animals; Apoptosis; Azacitidine; Cell Line, Tumor; Cell Movement; CpG Islands; Decitabine; DNA Methylation; Epithelium; Female; Focal Adhesion Kinase 1; Focal Adhesions; Gene Expression Regulation, Neoplastic; Humans; Loss of Heterozygosity; Mice; Mice, Nude; Nerve Tissue Proteins; Nuclear Proteins; Ovarian Neoplasms; Ovary; Polymorphism, Single Nucleotide; Promoter Regions, Genetic; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins pp60(c-src); rhoA GTP-Binding Protein; Stress Fibers; Tumor Suppressor Proteins | 2016 |
Regulation of TIMP-1 in Human Placenta and Fetal Membranes by lipopolysaccharide and demethylating agent 5-aza-2'-deoxycytidine.
Topics: Amnion; Azacitidine; Chorion; Chorionic Villi; Chromatin; Decidua; Decitabine; DNA Methylation; Epigenesis, Genetic; Extraembryonic Membranes; Female; Fetal Membranes, Premature Rupture; Gene Expression Regulation; Humans; Lipopolysaccharides; Placenta; Pregnancy; Real-Time Polymerase Chain Reaction; Tissue Inhibitor of Metalloproteinase-1; Transcription, Genetic | 2015 |
[Expression Analysis and Epigenetics of MicroRNA let-7b in Acute Lymphoblastic Leukemia].
Topics: Apoptosis; Azacitidine; CpG Islands; Decitabine; DNA Methylation; Epigenesis, Genetic; Humans; MicroRNAs; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Promoter Regions, Genetic; Real-Time Polymerase Chain Reaction | 2015 |
Aberrant GRK6 promoter methylation is associated with poor prognosis in hypopharyngeal squamous cell carcinoma.
Topics: Azacitidine; Carcinoma, Squamous Cell; Decitabine; DNA Methylation; Down-Regulation; G-Protein-Coupled Receptor Kinases; Gene Expression Regulation, Neoplastic; Humans; Hypopharyngeal Neoplasms; Neoplasm Invasiveness; Neoplasm Proteins; Prognosis; Promoter Regions, Genetic; RNA Interference; RNA, Messenger; RNA, Neoplasm; RNA, Small Interfering | 2016 |
Decitabine enhances chemosensitivity of early T-cell precursor-acute lymphoblastic leukemia cell lines and patient-derived samples.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Basic Helix-Loop-Helix Transcription Factors; Cell Line, Tumor; Cell Survival; Decitabine; Drug Synergism; Gene Expression Regulation, Leukemic; Humans; Jurkat Cells; Mice; Neoplasm Proteins; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Receptors, Interleukin-7; Reverse Transcriptase Polymerase Chain Reaction; Xenograft Model Antitumor Assays | 2016 |
Folate deficiency and DNA-methyltransferase inhibition modulate G-quadruplex frequency.
Topics: Azacitidine; Decitabine; DNA; DNA Modification Methylases; Folic Acid Deficiency; G-Quadruplexes; HeLa Cells; Humans | 2016 |
[Outcomes of refractory or relapsed DNMT3A + cytogenetically normal acute myeloid leukemia patients followed the therapy including decitabine combined with CAG or CAG-like regimen].
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Disease-Free Survival; DNA (Cytosine-5-)-Methyltransferases; DNA Methyltransferase 3A; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Mutation; Remission Induction; Retrospective Studies | 2015 |
DNA demethylation caused by 5-Aza-2'-deoxycytidine induces mitotic alterations and aneuploidy.
Topics: Aneuploidy; Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Blotting, Western; Cell Proliferation; Chromosome Aberrations; Colonic Neoplasms; Cytogenetic Analysis; Decitabine; DNA Methylation; Gene Expression Regulation, Neoplastic; Humans; Microscopy, Fluorescence; Mitosis; Ploidies; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured | 2016 |
Outcomes of patients with myelodysplastic syndromes who achieve stable disease after treatment with hypomethylating agents.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Treatment Outcome | 2016 |
Antenatal hypoxia induces epigenetic repression of glucocorticoid receptor and promotes ischemic-sensitive phenotype in the developing heart.
Topics: Animals; Animals, Newborn; Azacitidine; Binding Sites; Decitabine; DNA Methylation; Epigenesis, Genetic; Exons; Female; Hypoxia; Male; Maternal Exposure; Myocardial Reperfusion Injury; Oxygen; Phenotype; Pregnancy; Promoter Regions, Genetic; Protein Binding; Rats; Rats, Sprague-Dawley; Receptors, Glucocorticoid; Response Elements; Sp1 Transcription Factor | 2016 |
Prior hypomethylating agent use lacks impact on clinical outcome in patients with secondary acute myeloid leukemia arising from myelodysplastic syndromes treated with standard induction chemotherapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anthracyclines; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Survival Analysis; Treatment Outcome; Young Adult | 2016 |
Role of heme oxygenase-1 in demethylating effects on SKM-1 cells induced by decitabine.
Topics: Apoptosis; Azacitidine; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p15; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Gene Expression Regulation, Neoplastic; Heme Oxygenase-1; Humans; Myelodysplastic Syndromes; Neoplasm Proteins; RNA, Small Interfering | 2015 |
In vitro study of human mutL homolog 1 hypermethylation in inducing drug resistance of esophageal carcinoma.
Topics: Azacitidine; Cell Line, Tumor; Cisplatin; Decitabine; DNA Methylation; Drug Resistance, Neoplasm; Esophageal Neoplasms; Humans; MutL Protein Homolog 1; Promoter Regions, Genetic; RNA, Messenger | 2017 |
Emodin enhances the demethylation by 5-Aza-CdR of pancreatic cancer cell tumor-suppressor genes P16, RASSF1A and ppENK.
Topics: Azacitidine; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p16; Decitabine; DNA Methylation; Drug Synergism; Emodin; Enkephalins; Gene Expression Regulation, Neoplastic; Humans; Neoplasm Proteins; Pancreatic Neoplasms; Promoter Regions, Genetic; Protein Precursors; Sequence Analysis, DNA; Tumor Suppressor Proteins | 2016 |
Glycolic Acid Silences Inflammasome Complex Genes, NLRC4 and ASC, by Inducing DNA Methylation in HaCaT Cells.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Azacitidine; Calcium-Binding Proteins; CARD Signaling Adaptor Proteins; Cell Line; Cell Survival; Cytoskeletal Proteins; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Methyltransferase 3B; Epigenesis, Genetic; Gene Expression Regulation; Glycolates; Humans; Inflammasomes; Keratinocytes; Promoter Regions, Genetic; RNA Interference | 2016 |
Identification of Novel HLA-A*24:02-Restricted Epitope Derived from a Homeobox Protein Expressed in Hematological Malignancies.
Topics: Azacitidine; Case-Control Studies; Cell Line, Tumor; Cells, Cultured; Decitabine; Epitopes; HLA-A24 Antigen; Homeodomain Proteins; Humans; Leukemia, Myeloid; Monocytes; Neoplastic Stem Cells; T-Lymphocytes, Cytotoxic | 2016 |
The synergistic effect of 5Azadc and TSA on maintenance of pluripotency of chicken ESCs by overexpression of NANOG gene.
Topics: Animals; Azacitidine; Cell Differentiation; Cell Line; Chickens; Cloning, Molecular; Computational Biology; Decitabine; DNA Methylation; Drug Synergism; Embryonic Stem Cells; Fluorescent Antibody Technique; Gene Expression Regulation; Hydroxamic Acids; Nanog Homeobox Protein; Pluripotent Stem Cells; Promoter Regions, Genetic | 2016 |
5-Azacytidine Enhances the Mutagenesis of HIV-1 by Reduction to 5-Aza-2'-Deoxycytidine.
Topics: Anti-HIV Agents; Azacitidine; Chromatography, Liquid; Cytidine Triphosphate; Decitabine; DNA, Viral; HEK293 Cells; HIV Reverse Transcriptase; HIV-1; Humans; Mutagenesis; Oxidation-Reduction; Proviruses; Reverse Transcriptase Inhibitors; Reverse Transcription; Ribonucleotide Reductases; Sequence Analysis, DNA; Tandem Mass Spectrometry | 2016 |
Epigenetic Control of the Vasopressin Promoter Explains Physiological Ability to Regulate Vasopressin Transcription in Dehydration and Salt Loading States in the Rat.
Topics: Animals; Azacitidine; Cell Line; Decitabine; Dehydration; Demethylation; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Methyltransferase 3A; Epigenesis, Genetic; Hypothalamus; Male; Mutation; Osmolar Concentration; Promoter Regions, Genetic; Rats; Sodium Chloride; Vasopressins | 2016 |
Impact of Global and Gene-Specific DNA Methylation in de Novo or Relapsed Acute Myeloid Leukemia Patients Treated with Decitabine.
Topics: Adult; Aged; Azacitidine; CpG Islands; Decitabine; Disease-Free Survival; DNA; DNA Methylation; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Octamer Transcription Factor-3; Prognosis; SOXB1 Transcription Factors; Young Adult | 2016 |
Synergisitic and Antagonistic AML Cell Type-specific Responses to 5-Aza-2-deoxycitidine and 1-h-D-Arabinofuranoside.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cell Line, Tumor; Cell Survival; Cytarabine; Decitabine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Humans; Leukemia, Myeloid, Acute; Time Factors | 2016 |
Addition of 10-Day Decitabine to Fludarabine/Total Body Irradiation Conditioning is Feasible and Induces Tumor-Associated Antigen-Specific T Cell Responses.
Topics: Adult; Aged; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Azacitidine; CD8-Positive T-Lymphocytes; Decitabine; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2016 |
A genome-wide search for epigenetically [corrected] regulated genes in zebra finch using MethylCap-seq and RNA-seq.
Topics: Animals; Avian Proteins; Azacitidine; Cell Line, Tumor; CpG Islands; Decitabine; DNA Methylation; Epigenesis, Genetic; Female; Finches; Gene Regulatory Networks; Genome; Learning; Male; Memory; Nerve Tissue Proteins; Promoter Regions, Genetic; Sequence Analysis, DNA; Sequence Analysis, RNA | 2016 |
Infections in patients with acute myeloid leukemia treated with low-intensity therapeutic regimens: Risk factors and efficacy of antibiotic prophylaxis.
Topics: Adult; Aged; Aged, 80 and over; Antibiotic Prophylaxis; Antimetabolites, Antineoplastic; Azacitidine; Bacterial Infections; Cytarabine; Decitabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Risk Factors; Virus Diseases | 2016 |
Mixed-phenotype acute leukemia treated with decitabine.
Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Biomarkers, Tumor; Biopsy; Bone Marrow Examination; Cell Lineage; Decitabine; Female; Humans; Leukemia, Biphenotypic, Acute; Phenotype; Remission Induction; Treatment Outcome | 2016 |
[Promoter methylation status of SFRP genes and induced apoptosis by demethylation in Jurkat cells].
Topics: Apoptosis; Azacitidine; beta Catenin; Cell Proliferation; Decitabine; DNA Methylation; Down-Regulation; Gene Expression; Humans; Intercellular Signaling Peptides and Proteins; Jurkat Cells; Membrane Proteins; Promoter Regions, Genetic; Wnt Signaling Pathway | 2016 |
5-Aza-2'-Deoxycytidine and CDDP Synergistically Induce Apoptosis in Renal Carcinoma Cells via Enhancing the APAF-1 Activity.
Topics: Antineoplastic Agents; Apoptosis; Apoptotic Protease-Activating Factor 1; Azacitidine; Cell Line, Tumor; Cisplatin; Decitabine; DNA Methylation; Drug Synergism; Humans; Kidney Neoplasms | 2015 |
Induction of cancer testis antigen expression in circulating acute myeloid leukemia blasts following hypomethylating agent monotherapy.
Topics: Aged; Aged, 80 and over; Antigens, Neoplasm; Antineoplastic Agents; Azacitidine; Decitabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Membrane Proteins; Middle Aged | 2016 |
Influence of DNA-methylation on zinc homeostasis in myeloid cells: Regulation of zinc transporters and zinc binding proteins.
Topics: Azacitidine; Carrier Proteins; Cation Transport Proteins; Cells, Cultured; Decitabine; DNA Methylation; HL-60 Cells; Homeostasis; Humans; Myeloid Cells; Zinc | 2016 |
Transketolase-like 1 ectopic expression is associated with DNA hypomethylation and induces the Warburg effect in melanoma cells.
Topics: Azacitidine; Cell Line, Tumor; Cell Proliferation; Decitabine; DNA Methylation; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Glycolysis; Humans; Melanoma; Neoplasm Invasiveness; Neoplasm Metastasis; Promoter Regions, Genetic; Transketolase; Up-Regulation | 2016 |
Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents.
Topics: Aged; Aged, 80 and over; Alleles; Antimetabolites, Antineoplastic; Azacitidine; Cell Survival; Decitabine; DNA Methylation; Epigenesis, Genetic; Female; Gene Expression Regulation, Neoplastic; HEK293 Cells; High-Throughput Nucleotide Sequencing; Humans; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Mutation; Sequence Analysis, DNA; Sequence Analysis, RNA | 2016 |
[Effect of Decitabine on DKK1 Gene Demethylation in Leukemia Cells].
Topics: Apoptosis; Azacitidine; beta Catenin; Decitabine; DNA Methylation; Gene Expression Regulation, Bacterial; Genes, myc; HL-60 Cells; Humans; Intercellular Signaling Peptides and Proteins; Leukemia, Myeloid, Acute; RNA, Messenger; Wnt Signaling Pathway | 2016 |
Involvement of B-cell CLL/lymphoma 2 promoter methylation in cigarette smoke extract-induced emphysema.
Topics: Animals; Apoptosis; Azacitidine; Decitabine; DNA Methylation; Emphysema; Male; Mice; Mice, Inbred BALB C; Promoter Regions, Genetic; Proto-Oncogene Proteins c-bcl-2; Smoke; Smoking | 2016 |
High expression of the human equilibrative nucleoside transporter 1 gene predicts a good response to decitabine in patients with myelodysplastic syndrome.
Topics: Adult; Aged; Aged, 80 and over; Azacitidine; Cell Line; Decitabine; DNA Methylation; Equilibrative Nucleoside Transporter 1; Female; Gene Expression Regulation; Humans; Long Interspersed Nucleotide Elements; Male; Middle Aged; Multivariate Analysis; Myelodysplastic Syndromes; Remission Induction; Risk Factors; Survival Analysis; Treatment Outcome; Young Adult | 2016 |
Clinical Impact of Hypomethylating Agents in the Treatment of Myelodysplastic Syndromes.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Humans; Myelodysplastic Syndromes | 2016 |
Age-Related Changes in D-Aspartate Oxidase Promoter Methylation Control Extracellular D-Aspartate Levels and Prevent Precocious Cell Death during Brain Aging.
Topics: Age Factors; Aging; Animals; Animals, Newborn; Azacitidine; Brain; Cell Death; D-Aspartate Oxidase; D-Aspartic Acid; Decitabine; Embryo, Mammalian; Enzyme Inhibitors; Male; Methylation; Mice; Mice, Inbred C57BL; Mice, Transgenic; Neurons; Promoter Regions, Genetic; Receptors, N-Methyl-D-Aspartate; RNA, Messenger | 2016 |
Role of spermatogonial stem cells extract in transdifferentiation of 5-Aza-2'-deoxycytidine-treated bone marrow mesenchymal stem cells into germ-like cells.
Topics: Animals; Azacitidine; Bone Marrow Cells; Cell Transdifferentiation; Cells, Cultured; Decitabine; Male; Mesenchymal Stem Cells; Mice; Spermatogonia; Stem Cells | 2016 |
Effects of the combination of decitabine and homoharringtonine in SKM-1 and Kg-1a cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Azacitidine; Cell Proliferation; Decitabine; Harringtonines; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured | 2016 |
Biodegradable system for drug delivery of hydrolytically labile azanucleoside drugs.
Topics: Absorbable Implants; Antimetabolites, Antineoplastic; Azacitidine; Cells, Cultured; Decitabine; Humans; Infusion Pumps, Implantable; Magnetic Resonance Spectroscopy; Microspheres; Polymers | 2016 |
CETSA screening identifies known and novel thymidylate synthase inhibitors and slow intracellular activation of 5-fluorouracil.
Topics: Activation, Metabolic; Azacitidine; Biological Assay; Deamination; Decitabine; Drug Evaluation, Preclinical; Enzyme Inhibitors; Fluorouracil; Humans; Intracellular Space; K562 Cells; Kinetics; Phosphorylation; Small Molecule Libraries; Thymidylate Synthase; Time Factors | 2016 |
Decitabine enhances anti-CD33 monoclonal antibody BI 836858-mediated natural killer ADCC against AML blasts.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cells, Cultured; Combined Modality Therapy; Cytotoxicity, Immunologic; Decitabine; Drug Synergism; HL-60 Cells; Humans; Immunoglobulin Fc Fragments; Killer Cells, Natural; Leukemia, Myeloid, Acute; Recombinant Proteins; Sialic Acid Binding Ig-like Lectin 3 | 2016 |
The mechanism of apoliprotein A1 down-regulated by Hepatitis B virus.
Topics: Apolipoprotein A-I; Azacitidine; Case-Control Studies; CpG Islands; Decitabine; DNA Methylation; Down-Regulation; Epigenesis, Genetic; Gene Expression Regulation; Hep G2 Cells; Hepatitis B virus; Hepatitis B, Chronic; Host-Pathogen Interactions; Humans; Promoter Regions, Genetic | 2016 |
Methylation and expression of Epstein-Barr virus latent membrane protein 1, 2A and 2B in EBV-associated gastric carcinomas and cell lines.
Topics: Azacitidine; Cell Line, Tumor; Decitabine; DNA Methylation; Epstein-Barr Virus Infections; Gene Expression Regulation, Neoplastic; Gene Silencing; Herpesvirus 4, Human; Humans; Promoter Regions, Genetic; Stomach Neoplasms; Viral Matrix Proteins; Virus Latency | 2016 |
Prediction of key genes in ovarian cancer treated with decitabine based on network strategy.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Biomarkers, Tumor; Cell Cycle Proteins; Computational Biology; Cyclin B1; Databases, Genetic; Decitabine; Female; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Humans; Interleukin-1beta; Interleukin-2; Microarray Analysis; Nuclear Proteins; Ovarian Neoplasms; Phosphatidylinositol 3-Kinases; Reverse Transcriptase Polymerase Chain Reaction | 2016 |
Systematic discovery of drug action mechanisms by an integrated chemical genomics approach: identification of functional disparities between azacytidine and decitabine.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Survival; Colonic Neoplasms; Computational Biology; Decitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genomics; HCT116 Cells; HT29 Cells; Humans | 2016 |
Generation and characterization of two immortalized human osteoblastic cell lines useful for epigenetic studies.
Topics: Adaptor Proteins, Signal Transducing; Animals; Azacitidine; Bone Morphogenetic Proteins; Calcification, Physiologic; Calcitriol; Cell Differentiation; Cell Line; Decitabine; DNA Methylation; Epigenesis, Genetic; Genetic Markers; Humans; Mice; Mice, Nude; Osteoblasts; Osteocalcin; Osteogenesis; Tissue Scaffolds | 2017 |
Effects of 5-Aza-2'-Deoxycytidine, Bromodeoxyuridine, Interferons and Hydrogen Peroxide on Cellular Senescence in Cholangiocarcinoma Cells.
Topics: Azacitidine; Bile Duct Neoplasms; Bromodeoxyuridine; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Cellular Senescence; Cholangiocarcinoma; Cyclin-Dependent Kinase Inhibitor p21; Decitabine; DNA Damage; Humans; Hydrogen Peroxide; Interferons; Signal Transduction; Tumor Suppressor Protein p53 | 2016 |
Pattern of RECK CpG methylation as a potential marker for predicting breast cancer prognosis and drug-sensitivity.
Topics: Antineoplastic Agents; Azacitidine; Benzamides; Breast Neoplasms; CpG Islands; Decitabine; DNA Methylation; Dose-Response Relationship, Drug; Epigenesis, Genetic; Exons; Female; GPI-Linked Proteins; Histone Deacetylase Inhibitors; Humans; MCF-7 Cells; Methotrexate; Middle Aged; Neoplasm Grading; Neoplasm Staging; Promoter Regions, Genetic; Pyridines; Time Factors | 2016 |
Low-dose DNA-demethylating agent enhances the chemosensitivity of cancer cells by targeting cancer stem cells via the upregulation of microRNA-497.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cell Line, Tumor; Decitabine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Humans; MicroRNAs; Neoplastic Stem Cells; Up-Regulation | 2016 |
PRSS8 methylation and its significance in esophageal squamous cell carcinoma.
Topics: Azacitidine; Base Sequence; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Movement; Cell Proliferation; Decitabine; Disease-Free Survival; DNA Methylation; Down-Regulation; Enzyme Inhibitors; Esophageal Neoplasms; Female; Gene Expression Regulation, Neoplastic; HEK293 Cells; Humans; Male; Middle Aged; Promoter Regions, Genetic; RNA Interference; Sequence Homology, Nucleic Acid; Serine Endopeptidases | 2016 |
Simultaneous quantitative determination of 5-aza-2'-deoxycytidine genomic incorporation and DNA demethylation by liquid chromatography tandem mass spectrometry as exposure-response measures of nucleoside analog DNA methyltransferase inhibitors.
Topics: 5-Methylcytosine; Animals; Azacitidine; Cell Line, Tumor; Chromatography, Liquid; Decitabine; DNA; DNA Methylation; Humans; Limit of Detection; Linear Models; Methyltransferases; Mice; Mice, Nude; Reproducibility of Results; Tandem Mass Spectrometry | 2016 |
Factors affecting the persistence of drug-induced reprogramming of the cancer methylome.
Topics: Azacitidine; Breast Neoplasms; Cell Line, Tumor; Cellular Reprogramming; CpG Islands; Decitabine; DNA Methylation; Female; Gene Expression Regulation, Neoplastic; Genome, Human; Humans; Promoter Regions, Genetic | 2016 |
Isoform switching and exon skipping induced by the DNA methylation inhibitor 5-Aza-2'-deoxycytidine.
Topics: Azacitidine; Cell Line, Tumor; Decitabine; DNA Methylation; Enhancer of Zeste Homolog 2 Protein; Exons; Gene Expression Regulation, Neoplastic; Humans; Promoter Regions, Genetic; Protein Isoforms; Sequence Analysis, RNA; Urinary Bladder Neoplasms | 2016 |
The European Medicines Agency Review of Decitabine (Dacogen) for the Treatment of Adult Patients With Acute Myeloid Leukemia: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Female; Humans; Leukemia, Myeloid, Acute; Male | 2016 |
Azacitidine versus decitabine in patients with refractory anemia with excess blast-Results of multicenter study.
Topics: Aged; Anemia, Refractory, with Excess of Blasts; Antimetabolites, Antineoplastic; Azacitidine; Blood Component Transfusion; Cell Transformation, Neoplastic; Decitabine; Drug Evaluation; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Patient Selection; Propensity Score; Remission Induction; Retrospective Studies; Survival Rate | 2016 |
Low-dose decitabine plus all-trans retinoic acid in patients with myeloid neoplasms ineligible for intensive chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Decitabine; Dose-Response Relationship, Drug; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Tretinoin | 2016 |
IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression.
Topics: Antineoplastic Agents; Azacitidine; Brain Neoplasms; Decitabine; DNA Methylation; Down-Regulation; Gene Expression Regulation, Neoplastic; Glioma; GPI-Linked Proteins; Humans; Immunologic Surveillance; Intercellular Signaling Peptides and Proteins; Isocitrate Dehydrogenase; Killer Cells, Natural; Mutation; Real-Time Polymerase Chain Reaction; Transcriptome; Tumor Escape | 2016 |
Training Lymnaea in the presence of a predator scent results in a long-lasting ability to form enhanced long-term memory.
Topics: Analysis of Variance; Animals; Astacoidea; Azacitidine; Conditioning, Operant; Decitabine; DNA Methylation; Enzyme Inhibitors; Epigenesis, Genetic; Fresh Water; Lymnaea; Memory, Long-Term; Ponds; Respiration; Smell; Time Factors | 2016 |
Inhibition of DNA Methylation Suppresses Intestinal Tumor Organoids by Inducing an Anti-Viral Response.
Topics: Animals; Azacitidine; Cell Proliferation; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA Methylation; Gene Expression Profiling; Gene Knockdown Techniques; Immunity, Innate; Mice; Microarray Analysis; Organoids; Tumor Cells, Cultured | 2016 |
DNA Methylation Biphasically Regulates 3T3-L1 Preadipocyte Differentiation.
Topics: 3T3-L1 Cells; Adipocytes; Adipogenesis; Animals; Azacitidine; Cell Differentiation; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Methyltransferase 3A; Gene Knockdown Techniques; Lipogenesis; Mice; Promoter Regions, Genetic; Sterol Regulatory Element Binding Protein 1 | 2016 |
[Clinical Efficacy Comparison of Ultralow Dose of Decitabine and Cyclosporine on Low-risk and Intermediate-risk Type 1 of Myelodysplastic Syndrome].
Topics: Azacitidine; Cyclosporine; Decitabine; Humans; Myelodysplastic Syndromes; Pancytopenia; Retrospective Studies; Survival Rate; Treatment Outcome | 2016 |
Methylation-induced silencing of maspin contributes to the proliferation of human glioma cells.
Topics: Azacitidine; Cell Line, Tumor; Cell Movement; Cell Proliferation; Central Nervous System Neoplasms; CpG Islands; Decitabine; DNA Methylation; Gene Expression Regulation, Neoplastic; Gene Silencing; Glioma; Humans; Promoter Regions, Genetic; Serpins | 2016 |
Promoter methylation status of tumor suppressor genes and inhibition of expression of DNA methyltransferase 1 in non-small cell lung cancer.
Topics: Animals; Azacitidine; Benzamides; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Histone Deacetylase Inhibitors; Humans; Male; Mice, Inbred BALB C; Mice, Nude; Promoter Regions, Genetic; Pyridines | 2016 |
DNA demethylating agent decitabine broadens the peripheral T cell receptor repertoire.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Azacitidine; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Complementarity Determining Regions; Decitabine; DNA Methylation; Epigenesis, Genetic; Female; Humans; Immunotherapy; Male; Middle Aged; Neoplasms; Receptors, Antigen, T-Cell, alpha-beta; T-Lymphocytes | 2016 |
Altered methylation of glucosylceramide synthase promoter regulates its expression and associates with acquired multidrug resistance in invasive ductal breast cancer.
Topics: Adult; Azacitidine; Breast Neoplasms; Carcinoma, Ductal, Breast; Cell Line, Tumor; CpG Islands; Decitabine; DNA Methylation; Drug Resistance, Multiple; Enzyme Inhibitors; Female; Gene Expression Regulation, Neoplastic; Glucosyltransferases; Humans; MCF-7 Cells; Neoplasm Invasiveness; Promoter Regions, Genetic | 2016 |
Functional role and tobacco smoking effects on methylation of CYP1A1 gene in prostate cancer.
Topics: Aged; Aged, 80 and over; Apoptosis; Azacitidine; Cell Line, Tumor; CpG Islands; Cytochrome P-450 CYP1A1; Decitabine; DNA Methylation; Enhancer Elements, Genetic; Epigenesis, Genetic; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Oligonucleotide Array Sequence Analysis; Polymerase Chain Reaction; Promoter Regions, Genetic; Prostatic Hyperplasia; Prostatic Neoplasms; Sulfites; Tissue Array Analysis; Tobacco Smoking; Xenobiotics | 2016 |
Keeping sterile 0.9% sodium chloride, 5% dextrose, and lactated Ringer's solutions for injection cold enough for dilution of decitabine in isolators.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cold Temperature; Decitabine; Drug Compounding; Glucose; Humans; Injections, Intravenous; Isotonic Solutions; Ringer's Lactate; Saline Solution, Hypertonic; Serum Albumin; Serum Albumin, Human | 2016 |
MiR-153 as a Tumor Suppressor in Glioblastoma Multiforme is Downregulated by DNA Methylation.
Topics: Azacitidine; Cell Line, Tumor; Cell Proliferation; Decitabine; DNA Methylation; Down-Regulation; Genes, Tumor Suppressor; Glioblastoma; Humans; MicroRNAs; Promoter Regions, Genetic | 2016 |
MUC1-C induces DNA methyltransferase 1 and represses tumor suppressor genes in acute myeloid leukemia.
Topics: ADP-ribosyl Cyclase 1; Antigens, CD; Antigens, CD34; Azacitidine; Cadherins; Cell Line, Tumor; Cell Survival; Computational Biology; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA Methylation; Drug Synergism; Gene Expression Regulation, Leukemic; Gene Silencing; Genes, Tumor Suppressor; Humans; Leukemia, Myeloid, Acute; Mucin-1; NF-kappa B p50 Subunit; Promoter Regions, Genetic; RNA, Small Interfering; Transcription Factor RelA | 2016 |
Integrated genomic analysis of colorectal cancer progression reveals activation of EGFR through demethylation of the EREG promoter.
Topics: Azacitidine; Cell Line, Tumor; Colorectal Neoplasms; Decitabine; Disease Progression; DNA Methylation; Epiregulin; ErbB Receptors; Humans; Phosphorylation; Promoter Regions, Genetic | 2016 |
DNA Demethylation Rescues the Impaired Osteogenic Differentiation Ability of Human Periodontal Ligament Stem Cells in High Glucose.
Topics: Animals; Azacitidine; Bone Density; Cell Differentiation; Decitabine; Diabetes Mellitus, Experimental; DNA (Cytosine-5-)-Methyltransferase 1; DNA Methylation; Glucose; Humans; Osteogenesis; Periodontal Ligament; Rats; Stem Cells; Wnt Proteins | 2016 |
Dexamethasone Induces Cardiomyocyte Terminal Differentiation via Epigenetic Repression of Cyclin D2 Gene.
Topics: Animals; Animals, Newborn; Azacitidine; Cell Differentiation; Cell Proliferation; Cyclin D2; Decitabine; Dexamethasone; DNA Methylation; Down-Regulation; Epigenetic Repression; Female; Myocytes, Cardiac; Pregnancy; Promoter Regions, Genetic; Rats; Rats, Sprague-Dawley | 2016 |
Inhibition of DNA Methylation in the Developing Rat Brain Disrupts Sexually Dimorphic Neurobehavioral Phenotypes in Adulthood.
Topics: Aging; Animals; Animals, Newborn; Azacitidine; Behavior, Animal; Body Weight; Brain; Brain-Derived Neurotrophic Factor; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA Methylation; Female; Male; Maze Learning; Organ Size; Phenotype; Promoter Regions, Genetic; Rats, Sprague-Dawley; Receptor, trkB; RNA, Messenger; Rotarod Performance Test; Sex Characteristics | 2017 |
Only the complex N559-glycan in the synaptic vesicle glycoprotein 2C mediates high affinity binding to botulinum neurotoxin serotype A1.
Topics: Azacitidine; Botulinum Toxins, Type A; Decitabine; Glycosylation; Membrane Glycoproteins; Protein Binding; Surface Plasmon Resonance; Synaptic Vesicles | 2016 |
Upregulation of p27Kip1 by demethylation sensitizes cisplatin-resistant human ovarian cancer SKOV3 cells.
Topics: Antineoplastic Agents; Apoptosis; Azacitidine; Cell Cycle; Cell Line, Tumor; Cisplatin; Cyclin-Dependent Kinase Inhibitor p27; Decitabine; DNA Methylation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Ovarian Neoplasms | 2016 |
Methylation status of the promoter region of the human frizzled 9 gene in acute myeloid leukemia.
Topics: Azacitidine; Cell Line, Tumor; CpG Islands; Decitabine; DNA Methylation; Epigenesis, Genetic; Frizzled Receptors; Gene Expression Regulation, Leukemic; Gene Silencing; Genes, Tumor Suppressor; Humans; Leukemia, Myeloid, Acute; Promoter Regions, Genetic | 2016 |
Enhanced inhibition of clonogenic survival of human medulloblastoma cells by multimodal treatment with ionizing irradiation, epigenetic modifiers, and differentiation-inducing drugs.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cerebellar Neoplasms; Combined Modality Therapy; Decitabine; Dideoxynucleosides; Epigenesis, Genetic; Humans; Hydroxamic Acids; Medulloblastoma; Mice; Neurogenesis; Radiation-Sensitizing Agents; Resveratrol; Stilbenes; Treatment Outcome; Tretinoin; Valproic Acid; Vorinostat; Xenograft Model Antitumor Assays | 2016 |
The nucleotidohydrolases DCTPP1 and dUTPase are involved in the cellular response to decitabine.
Topics: Antineoplastic Agents; Azacitidine; Cell Line; Chromatography, Liquid; Decitabine; HeLa Cells; Humans; Pyrophosphatases; Tandem Mass Spectrometry | 2016 |
Upregulation of Key Molecules for Targeted Imaging and Therapy.
Topics: Animals; Azacitidine; Biomarkers, Tumor; Cell Line, Tumor; Decitabine; Drug Evaluation, Preclinical; Gene Expression Regulation, Neoplastic; Mice; Mice, Nude; Molecular Targeted Therapy; Neoplasms, Experimental; Organometallic Compounds; Pathology, Molecular; Positron-Emission Tomography; Receptors, Somatostatin; Reproducibility of Results; Sensitivity and Specificity; Up-Regulation | 2016 |
CD80 down-regulation is associated to aberrant DNA methylation in non-inflammatory colon carcinogenesis.
Topics: Aged; Azacitidine; B7-1 Antigen; Cell Line, Tumor; Colonic Neoplasms; Decitabine; DNA Methylation; Down-Regulation; Female; Gene Expression Regulation, Neoplastic; HT29 Cells; Humans; Male; Middle Aged; Promoter Regions, Genetic | 2016 |
Sustained expression of FMR1 mRNA from reactivated fragile X syndrome alleles after treatment with small molecules that prevent trimethylation of H3K27.
Topics: Azacitidine; Cell Line, Tumor; Decitabine; DNA Methylation; Enhancer of Zeste Homolog 2 Protein; Fragile X Mental Retardation Protein; Gene Expression Regulation; Histones; Humans; Male; Methylation; Microsatellite Repeats; Small Molecule Libraries; Up-Regulation | 2016 |
Decreased expression of connective tissue growth factor in non-small cell lung cancer is associated with clinicopathological variables and can be restored by epigenetic modifiers.
Topics: Adult; Aged; Aged, 80 and over; Azacitidine; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Connective Tissue Growth Factor; Decitabine; DNA Methylation; Down-Regulation; Epigenesis, Genetic; Female; Gene Expression Regulation, Neoplastic; HeLa Cells; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Lung Neoplasms; Male; Middle Aged; Prognosis; Promoter Regions, Genetic; Tumor Cells, Cultured | 2016 |
5-aza-2'-deoxycytidine impairs mouse spermatogenesis at multiple stages through different usage of DNA methyltransferases.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Cell Differentiation; Decitabine; DNA Methylation; DNA Modification Methylases; Germ Cells; Male; Mice; Mice, Inbred ICR; Seminiferous Tubules; Spermatocytes; Spermatogenesis; Spermatogonia; Testis | 2016 |
Human Leukocyte Antigen (HLA) Peptides Derived from Tumor Antigens Induced by Inhibition of DNA Methylation for Development of Drug-facilitated Immunotherapy.
Topics: Antigens, Neoplasm; Azacitidine; Brain Neoplasms; Cell Line, Tumor; Decitabine; DNA Methylation; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Glioblastoma; HLA Antigens; Humans; Immunotherapy; Peptides; Proteomics; Sequence Analysis, RNA | 2016 |
DNA methyltransferase inhibition increases efficacy of adoptive cellular immunotherapy of murine breast cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Breast Neoplasms; Cell Line, Tumor; Decitabine; DNA Modification Methylases; Enzyme Inhibitors; Female; Humans; Immunotherapy, Adoptive; Mammary Neoplasms, Experimental; MCF-7 Cells; Mice; Mice, Inbred BALB C; T-Lymphocytes | 2016 |
Densely ionizing radiation affects DNA methylation of selective LINE-1 elements.
Topics: Animals; Azacitidine; Decitabine; DNA Methylation; Histones; Long Interspersed Nucleotide Elements; Lung; Male; Mice; Mice, Inbred C57BL; Radiation, Ionizing; RAW 264.7 Cells | 2016 |
Identification of V-ATPase as a molecular sensor of SOX11-levels and potential therapeutic target for mantle cell lymphoma.
Topics: Azacitidine; beta Catenin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin D1; Decitabine; Doxycycline; Gene Expression Regulation, Neoplastic; Humans; Intercellular Signaling Peptides and Proteins; Lymphoma, Mantle-Cell; Macrolides; Membrane Proteins; RNA Interference; RNA, Small Interfering; SOXC Transcription Factors; Vacuolar Proton-Translocating ATPases; Wnt Proteins; Wnt Signaling Pathway | 2016 |
Rescued expression of WIF-1 in gallbladder cancer inhibits tumor growth and induces tumor cell apoptosis with altered expression of proteins.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Animals; Apoptosis; Azacitidine; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Transformation, Neoplastic; Decitabine; Disease Models, Animal; DNA Methylation; Female; Gallbladder Neoplasms; Gene Expression Regulation, Neoplastic; Heterografts; Humans; Male; Mice; Middle Aged; Promoter Regions, Genetic; Repressor Proteins | 2016 |
Decitabine inhibits tumor cell proliferation and up-regulates e-cadherin expression in Epstein-Barr virus-associated gastric cancer.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Cadherins; Cell Cycle; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cell Proliferation; Decitabine; Epithelial Cells; Epstein-Barr Virus Infections; Humans; Stomach Neoplasms | 2017 |
BNIP3L in myelodysplastic syndromes and acute myeloid leukemia: impact on disease outcome and cellular response to decitabine.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow; Case-Control Studies; Cell Line; Decitabine; DNA Methylation; Humans; Leukemia, Myeloid, Acute; Membrane Proteins; Myelodysplastic Syndromes; Proto-Oncogene Proteins; Survival Analysis; Treatment Outcome; Tumor Suppressor Proteins | 2016 |
Estrogen and promoter methylation in the regulation of PLA2G7 transcription.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Acetylation; Azacitidine; Base Sequence; Cell Line; Decitabine; DNA Methylation; Estrogens; Gene Expression Regulation; Genes, Reporter; Histones; Humans; Myocytes, Smooth Muscle; Promoter Regions, Genetic; Transcription, Genetic | 2016 |
Loss-of-function screening to identify miRNAs involved in senescence: tumor suppressor activity of miRNA-335 and its new target CARF.
Topics: Animals; Apoptosis Regulatory Proteins; Azacitidine; Cell Line, Tumor; Cellular Senescence; Decitabine; Genes, p16; Genes, Tumor Suppressor; Heterografts; Humans; Mice; Mice, Nude; MicroRNAs; Retinoblastoma Protein; RNA-Binding Proteins | 2016 |
Downregulation of thrombospondin-1 by DNA hypermethylation is associated with tumor progression in laryngeal squamous cell carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Decitabine; Disease Progression; DNA Methylation; Female; Gene Expression Regulation, Neoplastic; Humans; Laryngeal Neoplasms; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Thrombospondin 1; Transcriptional Activation | 2016 |
Inhibition of DNA Methylation Impairs Synaptic Plasticity during an Early Time Window in Rats.
Topics: Age Factors; Animals; Azacitidine; Decitabine; DNA Methylation; Enzyme Inhibitors; Hippocampus; Long-Term Potentiation; Male; Methyl-CpG-Binding Protein 2; Neuronal Plasticity; Organ Culture Techniques; Rats; Rats, Sprague-Dawley | 2016 |
Epigenetic modulation of AR gene expression in prostate cancer DU145 cells with the combination of sodium butyrate and 5'-Aza-2'-deoxycytidine.
Topics: Azacitidine; Butyric Acid; Cell Line, Tumor; Decitabine; DNA Methylation; Epigenomics; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Male; Promoter Regions, Genetic; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen | 2016 |
Sex steroid-induced DNA methylation changes and inflammation response in prostate cancer.
Topics: Azacitidine; Biomarkers, Tumor; Cell Line, Tumor; Chemokine CXCL5; Chemokines, CC; Cytokines; Decitabine; DNA Methylation; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Gonadal Steroid Hormones; Humans; Hydroxamic Acids; Inflammation; Interleukin-5; Male; Polymerase Chain Reaction; Promoter Regions, Genetic; Prostatic Neoplasms; Tissue Array Analysis; Tumor Cells, Cultured | 2016 |
Expression Profiles of SIRT1 and APP Genes in Human Neuroblastoma SK-N-SH Cells Treated with Two Epigenetic Agents.
Topics: Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Azacitidine; Cell Line, Tumor; Cell Survival; Decitabine; Dose-Response Relationship, Drug; Gene Expression Regulation, Neoplastic; Humans; Hydroxamic Acids; Neuroblastoma; Peptide Fragments; RNA, Messenger; Sirtuin 1; Time Factors | 2016 |
Report on outcomes of hypomethylating therapy for analyzing prognostic value of Revised International Prognostic Scoring System for patients with lower-risk myelodysplastic syndromes.
Topics: Adult; Aged; Aged, 80 and over; Azacitidine; Databases, Factual; Decitabine; DNA Methylation; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Retrospective Studies; Risk; Severity of Illness Index; Survival Analysis; Treatment Outcome | 2016 |
Methylation of IGF2 regulatory regions to diagnose adrenocortical carcinomas.
Topics: Adolescent; Adrenal Cortex Neoplasms; Adrenocortical Adenoma; Adrenocortical Carcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Cell Line, Tumor; Child; Decitabine; DNA Methylation; Female; Humans; Insulin-Like Growth Factor II; Male; Middle Aged; Regulatory Sequences, Nucleic Acid; RNA, Messenger; Young Adult | 2016 |
[Effects and related mechanism of 5-aza-2'-deoxycytidine on endothelial function in rats with hyperhomocysteinemia].
Topics: Acetylcholine; Amidohydrolases; Animals; Azacitidine; Decitabine; Diet; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; Endothelium, Vascular; Hyperhomocysteinemia; Male; Mesenteric Arteries; Nitric Oxide; Nitric Oxide Synthase Type III; Random Allocation; Rats; Rats, Sprague-Dawley | 2016 |
Olfactomedin 1 negatively regulates NF-κB signalling and suppresses the growth and metastasis of colorectal cancer cells.
Topics: Animals; Azacitidine; Biomarkers; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Decitabine; Disease-Free Survival; DNA Methylation; Down-Regulation; Enzyme Inhibitors; Extracellular Matrix Proteins; Female; Gene Expression Regulation, Neoplastic; Glycoproteins; Humans; Liver Neoplasms; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Middle Aged; NF-kappa B; NF-kappaB-Inducing Kinase; Prognosis; Protein Serine-Threonine Kinases; Signal Transduction | 2016 |
Disease characteristics and prognosis of myelodysplastic syndrome presenting with isolated thrombocytopenia.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Benzoates; Decitabine; Female; Humans; Hydrazines; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Retrospective Studies; Risk; Thrombocytopenia; Thrombopoietin | 2017 |
Decitabine enhances bortezomib treatment in RPMI 8226 multiple myeloma cells.
Topics: Antineoplastic Agents; Apoptosis; Azacitidine; Bortezomib; Caspase 3; Caspase 9; Cell Line, Tumor; Cell Proliferation; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Multiple Myeloma; Poly(ADP-ribose) Polymerases | 2016 |
Vitamin C increases viral mimicry induced by 5-aza-2'-deoxycytidine.
Topics: Apoptosis; Ascorbic Acid; Ascorbic Acid Deficiency; Azacitidine; Cell Proliferation; Decitabine; Dioxygenases; DNA Methylation; DNA-Binding Proteins; Drug Synergism; Endogenous Retroviruses; Enzyme Inhibitors; Female; Hematologic Neoplasms; Humans; Interferons; Male; Methyltransferases; Proto-Oncogene Proteins; RNA, Double-Stranded | 2016 |
Hypoxia inducible factor-1 mediates the expression of the immune checkpoint HLA-G in glioma cells through hypoxia response element located in exon 2.
Topics: 5' Untranslated Regions; Antineoplastic Agents; Azacitidine; Cell Line, Tumor; CpG Islands; Decitabine; DNA Methylation; Exons; Genes, MHC Class I; Glioma; HLA-G Antigens; Humans; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Immune System; Neoplasm Invasiveness; Polymorphism, Genetic; Promoter Regions, Genetic; Response Elements; Transcriptional Activation | 2016 |
Decitabine Treatment of Glioma-Initiating Cells Enhances Immune Recognition and Killing.
Topics: Animals; Azacitidine; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Decitabine; Fas Ligand Protein; fas Receptor; Gene Expression Regulation, Neoplastic; Genes, MHC Class I; Glioma; Humans; Intercellular Adhesion Molecule-1; Mice; Neoplastic Stem Cells; T-Lymphocytes, Cytotoxic; Up-Regulation; Xenograft Model Antitumor Assays | 2016 |
[Methylation and demethylation of SOX2 gene promoter in BGC-823 gastric cancer cells].
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Cell Line, Tumor; Cell Proliferation; Decitabine; DNA Methylation; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Promoter Regions, Genetic; Real-Time Polymerase Chain Reaction; RNA, Messenger; SOXB1 Transcription Factors; Stomach Neoplasms; Tumor Burden | 2016 |
An Epigenomic Approach to Improving Response to Neoadjuvant Cisplatin Chemotherapy in Bladder Cancer.
Topics: Antineoplastic Agents; Azacitidine; Biomarkers, Tumor; Cell Line, Tumor; Cisplatin; Decitabine; Doxorubicin; Drug Resistance, Neoplasm; Epigenomics; Etoposide; Homeodomain Proteins; Humans; Hydroxamic Acids; Methylation; Neoadjuvant Therapy; Promoter Regions, Genetic; Urinary Bladder Neoplasms; Vinblastine; Vorinostat | 2016 |
Hypermethylation and downregulation of glutathione peroxidase 3 are related to pathogenesis of melanoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Azacitidine; Child; Decitabine; DNA Methylation; Female; Gene Expression Regulation, Neoplastic; Glutathione Peroxidase; Humans; Male; Melanoma; Middle Aged; Promoter Regions, Genetic; RNA, Messenger | 2016 |
Decitabine prior to salvaged unrelated cord blood transplantation for refractory or relapsed childhood acute leukemia.
Topics: Adolescent; Antimetabolites, Antineoplastic; Azacitidine; Child; Child, Preschool; Cohort Studies; Cord Blood Stem Cell Transplantation; Decitabine; Female; Graft Survival; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Neutrophils; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prevalence; Recurrence; Remission Induction; Time Factors; Transplantation Conditioning; Treatment Outcome | 2016 |
Increased Expression of HYAL1 in Pancreatic Ductal Adenocarcinoma.
Topics: Azacitidine; Carcinoma, Pancreatic Ductal; Decitabine; Humans; Hyaluronic Acid; Hyaluronoglucosaminidase; Pancreatic Neoplasms | 2016 |
Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes.
Topics: Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Female; Humans; Kaplan-Meier Estimate; Male; Myelodysplastic Syndromes; Survival Rate; Treatment Outcome | 2016 |
Oxidative stress-induced epigenetic changes associated with malignant transformation of human kidney epithelial cells.
Topics: Acetylation; Animals; Azacitidine; Blotting, Western; Cell Line; Cell Transformation, Neoplastic; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Methyltransferase 3A; Enzyme Inhibitors; Epigenesis, Genetic; Epithelial Cells; Female; Gene Expression Regulation, Neoplastic; Histones; Humans; Hydrogen Peroxide; Kidney; Kidney Neoplasms; Mice, Nude; Oxidants; Oxidative Stress; Reverse Transcriptase Polymerase Chain Reaction; Transplantation, Heterologous | 2017 |
5-aza-2'-deoxycytidine Inhibits the Proliferation of Lung Fibroblasts in Neonatal Rats Exposed to Hyperoxia.
Topics: Animals; Animals, Newborn; Azacitidine; Bronchopulmonary Dysplasia; Cell Proliferation; Decitabine; Disease Models, Animal; Enzyme Inhibitors; Fibroblasts; Hyperoxia; Lung; Rats; Rats, Sprague-Dawley | 2017 |
Effects of 5-Aza-2'-deoxycytidine on expression of PP1γ in learning and memory.
Topics: Animals; Apoptosis; Azacitidine; Behavior, Animal; Cell Line; Cell Proliferation; Decitabine; DNA Methylation; DNA Modification Methylases; Down-Regulation; Enzyme Inhibitors; Gene Expression Regulation, Enzymologic; Hippocampus; Maze Learning; Mice, Inbred ICR; Protein Phosphatase 1; RNA, Messenger; Spatial Memory; Time Factors; Transcription, Genetic | 2016 |
Decitabine and 5-azacitidine both alleviate LPS induced ARDS through anti-inflammatory/antioxidant activity and protection of glycocalyx and inhibition of MAPK pathways in mice.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Azacitidine; Decitabine; Disease Models, Animal; DNA Methylation; Glycocalyx; Inflammation Mediators; Interleukin-1beta; Lipopolysaccharides; Lung; Male; MAP Kinase Signaling System; Mice, Inbred C57BL; Organ Size; Promoter Regions, Genetic; Respiratory Distress Syndrome; Tumor Necrosis Factor-alpha; Tumor Suppressor Proteins | 2016 |
Increased PD-1/STAT1 ratio may account for the survival benefit in decitabine therapy for lower risk myelodysplastic syndrome.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; B7-H1 Antigen; Biomarkers; CD4-CD8 Ratio; Decitabine; Female; Gene Expression; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Programmed Cell Death 1 Receptor; Proportional Hazards Models; STAT1 Transcription Factor; T-Lymphocytes; Treatment Outcome; Young Adult | 2017 |
Epigenetic silencing of tumor suppressor long non-coding RNA BM742401 in chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Apoptosis; Azacitidine; Case-Control Studies; Caspase 9; Cell Line, Tumor; Cell Proliferation; CpG Islands; Decitabine; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Epigenesis, Genetic; Female; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; MicroRNAs; Middle Aged; Neoplasm Staging; Promoter Regions, Genetic; RNA, Long Noncoding; Transfection | 2016 |
Possible role of intragenic DNA hypermethylation in gene silencing of the tumor suppressor gene NR4A3 in acute myeloid leukemia.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Blast Crisis; Case-Control Studies; Cells, Cultured; CpG Islands; Decitabine; DNA Methylation; DNA-Binding Proteins; Exons; Female; Gene Expression Regulation, Leukemic; Gene Silencing; Genes, Tumor Suppressor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Receptors, Steroid; Receptors, Thyroid Hormone | 2016 |
Hypermethylation of PRDM1/Blimp-1 promoter in extranodal NK/T-cell lymphoma, nasal type: an evidence of predominant role in its downregulation.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Biomarkers; Cell Line, Tumor; Decitabine; DNA Methylation; Epigenesis, Genetic; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Genetic Predisposition to Disease; Humans; Immunohistochemistry; Lymphoma, Extranodal NK-T-Cell; Male; MicroRNAs; Middle Aged; Positive Regulatory Domain I-Binding Factor 1; Promoter Regions, Genetic; Young Adult | 2017 |
DACT2 silencing by promoter CpG methylation disrupts its regulation of epithelial-to-mesenchymal transition and cytoskeleton reorganization in breast cancer cells.
Topics: Adaptor Proteins, Signal Transducing; Apoptosis; Azacitidine; Breast; Breast Neoplasms; Carcinogenesis; Carrier Proteins; Cell Line, Tumor; Cell Proliferation; CpG Islands; Decitabine; DNA Demethylation; DNA Methylation; Down-Regulation; Enzyme Inhibitors; Epithelial-Mesenchymal Transition; Female; Flow Cytometry; Fluorescent Antibody Technique; Gene Expression Regulation, Neoplastic; Gene Silencing; Genes, Tumor Suppressor; Glycogen Synthase Kinase 3; Humans; Neoplasm Proteins; Promoter Regions, Genetic; Proto-Oncogene Proteins c-akt; Wnt Signaling Pathway | 2016 |
Chicken GHR natural antisense transcript regulates GHR mRNA in LMH cells.
Topics: Animals; Azacitidine; Cell Line; Chickens; Decitabine; DNA Methylation; Exons; Female; Gene Expression Regulation; Gene Order; Gene Silencing; Histones; Promoter Regions, Genetic; Receptors, Somatotropin; RNA, Antisense; RNA, Messenger; Transcription, Genetic | 2016 |
Better transplant outcome with pre-transplant marrow response after hypomethylating treatment in higher-risk MDS with excess blasts.
Topics: Azacitidine; Bone Marrow; Bone Marrow Transplantation; Combined Modality Therapy; Decitabine; DNA Methylation; Enzyme Inhibitors; Female; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Myelodysplastic Syndromes; Retrospective Studies; Risk Factors; Transplantation, Homologous; Treatment Outcome | 2017 |
Induced Human Decidual NK-Like Cells Improve Utero-Placental Perfusion in Mice.
Topics: Animals; Azacitidine; CD56 Antigen; Cell Hypoxia; Decidua; Decitabine; Female; Gene Expression Profiling; Gene Expression Regulation; Humans; Immunocompromised Host; Killer Cells, Natural; Mice; Placenta; Pregnancy; Transforming Growth Factor beta | 2016 |
Inhibition of DNA methyltransferases regulates cocaine self-administration by rats: a genome-wide DNA methylation study.
Topics: Animals; Azacitidine; Brain; Cocaine; Cocaine-Related Disorders; CpG Islands; Cytidine; Decitabine; DNA; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Epigenesis, Genetic; Genome; Male; Phosphatidylinositol 3-Kinases; Promoter Regions, Genetic; Rats; Rats, Wistar; Reinforcement, Psychology; Self Administration | 2017 |
DNA methylation promotes paired box 2 expression via myeloid zinc finger 1 in endometrial cancer.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cell Line, Tumor; Cell Movement; Cell Survival; Decitabine; DNA Methylation; Endometrial Neoplasms; Female; Gene Expression Regulation, Neoplastic; Humans; Kruppel-Like Transcription Factors; PAX2 Transcription Factor; Promoter Regions, Genetic; RNA, Small Interfering; Up-Regulation | 2016 |
Genome-wide methylation profiling of ovarian cancer patient-derived xenografts treated with the demethylating agent decitabine identifies novel epigenetically regulated genes and pathways.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Methylation; Epigenesis, Genetic; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Ovarian Neoplasms; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2016 |
Inducible expression of cancer-testis antigens in human prostate cancer.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Azacitidine; Biomarkers, Tumor; Cell Line, Tumor; Decitabine; Gene Expression Regulation, Neoplastic; Humans; Hydroxamic Acids; Indoles; Male; Membrane Proteins; Neoplasm Proteins; Neoplastic Cells, Circulating; Panobinostat; Prostatic Neoplasms; Repressor Proteins; Testis | 2016 |
Differential response to hypomethylating agents based on sex: a report on behalf of the MDS Clinical Research Consortium (MDS CRC).
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Disease Progression; DNA Methylation; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Sex Factors; Treatment Outcome | 2017 |
[Clinical Comparation of Two Kinds of Chemotherapy Regimen in the Treatment of Elderly MDS Patients with AML Transformed by Abnormal Proliferation of Bone Marrow].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Marrow; Cell Proliferation; Decitabine; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Neutropenia; Quality of Life; Treatment Outcome | 2016 |
Hypermethylation of the HIC1 promoter and aberrant expression of HIC1/SIRT1 contribute to the development of thyroid papillary carcinoma.
Topics: Adult; Apoptosis; Azacitidine; Carcinoma, Papillary; Cell Cycle Checkpoints; Cell Proliferation; Cellular Senescence; Decitabine; DNA Methylation; Enzyme Inhibitors; Female; Gene Expression Regulation, Neoplastic; Humans; Kruppel-Like Transcription Factors; Male; Middle Aged; Promoter Regions, Genetic; Sirtuin 1; Thyroid Neoplasms | 2016 |
[Analysis of the impact of decitabine treatment cycles on efficacy and safety in patients of myelodysplastic syndrome-refractory anemia with excess blasts].
Topics: Anemia, Refractory, with Excess of Blasts; Azacitidine; Blood Cell Count; China; Decitabine; Humans; Pancytopenia; Prevalence; Remission Induction; Retrospective Studies; Treatment Outcome | 2016 |
PD1 and PDL1 upregulation and survival after decitabine treatment in lower risk MDS.
Topics: Azacitidine; B7-H1 Antigen; Decitabine; Humans; Myelodysplastic Syndromes; Up-Regulation | 2017 |
Evidence for a role of decitabine in the treatment of myeloid sarcoma.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Sarcoma, Myeloid; Treatment Outcome | 2017 |
DSS1 promoter hypomethylation and overexpression predict poor prognosis in melanoma and squamous cell carcinoma patients.
Topics: Azacitidine; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cell Line, Tumor; Decitabine; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Epigenesis, Genetic; Female; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Male; Melanoma; Promoter Regions, Genetic; Proteasome Endopeptidase Complex; Skin Neoplasms; Time Factors; Treatment Outcome; Up-Regulation; Uveal Neoplasms | 2017 |
Altered expression of miRNAs and methylation of their promoters are correlated in neuroblastoma.
Topics: Animals; Azacitidine; Cell Line, Tumor; Cell Proliferation; Computational Biology; CpG Islands; Databases, Genetic; Decitabine; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Epigenesis, Genetic; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Genetic Predisposition to Disease; High-Throughput Nucleotide Sequencing; Humans; Kaplan-Meier Estimate; Mice; MicroRNAs; Neuroblastoma; Phenotype; Prognosis; Promoter Regions, Genetic; Protein Interaction Maps; Signal Transduction; Time Factors | 2016 |
Epigenetic silencing of TET2 and TET3 induces an EMT-like process in melanoma.
Topics: 5-Methylcytosine; Animals; Azacitidine; Cell Line, Tumor; Chromatin Immunoprecipitation; Decitabine; Dioxygenases; Disease Progression; DNA (Cytosine-5-)-Methyltransferases; DNA Demethylation; DNA Methylation; DNA Methyltransferase 3A; DNA-Binding Proteins; Down-Regulation; Epigenesis, Genetic; Epithelial-Mesenchymal Transition; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Male; Melanoma; Mice; Mice, Inbred C57BL; Microscopy, Fluorescence; Promoter Regions, Genetic; Proto-Oncogene Proteins; RNA, Small Interfering; Transforming Growth Factor beta1; Xenograft Model Antitumor Assays | 2017 |
Hypomethylation reduced the aggressive potential of human malignant mesothelioma cells.
Topics: Apoptosis; Azacitidine; Cell Line, Tumor; Cell Movement; Cell Survival; CpG Islands; Decitabine; Disease Progression; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Methyltransferase 3A; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Humans; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant | 2016 |
Decitabine as a First-Line Treatment for Older Adults Newly Diagnosed with Acute Myeloid Leukemia.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Methylation; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Republic of Korea; Retrospective Studies; Treatment Outcome | 2017 |
The Yin-Yang Dynamics of DNA Methylation Is the Key Regulator for Smooth Muscle Cell Phenotype Switch and Vascular Remodeling.
Topics: 5-Methylcytosine; Animals; Aorta; Aortic Diseases; Apolipoproteins E; Atherosclerosis; Azacitidine; Cell Dedifferentiation; Cell Movement; Cell Proliferation; Cells, Cultured; Decitabine; Diet, High-Fat; Dioxygenases; Disease Models, Animal; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA-Binding Proteins; Enzyme Inhibitors; Epigenesis, Genetic; Genetic Predisposition to Disease; Mice, Knockout; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Nuclear Proteins; Phenotype; Promoter Regions, Genetic; Proto-Oncogene Proteins; Rats; Signal Transduction; Time Factors; Trans-Activators; Vascular Remodeling | 2017 |
Epigenetic regulation of macrophage polarization and inflammation by DNA methylation in obesity.
Topics: Animals; Azacitidine; Cytokines; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA Methylation; Epigenesis, Genetic; Inflammation; Insulin Resistance; Macrophages; Male; Mice; Mice, Inbred C57BL; Obesity; PPAR gamma; Promoter Regions, Genetic | 2016 |
Determinants of orofacial clefting I: Effects of 5-Aza-2'-deoxycytidine on cellular processes and gene expression during development of the first branchial arch.
Topics: Animals; Apoptosis; Azacitidine; Branchial Region; Cell Proliferation; Cleft Palate; Decitabine; DNA Methylation; Embryonic Development; Female; Gene Expression Profiling; Gene Expression Regulation, Developmental; Gestational Age; Mice, Inbred ICR; Pregnancy | 2017 |
Determinants of orofacial clefting II: Effects of 5-Aza-2'-deoxycytidine on gene methylation during development of the first branchial arch.
Topics: Animals; Azacitidine; Branchial Region; Cleft Palate; Decitabine; DNA Methylation; Embryonic Development; Female; Gene Expression Profiling; Gene Expression Regulation, Developmental; Gestational Age; Mice, Inbred ICR; Pregnancy | 2017 |
ESE3 Inhibits Pancreatic Cancer Metastasis by Upregulating E-Cadherin.
Topics: Animals; Antigens, CD; Azacitidine; Cadherins; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Movement; Decitabine; Humans; Mice; Neoplasm Invasiveness; Neoplasm Metastasis; Pancreatic Neoplasms; Promoter Regions, Genetic; Transcription Factors; Tumor Suppressor Proteins; Up-Regulation | 2017 |
TET1 Depletion Induces Aberrant CpG Methylation in Colorectal Cancer Cells.
Topics: Azacitidine; Caco-2 Cells; Cell Line, Tumor; Colorectal Neoplasms; CpG Islands; Decitabine; DNA Methylation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Gene Silencing; HCT116 Cells; HT29 Cells; Humans; Mixed Function Oxygenases; Proto-Oncogene Proteins; RNA, Small Interfering | 2016 |
TP53 mutations predict decitabine-induced complete responses in patients with myelodysplastic syndromes.
Topics: Azacitidine; Cell Transformation, Neoplastic; Chromosome Aberrations; Decitabine; Humans; Leukemia, Myeloid, Acute; Mutation; Myelodysplastic Syndromes; Predictive Value of Tests; Recurrence; Remission Induction; Survival Analysis; Treatment Outcome; Tumor Suppressor Protein p53 | 2017 |
HIV-1 Latency-Reversing Agents Prostratin and Bryostatin-1 Induce Blood-Brain Barrier Disruption/Inflammation and Modulate Leukocyte Adhesion/Transmigration.
Topics: Acetamides; Azacitidine; Azepines; Blood-Brain Barrier; Bryostatins; Cell Adhesion; Cell Adhesion Molecules; Cell Movement; Cells, Cultured; Chemokine CCL2; Cytokines; Decitabine; HIV-1; Humans; Inflammation; Intercellular Adhesion Molecule-1; Leukocytes; Phorbol Esters; Quinazolines; Receptors, Cell Surface; Virus Latency | 2017 |
Haematological cancer: TP53 mutations sensitize to decitabine.
Topics: Azacitidine; Decitabine; Genes, p53; Hematologic Neoplasms; Humans; Mutation | 2017 |
Synergistic Cytotoxic Effect of L-Asparaginase Combined with Decitabine as a Demethylating Agent in Pediatric T-ALL, with Specific Epigenetic Signature.
Topics: Asparagine; Aspartate-Ammonia Ligase; Azacitidine; Cell Line, Tumor; Cell Survival; Decitabine; DNA Methylation; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Epigenesis, Genetic; Humans; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Transcriptome | 2016 |
Epigenetic Silencing of the Human 18 kDa Translocator Protein in a T Cell Leukemia Cell Line.
Topics: Azacitidine; Base Sequence; Cell Line, Tumor; Decitabine; DNA Methylation; Epigenesis, Genetic; Gene Silencing; Humans; Leukemia, T-Cell; Promoter Regions, Genetic; Receptors, GABA | 2017 |
[Reactivated Expression of MicroRNA-124 in Patients with Myelodysplastic Syndromes after Demethylating Therapy].
Topics: Aged; Azacitidine; Bone Marrow Cells; Cell Count; Decitabine; DNA Methylation; Humans; MicroRNAs; Myelodysplastic Syndromes; Real-Time Polymerase Chain Reaction | 2016 |
Activation of oncogenic pathways in classical Hodgkin lymphoma by decitabine: A rationale for combination with small molecular weight inhibitors.
Topics: Azacitidine; Cell Line, Tumor; Cell Proliferation; Cell Survival; Decitabine; DNA Methylation; Epigenesis, Genetic; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Hodgkin Disease; Humans; Oligonucleotide Array Sequence Analysis; Oncogenes; Signal Transduction; Small Molecule Libraries | 2017 |
Clinical and biological significance of miR-23b and miR-193a in human hepatocellular carcinoma.
Topics: Azacitidine; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Decitabine; Disease-Free Survival; DNA Methylation; Down-Regulation; Epigenesis, Genetic; Female; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Liver Neoplasms; Male; MicroRNAs | 2017 |
Aberrant promoter methylation of hOGG1 may be associated with increased risk of non-small cell lung cancer.
Topics: A549 Cells; Aged; Asian People; Azacitidine; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Chi-Square Distribution; China; Decitabine; DNA Glycosylases; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Female; Gene Frequency; Genetic Association Studies; Genetic Predisposition to Disease; Haplotypes; Humans; Logistic Models; Lung Neoplasms; Male; Middle Aged; Odds Ratio; Phenotype; Polymorphism, Single Nucleotide; Promoter Regions, Genetic; Risk Assessment; Risk Factors | 2017 |
Establishment and characterization of hypomethylating agent-resistant cell lines, MOLM/AZA-1 and MOLM/DEC-5.
Topics: Azacitidine; Cell Line, Tumor; Cytogenetics; Decitabine; DNA Methylation; Humans; Leukemia, Myeloid, Acute; Prognosis | 2017 |
Human papillomavirus type 16 E6 suppresses microRNA-23b expression in human cervical cancer cells through DNA methylation of the host gene C9orf3.
Topics: Aminopeptidases; Apoptosis; Azacitidine; Blotting, Western; Cell Line, Tumor; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Enzyme Inhibitors; Female; Gene Expression Regulation, Neoplastic; HCT116 Cells; Human papillomavirus 16; Humans; MicroRNAs; Oncogene Proteins, Viral; Promoter Regions, Genetic; Proto-Oncogene Proteins c-met; Repressor Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Uterine Cervical Neoplasms | 2017 |
Direct Gingival Fibroblast/Osteoblast Transdifferentiation via Epigenetics.
Topics: Animals; Azacitidine; Bone Morphogenetic Protein 2; Cell Line; Cell Transdifferentiation; Cells, Cultured; Chromatin Immunoprecipitation; CpG Islands; Decitabine; DNA Methylation; Epigenesis, Genetic; Female; Fibroblasts; Gingiva; Humans; Male; Mice; Middle Aged; Osteoblasts; Osteogenesis; Real-Time Polymerase Chain Reaction; Signal Transduction; Tissue Engineering; Wnt Signaling Pathway; X-Ray Microtomography | 2017 |
Local myogenic pulp-derived cell injection enhances craniofacial muscle regeneration in vivo.
Topics: Adolescent; Azacitidine; Bicuspid; Cell Differentiation; Cells, Cultured; Decitabine; Dental Pulp; DNA Methylation; Humans; Masseter Muscle; Muscle Development; Muscle, Skeletal; Regeneration; Young Adult | 2017 |
Chronic myelomonocytic leukemia with double-mutations in DNMT3A and FLT3-ITD treated with decitabine and sorafenib.
Topics: Azacitidine; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methyltransferase 3A; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Mutation; Niacinamide; Phenylurea Compounds; Sorafenib | 2017 |
Decitabine priming prior to low-dose chemotherapy improves patient outcomes in myelodysplastic syndromes-RAEB: a retrospective analysis vs. chemotherapy alone.
Topics: Aclarubicin; Adult; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Idarubicin; Karyotype; Male; Middle Aged; Mutation; Retrospective Studies | 2017 |
Epigenetic Alterations Affecting Transcription Factors and Signaling Pathways in Stromal Cells of Endometriosis.
Topics: Adult; Azacitidine; Brain-Derived Neurotrophic Factor; Chromatin; Co-Repressor Proteins; Death-Associated Protein Kinases; Decitabine; DNA Methylation; DNA-Binding Proteins; Endometriosis; Endometrium; Epigenesis, Genetic; Female; Gene Ontology; Humans; Middle Aged; Molecular Sequence Annotation; Neoplasm Proteins; Organic Anion Transporters; Primary Cell Culture; Proto-Oncogene Mas; Receptor Tyrosine Kinase-like Orphan Receptors; Sequence Analysis, RNA; Signal Transduction; Stromal Cells; Transcription Factors; Wnt-5a Protein | 2017 |
Histone demethylase UTX counteracts glucocorticoid deregulation of osteogenesis by modulating histone-dependent and -independent pathways.
Topics: Animals; Azacitidine; beta Catenin; Cells, Cultured; Chromatin Immunoprecipitation; Core Binding Factor Alpha 1 Subunit; Decitabine; DNA Methylation; Glucocorticoids; Histone Demethylases; Histones; Immunoblotting; Intercellular Signaling Peptides and Proteins; Male; Methylation; Mice; Osteogenesis; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Sp7 Transcription Factor | 2017 |
Epigenetic regulation of HGF/Met receptor axis is critical for the outgrowth of bone metastasis from breast carcinoma.
Topics: Animals; Azacitidine; Bone Neoplasms; Breast Neoplasms; Cadherins; Cell Line, Tumor; Cell Nucleus; Decitabine; DNA Methylation; Epigenesis, Genetic; Female; Gene Expression Regulation, Neoplastic; Hepatocyte Growth Factor; Humans; Mice; Mice, Nude; Neoplasm Metastasis; Nuclear Proteins; Proto-Oncogene Proteins c-met; Signal Transduction; Tumor Microenvironment; Tumor Suppressor Proteins | 2017 |
Methylation decreases the Bin1 tumor suppressor in ESCC and restoration by decitabine inhibits the epithelial mesenchymal transition.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Animals; Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cell Cycle; Cell Movement; Cell Proliferation; Decitabine; DNA Methylation; Epithelial-Mesenchymal Transition; Esophageal Neoplasms; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Humans; Lymphatic Metastasis; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Nuclear Proteins; Prognosis; Promoter Regions, Genetic; Signal Transduction; Survival Rate; Tumor Cells, Cultured; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2017 |
Cold acclimation alters DNA methylation patterns and confers tolerance to heat and increases growth rate in Brassica rapa.
Topics: Acclimatization; Azacitidine; Brassica rapa; Cold Temperature; Decitabine; DNA Methylation; Gene Expression Regulation, Plant; Plant Leaves; Plant Proteins; Thermotolerance | 2017 |
Simple in vitro generation of human leukocyte antigen-G-expressing T-regulatory cells through pharmacological hypomethylation for adoptive cellular immunotherapy against graft-versus-host disease.
Topics: Azacitidine; Cell Culture Techniques; Cell Engineering; Cells, Cultured; Decitabine; DNA Methylation; Gene Expression Regulation; Graft vs Host Disease; HLA-G Antigens; Humans; Immunotherapy, Adoptive; T-Lymphocytes, Regulatory | 2017 |
Topics: Animals; Azacitidine; Cell Degranulation; Cell Proliferation; Cells, Cultured; Decitabine; Dermatitis, Contact; Disease Models, Animal; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Methyltransferase 3A; Down-Regulation; Enzyme-Linked Immunosorbent Assay; Epigenesis, Genetic; Female; Fluorescent Antibody Technique; Immunoglobulin E; Interleukin-3; Mast Cells; Mastocytosis, Systemic; Mice; Mice, Knockout; Mutation; Oxazolone; Passive Cutaneous Anaphylaxis; ras GTPase-Activating Proteins; RNA Interference; RNA, Small Interfering | 2017 |
A high-throughput small molecule screen identifies synergism between DNA methylation and Aurora kinase pathways for X reactivation.
Topics: Animals; Aurora Kinase A; Aurora Kinase B; Aurora Kinases; Azacitidine; Azepines; Cell Line; Decitabine; DNA Methylation; Drug Evaluation, Preclinical; Drug Synergism; Female; Gene Knockdown Techniques; Genes, X-Linked; Green Fluorescent Proteins; High-Throughput Screening Assays; Mice; Mice, Transgenic; Piperazines; Pyrimidines; X Chromosome; X Chromosome Inactivation | 2016 |
Evidence for Selective Benefit of Sequential Treatment With Hypomethylating Agents in Patients With Myelodysplastic Syndrome.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Methylation; Female; Humans; Male; Myelodysplastic Syndromes; Risk; Treatment Failure; Treatment Outcome | 2017 |
Decitabine before Low-Dose Cytarabine-Based Chemotherapy Combined with Human Leukocyte Antigen-Mismatched Stem Cell Microtransplantation Improved Outcomes in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Histocompatibility; HLA Antigens; Humans; Karyotype; Leukemia, Myeloid, Acute; Middle Aged; Prospective Studies; Remission Induction; Stem Cell Transplantation | 2017 |
Chronic hypoxia upregulates DNA methyltransferase and represses large conductance Ca2+-activated K+ channel function in ovine uterine arteries.
Topics: Altitude; Animals; Azacitidine; Decitabine; DNA (Cytosine-5-)-Methyltransferases; Female; Gene Expression Regulation, Enzymologic; Hypoxia; Potassium Channels, Calcium-Activated; Pregnancy; Sheep; Uterine Artery; Vasodilation | 2017 |
A histone deacetylase inhibitor enhances expression of genes inhibiting Wnt pathway and augments activity of DNA demethylation reagent against nonsmall-cell lung cancer.
Topics: Acetylation; Amides; Animals; Apoptosis; Azacitidine; Biomarkers, Tumor; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Proliferation; Decitabine; DNA Methylation; Drug Synergism; Drug Therapy, Combination; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Histones; Humans; Immunoenzyme Techniques; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured; Wnt Signaling Pathway; Xenograft Model Antitumor Assays | 2017 |
Testis specific Y-like 5: gene expression, methylation and implications for drug sensitivity in prostate carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA Methylation; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Neoplasm Grading; Nuclear Proteins; Promoter Regions, Genetic; Prostatic Neoplasms; Signal Transduction | 2017 |
[Decitabine Enhances the Sensitivity of Leukemia Stem Cell to Allo-NK Cell-Mediated Killing].
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cell Line, Tumor; Cytotoxicity, Immunologic; Decitabine; Histocompatibility Antigens Class I; Humans; Killer Cells, Natural; Leukemia; Leukocytes, Mononuclear; NK Cell Lectin-Like Receptor Subfamily K; Stem Cells | 2017 |
Inhibin-α gene mutations and mRNA levels in human lymphoid and myeloid leukemia cells.
Topics: Apoptosis; Azacitidine; Cell Line, Tumor; Cell Proliferation; CpG Islands; Decitabine; DNA Methylation; Enzyme Inhibitors; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Inhibins; Leukemia, Lymphoid; Leukemia, Myeloid; Loss of Heterozygosity; Mutation; Promoter Regions, Genetic; RNA, Messenger | 2017 |
The formation and modification of chromatin-like structure of human parvovirus B19 regulate viral genome replication and RNA processing.
Topics: Antiviral Agents; Azacitidine; Chromatin; Decitabine; DNA (Cytosine-5-)-Methyltransferases; Genome, Viral; HEK293 Cells; Host-Pathogen Interactions; Humans; Parvovirus B19, Human; Plasmids; RNA Splicing; RNA, Viral; Viral Proteins; Virus Replication | 2017 |
Efficacy of single-agent decitabine in relapsed and refractory acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Combined Modality Therapy; Comorbidity; Decitabine; Drug Resistance, Neoplasm; Female; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Retrospective Studies; Transplantation, Homologous; Treatment Outcome; Young Adult | 2017 |
Gene expression analysis of decitabine treated AML: high impact of tumor suppressor gene expression changes.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Biomarkers, Tumor; Decitabine; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Genes, Tumor Suppressor; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Transcriptome; Treatment Outcome | 2017 |
[Predict response to decitabine in patients with myelodysplastic syndrome and related neoplasms].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Azacitidine; Chromosome Aberrations; Chromosomes, Human, Pair 7; Decitabine; Female; Humans; Karyotype; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Neoplasms; Remission Induction; Retrospective Studies; Young Adult | 2017 |
DNA methyltransferase 1 may be a therapy target for attenuating diabetic nephropathy and podocyte injury.
Topics: Albuminuria; Animals; Azacitidine; Binding Sites; Cell Line; Cell Movement; Cell Proliferation; Cytoprotection; Decitabine; Diabetes Mellitus; Diabetic Nephropathies; Disease Models, Animal; DNA (Cytosine-5-)-Methyltransferase 1; DNA Methylation; Enzyme Inhibitors; Epigenesis, Genetic; Male; Mice, Inbred C57BL; Podocytes; Promoter Regions, Genetic; RNA Interference; Sp1 Transcription Factor; Time Factors; Transcription Factor RelA; Transfection | 2017 |
Demethylating agent decitabine disrupts tumor-induced immune tolerance by depleting myeloid-derived suppressor cells.
Topics: Animals; Apoptosis; Azacitidine; Cell Line, Tumor; Decitabine; Humans; Immune Tolerance; Lymphocyte Activation; Mice; Myeloid-Derived Suppressor Cells; Neoplasms; T-Lymphocytes | 2017 |
Long-term exposure to estrogen enhances chemotherapeutic efficacy potentially through epigenetic mechanism in human breast cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Azacitidine; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Decitabine; DNA Methylation; Doxorubicin; Drug Synergism; Epigenesis, Genetic; Estradiol; Estrogens; Female; Gene Expression Regulation, Neoplastic; Humans; Hydroxamic Acids; MCF-7 Cells | 2017 |
Repression of DOK7 mediated by DNMT3A promotes the proliferation and invasion of KYSE410 and TE-12 ESCC cells.
Topics: Azacitidine; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Methyltransferase 3A; Epigenesis, Genetic; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Muscle Proteins; Neoplasm Invasiveness; Promoter Regions, Genetic | 2017 |
A comparison of toxicities in acute myeloid leukemia patients with and without renal impairment treated with decitabine.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Cohort Studies; Comorbidity; Decitabine; Female; Humans; Kidney Diseases; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Treatment Outcome | 2018 |
Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents.
Topics: Aged; Aged, 80 and over; Anemia; Antilymphocyte Serum; Antineoplastic Agents; Arsenic; Azacitidine; Chromosome Deletion; Chromosomes, Human, Pair 5; Cyclosporine; Cytarabine; Decitabine; Disease Progression; Enzyme Inhibitors; Erythrocyte Transfusion; Female; Hematinics; Humans; Hydroxyurea; Immunologic Factors; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Recurrence; Retreatment; Retrospective Studies; Risk Factors; Survival Rate; Thalidomide; Treatment Failure; Tretinoin; Valproic Acid | 2017 |
Demethylation of induced pluripotent stem cells from type 1 diabetic patients enhances differentiation into functional pancreatic β cells.
Topics: Animals; Azacitidine; Cadaver; Cell Differentiation; Cells, Cultured; Decitabine; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Humans; Hyperglycemia; Induced Pluripotent Stem Cells; Insulin; Insulin Secretion; Insulin-Secreting Cells; Mice, Knockout; Microscopy, Electron, Transmission; Organoids; Secretory Vesicles; Tissue Scaffolds; Transplantation, Heterologous; Transplantation, Heterotopic | 2017 |
Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach.
Topics: Aged; Antineoplastic Agents; Azacitidine; Cytarabine; Decitabine; Female; Humans; Karyotype; Leukemia, Myeloid, Acute; Logistic Models; Male; Middle Aged; Multivariate Analysis; Neoplasms, Second Primary; Proportional Hazards Models; Remission Induction; Retrospective Studies; Treatment Outcome | 2017 |
Synergistic inhibitory effects of deferasirox in combination with decitabine on leukemia cell lines SKM-1, THP-1, and K-562.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Benzoates; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Decitabine; Deferasirox; Drug Synergism; Gene Expression Regulation; Humans; Iron Chelating Agents; Leukemia; Reactive Oxygen Species; Triazoles | 2017 |
Two-color fluorescent cytosine extension assay for the determination of global DNA methylation.
Topics: Azacitidine; Biological Assay; Cytosine; Decitabine; DNA Methylation; DNA Restriction Enzymes; Fluorescence; Hep G2 Cells; Humans; Liver; Primary Cell Culture | 2017 |
Increasing TIMP3 expression by hypomethylating agents diminishes soluble MICA, MICB and ULBP2 shedding in acute myeloid leukemia, facilitating NK cell-mediated immune recognition.
Topics: ADAM17 Protein; Adult; Aged; Azacitidine; Cell Line, Tumor; Chromosome Aberrations; Decitabine; DNA Methylation; Female; Gene Expression Regulation, Leukemic; GPI-Linked Proteins; Histocompatibility Antigens Class I; Humans; Intercellular Signaling Peptides and Proteins; Killer Cells, Natural; Leukemia, Myeloid, Acute; Male; Middle Aged; NK Cell Lectin-Like Receptor Subfamily K; Prognosis; Tissue Inhibitor of Metalloproteinase-3 | 2017 |
Decitabine reverses TGF-β1-induced epithelial-mesenchymal transition in non-small-cell lung cancer by regulating miR-200/ZEB axis.
Topics: Animals; Antineoplastic Agents; Azacitidine; Carcinoma, Non-Small-Cell Lung; Cell Survival; Decitabine; Epithelial-Mesenchymal Transition; Female; Humans; Lung Neoplasms; Mice; Mice, Inbred NOD; Mice, SCID; MicroRNAs; Neoplasms, Experimental; Transforming Growth Factor beta1; Tumor Cells, Cultured; Zinc Finger E-box-Binding Homeobox 1 | 2017 |
Hypomethylation agent decitabine restores drug sensitivity by depressing P-glycoprotein activity through MAPK signaling pathway.
Topics: ATP Binding Cassette Transporter, Subfamily B; Azacitidine; Decitabine; Female; Humans; K562 Cells; Leukemia, Myeloid, Acute; Male; MAP Kinase Signaling System; MCF-7 Cells; Neoplasm Proteins | 2017 |
Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Biomarkers; Bone Marrow; Cytogenetic Analysis; Decitabine; Female; Humans; Leukemia, Erythroblastic, Acute; Male; Middle Aged; Proportional Hazards Models; Retrospective Studies; Survival Analysis; Treatment Outcome | 2017 |
Non-homologous end joining induced alterations in DNA methylation: A source of permanent epigenetic change.
Topics: Alleles; Azacitidine; Cell Line, Tumor; Cell Transformation, Neoplastic; CpG Islands; Decitabine; DNA Breaks, Double-Stranded; DNA End-Joining Repair; DNA Methylation; Doxycycline; Epigenesis, Genetic; Green Fluorescent Proteins; HeLa Cells; Humans; Neoplasms | 2017 |
DNA methylation directly downregulates human cathelicidin antimicrobial peptide gene (CAMP) promoter activity.
Topics: Adult; Aged; Aged, 80 and over; Antimicrobial Cationic Peptides; Azacitidine; Biomarkers; Cathelicidins; Cell Line, Tumor; CpG Islands; Decitabine; DNA Methylation; Female; Gene Expression Regulation; Genes, Reporter; Humans; Ki-67 Antigen; Male; Middle Aged; Promoter Regions, Genetic | 2017 |
Atrial fibrillation is associated with hypermethylation in human left atrium, and treatment with decitabine reduces atrial tachyarrhythmias in spontaneously hypertensive rats.
Topics: Aged; Animals; Atrial Fibrillation; Azacitidine; Case-Control Studies; Decitabine; DNA Methylation; Electrocardiography; Female; Heart Atria; Homeobox Protein PITX2; Homeodomain Proteins; Humans; Male; Middle Aged; Promoter Regions, Genetic; Rats, Inbred SHR; Superoxide Dismutase; Tachycardia; Transcription Factors | 2017 |
Synergistic anti-cancer effects of epigenetic drugs on medulloblastoma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cell Line, Tumor; Cerebellar Neoplasms; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; Drug Synergism; Enzyme Inhibitors; Histone Deacetylase 1; Histone Deacetylase Inhibitors; Humans; Medulloblastoma; Sesquiterpenes | 2017 |
Mechanistic insights into epigenetic modulation of ethanol consumption.
Topics: Action Potentials; Alcohol Drinking; Animals; Azacitidine; Behavior, Animal; Binge Drinking; Decitabine; DNA Modification Methylases; Dopaminergic Neurons; Enzyme Inhibitors; Epigenesis, Genetic; Ethanol; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Male; Mice, Inbred C57BL; Reward; Time Factors; Transcriptome; Ventral Tegmental Area; Vorinostat | 2017 |
Hypermethylation of miRNA-589 promoter leads to upregulation of HDAC5 which promotes malignancy in non-small cell lung cancer.
Topics: Aged; Animals; Azacitidine; Carcinogenesis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Decitabine; DNA Methylation; Epithelial-Mesenchymal Transition; Female; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Male; Mice; MicroRNAs; Middle Aged; Neoplasm Invasiveness; Promoter Regions, Genetic; Xenograft Model Antitumor Assays | 2017 |
Successful Management of Decitabine prior to Full-Dose Idarubicin and Cytarabine in the Treatment of Refractory/Recurrent Acute Myeloid Leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Combined Modality Therapy; Cytarabine; Decitabine; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Retrospective Studies; Stem Cell Transplantation; Transplantation, Homologous | 2017 |
Epigenetic dysregulation of ID4 predicts disease progression and treatment outcome in myeloid malignancies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Azacitidine; Case-Control Studies; Cell Proliferation; Decitabine; Disease Progression; DNA Methylation; Epigenesis, Genetic; Female; HL-60 Cells; Humans; Inhibitor of Differentiation Proteins; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Remission Induction; Signal Transduction; Survival Analysis | 2017 |
Synergistic activity of everolimus and 5-aza-2'-deoxycytidine in medullary thyroid carcinoma cell lines.
Topics: Azacitidine; Carcinoma, Neuroendocrine; Decitabine; Drug Synergism; Everolimus; Gene Expression Regulation, Neoplastic; Genome-Wide Association Study; Humans; Neoplasm Proteins; Thyroid Neoplasms | 2017 |
Treatment of Donor Cells and Reconstructed Embryos with a Combination of Trichostatin-A and 5-aza-2'-Deoxycytidine Improves the Developmental Competence and Quality of Buffalo Embryos Produced by Handmade Cloning and Alters Their Epigenetic Status and Gen
Topics: Animals; Azacitidine; Buffaloes; Cloning, Organism; Decitabine; Embryo, Mammalian; Epigenesis, Genetic; Female; Gene Expression Regulation, Developmental; Hydroxamic Acids; Male | 2017 |
Epigenetic silencing of triple negative breast cancer hallmarks by Withaferin A.
Topics: ADAM Proteins; Antineoplastic Agents; Azacitidine; Cell Line, Tumor; Cell Movement; Cytokine TWEAK; Decitabine; DNA Methylation; Female; Glutathione Transferase; Humans; Malate Dehydrogenase; MCF-7 Cells; Membrane Proteins; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Triple Negative Breast Neoplasms; Withanolides | 2017 |
[Effects of decitabine on proliferation capacity and TFPI-2 expression in leukemia K562 cells].
Topics: Apoptosis; Azacitidine; Cell Proliferation; Decitabine; Glycoproteins; Humans; K562 Cells; Leukemia | 2017 |
Genome-wide DNA methylation analysis of articular chondrocytes identifies TRAF1, CTGF, and CX3CL1 genes as hypomethylated in osteoarthritis.
Topics: Aged; Aged, 80 and over; Arthritis, Rheumatoid; Azacitidine; Cartilage, Articular; Cells, Cultured; Chemokine CX3CL1; Chondrocytes; Connective Tissue Growth Factor; Decitabine; DNA Methylation; Epigenesis, Genetic; Female; Humans; Ligands; Male; Middle Aged; Osteoarthritis; Protein Domains; RNA, Messenger; Sample Size; Sequence Analysis, DNA; Tibia; TNF Receptor-Associated Factor 1 | 2017 |
Outcome of elderly patients after failure to hypomethylating agents given as frontline therapy for acute myeloid leukemia: Single institution experience.
Topics: Aged; Aged, 80 and over; Azacitidine; Decitabine; Disease-Free Survival; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Rate; Treatment Failure | 2017 |
HLJ1 (DNAJB4) Gene Is a Novel Biomarker Candidate in Breast Cancer.
Topics: Adult; Azacitidine; Biomarkers, Tumor; Breast Neoplasms; Cell Line, Tumor; Cohort Studies; CpG Islands; Decitabine; DNA Methylation; Down-Regulation; Epigenesis, Genetic; Female; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Histone Deacetylase Inhibitors; HSP40 Heat-Shock Proteins; Humans; Hydroxamic Acids; Kaplan-Meier Estimate; Precision Medicine; RNA, Messenger | 2017 |
Epigenetic regulation of the circadian clock: role of 5-aza-2'-deoxycytidine.
Topics: ARNTL Transcription Factors; Azacitidine; Carrier Proteins; Cell Line, Tumor; Circadian Clocks; CpG Islands; Decitabine; DNA Methylation; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Humans; Intracellular Signaling Peptides and Proteins; Nerve Tissue Proteins; Period Circadian Proteins; Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2017 |
Validation of response assessment according to international consortium for MDS/MPN criteria in chronic myelomonocytic leukemia treated with hypomethylating agents.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Methylation; Female; Humans; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Myelodysplastic-Myeloproliferative Diseases; Survival Analysis; Treatment Outcome | 2017 |
Diverse expression patterns and tumorigenic role of neurotensin signaling components in colorectal cancer cells.
Topics: Adaptor Proteins, Vesicular Transport; Azacitidine; Carcinogenesis; Cell Movement; Cell Proliferation; Colorectal Neoplasms; Decitabine; DNA Methylation; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; HCT116 Cells; Humans; Promoter Regions, Genetic; Receptors, Neurotensin; Signal Transduction | 2017 |
Bioinformatic analysis of the effects and mechanisms of decitabine and cytarabine on acute myeloid leukemia.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Computational Biology; Cytarabine; Databases, Genetic; Decitabine; DNA Methylation; Epigenesis, Genetic; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Gene Ontology; Gene Regulatory Networks; Humans; Leukemia, Myeloid, Acute; Molecular Sequence Annotation | 2017 |
With me or against me: Tumor suppressor and drug resistance activities of SAMHD1.
Topics: Acute Disease; Animals; Antimetabolites, Antineoplastic; Autoimmune Diseases of the Nervous System; Azacitidine; Cell Line, Tumor; Cell Proliferation; Cytarabine; Decitabine; Drug Resistance; Humans; Leukemia, Myeloid; Monomeric GTP-Binding Proteins; Mutation; Nervous System Malformations; SAM Domain and HD Domain-Containing Protein 1; Survival Analysis; Treatment Outcome; Tumor Suppressor Proteins | 2017 |
MiR-424 functions as a tumor suppressor in glioma cells and is down-regulated by DNA methylation.
Topics: Adult; Aged; Apoptosis; Azacitidine; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; CpG Islands; Decitabine; DNA Methylation; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Glioma; Humans; MicroRNAs; Middle Aged; Oligodeoxyribonucleotides, Antisense; Time Factors; Transduction, Genetic | 2017 |
5azadC treatment upregulates miR-375 level and represses HPV16 E6 expression.
Topics: Azacitidine; Cell Line, Tumor; Decitabine; DNA Methylation; Female; Gene Expression Regulation, Viral; Human papillomavirus 16; Humans; MicroRNAs; Oncogene Proteins, Viral; Papillomavirus Infections; Repressor Proteins; Up-Regulation; Uterine Cervical Neoplasms | 2017 |
DNA Methylation Mediated Down-Regulation of miR-370 Regulates Cell Growth through Activation of the Wnt/β-Catenin Signaling Pathway in Human Osteosarcoma Cells.
Topics: Azacitidine; beta Catenin; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Decitabine; DNA Methylation; Forkhead Box Protein M1; Humans; MicroRNAs; Wnt Signaling Pathway | 2017 |
Methylation dictates PI.f-specific CYP19 transcription in human glial cells.
Topics: Analysis of Variance; Aromatase; Azacitidine; Brain; Cell Line, Tumor; Decitabine; DNA Methylation; Enzyme Inhibitors; Epigenesis, Genetic; Estrogens; Humans; Neuroglia; Promoter Regions, Genetic; Transcription, Genetic | 2017 |
Epigenetic Combination Therapy for Children With Secondary Myelodysplastic Syndrome (MDS)/Acute Myeloid Leukemia (AML) and Concurrent Solid Tumor Relapse.
Topics: Adolescent; Antineoplastic Agents; Azacitidine; Decitabine; Drug Therapy, Combination; Epigenesis, Genetic; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Neoplasms, Second Primary; Palliative Care; Quality of Life; Vorinostat | 2017 |
Epigenetically silenced PTPRO functions as a prognostic marker and tumor suppressor in human lung squamous cell carcinoma.
Topics: Adult; Aged; Animals; Azacitidine; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; CpG Islands; Decitabine; Disease Models, Animal; DNA Methylation; Epigenesis, Genetic; Exons; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Genes, Tumor Suppressor; Heterografts; Humans; Lung Neoplasms; Male; Mice; Middle Aged; Prognosis; Receptor-Like Protein Tyrosine Phosphatases, Class 3 | 2017 |
Multiple drug transporters mediate the placental transport of sulpiride.
Topics: ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; Azacitidine; Carrier Proteins; Cell Line; Decitabine; Female; Humans; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Organic Anion Transporters, Sodium-Independent; Organic Cation Transport Proteins; Placenta; Pregnancy; Solute Carrier Family 22 Member 5; Sulpiride; Symporters; Trophoblasts | 2017 |
[The Study of Decitabine Effect on the Endometrial Carcinoma Xenografted in Nude Mice.]
Topics: Animals; Apoptosis; Azacitidine; Cell Line, Tumor; Cisplatin; Decitabine; DNA Methylation; Endometrial Neoplasms; Female; Humans; Medroxyprogesterone Acetate; Mice; Mice, Nude; Promoter Regions, Genetic; RNA, Messenger; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2016 |
Hematopoietic Cell Transplantation in Myelodysplastic Syndromes after Treatment with Hypomethylating Agents.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Disease Progression; DNA Methylation; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Recurrence; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome | 2017 |
5-Aza-2'-deoxycytidine in the medial prefrontal cortex regulates alcohol-related behavior and Ntf3-TrkC expression in rats.
Topics: Alcohol Drinking; Animals; Anxiety; Azacitidine; Blotting, Western; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methyltransferase 3A; DNA Methyltransferase 3B; Down-Regulation; Enzyme Inhibitors; Gene Expression; Male; Motor Activity; Neurotrophin 3; Prefrontal Cortex; Rats, Sprague-Dawley; Receptor, trkC; Reverse Transcriptase Polymerase Chain Reaction | 2017 |
Hypomethylating agent therapy use and survival in older patients with chronic myelomonocytic leukemia in the United States: A large population-based study.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Case-Control Studies; Decitabine; Female; Humans; Kaplan-Meier Estimate; Leukemia, Myelomonocytic, Chronic; Male; Medicare; Propensity Score; Proportional Hazards Models; Retrospective Studies; SEER Program; United States | 2017 |
5‑aza‑2'‑deoxycytidine promotes migration of acute monocytic leukemia cells via activation of CCL2‑CCR2‑ERK signaling pathway.
Topics: Azacitidine; Cell Differentiation; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chemokine CCL2; Decitabine; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Humans; Leukemia, Monocytic, Acute; MAP Kinase Signaling System; Receptors, CCR2 | 2017 |
Tumor antigen PRAME is up-regulated by MZF1 in cooperation with DNA hypomethylation in melanoma cells.
Topics: Antigens, Neoplasm; Azacitidine; Binding Sites; Cell Proliferation; CpG Islands; Decitabine; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; HCT116 Cells; Humans; Kruppel-Like Transcription Factors; Melanoma; Promoter Regions, Genetic; Protein Binding; RNA Interference; Signal Transduction; Skin Neoplasms; Transcription, Genetic; Transfection; Up-Regulation | 2017 |
DNA methylation inhibitor causes cell growth retardation and gene expression changes in feline lymphoma cells.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Cats; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Decitabine; DNA Methylation; DNA Replication; Gene Expression Regulation, Neoplastic; Promoter Regions, Genetic; Transcription Factors | 2017 |
Expansion of cancer germline antigen-specific cytotoxic T lymphocytes for immunotherapy.
Topics: Antigens, Neoplasm; Azacitidine; Decitabine; Dendritic Cells; Epitopes; Germ Cells; Humans; Immunotherapy, Adoptive; Interferon-gamma; Interleukins; Melanoma-Specific Antigens; Membrane Proteins; Neoplasm Proteins; Neoplasms; T-Lymphocytes, Cytotoxic | 2017 |
Combined epigenetic and differentiation-based treatment inhibits neuroblastoma tumor growth and links HIF2α to tumor suppression.
Topics: Animals; Azacitidine; Basic Helix-Loop-Helix Transcription Factors; Cell Proliferation; Chemotherapy, Adjuvant; Decitabine; Female; Genetic Therapy; Hypoxia-Inducible Factor 1, alpha Subunit; Mice; Mice, Nude; Neuroblastoma; Tretinoin | 2017 |
DNA methylation protects against cisplatin-induced kidney injury by regulating specific genes, including interferon regulatory factor 8.
Topics: Acute Kidney Injury; Animals; Antineoplastic Agents; Apoptosis; Azacitidine; Cell Line; Cisplatin; Decitabine; Disease Models, Animal; DNA (Cytosine-5-)-Methyltransferase 1; DNA Methylation; Epigenesis, Genetic; Gene Knockdown Techniques; Genome; Humans; Interferon Regulatory Factors; Kidney Tubules, Proximal; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Neoplasms; Rats; Sequence Analysis, DNA | 2017 |
Decitabine Priming Enhances Mucin 1 Inhibition Mediated Disruption of Redox Homeostasis in Cutaneous T-Cell Lymphoma.
Topics: Animals; Apoptosis; Azacitidine; Cell Line, Tumor; Decitabine; Gene Expression Regulation, Neoplastic; Humans; Lymphoma, T-Cell, Cutaneous; Mice; Mucin-1; Oxidation-Reduction; Oxidative Stress; Reactive Oxygen Species; Xenograft Model Antitumor Assays | 2017 |
Low-dose decitabine enhances chidamide-induced apoptosis in adult acute lymphoblast leukemia, especially for p16-deleted patients through DNA damage.
Topics: Adolescent; Adult; Aminopyridines; Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Benzamides; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p16; Decitabine; DNA Damage; Female; Gene Deletion; Histone Deacetylase Inhibitors; Humans; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Young Adult | 2017 |
Untargeted DNA-Demethylation Therapy Neither Prevents Nor Attenuates Ischemia-Reperfusion-Induced Renal Fibrosis.
Topics: Animals; Azacitidine; Collagen Type I; Cytokines; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA Methylation; Enzyme Inhibitors; Fibrosis; Kidney; Kidney Diseases; Kidney Tubules; Male; Mice; Mice, Inbred C57BL; Reperfusion Injury; Transforming Growth Factor beta | 2017 |
First-line Therapeutic Strategies for Myelodysplastic Syndromes.
Topics: Algorithms; Azacitidine; Decitabine; Enzyme Inhibitors; Erythrocyte Transfusion; Erythropoietin; Hematopoietic Stem Cell Transplantation; Humans; Myelodysplastic Syndromes; Risk Factors; Transplantation, Homologous | 2017 |
The oligodendrocyte lineage transcription factor 2 (OLIG2) is epigenetically regulated in acute myeloid leukemia.
Topics: Acute Disease; Azacitidine; Blotting, Western; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Decitabine; DNA Methylation; Epigenesis, Genetic; Gene Expression Regulation, Leukemic; HL-60 Cells; Humans; Jurkat Cells; Leukemia, Myeloid; Oligodendrocyte Transcription Factor 2; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; U937 Cells | 2017 |
Silencing of metallothionein 1A gene in melanoma.
Topics: 5' Untranslated Regions; Adolescent; Adult; Aged; Aged, 80 and over; Azacitidine; Cell Line, Tumor; Child; CpG Islands; Decitabine; DNA Methylation; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Male; Melanocytes; Melanoma; Metallothionein; Middle Aged; Nevus, Pigmented; Real-Time Polymerase Chain Reaction; Skin Neoplasms; Young Adult | 2017 |
Epigenetic silencing of LPP/miR-28 in multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Cell Line, Tumor; CpG Islands; Cytoskeletal Proteins; Decitabine; DNA Methylation; Epigenesis, Genetic; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; LIM Domain Proteins; Male; MicroRNAs; Middle Aged; Multiple Myeloma; Promoter Regions, Genetic | 2018 |
[The clinical safety and efficacy of low dose subcutaneous decitabine in treating acute myeloid leukemia and intermediate- or higer-risk myelodysplastic syndromes in the elderly patients].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Decitabine; Humans; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Patients; Remission Induction; Retrospective Studies; Treatment Outcome | 2017 |
Induction of senescence in cancer cells by 5'-Aza-2'-deoxycytidine: Bioinformatics and experimental insights to its targets.
Topics: Antineoplastic Agents; Azacitidine; Cell Death; Cell Line, Tumor; Cell Proliferation; Cellular Senescence; Computational Biology; Decitabine; Dose-Response Relationship, Drug; Humans; Neoplasms; Signal Transduction; Structure-Activity Relationship; Tumor Suppressor Protein p53 | 2017 |
TGF-β-mediated repression of MST1 by DNMT1 promotes glioma malignancy.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; Down-Regulation; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Glioma; Hepatocyte Growth Factor; Humans; Neoplasm Invasiveness; Proto-Oncogene Proteins; Transforming Growth Factor beta; Up-Regulation | 2017 |
PAQR3 overexpression suppresses the aggressive phenotype of esophageal squamous cell carcinoma cells via inhibition of ERK signaling.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Decitabine; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Gene Expression Regulation, Neoplastic; Humans; Intracellular Signaling Peptides and Proteins; Male; MAP Kinase Signaling System; Membrane Proteins; Mice; Mice, Nude; Middle Aged; Neoplasm Staging; Phenotype; RNA, Messenger; Signal Transduction | 2017 |
Early treatment initiation in lower-risk myelodysplastic syndromes produces an earlier and higher rate of transfusion independence.
Topics: Aged; Aged, 80 and over; Azacitidine; Blood Transfusion; Decitabine; Female; Hematinics; Humans; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Secondary Prevention; Thalidomide; Time Factors | 2017 |
Benefits of hypomethylating therapy in IPSS lower-risk myelodysplastic syndrome patients: A retrospective multicenter case series study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Retrospective Studies; Risk Assessment; Survival Rate; Young Adult | 2017 |
Time to response and survival in hypomethylating agent-treated acute myeloid leukemia.
Topics: Age Factors; Aged; Aged, 80 and over; Azacitidine; Decitabine; Disease-Free Survival; DNA Methylation; Enzyme Inhibitors; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Sex Factors; Survival Analysis; Time Factors; Treatment Outcome | 2018 |
Indirect regulation of CYP2C19 gene expression via DNA methylation.
Topics: Azacitidine; Constitutive Androstane Receptor; Cytochrome P-450 CYP2C19; Decitabine; DNA Methylation; Gene Expression Regulation, Enzymologic; Hep G2 Cells; Humans; Receptors, Cytoplasmic and Nuclear; Response Elements; Transcription, Genetic | 2018 |
Methylation of mitochondrial DNA displacement loop region regulates mitochondrial copy number in colorectal cancer.
Topics: Apoptosis; Azacitidine; Base Sequence; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colorectal Neoplasms; CpG Islands; Decitabine; DNA Copy Number Variations; DNA Methylation; DNA, Mitochondrial; Epigenesis, Genetic; Humans; Promoter Regions, Genetic; Regulatory Sequences, Nucleic Acid | 2017 |
Tobacco-Specific Carcinogens Induce Hypermethylation, DNA Adducts, and DNA Damage in Bladder Cancer.
Topics: Azacitidine; Benzo(a)pyrene; Biomarkers, Tumor; Butanones; Carcinogens; Cell Line, Tumor; Cohort Studies; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA Adducts; DNA Damage; DNA Methylation; Early Detection of Cancer; Female; Humans; Male; Metabolome; Metabolomics; Mutagens; Neoplasm Grading; Nicotiana; Nitrosamines; Polycyclic Aromatic Hydrocarbons; Risk Assessment; Smoking; Tobacco Products; Urinary Bladder Neoplasms | 2017 |
5-Aza-2'-deoxycytidine, a DNA methylation inhibitor, induces cytotoxicity, cell cycle dynamics and alters expression of DNA methyltransferase 1 and 3A in mouse hippocampus-derived neuronal HT22 cells.
Topics: Animals; Apoptosis; Azacitidine; Cell Cycle; Cell Line; Cell Proliferation; Cell Survival; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Methyltransferase 3A; Gene Expression Regulation, Enzymologic; Hippocampus; Mice | 2017 |
MN1 overexpression is driven by loss of DNMT3B methylation activity in inv(16) pediatric AML.
Topics: Adolescent; Azacitidine; Carcinogenesis; Cell Line, Tumor; Child; Child, Preschool; CpG Islands; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Methyltransferase 3B; Epigenesis, Genetic; Exons; Female; Gene Expression Regulation, Leukemic; Humans; Infant; Infant, Newborn; Leukemia, Myeloid, Acute; Male; Nucleic Acid Hybridization; Oligonucleotide Array Sequence Analysis; Oncogene Proteins, Fusion; Promoter Regions, Genetic; Trans-Activators; Tumor Suppressor Proteins | 2018 |
Durable remission with salvage decitabine and donor lymphocyte infusion (DLI) for relapsed early T-cell precursor ALL.
Topics: Aged; Azacitidine; Decitabine; Humans; Lymphocyte Transfusion; Male; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Remission Induction; Salvage Therapy; Treatment Outcome | 2017 |
5-Aza-2'-deoxycytidine induces human Tenon's capsule fibroblasts differentiation and fibrosis by up-regulating TGF-β type I receptor.
Topics: Adult; Azacitidine; Cell Count; Cell Differentiation; Cells, Cultured; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Methyltransferase 3A; Enzyme Inhibitors; Female; Fibroblasts; Fibrosis; Humans; Male; Middle Aged; Protein Serine-Threonine Kinases; Receptor, Transforming Growth Factor-beta Type I; Receptors, Transforming Growth Factor beta; Repressor Proteins; Tenon Capsule; Transforming Growth Factor beta; Up-Regulation | 2017 |
Hypermethylation of WIF1 and its inhibitory role in the tumor growth of endometrial adenocarcinoma.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adult; Aged; Animals; Azacitidine; Cell Line, Tumor; Cell Proliferation; CpG Islands; Decitabine; DNA Methylation; DNA, Neoplasm; Down-Regulation; Endometrial Neoplasms; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Mice; Mice, Nude; Middle Aged; Prognosis; Proto-Oncogene Proteins c-myc; Repressor Proteins | 2017 |
Bone-targeting nanoparticle to co-deliver decitabine and arsenic trioxide for effective therapy of myelodysplastic syndrome with low systemic toxicity.
Topics: Alendronate; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Azacitidine; Bone and Bones; Bone Marrow Cells; Cell Survival; Cells, Cultured; Decitabine; Mice, Transgenic; Myelodysplastic Syndromes; Nanoparticles; Oxides; Phosphatidylethanolamines; Polyethylene Glycols; Tissue Distribution | 2017 |
Decitabine for relapsed acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation.
Topics: Adolescent; Adult; Antimetabolites, Antineoplastic; Azacitidine; Child; Combined Modality Therapy; Decitabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Neoplasm Recurrence, Local; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Survival Analysis; Treatment Outcome; Young Adult | 2017 |
Patterns of infectious complications in acute myeloid leukemia and myelodysplastic syndromes patients treated with 10-day decitabine regimen.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Drug Administration Schedule; Female; Fever; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Humans; Incidence; Leukemia, Myeloid, Acute; Male; Middle Aged; Missouri; Mycoses; Myelodysplastic Syndromes; Neutropenia; Opportunistic Infections; Retrospective Studies; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Virus Diseases | 2017 |
Successful eltrombopag treatment of severe refractory thrombocytopenia in chronic myelomonocytic leukemia: Two cases reports: A CARE-compliant article.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Benzoates; Decitabine; Dioxygenases; DNA-Binding Proteins; Drug Monitoring; Female; Hematologic Agents; Humans; Hydrazines; Leukemia, Myelomonocytic, Chronic; Middle Aged; Mutation; Nuclear Proteins; Platelet Count; Proto-Oncogene Proteins; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Ribonucleoproteins; Serine-Arginine Splicing Factors; Thrombocytopenia; Thrombopoietin; Treatment Outcome | 2017 |
[Clinical Observation of Therapeutic Regimen Consisted of Decitabine Combined with Low-Dose IA Regimen for Myelodysplastic Syndrome-EB].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Decitabine; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Quality of Life; Retrospective Studies; Treatment Outcome | 2017 |
[Clinical Efficacy of Low-dose Decitabine Combined with CAG Regimen in Patients with Myelodysplastic Syndrome-refractory Anemia with Excess Blasts(MDS-RAEB)].
Topics: Aclarubicin; Anemia, Refractory, with Excess of Blasts; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Granulocyte Colony-Stimulating Factor; Humans; Myelodysplastic Syndromes; Retrospective Studies; Treatment Outcome | 2017 |
Analyzing epigenetic control of galectin expression indicates silencing of galectin-12 by promoter methylation in colorectal cancer.
Topics: Acetylation; Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cohort Studies; Colorectal Neoplasms; Decitabine; DNA Methylation; Down-Regulation; Epigenesis, Genetic; Epithelial Cells; Female; Galectins; Histones; Humans; Male; Middle Aged; Neoplasm Staging; Promoter Regions, Genetic; Protein Isoforms | 2017 |
Aberrant hypermethylation of the HOXD10 gene in papillary thyroid cancer with BRAFV600E mutation.
Topics: Apoptosis; Azacitidine; Carcinoma, Papillary; Cell Line, Tumor; Cell Movement; Decitabine; DNA Methylation; Down-Regulation; Epigenesis, Genetic; Female; Gene Expression Regulation, Neoplastic; Homeodomain Proteins; Humans; Male; Mutation; Neoplasm Invasiveness; Neoplasm Staging; Promoter Regions, Genetic; Proto-Oncogene Proteins B-raf; Thyroid Cancer, Papillary; Thyroid Neoplasms; Transcription Factors | 2018 |
Synergistic effects of the combination of 5-Aza‑CdR and suberoylanilide hydroxamic acid on the anticancer property of pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Cyclin-Dependent Kinase Inhibitor p16; Decitabine; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Hydroxamic Acids; Pancreatic Neoplasms; Signal Transduction; Tumor Suppressor Protein p53; Up-Regulation; Vorinostat | 2018 |
Decitabine-Induced Changes in Human Myelodysplastic Syndrome Cell Line SKM-1 Are Mediated by FOXO3A Activation.
Topics: Antimetabolites, Antineoplastic; Autophagy; Azacitidine; Cell Cycle Checkpoints; Cell Differentiation; Cell Line, Tumor; Decitabine; Epigenetic Repression; Forkhead Box Protein O3; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Myeloid, Acute; Monocytes; Myelodysplastic Syndromes; Phosphorylation | 2017 |
5-Aza-2'-deoxycytidine protects against emphysema in mice via suppressing p16
Topics: Animals; Azacitidine; Cells, Cultured; Cigarette Smoking; Cyclin-Dependent Kinase Inhibitor p16; Cytoprotection; Decitabine; Disease Models, Animal; Down-Regulation; Endothelial Progenitor Cells; Lung; Male; Mice, Inbred C57BL; Pulmonary Emphysema; Signal Transduction; Smoke | 2017 |
Down-regulation of p16 and MGMT promotes the anti-proliferative and pro-apoptotic effects of 5-Aza-dC and radiation on cervical cancer cells.
Topics: Apoptosis; Azacitidine; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p16; Cyclin-Dependent Kinase Inhibitor p18; Decitabine; DNA Modification Methylases; DNA Repair Enzymes; Down-Regulation; Female; Humans; Tumor Suppressor Proteins; Uterine Cervical Neoplasms; X-Rays | 2017 |
Treatment of relapsed AML and MDS after allogeneic stem cell transplantation with decitabine and DLI-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Lymphocyte Transfusion; Male; Middle Aged; Myelodysplastic Syndromes; Recurrence; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Analysis; Transplantation, Homologous; Treatment Outcome | 2018 |
MMP9 gene expression regulation by intragenic epigenetic modifications in breast cancer.
Topics: Azacitidine; Breast Neoplasms; Cell Line, Tumor; CpG Islands; Decitabine; DNA Methylation; Epigenesis, Genetic; Female; Gene Expression Regulation, Neoplastic; Humans; Matrix Metalloproteinase 9; MCF-7 Cells; Neoplasm Metastasis; Promoter Regions, Genetic; Sequence Analysis, DNA | 2018 |
Monophosphorylation by deoxycytidine kinase affects apparent cellular uptake of decitabine in HCT116 colon cancer cells.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Camptothecin; Colonic Neoplasms; Cytarabine; Decitabine; Deoxycytidine; Deoxycytidine Kinase; Equilibrative Nucleoside Transporter 1; Etoposide; Gemcitabine; HCT116 Cells; Humans; Irinotecan; Phosphorylation | 2017 |
The DNA-methyltransferase inhibitor 5-aza-2-deoxycytidine affects Humicola grisea enzyme activities and the glucose-mediated gene repression.
Topics: Azacitidine; Catabolite Repression; Cellulase; Decitabine; Enzyme Inhibitors; Enzymes; Gene Expression; Glucose; Sordariales; Triticum; Xylosidases | 2018 |
Development and in vitro evaluations of new decitabine nanocarriers for the treatment of acute myeloid leukemia.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Azacitidine; Biological Availability; Caco-2 Cells; Cell Line, Tumor; Decitabine; Drug Carriers; Drug Liberation; Drug Resistance, Neoplasm; Drug Stability; Ethylene Glycols; Humans; Leukemia, Myeloid, Acute; Lipids; Nanocapsules; Polysorbates | 2017 |
Hypermethylation of the SPARC promoter and its prognostic value for prostate cancer.
Topics: Azacitidine; Biomarkers, Tumor; Cell Line, Tumor; Cell Proliferation; Decitabine; DNA Methylation; Down-Regulation; Gene Expression Regulation, Neoplastic; Humans; Male; Neoplasm Grading; Osteonectin; Prognosis; Promoter Regions, Genetic; Prostatic Neoplasms; Survival Analysis | 2018 |
Treatment with a DNA methyltransferase inhibitor feminizes zebrafish and induces long-term expression changes in the gonads.
Topics: Animals; Azacitidine; Decitabine; DNA Modification Methylases; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Feminization; Male; Ovary; Sex Ratio; Transcriptome; Zebrafish | 2017 |
No benefit of hypomethylating agents compared to supportive care for higher risk myelodysplastic syndrome.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Azacitidine; Databases, Factual; Decitabine; Disease Progression; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Palliative Care; Republic of Korea; Retrospective Studies; Risk Assessment; Risk Factors; Time Factors; Transplantation, Homologous; Treatment Outcome; Young Adult | 2018 |
Decitabine, a DNA-demethylating agent, promotes differentiation via NOTCH1 signaling and alters immune-related pathways in muscle-invasive bladder cancer.
Topics: Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Azacitidine; beta-Galactosidase; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p16; Decitabine; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Humans; Interleukin-6; Keratin-5; Muscle, Smooth; Neoplasm Invasiveness; Receptor, Notch1; Signal Transduction; Treatment Outcome; Urinary Bladder Neoplasms | 2017 |
Long-term survival of older patients with MDS treated with HMA therapy without subsequent stem cell transplantation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Decitabine; DNA Methylation; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Retrospective Studies; Stem Cell Transplantation; Survival Rate; Survivors | 2018 |
[Curative Effect of Decitabine Combined with IAG Regimen for Senile Patients with Myelodysplastic Syndrome (MDS) Transformed Acute Myeloid Leukemia].
Topics: Alzheimer Disease; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Treatment Outcome | 2017 |
A mixed modality approach towards Xi reactivation for Rett syndrome and other X-linked disorders.
Topics: Animals; Azacitidine; Brain; Cell Line; Decitabine; DNA Methylation; Female; Gene Expression Profiling; Genetic Therapy; Male; Methyl-CpG-Binding Protein 2; Mice; Oligonucleotides, Antisense; Rett Syndrome; X Chromosome Inactivation | 2018 |
Immunotherapy of Myelodysplastic Syndrome: You Can Run, but You Can't Hide.
Topics: Antigens, Neoplasm; Azacitidine; Cell Line, Tumor; Decitabine; Humans; Immunotherapy; Male; Membrane Proteins; Myelodysplastic Syndromes; T-Lymphocytes; Vaccination | 2018 |
Decitabine and Melphalan Fail to Reactivate p73 in p53 Deficient Myeloma Cells.
Topics: Azacitidine; Base Sequence; Cell Line, Tumor; Cisplatin; CpG Islands; Decitabine; DNA Methylation; Gene Expression Regulation, Neoplastic; Humans; Melphalan; Multiple Myeloma; Tumor Protein p73; Tumor Suppressor Protein p53 | 2017 |
Topics: Adult; Aged; Azacitidine; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cell Line, Tumor; Decitabine; DNA Methylation; Down-Regulation; Early Detection of Cancer; Epigenesis, Genetic; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Promoter Regions, Genetic; Trefoil Factor-1 | 2017 |
Tumor suppressor activity of miR-451: Identification of CARF as a new target.
Topics: A549 Cells; Animals; Azacitidine; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Decitabine; DNA-Binding Proteins; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Mice; MicroRNAs; Neoplasm Transplantation; Neoplasms; Oligonucleotide Array Sequence Analysis; Signal Transduction; Transcription Factors; Up-Regulation | 2018 |
Outcomes with lower intensity therapy in TP53-mutated acute myeloid leukemia.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cladribine; Cytarabine; Decitabine; Drug Administration Schedule; Humans; Leukemia, Myeloid; Middle Aged; Mutation; Remission Induction; Survival Analysis; Treatment Outcome; Tumor Suppressor Protein p53 | 2018 |
A new option for remission induction in acute myeloid leukaemia.
Topics: Aged; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Decitabine; Humans; Leukemia, Myeloid, Acute; Remission Induction; Sulfonamides | 2018 |
WT1 mRNA level reflects disease changes and progression of myelodysplastic syndromes patients with 'stable disease'.
Topics: Adult; Aged; Azacitidine; Decitabine; Disease Progression; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; RNA, Messenger; WT1 Proteins | 2019 |
Decitabine augments cytotoxicity of cisplatin and doxorubicin to bladder cancer cells by activating hippo pathway through RASSF1A.
Topics: Azacitidine; Cisplatin; Cytotoxins; Decitabine; Doxorubicin; HeLa Cells; Hippo Signaling Pathway; Humans; Protein Serine-Threonine Kinases; Signal Transduction; Tumor Suppressor Proteins; Urinary Bladder Neoplasms | 2018 |
Sequential decitabine and carboplatin treatment increases the DNA repair protein XPC, increases apoptosis and decreases proliferation in melanoma.
Topics: Antineoplastic Agents; Apoptosis; Azacitidine; Carboplatin; Cell Line, Tumor; Cell Proliferation; CpG Islands; Decitabine; DNA Damage; DNA Methylation; DNA Repair; DNA-Binding Proteins; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Melanoma; Promoter Regions, Genetic | 2018 |
[Clinical Efficacy of Decitabine Combined with or without Cytarabine-based Low Dose Regimen for Senile patients with Acute Myeloid Leukemia].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Remission Induction; Retrospective Studies; Treatment Outcome | 2018 |
Epigenetic regulation by CpG methylation splits strong from retarded IFNγ-induced IL-18BP in epithelial versus monocytic cells.
Topics: Acetylation; Azacitidine; Cell Line; CpG Islands; Decitabine; DNA Methylation; Epigenesis, Genetic; Epithelial Cells; Histones; Humans; Intercellular Signaling Peptides and Proteins; Interferon-gamma; Lysine; Methyl-CpG-Binding Protein 2; Monocytes; Promoter Regions, Genetic; Protein Binding; RNA Polymerase II; Transcription Initiation Site; Transcription, Genetic | 2018 |
Combinatorial strategy of epigenetic and hormonal therapies: A novel promising approach for treating advanced prostate cancer.
Topics: Anticarcinogenic Agents; Azacitidine; beta Catenin; Caspase 3; Cell Proliferation; Cyclin D1; Decitabine; Disease Progression; Epigenesis, Genetic; Estrogen Receptor beta; Hormones; Humans; Hydroxamic Acids; Male; Methylation; Nitriles; Propionates; Prostate; Prostatic Neoplasms; Vascular Endothelial Growth Factor A | 2018 |
Combined Treatment with Valproic Acid and 5-Aza-2'-Deoxycytidine Synergistically Inhibits Human Clear Cell Renal Cell Carcinoma Growth and Migration.
Topics: Apoptosis; Azacitidine; Carcinoma, Renal Cell; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cell Proliferation; Decitabine; Drug Synergism; G1 Phase; Humans; Kidney Neoplasms; Valproic Acid | 2018 |
Intestinal absorption and activation of decitabine amino acid ester prodrugs mediated by peptide transporter PEPT1 and enterocyte enzymes.
Topics: Administration, Oral; Amino Acids; Animals; Azacitidine; Biological Availability; Cell Membrane Permeability; Decitabine; DNA Modification Methylases; Enterocytes; Enzyme Inhibitors; Esters; Intestinal Absorption; Intestinal Mucosa; Intestines; Male; Models, Animal; Peptide Transporter 1; Prodrugs; Rats; Rats, Sprague-Dawley | 2018 |
Expression of delta-like 3 is downregulated by aberrant DNA methylation and histone modification in hepatocellular carcinoma.
Topics: Acetylation; Azacitidine; Carcinoma, Hepatocellular; Cell Line, Tumor; Decitabine; DNA Methylation; Down-Regulation; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Histones; Humans; Intracellular Signaling Peptides and Proteins; Liver Neoplasms; Membrane Proteins; Promoter Regions, Genetic | 2018 |
Integrated data analysis identifies potential inducers and pathways during the endothelial differentiation of bone-marrow stromal cells by DNA methyltransferase inhibitor, 5-aza-2'-deoxycytidine.
Topics: Angiogenesis Inducing Agents; Azacitidine; Cell Differentiation; Cells, Cultured; Computational Biology; Decitabine; DNA Methylation; Endothelial Cells; Epigenesis, Genetic; Gene Expression Regulation; Gene Regulatory Networks; Humans; Mesenchymal Stem Cells | 2018 |
Suberanilohydroxamic acid prevents TGF-β1-induced COX-2 repression in human lung fibroblasts post-transcriptionally by TIA-1 downregulation.
Topics: Adenosine; Azacitidine; Cell Line; Cyclooxygenase 1; Cyclooxygenase 2; Decitabine; DNA Methylation; Enhancer of Zeste Homolog 2 Protein; Fibroblasts; Gene Expression Regulation; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Lung; Promoter Regions, Genetic; T-Cell Intracellular Antigen-1; Transforming Growth Factor beta1; Vorinostat | 2018 |
Efficacy and safety of decitabine against cutaneous granuloblastic sarcoma: a case report.
Topics: Aged; Azacitidine; Decitabine; Fatal Outcome; Female; Humans; Sarcoma, Myeloid; Skin Neoplasms | 2018 |
Culturing conditions highly affect DNA methylation and gene expression levels in MCF7 breast cancer cell line.
Topics: Azacitidine; Breast Neoplasms; Cell Culture Techniques; CpG Islands; Decitabine; DNA Methylation; Female; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Neoplasm Proteins; Promoter Regions, Genetic | 2018 |
Successful treatment of high-risk myelodysplastic syndrome with decitabine-based chemotherapy followed by haploidentical lymphocyte infusion: A case report and literature review.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Decitabine; Female; HLA Antigens; Humans; Lymphocyte Transfusion; Myelodysplastic Syndromes; Treatment Outcome | 2018 |
Brca1 Is Upregulated by 5-Aza-CdR and Promotes DNA Repair and Cell Survival, and Inhibits Neurite Outgrowth in Rat Retinal Neurons.
Topics: Animals; Azacitidine; BRCA1 Protein; Cell Survival; Cells, Cultured; Decitabine; DNA Repair; Enzyme Inhibitors; Neuronal Outgrowth; Rats; Rats, Sprague-Dawley; Retinal Neurons; Up-Regulation | 2018 |
Loss of RUNX3 is significantly associated with advanced tumor grade and stage in endometrial cancers.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Cell Line, Tumor; Core Binding Factor Alpha 3 Subunit; Decitabine; DNA Methylation; Endometrial Neoplasms; Female; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Promoter Regions, Genetic; RNA, Messenger | 2018 |
SATB2 targeted by methylated miR-34c-5p suppresses proliferation and metastasis attenuating the epithelial-mesenchymal transition in colorectal cancer.
Topics: 3' Untranslated Regions; Azacitidine; Cell Line, Tumor; Cell Movement; Cell Proliferation; Colorectal Neoplasms; Decitabine; DNA Methylation; Epithelial-Mesenchymal Transition; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Matrix Attachment Region Binding Proteins; MicroRNAs; Middle Aged; Prognosis; Promoter Regions, Genetic; RNA Interference; RNA, Small Interfering; Transcription Factors | 2018 |
Activity of decitabine in pericardial myeloid sarcoma.
Topics: Allografts; Antimetabolites, Antineoplastic; Azacitidine; Consolidation Chemotherapy; Decitabine; Drug Administration Schedule; Female; Heart Neoplasms; Humans; Leukemia, Myeloid, Acute; Pericardium; Positron Emission Tomography Computed Tomography; Remission Induction; Sarcoma, Myeloid; Stem Cell Transplantation; Treatment Outcome | 2018 |
DNA Methyltransferase Inhibition Promotes Th1 Polarization in Human CD4
Topics: Aged; Aged, 80 and over; Azacitidine; Cell Differentiation; Cell Proliferation; Cell Separation; Cells, Cultured; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; Female; Flow Cytometry; Forkhead Transcription Factors; Hematologic Neoplasms; Humans; Immunosuppression Therapy; Interferon-gamma; Interleukin-2 Receptor alpha Subunit; Male; Middle Aged; T-Lymphocytes, Regulatory; Th1 Cells | 2018 |
DNA methylation of a non-CpG island promoter represses NQO1 expression in rat arsenic-transformed lung epithelial cells.
Topics: Animals; Arsenic Trioxide; Arsenicals; Azacitidine; Cell Line, Transformed; Cell Transformation, Neoplastic; CpG Islands; Decitabine; DNA Methylation; Enzyme Inhibitors; Epithelial Cells; Gene Expression Regulation; Lung; NAD(P)H Dehydrogenase (Quinone); Oxides; Promoter Regions, Genetic; Rats | 2018 |
[Clinical Efficacy of Decitabine-Based Chemotherapy Regimens in the Treatment of Newly Diagnosed Elderly Patients with Acute Myeloid Leukemia].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Middle Aged; Remission Induction; Treatment Outcome | 2018 |
KRAB zinc-finger protein 382 regulates epithelial-mesenchymal transition and functions as a tumor suppressor, but is silenced by CpG methylation in gastric cancer.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Biomarkers, Tumor; Carcinogenesis; Cell Line, Tumor; Cell Movement; Cell Proliferation; CpG Islands; Decitabine; DNA Methylation; DNA-Binding Proteins; Down-Regulation; Epithelial-Mesenchymal Transition; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Male; Middle Aged; Promoter Regions, Genetic; Signal Transduction; Stomach; Stomach Neoplasms; Transcription Factors; Tumor Suppressor Proteins; Up-Regulation | 2018 |
Hypermethylated CD36 gene affected the progression of lung cancer.
Topics: Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Benzamides; CD36 Antigens; Cell Line, Tumor; Cell Movement; Cell Proliferation; Decitabine; Disease Progression; DNA Methylation; Down-Regulation; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mice; Neoplasm Invasiveness; Xenograft Model Antitumor Assays | 2018 |
Effect of Inhibition of DNA Methylation Combined with Task-Specific Training on Chronic Stroke Recovery.
Topics: Animals; Axons; Azacitidine; Brain-Derived Neurotrophic Factor; Decitabine; Disease Models, Animal; DNA Methylation; Exercise; Gene Expression Regulation; Humans; Male; Neuronal Plasticity; Rats; Stroke; Stroke Rehabilitation; Task Performance and Analysis | 2018 |
Selection of patients with myelodysplastic syndromes from a large electronic medical records database and a study of the use of disease-modifying therapy in the United States.
Topics: Aged; Aged, 80 and over; Anemia; Azacitidine; Databases, Factual; Decitabine; Electronic Health Records; Enzyme Inhibitors; Female; Hematinics; Humans; Immunologic Factors; Iron Chelating Agents; Lenalidomide; Male; Middle Aged; Multivariate Analysis; Myelodysplastic Syndromes; Proportional Hazards Models; Recurrence; Retrospective Studies; Thalidomide; Treatment Outcome; United States | 2018 |
[All-Trans Retinoic Acid and Decitabine Synergistically Induce Anti-Leukemia Effect on U937 Cell Line and Newly Diagnosed Elder AML Patients].
Topics: Azacitidine; Decitabine; Humans; Leukemia, Myeloid, Acute; Tretinoin; U937 Cells | 2018 |
[The safety of decitabine as bridging pretreatment regimen before hematopoietic stem cell transplantation in pediatric hematological malignancies].
Topics: Antimetabolites, Antineoplastic; Azacitidine; Child; Clinical Protocols; Decitabine; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Transplantation Conditioning | 2018 |
Development, validation, and clinical application of a high-performance liquid chromatography-tandem mass spectrometry assay for the quantification of total intracellular β-decitabine nucleotides and genomic DNA incorporated β-decitabine and 5-methyl-2'-d
Topics: Adult; Antimetabolites, Antineoplastic; Azacitidine; Chromatography, High Pressure Liquid; Clinical Trials, Phase II as Topic; Decitabine; Deoxycytidine; DNA; DNA Methylation; Humans; Leukocytes, Mononuclear; Limit of Detection; Neoplasms; Randomized Controlled Trials as Topic; Tandem Mass Spectrometry | 2019 |
Venetoclax with decitabine or azacitidine for AML.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials as Topic; Decitabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Multicenter Studies as Topic; Sulfonamides; Time Factors; Treatment Outcome | 2018 |
Secreted Frizzled Related Protein 2 Modulates Epithelial-Mesenchymal Transition and Stemness via Wnt/β-Catenin Signaling in Choriocarcinoma.
Topics: Animals; Azacitidine; Cell Line, Tumor; Cell Movement; Choriocarcinoma; Decitabine; Dishevelled Proteins; DNA Methylation; Down-Regulation; Epithelial-Mesenchymal Transition; Female; Humans; Matrix Metalloproteinase 2; Membrane Proteins; Mice; Mice, Nude; Promoter Regions, Genetic; RNA Interference; RNA, Small Interfering; Uterine Neoplasms; Wnt Signaling Pathway | 2018 |
Intensive chemotherapy vs. hypomethylating agents in older adults with newly diagnosed high-risk acute myeloid leukemia: A single center experience.
Topics: Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Azacitidine; Cytarabine; Decitabine; Female; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies | 2018 |
10-day decitabine schedule in acute myeloid leukaemia: no extra bang for the buck.
Topics: Aged; Azacitidine; Decitabine; Humans; Leukemia, Myeloid, Acute | 2019 |
Droplet digital PCR for the quantification of Alu methylation status in hematological malignancies.
Topics: Adult; Aged; Aged, 80 and over; Alu Elements; Azacitidine; Biomarkers, Tumor; Cell Line, Tumor; Decitabine; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Feasibility Studies; Female; Genetic Predisposition to Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Phenotype; Polymerase Chain Reaction; Predictive Value of Tests; Reproducibility of Results; Retrospective Studies | 2018 |
Venetoclax in AML: aiming for "just right".
Topics: Aged; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Decitabine; Humans; Leukemia, Myeloid, Acute; Sulfonamides | 2019 |
Development and validation of LC-MS/MS methods for the quantification of the novel anticancer agent guadecitabine and its active metabolite β‑decitabine in human plasma, whole blood and urine.
Topics: Antineoplastic Agents; Azacitidine; Chromatography, Liquid; Decitabine; Humans; Linear Models; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry | 2019 |
Effective oral hypomethylating drugs in intermediate-risk or high-risk myelodysplasia: a breakthrough?
Topics: Administration, Oral; Azacitidine; Decitabine; DNA Methylation; Humans; Myelodysplastic Syndromes; Risk | 2019 |
10-day vs 5-day decitabine: equivalence cannot be concluded.
Topics: Aged; Azacitidine; Decitabine; Humans; Leukemia, Myeloid, Acute | 2019 |
10-day vs 5-day decitabine: equivalence cannot be concluded - Authors' reply.
Topics: Azacitidine; Decitabine; Humans; Myelodysplastic Syndromes | 2019 |
[Effects of Low-Dose Decitabine on Soluble CD44, GDF11 Levels and Hematopoietic Function in Elderly Patients with MDS].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Morphogenetic Proteins; Decitabine; Growth Differentiation Factors; Hematopoietic Stem Cell Transplantation; Humans; Hyaluronan Receptors; Myelodysplastic Syndromes; Treatment Outcome | 2019 |
RBC transfusion independence among lower risk MDS patients receiving hypomethylating agents: a population-level analysis.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Methylation; Erythrocyte Transfusion; Female; Humans; Kaplan-Meier Estimate; Male; Medicare; Myelodysplastic Syndromes; Retrospective Studies; SEER Program; Severity of Illness Index; Treatment Outcome; United States | 2019 |
Venetoclax in patients with acute myeloid leukemia refractory to hypomethylating agents-a multicenter historical prospective study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Chemotherapy-Induced Febrile Neutropenia; Decitabine; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prospective Studies; Remission Induction; Sulfonamides; Survival Analysis; Transplantation, Homologous | 2019 |
Optimizing venetoclax dose in combination with low intensive therapies in elderly patients with newly diagnosed acute myeloid leukemia: An exposure-response analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials, Phase I as Topic; Cytarabine; Decitabine; DNA Methylation; Dose-Response Relationship, Drug; Humans; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Remission Induction; Sulfonamides; Treatment Outcome | 2019 |
Association of leukemia genetics with response to venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allografts; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Combined Modality Therapy; Decitabine; Disease-Free Survival; DNA, Neoplasm; Female; Hematopoietic Stem Cell Transplantation; High-Throughput Nucleotide Sequencing; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Neoplasm Proteins; Remission Induction; Retrospective Studies; Risk Assessment; Sulfonamides; Treatment Outcome; Young Adult | 2019 |
Novel prodrugs of decitabine with greater metabolic stability and less toxicity.
Topics: Animals; Area Under Curve; Azacitidine; Blood Chemical Analysis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Decitabine; DNA Methylation; Drug Stability; Gene Expression Regulation, Neoplastic; Injections, Intraperitoneal; Mice; Neoplasms; Prodrugs; Xenograft Model Antitumor Assays | 2019 |
Selective inactivation of hypomethylating agents by SAMHD1 provides a rationale for therapeutic stratification in AML.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Biomarkers, Tumor; Bone Marrow; Cell Line, Tumor; Decitabine; DNA Methylation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Leukemic; Humans; Leukemia, Myeloid, Acute; Mice; Patient Selection; Primary Cell Culture; Retrospective Studies; SAM Domain and HD Domain-Containing Protein 1; Treatment Outcome; Xenograft Model Antitumor Assays | 2019 |
Real-world data confirming the efficacy and safety of decitabine in acute myeloid leukaemia - results from a retrospective Belgian registry study.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Belgium; Decitabine; Humans; Leukemia, Myeloid, Acute; Registries; Retrospective Studies; Treatment Outcome | 2021 |
Validating the Demethylating Effects of 5-aza-2'-deoxycytidine in Insects Requires a Whole-Genome Approach.
Topics: Animals; Azacitidine; Decitabine; DNA Methylation; Epigenesis, Genetic; Female; Sex Ratio; Wasps | 2019 |
The Importance of Validating the Demethylating Effect of 5-aza-2'-deoxycytidine in Model Species (A Comment on Cook et al., "DNA Methylation and Sex Allocation in the Parasitoid Wasp
Topics: Animals; Azacitidine; Decitabine; DNA Methylation; Sex Ratio; Wasps | 2019 |
Ganoderic acid A/DM-induced NDRG2 over-expression suppresses high-grade meningioma growth.
Topics: Aged; Anaplasia; Animals; Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; bcl-2-Associated X Protein; Cell Death; Decitabine; DNA Methylation; Down-Regulation; Gene Knockdown Techniques; Heptanoic Acids; Humans; In Vitro Techniques; Lanosterol; Matrix Metalloproteinase 9; Meningeal Neoplasms; Meningioma; Mice; Mice, SCID; Middle Aged; Molecular Targeted Therapy; Neoplasm Grading; Phosphatidylinositol 3-Kinases; Phosphorylation; Promoter Regions, Genetic; Proto-Oncogene Proteins c-akt; TOR Serine-Threonine Kinases; Triterpenes; Tumor Suppressor Proteins; Wnt2 Protein; Xenograft Model Antitumor Assays | 2020 |
Comparative analysis of epigenetic inhibitors reveals different degrees of interference with transcriptional gene silencing and induction of DNA damage.
Topics: Adenosine; Arabidopsis; Azacitidine; Chromosome Aberrations; Cytidine; Decitabine; DNA Damage; DNA Methylation; DNA Repair; Epigenesis, Genetic; Gene Silencing; Heterochromatin; RNA Interference; Tandem Repeat Sequences | 2020 |
Targeting DNA methylation for treating triple-negative breast cancer.
Topics: Animals; Azacitidine; Cell Line, Tumor; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Methyltransferase 3A; DNA Methyltransferase 3B; Epigenesis, Genetic; Female; Gene Expression Regulation, Neoplastic; Humans; Mice; Promoter Regions, Genetic; Triple Negative Breast Neoplasms; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2019 |
Temporal DNA methylation pattern and targeted therapy in colitis-associated cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Azoxymethane; bcl-Associated Death Protein; Carcinogenesis; Cell Line, Tumor; Colitis; Colon; Colonoscopy; Colorectal Neoplasms; Decitabine; Disease Models, Animal; Disease Progression; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Dose-Response Relationship, Drug; Gene Expression Regulation, Neoplastic; Humans; Intestinal Mucosa; Male; Mice; Molecular Targeted Therapy; Phosphatidylinositol-3,4,5-Trisphosphate 5-Phosphatases; Up-Regulation | 2020 |
Comparison between 5-day decitabine and 7-day azacitidine for lower-risk myelodysplastic syndromes with poor prognostic features: a retrospective multicentre cohort study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Decitabine; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Longitudinal Studies; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Retrospective Studies; Survival Rate; Young Adult | 2020 |
A comment on "a prospective, multicenter study of low dose decitabine in adult patients with refractory immune thrombocytopenia" by Zhou et al.
Topics: Adult; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Humans; Prospective Studies; Purpura, Thrombocytopenic, Idiopathic | 2020 |
[Therapeatic Efficacy of Decitabine on Low and Moderate-Risk MDS Patients and the Prognostic Factors].
Topics: Azacitidine; Decitabine; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Prognosis; Retrospective Studies; Treatment Outcome | 2020 |
Real-world data on treatment patterns and outcomes of hypomethylating therapy in patients with newly diagnosed acute myeloid leukaemia aged ≥ 60 years.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Disease-Free Survival; Female; Follow-Up Studies; Humans; Hydroxyurea; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Survival Rate | 2020 |
Immuno-DNA binding directed template-free DNA extension and enzyme catalysis for sensitive electrochemical DNA methyltransferase activity assay and inhibitor screening.
Topics: Animals; Antibodies, Immobilized; Azacitidine; Biosensing Techniques; Decitabine; DNA; DNA Nucleotidylexotransferase; DNA-Cytosine Methylases; Electrochemical Techniques; Electrodes; Enzyme Assays; Enzyme Inhibitors; Immunoassay; Limit of Detection; Mice | 2020 |
5-Aza-2'-deoxycytidine advances the epithelial-mesenchymal transition of breast cancer cells by demethylating
Topics: Azacitidine; Breast Neoplasms; Cell Line, Tumor; CpG Islands; Decitabine; DNA Methylation; Epithelial-Mesenchymal Transition; Female; Gene Expression Regulation, Neoplastic; Humans | 2020 |
The impact of DNA demethylation on the upregulation of the NRN1 and TNFAIP3 genes associated with advanced gastric cancer.
Topics: Azacitidine; Biomarkers, Tumor; Cell Line, Tumor; Computational Biology; CpG Islands; Decitabine; DNA Demethylation; DNA Methylation; Epigenesis, Genetic; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; GPI-Linked Proteins; Humans; Neoplasm Staging; Neuropeptides; Prognosis; Stomach Neoplasms; Transcriptome; Tumor Necrosis Factor alpha-Induced Protein 3 | 2020 |
Venetoclax and hypomethylating agent therapy in high risk myelodysplastic syndromes: a retrospective evaluation of a real-world experience.
Topics: Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Decitabine; Humans; Myelodysplastic Syndromes; Retrospective Studies; Sulfonamides; Treatment Outcome | 2020 |
Activation of SIRT6 by DNA hypomethylating agents and clinical consequences on combination therapy in leukemia.
Topics: Acetylation; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Marrow; Cell Line, Tumor; Cytidine; Decitabine; DNA Methylation; Histones; Humans; Leukemia, Myeloid, Acute; Sirtuins | 2020 |
Optimizing 5-aza-2'-deoxycytidine treatment to enhance the development of porcine cloned embryos by inhibiting apoptosis and improving DNA methylation reprogramming.
Topics: Animals; Apoptosis; Azacitidine; Blastocyst; Cellular Reprogramming; Cloning, Organism; Decitabine; DNA Methylation; Embryonic Development; Gene Expression Regulation, Developmental; Insulin-Like Growth Factor II; Nuclear Transfer Techniques; Swine | 2020 |
Dose-Reduced Decitabine Might Bring Benefits for Elderly AML Patients with Complex Karyotype: a Case Report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Humans; Karyotype; Leukemia, Myeloid, Acute; Remission Induction; Treatment Outcome | 2020 |
Risk of tumor lysis syndrome in patients with acute myeloid leukemia treated with venetoclax-containing regimens without dose ramp-up.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Decitabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Risk Factors; Sulfonamides; Tumor Lysis Syndrome | 2021 |
Decitabine- and 5-azacytidine resistance emerges from adaptive responses of the pyrimidine metabolism network.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Cell Line, Tumor; Decitabine; Disease Models, Animal; DNA (Cytosine-5-)-Methyltransferase 1; DNA Methylation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Humans; Metabolic Networks and Pathways; Mice; Pyrimidines; Uridine Kinase | 2021 |
Predictive factors for response and survival in elderly acute myeloid leukemia patients treated with hypomethylating agents: a real-life experience.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow; Cause of Death; Cell Count; Decitabine; Disease Progression; Disease-Free Survival; DNA Methylation; DNA, Neoplasm; Female; Hemoglobins; Humans; Infections; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplastic Stem Cells; Proportional Hazards Models; Retrospective Studies; Treatment Outcome | 2020 |
DNA Methylation-Based Epigenetic Repression of SLC22A4 Promotes Resistance to Cytarabine in Acute Myeloid Leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cell Line, Tumor; Child; Clinical Trials, Phase III as Topic; Cytarabine; Datasets as Topic; Decitabine; DNA Methylation; Drug Resistance, Neoplasm; Epigenetic Repression; Female; Gene Expression Regulation, Leukemic; HEK293 Cells; Humans; Leukemia, Myeloid, Acute; Male; Organic Cation Transport Proteins; Progression-Free Survival; Randomized Controlled Trials as Topic; Symporters; Young Adult | 2021 |
Human papillomavirus-positivity is associated with EREG down-regulation and promoter hypermethylation in head and neck squamous cell carcinoma.
Topics: Alphapapillomavirus; Azacitidine; Carcinogenesis; Cell Line, Tumor; Decitabine; Disease Progression; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Methyltransferase 3A; Epigenesis, Genetic; Epiregulin; Gene Expression Regulation, Neoplastic; Humans; Neoplasm Proteins; Promoter Regions, Genetic; Squamous Cell Carcinoma of Head and Neck | 2020 |
Elevated TWIST1 expression in myelodysplastic syndromes/acute myeloid leukemia reduces efficacy of hypomethylating therapy with decitabine.
Topics: Azacitidine; Decitabine; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Nuclear Proteins; Twist-Related Protein 1 | 2020 |
Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group.
Topics: Allografts; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Combined Modality Therapy; Decitabine; DNA Methylation; Drug Evaluation; Febrile Neutropenia; Germany; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Leukocyte Count; Myelodysplastic Syndromes; Recurrence; Retrospective Studies; Salvage Therapy; Sulfonamides; Thrombocytopenia; Transplantation Conditioning; Tumor Lysis Syndrome | 2021 |
Venetoclax + hypomethylating agents combined with dose-adjusted HAG for relapsed/refractory acute myeloid leukemia: Two case reports.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Decitabine; Drug Combinations; Fatal Outcome; Granulocyte Colony-Stimulating Factor; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local; Sulfonamides; Young Adult | 2020 |
Hairpin-bisulfite sequencing of cells exposed to decitabine documents the process of DNA demethylation.
Topics: Azacitidine; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Demethylation; DNA Methylation; Humans; Sulfites | 2021 |
Micro-RNA-125a mediates the effects of hypomethylating agents in chronic myelomonocytic leukemia.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Disease Models, Animal; DNA Methylation; Gene Expression Regulation; Genome-Wide Association Study; Humans; Leukemia, Myelomonocytic, Chronic; Mice; RNA, Messenger | 2021 |
Treatment patterns and outcomes in patients with myelodysplastic syndromes treated with hypomethylating agents: a SEER-Medicare analysis.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Humans; Medicare; Myelodysplastic Syndromes; Treatment Outcome; United States | 2021 |
Evaluation of Reduced-Dose Decitabine and Azacitidine for Treating Myelodysplastic Syndromes: A Retrospective Study.
Topics: Aged; Azacitidine; China; Decitabine; Dose-Response Relationship, Drug; Drug Tapering; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Retrospective Studies; Treatment Outcome | 2021 |
Hypomethylating agents and venetoclax in acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials as Topic; Decitabine; DNA Methylation; DNA, Neoplasm; Humans; Leukemia, Myeloid, Acute; Recurrence; Salvage Therapy; Sulfonamides; Treatment Outcome | 2021 |
Inpatient versus outpatient hypomethylating agent induction for acute myeloid leukemia as a predictor for survival.
Topics: Aged; Aged, 80 and over; Azacitidine; Decitabine; Disease-Free Survival; Female; Humans; Impatiens; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Outpatients; Retrospective Studies; Survival Rate | 2021 |
Decitabine may improve CAR-T efficacy in refractory/relapsed acute leukemia patients carrying TP53 alterations.
Topics: Azacitidine; Decitabine; Humans; Immunotherapy, Adoptive; Leukemia, Myeloid, Acute; Receptors, Chimeric Antigen; Tumor Suppressor Protein p53 | 2021 |
Changes in Apoptotic Pathways in MOLM-13 Cell Lines after Induction of Resistance to Hypomethylating Agents.
Topics: Apoptosis; Azacitidine; bcl-2-Associated X Protein; Cell Line, Tumor; Cell Survival; Decitabine; Disease Progression; DNA Methylation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Models, Biological; Necrosis; Neoplasm Proteins; Promoter Regions, Genetic; Signal Transduction | 2021 |
A novel class of selective non-nucleoside inhibitors of human DNA methyltransferase 3A.
Topics: Azacitidine; Catalytic Domain; Decitabine; DNA; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Methyltransferase 3A; Drug Evaluation, Preclinical; Enzyme Inhibitors; Humans; Protein Binding; Pyrazolones; Pyridazines; Small Molecule Libraries | 2021 |
Noncanonical immune response to the inhibition of DNA methylation by Staufen1 via stabilization of endogenous retrovirus RNAs.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Cohort Studies; Cytoskeletal Proteins; Decitabine; DNA Methylation; Drug Resistance, Neoplasm; Endogenous Retroviruses; Female; Gene Expression Regulation, Leukemic; Gene Knockout Techniques; HCT116 Cells; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Progression-Free Survival; RNA Stability; RNA-Binding Proteins; RNA-Seq; RNA, Double-Stranded; RNA, Long Noncoding; RNA, Viral | 2021 |
The path to approval for oral hypomethylating agents in acute myeloid leukemia and myelodysplastic syndromes.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Biological Availability; Clinical Trials, Phase III as Topic; Decitabine; DNA Methylation; Drug Approval; Drug Combinations; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Randomized Controlled Trials as Topic; Remission Induction; Uridine | 2021 |
Minimal Residual Disease in Acute Myelogenous Leukemia Is Predictive, Unless You Are Over Age 60 and Treated with Decitabine.
Topics: Azacitidine; Decitabine; Humans; Leukemia, Myeloid, Acute; Middle Aged; Neoplasm, Residual | 2021 |
SPAG6-silencing enhances decitabine-induced apoptosis and demethylation of PTEN in SKM-1 cells and in a xenograft mouse model.
Topics: Animals; Apoptosis; Azacitidine; Decitabine; Demethylation; DNA Methylation; Gene Silencing; Heterografts; Mice; Microtubule Proteins; Myelodysplastic Syndromes; PTEN Phosphohydrolase | 2021 |
Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Blast Crisis; Bridged Bicyclo Compounds, Heterocyclic; Decitabine; Female; Humans; Male; Middle Aged; Myeloproliferative Disorders; Retrospective Studies; Sulfonamides; Survival Analysis; Treatment Outcome | 2021 |
The development and clinical use of oral hypomethylating agents in acute myeloid leukemia and myelodysplastic syndromes: dawn of the total oral therapy era.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes | 2021 |
Response to Hypomethylating Agents in Myelodysplastic Syndrome Is Associated With Emergence of Novel TCR Clonotypes.
Topics: Aged; Aged, 80 and over; Azacitidine; Clone Cells; Cohort Studies; Complementarity Determining Regions; Decitabine; DNA Methylation; Enzyme Inhibitors; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Polymerase Chain Reaction; Receptors, Antigen, T-Cell, alpha-beta; Sequence Analysis, DNA; T-Lymphocytes; Treatment Outcome | 2021 |
British Society for Haematology guidelines for the management of adult myelodysplastic syndromes.
Topics: Adult; Anemia; Antineoplastic Agents; Azacitidine; Blood Transfusion; Decitabine; Disease Management; Hematinics; Hematopoietic Stem Cell Transplantation; Hemorrhage; Humans; Iron Chelating Agents; Myelodysplastic Syndromes; Neutropenia; Thrombocytopenia | 2021 |
miR-23a mediates resistance to hypomethylating agents in myeloid neoplasms.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cell Line, Tumor; Decitabine; Drug Resistance, Neoplasm; Gene Expression Regulation, Leukemic; Humans; Leukemia, Myeloid; MicroRNAs; THP-1 Cells | 2021 |
Clinical evidence for a biological effect of epigenetically active decitabine in relapsed or progressive rhabdoid tumors.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Child; Decitabine; Humans; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Rhabdoid Tumor | 2021 |
TET2 Mutation and High miR-22 Expression as Biomarkers to Predict Clinical Outcome in Myelodysplastic Syndrome Patients Treated with Hypomethylating Therapy.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Biomarkers; Decitabine; Dioxygenases; DNA Methylation; DNA-Binding Proteins; Female; Humans; Male; MicroRNAs; Middle Aged; Mutation; Myelodysplastic Syndromes; Proto-Oncogene Proteins; Survival Rate; Treatment Outcome; Young Adult | 2021 |
Prognostic impact of conventional cytogenetics in acute myeloid leukemia treated with venetoclax and decitabine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Cytogenetic Analysis; Decitabine; Humans; Leukemia, Myeloid, Acute; Prognosis; Sulfonamides | 2021 |
Combination of azacytidine and curcumin is a potential alternative in decitabine-resistant colorectal cancer cells with attenuated deoxycytidine kinase.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cell Line, Tumor; Colorectal Neoplasms; Curcumin; Cytidine Deaminase; Decitabine; Deoxycytidine Kinase; DNA Methylation; Drug Resistance, Neoplasm; Drug Synergism; Humans | 2021 |
5-Azacitidine and Trichostatin A induce DNA damage and apoptotic responses in tongue squamous cell carcinoma: An in vitro study.
Topics: Azacitidine; Carcinoma, Squamous Cell; Decitabine; DNA Damage; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Matrix Metalloproteinase 2; Tongue; Tongue Neoplasms | 2022 |
RUNX1 mutations correlate with response to venetoclax combination therapies in relapsed/refractory acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Marrow Transplantation; Bridged Bicyclo Compounds, Heterocyclic; Combined Modality Therapy; Core Binding Factor Alpha 2 Subunit; Decitabine; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Sulfonamides; Survival Rate | 2021 |
Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia.
Topics: Animals; Azacitidine; Decitabine; DNA; DNA Methylation; DNA Modification Methylases; Leukemia, Myeloid, Acute; Mice | 2021 |
Oral hypomethylating agents: beyond convenience in MDS.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Female; Humans; Myelodysplastic Syndromes; Quality of Life; Uridine | 2021 |
Adult T-cell leukemia-lymphoma acquires resistance to DNA demethylating agents through dysregulation of enzymes involved in pyrimidine metabolism.
Topics: Antineoplastic Agents; Azacitidine; Cell Line, Tumor; Decitabine; Deoxycytidine Kinase; DNA Methylation; Drug Resistance, Neoplasm; Humans; Leukemia-Lymphoma, Adult T-Cell; Pyridines; Pyrimidines; Uridine Kinase | 2022 |
Decitabine Enhances Acute Myeloid Leukemia Cell Apoptosis through SH3BGRL Upregulation.
Topics: Apoptosis; Azacitidine; Cell Line, Tumor; Decitabine; DNA Methylation; Glutamic Acid; Humans; Leukemia, Myeloid, Acute; Proteins; RNA, Messenger; U937 Cells; Up-Regulation | 2022 |
Historical expectations with DNA methyltransferase inhibitor monotherapy in MDS: when is combination therapy truly "promising"?
Topics: Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA; Enzyme Inhibitors; Humans; Methyltransferases; Motivation; Myelodysplastic Syndromes; Treatment Outcome | 2022 |
Venetoclax in combination with hypomethylating agents in previously untreated patients with acute myeloid leukemia ineligible for intensive treatment: a real-life multicenter experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Decitabine; Humans; Leukemia, Myeloid, Acute; Retrospective Studies; Sulfonamides | 2022 |
Epigenetic Anti-Cancer Treatment With a Stabilized Carbocyclic Decitabine Analogue.
Topics: Azacitidine; Cell Line, Tumor; Decitabine; DNA Methylation; Enzyme Inhibitors; Epigenesis, Genetic; Humans | 2022 |
Tumor lysis syndrome and infectious complications during treatment with venetoclax combined with azacitidine or decitabine in patients with acute myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Decitabine; Febrile Neutropenia; Humans; Leukemia, Myeloid, Acute; Retrospective Studies; Sulfonamides; Tumor Lysis Syndrome | 2022 |
Prospective comparison of outcomes with azacitidine and decitabine in patients with AML ineligible for intensive chemotherapy.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Decitabine; Humans; Leukemia, Myeloid, Acute; Treatment Outcome | 2022 |
A real-world study of infectious complications of venetoclax combined with decitabine or azacitidine in adult acute myeloid leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Decitabine; Humans; Leukemia, Myeloid, Acute; Retrospective Studies; Sulfonamides; Treatment Outcome | 2022 |
Impact of Hypomethylating Agent Use on Hospital and Emergency Room Visits, and Predictors of Early Discontinuation in Patients With Higher-Risk Myelodysplastic Syndromes.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Methylation; Emergency Service, Hospital; Hospitals; Humans; Medicare; Myelodysplastic Syndromes; Treatment Outcome; United States | 2022 |
Epigenetic Silencing of
Topics: Azacitidine; Cell Line, Tumor; Decitabine; DNA Methylation; Epigenesis, Genetic; Gene Silencing; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Neoplasms, Second Primary; Proto-Oncogene Proteins c-mdm2; PTEN Phosphohydrolase | 2022 |
Hypomethylating agents combined with low-dose chemotherapy for elderly patients with acute myeloid leukaemia unfit for intensive chemotherapy: a real-world clinical experience.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Decitabine; Humans; Leukemia, Myeloid, Acute; Retrospective Studies; Treatment Outcome | 2023 |
5-Aza-dC promotes T-cell acute lymphoblastic leukemia cell invasion via downregulation of DNMT1 and upregulation of MMP-2 and MMP-9.
Topics: Animals; Azacitidine; Cell Line, Tumor; Decitabine; DNA; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Down-Regulation; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Mice; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; T-Lymphocytes; Up-Regulation | 2022 |
Effects of 5-Aza on neurogenesis contribute to learning and memory in the mouse hippocampus.
Topics: Animals; Azacitidine; Decitabine; DNA Methylation; Hippocampus; Mice; Neurogenesis | 2022 |
Comprehensive comparison between azacytidine and decitabine treatment in an acute myeloid leukemia cell line.
Topics: Azacitidine; Cell Line; Decitabine; DNA; DNA Methylation; Humans; Leukemia, Myeloid, Acute | 2022 |
[New treatment for myelodysplastic syndromes: luspatercept and oral hypomethylating agents].
Topics: Activin Receptors, Type II; Activins; Azacitidine; Cytidine Deaminase; Decitabine; Humans; Immunoglobulin Fc Fragments; Ligands; Myelodysplastic Syndromes; Recombinant Fusion Proteins; Treatment Outcome | 2022 |
Hypermethylation of RASSF1A gene in pediatric rhabdoid tumor of the kidney and clear cell sarcoma of the kidney.
Topics: Azacitidine; Cell Line, Tumor; Child; Decitabine; DNA Methylation; Humans; Kidney; Kidney Neoplasms; Nephroma, Mesoblastic; Rhabdoid Tumor; Sarcoma, Clear Cell; Tumor Suppressor Proteins | 2023 |
Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-naïve settings.
Topics: Azacitidine; Decitabine; Humans; Ipilimumab; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | 2023 |
Trichostatin A-Mediated Epigenetic Modulation Predominantly Triggers Transcriptomic Alterations in the Ex Vivo Expanded Equine Chondrocytes.
Topics: Animals; Azacitidine; Chondrocytes; Decitabine; DNA Methylation; Epigenesis, Genetic; Epigenomics; Histone Deacetylase Inhibitors; Histones; Horses; Hydroxamic Acids; Transcriptome | 2022 |
Ascertaining QUAZARs: slow-motion and light-speed development of oral azacitidine and decitabine.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | 2023 |
Preclinical efficacy of azacitidine and venetoclax for infant KMT2A-rearranged acute lymphoblastic leukemia reveals a new therapeutic strategy.
Topics: Azacitidine; Decitabine; Humans; Infant; Leukemia, Myeloid, Acute; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proto-Oncogene Proteins c-bcl-2 | 2023 |
All-trans retinoic acid enhances the cytotoxic effect of decitabine on myelodysplastic syndromes and acute myeloid leukaemia by activating the RARα-Nrf2 complex.
Topics: Aged; Animals; Antineoplastic Agents; Azacitidine; Decitabine; Humans; Leukemia, Myeloid, Acute; Mice; Myelodysplastic Syndromes; NF-E2-Related Factor 2; Reactive Oxygen Species; Tretinoin | 2023 |
Venetoclax with decitabine versus decitabine monotherapy in elderly acute myeloid leukemia: a propensity score-matched analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Decitabine; Humans; Leukemia, Myeloid, Acute; Propensity Score; Treatment Outcome | 2022 |
Absence of early platelet increment in healthy mice during decitabine treatment.
Topics: Animals; Azacitidine; Blood Platelets; Decitabine; Megakaryocytes; Mice; Myelodysplastic Syndromes; Treatment Outcome | 2022 |
Greater angiogenic and immunoregulatory potency of bFGF and 5-aza-2'-deoxycytidine pre-treated menstrual blood stem cells in compare to bone marrow stem cells in rat model of myocardial infarction.
Topics: Animals; Azacitidine; Bone Marrow Cells; Cell Differentiation; Cells, Cultured; Decitabine; Fibroblast Growth Factor 2; Myocardial Infarction; Rats; Stem Cells | 2022 |
Inhibition of SUMOylation enhances DNA hypomethylating drug efficacy to reduce outgrowth of hematopoietic malignancies.
Topics: Azacitidine; Burkitt Lymphoma; Cell Line, Tumor; Decitabine; DNA; Hematologic Neoplasms; Humans; Lymphoma, Large B-Cell, Diffuse; Sumoylation | 2023 |
The molecular mechanisms of apoptosis accompanied with the epigenetic regulation of the NY-ESO-1 antigen in non-small lung cancer cells treated with decitabine (5-aza-CdR).
Topics: Antibodies; Antigens, Neoplasm; Apoptosis; Azacitidine; Cell Line, Tumor; Decitabine; Epigenesis, Genetic; Humans; Lung Neoplasms; Membrane Proteins | 2023 |
Report of four acute myeloid leukemia patients with sustained complete remission with less frequent administration of decitabine and venetoclax.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Decitabine; Humans; Leukemia, Myeloid, Acute; Remission Induction | 2023 |
Possible regulation of ganglioside GD3 synthase gene expression with DNA methylation in human glioma cells.
Topics: Azacitidine; Cell Line, Tumor; Decitabine; DNA Methylation; Gangliosides; Gene Expression; Gene Expression Regulation, Neoplastic; Glioma; Humans; Promoter Regions, Genetic | 2023 |
Characterization of a multidisciplinary team's role in hospital discharge for patients receiving hypomethylating agents with venetoclax as induction therapy for acute myeloid leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Decitabine; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Patient Care Team; Patient Discharge; Treatment Outcome; Tumor Lysis Syndrome | 2023 |
Combined inhibition of histone deacetylase and cytidine deaminase improves epigenetic potency of decitabine in colorectal adenocarcinomas.
Topics: Adenocarcinoma; Azacitidine; Cell Line, Tumor; Colorectal Neoplasms; Cytidine Deaminase; Decitabine; DNA Methylation; Epigenesis, Genetic; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Prospective Studies; Tetrahydrouridine; Tumor Microenvironment; Tumor Suppressor Protein p53 | 2023 |
Characterisation of miRNA Expression in Dental Pulp Cells during Epigenetically-Driven Reparative Processes.
Topics: Azacitidine; Decitabine; Dental Pulp; Histone Deacetylase Inhibitors; Hydroxamic Acids; MicroRNAs; Vorinostat | 2023 |
The Effect of 5-aza,2'-deoxyCytidine (5 AZA CdR or Decitabine) on Extrinsic, Intrinsic, and JAK/STAT Pathways in Neuroblastoma and Glioblastoma Cells Lines.
Topics: Azacitidine; Cell Line; Cell Line, Tumor; Decitabine; Deoxycytidine; DNA Methylation; Glioblastoma; Humans; Janus Kinases; Neuroblastoma; Signal Transduction; STAT Transcription Factors | 2023 |
Molecular predictors for decitabine efficacy in meningiomas - a pilot study.
Topics: Azacitidine; Cell Line, Tumor; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Enzyme Inhibitors; Humans; Ki-67 Antigen; Meningeal Neoplasms; Meningioma; Myelin and Lymphocyte-Associated Proteolipid Proteins; Pilot Projects | 2023 |
WIF1 promoter hypermethylation induce endometrial carcinogenesis through the Wnt/β-catenin signaling pathway.
Topics: Adaptor Proteins, Signal Transducing; Animals; Azacitidine; beta Catenin; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; Decitabine; Endometrial Neoplasms; Female; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Nude; Wnt Signaling Pathway | 2023 |
Abbreviated venetoclax with decitabine or azacitidine in acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Decitabine; Humans; Leukemia, Myeloid, Acute | 2023 |
Mitotic perturbation is a key mechanism of action of decitabine in myeloid tumor treatment.
Topics: Adaptor Proteins, Signal Transducing; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA; DNA Methylation; Humans; Leukemia, Myeloid, Acute | 2023 |